<SEC-DOCUMENT>0001213900-24-024500.txt : 20240321
<SEC-HEADER>0001213900-24-024500.hdr.sgml : 20240321
<ACCEPTANCE-DATETIME>20240321072844
ACCESSION NUMBER:		0001213900-24-024500
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		81
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240321
DATE AS OF CHANGE:		20240321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		24769429

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0202038-20f_inflarx.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 21 04:12:20 UTC 2024 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:ifrx="http://www.inflarx.de.com/20231231" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES AND EXCHANGE COMMISSION</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-29454">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</span></p><div>



</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement" id="ixv-29455">&#9744;</ix:nonNumeric> <b>REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport" id="ixv-29456">&#9746;</ix:nonNumeric>
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-29457"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-29458">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-29459">2023</ix:nonNumeric></ix:nonNumeric></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport" id="ixv-29460">&#9744;</ix:nonNumeric> <b>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the transition period from <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span>to <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>.</b></span></p><div>



</div><p style="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentShellCompanyReport" id="ixv-29461">&#9744;</ix:nonNumeric> <b>SHELL
COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date of event requiring this shell company
report <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-29462">001-38283</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-125"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>InflaRx
N.V.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact name of Registrant as specified in its charter)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
<ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-29463">Netherlands</ix:nonNumeric></b><br/>
(Jurisdiction of incorporation or organization)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-144"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Winzerlaer
Str. 2</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2" id="ixv-29464">07745</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-29465">Jena</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-29466">Germany</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>+49
(3641) 508 180<br/>
</b>(Address of principal executive offices)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-29467">Dr.
Thomas Taapken</ix:nonNumeric>,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Financial Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tel:
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-29468">+49</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-29469">(3641) 508 180</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-29470">Winzerlaer
Str. 2</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2" id="ixv-29471">07745</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-29472">Jena</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-29473">Germany</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Copies
to</i>:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Sophia Hudson<br/>
Kirkland &amp; Ellis LLP<br/>
601 Lexington Avenue<br/>
New York, NY 10022<br/>
Phone: +1 (212) 446-4750</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</span></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</span></td> <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center; width: 2%">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-218"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Ordinary Shares, nominal value &#8364;0.12 per share</span></ix:nonNumeric></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-222"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">IFRX</span></ix:nonNumeric></td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-226"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The Nasdaq Stock Market LLC</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act:</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act:</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>None</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of outstanding ordinary shares as of December 31, 2023 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-29474">58,883,272</ix:nonFraction>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-29475">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-29476">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-29477">Yes</ix:nonNumeric>
&#9746;&#160;&#160;&#160;&#160;&#160;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-29478">Yes</ix:nonNumeric>
&#9746;&#160;&#160;&#160;&#160;&#160;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 5%">&#160;</td> <td style="width: 35%">Large Accelerated Filer &#9744;</td> <td style="width: 30%"><ix:nonNumeric contextRef="c0" name="dei:EntityFilerCategory" id="ixv-29479">Accelerated Filer</ix:nonNumeric> &#9746;</td> <td style="width: 30%">Non-accelerated Filer &#9744;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-29480">&#9744;</ix:nonNumeric></td> <td>&#160;</td> <td>&#160;</td></tr> </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided
pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; width: 0.25in; vertical-align: top">&#8224;</td>
    <td>The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:IcfrAuditorAttestationFlag" id="ixv-29481">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-29482">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
U.S. GAAP</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard" id="ixv-29483">International Financial Reporting Standards</ix:nonNumeric> as issued by the International Accounting Standards Board</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Other</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
Item 17&#160;&#160;&#160;&#160;&#160;&#9744; Item 18</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&#160;&#160;&#160;&#160;&#160;No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-29484">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>




</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>I</b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nfla<span style="text-transform: uppercase">R</span>x
<span style="text-transform: uppercase">N.V.</span></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Table
of Contents</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Page</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_001">FORWARD-LOOKING STATEMENTS</a></td>
    <td style="text-align: center; font-weight: bold">iv</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_002">ENFORCEMENT OF JUDGMENTS</a></td>
    <td style="text-align: center; font-weight: bold">vi</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_003">PART I</a></td>
    <td style="text-align: center; font-weight: bold">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_004">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></td>
    <td style="text-align: center; font-weight: bold">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; width: 8%">A.</td>
    <td style="width: 84%"><a href="#m_005">Directors and senior management</a></td>
    <td style="text-align: center; width: 8%">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_006">Advisers</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_007">Auditors</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_008">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</a></td>
    <td style="text-align: center; font-weight: bold">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_009">Offer statistics</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_010">Method and expected timetable</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_011">ITEM 3. KEY INFORMATION</a></td>
    <td style="text-align: center; font-weight: bold">1</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_012">Capitalization and indebtedness</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_013">Reasons for the offer and use of proceeds</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_014">Risk factors</a></td>
    <td style="text-align: center">2</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_015">History and development of the company</a></td>
    <td style="text-align: center">54</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_016">Business overview</a></td>
    <td style="text-align: center">55</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_017">Organizational structure</a></td>
    <td style="text-align: center">98</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_018">Property, plant and equipment</a></td>
    <td style="text-align: center">98</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_019">ITEM 4A. UNRESOLVED STAFF COMMENTS</a></td>
    <td style="text-align: center; font-weight: bold"> 99</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_020">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></td>
    <td style="text-align: center; font-weight: bold">99</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_021">Operating results</a></td>
    <td style="text-align: center">99</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_022">Financial operations overview</a></td>
    <td style="text-align: center">101</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_023">Liquidity and capital resources</a></td>
    <td style="text-align: center">108</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_024">Research and development, patents and licenses, etc.</a></td>
    <td style="text-align: center">111</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">E.</td>
    <td><a href="#m_025">Trend information</a></td>
    <td style="text-align: center">111</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">F.</td>
    <td><a href="#m_026">Critical accounting estimates</a></td>
    <td style="text-align: center">111</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_027">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></td>
    <td style="text-align: center; font-weight: bold">112</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_028">Directors and senior management</a></td>
    <td style="text-align: center">112</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_029">Compensation</a></td>
    <td style="text-align: center">115</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_030">Board practices</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_031">Employees</a></td>
    <td style="text-align: center">121</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">E.</td>
    <td><a href="#m_032">Share ownership</a></td>
    <td style="text-align: center">121</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">F.</td>
    <td><a href="#m_033">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation</a></td>
    <td style="text-align: center">121</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_034">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></td>
    <td style="text-align: center; font-weight: bold">122</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_035">Major shareholders</a></td>
    <td style="text-align: center">122</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_036">Related party transactions</a></td>
    <td style="text-align: center"> 125</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="3">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_037">ITEM 8. FINANCIAL INFORMATION</a></td>
    <td style="text-align: center; font-weight: bold">126</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_038">Consolidated statements and other financial information</a></td>
    <td style="text-align: center">126</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_039">Significant changes</a></td>
    <td style="text-align: center">126</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_040">ITEM 9. THE OFFER AND LISTING</a></td>
    <td style="text-align: center; font-weight: bold">127</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; width: 8%">A.</td>
    <td style="width: 84%"><a href="#m_041">Offering and listing details</a></td>
    <td style="text-align: center; width: 8%">127</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_042">Plan of distribution</a></td>
    <td style="text-align: center">127</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_043">Markets</a></td>
    <td style="text-align: center">127</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_044">Selling shareholders</a></td>
    <td style="text-align: center">127</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">E.</td>
    <td><a href="#m_045">Dilution</a></td>
    <td style="text-align: center">127</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">F.</td>
    <td><a href="#m_046">Expenses of the issue</a></td>
    <td style="text-align: center">127</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_047">ITEM 10. ADDITIONAL INFORMATION</a></td>
    <td style="text-align: center; font-weight: bold">128</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_048">Share capital</a></td>
    <td style="text-align: center">128</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_049">Memorandum and articles of association</a></td>
    <td style="text-align: center">128</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_050">Material contracts</a></td>
    <td style="text-align: center">128</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_051">Exchange controls</a></td>
    <td style="text-align: center">128</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">E.</td>
    <td><a href="#m_052">Taxation</a></td>
    <td style="text-align: center">128</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_053">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></td>
    <td style="text-align: center; font-weight: bold">151</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_054">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></td>
    <td style="text-align: center; font-weight: bold">151</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_055">Debt securities</a></td>
    <td style="text-align: center">151</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_056">Warrants and rights</a></td>
    <td style="text-align: center">151</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_057">Other securities</a></td>
    <td style="text-align: center">151</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_058">American Depositary Shares</a></td>
    <td style="text-align: center">151</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_059">PART II</a></td>
    <td style="text-align: center; font-weight: bold">152</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_060">ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></td>
    <td style="text-align: center; font-weight: bold">152</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_061">Defaults</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_062">Arrears and delinquencies</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_063">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></td>
    <td style="text-align: center; font-weight: bold">152</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_064">Material modifications to instruments</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_065">Material modifications to rights</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_066">Withdrawal or substitution of assets</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_067">Change in trustees or paying agents</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">E.</td>
    <td><a href="#m_068">Use of proceeds</a></td>
    <td style="text-align: center">152</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_069">ITEM 15. CONTROLS AND PROCEDURES</a></td>
    <td style="text-align: center; font-weight: bold">153</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">A.</td>
    <td><a href="#m_070">Disclosure controls and procedures</a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_071">Management&#8217;s annual report on internal control over financial reporting</a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_072">Attestation report of the registered public accounting firm</a></td>
    <td style="text-align: center">153</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_073">Changes in internal control over financial reporting</a></td>
    <td style="text-align: center">153</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_074">ITEM 16. RESERVED</a></td>
    <td style="text-align: center; font-weight: bold">153</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_075">ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</a></td>
    <td style="text-align: center; font-weight: bold">153</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_076">ITEM 16B. CODE OF ETHICS</a></td>
    <td style="text-align: center; font-weight: bold">153</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold"><a href="#m_077">ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></td>
    <td style="text-align: center; font-weight: bold">154</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; width: 8%">A.</td>
    <td style="width: 84%"><a href="#m_078">Audit fees</a></td>
    <td style="text-align: center; width: 8%">154</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">B.</td>
    <td><a href="#m_079">Audit-related fees</a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">C.</td>
    <td><a href="#m_080">Tax fees</a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">D.</td>
    <td><a href="#m_081">All other fees</a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">E.</td>
    <td><a href="#m_082">Audit Committee&#8217;s pre-approval policies and procedures</a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in">F.</td>
    <td><a href="#m_083">Audit work performed by other than principal accountant if greater than 50%</a></td>
    <td style="text-align: center">154</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_084">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></td>
    <td style="text-align: center; font-weight: bold">154</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_085">ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_086">ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_087">ITEM 16G. CORPORATE GOVERNANCE</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_088">ITEM 16H. MINE SAFETY DISCLOSURE</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_089">ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_090">ITEM 16J. INSIDER TRADING POLICIES</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_091">ITEM 16K. CYBERSECURITY RISK MANAGEMENT AND STRATEGY</a></td>
    <td style="text-align: center; font-weight: bold">155</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_092">PART III</a></td>
    <td style="text-align: center; font-weight: bold">157</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2" style="font-weight: bold">&#160;</td>
    <td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_093">ITEM 17. FINANCIAL STATEMENTS</a></td>
    <td style="text-align: center; font-weight: bold">157</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_094">ITEM 18. FINANCIAL STATEMENTS</a></td>
    <td style="text-align: center; font-weight: bold">157</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_095">ITEM 19. EXHIBITS</a></td>
    <td style="text-align: center; font-weight: bold">157</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td colspan="2" style="font-weight: bold"><a href="#m_096">Index to Consolidated Financial Statements</a></td>
    <td style="text-align: center; font-weight: bold">F-1</td></tr>
  </table><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context otherwise requires, all references in this Annual Report on Form 20-F, or this Annual Report, to &#8220;InflaRx
N.V.,&#8221; &#8220;InflaRx,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221;
or similar terms refer to InflaRx N.V. and its subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Presentation
of Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
report in Euros under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board,
or the IASB. We made rounding adjustments to some of the figures included in this Annual Report. Accordingly, numerical figures shown
as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Annual Report, unless otherwise indicated, translations from U.S. dollars to Euros (and vice versa) relating to payments made on
or before December 31, 2023, were made at the rate in effect at the time of the relevant payment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms &#8220;$&#8221; or &#8220;dollar&#8221; refer to U.S. dollars, and the terms &#8220;&#8364;&#8221; or &#8220;Euro&#8221; refer to
the currency introduced at the start of the third stage of European economic and monetary union pursuant to the treaty establishing the
European Community, as amended.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry
and Other Data</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained the industry, statistical and market data in this Annual Report from our own internal estimates and research as well as from
industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this Annual
Report involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys
and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important
factors, including those described in the section titled &#8220;ITEM 3. KEY INFORMATION &#8212; C. Risk factors.&#8221; These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademarks</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx<sup>&#174;</sup>,
GOHIBIC<sup>&#174;</sup> and Vilwaysi<sup>&#174;</sup> are our trademarks. The trademarks, trade names and service marks appearing in this
Annual Report are property of their respective owners. Solely for convenience, the trademarks and trade names in this Annual Report are
referred to without the symbols <sup>&#174; </sup>and &#8482;, but such references should not be construed as any indication that their
respective owners will not assert, to the fullest extent under applicable law, their rights thereto.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORWARD-LOOKING
STATEMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking
statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221;
&#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;believe,&#8221;
&#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions
intended to identify statements about the future. These statements speak only as of the date of this Annual Report and involve known
and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. We based these
forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe
may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation,
statements about the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to successfully commercialize and the receptiveness of GOHIBIC (vilobelimab) as a treatment for COVID-19 patients by U.S. hospitals,
our ability to positively influence treatment recommendations by medical/healthcare institutes, guideline bodies and other third-party
organizations;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding the size of the patient populations for, market opportunity for, coverage
                                            and reimbursement for, estimated returns and return accruals for, and clinical utility of
                                            GOHIBIC (vilobelimab) in its approved or authorized indication or for vilobelimab and any
                                            other product candidates, under an Emergency Use Authorization, or the EUA, and in the future
                                            if approved for commercial use in the United States or elsewhere;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to successfully implement The InflaRx Commitment Program, the success of our future
                                            clinical trials for vilobelimab&#8217;s treatment of COVID-19 and other debilitating or life-threatening
                                            inflammatory indications, including pyoderma gangrenosum, and any other product candidates,
                                            including INF904, and whether such clinical results will reflect results seen in previously
                                            conducted pre-clinical studies and clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing, progress and results of preclinical studies and clinical trials of vilobelimab, INF904
                                            and any other product candidates, including for the development of vilobelimab in several
                                            indications, including to treat PG, and statements regarding the timing of initiation and
                                            completion of studies or trials and related preparatory work, the period during which the
                                            results of the trials will become available, the costs of such trials and our research and
                                            development programs generally&#894;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
interactions with and the receptiveness and approval by regulators regarding the results of clinical trials and potential regulatory
approval or authorization pathways including related to our Marketing Authorization Application, or MAA, submission for vilobelimab and
our biologics license application submission, or BLA, for GOHIBIC (vilobelimab); the timing and outcome of any discussions or submission
of filings for regulatory approval or authorization of vilobelimab, INF904 or any other product candidate, and the timing of and our
ability to obtain and maintain full regulatory approval or the EUA, of vilobelimab or GOHIBIC (vilobelimab) for any indication; our ability
to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated autoimmune
and inflammatory diseases;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to protect, maintain and enforce our intellectual property protection for vilobelimab,
                                            INF904 and any other product candidates, and the scope of such protection;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the U.S. Food and Drug Administration, or the FDA, European Medicines Agency, or the EMA,
                                            or any comparable foreign regulatory authority will accept or agree with the number, design,
                                            size, conduct or implementation of our clinical trials, including any proposed primary or
                                            secondary endpoints for such trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of our future clinical trials for vilobelimab, INF904 and any other product candidates
                                            and whether such clinical results will reflect results seen in previously conducted preclinical
                                            studies and clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
expectations regarding the size of the patient populations for, the market opportunity for, the medical need for and clinical utility
of vilobelimab, INF904 or any other product candidates, if approved or authorized for commercial use;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            manufacturing capabilities and strategy, including the scalability and cost of our manufacturing
                                            methods and processes and the optimization of our manufacturing methods and processes, and
                                            our ability to continue to rely on our existing third-party manufacturers and our ability
                                            to engage additional third-party manufacturers for our planned future clinical trials and
                                            for commercial supply of vilobelimab and for the finished product GOHIBIC (vilobelimab);</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs
                                            for or ability to obtain additional financing;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding the scope of any approved indication for vilobelimab;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to defend against liability claims resulting from the testing of our product candidates
                                            in the clinic or, if, approved or authorized, any commercial sales;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            any of our product candidates obtain regulatory approval or authorization, our ability to
                                            comply with and satisfy ongoing drug regulatory obligations and continued regulatory overview;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to comply with enacted and future legislation in seeking marketing approval or authorization
                                            and commercialization;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            future growth and ability to compete, which depends on our retaining key personnel and recruiting
                                            additional qualified personnel; and       </span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            competitive position and the development of and projections relating to our competitors in
                                            the development of C5a and C5aR inhibitors and other therapeutic products being developed
                                            in similar medical conditions in which vilobelimab, INF904 or any other of our product candidates
                                            is being developed or our industry.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some
of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events
and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially
from those projected in the forward-looking statements. You should refer to the &#8220;ITEM 3. KEY INFORMATION: &#8212; 3. Risk factors.&#8221;
section of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those
expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties
may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these
factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Except as required
by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information
we describe in the reports we will file from time to time with the Securities and Exchange Commission, or the SEC, after the date of
this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ENFORCEMENT
OF JUDGMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a public company with limited liability (<i>naamloze vennootschap</i>) incorporated under the laws of the Netherlands and our headquarters
is located in Germany. Substantially all of our assets are located outside the United States. The majority of our executive officers
and directors reside outside the United States. As a result, it may not be possible for investors to effect service of process within
the United States upon such persons or to enforce against them or us in U.S. courts, including judgments predicated upon the civil liability
provisions of the federal securities laws of the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments,
other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United
States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands.
In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the
U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
court will have discretion to attach such weight to the judgment rendered by the relevant U.S. court as it deems appropriate. Under current
practice, the courts of the Netherlands may be expected to render a judgment in accordance with the judgment of the relevant foreign
court, provided that such judgment (i) is a final judgment and has been rendered by a court which has established its jurisdiction vis-&#224;-vis
the relevant Dutch companies or Dutch company, as the case may be, on the basis of internationally accepted grounds of jurisdiction,
(ii) has not been rendered in violation with the principles of proper procedure (<i>behoorlijke rechtspleging</i>), (iii) is not contrary
to the public policy of the Netherlands, and (iv) is not incompatible with (a) a prior judgment of a Dutch court rendered in a dispute
between the same parties, or (b) a prior judgment of a foreign court rendered in a dispute between the same parties, concerning the same
subject matter and based on the same cause of action, provided that such prior judgment is recognizable in the Netherlands. Dutch courts
may deny the recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages
granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. Enforcement
and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Civil Procedure Code.
If no leave to enforce is granted, claimants must litigate the claim again before a Dutch competent court.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dutch
civil procedure differs substantially from U.S. civil procedure in a number of respects. Insofar as the production of evidence is concerned,
U.S. law and the laws of several other jurisdictions based on common law provide for pre-trial discovery, a process by which parties
to the proceedings may prior to trial compel the production of documents by adverse or third parties and the deposition of witnesses.
Evidence obtained in this manner may be decisive in the outcome of any proceeding. No such pre-trial discovery process exists under Dutch
law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and Germany currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, in civil
and commercial matters. Consequently, a final judgment for payment or declaratory judgments given by a court in the United States, whether
or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in Germany. German courts may
deny the recognition and enforcement of a judgment rendered by a U.S. court if they consider the U.S. court not to be competent or the
decision to be in violation of German public policy principles. For example, judgments awarding punitive damages are generally not enforceable
in Germany. A German court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they
are necessary to compensate actual losses or damages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, actions brought in a German court against us, our directors, our senior management and the experts named herein to enforce
liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, German courts generally do not
award punitive damages. Litigation in Germany is also subject to rules of procedure that differ from U.S. rules, including with respect
to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs. German procedural law does not
provide for pre-trial discovery of documents, nor does Germany support pre-trial discovery of documents under the 1970 Hague Evidence
Convention. Proceedings in Germany would have to be conducted in the German language and all documents submitted to the court would,
in principle, have to be translated into German. For these reasons, it may be difficult for a U.S. investor to bring an original action
in a German court predicated upon the civil liability provisions of U.S. federal securities laws against us, our directors, our senior
management and the experts named in this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
I</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_005"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Directors
                                            and senior management</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_006"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Advisers</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_007"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Auditors</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_009"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offer
                                            statistics</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.       </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_010"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Method
                                            and expected timetable</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
3. KEY INFORMATION</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_012"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capitalization
                                            and indebtedness</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_013"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reasons
                                            for the offer and use of proceeds</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 9; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_014"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk
                                            factors</b></span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should carefully consider the risks and uncertainties described below and the other information in this Annual Report before making an
investment in our ordinary shares. Our business, financial condition or results of operations could be materially and adversely affected
if any of these risks occurs, and as a result, the market price of our ordinary shares could decline, and you could lose all or part
of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See &#8220;Forward-Looking
Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements
as a result of certain factors.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
factor summary</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the principal risks that could adversely affect our business, operations and financial results. This summary
does not address all of the risks that we face. For a more complete discussion of the material risks facing our business, see further
below.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our financial position and need for additional capital</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of never achieving or maintaining profitability and of investors losing their entire investment</span> Risk
related to obtaining additional funding and risk of delay, reduction or elimination of product discovery and development programs or
commercialization efforts</td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            related to limited operating history and history of commercializing pharmaceutical products Risk
related to grants funded by the German federal government</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to the discovery, development, manufacturing and commercialization of our product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            related to the discovery, development and commercialization of our product candidates</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            related to our dependence on the success of our product candidates, including our lead product
                                            candidate, vilobelimab</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            related to regulatory oversight over GOHIBIC (vilobelimab) for which we received the EUA,
                                            which may lead to a withdrawal or revocation of the granted the EUA</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            related to possible occurrence of clinical failure at any stage of clinical development</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of failing to maintain compliance with FDA requirements and/or remain in alignment with FDA
                                            feedback, which may prevent or delay the development, marketing or manufacturing of vilobelimab
                                            for the treatment of critically ill COVID-19 patients and, potentially, of vilobelimab in
                                            ulcerative PG</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of incurring additional significant expenses in connection with ongoing regulatory obligations
                                            and continued regulatory review of GOHIBIC (vilobelimab) and any other product candidates
                                            for which we receive approval or the EUA</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of incurring additional costs or experience delays in completing, or ultimately being unable
                                            to complete, the development and commercialization of product candidates, if clinical trials
                                            of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA
                                            and other regulators</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            if our product candidates cause or are perceived to cause undesirable side effects or have
                                            other properties that could delay or prevent their regulatory approval, limit the commercial
                                            profile of an approved label, or result in significant negative consequences following marketing
                                            approval, if any</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our dependence on third parties</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of reliance on third parties to conduct our clinical trials</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of dependence on third-party manufacturers and suppliers and maintaining key manufacturing
                                            relationships</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            related to the process of manufacturing biologics, such as vilobelimab, that is extremely
                                            susceptible to product loss</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            regarding the manufacturing process due to product risk and quality controls</span> Risk
that, if our third-party manufacturers are unable to increase the scale of their production of our product candidates and increase their
product yield, our manufacturing costs may increase and product commercialization may be delayed</td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            that, if we are unable to establish collaborations on commercially reasonable terms, we may
                                            have to alter our development and commercialization plans</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our intellectual property</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            related to our dependence on our ability to obtain, maintain, protect, defend and enforce
                                            patent, trade secret and other intellectual property protection</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            related to our patents covering our proprietary anti-C5a and anti C5aR technologies that
                                            may be subject to challenge, narrowing, circumvention and invalidation by third parties</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            related to uncertainty that we were the first to make the anti-C5a and anti-C5aR technologies
                                            claimed in our patents or patent applications or that we were the first to file for patent
                                            protection</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            related to patent application process and obtaining patents for which we have applied</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to employee matters and managing growth</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of having a limited number of employees to manage and operate our business</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of depending heavily on certain of our executive officers and directors</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of disruption to our business as a result of managing growth in business operations and number
                                            of personnel</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of liability to our business by improper activities of our employees and third-party contractors</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
related to our ordinary shares and our status as a public company</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            rated to the trading price of our ordinary shares, that has been and may in the future be
                                            highly volatile</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            associated with being a foreign private issuer and not being subject to U.S. proxy rules,
                                            following home country governance practices rather than the Nasdaq listing requirements</span> </td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
                                                                                                                                                     <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
related to us not anticipating paying any cash dividends on our share capital in the foreseeable future</span></td></tr>
                                                                                                                                                     </table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
risk factors</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of business impact resulting out of financial markets, changes to political and regulatory
                                            policies and economic conditions generally</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of legal, regulatory or market measures to address environmental objectives</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            of dilution to shareholders through raising capital, risk of restriction and/or relinquishment
                                            to rights to technologies and product candidates</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of facing substantial competition</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
                                            of product liability lawsuits</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
                                            of damage and disruption to our business through cyber-attacks and failure of telecommunication
                                            and information technology equipment</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
related to our financial position and need for additional capital</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may
never achieve or maintain profitability and investors may lose their entire investment</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred net losses of &#8364;42.7 million, &#8364;29.5&#160;million and &#8364;45.6&#160;million for the years ended December 31, 2023,
2022 and 2021, respectively. In addition, our accumulated deficit as of December 31, 2023, was &#8364;286.1&#160;million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our net losses to increase as we advance vilobelimab and other product candidates into additional clinical trials, as well as
larger and later-stage clinical trials. Further, we expect our net losses to increase as we advance the implementation of commercialization
of GOHIBIC (vilobelimab) in the United States under the EUA while investing in start-up commercialization and marketing activities. To
date, we have not commercialized any products other than for GOHIBIC (vilobelimab) for the treatment of severe COVID-19 or generated
any meaningful revenues from the sale of products other than limited initial sales of GOHIBIC (vilobelimab) and absent the realization
of sufficient revenues from product sales, we may never attain profitability. We have devoted substantially all of our financial resources
and efforts to research and development, including preclinical studies, clinical trials and manufacturing development. Our net losses
may fluctuate significantly from quarter to quarter and year to year. Net losses and negative cash flows have had, and will continue
to have, an adverse effect on our shareholders&#8217; equity and working capital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our expenses might increase if and as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            to develop and conduct clinical trials with respect to our lead product candidate, vilobelimab;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
                                            research, preclinical and clinical development efforts for any future product candidates,
                                            including IFX002 and INF904;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actively
                                            seek to identify additional research programs and additional product candidates;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
                                            regulatory and marketing approvals for our product candidates that successfully complete
                                            clinical trials, if any;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            sales, marketing, distribution and other commercial infrastructure now and in the future
                                            to commercialize various products for which we may obtain marketing authorization or approval,
                                            if any;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            the scale-up and validation of the manufacturing process and the manufacturing of larger
                                            quantities of product candidates for clinical development and, potentially, commercialization;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborate
                                            with strategic partners to optimize the manufacturing process for vilobelimab, IFX002, INF904
                                            and other pipeline products;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
                                            expand and protect our intellectual property portfolio;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            and retain additional personnel, such as commercial, marketing, clinical, quality control
                                            and scientific personnel; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
                                            operational, financial and management information systems and personnel, including personnel
                                            to support our product development as well as commercialization and help us comply with our
                                            obligations as a public company.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue
unless and until we are, or any future collaborator is, able to obtain marketing authorization or approval for, and successfully commercialize,
one or more of our product candidates. Successful commercialization will require achievement of key milestones, including completing
clinical trials of vilobelimab and any other product candidates, obtaining marketing authorization or approval for these product candidates,
manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain marketing authorization
or approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government
payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount
of revenues, and if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and,
even if we do, or any future collaborators do, we may never generate revenue that is large enough for us to achieve profitability. Even
if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety
of factors, many of which are beyond our control. In order to succeed, we will need to transition from a company with a research and
development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications
and delays, and may not be successful in such a transition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to become and remain profitable could depress the market price of our ordinary shares and could impair our ability to raise capital,
pay dividends, expand our business, diversify our product offerings or continue our operations. If we continue to suffer losses as we
have in the past, investors may not receive any return on their investment and may lose their entire investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or discontinue
our product discovery and development programs or commercialization efforts</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain
process that takes years to complete. For example, for the years ended December 31, 2023 and December 31, 2022, we used &#8364;37.8 million
and &#8364;33.7 million, respectively, in net cash for our operating activities, most of which were related to research and development
activities. We expect our expenses to increase in connection with our ongoing activities, particularly as we initiate new clinical trials
of, initiate new research and preclinical development efforts for, establish robust manufacturing processes for, establish comprehensive
commercialization and marketing processes and seek marketing authorization or approval for, our current product candidates or any future
product candidates, including those that we may acquire. In particular, we will incur significant expenses as we conduct our planned
clinical trial program and initiate new research and preclinical development efforts. In addition, after obtaining the EUA for GOHIBIC
(vilobelimab) in the United States and if we obtain marketing approval for any of our product candidates, we may incur significant commercialization
expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing
and distribution are not the responsibility of a future collaborator. Furthermore, we expect to incur significant additional costs associated
with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing
operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce or eliminate our
research and development programs or any future commercialization efforts.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to use our cash on hand primarily to fund our planned clinical trial programs, to initiate new research and preclinical development
efforts, to establish commercial scale manufacturing processes and for working capital and other general corporate purposes. We will
be required to expend significant funds in order to advance the development of vilobelimab in later stages of clinical development, as
well as other product candidates we may seek to develop, including IFX002 and INF904. We are also evaluating vilobelimab for a number
of additional indications. Any future development activities for our pipeline product candidates will depend heavily on the clinical
as well as commercialization and marketing success of vilobelimab in any indication.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing cash and cash equivalents will not be sufficient to fund all the efforts that we plan to undertake or to fund the completion
of development of any of our product candidates. Accordingly, we will be required to obtain further funding through public or private
equity offerings, debt financings, royalty-based financings, collaborations and licensing arrangements or other sources. Currently, we
do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or
at all. If we are unable to raise additional capital in sufficient amounts and on terms acceptable to us, we may have to significantly
delay, scale back or discontinue the development or commercialization of vilobelimab or any of our other product candidates or potentially
discontinue operations altogether. Our failure to raise capital as and when needed could have a negative impact on our financial condition
and our ability to pursue our business strategy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital
expenditure requirements under our current business plan for at least the next 24 months. Changing circumstances, some of which may be
beyond our control, could cause us to consume capital significantly faster than we anticipate, and we may need to seek additional funds
sooner than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope, progress, timing, costs and results of clinical trials of, and research and preclinical
                                            development efforts for, our current and future product candidates, particularly for vilobelimab;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of future product candidates and indications that we pursue and their development
                                            requirements;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            outcome, timing and costs of seeking regulatory approvals;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of preparation for and implementation of commercialization and commercialization activities
                                            for any of our product candidates that receive marketing authorization approval to the extent
                                            such costs are not the responsibility of any future collaborators, including the costs and
                                            timing of establishing product sales, marketing, distribution and commercial-scale manufacturing
                                            capabilities;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            effect of competing technological and market developments;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
                                            to receipt of marketing authorization or approval, revenue, if any, received from commercial
                                            sales of our current and future product candidates;</span></td></tr></table><div>

</div><p style="text-indent: 0pt; margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to enter into, and the terms and timing of, any collaborations, licensing or other arrangements;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            headcount growth and associated costs as we expand our research, development, manufacturing,
                                            regulatory and commercial activities;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of preparing, filing and prosecuting patent applications, maintaining and protecting
                                            our intellectual property rights including enforcing and defending intellectual property
                                            related claims; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            costs of operating as a public company.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
have a limited operating history and history of commercializing pharmaceutical products, which may make it difficult to evaluate the
prospects for our future viability</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
commenced operations in 2008. Our operations to date have been limited to establishing our Company, raising capital, developing our proprietary
anti-C5a and anti-C5aR technologies, identifying and testing potential product candidates and conducting clinical trials of our lead
product candidate, vilobelimab and establishing a commercial scale manufacturing process for vilobelimab. In April 2023, we received
the EUA for vilobelimab for the treatment of certain critically ill COVID-19 patients by the FDA. We have just started to arrange for
third parties to manufacture and distribute our product at small commercial scale on our behalf. However, we have not yet demonstrated
an ability to obtain full marketing approvals or conduct sales and marketing activities at large scale as necessary for successful product
commercialization. Also, we are still in early stages of clinical development with our other product candidates. Accordingly, you should
consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early
stages of development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future
success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing
and commercializing pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives.
We will eventually need to transition from a company with a predominant development focus to a company capable of supporting commercial
activities. We may not be successful in such a transition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year
due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly
or annual periods as indications of future operating performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be subject to risks in relation to financial grants received by the German federal government, which may result in the partial repayment
of such grants</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical Phase III study of vilobelimab in critically ill COVID-19 patients and certain manufacturing development related activities
of our product candidate vilobelimab were partly funded by the German federal government through a grant awarded to us in October 2021.
The grant was structured as a reimbursement of 80% of certain pre-specified expenses related to the clinical development and manufacturing
of vilobelimab. The grant period ended on June 30, 2023, as planned. In total, throughout the duration of the grant period and up to
the date hereof, we received a total amount of &#8364;33.3&#160;million. We might be subject to future audits by financial oversight authorities
of the German federal government or European regulatory bodies and a failure to pass these audits in case the authorities identify non-adherence
to all grant conditions could potentially lead to a retroactive revocation of parts of the funds awarded by the grant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the German federal government has, in the case of a special public interest, a non-exclusive and transferable right to use
intellectual property generated as part of the funded work. Contracts with third parties relating to the exploitation of the results
of the funded work must be disclosed to the agency managing the grant on behalf of the German federal government and any such contracts
with parties outside of the European Union require the prior consent of the German federal government to the extent they deviate from
a commercial exploitation plan previously approved by the German federal government. Additionally, we may be required to grant third
parties licenses to use such results under certain conditions. In certain scenarios, including if we come under the decisive influence
of foreign investors, the funded results are exclusively or predominantly used outside Germany without the prior consent of the German
federal government or if we are in breach of our obligations under the grant, the grant funding, including funding already received,
can be revoked.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exchange
rate fluctuations may materially affect our results of operations and financial condition</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential
future expense and revenue may be incurred or derived from outside the European Union, particularly the United States. As a result, our
business and our share price may be affected by fluctuations in foreign exchange rates between the euro and other currencies, particularly
the U.S. dollar, which may also have a significant impact on our reported results of operations and cash flows from period to period.
We currently do not have any exchange rate hedging arrangements in place.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may face the risk of substantial write-downs of inventory due to the excess or obsolescence of our inventory relating to GOHIBIC (vilobelimab)
due to expiration prior to sale or unsuitability for alternative use </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excess
purchase of raw materials and production of products or the commitments to purchase or produce such items may result in high inventory
levels that might not be commercially viable and could lead to the necessity to partially or fully write-down these items. Excess and
obsolescence risks for our inventory could arise from factors such as shelf-life expiration, overstocking, or events like supply chain
disruptions, manufacturing mistakes, raw material flaws which can result in errors, wastage, or delays and more. Whether such obsolescence
risks materialize, ultimately depends on market demand/penetration and medical need for our products, regulatory factors such as approvals
or approval withdrawals by regulatory agencies in the territories in which we intend to commercialize our product, the competitive landscape
of the markets in which we operate, including the development of comparable products by our competitors as well as our ability to command
prices at which we can be competitive and our own plans regarding alternative use of unfinished or finished products in our inventory
for alternative purposes, such as clinical trials in additional indications. Furthermore, changes in currency exchange rates can impact
the cost of imported goods and affect inventory valuations. In valuing our inventory, we make assumptions regarding these factors and
update these assumptions when applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.
Risks related to the discovery, development, manufacturing and commercialization of our product candidates</i></b></span></p><div>



</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are at a clinical development stage in our development efforts, our approach of targeting C5a or C5aR inhibition is novel and we may
not be able to successfully develop and commercialize any product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vilobelimab
is a novel therapeutic antibody and its potential therapeutic benefit is unproven, and C5a or C5aR inhibition to treat complement-mediated
autoimmune and inflammatory diseases has only been partly validated. We have not yet succeeded and may never succeed in demonstrating
efficacy and safety for vilobelimab in pivotal clinical trials or in obtaining marketing approval thereafter for severe COVID-19 or any
other indication. The aforementioned continues to be true, although GOHIBIC(vilobelimab) has been granted the EUA by the FDA for the
treatment of coronavirus disease 19, or COVID-19, in hospitalized adults when initiated within 48 hours of receiving invasive mechanical
ventilation, or IMV, or extracorporeal membrane oxygenation ECMO.&#160;If we are unsuccessful in our development efforts, we may not
be able to advance the development of our product candidates, commercialize products, raise capital, expand our business, or continue
our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
depend on the success of our product candidates, including our lead product candidate, vilobelimab, and if we are unable to obtain approval
for and commercialize our product candidates for one or more indications in a timely manner, our business will be materially harmed</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to timely complete clinical trials and obtain marketing authorization or approval for, and then successfully
commercialize, our product candidates, including our lead product candidate, vilobelimab, for one or more indications. Our product candidates
will require additional clinical development, preclinical and manufacturing development activities, marketing approval from government
regulators, commercial manufacturing, substantial investment, and significant marketing efforts before we generate any revenue from product
sales. We are not permitted to market or promote any product candidates in a jurisdiction before receiving marketing authorization or
approval from the relevant regulatory authority, including the FDA for marketing in the United States and EMA for marketing in Europe,
and we may never receive such marketing approvals or marketing authorizations beyond the EUA for GOHIBIC (vilobelimab) granted by the
FDA in April 2023.&#160;The success of our product candidates will depend on numerous factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raising
                                            additional funds, or entering into collaborations, necessary to complete the clinical development
                                            of and to commercialize of our product candidates;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            and timely completion of our ongoing clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
                                            of successful patient enrollment and completion of additional clinical trials on a timely
                                            basis;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy,
                                            safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable
                                            foreign regulatory authority for marketing approval;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timely
                                            receipt of marketing authorizations or approvals for our product candidates from applicable
                                            regulatory authorities;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            maintenance of existing, or the establishment of new, supply arrangements with third-party
                                            drug product suppliers and manufacturers;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            maintenance of existing, or the establishment of new, scaled production arrangements with
                                            third-party manufacturers to obtain finished products that are appropriately packaged for
                                            sale;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            and maintaining patent protection, trade secret protection and regulatory exclusivity, in
                                            the United States and elsewhere;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">protection
                                            of our rights in our intellectual property portfolio, including our licensed intellectual
                                            property;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
                                            launch of commercial sales following any marketing authorization or approval;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            continued acceptable safety profile following any marketing authorization or approval;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commercial
                                            acceptance by patients, the medical community and third-party payors;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inclusion
                                            of approved or, such as GOHIBIC (vilobelimab), authorized products in guidelines by medical
                                            bodies, including but not limited to National Institute of Health, or NIH, guidelines;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inclusion
                                            of approved or, such as GOHIBIC (vilobelimab), authorized products on hospitals formulary;
                                            and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to compete with other therapies.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       Additionally,
we cannot be sure that we can obtain necessary regulatory authorizations or approvals on a timely basis, if at all, for any of the products
we are developing or manufacturing or that we can maintain necessary regulatory authorizations or approvals for our existing products,
and all of the following could have a material adverse effect on our business:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
                                            delays in obtaining or failing to obtain required authorizations approvals;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
                                            of, or changes to, previously obtained authorizations or approvals;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to comply with existing or future regulatory requirements and;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            to manufacturing processes or manufacturing process standards following authorization or
                                            approval, or changing interpretations of these factors.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of such factors remain outside of our control, and if we are unable to achieve one or more of the objectives set forth above, our business
will be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GOHIBIC
(vilobelimab) for which we received the EUA is subject to continuing regulatory oversight, which might lead to a withdrawal or
revocation of the granted EUA, if the FDA considers the underlying requirements or conditions for the EUA not to be given anymore.
We may incur significant losses including loss of reputation, if we the EUA for GOHIBIC (vilobelimab) is withdrawn or revoked by the
FDA.</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOHIBIC
(vilobelimab) for which we received the EUA for the treatment of COVID-19 in certain hospitalized adult patients, pursuant to Section
564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. &#167;360bbb-3) is subject to continuing regulatory oversight, including
the determination and verification of underlying requirements such as a public health emergency, or a significant potential for a public
health emergency, that affects, or has a significant potential to affect, national security or the health and security of United States
citizens living abroad, and that involves the virus that causes COVID-19. The granted EUA will be effective until the declaration that
circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic is
terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act. If the conditions or requirements
for granting the EUA cease to be apparent in the future, or if reported drug safety events lead to a new situation in determining the
overall pharmacovigilance of vilobelimab, the FDA may suspend, withdraw or revoke the granted EUA. Any of these events could have a material
adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
failure may occur at any stage of clinical development, and the results of our clinical trials may not support our proposed indications
for our product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Success
in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure
that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. Moreover, success
in clinical trials in a particular indication does not ensure that a product candidate will be successful in other indications, even
for the same underlying disease. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered
significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical trials or successful
later-stage trials in other related indications, including in the context of controlling complement activation through C5 and C5a or
C5aR inhibition. For example, while others in our industry have attempted to develop C5a-specific antibodies, there is no approved therapy
inhibiting C5a. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway
and safety or efficacy observations made in clinical trials, including previously unreported adverse events as well as lack of efficacy
and patient benefit as reported by clinical trial investigators. In particular, development of antibodies that target C5a rather than
C5 to control complement activation is comparatively novel, and there is no approved therapy specifically targeting C5a. As a result,
inhibition of C5a rather than C5, which blocks signaling to the two receptors C5aR and C5L2, may have unforeseen consequences or negative
results that may lead to clinical failure or withdrawal in later stages of our product candidate development. Product candidates in later
stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical and initial
clinical trials for a variety of reasons, including differences in patient populations, changes in trial protocols and complexities of
larger, multi-center trials among others. We may fail to complete clinical trials and/or to meet predetermined endpoints in the clinical
trials, which may cause us to abandon a product candidate or an indication and may delay development of any other product candidates.
Any delay in, or termination of, our clinical trials will delay the submission of the Biologics License Application, or BLA, or the EUA
to the FDA, the MAA to the EMA or other similar applications with other relevant foreign regulatory authorities and, ultimately, our
ability to commercialize any of our product candidates and generate revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failure
to maintain compliance with FDA requirements and/or remain in alignment with FDA feedback may prevent or delay the development, marketing
or manufacturing of vilobelimab for the treatment of critically ill COVID-19 patients and, potentially, of vilobelimab in ulcerative
PG</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">       Our
manufacturing and laboratory facilities are periodically subject to inspection by the FDA and other governmental agencies to ensure they
meet production and quality requirements. Operations at these facilities could be interrupted or halted if the FDA or another governmental
agency deems the findings of such inspections unsatisfactory. Further, failure to comply with FDA or other regulatory requirements regarding
the development, marketing, promotion, manufacturing and distribution of vilobelimab could result in fines, unanticipated compliance
expenditures, recall or seizures of our products, total or partial suspension of production or distribution, restrictions on labeling
and promotion, termination of ongoing research, disqualification of data for submission to regulatory authorities, enforcement actions,
injunctions and criminal prosecution. If we do not meet applicable regulatory or quality standards, our products may be subject to recall,
and under certain circumstances, we may be required to notify applicable regulatory authorities about a recall.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GOHIBIC
(vilobelimab) and any other product candidates for which we receive approval or the EUA are subject to continuing regulatory oversight,
and we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional
expense. We may be subject to penalties if we fail to comply with regulatory requirements.</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOHIBIC
(vilobelimab) and any other product candidates for which we received or might receive approval or the EUA are subject to continuing regulatory
oversight, including the review of promotional materials and additional safety information, and the applicable regulatory authority may
still impose significant restrictions on the indicated uses or marketing of our product or impose ongoing requirements for potentially
costly post-approval studies or post-market surveillance. Advertising and promotional materials must comply with FDA rules and are subject
to FDA review, in addition to other potentially applicable federal and state laws. In other countries, advertising and promotional material
may be subject to similar rules. If we fail to comply with applicable regulatory requirements following authorization or approval of
any of our product candidates, a regulatory agency may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
a warning letter asserting that we are in violation of the law;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
an injunction or impose civil or criminal penalties or monetary fines;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
or withdraw the granted EUA or regulatory approval or revoke a license;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
any ongoing clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
product; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
to allow us to enter into supply contracts, including government contracts.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any authorized
or approved products and generate revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of any products we may identify and develop and could
have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we,
or any future collaborators, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the
development and commercialization of these product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
and any future collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States
without obtaining marketing approval or the EUA from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements
in their respective markets. We, and any future collaborators, must complete extensive preclinical development and clinical trials to
demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product development. It
is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical
evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis
of our clinical trials. In addition, many of our product candidates are in early stages of development or clinical testing. As a result,
it may be years before any of our product candidates receives regulatory approval, if at all, and additional clinical trials may fail
to demonstrate safety, efficacy or tolerability for our targeted indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
inability to successfully complete preclinical and clinical development could result in additional costs to us or any future collaborators
and impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties. Moreover, if
we or any future collaborators are required to conduct additional clinical trials or other testing of our product candidates beyond the
trials and testing that we or they contemplate, if we or they are unable to successfully complete clinical trials of our product candidates
or other testing or the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or there are unacceptable
safety concerns associated with our product candidates, we or any future collaborators may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
                                            additional unplanned costs, including costs relating to additional required clinical trials
                                            or preclinical testing;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            delayed in obtaining marketing approval for vilobelimab or any of our other product candidates;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            obtain marketing approval at all or the withdrawal or revocation of the EUA by the FDA;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval with labeling that includes significant use or distribution restrictions or significant
                                            safety warnings, including boxed warnings;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            subject to additional post-marketing testing or other requirements; or</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            required to remove the product from the market after obtaining marketing approval or the
                                            EUA.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain
regulatory approval to market any of our product candidates would significantly harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
product candidates may cause or be perceived to cause undesirable side effects or have other properties that could delay or prevent their
regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing
approval, if any</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and
could result in a more restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA or comparable foreign regulatory
authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected
characteristics. In addition, many of the patients that we enrolled in our clinical trials of vilobelimab suffer from serious pre-existing
disorders. While such disorders may lead to serious adverse events, or SAEs, during trial periods that may be found to be unrelated to
vilobelimab, such events may create a negative safety perception and adversely impact market acceptance of vilobelimab following any
approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
unacceptable side effects arise in the development of our product candidates, we, the FDA or comparable foreign regulatory authorities,
the Institutional Review Boards, or IRBs, or independent ethics committees at the institutions in which our studies are conducted or
elsewhere, or the Data Safety Monitoring Board, or DSMB, could suspend or terminate our clinical trials or the FDA or comparable foreign
regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications.
Side effects, whether treatment-related or not, could also affect patient recruitment or the ability of enrolled patients to complete
the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed
by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect
profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing
or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may
harm our business, financial condition and prospects significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive
effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable
side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously
believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities may withdraw their authorization or approval of the product or seize the product;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
                                            or any future collaborators, may need to recall the product, or be required to change the
                                            way the product is administered or conduct additional clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
                                            restrictions may be imposed on the marketing of, or the manufacturing processes for, the
                                            particular product;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            authorities may require the addition of labeling statements, such as a &#8220;black box&#8221;
                                            warning or a contraindication;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
                                            or any future collaborators, may be required to create a Medication Guide outlining the risks
                                            of the previously unidentified side effects for distribution to patients;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
                                            or any future collaborators, may be required to implement a REMS that imposes distribution
                                            and use restrictions or to conduct post-market studies or clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
                                            or any future collaborators, could be sued and held liable for harm caused to patients;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            product may become less competitive; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            reputation may suffer.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could harm our business and operations and could negatively impact our share price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
most advanced product candidates are either chimeric or humanized antibody proteins that could cause an immune response in patients,
resulting in the creation of harmful or neutralizing antibodies against these therapeutic proteins</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the safety, efficacy, manufacturing and regulatory hurdles faced by our product candidates, the administration of proteins
such as monoclonal antibodies that are chimeric or humanized, including our product candidates vilobelimab and IFX002, respectively,
can cause an immune response, resulting in the creation of antibodies against the therapeutic protein. These anti-drug antibodies, or
ADAs, can have no effect or can neutralize the effectiveness of the protein or require that higher doses be used to obtain a therapeutic
effect. Whether ADAs will be created and how they react can often not be predicted from preclinical or even clinical studies, and their
detection or appearance is often delayed. As a result, neutralizing antibodies may be detected at a later date or upon longer exposure
of patients with our product candidates, such as following more chronic administration in longer lasting clinical trials. In some cases,
detection of such neutralizing antibodies can even occur after pivotal clinical trials have been completed. Therefore, there can be no
assurance that neutralizing antibodies will not be detected in future clinical trials or at a later date upon longer exposure (including
after commercialization). If ADAs reduce or neutralize the effectiveness of our product candidates, the continued clinical development
or receipt of marketing approval for any of our product candidates could be delayed or prevented and, even if any of our product candidates
is approved, their commercial success could be limited, any of which would impair our ability to generate revenue and continue operations.
Low levels of ADAs were detected in previously completed clinical studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we complete the necessary preclinical studies and clinical trials for vilobelimab and any other product candidates, the marketing
approval process including the EUA process is expensive, time consuming and uncertain and may prevent us or any future collaborators
from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if,
and in which territories, we, or any future collaborators, will obtain marketing authorization or approval to commercialize a product
candidate</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive
regulation by the FDA and comparable foreign regulatory authorities. We, and any future collaborators, are not permitted to market our
product candidates in the United States or in other countries until we, or they, receive approval of a BLA or the EUA from the FDA or
marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of
development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received
marketing approval for any product candidate in the United States or in any other jurisdiction. We have limited experience in conducting
and managing the clinical trials necessary to obtain marketing approvals, including FDA approval of a BLA or EUA. Further, there is no
prior history of regulatory approval for product candidates targeting C5a inhibition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining marketing authorizations or approvals, both in the United States and elsewhere is lengthy, expensive and uncertain.
It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type,
complexity and novelty of the product candidates involved. Securing marketing approval, including the EUA, requires the submission of
extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish
the product candidate&#8217;s safety and efficacy. Securing marketing approval, including the EUA, also requires the submission of information
about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA or other
regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable
or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial
use. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during
the course of a drug candidate&#8217;s clinical development and may vary among jurisdictions. Any marketing approval, including the EUA,
we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially
viable. For example, the EUA for the GOHIBIC (vilobelimab) has been granted for the treatment of COVID-19 in hospitalized adults when
initiated within 48 hours of receiving IMV or ECMO. The FDA, EMA or any comparable foreign regulatory authorities may delay, limit or
deny approval of vilobelimab for many reasons, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to demonstrate that vilobelimab is safe and effective as a treatment for
                                            our targeted indications to the satisfaction of the FDA, the EMA or comparable foreign regulatory
                                            agencies;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may require additional clinical trials
                                            or non-clinical studies of vilobelimab in addition to those already performed or planned,
                                            either before approval or as a post-approval commitment, which would increase our costs and
                                            prolong our development time for vilobelimab;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of our clinical trials may not meet the level of statistical or clinical significance
                                            required by the FDA, EMA or comparable foreign regulatory authorities to obtain marketing
                                            approval;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may disagree with the number, design,
                                            size, conduct or implementation of our clinical trials, including designated clinical endpoints;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            population studied in the clinical program may not be sufficiently broad or representative
                                            to assure safety in the full population for which we seek approval;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            contract research organizations, or CROs, that we retain to conduct clinical trials may take
                                            actions outside of our control that materially adversely impact our clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may not find the data from preclinical
                                            studies and clinical trials sufficient to demonstrate that the clinical and other benefits
                                            of vilobelimab and any other product candidates outweigh its safety risks;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation
                                            of data from preclinical studies and clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may not accept data generated at clinical
                                            trial sites, including for non-compliance with cGCP;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            our BLA, when submitted, is reviewed by an advisory committee, the FDA may have difficulties
                                            scheduling an advisory committee meeting in a timely manner or the advisory committee may
                                            recommend against approval of our application or may recommend that the FDA require, as a
                                            condition of approval, additional preclinical studies or clinical trials, limitations on
                                            approved labeling or distribution and use restrictions;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may require development of a risk evaluation
                                            and mitigation strategy, or REMS, as a condition of approval;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may identify deficiencies in the manufacturing
                                            processes or facilities of our third-party manufacturers, including non-compliance with current
                                            Good Manufacturing Practices, or cGMP; or</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA, EMA or comparable foreign regulatory authorities may change their respective approval
                                            policies or adopt new regulations.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the large number of drugs in development in the biopharmaceutical industry, only a small percentage result in the submission of a BLA
to the FDA and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market vilobelimab,
any such approval may be subject to limitations on the indicated uses or patient populations for which we may market the product. Accordingly,
even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot assure you that vilobelimab
and/or any other product candidates will be successfully developed or commercialized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation
in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or
other regulatory authorities. The FDA or other regulatory authorities may conclude that a principal investigator, potentially including
because of a financial relationship with us, has a conflict of interest that has affected interpretation of the study. The FDA or other
regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility
of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications
by the FDA or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing authorization or approval
of one or more of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay in obtaining or failure to obtain required approvals could negatively impact our ability or that of any future collaborators to
generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely
impact our share price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
depend on enrollment of patients in our clinical studies for our product candidates. If we encounter difficulties enrolling patients
in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will also be required to identify and enroll a sufficient number of patients with PG, and potentially other indications, for our planned
or ongoing clinical trial of vilobelimab in these indications. Some of these are rare disease indications or indication with a relatively
small patient population. Trial participant enrollment could be limited in future trials given that many potential participants may be
ineligible because they are already undergoing treatment with approved medications or are participating in other clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
enrollment is affected by other factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">severity
                                            of the disease under investigation;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">design
                                            of the clinical trial protocol;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">size
                                            and nature of the patient population;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eligibility
                                            criteria for the trial in question;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
                                            risks and benefits of the product candidate under trial;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceived
                                            safety and tolerability of the product candidate;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">proximity
                                            and availability of clinical trial sites for prospective patients;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
                                            of competing therapies and clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217;
                                            and patients&#8217; perceptions as to the potential advantages of the drug being studied
                                            in relation to other available therapies, including standard-of-care and any new drugs that
                                            may be approved for the indications we are investigating;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efforts
                                            to facilitate timely enrollment in clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
                                            referral practices of physicians; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to monitor patients adequately during and after treatment.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there are only a limited number of specialist physicians who treat patients with these diseases and major clinical centers are concentrated
in a few geographic regions. We also may encounter difficulties in identifying and enrolling such patients with a stage of disease appropriate
for our ongoing or future clinical trials. In addition, the process of finding and diagnosing patients may prove costly. Our inability
to enroll a sufficient number of patients for any of our clinical trials, if any, would result in significant delays or may require us
to abandon one or more clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced slower recruitment than anticipated in the clinical trials of vilobelimab in severe COVID-19, PG and cSCC, because of
other compounds in clinical development for the same patient population, low disease prevalence, difficulties in diagnosis or due to
restrictions at clinical trial sites in light of the COVID-19 pandemic. Further delays in the completion of any clinical trials will
increase our costs, slow down our product candidate development and delay or potentially jeopardize our ability to commence marketing
and generate revenue. In addition, we may not be able to initiate or continue clinical trials required by the FDA, EMA or other foreign
regulatory agencies for vilobelimab or any of our other product candidates that we pursue if we are unable to locate and enroll a sufficient
number of eligible patients to participate in these clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if one of our product candidates receives marketing approval, including the EUA, it may fail to achieve the degree of market acceptance
by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may
not generate significant revenues or become profitable</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our other product candidates are approved by the appropriate regulatory authorities for marketing and sale or receives the EUA, they
may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.
As a general proposition, physicians are often reluctant to switch their patients from existing therapies, such as for the treatment
of cSCC, even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to
existing therapies and do not want to switch therapies unless their physicians recommend doing so or they are required to do so due to
lack of reimbursement for existing therapies. Further, we may face a lack of acceptance by the physician community of the efficacy of
targeting C5a to inhibit terminal complement activation compared to targeting C5, which is well established in clinical practice (such
as eculizumab). In addition, vilobelimab may not be accepted by physicians or patients if we cannot demonstrate, or if vilobelimab is
perceived as not having, strong duration of effect, including compared to existing treatments. The duration of effect of vilobelimab
has only been studied prospectively for durations less than the expected duration of any pivotal Phase III clinical trials. It is possible
that the effects seen in shorter term clinical trials will not be replicated at later time points or in larger clinical trials. Further,
even if we are able to demonstrate our product candidates&#8217; safety and efficacy to the FDA and other regulators, safety concerns
in the medical community may hinder market acceptance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources,
including management time and financial resources, and may not be successful. If any of our product candidates is approved but does not
achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree
of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            efficacy and safety of the product;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential advantages of the product compared to competitive therapies, notwithstanding success
                                            in meeting or exceeding clinical trial endpoints;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            the product is designated under physician treatment guidelines as a first-, second- or third-line
                                            therapy;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability, or the ability of any future collaborators, to offer the product for sale at competitive
                                            prices;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            product&#8217;s convenience and ease of administration compared to alternative treatments;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of the target patient population to try, and of physicians to prescribe, the
                                            product;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            or warnings, including distribution or use restrictions contained in the product&#8217;s
                                            approved labeling;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            strength of sales, marketing and distribution support;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the standard of care for the targeted indications for the product; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
                                            and amount of coverage and reimbursement from government payors, managed care plans and other
                                            third-party payors.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure of any of our product candidates, if authorized or approved, to find market acceptance would harm our business and could require
us to seek additional financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we, or any future collaborators, are able to commercialize any product candidate that we, or they, develop, the product may become
subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, any of which could harm our business</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Therefore, our ability, and the ability of any future collaborators, to commercialize any of our product candidates
will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from
third-party payors including government health administration authorities and public or private health coverage insurers. Third-party
payors decide which medications they will cover and establish reimbursement levels. We cannot be certain that reimbursement will be available
for vilobelimab or any of our product candidates. Also, we cannot be certain that less fulsome reimbursement policies will not reduce
the demand for, or the price we can charge for, our products, if approved. The insurance coverage and reimbursement status of newly approved
products for orphan diseases is particularly uncertain and failure to obtain or maintain adequate coverage and reimbursement for vilobelimab
or any other product candidates could limit our ability to generate revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
coverage and reimbursement are not available, or reimbursement is available only to limited levels, we, or any future collaborators,
may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount
may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient
return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party
payors and coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination
process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our
products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained
in the first instance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing
and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sales price of a
drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is
granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial
approval is granted. As a result, we, or any future collaborators, might obtain marketing approval for a product in a particular country,
but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively
impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our
ability or the ability of any future collaborators to recoup our or their investment in one or more product candidates, even if our product
candidates obtain marketing approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other
third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which
could affect our ability or that of any future collaborators to sell our product candidates profitably. These payors may not view our
products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any future collaborators,
or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives or other policy
measures by government authorities could cause us, or any future collaborators, to decrease the price we, or they, might establish for
products, which could result in lower than anticipated product revenues. If the prices for our products, if any, decrease or if governmental
and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may also be delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the indications
for which the drug is authorized or approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for reimbursement
does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sale and distribution. Reimbursement rates may vary, by way of example, according to the use of the product and the clinical setting
in which it is used. Reimbursement rates may also be based on reimbursement levels already set for lower cost drugs or may be incorporated
into existing payments for other services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies
and are challenging the prices charged. We cannot be sure that reimbursement coverage will be available for any product candidate that
we, or any future collaborator, commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement
for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from
countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment
rates from both government-funded and private payors for any of our product candidates for which we, or any future collaborator, obtain
marketing authorization or approval could significantly harm our operating results, our ability to raise capital needed to commercialize
products and our overall financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are unable to develop our sales, marketing and distribution capability on our own or through collaborations with marketing partners,
we will not be successful in commercializing our product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited marketing, sales or distribution capabilities and experience within our organization. If any of our product candidates is
authorized or approved, we either have to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize any such candidate, or to outsource this function to a third party. These activities were initiated in
2023 regarding the FDA&#8217;s EUA for GOHIBIC (vilobelimab) in the United States. Either of these options would be expensive and time
consuming. Some or all of these costs may be incurred in advance of any approval of our product candidates, including our lead candidate
vilobelimab. In addition, we may not be able to hire a sales force in the United States, Europe or other target market that is sufficient
in size or has adequate expertise in the medical markets that we intend to target. These risks may be particularly pronounced due to
our focus on severe COVID-19, as well as additional focus on PG, each of which are disease areas with relatively small patient populations.
Any failure or delay in the development of our or third parties&#8217; internal sales, marketing and distribution capabilities would
adversely impact the commercialization of vilobelimab and other future product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces
and established distribution systems, either to augment or to serve as an alternative to our own sales force and distribution systems.
Our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will
depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control.
If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any
authorized or approved products. If we are not successful in commercializing any authorized or approved products, our future product
revenue will suffer and we may incur significant additional losses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be subject to risks in relation to shelf-life expiration of drug product for GOHIBIC (vilobelimab), including but not limited to
substantial write-offs in the balance sheet</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
finished drug product for GOHIBIC (vilobelimab) for use of commercial purposes under the granted the EUA in the United States is subject
to limited shelf-life periods. If we fail to use such finished drug product for the intended use prior to its shelf-life expiration,
such drug product will have to be destroyed accordingly, which might cause additional and substantial costs and expense as well as which
might lead to substantial write-offs of destroyed drug product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates
or indications that may be more profitable or for which there is a greater likelihood of success</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited financial and managerial resources, and therefore we intend to focus on developing product candidates for specific indications
that we identify as most likely to succeed, in terms of both their potential for marketing authorization, approval and commercialization.
As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to
have greater commercial potential.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our
spending on current and future research and development programs and product candidates for specific indications may not yield any commercially
viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate,
we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in
which it would have been more advantageous for us to retain sole development and commercialization rights to the product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of vilobelimab or any other product candidate
we may develop</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk of failure for vilobelimab and any other product candidates we may develop such as INF904 is high. It is impossible to predict when
or if vilobelimab will prove to be effective and safe in humans or will receive full regulatory approval for the treatment of severe
COVID-19 or PG indication, or other indications. Additionally, before regulatory authorities grant marketing approval or the EUA for
vilobelimab, for any future indications, or any future product candidate that we seek to develop, we will be required to complete our
ongoing extensive clinical trials to demonstrate safety and efficacy in humans. Clinical testing is expensive, difficult to design and
implement, can take many years to complete and is inherently uncertain as to outcome. Moreover, preclinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily
in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during or as a result of the regulatory authorization and/or approval process that could delay
or prevent our ability to receive marketing approval or the EUA from regulators or commercialize vilobelimab or any future product candidate,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
                                            or institutional review boards may not authorize us or our investigators to commence a clinical
                                            trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trials of our product candidates may produce negative or inconclusive results, including
                                            failure to demonstrate statistical significance, and we may decide, or regulators may require
                                            us, to conduct additional clinical trials or abandon drug development programs;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            product candidates may have undesirable side effects or other unexpected characteristics,
                                            causing us or our investigators, regulators, ethics committees or institutional review boards
                                            to suspend or terminate the trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            third-party contractors may fail to comply with regulatory requirements or meet their contractual
                                            obligations to us in a timely manner, or at all; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators,
                                            ethics committees or institutional review boards may require that we or our investigators
                                            suspend or terminate clinical development for various reasons, including noncompliance with
                                            regulatory requirements or a finding that the participants are being exposed to unacceptable
                                            health risks.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also encounter delays if a clinical trial is suspended or terminated by us, by an overseeing ethics committee, by the institutional
review boards of the institutions in which such trials are being conducted, by the data safety monitoring board for such trial or by
the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical
trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen
safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of,
any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate
drug revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase
our costs, slow down our product candidate development and approval process and jeopardize our ability to commence drug sales and generate
revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors
that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory
approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
product development costs will further increase if we experience delays in testing or marketing approvals. Significant clinical trial
delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our
competitors to bring drugs to market before we do and impair our ability to successfully commercialize our product candidates. We are
evaluating applications for orphan drug or breakthrough therapy designation for vilobelimab in various indications, but we may be unable
to obtain any such designation or to maintain the benefits associated with orphan drug status, including market exclusivity, even if
that designation is granted</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are evaluating applications for orphan drug or breakthrough therapy designation for vilobelimab in some indications, and we may seek
orphan drug designation for other preclinical product candidates in our pipeline or that we may develop. In the United States and other
countries, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages, and user-fee waivers. After the FDA or other foreign regulatory agency grants orphan drug designation, the
generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey
any advantage in, or shorten the duration of, the FDA review and approval process. Breakthrough therapy designation is a process designed
to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates
that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint. Breakthrough therapy
designation may make us eligible for intensive guidance by the FDA on an efficient drug development program and organizational commitment
involving senior FDA managers, among others. Although we are evaluating applications for orphan drug or breakthrough therapy designation
in some indications, there can be no assurance that we will obtain such designations. Moreover, obtaining orphan drug or breakthrough
therapy designation for one indication does not mean we will be able to obtain such designation for another indication.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan drug designation from the FDA subsequently receives the first FDA approval for a particular active ingredient
for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not
approve any other applications, including a BLA, to market the same drug for the same indication for seven years, except in limited circumstances
such as if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient
quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Similarly,
the FDA can subsequently approve a drug with the same active moiety for the same condition during the exclusivity period if the FDA concludes
that the later drug is clinically superior, meaning the later drug is safer, more effective, or makes a major contribution to patient
care. Even if we were to obtain orphan drug designation for vilobelimab from the FDA, we may not be the first to obtain marketing approval
for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products, and thus approval of
vilobelimab could be blocked for seven years if another company obtains approval and orphan drug exclusivity for the same drug and same
condition before us. If we do obtain exclusive marketing rights in the United States, they may be limited if we seek approval for an
indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation
was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of the relevant patients.
Further, exclusivity may not effectively protect the product from competition because different drugs with different active moieties
can be approved for the same condition, the same drugs can be approved for different indications and might then be used off-label in
our approved indication, and different drugs for the same condition may already be approved and commercially available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we obtain FDA authorization or approval of vilobelimab or any of our other product candidates, we may never obtain authorization or
approval or commercialize our products outside of the United States</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any approved products outside of the United States, we must establish and comply with numerous and varying regulatory
requirements of other countries regarding clinical trial design, safety and efficacy. If approved by the relevant governmental authorities,
we expect to market vilobelimab for the treatment of COVID-19 and other indications in Europe and jurisdictions outside the United States,
in part due to the relatively larger patient population that exists in Europe as compared to that in the United States. Clinical trials
conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does
not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional
product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant
delays, difficulties and costs for us and may require additional preclinical studies or clinical trials, which would be costly and time
consuming and could delay or prevent introduction of vilobelimab or any of our other product candidates in those countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we expect to be subject to a variety of risks related to operating in other countries if we obtain the necessary approvals,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
                                            regulatory requirements in countries outside the United States;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            potential for so-called parallel importing (i.e., when a local seller, faced with high or
                                            higher local prices, opts to import goods from a foreign market (with low or lower prices)
                                            rather than buying them locally);</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
                                            changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
                                            weakness, including inflation, or political instability in particular foreign economies and
                                            markets;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
                                            reimbursement, pricing and insurance regimes;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
                                            with tax, employment, immigration and labor laws for employees living or traveling outside
                                            the United States;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
                                            taxes, including withholding of payroll taxes;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
                                            currency fluctuations, which could result in increased operating expenses and reduced revenue,
                                            and other obligations incident to doing business in another country;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
                                            staffing and managing foreign operations;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
                                            uncertainty in countries where labor unrest is more common than in the United States;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
                                            liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
                                            enforcing our contractual and intellectual property rights, especially in countries that
                                            do not protect intellectual property rights to the same extent as in the United States;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
                                            shortages resulting from any events affecting raw material supply or manufacturing capabilities
                                            as well as supply chain disruptions outside the United States; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
                                            interruptions, including as a results of geopolitical uncertainty and instability (including
                                            related to the Russia-Ukraine conflict).</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our partners fail to comply with regulatory requirements or to obtain and maintain required approvals, our target market will be
reduced, including if we are unable to market vilobelimab in Europe or elsewhere, and our ability to realize the full market potential
of our product candidates will be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
are subject to extensive government regulation and the failure to comply with these regulations may have a material adverse effect on
our operations and business</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
before and after approval of any product, we and our suppliers, contract manufacturers and clinical investigators are subject to extensive
regulation by governmental authorities in the United States and other countries, covering, among other things, testing, manufacturing,
quality control, clinical trials, post-marketing studies, labeling, advertising, promotion, distribution, import and export, governmental
pricing, price reporting and rebate requirements. Failure to comply with applicable requirements could result in one or more of the following
actions: warning letters; unanticipated expenditures; delays in approval or refusal to approve a product candidate; product recall or
seizure; interruption of manufacturing or clinical trials; operating or marketing restrictions; injunctions; criminal prosecution and
civil or criminal penalties including fines and other monetary penalties; adverse publicity; and disruptions to our business. Further,
government investigations into potential violations of these laws would require us to expend considerable resources and face adverse
publicity and the potential disruption of our business even if we are ultimately found not to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
FDA, EMA or other regulatory agency authorization or approval of our product candidates requires substantial time, effort and financial
resources and may be subject to both expected and unforeseen delays, and there can be no assurance that any approval will be granted
on any of our product candidates on a timely basis, if at all. The FDA, EMA or other regulatory agencies may decide that our data are
insufficient for authorization or approval of our product candidates and require additional preclinical, clinical or other studies or
additional work related to chemistry, manufacturing and controls, or CMC. If we are required to conduct additional trials or to conduct
other testing of our product candidates beyond that which we contemplate for regulatory approval, if we are unable to complete successfully
our clinical trials or other testing or if the results of these and other trials or tests fail to demonstrate efficacy or raise safety
concerns, we may face substantial additional expenses, be delayed in obtaining marketing approval for our product candidates or may never
obtain marketing approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also required to comply with extensive governmental regulatory requirements after a product has received marketing authorization
or approval. Governing regulatory authorities may require post-marketing studies that may negatively impact the commercial viability
of a product. Once on the market, a product may become associated with previously undetected adverse effects and/or may develop manufacturing
difficulties. As a result of any of these or other problems, a product&#8217;s regulatory approval could be withdrawn, which could harm
our business and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
current and future relationships with third-party payors, health care professionals and customers in the United States and elsewhere
may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health
information privacy and security and other healthcare laws and regulations, which could expose us to significant penalties</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription
of any product candidates for which we obtain marketing approval. Our current and future arrangements with health care professionals,
third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, including
the federal Anti-Kickback Statute and the federal civil False Claims Act, that may constrain the business or financial arrangements and
relationships through which we conduct clinical research, sell, market and distribute any drugs for which we obtain marketing approval.
In addition, we may be subject to transparency laws and patient privacy regulation in the United States and other jurisdictions in which
we conduct our business. The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate
include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons and entities
                                            from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly
                                            or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral
                                            of an individual for, or the purchase, order or recommendation of, any good or service, for
                                            which payment may be made under federal and state healthcare programs, such as Medicare and
                                            Medicaid. A person or entity does not need to have actual knowledge of the statute or specific
                                            intent to violate it to have committed a violation. Further, several courts have interpreted
                                            the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement
                                            involving remuneration is to induce referrals of federal healthcare covered business, the
                                            Anti-Kickback Statute has been violated. Moreover, the government may assert that a claim
                                            including items or services resulting from a violation of the federal Anti-Kickback Statute
                                            constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            civil and criminal false claims laws, including the federal civil False Claims Act (that
                                            can be enforced through civil whistleblower or qui tam actions), and the civil monetary penalties
                                            law, which impose criminal and civil penalties against individuals or entities for knowingly
                                            presenting, or causing to be presented, to the federal government, including the Medicare
                                            and Medicaid programs, claims for payment that are false or fraudulent or making a false
                                            statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes
                                            criminal and civil liability for, among other things, executing a scheme to defraud any healthcare
                                            benefit program or making false statements relating to healthcare matters. Similar to the
                                            federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge
                                            of the statute or specific intent to violate it to have committed a violation;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act of 2009,
                                            or HITECH, and their respective implementing regulations, which impose obligations on covered
                                            healthcare providers, health plans, and healthcare clearinghouses, as well as their business
                                            associates that create, receive, maintain or transmit individually identifiable health information
                                            for or on behalf of a covered entity, with respect to safeguarding the privacy, security
                                            and transmission of individually identifiable health information;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Physician Payments Sunshine Act, created under Section 6002 of Patient Protection and Affordable
                                            Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively
                                            the Affordable Care Act, and its implementing regulations, which requires specified manufacturers
                                            of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
                                            Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report
                                            annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related
                                            to payments or other &#8220;transfers of value&#8221; made to physicians, which is defined
                                            to include doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals
                                            and applicable manufacturers to report annually to CMS ownership and investment interests
                                            held by physicians and their immediate family members by the 90th day of each calendar year.
                                            All such reported information is publicly available; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous
                                            state and foreign laws and regulations, such as state anti-kickback and false claims laws,
                                            which may apply to sales or marketing arrangements and claims involving healthcare items
                                            or services reimbursed by non-governmental third-party payors, including private insurers;
                                            state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical
                                            industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated
                                            by the federal government or otherwise restrict payments that may be made to healthcare providers;
                                            state and foreign laws that require drug manufacturers to report information related to payments
                                            and other transfers of value to physicians and other healthcare providers or marketing expenditures;
                                            and state and foreign laws governing the privacy and security of health information in certain
                                            circumstances, many of which differ from each other in significant ways and often are not
                                            preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial
costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians
and other healthcare providers, some of whom may recommend, purchase or prescribe vilobelimab, if approved, may not comply with current
or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be
subject to significant civil, criminal and administrative penalties, including damages, fines, disgorgement, individual imprisonment,
exclusion from participation in government healthcare programs, such as Medicare and Medicaid, additional reporting requirements and
oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with
these laws and the curtailment or restructuring of our operations, which could have a material adverse effect on our business. If any
of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government
healthcare programs, which could also materially affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Enacted
and future legislation may increase the difficulty and cost for us to obtain marketing authorization or approval of and commercialize
vilobelimab and affect the prices we may obtain</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of vilobelimab, restrict or regulate post-approval activities
and affect our ability to profitably sell any product candidates for which we obtain marketing authorization or approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems
with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives such as the
Affordable Care Act in 2010, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare
spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries,
impose new taxes and fees on the health industry and impose additional health policy reforms. In the coming years, additional legislative
and regulatory changes could be made to governmental health programs that could significantly impact pharmaceutical companies and the
success of our drug candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included
aggregate reductions to Medicare payments to providers of 2% per fiscal year effective April 1, 2013, and, due to subsequent legislative
amendments to the statute, will stay in effect through 2025, unless additional congressional action is taken. The American Taxpayer Relief
Act of 2012, further reduced, among other things, Medicare payments to several providers, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare
and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and, accordingly, our
financial operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain
profitability, or commercialize our drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs.
We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of vilobelimab, if any, may be. In addition, increased
scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject
us to more stringent drug labeling and post-marketing testing and other requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Even
if we, or any future collaborators, obtain marketing approvals or the EUA for our product candidates, the terms of approvals and ongoing
regulation of our products may limit how we manufacture and market our products, which could impair our ability to generate revenue</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
marketing approval or the EUA has been granted, an approved product and its manufacturer and marketer are subject to ongoing review and
extensive regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion
for any of our product candidates for which we or they obtain marketing approval. Promotional communications with respect to prescription
drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s
approved labeling. Thus, we and any future collaborators will not be able to promote any products we develop for indications or uses
for which they are not approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, manufacturers of authorized and approved products and those manufacturers&#8217; facilities are required to comply with extensive
FDA requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating
to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements.
We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections
by the FDA to monitor and ensure compliance with cGMPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
assuming we, or any future collaborators, receive marketing approval for one or more of our product candidates, we, and any future collaborators,
and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including
manufacturing, production, product surveillance and quality control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
manufacturing and distribution of GOHIBIC (vilobelimab) is subject to a number of risks that could harm our reputation, business, financial
condition and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing processes of GOHIBIC(vilobelimab) is complex. We may encounter manufacturing difficulties, including difficulties related
to product storage and shelf-life. Such difficulties could result from the complexities of manufacturing product batches at a larger
scale, equipment failure, availability of excipients and other product components/ingredients (including related to choice and quality
of raw materials), analytical testing technology and product instability. Specifically, insufficient product stability or shelf-life
of GOHIBIC (vilobelimab) or its components could materially limit or delay our or our collaborators&#8217; ability to distribute and
commercialize GOHIBIC(vilobelimab) at the current price or at all. Further, if GOHIBIC(vilobelimab) becomes subject to a product recall,
including as the result of manufacturing errors, design/labeling defects or other deficiencies, our reputation would be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GOHIBIC
(vilobelimab) is a &#8220;cold-chain product&#8221; that must be shipped and stored at cold temperatures. We could lose supply of GOHIBIC
(vilobelimab) due to distribution difficulties, including generally related supply chain management (e.g., shelf-life expiration) and
specifically related to shipping and storing GOHBIC(vilobelimab) at cold temperatures. If so, we could incur additional manufacturing
costs in order to supply required quantities to U.S. hospitals under the EUA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such manufacturing and distribution difficulties may harm our reputation, business, financial condition and operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governments,
including those outside the United States, tend to impose strict price controls, which may adversely affect our revenues, if any</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
many countries, such as countries of the European Union, the pricing of prescription pharmaceuticals is subject to varying price control
mechanisms, often as part of national health systems. Other countries allow companies to fix their own prices for medical products but
monitor and control company profits. Pricing negotiations with governmental authorities can take considerable time after the receipt
of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we, or any future collaborators,
may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement
of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.
Additional price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product
candidates, and we believe the increasing emphasis on cost-containment initiatives in the European Union has and will continue to put
pressure on the pricing and usage of our product candidates. As a result, given the relatively smaller target markets for severe COVID-19
and PG, any reduced reimbursement for such product candidates may be insufficient for us to generate commercially reasonable revenue
and profits and would adversely affect our financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Any
of our product candidates for which we, or any future collaborators, obtain marketing approval or the EUA in the future could be subject
to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties
if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our products following
approval or the EUA</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of our product candidates for which we, or any future collaborators, obtain marketing approval or the EUA, as well as the manufacturing
processes, post-approval studies and measures, labeling, advertising and promotional activities for such product, among other things,
will be subject to ongoing requirements of and review by the FDA, the EMA and other regulatory authorities. These requirements include
submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating
to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the
distribution of samples to physicians and recordkeeping. Even if marketing approval or the EUA of a product candidate is granted, the
approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval,
including the requirement to implement a REMS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, the EMA and other regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of a product. The FDA and other agencies, including the Department of Justice, closely regulate and
monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and distributed only for
the authorized or approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions
on manufacturers&#8217; communications regarding off-label use and if we, or any future collaborators, do not market any of our product
candidates for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings
or enforcement action for off-label marketing. Violation of the FDCA and other statutes relating to the promotion and advertising of
prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and
state consumer protection laws, including the False Claims Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, later discovery of previously unknown adverse events or other problems with our products or their manufacturers or manufacturing
processes, or failure to comply with regulatory requirements, may yield various results, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the manufacturing of such products;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the labeling or marketing of such products;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on product distribution or use;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
                                            to conduct post-marketing studies or clinical trials;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
                                            letters or untitled letters;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
                                            of the products from the market;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
                                            of products;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on coverage by third-party payors;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            restitution or disgorgement of profits or revenues;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
                                            or withdrawal of marketing approvals, including the EUA;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            to permit the import or export of products;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure; or</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to successfully commercialize and generate revenue from sales of GOHIBIC (vilobelimab) is subject to a number of risks that could
harm our business, financial condition and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully commercialize GOHIBIC (vilobelimab) is subject to a number of risks that could impact our business, financial
condition and operating results. Specifically, our ability to generate revenue from sales of GOHIBIC (vilobelimab) is uncertain, including
due to the market opportunity for, and interest and perception in, GOHIBIC (vilobelimab). In particular, given fluctuations in the number
of patients developing severe symptoms from COVID-19 infections, the size of the addressable patient population and, thus, the market
opportunity for GOHIBIC (vilobelimab) is uncertain and may shrink over time. In addition, since GOHIBIC (vilobelimab) has the EUA, but
not the FDA approval, sales of GOHIBIC (vilobelimab) depend on whether healthcare providers at U.S. hospitals are interested in and receptive
to providing GOHIBIC (vilobelimab) as a treatment for COVID-19. Specifically, if GOHIBIC (vilobelimab) is not included in the treatment
guidelines issued by medical institutions and other third-party medical/healthcare organizations, such as the NIH, or if such institutions
and organizations do not recommend GOHIBIC (vilobelimab), hospitals may not be willing to make GOHIBIC (vilobelimab) available for treatment
of patients. For example, the NIH guidelines stipulate that there is insufficient evidence to recommend either for or against the use
of GOHIBIC (vilobelimab) for the treatment of critically ill COVID-19 patients. This neutral NIH guideline has negatively affected the
commercial adoption of GOHIBIC (vilobelimab) as many healthcare providers, particularly hospitals, rely on NIH treatment guidelines when
deciding to include prescription drugs to their formularies allowing for the placement of product orders by hospital staff. Ultimately,
if we are unable to successfully commercialize and generate revenue from sales of GOHIBIC (vilobelimab), our business, financial condition
and operating results could be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.
Risks related to our dependence on third parties</i></b></span></p><div>



</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our business could be harmed</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not independently conduct clinical trials of any of our product candidates. We rely on third parties, such as CROs, clinical data
management organizations, third-party consultants, medical institutions and clinical investigators, to conduct these clinical trials
and expect to rely on these third-parties to conduct clinical trials of any other product candidate that we develop. Any of these third
parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements
or do so on commercially reasonable terms. In addition, there is a natural transition period when a new CRO begins work. As a result,
delays would likely occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our
business, financial condition and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
although our reliance on these third parties for clinical development activities limits our control over these activities, we remain
responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements
and scientific standards. For example, notwithstanding the obligations of a CRO for a trial of one of our product candidates, we remain
responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols
for the trial. Moreover, the FDA, the EMA and potentially other regulatory agencies of different countries require us to comply with
requirements, commonly referred to as current Good Clinical Practices, or cGCP, for conducting, recording and reporting the results of
clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality
of trial participants are protected. The FDA and regulatory agencies inside the European Union and other regulatory agencies enforce
these cGCP regulations through periodic inspections of trial sponsors, principal investigators, clinical trial sites and IRBs. If we
or our third-party contractors fail to comply with applicable cGCP regulations, the clinical data generated in our clinical trials may
be deemed unreliable and the FDA or other regulatory agencies may require us to perform additional clinical trials before approving our
product candidates, which would delay the marketing approval process. We cannot be certain that, upon inspection, the FDA or other regulatory
agencies will determine that any of our clinical trials comply with cGCP. We are also required to register clinical trials and post the
results of completed clinical trials on a government-sponsored database, such as ClinicalTrials.gov in the United States, within certain
timeframes. The same requirement applies to clinical trials outside the United States, such as EudraCT.ema.europa.eu in Europe. Failure
to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements
with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs.
These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting
clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs.
If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines
or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may
be delayed in obtaining, marketing approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in
our efforts to, successfully commercialize our product candidates. In such an event, our financial results and the commercial prospects
for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could
be delayed, impaired or foreclosed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
reliance on foreign third-party manufacturers and suppliers increases our risk of obtaining adequate, timely and cost-effective product
candidates and products</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
manufacturing is subject to a number of risks, including political and economic disruptions, the imposition of tariffs, quotas and other
import or export controls, changes in governmental policies and geopolitical uncertainty and instability, which have created market volatility.
In particular, we rely on third-party manufacturer located in China and elsewhere for supply of vilobelimab. We outsource all manufacturing
of our product candidates and products to third parties while conducting certain quality control tests in-house. The supply chain and
manufacturing in China may, also as a result of the current global pandemic as well as the global political situation, significantly
impact our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
engage a third-party manufacturer located in China for the clinical supply of the final drug product formulation of vilobelimab. There
is no assurance that we would be able to timely secure needed alternative supply arrangements on satisfactory terms, or at all, if needed.
Our reliance on our manufacturer and our failure to secure alternative supply arrangements as needed could have a material adverse effect
on our ability to complete the development of our product candidates or, to commercialize them, if approved. There may be difficulties
in scaling up to commercial quantities or optimization of processes and formulation of vilobelimab and the costs of manufacturing could
be prohibitive.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we were able to establish and maintain arrangements with other third-party manufacturers, reliance on third-party manufacturers generally
entails additional risks beyond our control, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
                                            on third parties for manufacturing process development, regulatory compliance and quality
                                            assurance;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reliance
                                            on third parties for storage and safeguarding of substantially all inventory;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            and validation of new equipment and facilities required for additional scale-up or optimization
                                            of processes;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            to comply with cGMP and similar foreign standards;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            on supply availability resulting from capacity and scheduling constraints of third parties;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
                                            of qualified backup suppliers for those components that are purchased from a sole or single
                                            source supplier;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">closures
                                            and restrictions on critical facilities resulting from public health crises;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to freely import clinical trial material and potentially marketing material manufactured
                                            at our third-party manufacturer in China into the countries in which the clinical trials
                                            are being conducted or product potentially to be sold;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible breach of manufacturing agreements by third parties because of factors beyond our
                                            control; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possible termination or non-renewal of the manufacturing agreements by the third party, at
                                            a time that is costly or inconvenient to us, and our ability to obtain alternative supply.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing
capabilities, which could delay or impair our ability to obtain regulatory approval for our products. If we do find replacement manufacturers,
we may not be able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay
before new facilities could be qualified and registered with the FDA and other foreign regulatory authorities. In addition, a change
of the manufacturing facility contains inherent risks and is generally viewed as a major change in the manufacturing process such that
comparability studies have to be conducted to assure comparability between the before established manufacturing process and the newly
established manufacturing process potentially causing delays in the drug product supply or, in case of a non-comparability of the manufactured
drug product, warrant further additional pre-clinical and or clinical studies with such non-comparable drug product which may also be
imposed by any regulatory agency upon review of the comparability data. Any of the foregoing could have a material adverse effect on
our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
process of manufacturing biologics, such as vilobelimab, is extremely susceptible to product loss</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of manufacturing our products is complex, highly regulated and subject to several other risks. The process of manufacturing biologics,
such as vilobelimab, is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation
of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the
production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects
and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing
facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time
to investigate and remedy the contamination. Further, our product candidates that have been produced and are stored for later use may
degrade, become contaminated or suffer other quality defects, which may cause the affected product candidates to no longer be suitable
for their intended use in clinical trials or other development activities. If the defective product candidates cannot be replaced in
a timely fashion, we may incur significant delays in our development programs that could adversely affect the value of such product candidates
and, thus, adversely affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
manufacturing process is subject to quality control risks and related regulatory requirements</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
participate in the manufacturing process with crucial quality control testing within our own laboratories, and we hold the manufacturer
license for, and therefore oversee, the overall manufacturing process, and we are responsible for ensuring that this part of our business
also operates according to cGMP standards. Additionally, we hold an importing license. We therefore employ key personnel within the manufacturing
process, such as a head of quality assurance, a head of manufacturing and a qualified person.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,
our laboratories and our quality control system and related documentation and personnel, are also subject to frequent governmental inspections
to assure adherence to cGMP guidelines and to maintain our manufacturing and importing license. Related to these activities, there are
risks which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial
condition and prospects, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            loss of key personnel within the manufacturing activities could result in significant delays
                                            in the manufacturing and release testing of our drug candidate and replacement of such personnel
                                            could be time consuming and be associated with additional costs for us;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mistakes
                                            or misconduct within the release testing could result in false results which could result
                                            in both, the wrongfully rejection of a manufactured drug product from being released or the
                                            wrongfully acceptance of a dysfunctional drug product, causing data and trial results achieved
                                            with such drug product being false and potentially wrongly interpreted; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            inadequate cGMP compliance could result in a potential temporary or permanent loss of the
                                            manufacturing or importing license resulting from an inspection of regulatory agencies.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
third-party manufacturers, or we, may not be able to comply with the cGMP regulatory requirements applicable to vilobelimab and biologics,
including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the Quality System Regulation,
or QSR, or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to
comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil
penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions
and criminal prosecutions, any of which could significantly affect supplies of our product candidates. In addition, our third-party manufacturers
and suppliers and we are subject to FDA and other local regulatory authority inspection from time to time. Failure by our third-party
manufacturers and suppliers or us to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect
to our product candidate may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters
or injunctions or the loss of operating licenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we and our third-party manufacturers and suppliers are subject to numerous environmental, health and safety laws and regulations,
including those governing the handling, use, storage, treatment and disposal of waste products, and failure to comply with such laws
and regulations could result in significant costs associated with civil or criminal fines and penalties for such third parties. Based
on the severity of the regulatory action, our clinical or commercial supply of drug and packaging and other services could be interrupted
or limited, which could have a material adverse effect on our business, including our clinical research activities and our ability to
develop our product candidates and market our products following approval, if any.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or
increase the product yield of its manufacturing, then our costs to manufacture the product may increase and commercialization may be
delayed</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of vilobelimab
or any of our other product candidates in our pipeline or that we may develop, our third-party manufacturers will be required to increase
their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale
production could prove difficult or costly. Further, any claims in our manufacturing process as a result of scaling up or optimization
of the manufacturing, supply and fill process may result in the need to obtain regulatory approvals. If our third-party manufacturers
are not able to optimize manufacturing process to increase the product yield for our product candidates or are unable to produce increased
amounts of our product candidates while maintaining the quality of the product, then we may not be able to meet the demands of clinical
trials or market demands, which could decrease our ability to generate profits. Difficulty in achieving commercial scale-up production
or production optimization or the need for additional regulatory approvals as a result could have a material adverse impact on our business
and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
expect to seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to
alter our development and commercialization plans</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to seek one or more collaborators for the development and commercialization of one or more of our product candidates. Likely collaborators
may include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies.
In addition, if we obtain marketing authorization or approval for product candidates from foreign regulatory authorities, we may enter
into strategic relationships with international biotechnology or pharmaceutical companies for the commercialization of such product candidates
outside of the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend,
among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed
collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the potential differentiation
of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA,
the EMA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product
candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products.
The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration
and whether such a collaboration could be more attractive than the one with us for our product candidate. If we elect to increase our
expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not
be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product
candidates or bring them to market and generate product revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
are complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations
among large pharmaceutical companies that may have resulted in a reduced number of potential future collaborators. Any collaboration
agreements that we enter into in the future may contain restrictions on our ability to enter into potential collaborations or to otherwise
develop specified product candidates. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce
or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the
scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at
our own expense.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we enter into collaborations with third parties for the development and commercialization of our product candidates, our prospects with
respect to those product candidates will depend in significant part on the success of those collaborations</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to maintain existing collaborations and enter into additional collaborations for the development and commercialization of certain
of our product candidates and in certain geographies. We may have limited control over the amount and timing of resources that our collaborators
will dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements
will depend on any future collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.
In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements,
including funding obligations, prior to or upon the expiration of the agreed upon terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
involving our product candidates pose a number of risks, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            have significant discretion in determining the efforts and resources that they will apply
                                            to these collaborations;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not perform their obligations as expected;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not pursue development and commercialization of our product candidates or may elect not
                                            to continue or renew development or commercialization programs, based on clinical trial results,
                                            changes in the collaborators&#8217; strategic focus or available funding or external factors,
                                            such as an acquisition, that divert resources or create competing priorities;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may delay clinical trials, provide insufficient funding for a clinical trial program, stop
                                            a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or
                                            require a new formulation of a product candidate for clinical testing;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            could independently develop, or develop with third parties, products that compete directly
                                            or indirectly with our product candidates;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            collaborator with marketing and distribution rights to one or more products may not commit
                                            sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
                                            with collaborators, including disagreements over proprietary rights, including trade secrets
                                            and other intellectual property, contract interpretation, or the preferred course of research
                                            and development might cause delays or termination of the research, development or commercialization
                                            of product candidates, might lead to additional responsibilities for us with respect to product
                                            candidates, or might result in litigation or arbitration, any of which would be time-consuming
                                            and expensive;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may not properly prosecute, maintain, defend or enforce our intellectual property rights
                                            or may use our proprietary information or other intellectual property in such a way as to
                                            invite litigation that could jeopardize or invalidate our intellectual property or expose
                                            us to potential litigation;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
                                            may infringe, misappropriate or otherwise violate the intellectual property rights of third
                                            parties, which may expose us to litigation and potential liability;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
                                            may be terminated and, if terminated, may result in a need for additional capital to pursue
                                            further development or commercialization of the applicable product candidates; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaboration
                                            agreements may not lead to development or commercialization of product candidates in the
                                            most efficient manner or at all. If any future collaborator of ours is involved in a business
                                            combination, it could decide to delay, diminish or terminate the development or commercialization
                                            of any product candidate licensed to it by us.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in funding or disruptions at&#160;the FDA&#160;and other governmental agencies caused by funding shortages or global health concerns
could hinder their ability to perform normal business functions on which the operation of our business may rely, which could negatively
impact our business</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the&#160;FDA&#160;to review and clear or approve new product candidates and products can be affected by a variety of factors,
including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">government
                                            budget and funding levels, and statutory, regulatory and policy changes;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees;
                                            and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            government shutdowns and other events that may otherwise affect the FDA&#8217;s ability to
                                            perform routine functions.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Average
review times at the agency have fluctuated in recent years as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
if a prolonged government shutdown occurs, or if global health concerns continue to prevent or delay the&#160;FDA&#160;or other regulatory
authorities from conducting, at all or in a timely manner, their regular inspections, reviews or other regulatory activities, the ability
of the&#160;FDA&#160;or other regulatory authorities to timely review and process our regulatory submissions could be significantly impacted,
which could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>3.
Risks related to our intellectual property</i></b></span></p><div>



</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual property
protection</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual property
protection in the United States and other countries with respect to vilobelimab and other proprietary product candidates. If we do not
adequately protect, maintain, defend and enforce our intellectual property rights, competitors may be able to erode, negate or preempt
any competitive advantage we may have, which could adversely affect our business and ability to achieve profitability. To seek to protect
our proprietary position, we file patent applications in the United States and in certain other countries related to our novel product
candidates and their potential use in different medical indications that are important to our business. The patent application and approval
process is expensive and time-consuming and we may not be able to file and prosecute all necessary or desirable patent applications and
obtain and maintain issued patents at a reasonable cost or in a timely manner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the scope of the patent protection we obtain is not sufficiently broad, we may not be able to prevent others from developing and commercializing
technology and products similar or identical to ours. The degree of patent protection we require to successfully compete in the market
may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive
advantage. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable
aspects of our research and development output, such as our employees, contractors, prospective business collaborators, clinical investigators
and other third parties, any of these parties could breach the agreements and disclose such output before a patent application is filed,
which could jeopardize our ability to seek and obtain patent protection. In addition, publications of discoveries in the scientific literature
often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published
until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions
claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions,
and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial
value of our patent rights may be uncertain. Our pending and future patent applications may not result in patents being issued which
protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product
candidates. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its
scope can be reinterpreted after issuance. Even if our patent applications issue as patents, they may not issue in a form that will provide
us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with any
competitive advantage. For example, there can be no assurance that our issued patents contain and pending patent applications will contain,
when granted, claims of sufficient breadth to cover all antibodies alleged to be a biosimilar of our product candidates. Furthermore,
there can be no assurance that our issued patents will not be challenged at the United States Patent and Trademark Office, or USPTO,
or foreign patent offices or in court proceedings, and if any such challenge were successful, the scope of our issued patent claims could
be limited so as to not cover antibodies alleged to be a biosimilar of our product candidates. In addition, changes in either the patent
laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the
scope of our patent protection. In addition, the laws of other countries may not protect our rights to the same extent or in the same
manner as the laws of the United States. For example, patent laws in various jurisdictions, including significant commercial markets,
such as Europe, restrict the patentability of methods of treatment of the human body more than patent laws in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our future patents and patent applications and other intellectual property may be co-owned with third parties. If we are unable to
obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications or other intellectual
property, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could
market competing products and technology. In addition, we would need the cooperation of any such co-owners of our patents in order to
enforce such patents against third parties, and such cooperation may not be provided to us. Furthermore, we, or any future partners,
collaborators, or licensees, may fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our
patent position. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
patents covering our proprietary anti-C5a and anti C5aR technologies may be subject to challenge, narrowing, circumvention and invalidation
by third parties</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of our patents may be challenged, narrowed, circumvented, or invalidated by third parties. The issuance of a patent is not conclusive
as to its inventorship, scope, validity, or enforceability, and our patents may be challenged in the courts or patent offices in the
United States and elsewhere. We may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved
in opposition, derivation, revocation, reexamination, post-grant and <i>inter partes</i> review, or interference proceedings challenging
our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce
the scope of, enforceability or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party
patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention
or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other
features of patentability. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed,
invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology
and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result
in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our competitors and other third parties may be able to circumvent our patents by developing similar or alternative technologies
or products in a non-infringing manner. For example, a third party may develop a competitive therapy that provides benefits similar to
vilobelimab or other product candidates but that uses a technology that falls outside the scope of our patent protection. Our competitors
may also seek approval to market generic versions of any approved products and in connection with seeking such approval may claim that
our patents are invalid, unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both,
including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction
may find our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have
valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve
our business objectives. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our
product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates
could be negatively affected, which could have a material adverse effect on our business, financial condition, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
cannot be sure that we were the first to make the anti-C5a and anti-C5aR technologies claimed in our patents or patent applications or
that we were the first to file for patent protection</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent.
However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in
the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions
are not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to
make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of
such inventions. Similarly, we cannot be certain that parties from whom we may license or purchase patent rights were the first to make
relevant claimed inventions, or were the first to file for patent protection for them. If third parties have filed patent applications
on inventions claimed in our patents or applications on or before March 15, 2013, an interference proceeding in the United States can
be initiated by such third parties to determine who was the first to invent the subject matter covered our patent applications. If third
parties have filed such applications after March 15, 2013, a derivation proceeding in the United States can be initiated by such third
parties to determine whether our invention was derived from theirs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
patent application process is subject to numerous risks and there can be no assurance that we will be successful in obtaining patents
for which we have applied</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until
such patent is issued. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that
we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents.
These risks and uncertainties include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            USPTO and various foreign governmental patent agencies require compliance with a number of
                                            procedural, documentary, fee payment and other provisions during the patent process. There
                                            are situations in which noncompliance can result in abandonment or lapse of a patent or patent
                                            application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
                                            In such an event, competitors might be able to enter the market earlier than would otherwise
                                            have been the case;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            coverage claimed in a patent application can be significantly reduced before the patent is
                                            issued, and its scope can be reinterpreted after issuance;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patent
                                            applications may not result in any patents being issued;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patents
                                            that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented,
                                            narrowed, found to be unenforceable or otherwise may not provide any competitive advantage;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            competitors, many of whom have substantially greater resources and many of whom have made
                                            significant investments in competing technologies, may seek or may have already obtained
                                            patents that will limit, interfere with or eliminate our ability to make, use, and sell our
                                            potential product candidates;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
                                            may be significant pressure on the U.S. government and international governmental bodies
                                            to limit the scope of patent protection both inside and outside the United States for disease
                                            treatments that prove successful, as a matter of public policy regarding worldwide health
                                            concerns; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">countries
                                            other than the United States may have patent laws less favorable to patentees than those
                                            upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop
                                            and market competing product candidates.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>It
is difficult and costly to protect our intellectual property and our proprietary anti-C5a and anti-C5aR technologies, and we may not
be able to ensure their protection</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for the composition,
use and structure of our product candidates, the methods used to manufacture them, the related therapeutic targets and associated methods
of treatment as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our
product candidates from unauthorized making, using, selling, offering to sell or importing by third parties is dependent on the extent
to which we have rights under valid and enforceable patents that cover these activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate determination by the USPTO or by a court or other trier of fact in the United States, or any corresponding foreign patent offices
or courts or other triers of fact, on whether a claim meets all requirements of patentability cannot be assured. Although our C5a and
C5aR inhibitor portfolio consists of six families of patents and patent applications that we own directed to C5a and C5aR inhibitors
and related methods of use, we cannot predict the breadth of claims that may be allowed or enforced in our patents or patent applications,
in our future licensed patents or patent applications or in third-party patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot provide assurances that any of our patent applications will be found to be patentable, including over our own prior art patents,
publications or other disclosures. Furthermore, given the differences in patent laws in the United States, Europe and other foreign countries,
for example, the availability of grace periods for filing patent applications and what can be considered as prior art, we cannot make
any assurances as to the scope of any claims that may issue from our pending and future patent applications in the United States or in
other jurisdictions. Similarly, we cannot make any assurances as to the scope of any claims that may survive a proceeding initiated by
a third party challenging the patentability, validity or enforceability of our patents and patent applications in the United States or
in other jurisdictions. Any such challenge, if successful, could limit patent protection for our product candidates and/or materially
harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately
protect our rights or permit us to gain or keep our competitive advantage. For example:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may not be able to generate sufficient data to support patent applications that protect the
                                            entire breadth of developments in one or more of our programs;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
                                            is possible that one or more of our pending patent applications will not become an issued
                                            patent or, if issued, that the patent(s) will be insufficient to protect our technology or
                                            products, provide us with a basis for commercially viable products or provide us with any
                                            competitive advantages;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            our pending patent applications issue as patents, they may be challenged by third parties
                                            as not infringed, invalid or unenforceable under United States or foreign laws; or</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
                                            issued, the patents under which we hold rights may not be valid or enforceable.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to the extent that we are unable to obtain and maintain patent protection for one of our product candidates or in the event
that such patent protection expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of
a product or product candidate for follow-on indications. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Obtaining
and maintaining patent protection of our anti-C5a and anti-C5aR technologies depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or
eliminated for non-compliance with these requirements</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications are required to be paid
to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents
and applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process and after a patent has issued. There are situations in
which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of
patent rights in the relevant jurisdiction. We may enter into certain license agreements where we will not have the ability to maintain
or prosecute patents in the portfolio and must therefore rely on third parties to take such actions and comply with certain requirements.
Failure by us or our future or any existing licensors to maintain protection of our patent portfolio could have a material adverse effect
on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, it is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise
in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments.
If we fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced, eliminated,
invalid and/or unenforceable. If any of our present or future partners, collaborators, licensees, or licensors, are not fully cooperative
or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised.
If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents
may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could
impair our ability to prevent competition from third parties, which may have a material adverse effect on our business, financial condition,
results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time and if we do not
obtain protection under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments, and similar non-U.S.
legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty years after it is filed. Various
extensions may be available, however, the life of a patent, and the protection it affords, is limited. Given the amount of time required
for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before
or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with adequate and continuing
patent protection sufficient to exclude others from commercializing products similar to our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
upon the timing, duration and conditions of the FDA marketing approval of our product candidates, one or more of our U.S. patents may
be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as
the Hatch-Waxman Amendments and similar legislation in the EU and other jurisdictions. The Hatch-Waxman Amendments permit a patent term
extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product
development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total
of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method
for using it, or a method for manufacturing it may be extended. In Europe, a maximum of five and a half years of supplementary protection
can be achieved for an active ingredient or combinations of active ingredients of a medicinal product protected by a basic patent, if
a valid marketing authorization exists (which must be the first authorization to place the product on the market as a medicinal product)
and if the product has not already been the subject of supplementary protection. However, we may not receive an extension if we fail
to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements.
Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of
any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened
and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could
be reduced and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Others
may claim an ownership interest in our intellectual property and proprietary anti-C5a and anti-C5aR technologies which could expose us
to litigation and have a significant adverse effect on our prospects</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third party may claim an ownership interest in one or more of our, or our future or any existing licensors&#8217;, patents or other proprietary
or other intellectual property rights. A third party could bring legal actions against us and seek monetary damages and/or enjoin clinical
testing, manufacturing and marketing of the affected product or products. While we are presently unaware of any material claims or assertions
by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a
claim or an interest in any of such patents or other intellectual property. If we become involved in any litigation, it could consume
a substantial portion of our resources, and could cause a significant diversion of effort by our technical and management personnel.
If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license
to continue to manufacture or market the affected product, in which case we may be required, for example, to pay substantial royalties
or grant cross-licenses to our patents. We cannot, however, assure you that any such license will be available on acceptable terms, if
at all. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations
as a result of claims of patent infringement or other violations of other intellectual property rights. Further, the outcome of intellectual
property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility
of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony
of experts as to technical facts upon which experts may reasonably disagree. Any of the foregoing could have a material adverse effect
on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we are sued for infringing, misappropriating, or otherwise violating intellectual property rights of third parties, such litigation could
be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends, in part, on our ability to develop, manufacture, market and sell our product candidates without infringing,
misappropriating, or otherwise violating the proprietary or any other intellectual property rights of third parties. Third parties may
have U.S. and non-U.S. issued patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or
methods of use for the treatment of the disease indications for which we are developing our product candidates that may cover our product
candidates or approach to complement inhibition. If any third-party patents or patent applications are found to cover our product candidates
or their methods of use or manufacture, or our approach to complement inhibition, we may not be free to manufacture or market our product
candidates as planned without obtaining a license, which may not be available on commercially reasonable terms or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product
candidates, including interference and post-grant proceedings before the USPTO. There may be third-party patents or patent applications
with claims to materials, formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture
of our product candidates. Because patent applications can take many years to issue, there may be pending patent applications which may
later result in issued patents that our product candidates may be accused of infringing. In addition, third parties may obtain patents
in the future and claim that use of our technologies infringes upon these patents. Accordingly, third parties may assert infringement
claims against us based on intellectual property rights that exist now or arise in the future. The outcome of intellectual property litigation
is subject to uncertainties that cannot be adequately quantified in advance. The pharmaceutical and biotechnology industries have produced
a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types
of products or methods of use or manufacture. The scope of protection afforded by a patent is subject to interpretation by the courts,
and the interpretation is not always uniform. If we are sued for patent infringement, we would need to demonstrate that our product candidates,
products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable,
and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a
showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful
in these proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted
in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we may not have sufficient
resources to bring these actions to a successful conclusion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe, misappropriate, or otherwise violate a third party&#8217;s intellectual property right, we could be forced,
including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively,
we may be required to obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing
or commercializing the infringing product candidate or product. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access
to the same technologies licensed to us; alternatively or additionally, it could include terms that impede or destroy our ability to
compete successfully in the commercial marketplace. In addition, we could be found liable for monetary damages, including treble damages
and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing
our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated
the trade secrets or other confidential information of any third parties could have a similar negative impact on our business. Any of
the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming
ownership of what we regard as our own intellectual property and proprietary anti-C5a and anti-C5aR technologies</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our current and former employees and our licensors&#8217; current and former employees, including our senior management, were previously
employed at universities or at other biotechnology or pharmaceutical companies, including some which may be competitors or potential
competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work
for us, we may be subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets
or other proprietary information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages.
Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party
to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if
we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while we typically require our employees, consultants and contractors who are involved in the development of intellectual property
for us within the scope of such employees&#8217;, consultants&#8217; and contractors&#8217; employment or other engagement by us to execute
agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact
develops intellectual property that we regard as our own, or such agreements may be breached or alleged to be ineffective, which may
result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in
prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management
and scientific personnel. Any of the foregoing could have a material adverse effect on our business, financial condition, results of
operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may lose exclusivity to certain of our intellectual property rights to the German federal government</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold all of our intellectual property through our wholly owned subsidiary InflaRx GmbH in Germany. In the event of a national epidemic
or pandemic, the German federal government, and the Federal Ministry of Health and other authorities have the right to order the use
of our owned and in-licensed patents in the interest of the public welfare or the security of the Federal Republic of Germany. The German
federal government may issue such an order with respect to our owned and in-licensed patents and we may lose exclusivity with respect
to the technologies covered by such patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the research resulting in certain of our patents and technology, including patents and technology relating to our clinical development
in severe COVID-19, was funded in part by the German federal government. Results of such government funded research projects must, subject
to certain conditions, be made available free of charge for academic research and teaching in Germany and must be published in bi-annual
interim reports and a final report following completion of the funded work. Information relating to intellectual property generated,
commercial expectations, scientific chances of success, next steps and certain additional information must be disclosed to the German
government and to third parties for academic research and teaching upon request under a written confidentiality agreement. The German
federal government additionally has, in the case of a special public interest, a non-exclusive and transferable right to use intellectual
property generated as part of the funded work.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
of our employees and directors are subject to German law, including as it relates to the ownership of, and compensation for, inventions</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of our personnel, including some of our directors, work in Germany and may be subject to German employment law. Inventions that
may be the subject of a patent or of protection as a utility model as well as technical improvement proposals for other technical innovations
that may not be the subject of a patent or of protection as a utility model made by such employees are subject to the provisions of the
German Act on Employees&#8217; Inventions (<i>Gesetz &#252;ber Arbeitnehmererfindungen</i>), which regulates the ownership of, and compensation
for, inventions made by employees. We face the risk that disputes may occur between us and our current or past employees pertaining to
the sufficiency of compensation paid by us, allocation of rights to inventions under the German Act on Employee&#8217;s Inventions or
alleged non-adherence to the provisions of this act, any of which may be costly to resolve and take up our management&#8217;s time and
efforts whether we prevail or fail in such dispute. In addition, under the German Act on Employees&#8217; Inventions, certain employees
retain rights to patents they invented or co-invented and disclosed to us prior to October 1, 2009. While we believe that all of our
current and past German employee inventors have subsequently assigned to us their interest in patents and inventions they invented or
co-invented, there can be no assurance that all such assignments are fully effective. Even if we lawfully own all inventions of our employee
inventors who are subject to the German Act on Employees&#8217; Inventions, we are required under German law to reasonably compensate
such employees for the use of the patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our current or past employees obtain or retain ownership of any inventions or other intellectual property rights that we believe
we own, we may lose valuable intellectual property rights and may be required to obtain and maintain licenses from such employees to
such inventions or intellectual property rights, which may not be available on commercially reasonable terms or at all, or may be non-exclusive.
If we are unable to obtain and maintain a license to any such employee&#8217;s interest in such inventions or intellectual property rights,
we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. In
addition, any loss of exclusivity of our intellectual property rights could limit our ability to stop others from using or commercializing
similar or identical technology and products. Any of the foregoing events could have a material adverse effect on our business, financial
condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may not be able to enforce our intellectual property rights throughout the world</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting, maintaining, enforcing and defending patents on our product candidates in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United
States. The requirements for patentability may differ in certain countries, particularly in developing countries; thus, even in countries
where we do pursue patent protection, there can be no assurance that any patents will issue with claims that cover our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in the United States
and foreign intellectual property laws. Additionally, laws of some countries outside of the United States and Europe do not afford intellectual
property protection to the same extent as the laws of the United States and Europe. Many companies have encountered significant problems
in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, including
India, China and other countries, do not favor the enforcement of patents and other intellectual property rights. This could make it
difficult for us to stop the infringement of our patents or the misappropriation or other violations of our other intellectual property
rights. For example, many countries outside the United States have compulsory licensing laws under which a patent owner must grant licenses
to third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in certain countries outside
the United States and Europe. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop
and market their own products and, further, may export otherwise infringing products to jurisdictions where we have patent protection,
if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with our products, and
our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements
under which we may be granted a license to any patent rights may not give us sufficient rights to permit us to pursue enforcement of
our licensed patents or defense of any claims asserting the invalidity of these patents (or control of enforcement or defense) of such
patent rights in all relevant jurisdictions as requirements may vary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings
to enforce our patent rights in the United States or foreign jurisdictions, whether or not successful, could result in substantial costs
and divert our efforts and resources from other aspects of our business. Moreover, such proceedings could put our patents at risk of
being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert
claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be
commercially meaningful. Furthermore, while we intend to seek to protect our intellectual property rights in major markets for our product
candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to
market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate.
Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>We
may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming
and unsuccessful</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors and others may infringe, misappropriate or otherwise violate our patents or other intellectual property rights. To counter
infringement or unauthorized use, we may be required to file infringement or other claims, which can be expensive and time consuming
and divert the time and attention of our management and scientific personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe
their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement
proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that
we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of
such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the
other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in
a litigation or proceeding involving one or more of our patents could limit our ability to assert those patents against those parties
or other competitors and may curtail or preclude our ability to exclude third parties from developing, making and selling similar or
competitive products. Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity
and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of
discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other
interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could adversely affect
the price of our ordinary shares. Moreover, there can be no assurance that we will have sufficient financial or other resources to file
and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such
claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh
any benefit we receive as a result of the proceedings. Any such litigation could have a material adverse effect on our business, financial
condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our marks of interest
and our business may be adversely affected</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need
for name recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may
receive rejections that we are unable to overcome, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties
are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation
proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name
recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>If
we fail to comply with our obligations under any future or other intellectual property licenses with third parties, we could lose license
rights that are important to our business</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be reliant upon licenses to certain patent rights and proprietary anti-C5a and anti-C5aR technologies and other intellectual property
from third parties that are important or necessary to the development of our product candidates and the manufacture and other commercialization
of our products. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant
fields of use and in all territories in which we may wish to develop, manufacture or commercialize our technology and products in the
future. As a result, we may not be able to prevent competitors from developing, manufacturing and commercializing competitive products
in territories included in all of our licenses. Our licensors may have sublicensed patents and other intellectual property owned by a
third party, or relied on third-party consultants or collaborators or funds from third parties that have an ownership or other right,
title or interest in or to such in-licensed intellectual property, such that our licensors are not the sole and exclusive owners of the
patents and other intellectual property we in-license. This could have a material adverse effect on our competitive position, business,
financial conditions, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, agreements under which we may license patent rights may not give us control over patent filings prosecution or maintenance,
so that we may not be able to control which claims or arguments are presented and may not be able to secure, maintain, or successfully
enforce and defend necessary or desirable patent protection from those patent rights. We cannot be certain that patent filing prosecution
and maintenance activities by our licensors will be conducted in compliance with applicable laws and regulations or will result in valid
and enforceable patents. Even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our future
or any existing licensors, and cannot guarantee that we would receive it and on what terms. We cannot be certain that our future licensors
will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests
in any licensed patents. If we cannot obtain patent protection or enforce existing or future patents against third parties, it could
have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
agreements under which we may license technology or any other intellectual property to or from third parties are complex, and certain
provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement
that may arise could narrow what we believe to be the scope of our rights to the relevant technology or any other intellectual property,
or increase what we believe to be our financial or other obligations under the relevant agreement. Moreover, if disputes over technology
or other intellectual property that we may license prevent or impair our ability to maintain our licensing arrangements on commercially
acceptable terms, we may be unable to successfully develop manufacture and commercialize the affected product candidates, which could
have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may arise regarding intellectual property subject to a licensing agreement, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope of rights that may be granted under license agreements and other interpretation-related
                                            issues;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            extent to which our technology and processes infringe on intellectual property rights of
                                            the licensor that is not subject to the licensing agreement;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            sublicensing of patent and other rights under current and any future collaborative development
                                            relationships;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            diligence obligations under any license agreement and what activities satisfy such obligations;</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            inventorship and ownership of inventions and know-how and other intellectual property resulting
                                            from the joint creation or use of intellectual property by our license counterparties and
                                            us and our partners; and</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            priority of invention of patented technology.</span></td></tr></table><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our license counterparties might conclude that we have materially breached our license agreements and might
therefore terminate the license agreements, which may remove our ability to develop manufacture- and commercialize the product candidates
and technology covered by these license agreements. If any in-licenses are terminated, competitors may be able to seek regulatory approval
of, and to market, products identical to ours. It is possible that we may be unable to obtain any additional licenses that we require
at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to
redesign our product candidates, technology, or the methods for manufacturing them or to develop or license replacement technology, all
of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop, manufacture
or commercialize the affected product candidates, which could harm our competitive position, business, financial conditions, results
of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: S1 --><div>
</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>If
we are unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted and our business
would be harmed</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition to the protection afforded by patents, we also rely on trade secret protection for certain aspects of our intellectual
property. However, trade secrets are difficult to protect. We seek to protect these trade secrets, in part, by entering into
non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, consultants, independent
contractors, advisors, contract manufacturers, suppliers and other third parties. We also enter into confidentiality and invention
or patent assignment agreements with employees and certain consultants and independent contractors. Any party with whom we have
executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we
may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated
a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Additionally, if the steps taken to
maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the
trade secret. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other
third party, we would have no right to prevent such third party, or those to whom they communicate such technology or information,
from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently
developed or otherwise obtained by a competitor or other third party, it could have a material adverse effect on our business,
financial condition, results of operations and prospects.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
                                            related to employee matters and managing growth</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
only have a limited number of employees to manage and operate our business</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we had 66 full-time or part-time employees. Our focus on the development and commercialization of vilobelimab requires
us to optimize cash utilization and to manage and operate our business with limited personnel. We cannot assure you that we will be able
to hire additional employees and/or retain adequate staffing levels to develop and commercialize vilobelimab or run our operations or
to accomplish all the objectives that we otherwise would seek to accomplish.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
depend heavily on our executive officers and directors, and the loss of their services would materially harm our business</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
success depends, and will likely continue to depend, upon our ability to hire and retain the services of our current executive officers,
directors, principal consultants and others. We are highly dependent on the management, development, clinical, financial and business
development expertise of Niels Riedemann, our Chief Executive Officer, Renfeng Guo, our Chief Scientific Officer, Thomas Taapken, our
Chief Financial Officer, and, since July 2023, Camilla Chong, our Chief Medical Officer. Our ability to compete in the biotechnology
and pharmaceuticals industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
industry has experienced a high rate of turnover of management personnel in recent years. Any of our personnel may terminate their employment
at will. If we lose one or more of our executive officers or other key employees, our ability to implement our business strategy successfully
could be seriously harmed. Furthermore, replacing executive officers or other key employees may be difficult and may take an extended
period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop,
gain marketing approval of and commercialize products successfully.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Competition
to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key employees on
acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience
competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
rely on consultants and advisors, including scientific, strategic, regulatory and clinical advisors, to assist us in formulating our
research and development and commercialization strategy. Our consultants and advisors may be employed by other entities and may have
commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue
to attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
expect to expand scope of our operations, particularly in the areas of clinical development and regulatory affairs. To manage such growth,
we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit
and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth
activities. Moreover, our expected growth could require us to relocate to a different geographic area of the country. Due to our limited
financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not
be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit, attract and
train retain human capital. Competition for qualified, motivated, and highly-skilled executives, professionals and other key personnel
in biotechnology and pharmaceuticals industries is significant. Our inability to manage the expansion or relocation of our operations
effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of
employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures
and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to
effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced
and we may not be able to implement our business strategy, including the successful development and commercialization of our product
candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Our
employees, independent contractors, consultants, collaborators and CROs may engage in misconduct or other improper activities, including
non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to the risk that our employees, independent contractors, consultants, collaborators and CROs may engage in fraudulent conduct
or other illegal activity. Misconduct by those parties could include intentional, reckless or negligent conduct or disclosure of unauthorized
activities to us that violates: (i) the FDA regulations or similar regulations of comparable non-U.S. regulatory authorities, including
those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing and clinical trial
conduct standards, (iii) federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established
and enforced by comparable non-U.S. regulatory authorities, and (iv) laws that require the reporting of financial information or data
accurately. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials,
which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct,
and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses
or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting
our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil,
criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other
federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations,
any of which could have a material adverse effect on our ability to operate our business and our results of operations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
                                            related to our ordinary shares and our status as a public company</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>The
trading price of our ordinary shares has been and may in the future be highly volatile, which could result in substantial losses for
holders of our ordinary shares, and a decline in our share price and invite securities litigation against our company or our management</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
share price has been and is likely to be highly volatile in the future. The stock market in general and the market for smaller pharmaceutical
and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance
of particular companies. You should consider an investment in our ordinary shares as risky and invest only if you can withstand a significant
loss and wide fluctuations in the market value of your investment. The market price for our ordinary shares may be influenced by many
factors, including:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            timing, enrollment and results of clinical trials of vilobelimab and any other product candidates;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">regulatory
                                            actions with respect to vilobelimab, our other product candidates or our competitors&#8217;
                                            products and product candidates;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            success of the commercialization of GOHIBIC (vilobelimab);</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            success of existing or new competitive products or technologies;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">any
                                            delay in our development or regulatory filings for vilobelimab or any future product candidate
                                            and any adverse development or perceived adverse development with respect to the applicable
                                            regulatory authority&#8217;s review of such filings, including the FDA&#8217;s issuance of
                                            a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">announcements
                                            by us or our competitors of significant acquisitions, strategic partnerships, joint ventures,
                                            collaborations or capital commitments;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">commencement
                                            or termination of collaborations for our development programs;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">failure
                                            or discontinuation of any of our development programs;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">results
                                            of clinical trials of product candidates of our competitors;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">regulatory
                                            or legal developments in the United States and other countries;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">developments
                                            or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            recruitment or departure of key personnel;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            level of expenses related to any of our product candidates or clinical development programs;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            results of our efforts to develop additional product candidates or products;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">actual
                                            or anticipated changes in estimates as to financial results or development timelines;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">announcement
                                            or expectation of additional financing efforts;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">sales
                                            of our ordinary shares by us, our insiders or other shareholders;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">variations
                                            in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">changes
                                            in estimates or recommendations by securities analysts, if any, that cover our shares;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">changes
                                            in the structure of healthcare payment systems;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">market
                                            conditions in the pharmaceutical and biotechnology industries;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">general
                                            economic, industry, market and political conditions; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            other factors described in this &#8216;ITEM 3. KEY INFORMATION &#8212; 3. Risk factors&#8217;
                                            section.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
the past, securities class action litigation has often been brought against a company and its management following a decline in the market
price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price
volatility in recent years. Such litigation, if instituted against us, could cause us or members of our management to incur substantial
costs and divert management&#8217;s attention and resources from our business.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Future
sales, or the possibility of future sales, of a substantial number of our ordinary shares could adversely affect the price of the shares
and dilute shareholders</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Future
sales of a substantial number of our ordinary shares, or the perception that such sales will occur, could cause a decline in the market
price of our ordinary shares. If we or our existing shareholders sell substantial amounts of ordinary shares in the public market, or
the market perceives that such sales may occur, the market price of our ordinary shares and our ability to raise capital through an issue
of equity securities in the future at attractive terms or at all could be adversely affected.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
have broad discretion in the use of our cash on hand and may invest or spend it in a way with which you do not agree and in ways that
may not yield a return on your investment</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we had &#8364;12.8 million in cash and cash equivalents and &#8364;85.6 million in marketable securities. Our management
will have broad discretion in the use of such cash and could spend it in ways that do not improve our results of operations or enhance
the value of our ordinary shares. You will not have the opportunity to influence our decisions on how to use our cash on hand. The failure
by our management to apply these funds effectively could result in financial losses that could harm our business, cause the price of
our ordinary shares to decline and delay the development of our product candidates. Pending its use, we may invest our cash on hand in
a manner that does not produce income or that loses value.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
are a foreign private issuer and, as a result, we are not subject to U.S. proxy rules and are subject to Exchange Act reporting obligations
that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer
status. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange
Act that are applicable to U.S. domestic public companies, including (i) the sections of the Exchange Act regulating the solicitation
of proxies, consents or authorizations in respect of a security registered under the Exchange Act, (ii) the sections of the Exchange
Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from
trades made in a short period of time and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports
on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified
significant events. In addition, foreign private issuers are not required to file their Annual Report on Form 20-F until four months
after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their Annual Report on
Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure,
aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may not have the
same protections afforded to shareholders of companies that are not foreign private issuers.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>As
a foreign private issuer and as permitted by the listing requirements of Nasdaq, we follow certain home country governance practices
rather than the corporate governance requirements of Nasdaq</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a foreign private issuer. As a result, in accordance with the listing requirements of Nasdaq we rely on home country governance requirements
and certain exemptions thereunder rather than relying on the corporate governance requirements of Nasdaq. In accordance with Dutch law
and generally accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general
meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an
issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding
voting stock. Although we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders,
Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted
business practice in the Netherlands; thus, our practice will vary from the requirement of Nasdaq Listing Rule 5620(b). As permitted
by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule 5605(d), which requires, among
other things, an issuer to have a compensation committee that consists entirely of independent directors and makes determinations regarding
the independence of any compensation consultants, Nasdaq Listing Rule 5605(e), which requires independent director oversight of director
nominations, and Nasdaq Listing Rule 5605(b)(2), which requires an issuer to have a majority of independent directors on its board. In
addition, we have opted out of shareholder approval requirements, as included in the Nasdaq Listing Rules, for the issuance of securities
in connection with certain events such as the acquisition of shares or assets of another company, the establishment of or amendments
to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice
varies from the requirements of Nasdaq Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance
of securities in connection with such events. Accordingly, you may not have the same protections afforded to shareholders of companies
that are subject to these Nasdaq requirements.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
do not anticipate paying any cash dividends on our share capital in the foreseeable future. Accordingly, shareholders must rely on capital
appreciation, if any, for any return on their investment</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have never declared nor paid cash dividends on our share capital. We plan to retain all of our future earnings, if any, to finance the
operation, development and growth of our business. In addition, the terms of any future debt or credit agreements and any restrictions
imposed by applicable law may preclude us from paying dividends. As a result, capital appreciation, if any, of our ordinary shares will
be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">See
&#8220;ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS &#8212;1. Major shareholders.&#8221; elsewhere in this Annual Report
for more information regarding the ownership of our outstanding ordinary shares by our executive officers, directors and principal shareholders
and their affiliates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>If
securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price
and trading volume could decline</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
trading market for our ordinary shares depends in part on the research and reports that securities or industry analysts publish about
us or our business. We do not have any control over such analysts. There can be no assurance that analysts will cover us or provide favorable
coverage going forward. Securities or industry analysts may elect not to continue to provide research coverage of our ordinary shares,
and such lack of research coverage may negatively impact the market price of our ordinary shares. In the event we do have analyst coverage,
if one or more analysts downgrade our ordinary shares, change their opinion of our ordinary shares or publish inaccurate or unfavorable
research about our business, our share price would likely decline. In addition, if one or more analysts cease coverage of our company
or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading
volume to decline.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Our
ability to use our net operating loss carry forwards and other tax attributes may be limited</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
ability to utilize our NOLs, or NOLs, is limited, and may be limited further, under Section 8c of the German Corporation Income Tax Act
(<i>K&#246;rperschaftsteuergesetz</i>), or KStG, and Section 10a of the German Trade Tax Act (<i>Gewerbesteuergesetz</i>), or GewStG.
These limitations apply if a qualified ownership change, as defined by Section 8c KStG, occurs and no exemption is applicable. Generally,
a qualified ownership change occurs if more than 50% of the share capital or the voting rights are directly or indirectly transferred
to a shareholder or a group of shareholders within a period of five years. A qualified ownership change may also occur in case of a transaction
comparable to a transfer of shares or voting rights or in case of an increase in capital leading to a respective change in the shareholding.
In the case of such a qualified ownership change tax loss carry forwards expire in full. To the extent that the hidden reserves (<i>stille
Reserven</i>) taxable in Germany exceed the tax loss carry forward, they may be further utilized despite a qualified ownership change.
In case of a qualified ownership change within a group, tax loss carry forwards will be preserved if certain conditions are satisfied.
Alternatively, tax loss carry forwards may be retained upon application under certain conditions, to the extent that the corporation
has exclusively maintained the same business operations since its establishment or at least since the beginning of the third year prior
to qualified ownership change (<i>fortf&#252;hrungsgebundener Verlustvortrag</i>). If the aforementioned application is made and, after
the qualified change of ownership, this business operation is discontinued, the most recently determined tax loss carry forward (<i>fortf&#252;hrungsgebundener
Verlustvortrag</i>) would be lost.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">An
appeal has been filed by the fiscal court of Hamburg dated August 29, 2017 &#8211; 2 K 245/17 with regard to Section 8c, paragraph 1,
sentence 2 KStG (in its superseded version, now: Section 8c paragraph 1 sentence 1 KStG) that is, the forfeiture of all tax loss carryforwards
in case more than 50% of shares/voting rights will be assigned to a new shareholder. The appeal is still pending. It is unclear when
the Federal Constitutional Court will decide this case. According to statements in German legal literature, there are good reasons to
believe that the Federal Constitutional Court may come to the conclusion that Section 8, paragraph 1, sentence 2 KStG (in its superseded
version) is not in line with the German constitution.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we had NOL carry forwards for German corporate tax purposes of &#8364;196.0 million and for trade tax purposes &#8364;164
million available. Future changes in share ownership may also trigger an ownership change and, consequently, a Section 8c KStG, or a
Section 10a GewStG limitation. Any limitation may result in the expiration of the complete tax operating loss carry forwards before they
can be utilized. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carry forwards to reduce
German income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, our U.S. subsidiary, InflaRx Pharmaceuticals, Inc., had &#8364;12.96 million or $14.3 million of NOLs for U.S. federal
income tax purposes. Transfers or issuances of our equity may impair or reduce the ability of InflaRx Pharmaceuticals, Inc. to utilize
U.S. federal net operating loss carryforwards and certain other tax attributes in the future. Section 382 of the Internal Revenue Code
of 1986, as amended, or the Code, contains rules that limit the ability of a company that undergoes an &#8220;ownership change&#8221;
to utilize its net operating loss and tax credit carry forwards and certain built-in losses recognized in years after the ownership change.
An &#8220;ownership change&#8221; is generally defined as an increase in ownership of a corporation&#8217;s stock by more than 50 percentage
points over a rolling three-year period by stockholders that own (directly, indirectly or constructively) 5% or more of the stock of
a corporation at any time during the relevant rolling three-year period. If an ownership change occurs, Section 382 imposes an annual
limitation on the use of pre-ownership change NOLs, credits and certain other tax attributes to offset taxable income earned after the
ownership change. The annual limitation is generally equal to the product of the applicable long-term tax-exempt rate in effect for the
month in which the ownership change occurs and the value of the company&#8217;s stock immediately before the ownership change (subject
to some adjustments). For example, this annual limitation may be adjusted to reflect any unused annual limitation for prior years and
certain recognized (or treated as recognized) built-in gains and losses for the year. In addition, Section 383 generally limits the amount
of tax liability in any post-ownership change year that can be reduced by pre-ownership change tax credit carryforwards or capital loss
carryforwards. No assurance can be given that prior transactions have not resulted in an ownership change for purposes of Section 382
of the Code or that future transactions will not result in an ownership change. Even if a subsequent transaction does not result in an
ownership change, it may materially increase the likelihood that we will undergo an ownership change in the future. Sales of our common
shares by stockholders, whose interests may differ from our interests, may increase the likelihood that we or one of our subsidiaries
undergoes an ownership change. If we or our subsidiaries have or were to undergo an ownership change, it could result in increased future
tax liability to us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
may become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Since
incorporation we intend to have, on a continuous basis, our place of effective management in Germany. We will therefore be a tax resident
of Germany under German national tax law. By reason of our incorporation under Dutch law, we are also deemed tax resident in the Netherlands
under Dutch tax law. However, based on our current management structure and current tax laws of the United States, Germany and the Netherlands,
as well as applicable income tax treaties, and current interpretations thereof, we should be tax resident solely in Germany for the purposes
of the convention between the Federal Republic of Germany and the Netherlands for the avoidance of double taxation with respect to taxes
on income of 2012, or the German-Dutch tax treaty.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
sole tax residency in Germany for purposes of the German-Dutch tax treaty is subject to the application of the provisions on tax residency
as stipulated in the German-Dutch tax treaty as amended from time to time. The Multilateral Convention to Implement Tax Treaty Related
Measures to Prevent Base Erosion and Profit Shifting or the MLI, Germany and the Netherlands entered into, among other countries, should
not, as of this date, affect the German-Dutch tax treaty&#8217;s rules regarding tax residency.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
applicable tax laws, tax treaties or interpretations thereof may change, including the MLI choices and reservation. Furthermore, whether
we have our place of effective management in Germany and are as such solely tax resident in Germany is largely a question of fact and
degree based on all the circumstances, rather than a question of law, which facts and degree may also change. Changes to applicable laws
or interpretations thereof and changes to applicable facts and circumstances (for example, a change of board members or the place where
board meetings take place), or changes to applicable tax treaties, including a change to the application of the MLI may result in us
becoming a tax resident of a jurisdiction other than Germany. As a consequence, our overall effective income tax rate and income tax
expense could materially increase, which could have a material adverse effect on our business, results of operations, financial condition
and prospects, which could cause our share price and trading volume to decline.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
believe it is likely that we were a PFIC for U.S. federal income tax purposes in 2021, 2022 and 2023, and we may be a PFIC in one or
more future taxable years. U.S. shareholders may be subject to adverse U.S. federal income tax consequences in 2023 and in any future
taxable year in which we are a PFIC.</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
believe it is likely that we are a PFIC for U.S. federal income tax purposes in 2021, 2022 and 2023 and we may be a PFIC in one or more
future taxable years. In addition, we may, now or in the future directly or indirectly, hold equity interests in other PFICs. Under the
Code, we will be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries,
either (i) 75% or more of our gross income consists of passive income or (ii) 50% or more of the average quarterly value of our assets
consists of assets that produce, or are held for the production of, passive income. Passive income includes, among other things, dividends,
interest, certain non-active rents and royalties, and capital gains. It is possible that we will be a PFIC in any future taxable year
because, among other things, (i) we own a substantial amount of passive assets, including cash and securities that may give rise to passive
income, (ii) the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain
and may vary substantially over time and (iii) the composition of our income may vary substantially over time.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
we are a PFIC for any taxable year during which a U.S. investor holds ordinary shares, we would continue to be treated as a PFIC with
respect to that U.S. investor for all succeeding years during which the U.S. investor holds ordinary shares, even if we ceased to meet
the threshold requirements for PFIC status, unless certain exceptions apply. Such a U.S. investor may be subject to adverse U.S. federal
income tax consequences, including (i) the treatment of all or a portion of any gain on disposition as ordinary income, (ii) the application
of a deferred interest charge on such gain and the receipt of certain dividends and (iii) compliance with certain reporting requirements.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">For
further discussion, see &#8220;ITEM 10. ADDITIONAL INFORMATION &#8212;5. Taxation &#8212; Material U.S. Federal Income Tax Considerations
for U.S. Holders of Ordinary Shares.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime
and cause us to incur significant legal, accounting and other expenses</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements
of the Exchange Act applicable to U.S. domestic issuers. If in the future we are not a foreign private issuer as of the last day of the
second fiscal quarter in any fiscal year, we would be required to comply with all of the periodic disclosure, current reporting requirements
and proxy solicitation rules of the Exchange Act applicable to U.S. domestic issuers. In order to maintain our current status as a foreign
private issuer, either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of
the United States or (b)(i) a majority of our directors and executive officers may not be United States citizens or residents, (ii) more
than 50% of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United
States. If we were to lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable
to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required
to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance
costs to us if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher
than the costs we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would
increase our legal and financial compliance costs and would make some activities highly time consuming and costly. These rules and regulations
could also make it more difficult for us to attract and retain qualified directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>If
we ever pay dividends, we may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
do not intend to pay any dividends to holders of our shares. However, if we do pay dividends, we may need to withhold tax on such dividends
both in Germany and the Netherlands. As an entity incorporated under Dutch law any dividends distributed by us are subject to Dutch dividend
withholding tax on the basis of Dutch domestic law. However, on the basis of the double tax treaty between Germany and the Netherlands,
the Netherlands will be restricted from imposing dividend withholding tax if we continue to be a tax resident of Germany and our place
of effective management is in Germany. However, Dutch dividend withholding tax is still required to be withheld from dividends if and
when paid to Dutch resident holders of our shares (and non-Dutch resident holders of our shares that have a permanent establishment in
the Netherlands to which their shareholding is attributable). As a result, upon a payment (or deemed payment) of dividends, we will be
required to identify our shareholders in order to assess whether there are Dutch residents (or non-Dutch residents with a permanent establishment
to which the shares are attributable) in respect of which Dutch dividend tax has to be withheld. Such identification may not always be
possible in practice. If the identity of our shareholders cannot be determined, withholding of both German and Dutch dividend tax from
such dividend may occur, upon a payment of dividends.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
the withholding tax restriction referred to above is based on the current choices and reservation made by Germany under the MLI. If Germany
changes its MLI choices and reservation, we may not be entitled to any benefits of the double tax treaty between Germany and the Netherlands,
including the withholding tax restriction, as long as Germany and the Netherlands do not reach an agreement on our tax residency for
purposes of the double tax treaty between Germany and the Netherlands, except to the extent and in such manner as may be agreed upon
by the authorities. As a result, any dividends distributed by us during the period no such agreement has been reached between Germany
and the Netherlands, may be subject to withholding tax both in Germany and the Netherlands.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, a proposed law is pending before the Dutch parliament, namely the Emergency Act Conditional Exit Dividend Tax (<i>Spoedwet
conditionele eindafrekening dividendbelasting</i>) which would, if enacted, impose, possibly with retroactive effect, a dividend withholding
(exit) tax on certain deemed distributions if we cease to be a Dutch tax resident and become a tax resident of a jurisdiction that is
not a member of the EU or the EEA, when such jurisdiction does not satisfy certain conditions. In some cases, we would have a right to
recover the amount of tax from our shareholders when such shareholder is not entitled to an exemption.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Dividends
distributed on our shares to certain related entities in low-taxed or non-cooperative jurisdictions might in the future become subject
to an additional Dutch withholding tax on dividends, as of January 1, 2024</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have no plans to pay regular dividends on our ordinary shares. However, if we do pay dividends, under current Dutch tax law, dividends
paid by us to holders of our shares could become subject to Dutch dividend withholding tax at a rate of 15% under the Dutch Dividend
Withholding Tax Act (<i>Wet op de dividendbelasting 1965</i>), unless a domestic or treaty exemption or reduction applies; see &#8220;ITEM
10. ADDITIONAL INFORMATION &#8212; 5. Taxation &#8212; Material Dutch Tax Considerations.&#8221; As of January 1, 2024, a Dutch conditional
withholding tax will be imposed on dividends paid to related entities in jurisdictions that have a corporate income tax rate below 9%
(low-tax jurisdiction) or jurisdictions that are included on the EU&#8217;s blacklist of non-cooperative jurisdictions (non-cooperative
jurisdictions for tax purposes). In addition, the conditional withholding tax on dividends may also apply in situations where artificial
structures are put in place with the main purpose or one of the main purposes to avoid the conditional withholding tax or in the event
of a hybrid mismatch. The conditional withholding tax will be imposed at the highest Dutch corporate income tax rate in effect at the
time of the distribution (currently 25.8%). The conditional withholding tax on dividends will be reduced, but not below zero, by any
regular Dutch dividend withholding tax withheld in respect of the same dividend payment. As such, based on the currently applicable rates,
the overall effective tax rate of withholding the regular dividend withholding tax and conditional withholding tax will not exceed the
highest corporate income tax rate in effect at the time of the distribution (currently 25.8%). As of January 1, 2024, the withholding
tax rate on dividends paid to shareholders that are (A) entities related (<i>gelieerd</i>) to us and (B)(i) established in a low-taxing
state or non-cooperative jurisdiction for tax purposes, (ii) a hybrid entity or reverse hybrid entity or (iii) interposed to avoid tax
otherwise due by another entity, may rise from 15% to the highest corporate tax rate (currently 25.8%).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
are a Dutch public company with limited liability. The rights of our shareholders are different from the rights of shareholders in companies
governed by the laws of U.S. jurisdictions and may not protect investors in a similar fashion afforded by incorporation in a U.S. jurisdiction</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a public company with limited liability (<i>naamloze vennootschap</i>) organized under the laws of the Netherlands. Our corporate
affairs are governed by our Articles of Association and by the laws governing companies incorporated in the Netherlands. However, there
can be no assurance that Dutch law will not change in the future or that it will serve to protect investors in a similar fashion afforded
under corporate law principles in the United States, which could adversely affect the rights of investors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
rights of shareholders and the responsibilities of directors may be different from the rights and obligations of shareholders and board
members in companies governed by U.S. law. In the performance of its duties, our executive officers and board of directors are required
by Dutch law to consider the interests of our company, its shareholders, its employees and other stakeholders, in all cases with due
observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are
different from, or in addition to, your interests as a shareholder.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Provisions
of our Articles of Association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent,
delay or frustrate any attempt to replace or remove the members of our board of directors</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Under
Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. Our governance
arrangements include several provisions that may have the effect of making a takeover of our company more difficult or less attractive.
In this respect, our general meeting of shareholders granted the right to an independent foundation under Dutch law, or protective foundation,
to acquire preferred shares pursuant to a call option agreement, or the call option agreement, entered into between us and such foundation.
This call option under the call option agreement shall be continuous in nature and can be exercised repeatedly on multiple occasions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
the protective foundation exercises the call option pursuant to the call option agreement, an amount of preferred shares up to 100% of
our issued capital held by others than the protective foundation, minus one share, will be issued to the protective foundation. These
preferred shares will be issued to the protective foundation under the obligation to pay up to 25% of their nominal value upon issuance.
In order for the protective foundation to finance the issue price in relation to the preferred shares, the protective foundation is expected
to enter into a finance arrangement with a bank. As an alternative to securing financing with a bank, subject to applicable restrictions
under Dutch law, the call option agreement provides that the protective foundation may request us to provide, or cause our subsidiaries
to provide, sufficient funding to the protective foundation to enable it to satisfy the payment obligation (or part thereof) in cash
and/or to charge an amount equal to the payment obligation (or part thereof) against our profits and/or reserves in satisfaction of such
payment obligation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
protective foundation&#8217;s articles of association provide that it will promote and protect the interests of the company, the business
connected with the company and the company&#8217;s stakeholders from time to time, and repressing possible influences which could threaten
the strategy, continuity, independence and/or identity of the company or the business connected with it, to such an extent that this
could be considered to be damaging to the aforementioned interests. These influences may include a third party acquiring a significant
percentage of our ordinary shares, the announcement of an unsolicited public offer for our ordinary shares, shareholder activism, other
concentration of control over our ordinary shares or any other form of undue pressure on us to alter our strategic policies. The protective
foundation shall be structured to operate independently of us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
the protective foundation were to exercise its call option, the preferred shares to be issued pursuant thereto would be issued against
the obligation to pay up to 25% of their nominal value. The voting rights of our shares are based on nominal value and, as we expect
our ordinary shares to trade substantially in excess of nominal value, preferred shares issued at 25% of their nominal value can carry
significant voting power for a substantially reduced price compared to the price of our ordinary shares and thus can be used as a defensive
measure. These preferred shares will have both a liquidation and dividend preference over our ordinary shares and will accrue cash dividends
at a pre-determined rate. The protective foundation would be expected to require us to cancel its preferred shares once the perceived
threat to the company and its stakeholders has been removed or sufficiently mitigated or neutralized. However, subject to the same limitations
described above, the protective foundation would continue to have the right to exercise the call option in the future in response to
a new threat to the interests of us, our business and our stakeholders from time to time.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, certain provisions of our Articles of Association may make it more difficult for a third party to acquire control of us or
effect a change in our board of directors. These provisions include: a provision that our directors are appointed on the basis of a binding
nomination prepared by our board of directors which can only be overruled by a two-thirds majority of votes cast representing more than
50% of our issued share capital; a provision that our directors may only be removed by the general meeting of shareholders by a two-thirds
majority of votes cast representing more than 50% of our issued share capital (unless the removal is proposed by the board in which case
a simple majority of the votes can be sufficient); and a requirement that certain matters, including an amendment of our Articles of
Association, may only be brought to our shareholders for a vote upon a proposal by our board of directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
are not obligated to and do not comply with all the best practice provisions of the DCGC. This may affect your rights as a shareholder</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a Dutch public company with limited liability (<i>naamloze vennootschap</i>), and we are subject to the DCGC. The DCGC contains both
principles and best practice provisions that regulate relations between the board of directors and the shareholders (such as the general
meeting of shareholders). The DCGC is based on a &#8220;comply or explain&#8221; principle. Accordingly, companies are required to disclose
in their annual reports, filed in the Netherlands, whether they comply with the provisions of the DCGC. If they do not comply with those
provisions (for example, because of a conflicting Nasdaq requirement), the company is required to give the reasons for such non-compliance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, including
Nasdaq. We do not comply with all the best practice provisions of the DCGC. This may affect your rights as a shareholder and you may
not have the same level of protection as a shareholder in a Dutch company that fully complies with the DCGC.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Claims
of U.S. civil liabilities may not be enforceable against us</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are incorporated under the laws of the Netherlands, and our headquarters are located in Germany. Substantially all of our assets are
located outside the United States. The majority of our directors and executive officers reside outside the United States. As a result,
it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them
or us in U.S. courts, including judgements predicated upon the civil liability provisions of the federal securities laws of the United
States.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">There
is no treaty between the United States and the Netherlands for the mutual recognition and enforcement of judgements (other than arbitration
awards) in civil and commercial matters. Therefore, a final judgement for the payment of money rendered by any federal or state court
in the United States based on civil liability, whether or not predicated solely upon the U.S. federal securities laws, would not be enforceable
in the Netherlands unless the underlying claim is relitigated before a Dutch court of competent jurisdiction. Under current practice,
however, a Dutch court will generally, subject to compliance with certain procedural requirements, grant the same judgement without a
review of the merits of the underlying claim if such judgement (i) is a final judgement and has been rendered by a court which has established
its jurisdiction vis-&#224;-vis the relevant Dutch companies or Dutch company, as the case may be, on the basis of internationally
accepted grounds of jurisdiction, (ii) has not been rendered in violation of principles of proper procedure (<i>behoorlijke</i>&#160;<i>rechtspleging</i>),
(iii) is not contrary to the public policy of the Netherlands, and (iv) is not incompatible with (a) a prior judgement of a Netherlands
court rendered in a dispute between the same parties, or (b) a prior judgement of a foreign court rendered in a dispute between the same
parties, concerning the same subject matter and based on the same cause of action, provided that such prior judgement is capable of being
recognized in the Netherlands. Dutch courts may deny the recognition and enforcement of punitive damages or other awards.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Moreover,
a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary
to compensate actual losses or damages. Enforcement and recognition of judgements of U.S. courts in the Netherlands are solely governed
by the provisions of the Dutch Code of Civil Procedure. Based on the foregoing, there can be no assurance that U.S. investors will be
able to enforce any judgements obtained in U.S. courts in civil and commercial matters, including judgements under the U.S. federal securities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
United States and Germany do not have a treaty providing for the reciprocal recognition and enforcement of judgements in civil and commercial
matters. Consequently, a final judgement for payment or declaratory judgements given by a court in the United States, whether or not
predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in Germany. German courts may deny
the recognition and enforcement of a judgement rendered by a U.S. court if they consider the U.S. court not to be competent or the decision
to be in violation of German public policy principles. For example, judgements awarding punitive damages are generally not enforceable
in Germany. A German court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they
are necessary to compensate actual losses or damages.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, actions brought in a German court against us, our directors, our executive officers and the experts named herein to enforce
liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, German courts generally do not
award punitive damages. Litigation in Germany is also subject to rules of procedure that differ from the U.S. rules, including with respect
to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs. German procedural law does not
provide for pre-trial discovery of documents, nor does Germany support pre-trial discovery of documents under the 1970 Hague Evidence
Convention. Proceedings in Germany would have to be conducted in the German language and all documents submitted to the court would,
in principle, have to be translated into German. For these reasons, it may be difficult for a U.S. investor to bring an original action
in a German court predicated upon the civil liability provisions of the U.S. federal securities laws against us, our directors, our executive
officers and the experts named in this Annual Report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Based
on the lack of a treaty as described above, U.S. investors may not be able to enforce against us or directors, executive officers or
certain experts named herein who are residents of or possessing assets in the Netherlands, Germany, or other countries other than the
United States any judgements obtained in U.S. courts in civil and commercial matters, including judgements under the U.S. federal securities
laws.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">General
Risk Factors</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>General
economic, political and social conditions.</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Our business and results of operations may be adversely affected by disruptions in the financial
markets, changes to political and regulatory policies and economic conditions generally</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">General
economic, political and social conditions affect the United States, Europe and other global markets and our business. In particular,
U.S., European and other global markets, as well as our access to financing, may be affected by factors, including economic growth or
its sustainability, persistent inflation, supply chain disruptions, employment levels, work stoppages, labor shortages and labor disputes,
labor costs, wage stagnation, energy prices, oil, gas and fuel prices, fluctuations or other significant changes in both debt and equity
capital markets and currencies, liquidity of the global financial markets, the growth of global trade and commerce, trade policies, the
availability and cost of capital and credit (including as a result of increased interest rates) and investor sentiment and confidence.
Additionally, global markets may be adversely affected by the current or anticipated impact of cyber incidents or campaigns, military
conflict, including the Russia-Ukraine conflict as well as the Hamas-Israel conflict and rising tensions between China and Taiwan and
the relationship between China and the United States, or other geopolitical uncertainty and instability. The ongoing spread of variants
of infectious diseases, such as the COVID-19 virus, may interrupt, or delay, our clinical trial activities, regulatory reviews, manufacturing
activities and supply chain. The COVID-19 outbreak delayed enrollment in our clinical trials due to prioritization of hospital resources
towards the outbreak or other factors, and some patients may be unwilling to enroll in our trials or be unable to comply with clinical
trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct clinical
trials or release clinical trial results and could delay our ability to obtain regulatory approvals and commercialize our product candidates.
Any sudden or prolonged market downturn in the United States or elsewhere could adversely affect our business, results of operations
and financial condition, including capital and liquidity levels.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Legal,
regulatory or market measures to address environmental and other objectives may negatively affect our business or operations</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory
and legislative bodies in the United States, Europe and elsewhere continue to focus on environmental, social and governance, or ESG,
matters including increasing attention on relating to climate change, greenhouse gas emissions, carbon taxes, emissions trading schemes,
sustainable manufacturing, human rights and equity matters, and disclosure regarding the foregoing, many of which policies may be ambiguous,
inconsistent, dynamic or conflicting. We expect to experience increased restrictions, compliance costs, legal costs and expenses related
to such new or changing legal or regulatory requirements. Moreover, compliance with any such legal or regulatory requirements would require
us to devote substantial time and attention to these matters. In addition, we may still be subject to penalties or potential litigation
if such laws and regulations are interpreted or applied in a manner inconsistent with our practices. Additionally, we are subject to
increased attention from the media, stockholders, activists and other stakeholders on climate change, social and sustainability matters,
which could negatively affect our reputation or investor confidence.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
may not be able to maintain sufficient insurance to cover us for potential litigation or other risks</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
may not be able to maintain sufficient insurance on commercially reasonable terms or with adequate coverage levels against potential
liabilities we may face in connection with potential claims, which could have a material adverse effect on our business. We may face
a risk of loss from a variety of claims, including related to securities, antitrust, contracts, cybersecurity, fraud and various other
potential claims, whether or not such claims are valid. Insurance and other safeguards might only partially reimburse us for our losses,
if at all, and if a claim is successful and exceeds or is not covered by our insurance policies, we may be required to pay a substantial
amount in respect of such successful claim. Certain losses of a catastrophic nature, such as losses arising as a result of wars, earthquakes,
typhoons, terrorist attacks or other similar events, may be uninsurable or may only be insurable at rates that are so high that maintaining
coverage would cause an adverse impact on our business, our investment funds and their investments. In general, losses related to terrorism
are becoming harder and more expensive to insure against. Some insurers are excluding terrorism coverage from their all-risk policies.
In some cases, insurers are offering significantly limited coverage against terrorist acts for additional premiums, which can greatly
increase the total cost of casualty insurance for a property. As a result, we, our products and their investments may not be insured
against terrorism or certain other catastrophic losses.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Raising
additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
expect our expenses may increase in connection with expansion of operations. To the extent that we raise additional capital through the
issuance of ordinary shares, convertible securities or other equity securities, your ownership interest may be diluted, and the terms
of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights
as an ordinary shareholder. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements
that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital
expenditures, creating liens, redeeming shares or declaring dividends, that could adversely impact our ability to conduct our business.
In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate
amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development
of our product candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
we raise additional funds through collaborations or marketing, distribution or licensing arrangements with third parties, we may have
to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not
be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our
product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise
prefer to develop and market ourselves.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do, and reducing or eliminating our commercial opportunity</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we, or any future collaborators,
may develop. Our competitors also may obtain the FDA or other marketing approval for their products before we, or any future collaborators,
are able to obtain approval for ours, which could result in our competitors establishing a strong market position before we, or any future
collaborators, are able to enter the market.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Many
of our existing and potential future competitors have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining marketing approvals and marketing approved products than we
do, and may be able to reduce the price at which they sell their products. Mergers and acquisitions in the pharmaceutical and biotechnology
industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies
may also prove to be significant competitors, particularly if acquired by, or through collaborative arrangements with, large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing
clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary
for, the development of our product candidates.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
development and commercialization of new products is highly competitive. We expect that we, and any future collaborators, will face significant
competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide with respect
to any of our product candidates that we, or any future collaborators, may seek to develop or commercialize in the future. For example,
other pharmaceutical companies may commence development efforts for product candidates targeting the same indications as vilobelimab,
including PG and severe COVID-19 or any other indications we may target. For a detailed analysis of the competitive environment in which
we operate, see &#8220;ITEM 4. INFORMATION ON THE COMPANY &#8212; 2. Business Overview &#8212; Competition.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>If
any product liability lawsuits are successfully brought against us or any of our collaboration partners, we may incur substantial liabilities
and may be required to limit commercialization of our product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients and will
face an even greater risk if our product candidates are approved by regulatory authorities and introduced commercially. Product liability
claims may be brought against us or our partners by participants enrolled in our clinical trials, patients, health care providers or
others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such
claims, we may incur substantial liabilities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety
and quality of our products. We could be adversely affected if we are subject to negative publicity associated with illness or other
adverse effects resulting from patients&#8217; use or misuse of our products or any similar products distributed by other companies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Although
we maintain product liability insurance coverage, this insurance may not fully cover potential liabilities that we may incur. The cost
of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase
our insurance coverage if we commercialize any product that receives marketing approval. In addition, insurance coverage is becoming
increasingly expensive and difficult to obtain. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to
otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and
sale of our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>We
may be unsuccessful in evaluating material risks involved in future acquisitions</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
may, in the future, acquire companies, products and/or platforms that are complementary to our operational and customer needs. As part
of the process, we may conduct business, legal and financial due diligence to identify and evaluate material risks involved in any particular
transaction. Despite these efforts, we may be unsuccessful in ascertaining or evaluating all such risks. As a result, the intended advantages
of any given acquisition may not be realized. If we fail to identify certain material risks from one or more acquisitions we may be exposed
to significant costs and our business could be negatively impacted.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Cyber
incidents or other failures in IT systems could result in information theft, data corruption and significant disruption of our business
operations</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with
our business activities. As use of digital technologies has increased, cyber incidents, including deliberate cyber-attacks and attempts
to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication, both internal and those
provided by third-party service provider. These threats pose a risk to the security of our systems and networks, the confidentiality
and the availability and integrity of our data. The wars in Europe and in the Middle East, as well as the tensions between China and
Taiwan  may also result in heightened cybersecurity risk across our networks and platforms. We have implemented processes, procedures
and internal control to mitigate cybersecurity risks and cyber intrusions and rely on industry accepted security measures and technology
to securely maintain confidential and proprietary information maintained on our information systems. However, these measures, as well
as our increased awareness of the nature and extent of a risk of a cyber-incident, do not guarantee that a cyber-incident will not occur
or that our financial results, operations or confidential information will not be negatively impacted by such an incident, especially
because cyber threats change frequently or are not recognized until launched and because cyber incidents can originate from a wide variety
of sources. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other
contractors and consultants will be successful in protecting our clinical and other data that is stored on their systems.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
a cyber incident were to occur and cause interruptions in our operations or any destruction or loss, corruption or unavailability of
data, it could result in loss or misappropriation of confidential information, including trade secrets, other intellectual property or
financial information, and a material disruption of our development programs and business operations, any of which could lead to significant
delays or setbacks in our research and other further development and commercialization of our product candidates. For example, the loss
of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Finally, there has been significant evolution and developments in
the use of artificial intelligence technologies, such as artificial generative chatbots. We cannot fully determine the impact or cybersecurity
risk of such evolving technology to our business at this time.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Any
such cyber incident or destruction or loss of data could have a material adverse effect on our business and prospects. In addition, we
may suffer reputational harm or face litigation or adverse regulatory action as a result of cyber incidents, including cyber-attacks
or other data security breaches, and may incur significant additional expense to implement further data protection measures.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>The
legal and regulatory environment related to data privacy is becoming stricter, which could result in additional costs or changes to the
manner in which we handle personal information, and a failure to comply with such laws or regulations, or to otherwise protect personal
data in our possession or control, could result in fines, litigation, or other penalties as well as reputational damage</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are subject to laws, regulations, and contractual obligations related to privacy, data protection, information security, including (i)
the EU General Data Protection Regulation, which came into effect on May 25, 2018, and which provides for greater penalties for noncompliance
than previous European data protection laws, with potential fines of up to the greater of &#8364;20 million or 4% of total annual worldwide
turnover and (ii) the California Consumer Privacy Act, which came into effect on January 1, 2020, and provides for civil penalties for
violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
privacy, data protection and information security laws evolve and are implemented, interpreted and applied, our compliance costs may
increase, particularly in the context of ensuring that adequate data protection and data transfer mechanisms are in place. Additionally,
compliance with such obligations and regulations could significantly impact our current and planned privacy and information security
practices, our collection, use, sharing, retention and safeguarding of personal data, and our current and planned business activities
and operations. A failure to comply with such obligations or regulations could result in fines, litigation, or other penalties and adversely
impact our reputation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>If
our internal controls over financial reporting fail to be effective, such failure could result in material misstatements in our financial
statements, cause investors to lose confidence in our reported financial and other public information and have a negative effect on the
trading price of our ordinary shares</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Effective
internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation could cause us to fail to meet our reporting obligations. Section 404 of the Sarbanes-Oxley Act of 2002 requires
management of public companies to develop and implement internal controls over financial reporting and evaluate the effectiveness thereof.
If we fail to design and operate effective internal controls, it could result in material misstatements in our financial statements,
impair our ability to raise revenue, result in the loss of investor confidence in the reliability of our financial statements and subject
us to regulatory scrutiny and sanctions, which in turn could harm the market value of our ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Banking
system risk</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
regularly maintain cash balances at third-party financial institutions in excess of the FDIC or other comparable foreign country (i.e.,
Germany) deposit insurance limits. If any banks or financial institutions at which we maintain cash balances enter receivership or become
insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access
our existing cash, cash equivalents and investments, or to draw on our existing lines of credit, may be threatened and could have a material
adverse effect on our business and financial condition.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">ITEM 4. INFORMATION ON THE COMPANY</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_015"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">History
and development of the company</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system. We do this by applying
our proprietary technologies to discover, develop and commercialize first-in-class, highly potent and specific inhibitors of the complement
activation factor known as C5a and its receptor C5aR. The complement system is an integral part of the innate immune system and protects
the body, for example by recognizing and removing bacteria, viruses, and other infectious agents, collectively referred to as pathogens.
Terminal complement activation, to which the cleavage of C5 by C5-convertases is also referred to, leads to the release of C5a, which
acts through its receptor C5aR. In addition, terminal complement activation, i.e., the cleavage of C5a from C5, can also be achieved
directly through the extrinsic pathway by naturally occurring enzymes present throughout the body but not considered part of the complement
system. With our therapeutic product candidates, we target C5a and its receptor C5aR to selectively inhibit the powerful inflammatory
response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively
binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. We are and
have been developing vilobelimab in a wide array of complement-mediated diseases with significant unmet medical need. These include pyoderma
gangrenosum, or PG, a chronic inflammatory skin disorder for which we started a Phase&#160;III study with the first patient treated in
November 2023, the treatment of critically ill&#160;COVID-19&#160;patients, for which we concluded a Phase III study in March 2022 and subsequently
were granted the EUA by the FDA in April 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Up
to November 2023, we were also developing vilobelimab in cutaneous squamous cell carcinoma, or cSCC, in which we were running a Phase
II clinical study. We have also previously conducted Phase II studies with vilobelimab in other diseases, including hidradenitis suppurativa,
or HS, a chronic debilitating systemic inflammatory skin disease and ANCA-associated vasculitis, or AAV, a rare and life-threatening
autoimmune disease.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are also developing INF904, an orally administered, small-molecule inhibitor of C5aR, for which we have completed Phase I study in
healthy volunteers and plan to initiate Phase II clinical studies in the future. INF904 is a promising product candidate for being
developed in several disease areas of inflammation, where orally available therapeutics are not available or do not meet the medical
need. INF904 development will initially be targeted at chronic spontaneous urticaria, or CSU, and HS.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are also developing IFX002, a life-cycle management product for vilobelimab, which is currently in advanced pre-clinical stage.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
legal and commercial name is InflaRx N.V and we were incorporated under the laws of the Netherlands on June 6, 2017, and our headquarters,
as registered with the local court of Jena, is located in Jena, Germany. InflaRx was founded in 2007 as InflaRx GmbH by Professor Niels
Riedemann and Professor Renfeng Guo in Jena, Germany. Our agent for service of process in the United States is InflaRx Pharmaceuticals,
Inc. located at 600 South Wagner Road, Ann Arbor, Michigan 48103. Our principal executive offices and laboratories are located in Winzerlaer
Str. 2, 07745 Jena, Germany, telephone: (+49) 3641 508 180. We have additional offices in Planegg-Martinsried (Munich), Germany and in
Ann Arbor, Michigan, United States, where we also have laboratories.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
employ a total of 66 employees, 22 of whom have M.D. or Ph.D. degrees. Our management team has extensive experience in the field of complement
research, clinical research and the biopharmaceutical industry. Both our Chief Executive Officer and founder, Professor (Dr.) Niels Riedemann,
and our Chief Scientific Officer and founder, Professor Renfeng Guo, have over 20 years of complement research experience, having published
extensively on the role and function of C5a and its receptors. Our Chief Financial Officer, Dr.&#160;Thomas Taapken, has served in executive
positions and boards for various private and public European biotechnology companies over the last 19 years and has over 25 years total
experience in managerial roles in the biopharmaceutical and venture capital industries. Our Chief Medical Officer, Dr. Camilla Chong,
has 25 years of experience in the global pharmaceutical industry in the areas of clinical development, medical affairs, clinical operations,
regulatory and pharmacovigilance as well as the launch of new medicines.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
SEC maintains a website that contains reports and other information about issuers, like us, that file Electronically with the SEC. The
address of that website is www.sec.gov. Our website can be found at www.inflarx.de. The information on our website is not incorporated
by reference into this Annual Report, and you should not consider information contained on our website to be a part of this Annual Report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_016"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
overview</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">C5a
is a central mediator of the complement system and therefore a critical component of the innate immune system. The most prominent role
of the complement system is to help the body defend itself against invading microorganisms through several mechanisms, including the
rapid creation of an inflammatory environment and the production of factors that directly kill pathogens and recruit immune cells to
sites of infection. Activation of the complement system ultimately results in the generation of C5a by cleavage from C5. C5a creates
an inflammatory environment by attracting and strongly activating neutrophils as well as by causing many different cell types to generate
pro-inflammatory molecules. Such inflammation normally benefits the body by helping to fight infection, but excessive or uncontrolled
generation of C5a, as it occurs in certain diseases, can cause severe damage to the body&#8217;s own tissue, thereby contributing to
the pathophysiology of many autoimmune and inflammatory diseases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">While
the mode of action of C5a in inflammation has been intensely researched and confirmed, developing a highly specific antibody with the
ability to fully block C5a while preserving a critical innate defense mechanism, the formation of the Membrane Attack Complex, or MAC,
has been challenging. As such, there are currently no approved drugs that specifically target C5a. We identified antibodies, including
our lead product candidate vilobelimab, that potently and selectively bind to a conformational epitope that is formed by C5a upon the
cleavage of C5a from C5 that completely blocks C5a without compromising important upstream functions of the complement system, as well
as MAC formation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Unlike
its ligand C5a, C5aR can also be pharmacologically inhibited by small molecules. It is generally believed that blockade of C5a using
antibodies offers a fast, complete, and safe way to control C5a-induced inflammation. The advantage of a small molecule inhibitor to
C5aR is that it can be administered orally, thereby offering broad, long-term ease of administration to patients, especially for the
treatment of chronic diseases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Through
our in-house drug discovery efforts, we identified a potent inhibitor of the C5a receptor, INF904, which we believe is a promising candidate
for development. We are currently developing INF904, an oral, low molecular weight drug candidate that targets the C5aR receptor. We
plan on targeting complement-mediated, chronic auto-immune and inflammatory conditions where an oral small molecule is needed for patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Given
the different advantages of blocking C5a and C5aR, we believe that the development of both, C5a and C5aR blocking agents is possible
and potentially helpful to address a broader range of C5a/C5aR-molecular signaling axis-associated diseases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Based
on the broad anti-inflammatory properties, we are currently developing our lead anti-C5a antibody and our low molecular weight compound
INF904 in several diseases. An overview can be found in the pipeline description below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_001.jpg" style="height: 369px; width: 550px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 17.85pt"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Vilobelimab
for the treatment of PG</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">We
are developing vilobelimab for the treatment of&#160;PG. </span><span style="font-family: Times New Roman, Times, Serif">PG is a rare,
chronic inflammatory form of neutrophilic dermatosis characterized by accumulation of neutrophils in the affected skin areas. V<span>ilobelimab
was granted orphan drug designation for the treatment of PG by both the FDA in the United States and the EMA in Europe as well as fast
track designation by the FDA. After a series of interactions with </span>the <span>FDA on the results
of our successfully conducted Phase II clinical study and our plans for the further development</span> towards a potential BLA submission<span>,
</span>in 2023 we <span>announced </span>the start of a Phase III study with vilobelimab in ulcerative
PG. In November 2023, we announced the enrollment of the first patient in the study.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Vilobelimab
for the treatment of severe COVID-19</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
April 2023, we received an EUA from FDA for GOHIBIC (vilobelimab) for the treatment of critically ill, invasively mechanically ventilated
COVID-19 patients. The EUA is supported by the previously announced results of the multicenter Phase III PANAMO trial, which demonstrated
a relative reduction in 28-day all-cause mortality by 23.9%. Subsequently, in June 2023, we began the commercialization of GOHIBIC (vilobelimab)
in the United States under the EUA. Our MAA application for SARS-CoV-2 induced septic acute respiratory distress syndrome, or ARDS, receiving
IMV or ECMO for vilobelimab is under regulatory review by the European Committee for Medicinal Products for Human Use, or CHMP, under
the centralized procedure, which applies to all 27 member states of the EU. To support our development, we had received a total of &#8364;33.3&#160;million
as grant to us awarded by the German Federal Government for the period of October 2021 to June 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Vilobelimab
for the treatment of hidradenitis suppurativa, or HS</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have been developing vilobelimab for the treatment of HS. After having failed to meet our primary endpoint in an international Phase
IIb study in 2019, in a post-hoc analysis of the study data we showed multiple signals of efficacy for the vilobelimab high dose group
compared to the placebo group, demonstrating significant reductions in all combined inflammatory lesions, reductions of draining tunnels,
or dTs, and reductions of the IHS4 score. Subsequently, we had several interactions with the FDA with the goal of agreeing on the possible
design of a pivotal Phase III program for vilobelimab for the treatment of HS. Following the advice received in a Type A meeting with
the FDA, in the fourth quarter of 2021, we submitted a full clinical trial protocol for the planned clinical Phase III trial of vilobelimab
in HS and in January 2022 we initiated a randomized, double-blind, placebo-controlled, multi-center pivotal Phase III study to determine
efficacy and safety of vilobelimab in patients with moderate to severe HS and active dTs with a modified primary clinical endpoint called
m-HiSCR. Subsequently, the FDA provided conflicting advice to us, which was subsequently corrected, but in the meantime, we had halted
the Phase III clinical program and are currently evaluating next steps regarding the development of vilobelimab in HS. Based on the logistical
and financial effort necessary to successfully complete such a Phase III development program, we are assessing various future possible
options to further this development, including collaborations with pharmaceutical partners.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Vilobelimab
for the treatment of ANCA-associated vasculitis (AAV)</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have also been developing vilobelimab for the treatment of AAV. Our clinical development strategy for vilobelimab in AAV first focused
on acutely ill AAV patients, where we believe vilobelimab has the potential to successfully induce remission and reduce or eliminate
the need for high-dose corticosteroid, or HDCS, therapy and providing an improved safety profile. We also intend to focus on speed of
induction of remission and reducing the rate of renal replacement and kidney dysfunction. After the successful completion of two Phase
II studies in 2021, we are currently evaluating next steps regarding the development of vilobelimab in AAV. Based on the logistical and
financial effort necessary to successfully complete a pivotal Phase&#160;III development program, we are currently assessing possible
options to further this development including collaborations with pharmaceutical partners.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Anti-Ca5R
inhibitor INF904</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">To
expand the breadth of our anti-C5a/C5aR technologies, we are also developing INF904, a product candidate that targets the C5aR receptor.
In INF904, we discovered a small molecule C5aR inhibitor that in pre-clinical studies has shown potential for superior characteristics
to the only approved C5aR inhibitor, avacopan. INF904 has provided higher plasma exposure in animals, including non-human primates, and
improved inhibitory activity in a hamster neutropenia model compared to avacopan. Furthermore, in contrast to avacopan, in vitro experiments
showed INF904 has substantially less inhibition of the cytochrome P450 enzymes 3A4/5 (CYP3A4/5). INF904 demonstrated potential for anti-inflammatory
therapeutic effects in several preclinical disease models. In January 2024, we announced the positive results of a single and multiple
ascending dose study with INF904 in healthy volunteers. We plan to initiate Phase II clinical studies in the future. INF904 is a promising
product candidate for being developed in several disease areas of inflammation, where orally available therapeutics are not available
or a medical need exists despite availability of other therapies.</span></p><div>



</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>INF904
for the treatment of CSU</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We also intend to pursue development of INF904 for the treatment of CSU. CSU is a debilitating and unpredictable
skin disease characterized by intensely itchy hives / wheals and angioedema. The burden of this chronic disease is high and impacts sleep,
mental health, quality of life and productivity due to absences from school and work. CSU is estimated to affect around 40 million people
worldwide. CSU patients have been reported to show elevated C5a levels, a major activator of mast cells and basophils which are thought
to be significant contributors to CSU pathogenesis. In addition, studies suggest that complement activation (including C5a) in CSU can
lead to histamine release. Current treatments are limited, and a significant unmet need exists in a sizable proportion of patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>INF904
for the treatment of HS</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We also intend to pursue development of INF904 for the treatment of HS. HS is a chronic, recurrent, debilitating
neutrophil-driven inflammatory disease that can persist for years and tremendously impacts quality of life; it is characterized by abscesses,
nodules and draining tunnels which can flare and cause scarring. INF904 inhibits the known C5a-induced effects on neutrophil activation
and tissue accumulation of immune cells, including generation of tissue damaging mechanisms (enzyme release and oxidative radical formation)
as well as induction of NETosis &#8211; mechanisms thought to be involved in HS progression and draining tunnel formation. Clinical evidence
with existing C5a/C5aR products also supports that blocking this pathway reduces lesion counts. Patients&#8217; responses to treatment
with approved anti-TNF-alpha or anti-IL17 drugs are known to wane over time in a significant number of cases; and treatment with new mechanisms
are needed for these patients.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Anti-C5a
antibody IFX002</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are also developing IFX002 for the treatment of chronic inflammatory diseases. IFX002 is a highly potent anti- C5a antibody, which binds
to the same domain of the C5a protein as vilobelimab, but which has a higher humanization grade and altered pharmacokinetic properties
compared to vilobelimab. IFX002 is currently in preclinical development. We consider IFX002 to be a life-cycle management product to
vilobelimab, given the long remaining patent life of IFX002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Vilobelimab
for the treatment of cutaneous squamous cell carcinoma (cSCC)</i></b></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have been developing vilobelimab for the treatment of PD-1 / PD-L1 inhibitor resistant / refractory locally advanced or metastatic cSCC.
We have been recruiting patients in two independent arms, vilobelimab as monotherapy and in combination with pembrolizumab. The main
objectives of the trial were to assess the safety and antitumor activity of vilobelimab monotherapy and to determine the maximum tolerated
or recommended dose, safety and antitumor activity in the combination arm in order to evaluate and establish the safety of vilobelimab
in cSCC patients. The initial treatment responses of the study were encouraging. However, in view of the recent emergence of new alternative
treatments for cSCC and the recommendation by our U.S. and international clinical experts to change course and to study additional patients
with a higher dose of vilobelimab as monotherapy in a larger cohort, we have decided to cease the development in cSCC for the time being
to prioritize our efforts and to reallocate our resources towards the development of our orally available C5aR inhibitor INF904. Nonetheless,
patients who are currently in treatment will be treated for up to 24 months according to the protocol. However, we will not enroll any
new patients in the study and we will close clinical sites in which no patients are being treated. Our decision to wind down this clinical
study does not preclude us from considering the development of vilobelimab or INF904 in this or similar oncological indications in the
future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>For
more information on our technology or our development programs please refer to the detailed information included herein below.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our technology</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">C5a
is a central mediator of the complement system and therefore a critical component of the innate immune system. The most prominent role
of the complement system is to help the body defend itself against invading microorganisms through several mechanisms, including the
rapid creation of an inflammatory environment and the production of factors that directly kill pathogens and recruit immune cells to
sites of infection. Activation of the complement system ultimately results in the generation of C5a by cleavage from C5. C5a creates
an inflammatory environment by attracting and strongly activating neutrophils as well as by causing many different cell types to generate
pro-inflammatory molecules.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>The
complement system and role of the C5a/C5aR axis as critical component in the immune system and the need for control</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
complement cascade consists of approximately 30 interacting proteins and forms a critical component of the innate immune system. This
system protects the body, for example by recognizing and removing bacteria, viruses and other infectious agents, collectively referred
to as pathogens. Activation of the complement system leads to a series of enzyme-like reactions that produce factors that both directly
kill pathogens and recruit immune cells to sites of infection. This activation can be triggered via three major pathways: the classical
pathway, the mannose binding lectin, or MBL, pathway and the alternative pathway. Activation of any pathway will lead to the cleavage
of C3 and formation of C5-convertases. Terminal complement activation, which is also referred to as cleavage of C5, can be achieved by
these C5 convertases. In addition, terminal complement activation can also be achieved directly through the extrinsic pathway by naturally
occurring enzymes present throughout the body but not considered part of the complement system.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cleavage
of C5 results in the generation of C5a and C5b, two molecules with distinct biological activities. C5a is a strong inflammatory amplifier
that exerts its biological functions by binding to two different receptors, C5aR and C5L2. C5b on the other hand assembles with C6, C7,
C8 and many C9 molecules to form the MAC, an important intrinsic defense mechanism that causes the membranes of microorganisms to become
permeable, leading to their disintegration, or lysis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_002.jpg" style="height: 416px; width: 550px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Overview
of critical functions of the complement system</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
complement system serves many crucial functions within the innate immune response, such as:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Rapid
                                            creation of an inflammatory environment. </b>Production of pro-inflammatory molecules, such
                                            as C5a, optimizes the conditions under which enzymatic and other processes can act against
                                            microorganisms. These inflammatory conditions include the onset of a fever or release of
                                            aggressive enzymes and oxygen radicals by neutrophils.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Lysis
                                            of microorganisms through formation of the MAC. </b>A rapid, first-line defense mechanism
                                            resulting in the formation of pores in the cell membranes of invading microorganisms, leading
                                            to their disintegration.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Bridge
                                            to the adaptive immune system.</b> This function is promoted by an activation product of
                                            C3, called C3b, which tags particles and makes them visible and more easily processed by
                                            immune stimulatory cells. Such cells then present these particles to B-cells, which in turn
                                            generate antibodies against the particles, leading to targeted elimination. This mechanism
                                            takes a few weeks to take full effect.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Clearance
                                            of dead cell particles.</b> The complement system also serves various other purposes, including
                                            the clearance of dead cell particles from the body. This function is especially important
                                            because uncleared cell particles are believed to potentially induce generation of antibodies
                                            against normal cells and tissues, leading to autoimmune inflammatory responses and diseases.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Need
for control</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Complement
activation is a double-edged sword: the fast acting and relatively non-specific functions of pro-inflammatory responses driven by C5a
and the lysis of microorganisms through MAC formation are usually very tightly controlled. However, inappropriate activation of the system
can quickly turn it from a beneficial defense system into an uncontrolled inflammatory response. C5a&#8217;s uncontrolled activity in
certain disease states can generate an inflammatory environment within the body that results in tissue damage and promotes pro-inflammatory
T-cell autoimmune responses. The resulting tissue damage is believed to critically contribute to the disease progression of many acute
as well as chronic inflammatory and autoimmune diseases, particularly during flare-up phases. Examples of this include Lupus disease,
inflammatory bowel disease and neutrophil-driven diseases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Despite
the MAC&#8217;s role as a rapid, first-line defense mechanism, MAC formation can also result in damage to our body&#8217;s cells in some
diseases. Normally, the body&#8217;s cells and tissues are protected from MAC-mediated lysis through surface inhibitors that prevent
MAC formation. However, in paroxysmal nocturnal hemoglobinurea, or PNH, the patients&#8217; cells lack the ability to hold MAC inhibitors
on their cell surface, resulting in extreme susceptibility to MAC-related cell lysis. In addition, patients with diseases involving the
kidney endothelial cells, such as atypical hemolytic uremic syndrome and certain forms of glomerulonephritis, also often appear to be
burdened by MAC-related damage. Blockade of MAC formation in these very rare diseases can be lifesaving.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">While
blockade of MAC formation can be beneficial in certain circumstances, substantially blocking MAC formation can also result in susceptibility
to life-threatening infections. For example, patients dosed with drugs that block MAC formation, such as with the marketed antibody eculizumab,
must be immunized against meningococcal disease, which also carries the risk of side effects. Therefore, it is desirable to leave MAC
formation intact when blocking complement-mediated damage in the broad variety of diseases in which an uncontrolled inflammatory response,
and especially C5a, has been described as key driver of the damage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
believe that C5a is a key inflammatory mediator driving tissue damage in many inflammatory diseases and thus represents a very meaningful
drug target with large therapeutic potential. Therefore, we have conducted substantial research since our inception to generate highly
specific antibodies targeting only C5a while leaving MAC formation intact, to deliver an ideal therapeutic approach for this attractive
target.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Mechanisms
of C5 activation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">C5
can be produced by many cells, including epithelial cells of various organs, T-cells and other immune competent cells. Terminal C5 activation
does not require activation of the three complement pathways and related formation of C5-convertases. Other enzymes can also directly
cleave and activate C5, such that functionally active C5a can be generated in the complete absence of other complement components. For
example, in the absence of other complement factors in the cell culture, lung epithelial cells can generate C5 upon stimulation, and
lung macrophages can cleave and activate C5, leading to generation of C5a. This example illustrates that C5 can be activated and C5a
can be generated independently from the complement pathways.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
further demonstrated that direct enzymatic cleavage of C5 occurs uninhibited in the presence of eculizumab, a known C5 inhibitor that
binds to the MG-7 domain of C5 and hinders the C5 convertases from engaging and binding to C5. This research suggests that direct enzymatic
cleavage of C5a from C5 works through a mechanism that is not blocked by C5 inhibitors such as eculizumab. Our studies further demonstrate
that patients sufficiently dosed with eculizumab may still display elevated plasma C5a levels, implying that C5 inhibitors like eculizumab
are not capable of fully blocking and controlling the C5a signaling pathway. Therefore, in diseases in which it plays a key promoting
role, we believe targeting C5a directly may yield a meaningful therapeutic benefit.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>C5a
and its role in disease and inflammation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">C5a
is a small, 74-amino acid-spanning protein whose biochemical and immunological properties have been well documented in the scientific
literature. C5a creates an inflammatory environment by attracting and strongly activating neutrophils as well as by causing many different
cell types to generate pro-inflammatory and inflammation-related molecules. While this can help the body to respond strongly and rapidly
to infections by optimizing the defense environment, uncontrolled C5a generation can induce damage to the body&#8217;s tissues in a broad
variety of diseases. As a result, we believe that controlling and limiting C5a generation in the body may prevent the negative effects
of an over-activated C5a immune response.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">C5a
quickly interacts with at least two independent receptors&#8212;C5aR and C5L2 (sometimes referred to as C5aR2). C5aR and C5L2 serve as
a large signaling pool for effects elicited by C5a. C5aR has been well characterized as a signaling receptor that can be strongly upregulated
in almost any cell across a variety of disease settings. Although less understood, C5L2 has also been shown to promote inflammation and
negatively affect outcomes in various experimental disease settings by promoting the adverse effects, or AEs, elicited by uncontrolled
C5a. Importantly, various other complement activation products (e.g., C3a, C3a-desArg and C4a) have been shown to bind to C5L2 and elicit
effects different from those elicited by C5a. Thus, blocking specifically C5a as achieved by use of vilobelimab will eliminate only C5a
mediated effects.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Role
of C5a in neutrophil-driven inflammatory diseases</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
the inflammatory response, C5a is an accelerator or &#8220;booster&#8221; of inflammation. This role of C5a extends to a broad variety
of responses, including the following mechanisms:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">C5a
                                            boosts the generation of many different cytokines such as IL-8, IL-6, IL17, TNF-alpha and
                                            others in a variety of cell types as well as within the bloodstream;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">C5a
                                            induces a complex change in the cell-signaling cascade of immune-competent cells that leads
                                            to an altered and often intensified signal transduction of other known signaling stimuli,
                                            such as the toll-like receptor signaling;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">C5a
                                            affects T-cell responses and causes a pro-inflammatory response, leading to the generation
                                            of further pro-inflammatory cytokines; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">C5a
                                            is capable of inducing adhesion molecule expression on the surfaces of blood vessels, leading
                                            to neutrophil adherence to the internal vessel wall and migration through the vessel to the
                                            site of infection.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">When
C5a binds to its receptors on neutrophils, they are strongly activated and move to the source of damage or infection, through a process
referred to as chemotaxis, generating oxygen radicals and activated enzymes both believed to be major contributors to cellular and tissue
damage in the body. In addition, C5a has been suggested to induce neutrophil extracellular trap, or NET, formation and a process in which
neutrophils undergo a certain form of cell death while forming NETs called Netosis, which is believed to cause additional inflammation
and damage in the tissue. Given this central function, C5a is a powerful tool that, when inappropriately activated, is capable of promoting
damage to the body, ultimately leading to organ dysfunction and failure.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Neutrophil
activation is assessed by observing the upregulation of the neutrophil surface marker CD11b (an established method to demonstrate neutrophil
activation). In studies conducted in 2013 and 2014 as part of an investigative project in collaboration with an investigator from the
University of Athens, we found that CD11b, as a marker for neutrophil activation, was greatly enhanced in fresh human whole blood from
healthy volunteers when either recombinant human C5a was added or when plasma from hidradenitis suppurativa patients was added. Vilobelimab,
our highly specific anti-C5a antibody, completely inhibited neutrophil activation resulting from the addition of the HS plasma, suggesting
that C5a may be the key mediator in plasma from patients affected by this disease, leading to neutrophil activation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto 0pt 56.5pt; text-align: left; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.1pt 0pt 56.7pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Flow
cytometry assay in fresh human whole blood demonstrating CD11b increase on blood neutrophils as marker of neutrophil activation: recombinant
human C5a strongly activates human neutrophils in whole blood (huPP-ctr + 20 nM rhC5a), which can be fully blocked by addition of vilobelimab
(&#8220;IFX-1&#8221; in the above graph) (huPP-ctr + 20 nM rhC5a + 20 nM vilobelimab) (open white bars). Plasma from two different HS
patients (pat088 and pat092) also activates human neutrophils in whole blood and this effect can be fully blocked by the addition of
vilobelimab (middle and darker grey bars) thus implying that C5a in HS patient plasma is the key neutrophil activating factor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.1pt 0pt 56.7pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Various
chronic inflammatory and autoimmune diseases in humans are characterized by flare-up phases during which substantial tissue damage occurs.
Given C5a&#8217;s numerous inflammatory promoting functions, blocking it in chronic inflammatory diseases may have a positive effect
on T-cell function, overall control of the inflammatory status of the disease and a strong anti-inflammatory effect on neutrophils, which
may reduce tissue damage during the flare-up phases. Multiple international research groups have demonstrated in various inflammatory
animal models that blocking the C5a/C5aR signaling axis leads to reduced inflammation, improved organ performance and favorable outcomes
on clinical endpoints, including improved mortality rate, disease severity or damage scores.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">C5a
also has been described as a potential disturbing factor for a balanced T-cell response by down-regulating regulatory T-cells and promoting
pro-inflammatory T-cell responses. Research published in 2013 in Nature Immunology and the Journal of Experimental Medicine demonstrated
that blocking the C5a/C5aR signaling axis in mice restored regulatory T-cell function, inhibiting the progression of induced autoimmune
diseases. Therefore, C5a is a potential drug target for the treatment of autoimmune and chronic inflammatory diseases associated with
T-cell imbalance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Role
of C5a in cancer growth and metastatic disease</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Different
cancer cells have been found to generate their own C5a when cultured in vitro in the absence of any other complement factors or intact
complement pathways. This result is possible because cancer cells produce C5, together with enzymes to directly cleave C5, thereby generating
functionally active C5a. Recent research suggests that C5a contributes to cancer growth and metastatic disease, with multiple mechanisms
proposed in the literature to explain this phenomenon. C5a appears to be associated with the recruitment and activation of myeloid-derived
suppressor cells, or MDSCs, in tumors. Activating MDSCs suppresses the important T-cell-mediated mechanisms that usually inhibit tumor
growth. Recently published findings in Cancer Cell in 2018 confirmed this mode of action that has been suggested in earlier published
work. In addition, C5a generates a microenvironment favorable for tumor growth by increasing angiogenesis and enhancing the expression
of the checkpoint molecule PDL1, as well as other mediators that enable tumor growth. These and other existing data may explain why combined
therapy of anti-PD-1/PD-L1 and C5a blockade has been shown to effectively reduce tumor growth and metastasis in a pre-clinical mouse
model.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Role
of C5aR as potential target for therapeutic intervention</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Two
C5a receptors, C5aR (also known as C5aR1 or CD88) and C5aR2 (also known as C5L2 or GPR77), mediate the biological activities of C5a.
Activation of C5aR has broadly acknowledged proinflammatory effects, while the role of activation of C5aR2 remains less well understood
and recent scientific work has suggested a potential regulatory role on C5aR1 activation. In animal models of sepsis, anti-C5a treatment
ameliorated the development of inflammatory responses and improved survival. In addition, experimental evidence suggests that blockade
of C5aR signaling similarly improves survival in animals with sepsis. Finally, C5aR antagonists have shown excellent therapeutic effects
in numerous models of inflammatory diseases involving complement activation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Unlike
its ligand C5a, C5aR can be pharmacologically inhibited by small molecules. In October 2021, avacopan, an oral C5aR antagonist, received
market approval in the United States as an adjunctive treatment in adults for severe active ANCA-associated vasculitis (specifically
MPA and GPA) in combination with standard therapy including glucocorticoids.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">It
is generally believed that blockade of C5a using antibodies offers a fast, complete, and safe way to control C5a-induced inflammation.
The advantage of a low molecular weight compound inhibitor to C5aR is that it can be administered orally, thereby offering broad, long-term
ease of administration to patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Our
proprietary anti-C5a/C5aR technologies and product candidates</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Our
anti-C5a technology</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Despite
C5a&#8217;s well-characterized role in promoting inflammation and related tissue and organ damage in different diseases, no marketed
drug targeting C5a exists. Based on more than 17 years of research in this field, we believe the challenge in targeting C5a is to fully
block the biological functions of C5a in its natural environment and leave MAC formation intact. We believe our proprietary anti-C5a
technology enables us to overcome this challenge through our discovery of a novel epitope, or binding site, on C5a. We believe this conformational
epitope is formed only after the cleavage of C5a from the C5 molecule, suggesting that the three-dimensional structure of C5a changes
upon release from C5, creating new epitopes that are only present on the free C5a molecule. This permits binding to free C5a only after
it is cleaved from C5 and thus allows blocking of C5a while keeping MAC formation intact. We believe that this represents a breakthrough
in the field of terminal complement C5a inhibition and that this may be particularly valuable when treating diseases that are driven
by C5a, such as PG and severe COVID-19, cSCC, HS, AAV and others.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
identified antibodies, including our lead product candidate vilobelimab, that potently and selectively bind to a conformational epitope
that is formed by C5a upon the cleavage of C5a from C5 to completely block C5a without compromising important upstream functions of the
complement system, as well as MAC formation. We intend to discover and develop treatments leveraging our proprietary anti-C5a technology
to address a wide array of complement-mediated diseases with significant unmet needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_004.jpg" style="height: 338px; width: 550px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-left: 76.7pt; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.1pt 0pt 78pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A
conformational epitope on the surface of the C5a molecule allows for generation of highly specific blocking antibodies directed against
C5a.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.1pt 0pt 78pt; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.1pt 0pt 78pt; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.1pt 0pt 78pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
anti-C5a monoclonal antibodies are designed to have the following properties:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Complete
                                            immunological blockade and inhibition of C5a-induced effects:</b> The human body has an abundant
                                            capacity to generate C5a, and induce inflammatory effects through its two receptors, C5aR
                                            and C5L2. Therefore, our anti-C5a antibodies are designed to:</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td><span style="font-family: Times New Roman, Times, Serif">generate
                                            complete immunological blockade of the C5a molecule to achieve potent and effective treatments.
                                            Antibodies or inhibitors lacking this quality may leave a &#8220;signaling gap&#8221; for
                                            C5a, which, in a disease setting, will likely be sufficient to allow for strong pro-inflammatory
                                            effects. This signaling gap would limit the ability to silence the C5a/C5aR and C5a/C5L2
                                            signaling axis to achieve the desired therapeutic effect; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 36pt"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">o</span></td><td><span style="font-family: Times New Roman, Times, Serif">bind
                                            with high affinity to C5a to counteract the molecule&#8217;s rapid interactions with its
                                            two receptors, C5aR and C5L2, which are abundantly present on the vast majority of cell types
                                            in the human body and that can be upregulated in various disease settings.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Limited
                                            effect on MAC formation: </b>C5 blocking molecules that inhibit MAC formation in the blood
                                            increase the risk of life-threatening infections caused by encapsulated bacteria such as
                                            meningococci. Therefore, leaving MAC formation intact may offer a significant advantage in
                                            C5a driven diseases.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
believe that all these features are necessary for any drug targeting C5a, in order to achieve clinically meaningful pharmacological performance
for the treatment of C5a-driven diseases such as PG, severe COVID-19, cSCC or others. Furthermore, we believe that C5a-driven diseases
may not be effectively targeted with complement inhibitory approaches that do not specifically and fully block C5a. These approaches
such as blocking the complement pathway-driven cleavage of C5 or inhibiting the complement pathways upstream of C5, are characterized
by two fundamental shortcomings set forth below.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Inability
                                            to fully block C5a without targeting it directly:</b> C5a can be generated through C5 activation
                                            by various enzymes in the complete absence of the complement pathways. For example, blocking
                                            the complement C5-convertase-driven cleavage with the C5 inhibitor eculizumab cannot block
                                            direct enzymatic C5 activation and C5a generation in an experimental setting. This may explain
                                            why elevated C5a levels remain measurable in patients effectively dosed with eculizumab.
                                            Therefore, non-specific approaches that do not bind and inhibit C5a directly may fail to
                                            fully block its effects.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Lack
                                            of control over C5a&#8217;s signaling ability:</b> C5a receptors are abundantly present on
                                            the majority of cells in humans and can be strongly and rapidly upregulated in certain disease
                                            states. As such, even with low levels of C5a, the receptors create a large &#8220;signaling
                                            sink&#8221; providing an abundant ability for even small amounts of C5a to transmit a signal.
                                            Therefore, a fully blocking targeted C5a approach is warranted in order to achieve full control
                                            over C5a-induced signaling events that may be especially important in highly acute inflammatory
                                            settings.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Vilobelimab
as first-in-class anti-C5a monoclonal antibody</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
lead product candidate, vilobelimab, is an intravenously delivered monoclonal anti-C5a antibody. It is based on our proprietary anti-C5a
technology and was the first C5a monoclonal antibody to enter clinical development. Vilobelimab is differentiated by its ability to:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>fully
                                            inhibit C5a-induced signaling and derived biological functions</b>, as evidenced by its ability
                                            to completely prevent C5a-induced neutrophil activation in human whole blood; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>leave
                                            MAC formation intact</b>, as evidenced by testing the intact complement pathway driven MAC
                                            formation on red blood cells, leading to the lysis of these cells.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
completed one placebo-controlled, single-center Phase I study of vilobelimab in healthy volunteers and completed two double-blind, placebo-controlled,
multi-center Phase IIa studies in two acute care indications, early septic organ dysfunction and complex cardiac surgery. We also completed
a Phase IIa and a Phase IIb clinical study in HS, two Phase II studies in AAV, a Phase IIa study in PG and a Phase II/III clinical study
in critically ill, mechanically ventilated COVID-19 patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
all completed studies, vilobelimab was observed to be well tolerated. The placebo-controlled, multi-center Phase IIa studies in the two
acute care indications demonstrated that vilobelimab blocked C5a with high statistical significance (p-values &lt; 0.001) and that MAC
formation, as demonstrated by a CH50 assay (as described below), in the groups treated with vilobelimab was not influenced, with mean
CH50 values for treatment groups and control groups within the normal range.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">To
determine whether data is statistically significant, we use a &#8220;p-value,&#8221; which represents the probability that random chance
could explain the results. The FDA utilizes the reported statistical measures when evaluating the results of a clinical trial, including
statistical significance as measured by p-value as an evidentiary standard of efficacy, to evaluate the reported evidence of a product
candidate&#8217;s safety and efficacy. If not otherwise specified, we used a conventional 5% or lower p-value (p &lt; 0.05) to define
statistical significance for the clinical trials and studies and data presented in this Annual Report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Based
on our clinical trials completed to date as well as the results from an EpiScreen <i>ex vivo </i>immunogenicity T-cell response assay,
we believe that vilobelimab carries a low risk of provoking an immune response following administration. The immunogenicity assay used
peripheral blood mononuclear cells from 21 donors and tested how many donors&#8217; cells showed a CD4+ T-cell response following introduction
of vilobelimab <i>ex vivo</i>. A response rate of over 10% (or more than three out of 21) means the applicable protein is considered
to be high risk for immunogenicity, while a response rate of less than 10% means the protein is considered to be low risk. The results
of the assay for vilobelimab showed that zero out of the 21 donors had a T-cell response rate, as compared to a control arm (using the
A33 antibody), which showed a 30% response rate. In addition, based on an ADA detection assay conducted in connection with our Phase
IIb clinical trial in HS, 10% of patients had ADAs at any time during the study. Only one participant the presence of ADAs was associated
with any specific AE pattern indicating symptoms possibly related to the presence or emergence of ADAs leading to an immune reaction.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are currently evaluating vilobelimab in various disease indications. In all ongoing and completed clinical studies so far, we have never
observed effects that would raise doubts on the established safety of vilobelimab as a therapeutic drug candidate.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
will also continue to assess the potential for development of vilobelimab in other disease settings where we believe an anti-C5a antibody
could be successfully developed into a marketed therapy.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Development
of small molecule inhibitors of C5aR</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Two
C5a receptors, C5aR (also known as C5aR1 or CD88) and C5aR2 (also known as C5L2 or GPR77), mediate the biological activities of C5a.
Activation of C5aR has broadly acknowledged proinflammatory roles, while activation of C5aR2 remains less well understood and recent
scientific work has suggested a potential regulatory role on C5aR activation. C5aR is a G-protein-coupled-receptor expressed primarily
by granulocytes, and, especially under disease conditions, broadly in various tissues and other immune cell types, which mediates the
pathophysiological effects of C5a.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
animal models of sepsis, anti-C5a treatment ameliorated the development of inflammatory responses and improved survival. In addition,
experimental evidence suggests that blockade of C5aR signaling similarly improves survival in animals with sepsis. Unlike its ligand
C5a, C5aR can also be pharmacologically inhibited by low molecular weight compounds.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Low
molecular weight C5aR antagonists have shown excellent therapeutic effects in numerous in vitro and in vivo animal models of inflammatory
diseases involving complement activation. The advantage of a low molecular weight inhibitor of C5aR is that it can be administered orally,
thereby offering broad, long-term ease of administration to patients, especially for the treatment of chronic diseases. Through proper
clinical investigation of these small molecule C5aR antagonists in diseases induced by the activation of C5a/C5aR axis, the safety and
efficacy of these agents can be established.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Avacopan
is the first oral C5aR antagonist, which has market approval in the United States as an adjunctive treatment in adults for severe active
ANCA-associated vasculitis (specifically MPA and GPA) in combination with standard therapy, including glucocorticoids.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Through
our in-house drug discovery efforts, we identified a potent inhibitor of the C5a receptor, INF904, which we believe is a promising candidate
for development. We are currently developing INF904, an oral, low molecular weight drug candidate that targets the C5aR receptor. We
plan on targeting complement-mediated, chronic auto-immune and inflammatory conditions where an oral small molecule is needed for patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Given
the different advantages of blocking C5a and C5aR, we believe that the development of both C5a and C5aR blocking agents is possible and
potentially helpful to address a broader range of C5a/C5aR-molecular signaling axis-associated diseases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Our
preclinical and clinical development programs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Vilobelimab
for the treatment of PG</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">We
are developing vilobelimab for the treatment of&#160;PG. </span><span style="font-family: Times New Roman, Times, Serif">PG is a rare,
chronic inflammatory form of neutrophilic dermatosis characterized by accumulation of neutrophils in the affected skin areas. The exact
pathophysiology is not fully understood, but it is postulated that inflammatory cytokine production as well as neutrophil activation
and dysfunction contribute to a sterile inflammation in the skin. PG often presents as painful pustule or papule, mainly on the lower
extremities, which can rapidly progress to an extremely painful enlarging ulcer. Associated symptoms include fever, malaise, weight loss
and myalgia. PG usually has a devastating effect on a patient&#8217;s life due to the severe pain and induction of significant movement
impairment depending on lesions&#8217; location. The exact prevalence of PG is not yet known but is estimated that up to 51,000 patients
in the United States and Europe are affected by this disease.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">There
are 4 disease types recognized: ulcerative (the classical variant, which is the focus of our development), bullous (atypical), pustular,
and vegetative (superficial, granulomatous). The ulcerative variant is the most frequent and typical form of PG, with lesions predominantly
on the lower extremities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">There
are currently no drugs approved for the treatment of PG in the US or in Europe. The only locally approved treatment is adalimumab, which
has been approved in Japan but in no other country. There is no established standard of care based on controlled studies in PG. However,
due to the high medical need associated with the disease, certain drugs are used in medical practice as treatment attempts for affected
patients. These include certain orally administered drugs such as immunosuppressants, including cyclosporine or corticosteroids which
are sometimes also used concomitantly, as well as topically applied drugs such as tacrolimus and others. Lastly intravenously administered
TNF-alpha inhibitors such as infliximab or adalimumab or other biological drugs are also used as treatment attempt, despite the fact
that no formal regulatory approvals are in place.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">In
February 2019, we initiated an open label, multi-center Phase&#160;IIa&#160;exploratory study enrolling 19 patients with moderate to
severe PG in Canada, the U</span><span style="font-family: Times New Roman, Times, Serif">nited States <span>and
Poland. The objectives of this study were to evaluate the safety and efficacy of vilobelimab in this patient population&#160;in three
different doses and to determine the appropriate dose for the future development of vilobelimab in registrational Phase III studies for
the treatment of PG.</span></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">In&#160;April
2021,&#160;the study reached its enrollment target with 19 patients.&#160;In October 2021, we announced preliminary results from the
study.&#160;In&#160;the third dosing cohort at 2400mg biweekly, six of the seven patients achieved clinical remission with a PGA score
of &#8804; 1, which reflected a closure of the target ulcer. All patients in the third dosing cohort had elevated C5a levels at baseline
that were continuously suppressed after initiation of treatment with vilobelimab. </span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">From
all three dose cohorts in the study, two patients had related SAEs that were reported: one patient experienced an erysipelas leading
to hospitalization (judged as non-drug related by sponsor), another developed a rash due to a delayed hypersensitivity reaction and withdrew
from study. No dose-related AEs were found. Overall, the observed AE profile was in line with the underlying disease.&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">Final
results&#160;from all patients&#160;were presented at the American Academy of Dermatology Association, AAD, Annual Meeting in March 2022
in an oral late-breaker session by Afsaneh Alavi, MD, Associate Professor of Dermatology, Mayo Clinic. The reported final results showed
a dose-dependent effect in the highest dose cohort of 2400 mg, confirming the preliminary results with six out of seven patients showing
a clinical remission (Physician Global Assessment, or PGA, score &#8804; 1) and closure of the target ulcer in this dose cohort. The seventh
patient showed a slight improvement (PGA score 4) with a decrease of the target ulcer area of over 50%. During the follow-up period,
ulcers remained closed two months after treatment completion in all but one patient, and a sustained suppression of C5a was observed
for up to 20 days after the last dosing. </span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">With
these results, vilobelimab was granted orphan drug designation for the treatment of PG by both the FDA in the U</span><span style="font-family: Times New Roman, Times, Serif">nited
States <span>and the EMA in Europe as well as fast-track designation be the FDA. Furthermore, we announced
that we had a productive end-of-phase II meeting with the FDA related to our plans for a Phase III development program in PG in June
2022. In January 2023, we announced details related to the design of our planned Phase III study with vilobelimab in ulcerative PG.</span></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">The
Phase III study is designed to enroll patients in the United States, Europe and selected countries in other regions. The study design
is based on detailed feedback and recommendations from the FDA Division of Dermatology and Dentistry and was developed in close collaboration
with the Company&#180;s advisors from the United States, Europe and other regions. The multi-national, randomized, double-blind, placebo-controlled
Phase III trial has two arms: vilobelimab (2,400mg every other week) plus a low dose of corticosteroids and placebo plus the same low
dose of corticosteroids. In both arms, corticosteroid treatment will be initiated on day one and will be tapered off within the first
eight weeks of the treatment period. The primary endpoint of the study will be complete closure of the target ulcer at any time up to
26 weeks after initiation of treatment. Treatment will be discontinued for patients whose disease progresses or fails to improve at defined
time points during the study. The study has an adaptive trial design with an interim analysis blinded for the sponsor and investigators
(but unblinded for the independent data safety monitoring committee), which is planned upon enrollment of approximately 30 patients,
divided equally between the two arms of the study. The interim analysis with a set of predefined rules will take into account the then-observed
difference in complete target ulcer closure between the two arms and will then determine whether the trial sample size will be adapted
or whether the trial should be stopped due to futility. The enrollment period is projected to last at least two years, and its overall
period will depend on the total trial size after sample size adaptation. </span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">In
November 2023, we announced the enrollment of </span><span style="font-family: Times New Roman, Times, Serif">the first patient in the
trail.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Vilobelimab
for the treatment of critically ill, invasively mechanically ventilated COVID-19 patients</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Severe
COVID-19 is characterized by severe lung inflammation and activation of coagulation, frequently requiring mechanical ventilation while
the patient is in the intensive care unit. Mortality and morbidity rates are high among critically ill, invasively mechanically ventilated
patients with COVID-19, despite the established broad use of corticosteroids and other anti-inflammatory agents. Poor disease outcomes
have been associated with activation of the complement system, specifically the C5a/C5aR molecular signaling axis. Experimental studies
in other viral lung diseases have shown that C5a is a potent anaphylatoxin, attracting neutrophils and monocytes to the site of infection
that causes tissue damage, endothelialitis, and micro- thrombosis. Mouse studies also showed that blockade of the C5a/C5aR1 molecular
signaling axis limits the infiltration of myeloid cells in damaged organs and prevents excessive lung inflammation and endothelialitis.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Despite
wide-spread use of vaccines against SARS-CoV-2 and improvement in disease management, including use of immune modulators like anti-IL6
antibodies or JAK inhibitors, glucocorticosteroids and anti-coagulant therapy during the recent COVID-19 pandemic, mortality rates of
critically ill, intubated and mechanically ventilated patients have remained at levels over 50%. With 450 to 3,800 COVID-19 related fatalities
per week in the United States throughout 2023, according to the Centers of Disease Control and Prevention, or CDC, (<i>https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_select_00
</i>) this indicates the still prevailing medical need for effective therapies for the treatment of these patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">During
the COVID-19 pandemic of 2020-2023, it became clear that effective therapies for the treatment of severely or critically ill COVID-19
patients were not available or had not tested for this indication. In an effort to provide a contribution to this medical emergency and
based on our existing pre-clinical research on the role of C5a in viral-induced pneumonia, we decided to initiate a clinical development
program with vilobelimab in critically ill COVID-19 patients with severely progressed pneumonia.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Clinical
development</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
March 2020, we initiated a randomized open label multi-center trial Phase II/III clinical development program with vilobelimab in severe&#160;COVID-19&#160;patients with severely progressed pneumonia. In the Phase II part of the study, we evaluated vilobelimab treatment plus best
supportive care compared to best supportive care alone for up to 28 days. Relative change (%) from baseline to day 5 in oxygenation index
(defined as PaO2/FiO2 ratio) was assessed as the primary endpoint along with additional clinical parameters until day 28. In the study,
patients were randomized to two treatment arms, either Arm A, best supportive care and vilobelimab or Arm B, best supportive care alone.
The primary endpoint was the relative percentage change from baseline to day 5 in the oxygenation index (PaO2 / FiO2).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
June 17, 2020, we announced results from the Phase II part of the study. A total of 30 patients were randomized in the trial, and 15
patients were treated in each arm: vilobelimab plus best supportive care or best supportive care alone. Over a treatment period of 28
days, patients in the vilobelimab arm received a maximum of seven doses of 800 mg vilobelimab intravenously on separate days. At randomization,
18 patients were intubated (60%), and 12 patients (40%) had other oxygen supply. A higher number of patients with two or more comorbidities
associated with increased COVID-19 mortality were reported in the vilobelimab treatment group compared to best supportive care group.
Relative change in the oxygenation index at day 5 showed no differences between treatment groups. However, vilobelimab treatment was
associated with a lower 28-day all-cause mortality when compared to the best supportive care group, along with trends in disease improvement,
as evidenced by fewer patients experiencing renal impairment assessed by estimated glomerular filtration rates, more patients showing
reversal of blood lymphocytopenia and a greater lowering of lactate dehydrogenase concentrations. In vilobelimab-treated patients, pulmonary
embolisms reported as SAEs occurred less compared to the best supportive care arm. Also, a temporary increase of D-dimer levels, as potential
expression of induction of blood clot lysis, was detected in the first days after initiation of vilobelimab treatment. Twenty-eight-day
all-cause mortality in the vilobelimab treatment group was 13% (2 out of 15) versus 27% (4 out of 15) in the control group. In the best
supportive care group, four patients died of COVID-19-induced multi-organ failure, and three of them had pulmonary embolisms reported
as a SAE. In the vilobelimab arm, one patient died after an acute ventilator tube complication (leakage) and one patient with a history
of severe chronic obstructive pulmonary disease died of pulmonary failure.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">SAE
rates were comparable between groups, but the rate of pulmonary embolisms reported as SAEs was substantially lower in the vilobelimab
treatment group. Upon review of the safety data, the independent data safety monitoring board recommended continuation of the trial into
the Phase III part.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
the Phase III part of the study, <span>from September 2020 to October&#160;2021,&#160;we enrolled 369&#160;mechanically
ventilated patients with COVID-19 across sites in the E</span>uropean Union<span>, South&#160;America&#160;and
other regions. Patients were randomized 1:1 to receive either vilobelimab or placebo; most patients received standard of care (97% glucocorticosteroids,
98% anti-thrombotic agents).&#160;The primary endpoint is 28-day all-cause mortality; key secondary endpoints include assessment of organ
support and disease improvement.</span></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">In
March 2022, we announced that the Phase III part of the Phase II/III PANAMO study with mechanically ventilated COVID-19 patients was
successfully completed and showed a relative reduction in 28-day all-cause mortality of 23.9% (p = 0.094). At the recommendation of regulatory
authorities during the course of the trial, we changed the statistical analysis method for the primary endpoint. The original protocol
specified a non-stratified Cox regression analysis, and the final statistical analysis plan specified a site-stratified analysis intended
to account for the site stratification of patients at randomization. The original protocol specified analysis would have resulted in
a p-value of 0.027 (statistically significant), whereas the site-stratified Cox regression led to a p-value of 0.094 (not statistically
significant). Additionally, pre-specified logistic regression analyses of the 28-day mortality resulted in p-values of &lt;0.05 for three
out of the four pre-specified analyses. Furthermore, a pre-specified analysis of patients from Western European countries (n=209) showed
a relative reduction in 28-day all-cause mortality of 43% (vilobelimab 21.2% versus placebo 37.2%, hazard ratio: 0.5, p=0.014), suggesting
an improvement in mortality in line with the reported Phase II data of the PANAMO Phase II/III study.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Regulatory
activities</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2022, we announced the submission for EUA following encouraging interactions with the FDA at a Type B meeting held in summer
2022. Additionally, we were granted fast track designation from the FDA for vilobelimab for the treatment of critically ill, intubated,
mechanically ventilated COVID-19 patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
April 2023, the FDA issued the EUA for GOHIBIC (vilobelimab) for the treatment of COVID-19 in hospitalized adults when initiated within
48 hours of receiving IMV or ECMO.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
July 2023, we submitted a Marketing Authorization Application (MAA) for SARS-CoV-2 induced septic ARDS receiving IMV or ECMO to the EMA.
In August 2023, the EMA validated the MAA. This means that the application is now under regulatory review by the CHMP under the centralized
procedure, which applies to all 27 member states of the European Union.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">To
achieve full commercial scale and successfully reach the full market potential of the product in the future, we also aspire to obtain
full market approval for Gohibic (vilobelimab). We are therefore planning the submission of the BLA for full approval of Gohibic (vilobelimab)
in our COVID-19 indication and potentially, in the future, in similar indications that may apply to other virally induced acute respiratory
distress conditions. In October 2023, in furtherance of our continued efforts to obtain a BLA, we had an encouraging Type C meeting with
the FDA. In that meeting, the FDA indicated their willingness to collaborate with us in identifying a development pathway towards a BLA
for a broader ARDS label. To achieve this, we would need to conduct an additional well-controlled and adequately powered study in a broader
ARDS setting that demonstrates the safety and efficacy of vilobelimab. During the meeting, we discussed different options for such a
trial, including potential trial designs, patient population and trial power aspects.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are actively evaluating and working towards next steps to enable such a trial in a broader ARDS setting and are currently exploring different
funding options, including government grants as well as collaborations with third parties.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Commercialization</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
intend to seek full marketing authorization in major markets, including the United States and Europe. For this we might hire experts
in sales and marketing and build the necessary commercial and logistical infrastructure internally and/or with the potential assistance
of external service providers. In parallel, we also intend to seek partners to support our commercialization, such as partnerships in
select regions and potentially building commercial infrastructure in other regions if EUA is granted.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States for the treatment of COVID-19 in hospitalized
adults when initiated within 48 hours of receiving IMV or ECMO. We entered into agreements with certain subsidiaries of Cencora Inc.,
or Cencora (formerly known as AmerisourceBergen Corp.) to act as our U.S. distributor and to make GOHIBIC (vilobelimab) available for
order by U.S. hospital customers under the EUA. Cencora provides cold storage, cold-chain distribution services, inventory management
and secondary labeling/packaging, among other services. To support our commercial efforts, we have hired and are continuing to hire U.S.
experts with relevant experience in the commercialization of medical products in the hospital market, including in the areas of sales,
sales operations, marketing, market access, distribution, medical affairs and others. In addition, we are expanding the necessary infrastructure,
including IT systems, supply chain, financial reporting systems and inventory management systems both, internally and with the assistance
of external service providers.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
we expand our commercial efforts, we continue to enhance our commercial strategic plan, further expanding our sales force and medical
affairs teams, preparing relevant promotional and medical education materials to target healthcare providers and other stakeholders,
refining our medical affairs strategy to increase awareness of the EUA among the medical community, and initiating our sales efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
July 2023 and subsequently in October 2023, the NIH published and subsequently updated their guidelines for the treatment of COVID-19
patients. The NIH guidelines stipulate that there is insufficient evidence to recommend either for or against the use of vilobelimab
for the treatment of critically ill COVID-19 patients. This neutral NIH guideline recommendation has negatively affected the commercial
adoption of GOHIBIC (vilobelimab) as many healthcare providers, particularly hospitals, rely on NIH treatment guidelines when drafting
their formularies and placing new orders. We believe that the NIH analysis does not take into account positive factors that the FDA considered
in granting the EUA, and we are working to provide as much scientific evidence as possible to the NIH and others in the medical community
with the goal of reaching concurrence of the NIH guideline committee position with the detailed published FDA review and thus reconsidering
their recommendation for the treatment of critically ill COVID-19 patients with Gohibic (vilobelimab).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Governmental
funding</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
October 2021, we announced that we received a grant of up to &#8364;43.7 million from the German Ministry of Education and Research and
the German Ministry of Health to support our development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent
changes in our research and development plan and fewer costs projected within the timeframe of the grant, we were notified that the amount
available to us is &#8364;41.4 million. The grant is structured as a reimbursement of 80% of certain pre-specified expenses related to
the clinical development and manufacturing of vilobelimab. The grant period ended on June 30, 2023. In total, during the duration of
the grant period through December 31, 2023, we received &#8364;33.3 million to support our activities regarding the development of vilobelimab
as a new therapeutic agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial scale manufacturing
process to ensure the ability of being able to provide such treatment to the broader population.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Vilobelimab
for the treatment of cSCC</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">Cutaneous
squamous cell carcinoma, or cSCC, is the second most common skin cancer. The incidence of cSCC increases with increasing sun exposure
and age and individuals with fair skin and hair are more often affected. </span><span style="font-family: Times New Roman, Times, Serif">Approximately
200,000 to 400,000 cases of cSCC per year are being reported in the United States reaching up to estimates as high as 1 million per year.
Estimates in Europe vary by geographic location from approximately 30 cases in 100,000 people per year in northern Europe to approximately
10 cases in 100,000 people in southern Europe. The incidence of cSCC is increasing around the world. However, advanced and metastatic
forms of cSCC are rare. While treatment response rates of advanced and metastatic forms of cSCC with <span>programmed
cell death protein-1, or PD-1, / programmed death ligand-1, or PD-L1, </span>inhibitors is believed to be in the range of 50%, patients
frequently relapse, and resistant / refractory patients typically have a very poor prognosis.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">The
potential for local recurrence or metastasis of cSCC varies with the pathologic variant and localization of the primary lesion, and the
risk for metastasis in cSCC is approximately 2-5%. Advanced cSCC 10-year survival rates are less than 20% with regional lymph node involvement
and less than 10% with distant metastases. Patients with </span><span style="font-family: Times New Roman, Times, Serif">distant metastases
have median survival times of less than 2 years.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">We
are also developing vilobelimab for the treatment of PD-1 / PD-L1 inhibitor resistant / refractory, locally advanced or metastatic cSCC.
cSCC is the second most common skin cancer. The incidence of cSCC increases with cumulative sun exposure and age, and individuals with
fair skin and hair are more often affected. The potential for local recurrence or metastasis of cSCC varies with the pathologic variant
and localization of the primary lesion, and the risk for metastasis in cSCC is approximately 2%-5%. Advanced cSCC 10-year survival rates
are less than 20% with regional lymph node involvement and less than 10% with distant metastases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">In
the study, which was initiated in April 2021, we recruited patients in two independent arms, vilobelimab alone (Arm A) and vilobelimab
in combination with pembrolizumab (Arm B). The main objectives of the trial are to assess the safety and antitumor activity of vilobelimab
monotherapy, to determine the maximum tolerated or recommended dose in combination with pembrolizumab, as well as to evaluate the safety
and antitumor activity in the combination treatment arm in cSCC patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">As
of the date hereof, 10 patients were enrolled in Arm A, in which they received a run-in dose of 800 mg of vilobelimab on days 1, 4, 8
and 15, followed by a dose of 1,600 mg vilobelimab every two weeks starting on day 22. An interim analysis in Arm A of the 10 patients
was conducted in July 2023 and the treatment responses in Arm A were evaluated. The interim efficacy analysis showed that one patient
had a complete response (CR) and one patient continued with stable disease according to the protocol and as per &#8220;Response Evaluation
Criteria In Solid Tumors&#8221; (RECIST). The patient with the CR is still on treatment.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">After
five weeks of treatment with the first three patients in Arm A of the study, a safety assessment was successfully completed, and enrollment
in Arm B was also opened.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">In
Arm B, as of the date hereof, three patients have been treated in the first dosing cohort of the study (400 mg intravenous infusions
of vilobelimab on days 1, 4, 8 and 15 and 800 mg from day 22 and every two weeks thereafter, in addition to 400 mg of pembrolizumab on
day 8 and every six weeks thereafter). Six patients were treated in the next higher (second) dose cohort (600 mg intravenous infusions
of vilobelimab on days 1, 4, 8 and 15 and 1,200 mg from day 22 and every two weeks thereafter, in addition to 400 mg of pembrolizumab
on day 8 and every six weeks thereafter). In the third dosing cohort, six patients were treated at the highest planned dose per protocol
(800 mg intravenous infusions of vilobelimab on days 1, 4, 8 and 15 and 1,600 mg from day 22 and every two weeks thereafter, in addition
to 400 mg of pembrolizumab on day 8 and every six weeks thereafter). Each dose escalation was done per recommendation and after review
of the safety data by an independent Steering Committee comprised of external clinical advisors. In total, as of the date hereof, 15
patients were enrolled in Arm B (3+6+6 in the three dosing cohorts). Before proceeding with the second stage of the study in Arm B, the
interim efficacy data as assessed in recent discussions with our panel of experts showed one patient with partial response from the second
cohort, and one patient with partial response from the third cohort, who are still in treatment. </span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">The
treatment responses in the single dose Arm A and the initially observed results in the combination Arm B of the study were encouraging.
However, in view of the recent emergence of new alternative treatments for cSCC and the recommendation by our U.S. and international
experts to change course and to study additional patients with a higher dose of vilobelimab as monotherapy in a larger cohort, we have
decided to cease the development in cSCC for the time being. While we remain interested in further understanding of the potential monotherapeutic
effect of vilobelimab in this oncology indication, further research would require substantial resources and significantly extend the
timeline of the ongoing clinical program. Therefore, in November 2023, we decided to prioritize our efforts and to reallocate our resources
towards the development of our orally available C5aR inhibitor INF904.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; ">Patients
who are currently in treatment will be treated for up to 24 months according to the protocol. However, we will not enroll any new patients
in the study and we will close clinical sites in which no patients are being treated. Our decision to wind down this clinical study does
not preclude us from considering the development of vilobelimab or INF904 in this or similar oncological indications in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Vilobelimab
for the treatment of HS</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">HS
is a chronic debilitating systemic skin disease that results in painful inflammation of the hair follicles, most notably in the armpit,
groin and genital regions. The clinical hallmarks of this disease include very painful inflammatory nodules, boils or abscesses that
typically open and release odorous inflammatory fluids. In the more chronic form of the disease, patients experience dTs (previously
referred to as draining fistulas or sinus tracts), which ultimately lead to scarring and related functional disability in certain areas.
HS patients suffer primarily from pain and significant discomfort resulting from the constant formation of pus, often requiring the use
of bandages and diapers, resulting in social isolation. HS severely adversely affects patients&#8217; quality of life. HS typically presents
in the second and third decade of a patient&#8217;s life and often develops into a life-long debilitating chronic disease.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
target patient population for vilobelimab is HS patients displaying a moderate to severe form of the disease. In the United States, we
estimate that moderate to severe HS has a prevalence of up to 200,000 patients, although recent publications suggest a higher prevalence.
In Europe, the number of affected patients is also believed to be greater, with higher prevalence and incidence of HS in countries with
warmer climates.&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
accepted (but not approved) standard of care for HS patients includes topical, oral or intravenous antibiotic treatment, as well as surgery,
which often provide only temporary symptomatic relief. HS is recognized as a systemic autoimmune disease, for which there are numerous
suggested etiological factors, including genetics. Neutrophils are believed to play a potential disease-promoting role as well as certain
cytokines and mediators commonly found in autoimmune diseases such as TNF-alpha, IL-17, IL-1 and others. C5a promotes inflammatory mediators
and is a strong activator of neutrophils, which was the basis for our investigation of our C5a blocking drug candidate vilobelimab in
patients with HS. We established that patients suffering from HS show proof of significant systemic complement activation with elevated
plasma concentrations of C5a and other markers.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
only approved drug in the United States and in Europe to treat HS is adalimumab, an inhibitor of tumor necrosis factor-alpha, or TNF-alpha.
Although it provides clinical benefit to a portion of moderate to severe HS patients, approximately 50% or more of the patients did not
respond to adalimumab treatment. Therefore, a high unmet medical need among HS patients still persists.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
Hidradenitis Suppurativa Clinical Response, or HiSCR, score has been developed to assess the effectiveness of treatments for HS in clinical
trials. Patients are defined as HiSCR responders when a &#8805; 50% reduction in inflammatory lesion count, including abscesses and inflammatory
nodules, or AN, is observed. At the same time, no increase in abscesses or dTs when compared with baseline shall be observed. The HiSCR
is the primary endpoint that was used to support regulatory approval by the FDA and EMA of adalimumab for the treatment of HS patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
contrast to the dichotomous nature of the HiSCR, the IHS4 score was developed to score severity and track treatment response in a continuous
manner as an alternative to HiSCR. However, the IHS4 score has not yet been utilized as primary endpoint in late-stage clinical studies
in HS. This composite score weights the most fluctuating inflammatory nodules with one point, abscesses with two points and dTs with
four points.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have been developing vilobelimab for the treatment of HS. Initially we evaluated vilobelimab in a Phase&#160;IIa, single center open-label
study in 12 patients with severe HS, who had partly failed to respond to prior treatment attempts. Results from the trial demonstrated
a HiSCR response in 75% of patients at the end of eight weeks of treatment and in 83% of patients at the end of the 12-week trial observation
period, demonstrating initial clinical evidence of the product candidate&#8217;s disease-modifying effect. The results also demonstrated
that vilobelimab administration was well tolerated, with no drug-related adverse events detected and no infusion-related, allergic or
anaphylactic reactions were observed.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Subsequently,
we completed a larger multi-center, international Phase IIb study (SHINE) to determine the efficacy and safety of vilobelimab in moderate
to severe HS patients. The trial was a randomized, double-blind and placebo-controlled, multi-center study with five dose groups, including
one placebo group. After a placebo-controlled double-blind period of 16 weeks, each patient received vilobelimab open label for additional
28 weeks to assess long-term efficacy and safety. The main objective of the study was to evaluate a dose response signal assessed by
the HiSCR score at week 16 as the primary endpoint.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
June 2019, we announced the top-line results of the international SHINE Phase IIb study, in which we failed to meet our primary endpoint
utilizing HiSCR at week 16. The randomized, double-blind, placebo-controlled, multi-center study enrolled a total of 179 patients in
four active dose arms and a placebo arm at over 40 sites in 9 countries in North America and Europe. While the highest dose (1200mg every
two weeks) led to a 45.5% reduction in HiSCR, the placebo response amounted to 47.1% on the HiSCR endpoint. No difference could be detected
in treatment-emergent AEs between placebo and vilobelimab treatment groups.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
a subsequent post-hoc analysis published in July 2019, we showed multiple signals of efficacy for the vilobelimab high dose group compared
to the placebo group, demonstrating significant reductions in all combined inflammatory lesions, reductions of dT counts and reductions
of the IHS4 score. For example, at week 16, a statistically significant reduction of dT count relative to baseline in the high dose vilobelimab
group when compared to placebo could be observed (mean: -63.3% vs. -18.0%; p=0.0359; all patients with at least one dT at baseline).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
2021 we submitted a Special Protocol Assessment, or SPA, to the FDA for the Phase III HS program for vilobelimab HS, suggesting IHS4
as the primary efficacy endpoint, which was subsequently declined by the FDA. The FDA agreed to the dosing regimen in the protocol but
did not agree with the assessment of the primary endpoint using IHS4. We later held a Type A meeting with the FDA to align on the Phase
III study design and a proposed new primary endpoint instead of IHS4. The discussion focused on reaching consensus on the overall study
population and the primary endpoint measure. In September 2021, we announced the outcome of this meeting in which the FDA was supportive
of the proposed pivotal study program focusing on patients with active dTs. The FDA also supported a new primary efficacy endpoint that
would include measuring the reduction of all three inflammatory lesions associated with HS - inflammatory nodules, abscesses and dTs,
called m-HiSCR (modified HiSCR). A m-HISCR responder is defined as, relative to baseline, at least a 50% reduction of ANdT count and
at least a 50% reduction of dT count. The FDA provided advice on how to implement, name and validate the meaningfulness of the m-HiSCR
for the intended patient population, especially since a reduction in dT count is not adequately captured by the HiSCR. Following the
advice received in the Type A meeting, we submitted a full clinical trial protocol for the planned clinical Phase III trial of vilobelimab
in HS patients with actively draining disease to the FDA. Upon submission of study protocol for review, we received no comments from
FDA within the 30-day and 60-day review periods.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
January 2022, we initiated a randomized, double-blind, placebo-controlled, multi-center pivotal Phase III study to determine efficacy
and safety of vilobelimab in patients with moderate to severe HS and active dTs with the m-HiSCR as primary endpoint. In February 2022,
we paused the study after we receive an advice letter from the FDA that stated that the FDA recommended using the HiSCR as the primary
endpoint in the Phase III trial. The FDA advice was provided nearly three months after our protocol submission and contrasted with the
FDA advice provided to us in the Type A meeting held previously. However, the FDA did not issue a clinical hold. In March 2022, the FDA
corrected its advice to us. In the corrected advice letter, the FDA stated that, contrary to its February 2022 advice letter, the FDA
no longer recommended using the HiSCR as the primary endpoint for the chosen patient population, but gave recommendations related to
implementation of the m-HiSCR endpoint. Subsequently, we halted the Phase III clinical program and are currently evaluating next steps
regarding the development of vilobelimab in HS.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
February 2022, we also held a virtual research and development event in which we disclosed a post-hoc analysis of the m-HiSCR on the
Phase IIb SHINE data (as shown below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg" style="height: 471px; width: 550px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
data is consistent with the fact that in the Phase IIb SHINE study, significant reduction of dT count is only achieved within the high
dose group.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Based
on the logistical and financial effort necessary to successfully continue and complete a Phase III development program for vilobelimab
in HS, we are currently evaluating options to further this development in the future, including with a potential pharmaceutical partner.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Vilobelimab
for the treatment of anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">ANCA
associated vasculitis, or AAV is a rare, life-threatening autoimmune disease with a relapsing nature, characterized by necrotizing vasculitis,
an inflammation of blood vessels. The disease is characterized by life-threatening flare phases affecting the kidney function and other
organs leading to organ dysfunction and failure, a potentially fatal outcome unless treated appropriately. AAV predominantly affects
small vessels associated with anti-neutrophil cytoplasmic antibodies, or ANCA. It comprises three disease entities: GPA, or granulomatosis
with polyangiitis (known as Wegener&#8217;s Granulomatosis); MPA, or microscopic polyangiitis; and EGPA, or eosinophilic granulomatosis
with polyangiitis (known as Churg-Strauss syndrome).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">AAV
is designated as an orphan disease and affects approximately 40,000 and 75,000 patients in the United States and Europe, respectively.
In addition, AAV has a reported incidence of 4,000 and 7,500 new patients per year in the United States and Europe, respectively.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Because
of the life-threatening character of this disease, it is crucial to induce remission rapidly when a flare presents. The treatment to
induce remission differs from maintenance therapy. The current treatment regimen to induce remission uses a combination of High Dose
Corticosteroids, or HDCS, together with either rituximab or cyclophosphamide. In addition, avacopan has recently been approved and may
be added to these therapies. The long lasting HDCS therapy is associated with significant side effects and additional life-threatening
risks for the patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
disease promoting role of C5a for AAV is well established. A priming effect of C5a for neutrophils appears to be the essential factor
leading to neutrophil-related damage of the endothelial cells in the vessels. In addition, patients with acute AAV disease have significantly
elevated complement activation parameters in their plasma when compared to AAV patients in remission. In an experimental AAV disease
model in mice, it was shown that while C5aR deficiency leads to reduction in disease activity, C6 deficiency does not lead to such improvement,
suggesting that MAC formation might not play a major role in this disease. However, additional research is warranted to confirm this
conclusion.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have also been developing vilobelimab for the treatment of AAV. Our clinical development strategy for vilobelimab in AAV first focused
on acutely ill AAV patients, where we believe vilobelimab has the potential to successfully induce remission and reduce or eliminate
the need for high-dose corticosteroid, or HDCS, therapy and providing an improved safety profile. We also intended to focus on speed
of induction of remission and reducing the rate of renal replacement and kidney dysfunction.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
May 2021, we announced topline results from a randomized, triple blind, placebo-controlled Phase II clinical study with vilobelimab to
evaluate the efficacy and safety in patients with moderate to severe AAV, in which 19 patients were enrolled at centers in the United
States. Patients in all three groups received the standard of care dosing therapy consisting of rituximab or cyclophosphamide and were
randomized to either receive a low dose of vilobelimab in combination with a standard dose of glucocorticoids, a high dose of vilobelimab
in combination with a standard dose of glucocorticoids or placebo in combination with a standard dose of glucocorticoids. The primary
endpoint of the study was the number and percentage of subjects who experience at least one treatment-emergent AE per treatment group
at week 24. The key secondary endpoint of the study is a 50% reduction in Birmingham Vasculitis Activity Score, or BVAS, at week 16,
a well-established endpoint that has been used in the previous AAV studies, along with clinical remission. Overall, vilobelimab was safe
and well tolerated, as observed treatment-emergent AEs were reflective of the disease and SOC treatment. The proportion of patients achieving
a clinical response was defined as a 50% reduction in BVAS at week 16 (and no worsening in any body system) compared to baseline, and
clinical remission was defined as BVAS=0. Although the sample size of the trial was small and it is difficult to interpret results not
powered to show statistical significance, patients across all three treatment groups demonstrated a strong response at week 16, and more
patients treated with SOC plus vilobelimab had clinical remissions at various timepoints throughout the study compared to SOC plus placebo.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
November 2021, we announced topline results from a randomized, double-blind, placebo-controlled Phase II clinical study with vilobelimab
to evaluate efficacy and safety in patients with moderate to severe AAV, in which 54 patients were enrolled at centers in Europe. The
primary endpoint of the study was a 50% reduction in BVAS at week 16. Secondary efficacy endpoints being analyzed include clinical remission,
evaluation of the Vasculitis Damage Index, or VDI, reduction of glucocorticoid toxicity index, or GTI, several relevant biomarkers like
glomerular filtration rate, and patient reported outcomes. The study was conducted in two parts. In part 1, patients were randomized
to receive either vilobelimab plus a reduced dose of glucocorticoids, or placebo plus a standard dose of glucocorticoids. In part 2 of
the study, patients were randomized to receive either vilobelimab plus placebo, glucocorticoids or placebo plus a standard dose of glucocorticoids.
Patients in both arms received standard of care immunosuppressive therapy, consisting of rituximab or cyclophosphamide. The study achieved
its principal objective, demonstrating comparable clinical response of vilobelimab to standard of care, while significantly reducing
the need for glucocorticoid (GC) treatment in this life-threatening indication. Clinical response as well as remission were achieved
in comparably high rates in all three arms: clinical response at week 16 was observed in 16 out of 18 (88.9%) evaluable patients in the
group receiving vilobelimab alone; in 22 out of 23 (95.7%) patients receiving SDGC; and in 10 out of 13 (76.9%) patients in the vilobelimab
+ RDGC group. The GTI composite score at week 16 was substantially lowered in the vilobelimab only group (mean value of 0.8) when compared
to the SDGC group (mean value of 44.9) and the vilobelimab + RDGC group (mean value of 26.1). Assessment of the VDI at week 16 suggested
comparable values between groups with the vilobelimab only group showing the lowest value: vilobelimab only group (1.0), SDGC group (1.5)
and vilobelimab + RDGC group (1.9). eGFR, a secondary endpoint of the study, demonstrated no medically meaningful changes in all three
arms. The vilobelimab only group had the lowest number of reported treatment-emergent AEs, as well as related treatment-emergent AEs.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are currently evaluating next steps regarding the development of vilobelimab in AAV and are considering discussing the data from both
the U.S. and EU studies with regulatory authorities before determining next steps. Based on the logistical and financial effort necessary
to successfully complete a pivotal Phase III development program, we are currently assessing different options to further this development,
including with a potential pharmaceutical partner.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
clinical and pre-clinical development for vilobelimab</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Beyond
PG, severe COVID-19, cSCC, HS and AAV, the indications we described in the above sections, we keep exploring the possibility to advance
the clinical development of vilobelimab in additional inflammatory and chronic complement-mediated autoimmune disease indications for
which a good pre-clinical or clinical proof of concept exists and where C5a has been demonstrated as a critical disease promoting factor
or where similar mechanisms, such as neutrophil-driven systemic diseases affecting the skin and or other organs, are identified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>INF904
as orally administered low molecular weight molecule for inhibition of C5aR</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Inhibition
of the C5a/C5aR axis provides strong anti-inflammatory effects in a variety of diseases. Blockade of C5a using highly specific antibodies,
such as vilobelimab, may offer a fast, effective, and safe way to control C5a-induced inflammation. In addition to this approach, inhibition
of C5aR by oral small molecules may provide the ease of administration required for effective long-term treatment for more chronic inflammatory
diseases. To expand the breadth of our anti-C5a/C5aR technologies, we are also developing INF904, an oral, small molecule drug candidate
that targets the C5aR receptor. C5aR, a G-protein-coupled-receptor expressed primarily by granulocytes, mediates the pathophysiological
effects of C5a. In INF904, we discovered a small molecule C5aR inhibitor that in pre-clinical studies has shown potential for superior
characteristics to the only approved C5aR inhibitor, avacopan. INF904 has provided higher plasma exposure in animals, including non-human
primates, and improved inhibitory activity in a hamster neutropenia model compared to avacopan. Furthermore, in contrast to avacopan,
in vitro experiments showed INF904 has substantially less inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play an important
role in the metabolism of a variety of drugs, including glucocorticoids. No obvious toxicological findings, even in the highest dose
groups tested in required GLP toxicity analyses, were identified. INF904 demonstrated potential for anti-inflammatory therapeutic effects
in several preclinical disease models.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">All
IND-enabling studies, including certain GLP-toxicological studies, have been completed, and we conducted a Phase I single and multiple
ascending dose clinical study from November  2022 to January 2024.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2023, we announced the topline results from the single ascending dose, or SAD part of a randomized, double-blind, placebo-controlled
Phase I trial with INF904.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
SAD part of the Phase I first-in-human trial enrolled 62 healthy volunteers within six different dosing groups from 3 mg to 240 mg who
were randomly assigned to receive INF904 or a placebo. Different drug concentrations were tested for the 60 mg dosing group. The main
objectives were to assess safety and tolerability of single ascending doses under fasting conditions. Secondary endpoints included several
pharmacokinetic, or PK, parameters, and the effect of INF904 on C5a-induced neutrophil activation in blood samples from treated volunteers
ex vivo also was explored.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
results show that INF904 was well tolerated in treated patients and resulted in no safety signals of concern in single doses ranging
from 3 mg to 240 mg. The overall percentage of adverse events (AEs) was lower in the INF904 treated patients compared to the placebo
group, and no serious or severe AEs were observed at any dosing level. No related AEs were reported in conjunction with INF904 dosing.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Analysis
of INF904 PK in subject plasma samples revealed sustained exposure to INF904 with six hours to maximum concentration, or t<sub>max</sub>.
INF904 plasma levels were dose proportional for systemic exposure (AUC<sub>last</sub>) and nearly dose proportional for maximum concentration
(C<sub>max</sub>) over the dose range used in the study. With the 30 mg dose, INF904 reached a C<sub>max</sub> of 289 ng/ml with an AUC<sub>last
</sub>of 5197 h.ng/ml, which are approximately 3-fold and 10-fold, respectively, higher than the published Phase I data from the only
marketed comparator, avacopan.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Single
doses of 30 mg or higher of INF904 achieved &#8805;90% blocking of C5a induced up-regulation of the activation marker CD11b on neutrophils
in plasma samples from subjects <i>ex vivo</i> at 24 hours post dosing. This inhibition was achieved when 12.6 nM recombinant C5a was
added as stimulus in this assay, a C5a concentration which can be observed in patients with severe inflammatory conditions such as the
immuno-dermatological disease, hidradenitis suppurativa, or during life-threatening inflammation (e.g., in critically ill COVID-19 patients
or septic patients). Thus, INF904 inhibition of C5a-induced neutrophil activation in human plasma achieved the set goal for effective
C5aR control at disease relevant C5a levels.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
January 2024, we announced topline results from the multiple ascending dose, or MAD, part a randomized, double-blind, placebo-controlled
Phase I trial for INF904. The PK and pharmacodynamic, or PD parameters confirm the favorable data we observed during the SAD part of
the study, which provides support for the best-in-class potential of INF904. INF904 was well tolerated and there were no adverse safety
events of concern after repeated dosing in participants over the entire tested dose range.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
the MAD part of the randomized, double-blind, placebo-controlled Phase I trial, 24 participants received multiple doses of INF904 for
14 days of either 30 mg once per day, or QD, 30 mg twice per day, or BID, or 90 mg BID. The study&#8217;s primary objective was to evaluate
the safety and tolerability of repeated dosing. Several PK parameters were analyzed as secondary endpoints, and the effect of the dosing
scheme on C5a-induced neutrophil activation in blood samples from the participants was also explored in an ex vivo assay.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
safety analysis of INF904 in the MAD part of the Phase I study demonstrated that it was well tolerated in participants over the entire
dose range and resulted in no safety signals of concern. The overall percentage of AEs in INF904 treated participants was 77.8%, which
was lower than the 83.3% observed in the placebo group. There were no serious or severe AEs observed at any dosing level.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Analysis
of the PK profile showed that potential target AUC<sub>0-12h</sub>, C<sub>max</sub>, and trough values were achieved rapidly within 14
days of 30 mg BID dosing. INF904 exposure further increased proportionally with dosing up to 90 mg BID. These results were demonstrated
even when participants ingested the drug in a fasted state, suggesting that food is not required to achieve potentially therapeutic drug
levels.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Analysis
of the PD profile showed that the blocking activity of C5a-induced neutrophil activation by INF904 reached equal to or above 90% over
the 14-day dosing period for all tested doses in an ex vivo challenge assay where physiological and disease- relevant levels of C5a were
added to blood samples provided by the trial participants.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
parallel, we have progressed with the development of a commercially viable formulation of INF904 which we plan to introduce into Phase
II development towards the end of 2024.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are currently conducting additional required pre-clinical studies, including long-term chronic toxicology studies, to enable
longer-term dosing of INF904 for chronic inflammatory diseases. We currently plan to initiate a short-term dosing Phase II study
towards the end of 2024, followed by a longer-term dosing Phase II study in 2025. We initially plan to develop  INF904 for the
treatment of two initial immuno-dermatology indications: HS and CSU.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>IFX002
as follow-on anti-C5a monoclonal antibody product candidate</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">To
expand the breadth of our anti-C5a technologies, we are also developing IFX002 for the treatment of chronic inflammatory indications.
IFX002 is an advancement of the anti-C5a technology. It is a highly potent anti-C5a antibody with a higher humanization grade and altered
pharmacokinetic properties and is currently in pre-clinical development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">IFX002
is an injectable product candidate with a prolonged blood plasma half-life than vilobelimab, making it potentially more amenable for
the treatment of chronic inflammatory indications with less severe flares or closer to the onset of the disease. IFX002 shares the same
mechanism of action as vilobelimab in its potential to block C5a with high specificity but is designed for a dosing regimen that may
be more suitable for chronic therapy. Furthermore, IFX002 binds to the same epitope of free C5a as vilobelimab with comparable selectivity.
The pre-clinical development of IFX002 was partly supported by a grant from the German government. IFX002 will keep the performance relevant
properties to fully block C5a-induced biological effects while leaving MAC formation intact. We believe that IFX002 holds the potential
to treat various chronic inflammatory diseases and could benefit from a dosing regimen more suitable for chronic therapy. We also consider
IFX002 to be a life-cycle management product to vilobelimab, given the long remaining patent life of IFX002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Pipeline</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
intend to leverage our expertise within the complement field as well as our proprietary technologies to sustain our lead in the anti-C5a/anti-C5aR
space by developing a diverse pipeline focused on complement-mediated autoimmune and inflammatory diseases with high unmet need. Rights
to our proprietary anti-C5a/anti-C5aR technologies are currently expected to extend at least up to 2041 on the basis of our latest patents
granted.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
figure below summarizes key information about and the development status of our current pipeline of product candidates:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_006.jpg" style="height: 368px; width: 550px"/></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
goal is to maintain and further advance our leadership position within the anti-C5a/anti-C5aR complement space, delivering first-in-class
autoimmune and anti-inflammatory therapies to market. To achieve this goal, we expect to execute the strategies set forth below.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Advance
                                            vilobelimab in PG. </b>Based on the positively concluded open label Phase IIa study, we are
                                            conducting a Phase III pivotal clinical program after having received advice related to the
                                            clinical trial design from the FDA.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Proceed
                                            with clinical development of INF904.</b> We have conducted a single and multiple ascending
                                            dose study of our C5aR antagonist INF904 and currently are conducting additional required
                                            non-clinical studies to proceed to Phase II trials in patients.</span></td></tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Continue
to optimize the manufacturing process for vilobelimab.</b> We established a fully validated manufacturing process for vilobelimab with
an established and reputable CDMO with the goal of fulfilling the quality criteria to gain regulatory approval for such process. We are
establishing the final manufacturing of the finished pharmaceutical product (i.e., &#8220;fill and finish&#8221;) in Germany and are
considering the transfer of the drug substance manufacturing process from China to Germany or other countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Assess
development options for vilobelimab in HS, cSCC and AAV.</b> Following our decision to halt these development programs due to the resources
required to conduct these on our own, we are currently evaluating options regarding the development of vilobelimab in HS, cSCC and AAV.
Based on the logistical and financial effort necessary to successfully complete pivotal Phase III development programs in each of these
indications, such options include potential collaborations with a pharmaceutical partner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Pursue
                                            the further development of IFX002 to get prepared for potential clinical development.</b>
                                            We are developing IFX002 as an injectable with a longer half-life than vilobelimab, making
                                            it suitable for chronic inflammatory indications with less severe flares or closer to the
                                            onset of disease. Based on a patent lifetime potentially beyond 2040, we see this project
                                            as life-cycle management for vilobelimab and are conducting pre-clinical development work
                                            to get closer to the possible start of clinical development.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Solidify
                                            and continue to expand the breadth of our leadership position in the anti-C5a/anti-C5aR space
                                            by leveraging the full potential of our proprietary technologies and expertise in complement
                                            and inflammation research.</b> We intend to continue to discover and develop treatments that
                                            have the potential to address a broad spectrum of complement-mediated or immune response
                                            mediated indications with significant unmet need, either internally or in collaboration with
                                            a partner. To accomplish this, we continue to supplement our research and development activities
                                            with our discovery unit in Ann Arbor, Michigan and we are further building out our intellectual
                                            property portfolio and our business development capabilities.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Commercialize
GOHIBIC (vilobelimab) under the granted EUA either independently or in collaboration with pharmaceutical partners.</b> We are commercializing
Gohibic (vilobelimab) for severe COVID-19 in the United States independently, and assessing the options to commercialize the drug in
Europe independently or in collaboration with potential partners. We have employed a targeted commercial infrastructure to promote access
to vilobelimab through centers-of-excellence that treat patients suffering from the disease in these core markets in US. Outside of the
United States and Europe, we may pursue the approval and commercialization of vilobelimab for severe COVID-19 either independently or
in collaboration with others. For other indications, we intend to develop and commercialize vilobelimab either independently or through
collaborations with other parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>Advance
vilobelimab to market approval for severe COVID-19</b>: continue the approval process of MAA by the EMA and for a full BLA submission
to the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b>Explore
                                            the possibility to expand the applications of vilobelimab into related diseases.</b> If we
                                            gain regulatory approval in the United States or in Europe for the use of vilobelimab in
                                            severe COVID-19, we intend to explore the possibility of expanding the label into other critical
                                            care indications for which we have generated pre-clinical data in the past. Most notably,
                                            we may consider additional studies, potentially in collaboration with government agencies
                                            or commercial partners, to expand the label into a product for virally induced ARDS.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our intellectual
property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
aim to protect our product candidates and other commercially important proprietary anti-C5a and C5aR technologies by seeking and maintaining
U.S. and foreign patents that are intended to cover our product candidates and compositions, and their methods of use, the methods used
to manufacture them, the related therapeutic targets and associated methods of treatment and any other inventions that are commercially
important to our business. We also rely on trade secrets and know-how and other intellectual property rights to protect aspects of our
business that are not amenable to, or that we do not consider appropriate for, patent protection. Furthermore, we aim to protect our
trademarks, service marks, and trade names by seeking and maintaining U.S. and foreign trademark registrations. Our success will depend
significantly on our ability to obtain and maintain such patent and other proprietary protection, defend and enforce our patents, preserve
the confidentiality of our trade secrets and operate our business without infringing, misappropriating or otherwise violating any patents
or other intellectual property, including any proprietary rights of third parties. See the section titled &#8220;ITEM 3. KEY INFORMATION
&#8212; 3.&#160;Risk factors&#8212;Risks related to our intellectual property&#8221; for additional information.&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we owned ten issued U.S. patents and five pending U.S. non-provisional patent applications, 34 issued foreign patents,
including four granted European patents validated in 88 countries and two granted Eurasian patent validated in 16 countries, as well
as 84 foreign patent applications, including eight European patent applications and three Eurasian patent applications covering C5a and
C5aR inhibitors and associated methods of use.&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
patent portfolio relating to&#160;vilobelimab, IFX002 and INF904, as of&#160;December 31, 2023, is summarized below.&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we owned four issued U.S. patents covering the composition of matter of antibodies that block C5a and their use
in blocking C5a-induced biological effects in patients with diseases that involve acute or chronic inflammation, which would include
in their scope HS and AAV. In addition, we owned 20 issued foreign patents, including two granted European patents validated in 74 countries
and one Eurasian patent validated in nine countries, two pending foreign patent applications, including one pending European patent application,
covering the composition of matter of antibodies that block C5a and their use in the treatment of various diseases that involve acute
or chronic inflammation, which would include in their scope HS and AAV, and, depending on the jurisdiction of the applicable patent,
specifically cover the use of such antibodies in treating diseases such as ischemia and reperfusion related injuries, acute lung injury
and pneumonia.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
issued U.S. and foreign patents are expected to expire in 2030, excluding any additional term for patent term adjustments or patent term
extensions. If granted, the pending U.S. and foreign patents applications would be expected to expire in 2030, excluding any additional
term for patent term adjustments or patent term extensions.&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned two granted U.S. patents&#160;and four granted foreign patents, including one European patent validated
in three countries and one foreign patent application covering the use of certain binding moieties, such as antibodies, that inhibit
C5a for the treatment of viral pneumonia.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
issued, the U.S. and foreign patents are expected to expire in 2035, excluding any additional term for patent term adjustments or patent
term extension.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned three granted U.S. patents, one pending U.S. non-provisional patent application, eight granted foreign
patents, including one European patent validated in 12 countries and one granted Eurasian patent validated in eight countries, 25 pending
foreign patent applications, including three&#160;pending European patent applications covering the use of an inhibitor of C5a activity,
for example,&#160;vilobelimab, for treating HS and other cutaneous, neutrophilic inflammatory diseases.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
issued U.S. and foreign patents are expected to expire in 2038, excluding any additional term for patent term adjustments or patent term
extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned one U.S. patent application and 16 foreign patent applications including an European patent application
covering an improved C5a specific antibody.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
issued, the U.S. and foreign patents are expected to expire in 2041, excluding any additional term for patent term adjustments or patent
term extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned one pending U.S. non-provisional patent application and 16 foreign patent applications including
one European patent application covering the use of inhibitor of C5a activity, for example&#160;vilobelimab, for treating Corona viral
diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
issued, the U.S. and foreign patents based on the application under the PCT are expected to expire in 2040, excluding any additional
term for patent term adjustments or patent term extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned one granted U.S. patent, one pending U.S. non-provisional patent application, and 18 foreign patent
applications including one European patent application covering inhibitors of C5aR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
issued U.S. and foreign patents are expected to expire in 2040, excluding any additional term for patent term adjustments or patent term
extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned one U.S. patent application and one international patent application covering the use of an inhibitor
of C5a activity and standard of care inhibitors in the treatment of infectious pneumonia and infectious ARDS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
issued, the U.S. and foreign patents are expected to expire in 2043, excluding any additional term for patent term adjustments or patent
term extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of&#160;December 31, 2023, we owned two European patent applications covering the use of inhibitors of C5aR for the treatment of various
diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
issued, the U.S. and foreign patents are expected to expire in 2043, excluding any additional term for patent term adjustments or patent
term extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we owned trademark registrations for two trademarks, &#8220;GOHIBIC&#8221; and &#8220;Vilwaysi&#8221; in the United
States and 29 foreign countries, including 23 European countries and 7 foreign trademark applications for goods and services in the field
of pharmaceutical products, among others.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we owned two trademark registrations for &#8220;InflaRx&#8221; in the United States for goods and services in the
field of pharmaceutical preparations for the treatment of inflammatory, inflammatory-related, oncological and neurological diseases.
Outside the United States, as of December 31, 2023, we owned trademark registrations for &#8220;InflaRx&#8221; in 30 countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>UPC
</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Twenty-four
member states of the twenty-seven member EU states, with the exception of Poland, Spain and Croatia have acceded to the Agreement on
a Unified Patent Court, or UPCA, which provides for a Unitary Patent, or UP, and led to the establishment of a Unified Patent Court,
UPC. The UPCA has entered into force on June, 1 2023. Seventeen out of the twenty-four member states have fully ratified the UPCA when
it entered into force and participate in the UPCA from the start. The remaining seven EU member states are expected to join within the
next years. Since the start of the UPCA, a conventional European patent can be enforced centrally at the UPC but may also face central
revocation proceedings in the UPC, unless it is opted-out of the jurisdiction of the new court system.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
UPC has exclusive competence in respect of civil litigation on matters relating to European patents, Unitary Patents, supplementary protection
certificates issued for a product covered by such patents and European patent applications (for details see Article 32 of the UPCA).
Therefore, the UPC is not only competent to hear cases concerning UPs but also cases concerning traditional European patent applications
and patents (hereinafter &#8220;European patent(s)&#8221;), unless opted-out. The decision of the UPC in one country is binding in all
other states participating in the UPCA. The decision, however, does not have any legally binding effect in EU member states not participating
in the UPCA as well as in EPC contracting states which are not EU member states (e.g. Great Britain and Switzerland) and, therefore,
are not eligible to participate in the new system.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">It
is generally expected that the UPC will be patent holder friendly both when it comes to assessment of validity of granted patents and
infringement and that it may be beneficial for a patent holder to enforce and defend its patent at the UPC rather than at the EPO and/or
national nullity court or civil court. Presently, however, there is no case law of the UPC that would allow a prediction of how the UPC
may apply the patentability criteria when deciding on a central revocation action or a revocation counterclaim or how it will construe
a claim in a central infringement proceeding. In view of these uncertainties, which are immanent to any new system on one hand, and the
well-established practice of oppositions at the EPO as well as national invalidity and infringement proceedings on the other, we consider
it a cautious and recommendable approach to opt-out all European patent applications and granted European patents from the UPC and to
follow the case law of the UPC to determine the pros-and-cons of the UPC system. In case that the UPC appears to come to more favorable
decision on validity and/or infringement than the EPO and national courts, it should be reconsidered to opt-in for one or more European
patent or patent applications that have been previously opted out.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our collaboration
agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Co-development
agreement with <span style="font-size: 10pt">Staidson (Beijing) BioPharmaceuticals Co., Ltd. (as successor to Beijing Defengrei Biotechnology
Co. Ltd (BDB))</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
December 2015, we entered into a co-development agreement, or the Co-Development Agreement, with Beijing Defengrei Biotechnology Co.
Ltd., or BDB, for the use of the vilobelimab manufacturing cell line in BDB&#8217;s development of drug candidates for sale in China.
Pursuant to the agreement, we granted BDB an exclusive, non-transferable license to use the vilobelimab cell line and related intellectual
property solely to develop and commercialize in China BDB&#8217;s drug candidates BDB-001 and BDB-002, as well as molecules that bind
or interact with certain specified targets, or target-binding molecules.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the agreement, we are entitled to receive mid-single-digit percentage royalties on net sales of&#160;BDB&#8217;s&#160;products&#160;containing&#160;BDB-001
or BDB-002. We retain the right to develop and manufacture vilobelimab and IFX002 in China solely for the purpose of commercializing
products outside of China and to use the vilobelimab cell line and IFX002 cell line&#160;in China for non-commercial purposes. To the
extent that we are granted regulatory approval outside of China for commercialization of a product using vilobelimab or IFX002 for an
indication, and BDB does not pursue regulatory approval for BDB-001 or BDB-002 in the same or a substantially similar indication in China,
by providing written notice to BDB, we may elect to pursue regulatory approval to commercialize such products in the relevant indication
in China. Should we exercise such right, we would be required to pay BDB mid-single-digit percentage royalties on our net sales of such
products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Co-Development Agreement, BDB has the right to use the vilobelimab cell line to manufacture an anti-C5a antibody,
namely BDB-001. BDB-001 may only be commercialized in China (PRC) by BDB, and InflaRx is not directly involved in the
BDB-001 development, which remains the sole responsibility of BDB. Pursuant to the Co-Development Agreement, InflaRx owns all global
commercial rights outside China to any and all discoveries derived from the development of BDB-001. To support BDB&#8217;s
development of BDB-001, in 2020, InflaRx allowed BDB to conduct clinical studies with BDB-001 in Spain, India, Indonesia and
Bangladesh. However, InflaRx remains the sole owner of all commercial rights to BDB-001 outside of China, including in countries in
which BDB is conducting clinical trials. BDB has no rights to seek marketing authorization or to commercially exploit BDB-001
outside of China. Vilobelimab is not the product being tested in clinical trials by BDB in China. Rather, it is BDB&#8217;s own
antibody called BDB-001.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, we reserved the right to commercialize products containing BDB-001 and BDB-002 outside of China in indications for which we
elect not to commercialize vilobelimab or IFX002. To the extent that we exercise this right, we would be required to pay BDB low single-digit
percentage royalties on our net sales of such products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">BDB
must notify us without undue delay of tests it conducts on target-binding molecules. If any such test results in binding or interaction
with targets in a satisfactory manner to both BDB and us, BDB must notify us of such results and may, within a six-month period following
such notice, exercise an option to commence commercializing the successfully tested target-binding molecules in China. To the extent
that BDB exercises such option, BDB would be required to pay us low single-digit percentage royalties on net sales of products containing
such target-binding molecules. BDB also grants us the right to exploit any target-binding molecules outside of China or, to the extent
that BDB does not pursue regulatory approval in the same or a substantially similar indication, in China. To the extent that we exercise
such rights, we would be required to pay BDB low to mid single-digit percentage royalties on our net sales of such products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
November 2021, we entered into a second addendum to the Co-Development Agreement with BDB and Staidson (Beijing) BioPharmaceuticals Co.,
Ltd., or Staidson. Under the second addendum, BDB, being a wholly-owned affiliate of Staidson, assigned the Co-Development Agreement
to Staidson together with all rights and obligations thereunder.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
December 2022, we amended our existing co-development agreement with Staidson to support Staidson in its regulatory approval efforts
for its proprietary drug candidate BDB-001 for the treatment of COVID-19 in China. Pursuant to the amendment, we will receive increased
royalties of 10% on net sales of BDB-001 for the treatment of COVID-19 in China. We granted Staidson an exclusive license for use in
China to certain of our clinical, manufacturing and regulatory data regarding vilobelimab in order to support and facilitate the regulatory
filing for BDB-001 for the treatment of severely ill COVID-19 patients with the Chinese National Medical Products Administration, or
NMPA. Under the existing Co-Development Agreement,&#160;BDB-001 is being developed by Staidson for the treatment of severe COVID-19 and other
inflammatory diseases in China. The agreement continues to be in force unless earlier terminated. The agreement may be terminated upon
the mutual agreement of the parties, or by one party upon a breach by the other party that is not cured within 30 days after receiving
notice of such breach. In addition, either party may terminate the agreement if the other party challenges the terminating party&#8217;s
ownership of any intellectual property licensed to the non-terminating party under the agreement or undergoes certain bankruptcy or insolvency
events.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Concomitantly
to amending the Co-Development Agreement, we also entered into a share purchase agreement with Staidson Hong Kong Investment Company
Limited, an affiliate of Staidson and a limited liability company organized under the law of Hong Kong, pursuant to which Staidson Hong
Kong Investment Company Limited purchased ordinary shares from us for an aggregate amount of $2.5&#160;million (&#8364;2.3 million) at
a price of $5.00 per share, resulting in the sale of 500,000 shares. The share purchase agreement also includes an option pursuant to
which Staidson Hong Kong Investment Company Limited may purchase additional ordinary shares, at our discretion, for an aggregate amount
of an additional $7.5million. The option for such subsequent purchase will expire on the twelve-month anniversary of Staidson receiving
regulatory approval for BDB-001 in China. Such subsequent investment would be made at the greater of $5.00 per share or at a 20% premium
to the weighted average share price over the 15 trading days prior to the closing date of such subsequent investment.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Clinical
trial collaboration and supply agreement with Merck &amp; Co., Inc.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
March 20, 2020, we entered into a clinical trial collaboration and supply agreement with Merck &amp; Co., Inc. (known as MSD outside
the United States and Canada) to evaluate the combination of vilobelimab and Merck&#8217;s anti-PD-1 therapy, KEYTRUDA<sup>&#174;<span style="font-size: 10pt">1
</span></sup>(pembrolizumab) in patients with cSCC. Under the terms of the agreement, we conduct a Phase II clinical study with two vilobelimab
arms, including one with pembrolizumab. In November 2023, we announced the development stop of vilobelimab in cSCC to prioritize other
programs. Patients who are currently still in treatment will be treated for up to 24 months according to the protocol; however, no new
patients will be enrolled in the study and clinical sites in which no patients are currently being treated will be closed down.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Sales
and marketing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States for the treatment of COVID-19 in hospitalized
adults when initiated within 48 hours of receiving IMV or ECMO. In connection with the start of the commercialization, we entered into
agreements with certain subsidiaries of Cencora to act as the Group&#8217;s U.S. distributor and make GOHIBIC(vilobelimab) available
for order by U.S. hospital customers under the EUA. Cencora provides cold storage, cold-chain distribution services, inventory management
and secondary labeling/packaging, among other services.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">To
support our commercial efforts, we have hired and are continuing to hire U.S. experts with relevant experience in the commercialization
of medical products in the hospital market, including in the areas of sales, sales operations, marketing, market access, distribution,
medical affairs and others. In addition, we are expanding the necessary infrastructure, including IT systems, supply chain, financial
reporting systems and inventory management systems both, internally and with the assistance of external service providers.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
we expand our commercial efforts, we continue to enhance our commercial strategic plan, further expanding our sales force and medical
affairs teams, preparing relevant promotional and medical education materials to target healthcare providers and other stakeholders,
refining our medical affairs strategy to increase awareness of the EUA among the medical community, and furthering our sales efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td><td style="text-align: justify">KEYTRUDA&#174; is a registered trademark of Merck Sharp &amp;
Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
2023, we recognized revenues in the amount of &#8364;63,089 from product sales for the first time since our inception. Revenues reported
are sales to end customers (hospitals) in the United States.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">During
the twelve months ended December 31, 2023, the Group incurred &#8364;4.0 million of sales and marketing expenses. These expenses are mainly
composed of &#8364;1.0 million in personnel costs and &#8364;1.9 million in external services for distribution of Gohibic. The Group started
with its commercialization activities when the EUA was granted in April 2023. Prior to that, no sales and marketing expenses had been
incurred.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
also intend to independently pursue the commercialization of vilobelimab for PG in the United States and Europe, if and when approved
by the applicable regulators, by employing a targeted commercial infrastructure to promote access to vilobelimab through centers-of-excellence
that treat PG in these core markets. We believe that such an organization will be able to address the community of physicians who are
key specialists in treating the patient populations for which vilobelimab and any other product candidates are being developed. The responsibilities
of the organization would include developing educational initiatives with respect to approved products and establishing relationships
with key specialists in PG and any other relevant fields of medicine. The option to collaborate with a larger organization with an established
commercial infrastructure will also be evaluated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
might also consider pursuing the commercialization of vilobelimab in other indications or commercialization of our other development
products independently. However, we are also considering potential partnerships with larger companies that have a more established infrastructure
and greater financial resources in different areas, including in sales and marketing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates.
We intend to rely on existing third-party contract manufacturers to produce our products and intend to recruit additional personnel with
experience to manage the third-party contract manufacturers producing our product candidates and other product candidates or products
that we may develop in the future. In addition, we engaged additional third-party manufacturers in Germany, the United States and other
countries for activities related to potential sales, e.g. packaging and labeling of any of our approved products in the United States
and elsewhere. We hold a manufacturing and importing license and participate in the drug product release procedure for vilobelimab by
running a key immunological release assay in-house, allowing us to release only drug product batches that demonstrate the necessary,
pre-specified high biological blocking activity. Thus, we are responsible for overseeing the entire manufacturing process and we release
final fill-finished drug product with our qualified person.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary
products. While we believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages,
we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology
companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that
we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
in Pyoderma Gangrenosum</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">There
are currently no drugs approved for the treatment of PG in major markets. The only locally approved treatment is adalimumab, which has
been approved in Japan but in no other country on the basis of a small, locally conducted clinical trial. However, due to the high medical
need associated with the disease, certain drugs are used in regular medical practice as treatment attempts for affected patients. These
include certain orally administered drugs such as immunosuppressants, including cyclosporine or corticosteroids or antibiotics such as
dapsone. In addition, topically applied tacrolimus is used in certain cases. Lastly intravenously administered TNF-alpha inhibitors such
as infliximab or adalimumab or other biological drugs are also used, despite the fact that no formal regulatory approvals are in place.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of the date hereof, to our knowledge, other treatments in active clinical trials include:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orally
administered baricitinib, a janus kinase-1 and janus kinase-2, or JAK1/JAK2, inhibitor is currently being investigated in&#160;a&#160;proof-of-concept,&#160;open label Phase II study</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
injected spesolimab, an interleukin-36 receptor, or IL-36R, monoclonal antibody is currently being investigated in a Phase II open label
single-arm study</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orally
administered deucravacitinib, a janus kinase-2, or JAK2, inhibitor, is currently being investigated in a Phase I single arm with 10 patients</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered canakinumab, an anti-interleukin-1 beta, or IL-1 beta, monoclonal antibody in a 24 patients clinical Phase II trial of a
subtype of PG, a pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
the following developments have been terminated, completed or abandoned and have not advanced to registrational Phase III trials in recent
years or failed in previous clinical trials:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered gevokizumab, an anti-interleukin-1 beta, or IL-1 beta, monoclonal antibody in three clinical Phase III trials enrolling
16, 15 and nine patients and in a Phase II study enrolling eight patients</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered bermekimab, an anti-interleukin-1 alpha, or IL-1 alpha, monoclonal antibody in a clinical Phase II study enrolling 10 patients</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered ixekizumab, an anti-interleukin-17 alpha, or IL-17 alpha, monoclonal antibody in a clinical Phase II trial after enrolling
four patients</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orally
administered etrasimod, (APD334), a selective sphingosine-1-phosphate, or S1P-1, receptor modulator in a clinical Phase II trial enrolling
two patients</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered ustekinumab, a monoclonal antibody targeting the shared p40 subunit of interleukin-12, or IL-12 and&#160;interleukin-23, or IL-23,
described as being successfully treated in a patient on chronic immunosuppressive therapy in a single patient case-report study</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered secukinumab, an anti-interleukin-17 alpha, or IL-17 alpha, monoclonal antibody, described as being successfully treated
after failure of other systemic therapies in a single patient case-report study</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
approved for the treatment of PG, vilobelimab would potentially face competition from currently used therapies, such as glucocorticoids,
cyclosporin or other immunosuppressive therapies like adalimumab, infliximab or others.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
in the treatment of critically ill, invasively mechanically ventilated COVID-19 patients</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
approved for treatment of critically ill, invasively mechanically ventilated COVID-19 patients, vilobelimab would face competition from
currently used or approved therapeutics such as corticosteroids, the interleukin-1, or IL-1, inhibitor anakinra, IL-6 inhibitors such
as tocilizumab, JAK-inhibitors such as baricitinib and anti-thrombotic therapy. Given the high medical need for effective treatments
as a consequence of the COVID-19 pandemic, many different therapeutic entities and targets have or are still being assessed for the treatment
of this patient population. While the performance of clinical trials in a particular patient population is the prerequisite to be able
to gain regulatory approval for the treatment of that particular patient population, several clinical trials have been conducted in other
patient populations (e.g., hospitalized patients as opposed to our targeted sub-group of critically ill, invasively mechanically ventilated
patients) and results of these trials have partly been extrapolated into our targeted population. None of these treatments have received
EUA, and we are of the opinion that in order to gain full BLA approval, these treatments will need to show clinical efficacy in randomized
controlled clinical trials. Therefore, we believe that competition will mainly be faced by products developed for the intended use population.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Treatments
currently or previously under investigation or completed for severe COVID-19, including for the treatment of critically ill, mechanically
ventilated patients, include:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered sabizabulin, a microtubule disruptor, completed a Phase III study in 204 hospitalized
                                            COVID-19 patients at high risk of developing ARDS or death, demonstrating a 55% reduction
                                            in mortality at day 60. On November 9, 2022 the FDA Pulmonary-Allergy Drugs Advisory Committee
                                            voted 8-5 that the known and potential benefits of sabizabulin do not outweigh the known
                                            and potential risks of sabizabulin. On March 2, 2023 the sponsor of the trial, Veru Pharmaceuticals
                                            Inc. announced that the FDA declined to grant EUA for sabizabulin.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered nangibotide, a synthetic peptide and first-in-class triggering receptor in myeloid
                                            cell-1, or TREM-1, inhibitor in a randomized controlled Phase II trial in COVID-19 ICU patients.
                                            Results from this study showed a 43% relative reduction in 28-day all-cause mortality in
                                            the analyzed patient population.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered eculizumab, a monoclonal antibody inhibitor of C5, has been in an open label
                                            Phase II trial in patients with COVID-19 infection receiving Continuous-Positive-Airway-Pressure,
                                            or CPAP, ventilator support. Only 10 patients were treated with eculizumab in this non-randomized
                                            study and compared to 52 patients. Eculizumab was safe and well tolerated but did not show
                                            a major effect on reduction of mortality in this relatively small group of patients. No additional
                                            studies with eculizumab in this patient population have been reported.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered ravulizumab, a monoclonal antibody inhibitor of C5, in a Phase II study in patients
                                            with COVID-19 severe pneumonia, acute lung injury, or ARDS. This study has been stopped after
                                            an interim analysis and no results are available.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered avdoralimab (IPH5401), an anti-C5aR antibody, in an investigator initiated,
                                            double-blind, randomized Phase II study versus placebo in patients with COVID-19 severe pneumonia.
                                            208 patients were enrolled, and the program was stopped in July 2021 after the trial did
                                            not reach the primary endpoints.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered asunercept, a CD95-Fc fusion protein, specifically binding to and efficiently
                                            blocking CD95L, in a double-blind, randomized Phase II study in 438 patients suffering from
                                            severe COVID-19, which has been completed in October 2021 showing efficacy on certain outcome
                                            measures. While no full dataset has been published, asunercept tried further developed in
                                            a Phase III study with 636 patients. On August 18, 2023 the study has been terminated due
                                            to the lack of patients with only 34 patients recruited.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered AMY-101, a cyclic peptide targeting complement factor C3, in a Phase II clinical
                                            trial to assess safety and efficacy in patients with ARDS, due to COVID-19 infection did
                                            not meet its primary efficacy endpoint.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered APL-9, a protein specifically targeting C3, a central protein in the complement
                                            system of the immune system, in a Phase I/II study for the treatment of severe COVID-19 patients.
                                            After an interim analysis by an independent data monitoring committee, no meaningful reduction
                                            in the overall mortality rate in patients treated with APL-9 could be observed and thus the
                                            study was terminated early.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
in cSCC</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
approved in programmed death-1, or PD-1 and programmed death-ligand-1, or PD-L1 inhibitor, resistant / refractory, locally advanced or
metastatic cSCC, vilobelimab would face competition from currently used therapeutics such as epidermal growth factor receptor, or EGFR,
inhibitors such as cetuximab, chemotherapeutic agents such as cisplatin, doxorubicin, taxane, gemcitabine, methotrexate and 5-fluorouracil,
or 5-FU, as well as topically applied products such as imiquimod or tirbanibulin, even if some of these treatment are not all approved
for use in this indication.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, two PD-1 inhibitors are FDA approved to treat locally advanced or metastatic cSCC. Pembrolizumab, a monoclonal antibody targeting
PD-1 is indicated for recurrent or metastatic cSCC that is not curable by surgery or radiation as well as cemiplimab, a monoclonal antibody
targeting PD-1, which is indicated for metastatic cSCC or locally advanced cSCC for those patients that are not candidates for curative
surgery or radiation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
treatments currently under investigation include:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered cosibelimab, a monoclonal antibody targeting PD-L1, in a completed registration-enabling trial, showing an overall response
rate, or ORR, of 54.8%, submitted for BLA to the FDA in January 2023, accepted by FDA in March 2023. In December 2023 FDA issued a Complete
Response Letter due to the third party CMO finding. Despite of that the drug is expected to be approved in 2024</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered avelumab, a monoclonal antibody targeting PD-L1, in combination with radical radiation therapy, in a Phase II study for
the treatment of unresectable cSCC</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered cetuximab, a monoclonal antibody targeting EGFR, in combination with avelumab, a monoclonal antibody targeting PD-L1, in
a Phase II randomized trial in&#160;advanced&#160;cSCC</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered nivolumab, a monoclonal antibody targeting PD-1 in two Phase II trials, as monotherapy and in combination with ipilimumab,
a monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4, or CTLA-4, in a Phase II study</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orally
administered cobimetinib, a small molecule inhibitor of the mitogen-activated protein kinase, or MEK, in combination with atezulizumab,
a monoclonal antibody targeting PD-L1, in a Phase II study in advanced rare tumors, including metastatic cSCC</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered oncolytic vaccine using Maraba virus vector expressing melanoma antigen A3, or MAGE-A3, or MG1MA3, as monotherapy and as
booster after intramuscular priming with adenovirus vaccine with transgenic MAGE-A3 insertion, or AdMA3, in a Phase I/II trial in patients
with incurable advanced/metastatic MAGE-A3-expressing solid tumors, including cSCC</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intratumorally
injected oncolytic viral vector talimogene laherparepvec in combination with panitumumab a monoclonal antibody targeting EGFR (and also
in combination with other antibodies targeting PD-1 or PD-L1) in several Phase I and Phase II studies for the treatment of refractory
and/or advanced cSCC</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered nanrilkefusp alfa, an IL-15 superagonist as monotherapy or in combination with pembrolizumab in a Phase I multi-center open-label
Phase I/Ib study to evaluate the safety and preliminary efficacy of SO-C101 in relapsed/refractory, advanced/metastatic cSCC</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
infused ASP-1929 photoimmune therapy either as monotherapy or in combination with pembrolizumab in two Phase II studies for the treatment
of primary or recurrent locoregional cSCC. The trial has been discontinued due to the lack of efficacy in October 2023</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intratumorally
injected exosomes (CDK-002 or exoSTING) in an exploratory Phase I/II study, including several solid tumors (such as cSCC)</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
in HS</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Until
2023 the only approved and marketed systemically administered product to treat moderate to severe HS patients in the United States and
Europe was adalimumab, an inhibitor of tumor necrosis factor-alpha, or TNF-alpha. In 2023, the Phase 3 results were published for two
additional drugs, with the following outcomes::</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered secukinumab, an IL-17 alpha monoclonal antibody has been submitted and approved</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered bimekizumab, a monoclonal antibody blocking IL-17A/F, has completed Phase III studies and is currently in the process of
registration</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
we would develop and receive approval for vilobelimab in HS, we would face competition from currently approved therapeutics such as adalimumab,
secukinumab and bimekizumab (if approved), from topical therapies, including clindamycin, resorcinol and others, from intralesionally
applied corticosteroids, from orally administered antibiotics such as tetracycline, clindamycin, rifampicin, metronidazole, cephalosporin,
dapsone and others. In addition, a range of surgical procedures, laser and radiotherapy procedures are being investigated and used for
the treatment of HS. Finally, we could face competition from additional product candidates currently under development that might receive
approvals for HS before us.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Several
additional systemically administered product candidates have previously or are currently being investigated and developed to treat HS
with varying mechanisms of action:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered SAR442970, an anti-TNF-OX40L nanobody, is being investigated in a Phase 2 clinical
                                            trial in 84 moderate to severe HS patients</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered SAR444656, a low molecular weight IRAK4 degrader, is being investigated in a
                                            Phase 2 clinical trial in 99 moderate to severe HS patients</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered amlitelimab (SAR445229), a fully human OX40L binding antibody, is being investigated
                                            in a Phase 2 clinical trial in 84 moderate to severe HS patients</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered tofacitinib, an IFN signaling blocker, is being investigated in Phase II study
                                            in 47 patients with Down Syndrome to evaluate the efficacy of the drug in treatment of various
                                            skin diseases, including HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered povorcitinib (INCB 54707), a low molecular weight JAK-1 inhibitor, is being
                                            investigated in two Phase III clinical studies in 1,560 moderate to severe HS patients</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered avacopan, a low molecular weight C5aR inhibitor, completed a Phase II study
                                            in 435 moderate to severe HS patients in 2021</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered bermekimab, a monoclonal antibody targeting IL1-alpha, completed three Phase
                                            II clinical studies in a total of 337 patients with moderate to severe HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered izokibep, a selective inhibitor of IL-17A, is currently being investigated in
                                            a Phase IIb study with 180 patients and in the Phase III with 250 patients</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered sonelokimab (ALX 0761, M1095), a trivalent nanobody comprised of monovalent
                                            camelid-derived nanobodies specific to human interleukin IL-17A, IL-17F and human serum albumin
                                            VHHs, completed a 234 patient Phase II clinical trial in patients with active, moderate to
                                            severe HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered lutikizumab, a monoclonal antibody targeting IL-1alpha/beta is currently being
                                            investigated in 200 patient Phase II study in moderate to severe HS patients who failed Anti-TNF
                                            Therapy as well as patients na&#239;ve to biologic therapy</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered iscalimab (CFZ-533), a nondepleting anti-CD40 antibody, is being tested in a
                                            200 patient Phase II exploratory study in patients with moderate to severe HS in parallel
                                            with other experimental therapies, including LYS006, MAS825, remibrutinib (LOU064) and ianalumab
                                            (VAY736)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered LYS006, a selective inhibitor of leukotriene A4 hydrolase, or LTA4H, is being
                                            tested in a 200 patient Phase II exploratory study in patients with moderate to severe HS
                                            in parallel with other experimental therapies, including iscalimab (CFZ-533), MAS825, remibrutinib
                                            (LOU064) and ianalumab (VAY736)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered MAS825, a T-cell immunoglobulin and mucin domain 3, or TIM-3, inhibitor is being
                                            tested in a 200 patient Phase II exploratory study in patients with moderate to severe HS
                                            in parallel with other experimental therapies, including iscalimab (CFZ-533), LYS006, remibrutinib
                                            (LOU064) and ianalumab (VAY736)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered remibrutinib (LOU064), a low molecular weight Burton tyrosine kinase, or BTK,
                                            inhibitor, is being tested in a 200 patient Phase II exploratory study in patients with moderate
                                            to severe HS in parallel with other experimental therapies, including iscalimab (CFZ-533),
                                            LYS066, MAS825 and ianalumab (VAY736)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcunaeously
                                            administered ianalumab (VAY736), a fully human anti-BAFF-R monoclonal antibody, is being
                                            tested in a 200 patient Phase II exploratory study in patients with moderate to severe HS
                                            in parallel with other experimental therapies, including iscalimab (CFZ-533), LYS 066, MAS825
                                            and remibrutinib (LOU064)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered eltrekibart (LY3041658), a monoclonal antibody targeting and neutralizing several
                                            human chemokines of the CXC family containing the ELR peptidic motiv, is currently being
                                            evaluated in a clinical Phase II trial with 350 patients suffering from moderate to severe
                                            HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered upadacitinib, a Janus kinase inhibitor, is completed a Phase II clinical study
                                            with 68 patients study to investigate the treatment effect in moderate to severe HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered spesolimab, an interleukin-36, or IL-36, receptor (IL1RL2/IL1RAP) targeted antibody,
                                            is currently being developed for patients with HS and is in Phase II clinical testing in
                                            52 patients</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            and intravenously administered imsidolimab (ANB019), an antibody that inhibits the function
                                            of the interleukin-36-receptor, or IL-36R, completed a Phase II clinical trial in 149 patients
                                            in order to explore the immune response to imsidolimab in subjects with HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Topically
                                            administered ruxolitinib, a low molecular weights JAK1 and JAK2 inhibitor, formulated as
                                            1.5% cream is currently being investigated in Phase II with 93 patients with HS 	</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered PTM-001, an experimental drug development candidate with undisclosed mode of
                                            action is currently in a Phase II clinical study in 50 patients with moderate to severe HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Three
                                            different orally administered novel kinase inhibitors, were tested in a 194 patient Phase
                                            II exploratory study in patients with moderate to severe HS in parallel. Reported results
                                            in 2022 indicate that differences between placebo and tested dose regimens of experimental
                                            therapies PF 06826647 and PF 06650833 were not statistically significant, while PF 06700841
                                            showed superiority to placebo</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered orismilast, a phosphodiesterase-IV, or PDE-IV, inhibitor is currently being
                                            investigated in a clinical trial with 24 patients to assess the efficacy and safety of oral
                                            administration of orismilast for treatment of mild, moderate, or severe HS in adults</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">intravenously
                                            administered brodalumab, a monoclonal antibody targeting the IL-17 receptor, or IL17R, completed
                                            a Phase II clinical study for the treatment of moderate HS</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
consider the following product candidates that were under clinical investigation not being a competitive threat for the time being or
at all:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orally
administered RIST4721, an IL-8B receptor antagonist, has been tested in a Phase II clinical study in 33 patients with HS, the study has
been terminated due to safety findings</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered risankizumab, a monoclonal antibody targeting interleukin-23A, or IL-23A, was
                                            investigated in a clinical Phase II trial in 243 patients (which was completed in 2021) -differences
                                            between placebo and tested dose regimens of risankizumabwere not statistically significant</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            and subcutaneously administered guselkumab, a monoclonal antibody targeting IL-23, completed
                                            a Phase II clinical trial in 184 moderate to severe HS patients (which was completed in 2020)
                                            &#8211; differences between placebo and tested dose regimens of guselkumab were not statistically
                                            significant</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Intravenously
                                            administered anakinra, an IL-1 receptor antagonist, has been investigated in three Phase&#160;II
                                            trials in TNF-alpha treatment refractory patients (which was completed in 2017)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered apremilast, a phosphodiesterase-IV, or PDE-IV, has been investigated in a Phase&#160;II
                                            trial in 20 moderate to severe HS patients (which was completed in 2017)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered CJM112, a monoclonal antibody targeting IL-17A and IL-17A/F has completed a
                                            Phase II study in 66 patients suffering from moderate to severe, chronic HS (which was completed
                                            in 2016 and did not reach the primary outcome)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
                                            administered MEDI8968, an investigational monoclonal antibody drug candidate selective against
                                            IL-1R, has been investigated in a Phase II clinical trial in 221 moderate to severe HS patients
                                            (which was competed in 2014 and did not meet its primary outcome)</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Orally
                                            administered zunsemetinib (ATI-450), a mitogen-activated protein, or MAP, kinase-activated
                                            protein kinase 2, or MAPKAPK2, or MK2, inhibitor, is currently investigated in a Phase Iia
                                            clinical study with 95 patients study to investigate the treatment effect in moderate to
                                            severe HS. The study did not meet its primary endpoint</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Subcutaneously
administered ustekinumab, a monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23 completed a Phase II clinical trial
in 20 moderate to severe HS patients (which was completed in 2014)</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
in ANCA associated vasculitis</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
approved for the treatment of AAV, vilobelimab would potentially face competition from currently used therapies, including the low molecular
weight C5aR-inhibitor avacopan (FDA approved for this indication in October 2021), corticosteroids, azathioprine, methotrexate, cyclosporin,
mycophenolate mofetil and rituximab. The current standard of care to induce remission in acutely ill AAV patients is done through a combination
of either rituximab or azathioprine&#160;with HDCS. Rituximab is approved and marketed for this indication and label extension studies
are ongoing. Therapies to maintain remission include low dose corticosteroids, methotrexate, mycophenolate mofetil and rituximab. Mepolizumab,
a monoclonal antibody targeting interleuline-5, or IL-5, is also FDA approved to treat a type of AAV in adults called EGPA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered KYV-01, a fully human anti-CD19 CAR T-cell therapy, is investigated in a Phase I study in 24 patients with a number of autoimmune
diseases, including AAV</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered Obinutuzumab, an anti-CD20 monoclonal antibody, is investigated in a 30 patients Phase II study of PR3-Patients with AAV</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered MT 2990, a monoclonal antibody targeting interleukin-33, in a 10 patient Phase I study of patients with AAV</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered benralizumab a monoclonal antibody targeting interleukin-5, or IL-5 receptor or mepolizumab a monoclonal antibody targeting
IL-5, in a 140 patient Phase III clinical study within a type of AAV, EGPA</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered abatacept, a monoclonal antibody targeting CTLA-4, in a Phase III clinical study in 66 patients with relapsing, non-severe,
EGPA</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intravenously
administered depemokimab in a Phase III clinical trial with 160 patients with relapsing or refractory EGPA</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Orally
administered NS-229, a JAK-1 inhibitor, is in a Phase II clinical trial with 45 patients with EGPA</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
to INF904 by oral C5aR inhibitors</b></span></p><div>

</div><p style="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
completed a single and multiple ascending dose Phase I program with our oral C5aR inhibitor, INF904 in the second half in January 2024.
This program may prove the assumed favorable PK and safety profile and ease of administration required for effective long-term treatment
for chronic inflammatory diseases. The development of low molecular weight drug candidates through the different stages of clinical and
nonclinical development is a time-consuming and cost-intensive process. As of the date hereof, and to our knowledge, avacopan is the
only currently approved oral C5aR inhibitor for the treatment of AAV. If we ever and until we reach the market approval stage, we might
have encountered a variety of competing products and might potentially not be second to avacopan on the market. Even if marketed, INF904
might face future competition from other oral small molecules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
most advanced orally available C5aR inhibitor in active development to our knowledge is ACT-1014-6470. In a completed Phase I clinical
trial, the company developing the product reported positive data on safety in both, healthy subjects and patients with renal impairment.
However, neither the targeted indication for Phase II development of ACT-1014-6470 nor the status of development has yet been disclosed
publicly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
there are and have been several product candidates in pre-clinical and early clinical development. These include low molecular weight
compounds, cyclic peptides and other classes of drug candidates. To our knowledge, none of these drug candidates, with exception of avacopan,
was ever successfully tested in Phase III registration trials or has been under review at any regulatory agency. At least 10-15 different
C5aR-inhibitors have been mentioned to be in different stages of pre-clinical and early clinical development, but there have been no
updates on their respective development progress in recent years, therefore we assume most of these development programs were meanwhile
paused or terminated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Competition
from therapeutics agents in the field of terminal complement inhibition</b></span></p><div>

</div><p style="text-align: left; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">There
are several clinical or commercial stage companies focusing on the inhibition of C5aR with biological molecules, including monoclonal
antibodies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
C5a/C5aR1 signaling pathway plays an essential role in various inflammatory diseases. It has been discovered that C5a can be generated
not only by conventional complement activation pathways (classical, lectin, alternative) through C5a convertases, but also by a direct
enzymatic cleavage (enzymatic pathway) by various enzymes (e.g., thrombin and plasmin). It has been reported that C5a generation via
the enzymatic pathway is not affected by the upstream complement blockers, including C5 blockers like eculizumab. As such, controlling
and fully blocking C5a induced signaling in humans therefore warrants a targeted approach by directly blocking either C5a or C5aR1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">There
are currently several C5a and C5aR inhibitors in different stages of active clinical development:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Avdoralimab
(IPH5401), an anti-C5aR1 antibody is being investigated in different inflammatory diseases. A Phase II clinical trial evaluating the
safety and efficacy of avdoralimab in COVID-19 patients with severe pneumonia, did not meet its primary endpoints in all three cohorts
of the trial. The compound is not in active development as of today. A Phase II study in patients with bullous pemphigoid,
or BP, is ongoing,</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">STSA-1002,
an anti-C5a humanized antibody is currently in Phase Ib/II clinical trials in patients with ARDS.</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#160;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">AON-D21,
an anti-C5a L-aptamer is currently in Phase IIa clinical development for critically ill, intubated patients with pneumonia. In a single-ascending
dose study in healthy volunteers, AON-D21 was shown to be safe and well tolerated. A multiple-ascending dose study was completed in mid
2022.</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">MOR210,
an anti-C5aR antibody, is a novel human antibody directed against C5aR1. MOR210 was investigated as a treatment for relapsed or refractory
advanced solid tumors in a Phase I trial.</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">VIS954,
an anti-C5aR antibody is investigated in the Phase I SAD study in healthy adult participants.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: S2 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">More
broadly, in the terminal complement space, there are currently several approved drugs, including eculizumab and ravulizumab for the treatment
of Paroxysmal nocturnal hemoglobinuria, or PNH, and atypical hemolytic uremic syndrome, or aHUS, zilicoplan for the treatment of generalized
myasthenia gravis, or gMG, Avacincaptad pego for the treatment of geographical athropy, or GA. In addition, there are several development
programs to develop C5 inhibitors for other indications, including by Hoffmanm-La Roche AG, Akari Therapeutics Plc., Alnylam Pharmaceuticals,
Inc., Regeneron Pharmaceuticals, Inc. and Novartis AG.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Beyond
C5 and C5a, there are clinical stage companies targeting complement inhibition upstream from C5, such as C3, factor D and components
of the lectin pathway. These approaches will likely also result in a lowering of C5a generation in blood. Companies in this area include
Apellis Pharmaceuticals, Inc., UCB S.A., AstraZeneca plc and Omeros Corporation, among others. Furthermore, there are numerous additional
companies developing pre-clinical drug candidates that target terminal complement factors and their receptors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Summary</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
key competitive factors affecting the success of our product candidates, if approved or authorized, are likely to be their efficacy,
safety, dosing convenience, price and degree of market acceptance, as well as our or our partners marketing capabilities, the level of
competition and the availability of reimbursement from government and other third-party payors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective,
have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors
may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market. In addition, even if our product candidates
are approved for marketing and sale, they may fail to gain sufficient market acceptance by physicians, patients, third-party payors and
others in the medical community, including if physicians are reluctant to switch their patients from existing therapies (such as adalimumab
for the treatment of HS). See &#8220;ITEM 3. KEY INFORMATION &#8212; 3.&#160;Risk factors &#8212; Risks related to the discovery, development
and commercialization of our product candidates&#8212;Even if one of our product candidates receives marketing approval, it may fail
to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary
for commercial success, in which case we may not generate significant revenues or become profitable.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Government
regulation and product approval</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Government
authorities in all major pharmaceutical markets extensively regulate, among other things, the research, development, testing, manufacture,
packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing and import and export of pharmaceutical
products such as those we are developing. Although our initial focus will be on the United States and Europe, we intend to develop and
seek marketing approval for our products also in other countries and territories, such as Canada or Japan, and for markets that follow
the leading authorities, such as Brazil or South Korea. The processes for obtaining regulatory approvals in the United States, Europe
and other countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial
time and financial resources.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>FDA
approval process</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">All
of our current product candidates are subject to regulation in the United States by the FDA either as biological products, or biologics,
or as new chemical entities, or NCEs. The FDA subjects biologics and NCEs to extensive pre- and post-market regulation. The Public Health
Service Act, or PHSA, the Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations govern, among other
things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution,
post-approval monitoring and reporting, sampling, and import and export of biologics and NCEs. Failure to comply with applicable U.S.
requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs
or NDAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of
production or distribution, injunctions, fines or civil or criminal penalties.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The PHSA also provides
authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure
products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to
prevent the introduction or spread of communicable diseases in the United States and between states.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">BLA
and NDA application and approval</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
process required by the FDA before a new biologic or NCE may be marketed in the United States is long, expensive, and inherently uncertain.
Biologics and NCE development in the United States typically involves preclinical laboratory and animal tests, the submission to the
FDA of an IND (which must become effective before clinical testing may commence) and adequate and well-controlled clinical trials to
establish the safety, purity and potency (safety and effectiveness) of the biologic or NCE for each indication for which FDA approval
is sought. Developing the data to satisfy FDA pre-market approval requirements typically takes many years and the actual time required
may vary substantially based upon the type, complexity, and novelty of the product or disease.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Preclinical
studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient
and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug candidate
for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal
regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information,
analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA
as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue
after the IND is submitted.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">An
IND must become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is
required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this
30-day period, the clinical trial proposed in the IND may begin.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials involve the administration of the investigational new drug or biologic to healthy volunteers or patients with the condition under
investigation, all under the supervision of a qualified investigator. Clinical trials must be conducted (i) in compliance with federal
regulations, (ii) in compliance with good clinical practice, or GCP, which is an international standard meant to protect the rights and
health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and (iii) under protocols detailing
the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol
involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes
that the clinical trial either is not being conducted in accordance with requirements or presents an unacceptable risk to the clinical
trial subjects. The study protocol and informed consent information for subjects in clinical trials must also be submitted to an institutional
review board (IRB) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently,
for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. The study sponsor may also suspend a clinical
trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health
risk.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials to support BLAs or NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap
or be combined. In Phase I, the drug candidate is initially introduced into healthy human subjects or patients and is tested to assess
its pharmacokinetic, or PK, properties, pharmacological actions, side effects associated with increasing doses, and, if possible, early
evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer treatments, initial human
testing has to be conducted in the intended patient population. Phase II usually involves trials in a limited and well-specified patient
population to determine the effectiveness of the biologic for a particular indication, dosage tolerance and optimum dosage, and to identify
common AEs and potential safety risks. If a drug candidate demonstrates evidence of effectiveness and an acceptable safety profile in
Phase II evaluations, Phase III trials are undertaken to obtain additional information about clinical efficacy and safety in a larger
number of patients, representing the future intended use population, typically at geographically dispersed clinical trial sites. These
Phase III clinical trials are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of
the product to permit the FDA to evaluate the overall benefit-risk relationship of the biologic or NCE and to provide adequate information
for the labeling of the drug. Trials conducted outside of the United States under similar, GCP-compliant conditions in accordance with
local applicable laws may also be acceptable to the FDA in support of product licensing.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Sponsors
of clinical trials for investigational drugs must publicly disclose certain clinical trial information, including detailed trial design
and trial results in public government databases. These requirements are subject to specific timelines and apply to most controlled clinical
trials of FDA-regulated products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">After
completion of the required clinical testing, a BLA (for a biologic) or a NDA (for a NCE) is prepared and submitted to the FDA. FDA review
and approval of the BLA or NDA is required before marketing of the product may begin in the United States. The BLA or NDA must include
the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry,
manufacture and controls, and must demonstrate the safety and efficacy of the product based on these results. The BLA or NDA must also
contain extensive manufacturing information. The cost of preparing and submitting a BLA or NDA is substantial. Under federal law, the
submission of most BLAs or NDAs is additionally subject to a substantial application user fee, as well as an annual program user fee,
which may total several million dollars and are typically increased annually.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
FDA has 60 days from its receipt of a BLA or NDA to determine whether the application will be accepted for filing based on the agency&#8217;s
threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the
FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs and NDAs. Most such applications
for standard review drug candidates are reviewed within 10 months from the date the application is accepted for filing. Although the
FDA often meets its user fee performance goals, it can extend these timelines if necessary, and its review may not occur on a timely
basis. The FDA usually refers applications for novel drugs, or drugs which present difficult questions of safety or efficacy, to an advisory
committee&#8212;typically a panel that includes clinicians and other experts&#8212;for review, evaluation, and a recommendation as to
whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it frequently follows
such recommendations. Before approving a BLA or NDA, the FDA will typically inspect one or more clinical sites to assure compliance with
GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the
product unless it verifies that compliance with cGMP standards is satisfactory and the BLA or NDA contains data that provide substantial
evidence that the drug is safe and effective in the indication studied.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">After
the FDA evaluates the BLA or NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter.
A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information,
in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction
in a resubmission of the BLA or NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in
two or six months depending on the type of information included. The FDA approval is never guaranteed, and the FDA may refuse to approve
a BLA or NDA if applicable regulatory criteria are not satisfied.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Under
the PHSA, the FDA may approve a BLA or NDA if it determines that the product is safe, pure and potent and the facility where the product
will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications. The approval for a drug may be significantly
more limited than requested in the application, including limitations on the specific diseases and dosages or the indications for use,
which could restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions
be included in the product labeling. In addition, as a condition of BLA or NDA approval, the FDA may require a risk evaluation and mitigation
strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication
plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training
or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient
registries. The requirement for a REMS or use of a companion diagnostic with a drug can materially affect the potential market and profitability
of the drug. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance to
monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards
is not maintained or problems are identified following initial marketing.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">After
a BLA or NDA is approved, the product may also be subject to official lot release. As part of the manufacturing process, the manufacturer
is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to
official lot release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol
showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the
lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots
for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety,
purity, potency, and effectiveness of products. After approval of drugs, manufacturers must address any safety issues that arise, are
subject to recalls or a halt in manufacturing, and are subject to periodic inspection.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Emergency
use authorization</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
FDA can facilitate the availability and use of medical countermeasures needed during public health emergencies via EUA. When The United
States Secretary of Health and Human Services, or HHS Secretary, declares that an EUA is appropriate, FDA may authorize unapproved medical
products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat or prevent serious or life-threatening
diseases or conditions caused by chemical, biological, radiological or nuclear threat agents. For example, in January 2020, the HHS Secretary
determined that a public health emergency, or PHE, existed (and has subsequently extended the declaration on numerous occasions,) that
had a significant potential to affect national security or the health and security of U.S. citizens due to the emergence and spread of
COVID-19. Based on this determination, the HHS Secretary also declared that circumstances existed justifying EUA of certain medical products.
The EUA declaration is distinct from the PHE declaration. As long as the applicable EUA declaration and determination remains in effect,
an EUA may remain in effect beyond the duration of the PHE declaration if all other statutory conditions are met. Even if the EUA declaration
remains in effect, the FDA may revoke the EUA at any time if certain circumstances or criteria are met. We have been granted the EUA
for GOHIBIC (vilobelimab), for the treatment of COVID-19 in hospitalized adults when initiated within 48hours of receiving IMV or ECMO.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Adverse
event reporting an cGMP compliance</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Adverse
event reporting and submission of periodic reports are required following FDA approval of a BLA or NDA. The FDA also may require post-marketing
testing, known as Phase IV testing, REMS and surveillance to monitor the effects of an approved product, or may place conditions on an
approval that could restrict the distribution or use of the product. In addition, manufacture, packaging, labeling, storage and distribution
procedures must continue to conform to current cGMPs after approval. Drug manufacturers and certain of their subcontractors are required
to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced
inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers
must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory
authorities may withdraw product approvals, request product recalls or impose marketing restrictions through labeling changes or product
removals if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously
unrecognized problems are subsequently discovered.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Orphan
drug designation</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to biologics or NCEs intended to treat a rare disease or condition&#8212;generally
a disease or condition that affects fewer than 200,000 individuals annually in the United States. Orphan drug designation must be requested
before submitting a BLA or NDA. After the FDA grants orphan drug designation, the generic identity of the drug candidate and its potential
orphan use are disclosed publicly by the FDA. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration
of, the regulatory review and approval process. The first BLA or NDA applicant to receive FDA approval for a particular product to treat
a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for
that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market
the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan
drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition,
or the same drug for a different disease or condition or, a drug that is otherwise the same drug which may be clinically superior. Among
the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA or NDA application user fee.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Fast
track designation</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Fast
track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet
medical need. The purpose is to get important new drugs to the patient earlier. Fast track addresses a broad range of serious conditions.
Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on
such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less
severe condition to a more serious one. Filling an unmet medical need is defined as providing a therapy where none exists or providing
a therapy which may be potentially better than available therapy. Any drug being developed to treat or prevent a condition with no current
therapy is directed at an unmet need. If there are available therapies, a fast track drug must show some advantage over available therapy,
such as: showing superior effectiveness, effect on serious outcomes or improved effect on serious outcomes; avoiding serious side effects
of an available therapy; improving the diagnosis of a serious condition where early diagnosis results in an improved outcome; decreasing
a clinical significant toxicity of an available therapy that is common and causes discontinuation of treatment or ability to address
an emerging or anticipated public health need. A drug that receives fast track designation is eligible for some or all of the following:
more frequent meetings with the FDA to discuss the drug&#8217;s development plan and ensure collection of appropriate data needed to
support drug approval; more frequent written communication from FDA about such things as the design of the proposed clinical trials and
use of biomarkers; eligibility for Accelerated Approval and Priority Review, if relevant criteria are met; Rolling Review, which means
that a drug company can submit completed sections of its BLA or NDA for review by FDA, rather than waiting until every section of the
NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted
the entire application to the FDA. Fast track designation must be requested by the drug company. The request can be initiated at any
time during the drug development process. FDA will review the request and make a decision within sixty days based on whether the drug
fills an unmet medical need in a serious condition. Once a drug receives fast track designation, early and frequent communication between
the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures
that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have been granted orphan drug status and fast track designation for the PG indication in the United States for vilobelimab. We have also
been granted fast track designation for the COVID-19 indication in the United States. Depending on the outcome and available data of
vilobelimab studies in the other indications, we may apply for orphan drug status in the United States.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Accelerated
approval</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
FDA instituted its accelerated approval program to allow for earlier approval of drugs that treat serious conditions, and fill an unmet
medical need based on a surrogate endpoint. A surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical
sign or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The use of a surrogate
endpoint can considerably shorten the time required prior to receiving FDA approval. Drug companies are still required to conduct studies
to confirm the anticipated clinical benefit. These studies are known as Phase IV confirmatory trials. If the confirmatory trial shows
that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. If the confirmatory trial
does not show that the drug provides clinical benefit, FDA has regulatory procedures in place that could lead to removing the drug from
the market.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Priority
review</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
1992, under the Prescription Drug User Act, or PDUFA, FDA agreed to specific goals for improving the drug review time and created a two-tiered
system of review times &#8211; standard review and priority review. A priority review designation means FDA&#8217;s goal is to take action
on an application within six months (compared to 10 months under standard review). A priority review designation will direct overall
attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety
or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. Significant
improvement may be demonstrated by the following examples: evidence of increased effectiveness in treatment, prevention, or diagnosis
of condition; elimination or substantial reduction of a treatment-limiting drug reaction; documented enhancement of patient compliance
that is expected to lead to an improvement in serious outcomes; or evidence of safety and effectiveness in a new subpopulation. FDA decides
on the review designation for every application. However, an applicant may expressly request priority review. It does not affect the
length of the clinical trial period. FDA informs the applicant of a priority review designation within 60 days of the receipt of the
BLA or NDA. Designation of a drug as &#8220;Priority&#8221; does not alter the scientific/medical standard for approval or the quality
of evidence necessary.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">SPA
process</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">SPA
is a process in which companies may ask to meet with FDA to reach agreement on the design and size of certain clinical trials, clinical
studies, or animal studies to determine if they adequately address scientific and regulatory requirements for a study that could support
marketing approval. An SPA agreement indicates concurrence by FDA with the adequacy and acceptability of specific critical elements of
overall protocol design (e.g., entry criteria, dose selection, endpoints and planned analyses) for a study intended to support a future
marketing application. These elements are critical to ensuring that the trial conducted under the protocol can be considered an adequate
and well-controlled study that can support marketing approval. Feedback on these issues provides the benefit of certainty of adequacy
in planning a late-phase development strategy. However, an SPA agreement does not indicate FDA&#8217;s concurrence on every protocol
detail. The existence of an SPA agreement does not guarantee that FDA will file (accept) a BLA or NDA or that the results will be adequate
to support approval.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Other
healthcare laws and compliance requirements</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
the United States, our activities are potentially subject to regulation by federal, state and local authorities in addition to the FDA,
including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (for example,
the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice,
and state and local governments.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">EU
approval process</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally-authorized
medicinal products. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the development
of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of medicines
by working through a network of about 4,500 experts throughout the European Union, nominated by the member states. The EMA draws on resources
of over 40 National Competent Authorities, or the NCAs, of EU member states. The Paul Ehrlich Institute, or PEI, is one of the NCAs for
Germany, and regulates, among others, antibody products.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and generally
involves satisfactorily completing each of the following:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">preclinical
                                            laboratory tests, animal studies and formulation studies all performed in accordance with
                                            the applicable EU Good Laboratory Practice regulations;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">submission
                                            to the relevant national authorities of a clinical trial application or CTA for each trial
                                            in humans, which must be approved before the trial may begin in each country where patient
                                            enrollment is planned;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">performance
                                            of adequate and well-controlled clinical trials to establish the safety and efficacy of the
                                            product for each proposed indication;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">submission
                                            to the relevant competent authorities of a Marketing Authorization Application or MAA, which
                                            includes the data supporting safety and efficacy as well as detailed information on the manufacture
                                            and composition of the product in clinical development and proposed labelling;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">satisfactory
                                            completion of an inspection by the relevant national authorities of the manufacturing facility
                                            or facilities, including those of third parties, at which the product is produced to assess
                                            compliance with strictly enforced cGMP;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">potential
                                            audits of the non-clinical and clinical trial sites that generated the data in support of
                                            the MAA; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">review
                                            and approval by the relevant competent authority of the MAA before any commercial marketing,
                                            sale or shipment of the product.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Preclinical
studies</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Preclinical
tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal
studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the preclinical tests and formulation
of the compounds for testing must comply with the relevant international, EU and national legislation, regulations and guidelines. The
results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the
CTA.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Clinical
trial approval</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
Clinical Trials Regulation (EU) No 536/2014 repealed the Clinical Trials Directive 2001/20/EC, on January 31, 2022 and applies to all
new clinical trials from January 31, 2023. All ongoing trials must be transitioned to the new processes by 31 January 2025. The Clinical
Trials Regulation harmonizes the processes and supervision of clinical trials throughout the EU. Sponsors submit one application via
the Clinical Trials Information System, or CTIS, for approval to run a clinical trial in several European countries. The evaluation,
authorization and supervision of clinical trials are the responsibilities of EU member states and European Economic Area, or EEA, countries.&#160;The
CTIS application must be supported by an investigational medicinal product dossier, or IMPD, the study protocol and further supporting
information prescribed by the Clinical Trials Regulation and other applicable guidance documents. The CTIS process has predetermined
timelines which may vary depending on the phase of the study. The process includes timelines for one or more rounds of questions to be
answered or requests to be met by the regulatory authority.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Regulation
(EU) No 536/2014, includes transparency requirements (the proactive publication of clinical trial data in the EU database) with
associated rules on the timing of the publication of submitted documents at the time of, during and after completion of the clinical
trial. The transparency requirement can apply to documents included in the clinical trial application, or CTA, dossier provided in
CTIS, and all the clinical trial information submitted during the trial life cycle, with the exception of the quality related
documents, financial arrangements and some supervision related information.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Manufacturing
and import into the EU of investigational medicinal products is subject to the holding of appropriate authorizations and must be carried
out in accordance with cGMP.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Marketing
authorization application</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Authorization
to market a product in the EU member states proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition
procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics or
NCEs, fall under the centralized procedure, only this procedure will be described here.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Centralized
authorization procedure</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Certain
drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization
procedure for marketing authorization. A successful application under the centralized authorization procedure results in a marketing
authorization from the European Commission, which is automatically valid in all EU member states as well as in the other EEA, member
states (namely Norway, Iceland and Liechtenstein). The EMA and the European Commission administer the centralized authorization procedure.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Under
the centralized authorization procedure, the CHMP serves as the scientific committee that renders opinions about the safety, efficacy
and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#8217;s national drug
authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a
further member of the committee acting as a Co-Rapporteur. After approval, the Rapporteur(s) continue to monitor the product throughout
its life-cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped
when it is necessary to ask the applicant for clarification or further supporting data. The process is complex and involves extensive
consultation with the regulatory authorities of member states and a number of experts. Once the procedure is completed, a European Public
Assessment Report, or EPAR, is produced. If the CHMP concludes that the quality, safety and efficacy of the medicinal product is sufficiently
proven, it adopts a positive opinion. The CHMP&#8217;s opinion is sent to the European Commission, which uses the opinion as the basis
for its decision whether or not to grant a marketing authorization. If the opinion is negative, information is given as to the grounds
on which this conclusion was reached.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Policy
0070, which is intended to promote transparency of EMA decision making and clinical data, governs how EMA collects, reviews and publishes
clinical data submitted by applicants and Marketing Authorization Holders, or MAHs, through the centralized procedure.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">After
a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its
quality, safety and efficacy must be kept under review. Sanctions may be imposed for failure to adhere to the conditions of the marketing
authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Accelerated
assessment procedure</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">When
an application is submitted for a marketing authorization in respect of a drug for human use which is of major interest from the point
of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment
procedure pursuant to Article 14(9) of Regulation (EC) 726/2004. Under the accelerated assessment procedure, the CHMP is required to
issue an opinion within 150 days of receipt of a valid application, subject to clock stops. We believe that some of the disease indications
in which our product candidates are currently being or may be developed in the future qualify for this provision, and we will take advantage
of this provision as appropriate.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Conditional
approval</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
per Article 14(7) of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability
is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete clinical data than
are normally required, subject to specific obligations being imposed on the authorization holder. These specific obligations are to be
reviewed annually by the EMA. The list of these obligations shall be made publicly accessible. Such an authorization shall be valid for
one year, on a renewable basis.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Period
of authorization and renewals</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">A
marketing authorization is initially valid for five years and may then be renewed on the basis of a re-evaluation of the risk-benefit
balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder shall
provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including
all variants introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases
to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the Commission or the competent
authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization
which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing
member state within three years after authorization shall cease to be valid (the so-called sunset clause).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Orphan
drug designation</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Regulation
(EC) 141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">that
                                            it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically
                                            debilitating condition affecting not more than five in 10,000 persons in the European Union
                                            when the application is made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition
in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient
return to justify the necessary investment; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">that
                                            there exists no satisfactory method of diagnosis, prevention or treatment of the condition
                                            in question that has been authorized in the European Union or, if such method exists, the
                                            drug will be of significant benefit to those affected by that condition.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Regulation
(EC) 847/2000 sets out criteria for the designation of orphan drugs. An application for designation as an orphan product can be made
any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to
a 10-year period of market exclusivity, which means that no similar medicinal product can be authorized in the same indication. This
period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the
criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity.
In addition, derogation from market exclusivity may be granted on an individual basis in very selected cases, such as consent from the
marketing authorization holder, inability to supply sufficient quantities of the product or demonstration of &#8220;clinically relevant
superiority&#8221; by a similar medicinal product. Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000
are eligible for incentives made available by the European Union and by the member states to support research into, and the development
and availability of, orphan drugs.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
the MAA of a medicinal product designated as orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all studies conducted
in compliance with an agreed PIP, and a corresponding statement is subsequently included in the marketing authorization granted, the
10-year period of market exclusivity will be extended to 12 years.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
have been granted orphan drug status for the PG indication in the European Union for vilobelimab. Depending on the outcome and available
data of vilobelimab studies in the other indications, we may also apply for orphan drug status in Europe for these indications.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Regulatory
data protection</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Without
prejudice to the law on the protection of industrial and commercial property, marketing authorizations for new medicinal products benefit
from an 8+2+1 year period of regulatory protection.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">This
regime consists of a regulatory data protection period of eight years plus a concurrent market exclusivity of 10 years plus an additional
market exclusivity of one further year if, during the first eight years of those 10 years, the marketing approval holder obtains an approval
for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are determined to bring
a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party may reference the preclinical
and clinical data of the reference product beginning eight years after first approval, but the third party may market a generic version
of the reference product after only 10 (or 11) years have lapsed.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Other
international regulations</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales, and
distribution of pharmaceutical products. The approval process varies from country to country and the time to approval may be longer or
shorter than that required for FDA or European Commission approval.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Pharmaceutical
coverage, pricing and reimbursement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Significant
uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales
of our products will depend, in part, on the extent to which third-party payors, including government health programs in the United States
such as Medicare and Medicaid, commercial private and public health insurers and managed care organizations, provide coverage and establish
adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may
be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is
approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness
of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific drug products
on an approved list, or formulary, which might not include all of the approved products for a particular indication.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
order to secure coverage and reimbursement for any pharmaceutical product approved for sale, a company may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the
costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may not be considered
medically necessary or cost effective. Additionally, a payor&#8217;s decision to provide coverage for a drug product does not imply
that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug
product does not assure that other payors will also provide coverage for the drug product. Third-party reimbursement may not be
sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been
a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net
revenue and results. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement
status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage
policies and reimbursement rates may be implemented in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Outside
the United States, ensuring adequate coverage and payment for our products will face challenges. Pricing of prescription pharmaceuticals
is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt
of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of
our products or products to other available therapies. The conduct of such clinical trials could be expensive and result in delays in
our commercialization efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
the European Union, pricing and reimbursement schemes to restrict the range of drug products for which their national health insurance
systems provide reimbursement and to control the prices of medicinal products for human use vary widely from country to country. Some
countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the
completion of additional studies that compare the cost-effectiveness of a particular drug product to currently available therapies. EU
member states may also require approval of a specific price for a drug product or, instead, may adopt a system of direct or indirect
controls on the profitability of the company placing the drug product on the market. Other EU member states allow companies to fix their
own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly
prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the market entry of new pharmaceutical
products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing
within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement
and pricing arrangements.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_017"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif">C. Organizational structure</span></p><div>



</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">InflaRx
N.V. has two direct wholly-owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc., that are each listed in Exhibit 8.1 filed
herewith.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_018"></a></div><p style="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif">D. Property, plant and equipment</span></p><div>



</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
headquarters are in Jena, Germany, where we occupy approximately 8,000 square feet of office and laboratory space under a lease that
expires in December 2025. In addition, we occupy approximately 13,700 square feet of office space in Planegg-Martinsried (near Munich),
Germany under a lease that expires in May 2027. Furthermore, we have leased office and laboratory space in Ann Arbor, Michigan, United
States under a lease that expires in April 2026.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
4A. UNRESOLVED STAFF COMMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_021"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Operating
                                            results</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">You
should read the following discussion and analysis of our financial condition and results of operations together with the information
in our Consolidated Financial Statements and the notes thereto.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">The
following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB, which may differ in
material respects from generally accepted accounting principles in the United States and other jurisdictions. The following discussion
includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from
those anticipated in these forward-looking statements as a result of many factors, including those described under &#8220;ITEM 3. KEY
INFORMATION &#8212; 3.&#160;&#8216;Risk factors&#8217; and Forward-Looking Statements.&#8221;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">For
more information regarding our consolidated results, segment results, and liquidity and capital resources for the year ended December
31, 2022 as compared to the year ended December 31, 2021, refer to &#8220;<span style="text-transform: uppercase">Item 5. Operating and
Financial Review and Prospects</span>&#8221; in the Company&#8217;s 2022 Annual Report on Form 20-F, which information is incorporated
herein by reference.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Overview</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company pioneering anti-inflammatory therapeutics focused on applying our proprietary anti-C5a and C5aR technologies
to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement activation factor known as C5a
and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other
inflammatory diseases. Our lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal
antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical
settings. In April 2023, we received the EUA from the FDA for GOHIBIC (vilobelimab) for the treatment of critically ill, invasively mechanically
ventilated COVID-19 patients. Subsequently, in June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States.
We are also developing vilobelimab for the treatment of pyoderma gangrenosum, or PG, a chronic inflammatory skin disorder for which we
are currently conducting a Phase&#160;III study. Beyond PG, we have been developing vilobelimab to generate proof of concept data in
a wide array of complement-mediated diseases with significant unmet medical needs. For this purpose, we have previously conducted Phase
II studies with vilobelimab in HS, a chronic debilitating systemic inflammatory skin disease, in ANCA-associated vasculitis, or AAV,
a rare and life-threatening autoimmune disease and in cSCC, where we have recently decided to cease the development for the time being,
since further clinical development would require substantial resources and significantly extend the timeline of the ongoing clinical
program. We decided to prioritize our efforts and to reallocate our resources towards the development of our orally available C5aR inhibitor
INF904, an oral small-molecule drug candidate that targets the C5aR receptor. We plan on targeting complement-mediated, chronic autoimmune
and inflammatory conditions for which an oral small molecule is the preferred route of administration for patients. We have recently
completed a Phase I single ascending dose, or SAD, and multiple ascending dose, or MAD, study in healthy volunteers in which we were
able to confirm the favorable safety profile and the superior pharmacokinetic and pharmacodynamic profile of INF904. We are currently
conducting additional required pre-clinical studies, including long-term chronic toxicology studies, to enable longer-term dosing of
INF904 for chronic inflammatory diseases. We are also developing IFX002, a life-cycle management product for vilobelimab.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Since
our inception in December 2007, we have devoted substantially all our resources to establishing our company, raising capital, developing
our proprietary anti-C5a/C5aR technologies, identifying and testing potential product candidates and conducting clinical trials of our
lead product candidate, vilobelimab and additional product candidates IFX002 and INF904. To date, we have only generated minimal product
revenue and so far have primarily financed our operations through the issuance of securities in public offerings and private placements
and through other income from various grants, including a grant awarded by the German federal government for certain research and development
activities during the period from October 2021 to June 2023. As of December 31, 2023, we had cash and cash equivalents of &#8364;12.8&#160;million
and &#8364;85.6 million in marketable securities. In addition, as of December 31, 2023, we had received a total of &#8364;33.3&#160;million
to support the development of our COVID-19 clinical development as part of a grant awarded to us for the period of October 2021 to June
2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
July 8, 2020, we filed a Form F-3 registration statement with the SEC with respect to the offer and sale of securities of the
Company, or 2020-Shelf Registration Statement. We also filed a prospectus supplement with the SEC relating to an at-the-market
program providing for the sales of our stock over time of up to $50.0 million of our ordinary shares pursuant to a Sales Agreement
with SVB Leerink LLC. During the fiscal year 2023, we issued 3,235,723 ordinary shares under its at-the-market program resulting in
&#8364;14.4 million or $15.7 million in net proceeds. As of December 31, 2023, and throughout the term of the at-the-market program,
we have issued an aggregate total of 5,803,931 ordinary shares, resulting in a total of &#8364;26.2 million in net proceeds to us.
The term of the at-the-market program expired on July 8, 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Through
an underwritten public offering in April 2023, we sold and issued an aggregate of 10,823,529 ordinary shares, at a price of $4.25 per
share and have a nominal value of &#8364;0.12 per share, of which 1,411,764 were sold pursuant to the exercise of an overallotment option
by the underwriters. Net proceeds of this offering amounted to &#8364;38.7 million, after accounting for underwriting discounts and other
offering expenses.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
June&#160;30, 2023, we filed&#160;the 2023-Registration Statement under which no ordinary shares or active offering programs were issued
by the Company in the 2023 fiscal year. The aggregate initial offering price of the securities will not exceed $250&#160;million.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">During
the fiscal year 2023, we issued and registered a total of 120,257 ordinary shares resulting from the exercise of stock option rights
by former employees. All stock option rights had been granted under the 2017 Long-Term Incentive Plan. 14,930 stock options thereof were
already exercised in December 2022 and 105,327 were exercised during fiscal year 2023. The ordinary shares have a nominal value of &#8364;0.12
per share. 98,754 ordinary shares were sold at a price of $1.85 per share, and 21,503 ordinary shares were sold at a price of $3.35 per
share.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we had an accumulated deficit of &#8364;286.1 million. We have incurred significant net operating losses in every
year since our inception and expect to continue to incur comparable or increasing net operating losses for the foreseeable future. Our
net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses may increase significantly
if, and as we:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">expand
                                            our commercial efforts for GOHIBIC (vilobelimab) in the United States, by enhancing our commercial
                                            strategic plan, further expanding our sales force and medical affairs teams, preparing relevant
                                            promotional and medical education materials to target healthcare providers and other stakeholders,
                                            refining our medical affairs strategy to increase awareness of the EUA among the medical
                                            community, and expand our sales and marketing efforts;</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">continue
                                            to pursue regulatory activities for vilobelimab in the United States and Europe, including
                                            severe COVID-19, PG and potentially various other indications;</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">continue
                                            to manufacture vilobelimab while adhering to applicable regulatory standards to serve clinical
                                            and commercial needs;</span></td>
</tr></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">continue
                                            to advance vilobelimab through clinical development, including in PG and potentially other
                                            indications;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">evaluate
                                            and continue additional Phase II clinical development of INF904;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">initiate
                                            and continue research programs and development activities, including development of IFX002;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">actively
                                            seek to identify additional research programs and additional product candidates;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">maintain,
                                            expand and protect our intellectual property portfolio;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">hire
                                            and retain personnel, such as for research and development, regulatory affairs, business
                                            development and commercial operations, manufacturing and supply chain management, and others;
                                            and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">incur
                                            additional costs with operating as a public company, including expanding our operational,
                                            administrative, finance and management teams.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_022"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Financial
                                            operations overview</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
June 2023, we began the commercialization of GOHIBIC (vilobelimab) in the United States. In connection with the start of the commercialization,
the Group entered into agreements with certain subsidiaries of Cencora Inc. (formerly known as AmerisourceBergen Corp.) to act as the
Group&#8217;s U.S. distributor and make GOHIBIC (vilobelimab) available for order by U.S. hospital customers. Cencora provides cold storage,
cold-chain distribution services, inventory management and secondary labeling/packaging, among other services.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
2023, we realized revenues, totaling &#8364;63 thousand, from the product sales for the first time since its inception. Revenues reported
are sales to end customers (hospitals). Sales to distributors do not constitute completion of the earnings process and, thus, do not
result in the recognition of revenue for the Company under IFRS 15.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cost
                                            of Sales</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cost
of sales recognized during the twelve months ended December 31, 2023, of &#8364;0.5 million, are related to GOHIBIC (vilobelimab) revenues
in the United States and to write-downs of inventory.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Costs
of sales for products sold in these periods do not include costs of materials, as the associated costs of these materials were incurred
in prior periods, before the FDA granted the EUA for GOHIBIC (vilobelimab) in April 2023. These materials were recorded as &#8216;research
and development expenses&#8217; in the periods they were incurred.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
cost of sales during the twelve months ended December 31, 2023 mainly consists of write-downs of inventories that will expire prior to
their expected sale.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Other
                                            income</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
October 2021, we announced that we had been awarded a grant of up to &#8364;43.7 million from the German Ministry of Education and Research
and the German Ministry of Health to support certain research and development activities of vilobelimab for the treatment of severe COVID-19
patients. Due to subsequent changes in our research and development plan and fewer costs projected within the timeframe of the grant,
we were notified that the maximum total amount available to us was reduced to &#8364;41.4 million. The grant was structured as a reimbursement
of 80% of certain pre-specified expenses related to the clinical development and manufacturing of vilobelimab. The grant was awarded
for qualifying activities during the period from October 1, 2021 to June 30, 2023.During the duration of the grant period, as of December
31, 2023, we received a total of &#8364;33.3 million to support our activities regarding the development of vilobelimab as a new therapeutic
agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial scale manufacturing process to
ensure the ability of being able to provide such treatment to the broader population.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Sales
                                            and marketing expenses</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Sales
and marketing expenses have consisted principally of:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">external
                                            services for distribution of GOHIBIC to build <span style="font-size: 10pt">the necessary
                                            commercial and logistical infrastructure, </span>including external sales professionals;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">marketing
                                            activities;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">employee-related
                                            expenses, including salaries, benefits and stock-based compensation expense based upon employees&#8217;
                                            role within the organization; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">professional
                                            services fees in conjunction to enable making GOHIBIC available in the U.S.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
expense for sales and marketing amount to &#8364;4.0 million. These expenses are mainly comprised of &#8364;1.0 million in personnel costs,
&#8364;1.0 million in legal and consulting costs and &#8364;1.9 million in external services for distribution of GOHIBIC. The Group started
with its commercializ<span style="text-decoration:line-through">a</span>tion activities when the EUA was granted in April 2023. Prior to that, no sales and marketing
expenses had been incurred.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Research
                                            and development expenses</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses have consisted principally of:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">expenses
                                            incurred under agreements with CROs, contract manufacturing organizations, or CDMOs, consultants
                                            and independent contractors that conduct research and development, preclinical and clinical
                                            activities on our behalf;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">employee-related
                                            expenses, including salaries, benefits and stock-based compensation expense based upon employees&#8217;
                                            role within the organization; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">professional
                                            fees for lawyers related to the protection and maintenance of our intellectual property.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
total research and development expenses in 2023 were higher than our expenses in 2022 and higher than our expenses in 2021. Costs are
expected to increase in 2024 (as compared to 2023) as we advance the Phase III development of vilobelimab in PG and initiate the Phase
II development of INF904. The increase of research and development expenses in 2024 and future periods is expected to primarily relate
to the following key programs and activities:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Vilobelimab</i></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We expect our expenses associated with&#160;vilobelimab&#160;will increase in&#160;2024&#160;compared to&#160;2023,&#160;as we&#160;progress
to conduct the&#160;Phase III&#160;the clinical&#160;study&#160;in&#160;PG. In addition, we are incurring and expect to further incur
expenses in conjunction with the preparation and filing of full market authorizations for vilobelimab in the United States, Europe and
elsewhere. We might also potentially consider development of vilobelimab in&#160;additional indications. In addition, we are also incurring
expenses related to the manufacturing of clinical trial material and&#160;the completion of activities towards the final establishment
of commercial scale production.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b><i>INF904.
                                            </i></b>We are also developing INF904, a product candidate that targets the C5aR receptor.
                                            We expect to incur additional costs by advancing the clinical and non-clinical development
                                            of INF904. Specifically, we expect to incur expenses by developing a new formulation, conducting
                                            long-term toxicological studies in several animal species and initiation Phase II clinical
                                            trials. We plan to study INF904 in complement-mediated, chronic autoimmune and inflammatory
                                            conditions where an oral low molecular weight compound might have advantages or is needed
                                            for patients and where oral delivery is the medically preferred route of administration.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b><i>IFX002</i></b>.&#160;We
                                            are also developing IFX002 for the treatment of chronic inflammatory indications. IFX002
                                            is a highly potent anti-complement C5a antibody with a higher humanization grade and altered
                                            pharmacokinetic properties compared to vilobelimab and is currently in pre-clinical development.
                                            Expenses for this program mainly consist of salaries, costs for preclinical testing conducted
                                            by CROs and costs&#160;to produce&#160;preclinical material.&#160;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
                                            development programs</i></b>. Our other research and development expenses relate to our preclinical
                                            studies of other product candidates and discovery activities, expenses for which mainly consist
                                            of salaries, costs for production of preclinical compounds and costs paid to CROs.&#160;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
2023 and 2022, we incurred &#8364;41.0 million and &#8364;37.5 million of research and development expenses, respectively. Our research
and development expenses may vary substantially from period to period based on the timing of our research and development activities,
including due to timing of clinical trial initiation and potential enrollment.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
expense research and development costs as incurred. We recognize costs for certain development activities, such as preclinical studies
and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our
vendors such as patient enrollment or clinical site activations for services received and efforts expended. Research and development
activities are central to our business model.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing
and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net
cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing
drugs, including the uncertainty of:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">clinical
                                            trials or our product candidates producing negative or inconclusive results, including failure
                                            to demonstrate statistical significance;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and
                                            other related activities;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">delays
                                            in reaching, or failing to reach, agreement on acceptable clinical trial contracts or clinical
                                            trial protocols with prospective trial sites or prospective CROs, the terms of which can
                                            be subject to extensive negotiation and may vary significantly among different CROs and trial
                                            sites;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            cost of manufacturing clinical supplies and establishing commercial supplies of our product
                                            candidates and any products that we may develop;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">third-party
                                            contractors failing to comply with regulatory requirements or meet their contractual obligations
                                            to us in a timely manner, or at all;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            number and characteristics of product candidates that we pursue;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">undesirable
                                            side effects or other unexpected characteristics, causing us or our investigators, regulators
                                            or institutional review boards to suspend or terminate the trials;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">potential
                                            additional safety monitoring or other studies requested by regulatory agencies;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            cost, timing, and outcomes of regulatory approvals;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            number of trials required for approval;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            duration of patient follow-up;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            cost and timing of establishing sales, marketing, and distribution capabilities; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18.45pt"/><td style="width: 17.55pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            terms and timing of any collaborative, licensing and other arrangements that we may establish,
                                            including any milestone and royalty payments thereunder.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">A
change in the outcome of any of these variables with respect to the development of vilobelimab, IFX002 or any other product candidate
that we may develop could mean a significant change in the costs and timing associated with the development of such product candidate.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td><span style="font-family: Times New Roman, Times, Serif">General
                                            and administrative expenses</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
general and administrative expenses consist principally of:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">employee-related
                                            expenses, including salaries, benefits and stock-based compensation expense based upon employees&#8217;
                                            role within the organization;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">insurance
                                            expenses including directors&#180; and officers&#180; liability insurance premiums;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">professional
                                            fees for auditors and consulting expenses not related to research and development activities;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">professional
                                            fees for lawyers not related to the filing, prosecution, protection and maintenance of our
                                            intellectual property; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">cost
                                            of facilities, travel, communication and office expenses.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
expect that our general and administrative expenses will increase in the future as our business expands and we incur additional costs
associated with operating as a public company. These public company-related costs relate primarily to additional personnel, additional
legal fees, audit fees, directors&#8217; and officers&#8217; liability insurance premiums and costs associated with investor relations.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">7.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Results
                                            of operations</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
Group is exposed to the exchange rate between Euros and U.S. dollars. Due to the Company&#8217;s various registered offerings of ordinary
shares in U.S. dollars, the Group holds significant cash, cash equivalents and marketable securities in U.S. dollars. This could have
a material impact on our operating results.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
numbers below have been derived from our consolidated financial statements included elsewhere herein. The discussion below should be
read along with these consolidated financial statements, and it is qualified in its entirety by reference to them.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Comparison
of the years ended December 31, 2023 and 2022</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: 0in">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">63,089</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">63,089</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Cost of Sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(532,262</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(532,262</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Gross profit</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(469,173</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(469,173</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0in">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,001,299</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,001,299</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0in">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(41,024,131</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37,526,090</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,498,041</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,628,756</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,869,564</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,240,808</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0in">Other income and expenses (net)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,215,264</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,157,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,942,524</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Loss before interest and income taxes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(44,908,096</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(32,237,866</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(12,670,230</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0in">Net financial result</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,240,566</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,753,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(512,689</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Loss before tax</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(42,667,529</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,484,611</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(13,182,918</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Income tax expense</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Loss for the period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(42,667,529</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,484,611</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(13,182,918</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Exchange differences on translating operations in foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">125,085</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,206,810</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,081,725</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 0in">Total comprehensive loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(42,542,444</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(25,277,801</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(17,264,643</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Revenues</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">63,089</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">63,089</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">63,089</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">63,089</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
June 2023, we began the commercialization of GOHOBIC (vilobelimab) in the United States. In connection with the start of the commercialization,
we entered into agreements with certain subsidiaries of <span style="font-size: 10pt">Cencora Inc. (formerly known as AmerisourceBergen
Corp.) </span>to act as the Group&#8217;s U.S. distributor and make GOHIBIC (vilobelimab) available for order by U.S. hospital customers.
Cencora provides cold storage, cold-chain distribution services, inventory management and secondary labeling/packaging, among other services.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
2023, we recognized revenues from the product sales for the first time since our inception. Revenues reported are sales to end customers
(hospitals). Sales to distributors do not constitute the completion of a performance obligation towards a customer earnings process and,
thus, do not result in the recognition of revenue for the Company under IFRS 15.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Cost
of Sales</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Cost of Sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">532,262</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">532,262</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">532,262</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">532,262</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cost
of sales recognized during the twelve months ended December 31, 2023 are related to GOHBIC (vilobelimab) revenues in the United States.
Costs of sales for products sold in these periods do not include costs of materials, as the associated costs of these materials were
incurred in prior periods, before granting of the EUA for GOHIBIC (vilobelimab). The costs of manufacturing of these materials were recorded
as research and development expenses in the period they were incurred.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
cost of sales during the twelve months ended December 31, 2023 mainly consists of write-downs of inventories that will expire prior to
their expected sale. Early product batches subsequently capitalized in inventory were produced with material which had been manufactured
in previous years.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Sales
and marketing expenses</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,851,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,851,158</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Personnel expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,587</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,054,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,054,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,581</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,581</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total sales and marketing expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,001,299</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,001,299</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">During
the twelve months ended December 31, 2023 we incurred &#8364;4.0 million of sales and marketing expenses. These expenses are mainly composed
of &#8364;1.0 million in personnel costs, &#8364;1.0 million in legal and consulting costs and &#8364;1.9 external services, for distribution
of GOHIBIC.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and development expenses</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in">Third-party expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31,802,983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,543,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,259,480</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0in">Personnel expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,776,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,957,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(181,013</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,444,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,024,721</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">419,574</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,024,131</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">37,526,090</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,498,042</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses increased by &#8364;3.5 million for the year ended December 31, 2023 compared to the corresponding costs for
the year ended December 31, 2022 primarily due to higher third party material and manufacturing (CDMO) costs and from clinical trials,
which increased by &#8364;1.9 million.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>General
and administrative expenses</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,392,905</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,125,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,732,893</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal, consulting and audit fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,239,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,104,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135,185</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,996,042</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,639,142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(643,100</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,628,756</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,869,564</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(2,240,809</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses decreased by &#8364;2.2 million to &#8364;12.6 million for the year ended December&#160;31, 2023, from &#8364;14.9
million for the year ended December 31, 2022. This decrease is partially attributable to a &#8364;1.7 million decrease in personnel expenses,
driven by a decrease in expenses from share-based compensation. The decrease of other expenses by &#8364;0.6 million is primarily attributable
to lower D&amp;O insurance cost.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Net
financial result</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,804,827</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">608,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,196,148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,303</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,765</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,090</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,857</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net interest result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,769,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">563,429</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,205,770</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,529,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,924,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,395,308</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,371,261</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,482,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,888,862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net foreign exchange result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,841,872</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,442,298</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,284,170</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(252,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">565,711</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,240,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,753,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">512,690</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
financial result decreased by &#8364;0.5 million to &#8364;2.2&#160;million for the year ended December 31, 2023 compared to &#8364;2.7&#160;million
for the year ended December 31, 2022. This overall net decrease is mainly attributable to a decrease of &#8364;4.3 million in foreign
exchange result and &#8364;3.2 million higher interest income from marketable securities compared to the year ended December 31, 2022.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Comparison
of the years ended December 31, 2022 and 2021</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(37,526,090</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(35,697,935</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(1,828,155</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0in">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,869,564</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,984,722</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,884,842</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0in">Other income and expenses (net)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,157,788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,109,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Loss before interest and income taxes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(32,237,866</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(47,634,816</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,396,950</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0in">Net financial result</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,753,255</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,004,757</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">748,498</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Loss before tax</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,484,611</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(45,630,059</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,145,448</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0in">Income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Loss for the period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,484,611</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(45,630,059</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,145,448</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Exchange differences on translating operations in foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,206,810</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,777,061</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,570,251</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 0in">Total comprehensive loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(25,277,801</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(38,852,998</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,575,197</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Research
and development expenses</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in">Third-party expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,543,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,247,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">296,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0in">Personnel expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,957,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,941,813</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,016,053</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,024,721</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,509,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">515,680</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">37,526,090</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,697,935</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,828,155</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses increased by &#8364;1.8 million in the year ended December 31, 2022 compared to the year ended December 31, 2021.
This increase is mainly attributable to a &#8364;1.0 million increase in employee-related costs, mainly caused by a &#8364;0.9 million
increase in expenses from share-based compensation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>General
and administrative expenses</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Personnel expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,125,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,680</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">625,118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal, consulting and audit fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,104,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,065,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,039,201</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,639,142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,418,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,220,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,869,564</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,984,722</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,884,842</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses increased by &#8364;2.9 million to &#8364;14.9 million for the year ended December 31, 2022, from &#8364;12.0
million for the year ended December 31, 2021. This increase is partially attributable to a &#8364;0.9 million increase in expenses from
share-based compensation. Legal, consulting and audit fees and other expenses increased by &#8364;1.0 million to &#8364;3.1 million for
the year ended December 31, 2022, mainly due to higher consulting and legal costs, incurred in enhancing our internal control environment
as we are complying with the auditor attestation requirement of Section 404(b) of the Sarbanes&#8211;Oxley Act of 2002 for the first
time. The increase of other expenses by &#8364;1.2 million is primarily due to higher D&amp;O insurance cost.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Net
financial result</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">608,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">109,391</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">499,288</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,303</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,714</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,589</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,055</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,892</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net interest result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">563,429</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">84,622</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">478,807</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,924,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,569,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,354,862</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,482,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,605,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(876,699</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net foreign exchange result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,442,298</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,964,135</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">478,163</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(252,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(208,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,753,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,004,757</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">748,498</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
financial result increased by &#8364;0.7 million in the year ended December 31, 2022 compared to the year ended December 31, 2021. This
overall net increase is mainly attributable to a net increase of &#8364;0.5 million in foreign exchange income and expense and &#8364;0.5
million in higher interest income from marketable securities compared to the year ended December 31, 2021.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_023"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">C.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Liquidity
                                            and capital resources</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Overview
                                            on cash requirements and sources of liquidity</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Since
inception, we have incurred significant operating losses due to our research and development activities and G&amp;A costs. For the years
ended December 31, 2023 and 2022, we incurred net losses of &#8364;42.7 million and &#8364;29.5 million, respectively. Our primary uses
of cash are for working capital, operating leases and general corporate purposes.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
primary sources of funds are proceeds from the sale of our shares including our initial public offering and follow-on offerings. Additionally,
in 2021, we were awarded a grant from the German federal government under which we received &#8364;33.3 million between October 2021 and
June 2023. The grant period ended on June 30,&#160;2023. Historically, we have been able to fund our capital needs with cash from equity
financing through placement of shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Through
an underwritten public offering in April 2023, we sold and issued an aggregate of 10,823,529 ordinary shares, of which 1,411,764 were
sold pursuant to the exercise of an overallotment option by the underwriters. The ordinary shares were sold at a price of $4.25 per share
and have a nominal value of &#8364;0.12 per share. Proceeds of this offering after deducting &#8364;2.5 million ($2.8 million) in underwriting
discounts amounted to &#8364;39.1 million ($43.2 million). Other offering expenses amounted to &#8364;0.4 million, resulting in a total
of &#8364;38.7 million in net proceeds from this offering.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
June&#160;30, 2023, we filed&#160;a&#160;Form F-3&#160;(2023-Registration Statement)&#160;with the SEC&#160;with respect to the offer
and sale of securities of the Company, which became effective on July&#160;11, 2023. The aggregate initial offering price of the securities
that the Company may offer and sell under this prospectus will not exceed $250&#160;million. No ordinary shares were issued by the Company
under the 2023-Registration Statement within the fiscal year 2023 and no active offering programs have been launched.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
working capital did not include any indebtedness in 2023 or in 2022. </span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
cash and cash equivalents amounted to &#8364;12.8 million as of December 31, 2023 (2022: &#8364;16.3 million). We also held marketable
securities valued at &#8364;85.6 million (2022: &#8364;67.2 million) as of December 31, 2022. Our cash and cash equivalents primarily consist
of cash denominated in U.S. dollars and euros in bank deposit accounts. Our marketable securities consist of quoted debt securities issued
by financial institutions with investment grade credit ratings (BBB+ to AAA). Our cash is deposited at banks with equally high credit
ratings as assessed by international rating agencies.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
expect to finance our future operations and working capital needs in the near future predominantly with our cash and cash equivalents
and proceeds from the sale of our marketable securities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Cash
                                            flows - Comparison of the years ended December 31, 2023 and 2022</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
table below summarizes our consolidated statement of cash flows for the years ended December 31, 2023 and 2022:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(37,812,966</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(33,742,817</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash (used in)/from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,696,616</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,358,095</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,986,269</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,937,459</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash and cash equivalents at the beginning of the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,265,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,249,995</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><b>Exchange (losses)/gains on cash and cash equivalents</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(974,099</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><b>2,462,622</b></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at the end of the period</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,767,943</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,265,355</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Net
cash used in operating activities</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working
capital.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities increased to &#8364;37.8 million in the year ended December 31, 2023, from &#8364;33.8 million in the
year ended December 31, 2022, mainly due to lower income recognized from the German federal government grant, significant production
of inventory as well as higher expenditures from marketing and sales activities for GOHIBIC(vilobelimab), which were recorded for the
first time due to start of the commercialization of this product in 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Net
cash used in investing activities</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
cash used in investing activities during the year ended December 31, 2023 amounted to &#8364;17.7&#160;million due to net higher purchases
than proceeds of sales of marketable securities. During the previous year ending on December 31, 2022, &#8364;19.4 million of cash was
generated from the sale of marketable securities.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Net
cash from financing activities</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Net
cash generated from financing activities increased to &#8364;53.0&#160;million in the year ended December 31, 2023 from &#8364;1.9&#160;million
in the year ended December 31, 2022 primarily due to the share issuances through the underwritten public offering of April 2023 and through
utilization of the at-the-market facility prior to its expiration on July 8, 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Contractual
                                            obligations and commitments</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
table below sets forth our operating expenses and capital expenditures from contractual obligations as of December 31, 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Payments due by Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Less than<br/>
 1 year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between 1<br/>
 and 3 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Between 3<br/>
 and 5 Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">More than<br/>
 5 years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 40%; text-align: left">Unavoidable contractual (CRO, CDMO) commitments and other contractual obligations under operating contracts or services:</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,233,216</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,926,289</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,265,136</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">41,791</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Contractual lease obligations <br/>(incl. capitalized leases)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,158,363</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">397,942</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">760,421</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,391,579</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,324,231</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,025,557</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,791</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
enter into contracts with CROs and clinical sites for the conduct of clinical trials, professional consultants for expert advice and
other vendors like CDMOs for clinical supply manufacturing or other services in the normal course of business. These contracts can usually
be terminated with 30 to 180 days notice. In addition to this minimum duration, these contracts require full payment for services already
commenced. In the table above, the amounts for unavoidable contractual obligations assumes that the contracts were terminated on December
31, 2023 and would then continue to run for approximately 30 to 180 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Contractual
lease obligations</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Contractual
lease obligations mainly consist of payments pursuant to non-cancellable lease agreements relating to our leases of office space. The
lease term of our premises in Jena, Germany expires in December 2025. The lease term of our premises in Planegg-Martinsried, Germany
expires in May 2027. The lease term of our premises in Ann Arbor, Michigan, United States expires in April 2026.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Funding
requirements for future capital expenditure</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
believe that our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and capital expenditure
requirements under our current business plan for at least the next 24 months.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
anticipate that our expenses will increase in the next years in connection with our ongoing activities. In particular, we anticipate
that we might expand our sales and marketing efforts for GOHIBIC(vilobelimab) in the United States, we might advance our Phase III clinical
development program with vilobelimab in PG, pursue the further clinical development for INF904 and will advance preparation of necessary
submission documents for additional regulatory submissions to the EMA and for a full BLA submission to the FDA beyond the received the
EUA as granted by the FDA in April 2023 for GOHIBIC (vilobelimab). We will also explore clinical development of vilobelimab in several
other indications. We also plan to continue clinical development of INF904 and to initiate Phase II clinical trials once we selected
the appropriate indications. We also plan to continue preclinical development of IFX002. We plan to initiate new research and preclinical
development efforts. If clinical data is supportive, we may seek marketing approval for any product candidates that we successfully develop.
Additionally, we will validate our manufacturing process for vilobelimab to be able to apply for marketing authorization and to be able
to provide commercial grade product. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur
significant commercialization expenses related to establishing sales, marketing, distribution and other commercial infrastructure to
commercialize such products. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.
If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research
and development programs or future commercialization efforts.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Until
such time, if ever, that we can generate substantial meaningful product revenues, we expect to finance our cash needs through a combination
of equity offerings, debt financings, royalty-based financings, future collaborations, strategic alliances, licensing arrangements and
government grants. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interest
of our current shareholders will be diluted, and the terms of these securities may include voting or other rights that adversely affect
your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting
our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise
funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish
rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not
be favorable to us. Money received through government grants may require us to provide our product, if approved by regulatory authorities,
at unfavorable conditions in such jurisdictions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_024"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Research
                                            and development, patents and licenses, etc.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">See
&#8220;ITEM 4. INFORMATION ON THE COMPANY &#8212; 2. Business overview &#8212; Our intellectual property.&#8221;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_025"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">E.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Trend
                                            information</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">Other
than as disclosed elsewhere in this annual report on Form 20-F, we are not aware of any trends, uncertainties, demands, commitments,
or events for the year ended December 31, 2023 that are reasonably likely to have a material adverse effect on our net revenue, income,
profitability, liquidity, or capital resources, or that caused the disclosed financial information to be not necessarily indicative of
future operating results or financial condition (see &#8220;ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS&#8221;).</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_026"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">F.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Critical
                                            accounting estimates</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
consolidated financial statements are prepared in conformity with IFRS, as issued by the IASB. In preparing our consolidated financial
statements, we make judgements, estimates and assumptions about the application of our accounting policies which affect the reported
amounts of assets, liabilities, revenue and expenses. Our critical accounting judgements and sources of estimation uncertainty are described
in Note B.2. to our consolidated financial statements, which are included elsewhere in this Annual Report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_028"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Directors
                                            and senior management</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Board
of Directors and senior management team</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following table presents information about our Board of Directors and senior management as of the date of this Annual Report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Name</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Position</td><td style="font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Age</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Initial year of<br/> appointment at<br/> InflaRx GmbH,<br/>
 InflaRx N.V.<br/>
 or InflaRx<br/>
 Pharmaceuticals Inc. <br/>(as applicable)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Niels Riedemann</td><td style="width: 1%">&#160;</td>
    <td style="width: 49%; text-align: center; padding-left: 5.4pt">Executive Director and Chief Executive Officer</td><td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: center">52</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 15%; text-align: center">2007</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Renfeng Guo</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Executive Director and Chief Scientific Officer</td><td>&#160;</td>
    <td style="text-align: center">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2007</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Thomas Taapken</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Chief Financial Officer</td><td>&#160;</td>
    <td style="text-align: center">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2020</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Camilla Chong</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Chief Medical Officer</td><td>&#160;</td>
    <td style="text-align: center">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023 (from July)</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Derval O&#8217;Carroll</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Senior Vice President, Global Head of Regulatory Affairs and Compliance</td><td>&#160;</td>
    <td style="text-align: center">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023 (from April)</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Nicolas Fulpius</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Non-Executive Director and Chairman of the Board</td><td>&#160;</td>
    <td style="text-align: center">50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2007</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Richard Brudnick</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Non-Executive Director</td><td>&#160;</td>
    <td style="text-align: center">67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Mark Kubler</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Non-Executive Director</td><td>&#160;</td>
    <td style="text-align: center">49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2015</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Anthony Gibney</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Non-Executive Director</td><td>&#160;</td>
    <td style="text-align: center">53</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">2021</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9.35pt; padding-left: 9.35pt">Hege Hellstrom</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">Non-Executive Director</td><td>&#160;</td>
    <td style="text-align: center">58</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023 (from April)</span></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
terms for which Mark Kubler and Anthony Gibney have been appointed to the Board of Directors, will expire in 2024 and the terms for which
Richard Brudnick, Nicolas Fulpius, Renfeng Guo, Niels Riedemann and Hege Hellstrom have been appointed to the Board of Directors will
expire in 2026.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Ms.
Derval O&#8217;Carroll was promoted to SVP in April 2023 and effectively became part of our senior management team through her promotion.
Ms. Camilla Chong joined the Company as Chief Medical Officer effective July 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Unless
otherwise indicated, the current business address for our directors, senior management and key employees is InflaRx N.V., Winzerlaer
Strasse 2, 07745 Jena, Germany.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following is a brief summary of the business experience of our directors, senior management and key employees. Each director&#8217;s
tenure reflects such director&#8217;s tenure on InflaRx GmbH&#8217;s board.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Non-executive
directors</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Nicolas
Fulpius, Chairman</i>. One of the co-founders of InflaRx, Nicolas Fulpius has served as Chairman of the Board since its inception in
2007. Long active in the venture capital field between the United States and Europe, for the Lombard Odier Immunology fund, for Ultreia
Capital and as Partner at Affentranger Associates, Nicolas has become an entrepreneur at heart: he created, developed and helped finance
several companies in the Biotech, cleantech and ICT field. Recently, Mr. Fulpius was - among others - CEO of Veltigroup, CDO of Swisscom
and member of the Swisscom Ventures investment committee. In 2020, Nicolas Fulpius co-founded the Ansam Group one of the leading ICT
services company in Switzerland for which he is acting as CEO and Chairman. Nicolas Fulpius holds an MBA from the University of St. Gallen,
Switzerland, and a Masters in Science in Engineering from Stanford University, USA.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Richard
Brudnick</i>. Richard Brudnick currently serves as Chief Business Officer for Prime Medicine, Inc., a leader in the field of gene editing.
Prior to joining Prime Medicine, Mr. Brudnick was Chief Business Officer and Head of Strategy for Codiak BioSciences, a leader in the
field of exosome therapeutics. Before Codiak, Mr. Brudnick was Executive Vice President of Business Development and Alliance Management
at Bioverativ, Inc., a company he helped found in 2016. Until Bioverativ&#8217;s acquisition by Sanofi in March 2018, Mr. Brudnick led
business development efforts to build a significant pipeline in rare blood disorders, including an acquisition, a multi-product collaboration
and additional scientific collaborations and licenses. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course
of nearly 15 years, he initiated, led and completed transactions that led to several of the company&#8217;s marketed products and late-stage
pipeline, including Tecfidera, Spinraza, Leqembi and its biosimilars joint venture with Samsung. Mr. Brudnick also was CEO of a regional
pharmaceutical distribution business, which he sold to a strategic buyer; co-founded two companies; and was a strategy consultant at
Bain &amp; Company.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Mark
Kubler</i>. Mr. Kubler has served as a director on our board since 2015. Mr. Kubler has been a partner with the GIG Ltd., a venture capital
advisory firm with offices in Switzerland and Malta, since 2012. He previously served on the boards of WWM AG and Jobydu AG, each based
in Switzerland. Mr. Kubler was a managing director and corporate secretary of a private equity holding company from 2003 to 2010. Before
2003, he held various roles in international investment banks and boutiques. Mr. Kubler has a master&#8217;s degree in business and economics,
as well as a master&#8217;s degree in law from the University of St. Gallen, in Switzerland.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Anthony
Gibney </i>was formerly the Chief Business and Strategy Officer at Iveric Bio, overseeing the business development and corporate strategy
for the retina-focused, biotechnology company, through the closing of the sale of Iveric to Astellas for $5.9 billion in 2023. Prior
to Iveric, Mr. Gibney was the CFO and CBO at FogPharma, driving the business development and finance functions of the company. Mr. Gibney
served as the Chief Business Officer of Achillion Pharmaceuticals, Inc., where he was responsible for corporate and portfolio strategy,
business development and corporate communications and led the successful sale of Achillion to Alexion in 2020. Before Achillion, Tony
Gibney was a life sciences-focused investment banker for 24 years. From 2009 through 2017, he served as a managing director and co-head
of the biotechnology investment team for Leerink Partners LLC, where he was a senior leader of Leerink&#8217;s biopharmaceutical investment
banking franchise. From 1999 to 2009, he worked as a managing director at Merrill Lynch Inc. and executed a variety of significant financing
and M&amp;A transactions for various biotechnology companies. From 1993 to 1999, Mr. Gibney was an investment banker at Lehman Brothers
in the firm&#8217;s Healthcare Investment Banking Group. He graduated with distinction from Yale University in 1993 with a B.A. in History
and Economics.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Hege
Hellstrom</i> is currently Chief Commercial Officer in Advicenne, a French pharmaceutical company specializing in the development of
innovative treatments in Nephrology. She is a non-executive board member of Vivesto AB since 2019 and Camurus AB since 2020, both public
Swedish companies and she is also a member of the Audit Committee in both companies. She is the founder and managing director of Belnor
BV, an investment and consulting company. Mrs. Hellstrom has more than 30 years&#8217; experience in sales, marketing, strategy development,
commercialization, partner alliances and executive management. From 2013 to 2018, she worked as President Europe, Middle East, North
Africa and Russia in Sobi, a Swedish biopharmaceutical company where she led several launches in rare diseases such as haemophilia and
metabolic diseases. Before Sobi, she worked in Genzyme for 11 years in roles ranging from General manager in Benelux to head of Renal
and Endocrine business in Europe, LATAM and JAPAC. When Genzyme was acquired by Sanofi she continued as Global Vice-president of Cardiovascular
products in Sanofi. Before Genzyme she worked in Baxter Healthcare for 13 years. Mrs. Hellstrom holds a B.Sc., Biomedical Laboratory
Scientist from Oslo Metropolitan University, Norway.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Executive
directors&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Niels
Riedemann, Chief Executive Officer and Founder. </i>Professor Riedemann is one of our co-founders and has served as our Chief Executive
Officer since our inception in 2007. Prof. Riedemann has over 15 years of experience in the biotech industry and drug development as
well as over 20 years of experience in complement immunology research. He founded InflaRx in 2007 and has served as Chief Executive Officer
since inception of the company. He has been instrumental in and led numerous private and public financing rounds of the company and has
been the responsible lead for its Nasdaq IPO in 2017. He is named inventor on several internationally granted core patents of InflaRx.
As physician he has been appointed Vice Director (<i>Leitender Oberarzt</i>) of Intensive Care Medicine, and he has led a 50-bed University
ICU unit for over 6 years at Friedrich Schiller University, Jena, Germany until 2015. Before that, he received his board certification
as General Surgeon upon completion of his surgical fellowship at MHH (Hannover Medical School, Germany) in 2007 where he also received
his habilitation (equivalent to Ph.D.) and where he still holds an Adjunct Professorship (APL Professor). He spent three years as postdoctoral
research fellow at the University of Michigan, USA until 2003. He received his medical training at Albert Ludwig University (ALU), Freiburg,
Germany, and Stanford University, USA and graduated as Dr. med. (equivalent to M.D.) from ALU in 1998. His research has been awarded
with several national and international awards. He has received extensive extra-mural funding and published over 60 peer reviewed scientific
publications in highly ranked journals. He has served as a member on a Board of Directors and a Scientific Advisory Board of two large
scientific governmental funded programs. He currently serves as Co-Chair of the Health Politics working group of Bio-Deutschland and
he serves as member of the board of trustees for the German Sepsis Foundation.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Renfeng
Guo, Chief Scientific Officer and Founder. </i>Prof. Renfeng Guo co-founded InflaRx in 2007. Since its inception, he has headed scientific
development at InflaRx as the full-time CSO. Prof. Guo leverages his expertise in antibody research and inflammation, bringing together
a highly effectual research team for drug development to build a focused pipeline based on cutting-edge technology. His early research
led to the discovery of InflaRx&#8217;s leading drug, vilobelimab. He continues to be the driving force for the development of other
pipeline drugs as well as a key inventor for InflaRx&#8217;s intellectual property portfolio. Prof. Guo received his M.D. degree from
Norman Bethune Medical School in China and conducted post-doctoral research in the laboratory of Prof. Peter Ward at the University of
Michigan, Ann Arbor. After stints as a junior and senior faculty member beginning in 2001 at the University of Michigan, he is currently
an Adjunct Research Associate Professor. Prof. Guo has over 80 high-impact, peer reviewed publications in the fields of cancer, infectious
disease, and inflammation research.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Senior
management</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Thomas
Taapken, Chief Financial Officer. </i>Dr. Taapken joined lnflaRx as CFO in 2020. He has over 25 years of experience in senior
management positions within the life sciences sector and as a venture investor. He has previously held positions as CFO of Medigene
AG (publicly listed in Germany), as CEO and CFO of Epigenomics AG (publicly listed in Germany), where he led the company&#8217;s
efforts in gaining regulatory approval for the company&#8217;s lead product with the FDA and oversaw its subsequent introduction
into the US market, and as CFO at Biotie Therapies (publicly listed in Finland, now Acorda Therapeutics) and its predecessor
companies. Before that he was a venture investor for seven years with Deutsche Venture Capital (DVC) and Burrill &amp; Co. in the
US. Dr. Taapken started his career at Hoechst AG (now Sanofi). He holds a Ph.D. in organic chemistry from the Technical University
of Berlin and also studied economics, chemistry and physics at the University of G&#246;ttingen. Dr. Taapken is a Board member of
Scibase AB since 2017, he is Chairman of the Board at lmcyse SA since 2019 and Board member at memo therapeutics AG since 2021 until
the end of 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Camilla
Chong, Chief Medical Officer. </i>Dr. Camilla Chong joined as Chief Medical Officer, or CMO, in July 2023. She is a medical doctor with
25 years of experience in the global pharmaceutical industry. She has successfully led teams in clinical development, medical affairs,
clinical operations, regulatory and pharmacovigilance. Her extensive experience also includes the development and launch of new medicines
across different geographies in senior leadership roles at Kyowa Kirin, GlaxoSmithKline, Pfizer and Teva. Dr. Chong received her medical
degree from the Royal Free Hospital School of Medicine, University College London, UK. She holds a Diploma in Pharmaceutical Medicine
and was a member of the Faculty of Pharmaceutical Medicine (MFPM).</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Derval
O&#8217;Carroll, Senior Vice President Regulatory Affairs and Quality Assurance</i>. Ms. O&#8217;Carroll joined InflaRx as VP, Head
of Regulatory Affairs in 2022. She has over 30 years of experience in Regulatory Affairs with the last 19 years in senior management
positions contributing strategically to global product development and commercialization activities. She has previously held
positions as VP, Global Regulatory and Quality at rare disease company Amryt Pharmaceuticals for five years, Senior Director of
Regulatory Affairs at rare disease company Travere for two years and Managing Consultant at Regulatory Consultancy, Real Regulatory
for 11 years, where she worked on numerous drug development programs for international clients. She gained prior experience in a
number of roles which included drug, device and IVD products. Ms. O&#8217;Carroll has a proven track record of leading global
registration activities for innovative new products and is experienced in guiding teams through the FDA and EMA regulatory agency
interactions for pre-authorization, authorization and complex post marketing commitments. She holds an M.Sc in Biochemistry and an
M.B.A from University College, Dublin.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_029"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Compensation</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation
of directors and senior management</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
aggregate compensation, including benefits in kind, accrued or paid to our senior management, or Senior Management, with respect to the
year ended December 31, 2023, for services in all capacities amounted to &#8364;5,291,128. In 2023, we granted options to purchase 1,263,500
ordinary shares to our board of directors, or Board of Directors, and our Senior Management.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
aggregate compensation, including benefits in kind, accrued or paid to our Non-executive Directors with respect to the year ended December
31, 2023, for services in all capacities amounted to &#8364;606,677. In 2023 we granted options to purchase 157,500 ordinary shares to
our Non-executive Directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
refer to Note C.10. Share based payments of Directors, Senior Management and Non-executive Directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock&#160;options <br/>outstanding<br/> as of<br/> January&#160;1,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock&#160;options<br/> granted in<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> options<br/> exercised&#160;in<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock&#160;options<br/> outstanding<br/> as of<br/> December 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">weighted<br/> average<br/> exercise<br/> price <br/>in &#8364;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">weighted<br/> average<br/> remaining<br/> contractual<br/> life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Stock options not exercised 2023</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Senior Management including executive directors</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Prof. Niels C. Riedemann, CEO</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,289,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">548,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,837,714</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">6.24</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Prof. Renfeng Guo, CSO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,814,197</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,244,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.39</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Thomas Taapken, CFO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">397,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Camilla Chong, CMO</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.52</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Derval O&#8217;Carroll, Senior Vice President, Global Head of Regulatory Affairs and Compliance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">2.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,520,913</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,263,500</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,784,413</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Non-executive Directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Nicolas Fulpius, <br/>Chairman, and Member of the Audit Committee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">164,065</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.82</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Anthony Gibney, <br/>Chairman of the Audit Committee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,085</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.88</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Richard Brudnick, <br/>Member of the Audit Committee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">74,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.85</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.24</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Mark K&#252;bler, <br/>Member of the Audit Committee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.0</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Hege Hellstrom (from April 2023) <br/></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">3.87</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">9.4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,871,085</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1.398,500</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;&#160;&#160;&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,292,085</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
established a policy in respect of the remuneration of our directors in accordance with Dutch law. Such policy addresses the following
topics: the fixed and variable components of the remuneration (if any), remuneration in the form of shares and severance payments. The
policy for the Board of Directors was adopted and approved by the general meeting of shareholders prior to the consummation of our initial
public offering. The Board of Directors determines the remuneration of the directors in accordance with the compensation policy, with
the understanding that executive directors will not participate in the decision-making process regarding the determination of the compensation
of executive directors. Compensation schemes in the form of shares or rights to shares must be submitted by the Board of Directors to
the general meeting for its approval. Any such proposal must set out at least the maximum number of shares or rights to shares to be
granted to the directors and the criteria for granting or amendment.<i>&#160;</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we have no amounts set aside or accrued to provide pension, retirement or similar benefits to our senior managers
or directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Clawback
policy</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">We
have implemented a robust clawback policy to ensure accountability and alignment of executive compensation with long-term sustainable
financial performance. Under this policy, if our financial statements are restated due to material noncompliance with financial reporting
standards or as a result of fraudulent activities, the Board of Directors has the right to recover any incentive-based compensation that
was awarded to executive officers in excess of what they would have received under the restated financial results. The clawback provisions
apply to performance-based bonuses, equity-based compensation, and any other compensation that is tied to achieving certain financial
or non-financial targets. The policy is designed to discourage excessive risk-taking or dishonest behavior that could harm the long-term
interests of the company and its shareholders. The clawback policy specifies the procedures, timelines, and criteria for determining
when a clawback may be initiated, as well as the process for calculating and recovering the amounts. The Board of Directors, in consultation
with the Compensation Committee, will review each individual case and make determinations based on the specific circumstances.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">The
clawback policy is disclosed in our Corporate Governance Principles and is subject to oversight by the Compensation Committee and the
Board of Directors. We believe that the implementation of this policy reflects our commitment to maintaining strong corporate governance
practices and enhancing shareholder value.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Management
and director service agreements</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
entered into management services agreements with each of our executive management team members, including our two executive directors
that became effective upon the consummation of our initial public offering or at the time these managers joined the Company. The management
services agreements contain a termination notice period for us and the executive directors appointed as such by a general meeting of
shareholders. All of the management services agreements provide that the manager or executive director, as the case might be, may be
terminated in the event of an urgent cause (<i>dringende reden</i>) without advance notice. In the event that an executive director no
longer serves as an executive director but remains employed in his role as an executive employee of the Company, the executive director
will not be entitled to any contractual severance or termination payments. Rather, we will enter into an employment agreement with the
executive director, which may include substantially similar compensation terms as provided under the management services agreements.
The management services agreements contain post-termination restrictive covenants, including perpetual confidentiality, and post-termination
non-competition and non-solicitation covenants.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, we entered into letter agreements with each of our non-executive directors which became effective upon the consummation of
our initial public offering or at the time these directors were appointed to our board by a general meeting of shareholders. The letter
agreements may be terminated, without advance notice, if the non-executive director is removed from the Board of Directors, resigns from
the Board of Directors or such director&#8217;s term of office on the Board of Directors expires without his reappointment as a non-executive
director. Additionally, each letter agreement provides for compensation, including an annual cash fee, an annual equity grant, an annual
fee for membership on a committee of the Board of Directors, and an annual fee for acting as a chairperson of a committee of the Board
of Directors. Also, the letter agreements contain a perpetual confidentiality covenant.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Share
based compensation plans</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">2016
Plan</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Under
the Stock Option Plan 2016 Terms and Conditions, or the 2016 Plan, we granted rights to subscribe for our ordinary shares to directors,
senior management and key employees.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">All
outstanding option awards under the 2016 Plan automatically vested upon closing of our initial public offering.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
conjunction with the corporate reorganization undertaken prior to our initial public offering, all outstanding awards granted under the
2016 Plan or otherwise converted into awards exercisable for ordinary shares of InflaRx&#160;N.V. will be governed by the terms of the
2016 Plan.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">2017
Plan</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
conjunction with the closing of our initial public offering, we established a new omnibus plan, the 2017 Long Term Incentive Plan, or
the 2017 Plan, with the purpose of advancing the interests of our shareholders by enhancing our ability to attract, retain and motivate
individuals who are expected to make important contributions to us. The 2017 Plan governs issuances of equity incentive awards from and
after the closing of our initial public offering. The initial maximum number of ordinary shares available for issuance under equity incentive
awards granted pursuant to the 2017 Plan initially equaled 2,341,097 ordinary shares. On January 1, 2021 and on January 1 of each calendar
year thereafter, an additional number of shares equal to 4% of the total outstanding ordinary shares on December 31 of the immediately
preceding year (or any lower number of shares as determined by the Board of Directors) will become available for issuance under equity
incentive awards granted pursuant to the 2017 Plan.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
annual general meeting on July 16, 2020, approved an amendment to the 2017 Plan with effect from January 1, 2021:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">increasing
                                            the maximum annual number of ordinary shares in the Company&#8217;s capital available for
                                            issuance under the 2017 Plan, starting on January 1, 2021, to 4% (from 3%) of the Company&#8217;s
                                            outstanding ordinary shares (determined as of December 31 of the immediately preceding year);
                                            and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">removing
                                            certain restrictions from the 2017 Plan, which will allow the committee administering the
                                            2017 Plan and the Board to (i) lower the exercise price per share of any options and/or share
                                            appreciation rights issued under the 2017 Plan or take any other action treated as a &#8216;repricing&#8217;
                                            of an award and (ii) cancel any option and/or share appreciation rights in exchange for cash
                                            or another award granted under the 2017 Plan, in either case, without prior approval of the
                                            Company&#8217;s shareholders.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Plan
Administration</i>. The 2017 Plan is administered by a long-term incentive, or LTI, committee appointed by the Board of Directors, which
consists of not less than three directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Eligibility</i>.
Equity incentive awards may be granted to our employees, non-employee directors, consultants or other advisors, as well as holders of
equity compensation awards granted by a company that may be acquired by us in the future.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Awards</i>.
Equity incentive awards under the 2017 Plan may be granted in the form of stock options, stock appreciation rights, restricted stock,
restricted stock units, performance awards or other share-based awards. Stock options and stock appreciation rights will have an exercise
price determined by the plan committee but that is no less than fair market value of the underlying ordinary shares on the date of grant.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Vesting</i>.
The vesting conditions for grants under the equity incentive awards under the 2017 Plan will be set forth in the applicable award documentation.
However, subject to the acceleration provisions under certain circumstances described below, awards (other than replacement awards) may
not vest in full prior to the first anniversary of the grant date, with the exception that up to 5% of the shares available for issuance
under the 2017 Plan may provide for alternative vesting conditions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Termination
of Service and Change in Control</i>. In the event of a participant&#8217;s termination of employment, the plan committee may, in its
discretion, determine the extent to which an equity incentive award may be exercised, settled, vested, paid or forfeited. In the event
of a change in control of the company (as defined in the 2017 Plan), any then successor or surviving corporation may continue outstanding
awards, or convert or substitute such awards for award or right with respect to the stock of the successor or surviving corporation,
in which case, if a participant is terminated by the successor or surviving corporation without &#8220;cause&#8221; or for &#8220;good
reason&#8221; (in each case, as defined in the 2017 Plan) within 24 months following the change in control, all equity incentive awards
held by the participant will immediately vest. If any outstanding awards are not continued or converted following a change in control
of the company, then such awards will immediately vest, and options and stock appreciation rights will become fully exercisable. In connection
with a change of control, the plan committee may, in its discretion, take a number of other actions, including accelerating the vesting
of any equity incentive award or terminating or cancelling any equity incentive award for cash payment.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Insurance
and indemnification</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
current and future directors (and such other officer or employee as designated by the Board of Directors) have the benefit of indemnification
provisions in our Articles of Association. These provisions give the indemnified persons the right to recover from us amounts, including
litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the performance of their duties. However,
there is no entitlement to indemnification for acts or omissions which are considered to constitute malice, gross negligence, intentional
recklessness and/or serious culpability attributable to such indemnified person. In addition, upon the closing of our initial public
offering, we entered into agreements with our directors and executive officers to indemnify them against expenses and liabilities to
the fullest extent permitted by law. These agreements also provide, subject to certain exceptions, for indemnification for related expenses,
including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred by any of these individuals in any action
or proceeding. In addition to such indemnification, we provide our directors with directors&#8217; and officers&#8217; liability insurance.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Insofar
as indemnification of liabilities arising under the Securities Act may be permitted to directors or persons controlling us pursuant to
the foregoing provisions, we have been informed that, in the opinion of the SEC such indemnification is against public policy as expressed
in the Securities Act and is therefore unenforceable.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Compliance
with Nasdaq listing requirements</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are a foreign private issuer. As a result, in accordance with Nasdaq listing requirements, we comply with certain home country governance
requirements rather than complying with certain Nasdaq corporate governance requirements. In accordance with Dutch law and generally
accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general meetings
of shareholders in the United States. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which
requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of
the outstanding voting stock. Although we must provide shareholders with an agenda and other relevant documents for the general meeting
of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a
generally accepted business practice in the Netherlands, and thus our practice will vary from the requirement of Nasdaq Listing Rule
5620(b). As permitted by the listing requirements of Nasdaq, we also opted out of the requirements of Nasdaq Listing Rule 5605(d), which
requires an issuer to have a compensation committee that, among other things, consists entirely of independent directors and makes determinations
regarding the independence of any compensation consultants, Nasdaq Listing Rule 5605(e), which requires an issuer to have independent
director oversight of director nominations, and Nasdaq Listing Rule 5605(b)(2), which requires an issuer to have a majority of independent
directors on its board. In addition, we opted out of shareholder approval requirements for the issuance of securities in connection with
certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation
plans for employees and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Listing Rule
5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events.
For an overview of our corporate governance principles, see &#8220;ITEM 10. ADDITIONAL INFORMATION &#8212; 2. Memorandum and articles
of association.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_030"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">C.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Board
                                            practices</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Board
of Directors </b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
Board of Directors was composed of six members until the annual general meeting held on April 26, 2023, and seven members from such date
throughout the remaining period under review, two of whom are executive directors. Our executive directors and the chairman of our board
shall initially serve for four-year terms and our other non-executive directors shall initially serve for three-year terms, in each case
until the earlier of their successors being duly appointed, their resignation or their removal. After these terms, our directors may
be nominated for re-appointment for such terms as may be deemed appropriate by the Board of Directors. For the years of the directors&#8217;
initial appointment and term expiration dates, see &#8216;A. Directors and senior management.&#8217;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Nasdaq&#8217;s
board diversity rule</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Nasdaq&#8217;s
Board Diversity Rule, which was approved by the SEC on August 6, 2021, is a disclosure standard designed to encourage minimum board diversity
for companies and provide stakeholders with consistent, comparable disclosures concerning a company&#8217;s current board composition.
Nasdaq&#8217;s Board Diversity Rule requires companies listed on Nasdaq to publicly disclose board-level diversity statistics using a
standardized template.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td colspan="5" style="border: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Board
                                            Diversity Matrix (As of March 20, 2024)</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">To
    be completed by Foreign Issuers (with principal executive offices outside of the U.S.) and Foreign Private Issuers</span></p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Country
    of Principal Executive Offices</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    Private Issuer</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    Prohibited Under Home Country Law</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Number of Directors</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Female</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Male</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Binary</span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: top; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Gender</span></td></tr>
  <tr>
    <td colspan="5" style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    I: Gender Identity</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors</span></td>
    <td style="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td>
    <td style="vertical-align: top; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr>
    <td colspan="5" style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Part
    II: Demographic Background</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underrepresented
    Individual in Home Country Jurisdiction</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LGBTQ+</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did
    Not Disclose Demographic Background</span></td>
    <td colspan="4" style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
Board of Directors adopted a Diversity Policy in December 2021 as amended to become a Diversity &amp; Inclusion Policy in October 2023,
which is published on the Company&#8217;s website. This policy sets out diversity and inclusion aspects including our targets relating
to diversity in the composition of the Board of Directors. We believe that diversity encompasses acceptance and respect, recognizing
that each individual is unique. We are committed to supporting, valuing and leveraging diversity throughout the Company and in the composition
of the Board of Directors.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Board
committees</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Audit
committee</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
audit committee currently consists of Mr. Richard Brudnick, Mr. Nicolas Fulpius, Mr. Anthony Gibney, and Mr. Mark Kuebler. Mr. Anthony
Gibney is the audit committee&#8217;s chair. The audit committee assists the Board of Directors in overseeing our accounting and financial
reporting processes and the audits of our financial statements. In addition, the audit committee is directly responsible for the recommendation
for appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. The Board of
Directors has determined that each member of the audit committee satisfies the &#8220;independence&#8221; requirements set forth in Rule
10A-3 under the Exchange Act and each qualifies as an &#8220;audit committee financial expert,&#8221; as such term is defined in the
rules of the SEC. The audit committee is governed by a charter that complies with applicable Nasdaq rules, which charter has been posted
on our website.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
audit committee&#8217;s responsibilities include:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">recommending
                                            the appointment of the independent auditor to the general meeting of shareholders;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">the
                                            appointment, compensation, retention and oversight of any accounting firm engaged for the
                                            purpose of preparing or issuing an audit report or performing other audit services;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">pre-approving
                                            the audit services and non-audit services to be provided by our independent auditor before
                                            the auditor is engaged to render such services;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">evaluating
                                            the independent auditor&#8217;s qualifications, performance and independence, and presenting
                                            its conclusions to the full supervisory board on at least an annual basis;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            and discussing with the Board of Directors and the independent auditor the audit plan as
                                            well as our annual audited financial statements and quarterly financial statements prior
                                            to the filing of the respective annual and quarterly reports;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">overseeing
                                            the effectiveness and integrity of the internal audit function, ensuring its independence,
                                            objectivity, and adherence to established policies and procedures;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            our compliance with laws and regulations, including major legal and regulatory initiatives
                                            and also reviewing any major litigation or investigations against us that may have a material
                                            impact on our financial statements;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            internal audit results, including the effectiveness of the design and operation of our internal
                                            controls;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            the operation of and our compliance with our code of ethics;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            the operation of our compliance with our investment policy regulating all cash investment
                                            decisions regarding the investment of available cash amounts and the maintenance of the cash
                                            investment portfolio of all Company&#8217;s entities including all currency exchange transactions;
                                            </span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            the operation of our risk management system; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">approving
                                            or ratifying any related person transaction (as defined in our related person transaction
                                            policy) in accordance with our related person transaction policy and reviewing potential
                                            conflicts of interest involving our directors.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
audit committee meets as often as one or more members of the audit committee deem necessary, but in any event meets at least quarterly.
The audit committee meets at least once per year with our independent accountant without our executive directors being present.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Compensation
committee</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
compensation committee consists of Mr.&#160;Richard Brudnick, Mr. Nicolas Fulpius and Mr. Mark Kubler. Mr. Nicolas Fulpius is the compensation
committee&#8217;s chair. The compensation committee assists the Board of Directors in determining compensation for the directors. The
committee recommends to the Board of Directors for determination the compensation of each of our directors. Under SEC and Nasdaq rules,
there are heightened independence standards for members of the compensation committee, including a prohibition against the receipt of
any compensation from us other than standard director fees. As permitted by the listing requirements of Nasdaq, we opted out of Nasdaq
Listing Rule 5605(d), which requires that a compensation committee consist entirely of independent directors. The compensation committee
is governed by a charter that has been posted on our website.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
compensation committee&#8217;s responsibilities include:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">identifying,
                                            reviewing and approving corporate goals and objectives relevant to compensation of our executive
                                            officers and directors;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">analyzing
                                            the possible outcomes of the variable remuneration components and how they may affect the
                                            remuneration of our executive officers;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">determining
                                            any long-term incentive component of each executive officer&#8217;s compensation in line
                                            with the compensation policy and reviewing our executive officer compensation and benefits
                                            policies generally;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">preparing
                                            periodic compensation reports for the Board of Directors;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">reviewing
                                            and assessing risks arising from our employee compensation policies and practices and whether
                                            any such risks are reasonably likely to have a material adverse effect on us; and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">retaining
                                            or obtaining advice from a compensation consultant, legal counsel or other advisor as the
                                            compensation committee deems necessary or appropriate to carry out its responsibilities.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">Nomination
and corporate governance committee</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
nomination and corporate governance committee consists of Mr. Nicolas Fulpius, Ms. Hege Hellstrom and Mr. Mark Kubler. Mr. Nicolas Fulpius
is the nomination and corporate governance committee&#8217;s chair. The nomination and corporate governance committee assists the Board
of Directors in identifying individuals qualified to become members of the Board of Directors consistent with criteria established by
the Board of Directors and in developing our corporate governance principles. As permitted by the listing requirements of Nasdaq, we
opted out of Nasdaq Listing Rule 5605(e), which requires independent director oversight of director nominations. The nominating and corporate
governance committee is governed by a charter that has been posted on our website.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
nomination and corporate governance committee&#8217;s responsibilities include:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">preparing
and reviewing selection criteria and appointment procedures for the Board of Directors;</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">reviewing
the size and composition of the Board of Directors by taking into account any diversity and inclusion criteria and submitting proposals
for the composition profile of the Board of Directors;</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">leading
the Board of Directors in self-evaluation to determine whether it and its committees are functioning effectively;</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">preparing
and reviewing a plan for succession of directors by taking into account any diversity and inclusion criteria; and</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">submitting
proposals for the appointment or reappointment of directors.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_031"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Employees</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we had 66 employees, including 22 with M.D. or Ph.D. degrees. <span style="font-size: 10pt">As of December 31,
2022, we had 48 employees, including 18 with M.D. or Ph.D. degrees. As of December 31, 2021, we had 59 employees, including 18 with M.D.
or Ph.D. degrees.</span></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_032"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">E.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Share
                                            ownership</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">See
&#8220;ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS &#8212;1.&#160;Major shareholders.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_033"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">F.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Disclosure
                                            of a registrant&#8217;s action to recover erroneously awarded compensation</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we did not have an accounting restatement that required recovery of erroneously awarded incentive-based compensation
pursuant to our Clawback Policy. As of as of December 31, 2023, there were no outstanding balances of erroneously awarded incentive-based
compensation to be recovered from the application of the policy to a prior restatement. Our Clawback Policy is included as Exhibit 97.1
to this Annual Report.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_034"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_035"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Major
                                            shareholders</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following table presents information relating to the beneficial ownership of our ordinary shares as of December 31, 2023:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">each
person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares (as of the date
of such shareholder&#8217;s Schedule 13G filing for InflaRx N.V. with the SEC);</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">each
of our directors and senior management; and</span></td>
</tr></table><div>

</div><p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">all
directors and senior management as a group.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
number of ordinary shares beneficially owned by each entity, person or director is determined in accordance with the rules of the SEC,
and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership
includes any ordinary shares over which the individual has sole or shared voting power or investment power or to receive the economic
benefit of ownership of the shares, as well as any ordinary shares that the individual has the right to acquire within 60 days of December
31, 2023 through the exercise of any option, warrant or other right. The percentage of shares beneficially owned is computed on the basis
of 58,883,272 ordinary shares outstanding as of December 31, 2023. Ordinary shares that a person has the right to acquire within 60 days
of December 31, 2023 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but
are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage
ownership of all directors and senior management as a group. Except as otherwise indicated, and subject to applicable community property
laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person. All
shareholders have similar voting rights. As of December 31, 2023, 16,818,972 ordinary shares, representing approximately 28.6% of our
issued and outstanding ordinary shares, were held by 20 U.S. record holders.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">This
table is based upon information supplied by our named Senior Management, directors, and principal shareholder, and Schedules 13D and
13G filed with the SEC. The percentage of outstanding ordinary shares is computed on the basis of 58,883,272 ordinary shares outstanding
as of December 31, 2023. Ordinary shares that a person has the right to acquire within 60 days of December 31, 2023 are deemed outstanding
for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of
computing the percentage ownership of any other person.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Unless
otherwise indicated, the address of each beneficial owner listed in the table below is c/o InflaRx N.V., Winzerlaer Str. 2, 07745 Jena,
Germany.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares<br/>
    Beneficially Owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percent
    of</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5% Shareholders</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with Suvretta Capital Management LLC<sup>(1)</sup></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,733,910</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
    and senior management</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Niels Riedemann<sup>(2)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,851,622</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Renfeng Guo<sup>(3)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,951,841</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas Taapken<sup>(4)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">455,502</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Camilla
    Chong, officer from July 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derval O&#8217;Carroll<sup>(5)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nicolas Fulpius<sup>(6)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">631,986</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Brudnick<sup>(7)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">154,850</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Kubler<sup>(8)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,088,187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony Gibney<sup>(9)</sup></span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98,085</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hege
    Hellstrom, director from April 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and senior management as a group (10 persons)</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,257,073</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.8</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicates
beneficial ownership of less than 1% of the total outstanding ordinary shares.</span></td>
</tr></table><div>





</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td><span style="font-family: Times New Roman, Times, Serif">As
                                            per filing on Schedule 13G as of April 12, 2023, Aaron Cowen has beneficial ownership by
                                            virtue of his role as a control person of Suvretta Capital Management LLC. The address of
                                            Suvretta Capital Management LLC is 540 Madison Avenue, 7<sup>th</sup> Floor, New York, New
                                            York 10022.</span></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
<tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 1,068,908 ordinary shares, (b) 404,040 ordinary shares that may be acquired pursuant
                                            to the exercise of options which were issued pursuant to the 2016 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on November 18, 2031, (c) 126,005 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the Series B financing at an exercise
                                            price of &#8364;0.0012 per share, (d) 689,253 ordinary shares that may be acquired pursuant
                                            to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on December 13, 2025, (e) 5,409 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall expire on
                                            November 20, 2026, (f) 350,000 ordinary shares that may be acquired pursuant to the exercise
                                            of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
                                            share (after re-pricing on April 13, 2022 from $5.14 per share), which shall expire on January
                                            4, 2031, (g) 112,007 ordinary shares that may be acquired pursuant to the exercise of options
                                            which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
                                            re-pricing on April 13, 2022 from $2.99 per share), which shall expire on July 1, 2031, (h)
                                            548,000 ordinary shares that may be acquired pursuant to the exercise of options which were
                                            issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing
                                            on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, and (i)
                                            548,000 ordinary shares that may be acquired pursuant to the exercise of options which were
                                            issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which shall expire
                                            on January 24, 2033.</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 1,762,144 ordinary shares, (b) 336,672 ordinary shares that may be acquired pursuant
                                            to the exercise of options which were issued pursuant to the 2016 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on November 18, 2031, (c) 623,610 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on December 13, 2025, (d) 5,409 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall expire on
                                            November 20, 2026, (e) 275,000 ordinary shares that may be acquired pursuant to the exercise
                                            of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
                                            share (after re-pricing on April 13, 2022 from $5.14 per share), which shall expire on January
                                            4, 2031, (f) 88,006 ordinary shares that may be acquired pursuant to the exercise of options
                                            which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
                                            re-pricing on April 13, 2022 from $2.99 per share), which shall expire on July 1, 2031, (g)
                                            430,500 ordinary shares that may be acquired pursuant to the exercise of options which were
                                            issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after re-pricing
                                            on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032, and (h)
                                            430,500 ordinary shares that may be acquired pursuant to the exercise of options which were
                                            issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which shall expire
                                            on January 24, 2033.</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 3,500 ordinary shares, (b) 150,000 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $4.83 per share), which shall
                                            expire on September 17, 2028, (c) 50,000 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $5.14 per share), which shall
                                            expire on January 4, 2031, (d) 32,002 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $2.99 per share), which shall expire on
                                            July 1, 2031, (e) 110,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share
                                            (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January
                                            11, 2032, and (f) 110,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share,
                                            which shall expire on January 24, 2033.</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of 25,000 ordinary shares that may be acquired pursuant to the exercise of options which
                                            were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which shall
                                            expire on January 24, 2033.</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 467,921 ordinary shares, (b) 34,464 ordinary shares that may be acquired pursuant
                                            to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on December 13, 2025, (c) 30,000 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $5.14 per share), which shall
                                            expire on January 4, 2031, (d) 9,601 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $2.99 per share), which shall expire on
                                            July 1, 2031, (e) 45,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share
                                            (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January
                                            11, 2032, and (f) 45,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share,
                                            which shall expire on January 24, 2033.</span></td></tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 50,000 ordinary shares, (b) 18,450 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on February 4, 2027, (c) 20,000 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $5.14 per share), which shall expire on
                                            January 4, 2031, (d) 6,400 ordinary shares that may be acquired pursuant to the exercise
                                            of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per
                                            share (after re-pricing on April 13, 2022 from $2.99 per share), which shall expire on July
                                            1, 2031, (e) 30,000 ordinary shares that may be acquired pursuant to the exercise of options
                                            which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share (after
                                            re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January 11, 2032,
                                            and (f) 30,000 ordinary shares that may be acquired pursuant to the exercise of options which
                                            were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share, which shall
                                            expire on January 24, 2033.</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 960,015 ordinary shares, (b) 7,308 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the Series B financing at an exercise
                                            price of &#8364;0.0012 per share, (c) 34,464 ordinary shares that may be acquired pursuant
                                            to the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $3.35 per share), which shall
                                            expire on December 13, 2025, (d) 20,000 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $5.14 per share), which shall
                                            expire on January 4, 2031, (e) 6,400 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $2.99 per share), which shall expire on
                                            July 1, 2031, (f) 30,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share
                                            (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January
                                            11, 2032, and (g) 30,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share,
                                            which shall expire on January 24, 2033.</span></td></tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consists
                                            of (a) 10,000 ordinary shares, (b) 11,667 ordinary shares that may be acquired pursuant to
                                            the exercise of options which were issued pursuant to the 2017 Plan at an exercise price
                                            of $1.86 per share (after re-pricing on April 13, 2022 from $22.75 per share), which shall
                                            expire on February 7, 2026, (c) 16,418 ordinary shares that may be acquired pursuant to the
                                            exercise of options which were issued pursuant to the 2017 Plan at an exercise price of $1.86
                                            per share (after re-pricing on April 13, 2022 from $2.99) per share, which shall expire on
                                            July 1, 2031, (d) 30,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $1.86 per share
                                            (after re-pricing on April 13, 2022 from $4.13 per share), which shall expire on January
                                            11, 2032, and (e) 30,000 ordinary shares that may be acquired pursuant to the exercise of
                                            options which were issued pursuant to the 2017 Plan at an exercise price of $2.37 per share,
                                            which shall expire on January 24, 2033.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.85pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.85pt; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.85pt; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Significant
                                            changes in ownership by major shareholders</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
July 8, 2020, we filed the 2020-Shelf Registration Statement. We also filed with the SEC a prospectus supplement relating to an at-the-market
program providing for the sales of our stock over time of up to $50.0 million of our ordinary shares pursuant to a Sales Agreement with
SVB Leerink LLC.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, we had issued a total of 5,803,931 ordinary shares throughout the term of the at-the-market program, resulting
in a total of &#8364;26.2 million in net proceeds to us, of which 3,235,723 ordinary shares, resulting in &#8364;14.4 million in net proceeds
to us were issued during fiscal year 2023. The term of the at-the-market program expired on July 8, 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
April 2023 we sold and issued an aggregate of 10,823,529 ordinary shares in an underwritten public offering, of which 1,411,764 were
sold pursuant to exercise by the underwriters of an overallotment option. The ordinary shares were sold at a price of $4.25 per share
and have a nominal value of &#8364;0.12 per share. Proceeds of this offering after deducting underwriting discounts amounted to &#8364;39.1
million.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">On
June&#160;30, 2023, we filed&#160;a&#160;Form F-3, or the&#160;2023-Registration Statement,&#160;with the SEC&#160;with respect to the
offer and sale of securities of the Company, which became effective on July&#160;11, 2023. The aggregate initial offering price of the
securities that the Company may offer and sell under this prospectus will not exceed $250&#160;million. No ordinary shares were issued
by the Company under the 2023-Registration Statement within the fiscal year 2023 and no active offering programs have been launched.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">During
the fiscal year 2023, we issued and registered a total of 120,257 ordinary shares resulting from the exercise of stock option rights
by former employees. All stock option rights had been granted under the 2017 Plan. 14,930 stock options thereof were already exercised
in December 2022 and 105,327 were exercised during fiscal year 2023. The ordinary shares have a nominal value of &#8364;0.12 per share.
98,754 ordinary shares were sold at a price of $1.85 per share, and 21,503 ordinary shares were sold at a price of $3.35 per share.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Suvretta
Capital Management LLC and affiliated entities filed a Schedule 13G as of December 31, 2023, stating a shareholding of 5,733,910 shares
resulting in a holding of 9.7% in the Company.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_036"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Related
                                            party transactions</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following is a description of related party transactions we have entered since January 1, 2023 with any of our officers, directors and
the holders of more than 5% of our ordinary shares:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Indemnification
                                            agreements</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
entered into indemnification agreements with our directors and senior management. The indemnification agreements and our Articles of
Association require us to indemnify our directors to the fullest extent permitted by law. See &#8220;ITEM 6. DIRECTORS, SENIOR MANAGEMENT
AND EMPLOYEES &#8212; 2.&#160;Compensation &#8212; Insurance and indemnification&#8221; for a description of these indemnification agreements.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Agreements
                                            with Staidson and its affiliates</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">On
December 21, 2022, InflaRx GmbH and Staidson (Beijing) BioPharmaceuticals Co., Ltd., or Staidson, entered into a third addendum to the
Co-Development Agreement, dated as of December 28, 2015 (Co-Development Addendum). Pursuant to the terms of the Co-Development Addendum,
InflaRx GmbH will receive royalties of 10% on net sales of BDB-001 (as defined in the Co-Development Addendum) for COVID-19 in China.
InflaRx GmbH has granted Staidson an exclusive license for use in China to certain of InflaRx GmbH&#8217;s clinical, manufacturing and
regulatory documentation regarding vilobelimab in order to support and facilitate the regulatory filing for BDB-001 for the treatment
of severely ill COVID-19 patients with the Chinese National Medical Products Administration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">In
connection with the Co-Development Addendum, on December 21, 2022, the Company and Staidson Hong Kong Investment Company Ltd. entered
into the Purchase Agreement. Pursuant to the Purchase Agreement, the Company sold 500,000 ordinary shares with a nominal value of &#8364;0.12
per share, to Staidson Hong Kong Investment Company Ltd. at a price of $5.00 per share, and at an aggregate purchase price of $2,500,000.
Under the terms of the Purchase Agreement, at the Company&#8217;s option, Staidson Hong Kong Investment Company Ltd. may purchase additional
shares for an aggregate purchase price of $7,500,000, which is subject to certain conditions. ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Interests
                                            of experts and counsel</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_037"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
8. FINANCIAL INFORMATION</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_038"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Consolidated
                                            statements and other financial information</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Financial
                                            statements</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">See
&#8220;ITEM 18. FINANCIAL STATEMENTS,&#8221; which contains our audited financial statements prepared in accordance with IFRS-IASB.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Legal
                                            proceedings</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">From
time to time we are involved in legal proceedings that arise in the ordinary course of business. We believe that the outcome of these
proceedings, if determined adversely, will not have a material adverse effect on our financial position. During the period covered by
the audited and approved financial statements contained herein, we have not been a party to or paid any damages in connection with litigation
that has had a material adverse effect on our financial position. Any future litigation may result in substantial costs and be a distraction
to management and our employees. No assurance can be given that future litigation will not have a material adverse effect on our financial
position. For an additional discussion of certain risks associated with legal proceedings, see &#8220;ITEM 3. KEY INFORMATION &#8212;
3.&#160;Risk factors.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Dividends
                                            and dividend policy</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have never paid or declared any cash dividends on our ordinary shares, and we do not anticipate paying any cash dividends on our ordinary
shares in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion
of our business. Under Dutch law, we may only pay dividends to the extent our shareholders&#8217; equity (<i>eigen vermogen</i>) exceeds
the sum of the paid-up and called-up share capital plus the reserves required to be maintained by Dutch law or by our Articles of Association.
Subject to such restrictions, any future determination to pay dividends will be at the discretion of the Board of Directors and will
depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions,
restrictions imposed by applicable law and other factors the Board of Directors deems relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_039"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Significant
                                            changes</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">A
discussion of the significant changes in our business can be found under &#8220;ITEM 4. INFORMATION ON THE COMPANY &#8212; 1. History
and development of the company.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="m_040"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
9. THE OFFER AND LISTING</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_041"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Offering
                                            and listing details</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_042"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Plan
                                            of distribution</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_043"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">C.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Markets</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
ordinary shares began trading on the Nasdaq Global Select Market under the symbol &#8220;IFRX&#8221; on November&#160;8, 2017.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_044"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Selling
                                            shareholders</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_045"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">E.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Dilution</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_046"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">F.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Expenses
                                            of the issue</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_047"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">ITEM
10. ADDITIONAL INFORMATION</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_048"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Share
                                            capital</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_049"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">B.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Memorandum
                                            and articles of association</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Our
shareholders adopted the Articles of Association included as Exhibit 1.1. to the Annual Report on Form 20-F for the year ended December
31, 2022 filed with the SEC on March 22, 2023.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;We
incorporate by reference into this Annual Report the description of our Articles of Association contained in our F-3 registration statement
(File No. 333-273058) originally filed with the SEC on June 30, 2023, and effective as of July 11, 2023, as amended. Such description
sets forth a summary of certain provisions of our Articles of Association as currently in effect.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s Articles of Association in effect for the period under review was adopted by the annual general meeting on August 25,
2021 and is available on our website.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_050"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">C.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Material
                                            contracts</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Except
as otherwise disclosed in this Annual Report (including the Exhibits), we are not currently, and have not been in the last two years,
party to any material contract, other than contracts entered into in the ordinary course of business.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_051"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">D.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Exchange
                                            controls</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Not
applicable.</i></span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="m_052"></a></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">E.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Taxation</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">The
following summary contains a description of certain U.S. federal income, Dutch and German tax consequences of ownership and disposition
of our ordinary shares. the summary is based upon the tax laws of the United States, the Netherlands and Germany, and regulations thereunder
as of the date hereof, which are subject to change.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Material
U.S. Federal income Tax Considerations for<br/>
U.S. Holders of ORDINARY Shares</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following is a description of the material U.S. federal income tax consequences to the U.S. Holders, as defined below, of owning and
disposing of ordinary shares. It does not set forth all tax considerations that may be relevant to a particular person&#8217;s decision
to hold the ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">This
section applies only to a U.S. Holder that holds ordinary shares as capital assets for U.S. federal income tax purposes. In addition,
it does not set forth all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder&#8217;s particular
circumstances, including alternative minimum tax consequences, the potential application of the provisions of the Code known as the Medicare
contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">certain
financial institutions;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">dealers
                                            or traders in securities who use a mark-to-market method of tax accounting;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">persons
                                            holding ordinary shares as part of a hedging transaction, straddle, wash sale, conversion
                                            transaction or other integrated transaction or persons entering into a constructive sale
                                            with respect to the ordinary shares;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">persons
                                            whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">entities
                                            classified as partnerships for U.S. federal income tax purposes or other pass-through entities;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">tax-exempt
                                            entities, including an &#8220;individual retirement account&#8221; or &#8220;Roth IRA&#8221;;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">persons
                                            that own or are deemed to own 10% or more of our shares (by vote or value);</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">persons
                                            that acquire our shares directly or indirectly in connection with the performance of services;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">persons
                                            who are subject to Section 451(b) of the Code; or</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">persons
                                            holding ordinary shares in connection with a trade or business conducted outside of the United
                                            States.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
an entity that is classified as a partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal income tax
treatment of a partner will depend on the status of the partner and the activities of the partnership. Partnerships holding ordinary
shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal income tax consequences
of owning and disposing of the ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">This
section is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury regulations,
and the income tax treaty between Germany and the United States and the income tax treaty between the Netherlands and the United States
(as applicable and as the context requires the &#8220;Treaty&#8221;) all as of the date hereof, any of which is subject to change or
differing interpretations, possibly with retroactive effect. No assurance can be given that the IRS will agree with the views expressed
in this discussion, or that a court will not sustain any challenge by the IRS in the event of litigation. We have not obtained, nor do
we intend to obtain, a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">A
&#8220;U.S. Holder&#8221; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of ordinary shares, who is eligible
for the benefits of the Treaty and who is:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
citizen or individual resident of the United States;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">a
corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein
or the District of Columbia;</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">an
estate or trust the income of which is subject to U.S. federal income taxation regardless of its source: or</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">a
trust, if a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons are authorized
to control all substantial decisions of the trust.</span></td>
</tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">U.S.
Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing
of ordinary shares in their particular circumstances. In particular, because our group includes a U.S. subsidiary, InflaRx Pharmaceuticals,
Inc., and therefore under current law our subsidiary InflaRx GmbH is treated as a controlled foreign corporation (regardless of whether
we are or are not treated as a controlled foreign corporation), any U.S. Holder that owns or is deemed to own 10% or more of our shares
(by vote or value) is urged to consult its tax advisor regarding the potential application of the &#8220;Subpart F income&#8221; and
&#8220;global intangible low-taxed income&#8221; rules to an investment in our ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Taxation
                                            of distributions</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
discussed above under &#8220;ITEM 8. FINANCIAL INFORMATION &#8212; 1. Consolidated statements and other financial information &#8212;
1.3 Dividends and dividend policy,&#8221; we do not currently expect to make distributions on our ordinary shares. In the event that
we do make distributions of cash or other property, subject to the PFIC rules described below, distributions paid on ordinary shares,
other than certain pro rata distributions of ordinary shares, will be treated as dividends to the extent paid out of our current or accumulated
earnings and profits (as determined under U.S. federal income tax principles). For so long as we are treated as a PFIC with respect to
a U.S. Holder (or were treated as a PFIC with the respect to the U.S. Holder in the preceding taxable year), dividends paid to certain
non-corporate U.S. Holders will not be eligible for taxation as &#8220;qualified dividend income.&#8221; To the extent we are not treated
as a PFIC with respect to a U.S. Holder and were not treated as a PFIC with the respect to the U.S. Holder in the preceding taxable year
(if for example in future years we cease to meet the threshold requirements for PFIC status and the U.S. Holder initially acquires our
ordinary shares in a year in which we are not treated as a PFIC and we are not so treated thereafter or we were a PFIC with respect to
a U.S. Holder for a year during which a U.S. Holder holds ordinary shares but the U.S. Holder makes a valid deemed sale or deemed dividend
election under the applicable Treasury regulations with respect to its ordinary shares), for so long as our ordinary shares are listed
on Nasdaq or another established securities market in the United States or we are eligible for benefits under the Treaty, dividends paid
to such a U.S. Holder that is not a corporation would generally be eligible for taxation as &#8220;qualified dividend income&#8221; if
certain other requirements are met, which is generally taxable at rates not in excess of the long-term capital gain rate applicable to
such U.S. Holders. The amount of a dividend will include any amounts withheld by us in respect of German or Dutch income taxes. Subject
to the PFIC rules described below, the amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will
not be eligible for the dividends-received deduction available to U.S. corporations under the Code and  dividends will be included
in a U.S. Holder&#8217;s income on the date of the U.S. Holder&#8217;s receipt of the dividend. The amount of any dividend income paid
in euros will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive
receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency
gain or loss if the dividend is converted into U.S. dollars after the date of receipt. Generally, gain or loss, if any, resulting from
currency exchange fluctuations during the period from the date the dividend is paid to the date such payment is converted into U.S. dollars
will be treated as U.S. source ordinary income or loss.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Subject
to applicable limitations, German or Dutch income taxes withheld from dividends on ordinary shares at a rate not exceeding the rate provided
by the Treaty will be eligible for credit against the U.S. Holder&#8217;s U.S. federal income tax liability. German or Dutch taxes withheld
in excess of the rate applicable under the Treaty will not be eligible for credit against a U.S. Holder&#8217;s federal income tax liability.
The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of
foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may deduct foreign taxes, including
any German or Dutch income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election
to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. See
&#8220;ITEM 3. KEY INFORMATION &#8212; 3.&#160;Risk factors &#8212; Risks related to our ordinary shares and our status as a public company
if we ever pay dividends, we may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Sale
                                            or other disposition of ordinary shares</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Subject
to the PFIC rules described below, gain or loss realized on the sale or other disposition of ordinary shares will be capital gain or
loss, and will be long-term capital gain or loss if the U.S. Holder held the ordinary shares for more than one year. The amount of the
gain or loss will equal the difference between the U.S. Holder&#8217;s tax basis in the ordinary shares disposed of and the amount realized
on the disposition, in each case as determined in U.S. dollars.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td><span style="font-family: Times New Roman, Times, Serif">PFIC
                                            rules</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
believe it is likely that we were a PFIC for U.S. federal income tax purposes in 2021, 2022 and 2023, and we may be a PFIC in one or
more future taxable years. In addition, we may, now or in the future directly or indirectly, hold equity interests in other PFICs (any
such PFIC, a &#8220;Lower-tier PFIC&#8221;). Under the Code, generally a non-U.S. corporation will be a PFIC for any taxable year in
which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists
of passive income or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the
production of, &#8220;passive income.&#8221; For purposes of the above calculations, we will be treated as if we hold our proportionate
share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly or
indirectly own at least 25%, by value, of the shares of such corporation. Passive income includes, among other things, dividends, interest,
certain non-active rents and royalties, and capital gains. It is also possible that we will be a PFIC in any future taxable year because,
among other things, (i) we currently own a substantial amount of passive assets, including cash and securities that may give rise to
passive income, (ii) the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets,
is uncertain and may vary substantially over time, and (iii) the composition of our income may vary substantially over time. Accordingly,
there can be no assurance that we will not be a PFIC for any taxable year. If we are a PFIC for any year during which a U.S. Holder holds
ordinary shares, we would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the
U.S. Holder holds ordinary shares, even if we ceased to meet the threshold requirements for PFIC status, unless under certain circumstances
the U.S. Holder makes a valid deemed sale or deemed dividend election under the applicable Treasury regulations with respect to its ordinary
shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Under
attribution rules, assuming we are a PFIC, U.S. Holders will be deemed to own their proportionate shares of any Lower-tier PFICs and
will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (i) certain distributions
by a Lower-tier PFIC and (ii) a disposition of shares of a Lower-tier PFIC, in each case as if the U.S. Holder held such shares directly,
even if the U.S. Holder has not received the proceeds of those distributions or dispositions.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
we were a PFIC for any taxable year during which a U.S. Holder held ordinary shares (assuming such U.S. Holder has not made a timely
mark-to-market election, as described below), gain recognized by a U.S. Holder on a sale or other disposition (including certain
pledges) of the ordinary shares, or an indirect disposition of shares of a Lower-tier PFIC, would be allocated ratably over the U.S.
Holder&#8217;s holding period for the ordinary shares. The amounts allocated to the taxable year of the sale or other disposition
and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be
subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest
charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any distribution received by a
U.S. Holder on its ordinary shares (or a distribution by a Lower-tier PFIC to its shareholder that is deemed to be received by a
U.S. Holder) exceeds 125% of the average of the annual distributions on the ordinary shares received during the preceding three
years or the U.S. Holder&#8217;s holding period, whichever is shorter, that distribution would be subject to taxation in the same
manner as gain, described immediately above.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">A
U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market election with respect to its ordinary shares,
provided that the ordinary shares are &#8220;marketable.&#8221; Ordinary shares will be marketable if they are &#8220;regularly traded&#8221;
on a &#8220;qualified exchange&#8221; or other market within the meaning of applicable Treasury regulations. Our ordinary shares will
be treated as &#8220;regularly traded&#8221; in any calendar year in which more than a de minimis quantity of the ordinary shares is
traded on a qualified exchange on at least 15 days during each calendar quarter. Nasdaq, on which the ordinary shares are currently listed,
is a qualified exchange for this purpose. If a U.S. Holder makes the mark-to-market election, it will recognize as ordinary income any
excess of the fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis, and will recognize
an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at the end of
the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election).
If a U.S. Holder makes the election, the U.S. Holder&#8217;s tax basis in the ordinary shares will be adjusted to reflect the income
or loss amounts recognized. Any gain recognized on the sale or other disposition of ordinary shares in a year when we are a PFIC will
be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously
included as a result of the mark-to-market election). U.S. Holders should consult their tax advisers regarding the availability and advisability
of making a mark-to-market election in their particular circumstances.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, in order to avoid the application of the foregoing rules, a United States person that owns stock in a PFIC for U.S. federal
income tax purposes may make an election to treat the PFIC and each PFIC in which the PFIC holds equity interests as a qualified electing
fund (any such election, a QEF Election) with respect to each such PFIC if the PFIC provides the information necessary for such election(s)
to be made. In order to make such an election, a United States person would be required to make the QEF Election for each PFIC by attaching
a separate properly completed IRS Form 8621 for each PFIC to the United States person&#8217;s timely filed U.S. federal income tax return
generally for the first taxable year that the entity is treated as a PFIC with respect to the United States person. A U.S. Holder generally
may make a separate election to defer payment of taxes on the undistributed income inclusion under the QEF rules, but if deferred, any
such taxes are subject to an interest charge.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
a United States person makes a QEF Election with respect to a PFIC, the United States person will be currently taxable on its pro rata
share of the PFIC&#8217;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable
year that the entity is classified as a PFIC and will not be required to include such amounts in income when actually distributed by
the PFIC. If a U.S. Holder makes a QEF Election with respect to us, any distributions paid by us out of our earnings and profits that
were previously included in the U.S. Holder&#8217;s income under the QEF Election will not be taxable to the U.S. Holder. A U.S. Holder
will increase its tax basis in its ordinary shares by an amount equal to any income included under the QEF Election and will decrease
its tax basis by any amount distributed, if any, on the ordinary shares that is not included in its income. In addition, a U.S. Holder
will recognize capital gain or loss on the disposition of ordinary shares in an amount equal to the difference between the amount realized
and its adjusted tax basis in the ordinary shares. U.S. Holders should note that if they make QEF Elections with respect to us and Lower-tier
PFICs, if any, they may be required to pay U.S. federal income tax with respect to their ordinary shares for any taxable year significantly
in excess of any cash distributions, if any, received on the shares for such taxable year. U.S. Holders should consult their tax advisers
regarding making QEF Elections in their particular circumstances.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">In
addition, if we were a PFIC or, with respect to a particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid
a dividend or for the prior taxable year, the preferential dividend rates with respect to dividends paid to certain non-corporate U.S.
Holders would not apply.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">If
a U.S. Holder owns ordinary shares during any year in which we are a PFIC, the U.S. Holder must file annual reports, containing such
information as the U.S. Treasury may require on IRS Form 8621 (or any successor form) with respect to us, with the U.S. Holder&#8217;s
federal income tax return for that year, unless otherwise specified in the instructions with respect to such form.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
U.S. federal income tax rules relating to PFICs are very complex. U.S. Holders are strongly urged to consult their tax advisors with
respect to the impact of PFIC status on the purchase, ownership and disposition of our ordinary shares, the consequences to them of an
investment in a PFIC (and any Lower-tier PFICs), any elections available with respect to our ordinary shares and the IRS information
reporting obligations with respect to the purchase, ownership and disposition of ordinary shares of a PFIC.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
IRS has finalized Treasury Regulations that address various issues related to determining whether a foreign corporation is a PFIC and
whether a U.S. shareholder holds PFIC stock and released proposed Treasury Regulations that address various issues related to determining
whether a foreign corporation is a PFIC. These Treasury Regulations and proposed Treasury Regulations (if finalized) may affect whether
we are a PFIC in any future year. You should consult your tax adviser regarding the effect, if any, these Treasury Regulations may have,
or such proposed Treasury Regulations would have, on the determination of our PFIC status.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Information
                                            reporting and backup withholding</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Payments
of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries are subject
to information reporting, and may be subject to backup withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient
or (ii) in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is
not subject to backup withholding.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#8217;s U.S. federal
income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Information
                                            reporting with respect to foreign financial assets</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Certain
U.S. Holders who are individuals and certain entities may be required to report information relating to an interest in our ordinary shares,
subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by certain U.S. financial institutions).
U.S. Holders should consult their tax advisers regarding whether or not they are obligated to report information relating to their ownership
and disposition of the ordinary shares.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td><span style="font-family: Times New Roman, Times, Serif">Material
                                            Dutch tax considerations</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>General</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following is a general summary of certain material Dutch tax consequences of the acquisition, holding and disposal of our ordinary shares.
This summary does not purport to describe all possible tax considerations or consequences that may be relevant to a holder or prospective
holder of ordinary shares and does not purport to deal with the tax consequences applicable to all categories of investors, some of which
(such as trusts or similar arrangements) may be subject to special rules. In view of its general nature, this general summary should
be treated with corresponding caution. To the extent this summary relates to legal conclusions under current Netherlands tax law, and
subject to the qualifications it contains, it represents the opinion of NautaDutilh N.V., our special Dutch counsel. Holders or prospective
holders of shares should consult with their own tax advisors with regard to the tax consequences of investing in the shares in their
particular circumstances. The discussion below is included for general information purposes only.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">For
the purposes of this discussion, it is assumed that we are a tax resident of Germany under German national tax laws since we intended
to have, from our incorporation and on a continuous basis, our place of effective management in Germany. See Risk Factor &#8220;We may
become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Please
note that this summary does not describe the Dutch tax considerations for:</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 17.45pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">holders
                                            of our ordinary shares if such holders, and in the case of individuals, his or her partner
                                            or certain of their relatives by blood or marriage in the direct line (including foster children),
                                            have a substantial interest (<i>aanmerkelijk belang</i>) or deemed substantial interest (<i>fictief
                                            aanmerkelijk belang</i>) in the Company under the Dutch Income Tax Act 2001 (<i>Wet inkomstenbelasting
                                            2001</i>). Generally speaking, a holder of securities in a company is considered to hold
                                            a substantial interest in such company, if such holder alone or, in the case of individuals,
                                            together with his or her partner (as defined in the Dutch Income Tax Act 2001), directly
                                            or indirectly, holds (i) an interest of 5% or more of the total issued and outstanding capital
                                            of that company or of 5% or more of the issued and outstanding capital of a certain class
                                            of shares of that company; or (ii) rights to acquire, directly or indirectly, such interest;
                                            or (iii) certain profit sharing rights in that company that relate to 5% or more of the company&#8217;s
                                            annual profits and/or to 5% or more of the company&#8217;s liquidation proceeds. A deemed
                                            substantial interest may arise if a substantial interest (or part thereof) in a company has
                                            been disposed of, or is deemed to have been disposed of, on a non-recognition basis;</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 17.45pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">holders
                                            of our ordinary shares if the shares held by such holders qualify or qualified as a participation
                                            (<i>deelneming</i>) for purposes of the Dutch Corporate Income Tax Act 1969 (<i>Wet op de
                                            vennootschapsbelasting 1969</i>). Generally, a taxpayer&#8217;s shareholding of 5% or more
                                            in a company&#8217;s nominal paid-up share capital (or, in certain cases, in voting rights)
                                            qualifies as participation. A holder may also have a participation if such holder does not
                                            have a shareholding of 5% or more but a related entity (statutorily defined term) has a participation
                                            or if the company in which the shares are held is a related entity (statutorily defined term);</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 17.45pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">holders
                                            of shares who are individuals for whom the shares or any benefit derived from the shares
                                            are a remuneration or deemed to be a remuneration for (employment) activities or services
                                            performed by such holders or certain individuals related to such holders, whether within
                                            or outside an employment relation, that provides the holder, economically speaking, with
                                            certain benefits that have a relation to the relevant work activities or services (as defined
                                            in the Dutch Income Tax Act 2001); and</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 17.45pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">pension
                                            funds, investment institutions (<i>fiscale beleggingsinstellingen</i>), exempt investment
                                            institutions (<i>vrijgestelde beleggingsinstellingen</i>) (as defined in the Dutch Corporate
                                            Income Tax Act 1969) and other entities that are, in whole or in part, not subject to or
                                            exempt from corporate income tax in the Netherlands, as well as entities that are exempt
                                            from corporate income tax in their country of residence, such country of residence being
                                            another state of the European Union, Norway, Liechtenstein, Iceland or any other state with
                                            which the Netherlands have agreed to exchange information in line with international standards.</span></td></tr></table><div>

</div><p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">Except
as otherwise indicated, this summary only addresses Dutch national tax legislation and published regulations, whereby the Netherlands
and Dutch law means the part of the Kingdom of the Netherlands located in Europe and its law respectively, as in effect on the date hereof
and as interpreted in published case law (of the Dutch Supreme Court (<i>Hoge Raad der Nederlanden</i>)) until this date, without prejudice
to any amendment introduced (or to become effective) at a later date and/or implemented with or without retroactive effect. The applicable
tax laws or interpretations thereof may change, or the relevant facts and circumstances may change, and such changes may affect the contents
of this section, which will not be updated to reflect any such changes.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">This
discussion is for general information purposes and is not tax advice or a complete description of all Dutch tax consequences relating
to the acquisition, holding and disposal of our shares. Holders or prospective holders of our shares should consult their own tax advisor
regarding the tax consequences relating to the acquisition, holding and disposal of our shares in light of their particular circumstances.</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif"><b>Dividend
withholding tax</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">We
are incorporated under the laws of the Netherlands, and therefore a Dutch tax resident for Dutch domestic tax law purposes, including
the Dutch Dividend Withholding Tax Act 1969. As such, we are required to withhold Dutch dividend withholding tax at a rate of 15% from
dividends distributed by us (which withholding tax will not be borne by us but will be withheld by us from the gross dividends paid on
the shares). We are however also treated as a German tax resident for German domestic tax law purposes, since our place of effective
management is located in Germany. As long as we continue to have our place of effective management in Germany, and not in the Netherlands,
under the convention between the Federal Republic of Germany and the Netherlands for the avoidance of double taxation with respect to
taxes on income of 2012, we will be considered to be exclusively tax resident in Germany. Consequently, the Netherlands will be restricted
to impose Dutch dividend withholding tax on dividends distributed by us (we will not be required to withhold Dutch dividend withholding
tax). This exemption from withholding does not apply to dividends distributed by us to a holder of our ordinary shares who is resident
or deemed to be resident in the Netherlands for Dutch income tax purposes or Dutch corporation tax purposes or to a holder of our ordinary
shares that is neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable to a Dutch permanent
establishment of such non-resident holder, in which events the following applies. See Risk Factor &#8220;If we ever pay dividends, we
may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands.&#8221;</span></p><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: S3 --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed by us to individuals and corporate legal entities who are resident or deemed to be resident in the Netherlands for Dutch
tax purposes (&#8220;Dutch Resident Individuals&#8221; and &#8220;Dutch Resident Entities&#8221; as the case may be) or to holders of
our ordinary shares that are neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable to
a Dutch permanent establishment of such non-resident holder are subject to Dutch dividend withholding tax at a rate of 15%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expression &#8220;dividends distributed&#8221; includes, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distributions
                                            in cash or in kind, deemed and constructive distributions and repayments of paid-in capital
                                            not recognized for Dutch dividend withholding tax purposes;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">liquidation
                                            proceeds, proceeds of redemption of shares, or proceeds of the repurchase of shares by us
                                            or one of our subsidiaries or other affiliated entities to the extent such proceeds exceed
                                            the average paid-in capital of those shares as recognized for purposes of Dutch dividend
                                            withholding tax, unless in case of a repurchase, a particular statutory exemption applies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            amount equal to the par value of shares issued or an increase of the par value of shares,
                                            to the extent that it does not appear that a contribution, recognized for purposes of Dutch
                                            dividend withholding tax, has been made or will be made; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partial
                                            repayment of the paid-in capital, recognized for purposes of Dutch dividend withholding tax,
                                            if and to the extent that we have net profits (<i>zuivere winst</i>), unless the holders
                                            of shares have resolved in advance at a general meeting to make such repayment and the par
                                            value of the shares concerned has been reduced by an equal amount by way of an amendment
                                            of our Articles of Association.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dutch
Resident Individuals and Dutch Resident Entities can generally credit the Dutch dividend withholding tax against their income tax or
corporate income tax liability. The same applies to holders of our ordinary shares that are neither resident nor deemed to be resident
of the Netherlands if the shares are attributable to a Dutch permanent establishment of such non-resident holder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to legislation to counteract &#8220;dividend stripping,&#8221; a reduction, exemption, credit or refund of Dutch dividend withholding
tax is denied if the recipient of the dividend is not the beneficial owner (<i>uiteindelijk gerechtigde</i>) as described in the Dutch
Dividend Withholding Tax Act 1965 (<i>Wet op de dividendbelasting 1965</i>). This legislation generally targets situations in which a
shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends by a transaction with another
party. It is not required for these rules to apply that the recipient of the dividends is aware that a dividend stripping transaction
took place. The Dutch State Secretary for Finance takes the position that the definition of beneficial ownership introduced by this legislation
will also apply in the context of a double taxation convention. As of January 1, 2024, more stringent rules apply to the setoff, exemption
from, and reduction or refund of Dutch dividend withholding tax to address situations where a claim for setoff, exemption, reduction
or refund may align with the letter of Dutch tax law or a double taxation convention but goes against the underlying intention or spirit
of the dividend stripping rules, as perceived by the legislator. In addition, the burden of proof in cases related to dividend stripping
and beneficial owner status has in certain circumstances been shifted from the tax inspector to the person making a claim for a setoff,
reduction or refund of or exemption from Dutch dividend withholding tax. Furthermore, for shares traded on a regulated market, including
the Ordinary Shares, it has been codified that the record date is used when determining the person who is entitled to the dividend.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conditional
withholding tax on dividends (as of January 1, 2024)</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
it cannot be excluded that dividends distributed by us to certain related entities which are not resident in the Netherlands for Dutch
tax purposes will become subject to a Dutch conditional withholding tax in certain specific situations (see below), irrespectively of
the fact that we have our place of effective management in Germany and, therefore, are a tax resident of Germany under German national
tax laws. As of January 1, 2024, a Dutch conditional withholding tax will be imposed on dividends distributed by us to related entities
(<i>gelieerd</i>) resident in certain listed jurisdictions or in case of abusive arrangements (all within the meaning of the Dutch Withholding
Tax Act 2021; <i>Wet bronbelasting 2021</i>). The Dutch conditional withholding tax on dividends will be imposed at the highest Dutch
corporate income tax rate in effect at the time of the distribution (2024: 25.8%). The Dutch conditional withholding tax on dividends
will be reduced, but not below zero, by any regular Dutch dividend withholding tax withheld in respect of the same dividend distribution.
As such, based on the currently applicable rates, the overall effective tax rate of withholding the regular Dutch dividend withholding
tax (as described above) and the Dutch conditional withholding tax on dividends will not exceed the highest corporate income tax rate
in effect at the time of the distribution (2024: 25.8%).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxes
on income and capital gains</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dutch
resident entities </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
benefit derived or deemed to be derived from the shares held by a Dutch Resident Entity, including any capital gains realized on the
disposal thereof, will generally be subject to Dutch corporate income tax at a rate of 19% with respect to taxable profits up to &#8364;200,000
and 25.8% with respect to taxable profits in excess of that amount (rates and brackets for 2024).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dutch
resident individuals </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a holder of shares is a Dutch Resident Individual, any benefit derived or deemed to be derived from the ordinary shares is taxable at
the progressive income tax rates (with a maximum of 49.5%, rate for <span style="text-decoration:underline;text-decoration: none">2024</span>), if:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ordinary shares are attributable to an enterprise from which the holder of such shares derives
                                            a share of the profit, whether as an entrepreneur (<i>ondernemer</i>) or as a person who
                                            has a co-entitlement to the net worth (<i>medegerechtigd tot het vermogen</i>) of such enterprise,
                                            without being a shareholder, as defined in the Dutch Income Tax Act 2001); or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            holder of the ordinary shares is considered to perform activities with respect to such shares
                                            that go beyond ordinary asset management (<i>normaal, actief vermogensbeheer</i>) or derives
                                            benefits from the shares that are taxable as benefits from other activities (<i>resultaat
                                            uit overige werkzaamheden</i>).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taxation
of savings and investments </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the above-mentioned conditions (i) and (ii) do not apply to the Dutch Resident Individual, the ordinary shares will be subject to an
annual Dutch income tax under the regime for savings and investments (<i>inkomen uit sparen en beleggen</i>). Taxation only occurs insofar
the Dutch Resident Individual&#8217;s net investment assets for the year exceed a statutory threshold (<i>heffingvrij vermogen</i>).
The net investment assets for the year are the fair market value of the investment assets less the fair market value of the liabilities
on January 1 of the relevant calendar year (reference date; <i>peildatum</i>). Actual income or capital gains realized in respect of
the ordinary shares are as such not subject to Dutch income tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Dutch Resident Individual&#8217;s assets and liabilities taxed under this regime, including the ordinary shares, are allocated over the
following three categories: (a) bank savings (<i>banktegoeden</i>), (b) other investments (<i>overige bezittingen</i>), including the
ordinary shares, and (c) liabilities (<i>schulden</i>). The taxable benefit for the year (<i>voordeel uit sparen en beleggen</i>) is
equal to the product of (x) the total deemed return divided by the sum of bank savings, other investments and liabilities and (y) the
sum of bank savings, other investments and liabilities minus the statutory threshold, and is taxed at a flat rate of 36% (rate for 2024).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deemed return applicable to other investments, including the ordinary shares, is set at 6.04% for the calendar year 2024. Transactions
in the three-month period before and after January 1 of the relevant calendar year implemented to arbitrate between the deemed return
percentages applicable to bank savings, other investments and liabilities will for this purpose be ignored if the holder of ordinary
shares cannot sufficiently demonstrate that such transactions are implemented for other than tax reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current Dutch income tax regime for savings and investments was implemented in Dutch tax law following the decision of the Dutch Supreme
Court (<i>Hoge Raad</i>) of December 24, 2021 (ECLI:NL:2021:1963) (the &#8220;Decision&#8221;). In the Decision, the Dutch Supreme Court
ruled that the (old) system of taxation for savings and investments based on a deemed return may under specific circumstances contravene
with Section 1 of the First Protocol to the European Convention on Human Rights in combination with Section 14 of the European Convention
on Human Rights (the &#8220;EC-Human Rights&#8221;). A new court procedure is pending before the Dutch Supreme Court questioning whether
the current tax system for savings and investments is in line with the Decision. On September 18, 2023 (ECLI:NL:PHR:2023:655) the Attorney
General Wattel concluded that the new tax system is not in line with the Decision, except for the taxation of bank savings, as the system
is, in short, still based on a deemed return rather than actual returns, and as a result, the regime contravenes with the EC-Human Rights.
The decision of the Dutch Supreme Court is expected mid-2024. In addition, on September 8, 2023, the former cabinet published a law proposal
for a new tax system for savings and investments on the basis of actual returns according to an asset accumulation system, the &#8216;Actual
Return Box 3 Act&#8217; (<i>Wet werkelijk rendement box 3</i>). The proposed system is expected to come into effect on January 1, 2027
at the earliest. However, it is up to the new cabinet to submit a final law proposal to the Dutch parliament.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of ordinary shares are advised to consult their own tax advisor to ensure that the tax in respect of the ordinary shares is levied in
accordance with the applicable Dutch tax rules at the relevant time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-residents
of the Netherlands </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of our ordinary shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to Dutch taxes
on income or capital gains in respect of any payment under the ordinary shares or in respect of any gain or loss realized on the disposal
or deemed disposal of the ordinary shares, provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            holder does not have an interest in an enterprise or a deemed enterprise (as defined in the
                                            Dutch Income Tax Act and the Dutch Corporate Income Tax Act 1969) which, in whole or in part,
                                            is either effectively managed in the Netherlands or is carried out through a permanent establishment,
                                            a deemed permanent establishment or a permanent representative in the Netherlands and to
                                            which enterprise or part of an enterprise the ordinary shares are attributable; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the event such holder is an individual, such holder does not carry out any activities in
                                            the Netherlands with respect to the ordinary shares that go beyond ordinary asset management
                                            (<i>normaal, actief vermogensbeheer</i>) and does not derive benefits from the ordinary shares
                                            that are taxable as benefits from other activities in the Netherlands (<i>resultaat uit overige
                                            werkzaamheden</i>).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Gift
and inheritance tax</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Residents
of the Netherlands </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gift
or inheritance taxes will arise in the Netherlands with respect to a transfer of the ordinary shares by way of a gift by, or on the death
of, a holder of our ordinary shares who is resident or deemed to be resident in the Netherlands at the time of the gift or such holder&#8217;s
death.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-residents
of the Netherlands </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Dutch gift or inheritance taxes will arise on the transfer of our ordinary shares by way of gift by, or on the death of, a holder of
the ordinary shares who is neither resident nor deemed to be resident in the Netherlands, unless in the case of a gift of shares by an
individual who at the date of the gift was neither resident nor deemed to be resident in the Netherlands, such individual dies within
180 days after the date of the gift, while being resident or deemed to be resident in the Netherlands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of Dutch gift and inheritance taxes, amongst others, a person that holds the Dutch nationality will be deemed to be resident
in the Netherlands if such person has been resident in the Netherlands at any time during the 10 years preceding the date of the gift
or his/her death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding the Dutch nationality will be deemed
to be resident in the Netherlands if such person has been resident in the Netherlands at any time during the 12 months preceding the
date of the gift. Applicable tax treaties may override deemed residency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
for purposes of Netherlands gift and inheritance tax, a gift that is made under a condition precedent is deemed to have been made at
the moment such condition precedent is satisfied. If the condition precedent is fulfilled after the death of the donor, the gift is deemed
to be made upon the death of the donor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
taxes and duties</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Dutch value added tax and no Dutch registration tax, stamp duty or any other similar documentary tax or duty will be payable by a holder
of our ordinary shares on any payment in consideration for the holding or disposal of the ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a general summary of certain material Dutch tax consequences of the acquisition, holding and disposal of our ordinary shares.
This summary does not purport to describe all possible tax considerations or consequences that may be relevant to a holder or prospective
holder of ordinary shares and does not purport to deal with the tax consequences applicable to all categories of investors, some of which
(such as trusts or similar arrangements) may be subject to special rules. In view of its general nature, this general summary should
be treated with corresponding caution. To the extent this summary relates to legal conclusions under current Netherlands tax law, and
subject to the qualifications it contains, it represents the opinion of NautaDutilh N.V., our special Dutch counsel. Holders or prospective
holders of shares should consult with their own tax advisors with regard to the tax consequences of investing in the shares in their
particular circumstances. The discussion below is included for general information purposes only.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of this discussion, it is assumed that we are a tax resident of Germany under German national tax laws since we intended
to have, from our incorporation and on a continuous basis, our place of effective management in Germany. See Risk Factor &#8220;We may
become taxable in a jurisdiction other than Germany and this may increase the aggregate tax burden on us.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
note that this summary does not describe the Dutch tax considerations for:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
                                            of our ordinary shares if such holders, and in the case of individuals, his or her partner
                                            or certain of their relatives by blood or marriage in the direct line (including foster children),
                                            have a substantial interest (<i>aanmerkelijk belang</i>) or deemed substantial interest (<i>fictief
                                            aanmerkelijk belang</i>) in the Company under the Dutch Income Tax Act 2001 (<i>Wet inkomstenbelasting
                                            2001</i>). Generally speaking, a holder of securities in a company is considered to hold
                                            a substantial interest in such company, if such holder alone or, in the case of individuals,
                                            together with his or her partner (as defined in the Dutch Income Tax Act 2001), directly
                                            or indirectly, holds (i) an interest of 5% or more of the total issued and outstanding capital
                                            of that company or of 5% or more of the issued and outstanding capital of a certain class
                                            of shares of that company; (ii) rights to acquire, directly or indirectly, such interest;
                                            or (iii) certain profit sharing rights in that company that relate to 5% or more of the company&#8217;s
                                            annual profits and/or to 5% or more of the company&#8217;s liquidation proceeds. A deemed
                                            substantial interest may arise if a substantial interest (or part thereof) in a company has
                                            been disposed of, or is deemed to have been disposed of, on a non-recognition basis;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
                                            of our ordinary shares if the shares held by such holders qualify or qualified as a participation
                                            (<i>deelneming</i>) for purposes of the Dutch Corporate Income Tax Act 1969 (<i>Wet op de
                                            vennootschapsbelasting 1969</i>). Generally, a taxpayer&#8217;s shareholding of 5% or more
                                            in a company&#8217;s nominal paid-up share capital (or, in certain cases, in voting rights)
                                            qualifies as participation. A holder may also have a participation if such holder does not
                                            have a shareholding of 5% or more but a related entity (statutorily defined term) has a participation
                                            or if the company in which the shares are held is a related entity (statutorily defined term);</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">holders
                                            of shares who are individuals for whom the shares or any benefit derived from the shares
                                            are a remuneration or deemed to be a remuneration for (employment) activities or services
                                            performed by such holders or certain individuals related to such holders, whether within
                                            or outside an employment relation, that provides the holder, economically speaking, with
                                            certain benefits that have a relation to the relevant work activities or services (as defined
                                            in the Dutch Income Tax Act 2001); and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pension
                                            funds, investment institutions (<i>fiscale beleggingsinstellingen</i>), exempt investment
                                            institutions (<i>vrijgestelde beleggingsinstellingen</i>) (as defined in the Dutch Corporate
                                            Income Tax Act 1969) and other entities that are, in whole or in part, not subject to or
                                            exempt from corporate income tax in the Netherlands, as well as entities that are exempt
                                            from corporate income tax in their country of residence, such country of residence being
                                            another state of the European Union, Norway, Liechtenstein, Iceland or any other state with
                                            which the Netherlands have agreed to exchange information in line with international standards.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, this summary only addresses Dutch national tax legislation and published regulations, whereby the Netherlands
and Dutch law means the part of the Kingdom of the Netherlands located in Europe and its law respectively, as in effect on the date hereof
and as interpreted in published case law (of the Dutch Supreme Court (<i>Hoge Raad der Nederlanden</i>)) until this date, without prejudice
to any amendment introduced (or to become effective) at a later date and/or implemented with or without retroactive effect. The applicable
tax laws or interpretations thereof may change, or the relevant facts and circumstances may change, and such changes may affect the contents
of this section, which will not be updated to reflect any such changes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion is for general information purposes and is not tax advice or a complete description of all Dutch tax consequences relating
to the acquisition, holding and disposal of our shares. Holders or prospective holders of our shares should consult their own tax advisor
regarding the tax consequences relating to the acquisition, holding and disposal of our shares in light of their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividend
withholding tax</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the Netherlands, and therefore a Dutch tax resident for Dutch domestic tax law purposes, including
the Dutch Dividend Withholding Tax Act 1969. As such, we are required to withhold Dutch dividend withholding tax at a rate of 15% from
dividends distributed by us (which withholding tax will not be borne by us but will be withheld by us from the gross dividends paid on
the shares). We are however also treated as a German tax resident for German domestic tax law purposes, since our place of effective
management is located in Germany. As long as we continue to have our place of effective management in Germany, and not in the Netherlands,
under the convention between the Federal Republic of Germany and the Netherlands for the avoidance of double taxation with respect to
taxes on income of 2012, we will be considered to be exclusively tax resident in Germany. Consequently, the Netherlands will be restricted
to impose Dutch dividend withholding tax on dividends distributed by us (we will not be required to withhold Dutch dividend withholding
tax). This exemption from withholding does not apply to dividends distributed by us to a holder of our ordinary shares who is resident
or deemed to be resident in the Netherlands for Dutch income tax purposes or Dutch corporation tax purposes or to a holder of our ordinary
shares that is neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable to a Dutch permanent
establishment of such non-resident holder, in which events the following applies. See Risk Factor &#8220;If we ever pay dividends, we
may need to withhold tax on such dividends payable to holders of our shares in both Germany and the Netherlands.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed by us to individuals and corporate legal entities who are resident or deemed to be resident in the Netherlands for Dutch
tax purposes (&#8220;Dutch Resident Individuals&#8221; and &#8220;Dutch Resident Entities&#8221; as the case may be) or to holders of
our ordinary shares that are neither resident nor deemed to be resident of the Netherlands if the ordinary shares are attributable to
a Dutch permanent establishment of such non-resident holder are subject to Dutch dividend withholding tax at a rate of 15%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expression &#8220;dividends distributed&#8221; includes, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">distributions
                                            in cash or in kind, deemed and constructive distributions and repayments of paid-in capital
                                            not recognized for Dutch dividend withholding tax purposes;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">liquidation
                                            proceeds, proceeds of redemption of shares, or proceeds of the repurchase of shares by us
                                            or one of our subsidiaries or other affiliated entities to the extent such proceeds exceed
                                            the average paid-in capital of those shares as recognized for purposes of Dutch dividend
                                            withholding tax, unless in case of a repurchase, a particular statutory exemption applies;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            amount equal to the par value of shares issued or an increase of the par value of shares,
                                            to the extent that it does not appear that a contribution, recognized for purposes of Dutch
                                            dividend withholding tax, has been made or will be made; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partial
                                            repayment of the paid-in capital, recognized for purposes of Dutch dividend withholding tax,
                                            if and to the extent that we have net profits (<i>zuivere winst</i>), unless the holders
                                            of shares have resolved in advance at a general meeting to make such repayment and the par
                                            value of the shares concerned has been reduced by an equal amount by way of an amendment
                                            of our Articles of Association.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dutch
Resident Individuals and Dutch Resident Entities can generally credit the Dutch dividend withholding tax against their income tax or
corporate income tax liability. The same applies to holders of our ordinary shares that are neither resident nor deemed to be resident
of the Netherlands if the shares are attributable to a Dutch permanent establishment of such non-resident holder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to legislation to counteract &#8220;dividend stripping,&#8221; a reduction, exemption, credit or refund of Dutch dividend withholding
tax is denied if the recipient of the dividend is not the beneficial owner (<i>uiteindelijk gerechtigde</i>) as described in the Dutch
Dividend Withholding Tax Act 1965 (<i>Wet op de dividendbelasting 1965</i>). This legislation generally targets situations in which a
shareholder retains its economic interest in shares but reduces the withholding tax costs on dividends by a transaction with another
party. It is not required for these rules to apply that the recipient of the dividends is aware that a dividend stripping transaction
took place. The Dutch State Secretary for Finance takes the position that the definition of beneficial ownership introduced by this legislation
will also apply in the context of a double taxation convention.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Conditional
withholding tax on dividends (as of January 1, 2024)</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
it cannot be excluded that dividends distributed by us to certain related entities which are not resident in the Netherlands for Dutch
tax purposes will become subject to a Dutch conditional withholding tax in certain specific situations (see below), irrespectively of
the fact that we have our place of effective management in Germany and, therefore, are a tax resident of Germany under German national
tax laws. As of January 1, 2024, a Dutch conditional withholding tax will be imposed on dividends distributed by us to related entities
(<i>gelieerd</i>) resident in certain listed jurisdictions or in case of abusive arrangements (all within the meaning of the Dutch Withholding
Tax Act 2021; <i>Wet bronbelasting 2021</i>). The Dutch conditional withholding tax on dividends will be imposed at the highest Dutch
corporate income tax rate in effect at the time of the distribution (2022: 25.8%). The Dutch conditional withholding tax on dividends
will be reduced, but not below zero, by any regular Dutch dividend withholding tax withheld in respect of the same dividend distribution.
As such, based on the currently applicable rates, the overall effective tax rate of withholding the regular Dutch dividend withholding
tax (as described above) and the Dutch conditional withholding tax on dividends will not exceed the highest corporate income tax rate
in effect at the time of the distribution (2022: 25.8%).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxes
on income and capital gains</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dutch
resident entities</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
benefit derived or deemed to be derived from the shares held by a Dutch Resident Entity, including any capital gains realized on the
disposal thereof, will generally be subject to Dutch corporate income tax at a rate of 19% with respect to taxable profits up to &#8364;200,000
and 25.8% with respect to taxable profits in excess of that amount (rates and brackets for 2023).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dutch
resident individuals</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a holder of shares is a Dutch Resident Individual, any benefit derived or deemed to be derived from the ordinary shares is taxable at
the progressive income tax rates (with a maximum of 49.5%, rate for 2023), if:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ordinary shares are attributable to an enterprise from which the holder of such shares derives
                                            a share of the profit, whether as an entrepreneur (<i>ondernemer</i>) or as a person who
                                            has a co-entitlement to the net worth (<i>medegerechtigd tot het vermogen</i>) of such enterprise,
                                            without being a shareholder, as defined in the Dutch Income Tax Act 2001); or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            holder of the ordinary shares is considered to perform activities with respect to such shares
                                            that go beyond ordinary asset management (<i>normaal, actief vermogensbeheer</i>) or derives
                                            benefits from the shares that are taxable as benefits from other activities (<i>resultaat
                                            uit overige werkzaamheden</i>).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of savings and investments</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the above-mentioned conditions (i) and (ii) do not apply to the Dutch Resident Individual, the ordinary shares will be subject to an
annual Dutch income tax under the regime for savings and investments (<i>inkomen uit sparen en beleggen</i>). Taxation only occurs insofar
the Dutch Resident Individual&#8217;s net investment assets for the year exceed a statutory threshold (<i>heffingvrij vermogen</i>).
The net investment assets for the year are the fair market value of the investment assets less the fair market value of the liabilities
on January 1 of the relevant calendar year (reference date; <i>peildatum</i>). The ordinary shares are included as investment assets.
The taxable benefit for the year (<i>voordeel uit sparen en beleggen</i>) is taxed at a flat rate of 32% (rate for 2023). Actual income
or capital gains realized in respect of the ordinary shares are as such not subject to Dutch income tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
taxable benefit for the year is calculated as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Dutch Resident Individual&#8217;s assets and liabilities taxed under this regime, including
                                            the ordinary shares, are allocated over the following three categories: (a) bank savings,
                                            (b) other investments, including the ordinary shares, and (c) liabilities.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            return (<i>rendement</i>) in respect of these assets and liabilities is calculated as follows
                                            (the return is at a minimum nihil):</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            deemed return on the fair market value of the actual amount of bank savings and cash on January
                                            1 of the relevant calendar year; plus</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            deemed return on the fair market value of the actual amount of other investments, including
                                            the ordinary shares, on January 1 of the relevant calendar year; minus</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            deemed return on the sum of the fair market value of the actual amount of liabilities on
                                            January 1 of the relevant calendar year less the statutory threshold for liabilities (<i>drempel</i>).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            return percentage (%) (<i>rendementspercentage</i>) is calculated as follows:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">by
                                            dividing the return calculated under (ii) above by the net investment assets for the year
                                            of the Dutch Resident Individual; multiplied by 100.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            taxable base (<i>grondslag sparen en beleggen</i>) is calculated as follows:</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            net investment assets for the year of the Dutch Resident Individual; minus</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            applicable statutory threshold.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            taxable benefit for the year is equal to the taxable base calculated under (iv) above multiplied
                                            by the return percentage calculated under (iii) above.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the date hereof, the deemed returns for the different investment categories mentioned under (ii) above have been temporarily set at:
(a) 0.01%, (b) 5.69% and (c) 2.46%. The definitive percentages for the year 2023 will be published in the first months of 2024 and will
have retroactive effect to January 1, 2023. Transactions in the three-month period before and after January 1 of the relevant calendar
year implemented to arbitrate between the deemed return percentages applicable to bank savings, other investments and liabilities will
for this purpose be ignored if the holder of ordinary shares cannot sufficiently demonstrate that such transactions are implemented for
other than tax reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-residents
of the Netherlands</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
holder of our ordinary shares that is neither a Dutch Resident Entity nor a Dutch Resident Individual will not be subject to Dutch taxes
on income or capital gains in respect of any payment under the ordinary shares or in respect of any gain or loss realized on the disposal
or deemed disposal of the ordinary shares, provided that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
                                            holder does not have an interest in an enterprise or a deemed enterprise (as defined in the
                                            Dutch Income Tax Act and the Dutch Corporate Income Tax Act 1969) which, in whole or in part,
                                            is either effectively managed in the Netherlands or is carried out through a permanent establishment,
                                            a deemed permanent establishment or a permanent representative in the Netherlands and to
                                            which enterprise or part of an enterprise the ordinary shares are attributable; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            the event such holder is an individual, such holder does not carry out any activities in
                                            the Netherlands with respect to the ordinary shares that go beyond ordinary asset management
                                            (<i>normaal, actief vermogensbeheer</i>) and does not derive benefits from the ordinary shares
                                            that are taxable as benefits from other activities in the Netherlands (<i>resultaat uit overige
                                            werkzaamheden</i>).</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gift
and inheritance tax</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Residents
of the Netherlands</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gift
or inheritance taxes will arise in the Netherlands with respect to a transfer of the ordinary shares by way of a gift by, or on the death
of, a holder of our ordinary shares who is resident or deemed to be resident in the Netherlands at the time of the gift or such holder&#8217;s
death.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-residents
of the Netherlands</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Dutch gift or inheritance taxes will arise on the transfer of our ordinary shares by way of gift by, or on the death of, a holder of
the ordinary shares who is neither resident nor deemed to be resident in the Netherlands, unless in the case of a gift of shares by an
individual who at the date of the gift was neither resident nor deemed to be resident in the Netherlands, such individual dies within
180 days after the date of the gift, while being resident or deemed to be resident in the Netherlands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of Dutch gift and inheritance taxes, amongst others, a person that holds the Dutch nationality will be deemed to be resident
in the Netherlands if such person has been resident in the Netherlands at any time during the 10 years preceding the date of the gift
or his/her death. Additionally, for purposes of Dutch gift tax, amongst others, a person not holding the Dutch nationality will be deemed
to be resident in the Netherlands if such person has been resident in the Netherlands at any time during the 12 months preceding the
date of the gift. Applicable tax treaties may override deemed residency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
for purposes of Netherlands gift and inheritance tax, a gift that is made under a condition precedent is deemed to have been made at
the moment such condition precedent is satisfied. If the condition precedent is fulfilled after the death of the donor, the gift is deemed
to be made upon the death of the donor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
taxes and duties&#160;</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
Dutch value added tax and no Dutch registration tax, stamp duty or any other similar documentary tax or duty will be payable by a holder
of our ordinary shares on any payment in consideration for the holding or disposal of the ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>7.
Material German tax Considerations</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following section is a description of the material German tax considerations that become relevant when purchasing, holding or transferring
the Company&#8217;s shares. The Company has its sole place of management in Germany and, therefore, qualifies as a corporation subject
to German unlimited corporate income taxation; however, because a company&#8217;s tax residency depends on future facts regarding the
location in which the company is managed and controlled the German unlimited corporate income tax liability may change in the future.
This section does not set forth all German tax aspects that may be relevant for shareholders. The section is based on the German tax
law applicable as of the date of this document. It should be noted that the law may change following the date of this Annual Report and
that such changes may have retroactive effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
material German tax principles of purchasing, owning and transferring of shares are set forth in the following. This section does not
purport to be a comprehensive or complete analysis or listing of all potential tax effects of the purchase, ownership or disposition
of shares and does not set forth all tax considerations that may be relevant to a particular person&#8217;s decision to acquire ordinary
shares. All of the following is subject to change. Such changes could apply retroactively and could affect the consequences set forth
below. This section does not refer to any foreign account tax compliance act (or FATCA) aspects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders
are advised to consult their own tax advisers with regard to the application of German tax law to their particular situations, in particular
with respect to the procedure to be complied with to obtain a relief of withholding tax on dividends and on capital gains (<i>Kapitalertragsteuer</i>)
and with respect to the influence of double tax treaty provisions, as well as any tax consequences arising under the laws of any state,
local or other foreign jurisdiction. For German tax purposes, a shareholder may include an individual who or an entity that does not
have the legal title to the shares, but to whom nevertheless the shares are attributed, based either on such individual or entity owning
a beneficial interest in the shares or based on specific statutory provisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section does not constitute particular tax advice. Potential purchasers of the Company&#8217;s shares are urged to consult their own
tax advisers regarding the tax consequences of the purchase, ownership and disposition of shares in light of their particular circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Taxation
of dividends</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding
tax on dividends&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
distributed from a company to its shareholders are subject to withholding tax, subject to certain exemptions (for example, repayments
of capital from the tax equity account (<i>steuerliches Einlagekonto</i>)), as further described. The withholding tax rate is 25% plus
a 5.5% solidarity surcharge (<i>Solidarit&#228;tszuschlag</i>) thereon (for a total of 26.375%) of the gross dividend approved by the
ordinary shareholders&#8217; meeting. Withholding tax is to be withheld and passed on for the account of the shareholders by a domestic
branch of a domestic or foreign credit or financial services institution&#160;(<i>Kredit- und Finanzdienstleistungsinstitut</i>), by the domestic
securities trading company (<i>inl&#228;ndisches Wertpapierhandelsunternehmen</i>) or a domestic securities trading bank (<i>inl&#228;ndische
Wertpapierhandelsbank</i>) which keeps and administers the shares and disburses or credits the dividends or disburses the dividends to
a foreign agent, or by the securities custodian bank (<i>Wertpapiersammelbank</i>) to which the shares were entrusted for collective
custody if the dividends are distributed to a foreign agent by such securities custodian bank (which is referred to as the &#8220;Dividend
Paying Agent&#8221;). In case the shares are not held in collective deposit with a Dividend Paying Agent, the Company is responsible
for withholding and remitting the tax to the competent tax office.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
withholding tax is levied and withheld irrespective of whether and to what extent the dividend distribution is taxable at the level of
the shareholder and whether the shareholder is a person residing in Germany or in a foreign country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of dividends distributed to a company within the meaning of Art. 2 of the amended EU Directive 2011/96/EU of the Council of
November 30, 2011, or the EU Parent Subsidiary Directive, domiciled in another Member State of the European Union, an exemption from
the withholding tax will be granted upon request if further prerequisites are satisfied (<i>Freistellung im Steuerabzugsverfahren</i>).
This also applies to dividends distributed to a permanent establishment located in another Member State of the European Union of such
a parent company or of a parent company tax resident in Germany if the participation in the Company is effectively connected with this
permanent establishment. The key prerequisite for the application of the EU Parent Subsidiary Directive is that the shareholder has held
a direct participation in the share capital of the Company of at least 10% for at least one year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
withholding tax on distributions to other foreign resident shareholders is reduced in accordance with a double taxation treaty if Germany
has concluded such double taxation treaty with the country of residence of the shareholder and if the shareholder does not hold his shares
either as part of the assets of a permanent establishment or a fixed place of business in Germany or as business assets for which a permanent
representative has been appointed in Germany. The reduction of the withholding tax is procedurally granted in such a manner that the
difference between the total amount withheld, including the solidarity surcharge, and the tax liability determined on the basis of the
tax rate set forth in the applicable double taxation treaty (15% unless further qualifications are met) is refunded by the German tax
administration upon request (Federal Central Office for Taxes (<i>Bundeszentralamt f&#252;r Steuern</i>), main office in Bonn-Beuel,
An der K&#252;ppe 1, D-53225 Bonn).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the case of dividends received by corporations whose statutory seat and effective place of management are not located in Germany and
who are therefore not tax resident in Germany, two-fifths of the withholding tax deducted and remitted are refunded without the need
to fulfill all prerequisites required for such refund under the EU Parent Subsidiary Directive or under a double taxation treaty or if
no double taxation treaty has been concluded between Germany and the state of residence of the shareholder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to receive a refund pursuant to a double taxation treaty or the aforementioned option for foreign corporations, the shareholder
has to submit a completed form for refund (available at the Federal Central Office for Taxes (www.bzst.de) as well as at the German embassies
and consulates) together with a withholding tax certificate (<i>Kapitalertragsteuerbescheinigung</i>) issued by the institution that
withheld the tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability of an exemption from withholding tax in accordance with the EU Parent Subsidiary Directive or a double tax treaty and the
aforementioned options for a refund of the withholding tax (with or without protection under a double taxation treaty) depends on whether
certain additional prerequisites are fulfilled. The applicable withholding tax relief will only be granted if the preconditions of the
German anti-avoidance rules (or &#8220;Directive Override&#8221; or &#8220;Treaty Override&#8221;), in particular Section&#8239;50d,
paragraph&#8239;3 of the German Income Tax Act (<i>Einkommensteuergesetz</i>), are fulfilled.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned reductions of (or exemptions from) withholding tax are further restricted if (i) the applicable double taxation treaty
provides for a tax reduction resulting in an applicable tax rate of less than 15% and (ii) the shareholder is not a corporation that
directly holds at least 10% in the equity capital of the Company and is subject to tax on its income and profits in its state of residence
without being exempt. In this case, the reduction of (or exemption from) withholding tax is subject to the following three cumulative
prerequisites: (i) the shareholder must qualify as beneficial owner of the shares in the Company for a minimum holding period of 45 consecutive
days occurring within a period of 45 days prior and 45 days after the due date of the dividends, (ii) the shareholder has to bear at
least 70% of the change in value risk related to the shares in the Company during the minimum holding period without being directly
or indirectly hedged, and (iii) the shareholder must not be required to fully or largely compensate directly or indirectly the dividends
to third parties. However, these further prerequisites do not apply if the shareholder has been the beneficial owner of the shares in
the Company for at least one uninterrupted year upon receipt of the dividends. Furthermore, the special rules on the restriction of withholding
tax credit do not apply to a shareholder whose overall dividend earnings within an assessment period do not exceed &#8364;20,000 or that
has been the beneficial owner of the shares in the Company for at least one uninterrupted year upon receipt of the dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
individual or corporate shareholders tax resident outside Germany not holding the shares through a permanent establishment (<i>Betriebsst&#228;tte</i>)
in Germany or as business assets (<i>Betriebsverm&#246;gen</i>) for which a permanent representative (<i>st&#228;ndiger Vertreter</i>)
has been appointed in Germany, the remaining and paid withholding tax (if any) is final (i.e., not refundable) and settles the shareholder&#8217;s
limited tax liability in Germany. For individual or corporate shareholders tax resident in Germany (for example, those shareholders whose
residence, domicile, registered office or place of management is located in Germany) holding their shares as business assets, as well
as for shareholders tax resident outside of Germany holding their shares through a permanent establishment in Germany or as business
assets for which a permanent representative has been appointed in Germany, the withholding tax withheld (including solidarity surcharge)
can be credited against the shareholder&#8217;s personal income tax or corporate income tax liability in Germany. Any withholding tax
(including solidarity surcharge) in excess of such tax liability is refunded. For individual shareholders tax resident in Germany holding
the Company&#8217;s shares as private assets, the withholding tax is a final tax (<i>Abgeltungsteuer</i>), subject to the exceptions
described in the following section.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to special rules on the restriction of withholding tax credit, the credit of withholding tax is subject to the following three cumulative
prerequisites: (i) the shareholder must qualify as beneficial owner of the shares in the Company for a minimum holding period of 45 consecutive
days occurring within a period of 45 days prior and 45 days after the due date of the dividends, (ii) the shareholder has to bear at
least 70% of the change in value risk related to the shares in the Company during the minimum holding period without being directly or
indirectly hedged, and (iii) the shareholder must not be required to fully or largely compensate directly or indirectly the dividends
to third parties. Absent of the fulfillment of all of the three prerequisites, three-fifths of the withholding tax imposed on the dividends
must not be credited against the shareholder&#8217;s (corporate) income tax liability, but may, upon application, be deducted from the
shareholder&#8217;s tax base for the relevant assessment period. A shareholder that has received gross dividends without any deduction
of withholding tax due to a tax exemption without qualifying for a full tax credit has to notify the competent local tax office accordingly
and has to make a payment in the amount of the omitted withholding tax deduction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of dividend income of shareholders tax resident in Germany holding the Company&#8217;s shares as private assets</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
individual shareholders (individuals) resident in Germany holding the Company&#8217;s shares as private assets, dividends are subject
to a flat rate tax which is satisfied by the withholding tax actually withheld (<i>Abgeltungsteuer</i>). Accordingly, dividend income
will be taxed at a flat tax rate of 25% plus 5.5% solidarity surcharge thereon (in total 26.375%) and church tax (<i>Kirchensteuer</i>)
in case the shareholder is subject to church tax because of his individual circumstances. An automatic procedure for deduction of church
tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder has filed a blocking notice (<i>Sperrvermerk</i>)
with the German Federal Tax Office (details related to the computation of the concrete tax rate including church tax are to be discussed
with the individual tax adviser of the relevant shareholder). Except for an annual lump sum savings allowance (<i>Sparer-Pauschbetrag</i>)
of up to &#8364;1,000 (for individual filers) or up to &#8364;2,000 (for married couples and for partners in accordance with the registered
partnership law (<i>Gesetz &#252;ber die Eingetragene Lebenspartnerschaft</i>) filing jointly), private individual shareholders will
not be entitled to deduct expenses incurred in connection with the capital investment from their dividend income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
income tax owed for the dividend income is satisfied by the withholding tax withheld by the Dividend Paying Agent. However, if the flat
tax results in a higher tax burden as opposed to the private shareholder&#8217;s individual tax rate, the private shareholder can opt
for taxation at his individual personal income tax rate. In that case, the final withholding tax will be credited against the income
tax. However, pursuant to the German tax authorities and a court ruling, private shareholders are nevertheless not entitled to deduct
expenses incurred in connection with the capital investment from their income. The option can be exercised only for all capital income
from capital investments received in the relevant assessment period uniformly and married couples as well as partners in accordance with
the registered partnership law filing jointly may only jointly exercise the option.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exceptions
from the flat rate tax (satisfied by withholding at source) (<i>Abgeltungsteuer</i>) may apply&#8212;that is,&#160;only upon application&#8212;for
shareholders who have a shareholding of at least 25% in a company and for shareholders who have a shareholding of at least 1% in the
Company, work for that company in a professional capacity and have a material influence in the economic activity of aforementioned company.
In such a case, the same rules apply as for sole proprietors holding the shares as business assets (see below &#8220;&#8212;Taxation
of dividend income of shareholders tax resident in Germany holding the Company&#8217;s shares as business assets&#8212;(ii) Sole proprietors&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of dividend income of shareholders tax resident in Germany holding the Company&#8217;s shares as business assets</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder holds the Company&#8217;s shares as business assets, the taxation of the dividend income depends on whether the respective
shareholder is a corporation, a sole proprietor or a partnership.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(a)
Corporations</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
income of corporate shareholders is exempt from corporate income tax, provided that the incorporated entity holds a direct participation
of at least 10% in the share capital of a company at the beginning of the calendar year in which the dividends are paid. The acquisition
of a participation of at least 10% in the course of a calendar year is deemed to have occurred at the beginning of such calendar year
for the purpose of this rule. Participations in the share capital of the Company which a corporate shareholder holds through a partnership,
including co-entrepreneurships (<i>Mitunternehmerschaften</i>), are attributable to such corporate shareholder only on a pro rata basis
at the ratio of the interest share of the corporate shareholder in the assets of the relevant partnership. However, 5% of the tax exempt
dividends are deemed to be non-deductible business expenses for tax purposes and therefore are subject to corporate income tax (plus
solidarity surcharge) and trade tax; i.e.&#8239;tax exemption of 95%. Business expenses incurred in connection with the dividends received
are entirely tax deductible.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
trade tax purposes the entire dividend income is subject to trade tax (i.e.&#8239;the tax exempt dividends must be added back when determining
the trade taxable income), unless the corporation shareholder holds at least 15% of the Company&#8217;s registered share capital at the
beginning of the relevant tax assessment period (<i>Erhebungszeitraum</i>). In case of an indirect participation <i>via</i> a partnership
please refer to the section &#8220;Partnerships&#8221; below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the shareholding is below 10% in the share capital, dividends are taxable at the applicable corporate income tax rate of 15% plus 5.5%
solidarity surcharge thereon and trade tax (the rate of which depends on the municipalities the corporate shareholder resides in).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
regulations apply which abolish the 95% tax exemption, if the Company&#8217;s shares are held as trading portfolio assets in the
meaning of Section 340e German commercial code (<i>Handelsgesetzbuch</i>) by (i) a credit institution (<i>Kreditinstitut</i>), (ii)
a security institution (<i>Wertpapierinstitut), </i>(iii) a financial service institution (<i>Finanzdienstleistungsinstitut</i>), or
(iv) a financial enterprise within the meaning of the German Banking Act (<i>Kreditwesengesetz</i>), in case more than 50% of the
shares of such financial enterprise are held directly or indirectly by a credit institution, a security institution or a financial
service institution, as well as by a life insurance company, a health insurance company or a pension fund in case the shares are
attributable to the capital investments, resulting in fully taxable income.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(b)
Sole proprietors</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
sole proprietors (individuals) resident in Germany holding shares as business assets dividends are subject to the partial income rule
(<i>Teileink&#252;nfteverfahren</i>). Accordingly, only (i) 60% of the dividend income will be taxed at his/her individual personal income
tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend
income are deductible for tax purposes. In addition, the dividend income is entirely subject to trade tax if the shares are held as business
assets of a permanent establishment in Germany within the meaning of the GewStG, unless the shareholder holds at least 15% of the Company&#8217;s
registered share capital at the beginning of the relevant assessment period. The trade tax levied will be eligible for credit against
the shareholder&#8217;s personal income tax liability based on the applicable municipal trade tax rate and the individual tax situation
of the shareholder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(c)
Partnerships</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax (Unless the
option according to section&#160;1a of the German Corporate Income Tax Act was applied for that the partnership is taxed as a corporation).
In this regard, corporate income tax or personal income tax (and church tax, if applicable) as well as solidarity surcharge are levied
only at the level of the partner with respect to their relevant part of the profit and depending on their individual circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the partner is a corporation, the dividend income will be subject to corporate income tax plus solidarity surcharge (see &#8220;&#8212;(i) Corporations&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the partner is a sole proprietor (individual), the dividend income will be subject to the partial income rule (see &#8220;&#8212;(ii) Sole proprietors&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dividend income is subject to trade tax at the level of the partnership (provided that the partnership is liable to trade tax), unless
the partnership holds at least 15% of a company&#8217;s registered share capital at the beginning of the relevant assessment period,
in which case the dividend income is exempt from trade tax. There are no clear statutory provisions concerning the taxation of dividends
with regard to a corporate shareholder of the partnership. However, trade tax will be levied on 5% of the dividends to the extent they
are attributable to the shares of such corporate partners to whom at least 10% of the shares of the Company are attributable on a look-through
basis, since such portion of the dividends will be deemed to be&#160;non-deductible business expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax situation, the trade tax paid
at the level of the partnership is partly or entirely be credited against the partner&#8217;s personal income tax liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case of a corporation being a partner, special regulations will apply with respect to trading portfolio assets of credit institutions,
security institution, financial service institutions or financial enterprises within the meaning of the German Banking Act (<i>Kreditwesengesetz</i>)
or life insurance companies, health insurance companies or pension funds (see &#8220;&#8212;(i) Corporations&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,
the actual trade tax charge, if any, at the level of the partnership depends on the shareholding quota of the partnership and the nature
of the partners (e.g.&#8239;individual or corporation).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of dividend income of shareholders tax resident outside of Germany</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
foreign individual or corporate shareholders tax resident outside of Germany not holding the shares through a permanent establishment
in Germany or as business assets for which a permanent representative has been appointed in Germany, the deducted withholding tax (possibly
reduced by way of a tax relief under a double tax treaty or domestic tax law, such as in connection with the EU Parent Subsidiary Directive)
is final (that is, not refundable) and settles the shareholder&#8217;s limited tax liability in Germany, unless the shareholder is entitled
to apply for a withholding tax refund or exemption.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
contrast, individual or corporate shareholders tax resident outside of Germany holding the Company&#8217;s shares through a permanent
establishment in Germany or as business assets for which a permanent representative has been appointed in Germany are subject to the
same rules as applicable (and described above) to shareholders resident in Germany holding the shares as business assets. The withholding
tax withheld (including solidarity surcharge) is credited against the shareholder&#8217;s personal income tax or corporate income tax
liability in Germany.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>8.
Taxation of capital gains</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding
tax on capital gains</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
individual shareholders (individuals) resident in Germany holding shares as private assets, capital gains realized on the disposal
of shares are subject to final withholding tax. Accordingly, capital gains will be taxed at a flat tax rate of 25% plus 5.5%
solidarity surcharge thereon (in total 26.375%) and church tax, in case the shareholder is subject to church tax because of his
individual circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being
subject to church tax unless the shareholder has filed a blocking notice (<i>Sperrvermerk</i>) with the German Federal Tax Office
(details related to the computation of the concrete tax rate including church tax are to be discussed with the individual tax
adviser of the relevant shareholder). The taxable capital gain is calculated by deducting the acquisition costs of the shares and
the expenses directly related to the disposal from the proceeds of the disposal. Apart from that, except for an annual lump sum
savings allowance&#160;(<i>Sparer-Pauschbetrag</i>)&#160;of up to &#8364;<span style="text-decoration:underline;text-decoration: none">1,000 </span>(for individual filers) or up to &#8364;<span style="text-decoration:underline;font-family: Times New Roman, Times, Serif; text-decoration: none">2</span>,<span style="text-decoration:underline;font-family: Times New Roman, Times, Serif; text-decoration: none">000 </span>(for
married couples and for partners in accordance with the registered partnership law (<i>Gesetz &#252;ber die Eingetragene
Lebenspartnerschaft</i>) filing jointly), private individual shareholders will not be entitled to deduct expenses incurred in
connection with the capital investment from their capital gain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of capital gains realized by shareholders tax resident in Germany holding shares as private assets</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
individual shareholders (individuals) resident in Germany holding shares as private assets, capital gains realized on the disposal of
shares are subject to final withholding tax. Accordingly, capital gains will be taxed at a flat tax rate of 25% plus 5.5% solidarity
surcharge thereon (in total 26.375%) and church tax, in case the shareholder is subject to church tax because of his individual circumstances.
An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless
the shareholder has filed a blocking notice (<i>Sperrvermerk</i>) with the German Federal Tax Office (details related to the computation
of the concrete tax rate including church tax are to be discussed with the individual tax adviser of the relevant shareholder). The taxable
capital gain is calculated by deducting the acquisition costs of the shares and the expenses directly related to the disposal from the
proceeds of the disposal. Apart from that, except for an annual lump sum savings allowance (<i>Sparer-&#160;Pauschbetrag</i>) of up to &#8364;801
(for individual filers) or up to &#8364;1,602 (for married couples and for partners in accordance with the registered partnership law
(<i>Gesetz &#252;ber die Eingetragene Lebenspartnerschaft</i>) filing jointly), private individual shareholders will not be entitled
to deduct expenses incurred in connection with the capital investment from their capital gain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case the flat tax results in a higher tax burden as opposed to the private shareholder&#8217;s individual tax rate the private shareholder
can opt for taxation at his individual personal income tax rate. In that case, the withholding tax (including solidarity surcharge) withheld
will be credited against the income tax. However, pursuant to the German tax authorities the private shareholders are nevertheless not
entitled to deduct expenses incurred in connection with the capital investment from their income. The option can be exercised only for
all capital income from capital investments received in the relevant assessment period uniformly and married couples as well as for partners
in accordance with the registered partnership law filing jointly may only jointly exercise the option.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
losses arising from the sale of the shares can only be offset against other capital gains resulting from the disposition of the shares
or shares in other stock corporations during the same calendar year. Offsetting of overall losses with other income (such as business
or rental income) and other capital income is not possible. Such losses are to be carried forward and to be offset against positive capital
gains deriving from the sale of shares in stock corporations in future years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
final withholding tax will not apply if the seller of the shares or in case of gratuitous transfer, its legal predecessor has held, directly
or indirectly, at least 1% of the Company&#8217;s registered share capital at any time during the five years prior to the disposal. In
that case capital gains are subject to the partial income rule. Accordingly, only (i) 60% of the capital gains will be taxed at his individual
personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses
related to the capital gains are deductible for tax purposes. The withholding tax withheld (including solidarity surcharge) will be credited
against the shareholder&#8217;s personal income tax liability in Germany.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of capital gains realized by shareholders tax resident in Germany holding the Company&#8217;s shares as business assets&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a shareholder holds shares as business assets, the taxation of capital gains realized on the disposal of such shares depends on whether
the respective shareholder is a corporation, a sole proprietor or a partnership:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(a)
Corporations</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized on the disposal of shares by a corporate shareholder are generally exempt from corporate income tax and trade tax. However,
5% of the tax exempt capital gains are deemed to be non-deductible business expenses for tax purposes and therefore are subject to corporate
income tax (plus solidarity surcharge) and trade tax; i.e., tax exemption of 95%. Business expenses incurred in connection with the
capital gains are entirely tax deductible.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
losses incurred upon the disposal of shares or other impairments of the share value are not tax deductible. A reduction of profit is
also defined as any losses incurred in connection with a loan or security in the event the loan or the security is granted by a shareholder
or by a related party thereto or by a third person with the right of recourse against the before mentioned persons and the shareholder
holds directly or indirectly more than 25% of the company&#8217;s registered share capital.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
regulations apply, if the shares are held as trading portfolio assets by a credit institution, a security institution, a financial service
institution or a financial enterprise within the meaning of the German Banking Act (<i>Kreditwesengesetz</i>) as well as by a life insurance
company, a health insurance company or a pension fund (see &#8220;&#8212;(i) Corporations&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(b)
Sole proprietors</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the shares are held by a sole proprietor, capital gains realized on the disposal of the shares are subject to the partial income rule.
Accordingly, only (i) 60% of the capital gains will be taxed at his /her individual personal income tax rate plus 5.5% solidarity surcharge
thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend income are deductible for tax purposes.
In addition, 60% of the capital gains are subject to trade tax if the shares are held as business assets of a permanent establishment
in Germany within the meaning of the GewStG. The trade tax levied, depending on the applicable municipal trade tax rate and the individual
tax situation, is partly or entirely credited against the shareholder&#8217;s personal income tax liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(c)
Partnerships</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
case the shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax as well
as solidarity surcharge (and church tax) since partnerships qualify as transparent for German tax purposes (Unless the option according
to section&#160;1a of the German Corporate Income Tax Act was applied for that the partnership is taxed as a corporation). In this regard,
corporate income tax or personal income tax as well as solidarity surcharge (and church tax, if applicable) are levied only at the level
of the partner with respect to their relevant part of the profit and depending on their individual circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the partner is a corporation, the capital gains will be subject to corporate income tax plus solidarity surcharge (see &#8220;&#8212;(i)
Corporations&#8221;). Trade tax will be levied additionally at the level of the partner insofar as the relevant profit of the partnership
is not subject to trade tax at the level of the partnership. However, with respect to both corporate income and trade tax, the 95%-exemption
rule as described above applies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the partner is a sole proprietor (individual), the capital gains are subject to the partial income rule (see &#8220;&#8212;(ii) Sole
proprietors&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the partnership is liable to trade tax, 60% of the capital gains are subject to trade tax at the level of the partnership,
to the extent the partners are individuals, and 5% of the capital gains are subject to trade tax, to the extent the partners are corporations.
However, if a partner is an individual, depending on the applicable municipal trade tax rate and the individual tax situation, the trade
tax paid at the level of the partnership is credited against the partner&#8217;s personal income tax liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regard to corporate partners, special regulations apply if they are held as trading portfolio assets by credit institutions, a security
institution, financial service institutions or financial enterprises within the meaning of the German Banking Act or life insurance companies,
health insurance companies or pension funds, as described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><i>(d)
Taxation of capital gains realized by shareholders tax resident outside of Germany</i></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
gains realized on the disposal of the shares by a shareholder tax resident outside of Germany are subject to German taxation provided
that (i) the Company&#8217;s shares are held as business assets of a permanent establishment or as business assets for which a permanent
representative has been appointed in Germany, or (ii) the shareholder or, in case of a gratuitous transfer, its legal predecessor has
held, directly or indirectly at least 1% of the company&#8217;s shares capital at any time during a five years period prior to the disposal.
In these cases, capital gains are generally subject to the same rules as described above for shareholders resident in Germany. However,
it is unclear whether in case of a corporation being shareholder of the Company the 5% taxation (see &#8220;&#8212; Corporations&#8212;
Taxation of capital gains realized by shareholders tax resident in Germany holding the Company&#8217;s shares as business assets&#8221;)
applies or whether the capital gains are fully exempt from German tax.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
except for the cases referred to in (i) above, some of the double tax treaties concluded with Germany provide for a full exemption from
German taxation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inheritance
and gift tax</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer of the Company&#8217;s shares to another person by way of succession or donation is subject to German inheritance and gift
tax&#160;(<i>Erbschaft-und Schenkungsteuer</i>)&#160;if:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            descedent, the donor, the heir, the donee or any other beneficiary has his /her /its residence,
                                            domicile, registered office or place of management in Germany at the time of the transfer,
                                            or is a German citizen who has not stayed abroad for more than five consecutive years without
                                            having a residence in Germany;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(irrespective
                                            of the personal circumstances) the shares are held by the decedent or donor as business assets
                                            for which a permanent establishment in Germany is maintained or a permanent representative
                                            is appointed in Germany; or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(irrespective
                                            of the personal circumstances) at least 10% of the shares are held directly or indirectly
                                            by the decedent or person making the gift, himself or together with a related party in terms
                                            of Section&#8239;1 paragraph 2 Foreign Tax Act.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
regulations apply to qualified German citizens who maintain neither a residence nor their domicile in Germany but in a low tax jurisdiction
and to former German citizens, also resulting in inheritance and gift tax. The few double tax treaties on inheritance and gift tax which
Germany has entered into provide that German inheritance and gift tax is levied only in case of (i)&#8239;and, with certain restrictions,
in case of (ii).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
taxes</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
German capital transfer tax (<i>Kapitalverkehrsteuer</i>), value added tax (<i>Umsatzsteuer</i>), stamp duty (<i>Stempelgeb&#252;hr</i>)
or similar taxes are levied when acquiring, holding or transferring the Company&#8217;s shares. No value added tax will be levied unless
the shareholder validly opts for it. Net wealth tax (<i>Verm&#246;gensteuer</i>) is currently not levied in Germany.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 22, 2013, the Council of the European Union approved the resolution of the ministers of finance from 11 EU member states (including
Germany) to introduce Financial Transaction Tax, or FTT, within the framework of enhanced cooperation. On February 14, 2013, the European
Commission accepted the proposal for a Council Directive implementing enhanced cooperation in the area of financial transaction tax.
The plan focuses on levying a financial tax of 0.1% (0.01% for derivates) on the purchase and sale of financial instruments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
joint statement issued by 10 of the 11 participating EU member states in October 2016 reaffirmed the intention to introduce FTT. However,
at the moment not many details are available. Thus, it is not known to what extent the elements of the European Commission&#8217;s proposal
outlined in the preceding paragraph will be followed in relation to the taxation of shares. The FTT proposal remains subject to negotiation
between the participating Member States and is subject to political discussion. It may therefore be altered prior to the implementation,
the timing of which remains unclear. The European Commission has committed to putting forward a proposal by January 1, 2024 and has published
a working paper in June 2023. However, it is not expected that any proposal would be agreed on in the short term. Additional EU member
states may decide to participate. Prospective holders of the shares are advised to seek their own professional advice in relation to
FTT.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>9.
Dividends and paying agents</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>10.
Statement by experts</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>11.
Documents on display</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information
with the SEC, including Annual Reports and reports on Form 6-K. The SEC maintains a website that contains reports and other information
about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>12.
Subsidiary information</i></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_053"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
risk arises from our exposure to fluctuation in currency exchange rates. We are exposed to such market risks in the ordinary course of
our business as our exposure to the U.S. dollar broadens from future expenses and revenues that may be derived from the United States.
Currently, we do not have any exchange rate hedging arrangements in place.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not engage in activities involving other market price risks. For additional information on market risk, refer to Note D.12 &#8216;Risk&#8217;
within our audited financial statements and notes prepared in accordance with IFRS-IASB, included in &#8220;ITEM 18. FINANCIAL STATEMENTS.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_054"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_055"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Debt
                                            securities</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_056"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
                                            and rights</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Not
applicable.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_057"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
                                            securities</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_058"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>American
                                            Depositary Shares</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="m_059"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
II</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_060"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_061"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Defaults</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
matters to report.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_062"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Arrears
                                            and delinquencies</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
matters to report.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_063"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ITEM
14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_064"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
                                            modifications to instruments</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_065"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
                                            modifications to rights</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_066"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Withdrawal
                                            or substitution of assets</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_067"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
                                            in trustees or paying agents</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_068"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
                                            of proceeds</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="m_069"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
15. CONTROLS AND PROCEDURES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_070"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
                                            controls and procedures</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, under the supervision of and with the participation of our management, including our Chief Executive Officer and
Chief Financial Officer, we performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures
(as defined in Rule 13a-15(e) under the Exchange Act). There are inherent limitations to the effectiveness of any disclosure controls
and procedures system, including the possibility of human error and circumventing or overriding them. Even if effective, disclosure controls
and procedures can provide only reasonable assurance of achieving their control objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are
effective to provide reasonable assurance that the information we are required to disclose in the reports we file or submit under the
Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms
and (2) accumulated and communicated to our management to allow timely decisions regarding required disclosures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_071"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
                                            annual report on internal control over financial reporting</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined
in Rule 13a-15(f) of the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive
Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting
based upon criteria established in&#160;<i>Internal Control &#8211; Integrated Framework</i>&#160;(2013) by the Committee of Sponsoring
Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial
reporting was effective as of December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_072"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attestation
                                            report of the registered public accounting firm</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EY
GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft, or EY, an independent registered accounting firm, has issued an attestation report
on the effectiveness of our internal control over financial reporting as of December 31, 2023, which expressed an unqualified opinion
thereon, as stated in their report included herein. See &#8220;Reports of independent registered public accounting firm&#8221; on page
F-2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_073"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
                                            in internal control over financial reporting</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been certain changes in our internal control over financial reporting during the period covered by this Annual Report, relating
to the implementation of internal controls over inventory management and valuation following the manufacture of GOHIBIC (vilobelimab)
for commercial sale under the EUA in the United States, which have materially affected our internal control over financing reporting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_074"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16. RESERVED</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_075"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16A. AUDIT COMMITTEE FINANCIAL EXPERT</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors has determined that each of Mr. Anthony Gibney, Mr. Nicolas Fulpius, Mr. Mark Kuebler and Mr. Richard Brudnick is
an audit committee financial expert, as that term is defined by the SEC, and all four are independent for the purposes of SEC and Nasdaq
rules relating to the independence of the audit committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_076"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16B. CODE OF ETHICS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted a code of ethics that applies to all of our employees, officers and directors and posted the full text of our code of ethics
on the investor relations section of our website, www.inflarx.com. We intend to disclose future amendments to our code of ethics, or
any waivers of such code, on our website or in public filings. The information on our website is not incorporated by reference into this
Annual Report, and you should not consider information contained on our website to be a part of this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_077"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_078"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
                                            fees</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee has adopted a policy that requires the pre-approval of all services performed for us by our independent registered public
accounting firm. All audit-related services rendered by our independent registered public accounting firm were pre-approved by the audit
committee and are compatible with maintaining the auditor&#8217;s independence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the total fees billed (or expected to be billed), on a consolidated basis, by the independent registered public accounting
firm or their affiliates for providing audit and other professional services in each of the last two years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
fees in 2023 amounted to &#8364;1,009,952 and relate to audit services. These services were provided by our principal accountants, EY
GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft (formerly Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft) in connection
with&#160;our annual audit, quarterly reviews and review of registration statements for the Company. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
fees in 2022 amounted to &#8364;988,541 and relate to&#160;audit services. These services were provided by our principal accountants,
EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft (formerly Ernst &amp; Young GmbH Wirtschaftspr&#252;fungsgesellschaft) in connection
with&#160;our annual audit, quarterly reviews and review of registration statements for the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_079"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit-related
                                            fees</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_080"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax
                                            fees</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_081"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
                                            other fees</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_082"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
                                            Committee&#8217;s pre-approval policies and procedures</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit committee is responsible for the appointment, replacement, compensation, evaluation and oversight of the work of the independent
auditors. As part of this responsibility, the&#160;audit committee pre-approves all&#160;audit and non-audit services performed by the
independent auditors in order to assure that they do not impair the auditor&#8217;s independence from the Company&#160;in accordance
with the&#160;audit committee&#8217;s pre-approval policy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_083"></a></div><table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit
                                            work performed by other than principal accountant if greater than 50%</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Not
applicable. </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_084"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_085"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">ITEM
16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASERS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_086"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Not
applicable.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_087"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16G. CORPORATE GOVERNANCE</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
a description of the significant ways in which our corporate governance practices differ from those required for U.S. companies listed
on Nasdaq, see &#8220;ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES &#8212; 3.&#160;Board practices &#8212; Corporate governance
practices.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_088"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16H. MINE SAFETY DISCLOSURE</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_089"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_090"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16J. INSIDER TRADING POLICIES</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_091"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
16K. CYBERSECURITY RISK MANAGEMENT AND STRATEGY</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is responsible for reviewing the Company&#8217;s cybersecurity risk management and control systems in relation to
the financial reporting by the Company, including the Company&#8217;s cybersecurity strategy. Our Board of Directors has delegated periodic
oversight of, as appropriate cybersecurity risk management to the Audit Committee, who reports to our Board of Directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IT department is responsible for targeted and regular monitoring of cybersecurity risks. They independently and continuously monitor
cybersecurity risks and countermeasures to defend against such threats and, in the event of a cybersecurity threat or cybersecurity incident,
inform Executive Management, our Audit Committee and our Board of Directors. In addition to the regular meetings between Executive Management
and the individual risk owners mainly consisting out of the various departments&#8217; heads, a comprehensive cybersecurity risk analysis
for internal and external risks is carried out as appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cybersecurity risks identified and evaluated by the IT department are included in an overall risk catalogue. The identified cybersecurity
risks are recorded, described, documented and evaluated in the overall risk catalogue. Changes are also documented accordingly. According
to the priority of the cybersecurity risks as result of the risk evaluation, risks are addressed by concrete actions and, if appropriate
and possible, necessary countermeasures. In order to be able to react quickly and flexibly to cybersecurity risks, risk management is
integrated into existing processes and reporting channels. Our risk management program considers cybersecurity risks alongside other
company risks, and our enterprise risk professionals consult with company subject matter experts to gather information necessary to identify
cybersecurity risks and evaluate their nature and severity, as well as identify mitigations and assess the impact of those mitigations
on residual risk. We may engage third parties from time to time to conduct risk assessments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main cybersecurity risks we continuously monitor include threats and potential incidents resulting in the unavailability of central IT
systems, the loss of critical business data, data theft, intellectual property theft, fraud, extortion, harm to employees and patients,
violation of privacy laws and other litigation and legal risks, and risks to our reputation. The materialization of these cybersecurity
threats may materially affect or may be reasonably likely to materially affect the Company, including its business strategy, results
of operations, or financial condition. The unavailability of central IT systems for example, would result in an interruption or delay
of any clinical development activities of the Company. The loss of critical business data such as the results of clinical study reports
and underlying information, such as tables, listings and filings, could retrospectively destroy the work of several years of clinical
development and respective cost. Data theft could, if critical, confidential or proprietary business data is concerned, result in a loss
in strength of competition. Intellectual property theft can jeopardize our ability to generate revenue for our shareholders. Breach of
privacy laws can put our employees and patients at risk of additional cybersecurity and personal risks, which could lead to a litigation
and further costs for the Company. Cybersecurity risks may also result in our Company&#8217;s reputation being affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
Management, our IT department and employees are the foundation of an effective cybersecurity risk management. The Company implemented
IT Security guidelines, which stipulate measures to securely handle personal data, the settings for a reasonably secure password for
devices and software, the handling of mobile IT devices as well as the proper use of the internet and e-mail communication software.
The Company also implemented two-factor-authentication to access and use a Company user account, including e-mail. All employees as well
as all members of Executive Management are trained on IT security on a regular basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we do not believe that our business strategy, results of operations or financial condition have been materially adversely affected by
any cybersecurity incidents, we describe whether and how future incidents could have a material impact on our business strategy, results
of operations or financial condition in &#8220;Item 3 C. Risk Factors&#8212;General risk factors&#8212;Cyber incidents or other failures
in IT systems could result in information theft, data corruption and significant disruption of our business operations.&#8221; Additionally,
although we have insurance coverage for cybersecurity events, there can be no assurance that we will be able to maintain our insurance
coverage or it will be enough to cover the cost associated with one or more cybersecurity events. See &#8220;Item 3 C. Risk factors&#8212;General
risk factors&#8212;We may not be able to maintain sufficient insurance to cover us for potential litigation or other risks.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&#160;</p><div>

</div><div><a id="m_092"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
III</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_093"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
17. FINANCIAL STATEMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
responded to Item 18 in lieu of this item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_094"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
18. FINANCIAL STATEMENTS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
statements are filed as part of this Annual Report, see pages F-1 to F-35 to this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_095"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
19. EXHIBITS</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 9%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000121390023021874/f20f2022ex1-1_inflarxnv.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Association of InflaRx N.V., dated August 25, 2021 (English language translation) (incorporated herein by reference to Exhibit 1.1. to the Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on March 22, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000095010317011031/dp82669_ex0402.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement (incorporated herein by reference to Exhibit 4.2 to the post-effective amendment to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-220962) filed with the SEC on November 9, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2+</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000114036123032443/ny20009510x1_ex4-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Senior Indenture (incorporated herein by reference to Exhibit 4.2 to the Company&#8217;s Registration Statement on Form F-3 (File No. 333-273058) filed with the SEC on June 30, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3+</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000114036123032443/ny20009510x1_ex4-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Subordinated Indenture (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Registration Statement on Form F-3 (File No. 333-273058) filed with the SEC on June 30, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000121390023021874/f20f2022ex2-4_inflarxnv.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description of Rights of Each Applicable Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated herein by reference to Exhibit 2.4 to our Annual Report on Form 20-F for the year ended December 31, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&#8224;</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000095010317010902/dp82624_ex1003.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Development Agreement, dated December 28, 2015, between InflaRx GmbH and Beijing Defengrei Biotechnology Co. Ltd., as supplemented by Addendum No. 1 dated December 28, 2015 (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Amendment No. 4 to the Registration Statement on Form F-1 (File No. 333-220962) filed with the SEC on November 7, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000121390023021874/f20f2022ex4-4_inflarxnv.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum No. 2, dated as of November 9, 2022, between InflaRx GmbH and Beijing Defengrei Biotechnology Co. Ltd. (incorporated herein by reference to Exhibit 4.4 to the Annual Report on Form 20-G for the year ended December 31, 2022 filed with the SEC on March 22, 2023).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000114036122046454/brhc10045712_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addendum No. 3, dated as of December 21, 2022, between InflaRx GmbH and Staidson (Beijing) BioPharmaceuticals Co., Ltd., to the Co-Development Agreement, dated as of December 28, 2015 between InflaRx GmbH and Staidson (Beijing) BioPharmaceuticals Co., Ltd. (as successor to Beijing Defengrei Biotechnology Co. Ltd. (BDB)) (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 6-K with the SEC on December 21, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000114036122046454/brhc10045712_ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Purchase Agreement, dated as of December 21, 2022, between InflaRx N.V. and Staidson Hong Kong Investment Company Limited (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 6-K with the SEC on December 21, 2022).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000095010317009967/dp81461_ex1004.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement for directors and executive officers (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Registration Statement on Form F-1 (File No. 333-220962) filed with the SEC on October 13, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000114036123018212/ny20007658x4_ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated as of April 11, 2023, between InflaRx N.V. and Raymond James &amp; Associates, Inc., as representative of the underwriters named in Schedule 1 (incorporated herein by reference to Exhibit 1.1 to our Current Report on Form 6-K, dated April 13, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000095010317011321/dp82802_ex9900.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx Long-Term Incentive Plan (incorporated herein by reference to Exhibit 99 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-221656) filed with the SEC on November 17, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1708688/000114036120017017/brhc10013845_ex99-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to InflaRx Long-Term Incentive Plan (incorporated herein by reference to Exhibit 99.2 to the Company&#8217;s Registration Statement on Form S-8 (File No. 333-240185) filed with the SEC on July 30, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="ea020203801ex8-1_inflarx.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="ea020203801ex12-1_inflarx.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="ea020203801ex12-2_inflarx.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="ea020203801ex13-1_inflarx.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="ea020203801ex13-2_inflarx.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><a href="ea020203801ex15-1_inflarx.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea020203801ex97-1_inflarx.htm">Clawback Policy.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following materials from our Annual Report on Form 20-F for the year ended December 31, 2023 formatted as inline XBRL (eXtensible
    Business Reporting Language): (i) the Consolidated Financial Statements and (ii) the Notes to the Consolidated Financial Statements,
    tagged as blocks of text and in detail.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
                                            Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></td></tr>
</table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                            herewith.</span></td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">+</td><td style="font: 10pt Times New Roman, Times, Serif">Previously
filed.</td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
                                            treatment granted as to portions of the exhibit. Confidential materials omitted and filed
                                            separately with the SEC.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this Annual Report on Form 20-F on its behalf.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>InflaRx
    N.V.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Niels Riedemann</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Niels
    Riedemann</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and&#160;Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 21, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Thomas Taapken</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Taapken</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
March 21, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence -->-</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="m_096"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index
to Consolidated Financial Statements</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; width: 90%"><a href="#m_096">Index to Consolidated Financial Statements</a></td> <td style="width: 2%">&#160;</td> <td style="text-align: center; font-weight: bold; width: 8%">F-1</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_001">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-29485">1251</ix:nonNumeric>)</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-2</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_002">Report of Independent Registered Public Accounting Firm (PCAOB ID: 1251)</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-5</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_003">Consolidated statements of operations and comprehensive loss for the years ended December 31, 2023, 2022 and 2021</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-6</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_004">Consolidated statements of financial position as of December 31, 2023 and 2022</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-7</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_005">Consolidated statements of changes in shareholders&#8217; equity for the years ended December 31, 2023, 2022 and 2021</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-8</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_006">Consolidated statements of changes in shareholders&#8217; equity for the years ended December 31, 2023, 2022 and 2021</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-9</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&#160;</td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold"><a href="#f_007">Consolidated statements of cash flows for the years ended December 31, 2023, 2022 and 2021</a></td> <td>&#160;</td> <td style="text-align: center; font-weight: bold">F-10</td></tr> </table><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 167; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_001"></a></div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and the Board of Directors of InflaRx N.V.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated statements of financial position of InflaRx N.V. and subsidiaries (the Company) as of December
31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, changes in shareholders&#8217; equity and
cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the
&#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material
respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for
each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards as issued
by the International Accounting Standards Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s
internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 20, 2024 expressed
an unqualified opinion thereon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits
included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts
and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the
critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they
relate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Recognition
of clinical trial and contracted manufacturing expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-right: 5pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
    of the Matter</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            discussed in Note B.3 to the consolidated financial statements, the Company recognizes research
                                            and development (R&amp;D) expenses, which include costs for clinical trial and contracted
                                            manufacturing, charged by contract research organizations and contract manufacturing organizations
                                            (together, &#8220;clinical vendors&#8221;). The total clinical trial and contracted manufacturing
                                            expenses recognized in the year-ended December 31, 2023, amounted to &#8364;31.8 million and
                                            the related prepayments and accrued liabilities from R&amp;D projects were &#8364;3.7 million
                                            and &#8364;4.4 million, respectively, as of December 31, 2023.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&#8217;s determination of clinical trial and contracted manufacturing expenses involves estimating a percentage-of-completion,
    whereby the degree to which services have been rendered for the individual project activities contracted from the clinical vendors
    is assessed and estimated by management. While the Company&#8217;s estimates of clinical trial and contracted manufacturing expenses
    are primarily based on information received related to each study from its clinical vendors, the Company may need to make an estimate
    for costs incurred based on management judgment. Payments for these activities are based on the terms of the individual arrangements,
    which differ from the pattern of costs incurred.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing
    clinical trial and contracted manufacturing expenses was challenging, due to the judgement and subjectivity involved in management&#8217;s
    assessment of the progress of clinical trial and contracted manufacturing expenses, relative to the costs incurred, to estimate the
    related accrued liabilities and prepayments from R&amp;D projects, and the evaluation of the completeness and accuracy of the data
    used in the estimate.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-right: 5pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-right: 5pt; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
                                            We Addressed the Matter in Our Audit</i></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            obtained an understanding, evaluated the design and tested the operating effectiveness of
                                            controls related to the Company&#8217;s estimation of clinical vendor costs for clinical
                                            trial and contracted manufacturing expenses. For example, we tested controls over management&#8217;s
                                            review of the estimated percentage-of-completion used in determining the amount of clinical
                                            trial and contracted manufacturing expenses and the related impacts to prepayments and accrued
                                            liabilities from R&amp;D projects.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    assess the accounting for clinical trial and contracted manufacturing expenses, our audit procedures included, among others, testing
    the accuracy and completeness of the underlying data used in the percentage-of-completion estimates, by assessing the progress of
    the clinical trial activities through discussion with the Company&#8217;s R&amp;D project managers, who oversee these activities
    and by reviewing progress reports, invoices, and other correspondence provided by the clinical vendors to the R&amp;D project managers.
    We inspected the Company&#8217;s clinical vendor contracts, amendments, and pending change orders to assess whether the key financial
    and contractual terms align with the amounts recognized. We also performed analytical reviews of fluctuations in the percentage-of-completion
    by project throughout the period subject to audit. We compared invoices received from and cash disbursements made to clinical vendors
    prior to and following year-end and evaluated credit memos received from clinical vendors prior to and following year-end.</span></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net
realizable value of unfinished goods inventory</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.35pt; text-indent: 1.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-right: 5pt; font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description
    of the Matter</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 90%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            December 31, 2023, the Company&#8217;s net unfinished goods inventory balance was &#8364;10.6
                                            million, all of which relates to its severe COVID-19 treatment Gohibic. As discussed in Notes
                                            B.2, B.3 and D.5 of the consolidated financial statements, in order to value inventory, including
                                            unfinished goods, at the lower of cost or net realizable value, the Company reviews its inventory
                                            for excess amounts or obsolescence, primarily using estimates of expected future sales, which
                                            are sensitive to significant inputs and assumptions, such as expected medical need and expected
                                            market penetration.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditing
management&#8217;s estimate of the net realizable value of unfinished goods inventory, which is based, in part, on estimates of expected
future sales was complex and highly judgmental, due to the Company having a limited sales history to consider. Additionally, these estimates
rely, in part, on management&#8217;s assumptions about future events outside of the Company&#8217;s control, such as continuation of
the emergency use authorization in the United States and granting of marketing authorization in the European Union.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-right: 5pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="padding-right: 5pt; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How
We Addressed the Matter in Our Audit</i></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    test management&#8217;s estimate of the net realizable value of unfinished goods inventory, which is based, in part, on estimates
    of expected future sales, we performed audit procedures that included, among others, comparing inputs used in developing assumptions
    of medical need to data points observable from United States government COVID-19 data and the Company&#8217;s clinical trial results
    for Gohibic. We also compared inputs used in developing assumptions for market penetration, to studies on market share achievable
    in the pharmaceutical industry. We performed sensitivity analyses over the medical need and market penetration assumptions. We evaluated
    management&#8217;s comparison of unfinished goods inventory to the estimates of expected future sales, which included consideration
    of applicable inventory expiration dates. Additionally, we evaluated the reasonableness of management&#8217;s assessment of the probability
    that the emergency use authorization in the United States remains in place and that the marketing authorization in the European Union
    is granted, by reference to correspondence with the relevant regulatory authorities and inquiries of management in relation to the
    Company&#8217;s actions to achieve any required conditions for the authorizations. We also tested the clerical accuracy of the calculations
    underlying the Company&#8217;s estimates of expected future sales.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Munich,
Germany</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
20, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_002"></a></div><p style="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and the Board of Directors of InflaRx N.V.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on Internal Control Over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited InflaRx N.V. and subsidiaries&#8217; internal control over financial reporting as of December 31, 2023, based on criteria
established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013
framework) (the COSO criteria). In our opinion, InflaRx N.V. and subsidiaries (the Company) maintained, in all material respects, effective
internal control over financial reporting as of December 31, 2023, based on the COSO criteria.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated
statements of financial position of the Company as of December 31, 2023 and 2022, the related consolidated statements of operations and
comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31,
2023, and the related notes and our report dated March 20, 2024 expressed an unqualified opinion thereon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment
of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal
Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial
reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect
to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists,
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other
procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Definition
and Limitations of Internal Control Over Financial Reporting</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statementsfor external purposes in accordance with generally accepted accounting
principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that: (1) pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-29486">EY GmbH &amp; Co. KG Wirtschaftspr&#252;fungsgesellschaft</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-19833"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Munich,
Germany</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
20, 2024</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
statements of operations and comprehensive loss for the years ended December 31, 2023, 2022 and 2021</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 139.45pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td colspan="9" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in &#8364;, except for share data)</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 53%; font-weight: normal; font-style: normal">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.1.</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="eur" id="ixv-29487">63,089</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal; font-style: normal">Cost of sales</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.2.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="eur" id="ixv-29488">532,262</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><b>Gross profit</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossProfit" scale="0" sign="-" unitRef="eur" id="ixv-29489">469,173</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b style="-sec-ix-hidden: hidden-fact-4">&#8212;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b style="-sec-ix-hidden: hidden-fact-5">&#8212;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.3.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29490">4,001,299</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.4.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29491">41,024,131</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29492">37,526,090</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29493">35,697,935</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.5.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29494">12,628,756</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29495">14,869,564</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29496">11,984,722</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.6.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur" id="ixv-29497">13,219,704</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur" id="ixv-29498">20,159,169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur" id="ixv-29499">54,221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByFunction" scale="0" unitRef="eur" id="ixv-29500">4,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByFunction" scale="0" unitRef="eur" id="ixv-29501">1,381</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByFunction" scale="0" unitRef="eur" id="ixv-29502">6,381</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><b>Operating result</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29503">44,908,096</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29504">32,237,866</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29505">47,634,817</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur" id="ixv-29506">3,804,827</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur" id="ixv-29507">608,679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur" id="ixv-29508">109,391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Finance expenses</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur" id="ixv-29509">35,628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur" id="ixv-29510">45,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur" id="ixv-29511">24,769</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Foreign exchange result</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="eur" id="ixv-29512">1,841,872</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur" id="ixv-29513">2,442,297</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur" id="ixv-29514">1,964,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other financial result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.8.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29515">313,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" sign="-" unitRef="eur" id="ixv-29516">252,471</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" sign="-" unitRef="eur" id="ixv-29517">44,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><b>Income taxes</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b style="-sec-ix-hidden: hidden-fact-8">&#8212;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b style="-sec-ix-hidden: hidden-fact-9">&#8212;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b style="-sec-ix-hidden: hidden-fact-10">&#8212;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><b>Loss for the period</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29518">42,667,529</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29519">29,484,611</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29520">45,630,059</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" scale="0" unitRef="eur" id="ixv-29521">125,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" scale="0" unitRef="eur" id="ixv-29522">4,206,810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" scale="0" unitRef="eur" id="ixv-29523">6,777,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-transform: uppercase; text-align: left"><b>Total
    comprehensive loss</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29524">42,542,444</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29525">25,277,801</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29526">38,852,998</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Share information (based on loss for the period)</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.9.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-29527">54,940,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-29528">44,207,873</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares" id="ixv-29529">41,629,974</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><div style="-sec-ix-hidden: hidden-fact-13; -sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11">Loss per share (basic/diluted)</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="eurPershares" id="ixv-29530">0.78</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="eurPershares" id="ixv-29531">0.67</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="eurPershares" id="ixv-29532">1.10</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-transform: uppercase; text-align: left"><b>Loss
    for the period</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center"><b>&#160;</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29533">42,667,529</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29534">29,484,611</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29535">45,630,059</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td></tr>
  </table><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
statements of financial position as of December 31, 2023 and 2022</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 224.5pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Non-current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 65%; text-align: left">Property and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.1.</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-29536">289,577</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-29537">328,920</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.2.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="eur" id="ixv-29538">1,071,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="eur" id="ixv-29539">1,311,809</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.3.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="0" unitRef="eur" id="ixv-29540">68,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="0" unitRef="eur" id="ixv-29541">138,905</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.6.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentAssets" scale="0" unitRef="eur" id="ixv-29542">257,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentAssets" scale="0" unitRef="eur" id="ixv-29543">308,066</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.8.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-29544">9,052,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-29545">2,900,902</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="eur" id="ixv-29546">10,740,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="eur" id="ixv-29547">4,988,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Inventories</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.5.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="eur" id="ixv-29548">11,367,807</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current other assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.6.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="eur" id="ixv-29549">4,036,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="eur" id="ixv-29550">14,170,510</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax receivable</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.7.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="0" unitRef="eur" id="ixv-29551">3,791,564</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxAssetsCurrent" scale="0" unitRef="eur" id="ixv-29552">1,432,087</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-29553">732,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other financial assets</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="0" unitRef="eur" id="ixv-29554">77,504,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="0" unitRef="eur" id="ixv-29555">64,810,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.9.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29556">12,767,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29557">16,265,355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="eur" id="ixv-29558">109,468,483</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="eur" id="ixv-29559">97,411,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="eur" id="ixv-29560">120,208,552</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="eur" id="ixv-29561">102,399,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">EQUITY AND LIABILITIES</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Equity</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Issued capital</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="eur" id="ixv-29562">7,065,993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="eur" id="ixv-29563">5,364,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Share premium</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="0" unitRef="eur" id="ixv-29564">334,211,338</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="0" unitRef="eur" id="ixv-29565">282,552,633</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other capital reserves</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="eur" id="ixv-29566">40,050,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="eur" id="ixv-29567">36,635,564</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="eur" id="ixv-29568">286,127,819</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="eur" id="ixv-29569">243,460,290</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other components of equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur" id="ixv-29570">7,382,166</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur" id="ixv-29571">7,257,081</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total equity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29572">102,581,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29573">88,349,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Non-current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.2.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29574">745,716</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29575">987,307</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="0" unitRef="eur" id="ixv-29576">36,877</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="0" unitRef="eur" id="ixv-29577">36,877</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="eur" id="ixv-29578">782,593</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="eur" id="ixv-29579">1,024,184</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.11.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="eur" id="ixv-29580">11,974,362</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="eur" id="ixv-29581">4,987,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentGovernmentGrants" scale="0" unitRef="eur" id="ixv-29582">6,209,266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lease liabilities</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.2.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29583">374,329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29584">369,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Employee benefits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisionsForEmployeeBenefits" scale="0" unitRef="eur" id="ixv-29585">1,609,766</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentProvisionsForEmployeeBenefits" scale="0" unitRef="eur" id="ixv-29586">1,312,248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.11.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="eur" id="ixv-29587">2,885,772</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="eur" id="ixv-29588">147,608</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="eur" id="ixv-29589">16,844,229</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="eur" id="ixv-29590">13,026,036</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="eur" id="ixv-29591">17,626,822</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="eur" id="ixv-29592">14,050,220</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL EQUITY AND LIABILITIES</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="0" unitRef="eur" id="ixv-29593">120,208,552</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="0" unitRef="eur" id="ixv-29594">102,399,660</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
statements of changes in shareholders&#8217; equity for the years ended December 31, 2023, 2022 and 2021</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 153.6pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares <br/>outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued <br/>capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Share <br/>premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; width: 53%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance as of January 1, 2021</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 9%; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-29595">28,228,415</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29596">3,387,410</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29597">220,289,876</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IssuanceOfCommonShare" scale="0" unitRef="shares" id="ixv-29598">15,610,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29599">1,873,203</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29600">63,269,346</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur" id="ixv-29601">4,219,222</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Equity-settled share-based payments</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Share options exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares" scale="0" unitRef="shares" id="ixv-29602">365,326</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29603">43,839</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29604">970,744</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-29605">44,203,763</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29606">5,304,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29607">280,310,744</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Loss for the Period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IssuanceOfCommonShare" scale="0" unitRef="shares" id="ixv-29608">500,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29609">60,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29610">2,289,624</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur" id="ixv-29611">47,735</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Equity-settled share-based payments</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Share options exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-29612">44,703,763</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29613">5,364,452</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29614">282,552,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Loss for the Period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.(a).</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IssuanceOfCommonShare" scale="0" unitRef="shares" id="ixv-29615">14,059,252</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29616">1,687,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29617">54,796,819</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur" id="ixv-29618">3,360,626</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left">Equity-settled share-based payments</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.375in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Share options exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares" scale="0" unitRef="shares" id="ixv-29619">120,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29620">14,431</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29621">222,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.375in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 4pt">Balance as of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares" id="ixv-29622">58,883,272</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29623">7,065,993</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29624">334,211,338</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
statements of changes in shareholders&#8217; equity for the years ended December 31, 2023, 2022 and 2021</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 153.6pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other <br/>capital&#160;reserves</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/>
deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other<br/>
components&#160;of<br/>
equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br/>equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 41%; font-weight: bold; padding-bottom: 1.5pt">Balance as of January 1, 2021</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 9%; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29625">26,259,004</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="eur" id="ixv-29626">168,345,620</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="eur" id="ixv-29627">3,726,791</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29628">77,863,880</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss for the Period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29629">45,630,059</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29630">45,630,059</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-29631">6,777,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-29632">6,777,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29633">45,630,059</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="eur" id="ixv-29634">6,777,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29635">38,852,998</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29636">65,142,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur" id="ixv-29637">4,219,222</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity-settled share-based payments</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur" id="ixv-29638">4,332,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur" id="ixv-29639">4,332,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Share options exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29640">1,014,583</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29641">30,591,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="eur" id="ixv-29642">213,975,679</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29643">3,050,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29644">105,280,996</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29645">29,484,611</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29646">29,484,611</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-29647">4,206,810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-29648">4,206,810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29649">29,484,611</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="eur" id="ixv-29650">4,206,810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29651">25,277,801</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29652">2,349,624</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur" id="ixv-29653">47,735</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity-settled share-based payments</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur" id="ixv-29654">6,044,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur" id="ixv-29655">6,044,356</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Share options exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 1.5pt">Balance as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29656">36,635,564</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="eur" id="ixv-29657">243,460,290</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29658">7,257,080</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29659">88,349,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss for the period</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29660">42,667,529</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29661">42,667,529</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-29662">125,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-29663">125,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total comprehensive loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29664">42,667,529</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="eur" id="ixv-29665">125,085</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur" id="ixv-29666">42,542,444</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur" id="ixv-29667">56,483,929</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Transaction costs</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur" id="ixv-29668">3,360,626</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity-settled share-based payments</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur" id="ixv-29669">3,414,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur" id="ixv-29670">3,414,489</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt">Share options exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29671">236,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 4pt">Balance as of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29672">40,050,053</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" sign="-" unitRef="eur" id="ixv-29673">286,127,819</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29674">7,382,166</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur" id="ixv-29675">102,581,730</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="f_007"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 259.95pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
statements of cash flows for the years ended December 31, 2023, 2022 and 2021</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 217.4pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">Operating activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 53%; text-align: left">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29676">42,667,529</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29677">29,484,611</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-29678">45,630,059</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Adjustments for:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" unitRef="eur" id="ixv-29679">567,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" unitRef="eur" id="ixv-29680">596,597</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" unitRef="eur" id="ixv-29681">669,434</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net finance income</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29682">2,240,566</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29683">2,753,255</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForFinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29684">2,004,757</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Share-based payment expense</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="eur" id="ixv-29685">3,414,489</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="eur" id="ixv-29686">6,044,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" unitRef="eur" id="ixv-29687">4,332,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net foreign exchange differences</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" unitRef="eur" id="ixv-29688">413,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" unitRef="eur" id="ixv-29689">385,359</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" unitRef="eur" id="ixv-29690">111,606</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Changes in:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" scale="0" unitRef="eur" id="ixv-29691">732,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" scale="0" sign="-" unitRef="eur" id="ixv-29692">732,971</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" unitRef="eur" id="ixv-29693">7,825,182</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="eur" id="ixv-29694">3,308,485</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="eur" id="ixv-29695">7,094,467</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Employee benefits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="0" unitRef="eur" id="ixv-29696">297,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="0" sign="-" unitRef="eur" id="ixv-29697">64,024</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="0" sign="-" unitRef="eur" id="ixv-29698">3,290</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="0" unitRef="eur" id="ixv-29699">2,738,164</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="0" unitRef="eur" id="ixv-29700">9,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="0" unitRef="eur" id="ixv-29701">19,863</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Liabilities from government grants received</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.8.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" scale="0" sign="-" unitRef="eur" id="ixv-29702">6,209,266</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" scale="0" sign="-" unitRef="eur" id="ixv-29703">2,090,734</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" scale="0" unitRef="eur" id="ixv-29704">8,300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.11.&#160;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" unitRef="eur" id="ixv-29705">6,986,824</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" sign="-" unitRef="eur" id="ixv-29706">3,586,706</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="0" unitRef="eur" id="ixv-29707">316,112</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Inventories</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.5.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="0" sign="-" unitRef="eur" id="ixv-29708">11,367,807</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest received</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="eur" id="ixv-29709">1,732,284</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="eur" id="ixv-29710">1,287,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="eur" id="ixv-29711">1,070,235</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Interest paid</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="eur" id="ixv-29712">36,025</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="eur" id="ixv-29713">44,946</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="eur" id="ixv-29714">23,633</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29715">37,812,966</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29716">33,742,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29717">39,936,751</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchase of intangible assets and property and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="0" unitRef="eur" id="ixv-29718">81,100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="0" unitRef="eur" id="ixv-29719">162,391</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" scale="0" unitRef="eur" id="ixv-29720">37,778</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchase of current and non-current financial assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-29721">104,051,972</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-29722">64,474,543</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-29723">97,516,417</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Proceeds from the maturity of current financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" scale="0" unitRef="eur" id="ixv-29724">86,436,456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" scale="0" unitRef="eur" id="ixv-29725">83,995,029</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" scale="0" unitRef="eur" id="ixv-29726">71,603,310</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash from/ (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29727">17,696,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" unitRef="eur" id="ixv-29728">19,358,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="eur" id="ixv-29729">25,950,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" unitRef="eur" id="ixv-29730">56,483,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" unitRef="eur" id="ixv-29731">2,349,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingShares" scale="0" unitRef="eur" id="ixv-29732">65,142,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Transaction costs from issuance of ordinary shares</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.10.</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TransactionCostsFromIssuanceOfCommonShares" scale="0" unitRef="eur" id="ixv-29733">3,360,626</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TransactionCostsFromIssuanceOfCommonShares" scale="0" unitRef="eur" id="ixv-29734">47,735</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TransactionCostsFromIssuanceOfCommonShares" scale="0" unitRef="eur" id="ixv-29735">4,219,222</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Proceeds from exercise of share options</td><td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.10</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29736">236,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="0" unitRef="eur" id="ixv-29737">1,014,583</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Repayment of lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-29738">373,977</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-29739">364,430</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-29740">360,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash from financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="eur" id="ixv-29741">52,986,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="eur" id="ixv-29742">1,937,459</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="eur" id="ixv-29743">61,577,266</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" sign="-" unitRef="eur" id="ixv-29744">2,523,313</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" sign="-" unitRef="eur" id="ixv-29745">12,447,262</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" sign="-" unitRef="eur" id="ixv-29746">4,310,369</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" sign="-" unitRef="eur" id="ixv-29747">974,099</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29748">2,462,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29749">4,591,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29750">16,265,355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29751">26,249,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29752">25,968,681</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.9.</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29753">12,767,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29754">16,265,355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-29755">26,249,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Notes to the consolidated financial statements</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrx:DisclosureOfCorporateInformationTextBlock" id="ixv-22788"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. Corporate information</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of InflaRx N.V. and its subsidiaries (collectively, the &#8220;Group&#8221;) for the year ended December
31, 2023 were authorized for issue in accordance with a resolution of the Board of Directors on March 20, 2024. InflaRx N.V. (the &#8220;Company&#8221;)
is a Dutch public company with limited liability (<i>naamloze vennootschap</i>) with its corporate seat in Amsterdam, The Netherlands,
and is registered in the Commercial Register of The Netherlands Chamber of Commerce Business Register under CCI number 68904312. The
Company&#8217;s registered office is at Winzerlaer Stra&#223;e 2 in 07745 Jena, Germany. Since November 10, 2017, the Company&#8217;s
ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#8220;IFRX&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries, collectively, are a biotechnology group pioneering anti-inflammatory therapeutics by applying its proprietary
anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation
factor known as C5a and its receptor C5aR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable
returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity.
Subsidiaries are fully consolidated from the date on which control is obtained by the Group. They are deconsolidated from the date control
ceases. The acquisition method of accounting is used to account for business combinations by the Group. Intercompany transactions, balances
and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s subsidiaries as at December 31, 2023 are set out below. <ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory-c0_cont_1" escape="true" name="ifrx:DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" id="ixv-29756">Unless otherwise stated, such subsidiaries have share capital consisting
solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights
held by the Company.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">Place&#160;of&#160;business/<br/>
country&#160;of</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">Functional</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership
interest<br/>
held by the Company</b></span></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Name</td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>incorporation</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>currency</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Principal activities</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; font-weight: bold">InflaRx GmbH</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c50" name="ifrs-full:CountryOfIncorporation" id="ixv-29757">Jena and Munich, Germany</ix:nonNumeric></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><ix:nonNumeric contextRef="c50" name="ifrs-full:DescriptionOfFunctionalCurrency" id="ixv-29758">EUR</ix:nonNumeric></td><td style="padding-bottom: 1.5pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-29759">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-29760">100</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td><ix:nonNumeric contextRef="c50" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" id="ixv-29761">Operating subsidiary, R&amp;D, holder of all IP</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; width: 35%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">InflaRx Pharmaceuticals, Inc.</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c52" name="ifrs-full:CountryOfIncorporation" id="ixv-29762">Ann Arbor, MI, United States</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 7%; text-align: center"><ix:nonNumeric contextRef="c52" name="ifrs-full:DescriptionOfFunctionalCurrency" id="ixv-22880"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-29763">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" unitRef="pure" id="ixv-29764">100</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left; padding-bottom: 1.5pt"><ix:nonNumeric contextRef="c52" name="ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" id="ixv-29765">Operating subsidiary, R&amp;D, US commercialization</ix:nonNumeric></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory" id="ixv-22897"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Material accounting policies</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="ixv-22903"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.
Basis of preparation</i></b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as issued
by the International Accounting Standards Board (herein &#8220;IFRS&#8221;).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a historical cost basis. These consolidated financial statements of the Group
comprise the Company and its wholly owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc. The consolidated financial statements
are presented in Euro (&#8364;). The presentation currency of the Group is the Euro, as the functional currency of the largest operating
company, InflaRx GmbH, continues to be the Euro. Effective January 1, 2023, the functional currency of InflaRx N.V. changed from the
U.S. dollar to the Euro due to a change in the Company&#8217;s operational function and, in turn, a change in the primary currency of
its underlying transactions. This change in functional currency has been accounted for prospectively. The functional currency of InflaRx
Pharmaceuticals, Inc. is the U.S. dollar ($), as most of their income and expenses occurred in U.S. dollars in 2023. All financial information
presented in Euro has been rounded to the nearest Euro, unless stated otherwise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" id="ixv-22935"><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.
Summary of material accounting policies</i></b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section describes material accounting policies adopted in the preparation of these consolidated financial statements. These policies
have been consistently applied to all the years presented, unless otherwise stated.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" id="ixv-22947"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
</i></b><i><span style="font-variant: normal; font-weight: normal">New and amended standards adopted by the Group</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_2" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_3" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            17 insurance contracts</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 8 accounting policies, changes in accounting estimates and errors: definition of accounting
                                            estimates</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 12 deferred tax related to assets and liabilities arising from a single transaction</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 and IFRS practice statement 2 - disclosure of accounting policies</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_4" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
policies for the following IFRS standards have been applied starting in Q2 2023 for the first time, as no transactions in the scope of
these IFRS standards had been previously recognized.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_5" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS
                                            2 inventories&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_6" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to IAS 2, inventories are stated at the lower amount of their cost or at their net realizable value. Cost comprises direct material cost
and, where applicable, direct labor costs and those overhead costs that have been incurred in bringing the inventories to their present
location and condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling
price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Recognizing inventories
at net realizable value includes writing down inventories considered excess or obsolete.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_7" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            15 revenue from contracts with customers</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, the Company exclusively uses distributors to sell its products to end customers (e.g., hospitals). The end customers (e.g. hospitals)
have been determined to be the customer in these sales arrangements. As such, payments received from the distributors are not contract
liabilities but are rather &#8220;other liabilities&#8221; recognized in &#8220;other accrued liabilities.&#8221; Revenue is therefore
recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer, that is,
when the customer obtains control of that asset and is measured considering estimated return liabilities and expected rebates or cash
discounts.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="ifrx:DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" id="ixv-23036"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
</i></b><i><span style="font-variant: normal; font-weight: normal">New standard not yet adopted</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock-c0_cont_2" id="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following standards issued will be adopted in a future period, and the potential impact on the Group&#8217;s consolidated financial statements,
if any, is being assessed:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock-c0_cont_3" id="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IFRS 16 leases: leases on sale and leaseback</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 presentation of financial statements: classification of liabilities as current or
                                            non-current and non-current liabilities with covenants</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 21 effects of changes in foreign exchange rates: lack of exchangeability</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock-c0_cont_1" escape="true" name="ifrx:DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" id="ixv-23080"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
</i></b><i><span style="font-variant: normal; font-weight: normal">Current and non-current classification</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock-c0_cont_2" id="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group presents assets and liabilities in the statement of financial position based on current/non-current classification.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock-c0_cont_3" id="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets include assets that are sold, consumed or realized as part of the normal operating cycle (operating cycle is assumed to be 12
months), or cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after
the reporting period. All other assets are classified as non-current.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities, such as trade payables, lease liabilities or employee benefits with a term of up to 12 months, and payables for operating
costs or social security charges, are part of the working capital used in the Company&#8217;s normal operating cycle. Such operating
items are classified as current liabilities even if they are due to be settled more than 12 months after the reporting period. All other
liabilities are classified as non-current.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="ixv-23119"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
</i></b><i><span style="font-variant: normal; font-weight: normal">Foreign currency transactions</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in a foreign currency are initially translated into the respective functional currency using the spot rate prevailing on the dates of
the transaction. Monetary items which are not denominated in the functional currency are subsequently translated using the rate applicable
at the end of the period. The resulting currency gains and losses are recognized directly in profit or loss.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
consolidation, the assets and liabilities of operations in a currency other than Euro (the presentation currency of the Company) are
translated into Euros at the rate of exchange prevailing at the reporting date and their statements of operations are translated with
monthly average exchange rates during the reporting period. The exchange differences arising on translation for consolidation are recognized
in &#8216;other comprehensive income&#8217; (OCI). On disposal of a foreign operation, the component of OCI relating to that particular
foreign operation is reclassified to profit or loss. OCI is disclosed as &#8216;other components of equity&#8217; in consolidated statements
of financial position.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock-c0_cont_1" escape="true" name="ifrx:DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" id="ixv-23138"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(e)
</i></b><i><span style="font-variant: normal; font-weight: normal">Grants from government and similar bodies</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock-c0_cont_2" id="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects.
The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If
grant funds are received prior to qualifying expenses being incurred or assets purchased or prior to all grant conditions have been met,
such amounts are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other
operating income in the period in which the corresponding expenses are incurred (or, for expenses incurred prior to all grant conditions
being met, in the period in which reasonable assurance that all grant conditions will be met is attained). If the funds reimburse purchased
assets, the liability is reduced with a corresponding amount deducted from the asset&#8217;s carrying amount upon recording of the qualified
asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group up
to five years after concluding the project sponsored by the government.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the Group announced that it received a grant of up to &#8364;<ix:nonFraction contextRef="c54" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="6" unitRef="eur" id="ixv-29766">43.7</ix:nonFraction> million from the German Ministry of Education and Research
and the German Ministry of Health to support its development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent
changes in the Group&#8217;s research and development plan and fewer costs projected within the timeframe of the grant, it was notified
that the amount available to it was &#8364;<ix:nonFraction contextRef="c54" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAcquiredByWayOfGovernmentGrant" scale="6" unitRef="eur" id="ixv-29767">41.4</ix:nonFraction> million. The grant is structured as a reimbursement of <ix:nonFraction contextRef="c55" decimals="2" format="ixt:num-dot-decimal" name="ifrx:PercentageOfGrant" scale="-2" unitRef="pure" id="ixv-29768">80</ix:nonFraction>% of certain pre-specified expenses
related to the clinical development and manufacturing of vilobelimab. The grant period ended on June 30, 2023. In total, during the duration
of the grant period through December 31, 2023, the Group received &#8364;<ix:nonFraction contextRef="c56" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentGovernmentGrants" scale="6" unitRef="eur" id="ixv-29769">33.3</ix:nonFraction> million to support its activities regarding the development
of vilobelimab as a new therapeutic agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial
scale manufacturing process to ensure the ability of being able to provide such treatment to the broader population.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="ifrx_NotesToTheCashFlowStatementPolicyTextBlock-c0_cont_1" escape="true" name="ifrx:NotesToTheCashFlowStatementPolicyTextBlock" id="ixv-23157"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(f)
</i></b><i><span style="font-variant: normal; font-weight: normal">Notes to the cash flow statement, cash, and cash equivalents</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_NotesToTheCashFlowStatementPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated statements of cash flows have been prepared using the indirect method for cash flows from operating activities. The cash
disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash comprises cash on hand and demand
deposits. Cash equivalents are short-term bank deposits that are readily convertible to a known amount of cash and are not subject to
a significant risk of changes in value with an original maturity of three months or less. Interest paid and received is included in the
cash from operating activities.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="ixv-23171"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(g)
</i></b><i><span style="font-variant: normal; font-weight: normal">Research and development expenses</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses comprise third party services, wages and salaries, cost of materials, intellectual property related expenses,
depreciation and amortization of relevant equipment and intangibles as well as overhead. Research and development expenses mainly consist
of costs for clinical trials and manufacturing of the Company&#8217;s clinical drug products; additionally, costs are incurred for pre-clinical
activities as well as basic research activities.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development expenses were capitalized because
management assessed that not all the recognition criteria of IAS&#160;38 had been met. This assessment is due to the general uncertainties
in drug development and the unpredictability of regulatory requirements. Therefore, research and development expenditures are expensed
when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" id="ixv-23205"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(h)
</i></b><i><span style="font-variant: normal; font-weight: normal">Employee benefits</span></i></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Short-term employee benefits</i></span></p></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for wages and salaries and cash bonuses are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as employee benefits in the consolidated statements of financial position. A liability is recognized if the Group has a
present legal or constructive obligation to pay such amount as a result of past service provided by the employee and if such obligation
can be estimated reliably.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_3"><p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Share-based payment transactions</i></span></p></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense,
with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect
the number of awards for which the related service conditions are expected to be met, including an estimate of forfeitures, such that
the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based
payment awards with immediate vesting, the&#160;grant-date fair value of the share-based payment is measured to reflect such conditions and
there is no gain or loss recognized for differences between expected and actual outcomes.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="ixv-23237"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)
</i></b><i><span style="font-variant: normal; font-weight: normal">Lease arrangements</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of <ix:nonNumeric contextRef="c57" continuedAt="ifrx_RentalContractsFixedPeriod-c57_cont_1" format="ixt-sec:durwordsen" name="ifrx:RentalContractsFixedPeriod" id="ixv-29770">one</ix:nonNumeric>
to <ix:nonNumeric contextRef="c58" format="ixt-sec:durwordsen" name="ifrx:RentalContractsFixedPeriod" id="ixv-29771">three<ix:continuation id="ifrx_RentalContractsFixedPeriod-c57_cont_1"> years</ix:continuation></ix:nonNumeric> but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_7"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_2"><p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Right-of-use assets</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_8"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#8217;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_9"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Lease liabilities</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_10"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_11"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_4"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_12"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)
Short-term leases and leases of low-value assets</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_13"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_15" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_14"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Determining the lease term of contracts</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_16" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_15"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_17" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_16"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_18" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_17"><ix:continuation id="_DescriptionOfAccountingPolicyForLeasesExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_19" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" id="ixv-23338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)
</i></b><i><span style="font-variant: normal; font-weight: normal">Interest income</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_20" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_19"><ix:continuation id="_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_21" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" id="ixv-23354"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)
</i></b><i><span style="font-variant: normal; font-weight: normal">Intangible assets</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_22" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_21"><ix:continuation id="_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="ifrx:AmortizedPeriod" id="ixv-29773">three years</ix:nonNumeric>. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_23" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="ixv-23370"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)
</i></b><i><span style="font-variant: normal; font-weight: normal">Property and equipment</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_24" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_23"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_25" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_24"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_26" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_25"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_27" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_26"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory equipment: <ix:nonNumeric contextRef="c59" continuedAt="_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment-c59_cont_1" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="ixv-29774">three</ix:nonNumeric> to <ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="ixv-29775">13</ix:nonNumeric><ix:continuation id="_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment-c59_cont_1"> years</ix:continuation></span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment: <ix:nonNumeric contextRef="c61" continuedAt="_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment-c61_cont_1" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="ixv-29777">one</ix:nonNumeric> to <ix:nonNumeric contextRef="c62" format="ixt-sec:durwordsen" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" id="ixv-29778">five<ix:continuation id="_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment-c61_cont_1"> years</ix:continuation></ix:nonNumeric></span></td></tr></table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_28" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_27"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_29" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_28"><ix:continuation id="_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#8216;other income&#8217;
or &#8216;other expenses&#8217; in the consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_5"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_30" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_29"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" id="ixv-23446"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(m)
</i></b><i><span style="font-variant: normal; font-weight: normal">Impairment of assets</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_31" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_30"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_32" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_31"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there has been a change in the estimates used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_33" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_32"><ix:continuation id="_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no impairments or reversals of impairments in 2021, 2022 or 2023.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_34" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_33"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="ixv-23474"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(n)
</i></b><i><span style="font-variant: normal; font-weight: normal">Financial assets and liabilities (financial instruments)</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_35" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_34"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Definition</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_36" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_35"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#8217;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;D projects).</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_37" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_36"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Criteria for the recognition and derecognition, initial measurement</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_38" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_37"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_39" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_38"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_40" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_39"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iii) Subsequent measurement method</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_41" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_40"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considering
the Group&#8217;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_42" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_41"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_43" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_42"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#8216;3.8
Financial assets and financial liabilities.&#8217;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_6"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_44" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_43"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Criteria for realization of income and expenses</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_45" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_44"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_46" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_45"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_47" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_46"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14" id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#8216;C.8. Net Financial Result&#8217;.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_48" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_47"><ix:continuation id="_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_49" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="ixv-23587"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(o)
</i></b><i><span style="font-variant: normal; font-weight: normal">Fair Value Measurement</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_50" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_49"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#8216;D.8. Financial
assets and financial liabilities&#8217;).</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_51" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_50"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_52" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_51"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1, quoted prices in active markets for identical assets or liabilities.</span></td></tr></table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_53" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_52"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).</span></td></tr></table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_54" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_53"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).</span></td></tr></table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_55" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_54"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_56" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_55"><ix:continuation id="_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_57" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_56"><ix:nonNumeric contextRef="c0" continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="ixv-23654"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(p)
</i></b><i><span style="font-variant: normal; font-weight: normal">Income tax</span></i></span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_58" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_57"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_59" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_58"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Current income tax</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_60" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_59"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_61" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_60"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_62" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_61"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(ii) Deferred income tax</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_63" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_62"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_64" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_63"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8" id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_65" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_64"><ix:continuation id="_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#8217;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8" id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_7"><ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_66" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_65"><ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" id="ixv-23728"><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Significant accounting judgements, estimates and assumptions</span></p></ix:nonNumeric></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_67" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_66"><ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_2" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_68" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_67"><ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_3" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#8217;s accounting policies involve the following areas:</span></p></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_69" id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_68"><ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_4" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_3"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Accounting for share-based payments</i></span></p></ix:continuation></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_5" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:continuation id="_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-c0_cont_69">When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#8216;C.10.(b).</ix:continuation> Measurement of fair values of share options granted&#8217;). In 2023, the Company&#8217;s share price volatility
for the purposes of the calculation was determined on the basis of the <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="ifrx:AnnualizedAverageSharePricePeriod" id="ixv-29781">5</ix:nonNumeric>-year annualized average share price, which management believes
will be indicative of the share price development of the Company in future periods. This led to a range of applied volatility rates in
2023 of <ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29782">135</ix:nonFraction>% to <ix:nonFraction contextRef="c64" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-29783">145.66</ix:nonFraction>% for the different options granted during the year of this report.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_6" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company must estimate the number of equity instruments which will vest in future periods as awards may be forfeited prior to vesting
due to an awardee&#8217;s failure to satisfy a performance condition, including due to employment termination. An assumption of the forfeiture
rate is regularly made on the basis of historical information and adjusted to reflect future expectations. Revisions to the forfeiture
rate could result in a cumulative effect of the change in estimate for current and prior periods to be recognized in the period of change.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_7" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_6"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Measurement of third-party R&amp;D clinical trial and contracted manufacturing expense</i></span></p></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_8" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
measuring R&amp;D expenses for the reporting period, the Company estimates the amount of expense to recognize and liability to accrue
to the extent that invoices of the Company&#8217;s contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations
(&#8220;CDMOs&#8221;) are not yet received and exceed any prepayments made. The timing of the invoicing of project services by CROs follow
contractual billing schedules and can occur several months prior to or following a reporting period. This estimation involves determining
a percentage-of-completion whereby the degree to which services have been rendered for the individual project activities contracted from
the CRO and CDMOs is assessed and estimated by in-house R&amp;D project managers and reviewed by the controlling department. This percentage-of-completion
is used to measure the amount of the unbilled project activities which have already been rendered by the reporting date and the associated
R&amp;D expense and liability to recognize as a result.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_9" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage-of-completion estimates are based on the best information available at the time. However, additional information may become
available in the future and management may adjust the estimate in such future periods. In this event, the Company may be required to
record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. The
Company considers resulting increases or decreases in expenses as changes in estimates and reflects such changes in research and development
expenses in the period identified.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_10" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrued &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:AccruedIncomeIncludingContractAssets" scale="6" unitRef="eur" id="ixv-29784">4.4</ix:nonFraction> million as of December 31, 2023 and &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:AccruedIncomeIncludingContractAssets" scale="6" unitRef="eur" id="ixv-29785">2.3</ix:nonFraction> million as of December 31, 2022 (see Note &#8216;D.11. Trade and other
payables&#8217;) in third-party accruals in relation to its ongoing clinical trials and manufacturing activities. As of these dates, prepayments
were recorded for those payments made against which no services had yet been rendered (2023: &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="6" unitRef="eur" id="ixv-29786">3.7</ix:nonFraction> million, 2022: &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="6" unitRef="eur" id="ixv-29787">9.8</ix:nonFraction> million,
see Note &#8216;D.6. Other assets&#8217;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfChangesInAccountingPoliciesExplanatory-c0_cont_8"><ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_11" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_10"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Realizability of Inventories</i></span></p></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_12" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost and net realizable value. Net realizable value comprises the estimated sales proceeds less the necessary
expected costs up to the time of sale. For determining the net realizable value, at each reporting date, the Company estimates excess
and obsolete inventory primarily using a model of expected future sales and using assumptions with significant estimation uncertainty
such as expected medical need and expected market penetration.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_13" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these estimates rely, in part, on management&#8217;s assumptions about future events outside of the Company&#8217;s control, such as
continuation of the emergency use authorization in the United States and granting of marketing authorization in the European Union. In
making these assumptions, management assesses the probability of these authorizations remaining in place or being granted, as applicable,
by considering correspondence with the relevant regulatory authorities and the Company&#8217;s actions to achieve any required conditions
for the authorizations.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_14" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the possible alternative uses for raw materials, unfinished and finished products is taken into consideration.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_15" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly assesses market and sales trends, market conditions, disease prevalence, competitive landscape, and regulatory environment
to refine estimates for excess and obsolete inventory. Based on these assessments, and taking manufacturing lead-times into consideration,
management takes operational decisions to order inventory based on inventory aging and the criteria mentioned above.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_16" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-downs for the year ended December 31, 2023 amounted to &#8364;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InventoryWritedown2011" scale="3" unitRef="eur" id="ixv-29788">521</ix:nonFraction>k (prior year: &#8364;<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:InventoryWritedown2011" scale="3" unitRef="eur" id="ixv-29789">0</ix:nonFraction>k) and were mainly due to the expiration
of shelf life of finished goods.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
included in the model of expected future demand may require revision in future periods which could result in changes to the estimate
of excess and obsolete inventory and in inventory write-downs.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_1" escape="true" name="ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" id="ixv-23846"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Consolidated statements of operations and comprehensive loss</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>1. <ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRevenueExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRevenueExplanatory" id="ixv-29790">Revenues</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfRevenueExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="eur" id="ixv-29791">63,089</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="eur" id="ixv-29792">63,089</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Group began the commercialization of GOHIBIC (vilobelimab) in the United States. In connection with the start of the commercialization,
the Group entered into agreements with certain subsidiaries of Cencora Inc. (&#8220;Cencora&#8221;) (formerly known as AmerisourceBergen
Corp.) to act as the Group&#8217;s U.S. distributor and make GOHIBIC (vilobelimab) available for order by U.S. hospital customers. Cencora
provides cold storage, cold-chain distribution services, inventory management and secondary labeling/packaging, among other services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company realized revenues from the product sales for the first time since its inception. Revenues reported are sales to end
customers (hospitals). Sales to distributors do not constitute completion of a performance obligation towards a customer and, thus, do
not result in the recognition of revenue for the Company under IFRS 15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>2. <ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCostOfSalesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCostOfSalesExplanatory" id="ixv-29793">Cost of sales</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfCostOfSalesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Cost of Sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="eur" id="ixv-29794">532,262</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CostOfSales" scale="0" unitRef="eur" id="ixv-29795">532,262</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of sales recognized during the twelve months ended December 31, 2023, are related to GOHIBIC (vilobelimab) revenues in the United States
and to write-downs of inventory.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_2" id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of sales for products sold in these periods do not include costs of materials, as the associated costs of these materials were incurred
in prior periods, before the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted an Emergency Use Authorization (the &#8220;EUA&#8221;)
for GOHIBIC (vilobelimab) in April 2023. These materials were recorded as &#8216;research and development expenses&#8217; in the periods
they were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of sales during the twelve months ended December 31, 2023 mainly consists of write-downs of inventories that will expire prior to
their expected sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>3. <ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureOfSalesAndMarketingExpenseTextBlock" id="ixv-29796">Sales and marketing expenses</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29797">1,851,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29798">1,040,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29799">67,462</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29800">1,054,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29801">54,583</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total sales and marketing expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur" id="ixv-29802">4,001,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the twelve months ended December 31, 2023 the Group incurred &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="6" unitRef="eur" id="ixv-29803">4.0</ix:nonFraction> million of sales and marketing expenses in the United States of
America. These expenses are mainly composed of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:SellingExpense" scale="6" unitRef="eur" id="ixv-29804">1.0</ix:nonFraction> million in personnel costs and &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceCost" scale="6" unitRef="eur" id="ixv-29805">1.9</ix:nonFraction> million in external services for distribution
of GOHIBIC (vilobelimab). The Group started with its commercialization activities when the EUA was granted in April 2023. Prior to that,
no sales and marketing expenses had been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>4. Research and development expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfResearchAndDevelopmentExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory" id="ixv-24143"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased in 2023 compared to 2022 by &#8364;<ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" unitRef="eur" id="ixv-29806">3.5</ix:nonFraction> million. The table below shows the composition of research and
development expenses.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfResearchAndDevelopmentExpenseExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29807">31,802,983</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29808">28,543,503</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29809">28,247,081</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which clinical material and related manufacturing services</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29810">18,109,345</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29811">16,194,152</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29812">6,615,840</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which clinical, pre-clinical studies</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29813">13,693,638</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29814">12,349,351</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29815">21,631,240</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29816">6,776,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29817">6,957,866</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29818">5,941,813</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29819">1,500,670</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29820">2,456,571</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29821">1,622,898</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29822">1,758,283</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29823">1,690,448</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29824">1,074,710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29825">686,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29826">334,273</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29827">434,331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29828">41,024,131</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29829">37,526,090</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur" id="ixv-29830">35,697,935</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>5. General and administrative expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfGeneralAndAdministrativeExpenseExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory" id="ixv-24291"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses decreased by &#8364;<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="6" unitRef="eur" id="ixv-29831">2.2</ix:nonFraction> million in 2023 from the prior year, predominantly due to lower costs from equity-settled
share-based payments.</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfGeneralAndAdministrativeExpenseExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Employee benefits expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29832">5,392,905</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29833">7,125,798</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29834">6,500,680</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29835">1,846,356</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29836">3,587,785</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29837">2,709,307</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29838">3,239,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29839">3,104,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29840">2,065,423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29841">1,934,880</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29842">2,330,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29843">1,615,920</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation &amp; amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29844">507,905</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29845">526,325</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29846">551,566</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation expense for non-executive directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29847">305,984</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29848">248,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29849">271,248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c88" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29850">1,247,273</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29851">1,533,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29852">979,884</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29853">12,628,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29854">14,869,564</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-29855">11,984,722</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_3" id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_2"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>6. Other income</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income was &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="6" unitRef="eur" id="ixv-29856">13.2</ix:nonFraction> million, which is primarily attributable to income recognized from grant payments received from the German federal
government for the development of vilobelimab in severe COVID-19 patients, including expenses related to clinical development and manufacturing
process development. <ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureOfOtherIncomeExplanatoryTextBlock" id="ixv-29857">Other income decreased in 2023, compared to the prior year, due to the incurrence of less expenses eligible for
reimbursement under the grant and the end of the grant period on June 30, 2023.</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in">Other income from government grants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="0" unitRef="eur" id="ixv-29858">13,155,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="0" unitRef="eur" id="ixv-29859">20,116,542</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Further other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:LiabilityForFuturePolicyBenefitPeriodExpense" scale="0" unitRef="eur" id="ixv-29860">64,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:LiabilityForFuturePolicyBenefitPeriodExpense" scale="0" unitRef="eur" id="ixv-29861">42,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:LiabilityForFuturePolicyBenefitPeriodExpense" scale="0" unitRef="eur" id="ixv-29862">54,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="0" unitRef="eur" id="ixv-29863">13,219,704</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="0" unitRef="eur" id="ixv-29864">20,159,169</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="0" unitRef="eur" id="ixv-29865">54,221</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>7. Employee benefits expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfEmployeeBenefitsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory" id="ixv-24532"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the items of employee benefits expenses:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfEmployeeBenefitsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Wages and salaries</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29866">8,192,143</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29867">6,863,423</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29868">6,919,166</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Social security contributions (employer&#8217;s share)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29869">944,712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29870">672,534</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29871">671,697</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity-settled share-based payment expenses (see Note C.10. Share-based payments)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29872">3,414,488</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29873">6,044,356</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29874">4,332,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29875">659,002</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29876">503,351</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29877">519,425</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29878">13,210,345</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29879">14,083,664</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:Employeebenefitsexpense" scale="0" unitRef="eur" id="ixv-29880">12,442,493</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of employees as of December 31, 2023 increased to 66 (equivalent to 62.2 full time equivalents (FTEs)) from 48 employees (equivalent
to 44.3 FTEs) at the end of 2022 and 59 employees (equivalent to 55.9 FTEs) at the end of 2021. These numbers are as of December 31 and
do not constitute annual average numbers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>8. <ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfNetFinancialResultTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureOfNetFinancialResultTextBlock" id="ixv-29881">Net financial result</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="ifrx_DisclosureOfNetFinancialResultTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="eur" id="ixv-29882">3,804,827</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="eur" id="ixv-29883">608,679</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueFromInterest" scale="0" unitRef="eur" id="ixv-29884">109,391</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur" id="ixv-29885">16,538</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur" id="ixv-29886">23,303</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur" id="ixv-29887">10,714</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29888">19,090</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29889">21,947</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur" id="ixv-29890">14,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Financial result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29891">3,769,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29892">563,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncomeCost" scale="0" unitRef="eur" id="ixv-29893">84,622</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign exchange income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeIncome" scale="0" unitRef="eur" id="ixv-29894">5,529,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeIncome" scale="0" unitRef="eur" id="ixv-29895">6,924,697</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeIncome" scale="0" unitRef="eur" id="ixv-29896">5,569,836</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeExpense" scale="0" unitRef="eur" id="ixv-29897">7,371,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeExpense" scale="0" unitRef="eur" id="ixv-29898">4,482,399</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeExpense" scale="0" unitRef="eur" id="ixv-29899">3,605,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Foreign exchange result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeResult" scale="0" sign="-" unitRef="eur" id="ixv-29900">1,841,872</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeResult" scale="0" unitRef="eur" id="ixv-29901">2,442,298</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeResult" scale="0" unitRef="eur" id="ixv-29902">1,964,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OtherFinancialResult" scale="0" unitRef="eur" id="ixv-29903">313,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OtherFinancialResult" scale="0" sign="-" unitRef="eur" id="ixv-29904">252,471</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OtherFinancialResult" scale="0" sign="-" unitRef="eur" id="ixv-29905">44,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetFinancialResult" scale="0" unitRef="eur" id="ixv-29906">2,240,566</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetFinancialResult" scale="0" unitRef="eur" id="ixv-29907">2,753,256</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetFinancialResult" scale="0" unitRef="eur" id="ixv-29908">2,004,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
financial result decreased by &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:NetFinancialCost" scale="6" unitRef="eur" id="ixv-29909">0.5</ix:nonFraction>&#160;million from 2022 to 2023. This overall decrease was comprised of higher interest income
of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnDeposits" scale="6" unitRef="eur" id="ixv-29910">3.2</ix:nonFraction>&#160;million from marketable securities and short-term deposits in U.S. dollars held by the Company and its subsidiaries
(from &#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:ShortTermMarketableSecurities" scale="6" unitRef="eur" id="ixv-29911">0.6</ix:nonFraction>&#160;million in 2022 to &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:ShortTermMarketableSecurities" scale="6" unitRef="eur" id="ixv-29912">3.8</ix:nonFraction>&#160;million in 2023), a reduction in foreign exchange by &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="6" unitRef="eur" id="ixv-29913">4.3</ix:nonFraction>&#160;million (from
a gain of &#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ForeignExchangeGain" scale="6" unitRef="eur" id="ixv-29914">2.4</ix:nonFraction>&#160;million in 2022 to a loss of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ForeignExchangeLoss" scale="6" unitRef="eur" id="ixv-29915">1.8</ix:nonFraction>&#160;million in 2023) and higher other financial result of &#8364;<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="6" unitRef="eur" id="ixv-29916">0.6</ix:nonFraction>&#160;million
(from a loss of &#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" scale="6" unitRef="eur" id="ixv-29917">0.3</ix:nonFraction>&#160;million in 2022 to a gain of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" scale="6" unitRef="eur" id="ixv-29918">0.3</ix:nonFraction>&#160;million in 2023) due to an adjustment to the expected credit
loss allowance in 2023, which is deducted from the Company&#8217;s current and non-current financial assets (please also refer to Note
D.6. &#8216;Other assets&#8217;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency income and expenses arise from the translation of cash and cash equivalents, marketable securities and other financial assets
and liabilities denominated in foreign currencies at the exchange rates prevailing at the balance sheet date. All resulting translation
differences are recognized in the income statement. These gains and losses are caused by a change in exchange rates at the reporting
dates and may not ultimately be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_4" id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_3"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>9. Loss per share</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per ordinary share is calculated by dividing the loss of the period by the weighted average number of ordinary shares outstanding during
the period. The weighted number of ordinary shares outstanding for the financial year 2023 was <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:WeightedNumberOfCommonSharesOutstanding" scale="0" unitRef="shares" id="ixv-29919">54,940,137</ix:nonFraction>, for 2022 it amounted to <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:WeightedNumberOfCommonSharesOutstanding" scale="0" unitRef="shares" id="ixv-29920">44,207,873</ix:nonFraction>
and for 2021 it was <ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="ifrx:WeightedNumberOfCommonSharesOutstanding" scale="0" unitRef="shares" id="ixv-29921">41,629,974</ix:nonFraction>. Loss per share was &#8364;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:LossPerShare" scale="0" unitRef="eurPershares" id="ixv-29922">0.78</ix:nonFraction>, &#8364;<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrx:LossPerShare" scale="0" unitRef="eurPershares" id="ixv-29923">0.67</ix:nonFraction> and &#8364;<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrx:LossPerShare" scale="0" unitRef="eurPershares" id="ixv-29924">1.10</ix:nonFraction> in 2023, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company is in a loss-making situation, the diluted loss per share is the same as basic loss per share, because the weighted average
number of shares to be issued upon the exercise of the stock options, the only dilutive instruments issued, would produce an anti-dilutive
effect. Refer to Note &#8216;C.10. for the balances of outstanding share options.&#8217;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>10. Share-based payments</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>a) Equity-settled share-based payment arrangements</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-24869"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of its historical financing rounds prior to 2016, InflaRx GmbH established equity-settled share-based payment programs. Those
InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. in November 2017:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29925">148,433</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure">0.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29927">148,433</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure">0.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29929">148,433</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure" id="ixv-29931">148,433</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:NumberOfOutstandingShareOptions" scale="0" unitRef="pure">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29933">148,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="eurPershares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="usdPershares" id="ixv-29935">148,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" unitRef="eurPershares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average share price (WAEP)</span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for all options granted prior to 2016 outstanding at the end of the year was &#8364;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceOfOutstandingShareOptions" scale="0" unitRef="eurPershares" id="ixv-29937">0.01</ix:nonFraction> per share or less (2022: &#8364;<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceOfOutstandingShareOptions" scale="0" unitRef="eurPershares" id="ixv-29938">0.01</ix:nonFraction>
or less).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and conditions of the share option plan of 2016 (the &#8220;2016 Plan&#8221;), InflaRx GmbH granted rights to subscribe for
InflaRx GmbH&#8217;s common shares to directors, senior management, and key employees. <ix:nonNumeric contextRef="c132" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c132_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-29939">Those InflaRx GmbH options were converted into
options for ordinary shares of the Company in November 2017:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c132_cont_2" id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c132_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" scale="0" unitRef="shares" id="ixv-29940">888,632</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="usdPershares">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="eurPershares">1.74</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" scale="0" unitRef="shares" id="ixv-29943">888,632</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="usdPershares">3.35</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="eurPershares">2.96</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80; -sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><div style="-sec-ix-hidden: hidden-fact-81">&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" scale="0" unitRef="shares" id="ixv-29946">888,632</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="usdPershares">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="eurPershares">1.68</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" scale="0" unitRef="shares" id="ixv-29949">888,632</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="usdPershares">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" id="ix_13_fact" name="ifrx:NumberOfWeightedAverageSharesOutstanding" scale="0" unitRef="eurPershares">1.74</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfSharesOptionsExercisable" scale="0" unitRef="shares" id="ixv-29952">888,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" id="ix_14_fact" name="ifrx:WAEPExercisables" scale="0" unitRef="usdPershares">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" id="ix_15_fact" name="ifrx:WAEPExercisables" scale="0" unitRef="eurPershares">1.68</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfSharesOptionsExercisable" scale="0" unitRef="shares" id="ixv-29955">888,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" id="ix_16_fact" name="ifrx:WAEPExercisables" scale="0" unitRef="usdPershares">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" id="ix_17_fact" name="ifrx:WAEPExercisables" scale="0" unitRef="eurPershares">1.74</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c132_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $<ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ConversionRate" scale="0" unitRef="eurPershares" id="ixv-29958">0.9050</ix:nonFraction>, average rate 2023 $<ix:nonFraction contextRef="c68" decimals="4" format="ixt:num-dot-decimal" name="ifrx:AverageRate" scale="0" unitRef="eurPershares" id="ixv-29959">0.9246</ix:nonFraction>, December 31,2022 $<ix:nonFraction contextRef="c69" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ConversionRate" scale="0" unitRef="eurPershares" id="ixv-29960">0.9376</ix:nonFraction>, average rate 2022 $<ix:nonFraction contextRef="c69" decimals="4" format="ixt:num-dot-decimal" name="ifrx:AverageRate" scale="0" unitRef="eurPershares" id="ixv-29961">0.9489</ix:nonFraction></span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life for the share options outstanding under the <ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="ifrx:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" id="ixv-29962">2016</ix:nonNumeric> Plan as of December&#160;31,&#160;2023 was
<ix:nonNumeric contextRef="c70" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-29963">7.94</ix:nonNumeric> years (2022: <ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-29964">8.94</ix:nonNumeric> years).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_5" id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c143" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c143_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="ixv-25124"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the closing of its initial public offering, InflaRx N.V. established a new incentive plan (the &#8220;2017 Plan&#8221;).
The initial maximum number of ordinary shares available for issuance under equity incentive awards granted pursuant to the 2017 Plan
equals <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="ifrx:MaximumNumberOfCommonSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-29965">2,341,097</ix:nonFraction> ordinary shares. On January 1, 2021 and on January 1 of each calendar year thereafter, an additional number of shares
equal to <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ordinarySharesPercentage" scale="-2" unitRef="pure" id="ixv-29966">4</ix:nonFraction>% of the total outstanding ordinary shares on December 31 of the immediately preceding year (or any lower number of shares
as determined by the Board of Directors) will become available for issuance under equity incentive awards granted pursuant to the 2017
Plan:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c143_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c143_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfOutstandingSharesOption" scale="0" unitRef="shares" id="ixv-29967">4,985,523</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" id="ix_18_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="usdPershares">1.97</ix:nonFraction> /&#8364;<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" id="ix_19_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="eurPershares">1.84</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfOutstandingSharesOption" scale="0" unitRef="shares" id="ixv-29970">3,170,046</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" id="ix_20_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="usdPershares">3.95</ix:nonFraction> /&#8364;<ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" id="ix_21_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="eurPershares">3.49</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-29973">1,735,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" id="ix_22_fact" name="ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares">2.58</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" id="ix_23_fact" name="ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" scale="0" unitRef="eurPershares">2.39</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfShareOptionGrantedInSharebasedPaymentArrangement" scale="0" unitRef="shares" id="ixv-29976">1,966,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" id="ix_24_fact" name="ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares">1.98</ix:nonFraction> / &#8364;<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" id="ix_25_fact" name="ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" scale="0" unitRef="eurPershares">1.88</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfShareOptionExercisedInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-29979">31,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" id="ix_26_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares">2.70</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" id="ix_27_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" scale="0" unitRef="eurPershares">2.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfShareOptionExercisedInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-29982">136,259</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" id="ix_28_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares">2.22</ix:nonFraction> /&#8364;<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" id="ix_29_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" scale="0" unitRef="eurPershares">2.11</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-29985">105,327</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" id="ix_30_fact" name="ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares">2.16</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" id="ix_31_fact" name="ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="eurPershares">2.00</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" scale="0" sign="-" unitRef="shares" id="ixv-29988">14,930</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" id="ix_32_fact" name="ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="usdPershares">1.86</ix:nonFraction> /&#8364;<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" id="ix_33_fact" name="ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" scale="0" unitRef="eurPershares">1.76</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c156" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfOutstandingSharesOption" scale="0" unitRef="shares" id="ixv-29991">6,584,946</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" id="ix_34_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="usdPershares">2.12</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" id="ix_35_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="eurPershares">1.92</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfOutstandingSharesOption" scale="0" unitRef="shares" id="ixv-29994">4,985,523</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" id="ix_36_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="usdPershares">1.97</ix:nonFraction> /&#8364;<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" id="ix_37_fact" name="ifrx:NumberOfOutstandingsWeightedAverageEarningPershare" scale="0" unitRef="eurPershares">1.84</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" scale="0" unitRef="shares" id="ixv-29997">5,577,384</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" id="ix_38_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" scale="0" unitRef="usdPershares">2.01</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c152" decimals="2" format="ixt:num-dot-decimal" id="ix_39_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" scale="0" unitRef="eurPershares">1.82</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="ifrx:NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" scale="0" unitRef="shares" id="ixv-30000">4,157,148</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" id="ix_40_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" scale="0" unitRef="usdPershares">1.93</ix:nonFraction> /&#8364;<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" id="ix_41_fact" name="ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" scale="0" unitRef="eurPershares">1.81</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c143_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $<ix:nonFraction contextRef="c50" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ConversionRate" scale="0" unitRef="usdPershares" id="ixv-30003">0.9050</ix:nonFraction>, average rate 2023 $<ix:nonFraction contextRef="c50" decimals="4" format="ixt:num-dot-decimal" name="ifrx:AverageRate" scale="0" unitRef="usdPershares" id="ixv-30004">0.9246</ix:nonFraction>, December 31, 2022 $<ix:nonFraction contextRef="c51" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ConversionRate" scale="0" unitRef="usdPershares" id="ixv-30005">0.9376</ix:nonFraction>, average rate 2022 $<ix:nonFraction contextRef="c51" decimals="4" format="ixt:num-dot-decimal" name="ifrx:AverageRate" scale="0" unitRef="usdPershares" id="ixv-30006">0.9489</ix:nonFraction></span></ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life for the share options outstanding under the 2017 Plan as of December 31, 2023 was <ix:nonNumeric contextRef="c68" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30007">6.61</ix:nonNumeric> years
(2022: <ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30008">6.70</ix:nonNumeric> years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Options granted in 2023 vest over one year except for options granted on July 7, 2023 which partially vest over three years. Options
granted before 2023 vest over a period of one, two or three years, depending on the grant, with 1/2 or 1/3, respectively, of the options
vesting after the end of the 1st year from vesting start and the remaining options vesting quarterly in equal portions thereafter. Vesting
of these unvested share options is subject to a service condition at the time of vesting, and no market or performance conditions are
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average fair value of options granted during 2023 was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:WeightedAverageFairValueOptionsGrantedDuringTheYear" scale="0" unitRef="usdPershares" id="ixv-30009">2.58</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:WeightedAverageFairValueOptionsGrantedDuringTheYear" scale="0" unitRef="eurPershares" id="ixv-30010">2.39</ix:nonFraction> (2022 after repricing: $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrx:WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" scale="0" unitRef="usdPershares" id="ixv-30011">1.70</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrx:WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" scale="0" unitRef="eurPershares" id="ixv-30012">1.61</ix:nonFraction>). The range of
exercise prices for options outstanding at the end of the year was $<ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="usdPershares" id="ixv-30013">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c57" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="eurPershares" id="ixv-30014">1.74</ix:nonFraction> to $<ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="usdPershares" id="ixv-30015">5.14</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c58" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="eurPershares" id="ixv-30016">4.82</ix:nonFraction> (after repricing in 2022: $<ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="usdPershares" id="ixv-30017">1.86</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="eurPershares" id="ixv-30018">1.74</ix:nonFraction>
to $<ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="usdPershares" id="ixv-30019">5.14</ix:nonFraction>/&#8364;<ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="ifrx:ExercisePriceRange" scale="0" unitRef="eurPershares" id="ixv-30020">4.82</ix:nonFraction>).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares issued for share options exercised during the year were recorded to the commercial register by December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>b)
Measurement of fair values of share options granted under the 2017 Plan</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of options granted under the 2017 Plan was determined using the Black-Scholes valuation model. As the Company&#8217;s ordinary
shares are listed on the Nasdaq Global Select Market, the closing price of the ordinary shares at grant date was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="ixv-25306"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
significant inputs into the model are as follows (weighted average):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<ix:continuation continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_2" id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">FX rate as<br/>
 of grant<br/>
 date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price<br/>
 at grant<br/>
 date/<br/>
 Exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
 volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint<br/>
 based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free<br/>
 rate<br/>
 (interpolated,<br/>
 U.S.<br/>
 sovereign<br/>
 strips curve)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">2021</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 4</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30021">839,260</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30022">4.53</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c159" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30023">0.8133</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#8364;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30024">3.68</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30025">5.14</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c159" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30026">1.35</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonNumeric contextRef="c159" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30027">5.31</ix:nonNumeric></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c159" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30028">0.5</ix:nonFraction></td><td style="width: 0.5%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30029">31,668</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30030">4.57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30031">0.8133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30032">3.72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30033">5.14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30034">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c161" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30035">5.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c161" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30036">0.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30037">327,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30038">2.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30039">0.8458</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30040">2.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30041">2.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30042">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c163" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30043">5.31</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c163" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30044">0.98</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30045">20,710</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30046">2.66</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30047">0.8458</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30048">2.25</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30049">2.99</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30050">1.35</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30051">5.49</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30052">1.01</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30053">1,219,074</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left"/></tr>
  </table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OptionsGranted" scale="0" unitRef="shares" id="ixv-30054">1,219,074</ix:nonFraction> options granted in 2021, <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OptionsGranted" scale="0" unitRef="shares" id="ixv-30055">1,134,436</ix:nonFraction> were granted to members of the executive management or the Board of Directors. In 2021,
<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfStockOptionsForfeited" scale="0" unitRef="shares" id="ixv-30056">36,400</ix:nonFraction> options were forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>



<ix:continuation continuedAt="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_3" id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value per share option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">FX rate as of grant date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value per share option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date/ Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected life (midpoint based)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free rate (interpolated, U.S. sovereign strips curve)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">2022</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;12</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30057">1,516,666</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30058">3.66</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30059">0.8795</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8364;<ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30060">3.22</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30061">4.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30062">1.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c167" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30063">5.31</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c167" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30064">1.57</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;12</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30065">45,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30066">3.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30067">0.8795</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8364;<ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30068">3.24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30069">4.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30070">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30071">5.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c169" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30072">1.59</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repricing,&#160;April&#160;13</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30073">1.20</ix:nonFraction>-$<ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30074">1.63</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30075">0.9237</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8364;<ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30076">1.11</ix:nonFraction>-&#8364;<ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30077">1.50</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30078">1.86</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30079">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c172" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30080">1.83</ix:nonNumeric>-<ix:nonNumeric contextRef="c173" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30081">4.94</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c171" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30082">2.60</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November&#160;21</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30083">405,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30084">2.04</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30085">0.9760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">&#8364;<ix:nonFraction contextRef="c174" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30086">1.99</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30087">2.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30088">1.35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c174" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30089">4.0</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c174" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30090">4.15</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30091">1,966,666</ix:nonFraction></b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OptionsGranted" scale="0" unitRef="shares" id="ixv-30092">1,966,666</ix:nonFraction> options granted in 2022, <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OptionsGranted" scale="0" unitRef="shares" id="ixv-30093">1,223,500</ix:nonFraction> were granted to members of the executive management or the Board of Directors. In 2022,
<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfStockOptionsForfeited" scale="0" unitRef="shares" id="ixv-30094">136,259</ix:nonFraction> options were forfeited, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfOptionsExercised" scale="0" unitRef="shares" id="ixv-30095">14,930</ix:nonFraction> were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<ix:continuation id="_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FX rate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of<br/>
 grant<br/>
 date</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share<br/>
 price at<br/>
 grant<br/>
 date/</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/>
 price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
 volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected<br/>
 life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free<br/>
 rate<br/>
 (interpolated,<br/>
 U.S.<br/>
 sovereign<br/>
 strips curve)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">2023</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 24</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30096">1,454,250</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30097">2.11</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c176" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30098">0.9008</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#8364;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c176" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30099">1.90</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30100">2.37</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c176" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30101">1.35</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonNumeric contextRef="c176" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30102">5.30</ix:nonNumeric></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c176" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30103">3.571</ix:nonFraction></td><td style="width: 0.5%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30104">52,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30105">2.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30106">0.9008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30107">1.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30108">2.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30109">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c178" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30110">5.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c178" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30111">3.565</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30112">60,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30113">3.61</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30114">0.9361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30115">3.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30116">4.19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30117">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c180" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30118">4.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c180" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30119">3.820</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30120">57,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30121">3.59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30122">0.9184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30123">3.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30124">3.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30125">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c182" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30126">5.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c182" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30127">4.320</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30128">100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30129">3.64</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30130">0.9184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30131">3.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30132">3.89</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30133">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c184" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30134">6.10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c184" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30135">4.286</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30136">4,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30137">3.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30138">0.8911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30139">3.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30140">3.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30141">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c186" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30142">5.50</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c186" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30143">4.320</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30144">7,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuePerOptions" scale="0" unitRef="usdPershares" id="ixv-30145">3.15</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c188" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ForeignExchangeRateAsOfGrantDate" scale="0" unitRef="usdPershares" id="ixv-30146">0.9378</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#8364;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c188" decimals="2" format="ixt:num-dot-decimal" name="ifrx:FairValuesPerOptions" scale="0" unitRef="eurPershares" id="ixv-30147">2.95</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SharePriceAtGrantDateExercisePrices" scale="0" unitRef="usdPershares" id="ixv-30148">3.54</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c188" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30149">1.46</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c188" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" id="ixv-30150">5.50</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c188" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure" id="ixv-30151">4.320</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareOptionsGrantedOptions" scale="0" unitRef="shares" id="ixv-30152">1,735,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OptionsGranted" scale="0" unitRef="shares" id="ixv-30153">1,735,750</ix:nonFraction> options granted in 2023, <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OptionsGranted" scale="0" unitRef="shares" id="ixv-30154">1,136,000</ix:nonFraction> were granted to members of the executive management or the Board of Directors. In 2023,
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfStockOptionsForfeited" scale="0" unitRef="shares" id="ixv-30155">31,000</ix:nonFraction> options were forfeited, <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NumberOfOptionsExercised" scale="0" unitRef="shares" id="ixv-30156">105,327</ix:nonFraction> were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
dividends are <span style="-sec-ix-hidden: hidden-fact-84">nil</span> for all share options listed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
price volatility is calculated on the basis of annualized monthly volatility rate of the Company&#8217;s share price over the last five
years preceding the valuation date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of outcomes for the expected life of the instruments has been based on expectations on option holder behavior in the scenarios
considered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dividend yield has no impact due to the anti-dilution clause as defined in the 2017 Plan.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory" id="ixv-26284"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Notes to the consolidated statements of financial position</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>1. <ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="ixv-30157">Property and equipment</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property<br/>
 and<br/>
 equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Advance <br/>payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">At January 1, 2022</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" unitRef="eur" id="ixv-30158">1,267,611</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" unitRef="eur" id="ixv-30159">1,267,611</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30160">160,491</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30161">160,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30162">25,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30163">25,236</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" unitRef="eur" id="ixv-30164">1,453,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" unitRef="eur" id="ixv-30165">1,453,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30166">55,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30167">55,123</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">(<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementPropertyPlantAndEquipment" scale="0" sign="-" unitRef="eur" id="ixv-30168">2,595</ix:nonFraction></td><td style="font-weight: normal; font-style: normal; text-align: left">)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">(<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementPropertyPlantAndEquipment" scale="0" sign="-" unitRef="eur" id="ixv-30169">2,595</ix:nonFraction></td><td style="font-weight: normal; font-style: normal; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" sign="-" unitRef="eur" id="ixv-30170">14,342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" sign="-" unitRef="eur" id="ixv-30171">14,342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" unitRef="eur" id="ixv-30172">1,491,525</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" unitRef="eur" id="ixv-30173">1,491,525</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At January 1, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" sign="-" unitRef="eur" id="ixv-30174">993,238</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" sign="-" unitRef="eur" id="ixv-30175">993,238</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" scale="0" unitRef="eur" id="ixv-30176">113,894</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" scale="0" unitRef="eur" id="ixv-30177">113,894</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" sign="-" unitRef="eur" id="ixv-30178">17,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" sign="-" unitRef="eur" id="ixv-30179">17,286</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" sign="-" unitRef="eur" id="ixv-30180">1,124,419</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" sign="-" unitRef="eur" id="ixv-30181">1,124,419</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" scale="0" unitRef="eur" id="ixv-30182">93,791</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" scale="0" unitRef="eur" id="ixv-30183">93,791</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30184">2,594</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30185">2,594</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c225" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30186">13,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" scale="0" unitRef="eur" id="ixv-30187">13,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" sign="-" unitRef="eur" id="ixv-30188">1,201,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" scale="0" sign="-" unitRef="eur" id="ixv-30189">1,201,948</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Net book value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValuePropertyAndEquipment" scale="0" unitRef="eur" id="ixv-30190">328,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValuePropertyAndEquipment" scale="0" unitRef="eur" id="ixv-30191">328,920</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValuePropertyAndEquipment" scale="0" unitRef="eur" id="ixv-30192">289,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValuePropertyAndEquipment" scale="0" unitRef="eur" id="ixv-30193">289,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_2" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_1"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>2. <ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="ixv-30194">Right-of-use assets</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<ix:continuation id="_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Buildings</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cars</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%">At January 1, 2022</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30195">2,284,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30196">125,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30197">2,409,399</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="eur" id="ixv-30198">281,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="eur" id="ixv-30199">281,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" unitRef="eur" id="ixv-30200">13,645</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" unitRef="eur" id="ixv-30201">13,645</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c239" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30202">2,579,342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30203">125,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30204">2,704,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="eur" id="ixv-30205">91,125</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c242" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="eur" id="ixv-30206">49,004</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsToRightofuseAssets" scale="0" unitRef="eur" id="ixv-30207">140,128</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" sign="-" unitRef="eur" id="ixv-30208">9,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" sign="-" unitRef="eur" id="ixv-30209">9,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30210">2,661,118</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30211">174,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" unitRef="eur" id="ixv-30212">2,835,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At January 1, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30213">925,306</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c246" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30214">76,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30215">1,001,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="eur" id="ixv-30216">354,408</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c248" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="eur" id="ixv-30217">30,024</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="eur" id="ixv-30218">384,432</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" sign="-" unitRef="eur" id="ixv-30219">6,911</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" sign="-" unitRef="eur" id="ixv-30220">6,911</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30221">1,286,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30222">106,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30223">1,392,664</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="eur" id="ixv-30224">353,398</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="eur" id="ixv-30225">24,527</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationExpense" scale="0" unitRef="eur" id="ixv-30226">377,925</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" unitRef="eur" id="ixv-30227">7,003</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" scale="0" unitRef="eur" id="ixv-30228">7,003</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30229">1,633,020</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30230">130,566</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="ifrx:RightofuseAssetsRevaluationSurplus01" scale="0" sign="-" unitRef="eur" id="ixv-30231">1,763,586</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueOfRightOfUseAsset" scale="0" unitRef="eur" id="ixv-30232">1,292,717</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueOfRightOfUseAsset" scale="0" unitRef="eur" id="ixv-30233">19,092</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueOfRightOfUseAsset" scale="0" unitRef="eur" id="ixv-30234">1,311,809</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueOfRightOfUseAsset" scale="0" unitRef="eur" id="ixv-30235">1,028,098</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueOfRightOfUseAsset" scale="0" unitRef="eur" id="ixv-30236">43,568</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueOfRightOfUseAsset" scale="0" unitRef="eur" id="ixv-30237">1,071,666</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>3. <ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" id="ixv-30238">Intangible Assets</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<ix:continuation id="_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Purchased<br/>
 IT-software</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Advances<br/>
 paid for<br/>
 software</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" unitRef="eur" id="ixv-30239">720,942</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" unitRef="eur" id="ixv-30240">720,942</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30241">1,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30242">1,900</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c261" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30243">408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30244">408</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c263" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30245">723,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30246">723,250</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30247">25,977</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30248">25,977</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30249">7,009</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30250">7,009</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" sign="-" unitRef="eur" id="ixv-30251">111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" sign="-" unitRef="eur" id="ixv-30252">111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30253">716,130</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30254">25,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30255">742,107</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30256">485,726</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" sign="-" unitRef="eur" id="ixv-30257">485,726</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Amortization charge for the year*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30258">98,271</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30259">98,271</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" sign="-" unitRef="eur" id="ixv-30260">348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" sign="-" unitRef="eur" id="ixv-30261">348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" unitRef="eur" id="ixv-30262">584,345</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" unitRef="eur" id="ixv-30263">584,345</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30264">96,063</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30265">96,063</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" scale="0" sign="-" unitRef="eur" id="ixv-30266">7,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" scale="0" sign="-" unitRef="eur" id="ixv-30267">7,009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30268">111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c280" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" scale="0" unitRef="eur" id="ixv-30269">111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c281" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" unitRef="eur" id="ixv-30270">673,289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c283" decimals="0" format="ixt:num-dot-decimal" name="ifrx:IntangibleAssets" scale="0" unitRef="eur" id="ixv-30271">673,289</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c284" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueIntangibleAsset" scale="0" unitRef="eur" id="ixv-30272">138,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueIntangibleAsset" scale="0" unitRef="eur" id="ixv-30273">138,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c286" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueIntangibleAsset" scale="0" unitRef="eur" id="ixv-30274">42,841</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c287" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueIntangibleAsset" scale="0" unitRef="eur" id="ixv-30275">25,977</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"/><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NetBookValueIntangibleAsset" scale="0" unitRef="eur" id="ixv-30276">68,818</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets is included in the line items &#8216;research and development expenses&#8217; (2023: &#8364;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ResearchAndDevelopmentExpenses" scale="0" unitRef="eur" id="ixv-30277">858</ix:nonFraction>, 2022: &#8364;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ResearchAndDevelopmentExpenses" scale="0" unitRef="eur" id="ixv-30278">858</ix:nonFraction>,
2021: &#8364;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ResearchAndDevelopmentExpenses" scale="0" unitRef="eur" id="ixv-30279">10,192</ix:nonFraction>) and &#8216;general and administrative expenses&#8217; (2023: &#8364;<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-30280">95,205</ix:nonFraction>, 2022: &#8364;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-30281">97,413</ix:nonFraction>, 2021: &#8364;<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="eur" id="ixv-30282">105,790</ix:nonFraction>)
in the consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_3" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_2"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>4. Leases</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
obligations consist of payments pursuant to non-cancellable lease agreements mainly relating to the Company&#8217;s leases of office
space. The lease terms of the Company&#8217;s premises expire as follows: Jena, Germany in December 2025, Martinsried, Germany in May
2027 and Ann Arbor, Michigan, United States in April 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfLeasePrepaymentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfLeasePrepaymentsExplanatory" id="ixv-27354"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below, are the carrying amounts and the movements of the Group&#8217;s lease liabilities:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfLeasePrepaymentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Lease liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">As of January 1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="eur" id="ixv-30283">1,356,684</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="eur" id="ixv-30284">1,432,526</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="eur" id="ixv-30285">140,128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdditionalProvisionsOtherProvisions" scale="0" unitRef="eur" id="ixv-30286">281,429</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Derecognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="0" unitRef="eur" id="ixv-30287">20,555</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DecreaseThroughDerecognitionFinancialAssets" scale="0" unitRef="eur" id="ixv-30288">20,555</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30289">353,422</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30290">343,874</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term liability for accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="eur" id="ixv-30291">396</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" scale="0" unitRef="eur" id="ixv-30292">304</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" scale="0" sign="-" unitRef="eur" id="ixv-30293">2,391</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" scale="0" unitRef="eur" id="ixv-30294">6,854</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="eur" id="ixv-30295">1,120,048</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="eur" id="ixv-30296">1,356,684</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" id="ixv-27446"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the amounts recognized in profit or loss:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Depreciation expense of right-of-use assets (see Note E.2.)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="0" unitRef="eur" id="ixv-30297">377,925</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="0" unitRef="eur" id="ixv-30298">384,432</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" scale="0" unitRef="eur" id="ixv-30299">371,551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnBonds" scale="0" unitRef="eur" id="ixv-30300">19,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnBonds" scale="0" unitRef="eur" id="ixv-30301">21,947</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnBonds" scale="0" unitRef="eur" id="ixv-30302">14,055</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rental expense from leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="eur" id="ixv-30303">6,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="eur" id="ixv-30304">6,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RentalExpense" scale="0" unitRef="eur" id="ixv-30305">6,261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">Thereof short-term leases (included in administrative expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">&#8212;</div></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1.5pt">Thereof leases of low-value assets (included in administrative expenses)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" scale="0" unitRef="eur" id="ixv-30306">6,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" scale="0" unitRef="eur" id="ixv-30307">6,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" scale="0" unitRef="eur" id="ixv-30308">6,261</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total amounts recognized in profit or loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur" id="ixv-30309">403,276</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur" id="ixv-30310">412,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur" id="ixv-30311">391,867</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group had total cash outflows for leases of &#8364;<ix:nonFraction contextRef="c0" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="eur" id="ixv-30312">0.4</ix:nonFraction> million in 2023 (&#8364;<ix:nonFraction contextRef="c3" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="eur" id="ixv-30313">0.4</ix:nonFraction> million in 2022, &#8364;<ix:nonFraction contextRef="c4" decimals="1" format="ixt:num-dot-decimal" name="ifrs-full:CashOutflowForLeases" scale="0" unitRef="eur" id="ixv-30314">0.4</ix:nonFraction>&#160;million in 2021).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>5. <ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInventoriesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="ixv-30315">Inventory</ix:nonNumeric></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfInventoriesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Raw material and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" scale="0" unitRef="eur" id="ixv-30316">423,560</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Unfinished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:UnfinishedGoods" scale="0" unitRef="eur" id="ixv-30317">10,614,159</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="0" unitRef="eur" id="ixv-30318">330,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InventoriesTotal" scale="0" unitRef="eur" id="ixv-30319">11,367,807</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s inventory consists of materials relating to GOHIBIC (vilobelimab) primarily manufactured following the EUA for the US
market at the beginning of April 2023 (refer to Note A.2.) In the year ended December 31, 2023, inventory write-downs of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:WritedownsReversalsOfInventories" scale="6" unitRef="eur" id="ixv-30320">0.5</ix:nonFraction> million
were recognized due to the expected expiry of the shelf-life, prior to sale, of the related inventories and are included in cost of sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><!-- Field: Split-Segment; Name: S4 --><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_4" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">6.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOtherAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOtherAssetsExplanatory" id="ixv-27675"><span style="font-style: normal">Other assets</span></ix:nonNumeric></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<ix:continuation id="_DisclosureOfOtherAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160; 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;<br/>
</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PrepaidExpense" scale="0" unitRef="eur" id="ixv-30321">257,267</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PrepaidExpense" scale="0" unitRef="eur" id="ixv-30322">308,066</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NonCurrentOtherAssets" scale="0" unitRef="eur" id="ixv-30323">257,267</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NonCurrentOtherAssets" scale="0" unitRef="eur" id="ixv-30324">308,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepayments on research &amp; development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="0" unitRef="eur" id="ixv-30325">3,670,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Prepayments" scale="0" unitRef="eur" id="ixv-30326">9,776,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="0" unitRef="eur" id="ixv-30327">272,999</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="0" unitRef="eur" id="ixv-30328">1,841,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="0" unitRef="eur" id="ixv-30329">93,482</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="0" unitRef="eur" id="ixv-30330">2,552,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="0" unitRef="eur" id="ixv-30331">4,036,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherAdjustmentsToReconcileProfitLoss" scale="0" unitRef="eur" id="ixv-30332">14,170,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalOtherAsset" scale="0" unitRef="eur" id="ixv-30333">4,293,915</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalOtherAsset" scale="0" unitRef="eur" id="ixv-30334">14,478,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prepayments on research &amp; development projects
consists of prepayments on CRO and manufacturing contracts. Prepaid expenses mainly consist of prepaid insurance expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">7.</span></td><td style="text-align: justify"><span style="font-style: normal">Income tax Income tax reconciliation</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" id="ixv-30335">The table below shows a reconciliation between
the product of loss before tax multiplied by the Company&#8217;s applicable tax rate and current income taxes recognized in profit or
loss.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold">InflaRx Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Loss for the period (accounting profit before income tax)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="eur" id="ixv-30336">42,667,529</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="eur" id="ixv-30337">29,484,611</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="eur" id="ixv-30338">45,630,059</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrx:TaxRate" scale="-2" unitRef="pure" id="ixv-30339">28.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="ifrx:TaxRate" scale="-2" unitRef="pure" id="ixv-30340">29.2</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrx:TaxRate" scale="-2" unitRef="pure" id="ixv-30341">28.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax benefits at tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TaxBenefitsAtTaxRate" scale="0" unitRef="eur" id="ixv-30342">12,160,545</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TaxBenefitsAtTaxRate" scale="0" unitRef="eur" id="ixv-30343">8,610,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TaxBenefitsAtTaxRate" scale="0" unitRef="eur" id="ixv-30344">13,001,984</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Temporary differences and tax losses for which no deferred tax asset was recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" scale="0" sign="-" unitRef="eur" id="ixv-30345">12,127,977</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" scale="0" sign="-" unitRef="eur" id="ixv-30346">7,480,169</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" scale="0" sign="-" unitRef="eur" id="ixv-30347">10,988,805</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-recognition of tax effect on share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment" scale="0" sign="-" unitRef="eur" id="ixv-30348">32,182</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment" scale="0" sign="-" unitRef="eur" id="ixv-30349">1,251,830</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment" scale="0" sign="-" unitRef="eur" id="ixv-30350">1,959,606</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible expenses for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NondeductibleExpensesForTaxPurposesinDollars" scale="0" sign="-" unitRef="eur" id="ixv-30351">46,907</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NondeductibleExpensesForTaxPurposesinDollars" scale="0" sign="-" unitRef="eur" id="ixv-30352">22,067</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:NondeductibleExpensesForTaxPurposesinDollars" scale="0" sign="-" unitRef="eur" id="ixv-30353">3,758</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other differences due to tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OtherDifferencesDueToTaxRateinDollars" scale="0" unitRef="eur" id="ixv-30354">46,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OtherDifferencesDueToTaxRateinDollars" scale="0" unitRef="eur" id="ixv-30355">143,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OtherDifferencesDueToTaxRateinDollars" scale="0" sign="-" unitRef="eur" id="ixv-30356">49,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Income tax</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The tax rate applied above represents the weighted
average of the statutory tax rates in Germany and the United States. In Germany, InflaRx N.V. and its subsidiary InflaRx GmbH are subject
to corporate income tax (2023/2022/2021: <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:CorporateIncomeTax" scale="-2" unitRef="pure" id="ixv-30357"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrx:CorporateIncomeTax" scale="-2" unitRef="pure" id="ixv-30358"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrx:CorporateIncomeTax" scale="-2" unitRef="pure" id="ixv-30359">15</ix:nonFraction></ix:nonFraction></ix:nonFraction>%), a solidarity surcharge (2023/2022/2021: <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="ifrx:SolidaritySurcharge" scale="-2" unitRef="pure" id="ixv-30360"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="ifrx:SolidaritySurcharge" scale="-2" unitRef="pure" id="ixv-30361"><ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrx:SolidaritySurcharge" scale="-2" unitRef="pure" id="ixv-30362">0.8</ix:nonFraction></ix:nonFraction></ix:nonFraction>%) and trade taxes (2023: <ix:nonFraction contextRef="c0" decimals="5" format="ixt:num-dot-decimal" name="ifrx:TradeTaxes" scale="-2" unitRef="pure" id="ixv-30363">13.065</ix:nonFraction>%; 2022: <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="ifrx:TradeTaxes" scale="-2" unitRef="pure" id="ixv-30364">13.7</ix:nonFraction>%;
2021: <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrx:TradeTaxes" scale="-2" unitRef="pure" id="ixv-30365">12.8</ix:nonFraction>%). This equals an average total tax rate of 28.99 % in 2023 (2022: <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" unitRef="pure" id="ixv-30366">29.5</ix:nonFraction>%; 2021: <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="ifrs-full:AverageEffectiveTaxRate" scale="-2" unitRef="pure" id="ixv-30367">28.6</ix:nonFraction>%). InflaRx Pharmaceuticals, Inc., Ann
Arbor, Michigan, United States is subject to an average total tax rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrx:TotalTaxRate" scale="-2" unitRef="pure" id="ixv-30368">25.74</ix:nonFraction>% in 2023 (2022 <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="ifrx:TotalTaxRate" scale="-2" unitRef="pure" id="ixv-30369">25.74</ix:nonFraction>%; 2021: <ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="ifrx:TotalTaxRate" scale="-2" unitRef="pure" id="ixv-30370">25.74</ix:nonFraction>%), which is made up
of U.S. federal tax (2023, 2022, 2021: <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" scale="-2" unitRef="pure" id="ixv-30371"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" scale="-2" unitRef="pure" id="ixv-30372"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" scale="-2" unitRef="pure" id="ixv-30373">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>%) and state tax of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" scale="-2" unitRef="pure" id="ixv-30374"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" scale="-2" unitRef="pure" id="ixv-30375">4.74</ix:nonFraction></ix:nonFraction>% in 2023 (2022 and 2021: <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" scale="-2" unitRef="pure" id="ixv-30376">4.74</ix:nonFraction>%).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_5" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">a)</td><td>Tax losses carried forward</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group has total tax loss carryforwards of
&#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" scale="6" unitRef="eur" id="ixv-30377">243.8</ix:nonFraction> million (2022: &#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" scale="6" unitRef="eur" id="ixv-30378">211.3</ix:nonFraction> million) from three areas that cannot be utilized outside these areas:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023 the Group had &#8364;<ix:nonFraction contextRef="c2" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="6" unitRef="eur" id="ixv-30379">196</ix:nonFraction> million
(2022: &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" scale="6" unitRef="eur" id="ixv-30380">163.4</ix:nonFraction> million) for corporate income purposes and &#8364;<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="ifrx:TaxBasisOfInvestmentCostForIncomeTaxPurposes" scale="6" unitRef="eur" id="ixv-30381">164</ix:nonFraction> million (2022: &#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:TaxBasisOfInvestmentCostForIncomeTaxPurposes" scale="6" unitRef="eur" id="ixv-30382">131.6</ix:nonFraction> million) for trade tax purposes of
unrecognized and unused tax losses carried forward attributable to the tax group formed by InflaRx N.V. since 2018; these tax losses do
not expire and may not be used to offset taxable income elsewhere in the Group. Since January 1, 2018, InflaRx GmbH has distributed its
losses to the parent Company InflaRx N.V. under a profit and loss transfer agreement. This tax group was formed in Germany and is subject
to German tax legislation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Tax losses of InflaRx GmbH until December 31, 2017 (&#8364;<ix:nonFraction contextRef="c190" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:TaxEffectOfTaxLosses" scale="6" unitRef="eur" id="ixv-30383">34.8</ix:nonFraction>
million) are frozen from 2018 onwards due to the creation of a tax group with InflaRx N.V. Those losses of InflaRx GmbH do not expire
and may be used to offset future taxable income of InflaRx GmbH only.</td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>In addition, the Group still has tax loss carryforwards of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:TaxLossCarryforwards" scale="6" unitRef="usd" id="ixv-30384">14.3</ix:nonFraction> million or &#8364;<ix:nonFraction contextRef="c0" decimals="-4" format="ixt:num-dot-decimal" name="ifrx:TaxLossCarryforwards" scale="6" unitRef="eur" id="ixv-30385">12.97</ix:nonFraction> million (2022:&#160;$<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:TaxLossCarryforwards" scale="6" unitRef="usd" id="ixv-30386">14.1</ix:nonFraction>&#160;million or
&#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:TaxLossCarryforwards" scale="6" unitRef="eur" id="ixv-30387">13.2</ix:nonFraction> million) from the operations of InflaRx Pharmaceuticals, Inc. which can also only be utilized there, generally do not expire,
but are generally limited to offset tax obligation for <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:TaxableIncome" scale="-2" unitRef="pure" id="ixv-30388">80</ix:nonFraction>% of taxable income.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023, 2022 and 2021, no deferred
tax assets were recognized for the carryforward of unused tax losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">b)</td><td>Current income tax receivable</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Current income tax receivable includes tax claims
because of income tax withheld on interest income earned by the Group on the financial assets (2023: &#8364;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInterestReceivable" scale="0" unitRef="eur" id="ixv-30389">1,390,280</ix:nonFraction>, 2022: &#8364;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInterestReceivable" scale="0" unitRef="eur" id="ixv-30390">791,344</ix:nonFraction>).
The Company is reimbursed for the payments after filing a tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">8.</span></td><td style="text-align: justify"><span style="font-style: normal">Financial assets and financial
liabilities</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialAssetsExplanatory" id="ixv-30391">Set out below is an overview of financial assets
and liabilities, other than cash and short-term deposits included in cash equivalents, held by the Group as at December 31, 2023 and December
31, 2022:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DisclosureOfFinancialAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Financial assets and financial liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial assets at amortized cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Non-current financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-30392">9,052,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-30393">2,900,902</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:FinancialAssetsFromGovernmentGrants" scale="0" unitRef="eur" id="ixv-30394">732,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-30395">77,504,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-30396">64,791,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at amortized cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:LiabilitiesFromGovernmentGrants" scale="0" unitRef="eur" id="ixv-30397">6,209,266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="eur" id="ixv-30398">14,716,441</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="eur" id="ixv-30399">4,987,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The fair value of current and non-current financial
assets amounted to &#8364;<ix:nonFraction contextRef="c2" decimals="1" format="ixt:num-dot-decimal" name="ifrx:CurrentAndNonCurrentFinancialAssets" scale="0" unitRef="eur" id="ixv-30400">85.5</ix:nonFraction> million (level 1; 2022:&#160;&#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:CurrentAndNonCurrentFinancialAssets" scale="6" unitRef="eur" id="ixv-30401">68.5</ix:nonFraction> million). The Group&#8217;s financial assets at amortized cost consist
mainly of quoted debt securities with fixed interest rates with high credit rating (investment grade securities) by international rating
agencies such as S&amp;P Global and, therefore, are considered low credit risk investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maturities of all securities held as of December
31, 2023 are between one and seventeen months (2022: between one and sixteen months); they bear nominal fixed interest in the range of
<ix:nonFraction contextRef="c191" decimals="3" format="ixt:num-dot-decimal" name="ifrx:FixedInterest" scale="-2" unitRef="pure" id="ixv-30402">0.3</ix:nonFraction>% to <ix:nonFraction contextRef="c192" decimals="5" format="ixt:num-dot-decimal" name="ifrx:FixedInterest" scale="-2" unitRef="pure" id="ixv-30403">4.125</ix:nonFraction>% (2022: <ix:nonFraction contextRef="c193" decimals="3" format="ixt:num-dot-decimal" name="ifrx:FixedInterest" scale="-2" unitRef="pure" id="ixv-30404">0.0</ix:nonFraction>% to <ix:nonFraction contextRef="c194" decimals="5" format="ixt:num-dot-decimal" name="ifrx:FixedInterest" scale="-2" unitRef="pure" id="ixv-30405">4.125</ix:nonFraction>%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023, financial assets and
liabilities from government grants amount to &#8364; <span style="-sec-ix-hidden: hidden-fact-142">nil million</span>, due to the end of the grant period on June 30, 2023 (&#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:DueAmount" scale="6" unitRef="eur" id="ixv-30406">6.2</ix:nonFraction>&#160;million
as of December 31, 2022).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_6" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">9.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" id="ixv-28113"><span style="font-style: normal">Cash and cash equivalents</span></ix:nonNumeric></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<ix:continuation id="_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left">Deposits held in U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c288" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30407">4,120,951</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c289" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30408">3,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits held in Euro</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c290" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30409">1,020,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30410">5,140,951</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30411">3,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash held in U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c292" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="eur" id="ixv-30412">5,041,802</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c293" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="eur" id="ixv-30413">8,645,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash held in Euro</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c294" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="eur" id="ixv-30414">2,585,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c295" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="eur" id="ixv-30415">7,616,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="eur" id="ixv-30416">7,626,991</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Cash" scale="0" unitRef="eur" id="ixv-30417">16,261,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-30418">12,767,942</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="0" unitRef="eur" id="ixv-30419">16,265,354</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">10.</span></td><td style="text-align: justify"><span style="font-style: normal">Equity</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">a)</td><td>Issued capital</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023, the issued capital of
the Company is divided into <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-30420">58,883,272</ix:nonFraction> ordinary shares (2022: <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-30421">44,703,763</ix:nonFraction>). The nominal value per share is &#8364;<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="eurPershares" id="ixv-30422">0.12</ix:nonFraction>. All shares issued
are fully paid and have the same rights on the distribution of dividends and the repayment of capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On July&#160;8, 2020, the Company filed&#160;a&#160;Form
F-3&#160;(2020-Registration Statement)&#160;with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)&#160;with respect
to the offer and sale of securities of the Company.&#160;The Company&#160;also&#160;filed&#160;with the SEC a prospectus&#160;supplement&#160;relating
to&#160;an&#160;at-the-market&#160;program providing for the sale of up to&#160;$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:CommonShares" scale="6" unitRef="usd" id="ixv-30423">50.0</ix:nonFraction> million&#160;of its&#160;ordinary&#160;shares&#160;over
time&#160;pursuant a Sales Agreement with SVB&#160;Leerink&#160;LLC (the &#8220;Sales Agreement&#8221;).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2022, the Company had issued
<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-30424">2,568,208</ix:nonFraction> ordinary shares resulting in &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:CommonSharesIssued" scale="6" unitRef="eur" id="ixv-30425">11.8</ix:nonFraction> million in net proceeds to the Company with a remaining value authorized for sale under
the Sales Agreement of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:AssetsSoldUnderAgreementToRepurchaseCarryingAmount" scale="6" unitRef="usd" id="ixv-30426">35.2</ix:nonFraction> million. During the fiscal year 2023, the Company issued <ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-30427">3,235,723</ix:nonFraction> ordinary shares under its at-the-market
program resulting in &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:NetProceeds" scale="6" unitRef="eur" id="ixv-30428">14.4</ix:nonFraction> million or $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:NetProceeds" scale="6" unitRef="usd" id="ixv-30429">15.7</ix:nonFraction> million in net proceeds. Following these and previous issuances under this program, the
remaining value authorized for sale under the Sales Agreement amounted to $<ix:nonFraction contextRef="c197" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:AssetsSoldUnderAgreementToRepurchaseCarryingAmount" scale="6" unitRef="usd" id="ixv-30430">19.0</ix:nonFraction> million as of July&#160;8, 2023; the term of the at-the-market
program expired on July&#160;8, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Through an underwritten public offering in April
2023, the Company sold and issued an aggregate of <ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AggregateCommonShares" scale="0" unitRef="shares" id="ixv-30431">10,823,529</ix:nonFraction> ordinary shares, of which <ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" scale="0" unitRef="shares" id="ixv-30432">1,411,764</ix:nonFraction> were sold pursuant to the exercise of
an overallotment option by the underwriters. The ordinary shares were sold at a price of $<ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="usdPershares" id="ixv-30433">4.25</ix:nonFraction> per share and have a nominal value of &#8364;<ix:nonFraction contextRef="c198" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:ParValuePerShare" scale="0" unitRef="eurPershares" id="ixv-30434">0.12</ix:nonFraction>
per share. Proceeds of this offering after deducting &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:ProceedsOfferingCost" scale="6" unitRef="eur" id="ixv-30435">2.5</ix:nonFraction> million ($<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:ProceedsOfferingCost" scale="6" unitRef="usd" id="ixv-30436">2.8</ix:nonFraction> million) in underwriting discounts amounted to &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:UnderwritingDiscounts" scale="6" unitRef="eur" id="ixv-30437">39.1</ix:nonFraction>
million ($<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:UnderwritingDiscounts" scale="6" unitRef="usd" id="ixv-30438">43.2</ix:nonFraction> million). Other offering expenses amounted to &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="6" unitRef="eur" id="ixv-30439">0.4</ix:nonFraction> million, resulting in a total of &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:ProceedsFromOfferingCost" scale="6" unitRef="eur" id="ixv-30440">38.7</ix:nonFraction> million in net proceeds
from this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with amending the Co-Development
Agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd. (&#8220;Staidson&#8221;) on December 21, 2022, the Company entered into
a share purchase agreement with Staidson pursuant to which Staidson purchased ordinary shares of the Company for an aggregate amount of
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:DividendsPaidOrdinaryShares" scale="6" unitRef="usd" id="ixv-30441">2.5</ix:nonFraction> million (&#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:DividendsPaidOrdinaryShares" scale="6" unitRef="eur" id="ixv-30442">2.3</ix:nonFraction> million) at a price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:DividendsPaidOrdinarySharesPerShare" scale="0" unitRef="usdPershares" id="ixv-30443">5.00</ix:nonFraction> per share, resulting in the sale of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" scale="0" unitRef="shares" id="ixv-30444">500,000</ix:nonFraction> additional shares. Under the terms of
the share purchase agreement, at the Company&#8217;s option, Staidson may purchase additional shares for an aggregate purchase price of
$<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:AggregatePurchasePrice" scale="6" unitRef="usd" id="ixv-30445">7.5</ix:nonFraction> million, which is subject to certain conditions. The accounting impact of this put option is not material. On June&#160;30, 2023,
the Company filed&#160;a&#160;Form F-3&#160;(2023 Registration Statement)&#160;with the SEC&#160;with respect to the offer and sale of
securities of the Company, which became effective on July&#160;11, 2023. The aggregate initial offering price of the securities that the
Company may offer and sell under this prospectus will not exceed $<ix:nonFraction contextRef="c0" decimals="-6" format="ixt:num-dot-decimal" name="ifrx:AggregateInitialOffering" scale="6" unitRef="usd" id="ixv-30446">250</ix:nonFraction> million. No ordinary shares were issued by the Company under the
2023 Registration Statement in the fiscal year 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2023, the Company issued a total of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-30447">120,257</ix:nonFraction>
ordinary shares after former employees exercised stock option rights granted under the 2017 Long-Term Incentive Plan. The ordinary shares
have a nominal value of &#8364;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:NominalValue" scale="0" unitRef="eurPershares" id="ixv-30448">0.12</ix:nonFraction> per share. Therefrom, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OrdinarySharesValue" scale="0" unitRef="shares" id="ixv-30449">98,754</ix:nonFraction> ordinary shares were sold at a price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:OrdinaryShareSoldPrice" scale="0" unitRef="usdPershares" id="ixv-30450">1.85</ix:nonFraction> per share, and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesIssued" scale="0" unitRef="shares" id="ixv-30451">21,503</ix:nonFraction> ordinary
shares were sold at a price of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:SoldAtPrice" scale="0" unitRef="usdPershares" id="ixv-30452">3.35</ix:nonFraction>. The ordinary shares were registered in 2023, except <ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" scale="0" unitRef="shares" id="ixv-30453">14,930</ix:nonFraction> stock options which were exercised in
December 2022 with resulting ordinary shares having been registered in January 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_7" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">b)</td><td>Authorized capital</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">According to the articles of association of the
Company, up to <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:OrdinarySharePurchase" scale="0" unitRef="shares" id="ixv-30454">110,000,000</ix:nonFraction> ordinary shares and up to <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PreferredUnitIssued" scale="0" unitRef="shares" id="ixv-30455">110,000,000</ix:nonFraction> preferred shares with a nominal value of &#8364;<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" scale="0" unitRef="eur" id="ixv-30456">0.12</ix:nonFraction> per share are authorized
to be issued. All shares are registered shares. No share certificates shall be issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to deter acquisition bids, the Company&#8217;s
general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation, to exercise
a call option pursuant to the call option agreement, upon which preferred shares will be issued by the Company to the protective foundation
of up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:CompanyIssuedCapital" scale="-2" unitRef="pure" id="ixv-30457">100</ix:nonFraction>% of the Company&#8217;s issued capital held by others than the protective foundation, minus one share. The protective foundation
is expected to enter into a finance arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation
may request the Company to provide, or cause the Company&#8217;s subsidiaries to provide, sufficient funding to the protective foundation
to enable it to satisfy its payment obligation under the call option agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These preferred shares will have both a liquidation
and dividend preference over the Company&#8217;s ordinary shares and will accrue cash dividends at a pre-determined rate. The protective
foundation would be expected to require the Company to cancel its preferred shares once the perceived threat to the Company and its stakeholders
has been removed or sufficiently mitigated or neutralized. The Company believes that the call option does not represent a significant
fair value based on a level 3 valuation since the preferred shares are restricted in use and can be cancelled by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the year ended December 31, 2023, the Company
expensed &#8364;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpectedReimbursementOtherProvisions" scale="0" unitRef="eur" id="ixv-30458">70,000</ix:nonFraction> of ongoing costs to reimburse expenses incurred by the protective foundation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">c)</td><td>Nature and purpose of equity reserves</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the issued capital, the Company
discloses the following other reserves:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><i>Share premium</i> records the amounts paid in upon issuance of ordinary shares in excess of nominal value of &#8364;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:CommonSharesInExcessOfNominalValue" scale="0" unitRef="eurPershares" id="ixv-30459">0.12</ix:nonFraction> per share,
net of related transaction costs.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>The <i>other capital reserves</i> include the expense resulting from the issue of share options.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td><i>Accumulated deficit</i> includes the losses of previous reporting periods.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><i>Other components of equity</i> exclusively include
currency reserves from the conversion of financial statements in foreign currencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">11.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="ixv-28318"><span style="font-style: normal">Trade and other payables</span></ix:nonNumeric></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<ix:continuation id="_DisclosureOfTradeAndOtherPayablesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued liabilities from R&amp;D projects</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="0" unitRef="eur" id="ixv-30460">4,414,143</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="0" unitRef="eur" id="ixv-30461">2,254,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued liabilities from commercial activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:AccruedLiabilitiesFromCommercialActivities" scale="0" unitRef="eur" id="ixv-30462">1,400,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="eur" id="ixv-30463">5,102,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" scale="0" unitRef="eur" id="ixv-30464">1,566,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities and payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="0" unitRef="eur" id="ixv-30465">3,942,909</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherPayables" scale="0" unitRef="eur" id="ixv-30466">1,314,196</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total trade and other payables</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" scale="0" unitRef="eur" id="ixv-30467">14,860,134</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows" scale="0" unitRef="eur" id="ixv-30468">5,135,146</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities from R&amp;D projects include
services from the Company&#8217;s ongoing projects that have not yet been invoiced to the Company as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities from commercial activities
include services provided by commercial manufacturing partners that have not yet been invoiced to the Company as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other accrued liabilities and payables include
payments for GOHIBIC (vilobelimab) received from our distribution partner under the title distribution model, against which revenue will
be recognized at the time of final sale and delivery to hospital customers. These accrued liabilities payments amount to &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrx:PaymentsForAccruedPayments" scale="6" unitRef="eur" id="ixv-30469">2.7</ix:nonFraction> million
as of December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_8" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">12.</span></td><td style="text-align: justify"><span style="font-style: normal">Financial risk management</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">a)</td><td>Financial risk management objectives and policies</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group&#8217;s financial risks are predominantly
controlled by central treasury activities under an investment policy approved by the Board of Directors on November 3, 2022, as revised
on October, 27, 2023. Those treasury activities identify, evaluate and manage financial risks consistent with the Group&#8217;s operating
needs. The Board of Directors provides policies for overall risk management, covering specific areas, such as foreign exchange risk and
credit risk. The Company does not intend to use derivative financial instruments because the Group&#8217;s future risk exposures cannot
be reliably forecasted (volume of business activity, liquidity needs, foreign exchange exposure).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Hedging is not applied as most of the business
activity is intended to be executed in U.S. dollars and paid with the U.S. dollars funds raised in public offerings. The foreign exchange
exposure from costs incurred in currencies other than Euro is deemed immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group&#8217;s principal financial assets
comprise quoted debt securities with high credit ratings. Besides these financial assets, the Group has significant cash and cash equivalents.
The Group&#8217;s principal financial liabilities comprise trade and other payables. The main purpose of these financial assets, cash/cash
equivalents and liabilities are to finance the Group&#8217;s development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfMarketRiskExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfMarketRiskExplanatory" id="ixv-30470">The Group is exposed to market risk, credit risk
and liquidity risk. The Board of Directors reviews and adopts policies for managing each of these risks, which are summarized below. The
Group&#8217;s senior management oversees the management of these risks.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DisclosureOfMarketRiskExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 1.5pt; border: black 1pt solid; text-align: center; width: 12%; font-size: 10pt">&#160;</td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 37%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exposure</b></span></td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement</b></span></td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 31%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Management</b></span></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market risk</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c296" name="ifrs-full:DescriptionOfExposureToRisk" id="ixv-28451"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future development costs; Recognized financial assets and liabilities not denominated in Euro</span></ix:nonNumeric></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c296" name="ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets" id="ixv-28454"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forecasted cash flows Sensitivity analysis</span></ix:nonNumeric></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <ix:nonNumeric contextRef="c296" name="ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" id="ixv-28457"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Achievement of a natural hedge</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">in the future</p></ix:nonNumeric></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit risk</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <ix:nonNumeric contextRef="c297" name="ifrs-full:DescriptionOfExposureToRisk" id="ixv-28465"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Cash and cash equivalents,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">current and non-current<br/> financial assets</p></ix:nonNumeric></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <ix:nonNumeric contextRef="c297" name="ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets" id="ixv-28470"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Credit</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">rating</p></ix:nonNumeric></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <ix:nonNumeric contextRef="c297" name="ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" id="ixv-28474"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Diversification of bank deposits, Investment guidelines for</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">debt investments</p></ix:nonNumeric></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c298" name="ifrs-full:DescriptionOfExposureToRisk" id="ixv-28482"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D and G&amp;A cost, equity, trade and other payables</span></ix:nonNumeric></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <ix:nonNumeric contextRef="c298" name="ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets" id="ixv-28485"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rolling</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">cash flow forecast</p></ix:nonNumeric></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><ix:nonNumeric contextRef="c298" name="ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" id="ixv-28489"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability of funds through financing rounds or public offerings</span></ix:nonNumeric></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">b)</td><td>Market risk</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Market risk is the risk that changes in market
prices (e.g., due to foreign exchange rates) will affect the Group&#8217;s income, expenses or the value of its holdings of financial
instruments. The objective of market risk management is to identify, manage and control market risk exposures within acceptable parameters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Foreign exchange risk arises when commercial
transactions or recognized assets or liabilities are denominated in a currency that is not an entity&#8217;s functional currency. The
Group is exposed to transactional foreign currency risk to the extent that there is a mismatch between the currencies in which costs and
purchases are denominated and the respective functional currencies of Group companies. The functional currencies of Group companies are
primarily the Euro and U.S. dollars. The currencies in which these transactions and financial assets are primarily denominated are Euro
and U.S. dollars. The Group is exposed to the exchange rate between the Euro and the U.S. dollars. Due to the Company&#8217;s various
registered offerings of ordinary shares in U.S. dollars, the Group has significant cash and cash equivalents in U.S. dollars. Currently
the Group does not hedge U.S. dollars but intends to achieve a natural hedge by contracting suppliers in U.S. dollars in the future. In
2023, the Group recognized significant foreign exchange gains and losses as the natural hedge is not yet achieved and the functional currency
for InflaRx N.V. and InflaRx GmbH is Euro.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group is primarily exposed to changes in
U.S. dollar to Euro exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from U.S. dollar
denominated financial instruments at InflaRx N.V. and InflaRx GmbH.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_9" id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock-c0_cont_1" escape="true" name="ifrx:DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" id="ixv-30471">In 2023, if the Euro had weakened/strengthened
by <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrx:VariablesHeldConstant" scale="-2" unitRef="pure" id="ixv-30472">10</ix:nonFraction>% against the U.S. dollar with all other variables held constant, the Group&#8217;s loss would have been &#8364;<ix:nonFraction contextRef="c58" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="6" unitRef="eur" id="ixv-30473">1</ix:nonFraction> million higher/&#8364;<ix:nonFraction contextRef="c57" decimals="-6" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" scale="6" unitRef="eur" id="ixv-30474">1</ix:nonFraction>
million lower, mainly as a result of foreign exchange on translation of U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock-c0_cont_2" id="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx GmbH</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022 *</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current and non current financial assets (securities and accrued interest)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" scale="0" unitRef="eur" id="ixv-30475">80,935,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_42_fact" name="ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" scale="0" unitRef="eur">7,376,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" scale="0" unitRef="eur" id="ixv-30477">8,051,366</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_43_fact" name="ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" scale="0" unitRef="eur">4,356,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total assets exposed to the risk</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" scale="0" unitRef="eur" id="ixv-30479">88,986,563</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_44_fact" name="ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk" scale="0" unitRef="eur">11,733,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion rate Euro to U.S. dollars at reporting date 1/1.1050 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" id="ixv-28585"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Sensitivity analysis:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Conversion<br/>
 rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Profit/(loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">carrying<br/>
 amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Euro weakens against U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="4" format="ixt:num-dot-decimal" name="ifrx:SensitivityAnalysisConversionRate" scale="0" unitRef="eurPershares" id="ixv-30482">1.2155</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" unitRef="eur" id="ixv-30483">9,887,396</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="ifrx:SensitivityAnalysisCarryingAmount" scale="0" unitRef="eur" id="ixv-30484">98,873,959</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Euro strengths against U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c300" decimals="4" format="ixt:num-dot-decimal" name="ifrx:SensitivityAnalysisConversionRate" scale="0" unitRef="eurPershares" id="ixv-30485">0.9945</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur" id="ixv-30486">8,089,688</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="ifrx:SensitivityAnalysisCarryingAmount" scale="0" unitRef="eur" id="ixv-30487">80,896,875</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on the exchange rate fluctuations from
the last three years, the Company expects that exchange rate fluctuations of the Euro to the U.S. dollar between <ix:nonFraction contextRef="c57" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ExchangeRateFluctuations" scale="0" unitRef="eurPershares" id="ixv-30488">0.9945</ix:nonFraction> and <ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ExchangeRateFluctuations" scale="0" unitRef="eurPershares" id="ixv-30489">1.2155</ix:nonFraction> could
be reasonably possible. Compared to the exchange rate on the statement of financial position date (Euro to U.S. dollar at reporting date
is 1/1.1050), these rates could have a material impact on the Company&#8217;s total loss of the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">c)</td><td>Credit risk</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Credit risk is the risk that a counterparty will
not meet its obligations leading to a financial loss for the Company. The Company is exposed to credit risk mainly from its financing
activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Credit risk from balances with banks and financial
institutions is managed by the Company in accordance with the Company&#8217;s investment policy. Investment of financial resources which
are currently not used to fund R&amp;D or G&amp;A activities, are made only with counterparties within the credit limits approved by the
investment policy. For investments in Euro or U.S. dollar debt securities, a BBB+ to AAA credit rating (Standard &amp; Poors and Fitch
ratings; or equivalent ratings by Moody&#8217;s and DBRS) is required. Complex financial products as well as other investments denominated
in currencies other than Euros or U.S. dollars are not permitted by the investment policy. Counterparty credit limits and the investment
policy are discussed with the Company&#8217;s Audit Committee on an annual basis and may be updated throughout the year subject to approval
of the Company&#8217;s Audit Committee. The limits are set to minimize the concentration of risks and therefore mitigate financial loss
through a counterparty&#8217;s potential failure to make payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maximum exposure to counterparty credit risk
is &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:MaximumExposureToCreditRisk" scale="6" unitRef="eur" id="ixv-30490">99.3</ix:nonFraction> million at December 31, 2023 (December 31, 2022: &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:MaximumExposureToCreditRisk" scale="6" unitRef="eur" id="ixv-30491">84.0</ix:nonFraction> million). This amount equals the carrying amount at year end
of cash and cash equivalents (2023: &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" scale="6" unitRef="eur" id="ixv-30492">12.8</ix:nonFraction> million; 2022: &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" scale="6" unitRef="eur" id="ixv-30493">16.3</ix:nonFraction> million) and financial assets (2023: &#8364;<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="6" unitRef="eur" id="ixv-30494">86.6</ix:nonFraction> million; 2022:
&#8364;<ix:nonFraction contextRef="c200" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="6" unitRef="eur" id="ixv-30495">67.7</ix:nonFraction> million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">d)</td><td>Liquidity risk</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company monitors its risk of a shortage of
funds in every quarterly forecast as well as on an ongoing basis. The Company disclosed the maturities of its principal liabilities under
Note E &#8216;Commitments&#8217;. Prudent liquidity risk management involves maintaining sufficient cash and marketable securities and
the availability of funding to meet obligations when due. The Group continually monitors its risk of a shortage of funds using short and
mid-term liquidity planning. This takes into account of the expected cash flows from all activities. The management team performs regular
reviews of the budget.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has a history of significant operating
losses. Management expects that the Company incurs significant and increasing losses for the foreseeable future; as the Company may not
achieve or maintain profitability in the near future, it is dependent on capital contributions or other funding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfAuthorisationOfFinancialStatementsExplanatory-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group raised significant funding from various
registered offerings that it estimates will enable the Group to fund operating expenses and capital expenditure requirements for at least
24 months from December 31, 2023. The Group expects to require additional funding to continue to advance the development of product candidates.
In the event regulatory approval is received and the Company implements a strategy to commercialize the products itself, the Group would
require additional capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2023, as a result of the BMBF agreements (see
Notes C.6.) the Company received &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CashOnHand" scale="6" unitRef="eur" id="ixv-30496">8.8</ix:nonFraction> million in cash from the German Federal Government grant which contributes to its financing
of its operations. Such funds were used for finalizing the Company&#8217;s COVID-19 clinical research and development program, support
regulatory activities, establish a fully validated manufacturing process and to transfer the fill and finish process from China to Germany
to ensure future security of supply in Germany.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsExplanatory" id="ixv-30497">At the end of the reporting period, the Group
held the following deposits that are expected to readily generate cash inflows to meet the outstanding financial commitments.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DisclosureOfCommitmentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Liquidity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Short-term deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30498">5,140,951</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" scale="0" unitRef="eur" id="ixv-30499">3,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:BalancesWithBanks" scale="0" unitRef="eur" id="ixv-30500">7,626,992</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:BalancesWithBanks" scale="0" unitRef="eur" id="ixv-30501">16,261,932</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities (current and non-current)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DebtSecurities" scale="0" unitRef="eur" id="ixv-30502">85,727,461</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DebtSecurities" scale="0" unitRef="eur" id="ixv-30503">67,175,879</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other (non-current portion)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings" scale="0" unitRef="eur" id="ixv-30504">237,621</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings" scale="0" unitRef="eur" id="ixv-30505">237,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other (current)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" scale="0" unitRef="eur" id="ixv-30506">701,407</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" scale="0" unitRef="eur" id="ixv-30507">278,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total funds available</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalFundsAvailable" scale="0" unitRef="eur" id="ixv-30508">99,434,432</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalFundsAvailable" scale="0" unitRef="eur" id="ixv-30509">83,957,344</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">13.</span></td><td style="text-align: justify"><span style="font-style: normal">Capital management</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group&#8217;s policy for capital management
is to ensure that it maintains its liquidity in order to finance its operating activities, future business development and meet its liabilities
when due. The Group manages its capital structure primarily through equity. The Group does not have any financial liabilities, other
than trade and other payables or leasing liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No changes were made in the objectives, policies
or processes for managing capital during the year.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="ixv-28777"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">E.</td><td style="padding-right: 54.4pt">Commitments</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">1.</span></td><td style="text-align: justify"><span style="font-style: normal">Operating contracts or services</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group enters into contracts in the normal
course of business with CROs and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other
vendors for clinical supply manufacturing or other services. These contracts can usually be terminated with 30 to 180 days&#8217; notice.
In addition to this minimum duration, these contracts require full payment for services already rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2023, the Group did not have any commitments
to purchase property, plant and equipment or patents and trademarks (respectively <span style="-sec-ix-hidden: hidden-fact-161">nil</span> in 2022).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">2.</span></td><td style="text-align: justify"><span style="font-style: normal">Lease obligations</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="ixv-30510">The maturity analysis of lease liabilities is
disclosed in the following table:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_2" id="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for capitalized leases in 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual<br/>
 minimum<br/>
 lease<br/>
 obligations</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of<br/>
 discounting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="usd" id="ixv-30511">391,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="ifrx:EffectOfDiscounting" scale="0" unitRef="usd" id="ixv-30512">16,829</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-30513">374,329</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="usd" id="ixv-30514">760,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="ifrx:EffectOfDiscounting" scale="0" unitRef="usd" id="ixv-30515">14,559</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-30516">745,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="usd" id="ixv-30517">1,151,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:EffectOfDiscounting" scale="0" unitRef="usd" id="ixv-30518">31,389</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-30519">1,120,045</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-c0_cont_1"><ix:continuation continuedAt="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_3" id="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for capitalized leases in 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual<br/>
 minimum<br/>
 lease<br/>
 obligations</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of<br/>
 discounting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease<br/>
 liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="usd" id="ixv-30520">380,518</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="ifrx:EffectOfDiscounting" scale="0" unitRef="usd" id="ixv-30521">11,142</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-30522">369,376</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="usd" id="ixv-30523">999,482</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="ifrx:EffectOfDiscounting" scale="0" unitRef="usd" id="ixv-30524">12,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-30525">987,307</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GrossLeaseLiabilities" scale="0" unitRef="usd" id="ixv-30526">1,380,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:EffectOfDiscounting" scale="0" unitRef="usd" id="ixv-30527">23,317</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NetDeferredTaxLiabilities" scale="0" unitRef="usd" id="ixv-30528">1,356,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_4" id="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Maturity analysis for all lease obligations in 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Low value</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">leases</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short-term<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capitalized<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalLeases" scale="0" unitRef="usd" id="ixv-30529">397,942</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30530">4,816</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30531">1,968</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalizedLeases" scale="0" unitRef="usd" id="ixv-30532">391,158</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalLeases" scale="0" unitRef="usd" id="ixv-30533">760,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30534">146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalizedLeases" scale="0" unitRef="usd" id="ixv-30535">760,275</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalLeases" scale="0" unitRef="usd" id="ixv-30536">1,158,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30537">4,962</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30538">1,968</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalizedLeases" scale="0" unitRef="usd" id="ixv-30539">1,151,434</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory-c0_cont_4"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for all lease obligations in 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low value<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short-term<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capitalized<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalLeases" scale="0" unitRef="usd" id="ixv-30540">386,779</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30541">6,261</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalizedLeases" scale="0" unitRef="usd" id="ixv-30542">380,518</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalLeases" scale="0" unitRef="usd" id="ixv-30543">1,004,444</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30544">4,962</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalizedLeases" scale="0" unitRef="usd" id="ixv-30545">999,482</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalLeases" scale="0" unitRef="usd" id="ixv-30546">1,391,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" scale="0" unitRef="usd" id="ixv-30547">11,223</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:CapitalizedLeases" scale="0" unitRef="usd" id="ixv-30548">1,380,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Anticipated future lease expenses were converted
with the exchange rate as of December 31, 2023, <ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="ifrx:ExchangeRate" scale="0" unitRef="eur" id="ixv-30549">1</ix:nonFraction>&#160;Euro&#160;=&#160;<ix:nonFraction contextRef="c302" decimals="4" format="ixt:num-dot-decimal" name="ifrx:ExchangeRate" scale="0" unitRef="usd" id="ixv-30550">1.1050</ix:nonFraction> U.S. dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group applies the &#8216;lease of low-value
assets&#8217; recognition exemptions. The Group also applied the &#8216;short-term lease&#8217; exemption for leases with a maturity of
less than 12 months.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" id="ixv-29213"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">F.</td><td style="padding-right: 54.4pt">Other information</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">1.</span></td><td style="text-align: justify"><span style="font-style: normal">Segment reporting</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group predominantly operates as a R&amp;D
focused biopharmaceutical company applying its proprietary anti-C5a and C5aR technologies towards the development of novel therapeutic
products targeting diseases of high unmet medical need. However, since the EUA of its lead product vilobelimab for the treatment of severe
COVID-19 patient in April 2023, it also has commercial activities around the sales and marketing of GOHIBIC (vilobelimab) in the U.S.
The Group is not steered by segments. The Board of Directors is the chief operating decision maker. Management of resources and reporting
to the decision maker is based on the Group as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All operational activities are conducted in Germany
and the United States. Revenues in the amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Revenue" scale="0" unitRef="eur" id="ixv-30551">63,089</ix:nonFraction> were generated in 2023 (<span style="-sec-ix-hidden: hidden-fact-162"><span style="-sec-ix-hidden: hidden-fact-163">Nil</span></span> in 2022 and 2021). All revenues were generated in
the United States of America. The geographic location of the Group&#8217;s non-current assets are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>December 31, 2023: &#8364;<ix:nonFraction contextRef="c315" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="6" unitRef="eur" id="ixv-30552">10.6</ix:nonFraction> million in Germany and &#8364;<ix:nonFraction contextRef="c316" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="6" unitRef="eur" id="ixv-30553">0.1</ix:nonFraction> million in the United States; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>December 31, 2022: &#8364;<ix:nonFraction contextRef="c317" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="6" unitRef="eur" id="ixv-30554">4.9</ix:nonFraction> million in Germany and &#8364;<ix:nonFraction contextRef="c318" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="6" unitRef="eur" id="ixv-30555">0.1</ix:nonFraction> million in the United States.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None of the non-current assets are in the country
where the Company is incorporated (the Netherlands).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-style: normal">2.</span></td><td style="text-align: justify"><span style="font-style: normal">Related party transactions</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"><ix:nonNumeric contextRef="c0" continuedAt="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory-c0_cont_1" escape="true" name="ifrx:DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" id="ixv-30556">Compensation of the Group&#8217;s executive
management for the 12 months ending December 31, 2023:</ix:nonNumeric></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&#160;</p>

<ix:continuation id="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Executive and Board compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Executive management</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term employee benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherShorttermEmployeeBenefits" scale="0" unitRef="eur" id="ixv-30557">2,783,675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherShorttermEmployeeBenefits" scale="0" unitRef="eur" id="ixv-30558">2,774,485</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherShorttermEmployeeBenefits" scale="0" unitRef="eur" id="ixv-30559">2,817,792</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30560">2,507,453</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30561">4,808,094</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30562">3,347,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Sub-total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="0" unitRef="eur" id="ixv-30563">5,291,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c324" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="0" unitRef="eur" id="ixv-30564">7,582,579</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c325" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="0" unitRef="eur" id="ixv-30565">6,164,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-executive Board of Directors members</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherShorttermEmployeeBenefits" scale="0" unitRef="eur" id="ixv-30566">305,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherShorttermEmployeeBenefits" scale="0" unitRef="eur" id="ixv-30567">248,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherShorttermEmployeeBenefits" scale="0" unitRef="eur" id="ixv-30568">271,248</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30569">285,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30570">529,859</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c328" decimals="0" format="ixt:num-dot-decimal" name="ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="0" unitRef="eur" id="ixv-30571">488,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Sub-total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="0" unitRef="eur" id="ixv-30572">591,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="0" unitRef="eur" id="ixv-30573">778,584</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssetsAtAmortisedCost" scale="0" unitRef="eur" id="ixv-30574">760,185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total compensation</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalCompensation" scale="0" unitRef="eur" id="ixv-30575">5,882,288</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalCompensation" scale="0" unitRef="eur" id="ixv-30576">8,361,163</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrx:TotalCompensation" scale="0" unitRef="eur" id="ixv-30577">6,925,180</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Executive management comprises executive Directors
of the Board of Directors and members of the Senior management of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table above discloses short-term employee
benefits that were contractually agreed for the Board of Directors and executive management. As of December 31, 2023, &#8364;<ix:nonFraction contextRef="c319" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued" scale="6" unitRef="eur" id="ixv-30578">0.8</ix:nonFraction> million
were not paid but accrued (2022: &#8364;<ix:nonFraction contextRef="c320" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued" scale="6" unitRef="eur" id="ixv-30579">0.9</ix:nonFraction> million) for executive management and &#8364;<ix:nonFraction contextRef="c321" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued" scale="6" unitRef="eur" id="ixv-30580">0.1</ix:nonFraction> million (2022: &#8364;<ix:nonFraction contextRef="c322" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued" scale="6" unitRef="eur" id="ixv-30581">0.1</ix:nonFraction> million) for non-executive
members of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Remuneration of the Group&#8217;s executive management
comprises fixed and variable components and share-based payment awards. In addition, executive management receive supplementary benefits
and allowances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company entered into indemnification agreements
with its directors and senior management. The indemnification agreements and the Company&#8217;s Articles of Association require the Company
to indemnify its directors to the fullest extent permitted by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s current and future directors
(and such other officer or employee as designated by the Board of Directors) have the benefit of indemnification provisions in the Articles
of Association of InflaRx N.V. These provisions give the indemnified persons the right to recover from the Company amounts, including,
but not limited to, litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the performance
of their duties. However, there is no entitlement to indemnification for acts or omissions which are considered to constitute malice,
gross negligence, intentional recklessness and/or serious culpability attributable to such indemnified person. These agreements also provide,
subject to certain exceptions, for indemnification for related expenses including, among others, attorneys&#8217; fees, judgements, penalties,
fines and settlement amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, the
Company provides its directors with directors&#8217; and officers&#8217; liability insurance.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" id="ixv-29433"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in">G.</td><td style="padding-right: 54.4pt">Significant events after the reporting date</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 201; Options: Last --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-1" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="ifrs-full:CostOfSales" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-3" name="ifrs-full:CostOfSales" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="ifrs-full:GrossProfit" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-5" name="ifrs-full:GrossProfit" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-6" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-9" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" decimals="2" id="hidden-fact-11" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="eurPershares">0.67</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-12" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="eurPershares">0.78</ix:nonFraction>
<ix:nonFraction contextRef="c4" decimals="2" id="hidden-fact-13" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="eurPershares">1.10</ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-14" name="ifrs-full:Inventories" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-15" name="ifrs-full:CurrentFinancialAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-16" name="ifrs-full:CurrentGovernmentGrants" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-17" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-18" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-19" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-20" name="ifrs-full:ShareIssueRelatedCost" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c9" id="hidden-fact-21" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c11" id="hidden-fact-22" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-23" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-24" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-25" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-26" name="ifrs-full:ShareIssueRelatedCost" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-27" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-28" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-29" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-30" name="ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c15" id="hidden-fact-31" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-32" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-33" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-34" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-35" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c22" id="hidden-fact-36" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c21" id="hidden-fact-37" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-38" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-39" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-40" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-41" name="ifrs-full:IssueOfEquity" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-42" name="ifrs-full:IssueOfEquity" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-43" name="ifrs-full:IssueOfEquity" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-44" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c32" id="hidden-fact-45" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-46" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-47" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-48" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-49" name="ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-50" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-51" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-52" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-53" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-54" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-55" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-56" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-57" name="ifrs-full:CostOfSales" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-58" name="ifrs-full:CostOfSales" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-59" name="ifrs-full:CostOfSales" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-60" name="ifrs-full:CostOfSales" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c78" id="hidden-fact-61" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c79" id="hidden-fact-62" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c81" id="hidden-fact-63" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c82" id="hidden-fact-64" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c84" id="hidden-fact-65" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c86" id="hidden-fact-66" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c87" id="hidden-fact-67" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c89" id="hidden-fact-68" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c90" id="hidden-fact-69" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-70" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-71" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-72" name="ifrs-full:RevenueFromGovernmentGrants" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c126" id="hidden-fact-73" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c127" id="hidden-fact-74" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c128" id="hidden-fact-75" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-76" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c137" id="hidden-fact-77" name="ifrx:NumberOfOpionsExercisedDuring" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-78" name="ifrx:NumberOfSharesExercisedDuring" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c138" id="hidden-fact-79" name="ifrx:NumberOfSharesExercisedDuring" unitRef="eurPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c139" id="hidden-fact-80" name="ifrx:NumberOfOpionsExercisedDuring" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c140" id="hidden-fact-81" name="ifrx:NumberOfSharesExercisedDuring" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c140" id="hidden-fact-82" name="ifrx:NumberOfSharesExercisedDuring" unitRef="eurPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c171" id="hidden-fact-83" name="ifrx:ShareOptionsGrantedOptions" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-84" name="ifrx:ExpectedDividends" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c202" id="hidden-fact-85" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c205" id="hidden-fact-86" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c205" id="hidden-fact-87" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c208" id="hidden-fact-88" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c211" id="hidden-fact-89" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c211" id="hidden-fact-90" name="ifrx:DisposalsAndRetirementPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c211" id="hidden-fact-91" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c214" id="hidden-fact-92" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c217" id="hidden-fact-93" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c220" id="hidden-fact-94" name="ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c220" id="hidden-fact-95" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c223" id="hidden-fact-96" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c226" id="hidden-fact-97" name="ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c226" id="hidden-fact-98" name="ifrx:DisposalsAndRetirementPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c226" id="hidden-fact-99" name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c229" id="hidden-fact-100" name="ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c232" id="hidden-fact-101" name="ifrx:NetBookValuePropertyAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c234" id="hidden-fact-102" name="ifrx:NetBookValuePropertyAndEquipment" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c238" id="hidden-fact-103" name="ifrs-full:AdditionsToRightofuseAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c238" id="hidden-fact-104" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c242" id="hidden-fact-105" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c248" id="hidden-fact-106" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c252" id="hidden-fact-107" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c260" id="hidden-fact-108" name="ifrx:IntangibleAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c262" id="hidden-fact-109" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c262" id="hidden-fact-110" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c264" id="hidden-fact-111" name="ifrx:IntangibleAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c265" id="hidden-fact-112" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c266" id="hidden-fact-113" name="ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c266" id="hidden-fact-114" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c270" id="hidden-fact-115" name="ifrx:IntangibleAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-116" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c273" id="hidden-fact-117" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c276" id="hidden-fact-118" name="ifrx:IntangibleAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c279" id="hidden-fact-119" name="ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c279" id="hidden-fact-120" name="ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c279" id="hidden-fact-121" name="ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c282" id="hidden-fact-122" name="ifrx:IntangibleAssets" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c285" id="hidden-fact-123" name="ifrx:NetBookValueIntangibleAsset" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-124" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-125" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-126" name="ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-127" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-128" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-129" name="ifrx:UnfinishedGoods" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-130" name="ifrx:UnfinishedGoods" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-131" name="ifrs-full:FinishedGoods" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-132" name="ifrs-full:FinishedGoods" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-133" name="ifrs-full:InventoriesTotal" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-134" name="ifrs-full:InventoriesTotal" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-135" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-136" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-137" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-138" name="ifrx:FinancialAssetsFromGovernmentGrants" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-139" name="ifrx:LiabilitiesFromGovernmentGrants" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c291" id="hidden-fact-140" name="ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-141" name="ifrx:AccruedLiabilitiesFromCommercialActivities" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-142" name="ifrx:FinancialAssetsFromGovernmentGrantsAmount" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c307" id="hidden-fact-143" name="ifrs-full:GrossLeaseLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c308" id="hidden-fact-144" name="ifrx:EffectOfDiscounting" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c307" id="hidden-fact-145" name="ifrs-full:NetDeferredTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c313" id="hidden-fact-146" name="ifrs-full:GrossLeaseLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c314" id="hidden-fact-147" name="ifrx:EffectOfDiscounting" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c313" id="hidden-fact-148" name="ifrs-full:NetDeferredTaxLiabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c305" id="hidden-fact-149" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c308" id="hidden-fact-150" name="ifrx:TotalLeases" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c308" id="hidden-fact-151" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c307" id="hidden-fact-152" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c308" id="hidden-fact-153" name="ifrx:CapitalizedLeases" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c309" id="hidden-fact-154" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c311" id="hidden-fact-155" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c314" id="hidden-fact-156" name="ifrx:TotalLeases" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c314" id="hidden-fact-157" name="ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c313" id="hidden-fact-158" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c314" id="hidden-fact-159" name="ifrx:CapitalizedLeases" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-160" name="ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-161" name="ifrs-full:DepreciationPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-162" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-163" name="ifrs-full:Revenue" unitRef="eur" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-30748">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-30749">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-30750">00000</ix:nonNumeric>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-30751">00000</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-30752">0001708688</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="ifrx-20231231.xsd" xlink:type="simple"/></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact ix_1_fact hidden-fact-74 hidden-fact-76 ix_2_fact ix_3_fact ix_4_fact ix_5_fact" toRefs="ix_0_footnote"/>
<ix:relationship fromRefs="ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact ix_14_fact ix_15_fact ix_16_fact ix_17_fact" toRefs="ix_1_footnote"/>
<ix:relationship fromRefs="ix_18_fact ix_19_fact ix_20_fact ix_21_fact ix_22_fact ix_23_fact ix_24_fact ix_25_fact ix_26_fact ix_27_fact ix_28_fact ix_29_fact ix_30_fact ix_31_fact ix_32_fact ix_33_fact ix_34_fact ix_35_fact ix_36_fact ix_37_fact ix_38_fact ix_39_fact ix_40_fact ix_41_fact" toRefs="ix_2_footnote"/>
<ix:relationship fromRefs="ix_42_fact ix_43_fact ix_44_fact" toRefs="ix_3_footnote"/>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxGmbHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxGmbHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxPharmaceuticalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxPharmaceuticalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-01</xbrli:startDate>
    <xbrli:endDate>2021-10-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:GermanMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:OptionsGrantedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:OptionsGrantedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:IncomeStatementLocationAxis">ifrx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:IncomeStatementLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EmployeeBenefitsExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EmployeeBenefitsExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EmployeeBenefitsExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:LegalAndConsultingFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:LegalAndConsultingFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:LegalAndConsultingFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ManufacturingOfClinicalMaterialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ManufacturingOfClinicalMaterialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ManufacturingOfClinicalMaterialMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:clinicalPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:clinicalPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:clinicalPreclinicalStudiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:InsuranceExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:InsuranceExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:InsuranceExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:DepreciationAmortizationExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:DepreciationAmortizationExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:DepreciationAmortizationExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:CompensationExpenseForNonexecutiveBoardDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:CompensationExpenseForNonexecutiveBoardDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:CompensationExpenseForNonexecutiveBoardDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:WagesAndSalariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:WagesAndSalariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:WagesAndSalariesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:SocialSecurityContributionsemployersShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:SocialSecurityContributionsemployersShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:SocialSecurityContributionsemployersShareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXs61wHyckAg2nxvBikE1dTD+mD7F+hOhyP4JUKDa+ELwxhT8MZgkEf+kZKh9LsB5Bl51UtFYWeFaK0UqFEG6idGWj2iasVoEhjS4SNz7nGGfwAEve9SFnoCQi6WRBaBCpn5/XxaA+fqA=] CSR-->
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4OneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4OneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2OneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2OneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12OneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12OneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:RepricingApril13Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:RepricingApril13Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:RepricingApril13Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:November21Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:November21Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:MayThirtyOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:MayThirtyOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenOneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulyNineteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulyNineteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:SeptemberEighteenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:SeptemberEighteenMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:MarketProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:MarketProgramMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-08</xbrli:startDate>
    <xbrli:endDate>2023-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInEuroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInEuroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSEuroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSEuroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:MarketRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:WeakensAgainstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:StrengthsAgainstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:ExchangeRateCurrencyAxis">ifrx:CashHeldInUSEuroMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:ExchangeRateCurrencyAxis">ifrx:CashHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:DEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:UnitedStateOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:DEMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:UnitedStateOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveMembersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveMembersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit id="eurPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>ea020203801ex8-1_inflarx.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries of the Registrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font-size: 10pt"><B>Entity name</B></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font-size: 10pt"><B>Jurisdiction of organization</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt">InflaRx GmbH</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Germany</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font-size: 10pt">InflaRx Pharmaceuticals, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Delaware</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>ea020203801ex12-1_inflarx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.9pt 0pt 0; text-align: right">Exhibit 12.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 7.9pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION BY THE PRINCIPAL
EXECUTIVE OFFICER PURSUANT TO</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">I, Niels Riedemann, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual
Report on Form 20-F of InflaRx N.V.;</FONT></TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered
    by this report;</TD>
</TR></TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left">The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: left">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">c.</FONT></TD><TD STYLE="text-align: left">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: left">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: left">The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the
audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: March 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.4pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Niels Riedemann</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.4pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>ea020203801ex12-2_inflarx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 6.9pt 0pt 0; text-align: right">Exhibit 12.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 17.7pt 0pt 112.05pt; text-indent: -51.6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">CERTIFICATION BY THE PRINCIPAL
EXECUTIVE OFFICER PURSUANT TO</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">I, Thomas Taapken, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this Annual
Report on Form 20-F of InflaRx N.V.;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: left">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: left">The company&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: left">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: left">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 2.4pt; margin-bottom: 0pt; text-align: left">Evaluated the effectiveness of the company&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">d.</FONT></TD><TD STYLE="text-align: left">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: left">The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the
audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: left">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">b.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Any fraud, whether or not material,
that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: March 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Thomas Taapken</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>ea020203801ex13-1_inflarx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.9pt 0pt 0; text-align: right"><B>Exhibit 13.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 57.5pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 57.5pt; text-align: center"><B>CERTIFICATION BY THE PRINCIPAL
EXECUTIVE OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 57.5pt; text-align: center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 0.8in; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left">The certification set forth below is being submitted in
connection with the Annual Report on Form 20-F of InflaRx N.V. (the &ldquo;Company&rdquo;) for the fiscal year ended December 31,
2023 (the &ldquo;Report&rdquo;), I, Niels Riedemann, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left">the Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: March 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Niels Riedemann</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="padding-bottom: 8pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.1pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>ea020203801ex13-2_inflarx.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.9pt 0pt 0; text-align: right"><B>Exhibit 13.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 57.5pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 57.5pt; text-align: center"><B>CERTIFICATION BY THE PRINCIPAL
EXECUTIVE OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 57.5pt; text-align: center"><B>18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 54.7pt 0pt 0.8in; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The certification set forth below is being submitted in
connection with the Annual Report of InflaRx N.V. (the &ldquo;Company&rdquo;) for the fiscal year ended December 31, 2023 (the
&ldquo;Report&rdquo;), I, Thomas Taapken, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: left">the Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">the information contained in
the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">Date: March 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt">/s/ Thomas Taapken</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19.2pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>ea020203801ex15-1_inflarx.htm
<DESCRIPTION>CONSENT OF EY GMBH & CO. KG WIRTSCHAFTSPRUFUNGSGESELLSCHAFT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consent of Independent
Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We consent to the incorporation by reference
in the following Registration Statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Registration Statement (Form F-3 No. 333-273058) of InflaRx
N.V.</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">Registration Statement (Form S-8 No. 333-221656) pertaining
to the InflaRx N.V. Long-Term Incentive Plan, InflaRx Stock Option Plan 2016, InflaRx Options Issued Pursuant To The Series B Financing
Arrangement</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Registration Statement (Form S-8 No. 333-240185) pertaining to the InflaRx N.V. Long-Term Incentive Plan</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">of our reports dated March 20, 2024, with respect to the consolidated financial statements of InflaRx N.V. and the effectiveness of internal control over financial reporting of InflaRx N.V. included in this Annual Report (Form 20-F) of InflaRx N.V. for the year ended December 31, 2023.</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">/s/ EY GmbH &amp; Co. KG Wirtschaftspr&uuml;fungsgesellschaft</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Munich, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">March 21, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>8
<FILENAME>ea020203801ex97-1_inflarx.htm
<DESCRIPTION>CLAWBACK POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 97.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">31 October 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CLAWBACK POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INFLARX
N.V.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">PURPOSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">InflaRx N.V.
(the &ldquo;<U>Company</U>&rdquo;), believes that it is in the best interests of the Company and its shareholders and other stakeholders
to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company&rsquo;s pay-for-performance
compensation philosophy. The Company&rsquo;s Board of Directors (the &ldquo;<U>Board</U>&rdquo; and each member a &ldquo;Director&rdquo;)
has therefore adopted this policy, which provides for the recoupment of certain executive compensation in the event that the Company is
required to prepare an accounting restatement of its financial statements due to material noncompliance with any financial reporting requirement
under the federal securities laws (this &ldquo;<U>Policy</U>&rdquo;). This Policy is designed to comply with Section 10D of the Securities
Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), the rules promulgated thereunder, and the listing standards
of the national securities exchange on which the Company&rsquo;s securities are listed. This Policy also reflects certain rules of Dutch
law relating to the recoupment and/or adjustment of a Bonus (as defined below) from Directors under certain circumstances defined by Dutch
law (the &ldquo;<U>Dutch Clawback Rules</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ADMINISTRATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This Policy shall
be administered by the Compensation Committee of the Board (the &ldquo;<U>Compensation Committee</U>&rdquo;). Any determinations made
by the Compensation Committee shall be final and binding on all affected individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">COVERED EXECUTIVES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This Policy
applies to the Company&rsquo;s current and former executive officers (as determined by the Compensation Committee in accordance with Section
10D of the Exchange Act, the rules promulgated thereunder, and the listing standards of the national securities exchange on which the
Company&rsquo;s securities are listed) and such other senior executives or employees who may from time to time be deemed subject to this
Policy by the Compensation Committee (collectively, the &ldquo;<U>Covered Executives</U>&rdquo;). This Policy shall be binding and enforceable
against all Covered Executives. Notwithstanding the previous sentences of this paragraph, the Dutch Clawback Rules reflected in this Policy
also apply to any Bonus (as defined below) received by Directors as a matter of Dutch law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RECOUPMENT; ACCOUNTING RESTATEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In the event that the
Company is required to prepare an accounting restatement of its financial statements due to the Company&rsquo;s material
noncompliance with any financial reporting requirement under the securities laws, including (i) any required accounting restatement
to correct an error in previously issued financial statements that is material to the previously issued financial statements, or
(ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the
current period (each an &ldquo;Accounting Restatement&rdquo;), the Compensation Committee will reasonably promptly require
reimbursement or forfeiture of the Overpayment (as defined below) received by any Covered Executive (x) after beginning service as a
Covered Executive, (y) who served as a Covered Executive at any time during the performance period for such Incentive-Based
Compensation, and (z) during the three (3) completed fiscal years immediately preceding the date on which the Company is required to
prepare an Accounting Restatement and any transition period (that results from a change in the Company&rsquo;s fiscal year) within
or immediately following those three (3) completed fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">INCENTIVE-BASED COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For purposes of
this Policy, &ldquo;<U>Incentive-Based Compensation</U>&rdquo; means any compensation that is granted, earned, or vested based wholly
or in part upon the attainment of a financial reporting measures, including, but not limited to: (i) non-equity incentive plan awards
that are earned solely or in part by satisfying a financial reporting measure performance goal; (ii) bonuses paid from a bonus pool, where
the size of the pool is determined solely or in part by satisfying a financial reporting measure performance goal; (iii) other cash awards
based on satisfaction of a financial reporting measure performance goal; (iv) restricted stock, restricted stock units, stock options,
stock appreciation rights, and performance share units that are granted or vest solely or in part based on satisfaction of a financial
reporting measure performance goal; and (v) proceeds from the sale of shares acquired through an incentive plan that were granted or vested
solely or in part based on satisfaction of a financial reporting measure performance goal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Compensation
that would not be considered Incentive-Based Compensation includes, but is not limited to: (a) salaries; (b) bonuses paid solely based
on satisfaction of subjective standards, such as demonstrating leadership, and/or completion of a specified employment period; (c) non-
equity incentive plan awards earned solely based on satisfaction of strategic or operational measures; (d) wholly time-based equity awards;
and (e) discretionary bonuses or other compensation that is not paid from a bonus pool that is determined by satisfying a financial reporting
measure performance goal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A financial
reporting measure is: (i) any measure that is determined and presented in accordance with the accounting principles used in preparing
financial statements, or any measure derived wholly or in part from such measure, such as revenues, EBITDA, or net income and (ii) stock
price and total shareholder return. Financial reporting measures include, but are not limited to: revenues; net income; operating income;
profitability of one or more reportable segments; financial ratios (e.g., accounts receivable turnover and inventory turnover rates);
net assets or net asset value per share; earnings before interest, taxes, depreciation and amortization; funds from operations and adjusted
funds from operations; liquidity measures (e.g., working capital, operating cash flow); return measures (e.g., return on invested capital,
return on assets); earnings measures (e.g., earnings per share); sales per square foot or same store sales, where sales is subject to
an accounting restatement; revenue per user, or average revenue per user, where revenue is subject to an accounting restatement; cost
per employee, where cost is subject to an accounting restatement; any of such financial reporting measures relative to a peer group, where
the Company&rsquo;s financial reporting measure is subject to an accounting restatement; and tax basis income.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">OVERPAYMENT: AMOUNT SUBJECT TO RECOVERY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The amount
to be recovered will be the amount of Incentive-Based Compensation received that exceeds the amount of Incentive-Based Compensation that
otherwise would have been received had it been determined based on the restated amounts, and must be computed without regard to any taxes
paid (the &ldquo;<U>Overpayment</U>&rdquo;). Incentive-Based Compensation is deemed received in the Company&rsquo;s fiscal period during
which the financial reporting measure specified in the incentive-based compensation award is attained, even if the vesting, payment or
grant of the incentive-based compensation occurs after the end of that period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For Incentive-Based
Compensation based on stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to
mathematical recalculation directly from the information in the Accounting Restatement, the amount must be based on a reasonable estimate
of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation
was received, and the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation
to the exchange on which the Company&rsquo;s securities are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">METHOD OF RECOUPMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Compensation
Committee will determine, in its sole discretion, the method or methods for recouping any Overpayment hereunder which may include, without
limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD>requiring reimbursement of cash Incentive-Based Compensation previously paid;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="padding-right: 5.95pt">seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other
disposition of any equity-based awards granted as Incentive-Based Compensation;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 5.95pt">&nbsp;</TD></TR>
                                                                                         </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="padding-right: 5.95pt">offsetting any or all of the Overpayment from any compensation otherwise owed by the Company to the
Covered Executive;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 5.95pt">&nbsp;</TD></TR>
                            </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>cancelling outstanding vested or unvested equity awards; and/or</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                    </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="padding-right: 5.7pt">taking any other remedial and recovery action permitted by law, as determined by the Compensation Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">LIMITATION ON RECOVERY; NO ADDITIONAL PAYMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>The right
to recovery will be limited to Overpayments received during the three (3) completed fiscal years prior to the date on which the Company
is required to prepare an Accounting Restatement and any transition period (that results from a change in the Company&rsquo;s fiscal year)
within or immediately following those three (3) completed fiscal years. In no event shall the Company be required to award Covered Executives
an additional payment if the restated or accurate financial results would have resulted in a higher Incentive-Based Compensation payment.</U></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">RECOUPMENT AND ADJUSTMENT OF A BONUS UNDER DUTCH LAW</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For purposes
of the Dutch Clawback Rules, a &ldquo;Bonus&rdquo; means any variable Director compensation that is partly or entirely conditional on
the achievement of certain targets or the occurrence of certain events (e.g., signing bonuses, severance pay, cash bonuses, performance
awards and contributions to pension funds).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Under Dutch law,
the Company may and, if so directed by the Board shall, recoup all or part of a Bonus that has already been paid to a Director, to the
extent payment of such Bonus was based on inaccurate information as to the achievement of targets or the occurrence of events on which
the Bonus was based (as determined by the Board acting in good faith). The claim for recoupment of a Bonus will expire after a period
of five years has elapsed after the Company became aware that the Bonus was based on inaccurate information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In addition,
under Dutch law, the Board may (but is not required to) adjust a Director&rsquo;s entitlement to a Bonus that has not yet been paid to an appropriate
amount, if payment of the (unadjusted) Bonus would be unacceptable according to standards of reasonableness and fairness (as determined
by the Board acting in good faith).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">NO INDEMNIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company shall not indemnify
any Covered Executives against the loss of any incorrectly awarded Incentive-Based Compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">INTERPRETATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Compensation
Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for
the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements
of Section 10D of the Exchange Act and the applicable rules or standards adopted by the Securities and Exchange Commission or any national
securities exchange on which the Company&rsquo;s securities are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EFFECTIVE DATE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Without prejudice
to the application of the Dutch Clawback Rules in accordance with Dutch law, this Policy shall be effective as of the date it is adopted
by the Board (the &ldquo;<U>Effective Date</U>&rdquo;) and shall apply to Incentive-Based Compensation (including Incentive-Based Compensation
granted pursuant to arrangements existing prior to the Effective Date). Notwithstanding the foregoing, this Policy shall only apply to
Incentive-Based Compensation received (as determined pursuant to this Policy) on or after the effective date of NASDAQ Listing Rule 5608.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">AMENDMENT; TERMINATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Board may
amend this Policy from time to time in its discretion. The Board may terminate this Policy at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">OTHER RECOUPMENT RIGHTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>The Board
intends that this Policy will be applied to the fullest extent of the law. The Compensation Committee may require that any employment
or service agreement, cash- based bonus plan or program, equity award agreement, or similar agreement entered into on or after the adoption
of this Policy shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms
of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment
that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement,
cash-based bonus plan or program, or similar agreement and any other legal remedies available to the Company.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">IMPRACTICABILITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Compensation
Committee shall recover any Overpayment in accordance with this Policy except to the extent that the Compensation Committee determines
such recovery would be impracticable because:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>The
direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>Recovery
would violate home country law of the Company where that law was adopted prior to November 28, 2022; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(C)
Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the
Company, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">SUCCESSORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This Policy
shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (1 Q4# 2(  A$! Q$!_\0
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M?Y5B'J?K0!O?VO:^K_\ ?-']KVOJ_P#WS6!10!O_ -KVOJ__ 'S1_:]KZO\
M]\U@44 ;_P#:]KZO_P!\T?VO:^K_ /?-8%% &_\ VO:^K_\ ?-']KVOJ_P#W
MS6!10!O_ -KVOJ__ 'S4]M>171;RMWR]<C%<S6MHGWI_P_K0!L4444 %%%%
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MZHKA?-^)'_/MI7_?7_UZ/-^)'_/MI7_?7_UZ/9^:^\/:^3^X[JBN%\WXD?\
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M\^VE?]]?_7H\WXD?\^VE?]]?_7H]GYK[P]KY/[CNJ*X7S?B1_P ^VE?]]?\
MUZ/-^)'_ #[:5_WU_P#7H]GYK[P]KY/[CK[[HGXU3KEIY?B'A?,M]+]OF_\
MKU!YOC[_ )]]+_[Z'^-'L_-?>/VOD_N.PHKC_-\??\^^E_\ ?0_QH\WQ]_S[
MZ7_WT/\ &CV?FOO#VOD_N.PHKC_-\??\^^E_]]#_ !H\WQ]_S[Z7_P!]#_&C
MV?FOO#VOD_N.PHKC_-\??\^^E_\ ?0_QH\WQ]_S[Z7_WT/\ &CV?FOO#VOD_
MN.PHKC_-\??\^^E_]]#_ !H\WQ]_S[Z7_P!]#_&CV?FOO#VOD_N.U7_CU?\
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MSTZ]Z<I-22)IT8SI2FWJO3]?T.XHHHJSE"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"I?=$_&J=7+[HGXU3H **** "BBB@ HHHH
M **** )5_P"/5_\ >%15*O\ QZO_ +PJ*@ HHHH **** "BBB@ J6V_UWX&H
MJEMO]=^!H BHHHH **** "BBB@ HHHH **** )9ON1?[E15+-]R+_<J*@ HH
MHH **** "BBB@ HHHH EM_\ 7#Z'^58AZGZUMV_^N'T/\JQ#U/UH 2BBB@ H
MHHH **** "BBB@ K6T3[T_X?UK)K6T3[T_X?UH V**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHIDLL<$+S32+'&BEF=C@*!U)- #6N8$N([=Y
MHUFD!*1E@&8#K@=3BN?T3QQI.M^(=3T%!-:ZG82%6@N5"-*H_C3GE?\ ZQKR
MGQ/?7?Q,\1Q:KX?N8-(TW0V,=OKERQC^T7#$;40G^$G'Y\]<5RO@#PS<>,?%
M6KW-[XLEL?%UI/OA*X<L5/SMG.& Z8';VH ^I:*:@98U#MN8  MC&3ZTZ@#F
M/%L]M;W6C2307<[^?(J1VT0D9@8F#<?3OVK$\*ZA;Z;JXB\^ZOHKN.W@2[$"
MQQQ *WEHPSDN1D$X]!6QXVFMH8]+:[2Y$)N2K7%H7$T&4;YEV#..Q]C5#PWH
M/A^>\$^E7VIR1VLB2-!/O5"P!"'#J"<#/0_6N:5_::'LTG!83W[VU]-_PU_X
M.ATGB*(7FA7UBMU%;S7%NZHTC[>W)^GJ?>N5T6%+KQ!I3V^D:=I/V-7$K6]U
M$[3@H1L4)R5S\V3Z5O>,7FMM#GN[32HK^Y2-U'F!/W:$?,3NZC@9'>LO2X9_
M[<TYHO"^G:3'AW>;?"TDB[.B;.>I&3Z54]9HRP_NX=OO?JNVNE]=/)G:T445
MN>6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %2^Z
M)^-4_P 17._$IF6TT_:Q'[Q^AQV%>>>8_P#ST?\ [Z-=E+"^TCS7.*KB_9SY
M;'LOXBC\17C7F/\ \]'_ .^C1YC_ //1_P#OHUI]2_O&7U_^[^)[+^(H_$5X
MUYC_ //1_P#OHTGF2?\ /1_^^C1]2_O!]?\ [OXGLWXBC\17C/F2?\]'_P"^
MC1YDG_/1_P#OHT?4O[P?7O[OXGLV1ZBC(]17C'F2?\]'_P"^C1YDG_/1_P#O
MHT?4O[P?7O[OXGM@(^RMR/O#O461ZBO&/,D_YZ/_ -]&D\R3_GH__?1H^I?W
M@^O?W?Q/:,CU%&1ZBO%O,D_YZ/\ ]]&CS)/^>C_]]&CZE_>#Z]_=_$]IR/44
M9'J*\5\R3_GH_P#WT:/,D_YZ/_WT:7U+^\'U[^[^)[5D>HHR/45XIYDG_/1_
M^^C2>9)_ST?_ +Z-'U/^\/Z]_=_$]LR/45+;D>;U'0]Z\-\R3_GH_P#WT:/,
MD_YZ/_WT:/J?]X/KW]T]MR/449'J*\1,DG_/1_\ OHTAED_YZ/\ ]]&CZG_>
M#Z]_=/;\CU%&1ZBO#S+)_P ]'_[Z-)YLG_/1_P#OHT?4_P"\'U[^Z>XY'J*,
MCU%>&^;)_P ]'_[Z-'FR?\]'_P"^C1]3_O#^N_W3W+(]11D>HKPSS9/^>C_]
M]&D\V3_GH_\ WT:7U/S#Z[_=/=,CU%&1ZBO"?-D_YZ/_ -]&@RR?\]'_ .^C
M1]4\P^N_W3WN8C9%R/N>M19'J*\(,LG_ #T?_OHTTRR?\]'_ .^C1]4\P^N_
MW3WG(]1^=&1ZC\Z\%,LG_/1_^^C2&63_ )Z/_P!]&CZIYA]=_NGO>1ZC\Z,C
MU'YUX$99/^>K_P#?1I#+)_SU?_OHTOJGF/ZY_=/?LCU%&1ZBO /-D_YZ/_WT
M:0RR_P#/63_OHT?5/,/KG]T^@,CU%&1ZBOGWS9?^>LG_ 'T:3S9?^>LG_?1H
M^J^8?7/(^A[<@3#D=#W]JQ#C)Y%>(^=+_P ]9/\ OLTWS)/^>C_]]&E]5\Q_
M7/(]PR/449'J*\.\R3_GH_\ WT::99/^>C_]]&CZKYA];\CW/(]11^(KPHRR
M?\]'_P"^C4EO>W-I<QW$,SK+&P93N/6E]5\QK%^1[C169H.M0ZYIJW,>%E'R
MRQY^XW^'I6G7*TT[,[$TU=!1112&%:VB?>G_  _K636MHGWI_P /ZT ;%%%%
M !117+>-_'VC>!-.2XU)VDN)<B"UBY>3'\A[F@#J:*\4;XP>-C;_ -HQ?#RY
M_LS[P<^9G;ZYV_TKUO0]1FU;0[/4+BRDL9;B(2&WD8%H\]B: -"BBN:\2:U>
M6&IZ;963(&N'P^Y0>,@?XT =+116)]NUC_A)_LGV$?V;MSYV/;KGZ\8H VZ*
MYK1=9O-2\2:E;,R_8[;(0!1G.<=?P-:^L_;O[%O/[,Q]N\IO(S_>QQ2*A'FD
MHWM<NE@&"DC)Z#-+7FOPY\-Z[!JUUK7B#[0)BABB6X?<Q).2W7CIBO2J46VK
MLZ<9AX8>JZ<)J=NJVN%%%%4<@5\Z^/OB98>*_&$/A66^FL/"\=SY5]=1#YYR
M#^B9&/U]J]?^(7BN3PEX7ENK)$GU29A#96YR6DD/HHY; YQ[5X3X=^!/B/Q-
M;QZMJMW%I@NI#(\4L9,VTG.[;P!GG@XH W[B34?'FJ'P7X4B73]"LU:TOWB=
M)K3R@X*.AQDR$#US^IKUWP_X!\-^&DL3I^F0K<V<;1I=,N93N^\2W<G_ /55
MWPSX9TSPGHL.E:5 (X(QEF/WI&[LQ[DUL4 %%%% '->,;J:VM;$&\N+*PDN-
MMY=6RY>--IQS@[06P"<<5%X0O6N;K4H;;4+G4=+B,?V>ZN>6+$'>H; W 87G
MWQ6IKVMIHEM&WV6:[FF8K'!#C<V%+,<D@   FG:7K5OJ4[V\43QLEO#<88#!
M60$C&/3!!K+3GW.Y.7U:W)IWT[K7:]^F]O(?KUK!?:!?VUS<"W@D@97F)X08
MZG/85R&C:FNM^(=+6ZUO3)VLM[01V5O(K2L4*DDMP!C)P*ZSQ)!'=>&]1@E?
M8DD#*6V,^WCKM7D_05S7ASQ%=W&K6>G3ZO;3[D/[L:9- [A5ZAFX':IG\:-<
M,G]7FUTO\M-]GZ'<T445N>8%9>N>(=.\/6\4NH2LIE;9%'&A=Y#Z!1R:U*Y#
MQAI.JRZSHFMZ5:I>R:<[[[5I F]6&,@GC(H LW?C[0+*RL[N>XF6.\1VA'DM
MN;:<$8QD'/&*R;SQRVG2:[=F>.Z@M8H'M[58'1T,BY&]L=#^E+>66IWWB3PU
MJ^H6=M:K9B9KM//4B'><)UZD^H[U5U'0;NYU/QLV^W2/4;>&"W9IEYDV8VD9
MRISZ^M*Z*49/9&BOC$ZDGAVXL[E+5+ZY\F>&>W<F0[02J'''7[W0UJ/XTT1-
M=_L<3R/=>:(6*1,R(YZ*6 P#7+I9:M?0^$#<V<-M)I-Z(KA?M2-@!  >O4_W
M1DU)HD&M^']9U"RM[.RNK._U%I5OFN5&S/52G4L,=*+H.278Z"T\<Z'>ZI%I
M\<LZRS.4A>2!T25AU"L1@U%X)UF^UF+5VOI1(;?4)8(L*%P@Z#CK7%66B^)+
MS7-%N-1WSR6VHEY)WU!'C=0?^64>>, <]Z[#P+I]QIL.J_:?+'VO4);B'9(K
M[XR0,\&BZ!QDMT48_$GB?Q!J.HCPW;:>MC82F'?>%MT[CJ!CH*L7_B/7KWQ%
M_8&AV]G'=V]NLUY/=%F2,L!\JXZ]>M9]AIOBKPA?ZG;:3I5OJ5A>7#7$$C7
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MF*UL;33L-;Z?;N'W,#GD@GC(!/.> *[S2=%O(?%>HZI=QHJ29$)#Y.,_IP*
M,G0(I['QU<V2WD]Q$D9\QI"3DX!Y_$U/X>O);GQ#KE\\TA@A#;5+DJ.3T'T6
MKFC:-J%IK.KZC<Q('G#"$!P<\D_AT%0:1H&I6'AK4X'1!?71.T!QC&,=?Q-
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MTVUU2].G6MTMI- I,US<@A-P.-I!P 3U&#S26NGVFL3R6UG<?8VMH]TLER"
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M_O(K>^DN-/LUGE62ZS$^%W81=OR]/4U0'QWE2#3]0N?!]_'I5Z3''<B4,7E
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M_P!)OM0DN;BXU!X9)O/>T-R?(9\YSMKJJ* $    & .@H9@JECT R:6@\#-
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M+2[,.R:@J=N<$$'YU8$\<8S[5Z:J(BA415 )8 # !/4_6A8T1%14557.U0,
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M#Z'^58AZGZUMV_\ KA]#_*L0]3]: $HHHH **** "BBB@ HHHH *UM$^]/\
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M %N/7_"M[)I.FVILKK?=72ZD)9;S:<M)@G&!CH/6O?6TC3GW[K* [U"M\@Y
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M]/SZ?UH V**** "N U"*7QGX_O=#N+JXAT31[>)YX;>5HS<S29(#,I!VJHZ
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MHJ\Q_P"$RUW85^UK@G/^J7_"D_X3#7/^?M?^_2_X4?4ZG=!]=I]F>GT5Y?\
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M.G%:]OH$%OXHO-=6:0S74"0M&<;5"]QWK7HH *CG4/;R(>C*1^E24C<J1[4
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MA2?\*_O_ /G]M?R;_"O0:*/K57N/ZI2[?B>??\*_O_\ G]M?R;_"D_X5_?\
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ME^BJ']N:3_T$[/\ [_K_ (T?VYI/_03L_P#O^O\ C1ROL',NY?HJA_;FD_\
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M^-']IZ=_T$+/_P "$_QHY7V#F7<M455_M/3O^@A9_P#@0G^-']IZ=_T$+/\
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M'LH=D<K_ ,*X\+?] T_]_G_QH_X5QX6_Z!I_[_/_ (UU5%'M)]P]E#LCE?\
MA7'A;_H&G_O\_P#C1_PKCPM_T#3_ -_G_P :ZJBCVD^X>RAV1RO_  KCPM_T
M#3_W^?\ QH_X5QX6_P"@:?\ O\_^-=511[2?</90[(Y7_A7'A;_H&G_O\_\
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M^@:/^_K_ .-=%11[2?</90[(YW_A!?#?_0-'_?U_\:/^$%\-_P#0-'_?U_\
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M&C_OZ_\ C1_P@OAO_H&C_OZ_^-=%11[2?</90[(P)/ 7AE5C(TT?,N3^]?\
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M5%%%9F@5C?\ "6:#Y^IP'4X!)I:[[U3D>0/4\?RK9KY]N/\ D/?&'_KT_H:
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MG\N.4JHE"=2!UP<T >MT5SO@2YEN_ VCSSR-)(UN,NQR3@D=?PKHJ "BBB@
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MGUK$;[[?6@!**** "BBB@ HHHH **** "M31/]?+_NC^=9=:FB?Z^7_='\Z
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MO;&26$SP&ZBVB6,#)*\^G-2Z3XULM6MY[M;.]M[".)IEO)HP(W53@X(/7V-
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MH_G676IHG^OE_P!T?SH VJ*** "BN&_X0?7<?\CKJ'_?+?\ Q='_  A&N_\
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M_BZ.2/\ -^8<\_Y?Q1W-%<-_PA&N_P#0Z:A_WRW_ ,71_P (1KO_ $.FH?\
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MS#GG_+^*.YHKAO\ A"-=_P"ATU#_ +Y;_P"+H_X0C7?^ATU#_OEO_BZ.2/\
M-^8<\_Y?Q1W-%<-_PA&N_P#0Z:A_WRW_ ,71_P (1KO_ $.FH?\ ?+?_ !='
M)'^;\PYY_P OXH[FBN&_X0C7?^ATU#_OEO\ XNC_ (0C7?\ H=-0_P"^6_\
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MM,(YKHML?4),\1IG'4]!^)YP* .1U[XNW&I>%=>T36[$:I!=3.FG:A%&88V
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MRQ1116!T$W_+H/\ ?_I4-3?\N@_W_P"E0T %%%% !1110 4444 %2V_^L/\
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M^/NL2"<$F@#T&BO()M9U 7G@*WTZUU+4)YH)]2:VGO!O(9?E\R0X&T;SV[
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M%% $MO\ Z]?Q_E6(WWC]:V[?_7K^/\JQ&^\?K0 E%%% !1110 4444 %%%%
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M<<U-I7@)-)O] DAO2]OI-O<+AU^>:>;&Z4GH/XN/>ND_MS2?^@I9_P#?]?\
M&C^W-)_Z"EG_ -_U_P :.5]@YEW.)MOA[J\/A&UT=M7L_/TV_2]T^=;9L95R
MW[T%OFR6/3%37G@'4=6T_7)=3U:!]8U:!+1IH82L5O;JV2B*23S\V23U(KL/
M[<TG_H*6?_?]?\:/[<TG_H*6?_?]?\:.5]@YEW+D4200I%&H5$4*H'8#@4^J
M']N:3_T%+/\ [_K_ (T?VYI/_04L_P#O^O\ C1ROL',NY?HJA_;FD_\ 04L_
M^_Z_XT?VYI/_ $%+/_O^O^-'*^P<R[E^BJ']N:3_ -!2S_[_ *_XT?VYI/\
MT%+/_O\ K_C1ROL',NY?K,ET#39O$$6N2VPDU"&$P12.Q(C4G)VCH"?4<U)_
M;FD_]!2S_P"_Z_XT?VYI/_04L_\ O^O^-'*^P<R[E^BJ']N:3_T%+/\ [_K_
M (T?VYI/_04L_P#O^O\ C1ROL',NY?HJA_;FD_\ 04L_^_Z_XT?VYI/_ $%+
M/_O^O^-'*^P<R[E^BJ']N:3_ -!2S_[_ *_XT?VYI/\ T%+/_O\ K_C1ROL'
M,NY?HJA_;FD_]!2S_P"_Z_XT?VYI/_04L_\ O^O^-'*^P<R[E^BJ']N:3_T%
M+/\ [_K_ (T?VYI/_04L_P#O^O\ C1ROL',NY8FL[:XECEF@CDDCSL9ESC/6
MH5TC3D"!;*$"-2J_(. >M-_MS2?^@I9_]_U_QH_MS2?^@I9_]_U_QI<GD:*M
M)*RE^/\ P1PT?3E"@64.%C,8^7^$]10='TX@C[%#@Q^4?E_A]*;_ &YI/_04
ML_\ O^O^-']N:3_T%+/_ +_K_C1[/R_ ?UB?\[^__@CFTC3G#AK*$AT"-\@Y
M Z"A](TZ3S-UE ?,V[_D'..E-_MS2?\ H*6?_?\ 7_&C^W-)_P"@I9_]_P!?
M\:/9^7X!]8G_ #O[_P#@CVTG3W+EK.$[W#M\@Y8=#1_9.GEBWV.')D\W.T?>
M]:9_;FD_]!2S_P"_Z_XT?VYI/_04L_\ O^O^-'L_(/;S_G_'_@CUTG3U*D6<
M(*R&0?(.&/>D32=/3R]MG"/+)9?D'!/6F_VYI/\ T%+/_O\ K_C1_;FD_P#0
M4L_^_P"O^-'L_(/;S_G?W_\ !'+I&G)Y>VR@'EAE7Y!P#UJS;V\-K L,$:QQ
M*,*JC@54_MS2?^@I9_\ ?]?\:/[<TG_H*6?_ '_7_&A0MLA2K.6DI7^?_!+]
M%4/[<TG_ *"EG_W_ %_QH_MS2?\ H*6?_?\ 7_&GROL9\R[E^BJ']N:3_P!!
M2S_[_K_C1_;FD_\ 04L_^_Z_XT<K[!S+N+>_ZQ?I5:K,I%VL<UNRRQ,O#H00
M?QJ+[/+_ ,\S2*(Z*D^SR_\ /,T?9Y?^>9H CHJ3[/+_ ,\S1]GE_P">9H C
MHJ3[/+_SS-'V>7_GF: (Z*D^SR_\\S1]GE_YYF@!W_+H/]_^E0U9\F3[-MV'
M.[./PJ+[/+_SS- $=%2?9Y?^>9H^SR_\\S0!'14GV>7_ )YFC[/+_P \S0!'
M14GV>7_GF:/L\O\ SS- $=2V_P#K#_NFD^SR_P#/,U)##(KDE"/E(H KT5)]
MGE_YYFC[/+_SS- $=%2?9Y?^>9H^SR_\\S0!'14GV>7_ )YFC[/+_P \S0!'
M14GV>7_GF:/L\O\ SS- $=%2?9Y?^>9H^SR_\\S0 LWW8O\ <J*K$L,A6/"$
MX7!J/[/+_P \S0!'14GV>7_GF:/L\O\ SS- $=%2?9Y?^>9H^SR_\\S0!'14
MGV>7_GF:/L\O_/,T 1T5)]GE_P">9H^SR_\ /,T +;_Z]?Q_E6(WWC]:WH(9
M%F4E"!62;"ZW']P_6@"M15G[!=?\\'H^P77_ #P>@"M15G[!=?\ /!Z/L%U_
MSP>@"M15G[!=?\\'H^P77_/!Z *U%6?L%U_SP>C[!=?\\'H K5J:)_KI?]T5
M4^P77_/!ZNZ>AL1--=X@B"C+R$ #GUH V**** .5_P"%<>%O^@;_ .1G_P :
M/^%<>%O^@;_Y&?\ QKJJ*T]I/N9^RAV1RO\ PKCPM_T#?_(S_P"-'_"N/"W_
M $#?_(S_ .-=511[2?</90[(Y7_A7'A;_H&_^1G_ ,:/^%<>%O\ H&_^1G_Q
MKJJ*/:3[A[*'9'*_\*X\+?\ 0-_\C/\ XT?\*X\+?] W_P C/_C7544>TGW#
MV4.R.5_X5QX6_P"@;_Y&?_&C_A7'A;_H&_\ D9_\:ZJBCVD^X>RAV1RO_"N/
M"W_0-_\ (S_XT?\ "N/"W_0-_P#(S_XUU5%'M)]P]E#LCE?^%<>%O^@;_P"1
MG_QH_P"%<>%O^@;_ .1G_P :ZJBCVD^X>RAV1RO_  KCPM_T#?\ R,_^-'_"
MN/"W_0-_\C/_ (UU5%'M)]P]E#LCE?\ A7'A;_H&_P#D9_\ &C_A7'A;_H&_
M^1G_ ,:ZJBCVD^X>RAV1RO\ PKCPM_T#?_(S_P"-'_"N/"W_ $#?_(S_ .-=
M511[2?</90[(Y7_A7'A;_H&_^1G_ ,:/^%<>%O\ H&_^1G_QKJJ*/:3[A[*'
M9'*_\*X\+?\ 0-_\C/\ XT?\*X\+?] W_P C/_C7544>TGW#V4.R.5_X5QX6
M_P"@;_Y&?_&C_A7'A;_H&_\ D9_\:ZJBCVD^X>RAV1RO_"N/"W_0-_\ (S_X
MT?\ "N/"W_0-_P#(S_XUU5%'M)]P]E#LCE?^%<>%O^@;_P"1G_QH_P"%<>%O
M^@;_ .1G_P :ZJBCVD^X>RAV1RO_  KCPM_T#?\ R,_^-'_"N/"W_0-_\C/_
M (UU5%'M)]P]E#LCE?\ A7'A;_H&_P#D9_\ &C_A7'A;_H&_^1G_ ,:ZJBCV
MD^X>RAV1RO\ PKCPM_T#?_(S_P"-'_"N/"W_ $#?_(S_ .-=511[2?</90[(
MY7_A7'A;_H&_^1G_ ,:/^%<>%O\ H&_^1G_QKJJ*/:3[A[*'9'*_\*X\+?\
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M8YW_ (0C0_\ GC<_^!<O_P 51_PA&A_\\;G_ ,"Y?_BJZ*BCGEW#V<.QSO\
MPA&A_P#/&Y_\"Y?_ (JC_A"-#_YXW/\ X%R__%5T5%'/+N'LX=CG?^$(T/\
MYXW/_@7+_P#%4?\ "$:'_P \;G_P+E_^*KHJ*.>7</9P['._\(1H?_/&Y_\
M N7_ .*H_P"$(T/_ )XW/_@7+_\ %5T5%'/+N'LX=CG?^$(T/_GC<_\ @7+_
M /%4?\(1H?\ SQN?_ N7_P"*KHJ*.>7</9P['._\(1H?_/&Y_P# N7_XJC_A
M"-#_ .>-S_X%R_\ Q5=%11SR[A[.'8YW_A"-#_YXW/\ X%R__%4?\(1H?_/&
MY_\  N7_ .*KHJ*.>7</9P['._\ "$:'_P \;G_P+E_^*H_X0C0_^>-S_P"!
M<O\ \57144<\NX>SAV.=_P"$(T/_ )XW/_@7+_\ %4?\(1H?_/&Y_P# N7_X
MJNBHHYY=P]G#L<[_ ,(1H?\ SQN?_ N7_P"*H_X0C0_^>-S_ .!<O_Q5=%11
MSR[A[.'8YW_A"-#_ .>-S_X%R_\ Q5'_  A&A_\ /&Y_\"Y?_BJZ*BCGEW#V
M<.QSO_"$:'_SQN?_  +E_P#BJ/\ A"-#_P">-S_X%R__ !5=%11SR[A[.'8Y
MW_A"-#_YXW/_ (%R_P#Q5'_"$:'_ ,\;G_P+E_\ BJZ*BCGEW#V<.QSO_"$:
M'_SQN?\ P+E_^*H_X0C0_P#GC<_^!<O_ ,57144<\NX>SAV.=_X0C0_^>-S_
M .!<O_Q5'_"$:'_SQN?_  +E_P#BJZ*BCGEW#V<.QSO_  A&A_\ /&Y_\"Y?
M_BJ/^$(T/_GC<_\ @7+_ /%5T5%'/+N'LX=CG?\ A"-#_P">-S_X%R__ !5'
M_"$:'_SQN?\ P+E_^*KHJ*.>7</9P['._P#"$:'_ ,\;G_P+E_\ BJ/^$(T/
M_GC<_P#@7+_\57144<\NX>SAV.=_X0C0_P#GC<_^!<O_ ,51_P (1H?_ #QN
M?_ N7_XJNBHHYY=P]G#L<[_PA&A_\\;G_P "Y?\ XJC_ (0C0_\ GC<_^!<O
M_P 57144<\NX>SAV.=_X0C0_^>-S_P"!<O\ \51_PA&A_P#/&Y_\"Y?_ (JN
MBHHYY=P]G#L<[_PA&A_\\;G_ ,"Y?_BJ/^$(T/\ YXW/_@7+_P#%5T5%'/+N
M'LX=CG?^$(T/_GC<_P#@7+_\537\":!(A22VG=3U5KJ0@_\ CU=)11[27</9
MP[!1114%A1110 444T.I<J&!8=1GD4 .HHIH=68J&!8=0#R* '444C,%4LQ
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M[N!'("J;\!0/7H.?4T70<DNS^X[RBBBF0%%%% !1110 4444 %%%% !1110
M5S>JVS:IXJL[99YH%MK=YC)"<,"Q"CDCT!KI*,#.<<T <%+%)#:>(W\Z>=Y)
M([&*24Y8] >0/5JAU62QB?68[Z%IKJ%$M[*$J3M0(,,OIR<D^U>A8'H/6C:I
M.2!GIG% '(_V1#=ZIH^EW$>^WLK'S9$/1F.% /Y$UB7PL9[2^@E@+ZI+>"WB
M78<V\88*N/08_/->E8&<]Z3:,YP,^N* ."UB6PCN]874(3--!"D-C 5)PNW[
MR^G/4^U-NH!;W.G65W<6\%M;V"E!<Q%T>0_>. 0"P]Z[\JI.2!GIG%!56QD
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHKE_$?B#4[?6[#P_H-O:RZG=Q/</)=EA%!"N 6(7DDD@ "@#H)X+2]81S)%
M,T+!MK8)0]OI48TG3P019PY$GFCY?XO6O)=)\97.AZ?JFMWD-I_:^N:RUI$N
M]C @A4(7) +%!M/09YK?TSQ]K4J:<]]I]M]FN=8&G"[C22-)D:,LLB*_S#YA
MMYX/:ERI]"U4FE9-_>=TND:>A0K9PC8Q=?D'!/4TTZ9I=M&LC6MO&D0;#,
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MG1_:(/\ GM'_ -]"D^T0?\]H_P#OH5SAIM'(+VC.E^TP?\]H_P#OH4?:8/\
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M-IQIM A#333C330(0TVG&FTP&FFTXTV@!IIAIYIAH ::;3C3:!#3333C333
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M(AEMXI(EQA'0%1^% 'B>K:?IFD>"[6./Q'I-VHNI-5&FRR-':W<>"ODQ#).
M1\HYRW:O7?#20)X9TW[+8M8PM;HZVKDDP[AG:<^F<5>>RM9/+WVT+>5_J]T8
M.SZ>E3T %%%% !1110 4444 %%%% !1110 4444 %%9E_K^FZ9<?9[J=DDVA
ML"-FX/T%6K._M[^T%U;N6A.<$J1TZ\'F@"S16+'XLT>658TN7+LP4#R7ZG\*
MOZAJ5KI< FNY"D9;:"$+<_@* +=%9^G:W8:K(\=G*SL@RV8V7C\145[XCTS3
M[I[:YG=95QD")SU&>H% &K15:&^MY[ 7T;DVY0ONVD' Z\=>U9]OXITBZN(X
M(KAS)(P5087&2?<B@#9HJEJ.K6>E)&]Y(R"0D+A&;)_ 4FG:O9:J)/L<K/Y>
M-V49<9^HH O45CW7B;3+.YDMYI)A)&<,!"Y'Y@5?:^@73_MQ+>1Y?F9VG.W&
M>G6@"S163:>)--O;I+>!Y3(_"AH6 _,BI]1UBSTHQBZ9U,F=NV-FZ?04 7Z*
MIZ=JEKJD3R6K.RHVT[D*\_C5&;Q3I=O-)%)),'C8JP$#GD?A0!M456N;Z"TL
M3>2EA" #D*2<'IP.>]5+'Q#I^HW0M[=Y3(02 T3*./<B@#4HK-U'7+/2YEBN
M/.W,NX>7$S#'X58L-0@U*V\^WW[-Q7YT*G(]C0!.T2,<LH)I/(B_N"L@^*],
M$ACQ<[@VW_CW?K^5:5]?PZ=:FXGW[ 0/D0L>?84[BL2^1%_<%)]GB_N"J6GZ
M[9:G.T-OYV\+N.^)E&/J13;_ %^RTVY^SW'G[]H;Y(688/N!1=A9%_[/#_SS
M%'V:'_GF*CM+Z&]LQ=0A_+.<;D*GCV-9L7BK3994C47.YV"C-NX&3^%%V%D:
MWV:'_GF*3[+!_P \Q4.HZE;Z9"LMQYFUFVC8A8Y_"H].UFUU221+=9QL ),D
M10'Z9HNPLBU]E@_YYBC[)!_SS%9]YXBL[&Z>WECNBZ8R4@9A^8J[%>Q2Z>+U
M5D\HH7P4(; ]NN:+L+(?]DM_^>2TGV.W_P">2UFVWB:QNKF.".*[#R-M!>W8
M#\3VJWJ6JP:6L;3I,PD) \J,OT]<47861/\ 8[?_ )Y+1]BMO^>*U!INJV^J
M+(8$F41D ^;&4Z^F:JW7B6QM+F2"2*[+QG!*6[,/P-%V%D:'V*V_YXK1]AMO
M^>*TCWT2:?\ ;2LABV"3 0[L?3KFJ-GXCLKVZ2WBCN@[]"\#*/S-%V%D7_L%
MK_SQ6D^P6O\ SQ6H-1UB#3'C6:&YD+@D>3"7Q]<5)IVI1:G"\D,<\85MI$T9
M0_D:+L+(?_9]I_SP6D_LZT_YX+6=-XHLX9GC:UOR48J2MLQ!QZ&M*[OH[.R-
MTZ2L@ .V-"S<^U%V%D)_9UG_ ,\%H_LVS_Y]UJK8:];:A<B"*"[1B"<RP,B\
M>YIVHZU;Z9,L4L-U(S+N!AA+C\Q1=A9$_P#9EE_S[I^M']EV7_/NGZTMA?1Z
MC;>?$DJ+N*XE0HW'L:S?^$IL_-\O[+?YW;<_96Q1=A9&A_95C_S[)^M)_9-A
M_P ^R?K3[^^CTZV\^6.9UW!<1(7;GV%5]/UJ#4IVBBM[N,JN[=-"4!_$T786
M1+_9%A_SZI^M)_8^G_\ /JGZU#?:[!87)@DMKR1@ =T4!9>?>K=K>I=V0NDC
MF12"=DB;6X]J+L+(B_L;3_\ GU3]:D@TVSMI1)#;HCC@$5GQ>)K::9(Q9Z@I
M=@H+6S #/J:O:AJ,>FQ+))#/*&;;B&,N1]0*+L+(N45GZ=JT6IM(L<%U%L )
M\^(IG/IGK4-YX@M[*Z>W>UOG9,9:*W+*?H:0S6HJO'>))8"\$<H0IOV%,/CT
MQZUGVWB.WNKF.!;2_1I#@-);E5'U/:@#8HJCJ.IIIJQE[:YFWD@>1'OQCUHT
M[4TU)9"EM<P["!^_CV9^E %ZBL>X\116UQ)";#4',;%2R6Y*GZ'O5^2\6/3_
M +88IBNP/Y:IE^>V/6@"S1639Z]'>W20+8WT9;/S2P%5''<U-J.K)ISHKVMW
M-O!.8(BX'UH T**J:??KJ,#2K!/"%;;MGCV$_A5"7Q)%%,\9T_46V,5W+;D@
MX]* -JBJUW>+:6;7+132 8^2--S<^U5+'6EO[D0BQOH<@G?-#M7\Z -2BLW4
M-8&GSB(V-[/E=VZ"+</IGUJS8WHOK;SQ!/#R1LF3:W'M0!9HK$'B13($_LO4
M^3C/V?C^=:-_>BPMO.-O//\ ,%V0IN;ZXH M45G:=JXU"9XQ97D&U=VZ>+:#
M["F7VMK8W1@-A?38 .^&'<O/O0!J457MKL7-D+D0S1Y!/ER+AQCVK-A\1+-/
M'%_9FI)O8+N># 'N3F@#:HHHH *Y[Q1J1M9=&L8KVXM;B_OTB1H(E<L "[ [
MNBD+@D<BNAKE]>T+4=1\5:5J=NT'D:=:W1C5V()N)%"H>G0#=S[T 9UI\4-+
MO;ZVABTW5/LL]^=/%ZT*B$3;B N=V3G'4#C/-=)XA\06GAO2_MUVDL@:5(8H
MH5!>21SA5&2!R?4URVG^![VTTOP7I[20&+1YS=7I#',DNQL%>.?G<GG%;7C+
M3K_5M+6QMM)TW4[:4D3P7TS18_NLK*#R#^/H: (KKQM%96=F;K1]1CU*\E>*
M#3-J&9RO5N&VA .=Q..:9HOC_3-;N].M8K:[AFO6N8P)57$<D&-Z$@D$\\$9
M'!KE;CX=:Q%'X?FGCL/$$MA8R6D\-_.Z+EGW!E;#$X'R\]0*U?$7@O5]1TGP
M]'HQT_2+RQ=UE%N"(X8Y8RDGEC R0#QG'/- &G_PL/2WT^&YMK6]N9+J[EM;
M.WB12]R8SAG7)P$&#\Q(JJ_Q0TE-(M+W[!J+S7-Z]@MG'$KR^>F=RX#8(SQD
M$CFL_7_AZPN]!DTG3;#4+'2[-[/[!?2M&N#@B0, ?FXYR.<UJVGA2Z'B#PY>
M26FG6EEI5I/_ *+:9V)<28'RC X"YYZY- #KWXA6]DZPG1-6FNH[9;J]MX(E
M9K*,YQYGS8SP3@$G JH_B:7Q!K_@L:9+<6UI?QSZA-&V SPJF$# 9X+.IJAK
MGA+Q<U]XKCT2;3EM]>"$W4\CB6(",(8PH&.1G!SQGI6]H_A6XT[Q7!?NT7V*
MRT>+3K5%)W ALN2,<=%'X4 7M>\56^B7MMI\=E=ZCJ5TK/%9VB@OL7J[%B J
M]LD]:YS6_B4Z^&],U#0M*N[BYOK\67DR1C=%(KX=&&X?-@-C!(R.35W6=%\1
MVWC1_$.@QZ?<FXT\63QWDK1^20Y8., Y'/(XZ5FR>!=8TNP\,C39;2_N=.OI
M;V\%R[1+/+(&RX(!Q@L2!["@"#5/'MS8>/9,Z?JTMK9Z*+B>P@128F9]Q:3Y
MMH*HOK_%QFNDO_'>GVT=@+.TO-1N;ZU%[%;VRJ&6' .]RQ 4<XY/)K,O_"&K
M7-EXV>.2W6^UUEAMV+G"0! @#''!P7.!ZUGZQX N_P#A)!?VVD:3K%HUA#9K
M#J$S1_9S'D9&%(92#R/:@#9N/B7I4>FZ'=VUCJ-X^M([6=O;Q R$J.002,<]
M^GX5U]M*T]K%,\+PM(@8Q28W(2.AQW%<Y#X;G'C:RU:2.VCLK'2S:V\,/&R5
MF!<@8P%VJ /K744 %%%% !1110 4444 %%%% !1110 F >PI:*J7VIV>FHKW
MEPD0<X7/)8^P')H M8'H*7&:J0:G97+HD%PCL\7G*!W3.,_G6?>^*=-M/L1$
MHD2Z;Y67. O.6Z=,B@#;P!VI,#TH5@Z!E.589!JE-K&GP7RV4ER@N&( 3!."
M>F?3/O0!>I,#T%9UUX@TFSN6M[B^BCE3[RG/'L??VJS]OM?-FC\Y=\*"20?W
M5.<$_D: +.,T8 Z"L^?7=,M8()YKR-(YUW1$Y^8>N.N*1]=TN.UBNGO8A!*Q
M6-R>&(ZX_*@#1Q164OB71G,074(293M0<]<XY].?6M6@ Q15&^UG3M-D6.\N
MXXG89"G)./7CH/>FW.N:9:7"P3WL:2G!V]<9Z9],^] &A1BL*^UJ6VU#4$79
M]GL[+SFR.3(2<#Z8%:FG233:;;2W.WSGB5GVC R1DT 6:,444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !56^U&RTR%);ZYBMXY)%B1I&P&=CA5'N35JN2\5ZC
M.GB7POI4#HJ7%S)<7.Y%;]U%&6/4<?,5Y'- '6U%<W,-G:S7-Q((X84,DCGH
MJ@9)_*O(])UKQ7<1>&-:GUZ1DUC5S%#IX@0(;0EVRQQN)"KD'/ Q53Q1J^MZ
M_P"$M6U=-?DL[:ZU!M)L--CB0I,AD\HEB1NW'YCP1@"@#URWUW2[I[&.*]B,
ME_"9[:,G#2Q@ E@#SC!%:%>6^(/$5YX>U?5(M.$31:1IEI96J21@@7,[[5).
M,X"@$C.#5S63XB\,6=K:Q^)IM0U'6;J&RB>Y@CVVSMDO(H4#C:#A3GG% 'HU
M5+W5+#3K(WEY>0P6P8(97<!=Q.T#/KDXKSFRU+5K2^\:6LWBB[O+'1K!=ERT
M40DBF*L[<A<$@ #D=\=JI:%9:EH/AKP5I)U&:>;6+R*>:&>.-EBC"--*J_+W
M)')R?3% 'KU%>0:CXC\0W7A:Z\9V^NR6B"_^SZ=ID<*-'*@F\O:^1N+-ACP1
MBD\0ZYXHF@\7ZU9Z[+8V.DW26ME;10HWFSC8K!B03MW-C [_ $H ]@HKSOQC
MJ>LV&O:6+N_OM,T.:)(VO+".-]EVS@ 2[@2$[# ZGFO0U!"@$Y..OK0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !7.7_VFT\4+?'3[B\A^R^7#Y(!V
M/NR<Y/&1CFNCHH Y&_\ [2M=4U*:VTN>62>T2*W* ;$X);)SUR?QJ2.RN+"]
M\/H;.:6"VMF1C&H.R1@!EN>!UYKJJ* *UI<R7#3B2UD@$<I12^/W@'\0]JP(
M4O#XH%Q9VMY;QS.?MHG5?*8*,*RG.<].E=110!Y_(ETEG!I%QI\J2W>I;IYW
M VO\^[Y3U/ _"KFIIJB2Z]%;Z;<2RWK(D<R@;!'M"]<]>3Q772VL$\T,LL:M
M)"2T;'^$D8R/PJ:@#D;B&]TS5+EX-,FNC]AC@M&0 JF <@Y/'/YT_3]&FCN-
M"AGMF,-C:M*Q(X\YL<?4<FNKHH XV+1[EM(MXWM&6>]U$3W7R\H@<MS^0_.N
MIMKF2>>YC>UDA6)]J.^,2#'4>U6:* .:M_M-GXBU(S:;/<&[D01S* 4$8 &"
M2>,<G%4+32F>^NK?4+74G\^[9W\L@0.N?E)/7 &.*[2B@#D+W3KZY@UC%M)N
MO;R.%>.D*X!;Z=:ZY5"J% P , 4M% !1110 4444 0W#LBKM.,FJ_GR_WOTJ
M:[^ZOUJI5I:$2>I)]HE_O?I2?:)?[_Z5'255D3=DGVF;^_\ I2?:9O[_ .E1
MTVBR%=DGVJ;^_P#I2?:I_P#GI^E1TVG9"NR7[7/_ ,]#^5)]LG_YZ'\A45)1
M9!=DOVRX_P">A_(4AO+C_GH?R%0GI2&G9!=DWVVX_P">I_(4W[=<_P#/4_D*
MA[4VBR%=E@WUS_SU/Y"FF_NO^>I_(5 :0T6079/_ &A=?\]3^0I/[0NO^>Q_
M(57IIZT[(5V6#J-W_P ]C^0IIU*[_P">Q_(57---%D%V63J5Y_SV/Y"FG4[S
M_GN?R%5S3#19!=EDZK>_\]S^0I/[5OO^>Y_(55-,HLA<S+9U:^_Y[G_OD4TZ
MO?\ _/P?^^154TPT[(.9ELZQ?_\ /P?^^12'6=0_Y^#_ -\C_"J9IAHL@YF7
M3K6H_P#/R?\ OD?X4T:YJ*L#]H)QV*CFJ1IAHL@YF=W87L=_:K,G!Z,O]T^E
M6JX72]1;3KL/R8FXD7V]?K7<JP=%=3E6&0:PE&S-XRNA:***DL**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LZ]T+3M0OUOKFWWW
M*6\EJK[R,1R8W 8/? YZUHT4 9,7AO281I(CM HTE2MD-QQ$"NT]^>..:S%^
M'/A5=3_M :6#<"Y^U+F5RJ2YR65<X7)Y.!S74T4 8MWX2T2_BU2.ZL5E75&1
MKO<S?O"@ 4]>, #&,53/P_\ #;:.VF-92- 9UN"[7$AE\P# ;S"V[(''7I73
M44 86G^#= TO3+_3K/3DCM+_ #]JCW,?-RNTY).>12Z=X0T72FT]K6V<-IXD
M%LTDSR&,2 !N6)SP /8=*W** .;MO 7AJTU<:G#IP%PLIG13*[1QR'JZQD[5
M;W JT?">BMISZ>;,&U>[^VNF]OFFW[]Q.>?FYQTK:HH Y^X\%:#=:U_:T]H\
MESYJS;7G<Q&1>C^7G;D8'.*Z"BB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *R-0U&\_M./3--CA:X,9FDDFSMC7.!P.22:UZR;[1&N=1^W6]_/:2M
M%Y4AC"G<N<]QP?>@"E-K&JF:6W@ALQ+9P"6[>1FV;B"0J]^@SDU$NOZI<Q:3
M%:VUO]KOH6F<2$[8E&,'U[U9O?"ZW<MT4U&ZACNT59XTP=Y P#DC/U]:O6VD
M16U^EVKL3';+;(A PJ@YS]30!1CU+5[VYGCL8K,I:L(IGE+#S), L%QT SWJ
MD^KR6R7]_:6D;W$]^MI$"Q_>[>,GGCOTK4@T-[;4)9X-1N(X)9C.]N NTN>O
M.,X]J2W\/0P1V">?(XM)GGY _>.V>3],T 4QXBO+2/4EOH(7GM6C2-;<G#L_
M1>>^:ECUC4+.^DMM3CM>+1KI6@+?+MZJ<_SJ>?P[!/!>HT\HDN;@7'F#&49<
M;<>PQ3#X;66WO1<7T\US=Q>2]PP *I_=4#@"@#-@U_7I7TY396>Z_C9HTW,"
MF #N;VP>@JQ#XBO9-.B46\+ZA-=O:Q@$B,[>K^N !6NNE1+J4%X';,%N8(TP
M, $CGZ\ 51/AE$L[**"]FAGM)'D2=54DE\[L@\=Z )-%U&^O+R_MKU+<&T98
M]\).&8C)Z^V*V:SM'TB/2()HTFDF::4RO)*<L2<?X5HT %%%% !1110 4444
M %%%% %>[^ZOUJI5^:(R@ '&*A^R-_?'Y5::L0T[E6DJU]C;^^/RI/L;?WQ^
M5.Z)Y65:;5S[$W]\?E2?86_OC\J?,@Y64Z;5W[ W_/0?E2?V>W_/0?E1S(7*
MRE25=_LYO^>@_*C^SF_YZ#\J.9!RLH'I2&K_ /9K_P#/1?RI/[,?_GJOY4^9
M!RLS^U-K1_LM_P#GJOY4G]E/_P ]5_*CF0N5F<:0UI?V4_\ SU7\J3^R7_YZ
MK^5',@Y69E-/6M3^QW_Y[+^5)_8TG_/9?RI\R%R,RC336M_8LG_/9?RI/[$D
M_P">R_\ ?-',@Y)&2:8:V#H<G_/=?^^::="D_P">Z_\ ?-',@Y)&.:96T= D
M_P">Z_\ ?-)_PC\O_/PG_?)HYD+DD8IIAK</AZ7_ )^$_P"^333X<E_Y^$_[
MY-/G0<DC#-,-;Q\-R_\ /RG_ 'R::?#4O_/RG_?)HYT')(P33#70'PQ-_P _
M*?\ ?)H'A>0L-UTFW/.%.<4<Z#DD5=#TK[9/Y\R_N(ST/\1]/I77U'!#';PI
M%$NU%& *DK&3NS>,;(****DH**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (D M4# 2(  A$! Q$!_\0
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MR!%ZN4./SIT=I,YC)BD2.1L"0H=M/EI]D+GJ]V:W_"8Z]U^W?^04_P#B:/\
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M04_^)K%\F7C]VYW?=^4\_2@0RGI$YP<<*>OI]:?)3OLB?:5.[-K_ (3'7O\
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M_P 31_PF.O?\_P#_ .04_P#B:PJ*T]E#LC/VM3^9F[_PF.O?\_\ _P"04_\
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M7E<X"TVZT^6"Z$$9%PQ7<#%\V1^%1RTKVLBN>K;=FC_PF.O?\_\ _P"04_\
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M/[ZD8_F33+F>Q::TA@ND1+F9IY7'\.2"!7&\^_YT?YZT>PUW#VQW$^HV]O\
M8 9(W(E:.10Y<E3G&2?PK&\2,MC-!IELY$=NGS%3C<QZYK#CD:*59%)W*<@Y
MZ4L\TEU,\\S%W<Y8GN:<:+3N)U4U88SL[;G9F.,9/IVI*.M%="5F87"BBBF
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M#_X335_[Z?E1_P )IJ_]]/RH]O4[A]7I]C<_X0J'_GB/^_E'_"%0_P#/$?\
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MTSP#WKI;"SN;&QU2*[PDAMCA68$KTK5N[;9HMW',?/VI&8R415/S#[I'/YT
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M&D>N7D<6 BO\H7IC K/H **** "BBB@ [BNL\4?\B]HOT/\ *N3[BNL\4?\
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M.G)H X?BBNX@%J-3NK6%5,MI;".(HJDL<@DC/!/6N>\1LK:A'_H[PN(EW;P
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M6X_+_P"O1_PCNB>MQ^7_ ->CE8<\3B<GGDD9]:"23@L3CID]*[;_ (1S1/\
MIX_+_P"O1_PCNB>MQ^7_ ->CE8<Z.)!(/4@CM29R#DD_4]:[?_A'=$];C_/X
MT?\ ".Z)ZW'Y?_7I<K#G1Q)9BI!9L>YS1ECC)/' Y[5VW_".Z)ZW'Y?_ %Z/
M^$=T3_IX_+_Z]'*PYT<1GIDGBIK:ZFM;F.XB8B2,@@MSS78_\([HGK<?E_\
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MRL.='$45V_\ PCNB>MQ^7_UZ/^$=T3UN/R_^O3Y6'.CB**[?_A'=$];C\O\
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MZ/\ A'=$_P"GC\O_ *]'*PYT<117<?\ ".Z'_P!/'Y?_ %Z3_A'=$];C\O\
MZ]+E?8.>)Q%*.U=M_P ([H?<W'^?QI?^$>T+UG_S^-/E8<Z.JT;_ ) 6G_\
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M078VY5Q[CFCF'R'7-+$C%6DC5AC(+ 'GI3^*X6:XE@U>\D-Y!?2?Z'&9?*&
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M+ED91L;4PQQ&%?+0YC'H:!86HDD<0*'D^^<=36K_ &5=^B?]]4O]DW7]U?\
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M:G]E71'W4Y]6H_LJZS]U?^^J.>(<LC-%M"JQ@1*!'G:,?=SUJ-=.LX]P2VC
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M%% !24M% "44M% "44M% "4"EHH *3O2T4 %%%%  :3ZTM% "44M% !1110
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M $(5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1^#_ )^;G_OO_P"M0!K;A1N%9/\ PC\'_/S<_P#??_UJ/^$?@'/VFZ_[[_\
MK4 )XC/_ !*A_P!=H_\ T(5L5C?\(]:L5WS7#A6#89@1D<ULT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B/\
MX\8/^OF+_P!"%;%8_B/_ (\8/^OF+_T(5L4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !61XB_Y!?\ P,5K$X'%8OB6XBCT
MX([A7+ @>V: -L=!14<,J31J\;!E(R".]24 %%%% !1110 448HQ0 448HH
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M]"%;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_0A6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !WI",T&B@"EJ%L;F#:OWEY
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M444 %%%% !1110 4444 %%%% &/XC_X\8/\ KYB_]"%;%8_B/_CQ@_Z^8O\
MT(5L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 =Z2E[TA[T &10*BEE$,;2-G
M"C)P,U5_M:V]7_[YH2;)NNIH<4<50_M:V]7_ .^:/[6M?5_^^:?*PYHE[BEJ
MA_:UMZO_ -\TG]K6_J__ 'S1RR%SQ+_%+5#^UK?U;_OFC^U[;U?_ +YHY9!S
MQ+Q'%<[XJTZYO+2-[9GWHP#J#U%:9U:U]7_[YI/[5MNY;W&VCED'-'N6+*W:
MVLXH7<R,J@,Q[FK&*H_VM;#N_P#WS1_:]MZO_P!\T<LNP<T2_1Q5#^U[;U?_
M +YH_M:U]7_[YHY9!S1[E_BBJ']K6WJ__?-']K6WJ_\ WS1RL.:/<O451_M:
MU]7_ .^:/[6M?5_^^:.60^9%^C(JA_:UKZO_ -\U<1Q)&'7H1FBS6XTT]A]%
M(.E%(8M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% &/XC_ ./&#_KYB_\ 0A6Q6/XC_P"/
M&#_KYB_]"%;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 44F:,T +11FC(% !1110 4444 %%%% !1110 4444 %)1WHH JZC_
M ,>,WTKG*Z/4?^/&7_=KG*Z*6QRUMPHHHK;0PT#\1[YIHFB()$J$#J=XX^M9
M/B:62'1)"CM'&S!9I%."J=SGM6??Z7I<^F^1IL]G$[;2R[AM< @Y(]Z5T4D=
M.K!QE65A_LG(I?S_ ,]JP-%U+?9*EMIJ*BW#Q.(&^4%3C</K5!->OO[#FU,W
MMJ9&RHM]O,?S[<GGTHNA\K.N_/'K0/RKD;K6=2MFGM(;NVF=9K=4N%CRN)&(
M(QGDC%.;7KS3G)OIHI(89_L\DJIMQD$@^PZ"ES(.1G69)/%'Y_X5QK:[KC7,
M5L?(CF6WCF=7&,EB01],"DU2^U>YTS7'6\BMTMH5V*J98$@$\Y[4[H.1G9YH
MQTX-<CJNO7-A]FBAOH))5CB>0>7\K!FP3G-+=>(;RSFOS(\19+9YK>)5W!MO
MJ>V,]*+H.1G6BCMSU]JY!=7UK[#-(LEHWR"1')&5Z9&._&:Z32[I+W38+A)-
MX=0=^W;G\*>C$XM%NBBBBQ(5TUIS:Q?[M<S736G_ !ZQ_P"[6-4WH[D_:CM1
MU% KF.H6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!C^(_P#CQ@_Z^8O_ $(5L5C^(_\
MCQ@_Z^8O_0A6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444&@"&XF$%O)*W1%)^O%<+I-E?\ BZ&75+O4;BV0R%88XN H'K7<7<(N
M;66 GB12OZ5PNAZM=^%8)M*OM.N)=DA:.6%"0V>W% $WB/[1:'2+*ZU.2&)B
M1-<+P=N>":VO#-M:PQRR6VKR:BK87+G.VH;[7(!;VLVHZ/.PE5FP$+^7SP#@
M=ZS_  A9S-KFI:E%:/:64N!'&PQG\* .XHHHH **** "BBB@ HHHH **** "
MDI:* *M^";&4#KBN;KK'0.I4\@UC3Z1(')AY!]36U.2CN858MZHS**O?V3=?
MW1^=']DW7]U?SK7VD3#DEV*#HDL9CD571N&5AD'ZU5&EV"Q-&MM&%?K@?IFM
MG^RKH?PC\Z/[*NO[H_.GSQ'R,SH(8[:(1PQB-%[*,<U -.LT:3%M$/,'S@J,
M&MC^RKG^Z/SH_LJZ_NC\Z.>(N21DQV%K%'Y:6Z!-P?&T=1T-.DLK::.2.6"-
MUD.YU91R>U:?]E77/RK^=1W%C/;6[32*-L8SUI<\0Y)&?+96T\JR2PJTB=&Q
MS_\ JIWV:$HZF)"LHPXV_>'O6A'ID\L2N@&TC(YI_P#95UZ#\Z/:1#DD8W]F
M6+>7FVC.P83([=:>+&U$CR"!"[#:Q(SD'M6M_9-UG[J_G2?V3=9^ZOYT<\0Y
M)&0--LQ$T0MT"N<D58C1(HUCB5511@ "K_\ 95UZ+^=+_95UG.!GZT<Z#DDR
MC15[^R;K^ZOYTATJZ_NC\Z/:(.278I5T]J"+:,'KMK,@TEPX:8C [#FMD* !
MCM65229O3BUN I:**P-PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B/_CQ@_Z^8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "8?^>*?]\BD,4('^I3_ +Y% %'_ (2'3?\ GX%'_"0Z;_S\"KXAA)_U*?\
M?(I/+M^,Q1@'I\HH!:E'_A(=-_Y^!1_PD.F_\_ J_P"5!C_51_\ ?(I/*A_Y
MXI_WR* */_"0Z;_S\"C_ (2'3?\ GX%7_)@_YY1_]\BD\J#./*3_ +Y% %'_
M (2'3<?\? JGJ>M6%QID\4<^YG7  ^M;1AA_YXI_WR*3R8?^>2?BHH 2Q_X\
M8<C'R"K%,5U(^4@@<<4[=S0 M%-+8IV: "BBB@ HHHH **** "BBB@ HHHH
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MWE8E!R2#VIMCX5T>ZL?."S1>4/WL(E;#_K4VE:=#INKBVMK,)%*2&[DC'J:
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M8X%V G<<DDD^Y-6!^M2RDK(6EII_6@G [_A0,=129R.#0/TH&+1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF2:XF"2@JV,D8[9'I0!:\0SQZHRP0 R N,3=2O'2LH64^F7\3F1A;R$QN<C
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MD_'Y16GBLRS_ .0[J'T3_P!!%:E "8HQ2T4 )BC%+10 4444 %%%% !1110
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MHP2K$'!;FM>LGQ%_R#4Q_P ]X_\ T(4 -7P]9E0?-N^G_/PW^-+_ ,([9?\
M/6Z_\"'_ ,:U8P @^@IU &1_PCME_P ];K_P(?\ QH_X1VR_YZW7_@0_^-:]
M% &1_P ([9?\];K_ ,"'_P :/^$=LO\ GK=?^!#_ .-:]% &1_PCME_SUNO_
M  (?_&C_ (1VR_YZW7_@0_\ C6O10!D?\([9?\];K_P(?_&C_A';+_GK=?\
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M4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C_<;Z4M% &1X?/\
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M[U)IMG'IFF10!EPB_.Q/&?4T :-%-C(9 58,#T(.:=0 4444 %%%% !1110
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M@'ZBD+@'DXK)U'Q-IFES+#<W*B1B/E'49[GVI-I;EQA*3M%&M@_YZ4H !P
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M% !1110 4C_<;Z4M(_W&^E &3X>_Y!\O_7Q)_.M>LCP]_P @^7_KXD_G6O0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4QNHI],;WZ>U
M &0VME[RYMH+=I#;_?;> <XSTZXJG;^(Y_[)BO+RS99)6"HB,#O)/&/3\:GG
MT::?5ENC(D:*26:-0&D&,;6]O\*CAT.9+6"W>=3';R!XR!R0#GFHUN;KD)9=
M=>.1XTL9))(0#< ./W61D?7CTI)_$D22%+:&2YQ +@E3C"'///T-)=:/=B^N
MY[.Y"+>[?-#KG80,9'X41>'UM[B=XGPCV2VJJ>V"3G]:>HO="[\2QP6ZS10/
M.GE":0@A=BGOSUZUJ"Y?["+CRB6*Y\O<,_G7'WVFW$%X(RMP4AA54\N/>LQP
M,@UTL]I<:EH0@+&UG<*3M_AP<X_2DFQR44E8K+XE@\JZ\V$QR6VTR(KA\!NG
M(^E,'B5E+HVGS><@#F/</]6?XL]/PJ*+PU('OI7DB1KKRQMC0 +MS_C5^32&
M:XEF\W&^#RA[4:C]S8CG\0HLGEVUO)<-Y0E^4@94]^:S[C6G?4P\<\B6QL&E
MVKV<.!GZ]J9'I6H0:BT-K*$5;6.(NZY#'GD?2K1\,G<-D_ M6@)(ZDN&+?I1
M=A:"11O=5OO[6G5%N?L]O:"7Y)%&<YRQS].E:4OB2*V@MT"&>0PK)(2X4J"!
MSSUZ]J?)H9>:[D\[BXLUM>G0C//ZU"_AUHFBDC$,S"%(G$R CY0!N'Y47:8O
M<=DRPNOI-?16=M UP[Q+-O4X 4G&?TK:QC-9=GI/V75GO0RA3;+ $"X PQ.0
M/QK4 JT93:O9;![FL;Q#XBM] @BEN(W99&P"HZ5LD=Q7->,]7TS3=+":G;M,
MDQVJJKGG^E1-M1N71BI32:NCS+Q-XIU&]UB>ZTVZFCA&!&,XXP,_K7.27=U>
M.[7!>69C\Y8\Y]<U->RAKF26VB*QL?DB+;L#W-5V@=ID<2LNSJHZ&O*G)MZL
M^YH8:$(IQ5B2-HU81_Q#J*]<^'^OR7]JUA.29+=1M<GDBO)3$K$DCD=<=:V_
M#'B"W\,WOF2PF5WPH=I".._'TJZ,VIW?4QS+#>THM)7?0]WSVI,C&1TJI87\
M&HVJ7%NX>-QD$&K:CCFO4O=:'Q$HM.SW%'6G4W'I3J8O4**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#-U^.:70[M8&VR;,@
M_3FN;CS_ ,(P+E7/VCR,Y[YQ76:A#]HLIHMVS<A&[/2N)M3%'81VRW!D5-R.
M0.=P[4",>;4_+-G;7<22&-MS,@R&!'0^G6NIT^VA,'G1,X5DSRPS@?R%<G<1
M>7]M>#RQ#M!D#'D'CI1HFMV=A%<7LMVS*5,:6Q.230!U4<CF9RH9 _W,#J1W
M)KG-7<QROK!#-<W3%0 >(U[BKNA^)6NX55V3S&8HL0Y.#6E?"SMX)8;@@K.F
M[85^X?44 <U8:C!&=D)#&7C8YR<^M,U>?[%>VE]$<P\J^T\9QW%8^JZ/-97T
M$T3Y!9?+D^[C/3-7+>+_ (2&.2W1A&T?R[5.02.=V: ))-2(GC9;<M;2$%G3
M[OT/M6NCVTE@523;:@[E)Y!;T%8-O;D>'[RVQ(#&[J"#P2*2PB^R:,+6_G9%
M9MR,.@/I0!Z#X(-VUK.96)@+Y3/KWQ765E>'VB_LB"*, >6H4X[^]:M PHHH
MH **** "BBB@ HHHH **** "D?[C?2EI'^XWTH R?#W_ "#Y?^OB3^=:]9'A
M[_D'R_\ 7Q)_.M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ IK=:=3&ZB@",RQ^8(S(@<]%+#)_"J,6JK/K$FGQ0EA&FYY0ZX4^F.M<
MQ=QDP7RO!,VKF8>5(%.0,C[I[#%;>E6*0Z[?SFW57(&)-N-QYSS4<SN;*G%)
MNYK)=J;B:)U*^5@;B1ALC/%,N]2@L[-[EG5D3^ZPY/I7,ZC!<R7NM*JR[7GA
MVX[C9SBDOM.59+ZU2VS;;(G6/;\NXMR1^%%V"A'1LW-.UK^T)I(Y+22V9%#9
MD=2"",\8-:0GA(W)(A'0L&&!7+2QO8O?O'9M(BVRXB48W<=*S6@G^RW\<"MY
M3>4P\J/:N2XSCUX[T<S+=).[3T.[^T0X),T>,X^\.OI0\\:$;W5"?[S 5R%Y
MHZ+=:LB0OY:VZ&,#[N_!RP_VO>I'LGO+L_:8Y'1;#(!Z;P>#]:+LCDCIJ=8L
MJ.[!74E>H!&1]:8;J%4=O.CPGWCN''UKD;:&>Q&D7$<$KR2V<K7/',K!00&/
MKG-1V$#7>JR@VX%M-9/YD2Q84-N'#'N:.9@J5[N^QU4&J6]S);BW83),"0ZL
M/E '<=:M^?$6*"5"XZJ&!(_"N'L+4HNC26-N8Y1#,DAV8.X)QN_&IH8PTFFF
MT@F2]$^;MV7!*\[MQ],XQ1S,'33>YV*S1[BHD0N>=H89/TJ0=<]*XRQL6AL]
M-NQ%(+GS6W,?O;3V/M79#@#CC-4F1)<J'<]JY7Q[#<SZ!)%:V8N)'.W)_@]Z
MZH$TA /6E)<RL%*?)+G1X))X5UJ*T%V;-]H7;GO]2*RL-$ LOWO0C!KZ/*#!
MX'-<OXA\%V&MD2J!#.#DR*O+?6N2>%NO=/H<-G+YOWBT/$HXI$F,C2LV[C!Z
M 4][4SSJRQF0C@*!DUU \)WEOK\5C<12>3(^WS57(*UZ9HGA/3=&&Z*(/-U\
MQQDCZ5A3H3D]3T,5FE*$+1U;,_P%HUQI6DL;ASNGPRQG^ 5UXSQ2*FT$>M.
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M#K2W%S+<:J9II4EA0!1CJHKG=-EFDOI(IK=6G5,(P7/R^P[FMJ!;5',G[PQ
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M129&<4M !1110 4444 %%%% !1110 4444 %-8"G48!H A**'#[1NZ9QS3P
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M<,\NTMD889[<UH_\(O:1+9-:[8;BV96,@',F!@@_7K49\/7@L3;)?1#RYA+
M3%]WD$AN>: +E[K9L)%\VQG$1V[I,KQGVSGBE&M>9>S6]M9SS")MDDRXVJV
M<<GT(K.OO#$]]=33/=0-YNW)>$EE('.TYX!JY!I-[:7UQ):WD2VUP_F/&\9+
M;L '!STXH @T'6/M$DMH=\TZSR>8PZ1+GY<_6K&J7%W/JEOI=G.;=G0RR3*
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MG7BZA9I<K&R*^=N[J1G%6ZHZ7:365C';33>=Y>0KXP<=@:O4 %%%% !1110
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M1.BJN3NX/./6@#M@Z=G4Y]ZJW.HQVMY;0%6)N,X/88__ %USUQ!;V'B"+[+
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M0^9N8Y9Y'+,?Q-71TI,4HZ4 %%%% %6VLX;5YGB4AIFWNQ.23TJR*3;^M.H
M**** $/6JTEG#+=17+*3+%G:0?6K)&:1A\C?2@!%SDYS3AS63X>!-A*223]H
MDZGWK7H .@IIR>AP:=28- &5+H-C-</*WG#>_F.BRD(S>I7H:U%   48 X&.
MF*7;[\T;>: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNBJ4.CA'#2/G'0"M0# P*PJ24C:E!QW%HHHK(W"BBB@ HHHH **** "BB@T
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@4 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A @\# 2(  A$! Q$!_\0
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M^?6]_P# 9O\ "C^V8?\ GUO?_ 9O\* -*BLW^V8?^?6]_P# 9O\ "C^V8?\
MGUO?_ 9O\* -*BLW^V8?^?6]_P# 9O\ "C^VH!R;:] [DVS_ .% &E14-M=0
MWD(F@D#H>X_D?2I2<4 +152ZU*VLV1)68R/]V-%+,?? [>]0?VS#_P ^M[_X
M#-_A0!I45F_VS#_SZWO_ (#-_A1_;,/_ #ZWO_@,W^% &E16;_;,/_/K>_\
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MI]Y&!5E^H/-6J "BBB@#/FT/2[AYWEL87><@RL5Y?'3-/.D:<9K>;[%!YEN
ML+;!\@'0#Z5=HH III.GQRSRI9P![@8F.P?..X/UJ2SL+73X/(M($ACSG:@Q
MSZU8HH S))8W\06\:NI=(9-R@\CE<9IMD@O=0GOY!E8W,-N#T4#AF'N3G\!4
MDR@:[:D* 3#)DXZ\K4]A:_8K1+??OVDDMC&23G^M %JBBB@ HHHH **** "D
MQ2T4 )@4M9D>HW;ZO)9&R 1%5S+YH^Z20#C_ (":TA0 M%%% !1110 4444
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MADVIMQM^[W[UJ4 %%%% !1110 4444 %<OI/]N:MIZ7IUI8?,=\1K:*0H#$
M9)YZ5U%8?A'_ )%FV_WI?_1C4 48M.UG_A(+D#71N^RQ$M]C7D;GXQG_ #FI
M+XZUI3V4KZNEQ'+=Q0O&;55RK'!Y!XK732+-+TWJQ,+@GE][<_AGIR:I>)?^
M/?3O^PC;_P#H= &V*6BB@ HHHH **** "C%%% !1110 4444 %%%% !1110
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MA\AMKL[*1G:& X)/1A0!HT4F32T %%%% !1110 4444 %%%% !1110 4444
M%%%% 'EVK,+CQ7K*Q:?XD!22..6317 28; ?G!88;G&1VQ7?Z##!!H=E%;6<
MUG"D8"V\_P#K$]FY//X]ZX77-5TA/$U[#=^(M1TR;[7';M'!?+$N&CSYFTC@
M#H:[[21!_95M]GO7O8=GR7+R;S(/4MWH O4444 %%%% &7)&R^(8':5F5H9-
MJ$#"_=Z5J5ER&;_A(8 X01^3)L()R?NYS6I0 4444 %%%% !1110 5A^$?\
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MJ<QMUE_LN]W-+Y9CPFX#^^?FQM_7VK1Q28% &#?WLJW-WC3[IO) V8"_OO\
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M]?ID>],34IGA@D.F7BF638R$)NC']YOFZ?3)J_BEQ0!X9>3NMW>D6TS;)F
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MUE/0BO,/#5J;'Q1I\2>'].LMX9U6*VD>:)#N'S.3A3P,]^1B@#U,=**!THH
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MDA1_$?2GTR8.T$BQMMD*D*WH<<&@#SS3?&&JW&J6D;:C8W$L\JI+I45I(LL
M)YRY/\/4DC'%>BCK7%6WAK7;!;)+;5WG#RQ2WZ7$[,P*MEFC;T;&"IX]*[4=
M30 M%%% !63XBU"YTO0[B[M(U>92HRREE0%@"Y"\D*"3@>E:U9>O6%SJ6E26
MEK<O;O(Z!Y$<HVS<"X##D$KD9]Z ,#PMXBO=2U9[-]2L]6M_*,C7%K;/$(6!
M&%;)(.<GWXI?%ESX;CU.WCUG6[ZPN#$3'';W,L89<]2$X/-6])TC5M/UF-7U
M#[5I4$3I$7D)FR2"%?LVW!PW7GFL7XC07<LMFJ3V*6\BE0KV33W#..3L*@E0
M!W% '5^'#8-HT1TV[N+JUR=LMP[.[<\Y+<UK5SW@J-H?#%K&S3L5+<S&0MU_
MZ: -70T %%%% !1110 4444 %%%% !5'5;*POK!X]2C1K5")&+L5"[>0V01C
M%7JH:KJ<&D6?VFX660,ZQI'$FYW9C@ #O0!F>&9_#VH6Z7>AF-TMD-JI5RQ1
M=V<=3U/.?I715S7AO7])U!WL]+L[BWA :6-Y(=B3#=AV0YYPQP<XKI: "BBB
M@ HHHH \\\0F7_A*+V>*+4[2Q@2)=0NK&ZVNV0=K>7M.54<$CG\JZKPM+;S>
M&-/DM8?)@:+*)N+8&3SD]2>N?>F>(==GT4V7DZ9<WOVB=8F,(7Y0?JPY].U;
M2'**=I7(SM/44 .HHHH **** "BBB@ HHHH **** "N?\50>'X['^T]>C3RK
M93M=G*GGG:,$9)QT]JZ"L#Q)KFF:<J6.HVES=)<QN9$@A,@2(<,[XZ*,]J +
M^E_V?-;M?Z<R/%>MYS2HVX.< 9S^&*T!TK/TS4K/44F%B0T5NXBR,;3P#E2.
MHP16@.E !1110 4AI:0T >3&5;>$7%[:ZE!I<]P#8V8O2UN[>:!L==N4.?F"
MYP<8]J]:%8+Z].OBU=%_LJZ:%H#+]JPNS.1S][..<=,Y[8YK='2@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&("DD@#WH P8= CM/%,^M
MMJ5T3<1K$+>2;Y,@L<8[CYN!VY]:W\YK@AK1N]22"\.C7]DFI?Z/,UZ/-0[L
M+B,+RP/ YKO!0 M%%% !4<B^8C)N9=P(RIP1]/>I*HZM<K::5=SM<);[(6(E
M=@ AQP<GWH H>'M#C\/I<0#4+BZ>>5YL3R[BH)[#^9[U2\6W6@ VL&KW-U',
M"9(EL_,\P#H3^[!('Z5!H&I-J&M6[W\.D-?"S*I<6EYYTC*""V1M&U22#UJI
MXM>Y7Q&CZ<FI0R16BO>75E(F1#O./W;*=Y!W'C! ]: .H\/&P;1H6TRZDN;0
MY*R2R,[9SR"6YR#V/2M2N>\&36D^A&2R>26(W$N9Y7WM.V[F0G Z^G:NAH *
M*** "BBB@ HHHH **** "N<\;E?^$:F62T2YC:2,/YB.XC&X?/A/F./:NCK!
M\7K.WA^8P7 B"NKR@S^1OC!^9!)_"2.] '+?#XG^VKLG3XK4M "8$CE4V8#8
M$9W\?,/GP,>]>CUQ'@^WFM=7F3RGL;=X-PLYM2%V[L&'[P<G: #CKSFNWH *
M*** "BBB@#AO$GC6\TC6Y--M[>S4X0++=.X50W)D; QY8Q@\YR173Z%?R:KH
MEG?2QK')-'N*J25SZC/.#U'L:X3QU=7EMKKQ3ZJD-C,B'R!J"P,\8SN15(X8
MG!WDC@$5W/AY+F/P]8K=R"2<1#+!P^1V^8<'C'(ZT :E%%% !1110 4444 %
M%%% !1110 5QWC:\U"QN;.:S+VX\J1?M<5E]I?><;8\?PAO4^E=C7$^/((7N
M--DNC8W$!+QBQO;HP)(Y&0X(X) 4CGCF@#7\)V,]CI+1W6GVMG.S^9(+48CD
M) .\#^$]B/45OCI7+>!XXXM+NHHY[9D%RV(+69I8[?@?('/7U]!FNI'2@ HH
MHH *0TM(: .(;Q;KEM9_:K[142&YD"VABWL5/F!=LHQ\I(R01QQBNW%>2:9)
M!%XN9)-<2VOHI60W:7,LJ7CE_NNI&Q1C*X!X/2O6QTH 6BBB@ HHHH ****
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M8WB/1#KMG! LZ020SK.CR0B5<@$<J>#U[T 9O@*>XN=!>694"&8^48X$A4C
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,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (9 VH# 2(  A$! Q$!_\0
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M (5F?V1=>J?G1_9%UZI^='+#N'//L:?]J6?_ #V_\=/^%']J6?\ SV_\=/\
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M #V_\=/^%']J6?\ SV_\=/\ A69_9%UZI^=']D77JGYT<L.X<\^QI_VI9_\
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M ,]O_'3_ (5F?V1=>J?G1_9%UZI^='+#N'//L:?]J6?_ #V_\=/^%']J6?\
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M (5F?V1=>J?G1_9%UZI^='+#N'//L:?]J6?_ #V_\=/^%']J6?\ SV_\=/\
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M$5WN*Y3Q;H!O;.:XMG9) -SX. 0* .?MQIL41C-ZPD7[H7&!6U#8-);"66]
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M=)&Q,2LPP2,D"G_6@#VHQ2 :R+(A5QD'@BJL.EV5N^Z&V16P1D>AZU<Q2XH
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MG_7,?S-7-)_X\Q]:IZU_Q^)_US'\S5S2/^/,?6F_@1$?C9H444"L3H%HHHH
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MN?F(_BJP/0 8%+@<<=*6F(2EHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBP9_X2R]P?\ EC'6U7>?-!2TE+0 4444 %%%% !1110 4444 %%%% !1110
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M[I'_ !YCZU2UK_C\3_KF/YFKFD_\>8^M-_ B(_&S0I124"L3H%HHHH ****
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M1_R&;S]* +,.AV<*R_ZQC(A0EW).T]A4_P#9UL1:\'_1O]5STXQ5#^P;@_\
M,8O/TH_L"X_Z#%Y^E %[^R[3R[E-IQ<',G/?V]*BM-%L[.42)YC$+M&]RV![
M55_L"X_Z#%Y^E+_8-Q_T&+S]* +J:5:1V LE4^0IW ;N<YSUJ1+"!+E;A0?-
M6,1@Y_AK._L&X_Z#%Y^E']@W'_08O/TH G;0;%K:. *X6-BRD/@@DY/-*FAV
M,=E-:X<QS,7<ER23ZYJO_8-Q_P!!B\_2D_L"XS_R&+S]* +L>DVL>PX9BBE
M6;/!&*AMM L;6:.1!(?+.45W)"GV%0_V#<?]!B\_2C^P;C_H,7GZ4 7/[(M/
MLDEMM;RI'WL-W?.:ANM L;N1WD\P;UVN$<@,/>H?[!N/^@Q>?I1_8-Q_T&+S
M]* -"/3K:*6.15.Z- B\]AP*9?:7;:@R-+O#H,!D;:<52_L&X_Z#%Y^E']@7
M'_08O/TH O1:7;1/&XWEX_NEFS4,VAV4T1C96P7#Y#8.15?^P;C_ *#%Y^E!
MT"X/_,8O/TH L1Z'91P218=EE.YMSYR:6^TU)U:2+B<1E%.>,8QBJW]@7'_0
M8O/TI/[!N!G_ (G%Y^E %+2M(GMI80+5[:-1B;=+O$@],=JU[;1K:TE#Q/,
M"2 9"1S[54.A7!3_ )#-Z?RS2_V!<8Q_;-Y^E &WP.]+6)_8%Q_T&+S]*/[
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MC34$?,X_&2Q%3^ZCL=-M!8:;;V8.1#&$JV*;C&<#ZTY?2MSS1<4444 %%%%
M!111F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_6NMK,\/Z5'HVB6UC$,"-<GZGDUI53.:35W;8<**!102%%%% !1110 4444
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MX_$_ZYC^9JYI'_'F/K52^!$1^-FA110*P.@",TS&*DH(S0(CHI2M)TI@%%%
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M\;U#8.1D5)10 T#_ /50/PIU% "#@4M%% !124TMAMN1N/:@!]%%% !1110
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MG/ %A)-]MUZ?B:Z8HF?[@.0:IO0+79VT2".-(UQM4 #'M4E-'6G5F:!1110
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M0OL*G]Z6IW*V$ P?Y4M%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW;'6AJ1:X$8L<$GD=*TI],LKN-$N+:.18SE P^Z?:K7E@Q;-HVXVX/I1&-M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_3J*/85.P>WAW.ZS17"_P#"P/\ IU%!^(&#_P >OXT>PJ=@]O#N=U17"_\
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MP*.U(6 ;:2-WI0'47%%%'?TI@&*,4'B@$'H0:6P+4**0D X)&?2@D+]XX^M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^;WJQD<<UQDES+]A$1D(CN-0$+G=T4CU[5J7-EI6D:;<G>_E.%##S23UX^E
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MBM,J[O+P?2@#K<T54L79K52]PLY/21<<U:48% "T444 %%%% !1110 4444
M%07?_'I+_NFIZ@N_^/27_=-"W$]C$TO_ )",7X_R-=%7.Z7_ ,A&+\?Y&NBK
M6INC.ELS"UK_ (_$_P"N8_F:NZ1_QZ#ZU2UK_C\3_KF/YFKND?\ 'H/K52^!
M$1^-E\]#5#_F+G_=J^>AJA_S%S_NUBC=E_%&,BEHI#$P>_6HYH1-"T<G*MP:
MEI#0!DQ>';&*9'"ED0[DC/W5/K5PZ;;M/-*R!C,NUP>A%6>AYZGM2B@#+@T&
MU@F63YG"?<1^0OTIUSH5I<W)G.Y"PPX4X#_6M.B@"F=,MS++)L&9%"'Z8Q59
M]!MVB2)9941%V!5/&WTK5HH AAMX[>)8HD"HO050GT&TFN7G4O$TAS($. Y]
MZU:2@#-FT2"156.62$ 8(C.,_6G?V-9_8?L@B58\[LCKN]?K6A10!GVNCVUI
M,)P6>8#'F-UQ4E]IEMJ"J+E=Q7E3Z'UJY10!GVFCVUKYI7+O(NUI&^\1Z4V;
M1;66VC@*E1&<HX^\OTK1)R<=Z4=>: *$.CVL-O+%@N91AW;J:2XT>UN(8HV7
M:T7^K=?O)]*T:* ,.\T0+I%W;VG,\RD-(_5JHVFG7#7-J8(#:I$NV7(QYG%=
M3[T<^M %!M'M'MI(#$-LC;S['U%1)H-F+66"3=*), E^3QTK4H_G0!FVVBVU
MO<?:-SR3>68][G)P:MVUI':1>5$,)N+$>YJ?^=+0!F3:';R7+S(\D1D.9 AP
M'^M6#80-+#*1\T/W#Z5;I!0!533[=9+IB@/VK'F ]^,57MM%AM9D=)9=B'Y(
MR?E7Z5I"EH RWT&T>[-PH9-Q!9%X5B/6I9-)@;4$O4RDJ+MPO1AZ&K]% &9'
MHENERLS,[[22J,?E!-7+FV2[@D@F :)Q@@U/10!DV^@VEM/%.-[RQ B-GZK]
M*H6GAU);F_:ZW 2S;L+T<8[UT?0X[T >_2@!L<*Q1)%& L:C  ]*IQ:/;17<
MTZ[MLP(>/^$_A6A10!DQ>'[.*<.-QC4Y6(GY5^@K3:/?$R9QD8X[4^B@#(M_
M#]O;78N4FE,G0DGK3[G0K6YN6G)9#)CS G D^M:E% &?=:/:7,$46SRQ%_JV
M3@K]*=;:7;VEN\4609!AW_B;ZU>HH H_V5;?8!:;?D'1NX/K]:DLK&.QB\N,
MEO5FZFK5% %)]+MY#<DK_P ? (D]P:=)IT$D$,++E(@ H^E6Z* (;BVCNH##
M(/D(P143Z= [6I8?\>O,?Y8JW10!EW.@VEU/+*P9?._UJKT?ZU-_9-J/L@$8
M M#F(#MQBKU% %5;"%;B:<##S##&J\FB6LD"Q8*['WJXZJWJ*TJ* ,Z#1;2W
M2X55)^T8\PGJ<5(^EV[Q6L97Y;9P\?L15VB@"O>V45_;-;SKNC8@D54M=#M;
M6Z^T+N=E&$#<A![5IT4 4/[(LS:2VS1!HY6W.#W.<TRTT:WM+CS]SRR ;5:0
MYVCT%:5% &2_AZR:9F 98V;<\*_<8^I%37ND6UZT3L"DD0VHZ<$#TK0HH I6
M.F6VGES FTO]X^I]:NT44 !I*4TE %#4/]=;?[]7QT%4-0_UUM_OU?'053V1
M*W8M%%%24%%%% !2$XI:0]/>@!<T5&"H(3< QYVYY-/48% "T444 %(3CK2U
M$TB+C<RJ2< $]3Z4 29YI:8C*20&!(ZX/2GT 9VI:?)>W-I(CA1 Y8Y[Y%4T
M\/;?$;:CY@,+#<8O5^QK=HH YV7P_-)!<P-.OE7,I9P?3.<5+>>&+"6V1;:W
MB@FC=760#!R*W#2,0!R< #J: ,.?2[^&]%]8SPK</&$F67.P^XQ6E81WB1,U
M[(C2L>D?W1]*LJX==RL''J*<?>@#*@TP0SWDLS*T<Y)Q[5F>$K*5+6ZO&8F2
M9V";_P"'!('X5TY';&12(BI@*H4#H!0!AP:1>RZG]MO#;*ZK@- ""?KFEATK
M4+/3!:VSVSEI'9Q*"5(8\5O44 9ND:8=-LC$S LYRRK]U?8>U:0&!BBB@ I,
MBEICC(((X/?- #LC..]+4:%7&5<-_M U)0 4444 %%%% !4%W_QZ2_[IJ>H+
MO_CTE_W30MQ/8Q-+_P"0C%^/\C715SNE_P#(1B_'^1KHJUJ;HSI;,PM:_P"/
MQ/\ KF/YFKND?\>@^M4M:_X_$_ZYC^9JYI'_ !Z#ZU4O@1,?C9H'H:H?\Q<_
M[M7ST-4/^8N?]VL4;,OYXS45Q=0VL1EGD5$'<FI?7'6J6IZ;%JEFUM,2 WH:
M0RQ;W,5U"LT+AXVZ$5%J,K1:?-(APRC@TW3K"/3+..VBR50=32:KD:5/CKM]
M,T 5[758H]*M[B\F57DZ9/7FK2:E:/:/<K.AA0X=L]#[UR#B2*YTB7S1%%Y+
MKNDBWJ"3QD5=#_V=IE[=1R)=,QPP6':H.>NWO0!OPZQ8SA]DZ90;F&>0/6I6
MO[=;>.?S4\J3E&SPWTKE+?-WXEMHWF2426TBL8X-@7(Z'UHTY9;K4HM)="(]
M.F+J2.&0# H Z:76+&"?RI+A W&>?NYZ9I]SJ=G:LJRSH&8;@,]O6N0M(Y5%
MW;7%[%%(7.X/;[C@GCGZ5:OXK>RBM[BWNP;F&V"8EA+^8F>G/0T =8908#*A
M#+M+ U@Z#X@N-1OYK6ZACC;!>/;W7WK5MIFN-*$C1^6S1GY/PKE%26RTN+58
M8F:6WE'F#')C[B@#6U+7Y[;78K""*-HQ@RLW49]*GU_69].C06D2RS8\QU;M
M&.I^M8YMW6ULKN56,D\S2$XY"GD"K&R]U+7;R>$#RH5^SC</O*1DT :]SK,=
MMHB:AM+%T4J@ZDGM45LVO%HWG2S",1N"DY KG@EV-&GM94+3V<QDVX^\A/ %
M=);^(=/G6%8Y'+O@!=AZ^] ">)-2_LS29)8Y%29_E0D]Z+34+2SL(6FOO-\Q
M=R%SR?6H_%,8?1I,H'((V_+G'-4'-O9>((VO(AY+0_NCLRJ\#/':@#H%U.S>
MT:Z6XC,*?>?/ -1+K>G/ TXNH_*4@%\\<URUQ&)='UB6&-EMI'(4!<<Y'(%:
M.O6L2Z%:1QPJ%\R+<JIC/(ZT :HU_3"&*WD9QT&?O?2ITU.SDM/M:SH8!P7S
MQGTK'-G ?&: 6\?EBTSMV# .>M44N7TS2;YXH P$P !3*C+=<4 =%'K%E+%*
M\4R,T:EF7/(%9L?B:VN[ R1SQ13;RH$AP.M9U@&G\62(9H[A39,I9(?+7.>_
MK44(MI/"UU$L*^?'<$',?(^:@#JI=2MK.&,W,Z!W&0,_>^E*-5LC9M=BXC,"
MG#.#PI]ZY]'AM-=@:^&8S;GRRR9 YJC>J)=$UB:W0BTD9%10N/F#C/% '6P:
MO8W4QAAN8VDQD 'J/:EU*:2WLGD22-"H'S2'"UD7]O'#JFG-#"J84 E%Q5GQ
M4I;P_<A03T[9QR* +D^K6=IA9[B-7P#M)Y-5[_Q!:6FGK=HZR(QP,'O5.*W2
M3Q.#+"& A &Y<CH*R/) T'5BT.5BOY"!MZ#CH/2@#J_[8LA:Q3M<)MD7*\]?
M6I8]1M);5KI)XS"OWGSPOUK!N]2CWZ=#;+%%!+&6\YH-P7';'O63;"5]"U)S
MF2(7S.^U-H9,=AZ4 =6^O6 M9ITN$81C.,_E3](U6+5K".XB9=S#+*.U45N=
M,O-.FAMHD,GD$D>5C^'Z4OA:2!]!MDA4*Z)A_EP0WO0!NT@&*4=** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH #24II* *&H?ZZV_WZOCH*H:A_KK;_?J^.@JGLB5NQ:***DH****
M "D89%+2'MS0!CW4\<?B6TB,0:1K>1U;N,=JHMXCO3:S7J6J"UMW*R[L[C]*
MOW>GS3>(K2^4?NHK>2-N>YZ54;2;H^';^SV_O9G)09[$C_"@"]#K ;4)K>5
MJ",21M_>&,FHX]4N[FR:>WBC&Z0A#)D+M]3535](O)TLI;3'GQ1^4_/\+#!I
M^H:5<1V6GQ6J-+';$;XE?;O&/6@!UOXC M+MKI4$UJ0'\OE26Z8K-OKN_N+S
M1OMMLD8>[5T,><@>AJ6/0;F=-3\V,0BX,;QKG/*\XJ22VU?4)]-:XMQ"EK.K
M/\P.['?_ .M0!*^JI8KJ5Q% "T3*"!_%DXJ:#6+P7T$=Y;I'#<C]T1G<#Z-5
M:[T:ZF@U!549F=&3GT;)J]?6,TL]E,!Q P9N>F* *-UXBO%M+B_MX8?L<,OE
M,9"=VX'!_6MJXNWMM+EN9%4R1Q&0@=.!FN+MH"D5S?2(9HUN7/D^9@'YNNWO
M777*MJ.A3K&N))X64*?4B@#*/B.]2"TNI;+_ $>YX4*#N!QU^E68M4N#+<V>
MH0QB01,Z>7G:5 I)M-N6TS3(0/GMU&_GIQBI+K3YY=6$X'[O[,\>?<CB@"M'
MJ_D6%M':0JUQ<OLC7^$<=ZGOM7O=,TSSKFW1I_,6/:F=I+'M50Z1>6T%E/#'
MOGMGW-'G[PQ5C4+?4-6TY%D@$,@GCD"$@X //- $DVJWMO!#'+;H;R>39&@S
M@#U:EM]:EAGFMM1B2.:--ZF/[K#&>,TNL65S)<VU]:+OE@?)CS]]?0>E5UTZ
MZU.YFNKV+[.3&5BBR&*DC&21UH %UR_6"*_EMHQ82GC&=ZCU/:I9=9O)-7>P
MLK='VJC^8^< -SS5);+59]-ATB:V"0IA'N P^=?8=JTK+3Y;76[RX(_</%&B
M<]=HQ0!5O-=O5%_)9PPM%8L5E\PG)(&>*LRZAJ'V&">)+92Z!V,I(7!&<#WK
MFVMF>]U6^8-(B3%O+$FP/QW'>M.>*[O7M[R*S>: QA1 )-H0XZ^] %AO$K#1
MH;Q8-TC3+$R#U/I4]KJMT;]K2^@1&9-\13/(QT/O6>FB7JZ;!$4&];M)2 >B
MCK6I=6,TNM0W*C]VBD9]\8H SH=82ST2&6WB2-I)-@W\*"3WJ]=ZM<Z?80RW
M$*22R/MQ#D@CU%5K:QNK+1EMWL5NFW$M&6 []<U!#H]\-/C1@VX7#2!6?/EJ
M>U $XUO4Q>?8'M(_M4B[XB,[,>]/'B)AI<LTD2K/%,8&S]P,._TJR;&=O$%O
M=@?N8XF0G/<U5MK&ZLX+\-:+<>?=/*(R1\RF@#5TZ:YGMP]SY)8\@PDE2*N5
MBZ!8W%I]HDE5HHY2"D#-N\OUYK:H *@N_P#CTE_W34]07?\ QZ2_[IH6XGL8
MFE_\A&+\?Y&NBKG=+_Y",7X_R-=%6M3=&=+9F%K7_'XG_7,?S-7=(_X\_P :
MI:U_Q^)_US'\S5W2/^//\:J7P(F/\1E\]*H?\Q<_[H_E5\]*H?\ ,7/^[6*-
M6:%%%%(H*0@$8(R*6C.* &-%&R;&0%?3%"Q1HFQ4 7TQ3P01D&C(]: (TABC
MQL15QTP*<(T#EPH#'J<4ZB@")[>&1@7C4D=#BE>"*0@O&K%>F1TIX((R#FEH
M 3 QC'%)Y:;-FT;?3%.HH ;L4X^4<=/:E5%7[J@9]*4$'I29&<9&?2@!-BAR
MVT;B,$TU+>&.1G2-0S=2!4E)D9QD9]* !E5AA@"/>FR0QRIL= R^AIY('4T4
M ,\I-FS8-OIBE:-&&&4$>]*2!C) STI: &[%W[]HW8QFD\I-I78,'J,4^B@"
M-((H\;$5<#' [4"")2Q$:@M][CK3O,3&=ZX]<TH(/0@T ,DABE0(Z!E'0&G&
M-"FPH-OICBG49% #2BD@E02.E*R*ZE6 (/8TM% #0BAMVT9]:3RH]I78,$Y(
MQUI]% $1MX2@0QKM'(&*>L:*" H /48IU% $<<,<0(C15!ZX%*D21DE%"YZX
MIP(/0@TM !1110 44FX8SD4M !1110 4444 %%%% !1110 44@(.<$'%+0 4
M444 %% (/2B@ HHHH **** "BBB@ HHHH **** "BBB@ -)2FDH H:A_KK;_
M 'ZOCH*H:A_KK;_?J^.@JGLB5NQ:***DH**** "BBB@ HQ110 8Q1110 8HP
M,YHHH *,"BB@"@VBZ:T_G&TC,F<[N>M7\8&.U%% !@48HHH 3 HP.>.M+10
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M3>X X4>GUJ/5XKJ/5+*]@MVG6(%61#@\U70WVFZE/.FGR7$=PN_Y",J2>AH
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M_P#KUKT57/(CV<3(_L/_ *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\
MZ>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'
M_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_
M *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?
M^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[
M#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_C
MG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L
M/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\
MCG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\
MZ>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'
M_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_
M *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?
M^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[
M#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_C
MG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L
M/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\
MCG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\
MZ>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'
M_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_
M *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?
M^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[
M#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_C
MG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L
M/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\
MCG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\
MZ>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'
M_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_
M *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?
M^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[
M#_Z>/_'/_KT?V'_T\?\ CG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_C
MG_UZUZ*/:2#V<3(_L/\ Z>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L
M/_IX_P#'/_KT?V'_ -/'_CG_ ->M>BCVD@]G$R/[#_Z>/_'/_KT?V'_T\?\
MCG_UZUZ*/:2#V<3(_L/_ *>/_'/_ *]']A_]/'_CG_UZUZ*/:2#V<3(_L/\
MZ>/_ !S_ .O1_8?_ $\?^.?_ %ZUZ*/:2#V<3(_L/_IX_P#'/_KT?V'Z7'_C
MG_UZUZ*/:2#V<3)&AKD;I\_\!_\ KU=@LH8,;1SZU9HI.;>XU"*#%%%%26?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (% EP# 2(  A$! Q$!_\0
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M&H3:?I_]GP-S']I/GM'G&X<;<]\54\07^NCQAH*::+8P3QRM&DL[H)#LR?,
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M6OVSS;60O&\0X/4 @@]O>J8\7ZE;VUGJ=[8V4>F7+HNV.X+3Q*YPK,,8/49
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M QSSU-4-.\,S:5:)IT_@O3=2>)BJ7Q>("1<\,^X;@<=>M>BT4 -10D:J%"@
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M67CD9KJ** .2CL]8UWQ%IFH:EIRZ=;Z;O=4,ZR/+(PV_P\!0*ZVBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_I7K#^1H_P!*]8?R- $]%0?Z5ZP_D:/]*]8?R- $]%0?Z5ZP_D:/]*]8?R-
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MTO\ Y&[7_P#=MO\ T!JWJP=+_P"1NU__ ';;_P! :@#>HHHH **** "BBB@
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M]1$=G52H&!C;R6]*N>'[VYNK:ZAO'62XL[E[=I0NWS,8(;'8D$4 :U8.E_\
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MK^='VJ#_ )ZK^= $M%1?:H/^>J_G1]J@_P">J_G0!+147VJ#_GJOYT?:H/\
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MF>Q#X4&!Z48'I114E!@>E&!Z444 &!Z4444 %5[RPL]0C6.]M8;A%.X+-&'
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#Q?XO_ /(T6?\ UY+_ .AO7GU>@_%__D:+
M/_KR7_T-Z\^KTZ7P(\JM_$84445H9!1110!]'>#_ /D3M(_Z]4_E6W6)X/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHID<T4P)BD1P#@[6!P:
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M10 4444 %%%% !1110 4444 %%%% !1110 4A(4$GH.32TC,%4LQ  &23VH
MR;+Q)I]]J"V2?:(YG0O$)[=XQ*HZE"P&[&:2'Q/IEQ?);(\V))&BCG,+"*1Q
MU57Q@G@_D:Q]-U;3_$?B:&_6^M1%:B2&Q@\Y?-F9N'D*YR!@8 ^IK*$3#^R]
M"L-7L+^&"_22..!,S1(CECO(8@8Y&<#/ H [R_OX=.M_.F65@6"JD432,Q]
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MI8(;R.1-I8;,#>P*C(4\]\5K^'-:WZ7";^\\PS7<EO9SNN&N5!.UN!C) //
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M9&)].P[G\:QKZ&RL+CPRD.K?9M*BMY8$O8W0C=A<?.05&<-S^% '76NJ6UW
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MHH *P=+_ .1NU_\ W;;_ - :MZL'2_\ D;M?_P!VV_\ 0&H WJ*** "BBB@
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MU[EJG_((O?\ K@__ *":\-/4UZ6"V9Y>/^*(E%%%=YYP4444 =1X!_Y&=/\
MKF_\J]6KRGP#_P C.G_7-_Y5ZM7DXS^)\CV,%_"^84445R':%%%% 'B_Q?\
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M )"CRG_Y[/\ D* ):*B\I_\ GL_Y"CRG_P">S_D* .7\&?\ (6\4_P#84?\
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M7)>#/^0MXI_["C_R%=;0 4444 %5=3_Y!-Y_UP?_ -!-6JJZG_R";S_K@_\
MZ": ,;P%_P B-I'_ %Q_J:Z.N<\!?\B-I'_7'^IKHZ "BBB@ JGJW_(+G_W?
MZU<JGJW_ ""Y_P#=_K0!PU%%%,04444 %;WAC_CZF_W/ZBL&M[PQ_P ?4W^Y
M_44 =/1112&%%%% !7F?Q _Y&"+_ *]U_P#0FKTRO,_B!_R,$7_7NO\ Z$U
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M-_Y5ZM7E/@'_ )&=/^N;_P J]6KR<9_$^1[&"_A?,****Y#M"BBB@#Q?XO\
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M .^&_P */M<7J_\ WPW^% $U4]6_Y!<_^[_6IOM<7J__ 'PW^%4]4N8VTV<
MMG;_ '#Z_2@#C****8@HHHH *WO#'_'U-_N?U%8-;?AN58[F4MG[G92>X]*
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M4H(901T/- "T444 %%%% !65KFCRZU;?9AJ$MM WWTCC5M^"".2..1VK5HH
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M10 5O>&/^/J;_<_J*P:WO#'_ !]3?[G]10!T]%%%(84444 %>9_$#_D8(O\
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M**** "O9]!_Y%[3O^O:/_P!!%>,5[/H/_(O:=_U[1_\ H(H T****0PHHHH
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MG_G^U+_OZG_Q-=E10!QO_"MM)_Y_M2_[^I_\31_PK;2?^?[4O^_J?_$UV5%
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M9T4>TGW8>SAV7W')VG@"QL)Q-:ZGJD,H&-RS)G'_ 'Q5_P#X1N7_ *&'6O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_CTKG88]23PIH>KKKNI?;;J>&!V:7<FQVVXV'@D==QYS0!Z917#3W%UX?O\
M7K2'4KF2&/2Q=Q->2&4QRY9<@GG' XZ4SP[9WMWK5E=>9K$=O#;EKD7=_O66
M4XP557((^]Z#IQ0!V6H:C::59M=WLZPPJ0-Q[D] !U)/H*H6/B?3;Z\2S'VF
MWN9 3''=V[PF0#KMW 9_"L_Q0R)XC\+R7.!:"[D#%ONB0QGR\_CTH\9E7DT*
M"(@WK:G"T('W@HR7/TVYS0!L:UKFG^'['[7J,QCB+!1A2Q)]@/SJ3^U;3^TH
M-/+L+B>$SQ@J<,H(SSZ\CBO/O&&H?:H]?DO;+4%^SP/:V0-I(8@#C?*7QM&[
MH#GH/>MS5[E!9>'O$4:2Q):7"I+YL91A%(/+;(."!G:?UH Z.#6+&YUBZTJ*
M;-Y:HKRICH&Z<_E^=26>HVU_-=Q6[%FM9?)E.T@!\ D ]^HK@K69-,O+#Q;.
M0L6H7%REP_\ TR;F+_T6/^^JZKP=:O!X;MYIABXO&:[F_P!Z0[OT! _"@#>H
MHHH *\DE\5:VLK@7\F 3V'^%>MUX9/\ Z^3_ 'C0!K?\)9KG_00D_(?X5V?@
MG5+S4[:[:\G:5D90I...M>95Z%\.O^/.^_WU_D:8CM:P[GQ;I-I<2Q223E('
M\N:=+=VBB;T9P, \CZ5N5YC<1WMSI6N7^GR*/#QN9)+BS=P)90I/FE6Q\@8C
M[ISGU&:0SNM2U^PTN2**9II9YE+I#;0M*Y4=6VJ"<>](?$>E#1EU87:FS<[5
M95)9FSC:%Z[L\8QFL;19HI?'-]* 46;3+:2V5N"(OFR,?4U@VI4:E93[E^P-
MXEN2C#[I)0A2/^!;J .ZTO7;'5WFBMVE2>''FP3Q-%(@/0E6 .#ZUI5QFK2%
M?&.I2VS[7AT%_-9#@JVXE.?7J:SA;:C#8^&;I->U+S]2:.&Y9I=RE6C+?*IX
M4C'!Z_6@#T2BN N[R]T2W\56=OJ-PZVD4#VTES(9'1I,@@,>>H&,],U<\.65
MU)XA:\#:O'8Q6^WRKZ^\W=*3R0H=AC'KWZ"@#IM3U6RTBV$][,(T9@B  LSL
M>@51R3["JVG>(]/U*[-HAG@NMN\074#PNR^H# 9'TK,UAD3Q]X>:YP(##<+$
M6Z"8A<?CMSC\:/$Q63Q+X8AA(-XMVTF!U6((=Y/H.@^M &MK&OZ=H,<#W\QC
M\^01QA5+$GZ#MTY]ZG74[9M7?2]S"Z6$3[2IP4)QD'OS7F_B?4A=6VJWE[8Z
MC'<>?%!:J]E)LBA6523NQC+D9_[Y%=-KEY%9ZIH/B/;)%;DO;7!E0HRQR+E=
MP.",,HZ^M &_9:S8ZA?WUE;3;[BR8).N"-I(R/K4EAJ-MJ4<TEJY9(IGA8E2
M/F4X./7GO7GUI<'PS]C\07&%.JV=Q)/GO+DS1CZX)4?2NU\,:>VF>&[&VD'[
M[RP\I]7;YF_4F@#7HHHH 1E#*5/0C!K(3PS8)X8/A]3+]B,9C^]\^"<]<5L4
M4 5I["VNM/>PN(A+;/'Y;(W=<8K+L?"\5A<PR+JFJRQ0']W!+=%HUXP..I'L
M2:W:* .9N/ ^F7'VN,W%^EK=.TDMI'<%8B[=6V_7G'3VJ]J7ANRU.QL[9Y+F
M%K(J;>>"39)&0,<'Z5L44 9L6B6T6I6VH&2>2YM[7[*KR/N++D$EO5LCK3[3
M2+:SN=0GBW[[Z0239;C.W;QZ<"K]% &%_P (EIG]A6ND8F$-HV^"59"LL;9)
MW!AT/)J6R\/QVBW EU#4;PSQF)C<W&_:I]!@ 'WQFMBB@#'F\-6$_AJ/07\W
M['&B(,-\V%((YQ[4:MX;M=6O;:]:XN[6ZMU*++:S>6Q0\E3ZBMBB@""\69K&
MX6WV&<QL(]_*[L<9]LUYC;:%?0:);V>G:3KEGK:[0;G[1MMU?/S-P^"O7@+7
MJM% %"/28%UC^UF+&[-L+=CGY2H.[IZYJGJ/A>TU#43J"7-[97;($DELYC&9
M%'0-V.*VZ* ,8>%])'A^31/()LY<E\N2[,3G<6Z[L@'-5[/P=I]IJ5KJ+W%]
M=7EJ3Y<US.7."I7;SVP3T[UT-% '":7X-%W<ZU/>R:A9-<7\N?L\YC$\)QC<
M.XZ^_6NGF\/V,MG86B"6""QD22%(7*\KT!]16I10 4444 %<%!/K>@>)=>EB
M\.W5]!>W"21R12*HP%QWKO:* .2_X2K7?^A,O_\ O^E9>KW.N^([O18#X9N[
M..VU.&YDEDE5@%4G/3Z_I7H-% !7/:EX8@U?Q(+V^AAFLQ9^2%)(=7W[L@CI
MQQD&NAHH STT33(K.VM([.-+>VD$L,:\!7'1O<\GK5>\\+:)J%U+<W6G122S
M#$A)(#\8R0#@G'?K6Q10!F7_ (>TG4T@2\LHY1;C;$<D,H],@YQ[47?A[2+Z
M""&>PB*6XVP[,H8QZ*5P0/:M.B@#+?PYH\ME#9R:?"UO"2R1L,@$@@GW/)Y-
M/L-"TO3+::WM+**.*;_6@Y;S.,?,3DGCUK1HH RM.\-:-I5R;FRL(HIL$!^2
M5!ZA<GY1[#%:M%% !7,7/AV\FN99%>':[EAECZ_2NGHH Y/_ (1F]_YZ0?\
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M,ECNW+SQ"T*B;SK=T(+?= !').1P/45=L-2MM167[.S[HFVR1R1LCH<9&58
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M<+[FLW2]!N[/9YIB)728[/Y6)^=2V>W3D5GKX7U"V6T=88KIOL$5I/']NE@
M9,\@H/F!W'@B@#K8;^TN)_(AN(WD\I9MJG/R-T;Z'%4]5UZQTIO)GE<3F)I
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M6]ORK&&U>&60W;RM*Y*G<%880'!X%=70 50DU6)-7CTU89Y9F02.T:92)3D
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'N N,# 2(  A$! Q$!_\0
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M?ZJV_P!UOYT 1?VG=_\ /7]!1_:=W_SU_054HH M_P!IW?\ SU_04?VG=_\
M/7]!52B@"W_:=W_SU_04?VG=_P#/7]!52B@"W_:=W_SU_04?VG=_\]?T%5**
M +?]IW?_ #U_05LZ=,\]FKR-N8D\US==!I/_ !X+_O'^= %ZBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "J]]>P:;8S7ET^R"%2[MC.!5B
MN'^)-\WV"QT>%)99+V8%XX1N<QJ<D ?E^57"/-)(BI+EBV=)IGB'3M6TF34[
M25FMHMV\LI!7:,GCZ5FV7C_P]?7,,$=U(C3';&98616/IDC%<CH%\MEJ7B/2
MQ:7%E;W=K)<6T%PFQEPIR,?3^58]DMV^E>%H]5>--$>Y)CDB7YU8,>&)[9].
MWTK=48W?]=#F=>5E;^M3TK4?&VBZ7J,MA<23FXBQO6.!GQD9Z@5;O_$FFZ9H
MT.JW4CI;3;=GR'<=PR/EZUQ3?VA_PL;7?[.U*TL7\N/<]R@8,,#@<T_Q=?KJ
M'B?3-.DM9]1MK.$SW,=HF\NS# ./3H?QI>SC=(KVLK-_(]!L;V#4;&&\MGWP
M3('1L8R#5BN&^&=^YTJ[TB=9$FL9B D@PP1N1D?7-=S6,X\LFC>G+FBF%,ED
M6&%Y7.$12S'V%/JMJ7_(+N_^N+_^@FH1;,>7QKH<.A0:S)<2"RGD,<;>4V2P
MSVQGL:NS>(=-@&FEIRRZDX2V9%)#DC(^E>6+#'<?#?PQ!*,QR:H$8>H+,#1"
M;K2_%.B^&+O<PT_51);R'^*%^G^?<UT^RC^9R^VEU\COI_B'X<MKR:VENI5:
M&0QR-Y#E58'!YQ6G>^)-+L;2RNI+D/!>2+%!)$"X9CTZ5QGA>[TVV@\7#4Y8
M%@-]+N64CYA@] >M<W;1S)X$\/&4,$?6PT(;^Y_^O-+V<;_UV#VLK?UW/3M:
M\9:+H-TMK>7#M<D;O*AC+L!ZD#I5H^(]+'AXZ[]HSIX7=Y@4YZXQCKG/&*X[
MPQ<6=K\0_% U&2*.[>4&%IB!F/GH3[;:3QYJEI=P:1I.G(;JWN;@SRQV2AB\
M:-R !UR<_E2]FKI%^T=G(Z23QSH<>D6^I^?,UK<.R(4A9B&7J" .*BL_B!X?
MOC+Y$\Y$43S,3;N!M49/.*YGP5?+;:CXAT8VT]K%('N[6"X38R*1@C'Y?E3_
M  R!_P *:OCCGR;G^M-TXK\/Q)523_'\#L+GQ;HUIHEOJ\]ULM;D9ARAW/[!
M>M,T7QAHVO736MG<.+E5W>3-&48CU /6O/+*2&'4O DNH%5L1:-M,GW!)DXS
MVZ[?TK?UN6WO?BEX>&G/')<1([7+1$'"8XR1^/YT.FEIZ@JLGKZ'4Z7XITG6
M+^ZL;*Y+W%L3YB,A7H<$C/49JL_C?0H])74FN7\AYFA0"-M[NO4!>IKS:T@G
MTI;CQ99@L]EJTT-T@_CA8C^I/YCTJWH6DQ:UX0L'M]5BL-2M[Z>>T,I #<C/
M'Y4W2BM>@E5D].IZ?HVMV6O6;7-BTA1',;K(A1E8=B#]:T:Y/P+X@O-<M+Z/
M4(X?M5G/Y3S0?<E/J/R_E765A)6=CHA+FC<****DH*KWG^H'UJQ5>\_U ^M
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MZJV_W6_G0!GT444 (RJZ[64,/0C(I%CC0$)&BYZ[5 S3J* &+#$@8)%&H;J
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M_,_P.(_X2OQ7_P!";-_W^'^%'_"5^*_^A-F_[_#_  KMZ*.>/\J_$.27\S_
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M_P *CG\4>*7CPW@^8#/7SA_A7=U7O/\ 4#ZTN>/\J_$.27\S_ X/_A(_$O\
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M\2_]"E-_W^_^M1_PD?B7_H4IO^_W_P!:NMHHYX_RK\0Y)?S/\#DO^$C\2_\
M0I3?]_O_ *U'_"1^)?\ H4IO^_W_ -:NMHHYX_RK\0Y)?S/\#DO^$C\2_P#0
MI3?]_O\ ZU'_  D?B7_H4IO^_P!_]:NMHHYX_P J_$.27\S_  .2_P"$C\2_
M]"E-_P!_O_K4?\)'XE_Z%*;_ +_?_6KK:*.>/\J_$.27\S_ Y+_A(_$O_0I3
M?]_O_K4__A)?$_DA?^$1FV[LY\[_ .M755*?^/4?[_\ 2CGC_*OQ#DE_,_P.
M-_X2/Q+_ -"E-_W^_P#K4?\ "1^)?^A2F_[_ '_UJZVBCGC_ "K\0Y)?S/\
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M1_;NO_\ 0LR_]_:Z6BCGC_*OQ#DE_,_P.:_MW7_^A9E_[^T?V[K_ /T+,O\
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M[<Q363"YNFE,5DVZ*$[5&T' R>,G@<FNFK2'PHY,2K5I+^OQ"BBBK.<****
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M -_E_P :/[3L/^?ZU_[_ "_XT6877<M455_M/3_^?ZU_[_+_ (T?VGI__/\
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MC\4ZK8ZKK,\FKWEI=V5VBV=@L7[F:'(R2<8.1WS0![!13(G\R%'(QN4'%/H
M*Y7X@_\ (L'_ *[I_6NJKEOB#_R+!_Z[I_6M:/\ $CZF-?\ A2]#RG ]!1@>
M@I:*]P\ 3 ]!00/04M!H ;@>@HP/04M% Q"!Z"DP/04XTE "8'H*3 ]!3J2D
M A ]!28'H*4T4 -P/048'H*6B@!N!Z"DP/04ZDI#0W ]!1@>@I:* &D#T%)@
M>@IQIM #<#T%&!Z"EI*!B8'H*0@>@IU(:0#2!Z"D('H*<:::0Q,#T%(0/04Z
MD-(!I ]!32!Z"G&FF@!"!Z"FD#T%.-(:"AI ]!2%1Z"E-(:0#"!Z"D('H*<:
M::0Q"!Z"FX'H*<:0TAC2!Z"F$#T%/--- QI ]!3<#TIQI*0'IO@SQ'_:EK]A
MNG_TR%?E)_Y:)Z_4=ZZNO$](CO9-7MET[(NMX*$=O<^WK7M:[MHW8+8YQTS7
MG5X*,M.IZF'FY1UZ"T445@= 5T&D_P#'@O\ O'^=<_70:3_QX+_O'^= %ZBB
MB@ KSWXE_$67PE]CTG1[47FOZ@=MO"1D("<!B.^3P!7H5>!^)KB+2/VF=-OM
M:<16+Q)Y$LG"+^[*CGV?/YT :Y\'_&&YMOM[^-+>&]8;Q9J,(I_NY"X_0UZ7
M'J'_  COA>"Z\4:I;K+#$OVJZ8"-&?O@?7H!UKROXV7FK:3#'KVD^,;BV20Q
MV\6G6LN WWB7R&Y_+TK+\71SZOXU^'GA;7+J26Q:TAGN3,Y_?2MG=N)ZD[<?
M\"H ];\._$+PMXJO'L]'U:*>Y4%O**LC,!U(# 9_"J,^H(OC^:6XN3%:6<'S
M9;"YQZ=^6KS[Q%:V4G[0OAFR\/000RV<:F[^S(%"J-Q(;'^SQ^(KM="LX-5U
MS6-5NHUD@A=BJL,J3SV[X _6@#L;;5['4;":YM;H&*,$.^""G'7!KEO.DLO!
M.I7 U9KX2OMCE&X;22 >O-4-(<VO@76;L?+Y\A1 ./0<?G1JJ-;>!='L4'[R
MYD#X]<Y/]10!T.@ZUIUCIMAI]S>K]L= 6#$DY;D GUYK&\<>$K+Q)XCT[S]7
M^S2;!']GV%BZY)ROIW_*H_$6EVEJVCZ39(C7I<&1E'S'..2?KG\JT,_:OB0Q
M^\MG;_KM_P 6J6E)69T8;$U<-4]I2=G_ )F]<:KI'A^"&TFN4A6- B1C)(4#
M X%7[.\@O[5+FVD\R%_NM@C/YUQOA"*TU&34=4U'RI;@RX_?8(0?C^7X5VT4
M<<,2QQ(J1J,*JC  JC!MMW8^N?\ %?B:+P]8I'$CW.JWA,5C9PC,DTF.P[*.
MI)X KH*Q;+PS96?B&]UUWEN=0N<(LLY#>1&/^6<8_A7/)[DGF@1Y;X=^ J7<
MEUJ/CF_DO]1N9-Y%O,0!W)9B,DGVX%>P:5I5CHFFP:=IMLEM:0+MCC0<#_$^
M]7** "BBB@ KDO%?B.YT74[*,75O:6K;'=YTSYV9%5D4YPN%)8UUM<-XDNK^
MP\0EY]=TZWLY(/W4%Q9R2XP>I ;&??CTQ6=1M1T.S!0C*K:2OH]/Z3.D\/:E
M+JNEF[DVE6GE6%U4@21AR$8 ^H JEXKTJ;4ELF@MXI9('9@7OGMBA(QD% <]
MZL^%Y%FT**9-3_M(2.[_ &@*54Y8\*#T4= /:N>UR#6;C5H;:^T73M4L_,FD
MA>6X$9"X!4<C@@9SUS[5,G[BN:THVQ+<6E:_E^=OT-;P;*YLKZWEC,<UM=-%
M(INWN1G:I!#MV((XKI*P_"CP/H_^C6-C9PB1@J64ZRH?4[E YS6Y5P^%'-B7
M>M+2P5!?6<.H6%Q9S@F&>-HW ZX(P:GJO?W0L=.N;LH7$$3RE0<9V@G'Z59S
MG'2^#+FU\,7NE76NWUW8O +>)%MU)@0,#G Y8C&/I5FYLTN+_0;IX-01M'##
M;Y ._<H5<\]\9XSCOBMO0-=M]>TJTO(RD<L\0E-OY@9D!]:O1WMK*6$=S"Y5
M=Q"R X'K]*EI]&:0E!+WHW^;//3X6)TC4])$^J?9+R<31PFU4^3+O#LH;/.<
M?>/R^^:NW>D2OK\NK:9=:M8FZ5%N$CME/G*G4C=]T@<>I[9KMH;NVN(VDAN(
MI$7[S(X('U(H@O+:Z5FM[B&8+]XQN&Q]<46EW+YZ7\GXL\W3P?#'J270GU$6
MT=__ &@L9LE+<G.2_P!XCL%ZCKBNK\*Z<NF/J4:K=;KJZ>[?SHPH0OT4$$@\
M<\?C4Y\36S>*+718%6;[1;O-Y\<@*KM.-N!WK62[MI9)(X[B)WC^^JN"5^H[
M4)/N3*5-K2-OFSE(O L]C?3MI7B"]L+"XF\^6TC12-Q.3M8\J#3KSP1/_:=]
M>:/KMUI:WYW744<:NK-W89^Z:ZJ&ZM[ABL,\4A !(1P< ]#Q6%K?C/3-!UNQ
MTJZ$IFNR,,@!6,%MH+<\9-49$-UX&T^;P<GAR"62"*-E=)\;G$@;._ZGG\Z;
M-X(MY/!$7AI+MTC0JQGV LS!]Q)&>YJ?6_&%OHNK1Z;_ &=?WER\!GVVL8;"
M X)Y(J"?Q]IB:5IFH6UO>7BZC(8H(H(P7W#J""1S0!%J'@JYN=<N]2LM?N;
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M)90-O3&>>E8\'@O7O#C>&GT86>H-IEA-:-]JE,2I)(P8R+@'(X(QUQB@#M-
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M]<_^\:1/]8OU%+-_KG_WC0 RBBB@ HHHH **** "I8ON2_[M15+%]R7_ ':
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ME5%%%>X> %)2TE PI*6DH #24II*0"4E+24 %--.III#0E%%% QIIIIQIIH
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MQ]31N/J:2B@"2(GSDY/WA22,?,;D]31%_KD_WA22?ZQ_J: $W'U-&X^II**
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M!X1T*&.4;H_M%TT3,OJ T@./>O=+"XAN+*)H)(I%"A3Y3AE! Z9% %FBBB@
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M?^@?=?\ ?EO\*7,NX^5]BB:::NG2M1_Z!]U_WY;_  IITK4?^@?=_P#?EO\
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MRP6XD<$8D(+L>.6..M%IX+TJS@TF&-KADTRYDNX=T@.^5]V6?CG[[8Z5T5%
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M1L;N.[NTFDN'#!8L[5 &._<UV5% !1110 4444 %%%% !1110 4444 %%%%
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M8'C?_H:X?_ 9?\*[:BCVK[+[@]DN[^]G$_V!XW_Z&N'_ ,!E_P */[ \;_\
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M , 8Z/[%UW_H;I/_  !CK<HI^T?])![->?WLP_[%UW_H;I/_  !CH_L77?\
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M-_.IZ@U+_4VWT;^= &?1110 4444 %%%% !1110 5O:/_P >/_ S6#6]H_\
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MT*]M_P"! _QH_MSQU_T*]M_X$#_&NVHHYU_*@]F_YG^'^1Q/]N>.O^A7MO\
MP('^-']N>.O^A7MO_ @?XUVU%'.OY4'LW_,_P_R.)_MSQU_T*]M_X$#_ !H_
MMSQU_P!"O;?^! _QKMJ*.=?RH/9O^9_A_D<3_;GCK_H5[;_P('^-']N>.O\
MH5[;_P "!_C7;44<Z_E0>S?\S_#_ ".)_MSQU_T*]M_X$#_&C^W/'7_0KVW_
M ($#_&NVHHYU_*@]F_YG^'^1Q/\ ;GCK_H5[;_P('^-']N>.O^A7MO\ P('^
M-=M11SK^5![-_P S_#_(XG^W/'7_ $*]M_X$#_&C^W/'7_0KVW_@0/\ &NVH
MHYU_*@]F_P"9_A_D<3_;GCK_ *%>V_\  @?XT?VYXZ_Z%>V_\"!_C7;44<Z_
ME0>S?\S_  _R.)_MSQU_T*]M_P"! _QH_MSQU_T*]M_X$#_&NVHHYU_*@]F_
MYG^'^1Q/]N>.O^A7MO\ P('^-']N>.O^A7MO_ @?XUVU%'.OY4'LW_,_P_R.
M)_MSQU_T*]M_X$#_ !H_MSQU_P!"O;?^! _QKMJ*.=?RH/9O^9_A_D<3_;GC
MK_H5[;_P('^-']N>.O\ H5[;_P "!_C7;44<Z_E0>S?\S_#_ ".)_MSQU_T*
M]M_X$#_&C^W/'7_0KVW_ ($#_&NVHHYU_*@]F_YG^'^1Q/\ ;GCK_H5[;_P(
M'^-6X-7\12P :AX7E\T,<>1<Q[<?B>M=712<T_LH:@U]I_@<O_:.J?\ 0KWO
M_@3%_C1_:.J?]"O>_P#@3%_C7444N9=A\K[_ )'+_P!HZI_T*][_ .!,7^-'
M]HZI_P!"O>_^!,7^-=111S+L'*^_Y'+_ -HZI_T*][_X$Q?XT?VCJG_0KWO_
M ($Q?XUU%%',NP<K[_D<O_:.J?\ 0KWO_@3%_C1_:.J?]"O>_P#@3%_C7444
M<R[!ROO^1S"ZGJB,&'A>]R#G_CYB_P :0ZEJA))\+WO/_3S%_C7444<R[!RO
MO^1R_P#:.J?]"O>_^!,7^-']HZI_T*][_P"!,7^-=111S+L'*^_Y'+_VCJG_
M $*][_X$Q?XT?VCJG_0KWO\ X$Q?XUU%%',NP<K[_D<O_:.J?]"O>_\ @3%_
MC1_:.J?]"O>_^!,7^-=111S+L'*^_P"1R_\ :.J?]"O>_P#@3%_C2KJ>JJK
M>%[W##!_TF+_ !KIZ*.9=@Y7W_(Y?^T=4_Z%>]_\"8O\:/[1U3_H5[W_ ,"8
MO\:ZBBCF78.5]_R.7_M'5/\ H5[W_P "8O\ &C^T=4_Z%>]_\"8O\:ZBBCF7
M8.5]_P CE_[1U3_H5[W_ ,"8O\:/[1U3_H5[W_P)B_QKJ**.9=@Y7W_(Y?\
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M_P :/-O_ /H5[_\ \"HO\:["BCF78.5]_P CC_-O_P#H5[__ ,"HO\:/-O\
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M!US]:=7G>2I!!((Y!':NQT;4Q?V^UR//CX8>H]:F4+%1G?0TZ***@T"BBB@
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M.Z*M-#&P"LR\ ],]!TJS-H<$W]H9DD4WL2PL5(^10,87\S4G]MZ60Y&H6V$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!\&NET#2OLZ?:YUQ*P^13_  C_ !K<HJ7.ZL.,$G<****@T"BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>ifrx-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 21 04:12:18 UTC 2024 -->
<xs:schema elementFormDefault="qualified" targetNamespace="http://www.inflarx.de.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ifrx="http://www.inflarx.de.com/20231231" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ifrx-20231231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ifrx-20231231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ifrx-20231231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ifrx-20231231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement" id="ifrx_r_ConsolidatedIncomeStatement">
        <link:definition>001 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatementAlt0" id="ifrx_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>001 - Statement - Consolidated Statements of Operations and Comprehensive Loss Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals" id="ifrx_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>002 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet" id="ifrx_r_ConsolidatedBalanceSheet">
        <link:definition>003 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ShareholdersEquityType2or3" id="ifrx_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow" id="ifrx_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/CorporateInformation" id="ifrx_r_CorporateInformation">
        <link:definition>006 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/MaterialAccountingPolicies" id="ifrx_r_MaterialAccountingPolicies">
        <link:definition>007 - Disclosure - Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" id="ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>008 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition" id="ifrx_r_NotestotheConsolidatedStatementsofFinancialPosition">
        <link:definition>009 - Disclosure - Notes to the Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/Commitments" id="ifrx_r_Commitments">
        <link:definition>010 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherInformation" id="ifrx_r_OtherInformation">
        <link:definition>011 - Disclosure - Other Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate" id="ifrx_r_SignificantEventsAftertheReportingDate">
        <link:definition>012 - Disclosure - Significant Events After the Reporting Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy" id="ifrx_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/CorporateInformationTables" id="ifrx_r_CorporateInformationTables">
        <link:definition>996001 - Disclosure - Corporate Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables" id="ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLossTables">
        <link:definition>996002 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables" id="ifrx_r_NotestotheConsolidatedStatementsofFinancialPositionTables">
        <link:definition>996003 - Disclosure - Notes to the Consolidated Statements of Financial Position (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/CommitmentsTables" id="ifrx_r_CommitmentsTables">
        <link:definition>996004 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherInformationTables" id="ifrx_r_OtherInformationTables">
        <link:definition>996005 - Disclosure - Other Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" id="ifrx_r_ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable">
        <link:definition>996006 - Disclosure - Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails" id="ifrx_r_MaterialAccountingPoliciesDetails">
        <link:definition>996007 - Disclosure - Material Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails" id="ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLossDetails">
        <link:definition>996008 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofRevenuesTable" id="ifrx_r_ScheduleofRevenuesTable">
        <link:definition>996009 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofCostofsalesTable" id="ifrx_r_ScheduleofCostofsalesTable">
        <link:definition>996010 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Cost of sales</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable" id="ifrx_r_ScheduleofSalesandMarketingExpensesTable">
        <link:definition>996011 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable" id="ifrx_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996012 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable" id="ifrx_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996013 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable" id="ifrx_r_ScheduleofOtherIncomeTable">
        <link:definition>996014 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable" id="ifrx_r_ScheduleofEmployeeBenefitsExpensesTable">
        <link:definition>996015 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable" id="ifrx_r_ScheduleofNetFinancialResultTable">
        <link:definition>996016 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Net Financial Result</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable" id="ifrx_r_ScheduleofSharebasedPaymentsTable">
        <link:definition>996017 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable" id="ifrx_r_ScheduleofSharebasedpaymentsTable">
        <link:definition>996018 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable" id="ifrx_r_ScheduleofShareBasedpaymentsTable">
        <link:definition>996019 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable" id="ifrx_r_ScheduleofWeightedAverageTable">
        <link:definition>996020 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails" id="ifrx_r_NotestotheConsolidatedStatementsofFinancialPositionDetails">
        <link:definition>996021 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable" id="ifrx_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996022 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable" id="ifrx_r_ScheduleofRightofUseAssetsTable">
        <link:definition>996023 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable" id="ifrx_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996024 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable" id="ifrx_r_ScheduleofLeaseLiabilitiesTable">
        <link:definition>996025 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable" id="ifrx_r_ScheduleofAmountsRecognizedinProfitorLossTable">
        <link:definition>996026 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Amounts Recognized in Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofInventoryTable" id="ifrx_r_ScheduleofInventoryTable">
        <link:definition>996027 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable" id="ifrx_r_ScheduleofOtherAssetsTable">
        <link:definition>996028 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable" id="ifrx_r_ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable">
        <link:definition>996029 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable" id="ifrx_r_ScheduleofFinancialAssetsandLiabilitiesTable">
        <link:definition>996030 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable" id="ifrx_r_ScheduleofCashandCashEquivalentsTable">
        <link:definition>996031 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable" id="ifrx_r_ScheduleofTradeandOtherPayablesTable">
        <link:definition>996032 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable" id="ifrx_r_ScheduleofMarketRiskCreditRiskandLiquidityRiskTable">
        <link:definition>996033 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable" id="ifrx_r_ScheduleofCashCashEquivalentsandFinancialAssetsTable">
        <link:definition>996034 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash, Cash Equivalents and Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable" id="ifrx_r_ScheduleofSensitivityAnalysisTable">
        <link:definition>996035 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable" id="ifrx_r_ScheduleofOutstandingFinancialCommitmentsTable">
        <link:definition>996036 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Outstanding Financial Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/CommitmentsDetails" id="ifrx_r_CommitmentsDetails">
        <link:definition>996037 - Disclosure - Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable" id="ifrx_r_ScheduleofMaturityAnalysisofLeaseLiabilitiesTable">
        <link:definition>996038 - Disclosure - Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherInformationDetails" id="ifrx_r_OtherInformationDetails">
        <link:definition>996039 - Disclosure - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable" id="ifrx_r_ScheduleofCompensationoftheGroupsExecutiveManagementTable">
        <link:definition>996040 - Disclosure - Other Information (Details) - Schedule of Compensation of the Group&#8217;s Executive Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXs61wHyckAg2nxvBikE1dTD+mD7F+hOhyP4JUKDa+ELwxhT8MZgkEf+kZKh9LsB5Bl51UtFYWeFaK0UqFEG6idGWj2iasVoEhjS4SNz7nGGePLlsnxL0mJvX5+/z1JQqOTf/g3Fp1aJA=] CSR-->
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="ConsolidatedStatementsOfChangesInShareholdersEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract"/>
  <xs:element name="DisclosureOfCorporateInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfCorporateInformationAbstract"/>
  <xs:element name="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract"/>
  <xs:element name="ScheduleOfRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfRevenuesAbstract"/>
  <xs:element name="ScheduleOfCostOfSalesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfCostOfSalesAbstract"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfSalesAndMarketingExpensesAbstract"/>
  <xs:element name="ScheduleOfResearchAndDevelopmentExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfOtherIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfOtherIncomeAbstract"/>
  <xs:element name="ScheduleOfEmployeeBenefitsExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract"/>
  <xs:element name="ScheduleOfNetFinancialResultAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfNetFinancialResultAbstract"/>
  <xs:element name="ScheduleOfShareBasedPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfShareBasedPaymentsAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfWeightedAverageAbstract"/>
  <xs:element name="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract"/>
  <xs:element name="ScheduleOfOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfOtherAssetsAbstract"/>
  <xs:element name="ScheduleOfCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfCashAndCashEquivalentsAbstract"/>
  <xs:element name="ScheduleOfTradeAndOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfTradeAndOtherPayablesAbstract"/>
  <xs:element name="ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract"/>
  <xs:element name="OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract0"/>
  <xs:element name="ShareInformationBasedOnLossForThePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ShareInformationBasedOnLossForThePeriodAbstract"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract1"/>
  <xs:element name="NonCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonCurrentAssetsAbstract"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract2"/>
  <xs:element name="NonCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonCurrentLiabilitiesAbstract"/>
  <xs:element name="OperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AdjustmentsForAbstract"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract3"/>
  <xs:element name="ChangesInAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ChangesInAbstract"/>
  <xs:element name="InvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InvestingActivitiesAbstract"/>
  <xs:element name="FinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FinancingActivitiesAbstract"/>
  <xs:element name="InAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InAbstract"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract4"/>
  <xs:element name="UnlabeledAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract5"/>
  <xs:element name="a2021Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_a2021Abstract"/>
  <xs:element name="a2022Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_a2022Abstract"/>
  <xs:element name="a2023Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_a2023Abstract"/>
  <xs:element name="UnlabeledAbstract6" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract6"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AccumulatedDepreciationAbstract"/>
  <xs:element name="UnlabeledAbstract7" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract7"/>
  <xs:element name="NetBookValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetBookValueAbstract"/>
  <xs:element name="UnlabeledAbstract8" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract8"/>
  <xs:element name="AccumulatedDepreciationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AccumulatedDepreciationAbstract0"/>
  <xs:element name="UnlabeledAbstract9" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract9"/>
  <xs:element name="NetBookValueAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetBookValueAbstract0"/>
  <xs:element name="UnlabeledAbstract10" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract10"/>
  <xs:element name="AccumulatedAmortizationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AccumulatedAmortizationAbstract"/>
  <xs:element name="UnlabeledAbstract11" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnlabeledAbstract11"/>
  <xs:element name="NetBookValueAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetBookValueAbstract1"/>
  <xs:element name="InAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InAbstract0"/>
  <xs:element name="InAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InAbstract1"/>
  <xs:element name="InAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InAbstract2"/>
  <xs:element name="CurrentOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CurrentOtherAssetsAbstract"/>
  <xs:element name="FinancialAssetsAtAmortizedCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FinancialAssetsAtAmortizedCostAbstract"/>
  <xs:element name="FinancialLiabilitiesAtAmortizedCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract"/>
  <xs:element name="InAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InAbstract3"/>
  <xs:element name="ShortTermDepositsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ShortTermDepositsAbstract"/>
  <xs:element name="CashAtBanksAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CashAtBanksAbstract"/>
  <xs:element name="InAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InAbstract4"/>
  <xs:element name="ConversionRateEuroToUSDollarsAtReportingDate111050Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract"/>
  <xs:element name="ExecutiveManagementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExecutiveManagementAbstract"/>
  <xs:element name="NonExecutiveBoardOfDirectorsMembersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract"/>
  <xs:element name="IssuanceOfCommonShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_IssuanceOfCommonShare"/>
  <xs:element name="IncreaseDecreaseThroughExerciseOfOptionsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares"/>
  <xs:element name="AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars"/>
  <xs:element name="AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived"/>
  <xs:element name="PurchaseOfCurrentAndNoncurrentFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets"/>
  <xs:element name="TransactionCostsFromIssuanceOfCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TransactionCostsFromIssuanceOfCommonShares"/>
  <xs:element name="DisclosureOfCorporateInformationTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfCorporateInformationTextBlock"/>
  <xs:element name="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory"/>
  <xs:element name="AccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AccountingPoliciesAbstract"/>
  <xs:element name="DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock"/>
  <xs:element name="DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock"/>
  <xs:element name="DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock"/>
  <xs:element name="NotesToTheCashFlowStatementPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotesToTheCashFlowStatementPolicyTextBlock"/>
  <xs:element name="DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
  <xs:element name="DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory"/>
  <xs:element name="DisclosureOfSalesAndMarketingExpenseTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock"/>
  <xs:element name="DisclosureOfOtherIncomeExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock"/>
  <xs:element name="DisclosureOfNetFinancialResultTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfNetFinancialResultTextBlock"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems"/>
  <xs:element name="DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock"/>
  <xs:element name="DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory"/>
  <xs:element name="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"/>
  <xs:element name="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
  <xs:element name="LiabilityForFuturePolicyBenefitPeriodExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems"/>
  <xs:element name="Employeebenefitsexpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_Employeebenefitsexpense"/>
  <xs:element name="ForeignExchangeIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ForeignExchangeIncome"/>
  <xs:element name="ForeignExchangeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ForeignExchangeExpense"/>
  <xs:element name="ForeignExchangeResult" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ForeignExchangeResult"/>
  <xs:element name="OtherFinancialResult" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherFinancialResult"/>
  <xs:element name="NetFinancialResult" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetFinancialResult"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding"/>
  <xs:element name="NumberOfWeightedAverageSharesOutstanding" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfWeightedAverageSharesOutstanding"/>
  <xs:element name="NumberOfOpionsExercisedDuring" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfOpionsExercisedDuring"/>
  <xs:element name="NumberOfSharesExercisedDuring" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfSharesExercisedDuring"/>
  <xs:element name="NumberOfSharesOptionsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfSharesOptionsExercisable"/>
  <xs:element name="WAEPExercisables" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WAEPExercisables"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems"/>
  <xs:element name="NumberOfOutstandingSharesOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfOutstandingSharesOption"/>
  <xs:element name="NumberOfOutstandingsWeightedAverageEarningPershare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare"/>
  <xs:element name="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionExercisedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement"/>
  <xs:element name="NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement"/>
  <xs:element name="NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems"/>
  <xs:element name="ShareOptionsGrantedOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ShareOptionsGrantedOptions"/>
  <xs:element name="FairValuePerOptions" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FairValuePerOptions"/>
  <xs:element name="ForeignExchangeRateAsOfGrantDate" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ForeignExchangeRateAsOfGrantDate"/>
  <xs:element name="FairValuesPerOptions" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FairValuesPerOptions"/>
  <xs:element name="SharePriceAtGrantDateExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SharePriceAtGrantDateExercisePrices"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems"/>
  <xs:element name="PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01"/>
  <xs:element name="DisposalsAndRetirementPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment"/>
  <xs:element name="OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease"/>
  <xs:element name="NetBookValuePropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetBookValuePropertyAndEquipment"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems"/>
  <xs:element name="RightofuseAssetsRevaluationSurplus01" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_RightofuseAssetsRevaluationSurplus01"/>
  <xs:element name="IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions"/>
  <xs:element name="NetBookValueOfRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetBookValueOfRightOfUseAsset"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems"/>
  <xs:element name="IntangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_IntangibleAssets"/>
  <xs:element name="IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill"/>
  <xs:element name="DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill"/>
  <xs:element name="NetBookValueIntangibleAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetBookValueIntangibleAsset"/>
  <xs:element name="GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax"/>
  <xs:element name="UnfinishedGoods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnfinishedGoods"/>
  <xs:element name="PrepaidExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PrepaidExpense"/>
  <xs:element name="NonCurrentOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonCurrentOtherAssets"/>
  <xs:element name="TotalOtherAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TotalOtherAsset"/>
  <xs:element name="TaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TaxRate"/>
  <xs:element name="TaxBenefitsAtTaxRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TaxBenefitsAtTaxRate"/>
  <xs:element name="TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone"/>
  <xs:element name="NonrecognitionOfTaxEffectOnSharebasedPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment"/>
  <xs:element name="NondeductibleExpensesForTaxPurposesinDollars" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NondeductibleExpensesForTaxPurposesinDollars"/>
  <xs:element name="OtherDifferencesDueToTaxRateinDollars" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherDifferencesDueToTaxRateinDollars"/>
  <xs:element name="FinancialAssetsFromGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FinancialAssetsFromGovernmentGrants"/>
  <xs:element name="LiabilitiesFromGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LiabilitiesFromGovernmentGrants"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems"/>
  <xs:element name="AccruedLiabilitiesFromCommercialActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AccruedLiabilitiesFromCommercialActivities"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems"/>
  <xs:element name="CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems"/>
  <xs:element name="SensitivityAnalysisConversionRate" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SensitivityAnalysisConversionRate"/>
  <xs:element name="SensitivityAnalysisCarryingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SensitivityAnalysisCarryingAmount"/>
  <xs:element name="TotalFundsAvailable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TotalFundsAvailable"/>
  <xs:element name="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable"/>
  <xs:element name="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems"/>
  <xs:element name="EffectOfDiscounting" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_EffectOfDiscounting"/>
  <xs:element name="TotalLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TotalLeases"/>
  <xs:element name="ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed"/>
  <xs:element name="CapitalizedLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CapitalizedLeases"/>
  <xs:element name="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable"/>
  <xs:element name="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems"/>
  <xs:element name="PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
  <xs:element name="TotalCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TotalCompensation"/>
  <xs:element name="MaterialAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_MaterialAccountingPoliciesDetailsTable"/>
  <xs:element name="MaterialAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MaterialAccountingPoliciesDetailsLineItems"/>
  <xs:element name="PercentageOfGrant" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PercentageOfGrant"/>
  <xs:element name="RentalContractsFixedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_RentalContractsFixedPeriod"/>
  <xs:element name="AmortizedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AmortizedPeriod"/>
  <xs:element name="AnnualizedAverageSharePricePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AnnualizedAverageSharePricePeriod"/>
  <xs:element name="IncomeStatementLocationDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_IncomeStatementLocationDomainDomain"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable"/>
  <xs:element name="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems"/>
  <xs:element name="NetFinancialCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetFinancialCost"/>
  <xs:element name="ShortTermMarketableSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ShortTermMarketableSecurities"/>
  <xs:element name="WeightedNumberOfCommonSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WeightedNumberOfCommonSharesOutstanding"/>
  <xs:element name="LossPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LossPerShare"/>
  <xs:element name="ExercisePriceOfOutstandingShareOptions" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExercisePriceOfOutstandingShareOptions"/>
  <xs:element name="ConversionRate" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ConversionRate"/>
  <xs:element name="AverageRate" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AverageRate"/>
  <xs:element name="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
  <xs:element name="MaximumNumberOfCommonSharesAvailableForGrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MaximumNumberOfCommonSharesAvailableForGrant"/>
  <xs:element name="ordinarySharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ordinarySharesPercentage"/>
  <xs:element name="WeightedAverageFairValueOptionsGrantedDuringTheYear" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear"/>
  <xs:element name="WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd"/>
  <xs:element name="ExercisePriceRange" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExercisePriceRange"/>
  <xs:element name="OptionsGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OptionsGranted"/>
  <xs:element name="NumberOfStockOptionsForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfStockOptionsForfeited"/>
  <xs:element name="NumberOfOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NumberOfOptionsExercised"/>
  <xs:element name="ExpectedDividends" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExpectedDividends"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable"/>
  <xs:element name="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems"/>
  <xs:element name="ResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ResearchAndDevelopmentExpenses"/>
  <xs:element name="CorporateIncomeTax" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CorporateIncomeTax"/>
  <xs:element name="SolidaritySurcharge" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SolidaritySurcharge"/>
  <xs:element name="TradeTaxes" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TradeTaxes"/>
  <xs:element name="TotalTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TotalTaxRate"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent"/>
  <xs:element name="TaxBasisOfInvestmentCostForIncomeTaxPurposes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes"/>
  <xs:element name="TaxLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TaxLossCarryforwards"/>
  <xs:element name="TaxableIncome" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_TaxableIncome"/>
  <xs:element name="CurrentAndNonCurrentFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CurrentAndNonCurrentFinancialAssets"/>
  <xs:element name="FixedInterest" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FixedInterest"/>
  <xs:element name="FinancialAssetsFromGovernmentGrantsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_FinancialAssetsFromGovernmentGrantsAmount"/>
  <xs:element name="DueAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DueAmount"/>
  <xs:element name="CapitalOrdinarySharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CapitalOrdinarySharesIssued"/>
  <xs:element name="CommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CommonShares"/>
  <xs:element name="CommonSharesIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CommonSharesIssued"/>
  <xs:element name="AssetsSoldUnderAgreementToRepurchaseCarryingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NetProceeds"/>
  <xs:element name="AggregateCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AggregateCommonShares"/>
  <xs:element name="ProceedsOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ProceedsOfferingCost"/>
  <xs:element name="UnderwritingDiscounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnderwritingDiscounts"/>
  <xs:element name="ProceedsFromOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ProceedsFromOfferingCost"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AggregatePurchasePrice"/>
  <xs:element name="AggregateInitialOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AggregateInitialOffering"/>
  <xs:element name="NominalValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NominalValue"/>
  <xs:element name="OrdinarySharesValue" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OrdinarySharesValue"/>
  <xs:element name="OrdinaryShareSoldPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OrdinaryShareSoldPrice"/>
  <xs:element name="SoldAtPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SoldAtPrice"/>
  <xs:element name="OrdinarySharePurchase" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OrdinarySharePurchase"/>
  <xs:element name="PreferredUnitIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PreferredUnitIssued"/>
  <xs:element name="CompanyIssuedCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CompanyIssuedCapital"/>
  <xs:element name="CommonSharesInExcessOfNominalValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CommonSharesInExcessOfNominalValue"/>
  <xs:element name="PaymentsForAccruedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_PaymentsForAccruedPayments"/>
  <xs:element name="VariablesHeldConstant" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_VariablesHeldConstant"/>
  <xs:element name="ExchangeRateFluctuations" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExchangeRateFluctuations"/>
  <xs:element name="ExchangeRateCurrencyDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExchangeRateCurrencyDomainDomain"/>
  <xs:element name="CommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_CommitmentsDetailsTable"/>
  <xs:element name="CommitmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CommitmentsDetailsLineItems"/>
  <xs:element name="ExchangeRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExchangeRate"/>
  <xs:element name="LocationDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LocationDomainDomain"/>
  <xs:element name="OtherInformationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ifrx_OtherInformationDetailsTable"/>
  <xs:element name="OtherInformationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherInformationDetailsLineItems"/>
  <xs:element name="ExchangeRateCurrencyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ifrx_ExchangeRateCurrencyAxis"/>
  <xs:element name="IncomeStatementLocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ifrx_IncomeStatementLocationAxis"/>
  <xs:element name="LocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ifrx_LocationAxis"/>
  <xs:element name="AccumulatedAmortizationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AccumulatedAmortizationMember"/>
  <xs:element name="AdvancePaymentsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AdvancePaymentsMember"/>
  <xs:element name="AdvancesPaidForSoftwareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AdvancesPaidForSoftwareMember"/>
  <xs:element name="AfterOneYearButNotMoreThanFiveYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_AfterOneYearButNotMoreThanFiveYearsMember"/>
  <xs:element name="CashHeldInUSDollarsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CashHeldInUSDollarsMember"/>
  <xs:element name="CashHeldInUSEuroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CashHeldInUSEuroMember"/>
  <xs:element name="CompensationExpenseForNonexecutiveBoardDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember"/>
  <xs:element name="CostMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_CostMember"/>
  <xs:element name="DEMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DEMember"/>
  <xs:element name="DepositsHeldInEuroMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DepositsHeldInEuroMember"/>
  <xs:element name="DepositsHeldInUSDollarsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DepositsHeldInUSDollarsMember"/>
  <xs:element name="DepreciationAmortizationExpenseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DepreciationAmortizationExpenseMember"/>
  <xs:element name="EmployeeBenefitsExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_EmployeeBenefitsExpensesMember"/>
  <xs:element name="EquitysettledSharebasedPaymentExpenseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
  <xs:element name="EquitysettledSharebasedPaymentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_EquitysettledSharebasedPaymentExpensesMember"/>
  <xs:element name="ExecutiveManagementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExecutiveManagementMember"/>
  <xs:element name="ExecutiveMembersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ExecutiveMembersMember"/>
  <xs:element name="GermanMinistryOfEducationAndResearchMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_GermanMinistryOfEducationAndResearchMember"/>
  <xs:element name="InflaRxGmbHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InflaRxGmbHMember"/>
  <xs:element name="InflaRxPharmaceuticalIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InflaRxPharmaceuticalIncMember"/>
  <xs:element name="InsuranceExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_InsuranceExpensesMember"/>
  <xs:element name="January12Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_January12Member"/>
  <xs:element name="January12OneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_January12OneMember"/>
  <xs:element name="January4Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_January4Member"/>
  <xs:element name="January4OneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_January4OneMember"/>
  <xs:element name="JanuaryTwentyFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_JanuaryTwentyFourMember"/>
  <xs:element name="JanuaryTwentyFourOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_JanuaryTwentyFourOneMember"/>
  <xs:element name="July2Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_July2Member"/>
  <xs:element name="July2OneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_July2OneMember"/>
  <xs:element name="JulyNineteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_JulyNineteenMember"/>
  <xs:element name="JulySevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_JulySevenMember"/>
  <xs:element name="JulySevenOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_JulySevenOneMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LaboratoryEquipmentMember"/>
  <xs:element name="LegalAndConsultingFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LegalAndConsultingFeesMember"/>
  <xs:element name="LongTermIncentivePlan2016Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LongTermIncentivePlan2016Member"/>
  <xs:element name="LongTermIncentivePlan2017Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_LongTermIncentivePlan2017Member"/>
  <xs:element name="ManufacturingOfClinicalMaterialMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ManufacturingOfClinicalMaterialMember"/>
  <xs:element name="MarketProgramMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MarketProgramMember"/>
  <xs:element name="MaximumMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MaximumMember"/>
  <xs:element name="MayThirtyOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MayThirtyOneMember"/>
  <xs:element name="MinimumMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MinimumMember"/>
  <xs:element name="MoreThanFiveYearsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_MoreThanFiveYearsMember"/>
  <xs:element name="NonexecutiveBoardOfDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonexecutiveBoardOfDirectorsMember"/>
  <xs:element name="NonexecutiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_NonexecutiveMember"/>
  <xs:element name="November21Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_November21Member"/>
  <xs:element name="OptionPlan2016Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OptionPlan2016Member"/>
  <xs:element name="OptionsGrantedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OptionsGrantedMember"/>
  <xs:element name="OptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OptionsMember"/>
  <xs:element name="OtherExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherExpensesMember"/>
  <xs:element name="OtherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherMember"/>
  <xs:element name="RepricingApril13Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_RepricingApril13Member"/>
  <xs:element name="ResearchAndDevelopmentExpenseMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ResearchAndDevelopmentExpenseMember"/>
  <xs:element name="SeptemberEighteenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SeptemberEighteenMember"/>
  <xs:element name="SocialSecurityContributionsemployersShareMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_SocialSecurityContributionsemployersShareMember"/>
  <xs:element name="StockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_StockOptionMember"/>
  <xs:element name="StrengthsAgainstMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_StrengthsAgainstMember"/>
  <xs:element name="ThirdpartyExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ThirdpartyExpensesMember"/>
  <xs:element name="ThirdpartyServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ThirdpartyServicesMember"/>
  <xs:element name="UnitedStateOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_UnitedStateOneMember"/>
  <xs:element name="WAEPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WAEPMember"/>
  <xs:element name="WagesAndSalariesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WagesAndSalariesMember"/>
  <xs:element name="WeakensAgainstMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WeakensAgainstMember"/>
  <xs:element name="WithinOneYearMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_WithinOneYearMember"/>
  <xs:element name="clinicalPreclinicalStudiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_clinicalPreclinicalStudiesMember"/>
  <xs:element name="OtherInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_OtherInformationAbstract"/>
  <xs:element name="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract"/>
  <xs:element name="ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract"/>
  <xs:element name="ScheduleOfOutstandingFinancialCommitmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfRightofUseAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfRightofUseAssetsAbstract"/>
  <xs:element name="ScheduleOfSensitivityAnalysisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfSensitivityAnalysisAbstract"/>
  <xs:element name="ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ifrx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>ifrx-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 21 04:12:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedIncomeStatement" roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedBalanceSheet" roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedCashFlow" roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOtherIncomeTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofInventoryTable" roleURI="http://www.inflarx.de.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCashCashEquivalentsandFinancialAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SalesAndMarketingExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherExpenseByFunction" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_FinanceIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_FinanceCosts" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_RightofuseAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentFinancialAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentGovernmentGrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXs61wHyckAg2nxvBikE1dTD+mD7F+hOhyP4JUKDa+ELwxhT8MZgkEf+kZKh9LsB5Bl51UtFYWeFaK0UqFEG6idGWj2iasVoEhjS4SNz7nGGf4nLWMQY8htQe++SPp0Kl09WnCufpDbXI=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrx_TransactionCostsFromIssuanceOfCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_TransactionCostsFromIssuanceOfCommonShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrx_TransactionCostsFromIssuanceOfCommonShares" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" xlink:href="ifrx-20231231.xsd#ifrx_LiabilityForFuturePolicyBenefitPeriodExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnfinishedGoods" xlink:href="ifrx-20231231.xsd#ifrx_UnfinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrx_UnfinishedGoods" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_FinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccruedLiabilitiesFromCommercialActivities" xlink:href="ifrx-20231231.xsd#ifrx_AccruedLiabilitiesFromCommercialActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrx_AccruedLiabilitiesFromCommercialActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_OtherPayables" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable">
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>ifrx-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 21 04:12:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedIncomeStatement" roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedBalanceSheet" roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ShareholdersEquityType2or3" roleURI="http://www.inflarx.de.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedCashFlow" roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CorporateInformation" roleURI="http://www.inflarx.de.com/role/CorporateInformation"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_MaterialAccountingPolicies" roleURI="http://www.inflarx.de.com/role/MaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_NotestotheConsolidatedStatementsofFinancialPosition" roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_Commitments" roleURI="http://www.inflarx.de.com/role/Commitments"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_OtherInformation" roleURI="http://www.inflarx.de.com/role/OtherInformation"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_SignificantEventsAftertheReportingDate" roleURI="http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_AccountingPoliciesByPolicy" roleURI="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CorporateInformationTables" roleURI="http://www.inflarx.de.com/role/CorporateInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLossTables" roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_NotestotheConsolidatedStatementsofFinancialPositionTables" roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CommitmentsTables" roleURI="http://www.inflarx.de.com/role/CommitmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_OtherInformationTables" roleURI="http://www.inflarx.de.com/role/OtherInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofRevenuesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCostofsalesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCostofsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOtherIncomeTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofEmployeeBenefitsExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofNetFinancialResultTable" roleURI="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSharebasedPaymentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSharebasedpaymentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofShareBasedpaymentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofWeightedAverageTable" roleURI="http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofRightofUseAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofIntangibleAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofAmountsRecognizedinProfitorLossTable" roleURI="http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofInventoryTable" roleURI="http://www.inflarx.de.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOtherAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable" roleURI="http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofFinancialAssetsandLiabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofMarketRiskCreditRiskandLiquidityRiskTable" roleURI="http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCashCashEquivalentsandFinancialAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSensitivityAnalysisTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOutstandingFinancialCommitmentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofMaturityAnalysisofLeaseLiabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCompensationoftheGroupsExecutiveManagementTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_MaterialAccountingPoliciesDetails" roleURI="http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLossDetails" roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_NotestotheConsolidatedStatementsofFinancialPositionDetails" roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CommitmentsDetails" roleURI="http://www.inflarx.de.com/role/CommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_OtherInformationDetails" roleURI="http://www.inflarx.de.com/role/OtherInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.inflarx.de.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_SalesAndMarketingExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherExpenseByFunction" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ShareInformationBasedOnLossForThePeriodAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonCurrentAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrx_NonCurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherFinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonCurrentLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrx_NonCurrentLiabilitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NonCurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IssuanceOfCommonShare" xlink:href="ifrx-20231231.xsd#ifrx_IssuanceOfCommonShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrx_IssuanceOfCommonShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_OperatingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrx_OperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OperatingActivitiesAbstract" xlink:to="ifrx_AdjustmentsForAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ChangesInAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ChangesInAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrx_ChangesInAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_InvestingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_InvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrx_InvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_InvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_InvestingActivitiesAbstract" xlink:to="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_InvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_FinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrx_FinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_FinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TransactionCostsFromIssuanceOfCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_TransactionCostsFromIssuanceOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_FinancingActivitiesAbstract" xlink:to="ifrx_TransactionCostsFromIssuanceOfCommonShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_FinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_FinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashAndCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CorporateInformation">
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCorporateInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCorporateInformationTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_DisclosureOfCorporateInformationAbstract" xlink:to="ifrx_DisclosureOfCorporateInformationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/MaterialAccountingPolicies">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:to="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/Commitments">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherInformation">
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="ifrx_AccountingPoliciesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotesToTheCashFlowStatementPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_NotesToTheCashFlowStatementPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_NotesToTheCashFlowStatementPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CorporateInformationTables">
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCorporateInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_DisclosureOfCorporateInformationAbstract" xlink:to="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionPlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_OptionPlan2016Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_OptionPlan2016Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_LongTermIncentivePlan2017Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfCostOfSalesExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfNetFinancialResultTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfNetFinancialResultTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrx_DisclosureOfNetFinancialResultTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasePrepaymentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMarketRiskExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfMarketRiskExplanatory" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CommitmentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherInformationTables">
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationAbstract" xlink:to="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable">
    <loc xlink:type="locator" xlink:label="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:href="ifrx-20231231.xsd#ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_InflaRxGmbHMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxGmbHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_InflaRxGmbHMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_InflaRxPharmaceuticalIncMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxPharmaceuticalIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_InflaRxPharmaceuticalIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CountryOfIncorporation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_CountryOfIncorporation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfFunctionalCurrency" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfFunctionalCurrency"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_DescriptionOfFunctionalCurrency" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofRevenuesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfRevenuesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfRevenuesAbstract" xlink:to="ifrs-full_Revenue" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCostofsalesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfCostOfSalesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCostOfSalesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfCostOfSalesAbstract" xlink:to="ifrs-full_CostOfSales" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ThirdpartyExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_ThirdpartyExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_ThirdpartyExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EmployeeBenefitsExpensesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_LegalAndConsultingFeesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_OtherExpensesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ThirdpartyServicesMember" xlink:href="ifrx-20231231.xsd#ifrx_ThirdpartyServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_ThirdpartyServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ManufacturingOfClinicalMaterialMember" xlink:href="ifrx-20231231.xsd#ifrx_ManufacturingOfClinicalMaterialMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_ManufacturingOfClinicalMaterialMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_clinicalPreclinicalStudiesMember" xlink:href="ifrx-20231231.xsd#ifrx_clinicalPreclinicalStudiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_clinicalPreclinicalStudiesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EmployeeBenefitsExpensesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpenseMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_LegalAndConsultingFeesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_OtherExpensesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EmployeeBenefitsExpensesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_LegalAndConsultingFeesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_InsuranceExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_InsuranceExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_InsuranceExpensesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DepreciationAmortizationExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_DepreciationAmortizationExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_DepreciationAmortizationExpenseMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember" xlink:href="ifrx-20231231.xsd#ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_OtherExpensesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfOtherIncomeAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOtherIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherIncomeAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" xlink:href="ifrx-20231231.xsd#ifrx_LiabilityForFuturePolicyBenefitPeriodExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherIncomeAbstract" xlink:to="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherIncomeAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WagesAndSalariesMember" xlink:href="ifrx-20231231.xsd#ifrx_WagesAndSalariesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_WagesAndSalariesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SocialSecurityContributionsemployersShareMember" xlink:href="ifrx-20231231.xsd#ifrx_SocialSecurityContributionsemployersShareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_SocialSecurityContributionsemployersShareMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EquitysettledSharebasedPaymentExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrx_OtherMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_Employeebenefitsexpense" xlink:href="ifrx-20231231.xsd#ifrx_Employeebenefitsexpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:to="ifrx_Employeebenefitsexpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfNetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeIncome" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrx_ForeignExchangeIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeExpense" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrx_ForeignExchangeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeResult" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeResult"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrx_ForeignExchangeResult" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherFinancialResult" xlink:href="ifrx-20231231.xsd#ifrx_OtherFinancialResult"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrx_OtherFinancialResult" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetFinancialResult" xlink:href="ifrx-20231231.xsd#ifrx_NetFinancialResult"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrx_NetFinancialResult" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrx_OptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrx_WAEPMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrx_OptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrx_WAEPMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionPlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_OptionPlan2016Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="ifrx_OptionPlan2016Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageSharesOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_NumberOfWeightedAverageSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOpionsExercisedDuring" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOpionsExercisedDuring"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_NumberOfOpionsExercisedDuring" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfSharesExercisedDuring" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfSharesExercisedDuring"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_NumberOfSharesExercisedDuring" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfSharesOptionsExercisable" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfSharesOptionsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_NumberOfSharesOptionsExercisable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WAEPExercisables" xlink:href="ifrx-20231231.xsd#ifrx_WAEPExercisables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_WAEPExercisables" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrx_OptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrx_WAEPMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="ifrx_LongTermIncentivePlan2017Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOutstandingSharesOption" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingSharesOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfOutstandingSharesOption" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingsWeightedAverageEarningPershare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:to="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:to="ifrs-full_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_January4Member" xlink:href="ifrx-20231231.xsd#ifrx_January4Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_January4Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_January4OneMember" xlink:href="ifrx-20231231.xsd#ifrx_January4OneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_January4OneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_July2Member" xlink:href="ifrx-20231231.xsd#ifrx_July2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_July2Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_July2OneMember" xlink:href="ifrx-20231231.xsd#ifrx_July2OneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_July2OneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_January12Member" xlink:href="ifrx-20231231.xsd#ifrx_January12Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_January12Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_January12OneMember" xlink:href="ifrx-20231231.xsd#ifrx_January12OneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_January12OneMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_RepricingApril13Member" xlink:href="ifrx-20231231.xsd#ifrx_RepricingApril13Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_RepricingApril13Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_November21Member" xlink:href="ifrx-20231231.xsd#ifrx_November21Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_November21Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_JanuaryTwentyFourMember" xlink:href="ifrx-20231231.xsd#ifrx_JanuaryTwentyFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_JanuaryTwentyFourMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_JanuaryTwentyFourOneMember" xlink:href="ifrx-20231231.xsd#ifrx_JanuaryTwentyFourOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_JanuaryTwentyFourOneMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_MayThirtyOneMember" xlink:href="ifrx-20231231.xsd#ifrx_MayThirtyOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_MayThirtyOneMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_JulySevenMember" xlink:href="ifrx-20231231.xsd#ifrx_JulySevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_JulySevenMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_JulySevenOneMember" xlink:href="ifrx-20231231.xsd#ifrx_JulySevenOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_JulySevenOneMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_JulyNineteenMember" xlink:href="ifrx-20231231.xsd#ifrx_JulyNineteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_JulyNineteenMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SeptemberEighteenMember" xlink:href="ifrx-20231231.xsd#ifrx_SeptemberEighteenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrx_SeptemberEighteenMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_a2021Abstract" xlink:href="ifrx-20231231.xsd#ifrx_a2021Abstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:to="ifrx_a2021Abstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareOptionsGrantedOptions" xlink:href="ifrx-20231231.xsd#ifrx_ShareOptionsGrantedOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_ShareOptionsGrantedOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_FairValuePerOptions" xlink:href="ifrx-20231231.xsd#ifrx_FairValuePerOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_FairValuePerOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeRateAsOfGrantDate" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeRateAsOfGrantDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_ForeignExchangeRateAsOfGrantDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_FairValuesPerOptions" xlink:href="ifrx-20231231.xsd#ifrx_FairValuesPerOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_FairValuesPerOptions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SharePriceAtGrantDateExercisePrices" xlink:href="ifrx-20231231.xsd#ifrx_SharePriceAtGrantDateExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_SharePriceAtGrantDateExercisePrices" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_a2021Abstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrx_CostMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="1" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXs61wHyckAg2nxvBikE1dTD+mD7F+hOhyP4JUKDa+ELwxhT8MZgkEf+kZKh9LsB5Bl51UtFYWeFaK0UqFEG6idGWj2iasVoEhjS4SNz7nGGf4nLWMQY8htYoHF926soGW/hSphphSqv0=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdvancePaymentsMember" xlink:href="ifrx-20231231.xsd#ifrx_AdvancePaymentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrx_AdvancePaymentsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:href="ifrx-20231231.xsd#ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment" xlink:href="ifrx-20231231.xsd#ifrx_DisposalsAndRetirementPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccumulatedDepreciationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrx_AccumulatedDepreciationAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" xlink:href="ifrx-20231231.xsd#ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_AccumulatedDepreciationAbstract" xlink:to="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValuePropertyAndEquipment" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValuePropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrx_NetBookValuePropertyAndEquipment" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrx_CostMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_VehiclesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_RightofuseAssetsRevaluationSurplus01" xlink:href="ifrx-20231231.xsd#ifrx_RightofuseAssetsRevaluationSurplus01"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrx_RightofuseAssetsRevaluationSurplus01" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueOfRightOfUseAsset" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueOfRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrx_NetBookValueOfRightOfUseAsset" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_ComputerSoftwareMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdvancesPaidForSoftwareMember" xlink:href="ifrx-20231231.xsd#ifrx_AdvancesPaidForSoftwareMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrx_AdvancesPaidForSoftwareMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrx_CostMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccumulatedAmortizationMember" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedAmortizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrx_AccumulatedAmortizationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IntangibleAssets" xlink:href="ifrx-20231231.xsd#ifrx_IntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrx_IntangibleAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" xlink:href="ifrx-20231231.xsd#ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueIntangibleAsset" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueIntangibleAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrx_NetBookValueIntangibleAsset" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" xlink:href="ifrx-20231231.xsd#ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnBonds" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBonds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_InterestExpenseOnBonds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_RentalExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfInventoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnfinishedGoods" xlink:href="ifrx-20231231.xsd#ifrx_UnfinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfInventoryAbstract" xlink:to="ifrx_UnfinishedGoods" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfInventoryAbstract" xlink:to="ifrs-full_InventoriesTotal" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfOtherAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PrepaidExpense" xlink:href="ifrx-20231231.xsd#ifrx_PrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrx_PrepaidExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonCurrentOtherAssets" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherAssetsAbstract" xlink:to="ifrx_NonCurrentOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentOtherAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_CurrentOtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherAssetsAbstract" xlink:to="ifrx_CurrentOtherAssetsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CurrentOtherAssetsAbstract" xlink:to="ifrs-full_Prepayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CurrentOtherAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CurrentOtherAssetsAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherAssetsAbstract" xlink:to="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalOtherAsset" xlink:href="ifrx-20231231.xsd#ifrx_TotalOtherAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOtherAssetsAbstract" xlink:to="ifrx_TotalOtherAsset" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrx_TaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxBenefitsAtTaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TaxBenefitsAtTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrx_TaxBenefitsAtTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" xlink:href="ifrx-20231231.xsd#ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment" xlink:href="ifrx-20231231.xsd#ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NondeductibleExpensesForTaxPurposesinDollars" xlink:href="ifrx-20231231.xsd#ifrx_NondeductibleExpensesForTaxPurposesinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrx_NondeductibleExpensesForTaxPurposesinDollars" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherDifferencesDueToTaxRateinDollars" xlink:href="ifrx-20231231.xsd#ifrx_OtherDifferencesDueToTaxRateinDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrx_OtherDifferencesDueToTaxRateinDollars" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancialAssetsFromGovernmentGrants" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrx_FinancialAssetsFromGovernmentGrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LiabilitiesFromGovernmentGrants" xlink:href="ifrx-20231231.xsd#ifrx_LiabilitiesFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrx_LiabilitiesFromGovernmentGrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DepositsHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_DepositsHeldInUSDollarsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrx_DepositsHeldInUSDollarsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DepositsHeldInEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_DepositsHeldInEuroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrx_DepositsHeldInEuroMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSDollarsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrx_CashHeldInUSDollarsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashHeldInUSEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSEuroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrx_CashHeldInUSEuroMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShortTermDepositsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ShortTermDepositsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrx_ShortTermDepositsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ShortTermDepositsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashAtBanksAbstract" xlink:href="ifrx-20231231.xsd#ifrx_CashAtBanksAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrx_CashAtBanksAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CashAtBanksAbstract" xlink:to="ifrs-full_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccruedLiabilitiesFromCommercialActivities" xlink:href="ifrx-20231231.xsd#ifrx_AccruedLiabilitiesFromCommercialActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrx_AccruedLiabilitiesFromCommercialActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_OtherPayables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MarketRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MarketRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_MarketRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiquidityRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_LiquidityRiskMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExposureToRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExposureToRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrs-full_DescriptionOfExposureToRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:to="ifrs-full_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeakensAgainstMember" xlink:href="ifrx-20231231.xsd#ifrx_WeakensAgainstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrx_WeakensAgainstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_StrengthsAgainstMember" xlink:href="ifrx-20231231.xsd#ifrx_StrengthsAgainstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrx_StrengthsAgainstMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SensitivityAnalysisConversionRate" xlink:href="ifrx-20231231.xsd#ifrx_SensitivityAnalysisConversionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="ifrx_SensitivityAnalysisConversionRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="ifrs-full_ProfitLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SensitivityAnalysisCarryingAmount" xlink:href="ifrx-20231231.xsd#ifrx_SensitivityAnalysisCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="ifrx_SensitivityAnalysisCarryingAmount" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable">
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BalancesWithBanks" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_BalancesWithBanks" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DebtSecurities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_DebtSecurities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalFundsAvailable" xlink:href="ifrx-20231231.xsd#ifrx_TotalFundsAvailable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrx_TotalFundsAvailable" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WithinOneYearMember" xlink:href="ifrx-20231231.xsd#ifrx_WithinOneYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrx_WithinOneYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AfterOneYearButNotMoreThanFiveYearsMember" xlink:href="ifrx-20231231.xsd#ifrx_AfterOneYearButNotMoreThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrx_AfterOneYearButNotMoreThanFiveYearsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_MoreThanFiveYearsMember" xlink:href="ifrx-20231231.xsd#ifrx_MoreThanFiveYearsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrx_MoreThanFiveYearsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EffectOfDiscounting" xlink:href="ifrx-20231231.xsd#ifrx_EffectOfDiscounting"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrx_EffectOfDiscounting" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrs-full_NetDeferredTaxLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalLeases" xlink:href="ifrx-20231231.xsd#ifrx_TotalLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrx_TotalLeases" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" xlink:href="ifrx-20231231.xsd#ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CapitalizedLeases" xlink:href="ifrx-20231231.xsd#ifrx_CapitalizedLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrx_CapitalizedLeases" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable">
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveManagementMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_ExecutiveManagementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonexecutiveBoardOfDirectorsMember" xlink:href="ifrx-20231231.xsd#ifrx_NonexecutiveBoardOfDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_NonexecutiveBoardOfDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveManagementAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ifrx_ExecutiveManagementAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermEmployeeBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ExecutiveManagementAbstract" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="ifrx-20231231.xsd#ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ExecutiveManagementAbstract" xlink:to="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalCompensation" xlink:href="ifrx-20231231.xsd#ifrx_TotalCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ifrx_TotalCompensation" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_MaterialAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaterialAccountingPoliciesDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_MaterialAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrx_MaterialAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_MaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_MaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_MaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_GermanMinistryOfEducationAndResearchMember" xlink:href="ifrx-20231231.xsd#ifrx_GermanMinistryOfEducationAndResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_GermanMinistryOfEducationAndResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsGrantedMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsGrantedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_OptionsGrantedMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LaboratoryEquipmentMember" xlink:href="ifrx-20231231.xsd#ifrx_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" xlink:to="ifrx_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" xlink:to="ifrs-full_OfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_GovernmentGrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PercentageOfGrant" xlink:href="ifrx-20231231.xsd#ifrx_PercentageOfGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrx_PercentageOfGrant" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_CurrentGovernmentGrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_RentalContractsFixedPeriod" xlink:href="ifrx-20231231.xsd#ifrx_RentalContractsFixedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrx_RentalContractsFixedPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AmortizedPeriod" xlink:href="ifrx-20231231.xsd#ifrx_AmortizedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrx_AmortizedPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AnnualizedAverageSharePricePeriod" xlink:href="ifrx-20231231.xsd#ifrx_AnnualizedAverageSharePricePeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrx_AnnualizedAverageSharePricePeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccruedIncomeIncludingContractAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_OtherAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoryWritedown2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_InventoryWritedown2011" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails">
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_DefinedBenefitPlansAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncomeStatementLocationAxis" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrx_IncomeStatementLocationAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncomeStatementLocationDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrx_IncomeStatementLocationAxis" xlink:to="ifrx_IncomeStatementLocationDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncomeStatementLocationDomainDomain_0" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrx_IncomeStatementLocationAxis" xlink:to="ifrx_IncomeStatementLocationDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_InflaRxGmbHMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxGmbHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_InflaRxGmbHMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveManagementMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_ExecutiveManagementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="ifrx_LongTermIncentivePlan2017Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LongTermIncentivePlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2016Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="ifrx_LongTermIncentivePlan2016Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ResearchAndDevelopmentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_IncomeStatementLocationDomainDomain" xlink:to="ifrx_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_IncomeStatementLocationDomainDomain" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_SellingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_OtherFinanceCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_OtherIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetFinancialCost" xlink:href="ifrx-20231231.xsd#ifrx_NetFinancialCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_NetFinancialCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShortTermMarketableSecurities" xlink:href="ifrx-20231231.xsd#ifrx_ShortTermMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ShortTermMarketableSecurities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_ForeignExchangeGain" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_ForeignExchangeLoss" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_OtherFinancialAssets" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedNumberOfCommonSharesOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_WeightedNumberOfCommonSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_WeightedNumberOfCommonSharesOutstanding" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LossPerShare" xlink:href="ifrx-20231231.xsd#ifrx_LossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_LossPerShare" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExercisePriceOfOutstandingShareOptions" xlink:href="ifrx-20231231.xsd#ifrx_ExercisePriceOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ExercisePriceOfOutstandingShareOptions" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConversionRate" xlink:href="ifrx-20231231.xsd#ifrx_ConversionRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ConversionRate" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AverageRate" xlink:href="ifrx-20231231.xsd#ifrx_AverageRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_AverageRate" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaximumNumberOfCommonSharesAvailableForGrant" xlink:href="ifrx-20231231.xsd#ifrx_MaximumNumberOfCommonSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_MaximumNumberOfCommonSharesAvailableForGrant" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ordinarySharesPercentage" xlink:href="ifrx-20231231.xsd#ifrx_ordinarySharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ordinarySharesPercentage" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExercisePriceRange" xlink:href="ifrx-20231231.xsd#ifrx_ExercisePriceRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ExercisePriceRange" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsGranted" xlink:href="ifrx-20231231.xsd#ifrx_OptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_OptionsGranted" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfStockOptionsForfeited" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfStockOptionsForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_NumberOfStockOptionsForfeited" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOptionsExercised" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_NumberOfOptionsExercised" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExpectedDividends" xlink:href="ifrx-20231231.xsd#ifrx_ExpectedDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ExpectedDividends" order="30" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails">
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrs-full_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_MarketProgramMember" xlink:href="ifrx-20231231.xsd#ifrx_MarketProgramMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_MarketProgramMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_StockOptionMember" xlink:href="ifrx-20231231.xsd#ifrx_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_StockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_MinimumMember" xlink:href="ifrx-20231231.xsd#ifrx_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrx_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaximumMember" xlink:href="ifrx-20231231.xsd#ifrx_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrx_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ResearchAndDevelopmentExpenses" xlink:href="ifrx-20231231.xsd#ifrx_ResearchAndDevelopmentExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_ResearchAndDevelopmentExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WritedownsReversalsOfInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_WritedownsReversalsOfInventories" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CorporateIncomeTax" xlink:href="ifrx-20231231.xsd#ifrx_CorporateIncomeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CorporateIncomeTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SolidaritySurcharge" xlink:href="ifrx-20231231.xsd#ifrx_SolidaritySurcharge"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_SolidaritySurcharge" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TradeTaxes" xlink:href="ifrx-20231231.xsd#ifrx_TradeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_TradeTaxes" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalTaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TotalTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_TotalTaxRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" xlink:href="ifrx-20231231.xsd#ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" xlink:href="ifrx-20231231.xsd#ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes" xlink:href="ifrx-20231231.xsd#ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxLossCarryforwards" xlink:href="ifrx-20231231.xsd#ifrx_TaxLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_TaxLossCarryforwards" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxableIncome" xlink:href="ifrx-20231231.xsd#ifrx_TaxableIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_TaxableIncome" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInterestReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_CurrentInterestReceivable" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssets" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_FixedInterest" xlink:href="ifrx-20231231.xsd#ifrx_FixedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_FixedInterest" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancialAssetsFromGovernmentGrantsAmount" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsFromGovernmentGrantsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_FinancialAssetsFromGovernmentGrantsAmount" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DueAmount" xlink:href="ifrx-20231231.xsd#ifrx_DueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_DueAmount" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CapitalOrdinarySharesIssued" xlink:href="ifrx-20231231.xsd#ifrx_CapitalOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CapitalOrdinarySharesIssued" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommonShares" xlink:href="ifrx-20231231.xsd#ifrx_CommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CommonShares" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommonSharesIssued" xlink:href="ifrx-20231231.xsd#ifrx_CommonSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CommonSharesIssued" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount" xlink:href="ifrx-20231231.xsd#ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetProceeds" xlink:href="ifrx-20231231.xsd#ifrx_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_NetProceeds" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AggregateCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_AggregateCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_AggregateCommonShares" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ProceedsOfferingCost" xlink:href="ifrx-20231231.xsd#ifrx_ProceedsOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_ProceedsOfferingCost" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnderwritingDiscounts" xlink:href="ifrx-20231231.xsd#ifrx_UnderwritingDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_UnderwritingDiscounts" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ProceedsFromOfferingCost" xlink:href="ifrx-20231231.xsd#ifrx_ProceedsFromOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_ProceedsFromOfferingCost" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_DividendsPaidOrdinaryShares" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_DividendsPaidOrdinarySharesPerShare" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AggregatePurchasePrice" xlink:href="ifrx-20231231.xsd#ifrx_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_AggregatePurchasePrice" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_AggregateInitialOffering" xlink:href="ifrx-20231231.xsd#ifrx_AggregateInitialOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_AggregateInitialOffering" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NominalValue" xlink:href="ifrx-20231231.xsd#ifrx_NominalValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_NominalValue" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OrdinarySharesValue" xlink:href="ifrx-20231231.xsd#ifrx_OrdinarySharesValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_OrdinarySharesValue" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OrdinaryShareSoldPrice" xlink:href="ifrx-20231231.xsd#ifrx_OrdinaryShareSoldPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_OrdinaryShareSoldPrice" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_SoldAtPrice" xlink:href="ifrx-20231231.xsd#ifrx_SoldAtPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_SoldAtPrice" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_OrdinarySharePurchase" xlink:href="ifrx-20231231.xsd#ifrx_OrdinarySharePurchase"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_OrdinarySharePurchase" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PreferredUnitIssued" xlink:href="ifrx-20231231.xsd#ifrx_PreferredUnitIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_PreferredUnitIssued" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CompanyIssuedCapital" xlink:href="ifrx-20231231.xsd#ifrx_CompanyIssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CompanyIssuedCapital" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedReimbursementOtherProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_ExpectedReimbursementOtherProvisions" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommonSharesInExcessOfNominalValue" xlink:href="ifrx-20231231.xsd#ifrx_CommonSharesInExcessOfNominalValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_CommonSharesInExcessOfNominalValue" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_PaymentsForAccruedPayments" xlink:href="ifrx-20231231.xsd#ifrx_PaymentsForAccruedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_PaymentsForAccruedPayments" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_VariablesHeldConstant" xlink:href="ifrx-20231231.xsd#ifrx_VariablesHeldConstant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_VariablesHeldConstant" order="53" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" order="54" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateFluctuations" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_ExchangeRateFluctuations" order="55" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaximumExposureToCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRisk" order="56" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" order="57" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_FinancialAssets" order="58" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_CashOnHand" order="59" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CommitmentsDetails">
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_CommitmentsDetailsLineItems" xlink:to="ifrx_CommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateCurrencyAxis" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_CommitmentsDetailsTable" xlink:to="ifrx_ExchangeRateCurrencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateCurrencyDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrx_ExchangeRateCurrencyAxis" xlink:to="ifrx_ExchangeRateCurrencyDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateCurrencyDomainDomain_0" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrx_ExchangeRateCurrencyAxis" xlink:to="ifrx_ExchangeRateCurrencyDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashHeldInUSEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSEuroMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ExchangeRateCurrencyDomainDomain" xlink:to="ifrx_CashHeldInUSEuroMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSDollarsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_ExchangeRateCurrencyDomainDomain" xlink:to="ifrx_CashHeldInUSDollarsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRate" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_CommitmentsDetailsLineItems" xlink:to="ifrx_ExchangeRate" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherInformationDetails">
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrx_OtherInformationDetailsLineItems" xlink:to="ifrx_OtherInformationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_OtherInformationDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LocationAxis" xlink:href="ifrx-20231231.xsd#ifrx_LocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrx_OtherInformationDetailsTable" xlink:to="ifrx_LocationAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LocationDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_LocationDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrx_LocationAxis" xlink:to="ifrx_LocationDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_LocationDomainDomain_0" xlink:href="ifrx-20231231.xsd#ifrx_LocationDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrx_LocationAxis" xlink:to="ifrx_LocationDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_DEMember" xlink:href="ifrx-20231231.xsd#ifrx_DEMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_LocationDomainDomain" xlink:to="ifrx_DEMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnitedStateOneMember" xlink:href="ifrx-20231231.xsd#ifrx_UnitedStateOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_LocationDomainDomain" xlink:to="ifrx_UnitedStateOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveMembersMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveMembersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_ExecutiveMembersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonexecutiveMember" xlink:href="ifrx-20231231.xsd#ifrx_NonexecutiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrx_NonexecutiveMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationDetailsLineItems" xlink:to="ifrs-full_Revenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrx_OtherInformationDetailsLineItems" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="39" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>ifrx-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 21 04:12:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US">Operating result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Loss for the Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrs-full_ProfitLoss_lbl2" xml:lang="en-US">Profit/(loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">TOTAL EQUITY AND LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash from/ (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCorporateInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfCorporateInformationAbstract_lbl" xml:lang="en-US">Corporate Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfCorporateInformationAbstract" xlink:to="ifrx_DisclosureOfCorporateInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract_lbl" xml:lang="en-US">Schedule of Share Capital Consisting Solely of Ordinary Shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract" xlink:to="ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xml:lang="en-US">Material Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:to="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl0" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CostOfSales_lbl1" xml:lang="en-US">Cost of Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US">Business combinations [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfOtherIncomeAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfOtherIncomeAbstract_lbl" xml:lang="en-US">Schedule of other income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfOtherIncomeAbstract" xlink:to="ifrx_ScheduleOfOtherIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherFinanceIncome_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Outstanding at January 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl0" xml:lang="en-US">Outstanding at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_lbl" xml:lang="en-US">Options, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_lbl0" xml:lang="en-US">Options, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageSharesOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_NumberOfWeightedAverageSharesOutstanding_lbl" xml:lang="en-US">WAEP, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageSharesOutstanding" xlink:to="ifrx_NumberOfWeightedAverageSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrx_NumberOfWeightedAverageSharesOutstanding_lbl0" xml:lang="en-US">WAEP, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageSharesOutstanding" xlink:to="ifrx_NumberOfWeightedAverageSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl" xml:lang="en-US">Net defined benefit liability (asset) [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOutstandingSharesOption" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingSharesOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_NumberOfOutstandingSharesOption_lbl" xml:lang="en-US">Options, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingSharesOption" xlink:to="ifrx_NumberOfOutstandingSharesOption_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrx_NumberOfOutstandingSharesOption_lbl0" xml:lang="en-US">Options, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingSharesOption" xlink:to="ifrx_NumberOfOutstandingSharesOption_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingsWeightedAverageEarningPershare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl" xml:lang="en-US">WAEP, Outstanding beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" xlink:to="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl0" xml:lang="en-US">WAEP, Outstanding ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" xlink:to="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_lbl" xml:lang="en-US">Cumulative effect at date of initial application [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="ifrx_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl" xml:lang="en-US">Attribution of expenses by nature to their function [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:href="ifrx-20231231.xsd#ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl" xml:lang="en-US">Balance at beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:to="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl0" xml:lang="en-US">Balance at ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:to="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfRightofUseAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfRightofUseAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfRightofUseAssetsAbstract_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfRightofUseAssetsAbstract" xlink:to="ifrx_ScheduleOfRightofUseAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_RightofuseAssetsRevaluationSurplus01" xlink:href="ifrx-20231231.xsd#ifrx_RightofuseAssetsRevaluationSurplus01"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_RightofuseAssetsRevaluationSurplus01_lbl" xml:lang="en-US">Balance, beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RightofuseAssetsRevaluationSurplus01" xlink:to="ifrx_RightofuseAssetsRevaluationSurplus01_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrx_RightofuseAssetsRevaluationSurplus01_lbl0" xml:lang="en-US">Balance, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RightofuseAssetsRevaluationSurplus01" xlink:to="ifrx_RightofuseAssetsRevaluationSurplus01_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfIntangibleAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfIntangibleAssetsAbstract" xlink:to="ifrx_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IntangibleAssets" xlink:href="ifrx-20231231.xsd#ifrx_IntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrx_IntangibleAssets_lbl" xml:lang="en-US">Balance beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IntangibleAssets" xlink:to="ifrx_IntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="ifrx_IntangibleAssets_lbl0" xml:lang="en-US">Balance ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IntangibleAssets" xlink:to="ifrx_IntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrx_ScheduleOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">As of January 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">As of December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfInventoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfInventoryAbstract" xlink:to="ifrx_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_InventoriesTotal_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_InventoriesTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl" xml:lang="en-US">Total cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl" xml:lang="en-US">Total trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract_lbl" xml:lang="en-US">Schedule of Market Risk, Credit Risk and Liquidity Risk [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract" xlink:to="ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US">Types of risks [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Financial Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_lbl" xml:lang="en-US">Total assets exposed to the risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:to="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfSensitivityAnalysisAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfSensitivityAnalysisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfSensitivityAnalysisAbstract_lbl" xml:lang="en-US">Schedule of Sensitivity Analysis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfSensitivityAnalysisAbstract" xlink:to="ifrx_ScheduleOfSensitivityAnalysisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract_lbl" xml:lang="en-US">Schedule of Outstanding Financial Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl" xml:lang="en-US">Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_NotesAndOtherExplanatoryInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherInformationAbstract_lbl" xml:lang="en-US">Other Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherInformationAbstract" xlink:to="ifrx_OtherInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Significant events after the reporting date [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Foreign exchange result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl" xml:lang="en-US">Other financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:to="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations_lbl" xml:lang="en-US">Exchange differences on translation of foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract" xlink:to="ifrx_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract0" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract0" xlink:to="ifrx_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ShareInformationBasedOnLossForThePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ShareInformationBasedOnLossForThePeriodAbstract_lbl" xml:lang="en-US">Share information (based on loss for the period)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" xlink:to="ifrx_ShareInformationBasedOnLossForThePeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share (basic/diluted) (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Loss per share diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract1" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract1" xlink:to="ifrx_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonCurrentAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonCurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrx_NonCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US">Current other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xml:lang="en-US">Tax receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xml:lang="en-US">Financial assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinancialAssets_lbl" xml:lang="en-US">Other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherFinancialAssets_lbl0" xml:lang="en-US">Other financial amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract2" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract2" xlink:to="ifrx_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">EQUITY AND LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Other capital reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Other components of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonCurrentLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentLiabilitiesAbstract" xlink:to="ifrx_NonCurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xml:lang="en-US">Liabilities from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl0" xml:lang="en-US">Received grant amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl" xml:lang="en-US">Exchange differences on translation of foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IssuanceOfCommonShare" xlink:href="ifrx-20231231.xsd#ifrx_IssuanceOfCommonShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_IssuanceOfCommonShare_lbl" xml:lang="en-US">Issuance of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IssuanceOfCommonShare" xlink:to="ifrx_IssuanceOfCommonShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Equity-settled share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US">Share options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl" xml:lang="en-US">Share options exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US">Equity-settled share-based payments (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_OperatingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OperatingActivitiesAbstract" xlink:to="ifrx_OperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AdjustmentsForAbstract_lbl" xml:lang="en-US">Adjustments for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrx_AdjustmentsForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share-based payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US">Net foreign exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract3" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract3" xlink:to="ifrx_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ChangesInAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ChangesInAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ChangesInAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrx_ChangesInAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars_lbl" xml:lang="en-US">Financial assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived_lbl" xml:lang="en-US">Liabilities from government grants received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InvestingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_InvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InvestingActivitiesAbstract" xlink:to="ifrx_InvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_lbl" xml:lang="en-US">Proceeds from the maturity of current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_FinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancingActivitiesAbstract" xlink:to="ifrx_FinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US">Proceeds from exercise of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl1" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherExpenseByFunction_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByFunction" xlink:to="ifrs-full_OtherExpenseByFunction_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US">Net finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_lbl" xml:lang="en-US">Purchase of intangible assets and property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets_lbl" xml:lang="en-US">Purchase of current and non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:to="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TransactionCostsFromIssuanceOfCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_TransactionCostsFromIssuanceOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrx_TransactionCostsFromIssuanceOfCommonShares_lbl" xml:lang="en-US">Transaction costs from issuance of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TransactionCostsFromIssuanceOfCommonShares" xlink:to="ifrx_TransactionCostsFromIssuanceOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US">Other capital reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Other components of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCorporateInformationTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfCorporateInformationTextBlock_lbl" xml:lang="en-US">Corporate information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfCorporateInformationTextBlock" xlink:to="ifrx_DisclosureOfCorporateInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory_lbl" xml:lang="en-US">Schedule of Share Capital Consisting Solely of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" xlink:to="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CountryOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CountryOfIncorporation_lbl" xml:lang="en-US">Place of business/country of incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporation" xlink:to="ifrs-full_CountryOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfFunctionalCurrency" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfFunctionalCurrency"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfFunctionalCurrency_lbl" xml:lang="en-US">Functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfFunctionalCurrency" xlink:to="ifrs-full_DescriptionOfFunctionalCurrency_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US">Ownership interest held by the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_lbl" xml:lang="en-US">Principal activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:to="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl" xml:lang="en-US">Material accounting policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory_lbl" xml:lang="en-US">Consolidated statements of operations and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" xlink:to="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US">Schedule of Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl" xml:lang="en-US">Schedule of Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:to="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock_lbl" xml:lang="en-US">Schedule of Sales and Marketing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock" xlink:to="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InAbstract" xlink:href="ifrx-20231231.xsd#ifrx_InAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InAbstract_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract" xlink:to="ifrx_InAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock_lbl" xml:lang="en-US">Schedule of Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock" xlink:to="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US">Other income from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" xlink:href="ifrx-20231231.xsd#ifrx_LiabilityForFuturePolicyBenefitPeriodExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense_lbl" xml:lang="en-US">Further other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" xlink:to="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Schedule of Employee Benefits Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_Employeebenefitsexpense" xlink:href="ifrx-20231231.xsd#ifrx_Employeebenefitsexpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_Employeebenefitsexpense_lbl" xml:lang="en-US">Employee benefits expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_Employeebenefitsexpense" xlink:to="ifrx_Employeebenefitsexpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfNetFinancialResultTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfNetFinancialResultTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfNetFinancialResultTextBlock_lbl" xml:lang="en-US">Schedule of Net Financial Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfNetFinancialResultTextBlock" xlink:to="ifrx_DisclosureOfNetFinancialResultTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US">Financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract4" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract4" xlink:to="ifrx_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeIncome" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ForeignExchangeIncome_lbl" xml:lang="en-US">Foreign exchange income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeIncome" xlink:to="ifrx_ForeignExchangeIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeResult" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeResult"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ForeignExchangeResult_lbl" xml:lang="en-US">Foreign exchange result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeResult" xlink:to="ifrx_ForeignExchangeResult_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract5" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract5_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract5" xlink:to="ifrx_UnlabeledAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherFinancialResult" xlink:href="ifrx-20231231.xsd#ifrx_OtherFinancialResult"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OtherFinancialResult_lbl" xml:lang="en-US">Other financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherFinancialResult" xlink:to="ifrx_OtherFinancialResult_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetFinancialResult" xlink:href="ifrx-20231231.xsd#ifrx_NetFinancialResult"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetFinancialResult_lbl" xml:lang="en-US">Net financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetFinancialResult" xlink:to="ifrx_NetFinancialResult_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">Schedule of Share-Based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Exercisable at December 31 (in Euro per share and Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US">Schedule of Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOpionsExercisedDuring" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOpionsExercisedDuring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfOpionsExercisedDuring_lbl" xml:lang="en-US">Options, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOpionsExercisedDuring" xlink:to="ifrx_NumberOfOpionsExercisedDuring_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfSharesExercisedDuring" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfSharesExercisedDuring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfSharesExercisedDuring_lbl" xml:lang="en-US">WAEP, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfSharesExercisedDuring" xlink:to="ifrx_NumberOfSharesExercisedDuring_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfSharesOptionsExercisable" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfSharesOptionsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfSharesOptionsExercisable_lbl" xml:lang="en-US">Options, Exercisable at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfSharesOptionsExercisable" xlink:to="ifrx_NumberOfSharesOptionsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WAEPExercisables" xlink:href="ifrx-20231231.xsd#ifrx_WAEPExercisables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WAEPExercisables_lbl" xml:lang="en-US">WAEP,Exercisable at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WAEPExercisables" xlink:to="ifrx_WAEPExercisables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options, Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">WAEP, Granted during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options, Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">WAEP, Forfeited during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">WAEP, Exercised during the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">Options, Exercisable at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" xlink:to="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement_lbl" xml:lang="en-US">WAEP,Exercisable at December 31</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_a2021Abstract" xlink:href="ifrx-20231231.xsd#ifrx_a2021Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_a2021Abstract_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_a2021Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareOptionsGrantedOptions" xlink:href="ifrx-20231231.xsd#ifrx_ShareOptionsGrantedOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ShareOptionsGrantedOptions_lbl" xml:lang="en-US">Options	(in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareOptionsGrantedOptions" xlink:to="ifrx_ShareOptionsGrantedOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FairValuePerOptions" xlink:href="ifrx-20231231.xsd#ifrx_FairValuePerOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FairValuePerOptions_lbl" xml:lang="en-US">Fair value per option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FairValuePerOptions" xlink:to="ifrx_FairValuePerOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeRateAsOfGrantDate" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeRateAsOfGrantDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ForeignExchangeRateAsOfGrantDate_lbl" xml:lang="en-US">FX rate as of grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeRateAsOfGrantDate" xlink:to="ifrx_ForeignExchangeRateAsOfGrantDate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FairValuesPerOptions" xlink:href="ifrx-20231231.xsd#ifrx_FairValuesPerOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FairValuesPerOptions_lbl" xml:lang="en-US">Fair value per option	(in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FairValuesPerOptions" xlink:to="ifrx_FairValuesPerOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SharePriceAtGrantDateExercisePrices" xlink:href="ifrx-20231231.xsd#ifrx_SharePriceAtGrantDateExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SharePriceAtGrantDateExercisePrices_lbl" xml:lang="en-US">Share price at grant date / Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SharePriceAtGrantDateExercisePrices" xlink:to="ifrx_SharePriceAtGrantDateExercisePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Volatility rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Expected life (midpoint based)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free rate (interpolated, U.S. sovereign strips curve)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_a2022Abstract" xlink:href="ifrx-20231231.xsd#ifrx_a2022Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_a2022Abstract_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_a2022Abstract" xlink:to="ifrx_a2022Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_a2023Abstract" xlink:href="ifrx-20231231.xsd#ifrx_a2023Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_a2023Abstract_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_a2023Abstract" xlink:to="ifrx_a2023Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">Notes to the consolidated statements of financial position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment" xlink:href="ifrx-20231231.xsd#ifrx_DisposalsAndRetirementPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment" xlink:to="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract6" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract6"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract6_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract6" xlink:to="ifrx_UnlabeledAbstract6_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccumulatedDepreciationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedDepreciationAbstract" xlink:to="ifrx_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract7" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract7"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract7_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract7" xlink:to="ifrx_UnlabeledAbstract7_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetBookValueAbstract_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueAbstract" xlink:to="ifrx_NetBookValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValuePropertyAndEquipment" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValuePropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetBookValuePropertyAndEquipment_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValuePropertyAndEquipment" xlink:to="ifrx_NetBookValuePropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions_lbl" xml:lang="en-US">Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract8" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract8"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract8_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract8" xlink:to="ifrx_UnlabeledAbstract8_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccumulatedDepreciationAbstract0" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedDepreciationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AccumulatedDepreciationAbstract0_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedDepreciationAbstract0" xlink:to="ifrx_AccumulatedDepreciationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract9" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract9"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract9_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract9" xlink:to="ifrx_UnlabeledAbstract9_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueAbstract0" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetBookValueAbstract0_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueAbstract0" xlink:to="ifrx_NetBookValueAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueOfRightOfUseAsset" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueOfRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetBookValueOfRightOfUseAsset_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueOfRightOfUseAsset" xlink:to="ifrx_NetBookValueOfRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill_lbl" xml:lang="en-US">Exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract10" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract10"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract10_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract10" xlink:to="ifrx_UnlabeledAbstract10_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccumulatedAmortizationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedAmortizationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AccumulatedAmortizationAbstract_lbl" xml:lang="en-US">Accumulated amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedAmortizationAbstract" xlink:to="ifrx_AccumulatedAmortizationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnlabeledAbstract11" xlink:href="ifrx-20231231.xsd#ifrx_UnlabeledAbstract11"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnlabeledAbstract11_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract11" xlink:to="ifrx_UnlabeledAbstract11_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueAbstract1" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetBookValueAbstract1_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueAbstract1" xlink:to="ifrx_NetBookValueAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetBookValueIntangibleAsset" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueIntangibleAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetBookValueIntangibleAsset_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueIntangibleAsset" xlink:to="ifrx_NetBookValueIntangibleAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasePrepaymentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory_lbl" xml:lang="en-US">Schedule of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" xlink:to="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Short-term liability for accrued interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" xlink:href="ifrx-20231231.xsd#ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax_lbl" xml:lang="en-US">Foreign exchange difference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" xlink:to="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory_lbl" xml:lang="en-US">Schedule of Amounts Recognized in Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InAbstract0" xlink:href="ifrx-20231231.xsd#ifrx_InAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InAbstract0_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract0" xlink:to="ifrx_InAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Depreciation expense of right-of-use assets (see Note E.2.)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnBonds" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBonds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnBonds_lbl" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBonds" xlink:to="ifrs-full_InterestExpenseOnBonds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US">Rental expense from leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US">Thereof short-term leases (included in administrative expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl" xml:lang="en-US">Thereof leases of low-value assets (included in administrative expenses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Total amounts recognized in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InAbstract1" xlink:href="ifrx-20231231.xsd#ifrx_InAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InAbstract1_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract1" xlink:to="ifrx_InAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xml:lang="en-US">Raw material and supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnfinishedGoods" xlink:href="ifrx-20231231.xsd#ifrx_UnfinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnfinishedGoods_lbl" xml:lang="en-US">Unfinished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnfinishedGoods" xlink:to="ifrx_UnfinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InAbstract2" xlink:href="ifrx-20231231.xsd#ifrx_InAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InAbstract2_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract2" xlink:to="ifrx_InAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PrepaidExpense" xlink:href="ifrx-20231231.xsd#ifrx_PrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_PrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PrepaidExpense" xlink:to="ifrx_PrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonCurrentOtherAssets" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonCurrentOtherAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentOtherAssets" xlink:to="ifrx_NonCurrentOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentOtherAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_CurrentOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CurrentOtherAssetsAbstract_lbl" xml:lang="en-US">Current other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentOtherAssetsAbstract" xlink:to="ifrx_CurrentOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Prepayments_lbl" xml:lang="en-US">Prepayments on research &amp; development projects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAdjustmentsToReconcileProfitLoss_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="ifrs-full_OtherAdjustmentsToReconcileProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalOtherAsset" xlink:href="ifrx-20231231.xsd#ifrx_TotalOtherAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TotalOtherAsset_lbl" xml:lang="en-US">Total other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalOtherAsset" xlink:to="ifrx_TotalOtherAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory_lbl" xml:lang="en-US">Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss for the period (accounting profit before income tax)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TaxRate_lbl" xml:lang="en-US">Tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxRate" xlink:to="ifrx_TaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxBenefitsAtTaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TaxBenefitsAtTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TaxBenefitsAtTaxRate_lbl" xml:lang="en-US">Tax benefits at tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxBenefitsAtTaxRate" xlink:to="ifrx_TaxBenefitsAtTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" xlink:href="ifrx-20231231.xsd#ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone_lbl" xml:lang="en-US">Temporary differences and tax losses for which no deferred tax asset was recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" xlink:to="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment" xlink:href="ifrx-20231231.xsd#ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment_lbl" xml:lang="en-US">Non-recognition of tax effect on share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment" xlink:to="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NondeductibleExpensesForTaxPurposesinDollars" xlink:href="ifrx-20231231.xsd#ifrx_NondeductibleExpensesForTaxPurposesinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NondeductibleExpensesForTaxPurposesinDollars_lbl" xml:lang="en-US">Non-deductible expenses for tax purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NondeductibleExpensesForTaxPurposesinDollars" xlink:to="ifrx_NondeductibleExpensesForTaxPurposesinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherDifferencesDueToTaxRateinDollars" xlink:href="ifrx-20231231.xsd#ifrx_OtherDifferencesDueToTaxRateinDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OtherDifferencesDueToTaxRateinDollars_lbl" xml:lang="en-US">Other differences due to tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherDifferencesDueToTaxRateinDollars" xlink:to="ifrx_OtherDifferencesDueToTaxRateinDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancialAssetsAtAmortizedCostAbstract" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsAtAmortizedCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FinancialAssetsAtAmortizedCostAbstract_lbl" xml:lang="en-US">Financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="ifrx_FinancialAssetsAtAmortizedCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancialAssetsFromGovernmentGrants" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FinancialAssetsFromGovernmentGrants_lbl" xml:lang="en-US">Financial assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsFromGovernmentGrants" xlink:to="ifrx_FinancialAssetsFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:href="ifrx-20231231.xsd#ifrx_FinancialLiabilitiesAtAmortizedCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl" xml:lang="en-US">Financial liabilities at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LiabilitiesFromGovernmentGrants" xlink:href="ifrx-20231231.xsd#ifrx_LiabilitiesFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LiabilitiesFromGovernmentGrants_lbl" xml:lang="en-US">Liabilities from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LiabilitiesFromGovernmentGrants" xlink:to="ifrx_LiabilitiesFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InAbstract3" xlink:href="ifrx-20231231.xsd#ifrx_InAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InAbstract3_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract3" xlink:to="ifrx_InAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShortTermDepositsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ShortTermDepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ShortTermDepositsAbstract_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShortTermDepositsAbstract" xlink:to="ifrx_ShortTermDepositsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashAtBanksAbstract" xlink:href="ifrx-20231231.xsd#ifrx_CashAtBanksAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CashAtBanksAbstract_lbl" xml:lang="en-US">Cash at banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashAtBanksAbstract" xlink:to="ifrx_CashAtBanksAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US">Cash at banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">Schedule of Trade and Other Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InAbstract4" xlink:href="ifrx-20231231.xsd#ifrx_InAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InAbstract4_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract4" xlink:to="ifrx_InAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued liabilities from R&amp;D projects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccruedLiabilitiesFromCommercialActivities" xlink:href="ifrx-20231231.xsd#ifrx_AccruedLiabilitiesFromCommercialActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AccruedLiabilitiesFromCommercialActivities_lbl" xml:lang="en-US">Accrued liabilities from commercial activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccruedLiabilitiesFromCommercialActivities" xlink:to="ifrx_AccruedLiabilitiesFromCommercialActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US">Other accrued liabilities and payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMarketRiskExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl" xml:lang="en-US">Schedule of Market Risk, Credit Risk and Liquidity Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:to="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExposureToRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExposureToRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExposureToRisk_lbl" xml:lang="en-US">Exposure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExposureToRisk" xlink:to="ifrs-full_DescriptionOfExposureToRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets_lbl" xml:lang="en-US">Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" xlink:to="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets_lbl" xml:lang="en-US">Risk Management</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" xlink:to="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:to="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest_lbl" xml:lang="en-US">Current and non current financial assets (securities and accrued interest)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract" xlink:href="ifrx-20231231.xsd#ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract_lbl" xml:lang="en-US">Conversion rate Euro to U.S. dollars at reporting date 1/1.1050</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract" xlink:to="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl" xml:lang="en-US">Schedule of Sensitivity Analysis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SensitivityAnalysisConversionRate" xlink:href="ifrx-20231231.xsd#ifrx_SensitivityAnalysisConversionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SensitivityAnalysisConversionRate_lbl" xml:lang="en-US">Conversion rate (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SensitivityAnalysisConversionRate" xlink:to="ifrx_SensitivityAnalysisConversionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SensitivityAnalysisCarryingAmount" xlink:href="ifrx-20231231.xsd#ifrx_SensitivityAnalysisCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SensitivityAnalysisCarryingAmount_lbl" xml:lang="en-US">carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SensitivityAnalysisCarryingAmount" xlink:to="ifrx_SensitivityAnalysisCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl" xml:lang="en-US">Schedule of Outstanding Financial Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BalancesWithBanks" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BalancesWithBanks_lbl" xml:lang="en-US">Cash at banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DebtSecurities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DebtSecurities_lbl" xml:lang="en-US">Marketable Securities (current and non-current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DebtSecurities" xlink:to="ifrs-full_DebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_lbl" xml:lang="en-US">Other (non-current portion)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:to="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_lbl" xml:lang="en-US">Other (current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:to="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalFundsAvailable" xlink:href="ifrx-20231231.xsd#ifrx_TotalFundsAvailable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TotalFundsAvailable_lbl" xml:lang="en-US">Total funds available</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalFundsAvailable" xlink:to="ifrx_TotalFundsAvailable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US">Contractual minimum lease obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_EffectOfDiscounting" xlink:href="ifrx-20231231.xsd#ifrx_EffectOfDiscounting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_EffectOfDiscounting_lbl" xml:lang="en-US">Effect of discounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectOfDiscounting" xlink:to="ifrx_EffectOfDiscounting_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDeferredTaxLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxLiabilities" xlink:to="ifrs-full_NetDeferredTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalLeases" xlink:href="ifrx-20231231.xsd#ifrx_TotalLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TotalLeases_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalLeases" xlink:to="ifrx_TotalLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" xlink:href="ifrx-20231231.xsd#ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US">Low value leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US">Short-term leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CapitalizedLeases" xlink:href="ifrx-20231231.xsd#ifrx_CapitalizedLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CapitalizedLeases_lbl" xml:lang="en-US">Capitalized leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CapitalizedLeases" xlink:to="ifrx_CapitalizedLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory_lbl" xml:lang="en-US">Other information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory_lbl" xml:lang="en-US">Schedule of Compensation of the Group&#8217;s Executive Management</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" xlink:to="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveManagementAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExecutiveManagementAbstract_lbl" xml:lang="en-US">Executive management</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExecutiveManagementAbstract" xlink:to="ifrx_ExecutiveManagementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermEmployeeBenefits" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="ifrx-20231231.xsd#ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonExecutiveBoardOfDirectorsMembersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract_lbl" xml:lang="en-US">Non-executive Board of Directors members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract" xlink:to="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalCompensation" xlink:href="ifrx-20231231.xsd#ifrx_TotalCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TotalCompensation_lbl" xml:lang="en-US">Total Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalCompensation" xlink:to="ifrx_TotalCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">Significant events after the reporting date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ForeignExchangeExpense" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrx_ForeignExchangeExpense_lbl" xml:lang="en-US">Foreign exchange expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeExpense" xlink:to="ifrx_ForeignExchangeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" xlink:href="ifrx-20231231.xsd#ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease_lbl" xml:lang="en-US">Depreciation charge for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" xlink:to="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US">Depreciation charge for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" xlink:href="ifrx-20231231.xsd#ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" xlink:to="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US">Amortization charge for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl" xml:lang="en-US">Derecognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InflaRxGmbHMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxGmbHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InflaRxGmbHMember_lbl" xml:lang="en-US">InflaRx GmbH [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InflaRxGmbHMember" xlink:to="ifrx_InflaRxGmbHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InflaRxPharmaceuticalIncMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxPharmaceuticalIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InflaRxPharmaceuticalIncMember_lbl" xml:lang="en-US">InflaRx Pharmaceuticals, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InflaRxPharmaceuticalIncMember" xlink:to="ifrx_InflaRxPharmaceuticalIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ThirdpartyExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_ThirdpartyExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ThirdpartyExpensesMember_lbl" xml:lang="en-US">Third-party expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ThirdpartyExpensesMember" xlink:to="ifrx_ThirdpartyExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_EmployeeBenefitsExpensesMember_lbl" xml:lang="en-US">Employee benefits expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EmployeeBenefitsExpensesMember" xlink:to="ifrx_EmployeeBenefitsExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember_lbl" xml:lang="en-US">equity-settled share-based payment expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember_lbl0" xml:lang="en-US">Equity-settled share-based payment expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LegalAndConsultingFeesMember_lbl" xml:lang="en-US">Legal and consulting fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LegalAndConsultingFeesMember" xlink:to="ifrx_LegalAndConsultingFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OtherExpensesMember_lbl" xml:lang="en-US">Other expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherExpensesMember" xlink:to="ifrx_OtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ThirdpartyServicesMember" xlink:href="ifrx-20231231.xsd#ifrx_ThirdpartyServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ThirdpartyServicesMember_lbl" xml:lang="en-US">Third-party services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ThirdpartyServicesMember" xlink:to="ifrx_ThirdpartyServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ManufacturingOfClinicalMaterialMember" xlink:href="ifrx-20231231.xsd#ifrx_ManufacturingOfClinicalMaterialMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ManufacturingOfClinicalMaterialMember_lbl" xml:lang="en-US">Clinical material and related manufacturing services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ManufacturingOfClinicalMaterialMember" xlink:to="ifrx_ManufacturingOfClinicalMaterialMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_clinicalPreclinicalStudiesMember" xlink:href="ifrx-20231231.xsd#ifrx_clinicalPreclinicalStudiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_clinicalPreclinicalStudiesMember_lbl" xml:lang="en-US">Clinical, pre-clinical studies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_clinicalPreclinicalStudiesMember" xlink:to="ifrx_clinicalPreclinicalStudiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_InsuranceExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_InsuranceExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_InsuranceExpensesMember_lbl" xml:lang="en-US">Insurance expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InsuranceExpensesMember" xlink:to="ifrx_InsuranceExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DepreciationAmortizationExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_DepreciationAmortizationExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DepreciationAmortizationExpenseMember_lbl" xml:lang="en-US">Depreciation &amp; amortization expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DepreciationAmortizationExpenseMember" xlink:to="ifrx_DepreciationAmortizationExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember" xlink:href="ifrx-20231231.xsd#ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember_lbl" xml:lang="en-US">Compensation expense for non-executive directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember" xlink:to="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WagesAndSalariesMember" xlink:href="ifrx-20231231.xsd#ifrx_WagesAndSalariesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WagesAndSalariesMember_lbl" xml:lang="en-US">Wages and salaries [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WagesAndSalariesMember" xlink:to="ifrx_WagesAndSalariesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SocialSecurityContributionsemployersShareMember" xlink:href="ifrx-20231231.xsd#ifrx_SocialSecurityContributionsemployersShareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SocialSecurityContributionsemployersShareMember_lbl" xml:lang="en-US">Social security contributions (employer&apos;s share) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SocialSecurityContributionsemployersShareMember" xlink:to="ifrx_SocialSecurityContributionsemployersShareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_EquitysettledSharebasedPaymentExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_EquitysettledSharebasedPaymentExpensesMember_lbl" xml:lang="en-US">Equity-settled share-based payment expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EquitysettledSharebasedPaymentExpensesMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OtherMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherMember" xlink:to="ifrx_OtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OptionsMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsMember" xlink:to="ifrx_OptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WAEPMember_lbl" xml:lang="en-US">WAEP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WAEPMember" xlink:to="ifrx_WAEPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionPlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_OptionPlan2016Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OptionPlan2016Member_lbl" xml:lang="en-US">2016 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionPlan2016Member" xlink:to="ifrx_OptionPlan2016Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LongTermIncentivePlan2017Member_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LongTermIncentivePlan2017Member" xlink:to="ifrx_LongTermIncentivePlan2017Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrx_LongTermIncentivePlan2017Member_lbl0" xml:lang="en-US">Long-Term Incentive Plan 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LongTermIncentivePlan2017Member" xlink:to="ifrx_LongTermIncentivePlan2017Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="ifrx_LongTermIncentivePlan2017Member_lbl1" xml:lang="en-US">2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LongTermIncentivePlan2017Member" xlink:to="ifrx_LongTermIncentivePlan2017Member_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl0" xml:lang="en-US">Top of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl0" xml:lang="en-US">Bottom of Range [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_January4Member" xlink:href="ifrx-20231231.xsd#ifrx_January4Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_January4Member_lbl" xml:lang="en-US">January 4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January4Member" xlink:to="ifrx_January4Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_January4OneMember" xlink:href="ifrx-20231231.xsd#ifrx_January4OneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_January4OneMember_lbl" xml:lang="en-US">January 4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January4OneMember" xlink:to="ifrx_January4OneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_July2Member" xlink:href="ifrx-20231231.xsd#ifrx_July2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_July2Member_lbl" xml:lang="en-US">July 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_July2Member" xlink:to="ifrx_July2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_July2OneMember" xlink:href="ifrx-20231231.xsd#ifrx_July2OneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_July2OneMember_lbl" xml:lang="en-US">July 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_July2OneMember" xlink:to="ifrx_July2OneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_January12Member" xlink:href="ifrx-20231231.xsd#ifrx_January12Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_January12Member_lbl" xml:lang="en-US">January 12 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January12Member" xlink:to="ifrx_January12Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_January12OneMember" xlink:href="ifrx-20231231.xsd#ifrx_January12OneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_January12OneMember_lbl" xml:lang="en-US">January 12 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January12OneMember" xlink:to="ifrx_January12OneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_RepricingApril13Member" xlink:href="ifrx-20231231.xsd#ifrx_RepricingApril13Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_RepricingApril13Member_lbl" xml:lang="en-US">Repricing, April 13 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RepricingApril13Member" xlink:to="ifrx_RepricingApril13Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_November21Member" xlink:href="ifrx-20231231.xsd#ifrx_November21Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_November21Member_lbl" xml:lang="en-US">November 21 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_November21Member" xlink:to="ifrx_November21Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_JanuaryTwentyFourMember" xlink:href="ifrx-20231231.xsd#ifrx_JanuaryTwentyFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_JanuaryTwentyFourMember_lbl" xml:lang="en-US">January 24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JanuaryTwentyFourMember" xlink:to="ifrx_JanuaryTwentyFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_JanuaryTwentyFourOneMember" xlink:href="ifrx-20231231.xsd#ifrx_JanuaryTwentyFourOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_JanuaryTwentyFourOneMember_lbl" xml:lang="en-US">January 24 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JanuaryTwentyFourOneMember" xlink:to="ifrx_JanuaryTwentyFourOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MayThirtyOneMember" xlink:href="ifrx-20231231.xsd#ifrx_MayThirtyOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_MayThirtyOneMember_lbl" xml:lang="en-US">May 31 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MayThirtyOneMember" xlink:to="ifrx_MayThirtyOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_JulySevenMember" xlink:href="ifrx-20231231.xsd#ifrx_JulySevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_JulySevenMember_lbl" xml:lang="en-US">July 7 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JulySevenMember" xlink:to="ifrx_JulySevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_JulySevenOneMember" xlink:href="ifrx-20231231.xsd#ifrx_JulySevenOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_JulySevenOneMember_lbl" xml:lang="en-US">July 7 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JulySevenOneMember" xlink:to="ifrx_JulySevenOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_JulyNineteenMember" xlink:href="ifrx-20231231.xsd#ifrx_JulyNineteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_JulyNineteenMember_lbl" xml:lang="en-US">July 19 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JulyNineteenMember" xlink:to="ifrx_JulyNineteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SeptemberEighteenMember" xlink:href="ifrx-20231231.xsd#ifrx_SeptemberEighteenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SeptemberEighteenMember_lbl" xml:lang="en-US">September 18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SeptemberEighteenMember" xlink:to="ifrx_SeptemberEighteenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CostMember_lbl" xml:lang="en-US">Cost [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CostMember" xlink:to="ifrx_CostMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US">Accumulated depreciation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdvancePaymentsMember" xlink:href="ifrx-20231231.xsd#ifrx_AdvancePaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AdvancePaymentsMember_lbl" xml:lang="en-US">Advance payments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdvancePaymentsMember" xlink:to="ifrx_AdvancePaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_VehiclesMember_lbl" xml:lang="en-US">Cars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_VehiclesMember" xlink:to="ifrs-full_VehiclesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccumulatedAmortizationMember" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedAmortizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AccumulatedAmortizationMember_lbl" xml:lang="en-US">Accumulated amortization [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedAmortizationMember" xlink:to="ifrx_AccumulatedAmortizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerSoftwareMember_lbl" xml:lang="en-US">Purchased IT-software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerSoftwareMember" xlink:to="ifrs-full_ComputerSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AdvancesPaidForSoftwareMember" xlink:href="ifrx-20231231.xsd#ifrx_AdvancesPaidForSoftwareMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AdvancesPaidForSoftwareMember_lbl" xml:lang="en-US">Advances paid for software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdvancesPaidForSoftwareMember" xlink:to="ifrx_AdvancesPaidForSoftwareMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DepositsHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_DepositsHeldInUSDollarsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DepositsHeldInUSDollarsMember_lbl" xml:lang="en-US">Deposits held in U.S. dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DepositsHeldInUSDollarsMember" xlink:to="ifrx_DepositsHeldInUSDollarsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DepositsHeldInEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_DepositsHeldInEuroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DepositsHeldInEuroMember_lbl" xml:lang="en-US">Deposits held in Euro [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DepositsHeldInEuroMember" xlink:to="ifrx_DepositsHeldInEuroMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSDollarsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CashHeldInUSDollarsMember_lbl" xml:lang="en-US">Cash held in U.S. dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashHeldInUSDollarsMember" xlink:to="ifrx_CashHeldInUSDollarsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrx_CashHeldInUSDollarsMember_lbl0" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashHeldInUSDollarsMember" xlink:to="ifrx_CashHeldInUSDollarsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_CashHeldInUSEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSEuroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CashHeldInUSEuroMember_lbl" xml:lang="en-US">Cash held in U.S. Euro [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashHeldInUSEuroMember" xlink:to="ifrx_CashHeldInUSEuroMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrx_CashHeldInUSEuroMember_lbl0" xml:lang="en-US">Euro [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashHeldInUSEuroMember" xlink:to="ifrx_CashHeldInUSEuroMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MarketRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MarketRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MarketRiskMember_lbl" xml:lang="en-US">Market risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MarketRiskMember" xlink:to="ifrs-full_MarketRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US">Credit risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl0" xml:lang="en-US">Credit Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiquidityRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xml:lang="en-US">Liquidity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeakensAgainstMember" xlink:href="ifrx-20231231.xsd#ifrx_WeakensAgainstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WeakensAgainstMember_lbl" xml:lang="en-US">Euro weakens against U.S. dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeakensAgainstMember" xlink:to="ifrx_WeakensAgainstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_StrengthsAgainstMember" xlink:href="ifrx-20231231.xsd#ifrx_StrengthsAgainstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_StrengthsAgainstMember_lbl" xml:lang="en-US">Euro strengths against U.S. dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_StrengthsAgainstMember" xlink:to="ifrx_StrengthsAgainstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WithinOneYearMember" xlink:href="ifrx-20231231.xsd#ifrx_WithinOneYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WithinOneYearMember_lbl" xml:lang="en-US">Within one year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WithinOneYearMember" xlink:to="ifrx_WithinOneYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AfterOneYearButNotMoreThanFiveYearsMember" xlink:href="ifrx-20231231.xsd#ifrx_AfterOneYearButNotMoreThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AfterOneYearButNotMoreThanFiveYearsMember_lbl" xml:lang="en-US">After one year but not more than five years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AfterOneYearButNotMoreThanFiveYearsMember" xlink:to="ifrx_AfterOneYearButNotMoreThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MoreThanFiveYearsMember" xlink:href="ifrx-20231231.xsd#ifrx_MoreThanFiveYearsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_MoreThanFiveYearsMember_lbl" xml:lang="en-US">More than five years [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MoreThanFiveYearsMember" xlink:to="ifrx_MoreThanFiveYearsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveManagementMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExecutiveManagementMember_lbl" xml:lang="en-US">Executive Management [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExecutiveManagementMember" xlink:to="ifrx_ExecutiveManagementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonexecutiveBoardOfDirectorsMember" xlink:href="ifrx-20231231.xsd#ifrx_NonexecutiveBoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonexecutiveBoardOfDirectorsMember_lbl" xml:lang="en-US">Non-executive Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonexecutiveBoardOfDirectorsMember" xlink:to="ifrx_NonexecutiveBoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis_lbl" xml:lang="en-US">Property, plant and equipment by operating lease status [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncomeStatementLocationAxis" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncomeStatementLocationAxis" xlink:to="ifrx_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansAxis_lbl" xml:lang="en-US">Defined benefit plans [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateCurrencyAxis" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExchangeRateCurrencyAxis_lbl" xml:lang="en-US">Exchange Rate Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRateCurrencyAxis" xlink:to="ifrx_ExchangeRateCurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LocationAxis" xlink:href="ifrx-20231231.xsd#ifrx_LocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LocationAxis_lbl" xml:lang="en-US">Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LocationAxis" xlink:to="ifrx_LocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AccountingPoliciesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccountingPoliciesAbstract" xlink:to="ifrx_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US">German federal government</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant_lbl" xml:lang="en-US">Grant payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" xlink:to="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PercentageOfGrant" xlink:href="ifrx-20231231.xsd#ifrx_PercentageOfGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_PercentageOfGrant_lbl" xml:lang="en-US">Percentage of grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PercentageOfGrant" xlink:to="ifrx_PercentageOfGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_RentalContractsFixedPeriod" xlink:href="ifrx-20231231.xsd#ifrx_RentalContractsFixedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_RentalContractsFixedPeriod_lbl" xml:lang="en-US">Rental contracts fixed period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RentalContractsFixedPeriod" xlink:to="ifrx_RentalContractsFixedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AmortizedPeriod" xlink:href="ifrx-20231231.xsd#ifrx_AmortizedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AmortizedPeriod_lbl" xml:lang="en-US">Amortized period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AmortizedPeriod" xlink:to="ifrx_AmortizedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AnnualizedAverageSharePricePeriod" xlink:href="ifrx-20231231.xsd#ifrx_AnnualizedAverageSharePricePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AnnualizedAverageSharePricePeriod_lbl" xml:lang="en-US">Annualized average share price year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AnnualizedAverageSharePricePeriod" xlink:to="ifrx_AnnualizedAverageSharePricePeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccruedIncomeIncludingContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets_lbl" xml:lang="en-US">Accrued payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccruedIncomeIncludingContractAssets" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoryWritedown2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US">Inventory write-downs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingExpense_lbl" xml:lang="en-US">Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingExpense" xlink:to="ifrs-full_SellingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinanceCost_lbl" xml:lang="en-US">Personnel cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceCost" xlink:to="ifrs-full_OtherFinanceCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetFinancialCost" xlink:href="ifrx-20231231.xsd#ifrx_NetFinancialCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetFinancialCost_lbl" xml:lang="en-US">Net financial cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetFinancialCost" xlink:to="ifrx_NetFinancialCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl" xml:lang="en-US">Interest income increased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShortTermMarketableSecurities" xlink:href="ifrx-20231231.xsd#ifrx_ShortTermMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ShortTermMarketableSecurities_lbl" xml:lang="en-US">Short term marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShortTermMarketableSecurities" xlink:to="ifrx_ShortTermMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xml:lang="en-US">Foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ForeignExchangeGain_lbl" xml:lang="en-US">Gain on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeGain" xlink:to="ifrs-full_ForeignExchangeGain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ForeignExchangeLoss_lbl" xml:lang="en-US">Loss on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_lbl" xml:lang="en-US">Allowance for credit loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:to="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedNumberOfCommonSharesOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_WeightedNumberOfCommonSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WeightedNumberOfCommonSharesOutstanding_lbl" xml:lang="en-US">Weighted number of common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedNumberOfCommonSharesOutstanding" xlink:to="ifrx_WeightedNumberOfCommonSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LossPerShare" xlink:href="ifrx-20231231.xsd#ifrx_LossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LossPerShare_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LossPerShare" xlink:to="ifrx_LossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExercisePriceOfOutstandingShareOptions" xlink:href="ifrx-20231231.xsd#ifrx_ExercisePriceOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExercisePriceOfOutstandingShareOptions_lbl" xml:lang="en-US">Exercise price for options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExercisePriceOfOutstandingShareOptions" xlink:to="ifrx_ExercisePriceOfOutstandingShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConversionRate" xlink:href="ifrx-20231231.xsd#ifrx_ConversionRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ConversionRate_lbl" xml:lang="en-US">Conversion rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConversionRate" xlink:to="ifrx_ConversionRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AverageRate" xlink:href="ifrx-20231231.xsd#ifrx_AverageRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AverageRate_lbl" xml:lang="en-US">Average rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AverageRate" xlink:to="ifrx_AverageRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:to="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaximumNumberOfCommonSharesAvailableForGrant" xlink:href="ifrx-20231231.xsd#ifrx_MaximumNumberOfCommonSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_MaximumNumberOfCommonSharesAvailableForGrant_lbl" xml:lang="en-US">Maximum number of common shares available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaximumNumberOfCommonSharesAvailableForGrant" xlink:to="ifrx_MaximumNumberOfCommonSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ordinarySharesPercentage" xlink:href="ifrx-20231231.xsd#ifrx_ordinarySharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ordinarySharesPercentage_lbl" xml:lang="en-US">Ordinary shares percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ordinarySharesPercentage" xlink:to="ifrx_ordinarySharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear_lbl" xml:lang="en-US">weighted average fair value of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear" xlink:to="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd_lbl" xml:lang="en-US">Weighted average fair value options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" xlink:to="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExercisePriceRange" xlink:href="ifrx-20231231.xsd#ifrx_ExercisePriceRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExercisePriceRange_lbl" xml:lang="en-US">Exercise price range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExercisePriceRange" xlink:to="ifrx_ExercisePriceRange_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsGranted" xlink:href="ifrx-20231231.xsd#ifrx_OptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OptionsGranted_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsGranted" xlink:to="ifrx_OptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfStockOptionsForfeited" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfStockOptionsForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfStockOptionsForfeited_lbl" xml:lang="en-US">Options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfStockOptionsForfeited" xlink:to="ifrx_NumberOfStockOptionsForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NumberOfOptionsExercised" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NumberOfOptionsExercised_lbl" xml:lang="en-US">Options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOptionsExercised" xlink:to="ifrx_NumberOfOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExpectedDividends" xlink:href="ifrx-20231231.xsd#ifrx_ExpectedDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExpectedDividends_lbl" xml:lang="en-US">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExpectedDividends" xlink:to="ifrx_ExpectedDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ResearchAndDevelopmentExpenses" xlink:href="ifrx-20231231.xsd#ifrx_ResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ResearchAndDevelopmentExpenses" xlink:to="ifrx_ResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WritedownsReversalsOfInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WritedownsReversalsOfInventories_lbl" xml:lang="en-US">Inventory write-downs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WritedownsReversalsOfInventories" xlink:to="ifrs-full_WritedownsReversalsOfInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CorporateIncomeTax" xlink:href="ifrx-20231231.xsd#ifrx_CorporateIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CorporateIncomeTax_lbl" xml:lang="en-US">Corporate Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CorporateIncomeTax" xlink:to="ifrx_CorporateIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SolidaritySurcharge" xlink:href="ifrx-20231231.xsd#ifrx_SolidaritySurcharge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SolidaritySurcharge_lbl" xml:lang="en-US">Solidarity surcharge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SolidaritySurcharge" xlink:to="ifrx_SolidaritySurcharge_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TradeTaxes" xlink:href="ifrx-20231231.xsd#ifrx_TradeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TradeTaxes_lbl" xml:lang="en-US">Trade taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TradeTaxes" xlink:to="ifrx_TradeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl" xml:lang="en-US">Average total tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TotalTaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TotalTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TotalTaxRate_lbl" xml:lang="en-US">Total tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalTaxRate" xlink:to="ifrx_TotalTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" xlink:href="ifrx-20231231.xsd#ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent_lbl" xml:lang="en-US">Federal tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" xlink:href="ifrx-20231231.xsd#ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent_lbl" xml:lang="en-US">State tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax_lbl" xml:lang="en-US">Total tax loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl" xml:lang="en-US">Unused tax losses carried forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes" xlink:href="ifrx-20231231.xsd#ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes_lbl" xml:lang="en-US">Corporate income and trade tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes" xlink:to="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xml:lang="en-US">Tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxLossCarryforwards" xlink:href="ifrx-20231231.xsd#ifrx_TaxLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TaxLossCarryforwards_lbl" xml:lang="en-US">Tax loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxLossCarryforwards" xlink:to="ifrx_TaxLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_TaxableIncome" xlink:href="ifrx-20231231.xsd#ifrx_TaxableIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_TaxableIncome_lbl" xml:lang="en-US">Taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxableIncome" xlink:to="ifrx_TaxableIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInterestReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInterestReceivable_lbl" xml:lang="en-US">Current income tax receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInterestReceivable" xlink:to="ifrs-full_CurrentInterestReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssets_lbl" xml:lang="en-US">Current and non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentAndNonCurrentFinancialAssets" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FixedInterest" xlink:href="ifrx-20231231.xsd#ifrx_FixedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FixedInterest_lbl" xml:lang="en-US">Nominal fixed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FixedInterest" xlink:to="ifrx_FixedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_FinancialAssetsFromGovernmentGrantsAmount" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsFromGovernmentGrantsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_FinancialAssetsFromGovernmentGrantsAmount_lbl" xml:lang="en-US">Financial assets from government grants amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsFromGovernmentGrantsAmount" xlink:to="ifrx_FinancialAssetsFromGovernmentGrantsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DueAmount" xlink:href="ifrx-20231231.xsd#ifrx_DueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DueAmount_lbl" xml:lang="en-US">Due amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DueAmount" xlink:to="ifrx_DueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CapitalOrdinarySharesIssued" xlink:href="ifrx-20231231.xsd#ifrx_CapitalOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CapitalOrdinarySharesIssued_lbl" xml:lang="en-US">Capital ordinary shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CapitalOrdinarySharesIssued" xlink:to="ifrx_CapitalOrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Nominal value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommonShares" xlink:href="ifrx-20231231.xsd#ifrx_CommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CommonShares_lbl" xml:lang="en-US">Common shares over time (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonShares" xlink:to="ifrx_CommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommonSharesIssued" xlink:href="ifrx-20231231.xsd#ifrx_CommonSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CommonSharesIssued_lbl" xml:lang="en-US">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonSharesIssued" xlink:to="ifrx_CommonSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount" xlink:href="ifrx-20231231.xsd#ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount_lbl" xml:lang="en-US">Sales agreement amounts (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount" xlink:to="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NetProceeds" xlink:href="ifrx-20231231.xsd#ifrx_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NetProceeds_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetProceeds" xlink:to="ifrx_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AggregateCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_AggregateCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AggregateCommonShares_lbl" xml:lang="en-US">Aggregate ordinary shares sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregateCommonShares" xlink:to="ifrx_AggregateCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl" xml:lang="en-US">share sold (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ProceedsOfferingCost" xlink:href="ifrx-20231231.xsd#ifrx_ProceedsOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ProceedsOfferingCost_lbl" xml:lang="en-US">Proceeds offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ProceedsOfferingCost" xlink:to="ifrx_ProceedsOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnderwritingDiscounts" xlink:href="ifrx-20231231.xsd#ifrx_UnderwritingDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnderwritingDiscounts_lbl" xml:lang="en-US">Underwriting Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnderwritingDiscounts" xlink:to="ifrx_UnderwritingDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US">Other offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ProceedsFromOfferingCost" xlink:href="ifrx-20231231.xsd#ifrx_ProceedsFromOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ProceedsFromOfferingCost_lbl" xml:lang="en-US">Net proceeds from offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ProceedsFromOfferingCost" xlink:to="ifrx_ProceedsFromOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DividendsPaidOrdinaryShares_lbl" xml:lang="en-US">Ordinary share purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsPaidOrdinaryShares" xlink:to="ifrs-full_DividendsPaidOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DividendsPaidOrdinarySharesPerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="ifrs-full_DividendsPaidOrdinarySharesPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized_lbl" xml:lang="en-US">Sale of additional shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AggregatePurchasePrice" xlink:href="ifrx-20231231.xsd#ifrx_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregatePurchasePrice" xlink:to="ifrx_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_AggregateInitialOffering" xlink:href="ifrx-20231231.xsd#ifrx_AggregateInitialOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_AggregateInitialOffering_lbl" xml:lang="en-US">Aggregate public offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregateInitialOffering" xlink:to="ifrx_AggregateInitialOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NominalValue" xlink:href="ifrx-20231231.xsd#ifrx_NominalValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NominalValue_lbl" xml:lang="en-US">Nominal value (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NominalValue" xlink:to="ifrx_NominalValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OrdinarySharesValue" xlink:href="ifrx-20231231.xsd#ifrx_OrdinarySharesValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OrdinarySharesValue_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinarySharesValue" xlink:to="ifrx_OrdinarySharesValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OrdinaryShareSoldPrice" xlink:href="ifrx-20231231.xsd#ifrx_OrdinaryShareSoldPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OrdinaryShareSoldPrice_lbl" xml:lang="en-US">Ordinary shares sold at price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinaryShareSoldPrice" xlink:to="ifrx_OrdinaryShareSoldPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_SoldAtPrice" xlink:href="ifrx-20231231.xsd#ifrx_SoldAtPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_SoldAtPrice_lbl" xml:lang="en-US">Price sold (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SoldAtPrice" xlink:to="ifrx_SoldAtPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OrdinarySharePurchase" xlink:href="ifrx-20231231.xsd#ifrx_OrdinarySharePurchase"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OrdinarySharePurchase_lbl" xml:lang="en-US">Ordinary share purchase (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinarySharePurchase" xlink:to="ifrx_OrdinarySharePurchase_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PreferredUnitIssued" xlink:href="ifrx-20231231.xsd#ifrx_PreferredUnitIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_PreferredUnitIssued_lbl" xml:lang="en-US">Preferred shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PreferredUnitIssued" xlink:to="ifrx_PreferredUnitIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk_lbl" xml:lang="en-US">Nominal value per shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" xlink:to="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CompanyIssuedCapital" xlink:href="ifrx-20231231.xsd#ifrx_CompanyIssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CompanyIssuedCapital_lbl" xml:lang="en-US">Company issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CompanyIssuedCapital" xlink:to="ifrx_CompanyIssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedReimbursementOtherProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions_lbl" xml:lang="en-US">Reimburse expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedReimbursementOtherProvisions" xlink:to="ifrs-full_ExpectedReimbursementOtherProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommonSharesInExcessOfNominalValue" xlink:href="ifrx-20231231.xsd#ifrx_CommonSharesInExcessOfNominalValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_CommonSharesInExcessOfNominalValue_lbl" xml:lang="en-US">Common shares in excess of nominal value (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonSharesInExcessOfNominalValue" xlink:to="ifrx_CommonSharesInExcessOfNominalValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_PaymentsForAccruedPayments" xlink:href="ifrx-20231231.xsd#ifrx_PaymentsForAccruedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_PaymentsForAccruedPayments_lbl" xml:lang="en-US">Payments for accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PaymentsForAccruedPayments" xlink:to="ifrx_PaymentsForAccruedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_VariablesHeldConstant" xlink:href="ifrx-20231231.xsd#ifrx_VariablesHeldConstant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_VariablesHeldConstant_lbl" xml:lang="en-US">Variables held constant, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_VariablesHeldConstant" xlink:to="ifrx_VariablesHeldConstant_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_lbl" xml:lang="en-US">Foreign exchange on translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateFluctuations" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExchangeRateFluctuations_lbl" xml:lang="en-US">Exchange rate fluctuations (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRateFluctuations" xlink:to="ifrx_ExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaximumExposureToCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US">Credit risk</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXs61wHyckAg2nxvBikE1dTD+mD7F+hOhyP4JUKDa+ELwxhT8MZgkEf+kZKh9LsB5Bl51UtFYWeFaK0UqFEG6idGWj2iasVoEhjS4SNz7nGGf4nLWMQY8htW/qSuH80Qxl2gy8qk9XEw4=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_MaximumExposureToCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Plant and equipment or patents and trademark</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRate" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExchangeRate_lbl" xml:lang="en-US">Converted with the exchange rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRate" xlink:to="ifrx_ExchangeRate_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl" xml:lang="en-US">Executive management, non-executive members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">Basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">Summary of material accounting policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" xlink:to="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">New and amended standards adopted by the Group</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" xlink:to="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">New standard not yet adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock_lbl" xml:lang="en-US">Current and non-current classification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Foreign currency transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock_lbl" xml:lang="en-US">Grants from government and similar bodies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotesToTheCashFlowStatementPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_NotesToTheCashFlowStatementPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NotesToTheCashFlowStatementPolicyTextBlock_lbl" xml:lang="en-US">Notes to the cash flow statement, cash, and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotesToTheCashFlowStatementPolicyTextBlock" xlink:to="ifrx_NotesToTheCashFlowStatementPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US">Lease arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US">Impairment of assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial assets and liabilities (financial instruments)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock_lbl" xml:lang="en-US">Significant accounting judgements, estimates and assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:to="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_GermanMinistryOfEducationAndResearchMember" xlink:href="ifrx-20231231.xsd#ifrx_GermanMinistryOfEducationAndResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_GermanMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US">German Ministry of Education and Research [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_GermanMinistryOfEducationAndResearchMember" xlink:to="ifrx_GermanMinistryOfEducationAndResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LaboratoryEquipmentMember" xlink:href="ifrx-20231231.xsd#ifrx_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LaboratoryEquipmentMember" xlink:to="ifrx_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OptionsGrantedMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsGrantedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_OptionsGrantedMember_lbl" xml:lang="en-US">Options Granted [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsGrantedMember" xlink:to="ifrx_OptionsGrantedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ResearchAndDevelopmentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ResearchAndDevelopmentExpenseMember" xlink:to="ifrx_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LongTermIncentivePlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2016Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_LongTermIncentivePlan2016Member_lbl" xml:lang="en-US">2016 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LongTermIncentivePlan2016Member" xlink:to="ifrx_LongTermIncentivePlan2016Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MinimumMember" xlink:href="ifrx-20231231.xsd#ifrx_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MinimumMember" xlink:to="ifrx_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaximumMember" xlink:href="ifrx-20231231.xsd#ifrx_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaximumMember" xlink:to="ifrx_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MarketProgramMember" xlink:href="ifrx-20231231.xsd#ifrx_MarketProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_MarketProgramMember_lbl" xml:lang="en-US">Market Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MarketProgramMember" xlink:to="ifrx_MarketProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_StockOptionMember" xlink:href="ifrx-20231231.xsd#ifrx_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_StockOptionMember" xlink:to="ifrx_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_DEMember" xlink:href="ifrx-20231231.xsd#ifrx_DEMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_DEMember_lbl" xml:lang="en-US">Germany [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DEMember" xlink:to="ifrx_DEMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_UnitedStateOneMember" xlink:href="ifrx-20231231.xsd#ifrx_UnitedStateOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_UnitedStateOneMember_lbl" xml:lang="en-US">United State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnitedStateOneMember" xlink:to="ifrx_UnitedStateOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExecutiveMembersMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveMembersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_ExecutiveMembersMember_lbl" xml:lang="en-US">Executive [Members]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExecutiveMembersMember" xlink:to="ifrx_ExecutiveMembersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NonexecutiveMember" xlink:href="ifrx-20231231.xsd#ifrx_NonexecutiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrx_NonexecutiveMember_lbl" xml:lang="en-US">Non-executive [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonexecutiveMember" xlink:to="ifrx_NonexecutiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US">Entity&apos;s total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:href="ifrx-20231231.xsd#ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable_lbl" xml:lang="en-US">Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:to="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems_lbl" xml:lang="en-US">Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US">Entity&apos;s total for business combinations [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl" xml:lang="en-US">Net defined benefit liability (asset) [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetMember" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl" xml:lang="en-US">Opening balance before adjustment, cumulative effect at date of initial application [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US">Property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LineItemsByFunctionMember_lbl" xml:lang="en-US">Line items by function [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LineItemsByFunctionMember" xlink:to="ifrs-full_LineItemsByFunctionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US">Assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xml:lang="en-US">Intangible assets and goodwill [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US">Financial instruments, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US">Risks [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US">Aggregated time bands [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable_lbl" xml:lang="en-US">Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:to="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems_lbl" xml:lang="en-US">Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable_lbl" xml:lang="en-US">Other Information (Details) - Schedule of Compensation of the Group&#8217;s Executive Management [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:to="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems_lbl" xml:lang="en-US">Other Information (Details) - Schedule of Compensation of the Group&#8217;s Executive Management [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember_lbl" xml:lang="en-US">Property, plant and equipment by operating lease status [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaterialAccountingPoliciesDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_MaterialAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MaterialAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Material Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaterialAccountingPoliciesDetailsTable" xlink:to="ifrx_MaterialAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_MaterialAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MaterialAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Material Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrx_MaterialAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DefinedBenefitPlansMember_lbl" xml:lang="en-US">Defined benefit plans [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DefinedBenefitPlansMember" xlink:to="ifrs-full_DefinedBenefitPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_IncomeStatementLocationDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IncomeStatementLocationDomainDomain_lbl" xml:lang="en-US">IncomeStatementLocationDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncomeStatementLocationDomainDomain" xlink:to="ifrx_IncomeStatementLocationDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems_lbl" xml:lang="en-US">Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems_lbl" xml:lang="en-US">Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_ExchangeRateCurrencyDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExchangeRateCurrencyDomainDomain_lbl" xml:lang="en-US">ExchangeRateCurrencyDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRateCurrencyDomainDomain" xlink:to="ifrx_ExchangeRateCurrencyDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommitmentsDetailsTable_lbl" xml:lang="en-US">Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommitmentsDetailsTable" xlink:to="ifrx_CommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_CommitmentsDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommitmentsDetailsLineItems_lbl" xml:lang="en-US">Commitments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommitmentsDetailsLineItems" xlink:to="ifrx_CommitmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_LocationDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_LocationDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LocationDomainDomain_lbl" xml:lang="en-US">LocationDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LocationDomainDomain" xlink:to="ifrx_LocationDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherInformationDetailsTable_lbl" xml:lang="en-US">Other Information (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherInformationDetailsTable" xlink:to="ifrx_OtherInformationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrx_OtherInformationDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherInformationDetailsLineItems_lbl" xml:lang="en-US">Other Information (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherInformationDetailsLineItems" xlink:to="ifrx_OtherInformationDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AccruedLiabilitiesFromCommercialActivities_lbl0" xml:lang="en-US">Amount of accrued liabilities from commercial activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccruedLiabilitiesFromCommercialActivities" xlink:to="ifrx_AccruedLiabilitiesFromCommercialActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars_lbl0" xml:lang="en-US">Amount of financial assets from government grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived_lbl0" xml:lang="en-US">Amount of liabilities from government grants received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AggregateCommonShares_lbl0" xml:lang="en-US">Aggregate common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregateCommonShares" xlink:to="ifrx_AggregateCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AggregateInitialOffering_lbl0" xml:lang="en-US">The amount of aggregate initial offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregateInitialOffering" xlink:to="ifrx_AggregateInitialOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AggregatePurchasePrice_lbl0" xml:lang="en-US">The amount of aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregatePurchasePrice" xlink:to="ifrx_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AmortizedPeriod_lbl0" xml:lang="en-US">Amortized period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AmortizedPeriod" xlink:to="ifrx_AmortizedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AnnualizedAverageSharePricePeriod_lbl0" xml:lang="en-US">Annualized average share price period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AnnualizedAverageSharePricePeriod" xlink:to="ifrx_AnnualizedAverageSharePricePeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount_lbl0" xml:lang="en-US">Carrying amount of assets sold under agreements to repurchase when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under repurchase agreements exceeds 10 percent of total assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount" xlink:to="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_AverageRate_lbl0" xml:lang="en-US">The value of average rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AverageRate" xlink:to="ifrx_AverageRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_CapitalOrdinarySharesIssued_lbl0" xml:lang="en-US">The nominal number of capital arising from issuing ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CapitalOrdinarySharesIssued" xlink:to="ifrx_CapitalOrdinarySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_CapitalizedLeases_lbl0" xml:lang="en-US">The cash outflow for leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CapitalizedLeases" xlink:to="ifrx_CapitalizedLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_CommonShares_lbl0" xml:lang="en-US">Common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonShares" xlink:to="ifrx_CommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ConversionRate_lbl0" xml:lang="en-US">The value of conversion rates.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConversionRate" xlink:to="ifrx_ConversionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_CorporateIncomeTax_lbl0" xml:lang="en-US">The amount of current income tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CorporateIncomeTax" xlink:to="ifrx_CorporateIncomeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssets_lbl0" xml:lang="en-US">The amount of current and non-current financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentAndNonCurrentFinancialAssets" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest_lbl0" xml:lang="en-US">Current and non current financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of significant accounting policies for description of accounting policy current and noncurrent classification explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock_lbl0" xml:lang="en-US">Disclosure of significant accounting policies for description of accounting policy for grants from government.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policies for description of accounting policy new standards not yet adopted explanatory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about cash and cash equivalent and financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:to="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory_lbl0" xml:lang="en-US">The disclosure of detailed information about compensation of group executive management.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" xlink:to="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory_lbl0" xml:lang="en-US">The entire disclosure of consolidated statement of operation and comprehensive loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" xlink:to="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfNetFinancialResultTextBlock_lbl0" xml:lang="en-US">The disclosure of net financial result text block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfNetFinancialResultTextBlock" xlink:to="ifrx_DisclosureOfNetFinancialResultTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about other income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock" xlink:to="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock_lbl0" xml:lang="en-US">The disclosure of detailed information about sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock" xlink:to="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory_lbl0" xml:lang="en-US">The disclosure of detailed information of share capital consisting of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" xlink:to="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of significant accounting judgements estimates and assumptions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:to="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Disposal amount of property plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" xlink:to="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Disposals of property plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment" xlink:to="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_DueAmount_lbl0" xml:lang="en-US">Amount of due amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DueAmount" xlink:to="ifrx_DueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_EffectOfDiscounting_lbl0" xml:lang="en-US">Effect of discounting.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectOfDiscounting" xlink:to="ifrx_EffectOfDiscounting_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent_lbl0" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent_lbl0" xml:lang="en-US">Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_Employeebenefitsexpense_lbl0" xml:lang="en-US">The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_Employeebenefitsexpense" xlink:to="ifrx_Employeebenefitsexpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ExchangeRate_lbl0" xml:lang="en-US">Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRate" xlink:to="ifrx_ExchangeRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ExercisePriceOfOutstandingShareOptions_lbl0" xml:lang="en-US">The exercise price of outstanding share options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExercisePriceOfOutstandingShareOptions" xlink:to="ifrx_ExercisePriceOfOutstandingShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ExercisePriceRange_lbl0" xml:lang="en-US">Exercise price range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExercisePriceRange" xlink:to="ifrx_ExercisePriceRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ExpectedDividends_lbl0" xml:lang="en-US">The number of expected dividends.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExpectedDividends" xlink:to="ifrx_ExpectedDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed_lbl0" xml:lang="en-US">The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_FairValuePerOptions_lbl0" xml:lang="en-US">The fair value option per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FairValuePerOptions" xlink:to="ifrx_FairValuePerOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_FairValuesPerOptions_lbl0" xml:lang="en-US">The fair value per option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FairValuesPerOptions" xlink:to="ifrx_FairValuesPerOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_FinancialAssetsFromGovernmentGrants_lbl0" xml:lang="en-US">Amount of financial assets from government grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsFromGovernmentGrants" xlink:to="ifrx_FinancialAssetsFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_FinancialAssetsFromGovernmentGrantsAmount_lbl0" xml:lang="en-US">The amount of financial assets from government grants amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsFromGovernmentGrantsAmount" xlink:to="ifrx_FinancialAssetsFromGovernmentGrantsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_FixedInterest_lbl0" xml:lang="en-US">Fixed Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FixedInterest" xlink:to="ifrx_FixedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ForeignExchangeExpense_lbl0" xml:lang="en-US">The amount of foreign exchange expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeExpense" xlink:to="ifrx_ForeignExchangeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ForeignExchangeIncome_lbl0" xml:lang="en-US">The amount of foreign exchange loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeIncome" xlink:to="ifrx_ForeignExchangeIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ForeignExchangeRateAsOfGrantDate_lbl0" xml:lang="en-US">The foreign exchange rate as grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeRateAsOfGrantDate" xlink:to="ifrx_ForeignExchangeRateAsOfGrantDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ForeignExchangeResult_lbl0" xml:lang="en-US">The amount of foreign exchange result.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeResult" xlink:to="ifrx_ForeignExchangeResult_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax_lbl0" xml:lang="en-US">The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" xlink:to="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl0" xml:lang="en-US">Share options exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill_lbl0" xml:lang="en-US">The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions_lbl0" xml:lang="en-US">The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity&apos;s presentation currency. [Refer: Other provisions]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_IntangibleAssets_lbl1" xml:lang="en-US">The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IntangibleAssets" xlink:to="ifrx_IntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_IssuanceOfCommonShare_lbl0" xml:lang="en-US">Issuance of common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IssuanceOfCommonShare" xlink:to="ifrx_IssuanceOfCommonShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_LiabilitiesFromGovernmentGrants_lbl0" xml:lang="en-US">Amount of liabilities from government grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LiabilitiesFromGovernmentGrants" xlink:to="ifrx_LiabilitiesFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense_lbl0" xml:lang="en-US">Amount of expense (income) recognized due to changes in the accrued obligation to policyholders that relates to insured events.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" xlink:to="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_LossPerShare_lbl0" xml:lang="en-US">The number of loss per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LossPerShare" xlink:to="ifrx_LossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_MaximumNumberOfCommonSharesAvailableForGrant_lbl0" xml:lang="en-US">Maximum number of common shares available for grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaximumNumberOfCommonSharesAvailableForGrant" xlink:to="ifrx_MaximumNumberOfCommonSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NetFinancialCost_lbl0" xml:lang="en-US">The amount of net financial cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetFinancialCost" xlink:to="ifrx_NetFinancialCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NetFinancialResult_lbl0" xml:lang="en-US">The number of net financial result.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetFinancialResult" xlink:to="ifrx_NetFinancialResult_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NetProceeds_lbl0" xml:lang="en-US">Amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetProceeds" xlink:to="ifrx_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NominalValue_lbl0" xml:lang="en-US">Nominal value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NominalValue" xlink:to="ifrx_NominalValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NonCurrentOtherAssets_lbl0" xml:lang="en-US">The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentOtherAssets" xlink:to="ifrx_NonCurrentOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NondeductibleExpensesForTaxPurposesinDollars_lbl0" xml:lang="en-US">The amount of non-deductible expenses for tax purposes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NondeductibleExpensesForTaxPurposesinDollars" xlink:to="ifrx_NondeductibleExpensesForTaxPurposesinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment_lbl0" xml:lang="en-US">The amount of non-recognition of tax effect on share-based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment" xlink:to="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NotesToTheCashFlowStatementPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of significant accounting policies for notes to the cash flow statement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotesToTheCashFlowStatementPolicyTextBlock" xlink:to="ifrx_NotesToTheCashFlowStatementPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfOptionsExercised_lbl0" xml:lang="en-US">The number of options exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOptionsExercised" xlink:to="ifrx_NumberOfOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfOutstandingSharesOption_lbl1" xml:lang="en-US">The number of share options outstanding in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingSharesOption" xlink:to="ifrx_NumberOfOutstandingSharesOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl1" xml:lang="en-US">WAEP, Outstanding beginning.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" xlink:to="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The number of share options exercised in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The number of share options forfeited in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">The number of share options granted in a share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_NumberOfStockOptionsForfeited_lbl0" xml:lang="en-US">The number of stock options forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfStockOptionsForfeited" xlink:to="ifrx_NumberOfStockOptionsForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease_lbl0" xml:lang="en-US">Amount of depreciation expense for lessor&apos;s underlying asset for which right to use has been conveyed to lessee under operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" xlink:to="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OptionsGranted_lbl0" xml:lang="en-US">The amount of an expected dividend used to calculate the fair value of share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsGranted" xlink:to="ifrx_OptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OrdinarySharePurchase_lbl0" xml:lang="en-US">Ordinary share purchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinarySharePurchase" xlink:to="ifrx_OrdinarySharePurchase_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OrdinaryShareSoldPrice_lbl0" xml:lang="en-US">Ordinary share sold price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinaryShareSoldPrice" xlink:to="ifrx_OrdinaryShareSoldPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OrdinarySharesValue_lbl0" xml:lang="en-US">The number of shares value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinarySharesValue" xlink:to="ifrx_OrdinarySharesValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OtherDifferencesDueToTaxRateinDollars_lbl0" xml:lang="en-US">The amount of other differences due to tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherDifferencesDueToTaxRateinDollars" xlink:to="ifrx_OtherDifferencesDueToTaxRateinDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_OtherFinancialResult_lbl0" xml:lang="en-US">The amount of other finacial result.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherFinancialResult" xlink:to="ifrx_OtherFinancialResult_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_PaymentsForAccruedPayments_lbl0" xml:lang="en-US">The amount of payments for accrued payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PaymentsForAccruedPayments" xlink:to="ifrx_PaymentsForAccruedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_PercentageOfGrant_lbl0" xml:lang="en-US">Percentage of grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PercentageOfGrant" xlink:to="ifrx_PercentageOfGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_PreferredUnitIssued_lbl0" xml:lang="en-US">The number of preferred units issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PreferredUnitIssued" xlink:to="ifrx_PreferredUnitIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ProceedsFromOfferingCost_lbl0" xml:lang="en-US">The amount of proceeds from offering cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ProceedsFromOfferingCost" xlink:to="ifrx_ProceedsFromOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ProceedsOfferingCost_lbl0" xml:lang="en-US">Amount of proceeds offering cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ProceedsOfferingCost" xlink:to="ifrx_ProceedsOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl1" xml:lang="en-US">The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:to="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Purchase of current and non-current financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:to="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_RentalContractsFixedPeriod_lbl0" xml:lang="en-US">Rental contracts fixed period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RentalContractsFixedPeriod" xlink:to="ifrx_RentalContractsFixedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ResearchAndDevelopmentExpenses_lbl0" xml:lang="en-US">The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ResearchAndDevelopmentExpenses" xlink:to="ifrx_ResearchAndDevelopmentExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_RightofuseAssetsRevaluationSurplus01_lbl1" xml:lang="en-US">The amount of the revaluation surplus that relates to right-of-use assets. [Refer: Revaluation surplus; Right-of-use assets]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RightofuseAssetsRevaluationSurplus01" xlink:to="ifrx_RightofuseAssetsRevaluationSurplus01_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_SensitivityAnalysisCarryingAmount_lbl0" xml:lang="en-US">Amount of sensitivity analysis carrying amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SensitivityAnalysisCarryingAmount" xlink:to="ifrx_SensitivityAnalysisCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_SensitivityAnalysisConversionRate_lbl0" xml:lang="en-US">Amount of sensitivity analysis conversion rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SensitivityAnalysisConversionRate" xlink:to="ifrx_SensitivityAnalysisConversionRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized_lbl0" xml:lang="en-US">Number of additional shares authorized for issuance under share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ShareOptionsGrantedOptions_lbl0" xml:lang="en-US">Share options granted options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareOptionsGrantedOptions" xlink:to="ifrx_ShareOptionsGrantedOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_SharePriceAtGrantDateExercisePrices_lbl0" xml:lang="en-US">The share price at grant date and exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SharePriceAtGrantDateExercisePrices" xlink:to="ifrx_SharePriceAtGrantDateExercisePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ShortTermMarketableSecurities_lbl0" xml:lang="en-US">The amount of short term marketable securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShortTermMarketableSecurities" xlink:to="ifrx_ShortTermMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_SolidaritySurcharge_lbl0" xml:lang="en-US">Solidarity surcharge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SolidaritySurcharge" xlink:to="ifrx_SolidaritySurcharge_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes_lbl0" xml:lang="en-US">The aggregate cost of investments for Federal income tax purposes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes" xlink:to="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TaxLossCarryforwards_lbl0" xml:lang="en-US">Tax loss carryforwards .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxLossCarryforwards" xlink:to="ifrx_TaxLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone_lbl0" xml:lang="en-US">Tax losses for which no deferred tax asset was recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" xlink:to="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TotalCompensation_lbl0" xml:lang="en-US">Total Compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalCompensation" xlink:to="ifrx_TotalCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TotalFundsAvailable_lbl0" xml:lang="en-US">Amount of total funds available.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalFundsAvailable" xlink:to="ifrx_TotalFundsAvailable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TotalLeases_lbl0" xml:lang="en-US">Total leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalLeases" xlink:to="ifrx_TotalLeases_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TotalOtherAsset_lbl0" xml:lang="en-US">The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalOtherAsset" xlink:to="ifrx_TotalOtherAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TotalTaxRate_lbl0" xml:lang="en-US">The amount of  total tax rate .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalTaxRate" xlink:to="ifrx_TotalTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TradeTaxes_lbl0" xml:lang="en-US">The amount of trade taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TradeTaxes" xlink:to="ifrx_TradeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_TransactionCostsFromIssuanceOfCommonShares_lbl0" xml:lang="en-US">Transaction costs from issuance of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TransactionCostsFromIssuanceOfCommonShares" xlink:to="ifrx_TransactionCostsFromIssuanceOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_UnderwritingDiscounts_lbl0" xml:lang="en-US">Amount of underwriting discounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnderwritingDiscounts" xlink:to="ifrx_UnderwritingDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_UnfinishedGoods_lbl0" xml:lang="en-US">Amount of unfinished goods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnfinishedGoods" xlink:to="ifrx_UnfinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_VariablesHeldConstant_lbl0" xml:lang="en-US">The percent of variables held constant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_VariablesHeldConstant" xlink:to="ifrx_VariablesHeldConstant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_WAEPExercisables_lbl0" xml:lang="en-US">WAEP, exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WAEPExercisables" xlink:to="ifrx_WAEPExercisables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear_lbl0" xml:lang="en-US">Weighted average fair value options granted during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear" xlink:to="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd_lbl0" xml:lang="en-US">Weighted average fair value options granted during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" xlink:to="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_lbl0" xml:lang="en-US">Weighted average remaining contractual life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:to="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_WeightedNumberOfCommonSharesOutstanding_lbl0" xml:lang="en-US">Weighted number of common shares outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedNumberOfCommonSharesOutstanding" xlink:to="ifrx_WeightedNumberOfCommonSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_ordinarySharesPercentage_lbl0" xml:lang="en-US">The percentage of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ordinarySharesPercentage" xlink:to="ifrx_ordinarySharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_MaximumMember_lbl0" xml:lang="en-US">Upper limit of the provided range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaximumMember" xlink:to="ifrx_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ifrx_MinimumMember_lbl0" xml:lang="en-US">Lower limit of the provided range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MinimumMember" xlink:to="ifrx_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0" xml:lang="en-US">Proportion of ownership interest in subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ResearchAndDevelopmentExpenses_lbl1" xml:lang="en-US">Research And Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ResearchAndDevelopmentExpenses" xlink:to="ifrx_ResearchAndDevelopmentExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions_lbl0" xml:lang="en-US">Expected reimbursement, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedReimbursementOtherProvisions" xlink:to="ifrs-full_ExpectedReimbursementOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory_lbl1" xml:lang="en-US">Disclosure Of Share Capital Consisting Solely Of Ordinary Shares Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" xlink:to="ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl2" xml:lang="en-US">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_lbl1" xml:lang="en-US">Weighted Average Remaining Contractual Life Of Outstanding Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:to="ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl0" xml:lang="en-US">Non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets_lbl0" xml:lang="en-US">Description of reasons for fair value measurement, assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" xlink:to="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConversionRate_lbl1" xml:lang="en-US">Conversion Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConversionRate" xlink:to="ifrx_ConversionRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OptionsGranted_lbl1" xml:lang="en-US">Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsGranted" xlink:to="ifrx_OptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets_lbl1" xml:lang="en-US">Purchase Of Current And Noncurrent Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:to="ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl0" xml:lang="en-US">Issue of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfOpionsExercisedDuring_lbl0" xml:lang="en-US">Number Of Opions Exercised During</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOpionsExercisedDuring" xlink:to="ifrx_NumberOfOpionsExercisedDuring_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of general and administrative expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of financial assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Disclosure of employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl0" xml:lang="en-US">Finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ForeignExchangeResult_lbl1" xml:lang="en-US">Foreign Exchange Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeResult" xlink:to="ifrx_ForeignExchangeResult_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Interest received, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions_lbl1" xml:lang="en-US">Increase Decrease Through Net Exchange Difference Other Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl0" xml:lang="en-US">Other short-term employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermEmployeeBenefits" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfStockOptionsForfeited_lbl1" xml:lang="en-US">Number Of Stock Options Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfStockOptionsForfeited" xlink:to="ifrx_NumberOfStockOptionsForfeited_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ForeignExchangeExpense_lbl1" xml:lang="en-US">Foreign Exchange Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeExpense" xlink:to="ifrx_ForeignExchangeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OptionsMember_lbl0" xml:lang="en-US">Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsMember" xlink:to="ifrx_OptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Useful life measured as period of time, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl3" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonCurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non Current Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentLiabilitiesAbstract" xlink:to="ifrx_NonCurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExecutiveManagementMember_lbl0" xml:lang="en-US">Executive Management Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExecutiveManagementMember" xlink:to="ifrx_ExecutiveManagementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl0" xml:lang="en-US">Current provisions for employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_a2022Abstract_lbl0" xml:lang="en-US">a2022 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_a2022Abstract" xlink:to="ifrx_a2022Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AdvancesPaidForSoftwareMember_lbl0" xml:lang="en-US">Advances Paid For Software Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdvancesPaidForSoftwareMember" xlink:to="ifrx_AdvancesPaidForSoftwareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl0" xml:lang="en-US">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl2" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_January12Member_lbl0" xml:lang="en-US">January12 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January12Member" xlink:to="ifrx_January12Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CompanyIssuedCapital_lbl0" xml:lang="en-US">Company Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CompanyIssuedCapital" xlink:to="ifrx_CompanyIssuedCapital_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AccruedLiabilitiesFromCommercialActivities_lbl1" xml:lang="en-US">Accrued Liabilities From Commercial Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccruedLiabilitiesFromCommercialActivities" xlink:to="ifrx_AccruedLiabilitiesFromCommercialActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy New Standards Not Yet Adopted Explanatory Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetBookValueAbstract_lbl0" xml:lang="en-US">Net Book Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueAbstract" xlink:to="ifrx_NetBookValueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InflaRxPharmaceuticalIncMember_lbl0" xml:lang="en-US">Infla Rx Pharmaceutical Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InflaRxPharmaceuticalIncMember" xlink:to="ifrx_InflaRxPharmaceuticalIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ThirdpartyExpensesMember_lbl0" xml:lang="en-US">Thirdparty Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ThirdpartyExpensesMember" xlink:to="ifrx_ThirdpartyExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill_lbl1" xml:lang="en-US">Disposals And Retirement Intangible Assets Other Than Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" xlink:to="ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_VariablesHeldConstant_lbl1" xml:lang="en-US">Variables Held Constant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_VariablesHeldConstant" xlink:to="ifrx_VariablesHeldConstant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PrepaidExpense_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PrepaidExpense" xlink:to="ifrx_PrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl0" xml:lang="en-US">Other expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CorporateIncomeTax_lbl1" xml:lang="en-US">Corporate Income Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CorporateIncomeTax" xlink:to="ifrx_CorporateIncomeTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DebtSecurities_lbl0" xml:lang="en-US">Debt instruments issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DebtSecurities" xlink:to="ifrs-full_DebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IntangibleAssets_lbl2" xml:lang="en-US">Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IntangibleAssets" xlink:to="ifrx_IntangibleAssets_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Maturity Analysis Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract" xlink:to="ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_Employeebenefitsexpense_lbl1" xml:lang="en-US">Employeebenefitsexpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_Employeebenefitsexpense" xlink:to="ifrx_Employeebenefitsexpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DividendsPaidOrdinarySharesPerShare_lbl0" xml:lang="en-US">Dividends paid, ordinary shares per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:to="ifrs-full_DividendsPaidOrdinarySharesPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AccumulatedAmortizationMember_lbl0" xml:lang="en-US">Accumulated Amortization Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedAmortizationMember" xlink:to="ifrx_AccumulatedAmortizationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Additions other than through business combinations, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MarketProgramMember_lbl0" xml:lang="en-US">Market Program Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MarketProgramMember" xlink:to="ifrx_MarketProgramMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BalancesWithBanks_lbl0" xml:lang="en-US">Balances with banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl0" xml:lang="en-US">Proceeds from issuing shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeLoss_lbl0" xml:lang="en-US">Foreign exchange loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeLoss" xlink:to="ifrs-full_ForeignExchangeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0" xml:lang="en-US">Short-term deposits, classified as cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements Of Changes In Shareholders Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:to="ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd_lbl1" xml:lang="en-US">Weighted Average Fair Valuee Options Granted During The Year Usd</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" xlink:to="ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl0" xml:lang="en-US">Other non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FairValuePerOptions_lbl1" xml:lang="en-US">Fair Value Per Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FairValuePerOptions" xlink:to="ifrx_FairValuePerOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ShortTermMarketableSecurities_lbl1" xml:lang="en-US">Short Term Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShortTermMarketableSecurities" xlink:to="ifrx_ShortTermMarketableSecurities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy Current And Noncurrent Classification Explanatory Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SolidaritySurcharge_lbl1" xml:lang="en-US">Solidarity Surcharge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SolidaritySurcharge" xlink:to="ifrx_SolidaritySurcharge_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl0" xml:lang="en-US">Additions to right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl0" xml:lang="en-US">Cash outflow for leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalents Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="ifrx_ScheduleOfCashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SocialSecurityContributionsemployersShareMember_lbl0" xml:lang="en-US">Social Security Contributionsemployers Share Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SocialSecurityContributionsemployersShareMember" xlink:to="ifrx_SocialSecurityContributionsemployersShareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl2" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1" xml:lang="en-US">Payment Of Lease Liabilities Classified As Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CapitalizedLeases_lbl1" xml:lang="en-US">Capitalized Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CapitalizedLeases" xlink:to="ifrx_CapitalizedLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LegalAndConsultingFeesMember_lbl0" xml:lang="en-US">Legal And Consulting Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LegalAndConsultingFeesMember" xlink:to="ifrx_LegalAndConsultingFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_January4Member_lbl0" xml:lang="en-US">January4 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January4Member" xlink:to="ifrx_January4Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes_lbl1" xml:lang="en-US">Tax Basis Of Investment Cost For Income Tax Purposes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes" xlink:to="ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ManufacturingOfClinicalMaterialMember_lbl0" xml:lang="en-US">Manufacturing Of Clinical Material Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ManufacturingOfClinicalMaterialMember" xlink:to="ifrx_ManufacturingOfClinicalMaterialMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ForeignExchangeIncome_lbl1" xml:lang="en-US">Foreign Exchange Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeIncome" xlink:to="ifrx_ForeignExchangeIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NotesToTheCashFlowStatementPolicyTextBlock_lbl1" xml:lang="en-US">Notes To The Cash Flow Statement Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NotesToTheCashFlowStatementPolicyTextBlock" xlink:to="ifrx_NotesToTheCashFlowStatementPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0" xml:lang="en-US">Other property, plant and equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WAEPExercisables_lbl1" xml:lang="en-US">WAEPExercisables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WAEPExercisables" xlink:to="ifrx_WAEPExercisables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ShortTermDepositsAbstract_lbl0" xml:lang="en-US">Short Term Deposits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShortTermDepositsAbstract" xlink:to="ifrx_ShortTermDepositsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FinancingActivitiesAbstract_lbl0" xml:lang="en-US">Financing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancingActivitiesAbstract" xlink:to="ifrx_FinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock_lbl1" xml:lang="en-US">Disclosure Of Significant Accounting Judgements Estimates And Assumptions Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:to="ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl1" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssets_lbl1" xml:lang="en-US">Current And Non Current Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentAndNonCurrentFinancialAssets" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_EffectOfDiscounting_lbl1" xml:lang="en-US">Effect Of Discounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectOfDiscounting" xlink:to="ifrx_EffectOfDiscounting_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfSalesAndMarketingExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Sales And Marketing Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="ifrx_ScheduleOfSalesAndMarketingExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl0" xml:lang="en-US">Cash and cash equivalents if different from statement of financial position</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommonSharesInExcessOfNominalValue_lbl0" xml:lang="en-US">Common Shares In Excess Of Nominal Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonSharesInExcessOfNominalValue" xlink:to="ifrx_CommonSharesInExcessOfNominalValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FinancialAssetsAtAmortizedCostAbstract_lbl0" xml:lang="en-US">Financial Assets At Amortized Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="ifrx_FinancialAssetsAtAmortizedCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LongTermIncentivePlan2017Member_lbl2" xml:lang="en-US">Long Term Incentive Plan2017 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LongTermIncentivePlan2017Member" xlink:to="ifrx_LongTermIncentivePlan2017Member_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Exercised In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract10_lbl0" xml:lang="en-US">Unlabeled Abstract10</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract10" xlink:to="ifrx_UnlabeledAbstract10_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract11_lbl0" xml:lang="en-US">Unlabeled Abstract11</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract11" xlink:to="ifrx_UnlabeledAbstract11_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TaxRate_lbl0" xml:lang="en-US">Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxRate" xlink:to="ifrx_TaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TotalTaxRate_lbl1" xml:lang="en-US">Total Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalTaxRate" xlink:to="ifrx_TotalTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory_lbl1" xml:lang="en-US">Disclosure Of Consolidated Statements Of Operations And Comprehensive Loss Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" xlink:to="ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_RepricingApril13Member_lbl0" xml:lang="en-US">Repricing April13 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RepricingApril13Member" xlink:to="ifrx_RepricingApril13Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Forfeited In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl0" xml:lang="en-US">Government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OrdinarySharePurchase_lbl1" xml:lang="en-US">Ordinary Share Purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinarySharePurchase" xlink:to="ifrx_OrdinarySharePurchase_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiquidityRiskMember_lbl0" xml:lang="en-US">Liquidity risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number Of Weighted Average Earning Pershare Exercised In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherExpensesMember_lbl0" xml:lang="en-US">Other Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherExpensesMember" xlink:to="ifrx_OtherExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NondeductibleExpensesForTaxPurposesinDollars_lbl1" xml:lang="en-US">Nondeductible Expenses For Tax Purposesin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NondeductibleExpensesForTaxPurposesinDollars" xlink:to="ifrx_NondeductibleExpensesForTaxPurposesinDollars_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract_lbl" xml:lang="en-US">Schedule Of Amounts Recognized In Profit Or Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ForeignExchangeGain_lbl0" xml:lang="en-US">Foreign exchange gain</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ForeignExchangeGain" xlink:to="ifrs-full_ForeignExchangeGain_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock_lbl1" xml:lang="en-US">Disclosure Cash Cash Equivalents And Financial Assets Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:to="ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_January4OneMember_lbl0" xml:lang="en-US">January4 One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January4OneMember" xlink:to="ifrx_January4OneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfNetFinancialResultAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfNetFinancialResultAbstract_lbl" xml:lang="en-US">Schedule Of Net Financial Result Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfNetFinancialResultAbstract" xlink:to="ifrx_ScheduleOfNetFinancialResultAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InflaRxGmbHMember_lbl0" xml:lang="en-US">Infla Rx Gmb HMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InflaRxGmbHMember" xlink:to="ifrx_InflaRxGmbHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonCurrentOtherAssets_lbl1" xml:lang="en-US">Non Current Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentOtherAssets" xlink:to="ifrx_NonCurrentOtherAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PaymentsForAccruedPayments_lbl1" xml:lang="en-US">Payments For Accrued Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PaymentsForAccruedPayments" xlink:to="ifrx_PaymentsForAccruedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl0" xml:lang="en-US">Equity attributable to owners of parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract2" xlink:to="ifrx_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract1" xlink:to="ifrx_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_EquitysettledSharebasedPaymentExpensesMember_lbl0" xml:lang="en-US">Equitysettled Sharebased Payment Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EquitysettledSharebasedPaymentExpensesMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract4" xlink:to="ifrx_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract3" xlink:to="ifrx_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetBookValuePropertyAndEquipment_lbl0" xml:lang="en-US">Net Book Value Property And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValuePropertyAndEquipment" xlink:to="ifrx_NetBookValuePropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExecutiveMembersMember_lbl0" xml:lang="en-US">Executive Members Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExecutiveMembersMember" xlink:to="ifrx_ExecutiveMembersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract0" xlink:to="ifrx_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract9_lbl0" xml:lang="en-US">Unlabeled Abstract9</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract9" xlink:to="ifrx_UnlabeledAbstract9_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract6_lbl0" xml:lang="en-US">Unlabeled Abstract6</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract6" xlink:to="ifrx_UnlabeledAbstract6_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract5_lbl0" xml:lang="en-US">Unlabeled Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract5" xlink:to="ifrx_UnlabeledAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract8_lbl0" xml:lang="en-US">Unlabeled Abstract8</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract8" xlink:to="ifrx_UnlabeledAbstract8_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract7_lbl0" xml:lang="en-US">Unlabeled Abstract7</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract7" xlink:to="ifrx_UnlabeledAbstract7_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl1" xml:lang="en-US">Current government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, general and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AggregateCommonShares_lbl1" xml:lang="en-US">Aggregate Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregateCommonShares" xlink:to="ifrx_AggregateCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnBonds_lbl0" xml:lang="en-US">Interest expense on bonds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBonds" xlink:to="ifrs-full_InterestExpenseOnBonds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnitedStateOneMember_lbl0" xml:lang="en-US">United State One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnitedStateOneMember" xlink:to="ifrx_UnitedStateOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExercisePriceOfOutstandingShareOptions_lbl1" xml:lang="en-US">Exercise Price Of Outstanding Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExercisePriceOfOutstandingShareOptions" xlink:to="ifrx_ExercisePriceOfOutstandingShareOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OperatingActivitiesAbstract_lbl0" xml:lang="en-US">Operating Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OperatingActivitiesAbstract" xlink:to="ifrx_OperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExecutiveManagementAbstract_lbl0" xml:lang="en-US">Executive Management Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExecutiveManagementAbstract" xlink:to="ifrx_ExecutiveManagementAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_JulySevenMember_lbl0" xml:lang="en-US">July Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JulySevenMember" xlink:to="ifrx_JulySevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinancialAssets_lbl1" xml:lang="en-US">Other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExchangeRateCurrencyAxis_lbl0" xml:lang="en-US">Exchange Rate Currency Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRateCurrencyAxis" xlink:to="ifrx_ExchangeRateCurrencyAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AdvancePaymentsMember_lbl0" xml:lang="en-US">Advance Payments Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdvancePaymentsMember" xlink:to="ifrx_AdvancePaymentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DepositsHeldInUSDollarsMember_lbl0" xml:lang="en-US">Deposits Held In USDollars Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DepositsHeldInUSDollarsMember" xlink:to="ifrx_DepositsHeldInUSDollarsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WithinOneYearMember_lbl0" xml:lang="en-US">Within One Year Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WithinOneYearMember" xlink:to="ifrx_WithinOneYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnlabeledAbstract" xlink:to="ifrx_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_StockOptionMember_lbl0" xml:lang="en-US">Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_StockOptionMember" xlink:to="ifrx_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LossPerShare_lbl1" xml:lang="en-US">Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LossPerShare" xlink:to="ifrx_LossPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill_lbl1" xml:lang="en-US">Increase Decrease Through Net Exchange Difference Intangible Asset Other Than Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" xlink:to="ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl0" xml:lang="en-US">Income from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1" xml:lang="en-US">Increase (decrease) in number of ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ForeignExchangeRateAsOfGrantDate_lbl1" xml:lang="en-US">Foreign Exchange Rate As Of Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ForeignExchangeRateAsOfGrantDate" xlink:to="ifrx_ForeignExchangeRateAsOfGrantDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OptionsGrantedMember_lbl0" xml:lang="en-US">Options Granted Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionsGrantedMember" xlink:to="ifrx_OptionsGrantedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AverageRate_lbl1" xml:lang="en-US">Average Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AverageRate" xlink:to="ifrx_AverageRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetBookValueAbstract1_lbl0" xml:lang="en-US">Net Book Value Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueAbstract1" xlink:to="ifrx_NetBookValueAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0" xml:lang="en-US">Disclosure of research and development expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetBookValueAbstract0_lbl0" xml:lang="en-US">Net Book Value Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueAbstract0" xlink:to="ifrx_NetBookValueAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CostMember_lbl0" xml:lang="en-US">Cost Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CostMember" xlink:to="ifrx_CostMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Employee Benefits Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract" xlink:to="ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerSoftwareMember_lbl0" xml:lang="en-US">Computer software [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerSoftwareMember" xlink:to="ifrs-full_ComputerSoftwareMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl0" xml:lang="en-US">Non-current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0" xml:lang="en-US">Current accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OrdinarySharesValue_lbl1" xml:lang="en-US">Ordinary Shares Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinarySharesValue" xlink:to="ifrx_OrdinarySharesValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DEMember_lbl0" xml:lang="en-US">DEMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DEMember" xlink:to="ifrx_DEMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl0" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember_lbl0" xml:lang="en-US">Compensation Expense For Nonexecutive Board Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember" xlink:to="ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WritedownsReversalsOfInventories_lbl0" xml:lang="en-US">Write-downs (reversals of write-downs) of inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WritedownsReversalsOfInventories" xlink:to="ifrs-full_WritedownsReversalsOfInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_lbl0" xml:lang="en-US">Increase (decrease) in allowance account for credit losses of financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:to="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_JulySevenOneMember_lbl0" xml:lang="en-US">July Seven One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JulySevenOneMember" xlink:to="ifrx_JulySevenOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TotalFundsAvailable_lbl1" xml:lang="en-US">Total Funds Available</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalFundsAvailable" xlink:to="ifrx_TotalFundsAvailable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BuildingsMember_lbl0" xml:lang="en-US">Buildings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PercentageOfGrant_lbl1" xml:lang="en-US">Percentage Of Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PercentageOfGrant" xlink:to="ifrx_PercentageOfGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl0" xml:lang="en-US">Adjustments for share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">Selling, general and administrative expense [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfCostOfSalesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCostOfSalesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfCostOfSalesAbstract_lbl" xml:lang="en-US">Schedule Of Cost Of Sales Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfCostOfSalesAbstract" xlink:to="ifrx_ScheduleOfCostOfSalesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest_lbl1" xml:lang="en-US">Current And Non Current Financial Assetssecurities And Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:to="ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ThirdpartyServicesMember_lbl0" xml:lang="en-US">Thirdparty Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ThirdpartyServicesMember" xlink:to="ifrx_ThirdpartyServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl1" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WagesAndSalariesMember_lbl0" xml:lang="en-US">Wages And Salaries Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WagesAndSalariesMember" xlink:to="ifrx_WagesAndSalariesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax_lbl0" xml:lang="en-US">Gains (losses) on change in value of forward elements of forward contracts, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Prepayments_lbl0" xml:lang="en-US">Prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AccumulatedDepreciationAbstract0_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedDepreciationAbstract0" xlink:to="ifrx_AccumulatedDepreciationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease_lbl1" xml:lang="en-US">Operating Leases Income Statement Depreciation Expenses On Property Subject To Or Held For Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" xlink:to="ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl0" xml:lang="en-US">Current financial assets at amortised cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AfterOneYearButNotMoreThanFiveYearsMember_lbl0" xml:lang="en-US">After One Year But Not More Than Five Years Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AfterOneYearButNotMoreThanFiveYearsMember" xlink:to="ifrx_AfterOneYearButNotMoreThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_January12OneMember_lbl0" xml:lang="en-US">January12 One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_January12OneMember" xlink:to="ifrx_January12OneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax_lbl1" xml:lang="en-US">Gains Losses On Exchange Difference On Translation Net Of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" xlink:to="ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl0" xml:lang="en-US">Decrease through derecognition, financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingExpense_lbl0" xml:lang="en-US">Selling expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingExpense" xlink:to="ifrs-full_SellingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExpectedDividends_lbl1" xml:lang="en-US">Expected Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExpectedDividends" xlink:to="ifrx_ExpectedDividends_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement_lbl0" xml:lang="en-US">Number Of Weighted Average Earning Pershare Exercisable In Sharebased Payments Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl0" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for income tax [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl0" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_lbl0" xml:lang="en-US">Non-current portion of other non-current borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:to="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl0" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ordinarySharesPercentage_lbl1" xml:lang="en-US">ordinary Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ordinarySharesPercentage" xlink:to="ifrx_ordinarySharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfSharesOptionsExercisable_lbl0" xml:lang="en-US">Number Of Shares Options Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfSharesOptionsExercisable" xlink:to="ifrx_NumberOfSharesOptionsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InAbstract_lbl0" xml:lang="en-US">In Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract" xlink:to="ifrx_InAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_lbl0" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfRevenuesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfRevenuesAbstract_lbl" xml:lang="en-US">Schedule Of Revenues Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfRevenuesAbstract" xlink:to="ifrx_ScheduleOfRevenuesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl0" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AccumulatedAmortizationAbstract_lbl0" xml:lang="en-US">Accumulated Amortization Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedAmortizationAbstract" xlink:to="ifrx_AccumulatedAmortizationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CapitalOrdinarySharesIssued_lbl1" xml:lang="en-US">Capital Ordinary Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CapitalOrdinarySharesIssued" xlink:to="ifrx_CapitalOrdinarySharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IssuanceOfCommonShare_lbl1" xml:lang="en-US">Issuance Of Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IssuanceOfCommonShare" xlink:to="ifrx_IssuanceOfCommonShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl0" xml:lang="en-US">Profit (loss) from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TaxBenefitsAtTaxRate_lbl0" xml:lang="en-US">Tax Benefits At Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxBenefitsAtTaxRate" xlink:to="ifrx_TaxBenefitsAtTaxRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfOtherAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfOtherAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Other Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfOtherAssetsAbstract" xlink:to="ifrx_ScheduleOfOtherAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DepreciationAmortizationExpenseMember_lbl0" xml:lang="en-US">Depreciation Amortization Expense Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DepreciationAmortizationExpenseMember" xlink:to="ifrx_DepreciationAmortizationExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl0" xml:lang="en-US">Intangible assets and goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense_lbl1" xml:lang="en-US">Liability For Future Policy Benefit Period Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense" xlink:to="ifrx_LiabilityForFuturePolicyBenefitPeriodExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssets_lbl0" xml:lang="en-US">Current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number Of Weighted Average Earning Pershare Forfeited In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LiabilitiesFromGovernmentGrants_lbl1" xml:lang="en-US">Liabilities From Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LiabilitiesFromGovernmentGrants" xlink:to="ifrx_LiabilitiesFromGovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfWeightedAverageAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfWeightedAverageAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfWeightedAverageAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfWeightedAverageAbstract" xlink:to="ifrx_ScheduleOfWeightedAverageAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock_lbl1" xml:lang="en-US">Disclosure Of Sales And Marketing Expense Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock" xlink:to="ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncome_lbl0" xml:lang="en-US">Other finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory_lbl0" xml:lang="en-US">Disclosure of lease prepayments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" xlink:to="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl0" xml:lang="en-US">Accumulated depreciation and amortisation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0" xml:lang="en-US">Disclosure of changes in accounting policies [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AdjustmentsForAbstract_lbl0" xml:lang="en-US">Adjustments For Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForAbstract" xlink:to="ifrx_AdjustmentsForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxLiabilities_lbl0" xml:lang="en-US">Net deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxLiabilities" xlink:to="ifrs-full_NetDeferredTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl0" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInterestReceivable_lbl0" xml:lang="en-US">Current interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInterestReceivable" xlink:to="ifrs-full_CurrentInterestReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AmortizedPeriod_lbl1" xml:lang="en-US">Amortized Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AmortizedPeriod" xlink:to="ifrx_AmortizedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LongTermIncentivePlan2016Member_lbl0" xml:lang="en-US">Long Term Incentive Plan2016 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LongTermIncentivePlan2016Member" xlink:to="ifrx_LongTermIncentivePlan2016Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income Loss That May Be Reclassified To Profit Or Loss In Subsequent Periods Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:to="ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl0" xml:lang="en-US">Amortisation, intangible assets other than goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CashHeldInUSEuroMember_lbl1" xml:lang="en-US">Cash Held In USEuro Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashHeldInUSEuroMember" xlink:to="ifrx_CashHeldInUSEuroMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfWeightedAverageSharesOutstanding_lbl1" xml:lang="en-US">Number Of Weighted Average Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageSharesOutstanding" xlink:to="ifrx_NumberOfWeightedAverageSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CurrentOtherAssetsAbstract_lbl0" xml:lang="en-US">Current Other Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CurrentOtherAssetsAbstract" xlink:to="ifrx_CurrentOtherAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IncomeStatementLocationAxis_lbl0" xml:lang="en-US">Income Statement Location Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncomeStatementLocationAxis" xlink:to="ifrx_IncomeStatementLocationAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">Laboratory Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LaboratoryEquipmentMember" xlink:to="ifrx_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl1" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExercisePriceRange_lbl1" xml:lang="en-US">Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExercisePriceRange" xlink:to="ifrx_ExercisePriceRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl0" xml:lang="en-US">Other reserves [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_lbl0" xml:lang="en-US">Proceeds from disposal or maturity of available-for-sale financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FinancialAssetsFromGovernmentGrants_lbl1" xml:lang="en-US">Financial Assets From Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsFromGovernmentGrants" xlink:to="ifrx_FinancialAssetsFromGovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl0" xml:lang="en-US">Expense relating to variable lease payments not included in measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfTradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule Of Trade And Other Payables Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrx_ScheduleOfTradeAndOtherPayablesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfSharesExercisedDuring_lbl0" xml:lang="en-US">Number Of Shares Exercised During</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfSharesExercisedDuring" xlink:to="ifrx_NumberOfSharesExercisedDuring_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoriesTotal_lbl0" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesTotal" xlink:to="ifrs-full_InventoriesTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_July2Member_lbl0" xml:lang="en-US">July2 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_July2Member" xlink:to="ifrx_July2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Settlements State And Local Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MoreThanFiveYearsMember_lbl0" xml:lang="en-US">More Than Five Years Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MoreThanFiveYearsMember" xlink:to="ifrx_MoreThanFiveYearsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InsuranceExpensesMember_lbl0" xml:lang="en-US">Insurance Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InsuranceExpensesMember" xlink:to="ifrx_InsuranceExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_GermanMinistryOfEducationAndResearchMember_lbl0" xml:lang="en-US">German Ministry Of Education And Research Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_GermanMinistryOfEducationAndResearchMember" xlink:to="ifrx_GermanMinistryOfEducationAndResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetFinancialCost_lbl1" xml:lang="en-US">Net Financial Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetFinancialCost" xlink:to="ifrx_NetFinancialCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommonShares_lbl1" xml:lang="en-US">Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonShares" xlink:to="ifrx_CommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TransactionCostsFromIssuanceOfCommonShares_lbl1" xml:lang="en-US">Transaction Costs From Issuance Of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TransactionCostsFromIssuanceOfCommonShares" xlink:to="ifrx_TransactionCostsFromIssuanceOfCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount_lbl1" xml:lang="en-US">Assets Sold Under Agreement To Repurchase Carrying Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount" xlink:to="ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SharePriceAtGrantDateExercisePrices_lbl1" xml:lang="en-US">Share Price At Grant Date Exercise Prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SharePriceAtGrantDateExercisePrices" xlink:to="ifrx_SharePriceAtGrantDateExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_lbl0" xml:lang="en-US">Description of nature of entity&apos;s operations and principal activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:to="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ShareInformationBasedOnLossForThePeriodAbstract_lbl0" xml:lang="en-US">Share Information Based On Loss For The Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareInformationBasedOnLossForThePeriodAbstract" xlink:to="ifrx_ShareInformationBasedOnLossForThePeriodAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl0" xml:lang="en-US">Adjustments for depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl1" xml:lang="en-US">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_RightofuseAssetsRevaluationSurplus01_lbl2" xml:lang="en-US">Rightofuse Assets Revaluation Surplus01</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RightofuseAssetsRevaluationSurplus01" xlink:to="ifrx_RightofuseAssetsRevaluationSurplus01_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_November21Member_lbl0" xml:lang="en-US">November21 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_November21Member" xlink:to="ifrx_November21Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InAbstract3_lbl0" xml:lang="en-US">In Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract3" xlink:to="ifrx_InAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InAbstract2_lbl0" xml:lang="en-US">In Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract2" xlink:to="ifrx_InAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InAbstract1_lbl0" xml:lang="en-US">In Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract1" xlink:to="ifrx_InAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InAbstract0_lbl0" xml:lang="en-US">In Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract0" xlink:to="ifrx_InAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl0" xml:lang="en-US">Number of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InAbstract4_lbl0" xml:lang="en-US">In Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InAbstract4" xlink:to="ifrx_InAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl1" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl0" xml:lang="en-US">Gross lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetBookValueIntangibleAsset_lbl0" xml:lang="en-US">Net Book Value Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueIntangibleAsset" xlink:to="ifrx_NetBookValueIntangibleAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_lbl0" xml:lang="en-US">Financial assets held for managing liquidity risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:to="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number Of Weighted Average Earning Pershare Granted In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research And Development Expense Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ResearchAndDevelopmentExpenseMember" xlink:to="ifrx_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl0" xml:lang="en-US">Par value per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_JulyNineteenMember_lbl0" xml:lang="en-US">July Nineteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JulyNineteenMember" xlink:to="ifrx_JulyNineteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_lbl0" xml:lang="en-US">Other current borrowings and current portion of other non-current borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:to="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_JanuaryTwentyFourMember_lbl0" xml:lang="en-US">January Twenty Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JanuaryTwentyFourMember" xlink:to="ifrx_JanuaryTwentyFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ShareOptionsGrantedOptions_lbl1" xml:lang="en-US">Share Options Granted Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareOptionsGrantedOptions" xlink:to="ifrx_ShareOptionsGrantedOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear_lbl1" xml:lang="en-US">Weighted Average Fair Value Options Granted During The Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear" xlink:to="ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ChangesInAbstract_lbl0" xml:lang="en-US">Changes In Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ChangesInAbstract" xlink:to="ifrx_ChangesInAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TaxableIncome_lbl0" xml:lang="en-US">Taxable Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxableIncome" xlink:to="ifrx_TaxableIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OptionPlan2016Member_lbl0" xml:lang="en-US">Option Plan2016 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OptionPlan2016Member" xlink:to="ifrx_OptionPlan2016Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0" xml:lang="en-US">Additional provisions, other provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived_lbl1" xml:lang="en-US">Adjustments For Increase Decrease In Liabilities From Government Grant Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SoldAtPrice_lbl0" xml:lang="en-US">Sold At Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SoldAtPrice" xlink:to="ifrx_SoldAtPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonexecutiveBoardOfDirectorsMember_lbl0" xml:lang="en-US">Nonexecutive Board Of Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonexecutiveBoardOfDirectorsMember" xlink:to="ifrx_NonexecutiveBoardOfDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Share Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" xlink:to="ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl1" xml:lang="en-US">Increase Decrease Through Exercise Of Options Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl0" xml:lang="en-US">Trade and other payables, undiscounted cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0" xml:lang="en-US">Disclosure of trade and other payables [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment_lbl1" xml:lang="en-US">Nonrecognition Of Tax Effect On Sharebased Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment" xlink:to="ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant_lbl0" xml:lang="en-US">Intangible assets acquired by way of government grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" xlink:to="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for leases [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl0" xml:lang="en-US">Repayments of borrowings, classified as financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherFinancialResult_lbl1" xml:lang="en-US">Other Financial Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherFinancialResult" xlink:to="ifrx_OtherFinancialResult_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_RentalContractsFixedPeriod_lbl1" xml:lang="en-US">Rental Contracts Fixed Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_RentalContractsFixedPeriod" xlink:to="ifrx_RentalContractsFixedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FixedInterest_lbl1" xml:lang="en-US">Fixed Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FixedInterest" xlink:to="ifrx_FixedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock_lbl1" xml:lang="en-US">Disclosure Of Other Income Explanatory Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock" xlink:to="ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonCurrentAssetsAbstract_lbl0" xml:lang="en-US">Non Current Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonCurrentAssetsAbstract" xlink:to="ifrx_NonCurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WeightedNumberOfCommonSharesOutstanding_lbl1" xml:lang="en-US">Weighted Number Of Common Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeightedNumberOfCommonSharesOutstanding" xlink:to="ifrx_WeightedNumberOfCommonSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByFunction_lbl0" xml:lang="en-US">Other expense, by function</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByFunction" xlink:to="ifrs-full_OtherExpenseByFunction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl0" xml:lang="en-US">Interest income on impaired financial assets accrued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl2" xml:lang="en-US">Property Plant And Equipment Carrying Amount At Cost Of Revalued Assets01</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:to="ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations_lbl0" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation, other than translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl1" xml:lang="en-US">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Deferred tax expense (income) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl0" xml:lang="en-US">Other cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory_lbl0" xml:lang="en-US">Disclosure of financial instruments designated at fair value through profit or loss [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExchangeRate_lbl1" xml:lang="en-US">Exchange Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRate" xlink:to="ifrx_ExchangeRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherMember_lbl0" xml:lang="en-US">Other Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherMember" xlink:to="ifrx_OtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnDeposits_lbl0" xml:lang="en-US">Interest income on deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnDeposits" xlink:to="ifrs-full_InterestIncomeOnDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl0" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetFinancialResult_lbl1" xml:lang="en-US">Net Financial Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetFinancialResult" xlink:to="ifrx_NetFinancialResult_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_a2021Abstract_lbl0" xml:lang="en-US">a2021 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_a2021Abstract" xlink:to="ifrx_a2021Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfOutstandingSharesOption_lbl2" xml:lang="en-US">Number Of Outstanding Shares Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingSharesOption" xlink:to="ifrx_NumberOfOutstandingSharesOption_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Non-current restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AggregateInitialOffering_lbl1" xml:lang="en-US">Aggregate Initial Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregateInitialOffering" xlink:to="ifrx_AggregateInitialOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Interest paid, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory_lbl1" xml:lang="en-US">Disclosure Of Compensation Of The Groups Executive Management Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" xlink:to="ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AggregatePurchasePrice" xlink:to="ifrx_AggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed_lbl1" xml:lang="en-US">Expense Relating To Leases Of Lowvalue Asset For Which Recognition Exemption Has Been Used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfShareBasedPaymentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfShareBasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfShareBasedPaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Share Based Payments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfShareBasedPaymentsAbstract" xlink:to="ifrx_ScheduleOfShareBasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CommonSharesIssued_lbl0" xml:lang="en-US">Common Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CommonSharesIssued" xlink:to="ifrx_CommonSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAdjustmentsToReconcileProfitLoss_lbl0" xml:lang="en-US">Other adjustments to reconcile profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:to="ifrs-full_OtherAdjustmentsToReconcileProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Increase (decrease) through net exchange differences, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl0" xml:lang="en-US">Lease commitments for short-term leases for which recognition exemption has been used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl0" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DividendsPaidOrdinaryShares_lbl0" xml:lang="en-US">Dividends paid, ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendsPaidOrdinaryShares" xlink:to="ifrs-full_DividendsPaidOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_a2023Abstract_lbl0" xml:lang="en-US">a2023 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_a2023Abstract" xlink:to="ifrx_a2023Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure Of New And Amended Standards Adopted By The Group Explanatory Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" xlink:to="ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars_lbl1" xml:lang="en-US">Adjustments For Increase Decrease In Financial Assets From Government Grantsin Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:to="ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract_lbl0" xml:lang="en-US">Non Executive Board Of Directors Members Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract" xlink:to="ifrx_NonExecutiveBoardOfDirectorsMembersAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OtherDifferencesDueToTaxRateinDollars_lbl1" xml:lang="en-US">Other Differences Due To Tax Ratein Dollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OtherDifferencesDueToTaxRateinDollars" xlink:to="ifrx_OtherDifferencesDueToTaxRateinDollars_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office equipment [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OfficeEquipmentMember" xlink:to="ifrs-full_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_VehiclesMember_lbl0" xml:lang="en-US">Vehicles [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_VehiclesMember" xlink:to="ifrs-full_VehiclesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WeakensAgainstMember_lbl0" xml:lang="en-US">Weakens Against Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WeakensAgainstMember" xlink:to="ifrx_WeakensAgainstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NonexecutiveMember_lbl0" xml:lang="en-US">Nonexecutive Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NonexecutiveMember" xlink:to="ifrx_NonexecutiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_WAEPMember_lbl0" xml:lang="en-US">WAEPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_WAEPMember" xlink:to="ifrx_WAEPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TradeTaxes_lbl1" xml:lang="en-US">Trade Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TradeTaxes" xlink:to="ifrx_TradeTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock_lbl1" xml:lang="en-US">Description Of Accounting Policy For Grants From Government Poilcy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" xlink:to="ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement_lbl0" xml:lang="en-US">Number Of Other Equity Instrument Exercisable In Sharebased Payments Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" xlink:to="ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure Of Summary Of Material Accounting Policies Explanatory Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" xlink:to="ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MarketRiskMember_lbl0" xml:lang="en-US">Market risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MarketRiskMember" xlink:to="ifrs-full_MarketRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ProceedsOfferingCost_lbl1" xml:lang="en-US">Proceeds Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ProceedsOfferingCost" xlink:to="ifrx_ProceedsOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract_lbl0" xml:lang="en-US">Conversion Rate Euro To USDollars At Reporting Date111050 Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract" xlink:to="ifrx_ConversionRateEuroToUSDollarsAtReportingDate111050Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MaximumNumberOfCommonSharesAvailableForGrant_lbl1" xml:lang="en-US">Maximum Number Of Common Shares Available For Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaximumNumberOfCommonSharesAvailableForGrant" xlink:to="ifrx_MaximumNumberOfCommonSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_EquitysettledSharebasedPaymentExpenseMember_lbl1" xml:lang="en-US">Equitysettled Sharebased Payment Expense Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EquitysettledSharebasedPaymentExpenseMember" xlink:to="ifrx_EquitysettledSharebasedPaymentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CashHeldInUSDollarsMember_lbl1" xml:lang="en-US">Cash Held In USDollars Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashHeldInUSDollarsMember" xlink:to="ifrx_CashHeldInUSDollarsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_clinicalPreclinicalStudiesMember_lbl0" xml:lang="en-US">clinical Preclinical Studies Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_clinicalPreclinicalStudiesMember" xlink:to="ifrx_clinicalPreclinicalStudiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_JanuaryTwentyFourOneMember_lbl0" xml:lang="en-US">January Twenty Four One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_JanuaryTwentyFourOneMember" xlink:to="ifrx_JanuaryTwentyFourOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_CashAtBanksAbstract_lbl0" xml:lang="en-US">Cash At Banks Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_CashAtBanksAbstract" xlink:to="ifrx_CashAtBanksAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetBookValueOfRightOfUseAsset_lbl0" xml:lang="en-US">Net Book Value Of Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetBookValueOfRightOfUseAsset" xlink:to="ifrx_NetBookValueOfRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AccumulatedDepreciationAbstract" xlink:to="ifrx_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0" xml:lang="en-US">Adjustments for finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl0" xml:lang="en-US">Other finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl0" xml:lang="en-US">Disclosure of revenue [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Disposals And Retirement Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment" xlink:to="ifrx_DisposalsAndRetirementPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageEffectiveTaxRate_lbl0" xml:lang="en-US">Average effective tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageEffectiveTaxRate" xlink:to="ifrs-full_AverageEffectiveTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfNetFinancialResultTextBlock_lbl1" xml:lang="en-US">Disclosure Of Net Financial Result Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfNetFinancialResultTextBlock" xlink:to="ifrx_DisclosureOfNetFinancialResultTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SeptemberEighteenMember_lbl0" xml:lang="en-US">September Eighteen Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SeptemberEighteenMember" xlink:to="ifrx_SeptemberEighteenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk_lbl0" xml:lang="en-US">Nominal or principal amount of financial instrument on discontinuation of measurement at fair value through profit or loss because credit derivative is used to manage credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" xlink:to="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DueAmount_lbl1" xml:lang="en-US">Due Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DueAmount" xlink:to="ifrx_DueAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl0" xml:lang="en-US">Cash on hand</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnfinishedGoods_lbl1" xml:lang="en-US">Unfinished Goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnfinishedGoods" xlink:to="ifrx_UnfinishedGoods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CountryOfIncorporation_lbl0" xml:lang="en-US">Country of incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfIncorporation" xlink:to="ifrs-full_CountryOfIncorporation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory_lbl0" xml:lang="en-US">Disclosure of financial instruments at fair value through profit or loss [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceCost_lbl0" xml:lang="en-US">Other finance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceCost" xlink:to="ifrs-full_OtherFinanceCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ExchangeRateFluctuations_lbl0" xml:lang="en-US">Exchange Rate Fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ExchangeRateFluctuations" xlink:to="ifrx_ExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExposureToRisk_lbl0" xml:lang="en-US">Description of exposure to risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExposureToRisk" xlink:to="ifrs-full_DescriptionOfExposureToRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfOptionsExercised_lbl1" xml:lang="en-US">Number Of Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOptionsExercised" xlink:to="ifrx_NumberOfOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_UnderwritingDiscounts_lbl1" xml:lang="en-US">Underwriting Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_UnderwritingDiscounts" xlink:to="ifrx_UnderwritingDiscounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TotalLeases_lbl1" xml:lang="en-US">Total Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalLeases" xlink:to="ifrx_TotalLeases_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl0" xml:lang="en-US">Disclosure of cost of sales [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:to="ifrs-full_DisclosureOfCostOfSalesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl0" xml:lang="en-US">Description of accounting policy for interest income and expense [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_LocationAxis_lbl0" xml:lang="en-US">Location Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_LocationAxis" xlink:to="ifrx_LocationAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SensitivityAnalysisCarryingAmount_lbl1" xml:lang="en-US">Sensitivity Analysis Carrying Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SensitivityAnalysisCarryingAmount" xlink:to="ifrx_SensitivityAnalysisCarryingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TotalOtherAsset_lbl1" xml:lang="en-US">Total Other Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalOtherAsset" xlink:to="ifrx_TotalOtherAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl2" xml:lang="en-US">Number Of Outstandings Weighted Average Earning Pershare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare" xlink:to="ifrx_NumberOfOutstandingsWeightedAverageEarningPershare_lbl2"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US">Schedule Of Research And Development Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl0" xml:lang="en-US">Disclosure of market risk [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:to="ifrs-full_DisclosureOfMarketRiskExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1" xml:lang="en-US">Number Of Share Option Granted In Sharebased Payment Arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:to="ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets_lbl0" xml:lang="en-US">Accrued income including contract assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccruedIncomeIncludingContractAssets" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TotalCompensation_lbl1" xml:lang="en-US">Total Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TotalCompensation" xlink:to="ifrx_TotalCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MaximumMember_lbl1" xml:lang="en-US">Maximum Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MaximumMember" xlink:to="ifrx_MaximumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of restricted cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_StrengthsAgainstMember_lbl0" xml:lang="en-US">Strengths Against Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_StrengthsAgainstMember" xlink:to="ifrx_StrengthsAgainstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MinimumMember_lbl1" xml:lang="en-US">Minimum Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MinimumMember" xlink:to="ifrx_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_EmployeeBenefitsExpensesMember_lbl0" xml:lang="en-US">Employee Benefits Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EmployeeBenefitsExpensesMember" xlink:to="ifrx_EmployeeBenefitsExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl0" xml:lang="en-US">Maximum exposure to credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_MaximumExposureToCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ProceedsFromOfferingCost_lbl1" xml:lang="en-US">Proceeds From Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ProceedsFromOfferingCost" xlink:to="ifrx_ProceedsFromOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_PreferredUnitIssued_lbl1" xml:lang="en-US">Preferred Unit Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_PreferredUnitIssued" xlink:to="ifrx_PreferredUnitIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_SensitivityAnalysisConversionRate_lbl1" xml:lang="en-US">Sensitivity Analysis Conversion Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_SensitivityAnalysisConversionRate" xlink:to="ifrx_SensitivityAnalysisConversionRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FairValuesPerOptions_lbl1" xml:lang="en-US">Fair Values Per Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FairValuesPerOptions" xlink:to="ifrx_FairValuesPerOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_MayThirtyOneMember_lbl0" xml:lang="en-US">May Thirty One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_MayThirtyOneMember" xlink:to="ifrx_MayThirtyOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of authorisation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl0" xml:lang="en-US">Other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl0" xml:lang="en-US">Expense relating to leases of low-value assets for which recognition exemption has been used</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract_lbl" xml:lang="en-US">Schedule Of Compensation Of The Group SExecutive Management Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract" xlink:to="ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl0" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory_lbl0" xml:lang="en-US">Disclosure of information about methods, inputs and assumptions used for measuring obligations for returns, refunds and other similar obligations [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of commitments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoryWritedown2011_lbl0" xml:lang="en-US">Inventory write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets_lbl0" xml:lang="en-US">Description of how entity reflects its risk management strategy by using hedge accounting and designating hedging relationships that it frequently resets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" xlink:to="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0" xml:lang="en-US">Increase (decrease) through exercise of options, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl0" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DepositsHeldInEuroMember_lbl0" xml:lang="en-US">Deposits Held In Euro Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DepositsHeldInEuroMember" xlink:to="ifrx_DepositsHeldInEuroMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_July2OneMember_lbl0" xml:lang="en-US">July2 One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_July2OneMember" xlink:to="ifrx_July2OneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl0" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NetProceeds_lbl1" xml:lang="en-US">Net Proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NetProceeds" xlink:to="ifrx_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_InvestingActivitiesAbstract_lbl0" xml:lang="en-US">Investing Activities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_InvestingActivitiesAbstract" xlink:to="ifrx_InvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_OrdinaryShareSoldPrice_lbl1" xml:lang="en-US">Ordinary Share Sold Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_OrdinaryShareSoldPrice" xlink:to="ifrx_OrdinaryShareSoldPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfFunctionalCurrency_lbl0" xml:lang="en-US">Description of functional currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfFunctionalCurrency" xlink:to="ifrs-full_DescriptionOfFunctionalCurrency_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone_lbl1" xml:lang="en-US">Tax Losses For Which No Deferred Tax Asset Was Recognizedone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" xlink:to="ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_TaxLossCarryforwards_lbl1" xml:lang="en-US">Tax Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_TaxLossCarryforwards" xlink:to="ifrx_TaxLossCarryforwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl0" xml:lang="en-US">Current tax assets, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl1" xml:lang="en-US">Credit risk [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_NominalValue_lbl1" xml:lang="en-US">Nominal Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_NominalValue" xlink:to="ifrx_NominalValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl0" xml:lang="en-US">Tax effect of tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" xlink:to="ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl0" xml:lang="en-US">Equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Gains (losses) on financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FinancialAssetsFromGovernmentGrantsAmount_lbl1" xml:lang="en-US">Financial Assets From Government Grants Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialAssetsFromGovernmentGrantsAmount" xlink:to="ifrx_FinancialAssetsFromGovernmentGrantsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl1" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl0" xml:lang="en-US">Financial Liabilities At Amortized Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="ifrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_DisclosureOfCorporateInformationTextBlock_lbl0" xml:lang="en-US">Disclosure Of Corporate Information Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_DisclosureOfCorporateInformationTextBlock" xlink:to="ifrx_DisclosureOfCorporateInformationTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule Of General And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl0" xml:lang="en-US">Tax effect of foreign tax rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl0" xml:lang="en-US">Current raw materials and current production supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrx_AnnualizedAverageSharePricePeriod_lbl1" xml:lang="en-US">Annualized Average Share Price Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrx_AnnualizedAverageSharePricePeriod" xlink:to="ifrx_AnnualizedAverageSharePricePeriod_lbl1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>ifrx-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 21 04:12:18 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedIncomeStatement" roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedBalanceSheet" roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ShareholdersEquityType2or3" roleURI="http://www.inflarx.de.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedCashFlow" roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CorporateInformation" roleURI="http://www.inflarx.de.com/role/CorporateInformation"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_MaterialAccountingPolicies" roleURI="http://www.inflarx.de.com/role/MaterialAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_NotestotheConsolidatedStatementsofFinancialPosition" roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_Commitments" roleURI="http://www.inflarx.de.com/role/Commitments"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_OtherInformation" roleURI="http://www.inflarx.de.com/role/OtherInformation"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_SignificantEventsAftertheReportingDate" roleURI="http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_AccountingPoliciesByPolicy" roleURI="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CorporateInformationTables" roleURI="http://www.inflarx.de.com/role/CorporateInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLossTables" roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_NotestotheConsolidatedStatementsofFinancialPositionTables" roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CommitmentsTables" roleURI="http://www.inflarx.de.com/role/CommitmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_OtherInformationTables" roleURI="http://www.inflarx.de.com/role/OtherInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofRevenuesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofRevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCostofsalesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCostofsalesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOtherIncomeTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofEmployeeBenefitsExpensesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofNetFinancialResultTable" roleURI="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSharebasedPaymentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSharebasedpaymentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofShareBasedpaymentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofWeightedAverageTable" roleURI="http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofRightofUseAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofIntangibleAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofLeaseLiabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofAmountsRecognizedinProfitorLossTable" roleURI="http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofInventoryTable" roleURI="http://www.inflarx.de.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOtherAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable" roleURI="http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofFinancialAssetsandLiabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofTradeandOtherPayablesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofMarketRiskCreditRiskandLiquidityRiskTable" roleURI="http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCashCashEquivalentsandFinancialAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofSensitivityAnalysisTable" roleURI="http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofOutstandingFinancialCommitmentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofMaturityAnalysisofLeaseLiabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ScheduleofCompensationoftheGroupsExecutiveManagementTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_MaterialAccountingPoliciesDetails" roleURI="http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_ConsolidatedStatementsofOperationsandComprehensiveLossDetails" roleURI="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_NotestotheConsolidatedStatementsofFinancialPositionDetails" roleURI="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_CommitmentsDetails" roleURI="http://www.inflarx.de.com/role/CommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#ifrx_r_OtherInformationDetails" roleURI="http://www.inflarx.de.com/role/OtherInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ifrx-20231231.xsd#DocumentAndEntityInformation" roleURI="http://www.inflarx.de.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_SalesAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByFunction" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByFunction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_OtherExpenseByFunction" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_FinanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ShareInformationBasedOnLossForThePeriodAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ShareInformationBasedOnLossForThePeriodAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ShareInformationBasedOnLossForThePeriodAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareInformationBasedOnLossForThePeriodAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareInformationBasedOnLossForThePeriodAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals">
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="NonCurrentAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="NonCurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssetsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="NonCurrentLiabilitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentGovernmentGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentProvisionsForEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisionsForEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisionsForEmployeeBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherReservesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="6.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonShare" xlink:href="ifrx-20231231.xsd#ifrx_IssuanceOfCommonShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssuanceOfCommonShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IncreaseDecreaseThroughExerciseOfOptionsShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="OperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingActivitiesAbstract" xlink:to="AdjustmentsForAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ChangesInAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForAbstract" xlink:to="ChangesInAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" xlink:href="ifrx-20231231.xsd#ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="InvestingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_InvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="InvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfCurrentAndNoncurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="PurchaseOfCurrentAndNoncurrentFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="FinancingActivitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_FinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="FinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TransactionCostsFromIssuanceOfCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_TransactionCostsFromIssuanceOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="TransactionCostsFromIssuanceOfCommonShares" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CorporateInformation">
    <loc xlink:type="locator" xlink:label="DisclosureOfCorporateInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfCorporateInformationTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCorporateInformationAbstract" xlink:to="DisclosureOfCorporateInformationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/MaterialAccountingPolicies">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
    <loc xlink:type="locator" xlink:label="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:to="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/Commitments">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherInformation">
    <loc xlink:type="locator" xlink:label="OtherInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationAbstract" xlink:to="ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="AccountingPoliciesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotesToTheCashFlowStatementPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_NotesToTheCashFlowStatementPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NotesToTheCashFlowStatementPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CorporateInformationTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfCorporateInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCorporateInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCorporateInformationAbstract" xlink:to="DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OptionPlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_OptionPlan2016Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OptionPlan2016Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="LongTermIncentivePlan2017Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCostOfSalesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCostOfSalesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfCostOfSalesExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSalesAndMarketingExpenseTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="DisclosureOfSalesAndMarketingExpenseTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherIncomeExplanatoryTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="DisclosureOfOtherIncomeExplanatoryTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfNetFinancialResultTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfNetFinancialResultTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="DisclosureOfNetFinancialResultTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasePrepaymentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfLeasePrepaymentsExplanatory" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMarketRiskExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMarketRiskExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfMarketRiskExplanatory" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCommitmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsExplanatory" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CommitmentsTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherInformationTables">
    <loc xlink:type="locator" xlink:label="OtherInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationAbstract" xlink:to="DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract"/>
    <loc xlink:type="locator" xlink:label="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:href="ifrx-20231231.xsd#ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"/>
    <loc xlink:type="locator" xlink:label="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract" xlink:to="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="InflaRxGmbHMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxGmbHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InflaRxGmbHMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InflaRxPharmaceuticalIncMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxPharmaceuticalIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InflaRxPharmaceuticalIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable" xlink:to="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CountryOfIncorporation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CountryOfIncorporation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_CountryOfIncorporation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfFunctionalCurrency" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfFunctionalCurrency"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_DescriptionOfFunctionalCurrency" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems" xlink:to="ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofRevenuesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRevenuesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenuesAbstract" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenuesAbstract" xlink:to="ifrs-full_Revenue_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCostofsalesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCostOfSalesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCostOfSalesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfSalesAbstract" xlink:to="ifrs-full_CostOfSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CostOfSales_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCostOfSalesAbstract" xlink:to="ifrs-full_CostOfSales_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfSalesAndMarketingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSalesAndMarketingExpensesAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThirdpartyExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_ThirdpartyExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ThirdpartyExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EmployeeBenefitsExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EquitysettledSharebasedPaymentExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="LegalAndConsultingFeesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="OtherExpensesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfResearchAndDevelopmentExpensesAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ThirdpartyServicesMember" xlink:href="ifrx-20231231.xsd#ifrx_ThirdpartyServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ThirdpartyServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManufacturingOfClinicalMaterialMember" xlink:href="ifrx-20231231.xsd#ifrx_ManufacturingOfClinicalMaterialMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ManufacturingOfClinicalMaterialMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="clinicalPreclinicalStudiesMember" xlink:href="ifrx-20231231.xsd#ifrx_clinicalPreclinicalStudiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="clinicalPreclinicalStudiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EmployeeBenefitsExpensesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EquitysettledSharebasedPaymentExpenseMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="LegalAndConsultingFeesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="OtherExpensesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EmployeeBenefitsExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EmployeeBenefitsExpensesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitysettledSharebasedPaymentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EquitysettledSharebasedPaymentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LegalAndConsultingFeesMember" xlink:href="ifrx-20231231.xsd#ifrx_LegalAndConsultingFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="LegalAndConsultingFeesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InsuranceExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_InsuranceExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="InsuranceExpensesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepreciationAmortizationExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_DepreciationAmortizationExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="DepreciationAmortizationExpenseMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationExpenseForNonexecutiveBoardDirectorsMember" xlink:href="ifrx-20231231.xsd#ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="CompensationExpenseForNonexecutiveBoardDirectorsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="OtherExpensesMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherIncomeAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOtherIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherIncomeAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilityForFuturePolicyBenefitPeriodExpense" xlink:href="ifrx-20231231.xsd#ifrx_LiabilityForFuturePolicyBenefitPeriodExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherIncomeAbstract" xlink:to="LiabilityForFuturePolicyBenefitPeriodExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherIncomeAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEmployeeBenefitsExpensesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeBenefitsExpensesAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:to="ifrs-full_BusinessCombinationsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WagesAndSalariesMember" xlink:href="ifrx-20231231.xsd#ifrx_WagesAndSalariesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="WagesAndSalariesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SocialSecurityContributionsemployersShareMember" xlink:href="ifrx-20231231.xsd#ifrx_SocialSecurityContributionsemployersShareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="SocialSecurityContributionsemployersShareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquitysettledSharebasedPaymentExpensesMember" xlink:href="ifrx-20231231.xsd#ifrx_EquitysettledSharebasedPaymentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="EquitysettledSharebasedPaymentExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherMember" xlink:href="ifrx-20231231.xsd#ifrx_OtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="OtherMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="Employeebenefitsexpense" xlink:href="ifrx-20231231.xsd#ifrx_Employeebenefitsexpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems" xlink:to="Employeebenefitsexpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetFinancialResultAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfNetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueFromInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_RevenueFromInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeIncome" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ForeignExchangeIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeExpense" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ForeignExchangeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeResult" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeResult"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="ForeignExchangeResult" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherFinancialResult" xlink:href="ifrx-20231231.xsd#ifrx_OtherFinancialResult"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="OtherFinancialResult" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetFinancialResult" xlink:href="ifrx-20231231.xsd#ifrx_NetFinancialResult"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="NetFinancialResult" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedPaymentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="OptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="WAEPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedPaymentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="OptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="WAEPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionPlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_OptionPlan2016Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="OptionPlan2016Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWeightedAverageSharesOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="NumberOfWeightedAverageSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOpionsExercisedDuring" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOpionsExercisedDuring"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="NumberOfOpionsExercisedDuring" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesExercisedDuring" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfSharesExercisedDuring"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="NumberOfSharesExercisedDuring" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_0" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWeightedAverageSharesOutstanding_0" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="NumberOfWeightedAverageSharesOutstanding_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesOptionsExercisable" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfSharesOptionsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="NumberOfSharesOptionsExercisable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WAEPExercisables" xlink:href="ifrx-20231231.xsd#ifrx_WAEPExercisables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems" xlink:to="WAEPExercisables" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedPaymentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedPaymentsAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OptionsMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="OptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WAEPMember" xlink:href="ifrx-20231231.xsd#ifrx_WAEPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="WAEPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDefinedBenefitLiabilityAssetAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NetDefinedBenefitLiabilityAssetAxis" xlink:to="LongTermIncentivePlan2017Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingSharesOption" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingSharesOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfOutstandingSharesOption" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingsWeightedAverageEarningPershare" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingsWeightedAverageEarningPershare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfOutstandingsWeightedAverageEarningPershare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfShareOptionGrantedInSharebasedPaymentArrangement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionExercisedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfShareOptionExercisedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfShareOptionForfeitedInSharebasedPaymentArrangement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingSharesOption_0" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingSharesOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfOutstandingSharesOption_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOutstandingsWeightedAverageEarningPershare_0" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOutstandingsWeightedAverageEarningPershare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfOutstandingsWeightedAverageEarningPershare_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems" xlink:to="NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfWeightedAverageAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:to="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="January4Member" xlink:href="ifrx-20231231.xsd#ifrx_January4Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="January4Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January4OneMember" xlink:href="ifrx-20231231.xsd#ifrx_January4OneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="January4OneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2Member" xlink:href="ifrx-20231231.xsd#ifrx_July2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="July2Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2OneMember" xlink:href="ifrx-20231231.xsd#ifrx_July2OneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="July2OneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January12Member" xlink:href="ifrx-20231231.xsd#ifrx_January12Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="January12Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January12OneMember" xlink:href="ifrx-20231231.xsd#ifrx_January12OneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="January12OneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepricingApril13Member" xlink:href="ifrx-20231231.xsd#ifrx_RepricingApril13Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="RepricingApril13Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="November21Member" xlink:href="ifrx-20231231.xsd#ifrx_November21Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="November21Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JanuaryTwentyFourMember" xlink:href="ifrx-20231231.xsd#ifrx_JanuaryTwentyFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="JanuaryTwentyFourMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JanuaryTwentyFourOneMember" xlink:href="ifrx-20231231.xsd#ifrx_JanuaryTwentyFourOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="JanuaryTwentyFourOneMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayThirtyOneMember" xlink:href="ifrx-20231231.xsd#ifrx_MayThirtyOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="MayThirtyOneMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JulySevenMember" xlink:href="ifrx-20231231.xsd#ifrx_JulySevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="JulySevenMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JulySevenOneMember" xlink:href="ifrx-20231231.xsd#ifrx_JulySevenOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="JulySevenOneMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JulyNineteenMember" xlink:href="ifrx-20231231.xsd#ifrx_JulyNineteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="JulyNineteenMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeptemberEighteenMember" xlink:href="ifrx-20231231.xsd#ifrx_SeptemberEighteenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="SeptemberEighteenMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:to="ifrs-full_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="a2021Abstract" xlink:href="ifrx-20231231.xsd#ifrx_a2021Abstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems" xlink:to="a2021Abstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsGrantedOptions" xlink:href="ifrx-20231231.xsd#ifrx_ShareOptionsGrantedOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="ShareOptionsGrantedOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuePerOptions" xlink:href="ifrx-20231231.xsd#ifrx_FairValuePerOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="FairValuePerOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeRateAsOfGrantDate" xlink:href="ifrx-20231231.xsd#ifrx_ForeignExchangeRateAsOfGrantDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="ForeignExchangeRateAsOfGrantDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuesPerOptions" xlink:href="ifrx-20231231.xsd#ifrx_FairValuesPerOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="FairValuesPerOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceAtGrantDateExercisePrices" xlink:href="ifrx-20231231.xsd#ifrx_SharePriceAtGrantDateExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="SharePriceAtGrantDateExercisePrices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="a2021Abstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXs61wHyckAg2nxvBikE1dTD+mD7F+hOhyP4JUKDa+ELwxhT8MZgkEf+kZKh9LsB5Bl51UtFYWeFaK0UqFEG6idGWj2iasVoEhjS4SNz7nGGfwAEve9SFnoCvh6mjiJGCAbfimk+l/Cx0=] CSR-->
    <loc xlink:type="locator" xlink:label="AdvancePaymentsMember" xlink:href="ifrx-20231231.xsd#ifrx_AdvancePaymentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="AdvancePaymentsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="CostMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" xlink:href="ifrx-20231231.xsd#ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalsAndRetirementPropertyPlantAndEquipment" xlink:href="ifrx-20231231.xsd#ifrx_DisposalsAndRetirementPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="DisposalsAndRetirementPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_0" xlink:href="ifrx-20231231.xsd#ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" xlink:href="ifrx-20231231.xsd#ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetBookValuePropertyAndEquipment" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValuePropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems" xlink:to="NetBookValuePropertyAndEquipment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRightofUseAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfRightofUseAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRightofUseAssetsAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="CostMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BuildingsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BuildingsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_BuildingsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_VehiclesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_VehiclesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_VehiclesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetsRevaluationSurplus01" xlink:href="ifrx-20231231.xsd#ifrx_RightofuseAssetsRevaluationSurplus01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="RightofuseAssetsRevaluationSurplus01" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrs-full_DepreciationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightofuseAssetsRevaluationSurplus01_0" xlink:href="ifrx-20231231.xsd#ifrx_RightofuseAssetsRevaluationSurplus01"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="RightofuseAssetsRevaluationSurplus01_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NetBookValueOfRightOfUseAsset" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueOfRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems" xlink:to="NetBookValueOfRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:to="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LineItemsByFunctionMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LineItemsByFunctionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="ifrs-full_LineItemsByFunctionMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CostMember" xlink:href="ifrx-20231231.xsd#ifrx_CostMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="CostMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedAmortizationMember" xlink:href="ifrx-20231231.xsd#ifrx_AccumulatedAmortizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis" xlink:to="AccumulatedAmortizationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComputerSoftwareMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerSoftwareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ComputerSoftwareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesPaidForSoftwareMember" xlink:href="ifrx-20231231.xsd#ifrx_AdvancesPaidForSoftwareMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="AdvancesPaidForSoftwareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssets" xlink:href="ifrx-20231231.xsd#ifrx_IntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="IntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" xlink:href="ifrx-20231231.xsd#ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" xlink:href="ifrx-20231231.xsd#ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssets_0" xlink:href="ifrx-20231231.xsd#ifrx_IntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="IntangibleAssets_0" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NetBookValueIntangibleAsset" xlink:href="ifrx-20231231.xsd#ifrx_NetBookValueIntangibleAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems" xlink:to="NetBookValueIntangibleAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdditionalProvisionsOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalProvisionsOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_AdditionalProvisionsOtherProvisions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughDerecognitionFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_DecreaseThroughDerecognitionFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" xlink:href="ifrx-20231231.xsd#ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="GainsLossesOnExchangeDifferenceOnTranslationNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnBonds" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBonds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_InterestExpenseOnBonds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RentalExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_RentalExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountsRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofInventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnfinishedGoods" xlink:href="ifrx-20231231.xsd#ifrx_UnfinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="UnfinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_FinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoriesTotal" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoriesTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="ifrs-full_InventoriesTotal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpense" xlink:href="ifrx-20231231.xsd#ifrx_PrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="PrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCurrentOtherAssets" xlink:href="ifrx-20231231.xsd#ifrx_NonCurrentOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="NonCurrentOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentOtherAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_CurrentOtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="CurrentOtherAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Prepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Prepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="ifrs-full_Prepayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAdjustmentsToReconcileProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="ifrs-full_OtherAdjustmentsToReconcileProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalOtherAsset" xlink:href="ifrx-20231231.xsd#ifrx_TotalOtherAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="TotalOtherAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="TaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxBenefitsAtTaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TaxBenefitsAtTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="TaxBenefitsAtTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" xlink:href="ifrx-20231231.xsd#ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonrecognitionOfTaxEffectOnSharebasedPayment" xlink:href="ifrx-20231231.xsd#ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="NonrecognitionOfTaxEffectOnSharebasedPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NondeductibleExpensesForTaxPurposesinDollars" xlink:href="ifrx-20231231.xsd#ifrx_NondeductibleExpensesForTaxPurposesinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="NondeductibleExpensesForTaxPurposesinDollars" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherDifferencesDueToTaxRateinDollars" xlink:href="ifrx-20231231.xsd#ifrx_OtherDifferencesDueToTaxRateinDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="OtherDifferencesDueToTaxRateinDollars" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsFromGovernmentGrants" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="FinancialAssetsFromGovernmentGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilitiesFromGovernmentGrants" xlink:href="ifrx-20231231.xsd#ifrx_LiabilitiesFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="LiabilitiesFromGovernmentGrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DepositsHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_DepositsHeldInUSDollarsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="DepositsHeldInUSDollarsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositsHeldInEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_DepositsHeldInEuroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="DepositsHeldInEuroMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSDollarsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="CashHeldInUSDollarsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashHeldInUSEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSEuroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="CashHeldInUSEuroMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ShortTermDepositsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ShortTermDepositsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermDepositsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAtBanksAbstract" xlink:href="ifrx-20231231.xsd#ifrx_CashAtBanksAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="CashAtBanksAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Cash" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAtBanksAbstract" xlink:to="ifrs-full_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTradeAndOtherPayablesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfTradeAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedLiabilitiesFromCommercialActivities" xlink:href="ifrx-20231231.xsd#ifrx_AccruedLiabilitiesFromCommercialActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="AccruedLiabilitiesFromCommercialActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_OtherPayables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MarketRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MarketRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_MarketRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CreditRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LiquidityRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_LiquidityRiskMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExposureToRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExposureToRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrs-full_DescriptionOfExposureToRisk" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems" xlink:to="ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSensitivityAnalysisAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfSensitivityAnalysisAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSensitivityAnalysisAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:to="ifrs-full_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WeakensAgainstMember" xlink:href="ifrx-20231231.xsd#ifrx_WeakensAgainstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="WeakensAgainstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StrengthsAgainstMember" xlink:href="ifrx-20231231.xsd#ifrx_StrengthsAgainstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="StrengthsAgainstMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SensitivityAnalysisConversionRate" xlink:href="ifrx-20231231.xsd#ifrx_SensitivityAnalysisConversionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="SensitivityAnalysisConversionRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SensitivityAnalysisCarryingAmount" xlink:href="ifrx-20231231.xsd#ifrx_SensitivityAnalysisCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems" xlink:to="SensitivityAnalysisCarryingAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BalancesWithBanks" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_BalancesWithBanks" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DebtSecurities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_DebtSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalFundsAvailable" xlink:href="ifrx-20231231.xsd#ifrx_TotalFundsAvailable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOutstandingFinancialCommitmentsAbstract" xlink:to="TotalFundsAvailable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract" xlink:to="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="WithinOneYearMember" xlink:href="ifrx-20231231.xsd#ifrx_WithinOneYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="WithinOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AfterOneYearButNotMoreThanFiveYearsMember" xlink:href="ifrx-20231231.xsd#ifrx_AfterOneYearButNotMoreThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="AfterOneYearButNotMoreThanFiveYearsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MoreThanFiveYearsMember" xlink:href="ifrx-20231231.xsd#ifrx_MoreThanFiveYearsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="MoreThanFiveYearsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable" xlink:to="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfDiscounting" xlink:href="ifrx-20231231.xsd#ifrx_EffectOfDiscounting"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="EffectOfDiscounting" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NetDeferredTaxLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetDeferredTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrs-full_NetDeferredTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalLeases" xlink:href="ifrx-20231231.xsd#ifrx_TotalLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="TotalLeases" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" xlink:href="ifrx-20231231.xsd#ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalizedLeases" xlink:href="ifrx-20231231.xsd#ifrx_CapitalizedLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems" xlink:to="CapitalizedLeases" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable"/>
    <loc xlink:type="locator" xlink:label="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract" xlink:to="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExecutiveManagementMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ExecutiveManagementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonexecutiveBoardOfDirectorsMember" xlink:href="ifrx-20231231.xsd#ifrx_NonexecutiveBoardOfDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="NonexecutiveBoardOfDirectorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable" xlink:to="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExecutiveManagementAbstract" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ExecutiveManagementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermEmployeeBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExecutiveManagementAbstract" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:href="ifrx-20231231.xsd#ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExecutiveManagementAbstract" xlink:to="PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAtAmortisedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="ifrs-full_CurrentFinancialAssetsAtAmortisedCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalCompensation" xlink:href="ifrx-20231231.xsd#ifrx_TotalCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems" xlink:to="TotalCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
    <loc xlink:type="locator" xlink:label="MaterialAccountingPoliciesDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_MaterialAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="MaterialAccountingPoliciesDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_MaterialAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="MaterialAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="ifrx-20231231.xsd#ifrx_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis" xlink:to="ifrs-full_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GermanMinistryOfEducationAndResearchMember" xlink:href="ifrx-20231231.xsd#ifrx_GermanMinistryOfEducationAndResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="GermanMinistryOfEducationAndResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsGrantedMember" xlink:href="ifrx-20231231.xsd#ifrx_OptionsGrantedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="OptionsGrantedMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsTable" xlink:to="MaterialAccountingPoliciesDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_GovernmentGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfGrant" xlink:href="ifrx-20231231.xsd#ifrx_PercentageOfGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="PercentageOfGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentGovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_CurrentGovernmentGrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RentalContractsFixedPeriod" xlink:href="ifrx-20231231.xsd#ifrx_RentalContractsFixedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="RentalContractsFixedPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmortizedPeriod" xlink:href="ifrx-20231231.xsd#ifrx_AmortizedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="AmortizedPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualizedAverageSharePricePeriod" xlink:href="ifrx-20231231.xsd#ifrx_AnnualizedAverageSharePricePeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="AnnualizedAverageSharePricePeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AccruedIncomeIncludingContractAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccruedIncomeIncludingContractAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_AccruedIncomeIncludingContractAssets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_OtherAssets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InventoryWritedown2011" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InventoryWritedown2011"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaterialAccountingPoliciesDetailsLineItems" xlink:to="ifrs-full_InventoryWritedown2011" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CreditRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="InflaRxGmbHMember" xlink:href="ifrx-20231231.xsd#ifrx_InflaRxGmbHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="InflaRxGmbHMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExecutiveManagementMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveManagementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ExecutiveManagementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ifrs-full_DefinedBenefitPlansAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DefinedBenefitPlansMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DefinedBenefitPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="ifrs-full_DefinedBenefitPlansMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LongTermIncentivePlan2017Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2017Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="LongTermIncentivePlan2017Member" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermIncentivePlan2016Member" xlink:href="ifrx-20231231.xsd#ifrx_LongTermIncentivePlan2016Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DefinedBenefitPlansAxis" xlink:to="LongTermIncentivePlan2016Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementLocationAxis" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="IncomeStatementLocationAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeStatementLocationDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_IncomeStatementLocationDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:href="ifrx-20231231.xsd#ifrx_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable" xlink:to="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_SalesAndMarketingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_SellingExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinanceCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_OtherFinanceCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_OtherIncome" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetFinancialCost" xlink:href="ifrx-20231231.xsd#ifrx_NetFinancialCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="NetFinancialCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnDeposits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_InterestIncomeOnDeposits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShortTermMarketableSecurities" xlink:href="ifrx-20231231.xsd#ifrx_ShortTermMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ShortTermMarketableSecurities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeGain" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeGain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_ForeignExchangeGain" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ForeignExchangeLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ForeignExchangeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_ForeignExchangeLoss" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_OtherFinancialAssets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedNumberOfCommonSharesOutstanding" xlink:href="ifrx-20231231.xsd#ifrx_WeightedNumberOfCommonSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="WeightedNumberOfCommonSharesOutstanding" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossPerShare" xlink:href="ifrx-20231231.xsd#ifrx_LossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="LossPerShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOfOutstandingShareOptions" xlink:href="ifrx-20231231.xsd#ifrx_ExercisePriceOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ExercisePriceOfOutstandingShareOptions" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionRate" xlink:href="ifrx-20231231.xsd#ifrx_ConversionRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ConversionRate" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AverageRate" xlink:href="ifrx-20231231.xsd#ifrx_AverageRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="AverageRate" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumNumberOfCommonSharesAvailableForGrant" xlink:href="ifrx-20231231.xsd#ifrx_MaximumNumberOfCommonSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="MaximumNumberOfCommonSharesAvailableForGrant" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ordinarySharesPercentage" xlink:href="ifrx-20231231.xsd#ifrx_ordinarySharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ordinarySharesPercentage" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageFairValueOptionsGrantedDuringTheYear" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="WeightedAverageFairValueOptionsGrantedDuringTheYear" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" xlink:href="ifrx-20231231.xsd#ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRange" xlink:href="ifrx-20231231.xsd#ifrx_ExercisePriceRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ExercisePriceRange" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsGranted" xlink:href="ifrx-20231231.xsd#ifrx_OptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="OptionsGranted" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfStockOptionsForfeited" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfStockOptionsForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="NumberOfStockOptionsForfeited" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsExercised" xlink:href="ifrx-20231231.xsd#ifrx_NumberOfOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="NumberOfOptionsExercised" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedDividends" xlink:href="ifrx-20231231.xsd#ifrx_ExpectedDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems" xlink:to="ExpectedDividends" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CreditRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CreditRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CreditRiskMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarketProgramMember" xlink:href="ifrx-20231231.xsd#ifrx_MarketProgramMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="MarketProgramMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionMember" xlink:href="ifrx-20231231.xsd#ifrx_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="StockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="ifrs-full_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MinimumMember" xlink:href="ifrx-20231231.xsd#ifrx_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaximumMember" xlink:href="ifrx-20231231.xsd#ifrx_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsTable" xlink:to="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenses" xlink:href="ifrx-20231231.xsd#ifrx_ResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ResearchAndDevelopmentExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_CashOutflowForLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WritedownsReversalsOfInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WritedownsReversalsOfInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_WritedownsReversalsOfInventories" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateIncomeTax" xlink:href="ifrx-20231231.xsd#ifrx_CorporateIncomeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CorporateIncomeTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SolidaritySurcharge" xlink:href="ifrx-20231231.xsd#ifrx_SolidaritySurcharge"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="SolidaritySurcharge" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradeTaxes" xlink:href="ifrx-20231231.xsd#ifrx_TradeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="TradeTaxes" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AverageEffectiveTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageEffectiveTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_AverageEffectiveTaxRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalTaxRate" xlink:href="ifrx-20231231.xsd#ifrx_TotalTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="TotalTaxRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" xlink:href="ifrx-20231231.xsd#ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" xlink:href="ifrx-20231231.xsd#ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxBasisOfInvestmentCostForIncomeTaxPurposes" xlink:href="ifrx-20231231.xsd#ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="TaxBasisOfInvestmentCostForIncomeTaxPurposes" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TaxEffectOfTaxLosses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfTaxLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_TaxEffectOfTaxLosses" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxLossCarryforwards" xlink:href="ifrx-20231231.xsd#ifrx_TaxLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="TaxLossCarryforwards" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxableIncome" xlink:href="ifrx-20231231.xsd#ifrx_TaxableIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="TaxableIncome" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInterestReceivable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInterestReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_CurrentInterestReceivable" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAndNonCurrentFinancialAssets" xlink:href="ifrx-20231231.xsd#ifrx_CurrentAndNonCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CurrentAndNonCurrentFinancialAssets" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FixedInterest" xlink:href="ifrx-20231231.xsd#ifrx_FixedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="FixedInterest" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsFromGovernmentGrantsAmount" xlink:href="ifrx-20231231.xsd#ifrx_FinancialAssetsFromGovernmentGrantsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="FinancialAssetsFromGovernmentGrantsAmount" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueAmount" xlink:href="ifrx-20231231.xsd#ifrx_DueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="DueAmount" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalOrdinarySharesIssued" xlink:href="ifrx-20231231.xsd#ifrx_CapitalOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CapitalOrdinarySharesIssued" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ParValuePerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_ParValuePerShare" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonShares" xlink:href="ifrx-20231231.xsd#ifrx_CommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CommonShares" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesIssued" xlink:href="ifrx-20231231.xsd#ifrx_CommonSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CommonSharesIssued" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetsSoldUnderAgreementToRepurchaseCarryingAmount" xlink:href="ifrx-20231231.xsd#ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="AssetsSoldUnderAgreementToRepurchaseCarryingAmount" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="ifrx-20231231.xsd#ifrx_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="NetProceeds" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateCommonShares" xlink:href="ifrx-20231231.xsd#ifrx_AggregateCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="AggregateCommonShares" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsOfferingCost" xlink:href="ifrx-20231231.xsd#ifrx_ProceedsOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ProceedsOfferingCost" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnderwritingDiscounts" xlink:href="ifrx-20231231.xsd#ifrx_UnderwritingDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="UnderwritingDiscounts" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromOfferingCost" xlink:href="ifrx-20231231.xsd#ifrx_ProceedsFromOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ProceedsFromOfferingCost" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_DividendsPaidOrdinaryShares" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DividendsPaidOrdinarySharesPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DividendsPaidOrdinarySharesPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_DividendsPaidOrdinarySharesPerShare" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" xlink:href="ifrx-20231231.xsd#ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="ifrx-20231231.xsd#ifrx_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="AggregatePurchasePrice" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateInitialOffering" xlink:href="ifrx-20231231.xsd#ifrx_AggregateInitialOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="AggregateInitialOffering" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValue" xlink:href="ifrx-20231231.xsd#ifrx_NominalValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="NominalValue" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesValue" xlink:href="ifrx-20231231.xsd#ifrx_OrdinarySharesValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="OrdinarySharesValue" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareSoldPrice" xlink:href="ifrx-20231231.xsd#ifrx_OrdinaryShareSoldPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="OrdinaryShareSoldPrice" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SoldAtPrice" xlink:href="ifrx-20231231.xsd#ifrx_SoldAtPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="SoldAtPrice" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharePurchase" xlink:href="ifrx-20231231.xsd#ifrx_OrdinarySharePurchase"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="OrdinarySharePurchase" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreferredUnitIssued" xlink:href="ifrx-20231231.xsd#ifrx_PreferredUnitIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="PreferredUnitIssued" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyIssuedCapital" xlink:href="ifrx-20231231.xsd#ifrx_CompanyIssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CompanyIssuedCapital" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpectedReimbursementOtherProvisions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedReimbursementOtherProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_ExpectedReimbursementOtherProvisions" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonSharesInExcessOfNominalValue" xlink:href="ifrx-20231231.xsd#ifrx_CommonSharesInExcessOfNominalValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="CommonSharesInExcessOfNominalValue" order="50.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsForAccruedPayments" xlink:href="ifrx-20231231.xsd#ifrx_PaymentsForAccruedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="PaymentsForAccruedPayments" order="51.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VariablesHeldConstant" xlink:href="ifrx-20231231.xsd#ifrx_VariablesHeldConstant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="VariablesHeldConstant" order="52.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax" order="53.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateFluctuations" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ExchangeRateFluctuations" order="54.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_MaximumExposureToCreditRisk" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaximumExposureToCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRisk" order="55.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" order="56.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_FinancialAssets" order="57.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashOnHand" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOnHand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems" xlink:to="ifrs-full_CashOnHand" order="58.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CommitmentsDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotesAndOtherExplanatoryInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_CommitmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NotesAndOtherExplanatoryInformationAbstract" xlink:to="CommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateCurrencyAxis" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsTable" xlink:to="ExchangeRateCurrencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateCurrencyDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRateCurrencyDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeRateCurrencyAxis" xlink:to="ExchangeRateCurrencyDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CashHeldInUSEuroMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSEuroMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeRateCurrencyAxis" xlink:to="CashHeldInUSEuroMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CashHeldInUSDollarsMember" xlink:href="ifrx-20231231.xsd#ifrx_CashHeldInUSDollarsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeRateCurrencyAxis" xlink:to="CashHeldInUSDollarsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsTable" xlink:to="CommitmentsDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRate" xlink:href="ifrx-20231231.xsd#ifrx_ExchangeRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDetailsLineItems" xlink:to="ExchangeRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherInformationDetails">
    <loc xlink:type="locator" xlink:label="OtherInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherInformationDetailsTable" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OtherInformationDetailsLineItems" xlink:href="ifrx-20231231.xsd#ifrx_OtherInformationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationAbstract" xlink:to="OtherInformationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExecutiveMembersMember" xlink:href="ifrx-20231231.xsd#ifrx_ExecutiveMembersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ExecutiveMembersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonexecutiveMember" xlink:href="ifrx-20231231.xsd#ifrx_NonexecutiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="NonexecutiveMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LocationAxis" xlink:href="ifrx-20231231.xsd#ifrx_LocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsTable" xlink:to="LocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LocationDomainDomain" xlink:href="ifrx-20231231.xsd#ifrx_LocationDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LocationAxis" xlink:to="LocationDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DEMember" xlink:href="ifrx-20231231.xsd#ifrx_DEMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LocationAxis" xlink:to="DEMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnitedStateOneMember" xlink:href="ifrx-20231231.xsd#ifrx_UnitedStateOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LocationAxis" xlink:to="UnitedStateOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsTable" xlink:to="OtherInformationDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Revenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsLineItems" xlink:to="ifrs-full_Revenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsLineItems" xlink:to="ifrs-full_NoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherInformationDetailsLineItems" xlink:to="ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="ifrx-20231231.xsd#ifrx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572374196384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">InflaRx
N.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IFRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">58,883,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">P7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Winzerlaer
Str. 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">07745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jena<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, nominal value &#8364;0.12 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EY GmbH & Co. KG Wirtschaftspr&#252;fungsgesellschaft<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Munich,
Germany<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">00000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Winzerlaer
Str. 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">07745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jena<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dr.
Thomas Taapken<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3641) 508 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">00000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572371971056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">&#8364; 63,089<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(532,262)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="num">(469,173)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(4,001,299)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(41,024,131)<span></span>
</td>
<td class="num">(37,526,090)<span></span>
</td>
<td class="num">(35,697,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(12,628,756)<span></span>
</td>
<td class="num">(14,869,564)<span></span>
</td>
<td class="num">(11,984,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">13,219,704<span></span>
</td>
<td class="nump">20,159,169<span></span>
</td>
<td class="nump">54,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByFunction', window );">Other expenses</a></td>
<td class="num">(4,440)<span></span>
</td>
<td class="num">(1,381)<span></span>
</td>
<td class="num">(6,381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="num">(44,908,096)<span></span>
</td>
<td class="num">(32,237,866)<span></span>
</td>
<td class="num">(47,634,817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">3,804,827<span></span>
</td>
<td class="nump">608,679<span></span>
</td>
<td class="nump">109,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="num">(35,628)<span></span>
</td>
<td class="num">(45,250)<span></span>
</td>
<td class="num">(24,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange result</a></td>
<td class="num">(1,841,872)<span></span>
</td>
<td class="nump">2,442,297<span></span>
</td>
<td class="nump">1,964,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial result</a></td>
<td class="nump">313,240<span></span>
</td>
<td class="num">(252,471)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(42,667,529)<span></span>
</td>
<td class="num">(29,484,611)<span></span>
</td>
<td class="num">(45,630,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract', window );"><strong>Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations', window );">Exchange differences on translation of foreign currency</a></td>
<td class="nump">125,085<span></span>
</td>
<td class="nump">4,206,810<span></span>
</td>
<td class="nump">6,777,061<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">&#8364; (42,542,444)<span></span>
</td>
<td class="num">&#8364; (25,277,801)<span></span>
</td>
<td class="num">&#8364; (38,852,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareInformationBasedOnLossForThePeriodAbstract', window );"><strong>Share information (based on loss for the period)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding (in Shares)</a></td>
<td class="nump">54,940,137<span></span>
</td>
<td class="nump">44,207,873<span></span>
</td>
<td class="nump">41,629,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss per share (basic/diluted) (in Euro per share)</a></td>
<td class="num">&#8364; (0.78)<span></span>
</td>
<td class="num">&#8364; (0.67)<span></span>
</td>
<td class="num">&#8364; (1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">&#8364; (42,667,529)<span></span>
</td>
<td class="num">&#8364; (29,484,611)<span></span>
</td>
<td class="num">&#8364; (45,630,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences on translation of the financial statements of a parent company or a stand-alone entity to a different presentation currency. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ShareInformationBasedOnLossForThePeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ShareInformationBasedOnLossForThePeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572366776608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss per share diluted</a></td>
<td class="num">&#8364; (0.78)<span></span>
</td>
<td class="num">&#8364; (0.67)<span></span>
</td>
<td class="num">&#8364; (1.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572374078368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NonCurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">&#8364; 289,577<span></span>
</td>
<td class="nump">&#8364; 328,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,071,666<span></span>
</td>
<td class="nump">1,311,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">68,818<span></span>
</td>
<td class="nump">138,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">257,267<span></span>
</td>
<td class="nump">308,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">9,052,741<span></span>
</td>
<td class="nump">2,900,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">10,740,069<span></span>
</td>
<td class="nump">4,988,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">11,367,807<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Current other assets</a></td>
<td class="nump">4,036,650<span></span>
</td>
<td class="nump">14,170,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Tax receivable</a></td>
<td class="nump">3,791,564<span></span>
</td>
<td class="nump">1,432,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Financial assets from government grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">732,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">77,504,518<span></span>
</td>
<td class="nump">64,810,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">12,767,943<span></span>
</td>
<td class="nump">16,265,355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">109,468,483<span></span>
</td>
<td class="nump">97,411,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">120,208,552<span></span>
</td>
<td class="nump">102,399,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">7,065,993<span></span>
</td>
<td class="nump">5,364,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">334,211,338<span></span>
</td>
<td class="nump">282,552,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other capital reserves</a></td>
<td class="nump">40,050,053<span></span>
</td>
<td class="nump">36,635,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(286,127,819)<span></span>
</td>
<td class="num">(243,460,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Other components of equity</a></td>
<td class="nump">7,382,166<span></span>
</td>
<td class="nump">7,257,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">102,581,730<span></span>
</td>
<td class="nump">88,349,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NonCurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">745,716<span></span>
</td>
<td class="nump">987,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">36,877<span></span>
</td>
<td class="nump">36,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">782,593<span></span>
</td>
<td class="nump">1,024,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">11,974,362<span></span>
</td>
<td class="nump">4,987,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Liabilities from government grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,209,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">374,329<span></span>
</td>
<td class="nump">369,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisionsForEmployeeBenefits', window );">Employee benefits</a></td>
<td class="nump">1,609,766<span></span>
</td>
<td class="nump">1,312,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">2,885,772<span></span>
</td>
<td class="nump">147,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">16,844,229<span></span>
</td>
<td class="nump">13,026,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,626,822<span></span>
</td>
<td class="nump">14,050,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL EQUITY AND LIABILITIES</a></td>
<td class="nump">&#8364; 120,208,552<span></span>
</td>
<td class="nump">&#8364; 102,399,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisionsForEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisionsForEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NonCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NonCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NonCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NonCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373105072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholders' Equity - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Shares outstanding</div></th>
<th class="th"><div>Issued capital</div></th>
<th class="th"><div>Share premium</div></th>
<th class="th"><div>Other capital reserves</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Other components of equity</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,387,410<span></span>
</td>
<td class="nump">&#8364; 220,289,876<span></span>
</td>
<td class="nump">&#8364; 26,259,004<span></span>
</td>
<td class="num">&#8364; (168,345,620)<span></span>
</td>
<td class="num">&#8364; (3,726,791)<span></span>
</td>
<td class="nump">&#8364; 77,863,880<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">28,228,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,630,059)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(45,630,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange differences on translation of foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,777,061<span></span>
</td>
<td class="nump">6,777,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,630,059)<span></span>
</td>
<td class="nump">6,777,061<span></span>
</td>
<td class="num">(38,852,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,873,203<span></span>
</td>
<td class="nump">63,269,346<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65,142,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IssuanceOfCommonShare', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="nump">15,610,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,219,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,219,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,332,205<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,332,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Share options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,839<span></span>
</td>
<td class="nump">970,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,014,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares', window );">Share options exercised (in Shares)</a></td>
<td class="nump">365,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,304,452<span></span>
</td>
<td class="nump">280,310,744<span></span>
</td>
<td class="nump">30,591,209<span></span>
</td>
<td class="num">(213,975,679)<span></span>
</td>
<td class="nump">3,050,270<span></span>
</td>
<td class="nump">105,280,996<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">44,203,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,484,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,484,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange differences on translation of foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,206,810<span></span>
</td>
<td class="nump">4,206,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,484,611)<span></span>
</td>
<td class="nump">4,206,810<span></span>
</td>
<td class="num">(25,277,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">2,289,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,349,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IssuanceOfCommonShare', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(47,735)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,044,356<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,044,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Equity-settled share-based payments (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Share options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares', window );">Share options exercised (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,364,452<span></span>
</td>
<td class="nump">282,552,633<span></span>
</td>
<td class="nump">36,635,564<span></span>
</td>
<td class="num">(243,460,290)<span></span>
</td>
<td class="nump">7,257,080<span></span>
</td>
<td class="nump">88,349,440<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">44,703,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,667,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,667,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange differences on translation of foreign currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,085<span></span>
</td>
<td class="nump">125,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,667,529)<span></span>
</td>
<td class="nump">125,085<span></span>
</td>
<td class="num">(42,542,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,110<span></span>
</td>
<td class="nump">54,796,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,483,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IssuanceOfCommonShare', window );">Issuance of ordinary shares (in Shares)</a></td>
<td class="nump">14,059,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,360,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,360,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,414,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,414,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Equity-settled share-based payments (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Share options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
<td class="nump">222,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 236,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares', window );">Share options exercised (in Shares)</a></td>
<td class="nump">120,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,065,993<span></span>
</td>
<td class="nump">&#8364; 334,211,338<span></span>
</td>
<td class="nump">&#8364; 40,050,053<span></span>
</td>
<td class="num">&#8364; (286,127,819)<span></span>
</td>
<td class="nump">&#8364; 7,382,166<span></span>
</td>
<td class="nump">&#8364; 102,581,730<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">58,883,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IssuanceOfCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IssuanceOfCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572421486016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the Period</a></td>
<td class="num">&#8364; (42,667,529)<span></span>
</td>
<td class="num">&#8364; (29,484,611)<span></span>
</td>
<td class="num">&#8364; (45,630,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AdjustmentsForAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</a></td>
<td class="nump">567,780<span></span>
</td>
<td class="nump">596,597<span></span>
</td>
<td class="nump">669,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net finance income</a></td>
<td class="num">(2,240,566)<span></span>
</td>
<td class="num">(2,753,255)<span></span>
</td>
<td class="num">(2,004,757)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">3,414,489<span></span>
</td>
<td class="nump">6,044,356<span></span>
</td>
<td class="nump">4,332,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Net foreign exchange differences</a></td>
<td class="nump">413,017<span></span>
</td>
<td class="nump">385,359<span></span>
</td>
<td class="nump">111,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ChangesInAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars', window );">Financial assets from government grants</a></td>
<td class="nump">732,971<span></span>
</td>
<td class="num">(732,971)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">7,825,182<span></span>
</td>
<td class="num">(3,308,485)<span></span>
</td>
<td class="num">(7,094,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Employee benefits</a></td>
<td class="nump">297,518<span></span>
</td>
<td class="num">(64,024)<span></span>
</td>
<td class="num">(3,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">2,738,164<span></span>
</td>
<td class="nump">9,403<span></span>
</td>
<td class="nump">19,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived', window );">Liabilities from government grants received</a></td>
<td class="num">(6,209,266)<span></span>
</td>
<td class="num">(2,090,734)<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">6,986,824<span></span>
</td>
<td class="num">(3,586,706)<span></span>
</td>
<td class="nump">316,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="num">(11,367,807)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">1,732,284<span></span>
</td>
<td class="nump">1,287,200<span></span>
</td>
<td class="nump">1,070,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(36,025)<span></span>
</td>
<td class="num">(44,946)<span></span>
</td>
<td class="num">(23,633)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(37,812,966)<span></span>
</td>
<td class="num">(33,742,817)<span></span>
</td>
<td class="num">(39,936,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_InvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets', window );">Purchase of intangible assets and property and equipment</a></td>
<td class="num">(81,100)<span></span>
</td>
<td class="num">(162,391)<span></span>
</td>
<td class="num">(37,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets', window );">Purchase of current and non-current financial assets</a></td>
<td class="num">(104,051,972)<span></span>
</td>
<td class="num">(64,474,543)<span></span>
</td>
<td class="num">(97,516,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets', window );">Proceeds from the maturity of current financial assets</a></td>
<td class="nump">86,436,456<span></span>
</td>
<td class="nump">83,995,029<span></span>
</td>
<td class="nump">71,603,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash from/ (used in) investing activities</a></td>
<td class="num">(17,696,616)<span></span>
</td>
<td class="nump">19,358,095<span></span>
</td>
<td class="num">(25,950,885)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="nump">56,483,929<span></span>
</td>
<td class="nump">2,349,624<span></span>
</td>
<td class="nump">65,142,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TransactionCostsFromIssuanceOfCommonShares', window );">Transaction costs from issuance of ordinary shares</a></td>
<td class="num">(3,360,626)<span></span>
</td>
<td class="num">(47,735)<span></span>
</td>
<td class="num">(4,219,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of share options</a></td>
<td class="nump">236,943<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,014,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="num">(373,977)<span></span>
</td>
<td class="num">(364,430)<span></span>
</td>
<td class="num">(360,644)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="nump">52,986,269<span></span>
</td>
<td class="nump">1,937,459<span></span>
</td>
<td class="nump">61,577,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(2,523,313)<span></span>
</td>
<td class="num">(12,447,262)<span></span>
</td>
<td class="num">(4,310,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(974,099)<span></span>
</td>
<td class="nump">2,462,622<span></span>
</td>
<td class="nump">4,591,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,265,355<span></span>
</td>
<td class="nump">26,249,995<span></span>
</td>
<td class="nump">25,968,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">&#8364; 12,767,943<span></span>
</td>
<td class="nump">&#8364; 16,265,355<span></span>
</td>
<td class="nump">&#8364; 26,249,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expired 2023-01-01<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AdjustmentsForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AdjustmentsForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial assets from government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities from government grants received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ChangesInAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ChangesInAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_FinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_FinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_InvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_InvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of current and non-current financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TransactionCostsFromIssuanceOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs from issuance of common shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TransactionCostsFromIssuanceOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572445956736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfCorporateInformationAbstract', window );"><strong>Corporate Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfCorporateInformationTextBlock', window );">Corporate information</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1. Corporate information</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of InflaRx N.V. and its subsidiaries (collectively, the &#8220;Group&#8221;) for the year ended December
31, 2023 were authorized for issue in accordance with a resolution of the Board of Directors on March 20, 2024. InflaRx N.V. (the &#8220;Company&#8221;)
is a Dutch public company with limited liability (<i>naamloze vennootschap</i>) with its corporate seat in Amsterdam, The Netherlands,
and is registered in the Commercial Register of The Netherlands Chamber of Commerce Business Register under CCI number 68904312. The
Company&#8217;s registered office is at Winzerlaer Stra&#223;e 2 in 07745 Jena, Germany. Since November 10, 2017, the Company&#8217;s
ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#8220;IFRX&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiaries, collectively, are a biotechnology group pioneering anti-inflammatory therapeutics by applying its proprietary
anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation
factor known as C5a and its receptor C5aR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiaries
are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable
returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity.
Subsidiaries are fully consolidated from the date on which control is obtained by the Group. They are deconsolidated from the date control
ceases. The acquisition method of accounting is used to account for business combinations by the Group. Intercompany transactions, balances
and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s subsidiaries as at December 31, 2023 are set out below. Unless otherwise stated, such subsidiaries have share capital consisting
solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights
held by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">Place&#160;of&#160;business/<br/>
country&#160;of</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">Functional</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership
interest<br/>
held by the Company</b></span></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Name</td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>incorporation</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>currency</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Principal activities</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; font-weight: bold">InflaRx GmbH</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Jena and Munich, Germany</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">EUR</td><td style="padding-bottom: 1.5pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Operating subsidiary, R&amp;D, holder of all IP</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; width: 35%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">InflaRx Pharmaceuticals, Inc.</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt">Ann Arbor, MI, United States</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left; padding-bottom: 1.5pt">Operating subsidiary, R&amp;D, US commercialization</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfCorporateInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfCorporateInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfCorporateInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfCorporateInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369264944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract', window );"><strong>Material Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory', window );">Material accounting policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Material accounting policies</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.
Basis of preparation</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as issued
by the International Accounting Standards Board (herein &#8220;IFRS&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a historical cost basis. These consolidated financial statements of the Group
comprise the Company and its wholly owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc. The consolidated financial statements
are presented in Euro (&#8364;). The presentation currency of the Group is the Euro, as the functional currency of the largest operating
company, InflaRx GmbH, continues to be the Euro. Effective January 1, 2023, the functional currency of InflaRx N.V. changed from the
U.S. dollar to the Euro due to a change in the Company&#8217;s operational function and, in turn, a change in the primary currency of
its underlying transactions. This change in functional currency has been accounted for prospectively. The functional currency of InflaRx
Pharmaceuticals, Inc. is the U.S. dollar ($), as most of their income and expenses occurred in U.S. dollars in 2023. All financial information
presented in Euro has been rounded to the nearest Euro, unless stated otherwise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.
Summary of material accounting policies</i></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section describes material accounting policies adopted in the preparation of these consolidated financial statements. These policies
have been consistently applied to all the years presented, unless otherwise stated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
</i></b><i><span style="font-variant: normal; font-weight: normal">New and amended standards adopted by the Group</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            17 insurance contracts</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 8 accounting policies, changes in accounting estimates and errors: definition of accounting
                                            estimates</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 12 deferred tax related to assets and liabilities arising from a single transaction</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 and IFRS practice statement 2 - disclosure of accounting policies</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
policies for the following IFRS standards have been applied starting in Q2 2023 for the first time, as no transactions in the scope of
these IFRS standards had been previously recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS
                                            2 inventories&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to IAS 2, inventories are stated at the lower amount of their cost or at their net realizable value. Cost comprises direct material cost
and, where applicable, direct labor costs and those overhead costs that have been incurred in bringing the inventories to their present
location and condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling
price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Recognizing inventories
at net realizable value includes writing down inventories considered excess or obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            15 revenue from contracts with customers</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, the Company exclusively uses distributors to sell its products to end customers (e.g., hospitals). The end customers (e.g. hospitals)
have been determined to be the customer in these sales arrangements. As such, payments received from the distributors are not contract
liabilities but are rather &#8220;other liabilities&#8221; recognized in &#8220;other accrued liabilities.&#8221; Revenue is therefore
recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer, that is,
when the customer obtains control of that asset and is measured considering estimated return liabilities and expected rebates or cash
discounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
</i></b><i><span style="font-variant: normal; font-weight: normal">New standard not yet adopted</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following standards issued will be adopted in a future period, and the potential impact on the Group&#8217;s consolidated financial statements,
if any, is being assessed:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IFRS 16 leases: leases on sale and leaseback</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 presentation of financial statements: classification of liabilities as current or
                                            non-current and non-current liabilities with covenants</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 21 effects of changes in foreign exchange rates: lack of exchangeability</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
</i></b><i><span style="font-variant: normal; font-weight: normal">Current and non-current classification</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group presents assets and liabilities in the statement of financial position based on current/non-current classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets include assets that are sold, consumed or realized as part of the normal operating cycle (operating cycle is assumed to be 12
months), or cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after
the reporting period. All other assets are classified as non-current.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities, such as trade payables, lease liabilities or employee benefits with a term of up to 12 months, and payables for operating
costs or social security charges, are part of the working capital used in the Company&#8217;s normal operating cycle. Such operating
items are classified as current liabilities even if they are due to be settled more than 12 months after the reporting period. All other
liabilities are classified as non-current.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
</i></b><i><span style="font-variant: normal; font-weight: normal">Foreign currency transactions</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in a foreign currency are initially translated into the respective functional currency using the spot rate prevailing on the dates of
the transaction. Monetary items which are not denominated in the functional currency are subsequently translated using the rate applicable
at the end of the period. The resulting currency gains and losses are recognized directly in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
consolidation, the assets and liabilities of operations in a currency other than Euro (the presentation currency of the Company) are
translated into Euros at the rate of exchange prevailing at the reporting date and their statements of operations are translated with
monthly average exchange rates during the reporting period. The exchange differences arising on translation for consolidation are recognized
in &#8216;other comprehensive income&#8217; (OCI). On disposal of a foreign operation, the component of OCI relating to that particular
foreign operation is reclassified to profit or loss. OCI is disclosed as &#8216;other components of equity&#8217; in consolidated statements
of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(e)
</i></b><i><span style="font-variant: normal; font-weight: normal">Grants from government and similar bodies</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects.
The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If
grant funds are received prior to qualifying expenses being incurred or assets purchased or prior to all grant conditions have been met,
such amounts are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other
operating income in the period in which the corresponding expenses are incurred (or, for expenses incurred prior to all grant conditions
being met, in the period in which reasonable assurance that all grant conditions will be met is attained). If the funds reimburse purchased
assets, the liability is reduced with a corresponding amount deducted from the asset&#8217;s carrying amount upon recording of the qualified
asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group up
to five years after concluding the project sponsored by the government.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the Group announced that it received a grant of up to &#8364;43.7 million from the German Ministry of Education and Research
and the German Ministry of Health to support its development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent
changes in the Group&#8217;s research and development plan and fewer costs projected within the timeframe of the grant, it was notified
that the amount available to it was &#8364;41.4 million. The grant is structured as a reimbursement of 80% of certain pre-specified expenses
related to the clinical development and manufacturing of vilobelimab. The grant period ended on June 30, 2023. In total, during the duration
of the grant period through December 31, 2023, the Group received &#8364;33.3 million to support its activities regarding the development
of vilobelimab as a new therapeutic agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial
scale manufacturing process to ensure the ability of being able to provide such treatment to the broader population.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(f)
</i></b><i><span style="font-variant: normal; font-weight: normal">Notes to the cash flow statement, cash, and cash equivalents</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated statements of cash flows have been prepared using the indirect method for cash flows from operating activities. The cash
disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash comprises cash on hand and demand
deposits. Cash equivalents are short-term bank deposits that are readily convertible to a known amount of cash and are not subject to
a significant risk of changes in value with an original maturity of three months or less. Interest paid and received is included in the
cash from operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(g)
</i></b><i><span style="font-variant: normal; font-weight: normal">Research and development expenses</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses comprise third party services, wages and salaries, cost of materials, intellectual property related expenses,
depreciation and amortization of relevant equipment and intangibles as well as overhead. Research and development expenses mainly consist
of costs for clinical trials and manufacturing of the Company&#8217;s clinical drug products; additionally, costs are incurred for pre-clinical
activities as well as basic research activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development expenses were capitalized because
management assessed that not all the recognition criteria of IAS&#160;38 had been met. This assessment is due to the general uncertainties
in drug development and the unpredictability of regulatory requirements. Therefore, research and development expenditures are expensed
when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(h)
</i></b><i><span style="font-variant: normal; font-weight: normal">Employee benefits</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Short-term employee benefits</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for wages and salaries and cash bonuses are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as employee benefits in the consolidated statements of financial position. A liability is recognized if the Group has a
present legal or constructive obligation to pay such amount as a result of past service provided by the employee and if such obligation
can be estimated reliably.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Share-based payment transactions</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense,
with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect
the number of awards for which the related service conditions are expected to be met, including an estimate of forfeitures, such that
the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based
payment awards with immediate vesting, the&#160;grant-date fair value of the share-based payment is measured to reflect such conditions and
there is no gain or loss recognized for differences between expected and actual outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)
</i></b><i><span style="font-variant: normal; font-weight: normal">Lease arrangements</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of one
to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Right-of-use assets</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#8217;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Lease liabilities</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)
Short-term leases and leases of low-value assets</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Determining the lease term of contracts</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)
</i></b><i><span style="font-variant: normal; font-weight: normal">Interest income</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)
</i></b><i><span style="font-variant: normal; font-weight: normal">Intangible assets</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over three years. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)
</i></b><i><span style="font-variant: normal; font-weight: normal">Property and equipment</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory equipment: three to 13 years</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment: one to five years</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#8216;other income&#8217;
or &#8216;other expenses&#8217; in the consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(m)
</i></b><i><span style="font-variant: normal; font-weight: normal">Impairment of assets</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there has been a change in the estimates used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no impairments or reversals of impairments in 2021, 2022 or 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(n)
</i></b><i><span style="font-variant: normal; font-weight: normal">Financial assets and liabilities (financial instruments)</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Definition</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#8217;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;D projects).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Criteria for the recognition and derecognition, initial measurement</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iii) Subsequent measurement method</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considering
the Group&#8217;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#8216;3.8
Financial assets and financial liabilities.&#8217;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Criteria for realization of income and expenses</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#8216;C.8. Net Financial Result&#8217;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(o)
</i></b><i><span style="font-variant: normal; font-weight: normal">Fair Value Measurement</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#8216;D.8. Financial
assets and financial liabilities&#8217;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1, quoted prices in active markets for identical assets or liabilities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(p)
</i></b><i><span style="font-variant: normal; font-weight: normal">Income tax</span></i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Current income tax</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(ii) Deferred income tax</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#8217;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Significant accounting judgements, estimates and assumptions</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#8217;s accounting policies involve the following areas:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Accounting for share-based payments</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#8216;C.10.(b). Measurement of fair values of share options granted&#8217;). In 2023, the Company&#8217;s share price volatility
for the purposes of the calculation was determined on the basis of the 5-year annualized average share price, which management believes
will be indicative of the share price development of the Company in future periods. This led to a range of applied volatility rates in
2023 of 135% to 145.66% for the different options granted during the year of this report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company must estimate the number of equity instruments which will vest in future periods as awards may be forfeited prior to vesting
due to an awardee&#8217;s failure to satisfy a performance condition, including due to employment termination. An assumption of the forfeiture
rate is regularly made on the basis of historical information and adjusted to reflect future expectations. Revisions to the forfeiture
rate could result in a cumulative effect of the change in estimate for current and prior periods to be recognized in the period of change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Measurement of third-party R&amp;D clinical trial and contracted manufacturing expense</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
measuring R&amp;D expenses for the reporting period, the Company estimates the amount of expense to recognize and liability to accrue
to the extent that invoices of the Company&#8217;s contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations
(&#8220;CDMOs&#8221;) are not yet received and exceed any prepayments made. The timing of the invoicing of project services by CROs follow
contractual billing schedules and can occur several months prior to or following a reporting period. This estimation involves determining
a percentage-of-completion whereby the degree to which services have been rendered for the individual project activities contracted from
the CRO and CDMOs is assessed and estimated by in-house R&amp;D project managers and reviewed by the controlling department. This percentage-of-completion
is used to measure the amount of the unbilled project activities which have already been rendered by the reporting date and the associated
R&amp;D expense and liability to recognize as a result.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage-of-completion estimates are based on the best information available at the time. However, additional information may become
available in the future and management may adjust the estimate in such future periods. In this event, the Company may be required to
record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. The
Company considers resulting increases or decreases in expenses as changes in estimates and reflects such changes in research and development
expenses in the period identified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrued &#8364;4.4 million as of December 31, 2023 and &#8364;2.3 million as of December 31, 2022 (see Note &#8216;D.11. Trade and other
payables&#8217;) in third-party accruals in relation to its ongoing clinical trials and manufacturing activities. As of these dates, prepayments
were recorded for those payments made against which no services had yet been rendered (2023: &#8364;3.7 million, 2022: &#8364;9.8 million,
see Note &#8216;D.6. Other assets&#8217;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Realizability of Inventories</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost and net realizable value. Net realizable value comprises the estimated sales proceeds less the necessary
expected costs up to the time of sale. For determining the net realizable value, at each reporting date, the Company estimates excess
and obsolete inventory primarily using a model of expected future sales and using assumptions with significant estimation uncertainty
such as expected medical need and expected market penetration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these estimates rely, in part, on management&#8217;s assumptions about future events outside of the Company&#8217;s control, such as
continuation of the emergency use authorization in the United States and granting of marketing authorization in the European Union. In
making these assumptions, management assesses the probability of these authorizations remaining in place or being granted, as applicable,
by considering correspondence with the relevant regulatory authorities and the Company&#8217;s actions to achieve any required conditions
for the authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the possible alternative uses for raw materials, unfinished and finished products is taken into consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly assesses market and sales trends, market conditions, disease prevalence, competitive landscape, and regulatory environment
to refine estimates for excess and obsolete inventory. Based on these assessments, and taking manufacturing lead-times into consideration,
management takes operational decisions to order inventory based on inventory aging and the criteria mentioned above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-downs for the year ended December 31, 2023 amounted to &#8364;521k (prior year: &#8364;0k) and were mainly due to the expiration
of shelf life of finished goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
included in the model of expected future demand may require revision in future periods which could result in changes to the estimate
of excess and obsolete inventory and in inventory write-downs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes made to accounting policies by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373709152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory', window );">Consolidated statements of operations and comprehensive loss</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C. Consolidated statements of operations and comprehensive loss</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>1. Revenues</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">63,089</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">63,089</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2023, the Group began the commercialization of GOHIBIC (vilobelimab) in the United States. In connection with the start of the commercialization,
the Group entered into agreements with certain subsidiaries of Cencora Inc. (&#8220;Cencora&#8221;) (formerly known as AmerisourceBergen
Corp.) to act as the Group&#8217;s U.S. distributor and make GOHIBIC (vilobelimab) available for order by U.S. hospital customers. Cencora
provides cold storage, cold-chain distribution services, inventory management and secondary labeling/packaging, among other services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2023, the Company realized revenues from the product sales for the first time since its inception. Revenues reported are sales to end
customers (hospitals). Sales to distributors do not constitute completion of a performance obligation towards a customer and, thus, do
not result in the recognition of revenue for the Company under IFRS 15.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>2. Cost of sales</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Cost of Sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">532,262</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">532,262</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
of sales recognized during the twelve months ended December 31, 2023, are related to GOHIBIC (vilobelimab) revenues in the United States
and to write-downs of inventory.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of sales for products sold in these periods do not include costs of materials, as the associated costs of these materials were incurred
in prior periods, before the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) granted an Emergency Use Authorization (the &#8220;EUA&#8221;)
for GOHIBIC (vilobelimab) in April 2023. These materials were recorded as &#8216;research and development expenses&#8217; in the periods
they were incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of sales during the twelve months ended December 31, 2023 mainly consists of write-downs of inventories that will expire prior to
their expected sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>3. Sales and marketing expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,851,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">67,462</td><td style="font-style: italic; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,054,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,583</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total sales and marketing expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,001,299</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the twelve months ended December 31, 2023 the Group incurred &#8364;4.0 million of sales and marketing expenses in the United States of
America. These expenses are mainly composed of &#8364;1.0 million in personnel costs and &#8364;1.9 million in external services for distribution
of GOHIBIC (vilobelimab). The Group started with its commercialization activities when the EUA was granted in April 2023. Prior to that,
no sales and marketing expenses had been incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>4. Research and development expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased in 2023 compared to 2022 by &#8364;3.5 million. The table below shows the composition of research and
development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31,802,983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,543,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,247,081</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which clinical material and related manufacturing services</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">18,109,345</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">16,194,152</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">6,615,840</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which clinical, pre-clinical studies</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">13,693,638</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">12,349,351</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">21,631,240</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,776,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,957,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,941,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1,500,670</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">2,456,571</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1,622,898</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,758,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,690,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,074,710</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">686,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">334,273</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">434,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,024,131</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">37,526,090</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,697,935</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>5. General and administrative expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses decreased by &#8364;2.2 million in 2023 from the prior year, predominantly due to lower costs from equity-settled
share-based payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Employee benefits expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,392,905</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,125,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,680</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1,846,356</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">3,587,785</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">2,709,307</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,239,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,104,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,065,423</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,934,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,330,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,615,920</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation &amp; amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,905</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551,566</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation expense for non-executive directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,247,273</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,533,469</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">979,884</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,628,756</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,869,564</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,984,722</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>6. Other income</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income was &#8364;13.2 million, which is primarily attributable to income recognized from grant payments received from the German federal
government for the development of vilobelimab in severe COVID-19 patients, including expenses related to clinical development and manufacturing
process development. Other income decreased in 2023, compared to the prior year, due to the incurrence of less expenses eligible for
reimbursement under the grant and the end of the grant period on June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in">Other income from government grants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,155,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,116,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Further other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,627</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,219,704</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,159,169</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">54,221</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>7. Employee benefits expenses</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the items of employee benefits expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Wages and salaries</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,192,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,863,423</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,919,166</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Social security contributions (employer&#8217;s share)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">671,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity-settled share-based payment expenses (see Note C.10. Share-based payments)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,414,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,044,356</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,332,205</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659,002</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">503,351</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">519,425</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,210,345</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,083,664</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,442,493</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of employees as of December 31, 2023 increased to 66 (equivalent to 62.2 full time equivalents (FTEs)) from 48 employees (equivalent
to 44.3 FTEs) at the end of 2022 and 59 employees (equivalent to 55.9 FTEs) at the end of 2021. These numbers are as of December 31 and
do not constitute annual average numbers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>8. Net financial result</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,804,827</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">608,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">109,391</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,303</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,714</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,090</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,055</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Financial result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,769,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">563,429</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">84,622</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign exchange income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,529,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,924,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,569,836</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,371,261</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,482,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,605,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Foreign exchange result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,841,872</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,442,298</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,964,135</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(252,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,240,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,753,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,004,757</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
financial result decreased by &#8364;0.5&#160;million from 2022 to 2023. This overall decrease was comprised of higher interest income
of &#8364;3.2&#160;million from marketable securities and short-term deposits in U.S. dollars held by the Company and its subsidiaries
(from &#8364;0.6&#160;million in 2022 to &#8364;3.8&#160;million in 2023), a reduction in foreign exchange by &#8364;4.3&#160;million (from
a gain of &#8364;2.4&#160;million in 2022 to a loss of &#8364;1.8&#160;million in 2023) and higher other financial result of &#8364;0.6&#160;million
(from a loss of &#8364;0.3&#160;million in 2022 to a gain of &#8364;0.3&#160;million in 2023) due to an adjustment to the expected credit
loss allowance in 2023, which is deducted from the Company&#8217;s current and non-current financial assets (please also refer to Note
D.6. &#8216;Other assets&#8217;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency income and expenses arise from the translation of cash and cash equivalents, marketable securities and other financial assets
and liabilities denominated in foreign currencies at the exchange rates prevailing at the balance sheet date. All resulting translation
differences are recognized in the income statement. These gains and losses are caused by a change in exchange rates at the reporting
dates and may not ultimately be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>9. Loss per share</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
per ordinary share is calculated by dividing the loss of the period by the weighted average number of ordinary shares outstanding during
the period. The weighted number of ordinary shares outstanding for the financial year 2023 was 54,940,137, for 2022 it amounted to 44,207,873
and for 2021 it was 41,629,974. Loss per share was &#8364;0.78, &#8364;0.67 and &#8364;1.10 in 2023, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company is in a loss-making situation, the diluted loss per share is the same as basic loss per share, because the weighted average
number of shares to be issued upon the exercise of the stock options, the only dilutive instruments issued, would produce an anti-dilutive
effect. Refer to Note &#8216;C.10. for the balances of outstanding share options.&#8217;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>10. Share-based payments</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>a) Equity-settled share-based payment arrangements</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of its historical financing rounds prior to 2016, InflaRx GmbH established equity-settled share-based payment programs. Those
InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. in November 2017:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">148,433</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">148,433</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">148,433</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">148,433</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average share price (WAEP)</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise price for all options granted prior to 2016 outstanding at the end of the year was &#8364;0.01 per share or less (2022: &#8364;0.01
or less).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and conditions of the share option plan of 2016 (the &#8220;2016 Plan&#8221;), InflaRx GmbH granted rights to subscribe for
InflaRx GmbH&#8217;s common shares to directors, senior management, and key employees. Those InflaRx GmbH options were converted into
options for ordinary shares of the Company in November 2017:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">888,632</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.74</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">888,632</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.35/&#8364;2.96</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80; -sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><div style="-sec-ix-hidden: hidden-fact-81">&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">888,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.68</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">888,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.74</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">888,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.68</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">888,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.74</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31,2022 $0.9376, average rate 2022 $0.9489</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life for the share options outstanding under the 2016 Plan as of December&#160;31,&#160;2023 was
7.94 years (2022: 8.94 years).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the closing of its initial public offering, InflaRx N.V. established a new incentive plan (the &#8220;2017 Plan&#8221;).
The initial maximum number of ordinary shares available for issuance under equity incentive awards granted pursuant to the 2017 Plan
equals 2,341,097 ordinary shares. On January 1, 2021 and on January 1 of each calendar year thereafter, an additional number of shares
equal to 4% of the total outstanding ordinary shares on December 31 of the immediately preceding year (or any lower number of shares
as determined by the Board of Directors) will become available for issuance under equity incentive awards granted pursuant to the 2017
Plan:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,985,523</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.97 /&#8364;1.84</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,170,046</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.95 /&#8364;3.49</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,735,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.58/&#8364;2.39</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,966,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.98 / &#8364;1.88</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.70/&#8364;2.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(136,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22 /&#8364;2.11</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(105,327</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.16/&#8364;2.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,930</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86 /&#8364;1.76</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6,584,946</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.12/&#8364;1.92</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,985,523</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.97 /&#8364;1.84</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,577,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.01/&#8364;1.82</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,157,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.93 /&#8364;1.81</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31, 2022 $0.9376, average rate 2022 $0.9489</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average remaining contractual life for the share options outstanding under the 2017 Plan as of December 31, 2023 was 6.61 years
(2022: 6.70 years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
Options granted in 2023 vest over one year except for options granted on July 7, 2023 which partially vest over three years. Options
granted before 2023 vest over a period of one, two or three years, depending on the grant, with 1/2 or 1/3, respectively, of the options
vesting after the end of the 1st year from vesting start and the remaining options vesting quarterly in equal portions thereafter. Vesting
of these unvested share options is subject to a service condition at the time of vesting, and no market or performance conditions are
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average fair value of options granted during 2023 was $2.58/&#8364;2.39 (2022 after repricing: $1.70/&#8364;1.61). The range of
exercise prices for options outstanding at the end of the year was $1.86/&#8364;1.74 to $5.14/&#8364;4.82 (after repricing in 2022: $1.86/&#8364;1.74
to $5.14/&#8364;4.82).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
shares issued for share options exercised during the year were recorded to the commercial register by December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>b)
Measurement of fair values of share options granted under the 2017 Plan</i></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of options granted under the 2017 Plan was determined using the Black-Scholes valuation model. As the Company&#8217;s ordinary
shares are listed on the Nasdaq Global Select Market, the closing price of the ordinary shares at grant date was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
significant inputs into the model are as follows (weighted average):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">FX rate as<br/>
 of grant<br/>
 date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price<br/>
 at grant<br/>
 date/<br/>
 Exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
 volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint<br/>
 based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free<br/>
 rate<br/>
 (interpolated,<br/>
 U.S.<br/>
 sovereign<br/>
 strips curve)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">2021</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 4</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">839,260</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">4.53</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.8133</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#8364;</td><td style="width: 7%; text-align: right">3.68</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">5.14</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1.35</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">5.31</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.5</td><td style="width: 0.5%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">327,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">2.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.98</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.66</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">0.8458</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">2.25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">5.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">1.01</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,219,074</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left"></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the 1,219,074 options granted in 2021, 1,134,436 were granted to members of the executive management or the Board of Directors. In 2021,
36,400 options were forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>



<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value per share option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">FX rate as of grant date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value per share option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date/ Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected life (midpoint based)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free rate (interpolated, U.S. sovereign strips curve)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">2022</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;12</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,516,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.8795</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8364;3.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.31</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: right">1.57%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;12</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8364;3.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1.59%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repricing,&#160;April&#160;13</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.20-$1.63</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8364;1.11-&#8364;1.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.83-4.94</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2.60%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November&#160;21</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">405,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">0.9760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">&#8364;1.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right">4.15%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,966,666</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the 1,966,666 options granted in 2022, 1,223,500 were granted to members of the executive management or the Board of Directors. In 2022,
136,259 options were forfeited, 14,930 were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FX rate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of<br/>
 grant<br/>
 date</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share<br/>
 price at<br/>
 grant<br/>
 date/</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/>
 price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
 volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected<br/>
 life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free<br/>
 rate<br/>
 (interpolated,<br/>
 U.S.<br/>
 sovereign<br/>
 strips curve)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">2023</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 24</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,454,250</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">2.11</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.9008</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#8364;</td><td style="width: 7%; text-align: right">1.90</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">2.37</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1.35</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">5.30</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.571</td><td style="width: 0.5%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.565</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9361</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.820</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.320</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.286</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.320</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.15</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">0.9378</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#8364;</td><td style="padding-bottom: 4pt; text-align: right">2.95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.320</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,735,750</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the 1,735,750 options granted in 2023, 1,136,000 were granted to members of the executive management or the Board of Directors. In 2023,
31,000 options were forfeited, 105,327 were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
dividends are <span style="-sec-ix-hidden: hidden-fact-84">nil</span> for all share options listed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
price volatility is calculated on the basis of annualized monthly volatility rate of the Company&#8217;s share price over the last five
years preceding the valuation date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
range of outcomes for the expected life of the instruments has been based on expectations on option holder behavior in the scenarios
considered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dividend yield has no impact due to the anti-dilution clause as defined in the 2017 Plan.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of consolidated statement of operation and comprehensive loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369935408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Notes to the Consolidated Statements of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory', window );">Notes to the consolidated statements of financial position</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D. Notes to the consolidated statements of financial position</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>1. Property and equipment</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property<br/>
 and<br/>
 equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Advance <br/>payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">At January 1, 2022</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1,267,611</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1,267,611</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,453,339</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,453,339</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,123</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">(2,595</td><td style="font-weight: normal; font-style: normal; text-align: left">)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">(2,595</td><td style="font-weight: normal; font-style: normal; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,342</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,342</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,491,525</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,491,525</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At January 1, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(993,238</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(993,238</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(113,894</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(113,894</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,286</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,286</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,124,419</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,124,419</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,791</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,201,948</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,201,948</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Net book value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">328,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">328,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">289,577</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">289,577</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>2. Right-of-use assets</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Buildings</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cars</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%">At January 1, 2022</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">2,284,269</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">125,130</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">2,409,399</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,579,342</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">125,130</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,704,473</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,128</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,661,118</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">174,134</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,835,253</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At January 1, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(925,306</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(76,015</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,001,321</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(354,408</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,024</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(384,432</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,286,625</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(106,039</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,392,664</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353,398</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,527</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(377,925</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,633,020</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(130,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,763,586</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,292,717</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,092</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,311,809</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,028,098</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">43,568</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,071,666</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>3. Intangible Assets</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Purchased<br/>
 IT-software</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Advances<br/>
 paid for<br/>
 software</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">720,942</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">720,942</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">723,250</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">723,250</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,977</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,009</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,009</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">716,130</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,977</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">742,107</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(485,726</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(485,726</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Amortization charge for the year*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,271</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,271</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(584,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(584,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,063</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,063</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(673,289</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(673,289</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">138,905</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">138,905</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">42,841</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,977</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">68,818</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
of intangible assets is included in the line items &#8216;research and development expenses&#8217; (2023: &#8364;858, 2022: &#8364;858,
2021: &#8364;10,192) and &#8216;general and administrative expenses&#8217; (2023: &#8364;95,205, 2022: &#8364;97,413, 2021: &#8364;105,790)
in the consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>4. Leases</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
obligations consist of payments pursuant to non-cancellable lease agreements mainly relating to the Company&#8217;s leases of office
space. The lease terms of the Company&#8217;s premises expire as follows: Jena, Germany in December 2025, Martinsried, Germany in May
2027 and Ann Arbor, Michigan, United States in April 2026.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below, are the carrying amounts and the movements of the Group&#8217;s lease liabilities:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Lease liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">As of January 1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,356,684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,432,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Derecognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,555</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,555</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353,422</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(343,874</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term liability for accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(396</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,391</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,120,048</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,356,684</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the amounts recognized in profit or loss:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Depreciation expense of right-of-use assets (see Note E.2.)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">377,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">384,432</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">371,551</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rental expense from leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,261</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">Thereof short-term leases (included in administrative expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">&#8212;</div></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1.5pt">Thereof leases of low-value assets (included in administrative expenses)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">6,261</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">6,261</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">6,261</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total amounts recognized in profit or loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">403,276</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">412,640</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">391,867</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group had total cash outflows for leases of &#8364;0.4 million in 2023 (&#8364;0.4 million in 2022, &#8364;0.4&#160;million in 2021).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: normal 10pt Times New Roman, Times, Serif"><b>5. Inventory</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Raw material and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">423,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Unfinished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,614,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">330,087</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,367,807</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s inventory consists of materials relating to GOHIBIC (vilobelimab) primarily manufactured following the EUA for the US
market at the beginning of April 2023 (refer to Note A.2.) In the year ended December 31, 2023, inventory write-downs of &#8364;0.5 million
were recognized due to the expected expiry of the shelf-life, prior to sale, of the related inventories and are included in cost of sales.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">6.</span></td><td style="text-align: justify"><span style="font-style: normal">Other assets</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160; 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;<br/>
</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">257,267</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">308,066</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">257,267</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">308,066</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepayments on research &amp; development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,670,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,776,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,841,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,482</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,552,071</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,036,648</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,170,511</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,293,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,478,577</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Prepayments on research &amp; development projects
consists of prepayments on CRO and manufacturing contracts. Prepaid expenses mainly consist of prepaid insurance expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">7.</span></td><td style="text-align: justify"><span style="font-style: normal">Income tax Income tax reconciliation</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below shows a reconciliation between
the product of loss before tax multiplied by the Company&#8217;s applicable tax rate and current income taxes recognized in profit or
loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold">InflaRx Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Loss for the period (accounting profit before income tax)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(42,667,529</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(29,484,611</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(45,630,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax benefits at tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,160,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,610,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,001,984</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Temporary differences and tax losses for which no deferred tax asset was recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,127,977</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,480,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,988,805</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-recognition of tax effect on share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32,182</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,251,830</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,959,606</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible expenses for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,907</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,067</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,758</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other differences due to tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,686</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(49,815</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Income tax</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The tax rate applied above represents the weighted
average of the statutory tax rates in Germany and the United States. In Germany, InflaRx N.V. and its subsidiary InflaRx GmbH are subject
to corporate income tax (2023/2022/2021: 15%), a solidarity surcharge (2023/2022/2021: 0.8%) and trade taxes (2023: 13.065%; 2022: 13.7%;
2021: 12.8%). This equals an average total tax rate of 28.99 % in 2023 (2022: 29.5%; 2021: 28.6%). InflaRx Pharmaceuticals, Inc., Ann
Arbor, Michigan, United States is subject to an average total tax rate of 25.74% in 2023 (2022 25.74%; 2021: 25.74%), which is made up
of U.S. federal tax (2023, 2022, 2021: 21%) and state tax of 4.74% in 2023 (2022 and 2021: 4.74%).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">a)</td><td>Tax losses carried forward</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group has total tax loss carryforwards of
&#8364;243.8 million (2022: &#8364;211.3 million) from three areas that cannot be utilized outside these areas:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023 the Group had &#8364;196 million
(2022: &#8364;163.4 million) for corporate income purposes and &#8364;164 million (2022: &#8364;131.6 million) for trade tax purposes of
unrecognized and unused tax losses carried forward attributable to the tax group formed by InflaRx N.V. since 2018; these tax losses do
not expire and may not be used to offset taxable income elsewhere in the Group. Since January 1, 2018, InflaRx GmbH has distributed its
losses to the parent Company InflaRx N.V. under a profit and loss transfer agreement. This tax group was formed in Germany and is subject
to German tax legislation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: left">Tax losses of InflaRx GmbH until December 31, 2017 (&#8364;34.8
million) are frozen from 2018 onwards due to the creation of a tax group with InflaRx N.V. Those losses of InflaRx GmbH do not expire
and may be used to offset future taxable income of InflaRx GmbH only.</td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>In addition, the Group still has tax loss carryforwards of $14.3 million or &#8364;12.97 million (2022:&#160;$14.1&#160;million or
&#8364;13.2 million) from the operations of InflaRx Pharmaceuticals, Inc. which can also only be utilized there, generally do not expire,
but are generally limited to offset tax obligation for 80% of taxable income.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023, 2022 and 2021, no deferred
tax assets were recognized for the carryforward of unused tax losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">b)</td><td>Current income tax receivable</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Current income tax receivable includes tax claims
because of income tax withheld on interest income earned by the Group on the financial assets (2023: &#8364;1,390,280, 2022: &#8364;791,344).
The Company is reimbursed for the payments after filing a tax return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">8.</span></td><td style="text-align: justify"><span style="font-style: normal">Financial assets and financial
liabilities</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Set out below is an overview of financial assets
and liabilities, other than cash and short-term deposits included in cash equivalents, held by the Group as at December 31, 2023 and December
31, 2022:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Financial assets and financial liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial assets at amortized cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Non-current financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,052,741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,900,902</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">732,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,504,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,791,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at amortized cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,209,266</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,716,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,987,538</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The fair value of current and non-current financial
assets amounted to &#8364;85.5 million (level 1; 2022:&#160;&#8364;68.5 million). The Group&#8217;s financial assets at amortized cost consist
mainly of quoted debt securities with fixed interest rates with high credit rating (investment grade securities) by international rating
agencies such as S&amp;P Global and, therefore, are considered low credit risk investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maturities of all securities held as of December
31, 2023 are between one and seventeen months (2022: between one and sixteen months); they bear nominal fixed interest in the range of
0.3% to 4.125% (2022: 0.0% to 4.125%).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023, financial assets and
liabilities from government grants amount to &#8364; <span style="-sec-ix-hidden: hidden-fact-142">nil million</span>, due to the end of the grant period on June 30, 2023 (&#8364;6.2&#160;million
as of December 31, 2022).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">9.</span></td><td style="text-align: justify"><span style="font-style: normal">Cash and cash equivalents</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left">Deposits held in U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,120,951</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits held in Euro</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,020,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,140,951</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,422</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash held in U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,041,802</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,645,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash held in Euro</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">2,585,190</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">7,616,918</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,626,991</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,261,932</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,767,942</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,265,354</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">10.</span></td><td style="text-align: justify"><span style="font-style: normal">Equity</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">a)</td><td>Issued capital</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2023, the issued capital of
the Company is divided into 58,883,272 ordinary shares (2022: 44,703,763). The nominal value per share is &#8364;0.12. All shares issued
are fully paid and have the same rights on the distribution of dividends and the repayment of capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On July&#160;8, 2020, the Company filed&#160;a&#160;Form
F-3&#160;(2020-Registration Statement)&#160;with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)&#160;with respect
to the offer and sale of securities of the Company.&#160;The Company&#160;also&#160;filed&#160;with the SEC a prospectus&#160;supplement&#160;relating
to&#160;an&#160;at-the-market&#160;program providing for the sale of up to&#160;$50.0 million&#160;of its&#160;ordinary&#160;shares&#160;over
time&#160;pursuant a Sales Agreement with SVB&#160;Leerink&#160;LLC (the &#8220;Sales Agreement&#8221;).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2022, the Company had issued
2,568,208 ordinary shares resulting in &#8364;11.8 million in net proceeds to the Company with a remaining value authorized for sale under
the Sales Agreement of $35.2 million. During the fiscal year 2023, the Company issued 3,235,723 ordinary shares under its at-the-market
program resulting in &#8364;14.4 million or $15.7 million in net proceeds. Following these and previous issuances under this program, the
remaining value authorized for sale under the Sales Agreement amounted to $19.0 million as of July&#160;8, 2023; the term of the at-the-market
program expired on July&#160;8, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Through an underwritten public offering in April
2023, the Company sold and issued an aggregate of 10,823,529 ordinary shares, of which 1,411,764 were sold pursuant to the exercise of
an overallotment option by the underwriters. The ordinary shares were sold at a price of $4.25 per share and have a nominal value of &#8364;0.12
per share. Proceeds of this offering after deducting &#8364;2.5 million ($2.8 million) in underwriting discounts amounted to &#8364;39.1
million ($43.2 million). Other offering expenses amounted to &#8364;0.4 million, resulting in a total of &#8364;38.7 million in net proceeds
from this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In connection with amending the Co-Development
Agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd. (&#8220;Staidson&#8221;) on December 21, 2022, the Company entered into
a share purchase agreement with Staidson pursuant to which Staidson purchased ordinary shares of the Company for an aggregate amount of
$2.5 million (&#8364;2.3 million) at a price of $5.00 per share, resulting in the sale of 500,000 additional shares. Under the terms of
the share purchase agreement, at the Company&#8217;s option, Staidson may purchase additional shares for an aggregate purchase price of
$7.5 million, which is subject to certain conditions. The accounting impact of this put option is not material. On June&#160;30, 2023,
the Company filed&#160;a&#160;Form F-3&#160;(2023 Registration Statement)&#160;with the SEC&#160;with respect to the offer and sale of
securities of the Company, which became effective on July&#160;11, 2023. The aggregate initial offering price of the securities that the
Company may offer and sell under this prospectus will not exceed $250 million. No ordinary shares were issued by the Company under the
2023 Registration Statement in the fiscal year 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2023, the Company issued a total of 120,257
ordinary shares after former employees exercised stock option rights granted under the 2017 Long-Term Incentive Plan. The ordinary shares
have a nominal value of &#8364;0.12 per share. Therefrom, 98,754 ordinary shares were sold at a price of $1.85 per share, and 21,503 ordinary
shares were sold at a price of $3.35. The ordinary shares were registered in 2023, except 14,930 stock options which were exercised in
December 2022 with resulting ordinary shares having been registered in January 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">b)</td><td>Authorized capital</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">According to the articles of association of the
Company, up to 110,000,000 ordinary shares and up to 110,000,000 preferred shares with a nominal value of &#8364;0.12 per share are authorized
to be issued. All shares are registered shares. No share certificates shall be issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In order to deter acquisition bids, the Company&#8217;s
general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation, to exercise
a call option pursuant to the call option agreement, upon which preferred shares will be issued by the Company to the protective foundation
of up to 100% of the Company&#8217;s issued capital held by others than the protective foundation, minus one share. The protective foundation
is expected to enter into a finance arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation
may request the Company to provide, or cause the Company&#8217;s subsidiaries to provide, sufficient funding to the protective foundation
to enable it to satisfy its payment obligation under the call option agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These preferred shares will have both a liquidation
and dividend preference over the Company&#8217;s ordinary shares and will accrue cash dividends at a pre-determined rate. The protective
foundation would be expected to require the Company to cancel its preferred shares once the perceived threat to the Company and its stakeholders
has been removed or sufficiently mitigated or neutralized. The Company believes that the call option does not represent a significant
fair value based on a level 3 valuation since the preferred shares are restricted in use and can be cancelled by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For the year ended December 31, 2023, the Company
expensed &#8364;70,000 of ongoing costs to reimburse expenses incurred by the protective foundation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">c)</td><td>Nature and purpose of equity reserves</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to the issued capital, the Company
discloses the following other reserves:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><i>Share premium</i> records the amounts paid in upon issuance of ordinary shares in excess of nominal value of &#8364;0.12 per share,
net of related transaction costs.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>The <i>other capital reserves</i> include the expense resulting from the issue of share options.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td><i>Accumulated deficit</i> includes the losses of previous reporting periods.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><i>Other components of equity</i> exclusively include
currency reserves from the conversion of financial statements in foreign currencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">11.</span></td><td style="text-align: justify"><span style="font-style: normal">Trade and other payables</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued liabilities from R&amp;D projects</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,414,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,254,550</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued liabilities from commercial activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,400,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,102,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,566,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities and payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,942,909</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,314,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total trade and other payables</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,860,134</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,135,146</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities from R&amp;D projects include
services from the Company&#8217;s ongoing projects that have not yet been invoiced to the Company as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accrued liabilities from commercial activities
include services provided by commercial manufacturing partners that have not yet been invoiced to the Company as of the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other accrued liabilities and payables include
payments for GOHIBIC (vilobelimab) received from our distribution partner under the title distribution model, against which revenue will
be recognized at the time of final sale and delivery to hospital customers. These accrued liabilities payments amount to &#8364;2.7 million
as of December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">12.</span></td><td style="text-align: justify"><span style="font-style: normal">Financial risk management</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">a)</td><td>Financial risk management objectives and policies</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group&#8217;s financial risks are predominantly
controlled by central treasury activities under an investment policy approved by the Board of Directors on November 3, 2022, as revised
on October, 27, 2023. Those treasury activities identify, evaluate and manage financial risks consistent with the Group&#8217;s operating
needs. The Board of Directors provides policies for overall risk management, covering specific areas, such as foreign exchange risk and
credit risk. The Company does not intend to use derivative financial instruments because the Group&#8217;s future risk exposures cannot
be reliably forecasted (volume of business activity, liquidity needs, foreign exchange exposure).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Hedging is not applied as most of the business
activity is intended to be executed in U.S. dollars and paid with the U.S. dollars funds raised in public offerings. The foreign exchange
exposure from costs incurred in currencies other than Euro is deemed immaterial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group&#8217;s principal financial assets
comprise quoted debt securities with high credit ratings. Besides these financial assets, the Group has significant cash and cash equivalents.
The Group&#8217;s principal financial liabilities comprise trade and other payables. The main purpose of these financial assets, cash/cash
equivalents and liabilities are to finance the Group&#8217;s development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group is exposed to market risk, credit risk
and liquidity risk. The Board of Directors reviews and adopts policies for managing each of these risks, which are summarized below. The
Group&#8217;s senior management oversees the management of these risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 1.5pt; border: black 1pt solid; text-align: center; width: 12%; font-size: 10pt">&#160;</td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 37%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exposure</b></span></td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement</b></span></td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 31%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Management</b></span></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market risk</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future development costs; Recognized financial assets and liabilities not denominated in Euro</span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forecasted cash flows Sensitivity analysis</span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Achievement of a natural hedge</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">in the future</p></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit risk</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Cash and cash equivalents,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">current and non-current<br/> financial assets</p></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Credit</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">rating</p></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Diversification of bank deposits, Investment guidelines for</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">debt investments</p></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D and G&amp;A cost, equity, trade and other payables</span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rolling</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">cash flow forecast</p></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability of funds through financing rounds or public offerings</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">b)</td><td>Market risk</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Market risk is the risk that changes in market
prices (e.g., due to foreign exchange rates) will affect the Group&#8217;s income, expenses or the value of its holdings of financial
instruments. The objective of market risk management is to identify, manage and control market risk exposures within acceptable parameters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Foreign exchange risk arises when commercial
transactions or recognized assets or liabilities are denominated in a currency that is not an entity&#8217;s functional currency. The
Group is exposed to transactional foreign currency risk to the extent that there is a mismatch between the currencies in which costs and
purchases are denominated and the respective functional currencies of Group companies. The functional currencies of Group companies are
primarily the Euro and U.S. dollars. The currencies in which these transactions and financial assets are primarily denominated are Euro
and U.S. dollars. The Group is exposed to the exchange rate between the Euro and the U.S. dollars. Due to the Company&#8217;s various
registered offerings of ordinary shares in U.S. dollars, the Group has significant cash and cash equivalents in U.S. dollars. Currently
the Group does not hedge U.S. dollars but intends to achieve a natural hedge by contracting suppliers in U.S. dollars in the future. In
2023, the Group recognized significant foreign exchange gains and losses as the natural hedge is not yet achieved and the functional currency
for InflaRx N.V. and InflaRx GmbH is Euro.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group is primarily exposed to changes in
U.S. dollar to Euro exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from U.S. dollar
denominated financial instruments at InflaRx N.V. and InflaRx GmbH.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2023, if the Euro had weakened/strengthened
by 10% against the U.S. dollar with all other variables held constant, the Group&#8217;s loss would have been &#8364;1 million higher/&#8364;1
million lower, mainly as a result of foreign exchange on translation of U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx GmbH</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022 *</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current and non current financial assets (securities and accrued interest)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">80,935,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,376,866</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,051,366</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,356,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total assets exposed to the risk</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">88,986,563</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,733,378</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion rate Euro to U.S. dollars at reporting date 1/1.1050 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Sensitivity analysis:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Conversion<br/>
 rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Profit/(loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">carrying<br/>
 amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Euro weakens against U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.2155</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,887,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98,873,959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Euro strengths against U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,089,688</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,896,875</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Based on the exchange rate fluctuations from
the last three years, the Company expects that exchange rate fluctuations of the Euro to the U.S. dollar between 0.9945 and 1.2155 could
be reasonably possible. Compared to the exchange rate on the statement of financial position date (Euro to U.S. dollar at reporting date
is 1/1.1050), these rates could have a material impact on the Company&#8217;s total loss of the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">c)</td><td>Credit risk</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Credit risk is the risk that a counterparty will
not meet its obligations leading to a financial loss for the Company. The Company is exposed to credit risk mainly from its financing
activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Credit risk from balances with banks and financial
institutions is managed by the Company in accordance with the Company&#8217;s investment policy. Investment of financial resources which
are currently not used to fund R&amp;D or G&amp;A activities, are made only with counterparties within the credit limits approved by the
investment policy. For investments in Euro or U.S. dollar debt securities, a BBB+ to AAA credit rating (Standard &amp; Poors and Fitch
ratings; or equivalent ratings by Moody&#8217;s and DBRS) is required. Complex financial products as well as other investments denominated
in currencies other than Euros or U.S. dollars are not permitted by the investment policy. Counterparty credit limits and the investment
policy are discussed with the Company&#8217;s Audit Committee on an annual basis and may be updated throughout the year subject to approval
of the Company&#8217;s Audit Committee. The limits are set to minimize the concentration of risks and therefore mitigate financial loss
through a counterparty&#8217;s potential failure to make payments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maximum exposure to counterparty credit risk
is &#8364;99.3 million at December 31, 2023 (December 31, 2022: &#8364;84.0 million). This amount equals the carrying amount at year end
of cash and cash equivalents (2023: &#8364;12.8 million; 2022: &#8364;16.3 million) and financial assets (2023: &#8364;86.6 million; 2022:
&#8364;67.7 million).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">d)</td><td>Liquidity risk</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company monitors its risk of a shortage of
funds in every quarterly forecast as well as on an ongoing basis. The Company disclosed the maturities of its principal liabilities under
Note E &#8216;Commitments&#8217;. Prudent liquidity risk management involves maintaining sufficient cash and marketable securities and
the availability of funding to meet obligations when due. The Group continually monitors its risk of a shortage of funds using short and
mid-term liquidity planning. This takes into account of the expected cash flows from all activities. The management team performs regular
reviews of the budget.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company has a history of significant operating
losses. Management expects that the Company incurs significant and increasing losses for the foreseeable future; as the Company may not
achieve or maintain profitability in the near future, it is dependent on capital contributions or other funding.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group raised significant funding from various
registered offerings that it estimates will enable the Group to fund operating expenses and capital expenditure requirements for at least
24 months from December 31, 2023. The Group expects to require additional funding to continue to advance the development of product candidates.
In the event regulatory approval is received and the Company implements a strategy to commercialize the products itself, the Group would
require additional capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2023, as a result of the BMBF agreements (see
Notes C.6.) the Company received &#8364;8.8 million in cash from the German Federal Government grant which contributes to its financing
of its operations. Such funds were used for finalizing the Company&#8217;s COVID-19 clinical research and development program, support
regulatory activities, establish a fully validated manufacturing process and to transfer the fill and finish process from China to Germany
to ensure future security of supply in Germany.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the end of the reporting period, the Group
held the following deposits that are expected to readily generate cash inflows to meet the outstanding financial commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Liquidity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Short-term deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,140,951</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,626,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,261,932</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities (current and non-current)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,727,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,175,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other (non-current portion)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other (current)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">701,407</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">278,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total funds available</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">99,434,432</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">83,957,344</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">13.</span></td><td style="text-align: justify"><span style="font-style: normal">Capital management</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group&#8217;s policy for capital management
is to ensure that it maintains its liquidity in order to finance its operating activities, future business development and meet its liabilities
when due. The Group manages its capital structure primarily through equity. The Group does not have any financial liabilities, other
than trade and other payables or leasing liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">No changes were made in the objectives, policies
or processes for managing capital during the year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the authorisation of financial statements for issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369261424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">E.</td><td style="padding-right: 54.4pt">Commitments</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">1.</span></td><td style="text-align: justify"><span style="font-style: normal">Operating contracts or services</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group enters into contracts in the normal
course of business with CROs and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other
vendors for clinical supply manufacturing or other services. These contracts can usually be terminated with 30 to 180 days&#8217; notice.
In addition to this minimum duration, these contracts require full payment for services already rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2023, the Group did not have any commitments
to purchase property, plant and equipment or patents and trademarks (respectively <span style="-sec-ix-hidden: hidden-fact-161">nil</span> in 2022).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">2.</span></td><td style="text-align: justify"><span style="font-style: normal">Lease obligations</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The maturity analysis of lease liabilities is
disclosed in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for capitalized leases in 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual<br/>
 minimum<br/>
 lease<br/>
 obligations</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of<br/>
 discounting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">374,329</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,151,434</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">31,389</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,120,045</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for capitalized leases in 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual<br/>
 minimum<br/>
 lease<br/>
 obligations</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of<br/>
 discounting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease<br/>
 liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">380,518</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,142</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">369,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">999,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">987,307</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,380,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,317</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,356,683</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Maturity analysis for all lease obligations in 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Low value</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">leases</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short-term<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capitalized<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">397,942</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,816</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,968</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,158</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,158,363</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,962</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,968</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,151,434</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for all lease obligations in 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low value<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short-term<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capitalized<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">386,779</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,261</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">380,518</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,004,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">999,482</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,391,223</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,223</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,380,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Anticipated future lease expenses were converted
with the exchange rate as of December 31, 2023, 1&#160;Euro&#160;=&#160;1.1050 U.S. dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group applies the &#8216;lease of low-value
assets&#8217; recognition exemptions. The Group also applied the &#8216;short-term lease&#8217; exemption for leases with a maturity of
less than 12 months.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370809872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationAbstract', window );"><strong>Other Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory', window );">Other information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">F.</td><td style="padding-right: 54.4pt">Other information</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">1.</span></td><td style="text-align: justify"><span style="font-style: normal">Segment reporting</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Group predominantly operates as a R&amp;D
focused biopharmaceutical company applying its proprietary anti-C5a and C5aR technologies towards the development of novel therapeutic
products targeting diseases of high unmet medical need. However, since the EUA of its lead product vilobelimab for the treatment of severe
COVID-19 patient in April 2023, it also has commercial activities around the sales and marketing of GOHIBIC (vilobelimab) in the U.S.
The Group is not steered by segments. The Board of Directors is the chief operating decision maker. Management of resources and reporting
to the decision maker is based on the Group as a whole.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All operational activities are conducted in Germany
and the United States. Revenues in the amount of $63,089 were generated in 2023 (<span style="-sec-ix-hidden: hidden-fact-162"><span style="-sec-ix-hidden: hidden-fact-163">Nil</span></span> in 2022 and 2021). All revenues were generated in
the United States of America. The geographic location of the Group&#8217;s non-current assets are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>December 31, 2023: &#8364;10.6 million in Germany and &#8364;0.1 million in the United States; and</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in">&#9679;</td><td>December 31, 2022: &#8364;4.9 million in Germany and &#8364;0.1 million in the United States.</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None of the non-current assets are in the country
where the Company is incorporated (the Netherlands).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-style: normal">2.</span></td><td style="text-align: justify"><span style="font-style: normal">Related party transactions</span></td>
</tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">Compensation of the Group&#8217;s executive
management for the 12 months ending December 31, 2023:</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Executive and Board compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Executive management</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term employee benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,783,675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,774,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,817,792</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,507,453</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,808,094</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,347,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Sub-total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,291,128</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,582,579</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,164,995</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-executive Board of Directors members</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">285,177</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">529,859</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">488,937</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Sub-total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">591,160</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">778,584</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">760,185</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total compensation</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,882,288</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,361,163</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,925,180</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Executive management comprises executive Directors
of the Board of Directors and members of the Senior management of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table above discloses short-term employee
benefits that were contractually agreed for the Board of Directors and executive management. As of December 31, 2023, &#8364;0.8 million
were not paid but accrued (2022: &#8364;0.9 million) for executive management and &#8364;0.1 million (2022: &#8364;0.1 million) for non-executive
members of the Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Remuneration of the Group&#8217;s executive management
comprises fixed and variable components and share-based payment awards. In addition, executive management receive supplementary benefits
and allowances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company entered into indemnification agreements
with its directors and senior management. The indemnification agreements and the Company&#8217;s Articles of Association require the Company
to indemnify its directors to the fullest extent permitted by law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&#8217;s current and future directors
(and such other officer or employee as designated by the Board of Directors) have the benefit of indemnification provisions in the Articles
of Association of InflaRx N.V. These provisions give the indemnified persons the right to recover from the Company amounts, including,
but not limited to, litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the performance
of their duties. However, there is no entitlement to indemnification for acts or omissions which are considered to constitute malice,
gross negligence, intentional recklessness and/or serious culpability attributable to such indemnified person. These agreements also provide,
subject to certain exceptions, for indemnification for related expenses including, among others, attorneys&#8217; fees, judgements, penalties,
fines and settlement amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, the
Company provides its directors with directors&#8217; and officers&#8217; liability insurance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about the methods, inputs and assumptions used for measuring obligations for returns, refunds and other similar obligations in contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572448667472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events After the Reporting Date<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Significant events after the reporting date [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory', window );">Significant events after the reporting date</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.25in">G.</td><td style="padding-right: 54.4pt">Significant events after the reporting date</td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370369840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>1.
Basis of preparation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as issued
by the International Accounting Standards Board (herein &#8220;IFRS&#8221;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared on a historical cost basis. These consolidated financial statements of the Group
comprise the Company and its wholly owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc. The consolidated financial statements
are presented in Euro (&#8364;). The presentation currency of the Group is the Euro, as the functional currency of the largest operating
company, InflaRx GmbH, continues to be the Euro. Effective January 1, 2023, the functional currency of InflaRx N.V. changed from the
U.S. dollar to the Euro due to a change in the Company&#8217;s operational function and, in turn, a change in the primary currency of
its underlying transactions. This change in functional currency has been accounted for prospectively. The functional currency of InflaRx
Pharmaceuticals, Inc. is the U.S. dollar ($), as most of their income and expenses occurred in U.S. dollars in 2023. All financial information
presented in Euro has been rounded to the nearest Euro, unless stated otherwise.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock', window );">Summary of material accounting policies</a></td>
<td class="text"><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>2.
Summary of material accounting policies</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
section describes material accounting policies adopted in the preparation of these consolidated financial statements. These policies
have been consistently applied to all the years presented, unless otherwise stated.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock', window );">New and amended standards adopted by the Group</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)
</i></b><i><span style="font-variant: normal; font-weight: normal">New and amended standards adopted by the Group</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            17 insurance contracts</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 8 accounting policies, changes in accounting estimates and errors: definition of accounting
                                            estimates</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 12 deferred tax related to assets and liabilities arising from a single transaction</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 and IFRS practice statement 2 - disclosure of accounting policies</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
policies for the following IFRS standards have been applied starting in Q2 2023 for the first time, as no transactions in the scope of
these IFRS standards had been previously recognized.</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS
                                            2 inventories&#160;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to IAS 2, inventories are stated at the lower amount of their cost or at their net realizable value. Cost comprises direct material cost
and, where applicable, direct labor costs and those overhead costs that have been incurred in bringing the inventories to their present
location and condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling
price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Recognizing inventories
at net realizable value includes writing down inventories considered excess or obsolete.</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            15 revenue from contracts with customers</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, the Company exclusively uses distributors to sell its products to end customers (e.g., hospitals). The end customers (e.g. hospitals)
have been determined to be the customer in these sales arrangements. As such, payments received from the distributors are not contract
liabilities but are rather &#8220;other liabilities&#8221; recognized in &#8220;other accrued liabilities.&#8221; Revenue is therefore
recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer, that is,
when the customer obtains control of that asset and is measured considering estimated return liabilities and expected rebates or cash
discounts.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock', window );">New standard not yet adopted</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)
</i></b><i><span style="font-variant: normal; font-weight: normal">New standard not yet adopted</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following standards issued will be adopted in a future period, and the potential impact on the Group&#8217;s consolidated financial statements,
if any, is being assessed:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IFRS 16 leases: leases on sale and leaseback</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 presentation of financial statements: classification of liabilities as current or
                                            non-current and non-current liabilities with covenants</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 21 effects of changes in foreign exchange rates: lack of exchangeability</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock', window );">Current and non-current classification</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)
</i></b><i><span style="font-variant: normal; font-weight: normal">Current and non-current classification</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group presents assets and liabilities in the statement of financial position based on current/non-current classification.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
assets include assets that are sold, consumed or realized as part of the normal operating cycle (operating cycle is assumed to be 12
months), or cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after
the reporting period. All other assets are classified as non-current.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
liabilities, such as trade payables, lease liabilities or employee benefits with a term of up to 12 months, and payables for operating
costs or social security charges, are part of the working capital used in the Company&#8217;s normal operating cycle. Such operating
items are classified as current liabilities even if they are due to be settled more than 12 months after the reporting period. All other
liabilities are classified as non-current.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
</i></b><i><span style="font-variant: normal; font-weight: normal">Foreign currency transactions</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions
in a foreign currency are initially translated into the respective functional currency using the spot rate prevailing on the dates of
the transaction. Monetary items which are not denominated in the functional currency are subsequently translated using the rate applicable
at the end of the period. The resulting currency gains and losses are recognized directly in profit or loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
consolidation, the assets and liabilities of operations in a currency other than Euro (the presentation currency of the Company) are
translated into Euros at the rate of exchange prevailing at the reporting date and their statements of operations are translated with
monthly average exchange rates during the reporting period. The exchange differences arising on translation for consolidation are recognized
in &#8216;other comprehensive income&#8217; (OCI). On disposal of a foreign operation, the component of OCI relating to that particular
foreign operation is reclassified to profit or loss. OCI is disclosed as &#8216;other components of equity&#8217; in consolidated statements
of financial position.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock', window );">Grants from government and similar bodies</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(e)
</i></b><i><span style="font-variant: normal; font-weight: normal">Grants from government and similar bodies</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects.
The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If
grant funds are received prior to qualifying expenses being incurred or assets purchased or prior to all grant conditions have been met,
such amounts are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other
operating income in the period in which the corresponding expenses are incurred (or, for expenses incurred prior to all grant conditions
being met, in the period in which reasonable assurance that all grant conditions will be met is attained). If the funds reimburse purchased
assets, the liability is reduced with a corresponding amount deducted from the asset&#8217;s carrying amount upon recording of the qualified
asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group up
to five years after concluding the project sponsored by the government.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2021, the Group announced that it received a grant of up to &#8364;43.7 million from the German Ministry of Education and Research
and the German Ministry of Health to support its development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent
changes in the Group&#8217;s research and development plan and fewer costs projected within the timeframe of the grant, it was notified
that the amount available to it was &#8364;41.4 million. The grant is structured as a reimbursement of 80% of certain pre-specified expenses
related to the clinical development and manufacturing of vilobelimab. The grant period ended on June 30, 2023. In total, during the duration
of the grant period through December 31, 2023, the Group received &#8364;33.3 million to support its activities regarding the development
of vilobelimab as a new therapeutic agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial
scale manufacturing process to ensure the ability of being able to provide such treatment to the broader population.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotesToTheCashFlowStatementPolicyTextBlock', window );">Notes to the cash flow statement, cash, and cash equivalents</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(f)
</i></b><i><span style="font-variant: normal; font-weight: normal">Notes to the cash flow statement, cash, and cash equivalents</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated statements of cash flows have been prepared using the indirect method for cash flows from operating activities. The cash
disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash comprises cash on hand and demand
deposits. Cash equivalents are short-term bank deposits that are readily convertible to a known amount of cash and are not subject to
a significant risk of changes in value with an original maturity of three months or less. Interest paid and received is included in the
cash from operating activities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development expenses</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(g)
</i></b><i><span style="font-variant: normal; font-weight: normal">Research and development expenses</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses comprise third party services, wages and salaries, cost of materials, intellectual property related expenses,
depreciation and amortization of relevant equipment and intangibles as well as overhead. Research and development expenses mainly consist
of costs for clinical trials and manufacturing of the Company&#8217;s clinical drug products; additionally, costs are incurred for pre-clinical
activities as well as basic research activities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development expenses were capitalized because
management assessed that not all the recognition criteria of IAS&#160;38 had been met. This assessment is due to the general uncertainties
in drug development and the unpredictability of regulatory requirements. Therefore, research and development expenditures are expensed
when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(h)
</i></b><i><span style="font-variant: normal; font-weight: normal">Employee benefits</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Short-term employee benefits</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
for wages and salaries and cash bonuses are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as employee benefits in the consolidated statements of financial position. A liability is recognized if the Group has a
present legal or constructive obligation to pay such amount as a result of past service provided by the employee and if such obligation
can be estimated reliably.</span></p><p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Share-based payment transactions</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense,
with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect
the number of awards for which the related service conditions are expected to be met, including an estimate of forfeitures, such that
the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based
payment awards with immediate vesting, the&#160;grant-date fair value of the share-based payment is measured to reflect such conditions and
there is no gain or loss recognized for differences between expected and actual outcomes.</span></p><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)
</i></b><i><span style="font-variant: normal; font-weight: normal">Lease arrangements</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of one
to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.</span></p><p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Right-of-use assets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#8217;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Lease liabilities</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)
Short-term leases and leases of low-value assets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Determining the lease term of contracts</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)
</i></b><i><span style="font-variant: normal; font-weight: normal">Interest income</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)
</i></b><i><span style="font-variant: normal; font-weight: normal">Intangible assets</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over three years. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)
</i></b><i><span style="font-variant: normal; font-weight: normal">Property and equipment</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory equipment: three to 13 years</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment: one to five years</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#8216;other income&#8217;
or &#8216;other expenses&#8217; in the consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(m)
</i></b><i><span style="font-variant: normal; font-weight: normal">Impairment of assets</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there has been a change in the estimates used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no impairments or reversals of impairments in 2021, 2022 or 2023.</span></p><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(n)
</i></b><i><span style="font-variant: normal; font-weight: normal">Financial assets and liabilities (financial instruments)</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Definition</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#8217;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;D projects).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Criteria for the recognition and derecognition, initial measurement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iii) Subsequent measurement method</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considering
the Group&#8217;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#8216;3.8
Financial assets and financial liabilities.&#8217;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Criteria for realization of income and expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#8216;C.8. Net Financial Result&#8217;.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(o)
</i></b><i><span style="font-variant: normal; font-weight: normal">Fair Value Measurement</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#8216;D.8. Financial
assets and financial liabilities&#8217;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1, quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.</span></p><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(p)
</i></b><i><span style="font-variant: normal; font-weight: normal">Income tax</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Current income tax</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(ii) Deferred income tax</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#8217;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Significant accounting judgements, estimates and assumptions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#8217;s accounting policies involve the following areas:</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Accounting for share-based payments</i></span></p>When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#8216;C.10.(b).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Lease arrangements</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(i)
</i></b><i><span style="font-variant: normal; font-weight: normal">Lease arrangements</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of one
to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.</span></p><p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)
Right-of-use assets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#8217;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Lease liabilities</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(iii)
Short-term leases and leases of low-value assets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Determining the lease term of contracts</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory', window );">Interest income</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(j)
</i></b><i><span style="font-variant: normal; font-weight: normal">Interest income</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Intangible assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(k)
</i></b><i><span style="font-variant: normal; font-weight: normal">Intangible assets</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over three years. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(l)
</i></b><i><span style="font-variant: normal; font-weight: normal">Property and equipment</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Laboratory equipment: three to 13 years</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment: one to five years</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assets&#8217; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#8216;other income&#8217;
or &#8216;other expenses&#8217; in the consolidated statements of operations and comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment of assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(m)
</i></b><i><span style="font-variant: normal; font-weight: normal">Impairment of assets</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#8217;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
there has been a change in the estimates used to determine the asset&#8217;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no impairments or reversals of impairments in 2021, 2022 or 2023.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial assets and liabilities (financial instruments)</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(n)
</i></b><i><span style="font-variant: normal; font-weight: normal">Financial assets and liabilities (financial instruments)</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Definition</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#8217;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;D projects).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(ii)
Criteria for the recognition and derecognition, initial measurement</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iii) Subsequent measurement method</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Considering
the Group&#8217;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#8216;3.8
Financial assets and financial liabilities.&#8217;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(iv) Criteria for realization of income and expenses</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#8216;C.8. Net Financial Result&#8217;.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(o)
</i></b><i><span style="font-variant: normal; font-weight: normal">Fair Value Measurement</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#8216;D.8. Financial
assets and financial liabilities&#8217;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            1, quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(p)
</i></b><i><span style="font-variant: normal; font-weight: normal">Income tax</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(i) Current income tax</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>
(ii) Deferred income tax</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#8217;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock', window );">Significant accounting judgements, estimates and assumptions</a></td>
<td class="text"><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Significant accounting judgements, estimates and assumptions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#8217;s accounting policies involve the following areas:</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(a)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Accounting for share-based payments</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#8216;C.10.(b). Measurement of fair values of share options granted&#8217;). In 2023, the Company&#8217;s share price volatility
for the purposes of the calculation was determined on the basis of the 5-year annualized average share price, which management believes
will be indicative of the share price development of the Company in future periods. This led to a range of applied volatility rates in
2023 of 135% to 145.66% for the different options granted during the year of this report.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company must estimate the number of equity instruments which will vest in future periods as awards may be forfeited prior to vesting
due to an awardee&#8217;s failure to satisfy a performance condition, including due to employment termination. An assumption of the forfeiture
rate is regularly made on the basis of historical information and adjusted to reflect future expectations. Revisions to the forfeiture
rate could result in a cumulative effect of the change in estimate for current and prior periods to be recognized in the period of change.</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(b)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Measurement of third-party R&amp;D clinical trial and contracted manufacturing expense</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
measuring R&amp;D expenses for the reporting period, the Company estimates the amount of expense to recognize and liability to accrue
to the extent that invoices of the Company&#8217;s contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations
(&#8220;CDMOs&#8221;) are not yet received and exceed any prepayments made. The timing of the invoicing of project services by CROs follow
contractual billing schedules and can occur several months prior to or following a reporting period. This estimation involves determining
a percentage-of-completion whereby the degree to which services have been rendered for the individual project activities contracted from
the CRO and CDMOs is assessed and estimated by in-house R&amp;D project managers and reviewed by the controlling department. This percentage-of-completion
is used to measure the amount of the unbilled project activities which have already been rendered by the reporting date and the associated
R&amp;D expense and liability to recognize as a result.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
percentage-of-completion estimates are based on the best information available at the time. However, additional information may become
available in the future and management may adjust the estimate in such future periods. In this event, the Company may be required to
record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. The
Company considers resulting increases or decreases in expenses as changes in estimates and reflects such changes in research and development
expenses in the period identified.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accrued &#8364;4.4 million as of December 31, 2023 and &#8364;2.3 million as of December 31, 2022 (see Note &#8216;D.11. Trade and other
payables&#8217;) in third-party accruals in relation to its ongoing clinical trials and manufacturing activities. As of these dates, prepayments
were recorded for those payments made against which no services had yet been rendered (2023: &#8364;3.7 million, 2022: &#8364;9.8 million,
see Note &#8216;D.6. Other assets&#8217;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(c)</i></b></span> <span style="font: normal 10pt Times New Roman, Times, Serif"><i>Realizability of Inventories</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost and net realizable value. Net realizable value comprises the estimated sales proceeds less the necessary
expected costs up to the time of sale. For determining the net realizable value, at each reporting date, the Company estimates excess
and obsolete inventory primarily using a model of expected future sales and using assumptions with significant estimation uncertainty
such as expected medical need and expected market penetration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
these estimates rely, in part, on management&#8217;s assumptions about future events outside of the Company&#8217;s control, such as
continuation of the emergency use authorization in the United States and granting of marketing authorization in the European Union. In
making these assumptions, management assesses the probability of these authorizations remaining in place or being granted, as applicable,
by considering correspondence with the relevant regulatory authorities and the Company&#8217;s actions to achieve any required conditions
for the authorizations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the possible alternative uses for raw materials, unfinished and finished products is taken into consideration.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly assesses market and sales trends, market conditions, disease prevalence, competitive landscape, and regulatory environment
to refine estimates for excess and obsolete inventory. Based on these assessments, and taking manufacturing lead-times into consideration,
management takes operational decisions to order inventory based on inventory aging and the criteria mentioned above.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
write-downs for the year ended December 31, 2023 amounted to &#8364;521k (prior year: &#8364;0k) and were mainly due to the expiration
of shelf life of finished goods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
included in the model of expected future demand may require revision in future periods which could result in changes to the estimate
of excess and obsolete inventory and in inventory write-downs.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income and expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting policies for description of accounting policy current and noncurrent classification explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting policies for description of accounting policy for grants from government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policies for description of accounting policy new standards not yet adopted explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting judgements estimates and assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotesToTheCashFlowStatementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting policies for notes to the cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotesToTheCashFlowStatementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373709152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfCorporateInformationAbstract', window );"><strong>Corporate Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory', window );">Schedule of Share Capital Consisting Solely of Ordinary Shares</a></td>
<td class="text">Unless otherwise stated, such subsidiaries have share capital consisting
solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights
held by the Company.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">Place&#160;of&#160;business/<br/>
country&#160;of</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">Functional</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td><td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership
interest<br/>
held by the Company</b></span></td><td style="vertical-align: bottom; text-align: center">&#160;</td><td style="vertical-align: bottom; text-align: center; font-weight: bold">&#160;</td>
    <td style="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold">Name</td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>incorporation</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>currency</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>2022</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td><td style="vertical-align: bottom; text-align: center"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><b>Principal activities</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; font-weight: bold">InflaRx GmbH</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">Jena and Munich, Germany</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">EUR</td><td style="padding-bottom: 1.5pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td>Operating subsidiary, R&amp;D, holder of all IP</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; width: 35%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">InflaRx Pharmaceuticals, Inc.</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt">Ann Arbor, MI, United States</td><td style="width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 20%; text-align: left; padding-bottom: 1.5pt">Operating subsidiary, R&amp;D, US commercialization</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfCorporateInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfCorporateInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information of share capital consisting of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572374174720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Schedule of Revenues</a></td>
<td class="text">Revenues<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">63,089</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">63,089</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCostOfSalesExplanatory', window );">Schedule of Cost of sales</a></td>
<td class="text">Cost of sales<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in">Cost of Sales</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">532,262</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">532,262</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock', window );">Schedule of Sales and Marketing Expenses</a></td>
<td class="text">Sales and marketing expenses<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,851,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,040,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">67,462</td><td style="font-style: italic; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,054,971</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,583</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total sales and marketing expenses</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,001,299</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses increased in 2023 compared to 2022 by &#8364;3.5 million. The table below shows the composition of research and
development expenses.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Third-party services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">31,802,983</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,543,503</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">28,247,081</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which clinical material and related manufacturing services</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">18,109,345</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">16,194,152</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">6,615,840</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which clinical, pre-clinical studies</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">13,693,638</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">12,349,351</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">21,631,240</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Employee benefits expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,776,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,957,866</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,941,813</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1,500,670</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">2,456,571</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1,622,898</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,758,283</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,690,448</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,074,710</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">686,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">334,273</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">434,331</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,024,131</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">37,526,090</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">35,697,935</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses decreased by &#8364;2.2 million in 2023 from the prior year, predominantly due to lower costs from equity-settled
share-based payments.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Employee benefits expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,392,905</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,125,798</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,500,680</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">of which equity-settled share-based payment expense</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">1,846,356</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">3,587,785</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">2,709,307</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Legal and consulting fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,239,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,104,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,065,423</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,934,880</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,330,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,615,920</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation &amp; amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,905</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">526,325</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">551,566</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Compensation expense for non-executive directors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,984</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,247,273</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,533,469</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">979,884</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,628,756</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,869,564</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,984,722</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock', window );">Schedule of Other Income</a></td>
<td class="text">Other income decreased in 2023, compared to the prior year, due to the incurrence of less expenses eligible for
reimbursement under the grant and the end of the grant period on June 30, 2023.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 0in">Other income from government grants</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,155,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20,116,542</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in">Further other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,454</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,627</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,219,704</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">20,159,169</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">54,221</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Schedule of Employee Benefits Expenses</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the items of employee benefits expenses:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Wages and salaries</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,192,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,863,423</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,919,166</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Social security contributions (employer&#8217;s share)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">944,712</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">672,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">671,697</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity-settled share-based payment expenses (see Note C.10. Share-based payments)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,414,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,044,356</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,332,205</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">659,002</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">503,351</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">519,425</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,210,345</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,083,664</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,442,493</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfNetFinancialResultTextBlock', window );">Schedule of Net Financial Result</a></td>
<td class="text">Net financial result<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,804,827</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">608,679</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">109,391</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,538</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(23,303</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,714</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(19,090</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,947</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,055</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Financial result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,769,199</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">563,429</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">84,622</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Foreign exchange income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,529,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,924,697</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,569,836</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,371,261</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,482,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,605,701</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Foreign exchange result</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,841,872</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,442,298</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,964,135</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other financial result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">313,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(252,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(44,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,240,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,753,256</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,004,757</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Schedule of Share-Based payments</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the course of its historical financing rounds prior to 2016, InflaRx GmbH established equity-settled share-based payment programs. Those
InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. in November 2017:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">148,433</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">148,433</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 9%; text-align: right">0.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">148,433</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">148,433</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">0.01</td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average share price (WAEP)</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Share-based payments</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
significant inputs into the model are as follows (weighted average):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">FX rate as<br/>
 of grant<br/>
 date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price<br/>
 at grant<br/>
 date/<br/>
 Exercise<br/>
 price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
 volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint<br/>
 based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free<br/>
 rate<br/>
 (interpolated,<br/>
 U.S.<br/>
 sovereign<br/>
 strips curve)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">2021</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 4</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">839,260</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">4.53</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.8133</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#8364;</td><td style="width: 7%; text-align: right">3.68</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">5.14</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1.35</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">5.31</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.5</td><td style="width: 0.5%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 4</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,668</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.57</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">327,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8458</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">2.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.98</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 2</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,710</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.66</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">0.8458</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">2.25</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.99</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">5.49</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">1.01</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,219,074</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left"></td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value per share option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">FX rate as of grant date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value per share option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share price at grant date/ Exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected life (midpoint based)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free rate (interpolated, U.S. sovereign strips curve)</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">2022</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 9%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;12</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,516,666</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.8795</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8364;3.22</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5.31</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: right">1.57%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;12</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8364;3.24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">1.59%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repricing,&#160;April&#160;13</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.20-$1.63</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9237</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8364;1.11-&#8364;1.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.86</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.83-4.94</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">2.60%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November&#160;21</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">405,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">0.9760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">&#8364;1.99</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.44</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">4.0</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: right">4.15%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,966,666</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Share options granted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FX rate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>as of<br/>
 grant<br/>
 date</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value<br/>
 per share</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share<br/>
 price at<br/>
 grant<br/>
 date/</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/>
 price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Expected<br/>
 volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected<br/>
 life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Risk-free<br/>
 rate<br/>
 (interpolated,<br/>
 U.S.<br/>
 sovereign<br/>
 strips curve)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">2023</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 24</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,454,250</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">2.11</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">0.9008</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#8364;</td><td style="width: 7%; text-align: right">1.90</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 7%; text-align: right">2.37</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1.35</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">5.30</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3.571</td><td style="width: 0.5%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.565</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 31</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9361</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.820</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.320</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 7</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.64</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.34</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.286</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 19</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.8911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.46</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.320</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18</span></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.15</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">0.9378</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#8364;</td><td style="padding-bottom: 4pt; text-align: right">2.95</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">1.46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">4.320</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,735,750</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionPlan2016Member', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of Share-based payments</a></td>
<td class="text">Those InflaRx GmbH options were converted into
options for ordinary shares of the Company in November 2017:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">888,632</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.74</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">888,632</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.35/&#8364;2.96</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80; -sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><div style="-sec-ix-hidden: hidden-fact-81">&#160;</div></div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">888,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.68</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">888,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.74</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">888,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.68</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">888,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86/&#8364;1.74</span></td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31,2022 $0.9376, average rate 2022 $0.9489</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_LongTermIncentivePlan2017Member', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Schedule of Share-Based payments</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
conjunction with the closing of its initial public offering, InflaRx N.V. established a new incentive plan (the &#8220;2017 Plan&#8221;).
The initial maximum number of ordinary shares available for issuance under equity incentive awards granted pursuant to the 2017 Plan
equals 2,341,097 ordinary shares. On January 1, 2021 and on January 1 of each calendar year thereafter, an additional number of shares
equal to 4% of the total outstanding ordinary shares on December 31 of the immediately preceding year (or any lower number of shares
as determined by the Board of Directors) will become available for issuance under equity incentive awards granted pursuant to the 2017
Plan:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022 <br/>WAEP*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold">Outstanding at January 1</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">4,985,523</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.97 /&#8364;1.84</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 9%; font-weight: bold; text-align: right">3,170,046</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.95 /&#8364;3.49</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Granted during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,735,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.58/&#8364;2.39</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,966,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.98 / &#8364;1.88</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Forfeited during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(31,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.70/&#8364;2.50</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(136,259</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.22 /&#8364;2.11</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Exercised during the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(105,327</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.16/&#8364;2.00</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,930</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.86 /&#8364;1.76</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Outstanding at December 31</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6,584,946</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.12/&#8364;1.92</span></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4,985,523</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.97 /&#8364;1.84</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Exercisable at December 31</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,577,384</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.01/&#8364;1.82</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,157,148</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.93 /&#8364;1.81</span></td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31, 2022 $0.9376, average rate 2022 $0.9489</span></td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCostOfSalesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the cost of sales. [Refer: Cost of sales]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCostOfSalesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfNetFinancialResultTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of net financial result text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfNetFinancialResultTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about other income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_LongTermIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_LongTermIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572374118144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfFinancialPositionAbstract', window );"><strong>Notes to the Consolidated Statements of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property<br/>
 and<br/>
 equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Advance <br/>payments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 1.5pt">At January 1, 2022</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1,267,611</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">1,267,611</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,491</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,491</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,236</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,453,339</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,453,339</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,123</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,123</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">(2,595</td><td style="font-weight: normal; font-style: normal; text-align: left">)</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal">&#160;</td>
    <td style="font-weight: normal; font-style: normal; text-align: left">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right">(2,595</td><td style="font-weight: normal; font-style: normal; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,342</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,342</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,491,525</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,491,525</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At January 1, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(993,238</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(993,238</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(113,894</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(113,894</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,286</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,286</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,124,419</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,124,419</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,791</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,791</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,594</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,668</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,201,948</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,201,948</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Net book value</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">328,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">328,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">289,577</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">289,577</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of Right-of-Use Assets</a></td>
<td class="text">Right-of-use assets<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Buildings</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Cars</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 64%">At January 1, 2022</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">2,284,269</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">125,130</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">2,409,399</td><td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,645</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,579,342</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">125,130</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,704,473</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,125</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,004</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,128</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,661,118</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">174,134</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,835,253</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At January 1, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(925,306</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(76,015</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,001,321</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(354,408</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,024</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(384,432</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,911</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,286,625</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(106,039</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,392,664</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Depreciation charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353,398</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(24,527</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(377,925</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,633,020</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(130,566</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,763,586</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,292,717</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">19,092</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,311,809</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,028,098</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">43,568</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,071,666</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Schedule of Intangible Assets</a></td>
<td class="text">Intangible Assets<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Purchased<br/>
 IT-software</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Advances<br/>
 paid for<br/>
 software</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; font-weight: bold">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">At January 1, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">720,942</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">720,942</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,900</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">408</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">723,250</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">723,250</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,977</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,977</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,009</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,009</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(111</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">716,130</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,977</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">742,107</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>At January 1, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(485,726</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(485,726</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Amortization charge for the year*</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,271</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,271</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(584,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(584,345</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization charge for the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,063</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(96,063</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,009</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,009</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exchange differences</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(673,289</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(673,289</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">At December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">138,905</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">138,905</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; font-weight: bold">At December 31, 2023</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">42,841</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,977</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 4pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">68,818</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasePrepaymentsExplanatory', window );">Schedule of Lease Liabilities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below, are the carrying amounts and the movements of the Group&#8217;s lease liabilities:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Lease liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">As of January 1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,356,684</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,432,526</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,128</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281,429</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Derecognition</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,555</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20,555</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(353,422</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(343,874</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term liability for accrued interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(396</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign exchange difference</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,391</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,120,048</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,356,684</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory', window );">Schedule of Amounts Recognized in Profit or Loss</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the amounts recognized in profit or loss:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Depreciation expense of right-of-use assets (see Note E.2.)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">377,925</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">384,432</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">371,551</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest expense on lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,055</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rental expense from leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,261</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left">Thereof short-term leases (included in administrative expenses)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125">&#8212;</div></td><td style="text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><div style="-sec-ix-hidden: hidden-fact-126">&#8212;</div></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1.5pt">Thereof leases of low-value assets (included in administrative expenses)</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">6,261</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">6,261</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right">6,261</td><td style="padding-bottom: 1.5pt; font-style: italic; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total amounts recognized in profit or loss</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">403,276</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">412,640</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">391,867</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Schedule of Inventory</a></td>
<td class="text">Inventory<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Raw material and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">423,560</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-128">&#160;&#160;&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Unfinished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,614,159</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">330,087</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-131">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,367,807</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Schedule of Other Assets</a></td>
<td class="text"><span style="font-style: normal">Other assets</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160; 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;<br/>
</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">257,267</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">308,066</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">257,267</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">308,066</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepayments on research &amp; development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,670,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,776,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">272,999</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,841,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">93,482</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,552,071</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,036,648</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,170,511</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,293,915</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,478,577</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory', window );">Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss</a></td>
<td class="text">The table below shows a reconciliation between
the product of loss before tax multiplied by the Company&#8217;s applicable tax rate and current income taxes recognized in profit or
loss.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold">InflaRx Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Loss for the period (accounting profit before income tax)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(42,667,529</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(29,484,611</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(45,630,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tax benefits at tax rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,160,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,610,381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,001,984</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Temporary differences and tax losses for which no deferred tax asset was recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,127,977</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,480,169</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,988,805</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-recognition of tax effect on share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32,182</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,251,830</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,959,606</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-deductible expenses for tax purposes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,907</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,067</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,758</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Other differences due to tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">46,521</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,686</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(49,815</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Income tax</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Schedule of Financial Assets and Liabilities</a></td>
<td class="text">Set out below is an overview of financial assets
and liabilities, other than cash and short-term deposits included in cash equivalents, held by the Group as at December 31, 2023 and December
31, 2022:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Financial assets and financial liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Financial assets at amortized cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Non-current financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,052,741</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,900,902</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-138">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">732,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,504,518</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,791,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Financial liabilities at amortized cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,209,266</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,716,441</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,987,538</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><span style="font-style: normal">Cash and cash equivalents</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; text-align: left">Deposits held in U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,120,951</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Deposits held in Euro</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,020,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,140,951</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,422</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash held in U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,041,802</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,645,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash held in Euro</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">2,585,190</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">7,616,918</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,626,991</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,261,932</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,767,942</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,265,354</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Schedule of Trade and Other Payables</a></td>
<td class="text"><span style="font-style: normal">Trade and other payables</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued liabilities from R&amp;D projects</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,414,143</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,254,550</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued liabilities from commercial activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,400,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-141">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,102,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,566,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities and payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,942,909</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,314,196</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total trade and other payables</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,860,134</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,135,146</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMarketRiskExplanatory', window );">Schedule of Market Risk, Credit Risk and Liquidity Risk</a></td>
<td class="text">The Group is exposed to market risk, credit risk
and liquidity risk. The Board of Directors reviews and adopts policies for managing each of these risks, which are summarized below. The
Group&#8217;s senior management oversees the management of these risks.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 1.5pt; border: black 1pt solid; text-align: center; width: 12%; font-size: 10pt">&#160;</td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 37%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exposure</b></span></td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Measurement</b></span></td>
    <td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 31%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk Management</b></span></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market risk</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future development costs; Recognized financial assets and liabilities not denominated in Euro</span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forecasted cash flows Sensitivity analysis</span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Achievement of a natural hedge</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">in the future</p></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit risk</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Cash and cash equivalents,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">current and non-current<br/> financial assets</p></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Credit</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">rating</p></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Diversification of bank deposits, Investment guidelines for</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">debt investments</p></td></tr>
  <tr>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity</b></span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D and G&amp;A cost, equity, trade and other payables</span></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rolling</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">cash flow forecast</p></td>
    <td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Availability of funds through financing rounds or public offerings</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock', window );">Schedule of Cash, Cash Equivalents and Financial Assets</a></td>
<td class="text">In 2023, if the Euro had weakened/strengthened
by 10% against the U.S. dollar with all other variables held constant, the Group&#8217;s loss would have been &#8364;1 million higher/&#8364;1
million lower, mainly as a result of foreign exchange on translation of U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx GmbH</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022 *</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current and non current financial assets (securities and accrued interest)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">80,935,197</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,376,866</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,051,366</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,356,512</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total assets exposed to the risk</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">88,986,563</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,733,378</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Conversion rate Euro to U.S. dollars at reporting date 1/1.1050 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.</td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Schedule of Sensitivity Analysis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Sensitivity analysis:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Conversion<br/>
 rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Profit/(loss)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">carrying<br/>
 amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Euro weakens against U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.2155</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">9,887,396</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">98,873,959</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Euro strengths against U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9945</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,089,688</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,896,875</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsExplanatory', window );">Schedule of Outstanding Financial Commitments</a></td>
<td class="text">At the end of the reporting period, the Group
held the following deposits that are expected to readily generate cash inflows to meet the outstanding financial commitments.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Liquidity</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Short-term deposits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">5,140,951</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,626,992</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,261,932</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Marketable Securities (current and non-current)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">85,727,461</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">67,175,879</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other (non-current portion)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,621</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,296</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other (current)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">701,407</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">278,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total funds available</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">99,434,432</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">83,957,344</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial instruments measured at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial instruments designated at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasePrepaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of lease prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasePrepaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMarketRiskExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of market risk. [Refer: Market risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMarketRiskExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 145<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about cash and cash equivalent and financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572374099216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract', window );"><strong>Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Schedule of Maturity Analysis of Lease Liabilities</a></td>
<td class="text">The maturity analysis of lease liabilities is
disclosed in the following table:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for capitalized leases in 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual<br/>
 minimum<br/>
 lease<br/>
 obligations</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of<br/>
 discounting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,158</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">16,829</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">374,329</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,559</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-145">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,151,434</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">31,389</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,120,045</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for capitalized leases in 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contractual<br/>
 minimum<br/>
 lease<br/>
 obligations</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of<br/>
 discounting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Lease<br/>
 liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">380,518</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,142</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">369,376</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">999,482</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">987,307</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-146">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,380,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">23,317</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,356,683</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Maturity analysis for all lease obligations in 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><p style="margin-top: 0; margin-bottom: 0">Low value</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">leases</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short-term<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capitalized<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">397,942</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,816</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,968</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">391,158</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,421</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">760,275</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,158,363</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,962</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,968</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,151,434</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity analysis for all lease obligations in 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low value<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Short-term<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capitalized<br/>
 leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Within one year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">386,779</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,261</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">380,518</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">After one year but not more than five years</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,004,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">999,482</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">More than five years</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,391,223</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,223</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">&#8212;</div></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,380,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369935408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationAbstract', window );"><strong>Other Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory', window );">Schedule of Compensation of the Group&#8217;s Executive Management</a></td>
<td class="text">Compensation of the Group&#8217;s executive
management for the 12 months ending December 31, 2023:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Executive and Board compensation</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Executive management</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Short-term employee benefits</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,783,675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,774,485</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,817,792</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,507,453</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,808,094</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,347,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Sub-total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,291,128</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,582,579</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,164,995</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-executive Board of Directors members</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Short-term employee benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">305,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">248,725</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,248</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payments</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">285,177</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">529,859</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">488,937</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Sub-total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">591,160</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">778,584</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">760,185</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Total compensation</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,882,288</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,361,163</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,925,180</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about compensation of group executive management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370365648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxGmbHMember', window );">InflaRx GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems', window );"><strong>Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Place of business/country of incorporation</a></td>
<td class="text">Jena and Munich, Germany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfFunctionalCurrency', window );">Functional currency</a></td>
<td class="text">EUR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest held by the Company</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Operating subsidiary, R&D, holder of all IP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxPharmaceuticalIncMember', window );">InflaRx Pharmaceuticals, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems', window );"><strong>Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CountryOfIncorporation', window );">Place of business/country of incorporation</a></td>
<td class="text">Ann Arbor, MI, United States<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfFunctionalCurrency', window );">Functional currency</a></td>
<td class="text">USD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">Ownership interest held by the Company</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities', window );">Principal activities</a></td>
<td class="text">Operating subsidiary, R&D, US commercialization<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CountryOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The country in which the entity is incorporated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 138<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_138_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CountryOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfFunctionalCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the currency of the primary economic environment in which the entity operates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 57<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_57_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfFunctionalCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the nature of the entity's operations and principal activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 138<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_138_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxPharmaceuticalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxPharmaceuticalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373431200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material Accounting Policies (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">German federal government</a></td>
<td class="nump">&#8364; 43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant', window );">Grant payment received</a></td>
<td class="nump">&#8364; 41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PercentageOfGrant', window );">Percentage of grant</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Received grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">&#8364; 6,209,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AmortizedPeriod', window );">Amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AnnualizedAverageSharePricePeriod', window );">Annualized average share price year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccruedIncomeIncludingContractAssets', window );">Accrued payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,400,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoryWritedown2011', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 521,000<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RentalContractsFixedPeriod', window );">Rental contracts fixed period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RentalContractsFixedPeriod', window );">Rental contracts fixed period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_GermanMinistryOfEducationAndResearchMember', window );">German Ministry of Education and Research [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentGovernmentGrants', window );">Received grant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionsGrantedMember', window );">Options Granted [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionsGrantedMember', window );">Options Granted [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Volatility rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment [Member] | Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrs-full_OfficeEquipmentMember', window );">Office Equipment [Member] | Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaterialAccountingPoliciesDetailsLineItems', window );"><strong>Material Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccruedIncomeIncludingContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets representing income that has been earned but is not yet a receivable, including contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccruedIncomeIncludingContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets acquired through government grants. [Refer: Government grants; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 122<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_122_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoryWritedown2011">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoryWritedown2011</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AmortizedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AmortizedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AnnualizedAverageSharePricePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annualized average share price period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AnnualizedAverageSharePricePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_MaterialAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_MaterialAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PercentageOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PercentageOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_RentalContractsFixedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental contracts fixed period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_RentalContractsFixedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_GermanMinistryOfEducationAndResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_GermanMinistryOfEducationAndResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionsGrantedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_OptionsGrantedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572371647760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expense</a></td>
<td class="nump">&#8364; 4,001,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingExpense', window );">Expense</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceCost', window );">Personnel cost</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">41,024,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,526,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,697,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">12,628,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,869,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,984,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">13,219,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,159,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 54,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetFinancialCost', window );">Net financial cost</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnDeposits', window );">Interest income increased</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShortTermMarketableSecurities', window );">Short term marketable securities</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Foreign exchange</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeGain', window );">Gain on foreign exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ForeignExchangeLoss', window );">Loss on foreign exchange</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Other financial amount</a></td>
<td class="nump">77,504,518<span></span>
</td>
<td class="nump">&#8364; 77,504,518<span></span>
</td>
<td class="nump">64,810,135<span></span>
</td>
<td class="nump">&#8364; 64,810,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets', window );">Allowance for credit loss</a></td>
<td class="nump">&#8364; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_WeightedNumberOfCommonSharesOutstanding', window );">Weighted number of common shares outstanding | shares</a></td>
<td class="nump">54,940,137<span></span>
</td>
<td class="nump">54,940,137<span></span>
</td>
<td class="nump">44,207,873<span></span>
</td>
<td class="nump">44,207,873<span></span>
</td>
<td class="nump">41,629,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_LossPerShare', window );">Loss per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExercisePriceOfOutstandingShareOptions', window );">Exercise price for options outstanding | &#8364; / shares</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear', window );">weighted average fair value of options granted | (per share)</a></td>
<td class="nump">&#8364; 2.39<span></span>
</td>
<td class="nump">&#8364; 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd', window );">Weighted average fair value options granted | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.61<span></span>
</td>
<td class="nump">&#8364; 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OptionsGranted', window );">Options granted | shares</a></td>
<td class="nump">1,735,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,966,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,219,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfStockOptionsForfeited', window );">Options forfeited | shares</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOptionsExercised', window );">Options exercised | shares</a></td>
<td class="nump">105,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExpectedDividends', window );">Expected dividends | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncomeStatementLocationAxis=ifrx_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">&#8364; 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncomeStatementLocationAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrx_LongTermIncentivePlan2017Member', window );">2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConversionRate', window );">Conversion rate | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.9376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AverageRate', window );">Average rate | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.9246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.9489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="text">6 years 7 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_MaximumNumberOfCommonSharesAvailableForGrant', window );">Maximum number of common shares available for grant | shares</a></td>
<td class="nump">2,341,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ordinarySharesPercentage', window );">Ordinary shares percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DefinedBenefitPlansAxis=ifrx_LongTermIncentivePlan2016Member', window );">2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="text">7 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExercisePriceRange', window );">Exercise price range | (per share)</a></td>
<td class="nump">&#8364; 1.74<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
<td class="nump">&#8364; 1.74<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExercisePriceRange', window );">Exercise price range | (per share)</a></td>
<td class="nump">&#8364; 4.82<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="nump">&#8364; 4.82<span></span>
</td>
<td class="nump">5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxGmbHMember', window );">InflaRx GmbH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConversionRate', window );">Conversion rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AverageRate', window );">Average rate | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.9246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.9489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveManagementMember', window );">Executive Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OptionsGranted', window );">Options granted | shares</a></td>
<td class="nump">1,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,223,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfStockOptionsForfeited', window );">Options forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Other financial amount</a></td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="nump">&#8364; 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the allowance account used to record the impairment of financial assets due to credit losses. [Refer: Financial assets; Allowance account for credit losses of financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on deposits. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AverageRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of average rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AverageRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of conversion rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExercisePriceOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExercisePriceOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExpectedDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of expected dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExpectedDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_LossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_LossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_MaximumNumberOfCommonSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_MaximumNumberOfCommonSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NetFinancialCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net financial cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NetFinancialCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfStockOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of stock options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfStockOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ShortTermMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short term marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ShortTermMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value options granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value options granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_WeightedNumberOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted number of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_WeightedNumberOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ordinarySharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ordinarySharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IncomeStatementLocationAxis=ifrx_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IncomeStatementLocationAxis=ifrx_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IncomeStatementLocationAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IncomeStatementLocationAxis=ifrs-full_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrx_LongTermIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrx_LongTermIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DefinedBenefitPlansAxis=ifrx_LongTermIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DefinedBenefitPlansAxis=ifrx_LongTermIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_InflaRxGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370685616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Revenues - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfRevenuesAbstract', window );"><strong>Schedule Of Revenues Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">&#8364; 63,089<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total</a></td>
<td class="nump">&#8364; 63,089<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572371234336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Cost of sales - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfCostOfSalesAbstract', window );"><strong>Schedule Of Cost Of Sales Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of Sales</a></td>
<td class="nump">&#8364; 532,262<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Total</a></td>
<td class="nump">&#8364; 532,262<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfCostOfSalesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfCostOfSalesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370845216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">&#8364; 4,001,299<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyExpensesMember', window );">Third-party expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">1,851,158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember', window );">Employee benefits expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">1,040,587<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember', window );">equity-settled share-based payment expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">67,462<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember', window );">Legal and consulting fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">1,054,971<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember', window );">Other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">&#8364; 54,583<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572381027440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 41,024,131<span></span>
</td>
<td class="nump">&#8364; 37,526,090<span></span>
</td>
<td class="nump">&#8364; 35,697,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyServicesMember', window );">Third-party services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">31,802,983<span></span>
</td>
<td class="nump">28,543,503<span></span>
</td>
<td class="nump">28,247,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_ManufacturingOfClinicalMaterialMember', window );">Clinical material and related manufacturing services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">18,109,345<span></span>
</td>
<td class="nump">16,194,152<span></span>
</td>
<td class="nump">6,615,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_clinicalPreclinicalStudiesMember', window );">Clinical, pre-clinical studies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">13,693,638<span></span>
</td>
<td class="nump">12,349,351<span></span>
</td>
<td class="nump">21,631,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember', window );">Employee benefits expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">6,776,853<span></span>
</td>
<td class="nump">6,957,866<span></span>
</td>
<td class="nump">5,941,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember', window );">Equity-settled share-based payment expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,500,670<span></span>
</td>
<td class="nump">2,456,571<span></span>
</td>
<td class="nump">1,622,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember', window );">Legal and consulting fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,758,283<span></span>
</td>
<td class="nump">1,690,448<span></span>
</td>
<td class="nump">1,074,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember', window );">Other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">&#8364; 686,012<span></span>
</td>
<td class="nump">&#8364; 334,273<span></span>
</td>
<td class="nump">&#8364; 434,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_ThirdpartyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_ManufacturingOfClinicalMaterialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_ManufacturingOfClinicalMaterialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_clinicalPreclinicalStudiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_clinicalPreclinicalStudiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370654400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 12,628,756<span></span>
</td>
<td class="nump">&#8364; 14,869,564<span></span>
</td>
<td class="nump">&#8364; 11,984,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember', window );">Employee benefits expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,392,905<span></span>
</td>
<td class="nump">7,125,798<span></span>
</td>
<td class="nump">6,500,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember', window );">Equity-settled share-based payment expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,846,356<span></span>
</td>
<td class="nump">3,587,785<span></span>
</td>
<td class="nump">2,709,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember', window );">Legal and consulting fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,239,809<span></span>
</td>
<td class="nump">3,104,624<span></span>
</td>
<td class="nump">2,065,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_InsuranceExpensesMember', window );">Insurance expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,934,880<span></span>
</td>
<td class="nump">2,330,624<span></span>
</td>
<td class="nump">1,615,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_DepreciationAmortizationExpenseMember', window );">Depreciation &amp; amortization expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">507,905<span></span>
</td>
<td class="nump">526,325<span></span>
</td>
<td class="nump">551,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember', window );">Compensation expense for non-executive directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">305,984<span></span>
</td>
<td class="nump">248,724<span></span>
</td>
<td class="nump">271,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember', window );">Other expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 1,247,273<span></span>
</td>
<td class="nump">&#8364; 1,533,469<span></span>
</td>
<td class="nump">&#8364; 979,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EmployeeBenefitsExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_LegalAndConsultingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_InsuranceExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_InsuranceExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_DepreciationAmortizationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_DepreciationAmortizationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370353840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Other Income - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfOtherIncomeAbstract', window );"><strong>Schedule of other income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Other income from government grants</a></td>
<td class="nump">&#8364; 13,155,250<span></span>
</td>
<td class="nump">&#8364; 20,116,542<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_LiabilityForFuturePolicyBenefitPeriodExpense', window );">Further other income</a></td>
<td class="nump">64,454<span></span>
</td>
<td class="nump">42,627<span></span>
</td>
<td class="nump">54,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Total</a></td>
<td class="nump">&#8364; 13,219,704<span></span>
</td>
<td class="nump">&#8364; 20,159,169<span></span>
</td>
<td class="nump">&#8364; 54,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_LiabilityForFuturePolicyBenefitPeriodExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) recognized due to changes in the accrued obligation to policyholders that relates to insured events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_LiabilityForFuturePolicyBenefitPeriodExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369583472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_Employeebenefitsexpense', window );">Employee benefits expenses</a></td>
<td class="nump">&#8364; 13,210,345<span></span>
</td>
<td class="nump">&#8364; 14,083,664<span></span>
</td>
<td class="nump">&#8364; 12,442,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_WagesAndSalariesMember', window );">Wages and salaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_Employeebenefitsexpense', window );">Employee benefits expenses</a></td>
<td class="nump">8,192,143<span></span>
</td>
<td class="nump">6,863,423<span></span>
</td>
<td class="nump">6,919,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_SocialSecurityContributionsemployersShareMember', window );">Social security contributions (employer's share) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_Employeebenefitsexpense', window );">Employee benefits expenses</a></td>
<td class="nump">944,712<span></span>
</td>
<td class="nump">672,534<span></span>
</td>
<td class="nump">671,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpensesMember', window );">Equity-settled share-based payment expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_Employeebenefitsexpense', window );">Employee benefits expenses</a></td>
<td class="nump">3,414,488<span></span>
</td>
<td class="nump">6,044,356<span></span>
</td>
<td class="nump">4,332,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_Employeebenefitsexpense', window );">Employee benefits expenses</a></td>
<td class="nump">&#8364; 659,002<span></span>
</td>
<td class="nump">&#8364; 503,351<span></span>
</td>
<td class="nump">&#8364; 519,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_Employeebenefitsexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_Employeebenefitsexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_WagesAndSalariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_WagesAndSalariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_SocialSecurityContributionsemployersShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_SocialSecurityContributionsemployersShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_EquitysettledSharebasedPaymentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=ifrx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=ifrx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373057776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Net Financial Result - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfNetFinancialResultAbstract', window );"><strong>Schedule Of Net Financial Result Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">&#8364; 3,804,827<span></span>
</td>
<td class="nump">&#8364; 608,679<span></span>
</td>
<td class="nump">&#8364; 109,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expenses</a></td>
<td class="num">(16,538)<span></span>
</td>
<td class="num">(23,303)<span></span>
</td>
<td class="num">(10,714)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="num">(19,090)<span></span>
</td>
<td class="num">(21,947)<span></span>
</td>
<td class="num">(14,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial result</a></td>
<td class="nump">3,769,199<span></span>
</td>
<td class="nump">563,429<span></span>
</td>
<td class="nump">84,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeIncome', window );">Foreign exchange income</a></td>
<td class="nump">5,529,389<span></span>
</td>
<td class="nump">6,924,697<span></span>
</td>
<td class="nump">5,569,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeExpense', window );">Foreign exchange expense</a></td>
<td class="num">(7,371,261)<span></span>
</td>
<td class="num">(4,482,399)<span></span>
</td>
<td class="num">(3,605,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeResult', window );">Foreign exchange result</a></td>
<td class="num">(1,841,872)<span></span>
</td>
<td class="nump">2,442,298<span></span>
</td>
<td class="nump">1,964,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherFinancialResult', window );">Other financial result</a></td>
<td class="nump">313,240<span></span>
</td>
<td class="num">(252,471)<span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetFinancialResult', window );">Net financial result</a></td>
<td class="nump">&#8364; 2,240,566<span></span>
</td>
<td class="nump">&#8364; 2,753,256<span></span>
</td>
<td class="nump">&#8364; 2,004,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ForeignExchangeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of foreign exchange expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ForeignExchangeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ForeignExchangeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of foreign exchange loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ForeignExchangeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ForeignExchangeResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of foreign exchange result.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ForeignExchangeResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NetFinancialResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of net financial result.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NetFinancialResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OtherFinancialResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other finacial result.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OtherFinancialResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfNetFinancialResultAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfNetFinancialResultAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370834928">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrx_OptionsMember', window );">Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,433<span></span>
</td>
<td class="nump">148,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,433<span></span>
</td>
<td class="nump">148,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable at December 31 (in Euro per share and Dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,433<span></span>
</td>
<td class="nump">$ 148,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrx_WAEPMember', window );">WAEP [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at January 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Exercisable at December 31 (in Euro per share and Dollars per share) | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average share price (WAEP)</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrx_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrx_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrx_WAEPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrx_WAEPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373600384">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments - 2016 Plan [Member]<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrx_OptionsMember', window );">Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding', window );">Options, Outstanding beginning</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOpionsExercisedDuring', window );">Options, Exercised during the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding', window );">Options, Outstanding ending</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfSharesOptionsExercisable', window );">Options, Exercisable at December 31</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember', window );">WAEP [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageSharesOutstanding', window );">WAEP, Outstanding beginning | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 1.74<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">&#8364; 2.96<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfSharesExercisedDuring', window );">WAEP, Exercised during the year | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageSharesOutstanding', window );">WAEP, Outstanding ending | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1.68<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_WAEPExercisables', window );">WAEP,Exercisable at December 31 | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 1.68<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="nump">&#8364; 1.74<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31,2022 $0.9376, average rate 2022 $0.9489</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfOpionsExercisedDuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfOpionsExercisedDuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfSharesExercisedDuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfSharesExercisedDuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfSharesOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfSharesOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfWeightedAverageSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfWeightedAverageSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_WAEPExercisables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>WAEP, exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_WAEPExercisables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrx_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrx_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrx_OptionPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrx_OptionPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572371994544">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments - Long-Term Incentive Plan 2017 [Member]<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrx_OptionsMember', window );">Options [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOutstandingSharesOption', window );">Options, Outstanding beginning | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,985,523<span></span>
</td>
<td class="nump">4,985,523<span></span>
</td>
<td class="nump">3,170,046<span></span>
</td>
<td class="nump">3,170,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement', window );">Options, Granted during the year | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,735,750<span></span>
</td>
<td class="nump">1,735,750<span></span>
</td>
<td class="nump">1,966,666<span></span>
</td>
<td class="nump">1,966,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement', window );">Options, Forfeited during the year | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(31,000)<span></span>
</td>
<td class="num">(31,000)<span></span>
</td>
<td class="num">(136,259)<span></span>
</td>
<td class="num">(136,259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement', window );">Options, Exercised during the year | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(105,327)<span></span>
</td>
<td class="num">(105,327)<span></span>
</td>
<td class="num">(14,930)<span></span>
</td>
<td class="num">(14,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOutstandingSharesOption', window );">Options, Outstanding ending | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,584,946<span></span>
</td>
<td class="nump">6,584,946<span></span>
</td>
<td class="nump">4,985,523<span></span>
</td>
<td class="nump">4,985,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement', window );">Options, Exercisable at December 31 | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,577,384<span></span>
</td>
<td class="nump">5,577,384<span></span>
</td>
<td class="nump">4,157,148<span></span>
</td>
<td class="nump">4,157,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember', window );">WAEP [Member] | Top of range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOutstandingsWeightedAverageEarningPershare', window );">WAEP, Outstanding beginning | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement', window );">WAEP, Granted during the year | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement', window );">WAEP, Forfeited during the year | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement', window );">WAEP, Exercised during the year | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOutstandingsWeightedAverageEarningPershare', window );">WAEP, Outstanding ending | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement', window );">WAEP,Exercisable at December 31 | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember', window );">WAEP [Member] | Bottom of range [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems', window );"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOutstandingsWeightedAverageEarningPershare', window );">WAEP, Outstanding beginning | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement', window );">WAEP, Granted during the year | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement', window );">WAEP, Forfeited during the year | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement', window );">WAEP, Exercised during the year | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfOutstandingsWeightedAverageEarningPershare', window );">WAEP, Outstanding ending | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement', window );">WAEP,Exercisable at December 31 | &#8364; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#8364;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31, 2022 $0.9376, average rate 2022 $0.9489</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfOutstandingSharesOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfOutstandingSharesOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfOutstandingsWeightedAverageEarningPershare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>WAEP, Outstanding beginning.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfOutstandingsWeightedAverageEarningPershare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrx_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrx_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrx_LongTermIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDefinedBenefitLiabilityAssetAxis=ifrx_LongTermIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrx_WAEPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572362070544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average<br></strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">1,735,750<span></span>
</td>
<td class="nump">1,735,750<span></span>
</td>
<td class="nump">1,966,666<span></span>
</td>
<td class="nump">1,966,666<span></span>
</td>
<td class="nump">1,219,074<span></span>
</td>
<td class="nump">1,219,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4Member', window );">January 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,260<span></span>
</td>
<td class="nump">839,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4Member', window );">January 4 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4OneMember', window );">January 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,668<span></span>
</td>
<td class="nump">31,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4OneMember', window );">January 4 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2Member', window );">July 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,436<span></span>
</td>
<td class="nump">327,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2Member', window );">July 2 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2OneMember', window );">July 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,710<span></span>
</td>
<td class="nump">20,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
<td class="text">5 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.01%<span></span>
</td>
<td class="nump">1.01%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2OneMember', window );">July 2 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12Member', window );">January 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,516,666<span></span>
</td>
<td class="nump">1,516,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12Member', window );">January 12 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12OneMember', window );">January 12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12OneMember', window );">January 12 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_RepricingApril13Member', window );">Repricing, April 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_RepricingApril13Member', window );">Repricing, April 13 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_RepricingApril13Member', window );">Repricing, April 13 [Member] | Top of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">4 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_November21Member', window );">November 21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_November21Member', window );">November 21 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourMember', window );">January 24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">1,454,250<span></span>
</td>
<td class="nump">1,454,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">3.571%<span></span>
</td>
<td class="nump">3.571%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourMember', window );">January 24 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourOneMember', window );">January 24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">52,500<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 1.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">3.565%<span></span>
</td>
<td class="nump">3.565%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourOneMember', window );">January 24 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_MayThirtyOneMember', window );">May 31 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">60,500<span></span>
</td>
<td class="nump">60,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">3.82%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_MayThirtyOneMember', window );">May 31 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenMember', window );">July 7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenMember', window );">July 7 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenOneMember', window );">July 7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">4.286%<span></span>
</td>
<td class="nump">4.286%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenOneMember', window );">July 7 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulyNineteenMember', window );">July 19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulyNineteenMember', window );">July 19 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_SeptemberEighteenMember', window );">September 18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareOptionsGrantedOptions', window );">Options (in Shares) | shares</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ForeignExchangeRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FairValuesPerOptions', window );">Fair value per option (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.46%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Expected life (midpoint based)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">4.32%<span></span>
</td>
<td class="nump">4.32%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_SeptemberEighteenMember', window );">September 18 [Member] | Bottom of range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_a2021Abstract', window );"><strong>2021</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SharePriceAtGrantDateExercisePrices', window );">Share price at grant date / Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_FairValuePerOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value option per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_FairValuePerOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_FairValuesPerOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value per option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_FairValuesPerOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ForeignExchangeRateAsOfGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The foreign exchange rate as grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ForeignExchangeRateAsOfGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ShareOptionsGrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share options granted options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ShareOptionsGrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_SharePriceAtGrantDateExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The share price at grant date and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_SharePriceAtGrantDateExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_a2021Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_a2021Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January4OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_July2OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_January12OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_RepricingApril13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_RepricingApril13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_November21Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_November21Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JanuaryTwentyFourOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_MayThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_MayThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulySevenOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulyNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_JulyNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_SeptemberEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrx_SeptemberEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572361217632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details)<br> &#8364; / shares in Units, $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow for leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WritedownsReversalsOfInventories', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CorporateIncomeTax', window );">Corporate Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SolidaritySurcharge', window );">Solidarity surcharge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TradeTaxes', window );">Trade taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.065%<span></span>
</td>
<td class="nump">13.065%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageEffectiveTaxRate', window );">Average total tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
<td class="nump">29.50%<span></span>
</td>
<td class="nump">28.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalTaxRate', window );">Total tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.74%<span></span>
</td>
<td class="nump">25.74%<span></span>
</td>
<td class="nump">25.74%<span></span>
</td>
<td class="nump">25.74%<span></span>
</td>
<td class="nump">25.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent', window );">Federal tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent', window );">State tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
<td class="nump">4.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax', window );">Total tax loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 243,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 211,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes', window );">Corporate income and trade tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 12,970,000<span></span>
</td>
<td class="nump">$ 14.3<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TaxableIncome', window );">Taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInterestReceivable', window );">Current income tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,390,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CurrentAndNonCurrentFinancialAssets', window );">Current and non-current financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FinancialAssetsFromGovernmentGrantsAmount', window );">Financial assets from government grants amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DueAmount', window );">Due amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CapitalOrdinarySharesIssued', window );">Capital ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,883,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,703,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommonShares', window );">Common shares over time (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,257<span></span>
</td>
<td class="nump">120,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommonSharesIssued', window );">Common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount', window );">Sales agreement amounts (in Dollars) | $</a></td>
<td class="nump">$ 19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,400,000<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AggregateCommonShares', window );">Aggregate ordinary shares sold (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,823,529<span></span>
</td>
<td class="nump">10,823,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">share sold (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ProceedsOfferingCost', window );">Proceeds offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_UnderwritingDiscounts', window );">Underwriting Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,100,000<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ProceedsFromOfferingCost', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinaryShares', window );">Ordinary share purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,300,000<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendsPaidOrdinarySharesPerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized', window );">Sale of additional shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AggregatePurchasePrice', window );">Aggregate purchase price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AggregateInitialOffering', window );">Aggregate public offering (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NominalValue', window );">Nominal value (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OrdinarySharesValue', window );">Ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OrdinaryShareSoldPrice', window );">Ordinary shares sold at price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Ordinary shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SoldAtPrice', window );">Price sold (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OrdinarySharePurchase', window );">Ordinary share purchase (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PreferredUnitIssued', window );">Preferred shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk', window );">Nominal value per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CompanyIssuedCapital', window );">Company issued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedReimbursementOtherProvisions', window );">Reimburse expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommonSharesInExcessOfNominalValue', window );">Common shares in excess of nominal value (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PaymentsForAccruedPayments', window );">Payments for accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_VariablesHeldConstant', window );">Variables held constant, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 99,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrx_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FixedInterest', window );">Nominal fixed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrx_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FixedInterest', window );">Nominal fixed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
<td class="nump">4.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Foreign exchange on translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExchangeRateFluctuations', window );">Exchange rate fluctuations (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.2155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of Range [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax', window );">Foreign exchange on translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExchangeRateFluctuations', window );">Exchange rate fluctuations (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.9945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_MarketProgramMember', window );">Market Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,235,723<span></span>
</td>
<td class="nump">3,235,723<span></span>
</td>
<td class="nump">2,568,208<span></span>
</td>
<td class="nump">2,568,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Ordinary shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,930<span></span>
</td>
<td class="nump">14,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 86,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 67,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current interest receivable. [Refer: Interest receivable]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid by the entity on ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2023-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendsPaidOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends paid per ordinary share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 34<br> -IssueDate 2023-01-01<br> -Paragraph 16A<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=34&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16A_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendsPaidOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedReimbursementOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount expected to be reimbursed by another party on expenditures to settle other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedReimbursementOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on change in value of forward elements of forward contracts, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35K<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or principal amount of a financial instrument on discontinuation of its measurement at fair value through profit or loss, because a credit derivative is used to manage the credit risk of that financial instrument. [Refer: Credit risk [member]; Derivatives [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 24G<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24G_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WritedownsReversalsOfInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised resulting from the write-down of inventories to net realisable value or reversals of those write-downs. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WritedownsReversalsOfInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AggregateCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AggregateCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AggregateInitialOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate initial offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AggregateInitialOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of assets sold under agreements to repurchase when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under repurchase agreements exceeds 10 percent of total assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CapitalOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal number of capital arising from issuing ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CapitalOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CommonSharesInExcessOfNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CommonSharesInExcessOfNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CompanyIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CompanyIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CurrentAndNonCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current and non-current financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CurrentAndNonCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of due amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_FinancialAssetsFromGovernmentGrantsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets from government grants amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_FinancialAssetsFromGovernmentGrantsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_FixedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_FixedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OrdinarySharePurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary share purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OrdinarySharePurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OrdinaryShareSoldPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary share sold price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OrdinaryShareSoldPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OrdinarySharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OrdinarySharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PaymentsForAccruedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payments for accrued payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PaymentsForAccruedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PreferredUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of preferred units issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PreferredUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ProceedsFromOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ProceedsFromOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ProceedsOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ProceedsOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_SoldAtPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_SoldAtPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_SolidaritySurcharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Solidarity surcharge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_SolidaritySurcharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of investments for Federal income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax loss carryforwards .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TotalTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of  total tax rate .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TotalTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TradeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TradeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_UnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of underwriting discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_UnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_VariablesHeldConstant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of variables held constant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_VariablesHeldConstant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrx_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrx_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrx_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrx_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_MarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_MarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572374337184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValuePropertyAndEquipment', window );">Net book value</a></td>
<td class="nump">&#8364; 289,577<span></span>
</td>
<td class="nump">&#8364; 328,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at beginning</a></td>
<td class="nump">1,453,339<span></span>
</td>
<td class="nump">1,267,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">55,123<span></span>
</td>
<td class="nump">160,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(2,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange differences</a></td>
<td class="num">(14,342)<span></span>
</td>
<td class="nump">25,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at ending</a></td>
<td class="nump">1,491,525<span></span>
</td>
<td class="nump">1,453,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at beginning</a></td>
<td class="num">(1,124,419)<span></span>
</td>
<td class="num">(993,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange differences</a></td>
<td class="nump">13,668<span></span>
</td>
<td class="num">(17,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at ending</a></td>
<td class="num">(1,201,948)<span></span>
</td>
<td class="num">(1,124,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease', window );">Depreciation charge for the year</a></td>
<td class="num">(93,791)<span></span>
</td>
<td class="num">(113,894)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Property and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValuePropertyAndEquipment', window );">Net book value</a></td>
<td class="nump">289,577<span></span>
</td>
<td class="nump">328,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Property and equipment [Member] | Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at beginning</a></td>
<td class="nump">1,453,339<span></span>
</td>
<td class="nump">1,267,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">55,123<span></span>
</td>
<td class="nump">160,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="num">(2,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange differences</a></td>
<td class="num">(14,342)<span></span>
</td>
<td class="nump">25,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at ending</a></td>
<td class="nump">1,491,525<span></span>
</td>
<td class="nump">1,453,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember', window );">Property and equipment [Member] | Accumulated depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at beginning</a></td>
<td class="num">(1,124,419)<span></span>
</td>
<td class="num">(993,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange differences</a></td>
<td class="nump">13,668<span></span>
</td>
<td class="num">(17,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at ending</a></td>
<td class="num">(1,201,948)<span></span>
</td>
<td class="num">(1,124,419)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease', window );">Depreciation charge for the year</a></td>
<td class="num">(93,791)<span></span>
</td>
<td class="num">(113,894)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrx_AdvancePaymentsMember', window );">Advance payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValuePropertyAndEquipment', window );">Net book value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrx_AdvancePaymentsMember', window );">Advance payments [Member] | Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrx_AdvancePaymentsMember', window );">Advance payments [Member] | Accumulated depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01', window );">Balance at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease', window );">Depreciation charge for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisposalsAndRetirementPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisposalsAndRetirementPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NetBookValuePropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NetBookValuePropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation expense for lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OtherPropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrx_AdvancePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrx_AdvancePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572372018400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValueOfRightOfUseAsset', window );">Net book value</a></td>
<td class="nump">&#8364; 1,071,666<span></span>
</td>
<td class="nump">&#8364; 1,311,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValueOfRightOfUseAsset', window );">Net book value</a></td>
<td class="nump">1,028,098<span></span>
</td>
<td class="nump">1,292,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember', window );">Cars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValueOfRightOfUseAsset', window );">Net book value</a></td>
<td class="nump">43,568<span></span>
</td>
<td class="nump">19,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, beginning</a></td>
<td class="nump">2,704,473<span></span>
</td>
<td class="nump">2,409,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">140,128<span></span>
</td>
<td class="nump">281,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions', window );">Exchange differences</a></td>
<td class="num">(9,349)<span></span>
</td>
<td class="nump">13,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, ending</a></td>
<td class="nump">2,835,253<span></span>
</td>
<td class="nump">2,704,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, beginning</a></td>
<td class="nump">2,579,342<span></span>
</td>
<td class="nump">2,284,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">91,125<span></span>
</td>
<td class="nump">281,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions', window );">Exchange differences</a></td>
<td class="num">(9,349)<span></span>
</td>
<td class="nump">13,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, ending</a></td>
<td class="nump">2,661,118<span></span>
</td>
<td class="nump">2,579,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member] | Cars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, beginning</a></td>
<td class="nump">125,130<span></span>
</td>
<td class="nump">125,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">49,004<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions', window );">Exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, ending</a></td>
<td class="nump">174,134<span></span>
</td>
<td class="nump">125,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, beginning</a></td>
<td class="num">(1,392,664)<span></span>
</td>
<td class="num">(1,001,321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation charge for the year</a></td>
<td class="num">(377,925)<span></span>
</td>
<td class="num">(384,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions', window );">Exchange differences</a></td>
<td class="nump">7,003<span></span>
</td>
<td class="num">(6,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, ending</a></td>
<td class="num">(1,763,586)<span></span>
</td>
<td class="num">(1,392,664)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, beginning</a></td>
<td class="num">(1,286,625)<span></span>
</td>
<td class="num">(925,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation charge for the year</a></td>
<td class="num">(353,398)<span></span>
</td>
<td class="num">(354,408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions', window );">Exchange differences</a></td>
<td class="nump">7,003<span></span>
</td>
<td class="num">(6,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, ending</a></td>
<td class="num">(1,633,020)<span></span>
</td>
<td class="num">(1,286,625)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Accumulated depreciation [Member] | Cars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, beginning</a></td>
<td class="num">(106,039)<span></span>
</td>
<td class="num">(76,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation charge for the year</a></td>
<td class="num">(24,527)<span></span>
</td>
<td class="num">(30,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions', window );">Exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_RightofuseAssetsRevaluationSurplus01', window );">Balance, ending</a></td>
<td class="num">&#8364; (130,566)<span></span>
</td>
<td class="num">&#8364; (106,039)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NetBookValueOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NetBookValueOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_RightofuseAssetsRevaluationSurplus01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the revaluation surplus that relates to right-of-use assets. [Refer: Revaluation surplus; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_RightofuseAssetsRevaluationSurplus01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370862112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValueIntangibleAsset', window );">Net book value</a></td>
<td class="nump">&#8364; 68,818<span></span>
</td>
<td class="nump">&#8364; 138,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_ComputerSoftwareMember', window );">Purchased IT-software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValueIntangibleAsset', window );">Net book value</a></td>
<td class="nump">42,841<span></span>
</td>
<td class="nump">138,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrx_AdvancesPaidForSoftwareMember', window );">Advances paid for software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NetBookValueIntangibleAsset', window );">Net book value</a></td>
<td class="nump">25,977<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance beginning</a></td>
<td class="num">(723,250)<span></span>
</td>
<td class="nump">720,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">25,977<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="num">(7,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance ending</a></td>
<td class="nump">742,107<span></span>
</td>
<td class="nump">723,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member] | Purchased IT-software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance beginning</a></td>
<td class="num">(723,250)<span></span>
</td>
<td class="nump">720,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="num">(7,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="num">(111)<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance ending</a></td>
<td class="nump">716,130<span></span>
</td>
<td class="nump">723,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember', window );">Cost [Member] | Advances paid for software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">25,977<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance ending</a></td>
<td class="nump">25,977<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_AccumulatedAmortizationMember', window );">Accumulated amortization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance beginning</a></td>
<td class="nump">584,345<span></span>
</td>
<td class="num">(485,726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge for the year</a></td>
<td class="num">(96,063)<span></span>
</td>
<td class="num">(98,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">7,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="nump">111<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance ending</a></td>
<td class="num">(673,289)<span></span>
</td>
<td class="num">(584,345)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_AccumulatedAmortizationMember', window );">Accumulated amortization [Member] | Purchased IT-software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance beginning</a></td>
<td class="nump">584,345<span></span>
</td>
<td class="num">(485,726)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge for the year</a></td>
<td class="num">(96,063)<span></span>
</td>
<td class="num">(98,271)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="nump">7,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="nump">111<span></span>
</td>
<td class="num">(348)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance ending</a></td>
<td class="num">(673,289)<span></span>
</td>
<td class="num">(584,345)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_AccumulatedAmortizationMember', window );">Accumulated amortization [Member] | Advances paid for software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance beginning</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization charge for the year</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill', window );">Exchange differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_IntangibleAssets', window );">Balance ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal amount of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_IntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_IntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NetBookValueIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NetBookValueIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrx_AdvancesPaidForSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrx_AdvancesPaidForSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_CostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_AccumulatedAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis=ifrx_AccumulatedAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369532672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Lease Liabilities - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfLeaseLiabilitiesAbstract', window );"><strong>Schedule of Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">As of January 1</a></td>
<td class="nump">&#8364; 1,356,684<span></span>
</td>
<td class="nump">&#8364; 1,432,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalProvisionsOtherProvisions', window );">Additions</a></td>
<td class="nump">140,128<span></span>
</td>
<td class="nump">281,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets', window );">Derecognition</a></td>
<td class="num">(20,555)<span></span>
</td>
<td class="num">(20,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments</a></td>
<td class="num">(353,422)<span></span>
</td>
<td class="num">(343,874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss', window );">Short-term liability for accrued interest expense</a></td>
<td class="num">(396)<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax', window );">Foreign exchange difference</a></td>
<td class="num">(2,391)<span></span>
</td>
<td class="nump">6,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">As of December 31</a></td>
<td class="nump">&#8364; 1,120,048<span></span>
</td>
<td class="nump">&#8364; 1,356,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional other provisions made. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughDerecognitionFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in financial assets resulting from derecognition. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph IG20B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughDerecognitionFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369560896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Amounts Recognized in Profit or Loss - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract', window );"><strong>Schedule Of Amounts Recognized In Profit Or Loss Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss', window );">Depreciation expense of right-of-use assets (see Note E.2.)</a></td>
<td class="nump">&#8364; 377,925<span></span>
</td>
<td class="nump">&#8364; 384,432<span></span>
</td>
<td class="nump">&#8364; 371,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBonds', window );">Interest expense on lease liabilities</a></td>
<td class="nump">19,090<span></span>
</td>
<td class="nump">21,947<span></span>
</td>
<td class="nump">14,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense from leases</a></td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed', window );">Thereof short-term leases (included in administrative expenses)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities', window );">Thereof leases of low-value assets (included in administrative expenses)</a></td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Total amounts recognized in profit or loss</a></td>
<td class="nump">&#8364; 403,276<span></span>
</td>
<td class="nump">&#8364; 412,640<span></span>
</td>
<td class="nump">&#8364; 391,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBonds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on bonds issued. [Refer: Interest expense; Bonds issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBonds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572372950368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Inventory - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfInventoryAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies', window );">Raw material and supplies</a></td>
<td class="nump">&#8364; 423,560<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_UnfinishedGoods', window );">Unfinished goods</a></td>
<td class="nump">10,614,159<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">330,087<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesTotal', window );">Total</a></td>
<td class="nump">&#8364; 11,367,807<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_UnfinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unfinished goods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_UnfinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370850432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Other Assets - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfOtherAssetsAbstract', window );"><strong>Schedule Of Other Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">&#8364; 257,267<span></span>
</td>
<td class="nump">&#8364; 308,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">257,267<span></span>
</td>
<td class="nump">308,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NonCurrentOtherAssets', window );">Total</a></td>
<td class="nump">257,267<span></span>
</td>
<td class="nump">308,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CurrentOtherAssetsAbstract', window );"><strong>Current other assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments on research &amp; development projects</a></td>
<td class="nump">3,670,167<span></span>
</td>
<td class="nump">9,776,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">272,999<span></span>
</td>
<td class="nump">1,841,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Others</a></td>
<td class="nump">93,482<span></span>
</td>
<td class="nump">2,552,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss', window );">Total</a></td>
<td class="nump">4,036,648<span></span>
</td>
<td class="nump">14,170,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalOtherAsset', window );">Total other assets</a></td>
<td class="nump">&#8364; 4,293,915<span></span>
</td>
<td class="nump">&#8364; 14,478,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsToReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsToReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CurrentOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CurrentOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NonCurrentOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NonCurrentOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TotalOtherAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TotalOtherAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572370400288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract', window );"><strong>Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss for the period (accounting profit before income tax)</a></td>
<td class="num">&#8364; (42,667,529)<span></span>
</td>
<td class="num">&#8364; (29,484,611)<span></span>
</td>
<td class="num">&#8364; (45,630,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TaxRate', window );">Tax rate</a></td>
<td class="nump">28.60%<span></span>
</td>
<td class="nump">29.20%<span></span>
</td>
<td class="nump">28.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TaxBenefitsAtTaxRate', window );">Tax benefits at tax rate</a></td>
<td class="nump">&#8364; 12,160,545<span></span>
</td>
<td class="nump">&#8364; 8,610,381<span></span>
</td>
<td class="nump">&#8364; 13,001,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone', window );">Temporary differences and tax losses for which no deferred tax asset was recognized</a></td>
<td class="num">(12,127,977)<span></span>
</td>
<td class="num">(7,480,169)<span></span>
</td>
<td class="num">(10,988,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment', window );">Non-recognition of tax effect on share-based payments</a></td>
<td class="num">(32,182)<span></span>
</td>
<td class="num">(1,251,830)<span></span>
</td>
<td class="num">(1,959,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NondeductibleExpensesForTaxPurposesinDollars', window );">Non-deductible expenses for tax purposes</a></td>
<td class="num">(46,907)<span></span>
</td>
<td class="num">(22,067)<span></span>
</td>
<td class="num">(3,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherDifferencesDueToTaxRateinDollars', window );">Other differences due to tax rate</a></td>
<td class="nump">46,521<span></span>
</td>
<td class="nump">143,686<span></span>
</td>
<td class="num">(49,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NondeductibleExpensesForTaxPurposesinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-deductible expenses for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NondeductibleExpensesForTaxPurposesinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-recognition of tax effect on share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OtherDifferencesDueToTaxRateinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other differences due to tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OtherDifferencesDueToTaxRateinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TaxBenefitsAtTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TaxBenefitsAtTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax losses for which no deferred tax asset was recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369528624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Financial Assets and Liabilities - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract', window );"><strong>Schedule of Financial Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Non-current financial assets</a></td>
<td class="nump">&#8364; 9,052,741<span></span>
</td>
<td class="nump">&#8364; 2,900,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_FinancialAssetsFromGovernmentGrants', window );">Financial assets from government grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">732,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other current financial assets</a></td>
<td class="nump">77,504,518<span></span>
</td>
<td class="nump">64,791,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_LiabilitiesFromGovernmentGrants', window );">Liabilities from government grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,209,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">&#8364; 14,716,441<span></span>
</td>
<td class="nump">&#8364; 4,987,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_FinancialAssetsFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial assets from government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_FinancialAssetsFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_LiabilitiesFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities from government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_LiabilitiesFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572362054992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShortTermDepositsAbstract', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">&#8364; 5,140,951<span></span>
</td>
<td class="nump">&#8364; 3,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CashAtBanksAbstract', window );"><strong>Cash at banks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at banks</a></td>
<td class="nump">7,626,991<span></span>
</td>
<td class="nump">16,261,932<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">12,767,942<span></span>
</td>
<td class="nump">16,265,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_DepositsHeldInUSDollarsMember', window );">Deposits held in U.S. dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShortTermDepositsAbstract', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">4,120,951<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_DepositsHeldInEuroMember', window );">Deposits held in Euro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ShortTermDepositsAbstract', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">1,020,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_CashHeldInUSDollarsMember', window );">Cash held in U.S. dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CashAtBanksAbstract', window );"><strong>Cash at banks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at banks</a></td>
<td class="nump">5,041,802<span></span>
</td>
<td class="nump">8,645,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_CashHeldInUSEuroMember', window );">Cash held in U.S. Euro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CashAtBanksAbstract', window );"><strong>Cash at banks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash at banks</a></td>
<td class="nump">&#8364; 2,585,190<span></span>
</td>
<td class="nump">&#8364; 7,616,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CashAtBanksAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CashAtBanksAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ShortTermDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ShortTermDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_DepositsHeldInUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_DepositsHeldInUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_DepositsHeldInEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_DepositsHeldInEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_CashHeldInUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_CashHeldInUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_CashHeldInUSEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=ifrx_CashHeldInUSEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572372837488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Trade and Other Payables - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfTradeAndOtherPayablesAbstract', window );"><strong>Schedule Of Trade And Other Payables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued liabilities from R&amp;D projects</a></td>
<td class="nump">&#8364; 4,414,143<span></span>
</td>
<td class="nump">&#8364; 2,254,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_AccruedLiabilitiesFromCommercialActivities', window );">Accrued liabilities from commercial activities</a></td>
<td class="nump">1,400,382<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Accounts payable</a></td>
<td class="nump">5,102,700<span></span>
</td>
<td class="nump">1,566,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other accrued liabilities and payables</a></td>
<td class="nump">3,942,909<span></span>
</td>
<td class="nump">1,314,196<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows', window );">Total trade and other payables</a></td>
<td class="nump">&#8364; 14,860,134<span></span>
</td>
<td class="nump">&#8364; 5,135,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph IG31A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG31A&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_AccruedLiabilitiesFromCommercialActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities from commercial activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_AccruedLiabilitiesFromCommercialActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373256784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_MarketRiskMember', window );">Market risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExposureToRisk', window );">Exposure</a></td>
<td class="text">Future development costs; Recognized financial assets and liabilities not denominated in Euro<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets', window );">Measurement</a></td>
<td class="text">Forecasted cash flows Sensitivity analysis<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets', window );">Risk Management</a></td>
<td class="text">Achievement of a natural hedge in the future<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExposureToRisk', window );">Exposure</a></td>
<td class="text">Cash and cash equivalents, current and non-current financial assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets', window );">Measurement</a></td>
<td class="text">Credit rating<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets', window );">Risk Management</a></td>
<td class="text">Diversification of bank deposits, Investment guidelines for debt investments<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExposureToRisk', window );">Exposure</a></td>
<td class="text">R&D and G&A cost, equity, trade and other payables<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets', window );">Measurement</a></td>
<td class="text">Rolling cash flow forecast<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets', window );">Risk Management</a></td>
<td class="text">Availability of funds through financing rounds or public offerings<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExposureToRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of exposures to risks arising from financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExposureToRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of how the entity reflects its risk management strategy by using hedge accounting and designating hedging relationships that it frequently resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 23C<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23C_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the reasons for the fair value measurement of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_MarketRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_MarketRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572369049664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash, Cash Equivalents and Financial Assets - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract', window );"><strong>Schedule of Cash, Cash Equivalents and Financial Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest', window );">Current and non current financial assets (securities and accrued interest)</a></td>
<td class="nump">&#8364; 80,935,197<span></span>
</td>
<td colspan="2" class="nump">&#8364; 7,376,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Cash and cash equivalents</a></td>
<td class="nump">8,051,366<span></span>
</td>
<td colspan="2" class="nump">4,356,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk', window );">Total assets exposed to the risk</a></td>
<td class="nump">&#8364; 88,986,563<span></span>
</td>
<td colspan="2" class="nump">&#8364; 11,733,378<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets held for managing liquidity risk (for example, financial assets that are readily saleable or expected to generate cash inflows to meet cash outflows on financial liabilities). [Refer: Liquidity risk [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11E<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11E&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current and non current financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572361049552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrx_WeakensAgainstMember', window );">Euro weakens against U.S. dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SensitivityAnalysisConversionRate', window );">Conversion rate (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 1.2155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit/(loss)</a></td>
<td class="nump">&#8364; 9,887,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SensitivityAnalysisCarryingAmount', window );">carrying amount</a></td>
<td class="nump">&#8364; 98,873,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrx_StrengthsAgainstMember', window );">Euro strengths against U.S. dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems', window );"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SensitivityAnalysisConversionRate', window );">Conversion rate (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.9945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Profit/(loss)</a></td>
<td class="num">&#8364; (8,089,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_SensitivityAnalysisCarryingAmount', window );">carrying amount</a></td>
<td class="nump">&#8364; 80,896,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_SensitivityAnalysisCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sensitivity analysis carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_SensitivityAnalysisCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_SensitivityAnalysisConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sensitivity analysis conversion rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_SensitivityAnalysisConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrx_WeakensAgainstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrx_WeakensAgainstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrx_StrengthsAgainstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrx_StrengthsAgainstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373051504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Outstanding Financial Commitments - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract', window );"><strong>Schedule of Outstanding Financial Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents', window );">Short-term deposits</a></td>
<td class="nump">&#8364; 5,140,951<span></span>
</td>
<td class="nump">&#8364; 3,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Cash at banks</a></td>
<td class="nump">7,626,992<span></span>
</td>
<td class="nump">16,261,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DebtSecurities', window );">Marketable Securities (current and non-current)</a></td>
<td class="nump">85,727,461<span></span>
</td>
<td class="nump">67,175,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings', window );">Other (non-current portion)</a></td>
<td class="nump">237,621<span></span>
</td>
<td class="nump">237,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings', window );">Other (current)</a></td>
<td class="nump">701,407<span></span>
</td>
<td class="nump">278,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalFundsAvailable', window );">Total funds available</a></td>
<td class="nump">&#8364; 99,434,432<span></span>
</td>
<td class="nump">&#8364; 83,957,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of instruments issued by the entity that represent indebtedness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current other borrowings. [Refer: Other borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TotalFundsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total funds available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TotalFundsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572380274336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsLineItems', window );"><strong>Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Plant and equipment or patents and trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExchangeRateCurrencyAxis=ifrx_CashHeldInUSEuroMember', window );">Euro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsLineItems', window );"><strong>Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExchangeRate', window );">Converted with the exchange rate | &#8364;</a></td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExchangeRateCurrencyAxis=ifrx_CashHeldInUSDollarsMember', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsLineItems', window );"><strong>Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExchangeRate', window );">Converted with the exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CommitmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CommitmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExchangeRateCurrencyAxis=ifrx_CashHeldInUSEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExchangeRateCurrencyAxis=ifrx_CashHeldInUSEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExchangeRateCurrencyAxis=ifrx_CashHeldInUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExchangeRateCurrencyAxis=ifrx_CashHeldInUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572373576128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems', window );"><strong>Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Contractual minimum lease obligations</a></td>
<td class="nump">$ 1,151,434<span></span>
</td>
<td class="nump">$ 1,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_EffectOfDiscounting', window );">Effect of discounting</a></td>
<td class="nump">31,389<span></span>
</td>
<td class="nump">23,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Lease liabilities</a></td>
<td class="nump">1,120,045<span></span>
</td>
<td class="nump">1,356,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalLeases', window );">Total</a></td>
<td class="nump">1,158,363<span></span>
</td>
<td class="nump">1,391,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed', window );">Low value leases</a></td>
<td class="nump">4,962<span></span>
</td>
<td class="nump">11,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short-term leases</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CapitalizedLeases', window );">Capitalized leases</a></td>
<td class="nump">1,151,434<span></span>
</td>
<td class="nump">1,380,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrx_WithinOneYearMember', window );">Within one year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems', window );"><strong>Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Contractual minimum lease obligations</a></td>
<td class="nump">391,158<span></span>
</td>
<td class="nump">380,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_EffectOfDiscounting', window );">Effect of discounting</a></td>
<td class="nump">16,829<span></span>
</td>
<td class="nump">11,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Lease liabilities</a></td>
<td class="nump">374,329<span></span>
</td>
<td class="nump">369,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalLeases', window );">Total</a></td>
<td class="nump">397,942<span></span>
</td>
<td class="nump">386,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed', window );">Low value leases</a></td>
<td class="nump">4,816<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short-term leases</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CapitalizedLeases', window );">Capitalized leases</a></td>
<td class="nump">391,158<span></span>
</td>
<td class="nump">380,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrx_AfterOneYearButNotMoreThanFiveYearsMember', window );">After one year but not more than five years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems', window );"><strong>Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Contractual minimum lease obligations</a></td>
<td class="nump">760,275<span></span>
</td>
<td class="nump">999,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_EffectOfDiscounting', window );">Effect of discounting</a></td>
<td class="nump">14,559<span></span>
</td>
<td class="nump">12,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Lease liabilities</a></td>
<td class="nump">745,716<span></span>
</td>
<td class="nump">987,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalLeases', window );">Total</a></td>
<td class="nump">760,421<span></span>
</td>
<td class="nump">1,004,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed', window );">Low value leases</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short-term leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CapitalizedLeases', window );">Capitalized leases</a></td>
<td class="nump">760,275<span></span>
</td>
<td class="nump">999,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrx_MoreThanFiveYearsMember', window );">More than five years [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems', window );"><strong>Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Contractual minimum lease obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_EffectOfDiscounting', window );">Effect of discounting</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxLiabilities', window );">Lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalLeases', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed', window );">Low value leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Short-term leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_CapitalizedLeases', window );">Capitalized leases</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the lease commitments for short-term leases accounted for applying paragraph 6 of IFRS 16. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CapitalizedLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CapitalizedLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_EffectOfDiscounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of discounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_EffectOfDiscounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TotalLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TotalLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrx_WithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrx_WithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrx_AfterOneYearButNotMoreThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrx_AfterOneYearButNotMoreThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrx_MoreThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrx_MoreThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572372962048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Information (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationDetailsLineItems', window );"><strong>Other Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">&#8364; 63,089<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non current assets</a></td>
<td class="nump">10,740,069<span></span>
</td>
<td class="nump">4,988,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_LocationAxis=ifrx_DEMember', window );">Germany [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationDetailsLineItems', window );"><strong>Other Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non current assets</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_LocationAxis=ifrx_UnitedStateOneMember', window );">United State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationDetailsLineItems', window );"><strong>Other Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non current assets</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveMembersMember', window );">Executive [Members]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationDetailsLineItems', window );"><strong>Other Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued', window );">Executive management, non-executive members</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_NonexecutiveMember', window );">Non-executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_OtherInformationDetailsLineItems', window );"><strong>Other Information (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued', window );">Executive management, non-executive members</a></td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="nump">&#8364; 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest on impaired financial assets accrued after impairment using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. [Refer: Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_20_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_OtherInformationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_OtherInformationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_LocationAxis=ifrx_DEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_LocationAxis=ifrx_DEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_LocationAxis=ifrx_UnitedStateOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_LocationAxis=ifrx_UnitedStateOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_NonexecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_NonexecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140572372941824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Information (Details) - Schedule of Compensation of the Group&#8217;s Executive Management - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExecutiveManagementAbstract', window );"><strong>Executive management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_TotalCompensation', window );">Total Compensation</a></td>
<td class="nump">&#8364; 5,882,288<span></span>
</td>
<td class="nump">&#8364; 8,361,163<span></span>
</td>
<td class="nump">&#8364; 6,925,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveManagementMember', window );">Executive Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExecutiveManagementAbstract', window );"><strong>Executive management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">2,783,675<span></span>
</td>
<td class="nump">2,774,485<span></span>
</td>
<td class="nump">2,817,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Share-based payments</a></td>
<td class="nump">2,507,453<span></span>
</td>
<td class="nump">4,808,094<span></span>
</td>
<td class="nump">3,347,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost', window );">Total</a></td>
<td class="nump">5,291,128<span></span>
</td>
<td class="nump">7,582,579<span></span>
</td>
<td class="nump">6,164,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_NonexecutiveBoardOfDirectorsMember', window );">Non-executive Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_ExecutiveManagementAbstract', window );"><strong>Executive management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">305,983<span></span>
</td>
<td class="nump">248,725<span></span>
</td>
<td class="nump">271,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Share-based payments</a></td>
<td class="nump">285,177<span></span>
</td>
<td class="nump">529,859<span></span>
</td>
<td class="nump">488,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost', window );">Total</a></td>
<td class="nump">&#8364; 591,160<span></span>
</td>
<td class="nump">&#8364; 778,584<span></span>
</td>
<td class="nump">&#8364; 760,185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 9<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_ExecutiveManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_ExecutiveManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrx_TotalCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrx_TotalCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_ExecutiveManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_NonexecutiveBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrx_NonexecutiveBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>75
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M _C_6@CU]* ':-YVS?\#4$L#!!0    ( )([=5C<,,"MBP(  *\&   8
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M9QW],S%VE9CJU73?*)(WC0+G6TA5MWE]7]UMGN]BT3B,*CY)A5@F21HYN87
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M18^I"R46$_88,30XY>X4TZ_1)\0]AD47R1**3QAA5;@%HDZ<(&Q_TJXP/FQ
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M2'1H<X2I"8[JIP83:_G\*H_:#K6H=OCAI-4-7LGEPA?5I?MA%$I.3I1=V(Y
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MQ'R+G/KMD[OK5W<W3Y["G>GR-Z\/P#H_^X:Z+I1A [<^6W[]U1-NPJ(?NOJ
M0V:KNNOJ/?V)?<M#@Q? [YL:_!#Y@ _ M]S1]-[\#U!+ P04    " "2.W58
M9?Y2^8\7  #F00  &    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;,U<67/<
M1I)^QZ^HX$@3Y 0(XCXD61&ZK8FQI!!];,3&/H"-:C8L-- &T*2XOWZ_S*K"
MT9=ESWIC'VQV U5967E\>52UGMTW[9=N)64OOJZKNOON;-7WFR=75]UB)==Y
MYS0;6>/-LFG7>8^O[>U5MVEE7O"D=77ENVY\M<[+^NSY,W[VJ7W^K-GV55G+
M3ZWHMNMUWCZ\E%5S_]V9=V8>?"YO5ST]N'K^;)/?RFO9_[3YU.+;U4"E*->R
M[LJF%JU<?G?VPGOR,J3Q/.#G4MYWD\^"=G+3-%_HR_OBNS.7&)*57/1$(<>?
M._E*5A41 AN_:9IGPY(T<?K94'_+>\=>;O).OFJJ7\JB7WUWEIZ)0B[S;=5_
M;NZ_EWH_$=%;-%7'_Q?W:FSBGXG%MNN;M9X,#M9EK?[F7[4<)A-2]\@$7T_P
MF6^U$'/Y.N_SY\_:YEZT-!K4Z -OE6>#N;(FI5SW+=Z6F-<_?]7475.51=[+
M0ESW^ .)]YUHEN+C1K8YB:X3>5V(5\T::E^1/NZD^%?3=<^N>G! =*X6>K67
M:C7_R&J>+WYHZG[5B3=U(8LY@2NP/O#O&_Y?^B<IOI8+1P2>+7S7#T[0"P9Y
M!$PO^ OD(?[SQ4W7MS"T_SHD&K5P>'AA<KXGW29?R._.0+:3[9T\>_[WOWFQ
M^_3$ML)A6^$IZO-M=;-M-?-M+6;;JHZH^7=6<\2_LZ#P'/%9WLEZ*SN+]$K*
M]>E_GG5>UN+O?TN#.'QZ89E!(@YL-\WHA>_Y3\U?Z\>FSZLC+\7[VOKGMI9L
M.+;H5U*\:YOM1MS(V[SF[^!L+=M%F5?E?S/#Q/V[C]^_?_G^E3B_*ZOF1E;E
M.K^Y$*6:\5-=#G;3.5@"-.I: ]!]V:]X%,31]D3KX"*V-?("D<D6!,NZ;T1^
MVTHM12:UD&T/U 6>WG1E4>9M*5F^KV2]:-H<J\,USFF[OOM4/^1OWM,+<4YX
M+MOJ07RIFWN@8R=>X'O9-=MV(5_*]E;6UJNFW3@7@M9>]#1DX(R%F#SMQ$_.
MM2.*$F9?WFS[IF65KO,O\HB@\KN\K/*;2@HP()JVD$#5!T5FU72;DC2F<$^V
M$*'FV]JTS5U98(, /#(H/+N5-G^[7*Q(# ,3)&ORGW(A.QNB@XU@^ .XJC&'
M!,A,=A*Z*1"(!/@!>_7M%=SO2WZ+3[;(UTU]*QILN!V(D4*MT5P( /+Z :&)
M= <MM<8<EVVSYB'@NMA"=%U>T6/LF)XNR[;K18_8)KJR7DA10J7T84.\C[8/
M@INF)8/*6ZEI0!>R+JQ!0N+<2*V[<,2U&3/12">*1M1-3Z;8]66_[=GH-I4T
M)IT+>"3'=V*FN:G*6V7N?7.?MP7<=- (28YVOX5DB\8BL@ K1$#C 2VD>@LO
MT*2U2(:M&YEM:U+\^[>?KX47.<(GP.C8)WB;)[W>C%2;C0+?]F/_B.\?><NK
M668UPS3IL-BVT#_SVM_+"HBT5@%+4L 2"#=R?0/63<BQ63>MK!CH(/G#9C^8
MQB&@L,@<,?6^Q</+ N[(?CQ8KA).-_)+TM2FU8F.'$*1[21ILFR*0>>PJFI;
MD,([!;[(8S "UF(;?\Z[K@'\$#O#*$5K&"ON@4)$:]L"C2PLML$JK5G,!F:"
M):EV1I[\MFD*=K+7[?96O"B0N)!!*JLZIV$:EMZ^?C% TFV;UVSLM7BS9@!:
M !C QXMMOVI:@\'3Z6]^&J9;))2CX/P"#%>L,$?\>&AS9 (M:1A282.)GU(4
MSMO%BC=20(%5LV'TD%^1$G>RTR!H=*JE0?#],)<8KVDMIA;^APU-4(8-N"8O
M+K6:CA@,Q8%^E?<($U5%W):MU!KK&V*O;'D/"X[-X 89E,$.!=_M%X #N#,[
M/>F//Z[*MKC<(*8]#!.$9Z>19WM1NN>8;P ]S8.4,)I:+@GZ)I/<T+6C--F;
M1)M=E="%_&U;]@^7G>S[BKA?P?TN*2TOQ"9_F*I'Q(D=QK[U+\3S2F<:-4$5
M;6PIU7)1:&>)M[?<1\;]@2^,BM+@",1T)^0F0MMU/=O/]M./UZQ_Z]OU/V8%
MQJR,"D+'16E051IS3S)T"'\PR>+@O\B-=PSC"=T&RUMO&A(TUM K>Y.5"140
MD"C?J322$ _#R&PZ4GZ%]]4D/1U;&=.F(=PZEFLQBUH2G$F!(\Z'R)3V4S8N
M^Q"/L,0]DDS>/6!#W,/1#>+L ,0G[2KL1#:"W&F1KO("MBSKB;N'%,1_!SV&
M$=;1$2"(Y*)3'+(1D [R5D4:=D?D3EK"@1,9"2L1]9QFW5#=#3]I[CN3;T*+
MDP ]LFD=8L+Y9M\?5 F335W?SN R?FI'86!'+G_TPP2IN#=Z\P)I%ZRN&M"8
MI66B*?*1[1+Z4T@YD/=2VW,S.P@CX<6VEX6 &5_$=NQ%=AJZ^]1M@)^\'-;J
M^FU!YN %=ISAOR 5G@]R(!EYPO?P!"X+0B>0*K:3) ;$!?B418F=QK&(["S$
MSKW@3Z&5!R&Y=IRXPK?#*+8CP!)8\7T[S=*3()9$D"QDC=&9:X=A2L"6A';B
MN;M %J>Q[:((#X+0]I- A/@;!)Y&,G#O^I!FX(D@L2,?8S-7!!'H)G861 *9
MVCN(HM6LY).X?C?!##W&.C6FD,:T1POV'7^*$6QWDU2:G/(!QLKJ+!K0A?<"
MEPKDEW 'F#FVJH"'9\V%;QT0_N\8]PG]1W:0P<+=2"2VYT=VDJ6P!-9@ZOY)
M_:=A# N,14 1T$[2"):0D*&[R0G]![8?9/"W#)\\-X3%A)CGQI$=^H'U'H-;
M3NLG03:#UM.4#"T(7)[@L?-DOFN]EA NI8.DA+_GZ\U3*H7:WL"I83=R$]X^
M64G@XR^B?13'%B7X&# ?3-A>-_6E_"H76[:# BG)@HN3P,7"*7@.4SLAWA-R
MOG37<CT&#[)9K!,$B.R9R!)L/ VU]<*'8V!, @EZV%^<@1_LS"/JH R$<(0B
M"EA%+:.^6/K+O<K[.%0%HQW:6I%E1P8(\"]A<'FOHA3C*RQ/DYA4$6Q_'%T&
M4Z/7$ELO1I-^)ZGD@AH+=I?;Y@XQD8W"E$M30(913<(@.4B'MPC/KS[^_/[U
MI9=A*80Y+&7KM'\6I28ERH"$4_(JN$T ETINP&TW';4CP=&)M;O:LP"UZ[;:
M4>FQ#I5<;RY%1<L,G&*#MZ7N$%BM+-<WV[93=;LJ&XF $BX73OB&G,GT4[34
M.1<7L$'N\<#,56P_Z>^SO2D5CBIANAPTO"BR_0CNX]H> E 4#N6E]7;;,HUF
M2BD. >BA",D^$\HE4:\8FX7W>AF\/&1J469[L&LU1"2..(% 5%$LFPJHQV4$
MV^(8Y9'=K;DFD$<I/#DIBU_R6YWQ(/=1K26$76">%U+,2^. \(6BGT=,Q]8U
M%9&4ST&QP#S"J2&7Z\2YYJ,=&D>,A1<B"RE0P3D3'WX=XB^%L<1Z\\W(">(=
M]O>AZ>$*CN>BDCF ]!> QQ"X$*8$U"Y6):BEZ.?;OAMIW<?0@.OZ0+> DX$(
MFPO]:*HM5R4>2.Q3Y Z$,(C7T&V8!:R3>LMI^T3T'=64^+Z?TH_Y'=P"&<0Y
MQ8L[Y)K8'3VA@+C<HH;C7M'X$EM^^^.;[N)"62DB_KC6A(8%&F'H!((' [:F
MOL)Z)_U&V>'9Q$$4(6T_,MLSM8+:L2H5]G:J\LJ]!E1>UUL*:' O&)HAX8C4
M$1\D\(]B.]N3ZBZ=--7WW"3M>N-O :(A @!\+7939%29X'0Q\\:1H^F0 R,!
MO!#G0*\ :2H^0<>)%XH)9>!(18H259G?E)4J)\YA')0@T5Q$F3#AN3",*,+<
MMSM; %L)8I*'4C!BY\E$2M':M]XV +E;BI:+55[?2K./""D8^$XS\C+D97 +
M>@8BV/C^+!-LSQ,[H!@:>\0/63SB/%;%%Q@LHFWB>L3?[GS-YCDE(O@O\3%#
MF;:?44J9Q90:&D_9U1!4'5#2#%E$F)6HQ:G\A8"L0SH%<9^J?=@]\IP(LR/Z
MY$)W2920&5A[4PYEC>Y8]RAW8#-1]1%W>Q"["<;SJAKF<[CG@X=2%[2K\E9!
M]LR6K+'4G20%:AE5"2K<5:!7&L1<(6&Z!*$U%N1BB^MNU2H'9.=PEI6L>!/3
MIBC-I;'3AKYUSHL->XUW,F3>Z<!BNIL_7]@BA_"H4ZB?+G?U/DJ2H,+,YV6M
M7-Q2:WV4@N^$AQC(U;G-M#&PSPKO3\NY.6Q$(X')3K4(]M9P)^S.>-GA>7\<
M>-&Y"-*OO/AUV_5KC7B,<:8W!F,IRM[B=7,*M9Q)#[G.D!H6+.!I:J=5.D0[
ME>VHA(4R8?-]E$#>(=8!5#8*:/*J:^C06W(C@H*;]=I!!JM[D\H)U1R]R 6U
M75FWELZM'@R2T*J3CD[9R9%35&9U5PW'6XN\4RT+_C ).?8)@]_5IN*+Z[\I
M8!:RYJI-MUR,)6INF9@.,@,F<7L*%0F=&E&>HP?<("<A5:A["W3(Z(@7E3$C
M3HC&;5E%N80<*=GL=+=^2-1U.TS+:3BG-*&-+$EMD6Q 3U_D6XU N1@0>Y=G
MS:@ZP:%LNE"/.<M^X'!(G%+? Q7%C1Q.D1R1.>HT>4-'3Y3*\%>+OC8MDGHZ
MLE+/87I(XQ=;E=F#H:*\*PO35C;N,O:F#>#<\UT%:G;/XB\?SLY6P/QM#ZG4
M3+086Y:*GNHS#=2^C<IX"F;,A:H#E1 1+%-+%G'!"Q*;Q[)?ESV5H=M:5S (
M+#X*T#0)V,CT,(^&$8F0&B>9G27AGB@G=9[K)*D]P9MDWJ_TW-'3AV2)5K')
MS @A4,U5#S \;OD/*%XRV"NTNESG7[AWA:Q''>ZJLJZLMK23:LY;J7+W+E]S
M(H4$MESLC*&C%K:_@WJ<))]:\)#5#1'NMABUW32U]B_JD7;26$?7-XLOHN'C
MQTZQV%#'E_FD<AU>T+=;5<<J8D"_9HL0IHZA) -IW9>79HHEX7.+GOJ@$PPS
M\*7R=&,)VIO5Y8")I2BI:+8<<]IR+,,7^87XAJHA;UMR4S7E?6VIGBA5F'R$
M@H=(&.@0A0ID;:/@I87Q%=UPB@)#0.:(^<LJ__Q5O%O??"^0-@ <2V!2\2V-
M'T@.->6Z(R=J.FG-:.E-JV,DY,W0;V_N 9AW^@!][FC+@:</SL\.6>(')#]L
M%6 Y&8N^,9WVK8\3H0.X_IDC.0=-#V5.:H=!8)Q"N(Y[^*'U1IO4[ 25'7OW
MX&/OK&6^^+1V^,/+<W#ZTT3^(7[1#F498%0F"*W#Q,]_>?'FTP47>8,#J3>D
M"4HOC6;,N<+,6F:F/:^F!EG-T ELCM@ .MPE.2>%/9D.LO0KQ/^?J#VBCI20
M?)KK-5A1L66\?>)68@/74P4=.)P>K?*#3WAK#EAWK-WLL26),=!0VKI R:\:
M-]/!8QK4K-=T.V, IZ$/:".GJ$E:XRT-F_G_(A_&^E3[BOA67[%^QU=FN/WO
MN4J:HM8,?/$(J6]\-421)!S?!$X070V)=!9_N].<<I(C"\?I<99.N<N?(?</
MNNX%L=--34OE/YPBL=1K::SUR:P%PH)]Y#J9&[GVD(G0;#&\\D. [,XDG]\$
M2;P_2;T*43&3D^YE.:VDDTP2(3>GJ-$)C*_*Y7@_919R9AX[MAX'SSC:UX$;
M6PD885T./IL.3R[X)A&8^'5;[]P-6R#>TW(Z%I5TE09,;K:(+ L\13#E^TDS
ME)]&GES4\IYO$]4<NMG!=QP[F3FV8_W(*;!::9U_+=?;]8ED;GZ%B](!SL65
M@%3@FZR?JRM$ R0BTF[SL=8:N+$PDVYCT$F<9[M9LKNN(S[6H[_9*N'CZF/R
MF/MN.9W]4=52Y*KU3"LAOUX"%6U5\BE(Q'9W,R;%!N>8CPU"]-S]FQK#'I34
M,Q_2\\KU&O6CRO#I5$7R7&;HG&_*/>A#JSTF<BJ6",/+6@Y9^\L&DF2#,Z!Y
MH6YX("7D*N]_6R\6Z>4/PB"2]Y0:5P'!!)0XXD0:T@E5XMIN&!,69M'P,G#"
MS'JG.=F%0L].@LA.(E<\\ITH'0$TR+@K%=MQ'/-JJ;B:]!]2:G$M97F(YCE<
ME3M31#-Q1YI8Y=P+8MN/,O42&Q[?>J?RG'//C>S 3]0\+QZGN2[W!;. %R3T
MG(@EB4^!>VQ'*=5#,=/TQVF9?U+4IQ ><Y+$#J /T'2]R32BZ46)C>R(:093
MFM[_(<R+_R<XG_PNSHO8B3V%ZI;&^1@6->#\BZJR/NZDA>9L^XY;RW=228^-
M2'ZE6Z!*HCNS^"P+2)*8Q;G[1%<O -MX/E+K5ZU4] @T%1G+D-%7]788R(<3
MLR4Q@QKPOA'-C)1-S4RI\:\>S]IL%;R\*Y\F>%?!O#ZV#1KJ_5BT*%LZP?%N
M%NR!(18$]Z?,4'5AVASVC>HU(C+C -U(_>A2,S5D&,BY_4)CQA#@B)_5>&NX
MZ;BMB80IU :Z)?=B?\565&-17T$9<VJ3Q_/Y#!W0*L*V[O/IEIE05R6'&[:3
ME!RK6?EF@]A.GNH<MN=E7K;B+J^V4EV?G]N%QJ'!(/=1\ERU+UC>K:22!1.>
MD(>/T(<,S]-7J[@^ICMA\RJGFUGE-Q8S^]DP!/DH<KS0/ P)=LYWF#/]W"<'
MDLU#!+2CZ6BLVQW$[ER?\BAXS^^ ZA@X7B;#J]NRZ]5=]3T<<,3-A?6#S+MM
M*\U1_:BS;HCK>ZH[A#5\KGM2X8=FW<\SAFUG=O>RRA=?+J\7JX9NL!%-U>I=
M-X6LJ'=UL%UM\ALC46*^*CL-0S3C0]X5^6_B7=7<0#S7_"LK\0.;NSU+9%6%
M;#!@-Y74Y^K<PN5-4$#1MPRLKKRMRR5<HZ;SF,V6\V&M&^;?'#FJ<W DVKNN
M<_'$NCXH>0/);R>25@7QV_]0828_]/)ZT@YX8TX)A@\<8<[79;%IP*?X7'9?
M+I? 3XO/+$V.A((PR&P_1CXC0B<*A(O8.FE%!%1K/1)DXL)S^-85@C:=<CV>
MT(#MQ3P.)))]$HF_0P*)C29!,<072%3L,$!:(7PG#HE J.[J,@'D/0&_RK(9
M#TBQ!@H^G9*ZBD!\@$"T0R"D3ZX' AY?>G !!A^7W*T8'^SJ2>$ _,RSO2!D
MCME5S7M8PUJJXV=M8N,=H\GO/734W\^@^3<ZO(*%K"]$IC;K)BQ-!NE\NQU-
M>C9[%H6E)_9^:M+4TF9><B7>S)M/@_G=-73>45&:?\PDN0-Y,5JF8NR<3STW
M#1\CV.J<LJ.T@(]GZ$KNAD^P[N2%Q=G_D.[[=!O+TQDX62X;0H+4?CPU]=E(
MO6!B2!YL]O&42AAQ.OY(&?\>B7"'!(P9)++'UF<3,&Q]@=<;;VDC<OCN)?X?
MDXME?I!,>OO>Y?"9"@O!23E3QZ?@,J12'7;M/K;&GA"*&]?PB<29G"9+X,9C
M3I[QFU ['5W+!M<1&;PI4P:#-P\.&[Q/!N_[=''6_6L,WK<M4^<<MGA;Z)*%
M'P^1\Y@C?% E[$D\!1_'('6PZ7U4/6Z]7)D.9L37&$.Z.Q4I#7F,6*X[HA)4
MI%[!%HPUNK YNFO[>$HH\EGR3"4X0,7?H1(QE9CP]8?\@0LW5U,(J#Z@0B;V
M)O@<*.CV,F,J3"'U78.OB4 =9GP"2@(%#Q7;A()ZE1(%E(?,0^@$4PJ>ZXYN
M%1X@$<Y(Q'3D%3H^/$&3 'OAR$1$CIEYTVUXRNVS0TQ<HY!1GN.E*%J,-+R(
MI9%,8T46J17" V3&\G_P'?/@L.\$*EC$S/A?XCL!@H7J'QQU'=T*V/&=P:@M
M/JB5=*)$UE\#N=@/+ 7I$R2?'_'JY(M.!GD/ZAH5GV3SKT>H#!SGLM_-N]SS
MZW<F.;O3^625=W0EX4Y:JG$Y-JWH[9@\J@-WRE1-K4#U #6AQA\YRED(,AVQ
MR3GBBHXXZ6<3ZEA,7Q=>]/JGP70=02$$4E?^E:A<Y7=T0J#/[+N%1"I9-IW%
M/XDJY/!#*R-<\5#2+1M:"+58"0$@1YU<0IT<6&*91<7GJIQ(+SF+U@L-6;9S
MZ(?85Y/?WO.OUNA?&*"3CFW=JY_A#T^'?\3@A?KM_CA<_0L(2)]OZ;Y!)9>8
MZCI)=*:.5\R7OMGP+_EOFKYOUOQQ)7/LG ;@_;)I>O.%%AC^:8?G_P-02P,$
M%     @ DCMU6#;,H>\!)P  17(  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&ULK7U9<]Q&ENX[?D6&QNH@YT(0U@(@V8Z@*,NM#LE6B';/PXW[ !:R
MBFBA@#(64NQ??\^2F4B@4+0\,Q&VR$(AMY-G^<Z2R>\?VNY+?R?E(+X>ZJ;_
MX=G=,!Q?O7S9;^_DH>B]]B@;^&;7=H=B@(_=_F5_[&114J-#_3+T_<W+0U$U
MSW[\GIY]ZG[\OAV'NFKDIT[TX^%0=(]O9-T^_/ L>*8??*[V=P,^>/GC]\=B
M+V_D\/OQ4P>?7II>RNH@F[YJ&]')W0_/KH)7;V)\GU[X9R4?>NMW@2NY;=LO
M^.%]^<,S'R<D:[D=L(<"?MS+:UG7V!%,XP_5YS,S)#:T?]>]OZ.UPUINBUY>
MM_5_5>5P]\.S[)DHY:X8Z^%S^_!WJ=:38'_;MN[I7_' [Z;^,[$=^Z$]J,8P
M@T/5\,_BJZ*#U2 [UR!4#4*:-P]$LWQ;#,6/WW?M@^CP;>@-?Z&E4FN87-7@
MIMP,'7Q;0;OAQU_:0?9B:,5P)\5UV_1M797%($MQ,\ /(/_0BW8GWE5-T6RK
MHA:?VKY"@G[_<H#QL9>76S76&QXK/#-6$(J/;3/<]>*GII3EO(.7,'$S^U#/
M_DWX9(]OY=834>"*T ^C)_J+##4BZB_Z7Z>&^+]7M_W0 9/]OS7"\+#Q^K H
M>*_Z8[&5/SP#R>IE=R^?_?BW_P@V_NLG%A6;1<5/]3Y?U-9>5#];U,XLZOC$
M%C\]UEM/_/>'$X$G/G6@;[KA411-*>0?8W7$!HYY?%7>0RLI?FN'HG:NVWX0
M%U4C_O8?6;2)7U\Z5X/X1]&,H%\$LT4(/\--ZFZ" -\*@_#U],2Y*DL:NA=
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M15<24VO W%NK(TU.#JUZ$XV6HS1H&$=>9H#OQ2RH$0:!%^GO+MDY&>XZ<(J
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M\';55SN#P/X2?0.8_0Z-)=@A?(PR>X%!LW[0- 923MU=HB!0/PVI8Y@BMW(
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MA5B&!N8_.YDH_(^!<UCMI+F"P JYP..&J;.5LNP7E1>\!HS9HYW%;E1Z=AQ
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M"#GF?-B:T#Y?Q-"=3&!N:C!Q8I73\&PLH;77>*(%R?\UYYJ0U5B_+DQ;;Z(
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M<TO;4LC!YK!FWW5\ASNB[2L,OI<F;32P+E/*GLE9T:,<"])"KWK"T7E- 6G
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MTAC@]TH(O1^8!::_2:O_ %!+ P04    " "2.W58PWDZM%,(  !<$P  &0
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M[31;9A@[R$@\H)0<L2<SE-QIP71:E87;ZMTH^'8[VZ#]E+@,$;T^^8']*.Y
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MJD\@/)YAL,,#'JZ"6Q<,-H9V.O&VB;(5D1?[1[38/0$SW03R&(_ @!/Q,LY
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M4R]<"BO$@M%2\YQ9,-2^X:?^*D*_:ZGE#696!;J$W@5LTHFP&4@7I@%'H7K
M&@%@O1KZ'@S51^PF8+K$CR:;=_'MN_>70V$6G7F"CT]D'/AS,R%AYULV?.X*
MV/7NN\&K8Z^U$B@:WR2)"U?MKNAV%'")X (N*Y/&2J'3&RVQ(AIO2!I&'36
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M<_TQO6#W!^_U&N_)1W8"2>]*WQ-!+-@!W1>-U/HCVF;+M4]3] RVJ<F(O(L
M:Y^\(X+AI.S.X2"3O>!/"D.T(E1&]B(U<AK $&J@Z9R%7Q)ZW RW* @<OHA(
M/9G%\1C6:]NWIC6OOR)1^L:6I>,"IJ\?86Z'_Q:Y%PO_7M[=/'H,=X;+7W^U
M!W;ZR3344Z6T:[CUR?*+9X^XX91^:.L]#IFNZK:M=_3G%OC4-G@!_+ZNP3:1
M#_B 0]U\I.F]_D]02P,$%     @ DCMU6'%XVK!, P   @<  !D   !X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULE57;;MLX$'WW5PQ4;+$+&)$LIVF1V@8<
MIY<42&/8]>[#8A\H:6P1I4B50\7Q?GV'E*PF0&*@+Q0O,V?.7#79&_N=2D0'
M#Y72-(U*Y^K+.*:\Q$K0F:E1\\O6V$HX/MI=3+5%402E2L5IDES$E9 ZFDW"
MW=+.)J9Q2FI<6J"FJH0]7*$R^VDTBHX7*[DKG;^(9Y-:['"-;E,O+9_B'J60
M%6J21H/%[32:CRZOSKU\$/A;XIX>[<%[DAGSW1]NBFF4>$*H,'<>0?#G'A>H
ME =B&C\ZS*@WZ14?[X_H'X/O[$LF"!=&_2,+5TZC=Q$4N!6-<BNS_XR=/V\\
M7FX4A17VK>S%.(*\(6>J3ID95%*W7_'0Q>&1PKOD!86T4T@#[]908'DMG)A-
MK-F#]=*,YC?!U:#-Y*3V25D[RZ^2]=QL86QMK' (-[I-L8_5G]]$II#^FL2.
M;7C).._PKEJ\] 6\40JW1KN2X(,NL'@*$#.YGF%Z9'B5GD2\QOP,QJ,AI$DZ
M/H$W[CT>![SQ;WG\[SPC9[E&_GO.YQ;Q_'E$WS>75(L<IQ$W!J&]QVCV^M7H
M(GE_@N]YS_?\%/ILS7U8- K!;&%="HNP$+5T0L'"<&^0DWH':Z-0';S(G2VD
MYO9J9>DY;T[;VVC./(%Q)=J]) 1R'*QBR'V;E[QD) LIK$2"4MSS<^"4=YSR
MGM. >D[FR"G($KA2./!:):H""FFY15DR._ +NV>J6NC#$(0NPD5M#6<LI,F#
M[35:*F4-4CMD.$<M#OYHA**@<6]"5*QO21J$UZ?@9X.EXH1YO*PAC@!1#!\;
M'48%NW%W-#(X&AE\%16RR;PK'\\F;ZQ%G1]":?HEA:5E$5DS1)@WTG&<!EQH
M2JP>X%.5?88OJ$5P[;;1,B^'\ FY"/4!/FQ6,$H2^*-;[VKT=MB//N@<E-5K
M4=7OKX=0&E6@]1X(I>!FV5M9<I K=JYQ,N> #+G.N8/F6L/<9L8.X?9F"!LM
M.:FP]KDEV*RO?\?T9LUYKBJTN11*_A^"\5REQX_F$DOOPO0EUFVT:T=4?]L/
M^'D[UWZ)MW^'6V%W4A,HW+)J<O;V3=2F]WAPI@Y3+C..9V;8EOR30NL%^'UK
MC#L>O('^MS?["5!+ P04    " "2.W58X3O]&BH.   T+   &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6S-6MENXT86?>=7%)SNP YHN58NO0&])AVD
M%[0[R0#!/-!2R>*$(A62LMOS]7-N<;4MLQ5G9I '6Q3).G7OK7.W*CVY+,K?
MJY6U-?NRSO+JZ<&JKC>/3DZJ^<JNDVI6;&R.)\NB7"<UOI;G)]6FM,G"#5IG
M)Y+SX&2=I/G!LR?NWL?RV9-B6V=I;C^6K-JNUTEY]<)FQ>73 W'0W?B4GJ]J
MNG'R[,DF.;>GMOYY\['$MY,>99&N;5ZE1<Y*NWQZ\%P\>B%B&N#>^"6UE]7H
MFI$J9T7Q.WUYNWAZP$DBF]EY31 )/B[L2YMEA 0Y_FA!#_HY:>#XND-_XY2'
M,F=)95\6V:_IHEX]/8@.V,(NDVU6?RHN?["M0H;PYD56N?_LLGV7'[#YMJJ+
M=3L8$JS3O/E,OK2&V&> ; =()W<SD9/R55(GSYZ4Q24KZ6V@T853U8V&<&E.
MJW):EWB:8ES][&615T66+I+:+MAIC0^8O*Y8L60?-K9,R'052_(%>UFLL>XK
M6I +RWXJJHH=?D[.,EL=/3FI(0H!GLS;:5\TT\H[IA62O2OR>E6QU_G"+JX#
MG$"'7A'9*?)"3B*^LO,94\)GDDLU@:=ZPRB'I_Z7AF&__018]A:#JW_NLE(C
M@]XM WGDHVJ3S.W3 \Q0V?+"'CS[]AL1\,<3&NI>0SV%_NP4'K[89I94^F0O
M;+ZUU2X9)U%VR]C!>;08M"*2_@GO,,W9M]]$*M"/C[SN)18HGT<Q/9!"/NX^
MO<]%G61W/&03^IM>?[.W_B^+JJ;/*LEV&V$2:K<1KF%.6J)[\Y3>9$9)7P;R
M#GO<\73*($%OD&!O@S2B$+W?)>7OMD[S<_;Z"W)!M=L^D\B[[3-,L>ZGL.T4
MD^;ZO$K+Q?$F*>NK?@ 3?F2$+TQTRVZOUYNLN+*6G=G<+E/X\&@0U]PW47AK
M$$QPN4KG*V;_V*;UU7%EZSI#)*A626F/*0\LV":YHIC0P;$@]'4@O9_L.=:)
M])HC1" [D&)+VTQGM!^'XM9T'^J5+0>Y\):)U!T,J";LQK3/N?!E_*<\)NP)
M$OZ)B%'9I(2!2)!7<.6LV#AK3+%D$OZN4-+,X]$\B]$\O<II/D<]0@L"DCC>
MS!&1L4P+5A<-A\ZN.O:HF4$:S3)$[QG[O+*LID@-:J \P>(6EQ7#4CB$HDI=
MX0!ERY&RWBXA9GL3EM1*YQ ;N2KBTH^QSC+RC5:^X>Y2ZA A3PP4G,-0Z1PK
MCR+$EFE+KM)F+C>MDWR[1'&S+8D(/;R(?,%C7VG#1."+6,,W) O\0!@_TOPV
MNL]@].-^KJK>+E+"47X0XT]%3$C  =(()@7N@&< FG"OP _# 'ZI<!6;T(^"
M@!D_UM!<J'NYF("1N!^$G$E?F\ W\"6((J4?Q=&DYX4&EH6M\7;,?:TC\L90
M^Z'@-[TOB *?HT)12OLR5$SC4RG1NA^DYQ+65(*IT#<2[\:<*0/<T(^5F7*T
MJ'>T:&]'^QYF+5NUGB]0 J953>4':HTI5YN<8+>KM3,Y3TNNS]3;9F$[9QM\
M2LYDYU.]"R[+8NT\:5.F1<FNX#Z.8(L"N$E>9U=LL;7DH' \&'^.%%@UHZ[3
MP=M!AZ^XVP0CC:]B^!PW+/2%-'X81^"FXU3$[\G(2 ?PB8 I2B1^&!EP,R37
MX^$$(Y4O58P($.-*< T.:XSC@?&U5-Y;O%PF^=R.<U4,'D8145\I[@8(Y\ZQ
MY-XK"^/.4U>6LF^3]>8Q2]9%6:?_;FYUXAH>.O6)MTKB$TG3!(%'12Q>N/XR
MFCZ6%_FQ_6+G6\>#18I9ZJ*$_!P31Y!91WY(LH<4#J*;OB1<.",OPCQ*(4'&
M+ ZA>*1;?T)4"1#U0EA00+\@ACS03! ZD.64/\6]/\5[^U,CX-L<(=[N<IQ)
MI-V.TT"F#G+D(:TO^-?RT4V?:+V ;@-@6Y:65AUR(LF/B&NS]#RE3(4U\4J;
MKL^V9>5:$K9%!U4Z@'-0IG9LHV\6G\ 9'J!M20O<R]F/6W0EX)"3;]J9KNGF
M_/.\N+!E[J9VN"Y'"&-\:<!-[@OD&Z/["M5[LRT=1C%&"C3BMV::%C^D>D?*
M+L "38H8+J0=FHE] =(TKTR10?"AY^5[TZ$/%B^Z8#$55:>!=[,#58:W+#+$
M.7+^IMX8*HV4>D,2Q-X9M1Y-+M"OR7E;#J(P3$K*V4C]B')"4]Z-T$ AHE &
M%F3)P#LMYE1#5/#I$E&.(E-=IF?;IJ,];.4HW?*%CZLF^AVQ6%.R1 D12GBR
MQB>ETM![O7>L!'@%_=X7M64O9X+/V.F.V'Z$@*@1"71$H9EC5@JNE('1^'#3
M$C( +3B7B&?*%20&RFEIQA3B3?&#BCA"_4(Q!34#"*=C-4FCT=:)V)M&[VW-
MWE!F<[9%T8I8OY- DY"["438RQZ[=-B3E'B;HTZTZ"E;9U/(,PBM<+2 1ZB>
M8N9*PU@,;PY+1-Z+8N^('2)T*92DN((M0Z'9"!E!)*,HQ[(T.4LS5,IN;.R*
M(1J+^*U#-Q8+8 S&OKFA L0*$>T%>A7C2!JSB/*@]-X4B'#GE(?FJR0_MYT>
M!N46Y(YB8C-J,-"/[@$$BM\>U:6QP]!7E)T"0?(0LY!!,2N^@!C(8R$7)-_-
M\:V8AY3B\1=*C&@H)&,J'^. RL".D3=7" 6^H@(9MC 8%3:34W\& WF[UA3@
MDMI15,FH( Q&&[KB6+O0A).<E0-GY?X]OO.^%]>\;R=GIR'?YE[3,E%&(ER*
M72O4CD7I.HE63<2^LD"NJMKTYWHSD VI>)DEG[ZP[]=G/S!P"P$RK2#E/E78
MIBR0@]85]7)%9;UK6,6F"6FH+TF\'&FK=FD94W?/J,0IR@5$+*^:&5PP[G#>
MSWZ941Y_CYRW/L,J0^1PB,>#!TKOP[:&[/F"%$UJ]B/:,L)$?X(*22O5N2?C
M,[[[IO?ZBRWG*>FW:+HYLBN5";>:^5O[!]<G?V7GC;CJ'M.[!'5OD._8KVXG
M')5[ H,C.35FI55'87/XZ_/7'X^FJ#QLT(K)W=$=5#[[.I7OL>'JW-NK$!K2
M)0B=4UC=P-X-D6B)UL7"HLJ'D@DQBE(]@N%E:P?6VN'HD>?$[+GGJB<\_]!^
M?Y.D);M(LFWW"GOS#X8&S,'>?G@Z,BO5+'/"ZB^R= EKK]/%IH"<[%-:_7Z\
M+*WU7+KHV*E9A"Y$!IP]8'J&1IW/T)H/2ZIF081'9H;H+V9H;LT,;. SPQZ.
M,!0J ?<>(,+;$ B<UR%0)[806_2!:+1E""(%>$O.D*<!H)M]/ > ]E*Y1PC9
M8QD0@WL$20F*-P#!#@!S T#3%2C\T!.NV.2AWG]Q4$>WG+Z]3.!B4VS3P<'D
MH/'R)?5HU GKXL#-Q;TH,C1H&15M=ZVS<X&C8;D;P5 =(&]O"K=CY+.?9Z<S
M5E$9[Q(>NOQT4S&4@Q?VR'/!K(]>DOHV1.D@H.51K77#V P;:E*ZE1=JM#H"
M1'@X1M'&);X'#:-N0>@;$& ((.*'WB=+-D!8\]ES7%%IUP>_!V(F^3'^!\3;
M6*JP0Q0S(8[[:T/SBED4-.BX4L=Z%FLB"W_H#;%=,,T[.>6,$Q/C$+[1(X%
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M%B.B*T9$2GP$ZHWR@2XN(<>JDZ.)U23' *F9362L@<%1PE0;G;A[T)6H'=U
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M#E#&5G,MF>M2<Z6')I^V7&EH(8C(^R(N$VY;I8!5J)T)EE%6UGJ.DV)'!U4
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M=K6)$_&HXJ\HU)*+JL:AKO$.#P90K&W]*.)UG.90%ZT8)%CQF-8PEJQM*3S
M$[7*.;^BDJYJ0"YSJM-/I>ECL<>T3?Q 5;CJ<H<MMBE.#+:S2=>@>]&.&^TX
MSE"5IJ O(K,G1M?4:$$1SF?XO)F.!;"-O,HZ@QSLX>70T1I_Y*ZA+K)_7?QM
MP;KOJN[M_9\7ACZD@]0_QND-M6>>/ 0HYCR?4]']U=@QCV/K\TKA79_AGM]-
MO!"HB"/*5E$ \.,$/K*8;QR-"8!5ED?M11])G.X>/+O%1PW'0=H@(^ 0@SH[
M"C'7=Z@W&3@.&(7&59%SX*"F&96P;)E8-@)TP'PEXDC)D2;A1L*%O; M((:?
M.=5P)V25KA'6H/F"0VE3K8UUO4:8TD&0&X=P?/Z$E9 =:V_YQ.T#.K"[Z\6<
ME_?W<?;I%W+#H'W9!.U)=_Y#EW*'">&5&.A7M]0NSLD)7W27=6.;8O7KH%!U
M_C\Z"WLA;<]#:1BB,**[K"@TP\"A;H=>W4:2(^NM112YGCB'#861Z8=THPSS
M"R,87>#-@J7^#LL^_1+KK_N:PA%]S32(I%? DZG.-I/Z_P-76)<Z4*H\:6\Y
M>YO57;A!1#0X5'(R[FZ]NAJKWE"%6^I&T;+6?D0?AJ<(>VM$:/84]LHTUVB
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M+W=O<FMS:&5E=',O<VAE970Q."YX;6RE5EUOVS84??>ON%"!H@782*2^$]M
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M^$:Y3WK[B^CK23W>7"O;/F';S4TQXWQCG:[[8&S7LNG>_&NOPT% $3T3P/H
MUO+N$K4LWW/'IV.CMV#\;$3S'VVI;322DXW_*??.X*C$.#>]UG4M':KL++QY
MX#,E[-MQZ!#9CX?S'N6J0V'/H% &M[IQ*PL?FH58? L0(J6!%]OQNF(G$=^+
M^1G$E "+6'P"+Q[JC%N\^#_4^<?ES#J#?OCS6*4=3G(<QZ^1<[OF<S$)<!%8
M81Y%,'W]BF;1Q0F6R< R.84^O<<UM]@H ;J"6^XV1KHGN&RX>K+2^LX;@0Z$
M&\EG4DDGA3U6P<D<QRMX6 ET59^0'R14;4*U3PC2CA;2SI6V8@&R 8>AE5:X
MNF6S!.<M=#ZZ_0X+]P^8\[5T7,F_,;(%MA[ _V&X1OOX7[+A"CY4%:[9?;D'
MV4=O,.#UJR+.DHNWH\_2K;"M&P%/@AN(2TIH6@#-2,%*B/.$Q*P<759.F/VL
MV<9!HQW4V@ADSQNH<&-HQRSD6418G@)-2)J6D"<IR6DVNCTV%WDPRB[^_1X]
M:"P2/!5*DCCQ-HZ+TG>PB$1)^E)UV"EU?J!($9&4HB*8/&$09R6)\^Q%BI1E
M29*" 66$HC!ED9,XRG].$4\GBB)@,8EI[CO2C&1%_(PB7*G>@'JFY)+[?7QO
MF0[T!E?8(U<;L=/L?J6->X?UU7"]5_2(5W)2HB0)*6B&3,JLV/GGQ89)&$7#
M9$/9O8E>I-$1]Q0DSF(D6&:L)SAXZB<$8]\)]HQ2/S!41O*\A(RPC [<>YN]
M2#B*3DA(DB1]A3NLWF__3SS_)QEZA':OW;2] X]MUN'!,5H+LVPO"Q;F>M.X
M[D0=>H?[R&5W#.^G=Y>96VZ6$J57HL+0Z"Q/ S#=!:%K.+UN#^69=GC$MY\K
MO%,)XR?@>*6UVS5\@N&6-OT'4$L#!!0    ( )([=5@98^%)/ ,   4'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;(U5WV_C-@Q^SU]!^(##':#6
MMOQ+;I, 3;O;[J%;<;EM#\,>E)A)C+.E3%(N[7\_RD[<')!F>[%)B?SXD1*I
M\5Z;;W:#Z."Y;92=!!OGMC=A:)<;;*6]UEM4M+/2II6.5+,.[=:@K#JGM@EY
M%.5A*VL53,?=VI.9CO7.-;7")P-VU[;2O,RPT?M)$ ?'A2_U>N/\0C@=;^4:
MY^A^WSX9TL(!I:I;5+;6"@RN)L%=?#-+O7UG\$>->WLB@\]DH?4WKWRN)D'D
M"6&#2^<1)/V^XSTVC0<B&O\<,(,AI'<\E8_HG[K<*9>%M'BOFS_KRFTF@0B@
MPI7<->Z+WO^"AWPRC[?4C>V^L.]M<XJXW%FGVX,SZ6VM^K]\/M3AQ$%$;SCP
M@P/O>/>!.I8/TLGIV.@]&&]-:%[H4NV\B5RM_*',G:'=FOS<]#>W00.?57^\
MODX?OLI%@_;C.'2$[ZW"Y0%KUF/Q-[!B#H]:N8V%GU2%U8\ (1$;V/$CNQF_
MB/B RVM(8@8\XLD%O&3(-NGPDO^=[5]W"^L,W8V_S^7;HZ7GT7R_W-BM7.(D
MH(:P:+YC,'W_+LZCVPM<TX%K>@E].J?^JW8-@E[!O6ZI"VU/F71* WXV>K=]
M_T[PN+BEBC_C<N<O.#Q*1=U$?>/.970QYOF,_CLX'H./VB$X4(T[4[H5;7\K
M4%6U6@,=*K8+.H?CP=Z,7ME+5<%,2U/!\C2L-_,?[C_QZ$.M@*(G>7K[\<3Y
M-?IHOM'&73DT+6"[;?0+(BQ0X:IV%C@K1,+R(O-2D;)4>$G$!2M*3J[2X)5O
M]0JV\L7#>9<L*EB:)9 R$0D6E2DD+$D+QJ-D--\MKIQVLH&,\3)F,1=0L$R0
M5U%"SN(\9669C7[5ZFHHUB%/JNA#;6A(:6.A[2IC+]-/HHR5@NJ1"E9PHE[$
MC.0WB(N,Q44!&2^9R$I(A6!E4IQ2]H3S"(I"$.44BCQBL<A&7[O='XXA8X)R
MXD* 8$GNW1+*KN040D1P[M*')Z.I1;/N!K EU)UR_90:5H<9?]>/ME?S_H%X
ME&9=*PL-KL@UNBZR $P_='O%Z6TWZ!;:T=CLQ V]4VB\ >VOM'9'Q0<87K[I
MOU!+ P04    " "2.W58D\39=M0#  #T#P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6S-5VV/XC80_BM6*IU:B6Y(8%\/D!;V7JB*%H%H/YSZP20#
ML<ZQ4]M9=N_7=VRR 4Y9[QZB:K] ['@>S_/,>.+I;:3ZJC, 0QYS+G0_R(PI
M;L)0)QGD5)_) @2^64F54X-#M0YUH8"FSBCG8=QN7X0Y92(8]-S<5 UZLC2<
M"9@JHLL\I^II"%QN^D$4/$_,V#HS=B(<] JZACF813%5. IKE)3E(#23@BA8
M]8/;Z&84=:V!6_$'@XW>>R:6RE+*KW8P3OM!VWH$'!)C(2C^/< (.+=(Z,??
M%6A0[VD-]Y^?T3\Z\DAF236,)/^3I2;K!U<!26%%2VYF<O,9*D+G%B^17+M?
MLJG6M@.2E-K(O#)&#W(FMO_TL1)BSZ![]8)!7!G$WQF@,LT&G<J@XXAN/7.T
M[JBA@YZ2&Z+L:D2S#TX;9XULF+!AG!N%;QG:F<%(JD(J:H",Q38IK+@_WX&A
MC.M?R*]DCIF3EAR(7)%Y1A60$2V8H9R,)$93&R;69"XY\">[Y%ZE3&!";-?J
M7FC02[M7F%0>#;<>Q2]X%,5D(H7)-/D@4D@/ 4*D5W.,GSD.8R_B'21GI!.U
M2-R..PT.C=YN'GO<Z=22=QQ>]P4\%)K3V2/YE"\_DR\3R)>@_FK2R0MCS_>-
M+F@"_0 /L ;U ,'@W4_11?M]$\<3@1TP[M:,NPZ]\Q\E&?GR.^Y(Q@9RW:AD
M]Y1*G@CL0,GS6LES;^Y,.2);!9:EQE=:8P$HA5%.%2:22FB4MTD&/_9O("BA
M(B634K D:Y%/@*$23TT:>)&.U."BUN#"Z^?'4KA/ "9'4BH%(FER<>@'^;"8
M-?'R&AW)Z[+F=>EUZ7XC0.F,%1A( XAO2 8\)<LG8C(\$#(OFJ,QW.)>.US[
MW7X81+WP89^7;\6!LU>ULU?^1%28;:S &+@/,3.LN=;[4>X+L-F*9UN72\U2
MAF>Z16;O:%Z\OVN13/(4E$UMRCD93YLBYMW@R(A=UR)<OZF23[$*Y;A):5A"
MN6YAF<-/AJ^T>W%_M""=".Q @JB]NT"T_]_%O?+O1&*>"NU0S;WK6/0O%OA7
MP&^%(+=J*56+3,8MLA#,0$KF!H/7='A'?KACM8AW6L2G*/2OH"SF=XW<O%;'
M<MO= 2/_)?#X8E\!^ZJ]=\FAP[LK7.2]U[RYX+\"\TK%7\Q)(O,<5,(H9]]>
M2O21?Y<?C5ZXUS_AWFO75FKB3MZVS:AGZ];UUC5LW\T/;4OK^K(=S+8?GE"U
M9D(3#BN$;)]=X@U*;5O,[<#(PG5I2VFPYW./&;;EH.P"?+^2TCP/[ 9UHS_X
M!U!+ P04    " "2.W58H='K%7,&  #B,@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6R]FUUOVS84AO\*X0)%"ZRQ1?DS=0PD4;85:)# 7;N+8A>,
M3-M")=&EZ#@9]N-'2HIHQO*)U9ZZ%XT_=%Z2CWS(\XK2>"/DMVS)N2(/29QF
M9ZVE4JO3=CL+ESQAV8E8\51_,Q<R84J_E8MVMI*<S?*@)&[33J??3EB4MB;C
M_+-;.1F+M8JCE-]*DJV3A,G'"QZ+S5G+:SU],(T62V4^:$_&*[;@G[CZO+J5
M^EV[4IE%"4^S2*1$\OE9Z]P[#?R1"<B/^!+Q3;;UFIBAW GQS;SY,#MK=4R/
M>,Q#9228_G//+WD<&R7=C^^E:*MJTP1NOWY2_ST?O![,'<OXI8C_CF9J>=8:
MMLB,S]DZ5E.Q^9.7 ^H9O5#$6?X_V13']@8M$JXS)9(R6/<@B=+B+WLH06P%
M:)WZ %H&T.<!_3T!?AG@/P_H[@GHE@'=G$PQE)Q#P!2;C*78$&F.UFKF10XS
MC];#CU)SWC\IJ;^-=)R:7#/%9<1B<AZ&8IVJ*%V06Q%'8<0S\B;@BD5Q]I:\
M(U>?I^3-ZU=#O]]]_W;<5KIMH] .RW8NBG;HGG8\<BU2M<S(53KCLYKXRQ?B
M*2#0UH.N1DZ?1GY!0<6;4)T0O_,;H1WJU74(#@]XJ,.]/-RO"0\.#Z? :/SJ
M//JYGO]SY_'K1QU'/BB>9/_4G<2BD6Y](V8..LU6+.1G+3W)9%S>\];D]2NO
MWWE?!Q!3+$ 2<^!V*[A=2'WR!]<S3$KF?,:E1KP0]URF>O)3=0@+J7XN96;=
M^TG7'W3,OW'[?AL/V&93/$AB#IY>A:<'XY$L563%'@T2O1B$7$_E=3E^T=ME
MXW7KV( --F6#).:PZ5=L^B";6RY#344OH43,R<*0J@-3B(RVP'1.AL^8@ TU
M98(DYC 95$P&()-I^0LI<!"6F FKC@HHTW0V^@$Q4D=NL/,;[M/.B/;[U>ER
MH PK*$,0RGDBI(K^U516>B(7M>D#*C3E 7?')X^<R:P. %(O'$JCBM((II2F
M:Q;GF)B>A$U:94LF.5G)*.1YG^O @:)-P<$][.T'A]0+!YS7L85>!T87AG)M
M?E[%/%U;PH$*33F5:LYL7S?9!^6!O:T#J>\>Z(YYJ[CUP#'?J"67A&495W5G
MY (.;SQ@;V<<M2M_4'/@: @-F-H!4W# '])[?6Z%?"0;&2G^;B8V:?W(09W&
M(Z<[I[I'O9J![QZW;\BV\/7 TF]R(90V269UG;)4SP=?KWERQV5M>0M+-1XU
M:H&+I>9BM"6NUSV&@? PJ]I+5+4 2\TE;*MD#RZ3IZ8.C$FH;:QDH<K(/'H
MEWM8KS%+N'?>OL4SP.J&B\T6T!Y<0?\E5@<F-V:!?(FJ%F"IN0QMP>T-CI+<
MJ 4YJEJ I>82MM6[!]?+S9,;M9A_H7= -8_5#Y>;K><]N%PN+ZU<1VF4*5VV
MZ$R_FJU#5EP43F=DJAME,ES"J8]:X*.J!5AJ[D5.6_;3SC%2GZ): U2U $O-
M)6Q-!H5-QL&7,V"=Q@R]G5K:]_TZNX'5KLO'>A(*>Y*;E4GFC.27"36FIT0F
M_Y$FM3O<2F-ZF&H!EII+V%H@>I2+_Q35':&J!5AJ+F'KCBB\ _!%Q'I)BB/U
M2*2&76NI88G&^+H[EX2]$[_W/+5_A:6AUM)0V#0 J7UPV0XWT1@;ZLX!EIJ+
MUUH?VC]*7J,:(U2U $O-)6R-$86W(@[*:U374ZJ9:YY;B=WM;>T?E&1^A:&A
MUM!0V#)\9'="(S&7$J^^KZ-5OK?WHTLWJM=!50NPU%S,UO_0T5%2'-4 H:H%
M6&KN?1'6 /GPOL=5IJ*$F=5IG?'Y.B:Q+M9K$QT6:GSW ]PMP))C]<,%9OV,
M#_N9ES+_X)4=;J<Q3TRU $O-96P]D4^/<KL.JB="50NPU%S"6_=#P=M"#=(>
M]Z8GN%L>E/>_PN/XUN/XL,>YF<_-'OI/K_9P,XUYHFX!8:FYB*U?\GM'27M4
MRX2J%F"IN82M9?+AW:(&:8_JBE[HUO[=-:QNN+RL ?)A P0E_>$+/:I#0E4+
ML-1<OM9&^<.C9#RJ@T)5"[#47,+60?GP#E*#C$<U22]T"[@/#*L?!;#VULW_
M"9>+_"&*C.2_MN)N^.K3ZD&-\_SQA&>?7WJG0?&XA94IGOZX9G(1I1F)^5Q+
M=DX&>HZ7Q0,5Q1LE5ODC!G=YF9"_7'(VX](<H+^?"Z&>WI@&JL=:)O\#4$L#
M!!0    ( )([=5@V7VN9H@L  -]K   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;,V=;6_;.!+'OPKA72RZP"$6J2>KFP1H++%;8'LMTMOKB\6]4&PF
M%BI+/DE.4F __%&R;)H2/9&\L[CT1?T0Z3<4_Q3)&0[ERZ>\^%:NA*C(\SK-
MRJO)JJHV;Z?3<K$2Z[B\R#<BDW^YSXMU7,F/Q<.TW!0B7C8GK=,ILRQONHZ3
M;')]V7SWN;B^S+=5FF3B<T'*[7H=%]]O1)H_74WH9/_%;?*PJNHOIM>7F_A!
M?!'5[YO/A?PT/5"6R5ID99)GI!#W5Y-W]"WWK/J$YHA_)^*I/'I/ZDNYR_-O
M]8</RZN)59=(I&)1U8A8OCR*N4C3FB3+\=\6.CG8K$\\?K^G\^;BY<7<Q:68
MY^G79%FMKB:S"5F*^WB;5K?YTZ^BO2"WYBWRM&S^)T_ML=:$++9EE:_;DV4)
MUDFV>XV?VXHX.L$Y=0)K3V!#3[#;$^RA)SCM"<[0$]SV!'?H"5Y[@M?4_:ZR
MFIH.XRJ^OBSR)U+41TM:_::1JSE;5G"2U2WK2U7(OR;RO.IZGF=EGB;+N!)+
M\J62+[+95"7)[\FGC2CB6OZ2Q-F2S/.U;+NKNE$]"O);7I;D32BJ.$G+GR^G
ME2Q+39PN6KLW.[OLA%W*R,<\JU8EB;*E6.J J;R(PY6P_97<,) 8BL4%L>D_
M"+.83:+?;\F;GWZ8V9[SR\^D?4.FI%S%A2C;%T.QY^<;^7$ /AR.9V=?0W2^
MD2'7P(?CZ3G7H*EO']JQW5BU_]9V3/[X37+)!WEV^1]3H]X5PC$7HAX%WI:;
M>"&N)M)$*8I',;G^Z0?J6;^8FAHF+,2$19@PC@33FH5S:!8.1+_^$J=B)[L<
M-[^)*LD>B'B6PW(I3/+N8%X#J\?DQVO'LB@+@LOIX[%RH-&QRIT!(R;1, O%
M_WJA-+W<@UXNJ%=T6IO=B>Z1-M1J_G6T 0V,U083%F'".!),4\D[J.2!*GT6
M19EGF4C)(B\KDUA>7ZS )!9H9ZQ8F+ ($\:18)I8_D$L'Q3K5A+C8K%J>L&E
M>)3.Q*8>&Z%^T._)YU"+.=2F'?U TV/UZUNU?9=Y5M!I-1&F56ZPZGJ!']CN
MP:I6[[-#O<_ >G\O,CGO2)MJCY=RZIZ453T/D9..MN9-DZN;6?_.81Z;^:[7
MJ7K0^MBJ-UAU9E[@>DZGZC&M<H-5&LP<GS%SU0>'J@_ JO]4K41!DFR1KXW-
M.^C;M1D-?*MSM7/0S-@Z[EME%G4#ZG5F%Q&F51[TIC2NPQ@U5S"UE-MH@57\
M3U&1^R2+LT42GQX&6LCQ-;NF8: ]SGOAN! NU-@N'I7&L6BZ($=^/ 4%^9!5
M0G*KMMG7+X6(RZYKW>I"^YT>,PH#&AU[!Z#2(E0:QZ+I\C$E'X,=E55>5$1*
MN&X]E?@N%:04BVV15(EYJ&B1FHHSHXJ@[=$J]LUZ!JL1JE6.1=/U4>$%"KJI
MUSPO1/*0R:%[L8JS!^.PTB*T:9-MU /5\T>E1:@TCD7355/>/X7=__=QDI$\
M(_=#U,/TG^>HM+"E:7,'QWC/H08!L&BZ>BH60.%@0!.;&ZJ>(3Q@[@M1XP.H
MM B5QK%HNGHJ1D#A(,%N$J[FB/$ZWV;F66(_6N#[KN6X=-85S^O-$\U'A@:F
MY\RH18_<NK;2^TSSD1R^X',K5/GQ%';DWZ5I_B0K4]0W!)&SNV52D53>(\8Z
M]7M791Z*4#WX@58C5*L<BZ;KHOQ\"COZ7YO52[$DV79])YM\?B_]H?5:=ESM
M(D>^K<HJSI9U\/G/T^LJ-[3O#[M.X,B6Z'=5&WID:#C2<9CESWR[J\G0([GI
M2.JQ(/"=$VZE<MPI[+DW7?Y&5F)32[*VNBM&QGK;,?VC\E@7?J_O0'7FC38]
MOUNGJ*Y\2YL=CW$7)SQYICQY!GORT;,H%DDIR*9(VKXEW^R6R_2&.T2*UA:E
M6KU8W; A7*2Q6@PS&J$:Y5@T737E[C/8W7_:=SKQHRCB!ZE;G!3D,4ZWHNZ
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M?14=/F90:(Y*"U%I$2J-8]'TUJ'"7\Y+V6):PG_1] (O)ANW4#VAU^]-V-N
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M?[_/\VK_H39P^$VOZ_\!4$L#!!0    ( )([=5BX9+8:F0(  /4'   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U5[T_;,!#]5ZP@(9 V\K,=@S02
M;9DV:0C4CNVSFUR;",?.;*=E__W.3IH5E%:=X$MMG_V>[SVG=_%&R">5 VCR
M7#*N1DZN=77ENBK-H:3J0E3 <6<I9$DU+N7*594$FEE0R=S \X9N20ON)+&-
M/<@D%K5F!8<'251=EE3^&0,3FY'C.]O K%CEV@3<)*[H"N:@'ZL'B2NW8\F*
M$K@J!"<2EB/GQK^:#LQY>^!G 1NU,R=&R4*()[/XEHT<SR0$#%)M&"@.:Y@
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MF@.XOQ1";Q?F@J[3)W\!4$L#!!0    ( )([=5@F?\]MH (   8(   9
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MD4+;+]LT>SV')2N-LFC %$&1EW7+7QH?=@!^?P\@: #!6T"T!Q V@/!80-0
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MEBJ7PV?HZOL=^O#^W6C@.9\^3DPAMZ$68R[+)5\62[:?63*VT0U-1<C151I
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MP/R^$$(_GM@;-'M29O\!4$L#!!0    ( )([=5@1O<1=/P4  +@B   9
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MOOX*C9[(\*6<2ON+UDVLYZ!T*14O&[#.H"Q8_22OC0\=@!_O > &@+<!X1Y
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M_5\!A G0^W/.U69B7M#^^TC^ 5!+ P04    " "2.W58&HFS.BL$  "'%@
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M((R _K[@7+T,S )-[WGR'U!+ P04    " "2.W58C(7W-^L#  !E#0  &0
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MD:A$9IP%MY>MF(NJ<DXVCW][TV!XIPO<OW]U_]+"6YAGKL5<5O^4N2FF01*
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M; NMNC-]US!RW9YRGZ6Q9^;VMK#?04(Y@?U_*:5Y;;@7#%]6L_\!4$L#!!0
M   ( )([=5C%E__Q6@0  "89   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;-5978_:.!1]WU]AI:MJ1MI.XH2O4D :(&B[ZJBHJ)V'T3YXR 6B)C%K
M&YB1]L>OG60"F0TFJ5RM]H7$CN_Q]3DW\;UF<*#L.]\ "/041PD?6ALAMGW;
MYLL-Q(3?T"TD\LF*LI@(V61KFV\9D" UBB/;=9R.'9,PL4:#M&_.1@.Z$U&8
MP)PAOHMCPI['$-'#T,+62\>7<+T1JL,>#;9D#0L07[=S)EMV@1*$,20\I EB
ML!I:M[@_PQUED([X%L*!G]PCM91'2K^KQL=@:#G*(XA@*10$D9<]3""*%)+T
MXZ\<U"KF5(:G]R_HLW3Q<C&/A,.$1O=A(#9#JV>A %9D%XDO]/ [Y MJ*[PE
MC7CZBP[Y6,="RQT7-,Z-I0=QF&17\I03<6* O3,&;F[@OC)PVV<,O-S JVO0
MR@U:=0W:N4&[KD$G-TC%M#.R4J:G1)#1@-$#8FJT1%,WJ5RIM20X3%1D+023
M3T-I)T83FG :A0$1$*"%D!<9-H(CND*?M\"(DI\CD@1H0F,9NQL55'M GRCG
MZ&H*@H01OT;OT$+&?+"+0%DN-H3!.R5X@.;D.44<V$*ZJR:UE[EKD\PU]XQK
MV$5W-!$;COPD@* ,8,MU%HMU7Q8[<;6(4UC>( __AES']=#;-SVOT_J ;,25
MOU4>3NOCN77P_";^_:I#FC7Q[!Q2B42OB!@OA6Z=@?Z\S6+BX0[B1V!_5@FK
M15 ?RS[?DB4,+1E1'-@>K-';-[CC?*C2P"28;Q)L9@BL)$.KD*&5HGO_]8N+
M'C[)J=%'.0&O%+ME4FR38+Y)L)DAL)+8[4+LMOZ=VPDNI)9ALD9$H#](LI-I
M ,)5<F1([11)Y17[$6[U6IXWL/>G1-<;YFO]:DJA(; 2A9V"PHZ60O\)V#)4
M@1WLF.)1;  ] V%5'&JAJAU%5=%L",?_ 9SS*A@"*ZG0+53H-@EDN4VEFXC<
MJJIDZ-8+Y7K#?*UG34DT!%8BL5>0V*L3RN11?K3+)**K,$'^CE$DMX!LRT^W
M@"F-(L+XL?<:_:W/+R9:%YI^U4V"^1F8+&;T>L\NCRNQ_[Y@_[V6_?M;?ZY-
M?K3F39DS">:;!)L9 BMI@)UCV>+\3]*?W%%#>AM%\XVBS4RAE24_J52QJ21H
M? 'J 5=+F=?*^.23X=PX^-5^4V^8K_>A,?F&T,KDNT?R76/IT_@"UCGVM58-
MLBY30/Z/ &D4-(165O!8MN,+=7N3U&M\ >R<A%Z]%ZC6,%_O0V/Z?T:UCH_E
M.M86B*:2MAJ'3.,+GIS3+K/J7I"NSBA?[T%CY7Y&Z8U5[5WN.9:26%]+2@;1
M?7IF#<$O9"_3C37DPFU9N 1TI9+$ZZK9[9.CVAC8.CU4YVA)=XG(#G^*WN+@
M?IP>5[_JG^#^%%?TW^)VW\\.TO_UI".?9,?&QZFS?Q#N"%N',F&*8"7=<&ZZ
MLIIBV:%\UA!TFQXB/U(A:)S>;H $P-0 ^7Q%J7AIJ F*OT9&_P!02P,$%
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MP-7S %?> 5:+Y2;ZM%@]U-'^TT6T/HYWW\AZ,:$C2\($"9,D3)$P_0B+2R,
MV7F>]@___'GXY_[A_^]H_Y&RCA;'#Y@WF\7=+CI\].Q+@)<4F@ 2)DB8)&&*
MA.E'6#PW$C [K^+TA0S$LU8YS,)/ L=SOGS8K(_?.Y[R#^=^]X-EKTKP=A<:
M%90F4)I$::JAF;_BZ7E1.1<"JD\[+(:?BKUAD7_<U^\/+NG3>K78+5?+W9?>
M#'@IP1D@:0*E292F&MIAD(W?\EF<YFX,AAO:(YRT(YR,&^'5\D,=?7>[O+Y?
M+_<7AH-AOOZ^=["]P.#!)FD"I4F4I@8&(H^^U(O--DJCVT?WFL3[J_.77HN'
MH.S M (O]JJ@RU^7V]__\F%3UX\W$_L+QZ[>W!].#_7U#]'?S]^=1]OUIWI3
M+V_NHNUNL[S?1N\?]C^;_C"AX@^E"90F49IJ:.X)8=8Y<0RVLV/0*KO8[^RZ
MDFE_O_!VO=NM;P]WE_N;RYO:ZY_\_."1)VD"I4F4IE":IFAVBEI3&>>3/%2,
MVDF4)E":1&D*I6F*9H>C=92QUW9='AU4=+]9OM]_9MT9'UCWGT?D'_7F_7+;
M_'-OA%"7B=($2I,H3:$TW= LDY&?QR]4..)65<9^5SFNQN&'!&< =90H3:(T
MA=(T1;.CTDK/N)IVC4$M)TH3*$VB-(72-$6SP]$JT=CO1$-K'GY<<&A0,XK2
M)$I3#<VL:*1QT=5=0\WLV4>M]$PF2,^^\?5S0L<7I0F4)E&:0FFZH;GUC_*%
M&+0Z,_'KS) *B!\5G 34::(TB=(42M,-;70=)&G%9^*79'0=Q-]=<%Y0+8K2
M)$I3#<VN@Y2)<V&@^K3#TDK/Q"\]1]9!_)3@#* V$Z5)E*:2?DO9K8.,:&B/
M<.LS$[_/#*^#^('!@XT*3)0F49H:&(BGXD71%"]ZKPJG(.R M*HR\<^J9.L>
M_LZ"PX,*3I0F49IJ:(-UC^%V=@Q:*9GXI>3)=0\_/WCD42^)TB1*4RA-4S0[
M1:V^3,I)3BI!A25*$RA-HC2%TC1%L\/1"LO$/TWSM+J''QX<(51KHC2)TA1*
MTTG/#,Z7ZQY)ZRL3OZ_\Z6'U)4K\%QA44:(T@=(D2E,H35,T^RF[5GBFLTD7
MF!3UFRA-H#2)TA1*TQ3-#D>K05._!@TM>OAQP:%!52A*DRA--32KFI&46>H\
M+ZB'V]D#W3K.=(+C[!UA5%ZB-('2)$I3*$TW-.NF(3DO7KAI2(UGKOWV,J3L
MX4<%)X%]%)M]%IM]&)M]&COM+7MD^0N5T+3UG*G?C=%E#W]WP7E!+2A*DRA-
M-33[5SU)W2L#U*<=EM9YIG[G.;+LX:<$9P"5F2A-HC25]DO*;MEC1$-[A%N=
MF?IU9GC9PP\,'FS47Z(TB=+4P$"$//Z!H.S M.8R]4^\9,L@_LZ"PX3Z3I0F
M49IJ:)WRQMR=4#6BH1V$UE*F?DOIF*C *H@?'CSPJ*5$:1*E*92F*9H=H59F
MIO-ID@HUF"A-H#2)TA1*TQ3-?B54:S S_Y3-TZH@?GAHA%":0&D2I2F4IK.>
M>9S)^7S>?^W)6H&9^07FB"J(GQ < -19HC2)TA1*TQ3-SDGK/[-DT@4F0W4G
M2A,H3:(TA=(T1;/#T5K1S&]%@]\ZB)I1E"90FD1IJJ&9U8UD5L;N*Z\&F]G#
M;+Q;<H+P[!U?U&2B-('2)$I3*$TW-+<&\D(I+&M59N97F2$U$#\J. FHST1I
M$J4IE*8;VN@:2-9*S\POR.@:B+^[X+R@2A2E292F&II3 W'E-]6G'996>&9^
MX3FR!N*G!&< -9DH3:(TE?4+RFX-9$1#>X1;DYGY369X#<0/#!YLU%ZB-(G2
MU,! /!4N\N?"1?%B#01!V8%IO67FGX3)UD#\G06'";6=*$VB--70.B>$6>R>
M.88;VN]9;QUE[G>4I]5 _/#0@4=I J5)E*90FJ9H=H1:E9G'DQ15COI+E"90
MFD1I"J5IBF:'H_67N7_^YFDU$#\\.$*HY41I$J4IE*;SWDF=+]5 \E9?YGY]
M^?0@8NRO@_@IP2% K25*DRA-H31-T>RLM XTSZ9=9%#EB=($2I,H3:$T3='L
M<!BK!?G-:&@=Q(\+#@V[=%#>*2+$>=RSE-/8A@K=/TW1[*%NQ6<^07SVCC%J
M-%&:0&DR[WE!97K>C0'Z]#E%LV/0*LW<KS1#:B%^5' 24*^)TF1#<^L-Y3R;
M&_^YN4 ?/*=H=BY:$9I/6!_HA+J(O[O@[*":M*'9O_9)XEXF4/V)TC1%L\/2
M2M#<+T%'UD7\E. ,H'8S?T$,NK4'.;:A0O=/4S1[B<#6;A9^NQE>%_$#0P<;
MI8F!@PUX_D)R*(4>HZ9H=F!:EUGXIV6R=1%_9\%A0@UH\<)Z/,8K2INHC&RH
MT/W3%,T.0NLM"[^W['%3@;41?P?!@X^Z2Y0F49I":9JBV3%J%6<Q;;'P G6:
M*$V@-(G2%$K3%,T.1^LT"Z\6.[$VXH<'1P@UGRA--C3G7=IQZEY_4*5)T>QL
MM$JS&+<"^D!MQ$\)#@%J,E&:1&D*I6F*9F?%6 E]XE+H[%KH[&+H[&KH['+H
M['KH7\.4%JTI+=@ET?VXX-"@MK3H+BJ>Y;/9S/W$,JJ90O=-4S1[F%OQ64 +
MH_LYP>.+&DV4)HN>%UAVUR=6:*>:HMDQ:)5FP2V0[D<%)P'UFBA-%OU+D?OK
M(N@N:(IFY:)L16CY;9=,]W<7FAV4)LJ^9<F3S+E(H'TJE*8IFAV65H*6R)+I
M?DIP!E"[68Y<EER.;:C0_=,4S1[AUFZ6])+I?F#P8*,V<^!@1RS'(4]'*/28
M-$6S ])ZR_);+I'N[RPX/*CM+%]8CR>?NV>*D0T5NG^:HME!:!UEZ7>4I]=!
M_!T$#S[J*5&:1&D*I6F*9L>HU9GEM%722]1?HC2!TB1*4RA-4S0['*V_++_F
M*NE^>'"$4,N)TF39,]&SIPZ"=JHIFIV-5E^6 R_KK \#O[R[^2'Z<?_5*HI3
M_]4&U9<H3: TB=(42M,4S0Y-*T/+:>NEEZC[1&D"I4F4IE":IFAV.%I%6K+K
MI?MQP:%!->D46M2;%PBDT./3%,V*2M5:TVK F@;8=#\J-"8H3: TV= <FSY/
M4G="(-JMIFAV%EHI6B%2U$\)C@$J1:NQ4G1L0X7NGZ9H]@BW4K3R2S[6>?D[
M"PX"*DP;FCN^B?N(X<AV"MT[3='L&+3JLQI0GYY/'('JR]]3< 90[XG2)$I3
M*$U3-#M/K4&MLDD?1BK4BZ(T@=(D2E,H35,T.QRM%ZT&WNDY=MJ.GQ.<%E24
MHC39T!+SHA.?)^XE!Q6@%,U.02M JV_[-D]_=\%A095HU7UC9GP>Q^Z=!SJA
M$Z5IBF:'I36BE=^(GF;+_?#@:*!^%*7)AA;;2:LZ]ZZH^*1H=C9:\5G1[P'U
M X/S@"K1@8.-CY,RHOGS,ZKS%Q]WQ4@*/4)-T>RXM"JT&G@+J/^CSG^N[T=^
MSD$5*4H3*$VB-(72-$6SPC1O9>E\VGKM<U2,HC2!TB1*4RA-4S0['*T]G?OM
MZ>C/.7Y.<%I0?XK29$-S[D\*MYJ/=JHIFAV#5K'.)ZSF?L(''7]WP6E!)6M#
MJZSA=4T[VJ5":9JBV5EI/>S<[V'#[V7]P. TH+IUX&"S9H)Q'#_=@U8OWLQR
M*(4>HZ9H=F!:T3KWNKK+_UA_.MZB'EY6X[M;]6."8X**5Y0F49I":9JBV6%I
MQ>M\VH34.>I949I :1*E*92F*9H=CM;'SOT^-G2*D!\7'!K4MS8TZV'H6<]#
MTR/;*73O-$6S![IUJ?.!UXB._EB":E.4)E":G/=HT^1\EKDQ0+4I1;-CT&K3
M^<##\P'SO/RHX"2@PA2ER8:6Q/8\K](UZ&BOFJ+946B5Z'S@ 7KZ$RJJ1E&:
M:&BV@'"?@Y=HGPJE:8IFA26>M<[S\/6H#ZG^68$#F- 8L#CQA!N>&#BZI6)W
M46,X9Z1C8Z1'SO\<K2,&B.&#CLK,H>-M-$+?A6'ZIHH]"(WAG%@D1BR^Y:31
M@=["(X,:S2><^]N?Q=WSQ,B6BMU%C>&<0*1&(/SZK<]"!4X;'>@B/ 6HR61Q
MDL4I%J<QG).GS,A3-DE4/6V'A03UF"Q.LCC%XC2&<T*2&R'Q3R,];4[8 #T\
M2JCU9''R"><(CLP5'&RW&L,Y&2F,C/BEYM.;/))LX.*#RDP6)UB<9'&*Q6D,
MYV2F-#)33KSXH#Z4Q0D6)UF<8G$:PSDAJ8R0^.UI:+7DB6>M7)?E69([M8:K
MT2W%P#Z&#SGZ_#R+TQC.&?*Y,>03+&G_6*/^\PGG7+S=QP<$VZUD<8K%:0QG
MQR$V+&C,/2<_P I.1-S_-/IL5KF90#N6+$ZQ.(WAG$P8OC2>,./SA$+*4W_V
M?+JY>\7P[U7PG02*DRQ.L3B-X9S,&#(U'OE:TH%J2MQO%SM5B*O1+<7 KH6/
M-#JQD\5I#.>,M&%)8WIRYQ"QLV1=_.*TQRN0)098X<%A=2B*TQC."8ZA0V.O
M2Z/K+4UO26*?']*\C#NGDK%-Q< QA$>"E9\H3F,X)Q*&_(S'+95DB*W0@HN_
MA_![4E: HCC)XA2+TQC.B9/A2>-IJRD];8>%A!6C*$ZR.,7B-(9S0F*(T?AK
M/H0_0 ^/4N^<3?=];(+M5K(XQ>(TAG,R8GC1V.]%QQ9<_)CP,*!32EF<9'&*
MQ6D,YV3&$*OQ?.+%A_6H*$ZP.,GB%(O3&,X.26+HUL2O6X,++@W/+*/D2>X^
MVG$ULIT8V+_@X49QBL5I#.<,MV%2$^C9^0%0\$DBZ7E"/>F\;UZPW4H6IUB<
MQG!.' Q)F@P\0Q]2;/&SPA.1C"VVH!U+%J=8G,9P3B8,G9KXA25>;&GZ<QX-
M23H7#'9F*8J3+$ZQ.(WAG- 8*C7QJ]2QU98&,Z+:,K:E&-BU\)%F#2F*TQC.
M&6G#D"9^0SJAVC) '+$@WA7 $ .,\*"P[A/%:0SG!,5PGXE_CBA<76EZZY9,
MBNZI8VQ3,7 ,X9%@32>*TQC.B81A.A._Z02J*_X>PF]"V<FB*$ZR.,7B-(9S
MXF1(T63:TDQ/VV$A82THBI,L3K$XC>&<D!@6-/%/+SVQNN*GAT>I=\YIM[J"
M=BM9G&)Q&L/9&4D-"9KZ)>C/BR]1ZG_1UP B. @H3K XR>(4B],8SLF+85'3
M>-J%)V6E*8H3+$ZR.,7B-(9S0F*XU=3O5H,K*PW/K)@4LY[*RKAV8F#_PH>;
MU:8H3F,X9[@-;9I.T*;]X\P^D=_@K%N*]+SH3"1$NY4L3K$XC>&<.!A"-/4+
MT:#*BI\5GHBLM[*2]F2"5:<H3K$XC>&<3!CJ-)VP0-,IE96F/_LW/ZTZ%PQV
M"BF*DRQ.L3B-X9S0&!HU]6O4L965!C.BLC*VI1C8M?"19NTHBM,8SAEIPXZF
M?CLZH;(R0,S&5%9.9X@!1GA06.^)XC2&<X)B>,_4/QD4KJPTO;GG@[3JE.C'
MMA0#1Q >"-9QHCB-X9Q &(XS]3M.QU^%UE3\]/#;3W8^*(J3+$ZQ.(WA["AE
MA@K-IJV\]+0=%1(4)UB<9'&*Q6D,YX3$\)^9?Q;IB345/ST\2CU32[/S>.Y>
MD]!N)8M3+$YC."<CAO[,_/KSIX?5EZCT7WC\B/ @L&\H17&2Q2D6IS&<DQ?#
MGV;IQ L/JTM1G&!QDL4I%J<QG!,2PZIF?JL:7%-I>-93*&5G(9*KD>W$P/Z%
M#S<K3%&<QG#.<!O"-(-6M!\ A9\D>M[KF9[GW5L*5H6B.,7B-(9SXF"HT&Q@
M:?N0FHJ?%9Z(HK>F$E=9)Q.L-$5QBL5I#.=DPI"FV815ETZIJ33]5=9O?MJY
M7K#S1E&<9'&*Q6D,YV3&\*?9R)7M!THJ6;_NW(>^$X>1+<7 KH6/-"M&49S&
M<,Y(&V(T\XO1"265 >*HAU5.9X@!1GA06.V)XC2&LX.2&]HS]\\ A4LJ>?_2
M1EG:*:F,;2D&CB X$"A.L3B-X9Q &(HS]RM.1U^%EE3\]."[3Q0G6)QD<8K%
M:0SG1,DPH7DRS6SEK/Y$<8+%21:G6)S&<$Y(#/V9^Z>/GEA2\=/#H]0[I[3J
M^ ^T6\GB%(O3&,[)B&$_<[_]'%-2\2/"@T#B!(N3+$ZQ.(WAG+P8^C2?MB[]
MTW982-CYI2A.LCC%XC2&<T)B2-6<79_^B6>MHS*;]=141C84 WL8/N"L,45Q
M&L,Y VX8TQQ:IWX %'Z:Z'FS:'I>= 0ZVJUD<8K%:0SGQ,&0H3FW7OT *SP1
MU=BB"MJQ9'&*Q6D,YV3"T*;YMUVX_JD_YT&5K'/%8&>.HCC)XA2+TQC.#DUA
M*-2"6;Z^>&'9]VY596Q+,;!KP2.-XA2+TQC.&6G#C1;X\O4#Q**IB,2/%9&H
M>'FY%8HD!DCAH6$M*(K3&,X)C6%!BV^ZN'W3F_N.KRRINJ>1L4W%P#&$1X)U
MGBA.8S@G$H;S+/S.\\0:BY\>?#.*X@2+DRQ.L3B-X9PH&6JTR*:IKH+UH2A.
ML#C)XA2+TQC."8GA0XNONK*]GQX>I=XYIMT:"]JM9'&*Q6D,YV3$T*'%P,KV
MAVM2/!^X\K!S2U&<8'&2Q2D6IS&<$QA#IQ83E[4O6'N*X@2+DRQ.L3B-X9R0
M&)*U@)>U+[J+U6<])991S<3 WH4/-FM/49S&<,Y@&_:TH!:T]X/"3Q$]+Q=-
MS_/.:UW0;B6+4RQ.8S@[#J7A14MP07L_*S@19>^"]M4\[KP)#.U8LCC%XC2&
M<S)A&-3R&R]HW_1G_^;''17FWZW@FP@4)UF<8G$:PSFA,0QJR:QH7[ZP3GVW
MP#*VI1C8M?"19L4HBM,8SAEI0XR6^(KV \11CZV<SA #C/"@L-H3Q6D,YP3%
MT)ZEUYG1196FMQ&/K8QM*0:.(#P0K.)$<1K#.8$P%&<YL'Z]HZ]":RI^?/C]
M)SLS%,5)%J=8G,9P3I8,%5I.7+R^9/4GBA,L3K(XQ>(TAG-"8NC/\JLN7N^G
MAT>I=XKIO%-30;N5+$ZQ.(WAG(P8]K/TV\]W]?WN>,V)XFK@\L/.+T5Q@L5)
M%J=8G,9P3FH,C5I.7+Z^9*TIBA,L3K(XQ>(TAK-#4AERM8*7KZ^ZR]*7/6NL
MC&HF!O8N>+!1G&)Q&L,Y@VU8TXI:O-X/"CY%5#UO&$W/XTYA!>U6LCC%XC2&
M<^)@^- *7+S>SPI/1/_B]6G96;P>[5BR.,7B-(9S,F&8T^H;+UY?=1>O3\[G
MG34U_+L5?!.!XB2+4RQ.8S@G-(9%K?P6=6QAI>J7GCV%E;$MQ<"NA8\TJT=1
MG,9PSD@;>K3"%Z\?((XJK)S.$ .,\*"P[A/%:0SG!,5PG]4W7;R^ZE]RJ:>P
M,K:E&#B"\$"PGA/%:0SG!,+PG-6 Y^QS6*'5%7\?X3>A[)10%"=9G&)Q&L,Y
M@3*D:#5Q\?J*=: H3K XR>(4B],8S@F)X4"KK[IXO9\>'J7^^:6=ES6@W4H6
MIUB<QG"/&;G8?JSKG5CL%I>O;^O-37U5KU;[6XOUP]T>?W CS]^--O6'0X1>
M_9B<772^_S9^I>/#]R]:S.7K^\5-_?-B<[.\VT:K^L,>.3L_U)DWRYN/SW_9
MK>_W@WP6_7:\M!V__%@OKNO-H<'^WS^LU[NGOQPZ^+S>_'[<[<O_!U!+ P04
M    " "2.W58*+F_P!,3  !,[0  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6S-G5MOVSK:A?^*D-D8= -[$NML=]( ;2SQ@.G>00_S76S,A6HSCE!;
M\DART@+SXS])5DQ39FBILP9H+YK8H9Y7LM=+D5PD=?V4%U_+!R$JZ]MFG95O
M+AZJ:OOZZJI</(A-4E[F6Y'5?[G/BTU2U2^+U56Y+42R; _:K*^<R22XVB1I
M=G%SW;YW5]Q<Y[MJG6;BKK#*W6:3%-_?B77^].;"OGA^XT.Z>JB:-ZYNKK?)
M2GP4U>?M75&_NCI0ENE&9&6:9U8A[M]<O+5?\VE[0%OBGZEX*H]^MYI+^9+G
M7YL7;/GF8M*<D5B+1=4@DOK'H[@5ZW5#JL_CWQWTXA"S.?#X]V=ZW%Y\?3%?
MDE+<YNO_2Y?5PYN+Z86U%/?);EU]R)^HZ"[(;WB+?%VV_UM/7=G)A;78E56^
MZ0ZNSV"39ON?R;?N@S@ZP'%>.,#I#G!Z!W@O17"[ ]RA!WC= 5[_E&8O'.!W
M!_A##PBZ X*A%QUV!X1##YAV!TQ[![@O'3#K#I@-/<">/']SDU9!^Z^\U<L\
MJ9*;ZR)_LHJF?,UK?FE%UQY?RR3-FOSX6!7U7]/ZN.KF][P2I57E5O4@K-L\
M*_-UNDPJL;0^5O6/.A.JTLKOK3C-DFR1)FOK+B_35MJOYJ)*TG7YJ_77OTS=
MP/N[=665#TE1\]+,^IRE5?F;]8O^S?KW]^EZ76/*ZZNJOH[F;*X6W3G?[L_9
M>>&<;<=ZGV?50VE%V5(L5<!5_0$</@7G^5-XYQB)?+>^M";3WRQGXKC6YX]S
MZ]4OO^I.S(R9B\6EY=H=)OK\P7K5?32:SVC_0Q-D/B9(=Z['G_.+X&@XV.F=
M_8O,> SS^61?I)'A-%L]0PV,#H;9X5D8,\/>;HL:-NF^E.'?-1^#/?,=*\IW
M#_GOMA'<_V7^__F/FFJQNGCY+\U%OMN?@J<_A:8%\+K<)@OQYJ*^Q9>B>!07
M-W_]BQU,_JY+021LCH1%2%B,A!$DC")A# GC()B22-XAD3P3_>9#34R*Q8.5
M9,NZ@?98MSRW3?98XEO=EBVUV?_.B!R;&'M8T,*:9O'CS=2?7E\]'NL=&3 :
M$#!&!B2G >V)/7/4D!09DB%A' 13].D?].D;]4E$)HJZ^F[DF2SKMF1:5D72
M=$Z>%:H3J)$Y5J![F'_T]<U\9^+W)(H,&6E"AI[M]D2*#$E.0]H3/YQ->BI%
MQF1(& ?!%)4&!Y4&1I7>)N6#57?C[^M^NU7W_JVU2%ZH.XV@L=+<P^SIT;<V
MN?1ZRD1&C/8P8\ 8&9 ,"$B1 1D2QD$P193A092A490L>ZQOY'GQW7HJTDK\
M;9D_:;NM[XR8L9(,3VYV_J3YUQ,E,F:$A,5(&$'"*!+&D# .@BDRGQYD/C77
MO7FQS>LF0=V3RQ;Y1EB?DF\ZE1LI8U6^A\V46LGN-PF&%(J&%(J'%")#"E'D
MI\"0, Z"*1J:'30T,VKH8SM\4->2WZUR5_>&DF*E;5<:*6,UM(<U(Z-'7]AD
MTN_[#"L6#2L6#RM&AA6CR,^#(6$<!%/49$_DZ/3$J*=/1;(45I5\T[<!S4>/
MU5%'<QPU\]U)T*^0!I>,NI(] =ANV)/3P'+DA7).7U#03X9!:1Q%4S5UY'C8
M1DV]?:P[PJM:57E5]X=K;5G-34\K+R-HM+R0M#F4%G6TGJR<6?_^.; <>:'<
M-.C+%'D5#$KC*)HJ4T?*U#%7?>?E:02,EJ>C_<K\L-\-'EHP&EHP'EJ0#"U(
MH1\-@](XBJ;J2AH^MG$8_"86RW8@L-*W[LU'CQ:5JVE+.W9?44-*18-*Q8-*
MD4&E*/2S8% :1]%4%4FWPS;;':T[^**&H+Y&1^NWH;W3BFE@P6AHP7AH03*T
M((5^- Q*XRB:*BEI4-AFAT+>\-9Y65J+I"B^W^?%4U(L]8U_J#G1T8['VQS/
MG>J&W*"!(UU@N^Y*G :.H8$)E$:A- :E<11-%;;T-&RSJ?$YVY5B>5"VV&L[
MK=_JY*U5-]3?Z&B**S4+)EIU0VT.7># ];3JAMH=4!J%TAB4QE$T5=W2'+'-
M[H@<-D[WP\:-PUP]C]MHI0WU23J:JC!/+VVH6:(+[-J!5MI0+P1*HU :@](X
MBJ9*6QHBMMD1^72HL;4RAAHA4-H<2HN@M!A*(U :[6C'C3'7TS4"&30N1]%4
MH4O7QC;;-I^&-[JASDU'4V9T.;-05W7O2SK''2S;NW3[/;N9IDYVM%6R'G@R
M4("\7@JE,2B-HVCJ!'SI]#AGG)[D6_)E_=R(T$G/#!@KO8ZFC@#U+<,AA2+H
M><50&H'2*)3&H#2.HJGRE::28S:5;G=%T<SV[=K [;"]6(CTL1&U5LU0;ZFC
M*16I.YLXTWX]"@T;=;3CZC:<V:[7'T>#1B50&H72&)3&4315U-*"<LP6U+.H
MFQY=EF=_6W2O[P^+09*Z<5QI&PIF]&A]=\;/\?3%J7_9]^6A0:..=JSN8*J;
MA!=#XQ(HC4)I#$KC*)JJ;VF%.6>LL)Z.K?LBWUBK_%$46;MV8U4DS?JG9)/O
MLDJK<JA;]B,T2]?]@YY6!*7%4!J!TBB4QJ TCJ*IN2(-/\=L^,UWPI0'4,</
M2IM#:5%'.VYI!=H.)C0L@=(HE,:@-(ZBJ3J7+J1C=B%ODVW:^)!YL:SO#L7W
MP^KULMR)I?4JS:R/[3N_6O]Y>5WO.W.4T0EQNJC(GTZGKA,Z_180U)O4Q/6\
M<.*&07\)%30N@=(HE,:@-(ZBJ6J7UJ1CMB9_SS>URM?68[*NZ_>M*/:2KJ7]
MZO!"MQS^G9D[6M][6JB,L]@GVH8ZDU!:#*41*(U":6S0=\6[4O9Q,>_2D1TV
M5;#2;73.N8V;39X]5\I-2]VJTHUHZ^5YOEXG15LQ_Z+5+-1WA-+F'<U6UWOU
M1QJAZ[.@- *E42B-06D<15,S0)J2CMF4_.._;)A 7<N.IO@MSL3QPW[5/:Q<
M!#V[&$HC4!J%TAB4QE$T5>'2C73,;J1:Q^_UK94RU(N$TN906N1H?%);9TO'
MT+@$2J-0&H/2.(JF;L(DW4_7['Y^3-:UU)-5(=HME[J1EG)0LZ9#*TT'>Z;J
MXM8<?ZRZH;0(2HL[FF+LN_YEKX%*H$$IE,:@-(ZBJ=*6SJAK=D9_%Y6U+?*%
M$/H9)>;#Q];BKL8(]7333>==274"B'_9;Y% 3R^&T@B41J$T!J5Q%$W5L#1"
M7;,1^G95U\RK9HYK?UBPS-?#V][F**.ECJ3-H;0(2HNA- *E42B-N:>6LSV9
M.J[O]&[H?$A)5>U'6T*:;=']$. X96.W>,3N\8C=Y!&[RR-VFT?L/H_8C1[=
M4[UZMAT&7E_8YPNJNI86IFNV,.^Z5HB5W]^+(LU6UB(OM7:F&31:SM[)%3G:
MO9RZ@LHL%^=DOB'TY&(HC4!I%$IC4!I'T50M2YO2-=N4G[.E*)KMR!H9S]-R
MT?87M5J&.I'NJ2/HSFRMF/U3,7MNOQ\604\OAM((E$:A- :E<11-5;.T(5VS
M#?E']2 *62V;MLPUDT;+^71YHKZS"+4>H;082B-0&H72&)3&4315\]+)=,U.
MYO&XR'[BX;/^M;*'>I?NZ=)%=QIJA0]=,@FEQ5 :@=(HE,:@-(ZBJ<*7!J8[
MQL"TMNT^@?KMI\VDT:H_7=SGZ/99F'<%E:%!IS_9/(*>7 RE$2B-0FD,2N,H
MFBIFZ56Z9J_RKD@7QQ.GC@P;^6YKW1P>WJ$5.M3*A-+F'4V=FM+/!63$&$HC
M4!J%TAB4QE$T]0$8TL3TSIN8S;-BDN6R?4),LGX>)1\ZC&@.,#8-.IHR:U97
MW0\L%T'/+H;2")1&H30&I7$4316YM#.],[N''JR@YX9+W8IO[@%#K'HS>[2^
MH1N*>AH_-#QI]$!CQE :@=(HE,:@-(ZBJ3D@[5!OJ!VZW7U9IPLY<C,H": N
M*)0V[VA*6\<YF8<+C1E#:01*HU :@](XBJ8F@71)/;-+JBZ=:(0?[8I<;?3W
M'P2H30>H==K1SJRD@,:,H+082B-0&H72&)3&430U'8X>?V<V5_O3T@<W^:%6
MJW=JM<ZFH=_?*18:-(+28BB-0&D42F-0&D?15/U+0]8S&[)]_;?39Y+JM',P
M9EC(''-T<B!I\XZFK/"R+Z<G'0:HOPNE$2B-0FD,2N,HFIH<TM_USOB[/WIS
M@)J]WJG9Z]C^Q.W?'*!>+Y060VD$2J-0&H/2.(JFZE]ZO9[9Z]V[!(<9E3]R
M)X#ZOU#:O*,I=P+WTCVY$T#-7RB-0&D42F-0&D?1U$R0YJ_W0^;O\#L"U!'V
M-,M2]Y/93DT"Z(ZZ4%H,I1$HC4)I#$KC*)J:"]([]LYYQ^)>%(58CFX60=UB
M3[-G[DM) %W5"J7%4!J!TBB4QJ TCJ*I3Z67IK%O-HU?V(%&JWLS:JSN.]J9
MH5)HS A*BZ$T J51*(U!:1Q%4R4O+63_S%[!^6:;9-^?=^Y8['<<TPH>ZA=W
MM./=K/M/8CM?)(*>4PRE$2B-0FD,2N,HFBIAZ0#[9@?X@T@W7W9%W7 WS=4W
M0T;+=T\[MF9U3PJ !HV@M!A*(U :A=(8E,91-%7MTNKUS59O;T.:K!;]0I3-
M.D(K [G YC,8G2J#7&!HS A*BZ$T J51*(U!:1Q%4S-%NL"^V06^2[XW^]>4
MS9/MK&2Q*)H&SCI-OJ3KM$I?D#[4 >YHR@0>[<H6:-@(2HNA- *E42B-06D<
M15/5+SU@W^P!_S,ITN9Y'Z7U(-9UPS[/RBK)JM^:V\&B3HMDI5WE8J:.3@#_
MI D_Z3_6:#ZD4 0]KQA*(U :A=(8E,91-%73TKKUS=;M;2&6:645:?E5JUVH
M0]O1CBOOV4R[1 L:-_)/G>&I]A&2,30N@=(HE,:@-(ZBJ2J6!JQO-F 72?G0
M/L:F_47\>Y?6#7;QPHX)9M9H36L>$^IHGRL-C1MU-&4GM$#[6&EH7 *E42B-
M06D<15,U+:U4WVREWC92WC]D3+\_JOGXT3H^73T[U<L8ZI1":3&41J T"J4Q
M*(VC:*K4I5/JFYW2]VF6;G8;Z\_W8O-%%/_2JAUJBD)I<R@M@M)B*(U :11*
M8U :1]&4E BD;QKL32KW1=^TJON956Y5#\*ZK7N:^3I=)I586A^K^L=^%":_
MM^0SSN[RLEV6:[V:BRI)U^6OUI__J*D6JXN7VIP*H(8KE#:'TB(H+8;2")1&
MH30&I7$43<TI:<P&9[8J[@;S[]-O=1ZE627J*-H- LV@T8FQI]G'2V\GEY.3
MF<D#RT7!J8O;;_.?+T*@UTBA- :E<11-E9TT4P.SF?H^^7:V=6-&C!8<=-$L
ME!9!:3&41J T"J4Q*(VC:&I*2,<U<'^"U@W4<X72YE!:!*7%4!J!TBB4QJ T
MCJ*I.26]V<#LS8YHW4 =V8[6/.OYN-7BV4[_\=V#2T:#2\:#2Q+H55,HC4%I
M'$53A2AMTL!LDW[*MTW=_2')5L+<Z($:HU#:'$J+H+082B-0&H72&)3&430U
M+Z35&@0_0:,':MA":7,H+8+28BB-0&D42F-0&D?1U)R2QF]@-G[CO!#IJIVQ
M^=#>;^IDJ8HD*]=)DSC:#(':OX'&AM6NK8*&C:"T&$HC4!J%TAB4QE$T5?S2
M(0[,#G'T+/JBV:OM?KU;5+M6]N5_,5/9''-T>NQIMGN<'Y>.[9_T#:"N,I06
M0VD$2J-0&H/2.(JFIH=TE0.SJ_PNKZIVV_TA71&HNPRES:&T"$J+H30"I5$H
MC4%I'$534B.4[G+X$[C+(=1=AM+F4%H$I<50&H'2*)3&H#2.HJDY)=WET.PN
M_T!7Q$P<G2&:9^-JNR+0L!&4%D-I!$JC4!J#TCB*IHI?>MRAV>/^GW1%S#%'
MIX=SVA697,YFGC^1__H+::"G$$%I,91&H#0*I3$HC:-H:JI([SLTKS9^GQ1?
M167=%?FJ2,RS0LRDT0D =;"AM A*BZ$T J51*(U!:1Q%4S-#.MBA]Q/T2J#F
M-Y0VA](B*"V&T@B41J$T!J5Q%$W-*6G&A^/VK>XV)1JZ%9V9/CI;-$\7=EP_
M=/HS88<6C#0%'3^8.I/>4[7CH04)](HIE,:@-(ZBJ<J4=GAH7GG\L<H77ZT_
MMFW];6P%02UM*&T.I4506@RE$2B-0FD,2N,HFIH7TM(.PY^@%00UP:&T.906
M06DQE$:@- JE,2B-HVAJ3DFG/!RS+?7X5A#4$P\UNU)[,_=DE'90L0AZ;C&4
M1J T"J4Q*(VC:*J^I=4=FJWN;A>7#VGYU=R4@MK<4-H<2HN@M!A*(U :A=(8
ME,91-"4MIM+FGOX$-O<4:G-#:7,H+8+28BB-0&D42F-0&D?1U)R2-O?TC,U]
MR)6D+(5^AR4S8G1*G/K:TR#0&=O0N)$F;A#J]IJ,H7$)E$:A- :E<11M+^6K
M\D&(:IY4R<WU1A0K<2O6Z]):Y+NL:NX11^]:A;BOI6Z_?NM<7)V\?VN_IK;F
M?6:_YNW[5Q)_<[U-5N)]4JS2K+36XKX.-;ELAM:*=/5P>%'EVS<7]=5^:><D
MMK\^B&0IBJ9 _??[O+Y5=2^: $]Y\;6]G)O_!U!+ P04    " "2.W58%I.=
M!N &  ! ,P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6S56]MNVS@0
M_17"!8H6V-0F*<E6ZAA(G!0ML"V"!MU]*/9!L>A8J"RZ$ITTP'[\4K(JFA8U
MEFQZT;[$EPP/YPQ'PS.B-7[BZ;=LP9A /Y9QDEWT%D*LSOO];+9@RR![PU<L
MD?^9\W09"/DQ?>AGJY0%83%H&??)8.#UET&4]";CXKO;=#+F:Q%'";M-4;9>
M+H/T^8K%_.FBAWL_O_@</2Q$_D5_,EX%#^R.B2^KVU1^ZE<H8;1D21;Q!*5L
M?M&[Q.=3U\T'%!9_1>PIVWJ/<BKWG'_+/WP(+WJ#W",6LYG((0+Y\LBF+(YS
M).G']Q*T5\V9#]Q^_Q/]74%>DKD/,C;E\=]1*!87O5$/A6P>K&/QF3^]9R6A
MPL$9C[/B+WHJ;0<]-%MG@B_+P=*#991L7H,?92"V!F"O80 I!Y#= 4[# %H.
MH 71C6<%K>M !)-QRI]0FEM+M/Q-$9MBM&03)?DRWHE4_C>2X\3D$Q<L0X(C
ML6!HRI.,QU$8"!:B.R%?Y(*)#/$Y>A<E03*+@AC=\BPJ5N#5-1-!%&>OT1FZ
MD^D5KF.6F]ZF,LE2\8R")$0WW]?1*D>11C=?/J-7+U^,J.>\?3WN"^E^[D1_
M5KIZM7&5-+B*"?K($['(T$T2LE 'Z$O>%7GRD_P5 1&OV>P-HO@/1 :$&AR:
MMA]. '=HM1:TP*,->)>SV7JYCHOHATQ>E3+>>:1-H=H@.6:D_-H_SU;!C%WT
M)$S&TD?6F[Q\@;W!6Q--2V :::<B[4#HDT^R5.57.7H,XC4S4=V,]XKQ>55Z
MG)"1[PZ'X_[C-HFZ&95V9%"9:>ZYE7LNZ-Z49P)]_<B6]RS]Q^0=.+SK0E@"
MTYAZ%5,/S+[_KQ)\_5-.C3Y(S,P84L]F2"V!:2$=5B$=@LES%<0R5 P%,L79
M0Y0D4?)@(KQ!<;=2%SLNI=3?27&#'?&&'L;F'!]5;HY -R_#L%C'S.3;J#:G
MZ^*\6FJ>U:UD"!V_P3&_<LP'';N.LA7/@MCHF%^;\HRXOKOC&#C!@<N/!VIS
M'8 $;G[,%D'RP% 8S><L93(9C%Q*&(T,=JA#=M@8[(A+J&<.,]X2 ;AMHK(D
M;,C2$D-/4Q^[9#?F1D,]GW4_B?*3P)G:L$."%1K&[%I/;*'I$5 2 <,:X=>I
MTMBJ!+&%IH=5B1 ,JY"VE;J$T2]43!P'[]9JDZ7O4T)'#1>!4B08EB1@52S'
MZA7"=W:=.X70P$II8'#7;5\6O7HAH9XWVF53-SO#0S)J*HMJ^\:M]V^@+-9W
MY3-,!MAW:GZ:+'>21_=4[>!X9*UUP* :Z'SA6D+3B2N%@/=(A.U=0&95*K-J
MSM.B/#ZS(#4&P" =?#K<4BLE-8,=QG2T=3GI;:?2!036!5K)9:KD KL8C-AU
MU6RAZ?R5WB#86KH24+IT)FX)32>N! R!!<S^;K<$T JXJ=TUV$']+E$*@X!;
M[;[<1/^BO3TQ/$/G)3N%-"!*&A#G-U%<!-0PG<-J"4T/JU(Q!%8Q;147J0L:
M<W-L,H2Z8Z+D"H'E"M@?D[KX,#7(!C.H0R9*HQ!8HX!JD!@4AZ%)AJ<X-!64
M>"'P_8>V<I#4[S(8NV2#'= E$Z4U"*PU6LE!4A<-YB[9: ATR52I"WJ4NI 5
M_* ^&IZU\SWG4R@0JA0(A17(KU/5J55]8PM-#ZO2-Q36-VVK.JVKEX8^VF0)
M]=%TZ[0%%CI@Y2S'[NFCX1D.C;:2)A2^:]&V<-+ZO0A3'VTP@_IHJO9ZVGJO
M;RZ<M+Y_-_311DNHCZ9JJZ?P(4BG(SBKYQ2VT'3B2D;0/3+B@#Z:&M2%J8\V
MV4%]-%7*@>X[N7@L$FL5/&\J-KA_6;WO80M-9ZZT"/7M):JE0Y"2^"F.5!PE
M;AQ8W+0X+SY 62 34PM .DFE3ASX/*8QK]MTWS!VU^6VA:9'0@D*A_PF.LVQ
M>HQD"TT/J](^#JQ]VNHT&*;+M70\D$YUZ_<EL$@"NW=X;!=^QP/I_)2X<HXX
M#H+'=N%WBA,C1^DRQ\Z)$0S3A>_Q0#I5I<0<"X=.,$87GL<#Z3R5=G,.U&Z'
MWI^ Y^M<H$^A[QRE[QQ8W_U"^YY5]6@+3?\QGU*/+JP>V^Y[,$R'Z\L"D$Y5
M:4@7UI#@O@"/[<+O%/+05?+0A>\WM=T78)@N?(\'TJDJR>:VEFS-^P*,T86G
M9;WF*KWFPN=M73I;U^J)F"TTG?C6+XWW"+D#;L' D%W6^WB@#>W^UK,(2R8Y
MY(]H9&C&UXG8_#*_^K9Z#.2R>/AAY_LK?#[=/,RA8#;/EGR4H8F2#,5L+B$'
M;X;2]W3SN,;F@^"KXHF'>RX$7Q9O%RP(69H;R/_/N=Q=RP_Y!-5#,Y/_ %!+
M P04    " "2.W580""@,'@&  !L*@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6S56EUOVS84_2N$"Q0M4-?\TE?J&$B<%BNP%D&#;@_%'A2+CH5*
MHB?*20OLQX^25=&4*$9.- Q^L2WY\NC>R\O#(Y+S!YY_%QO&"O C33)Q/MD4
MQ?9L-A.K#4M#\99O62;_6?,\#0MYF=_-Q#9G850U2I,9AM"=I6&<31;SZMYU
MOICS79'$&;O.@=BE:9C_O&0)?SB?H,FO&U_BNTU1WI@MYMOPCMVPXNOV.I=7
MLP8EBE.6B9AG(&?K\\D%.EM2MVQ06?P1LP=Q\!N4H=QR_KV\^!B=3V#I$4O8
MJB@A0OEUSY8L24HDZ<??->BD>6;9\/#W+_0/5? RF-M0L"5/_HRC8G,^\2<@
M8NMPEQ1?^,-OK [(*?%6/!'5)WBH;>$$K':BX&G=6'J0QMG^._Q1)^*@ 7)[
M&N"Z 6XWH#T-2-V 5('N/:O"N@J+<#'/^0/(2VN)5OZH<E.UEM'$6=F--T4N
M_XUENV+QF1=,@(*#8L/ DF>")W$4%BP"-X7\DAU6",#7X$.<A=DJ#A-PS45<
M]<"K*U:$<2)>@RFXD>45[1)6FE:E,.7KZ5?!P(403"),P?NO7\"KER]\XM)W
MK^>S0OI>>C!;U7Y>[OW$/7XB##[QK-@(\#Z+6*0#S&303>3X5^27V(IXQ59O
M 4%O (:8&!Q:#F^.+>Z0IB-(A4?^WX[X]KM\+O@H <5?IE[8.TG-3I:<<B:V
MX8J=3R1I");?L\GBY0ODPG>F#(X$IN63-OFD-O3%9TF!)7N ^S#9,5.H^_9N
MU;YDN_L%@AYR77<^NS^,PF!'$/)AT-AI#CJ-@X[5P<M=G$1Q=@>^?6+I+<N-
MW6&%.+8[1@+3HG6;:-U3*&]WS'R.!*;ETVORZ3VSO/?M':V\L:Q:OU7>!CL<
M8 ]YYO+V&P=]JX/+,!?6TK8V/[8K1@+3(@V:2(-3*.U@S'R.!*;E$T&E2> S
MB[L&.*Q:2ARW7=L&,Q3  )M+&QV()F0O;BX*:W';VQ_;&V.AZ=%B%2T^A0*O
MO1PKIR.AZ3E5:@]9Q<_B,DQDKM@;<,ONXBR3.L 8,NG4+_8@I1YI%[K!D,*
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MAT(^"Y:Q^B)6O_)-0FZ.-Q6Q+/ZBU<;6Z:'I4BJ1;)QU!$F4KE^#'YN)V'+
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MEUJCR_VW.;EZ_VX8)M''#V/7(!E[)#=K#GY;'SQXY>!^0+Y(80I-[D4.^3&
MBRJT4@1[*6Z#LX@I9'T2^K^1P O"C@/=7>X>=+BGE[O[9]B$;6##"B]\!:^-
MR-?.B#RT$?G:1.1FH8W"-.P*1;U5U+V5K4S7>DTSF#A8>C2H+3C3]^_\Q/O8
M)>-;@J5O!'8D<=1*')U#QY A*.9$E0WPA)585PF@;*WIR65O@W.J-:#T5QJ
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M&N_#$B&]_@!%5W6K64^,7%?-UT(:;.6J88'=.2AK@/\O);X)S<1NT/;[T_\
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MA"J O"WDVHYDC:F%'IE4E95IYJKX!:X-U/R"J7JHZ^@%^G(Z^1=02P,$%
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M6HZ=@8,**/&*JCN^^02MG]CPY9Q*>T6;-M9S4+Z2BE<M6"NH"&ON^+'-PQ;
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M*JEY]9&AFDBV*<_ICTRJ4W\YS#!*,=<&ZOF:J;-Z/=%'_^93S^)_4$L#!!0
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MKG,%%SS#["6 :[QL7 V>7#T-=B*>8]J&T/\ @1>$<'%[ ZW]O3B,.L<'4 _
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M\;*DJHDW1A^?'M'H_"QR ^_Z8F(J<*+UF&FK^K91[1Q1?4?22^3:'Y!C.>X
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M-=O'ZJ-\^(/7"7F%WE+&>?D7/=2QS@0M][F223U8.TA$6KVS;W4A#@9@?V
MJ0>0[@!W8 "M!] RT<I9F=8U4VP^R^0#RHIHK59\*&M3CM;9B+0XC7<JT]\*
M/4[-KV22"*7/B\K1JVNNF(CSU^@-NM/7RVH?<R37Z):I?2;4([I(6?R8B[S8
M><-U\="-8 L1"R5XK@=]NKM&KWY^/9LJ[:S0GRYK%Y>5"S+@ A-T*U.US=&[
M=,57;8&I3JG)BSSE=4E Q6N^?(LH_A41AU"+H:OQPPE@AS9EIJ4>_?_+_.5&
M:Z/WBB?YW[9*5T9<NY%B53C+=VS)SR=ZVN<\N^>3^2\_8=_YS5:E$XFU:N8V
M-7,A=5VS5&5ZFN]97%SY(MDG*"[+(1>QV+!B&<AM%:ADBQFG=8MU['Z.L8==
MZLZF]X?9V0)IZ.A7$]AR[C7./=#YN_5:KU+%Z5N)?"GWJ1+IQN:TDO$.CD^U
M@:ACLQ]%*,6!W:/?>/1!C]6%%9L+R^;/[QT98PT(U^LXM,11S_=#:O<8-!X#
MT..?4K'8YBNP^/)"ZM..+TL<C3 A [["QE<(UTZ'W[-XSZOKT5JZL'=H-_))
MQU\_" ^[BQIW$>CN;BLS]4;Q+ 'L1?TC1W[8L0<>QS[[$3#QL6.@Y,!3G^V$
M/O7B7[X"<JA%O._.<UL@-,_Q 3TQ:/2S4%N1(JE7Y$?.,O3EEB<+GED79ECJ
MV)7Y5&KMQ(E)G/PH0*N=G*IN)U)KU\WT 1A$YO.A5NNV6!$5JU[W6K?$A8Z'
MPX%+W= 8PS@>#;5:IS7;_)!TJ68+P]@E SX->S$,WU%@PQ;R!B[MF[3$^1$-
M_ &7AKX8QN\@VG"?I30*(K>+#EM<Z =!-.#,,!?#T!T#-]P'JQMBOVNQ'^43
M'P\8-/#%,'U'\0U;T-H'''RD9Q#.,!K#D!Y)N#ZF[9/>$@=,>F) 3& 07ZQU
MG0W>%GN%4JE0(C..U):E:*UOPLOO<I!]\&&.7<-/I=8NBH$^P3\*^\A)>X93
MJ;7K9GH& K+U^>RK=0\O[\!W2-"]#;'$15'DA@-,(8;:!*;V:/:1/GVQZWE=
MK-C""#[(I^W3,)K C![%/M(';^!Z06_YML1%84"=@1M/8@A-8$(/LH_T::O/
MLTMPUUD_#NN[4OT:L&:P3+YS5SP"?L1RM^OVBM</:MW_M?T9.!,8SJ/8!VN,
MHEJ=Q,N%VGD:QA.8\>/P2/J0MZ\+_3AP73 4)S#%;X_FX#-NJ8'U_$1J[9\T
M37- G1^%@_2D_<.IU-IU,_T#A7\T>#8'8=TC)O8)A-JYFQZ PCW :)+".L?D
M^G*A=JX'O_G#7<,H&L,:Q^3Y<J%VGJ;KH'#7,<AS>-PQN;U<J)V;Z57H=WY-
M&-$0P!+'I/ERH7::IN^A<-\SJJ^ -8[)\^5"[3Q-_T3A_FE<7P&+')/HJ1JH
MZ<$3WH1GF_+!=X[*!;1Z*-KL;1ZN7Y2/E#O[+_'95?6(W,A43^QO6;81::[+
MLM:2SMM 7XQ9]1"\VE!R5SY'7DBE9%)^W'*VXED1H+]?2ZF>-HH#-/^*,/\/
M4$L#!!0    ( )([=5CG&NT:Q0,   \6   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;+68;6_;-A#'OPJA D4+M-%C9#FU!311M@58MB!!MA?%7C#2
MV18JD1Y)V^FW'RG)DA4KG.TR>1'KX>ZGN[]XTNDF&\J^\P6 0,]E0?C46@BQ
MO+!MGBZ@Q/R,+H'(,S/*2BSD+IO;?,D 9Y536=B>XX1VB7-BQ9/JV!V+)W0E
MBIS '4-\59:8_;B$@FZFEFMM#]SG\X50!^QXLL1S> #QN+QC<L]N*5E> N$Y
M)8C!;&I]=2\2=Z0<*HN_<MCPG6VD4GFB]+O:N<FFEJ,B@@)2H1!8_JSA"HI"
MD60<_S90J[VF<MS=WM)_J9*7R3QA#E>T^#O/Q&)J11;*8(97A;BGF]^@2>A<
M\5):\.H_VM2V06"A=,4%+1MG&4&9D_H7/S="[#BXX2L.7N/@O71X[0I^X^ ?
MZA T#D&E3)U*I4."!8XGC&X04]:2IC8J,2MOF7Y.U'U_$$R>S:6?B/\4"V#H
MAM0K2-V)#PD(G!?\(_J,KA_OT8?W[R(_#+Y\G-A"7E"YV6D#OZSAWBMPUT.W
ME(@%1]<D@ZP/L&6D;;C>-MQ+3TM,(#U#OOL)>8[G#P1T=;B[-^">'.[N:K+Q
M6_']BN>?(/ZWWZ4QNA%0\G^&E*_)P3!9/2TN^!*G,+7DXX #6X,5OW_GALZ7
M(=5,PA)#L)ZB0:MHH*/'][ &L@(^I%CM&5:>ZG&XCD/?B<83>[TKA98_'#T:
M4N'G.3T!SEL!SK4"_"$74;IB#(A F',0@U+4C/,=*5QG%,A7Q4LU]@V#<12%
MCM>W2[1!G7C/PS;E4)ORKR"KA_Q WVZA? (V6"U:PK'58A*6&(+UE!NURHW>
M[/DS,JFH25AB"-93-&H5C0R47S10?J&C_EZ4W[YA,!ZP2[1!G9CRN$UYK$WY
MD>0",O0@L !M#6HQQZX8D[#$$*PGG^MT'9CS9E78H V):I26F*+U9=UI;%T#
MI=A ^K4X4(D'VB7ZH$Y-VNN2]K1)7S]#NE)?4MM*?&79:"E'+QN3M,04K:]@
MUY*[;]>3NT:;<J.TQ!2M+VO7E[OZQKQ;F+)7PW,H95E^0H22S]"=J5?LH++!
M7OE%@V6Z;S?XPM1'>ZH:79/N_F^7OI.W[J6I!QV]I$S2$E.TOHA=V^^&;U>I
M1C\(C-(24[2^K-TW@:MMD'^Z4D=[G]G#+]3#[!)]M,>J8>],RDI@\VKBR%%*
M5T344ZCV:#O5_%K-\EX<OU33SFH"UV'J4>DM9O.<<%3 3"*=LY&L$E9/'^L=
M09?5/.Z)"D'+:G,!. .F#.3Y&:5BNZ,NT,Z X_\ 4$L#!!0    ( )([=5@:
M(D10]@,  + 0   9    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;*U876_;
M-A3]*X0*%"VP1"+U126V@3KJNCYD"Y)U>QCV0%O7ME!)]"@Z3O[]2$F1+9E6
M74 OL4B=>WC/$7G!F\F>B^_E!D"BESPKRJFUD7)[8]OE<@,Y*Z_Y%@KU9L5%
MSJ0:BK5=;@6PI K*,YLX3F#G+"VLV:2:>Q"S"=_)+"W@0:!RE^=,O,XAX_NI
MA:VWB<=TO9%ZPIY-MFP-3R"_;1^$&MDM2Y+F4)0I+Y" U=3ZA&]B[.F "O%7
M"OORZ!EI*0O.O^O!UV1J.3HCR& I-053/\]P!UFFF50>_S6D5KNF#CQ^?F/_
MM1*OQ"Q8"7<\^SM-Y&9J40LEL&*[3#[R_6_0"/(UWY)G9?47[1NL8Z'EKI0\
M;X)5!GE:U+_LI3'B*  '9P)($T#Z =Z9 +<)<"\-\)J RFJ[EE+Y$#/)9A/!
M]TAHM&+3#Y695;22GQ;ZNS])H=ZF*D[._I ;$.AK4>\@_24^Q"!9FI4?T15Z
M4MLLV66 ^ K=\5QMMK(&J;$*1%\$WVW?OZ,$A[<E^OP"RYW^C.B>%6K3J.TA
M%<GG;X_H@P*Y@7?[<6)+E;5>VUXV&<[K#,F9##%!][R0&\5?))!T"6PEM]5,
MWC3/R2!C#,MKY.)?$'&(:TCH[O)P8@B/+P_' VK<]@NZ%9][AN_@>MZZ;G*Y
M9O',++J\W)1;MH2II>I'">(9K-G[=SAP;DT.C4D6CT36<<]KW?.&V&=_<LFR
MSMXV>5=S!!6'KJ3/,Y]20BB=V,_'MISBU*['.'"[N/@4%T3$Q]1I<1TQ?BO&
M'Q1C/(#_W$.^ /&O2=<@W<_NB3')XI'(.C8&K8W!*"<J&-.],<GBD<@Z[H6M
M>^'@)GS:<"&O)(@<0;[-^"L 6D !JU26)A=K-O_H+)!0G9K0[YTM$R[T/-K#
MQ08<Q6$8$?/9HJTL^@-93,"5OF(D:,M>]9XPRJ&GR_M.Z/F]$G!WBO.H0YW(
MZ\DYQ;FN%Q+'-<N)6CG1C^N>*?_H9#V?1!B3?JD[Q84^)7X8]?(_Q04X\*+(
M-^>/G</%Q1E4\#LOKJ ]J7/.1**O)7$JU)62BW*P\ US_^S9'94M'HNMZ^O1
MA1"/4OT:FK$L'),M'HNM:R$Y6$A&+8$-7>>0.WY$^S7#@",>#4F_!)IP(5;0
M,V?N<-7$@W>QBXM@0],MPKZJPGU!ISA5;:C?+R(&G$=IY(9G!!UN?_B"ZY]1
M@>'*I\I@X/05G.+"D/JT7\9-N,#!M%\&[:-6+@>QKEKB$BWYKI!UA]/.MFWW
MIZK9[,W/=3M>M8@'FKJ7OV=BG18ERF"E*)WK4-DJZO:X'DB^K1K&!9>J_:P>
M-\ 2$!J@WJ\XEV\#O4#[3XK9_U!+ P04    " "2.W58,%<ECL,#  "+'0
M#0   'AL+W-T>6QE<RYX;6S=6=U.VS 4?I4HP 321)ID39K15MHJ(4W:)B2X
MV!UR&Z>UY/S,=5F[RSW/GFI/,I\X37_P*8&+T:P5Q/;)]YWO'!_;)/3G<L7I
M[8Q2:2U3GLT']DS*XKWCS"<SFI+Y95[03%F27*1$JJZ8.O-"4!+/ 91RQ^MT
M B<E++.'_6R17J=R;DWR128'MAO48Y:^?(IA])UM:;Y1'M.!?7_^YOLBEU=_
M?OVV=.OD[<E)Y_[BZK'EO#1=V(Z1N-N(^+)SB%M9,?J@(?U!=HP\W"4O[SY3
M3!IWAL%Z!I@*88.$#@:.FN;KB81A086=Q@Z>\H"Z<,T)Z&PG  5["'@7C<)]
M<WBG2!F?-BGB$%D=IW@)GS8LX+!K#'<K5@R(5/Z^IL.J<%UA(_H#W!AQKZ'N
M@[(Q\@@IGIVU5RT^I]H:A_TDSS8[I&_K <5/4FH]$#ZP1X2SL6" 2DC*^$H/
M>S PR7DN+*FV9N70A9'Y3VUV=0]V[8HG95DN2M_:@_X]KF[?,ZQ[()!Q7@OT
M;#TP[!=$2BJR:]4I;RX''YFLJGVW*I3"J2 KU^O:&T!Y44[&N8BIV)P4]GIH
MV.<T 3F"36=PE7GA@%'*/%6-F)%IGI%2PQI1-13MA')^"T?:MV2'>YELS5RY
M*65U4PFJFII&=X!_FTUS;]%Z_HMXK8(]Y/+C0H63E7TH-GHC:,*697^9U (P
M=A=G)T7!5Q\XFV8IU<$W=CCLDS7.FN6"_53>H%0F:H *VWJ@0K+)]L@/08H[
MNI3K<EHFN&:OA9K_;9ZG-*."\&W1JO:/.<LO5NR'KR6YW%7V!1LU5G^F'KO(
M;AM$!FT0V8J:[!V_2#\Z?HW5H\^1BPQ?;6=_CDBW#2*]-HCTVR"R#:=BV(93
M,6S#J1BVX50,6W J5J\+CDZD4SW6;CT[[SPYUZ,6O*$8V%_AC0??.+7&"\8E
MRZK>C,4QS1X]0"MZ2<:<[O*K^V.:D 67=[5Q8&_:7VC,%FE4WW4#B:CNVK0_
M0WAN4+\>4;Y8%M,EC4=55TS'9=-2#>6U^@!@WW)=?LP6#*-M9@O8,#^8 @RC
M49B?_RF>'AJ/MF':>D9+#\7T4(Q&F2RC\HOY,6,B]3%'&D6^'P181D<CHX(1
MEK<@@!\S&Z8-$)@?\/2\7..SC5?(X3K YO10A6"1XI6(18KG&BSFO $BBLRS
MC?D!!#8+6.V ?[,?J"DSQO=A5C%MV K&+5&$6: 6S34:!$AV OB:YP=;);X?
M168+V,P*?!^SP&K$+9@"T(!9?+\\!_?.(V=]3CF;?[\._P)02P,$%     @
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MY_\GU>5\;[H^_K+\/CEZ>R\X!_B3X/$+4$L#!!0    ( )([=5@A7:<FS0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " "2.W58"W_\2N\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "2.W58
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( )([=5CG8JR#WP8   <@   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "2.W58
MNXPQ,E4&  #Y&@  &               @($C#P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ DCMU6-PPP*V+ @  KP8  !@
M     ("!KA4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M )([=5CC9-<(9P8  "H=   8              " @6\8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " "2.W58YS9?1;0)  ":5@  &
M            @($,'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ DCMU6"!B*?@G"   +B0  !@              ("!]B@  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )([=5@*8G,@[ 4  /T,
M   8              " @5,Q  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " "2.W58)Z!Z+^0J  "#A@  &               @(%U-P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ DCMU6&7^4OF/
M%P  YD$  !@              ("!CV(  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( )([=5@VS*'O 2<  $5R   9              "
M@51Z  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ DCMU
M6."4WD=X!0  ,@T  !D              ("!C*$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " "2.W58PWDZM%,(  !<$P  &0
M        @($[IP  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( )([=5@ .\FW&P(   \%   9              " @<6O  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ DCMU6%<%1,2O+0  PM
M !D              ("!%[(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " "2.W58<7C:L$P#   "!P  &0              @(']WP
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )([=5CA._T:
M*@X  #0L   9              " @8#C  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ DCMU6%<%.^H!$   C#   !D
M ("!X?$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "2
M.W580+?0)*P#  "Q"0  &0              @($9 @$ >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( )([=5@98^%)/ ,   4'   9
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M970R,RYX;6Q02P$"% ,4    " "2.W58)G_/;: "   &"   &0
M    @('-(@$ >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M )([=5@]%B9J100  .\;   9              " @:0E 0!X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ DCMU6%C1N21+!0  GR(  !D
M             ("!("H! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " "2.W58$;W$73\%  "X(@  &0              @(&B+P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( )([=5CQPU^U] (
M (D(   9              " @1@U 0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ DCMU6!J)LSHK!   AQ8  !D              ("!
M0S@! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "2.W58
MC(7W-^L#  !E#0  &0              @(&E/ $ >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( )([=5C%E__Q6@0  "89   9
M      " @<=  0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ DCMU6#*\<Q60!   D!<  !D              ("!6$4! 'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "2.W589[L/1Y(&  "@*@
M&0              @($?2@$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( )([=5A?4.7!K!D  +>. 0 9              " @>A0 0!X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ DCMU6"BYO\ 3
M$P  3.T  !D              ("!RVH! 'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " "2.W58%I.=!N &  ! ,P  &0
M@($5?@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )([
M=5A (* P> 8  &PJ   9              " @2R% 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ DCMU6+(XD>BP!@  RC   !D
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M=#0R+GAM;%!+ 0(4 Q0    ( )([=5AS%_]94P0  /(-   9
M  " @>V@ 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
MDCMU6*@7$ECJ @  @ @  !D              ("!=Z4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " "2.W58O^=\)+D#  #V$0  &0
M            @(&8J $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( )([=5B:!R*+_P(  %T(   9              " @8BL 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ DCMU6(<0O:<-!
MA \  !D              ("!OJ\! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " "2.W58XV-5@EP#  #D"   &0              @($"
MM $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )([=5C[
MIQ$A,@,  (T*   9              " @96W 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ DCMU6"6!M*$? P  Q @  !D
M     ("!_KH! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )([=5@P5R6.PP,  (L=   -              "
M 9S/ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ DCMU6)>*NQS     $P(
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9>&UL4$L%!@     ^ #X Z1   (7< 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>332</ContextCount>
  <ElementCount>401</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>90</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/CorporateInformation</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/MaterialAccountingPolicies</Role>
      <ShortName>Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Notes to the Consolidated Statements of Financial Position</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Other Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherInformation</Role>
      <ShortName>Other Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Significant Events After the Reporting Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate</Role>
      <ShortName>Significant Events After the Reporting Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/MaterialAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Corporate Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/CorporateInformationTables</Role>
      <ShortName>Corporate Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/CorporateInformation</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Notes to the Consolidated Statements of Financial Position (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/Commitments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Other Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherInformationTables</Role>
      <ShortName>Other Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherInformation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable</Role>
      <ShortName>Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/CorporateInformationTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Material Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails</Role>
      <ShortName>Material Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofRevenuesTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Cost of sales</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofCostofsalesTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Cost of sales</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Other Income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Net Financial Result</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Net Financial Result</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Lease Liabilities</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Amounts Recognized in Profit or Loss</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Amounts Recognized in Profit or Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Inventory</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Other Assets</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Other Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Financial Assets and Liabilities</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Trade and Other Payables</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Trade and Other Payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash, Cash Equivalents and Financial Assets</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash, Cash Equivalents and Financial Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Outstanding Financial Commitments</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable</Role>
      <ShortName>Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Outstanding Financial Commitments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/CommitmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable</Role>
      <ShortName>Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/CommitmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherInformationDetails</Role>
      <ShortName>Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0202038-20f_inflarx.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Other Information (Details) - Schedule of Compensation of the Group???s Executive Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable</Role>
      <ShortName>Other Information (Details) - Schedule of Compensation of the Group???s Executive Management</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressPostalZipCode, ifrs-full:DilutedEarningsLossPerShare -  ea0202038-20f_inflarx.htm 22495, 22496, 22497, 22650, 22651</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: ifrx:NumberOfOpionsExercisedDuring -  ea0202038-20f_inflarx.htm 22564</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" original="ea0202038-20f_inflarx.htm">ea0202038-20f_inflarx.htm</File>
    <File>ifrx-20231231.xsd</File>
    <File>ifrx-20231231_cal.xml</File>
    <File>ifrx-20231231_def.xml</File>
    <File>ifrx-20231231_lab.xml</File>
    <File>ifrx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="44">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="780">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>82
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0202038-20f_inflarx.htm": {
   "nsprefix": "ifrx",
   "nsuri": "http://www.inflarx.de.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "ea0202038-20f_inflarx.htm"
     ]
    },
    "schema": {
     "local": [
      "ifrx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ifrx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ifrx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ifrx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ifrx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 258,
   "keyCustom": 143,
   "axisStandard": 17,
   "axisCustom": 3,
   "memberStandard": 19,
   "memberCustom": 64,
   "hidden": {
    "total": 169,
    "http://www.inflarx.de.com/20231231": 52,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 112,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 332,
   "entityCount": 1,
   "segmentCount": 90,
   "elementCount": 630,
   "unitCount": 6,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 780,
    "http://xbrl.sec.gov/dei/2023": 44
   },
   "report": {
    "R1": {
     "role": "http://www.inflarx.de.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
     "longName": "001 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:GrossProfit",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "002 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
     "longName": "003 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inflarx.de.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Consolidated Statements of Changes in Shareholders' Equity",
     "shortName": "Consolidated Statements of Changes in Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "ifrs-full:Equity",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedCashFlow",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:AdjustmentsForDepreciationExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inflarx.de.com/role/CorporateInformation",
     "longName": "006 - Disclosure - Corporate Information",
     "shortName": "Corporate Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfCorporateInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfCorporateInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inflarx.de.com/role/MaterialAccountingPolicies",
     "longName": "007 - Disclosure - Material Accounting Policies",
     "shortName": "Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "008 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition",
     "longName": "009 - Disclosure - Notes to the Consolidated Statements of Financial Position",
     "shortName": "Notes to the Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inflarx.de.com/role/Commitments",
     "longName": "010 - Disclosure - Commitments",
     "shortName": "Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inflarx.de.com/role/OtherInformation",
     "longName": "011 - Disclosure - Other Information",
     "shortName": "Other Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate",
     "longName": "012 - Disclosure - Significant Events After the Reporting Date",
     "shortName": "Significant Events After the Reporting Date",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inflarx.de.com/role/CorporateInformationTables",
     "longName": "996001 - Disclosure - Corporate Information (Tables)",
     "shortName": "Corporate Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrx:DisclosureOfCorporateInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrx:DisclosureOfCorporateInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables",
     "longName": "996002 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Tables)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables",
     "longName": "996003 - Disclosure - Notes to the Consolidated Statements of Financial Position (Tables)",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inflarx.de.com/role/CommitmentsTables",
     "longName": "996004 - Disclosure - Commitments (Tables)",
     "shortName": "Commitments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inflarx.de.com/role/OtherInformationTables",
     "longName": "996005 - Disclosure - Other Information (Tables)",
     "shortName": "Other Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable",
     "longName": "996006 - Disclosure - Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares",
     "shortName": "Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c50",
      "name": "ifrs-full:CountryOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrx:DisclosureOfCorporateInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c50",
      "name": "ifrs-full:CountryOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrx:DisclosureOfCorporateInformationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
     "longName": "996007 - Disclosure - Material Accounting Policies (Details)",
     "shortName": "Material Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c54",
      "name": "ifrs-full:GovernmentGrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c54",
      "name": "ifrs-full:GovernmentGrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
     "longName": "996008 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details)",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:SellingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inflarx.de.com/role/ScheduleofRevenuesTable",
     "longName": "996009 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Revenues",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://www.inflarx.de.com/role/ScheduleofCostofsalesTable",
     "longName": "996010 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Cost of sales",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Cost of sales",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable",
     "longName": "996011 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c77",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996012 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c91",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996013 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:GeneralAndAdministrativeExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c80",
      "name": "ifrs-full:GeneralAndAdministrativeExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable",
     "longName": "996014 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Other Income",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Other Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable",
     "longName": "996015 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:Employeebenefitsexpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:Employeebenefitsexpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable",
     "longName": "996016 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Net Financial Result",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Net Financial Result",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:RevenueFromInterest",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable",
     "longName": "996017 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c122",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c124",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable",
     "longName": "996018 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c133",
      "name": "ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c136",
      "name": "ifrx:NumberOfWeightedAverageSharesOutstanding",
      "unitRef": "eurPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
     "longName": "996019 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c144",
      "name": "ifrx:NumberOfOutstandingSharesOption",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c148",
      "name": "ifrx:NumberOfOutstandingsWeightedAverageEarningPershare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable",
     "longName": "996020 - Disclosure - Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:ShareOptionsGrantedOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c159",
      "name": "ifrx:FairValuePerOptions",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
     "longName": "996021 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details)",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:ResearchAndDevelopmentExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:ResearchAndDevelopmentExpenses",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996022 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrx:NetBookValuePropertyAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrx:NetBookValuePropertyAndEquipment",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable",
     "longName": "996023 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrx:NetBookValueOfRightOfUseAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrx:NetBookValueOfRightOfUseAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996024 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrx:NetBookValueIntangibleAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrx:NetBookValueIntangibleAsset",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable",
     "longName": "996025 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Lease Liabilities",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c37",
      "name": "ifrs-full:LeaseLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable",
     "longName": "996026 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Amounts Recognized in Profit or Loss",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Amounts Recognized in Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inflarx.de.com/role/ScheduleofInventoryTable",
     "longName": "996027 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Inventory",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable",
     "longName": "996028 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Other Assets",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Other Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:PrepaidExpense",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable",
     "longName": "996029 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:ProfitLossBeforeTax",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable",
     "longName": "996030 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Financial Assets and Liabilities",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:OtherNoncurrentFinancialAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable",
     "longName": "996031 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:Cash",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable",
     "longName": "996032 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Trade and Other Payables",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Trade and Other Payables",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable",
     "longName": "996033 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c296",
      "name": "ifrs-full:DescriptionOfExposureToRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c296",
      "name": "ifrs-full:DescriptionOfExposureToRisk",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable",
     "longName": "996034 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash, Cash Equivalents and Financial Assets",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash, Cash Equivalents and Financial Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable",
     "longName": "996035 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c299",
      "name": "ifrx:SensitivityAnalysisConversionRate",
      "unitRef": "eurPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c299",
      "name": "ifrx:SensitivityAnalysisConversionRate",
      "unitRef": "eurPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable",
     "longName": "996036 - Disclosure - Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Outstanding Financial Commitments",
     "shortName": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Outstanding Financial Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:BalancesWithBanks",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inflarx.de.com/role/CommitmentsDetails",
     "longName": "996037 - Disclosure - Commitments (Details)",
     "shortName": "Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c301",
      "name": "ifrx:ExchangeRate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c301",
      "name": "ifrx:ExchangeRate",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable",
     "longName": "996038 - Disclosure - Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities",
     "shortName": "Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inflarx.de.com/role/OtherInformationDetails",
     "longName": "996039 - Disclosure - Other Information (Details)",
     "shortName": "Other Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrs-full:Revenue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c315",
      "name": "ifrs-full:NoncurrentAssets",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable",
     "longName": "996040 - Disclosure - Other Information (Details) - Schedule of Compensation of the Group\u2019s Executive Management",
     "shortName": "Other Information (Details) - Schedule of Compensation of the Group\u2019s Executive Management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ifrx:TotalCompensation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ifrx:TotalCompensation",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0202038-20f_inflarx.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ifrx_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccruedIncomeIncludingContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccruedIncomeIncludingContractAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payment",
        "label": "Accrued income including contract assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets representing income that has been earned but is not yet a receivable, including contract assets. [Refer: Contract assets]"
       }
      }
     },
     "auth_ref": [
      "r228",
      "r229"
     ]
    },
    "ifrx_AccruedLiabilitiesFromCommercialActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AccruedLiabilitiesFromCommercialActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities from commercial activities",
        "documentation": "Amount of accrued liabilities from commercial activities.",
        "label": "Accrued Liabilities From Commercial Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AccumulatedAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AccumulatedAmortizationMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated amortization [Member]",
        "label": "Accumulated Amortization Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AccumulatedDepreciationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AccumulatedDepreciationAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation [Member]",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r234",
      "r238",
      "r240",
      "r241"
     ]
    },
    "ifrs-full_AdditionalProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additional provisions, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additional other provisions made. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AdjustmentsForAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AdjustmentsForAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for:",
        "label": "Adjustments For Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Adjustments for decrease (increase) in other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_AdjustmentsForFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net finance income",
        "label": "Adjustments for finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Adjustments for increase (decrease) in employee benefit liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrx_AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets from government grants",
        "documentation": "Amount of financial assets from government grants.",
        "label": "Adjustments For Increase Decrease In Financial Assets From Government Grantsin Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from government grants received",
        "documentation": "Amount of liabilities from government grants received.",
        "label": "Adjustments For Increase Decrease In Liabilities From Government Grant Received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Adjustments for increase (decrease) in other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment expense",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign exchange differences",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r193",
      "r245"
     ]
    },
    "ifrx_AdvancePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AdvancePaymentsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance payments [Member]",
        "label": "Advance Payments Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AdvancesPaidForSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AdvancesPaidForSoftwareMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances paid for software [Member]",
        "label": "Advances Paid For Software Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AfterOneYearButNotMoreThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AfterOneYearButNotMoreThanFiveYearsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one year but not more than five years [Member]",
        "label": "After One Year But Not More Than Five Years Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AggregateCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AggregateCommonShares",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate ordinary shares sold (in Shares)",
        "documentation": "Aggregate common shares.",
        "label": "Aggregate Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AggregateInitialOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AggregateInitialOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate public offering (in Dollars)",
        "documentation": "The amount of aggregate initial offering.",
        "label": "Aggregate Initial Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price (in Dollars)",
        "documentation": "The amount of aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r106",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r130",
      "r145",
      "r186",
      "r203",
      "r206"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization charge for the year",
        "label": "Amortisation, intangible assets other than goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrx_AmortizedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AmortizedPeriod",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized period",
        "documentation": "Amortized period.",
        "label": "Amortized Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_AnnualizedAverageSharePricePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AnnualizedAverageSharePricePeriod",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annualized average share price year",
        "documentation": "Annualized average share price period.",
        "label": "Annualized Average Share Price Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r101",
      "r102",
      "r103",
      "r166",
      "r169"
     ]
    },
    "ifrx_AssetsSoldUnderAgreementToRepurchaseCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AssetsSoldUnderAgreementToRepurchaseCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agreement amounts (in Dollars)",
        "documentation": "Carrying amount of assets sold under agreements to repurchase when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under repurchase agreements exceeds 10 percent of total assets.",
        "label": "Assets Sold Under Agreement To Repurchase Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable",
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Attribution of expenses by nature to their function [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r226"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ]
    },
    "ifrs-full_AverageEffectiveTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageEffectiveTaxRate",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average total tax rate",
        "label": "Average effective tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrx_AverageRate": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "AverageRate",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average rate",
        "documentation": "The value of average rate.",
        "label": "Average Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash at banks",
        "label": "Balances with banks"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share (basic/diluted) (in Euro per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bottom of range [Member]",
        "verboseLabel": "Bottom of Range [Member]",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r124",
      "r137",
      "r195",
      "r196",
      "r248"
     ]
    },
    "ifrs-full_BuildingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BuildingsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building [Member]",
        "label": "Buildings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217"
     ]
    },
    "ifrx_CapitalOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CapitalOrdinarySharesIssued",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital ordinary shares issued (in Shares)",
        "documentation": "The nominal number of capital arising from issuing ordinary shares.",
        "label": "Capital Ordinary Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CapitalizedLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CapitalizedLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized leases",
        "documentation": "The cash outflow for leases.",
        "label": "Capitalized Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash at banks",
        "label": "Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r84",
      "r97"
     ]
    },
    "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable": {
       "parentTag": "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents if different from statement of financial position"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrx_CashAtBanksAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CashAtBanksAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash at banks",
        "label": "Cash At Banks Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash from financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r85"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash from/ (used in) investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r85"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash flows from (used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r78",
      "r85"
     ]
    },
    "ifrx_CashHeldInUSDollarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CashHeldInUSDollarsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails",
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash held in U.S. dollars [Member]",
        "verboseLabel": "USD [Member]",
        "label": "Cash Held In USDollars Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CashHeldInUSEuroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CashHeldInUSEuroMember",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails",
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash held in U.S. Euro [Member]",
        "verboseLabel": "Euro [Member]",
        "label": "Cash Held In USEuro Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashOnHand": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOnHand",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received",
        "label": "Cash on hand"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash outflow for leases",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/OtherInformationDetails",
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable",
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrx_ChangesInAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ChangesInAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in:",
        "label": "Changes In Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r104",
      "r116"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r104",
      "r116"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r156",
      "r157"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r152",
      "r155",
      "r156",
      "r157"
     ]
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrx_CommitmentsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommitmentsDetailsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommitmentsDetailsScheduleofMaturityAnalysisofLeaseLiabilitiesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments (Details) - Schedule of Maturity Analysis of Lease Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CommitmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommitmentsDetailsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommonShares",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares over time (in Dollars)",
        "documentation": "Common shares.",
        "label": "Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CommonSharesInExcessOfNominalValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommonSharesInExcessOfNominalValue",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares in excess of nominal value (in Euro per share)",
        "label": "Common Shares In Excess Of Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CommonSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CommonSharesIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issued",
        "label": "Common Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CompanyIssuedCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CompanyIssuedCapital",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company issued capital",
        "label": "Company Issued Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CompensationExpenseForNonexecutiveBoardDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CompensationExpenseForNonexecutiveBoardDirectorsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense for non-executive directors [Member]",
        "label": "Compensation Expense For Nonexecutive Board Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "terseLabel": "Total comprehensive loss",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r27",
      "r87",
      "r89",
      "r95",
      "r194"
     ]
    },
    "ifrs-full_ComputerSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerSoftwareMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased IT-software [Member]",
        "label": "Computer software [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrx_ConsolidatedStatementsOfChangesInShareholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsOfChangesInShareholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements Of Changes In Shareholders Equity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofEmployeeBenefitsExpensesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Employee Benefits Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofGeneralandAdministrativeExpensesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of General and Administrative Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofResearchandDevelopmentExpensesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Research and Development Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSalesandMarketingExpensesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Sales and Marketing Expenses [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofShareBasedpaymentsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-Based payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedPaymentsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based Payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofSharebasedpaymentsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Share-based payments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsScheduleofWeightedAverageTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) - Schedule of Weighted Average [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossDetailsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossTablesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConsolidatedStatementsofOperationsandComprehensiveLossTablesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ConversionRate": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ConversionRate",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion rate",
        "documentation": "The value of conversion rates.",
        "label": "Conversion Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CorporateIncomeTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CorporateIncomeTax",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Income Tax",
        "documentation": "The amount of current income tax.",
        "label": "Corporate Income Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CorporateInformationDetailsScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Information (Details) - Schedule of Share Capital Consisting Solely of Ordinary Shares [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CostMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable",
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost [Member]",
        "label": "Cost Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ScheduleofCostofsalesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of Sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r34"
     ]
    },
    "ifrs-full_CountryOfIncorporation": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CountryOfIncorporation",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Place of business/country of incorporation",
        "label": "Country of incorporation"
       }
      },
      "en": {
       "role": {
        "documentation": "The country in which the entity is incorporated."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_CreditRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CreditRiskMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit risk [Member]",
        "verboseLabel": "Credit Risk [Member]",
        "label": "Credit risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r199"
     ]
    },
    "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CumulativeEffectAtDateOfInitialApplicationAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative effect at date of initial application [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities from R&amp;D projects",
        "label": "Current accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrx_CurrentAndNonCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CurrentAndNonCurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and non-current financial assets",
        "documentation": "The amount of current and non-current financial assets.",
        "label": "Current And Non Current Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable": {
       "parentTag": "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and non current financial assets (securities and accrued interest)",
        "documentation": "Current and non current financial assets.",
        "label": "Current And Non Current Financial Assetssecurities And Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r91",
      "r194"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets from government grants",
        "label": "Current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_CurrentFinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentFinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Current financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets measured at amortised cost. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from government grants",
        "verboseLabel": "Received grant amount",
        "label": "Current government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_CurrentInterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current income tax receivable",
        "label": "Current interest receivable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current interest receivable. [Refer: Interest receivable]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r93",
      "r194"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_CurrentOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "CurrentOtherAssetsAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current other assets",
        "label": "Current Other Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_CurrentProvisionsForEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentProvisionsForEmployeeBenefits",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Current provisions for employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions for employee benefits. [Refer: Provisions for employee benefits]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRawMaterialsAndCurrentProductionSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw material and supplies",
        "label": "Current raw materials and current production supplies"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]"
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax receivable",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrx_DEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DEMember",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany [Member]",
        "label": "DEMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DebtSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities (current and non-current)",
        "label": "Debt instruments issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of instruments issued by the entity that represent indebtedness."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_DecreaseThroughDerecognitionFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseThroughDerecognitionFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Derecognition",
        "label": "Decrease through derecognition, financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in financial assets resulting from derecognition. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r207"
     ]
    },
    "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term liability for accrued interest expense",
        "label": "Deferred tax expense (income) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DefinedBenefitPlansAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DefinedBenefitPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DefinedBenefitPlansMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plans [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrx_DepositsHeldInEuroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DepositsHeldInEuroMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits held in Euro [Member]",
        "label": "Deposits Held In Euro Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DepositsHeldInUSDollarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DepositsHeldInUSDollarsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits held in U.S. dollars [Member]",
        "label": "Deposits Held In USDollars Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense of right-of-use assets (see Note E.2.)",
        "label": "Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense, amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss. [Refer: Depreciation and amortisation expense; Impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrx_DepreciationAmortizationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DepreciationAmortizationExpenseMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation &amp; amortization expense [Member]",
        "label": "Depreciation Amortization Expense Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation charge for the year",
        "label": "Depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plant and equipment or patents and trademark",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r47"
     ]
    },
    "ifrx_DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current and non-current classification",
        "documentation": "Disclosure of significant accounting policies for description of accounting policy current and noncurrent classification explanatory.",
        "label": "Description Of Accounting Policy Current And Noncurrent Classification Explanatory Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits",
        "label": "Description of accounting policy for employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets and liabilities (financial instruments)",
        "label": "Description of accounting policy for financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transactions",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrx_DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants from government and similar bodies",
        "documentation": "Disclosure of significant accounting policies for description of accounting policy for grants from government.",
        "label": "Description Of Accounting Policy For Grants From Government Poilcy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of assets",
        "label": "Description of accounting policy for impairment of assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of assets."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax",
        "label": "Description of accounting policy for income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Description of accounting policy for intangible assets and goodwill [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for intangible assets and goodwill. [Refer: Intangible assets and goodwill]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Description of accounting policy for interest income and expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income and expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease arrangements",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrx_DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New standard not yet adopted",
        "documentation": "Disclosure of accounting policies for description of accounting policy new standards not yet adopted explanatory.",
        "label": "Description Of Accounting Policy New Standards Not Yet Adopted Explanatory Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "verboseLabel": "Volatility rates",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DescriptionOfExposureToRisk": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExposureToRisk",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exposure",
        "label": "Description of exposure to risk"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of exposures to risks arising from financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_DescriptionOfFunctionalCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfFunctionalCurrency",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional currency",
        "label": "Description of functional currency"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the currency of the primary economic environment in which the entity operates."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "ifrs-full_DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk Management",
        "label": "Description of how entity reflects its risk management strategy by using hedge accounting and designating hedging relationships that it frequently resets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of how the entity reflects its risk management strategy by using hedge accounting and designating hedging relationships that it frequently resets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal activities",
        "label": "Description of nature of entity's operations and principal activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the nature of the entity's operations and principal activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfReasonsForFairValueMeasurementAssets",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement",
        "label": "Description of reasons for fair value measurement, assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the reasons for the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free rate (interpolated, U.S. sovereign strips curve)",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share diluted",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "ifrx_DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash, Cash Equivalents and Financial Assets",
        "documentation": "The disclosure of detailed information about cash and cash equivalent and financial assets.",
        "label": "Disclosure Cash Cash Equivalents And Financial Assets Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAuthorisationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAuthorisationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes to the consolidated statements of financial position",
        "label": "Disclosure of authorisation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the authorisation of financial statements for issue."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material accounting policies",
        "label": "Disclosure of changes in accounting policies [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of changes made to accounting policies by the entity."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/Commitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Financial Commitments",
        "label": "Disclosure of commitments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrx_DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Compensation of the Group\u2019s Executive Management",
        "documentation": "The disclosure of detailed information about compensation of group executive management.",
        "label": "Disclosure Of Compensation Of The Groups Executive Management Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated statements of operations and comprehensive loss",
        "documentation": "The entire disclosure of consolidated statement of operation and comprehensive loss.",
        "label": "Disclosure Of Consolidated Statements Of Operations And Comprehensive Loss Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations and Comprehensive Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisclosureOfCorporateInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfCorporateInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisclosureOfCorporateInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfCorporateInformationTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/CorporateInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate information",
        "label": "Disclosure Of Corporate Information Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCostOfSalesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCostOfSalesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cost of sales",
        "label": "Disclosure of cost of sales [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the cost of sales. [Refer: Cost of sales]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Disclosure of detailed information about intangible assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Benefits Expenses",
        "label": "Disclosure of employee benefits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_DisclosureOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities",
        "label": "Disclosure of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss",
        "label": "Disclosure of financial instruments at fair value through profit or loss [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial instruments measured at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amounts Recognized in Profit or Loss",
        "label": "Disclosure of financial instruments designated at fair value through profit or loss [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial instruments designated at fair value through profit or loss. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralAndAdministrativeExpenseExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "label": "Disclosure of general and administrative expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of general and administrative expenses. [Refer: Administrative expenses]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other information",
        "label": "Disclosure of information about methods, inputs and assumptions used for measuring obligations for returns, refunds and other similar obligations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about the methods, inputs and assumptions used for measuring obligations for returns, refunds and other similar obligations in contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInventoriesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Disclosure of inventories [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_DisclosureOfLeasePrepaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasePrepaymentsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Liabilities",
        "label": "Disclosure of lease prepayments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of lease prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfMarketRiskExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMarketRiskExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Market Risk, Credit Risk and Liquidity Risk",
        "label": "Disclosure of market risk [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of market risk. [Refer: Market risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity Analysis of Lease Liabilities",
        "label": "Disclosure of maturity analysis of operating lease payments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrx_DisclosureOfNetFinancialResultTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfNetFinancialResultTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Financial Result",
        "documentation": "The disclosure of net financial result text block.",
        "label": "Disclosure Of Net Financial Result Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New and amended standards adopted by the Group",
        "label": "Disclosure Of New And Amended Standards Adopted By The Group Explanatory Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant events after the reporting date [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/SignificantEventsAftertheReportingDate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant events after the reporting date",
        "label": "Disclosure of non-adjusting events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of non-adjusting events after the reporting period. [Refer: Non-adjusting events after reporting period [member]]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based payments",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Assets",
        "label": "Disclosure of other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrx_DisclosureOfOtherIncomeExplanatoryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfOtherIncomeExplanatoryTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Income",
        "documentation": "The disclosure of detailed information about other income.",
        "label": "Disclosure Of Other Income Explanatory Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Right-of-Use Assets",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "label": "Disclosure of research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfRestrictedCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRestrictedCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Cash and Cash Equivalents",
        "label": "Disclosure of restricted cash and cash equivalents [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrx_DisclosureOfSalesAndMarketingExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfSalesAndMarketingExpenseTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sales and Marketing Expenses",
        "documentation": "The disclosure of detailed information about sales and marketing expenses.",
        "label": "Disclosure Of Sales And Marketing Expense Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sensitivity Analysis",
        "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrx_DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/CorporateInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital Consisting Solely of Ordinary Shares",
        "documentation": "The disclosure of detailed information of share capital consisting of ordinary shares.",
        "label": "Disclosure Of Share Capital Consisting Solely Of Ordinary Shares Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based payments",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrx_DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant accounting judgements, estimates and assumptions",
        "documentation": "Disclosure of significant accounting judgements estimates and assumptions.",
        "label": "Disclosure Of Significant Accounting Judgements Estimates And Assumptions Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of material accounting policies",
        "label": "Disclosure Of Summary Of Material Accounting Policies Explanatory Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Trade and Other Payables",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrx_DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Disposals",
        "documentation": "Disposal amount of property plant and equipment.",
        "label": "Disposals And Retirement Intangible Assets Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DisposalsAndRetirementPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DisposalsAndRetirementPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals",
        "documentation": "Disposals of property plant and equipment.",
        "label": "Disposals And Retirement Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DividendsPaidOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share purchase",
        "label": "Dividends paid, ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends paid by the entity on ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_DividendsPaidOrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DividendsPaidOrdinarySharesPerShare",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Dividends paid, ordinary shares per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of dividends paid per ordinary share."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrx_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_DueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "DueAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due amount",
        "documentation": "Amount of due amount.",
        "label": "Due Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_EffectOfDiscounting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "EffectOfDiscounting",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of discounting",
        "documentation": "Effect of discounting.",
        "label": "Effect Of Discounting"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "ifrx_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.",
        "label": "Effective Income Tax Rate Reconciliation Tax Settlements State And Local Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate Percent"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r34",
      "r177"
     ]
    },
    "ifrx_EmployeeBenefitsExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "EmployeeBenefitsExpensesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits expenses [Member]",
        "label": "Employee Benefits Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_Employeebenefitsexpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "Employeebenefitsexpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits expenses",
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.",
        "label": "Employeebenefitsexpense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r141"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/OtherInformationDetails",
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r21",
      "r86",
      "r88",
      "r101",
      "r102",
      "r103"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL EQUITY AND LIABILITIES",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other components of equity",
        "label": "Equity attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParentMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other components of equity",
        "label": "Equity attributable to owners of parent [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrx_EquitysettledSharebasedPaymentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "EquitysettledSharebasedPaymentExpenseMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "equity-settled share-based payment expense [Member]",
        "verboseLabel": "Equity-settled share-based payment expense [Member]",
        "label": "Equitysettled Sharebased Payment Expense Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_EquitysettledSharebasedPaymentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "EquitysettledSharebasedPaymentExpensesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-settled share-based payment expenses [Member]",
        "label": "Equitysettled Sharebased Payment Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExchangeRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExchangeRate",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted with the exchange rate",
        "documentation": "Exchange Rate",
        "label": "Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExchangeRateCurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExchangeRateCurrencyAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Rate Currency [Axis]",
        "label": "Exchange Rate Currency Axis"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExchangeRateCurrencyDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExchangeRateCurrencyDomainDomain",
     "presentation": [
      "http://www.inflarx.de.com/role/CommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExchangeRateCurrencyDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExchangeRateFluctuations": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExchangeRateFluctuations",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange rate fluctuations (in Euro per share)",
        "label": "Exchange Rate Fluctuations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExecutiveManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExecutiveManagementAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive management",
        "label": "Executive Management Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExecutiveManagementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExecutiveManagementMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Management [Member]",
        "label": "Executive Management Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExecutiveMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExecutiveMembersMember",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive [Members]",
        "label": "Executive Members Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExercisePriceOfOutstandingShareOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExercisePriceOfOutstandingShareOptions",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price for options outstanding",
        "documentation": "The exercise price of outstanding share options.",
        "label": "Exercise Price Of Outstanding Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExercisePriceRange": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExercisePriceRange",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price range",
        "documentation": "Exercise price range.",
        "label": "Exercise Price Range"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ExpectedDividends": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExpectedDividends",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividends",
        "documentation": "The number of expected dividends.",
        "label": "Expected Dividends"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedReimbursementOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedReimbursementOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimburse expenses",
        "label": "Expected reimbursement, other provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount expected to be reimbursed by another party on expenditures to settle other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrx_ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Low value leases",
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets.",
        "label": "Expense Relating To Leases Of Lowvalue Asset For Which Recognition Exemption Has Been Used"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereof short-term leases (included in administrative expenses)",
        "label": "Expense relating to leases of low-value assets for which recognition exemption has been used"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to leases of low-value assets accounted for applying paragraph 6 of IFRS 16. This expense shall not include the expense relating to short-term leases of low-value assets."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereof leases of low-value assets (included in administrative expenses)",
        "label": "Expense relating to variable lease payments not included in measurement of lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to variable lease payments not included in the measurement of lease liabilities. Variable lease payments are the portion of payments made by a lessee to a lessor for the right to use an underlying asset during the lease term that varies because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrx_FairValuePerOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "FairValuePerOptions",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per option",
        "documentation": "The fair value option per share.",
        "label": "Fair Value Per Options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_FairValuesPerOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "FairValuesPerOptions",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value per option\t(in Euro per share)",
        "documentation": "The fair value per option.",
        "label": "Fair Values Per Options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial result",
        "label": "Finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r148",
      "r152",
      "r153",
      "r156",
      "r202"
     ]
    },
    "ifrx_FinancialAssetsFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "FinancialAssetsFromGovernmentGrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets from government grants",
        "documentation": "Amount of financial assets from government grants.",
        "label": "Financial Assets From Government Grants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_FinancialAssetsFromGovernmentGrantsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "FinancialAssetsFromGovernmentGrantsAmount",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets from government grants amount",
        "documentation": "The amount of financial assets from government grants amount.",
        "label": "Financial Assets From Government Grants Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialAssetsHeldForManagingLiquidityRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsHeldForManagingLiquidityRisk",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashCashEquivalentsandFinancialAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets exposed to the risk",
        "label": "Financial assets held for managing liquidity risk"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets held for managing liquidity risk (for example, financial assets that are readily saleable or expected to generate cash inflows to meet cash outflows on financial liabilities). [Refer: Liquidity risk [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrx_FinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "FinancingActivitiesAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Financing Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Current finished goods"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r236"
     ]
    },
    "ifrx_FixedInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "FixedInterest",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal fixed interest",
        "documentation": "Fixed Interest",
        "label": "Fixed Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ForeignExchangeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ForeignExchangeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Foreign exchange expense",
        "documentation": "The amount of foreign exchange expense.",
        "label": "Foreign Exchange Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on foreign exchange",
        "label": "Foreign exchange gain"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56"
     ]
    },
    "ifrx_ForeignExchangeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ForeignExchangeIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange income",
        "documentation": "The amount of foreign exchange loss.",
        "label": "Foreign Exchange Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ForeignExchangeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ForeignExchangeLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on foreign exchange",
        "label": "Foreign exchange loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56"
     ]
    },
    "ifrx_ForeignExchangeRateAsOfGrantDate": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ForeignExchangeRateAsOfGrantDate",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FX rate as of grant date",
        "documentation": "The foreign exchange rate as grant date.",
        "label": "Foreign Exchange Rate As Of Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ForeignExchangeResult": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ForeignExchangeResult",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange result",
        "documentation": "The amount of foreign exchange result.",
        "label": "Foreign Exchange Result"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total tax loss carryforwards",
        "label": "Gains (losses) on change in value of forward elements of forward contracts, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on change in value of forward elements of forward contracts, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrx_GainsLossesOnExchangeDifferenceOnTranslationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "GainsLossesOnExchangeDifferenceOnTranslationNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange difference",
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]",
        "label": "Gains Losses On Exchange Difference On Translation Net Of Tax"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange on translation",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on translation of foreign currency",
        "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange result",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56"
     ]
    },
    "ifrs-full_GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total amounts recognized in profit or loss",
        "label": "Gains (losses) on financial assets at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on financial assets at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "General and administrative expenses",
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrx_GermanMinistryOfEducationAndResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "GermanMinistryOfEducationAndResearchMember",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "German Ministry of Education and Research [Member]",
        "label": "German Ministry Of Education And Research Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GovernmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "German federal government",
        "label": "Government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual minimum lease obligations",
        "label": "Gross lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r204"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location Axis"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_IncomeStatementLocationDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IncomeStatementLocationDomainDomain",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IncomeStatementLocationDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "verboseLabel": "Income tax",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r30",
      "r36",
      "r37",
      "r38",
      "r62",
      "r100",
      "r165"
     ]
    },
    "ifrs-full_IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit loss",
        "label": "Increase (decrease) in allowance account for credit losses of financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the allowance account used to record the impairment of financial assets due to credit losses. [Refer: Financial assets; Allowance account for credit losses of financial assets]"
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-settled share-based payments (in Shares)",
        "verboseLabel": "Ordinary shares issued (in Shares)",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options exercised",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrx_IncreaseDecreaseThroughExerciseOfOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IncreaseDecreaseThroughExerciseOfOptionsShares",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share options exercised (in Shares)",
        "documentation": "Share options exercised.",
        "label": "Increase Decrease Through Exercise Of Options Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences",
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]",
        "label": "Increase Decrease Through Net Exchange Difference Intangible Asset Other Than Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences",
        "documentation": "The increase (decrease) in other provisions resulting from foreign currency exchange rate changes on provisions measured in a currency different from the entity's presentation currency. [Refer: Other provisions]",
        "label": "Increase Decrease Through Net Exchange Difference Other Provisions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences",
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-settled share-based payments",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrx_InflaRxGmbHMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "InflaRxGmbHMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InflaRx GmbH [Member]",
        "label": "Infla Rx Gmb HMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_InflaRxPharmaceuticalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "InflaRxPharmaceuticalIncMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InflaRx Pharmaceuticals, Inc. [Member]",
        "label": "Infla Rx Pharmaceutical Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_InsuranceExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "InsuranceExpensesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expenses [Member]",
        "label": "Insurance Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_IntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "negatedPeriodEndLabel": "Balance ending",
        "documentation": "The amount of intangible assets for which fair value was used as their deemed cost in the opening IFRS statement of financial position. [Refer: Intangible assets other than goodwill]",
        "label": "Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsAcquiredByWayOfGovernmentGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAcquiredByWayOfGovernmentGrant",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant payment received",
        "label": "Intangible assets acquired by way of government grant"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets acquired through government grants. [Refer: Government grants; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Intangible assets and goodwill"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwillMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "ifrs-full_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expenses",
        "label": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r164",
      "r171"
     ]
    },
    "ifrs-full_InterestExpenseOnBonds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnBonds",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on lease liabilities",
        "label": "Interest expense on bonds"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on bonds issued. [Refer: Interest expense; Bonds issued]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_InterestIncomeOnDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnDeposits",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income increased",
        "label": "Interest income on deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on deposits. [Refer: Interest income]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_InterestIncomeOnImpairedFinancialAssetsAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnImpairedFinancialAssetsAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive management, non-executive members",
        "label": "Interest income on impaired financial assets accrued"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest on impaired financial assets accrued after impairment using the rate of interest used to discount the future cash flows for the purpose of measuring the impairment loss. [Refer: Interest income]"
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest received",
        "label": "Interest received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r53",
      "r180"
     ]
    },
    "ifrs-full_InventoriesTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoriesTotal",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_InventoryWritedown2011": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InventoryWritedown2011",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-downs",
        "label": "Inventory write-down"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r54"
     ]
    },
    "ifrx_InvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "InvestingActivitiesAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Investing Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_IssuanceOfCommonShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "IssuanceOfCommonShare",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (in Shares)",
        "documentation": "Issuance of common shares.",
        "label": "Issuance Of Common Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrx_January12Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "January12Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 12 [Member]",
        "label": "January12 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_January12OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "January12OneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 12 [Member]",
        "label": "January12 One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_January4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "January4Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 4 [Member]",
        "label": "January4 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_January4OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "January4OneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 4 [Member]",
        "label": "January4 One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_JanuaryTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "JanuaryTwentyFourMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 24 [Member]",
        "label": "January Twenty Four Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_JanuaryTwentyFourOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "JanuaryTwentyFourOneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 24 [Member]",
        "label": "January Twenty Four One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_July2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "July2Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2 [Member]",
        "label": "July2 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_July2OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "July2OneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2 [Member]",
        "label": "July2 One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_JulyNineteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "JulyNineteenMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 19 [Member]",
        "label": "July Nineteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_JulySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "JulySevenMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 7 [Member]",
        "label": "July Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_JulySevenOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "JulySevenOneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 7 [Member]",
        "label": "July Seven One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term leases",
        "label": "Lease commitments for short-term leases for which recognition exemption has been used"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the lease commitments for short-term leases accounted for applying paragraph 6 of IFRS 16. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "As of January 1",
        "periodEndLabel": "As of December 31",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrx_LegalAndConsultingFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LegalAndConsultingFeesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and consulting fees [Member]",
        "label": "Legal And Consulting Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r101",
      "r102",
      "r103",
      "r166",
      "r170"
     ]
    },
    "ifrx_LiabilitiesFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LiabilitiesFromGovernmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities from government grants",
        "documentation": "Amount of liabilities from government grants.",
        "label": "Liabilities From Government Grants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LiabilityForFuturePolicyBenefitPeriodExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LiabilityForFuturePolicyBenefitPeriodExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable": {
       "parentTag": "ifrs-full_OtherFinanceIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Further other income",
        "documentation": "Amount of expense (income) recognized due to changes in the accrued obligation to policyholders that relates to insured events.",
        "label": "Liability For Future Policy Benefit Period Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LineItemsByFunctionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LineItemsByFunctionMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable",
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line items by function [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r226"
     ]
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity [Member]",
        "label": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r199"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LocationAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Location [Axis]",
        "label": "Location Axis"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LocationDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LocationDomainDomain",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LocationDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LongTermIncentivePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LongTermIncentivePlan2016Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan [Member]",
        "label": "Long Term Incentive Plan2016 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LongTermIncentivePlan2017Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LongTermIncentivePlan2017Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables",
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "verboseLabel": "Long-Term Incentive Plan 2017 [Member]",
        "netLabel": "2017 [Member]",
        "label": "Long Term Incentive Plan2017 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_LossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "LossPerShare",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "documentation": "The number of loss per share.",
        "label": "Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ManufacturingOfClinicalMaterialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ManufacturingOfClinicalMaterialMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical material and related manufacturing services [Member]",
        "label": "Manufacturing Of Clinical Material Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_MarketProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MarketProgramMember",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Program [Member]",
        "label": "Market Program Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MarketRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MarketRiskMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market risk [Member]",
        "label": "Market risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency risk, interest rate risk and other price risk. [Refer: Currency risk [member]; Interest rate risk [member]; Other price risk [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r199"
     ]
    },
    "ifrx_MaterialAccountingPoliciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MaterialAccountingPoliciesDetailsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_MaterialAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MaterialAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r106",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r130",
      "r145",
      "r158",
      "r186",
      "r203"
     ]
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaximumExposureToCreditRisk",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit risk",
        "label": "Maximum exposure to credit risk"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrx_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_MaximumNumberOfCommonSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MaximumNumberOfCommonSharesAvailableForGrant",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of common shares available for grant",
        "documentation": "Maximum number of common shares available for grant.",
        "label": "Maximum Number Of Common Shares Available For Grant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_MayThirtyOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MayThirtyOneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 31 [Member]",
        "label": "May Thirty One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_MoreThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "MoreThanFiveYearsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than five years [Member]",
        "label": "More Than Five Years Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NetBookValueIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NetBookValueIntangibleAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net book value",
        "label": "Net Book Value Intangible Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NetBookValueOfRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NetBookValueOfRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net book value",
        "label": "Net Book Value Of Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NetBookValuePropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NetBookValuePropertyAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net book value",
        "label": "Net Book Value Property And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Net deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      }
     },
     "auth_ref": [
      "r232"
     ]
    },
    "ifrs-full_NetDefinedBenefitLiabilityAssetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetDefinedBenefitLiabilityAssetAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net defined benefit liability (asset) [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrx_NetFinancialCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NetFinancialCost",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net financial cost",
        "documentation": "The amount of net financial cost.",
        "label": "Net Financial Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NetFinancialResult": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NetFinancialResult",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net financial result",
        "documentation": "The number of net financial result.",
        "label": "Net Financial Result"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NetProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NetProceeds",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "documentation": "Amount of net proceeds.",
        "label": "Net Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal value per shares",
        "label": "Nominal or principal amount of financial instrument on discontinuation of measurement at fair value through profit or loss because credit derivative is used to manage credit risk"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or principal amount of a financial instrument on discontinuation of its measurement at fair value through profit or loss, because a credit derivative is used to manage the credit risk of that financial instrument. [Refer: Credit risk [member]; Derivatives [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrx_NominalValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NominalValue",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal value (in Euro per share)",
        "documentation": "Nominal value.",
        "label": "Nominal Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NonCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NonCurrentAssetsAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Non Current Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NonCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NonCurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non Current Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NonCurrentOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NonCurrentOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]",
        "label": "Non Current Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "terseLabel": "Non current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r92",
      "r194"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r19",
      "r94",
      "r194"
     ]
    },
    "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (non-current portion)",
        "label": "Non-current portion of other non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_NoncurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "cash and cash equivalents",
        "label": "Non-current restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrx_NondeductibleExpensesForTaxPurposesinDollars": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NondeductibleExpensesForTaxPurposesinDollars",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses for tax purposes",
        "documentation": "The amount of non-deductible expenses for tax purposes.",
        "label": "Nondeductible Expenses For Tax Purposesin Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NonexecutiveBoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NonexecutiveBoardOfDirectorsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-executive Board of Directors [Member]",
        "label": "Nonexecutive Board Of Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NonexecutiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NonexecutiveMember",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-executive [Member]",
        "label": "Nonexecutive Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NonrecognitionOfTaxEffectOnSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NonrecognitionOfTaxEffectOnSharebasedPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-recognition of tax effect on share-based payments",
        "documentation": "The amount of non-recognition of tax effect on share-based payments.",
        "label": "Nonrecognition Of Tax Effect On Sharebased Payment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotesToTheCashFlowStatementPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotesToTheCashFlowStatementPolicyTextBlock",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes to the cash flow statement, cash, and cash equivalents",
        "documentation": "Disclosure of significant accounting policies for notes to the cash flow statement.",
        "label": "Notes To The Cash Flow Statement Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofCashandCashEquivalentsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofIntangibleAssetsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Intangible Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofMarketRiskCreditRiskandLiquidityRiskTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Market Risk, Credit Risk and Liquidity Risk [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofPropertyandEquipmentTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Property and Equipment [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofRightofUseAssetsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Right-of-Use Assets [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsScheduleofSensitivityAnalysisTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) - Schedule of Sensitivity Analysis [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NotestotheConsolidatedStatementsofFinancialPositionDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NotestotheConsolidatedStatementsofFinancialPositionDetailsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_November21Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "November21Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 21 [Member]",
        "label": "November21 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfOpionsExercisedDuring": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfOpionsExercisedDuring",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercised during the year",
        "label": "Number Of Opions Exercised During"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfOptionsExercised",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised",
        "documentation": "The number of options exercised.",
        "label": "Number Of Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable at December 31",
        "label": "Number Of Other Equity Instrument Exercisable In Sharebased Payments Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at January 1",
        "periodEndLabel": "Outstanding at December 31",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134",
      "r137"
     ]
    },
    "ifrx_NumberOfOutstandingSharesOption": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfOutstandingSharesOption",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding beginning",
        "periodEndLabel": "Options, Outstanding ending",
        "documentation": "The number of share options outstanding in a share-based payment arrangement.",
        "label": "Number Of Outstanding Shares Option"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfOutstandingsWeightedAverageEarningPershare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfOutstandingsWeightedAverageEarningPershare",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "WAEP, Outstanding beginning",
        "periodEndLabel": "WAEP, Outstanding ending",
        "documentation": "WAEP, Outstanding beginning.",
        "label": "Number Of Outstandings Weighted Average Earning Pershare"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfShareOptionExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfShareOptionExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Forfeited during the year",
        "documentation": "The number of share options exercised in a share-based payment arrangement.",
        "label": "Number Of Share Option Exercised In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfShareOptionForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfShareOptionForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercised during the year",
        "documentation": "The number of share options forfeited in a share-based payment arrangement.",
        "label": "Number Of Share Option Forfeited In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfShareOptionGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfShareOptionGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Granted during the year",
        "documentation": "The number of share options granted in a share-based payment arrangement.",
        "label": "Number Of Share Option Granted In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised during the year",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrx_NumberOfSharesExercisedDuring": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfSharesExercisedDuring",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP, Exercised during the year",
        "label": "Number Of Shares Exercised During"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares (in Shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrx_NumberOfSharesOptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfSharesOptionsExercisable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options, Exercisable at December 31",
        "label": "Number Of Shares Options Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrx_NumberOfStockOptionsForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfStockOptionsForfeited",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options forfeited",
        "documentation": "The number of stock options forfeited.",
        "label": "Number Of Stock Options Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP,Exercisable at December 31",
        "label": "Number Of Weighted Average Earning Pershare Exercisable In Sharebased Payments Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP, Forfeited during the year",
        "label": "Number Of Weighted Average Earning Pershare Exercised In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP, Exercised during the year",
        "label": "Number Of Weighted Average Earning Pershare Forfeited In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP, Granted during the year",
        "label": "Number Of Weighted Average Earning Pershare Granted In Sharebased Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_NumberOfWeightedAverageSharesOutstanding": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "NumberOfWeightedAverageSharesOutstanding",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "WAEP, Outstanding beginning",
        "periodEndLabel": "WAEP, Outstanding ending",
        "label": "Number Of Weighted Average Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment [Member]",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrx_OperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OperatingActivitiesAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Operating Activities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation charge for the year",
        "documentation": "Amount of depreciation expense for lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.",
        "label": "Operating Leases Income Statement Depreciation Expenses On Property Subject To Or Held For Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OptionPlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OptionPlan2016Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossTables",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan [Member]",
        "label": "Option Plan2016 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OptionsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OptionsGranted",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted",
        "documentation": "The amount of an expected dividend used to calculate the fair value of share options granted.",
        "label": "Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OptionsGrantedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OptionsGrantedMember",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Granted [Member]",
        "label": "Options Granted Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OptionsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options [Member]",
        "label": "Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OrdinarySharePurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OrdinarySharePurchase",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary share purchase (in Shares)",
        "documentation": "Ordinary share purchase.",
        "label": "Ordinary Share Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OrdinaryShareSoldPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OrdinaryShareSoldPrice",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares sold at price (in Dollars per share)",
        "documentation": "Ordinary share sold price.",
        "label": "Ordinary Share Sold Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares outstanding",
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r230"
     ]
    },
    "ifrx_OrdinarySharesValue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OrdinarySharesValue",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares (in Shares)",
        "documentation": "The number of shares value.",
        "label": "Ordinary Shares Value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherAdjustmentsToReconcileProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAdjustmentsToReconcileProfitLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Other adjustments to reconcile profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Adjustments to reconcile profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_OtherCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash and cash equivalents",
        "label": "Other cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrx_OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherComprehensiveIncomeLossThatMayBeReclassifiedToProfitOrLossInSubsequentPeriodsAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:",
        "label": "Other Comprehensive Income Loss That May Be Reclassified To Profit Or Loss In Subsequent Periods Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange differences on translation of foreign currency",
        "label": "Other comprehensive income, net of tax, exchange differences on translation, other than translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to exchange differences on translation of the financial statements of a parent company or a stand-alone entity to a different presentation currency. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_OtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current other assets",
        "label": "Other current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (current)",
        "label": "Other current borrowings and current portion of other non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current financial assets",
        "label": "Other current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrx_OtherDifferencesDueToTaxRateinDollars": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherDifferencesDueToTaxRateinDollars",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other differences due to tax rate",
        "documentation": "The amount of other differences due to tax rate.",
        "label": "Other Differences Due To Tax Ratein Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherExpenseByFunction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherExpenseByFunction",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses",
        "label": "Other expense, by function"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'function of expense' form for its analysis of expenses."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r61",
      "r178"
     ]
    },
    "ifrs-full_OtherExpenseByNature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherExpenseByNature",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other offering expenses",
        "label": "Other expenses, by nature"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r177"
     ]
    },
    "ifrx_OtherExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherExpensesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses [Member]",
        "label": "Other Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherFinanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel cost",
        "label": "Other finance cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_OtherFinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Other finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial result",
        "label": "Other finance income (cost)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_OtherFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial assets",
        "verboseLabel": "Other financial amount",
        "label": "Other financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrx_OtherFinancialResult": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherFinancialResult",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financial result",
        "documentation": "The amount of other finacial result.",
        "label": "Other Financial Result"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r177",
      "r178"
     ]
    },
    "ifrx_OtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OtherInformationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherInformationDetailsLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information (Details) - Schedule of Compensation of the Group\u2019s Executive Management [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherInformationDetailsScheduleofCompensationoftheGroupsExecutiveManagementTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information (Details) - Schedule of Compensation of the Group\u2019s Executive Management [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OtherInformationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherInformationDetailsTable",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Information (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "OtherMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "label": "Other Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current financial assets",
        "label": "Other non-current financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_OtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities and payables",
        "label": "Other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment [Member]",
        "label": "Other property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other capital reserves",
        "label": "Other reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other capital reserves",
        "label": "Other reserves [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25"
     ]
    },
    "ifrs-full_OtherShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherShorttermEmployeeBenefits",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term employee benefits",
        "label": "Other short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]"
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nominal value per share",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrx_PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payments",
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]",
        "label": "Payment Of Lease Liabilities Classified As Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_PaymentsForAccruedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PaymentsForAccruedPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for accrued liabilities",
        "documentation": "The amount of payments for accrued payments.",
        "label": "Payments For Accrued Payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Payments of lease liabilities, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrx_PercentageOfGrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PercentageOfGrant",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of grant",
        "documentation": "Percentage of grant.",
        "label": "Percentage Of Grant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_PreferredUnitIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PreferredUnitIssued",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares (in Shares)",
        "documentation": "The number of preferred units issued.",
        "label": "Preferred Unit Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_PrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PrepaidExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Prepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Prepayments",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments on research &amp; development projects",
        "label": "Prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the maturity of current financial assets",
        "label": "Proceeds from disposal or maturity of available-for-sale financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of share options",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of ordinary shares",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ifrx_ProceedsFromOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ProceedsFromOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from offering",
        "documentation": "The amount of proceeds from offering cost.",
        "label": "Proceeds From Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ProceedsOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ProceedsOfferingCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds offering cost",
        "documentation": "Amount of proceeds offering cost.",
        "label": "Proceeds Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow",
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss for the period",
        "terseLabel": "Loss for the period",
        "verboseLabel": "Loss for the Period",
        "netLabel": "Profit/(loss)",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r26",
      "r79",
      "r87",
      "r89",
      "r166",
      "r168",
      "r194",
      "r198"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss for the period (accounting profit before income tax)",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r142",
      "r177",
      "r178",
      "r209",
      "r210"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating result",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r231"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment by operating lease status [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusMember",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment by operating lease status [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all property, plant and equipment when disaggregated by the operating lease status by a lessor. It also represents the standard value for the 'Property, plant and equipment by operating lease status' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrx_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "documentation": "The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]",
        "label": "Property Plant And Equipment Carrying Amount At Cost Of Revalued Assets01"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r46",
      "r188",
      "r197"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareCapitalConsistingSolelyofOrdinarySharesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest held by the Company",
        "label": "Proportion of ownership interest in subsidiary"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r90"
     ]
    },
    "ifrx_PurchaseOfCurrentAndNoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "PurchaseOfCurrentAndNoncurrentFinancialAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of current and non-current financial assets",
        "documentation": "Purchase of current and non-current financial assets.",
        "label": "Purchase Of Current And Noncurrent Financial Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets and property and equipment",
        "label": "Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets. [Refer: Intangible assets other than goodwill; Investment property; Other non-current assets; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable",
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r124",
      "r137",
      "r195",
      "r196",
      "r248"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r124",
      "r137",
      "r195",
      "r196",
      "r248"
     ]
    },
    "ifrx_RentalContractsFixedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "RentalContractsFixedPeriod",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental contracts fixed period",
        "documentation": "Rental contracts fixed period.",
        "label": "Rental Contracts Fixed Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RentalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RentalExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofAmountsRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental expense from leases",
        "label": "Rental expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense recognised on rental activities."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of lease liabilities",
        "label": "Repayments of borrowings, classified as financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrx_RepricingApril13Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "RepricingApril13Member",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repricing, April 13 [Member]",
        "label": "Repricing April13 Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Research and development expense",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrx_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research And Development Expense Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.",
        "label": "Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r184"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r179"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/OtherInformationDetails",
      "http://www.inflarx.de.com/role/ScheduleofRevenuesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Revenues",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r96",
      "r142",
      "r162",
      "r167",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r194"
     ]
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable": {
       "parentTag": "ifrs-full_OtherFinanceIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income from government grants",
        "label": "Income from government grants"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ifrs-full_RevenueFromInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r163",
      "r171",
      "r226"
     ]
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r115"
     ]
    },
    "ifrx_RightofuseAssetsRevaluationSurplus01": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "RightofuseAssetsRevaluationSurplus01",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning",
        "periodEndLabel": "Balance, ending",
        "documentation": "The amount of the revaluation surplus that relates to right-of-use assets. [Refer: Revaluation surplus; Right-of-use assets]",
        "label": "Rightofuse Assets Revaluation Surplus01"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement",
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sales and marketing expenses",
        "terseLabel": "Sales and marketing expenses",
        "verboseLabel": "Sales and marketing expense",
        "label": "Sales and marketing expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrx_ScheduleOfAmountsRecognizedInProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfAmountsRecognizedInProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Amounts Recognized In Profit Or Loss Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfApplicableTaxRateAndCurrentIncomeTaxesRecognizedInProfitOrLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Applicable Tax Rate and Current Income Taxes Recognized in Profit or Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash And Cash Equivalents Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfCashCashEquivalentsAndFinancialAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash, Cash Equivalents and Financial Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfCompensationOfTheGroupSExecutiveManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Compensation Of The Group SExecutive Management Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfCostOfSalesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfCostOfSalesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cost Of Sales Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfEmployeeBenefitsExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfEmployeeBenefitsExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Employee Benefits Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfInventoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfInventoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfMarketRiskCreditRiskAndLiquidityRiskAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Market Risk, Credit Risk and Liquidity Risk [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfMaturityAnalysisOfLeaseLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Maturity Analysis Of Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfNetFinancialResultAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfNetFinancialResultAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Financial Result Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfOutstandingFinancialCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfOutstandingFinancialCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Outstanding Financial Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfResearchAndDevelopmentExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Research And Development Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Revenues Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfRightofUseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfRightofUseAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right-of-Use Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfSalesAndMarketingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfSalesAndMarketingExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Sales And Marketing Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfSensitivityAnalysisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfSensitivityAnalysisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Sensitivity Analysis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfShareBasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfShareBasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfShareCapitalConsistingSolelyOfOrdinarySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital Consisting Solely of Ordinary Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfTradeAndOtherPayablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfTradeAndOtherPayablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Trade And Other Payables Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ScheduleOfWeightedAverageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ScheduleOfWeightedAverageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense",
        "label": "Selling expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses [Member]",
        "label": "Selling, general and administrative expense [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount of expense relating to selling, general and administrative activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r226"
     ]
    },
    "ifrx_SensitivityAnalysisCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SensitivityAnalysisCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "carrying amount",
        "documentation": "Amount of sensitivity analysis carrying amount.",
        "label": "Sensitivity Analysis Carrying Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_SensitivityAnalysisConversionRate": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SensitivityAnalysisConversionRate",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion rate (in Euro per share)",
        "documentation": "Amount of sensitivity analysis conversion rate.",
        "label": "Sensitivity Analysis Conversion Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_SeptemberEighteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SeptemberEighteenMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "September 18 [Member]",
        "label": "September Eighteen Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of additional shares (in Shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Share Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding beginning",
        "periodEndLabel": "Options, Outstanding ending",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ShareInformationBasedOnLossForThePeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ShareInformationBasedOnLossForThePeriodAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share information (based on loss for the period)",
        "label": "Share Information Based On Loss For The Period Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction costs",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrx_ShareOptionsGrantedOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ShareOptionsGrantedOptions",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options\t(in Shares)",
        "documentation": "Share options granted options.",
        "label": "Share Options Granted Options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share premium",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrx_SharePriceAtGrantDateExercisePrices": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SharePriceAtGrantDateExercisePrices",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price at grant date / Exercise price",
        "documentation": "The share price at grant date and exercise price.",
        "label": "Share Price At Grant Date Exercise Prices"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "share sold (in Shares)",
        "label": "Number of shares reserved for issue under options and contracts for sale of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrx_ShortTermDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ShortTermDepositsAbstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "label": "Short Term Deposits Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ShortTermMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ShortTermMarketableSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short term marketable securities",
        "documentation": "The amount of short term marketable securities.",
        "label": "Short Term Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermDepositsClassifiedAsCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable",
      "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "label": "Short-term deposits, classified as cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrx_SocialSecurityContributionsemployersShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SocialSecurityContributionsemployersShareMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Social security contributions (employer's share) [Member]",
        "label": "Social Security Contributionsemployers Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_SoldAtPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SoldAtPrice",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price sold (in Dollars per share)",
        "label": "Sold At Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_SolidaritySurcharge": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "SolidaritySurcharge",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Solidarity surcharge",
        "documentation": "Solidarity surcharge",
        "label": "Solidarity Surcharge"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes to the Consolidated Statements of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Stock Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_StrengthsAgainstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "StrengthsAgainstMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro strengths against U.S. dollars [Member]",
        "label": "Strengths Against Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TaxBasisOfInvestmentCostForIncomeTaxPurposes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TaxBasisOfInvestmentCostForIncomeTaxPurposes",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate income and trade tax",
        "documentation": "The aggregate cost of investments for Federal income tax purposes.",
        "label": "Tax Basis Of Investment Cost For Income Tax Purposes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TaxBenefitsAtTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TaxBenefitsAtTaxRate",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits at tax rate",
        "label": "Tax Benefits At Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfTaxLosses",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax losses",
        "label": "Tax effect of tax losses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrx_TaxLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TaxLossCarryforwards",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax loss carryforwards",
        "documentation": "Tax loss carryforwards .",
        "label": "Tax Loss Carryforwards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary differences and tax losses for which no deferred tax asset was recognized",
        "documentation": "Tax losses for which no deferred tax asset was recognized.",
        "label": "Tax Losses For Which No Deferred Tax Asset Was Recognizedone"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TaxRate",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofApplicableTaxRateandCurrentIncomeTaxesRecognizedinProfitorLossTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax rate",
        "label": "Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TaxableIncome",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxable income",
        "label": "Taxable Income"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ThirdpartyExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ThirdpartyExpensesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third-party expenses [Member]",
        "label": "Thirdparty Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ThirdpartyServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ThirdpartyServicesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third-party services [Member]",
        "label": "Thirdparty Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Top of range [Member]",
        "verboseLabel": "Top of Range [Member]",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r124",
      "r137",
      "r195",
      "r196",
      "r248"
     ]
    },
    "ifrx_TotalCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TotalCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCompensationoftheGroupsExecutiveManagementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Compensation",
        "documentation": "Total Compensation.",
        "label": "Total Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TotalFundsAvailable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TotalFundsAvailable",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOutstandingFinancialCommitmentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total funds available",
        "documentation": "Amount of total funds available.",
        "label": "Total Funds Available"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TotalLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TotalLeases",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "documentation": "Total leases.",
        "label": "Total Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TotalOtherAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TotalOtherAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other assets",
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]",
        "label": "Total Other Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TotalTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TotalTaxRate",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total tax rate",
        "documentation": "The amount of  total tax rate .",
        "label": "Total Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade and other payables",
        "label": "Trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesUndiscountedCashFlows",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofTradeandOtherPayablesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total trade and other payables",
        "label": "Trade and other payables, undiscounted cash flows"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r208"
     ]
    },
    "ifrx_TradeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TradeTaxes",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade taxes",
        "documentation": "The amount of trade taxes.",
        "label": "Trade Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_TransactionCostsFromIssuanceOfCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "TransactionCostsFromIssuanceOfCommonShares",
     "crdr": "credit",
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Transaction costs from issuance of ordinary shares",
        "documentation": "Transaction costs from issuance of common shares",
        "label": "Transaction Costs From Issuance Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails",
      "http://www.inflarx.de.com/role/ScheduleofMarketRiskCreditRiskandLiquidityRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r144",
      "r150",
      "r151"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r144",
      "r150",
      "r151"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrx_UnderwritingDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "UnderwritingDiscounts",
     "crdr": "credit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting Discounts",
        "documentation": "Amount of underwriting discounts.",
        "label": "Underwriting Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_UnfinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "UnfinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable": {
       "parentTag": "ifrs-full_InventoriesTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfinished goods",
        "documentation": "Amount of unfinished goods.",
        "label": "Unfinished Goods"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_UnitedStateOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "UnitedStateOneMember",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United State [Member]",
        "label": "United State One Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses carried forward",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "presentation": [
      "http://www.inflarx.de.com/role/MaterialAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives",
        "label": "Useful life measured as period of time, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrx_VariablesHeldConstant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "VariablesHeldConstant",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variables held constant, percentage",
        "documentation": "The percent of variables held constant.",
        "label": "Variables Held Constant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofRightofUseAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cars [Member]",
        "label": "Vehicles [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r233"
     ]
    },
    "ifrx_WAEPExercisables": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WAEPExercisables",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP,Exercisable at December 31",
        "documentation": "WAEP, exercisable.",
        "label": "WAEPExercisables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_WAEPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WAEPMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofShareBasedpaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable",
      "http://www.inflarx.de.com/role/ScheduleofSharebasedpaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WAEP [Member]",
        "label": "WAEPMember"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_WagesAndSalariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WagesAndSalariesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofEmployeeBenefitsExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wages and salaries [Member]",
        "label": "Wages And Salaries Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_WeakensAgainstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WeakensAgainstMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSensitivityAnalysisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro weakens against U.S. dollars [Member]",
        "label": "Weakens Against Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofSharebasedPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at December 31 (in Euro per share and Dollars per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrx_WeightedAverageFairValueOptionsGrantedDuringTheYear": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WeightedAverageFairValueOptionsGrantedDuringTheYear",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "weighted average fair value of options granted",
        "documentation": "Weighted average fair value options granted during the year.",
        "label": "Weighted Average Fair Value Options Granted During The Year"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value options granted",
        "documentation": "Weighted average fair value options granted during the year.",
        "label": "Weighted Average Fair Valuee Options Granted During The Year Usd"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life",
        "documentation": "Weighted average remaining contractual life.",
        "label": "Weighted Average Remaining Contractual Life Of Outstanding Share Options"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails",
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (midpoint based)",
        "verboseLabel": "Weighted average remaining contractual life",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares outstanding (in Shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrx_WeightedNumberOfCommonSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WeightedNumberOfCommonSharesOutstanding",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted number of common shares outstanding",
        "documentation": "Weighted number of common shares outstanding.",
        "label": "Weighted Number Of Common Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_WithinOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "WithinOneYearMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofMaturityAnalysisofLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year [Member]",
        "label": "Within One Year Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WritedownsReversalsOfInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WritedownsReversalsOfInventories",
     "crdr": "debit",
     "presentation": [
      "http://www.inflarx.de.com/role/NotestotheConsolidatedStatementsofFinancialPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-downs",
        "label": "Write-downs (reversals of write-downs) of inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised resulting from the write-down of inventories to net realisable value or reversals of those write-downs. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrx_a2021Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "a2021Abstract",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofWeightedAverageTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021",
        "label": "a2021 Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_clinicalPreclinicalStudiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "clinicalPreclinicalStudiesMember",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical, pre-clinical studies [Member]",
        "label": "clinical Preclinical Studies Member"
       }
      }
     },
     "auth_ref": []
    },
    "ifrx_ordinarySharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inflarx.de.com/20231231",
     "localname": "ordinarySharesPercentage",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares percentage",
        "documentation": "The percentage of ordinary shares.",
        "label": "ordinary Shares Percentage"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_138_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "140",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "145",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "57",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_57_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "34",
   "IssueDate": "2023-01-01",
   "Paragraph": "16A",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=34&code=ifrs-tx-2023-en-r&anchor=para_16A_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_85_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "122",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_122_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_126_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "95",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_95&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23C",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23C_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24G",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24G_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11E",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11E&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_20_d&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG20B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "9",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Note": "Expired 2023-01-01",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>83
<FILENAME>0001213900-24-024500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-024500-xbrl.zip
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MD@SLIV0:8:6AL7O2J4RK<T<->XG#T<-Z#3]U*$'Q^<Y/#JYQI!1L<3;Z U:
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M_5_ ^'__&50=DQ&%E1)5I#R4S>>#C[^WQ[#98]C)LWLWD-Y[9Q6C:Y9W7PG
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M\85:Z(9!:>9AOAZP V BJ5'KD&E@IP&TE@2E-#([L5>2)4N:F'-J-,V+*+C
M>:,:AC*0BY>SV;R84 #F&]L'\([?IGZ@8%D@/ -?72C6K'A;<Z1XWB;X,"EV
MN[30?&V.O38?C</ 1RVO4SHIG/WEU(<MA1=S0SZ$$D5C\0\4Q\#_I)CZDZGP
M%*B Q$$SL*EC/'7=_2[&1L)>IOC'%VA@PC?P0W^&6P%LU-%MACM:?V7V&<$:
M/)6XL3\RVZ@0MXC[N/AI )\:^[J^I3=]W=MY)PZZPFYGW#4"XYPV*D??-_.
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MM"&=5E=O=?7-.U& U%/,/"HX#Y*@PJQ^EYD!RK  K7),A,E34O5S-;R^F:M
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M.!KERCG[,HS((E-%31;E:G[T&LC >#V($41):D1_:<AFDP&9'7E6.Z4DT?/
M=T9S]/H6_N.E=]4_WVD<UJJDX)NB+OP[MLI[U'=$O: -R?/FK0EAA:V)L!G'
M<)-9P-M4.$$7,G( #3BV^E7()\G7',@0,3I6*&!-]Z+"?I-L/@\654<YU2MI
M(W6,!NZ4-"9F\_7!AK^T[M,R[)9A7[M\($<BT2P0%;^0^%P43B+D1T'$?"\O
MCKQ0P+XZR-VQR,A@I\[R6D,<!O6Z9F86<9P2IS2!MX)?Z5K$<-(2?$OP+<%O
MNE[(Q&[0N,KM)ZLRIN)N:8FP)<*6"&\8X?746*&W<H)8'E@,;[YS ^D3,C>Z
M$RD74N.WB52QH: E]@W=F[K\BS5[@?X9?]Q9X3[IF !0KL#+0/W%/8\M'VCY
M@)F1WZQ0E9R8JXC8J+]7R7_K5)P,S7.0%T7^8P)#)N-%KO][&&JV9A&-X%[)
M G[$.#2\TH\N$$]-7;:\H>4-+6^XH8Y@4Z@*)440R4G&%GF@)K[&8N=J"$68
M.[,\.7@EWV@<![4Q3&2;U]72=TO?UZ5O3;R3.+K4@K="\0HSU+F@AW&!$Q,J
MB!5J!DC9W]0"*X"2* Q5H*N%W#CSTZ:Q$LO)]F<&EV>,:&;YR.]H:/Z_EN!;
M@F\)_AH$SS1-\%L:ATLCZ=44.%9A_>RN*93:J,?"$B2_F1BO>9NI'Z'2$3^<
M^B,>V<;RPE(1E6%''VVJ)&*DR#S@L52S0"#J*1JETJ2"Y/""20$M_\/LCPWY
M0)86(W3\TZ#==^^([=T.!DY#N)M7+=S-K [NID6[J;E8+4(SS?YG1;"TZ_!<
M&3MQ2IBS8,Y9C3)6P#%W\D9NS V!NVF0=HTES'SJ3^PWQ!H;^6_@&2=_!E\Z
M4HM(QV7161-' 2,[6\#O)A,E_1%\JTS,R[ET<UP&FV6@??Z;R@5=/W:S&0)/
M(]2\3I+E3AB4V+OZ379+.0;>9:[LNAFG"Y;1?W5GCJ5&'([5B$.+U*(1QSJ@
MWM^+'<K;45G=.5<T%GF;=Q;9K>\LXI@^)?6@R90+:57'EKJA7!T+^4<]29Q5
M\,7K#Z4K/@/O0N=>I]3V!149./4HN,#?J_#"CZ.0.JX1"<76/BQ?<\(>5H2%
MIV?HSR@]"O^KP>]2E-%X&T!S2GQ=>X(Y2\#42(VA8CFZE]S"=>T;NZ*/>*J\
M5SF,=M%KYE(96L.^.W"YD5KRICIKP8WKSI3RPRF>HE&H)=YA>*@K!M^I/D8F
M)HW"<T:+I>X(,!\OXN4'L-&X5FK< T>:S1F!&ZW""Y]:UBRAM-LSU+#Q<-C(
MB/RPD^>VR]*6.#A."&=GM1#JE&F](]RI#">J2N0&AQQ[!MIDU!%3$*YT=W"N
M,#;MIG5(!1_4(.#%NYW+HN6/H5YNS8D-G7B+Q]@&:>D&%35'9PJVO<A&A+VG
M^3,.55'83C\=',#-&Z<JME'.:]HD/M6^/)7N%#L/N3O% -GO ?6C<$Z.Q#^_
M'GYL>U/<92LW5#*DYDE<'QAJ=S6!NRO/BFL_?^]_"*6<!=%_L"DH<-DH38 0
MY^]?^!\0IM6-8B L@AY@I%0D0&"#.3[-,?$K8(1>D6\V5=(#/2@&@DT<H-$@
MXH[?P"D^(IY:N.B*LZ(!!K8P" )C/6+#&JV?F>>B+$U\3RTCH[*",Y-_<)%C
MGC4'K$7W9!C[+DZ"D!: H;L:)X2&6S.L)9$Z*.\L]:<D\_SP0B6L!$2F]6FB
MFQ<1D!,E*M/N^Z&SC.R:S0G* ZNSR;W'<$-17E1N,A&P'R]^E9%4H^I3T+#B
MM%1'^4?F35BNL/#E4YM'.J? !_N].'H'1:"?&+V1F+_RJ.%>4G!F^Z3+6_18
M">1QDS<V;RW?(..SLNE0-Z< NM**RE1>* -93[6V%WX)T0L(P\>[2BJK&TW"
MPA^F;Z+Q3N5WK.,89Q2UF![YNO!9R$ONLPWWE*]<.52%&G!*W;@.X.J1U9YB
MDVM)^:1!_@*:F^X4+"8(_H,*L>1K7X9)=G@K"N4)GB3UK*""A#M_$3$0]53N
M.#R;6U\(L8)JCDN<::3,EOR'U7.](:0/ZFE8>]]UA@A:[;&%8I)FBU6Q'0@\
M<?TP&DZ,:@'(_X8&TUA>D#W"&Z6C_4#\";*Z_ U,K4[!(^#TT:.F,'L!63@L
M0Z.)Y6HNSI7T-03EIEPGG8&@1T ()0Z"P O^@(U+M,U9MP./E;8>.V?P$X=/
MBTZ72!XMUY@1[;"I9YJ"[<[BYE)A=S=C1>>7)[\ANG=.WK/;NDYPFT B>DK-
M-(#[//;)?/I*"H)F/B!?$,S+S4'J4%K5*0TH6D=*I\+R5>19V&3C$S0]T!5U
M_\EMB,JE+Z:KL1!X0SJ:XU&;'ZE;[N6//O=_0GI<XC](7\N48_$@)F7\2=Y/
M&G4<6&6)0D#(;OW]OW9V]MYMP9].:9J'68J>)-+1--:@_1%WH:;MDXG2.]71
MGB%L7.0G#'E(778Y8HC*%,$\P%PF<911I')<FE+'>>[#HG'FK-/8"_1QQI%.
M8,@W&HXX!!$1*(U/B;X&UFX\-$%1C1RI:13%@?_'-^*8TS298RY$."%5L@/[
M[/-.XSO)\R5C@M.B\5E;G4?POXN:6\*.A^?^13X"JJ8SK'A%!DKS?"Y_0KTW
M]F$7[8LA\SW%4[,72JZ=>98J9Z322]P&RKR6,V5:OI()^GRT:F #N;%F:+%Z
M:.3><'!YQC=\Z1@_)$M)[C@KR3%DC:#]3&/!<'FU][LR7>H<S&)LE>2RMXG=
M0,"K#!M8JQ3,L9X8A9 G9W)B.1VT,F [JLJG@6^!'<M<UL+E#"XL#:E'<B8Q
MT(FA.YL)<72=Y7+Q7FR'IJ^4[G!I'$4+LBA"A?HXPH28N'Z8H#=!^^NXN@:G
MKT?LBD&Q5,=ZJ7$:%CHW_,/2RVLVF":@%9$);D98\-EE99QWZ8 TJ"\YH1U$
MG@(58PPD( (EV8=EC 4X8[U='1;BDCRW&64RIY@FJ'1V,0IX,BT$QS^L4S%2
MGI;1RO)[F3V=A</:<\%DV8.<V*TCC1>9+U[E]\2%BJ;END<LM95,HK&,C6S1
MX5I]H14RDI!ODV90<)]8G01-.;<WC&6HX7XUO=MB)BDX%ZK_\!]\7K,J5N]C
MM46UJSDD(AD"QFH&VF 9JSEF+BSP>^41*"4R$&9U!)O(G?'@#@<U2_,B-\N[
M8TH/7I<H=C%:3>*M)( \+P#C-WX:4LEQUQF8'6+MWFH=/\/RW-AH-!X85:2:
M:U90P=PL5M$5QY%AVDL;DN\&E20GV@O#-P3VLZ70!V2':^?6W=C?N8'M;,#
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M1SRK8*X6ZZ3.6CFOU92NN9%^GV/*4;%O#L)H&S310H+0JR\)WEAQY:44,Y0
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M5?Z%X@CKX&N_TV@6/ S"&A)CP#8DA&7IQ?)2!KI5H@4\B2\Q8+/ZA2T+:%E
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MYU?C&/<>41J!97O3X,MF>7-M-F#AX9Y'B9^C/(0*?H(%H'9[*+;)'_T^/)4
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M 4#OOG;;L'J V&V4 (!ALB0K>CQ2.7A \*[D94!=Z?T+_T,3'O[TK]9=SGY
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M*] 5YC!<Y.F[8#FM_9 <4-3 L&CW30TQB2,6;1Q1(*./D_2YJ##;U,+1DJM
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M-OEL\MGDWR-EC6:PH^)2-)?.QA\*VH8;"^B6\9! MKYL?=GZ'O=_<8^,S G
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M.S&;TG%35S])?K1OFX:.X8')!R^\'2!LP7?-5-DZQ^&776B\V?L9@RDILN'
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M&WHLHUK2/6#\,)HWS&C]Y[#Z[UW!S*+NQP-] AP?='SLVGL>3%UU@TBQHC:
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MUP[T ]GR2J3NQ='K[.ZTA\X#N4^\>M5U[0OP-XGN>GM7K[U"[RX"VVBJ5//
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M5".C]%K2:=:T\[UDC[\N1.U<>M)PS[LCZ\:S''=4^=6/"9_Y(USVJ ]TG;C
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MIMVUMZ(2_T8I[MFO>GU4_9YZ\9>??/+'>2MAC__=F]=_]8%[C?H@' /KA-8
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M]Q4RZ:^C0QCAV-#4*ZTBC">0$QIK(34>/;9J<5=UM1,((V +NW&7*M:3DS>
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M'.DX^=!4XY1HK_O"$P?_*B8W5D/Q\^/.O=/-AXT[KL>7:B6][ZNIUI=$2 ]
M2?0[T5LIN1C'$4#++4K'S/K__HVY9]VR^-.2T4QQ 0&OIKYM4KQ#PLTMH@P<
M\W2]WQ92.P""B0-$,T"*2\C(:6N44E"UU"@6[IOB[M=DEI'^N3?TU"&+[(EB
MGS Z/X!CBT^C0[L3E(:$)W1BM'MZ2^NZ[X9#E,2E$-IC1<O9])#G:8]5!,8I
MSN9"@CQL)(J8Z&1B"2O37[IU;5B21V!IS(PVDOHV.[\YW, ^Q]&D^+8[%D;
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MW>Z\?]%C+QH%9JD%!,!"+81S2*9$'[&ABG]J0RU4AH)/0XO+RPC.:'-T$L6
M7Z>3>=_=SL?PWB?AR/5?+2D]:];"6"^?P/1QU\F) ?P&3GUX63H_3JC-TW._
MJ\A+JF^EO_8C<]L*_!KT4GI*^,3UQ6-PBV@,[BBOB(=RVR;0/6$X:D&W* %=
MK4Z4&UWT=_MJ-WTN^K@E$ C1 3:LG!\-QE5L_;;@M=LPKT2(8?2\C":X.:C;
MUZNN7=80F;BK>0]TGI,E>B5">T9?9L7HP-(U.5,X&9D442#F"Z*7YIYYV'!M
M5%"3$90Q>F%FT@(9)J@0I&N#_0=.Y+71UN* ).,JF)3?*%:<1H![MS[I\1K=
M]<W"^!LOK903.3YCEPB0Y!-J8+@+ .1U2;"\#GH)3'^R=K<=W^$2(@OQ=:6F
M"U(>9Z_"!KKUK991*"%%)N9A-"V$J64B3R&#H["QX[KP4'-R:*2#-<?F\KCP
M>XBH+K+G3!+G&*>XKC$BB8C7$?C.-(-@$I;*!G<W%:5(L']-(LA,03 31L2C
M@%#XZ,]9B&(UGK&L "_P#@U5&5"@9WB^R"+2ASG[@1PL_5L$2^!0F<Y"4HZ,
M,9-"2-%,&>$".5(.E)YX]=^[PK-V'A_(E05RW0TVM'Y&GH$/*\>@U6!VU;+E
MD(*K+M@1Y+.V[6X]SC6[@EZN:WH7-+6X@,%9=,ON1>5Z6@["+H0!_AHX5:YS
MUAXAGX.;M\%_<U@%YYWBE'#*KHR+%0$8$.<1">\KGP)#",+NC5Z.]&#Q+;TO
MYC<)MR3,=EP%HPOU;=.XG3V\\Z# WYU%D17@/FN/ P3PU@8XR^@?1S5:G+91
M54<N_)%XV>>V^N]P<G)5(;817\P>VU=_HBA\G_C4=;L:F 0H,/3;3BH#06GD
MIC<=8X".*8%0Q(A;A,I6M>9RFRA<\:Z/Y)O8.MNTGGN^U29,X)L@E'-.P"T%
M2UIX(>?'AQ,_>(0(H0]*,O]![C;F;N/TBJI933XN;- A];@S,";U'V?ZYZG/
MK(5,7TX\+3-#6G"C@0*7JX/@337J]/B<R>YI)HQ!NR_< 64]H+VM!VV<OF]7
M-3M1X0^/.+F9^ >!SI!G:[)/RCZ)5[2O*5Q_-Q.)#P86%/&$ #AR26./,/9$
M&XJY@D1#','(W\WU2[3UMI+VW'=M<RN$NYW[00(V:>7%';L19QRJIH*$U(6O
M5=1]UCJB2U,RY Y'H9;"M=>G?J/:\B/"NC)T)TV&0G"HGNAWM:TI,IN'+PTM
MQ.1&Y1[EX8_AK;QZQ(WHK1\ZT.UGC%CVD-E#^JAM'IL%)4A*?2QY840^-?:&
M53!$\IA(!ZN.D384&M'*$"Q9$#C7)XU:>MUYMCD>DZIBJ1!F\ST7/_E0\+#G
M,3;UVSPV-3$V]?L\-O6$8U//O'*"CL@5WDWH;;AR"MD7TY9P Q6N\Y)D1"0*
M15\=D[Q&H(+ 1)[*R]W5O5>X$IC>?_[''UY^^OO/>DU>HZL+2SEZ[2N_K&@M
M;K]LU[6TLO%;_U<+D]]*0?(;_R,E-#/^[[??E#)++H0L%T4Q+ND'W2R^"K3
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M9+=:R0C7QJK4GE=,:B3/LN\1F%J:=ZQ%![%KG;>'6? C821]F[@(&%7'I&P
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M<MNL@-V#RYW6"HTG"!- <N=-D/S.LQH6,2Q7OY6(36;4",W8#)?.1,P\)7Z
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MAN!_E3:Z6<HXXC^$[BUYMJ0%1<W:J<^J+2#:K\=H]4$1?\![(:Y$0+*$$WG
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MX'[U+85 "/,CMLEPLS"(L^Q_FAZV"2>DP(,IF8]:G'GRKF0OC<Q\1W%")-O
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M."3D/$1@A;1 WJ+CBZ) 2G%>D<@CS;?,-3U1N$_N(.YJ:C(5Y(0:2W-=7R"
M:+H'3S*=["@VV[*6[.O4$KN-<7*G&*?LFBQ15;["N1&#- A]#SW7TF-P-WQ%
MDAAV34O]#1RU8Y4(<4S1V@:\$19KKM4B(IX_0V#<(O1O,SY*04W\RD)/N.U(
M'#X91K&\<9U8W=C.,'OA'^&A_W/?.M.8J6NBABTNV1\P5-@> PNF;?=JLZQN
MS:YX3;V8Y8)D0]!T8+VVW""V;CZG[_!R'[Y\)(#X)R^ O__\-VYUYG^4G;[0
M/#1-QI><K?L6ET(NR,T74IGY<JFUV[_X%NZ?/14 !O[Q&7<EO835<[[<N7O?
ME-_^]3_^_?%GGW_=HCH'6/CUKMOYWK<78)MW__SFD_+;^S2DO[[8_86'H3=Z
M]+ 8W.DEG1UR\0PO_A=_[=N%G[XD_!$N>N9>4C&''DL*MMQ2ANE!@34C)#1F
M1/@@HMKCRH/)Y32EF0 >+*%!>=/4302NX+S&E.89#$-J9G!('[F=7@Y&1:<+
MP2*>//Q3PDP0$IV2F11D!"OR4!&+\S%842"G0W^" Z#NUKYM_0JKD$52HF,@
M1]OTVR'D03&<A4'XKC$!)"PBY\<>"-<35_WQR:294MH4:#S,S.+HH&P5 U.$
ML::5U_11F_1ZV#&Y;.D8+D,E!?8?NZMT54%GX^!E?,HSJ,\+'SUSXN7HE=EO
M//:4:"FG;*E_O2TY0;?NJTKJL=K:P6XF_GQ9KL#4D+?68F\^KNH.]BRX+\_Y
M=S6M:+P/31%<D+<#N(^OE]XSBF1Z%)2MW^O&E@VM)@'#K@XFRA]]/IJ1^-Z.
M3$18*K22\H,30S[U IT3?KX5+GFM9!MB/2K)PH;M\'9G[KS:(;J+G=?#5Y=G
MY?H(8NX1NVTTKL2:C>^7JU;Y\ TMHWUSR!P$LUZ!%TD^] :N(3<*%>@ SC'M
MMO ;!.D@S"1%"!"[ :Q3\)_Y,WB9A8?CH!8$$KU=0D;AGD.7#FD=FF-O M<0
MDL&OP?0^>?SU9=O7%]V%7^"C8T?I?_L6GF ';C)LM0M:7L1(0<@'3#QMF(H'
MX=-FYDK!_7-K%**Y">\2!Q*A"F%(.:>GQW."5XMJI7XEU!,-%40Q44=>.,-L
M<'8G7_=-3^HFGE0<?3SHX&:S__O1/.=YC:5S7U3$[T7,7MBG$%#2TFD D5)+
MT)P?B\VB;R^R%74ZG/<76(Q__!72 CSZ@NLPC[[.'F=_S1Y_]N03^!5A4KB*
M@K8B^@,YICD*B&RWE]FCW&&+$&5]'Y.CD-T3W&37HP_D$9!"F"T,*>OF^C^M
M9V$NE(7K/*+KW&>35':Y%B77OE1^7"P$IWM$+:+3<W+D5?#9^DEZL*IU+CIL
M:A$!*P@=KJU?P%W[,MNPD>G RK;<Y ZF!$<)AG99H<6ZOO3,S_8#/#K"*Y\V
MPC/&$A9/Z870?9$U8.799."8#7:",#RHKAED-\4I9$U.<'?1L&#C!^.&Z?BX
M:!K,-!4=P8D;M_!5Z:]\M.U'AX1'";FS<C"@=B):?B4'"J\M??_9S>_?R?N_
MKRC/$OGI:H.PEH=;FG'-INJC><Z;N$@@/AOZ-6L*:&11*.(==_RV;[=$_@!7
M5 Z3KSX_>QCX2# ^64L.:/ 5_?SGG[GPZ:NBK#AP84(MJY_$,4CT-X*'OX.)
MNJ .E;$W0NX"=4Y2QS(Z;\5$, 5?=C;TX^C-A&U@#,#GC3_3W2/Q![MNX','
M)#7OV<VV\C)5QY,?7',CC]E)9E@]Y6%7!)%W(=*&<BK1,T=KD0]YL33] O[N
M YF2FS,QE"Q$H@\G+UWX/O QQ,4U<$43VZ8)P6U#K(J"V-2ITEAII=@=@J[0
M\5$F Y]-SD?SG =-#BY-Z@A%JKER519(#/VL7E?%\]?9+PD5:8=_6)[E [ZD
MKR+W$>SB__/HL[-/XR_6E&PB T1W6?.)Z\QZ5G-TA@D>BOPYOA><<!0B9/HX
MXLW9;+'=DW0NB Z'VS #5^31\9NTF+-C.K@MD_RH1HZ3>=*$S^XL6+E/OWRL
M!NE936$L0G4@M.\]^!HK@D(_^NK+SR=[^?$#N?8X=])-S:0_N.V'CQ[9:^DS
M%.Y>- S4%G32T$0+K,B9="'Z*Q/3015<>&0!^4VDCW5Z%GU9X891&B;4([FH
M*>T OZ3TD>D('F<=SF\:+;I.$8ZN>;JB&R:#$J!38:/YP#W+;?(0)E@7F?D2
M8=(OO-LV)0'CL0X(QT!350RC:KU_P%$Y9\=09 6OI=DS>@,P@.R>)N)RFY1#
MM"0Z>*AS0?F$^]F3/X7RDN;]N(=_[9*Q$RDBOF-L-5KUH8$^=#<='"1%^E/G
M-.<?\V31,DJ3YK0@A)DSYV^3D)3A\3:Z)B>:>;7<8OM@!\%ZW8W.5#IK\>WJ
M@G&C!<,1":/@S!B31>(Q5:'>O-)T:0^W :$V]<4#S#S@*!Y(RSGY6]@LPL2Q
M @UUU'M/'&QTZDZM99LG3KC6U#^!]SA8BN5F S,&=ZSVQBV92/2(#^"4.*98
M_=8S&KR[3^WTX!(5Z %)'F8\0>),\!<YW&O]FNK2N+[ZND<_8?R]=2.Y*-W+
M]<KINS5[_1XYGIY"[,):@?O10A#5-)-0L*U0W"V3 B0EV+@X/S4OEL8EG3M$
MDHH&-?5G,#,)SP/+>3=>IK0]N!V,'3\^56A#3Z[KH0T,)A"WM&:?X6%<\M>S
M[.\6:B#WNH"M+Q$E3ZC)C7=<8F>*"'3?V'Q.;5]Z(286,-O8R6+#DR0PQHGK
ME]PLD/Q%7W'B5F?9]SCB4BEVE8DH7BFV1]H+C39MCOR%N "5:0&+,FJZN;?P
M%43LEQC%TYBOI8-1#K7)>1@>P4H'+"5YV+ NHEJMM4;/N:$S ]E:%**Q*M=8
MB@@TY.&ON1#X'1\N E7J  D(+A;V'24G\WB.$X9@^T7IHVOASRWE)H[,!LWP
MD")QZ/Z[#]KS_SA)!!_/Z-H)=.UG,[IV1M?>(:#-K]ZQ_Z2QK%9HB^PW\,F[
M%7<[J;.+@876;MD;++OQ*5)<7&"107)6B[[%^C#APV;<S1U.L+S \BVE-6*0
M=LW>1+W2+OH<7V2A4,^F!R>DZ$IE:<#N;2+&4G[CS# AQ[H_H5W)#Z)*!X4'
MZ,+3>H%C'AO0R /6M<8E;TDD,BM (>6BXOHL^_->:B3JIJ0/P=\.U!>!S8\2
MORML\ELE=Y[@HG#V&N&^/S;7V V99]P,+SV/RL1F'CTJ05($*1^0ZP2RO'_4
M!%MZ@44BF-%THR7#R1V$(M<HKU!8J([-L5+,0IQ_]I;D_&T16V 8:IHU38GT
M^RU\.AG85TAN;1B01C?JK+L0"M97(H&S\+MK[^ND1/7<"\N?>;$3SQ8N7UPU
MY4J)$%9-3_ :L%"QO5[Y"C$@+EY[(M536NDU5D$?AQP4W_!!?($T/_L/QTN<
MS=<M8(/4 VM6[W*T;FV >61=4$TX85-(@"3R94O]6:?WQ0W:[<HM<NI$XH]#
M=XM)4V&T**5H"__EQ-!/$/J4>"TI]NI&@P\]P_0(F1D$%K[D*S[W=&/W$]C%
M7@C@?V$:P>S/>%!_WS:=%M=^87[,%Y?EFFF#>,_\]+=G1ZU01OXR/=VN$3*;
M3#E%D#"+S ^;%0>Q-"6':>H0.@/#RZV*T8&Y"8DE3AN;'E [W?,^_FB>$]MT
M+*F8'))Y<JHQ?'+R+&/4@R8/ HVN+&CX2X,,:"K2YMLKJ<W^P.!"S%QC(H66
MN0ND/R=X-X% NQ!*'CE!ARZ&?AQ1S#"!) >404#8J8E!X4=*2ZX\Z;H$+Z-@
MSRE;ENVRWV#3,W&Z68ZY]$KL]5""%R\J4G9\U5 "U[S-4RF7BW)%)#;HW)%9
M)R]C\IOQCLEXLWMKF]VU/$%$OQ0U^L3;H.FGIG&G'Q"2N5WQ2O[.N.GI<:1>
M45P9X<Z'#3TNG+18WW>.@B:^0/)JJ4IS0_0D]?@ *EA*U9TZ<.#MQB5F7#K*
MX+.XAO[.H8IBW6G3S40:,BVG!R(L(885)2HM"H@'&WN,)K57<M/%$^"GCKOG
M&_+(;M75,]%,.;?U?(3/^0W$_"5F&A2\5NZX<X,:U4):G"!OV2\_/'LZJK5G
M$[5VW(2/'SYF%,!C6DP,!\!_B3C-(ERQK*7QS5%E4DL'DN^07@ &$23T1B.@
MBFZ80\,S.UJ'^*D*<D6N&6?O'(MO&I?2F,\0['N[A,F'OD+^*#OAICU0O),M
M<,,.H-J\F]X!2:62+T$(7^E6B66I UTZ>88[1W$NL0X5RN4X%-QI2J7O&!NB
M9;%%\OP$#YC:*+D!7@Q.:ZW@5DWSZH%*.'+H,$P9V))4[GQ) T2UA2]2# .>
M6Q<M@D?D'03&300-(,PX'M--RUH(!%!.81"%--=&*8!$LXQY&9V]ME U2F&5
M5+,89@@7O40EOY"(820 3T$^&--9]DLZ1F&C[-*(3>E' _]3[O3]Y6%648)#
MQ"W;P(S5-ONB,JDFJ1Y345RAU*R$6_FT"IJL3L/$95\ZNED%*8Y-C19?US7A
M"@9JJ5Q%MV^(9],Z?D&0SG3OT_APYUS00Z(@*':S\S6< B2#W@6^PK#VXFOD
MRW!Y?^=IV@8+!5\=/;EN9CLP*=."4TIS%D9.D'1^%4[['8D+USPY;DE$^5 *
M(96Q0*A&$SE!-5&Z\3=>:/;&/IKG?+9VXY-F9&D%D,5NB6@RE4(81S:^&[,?
M7"L%@>6!P&QR1,_(+=$2.YN\Q=V2WH-&5:%\\!);!'$P#--)1D99\]N,S0O>
M ^D)&#D M\7XT7%W&GR(3JZ$1C;L4183PCYBXON.3.\BM2S]N*))/YRNVSF1
M[H 3.24%1#.J!+W$H(BH/E+EXJV-[Y,( !')4G9AUQ=F:D:VS)RDCF+8E>=^
MVW"08Z#<8HA><V*#;J&)06QZ*[<[>PA'+L%HB C/7D;V^@BY4E6QF:WVHWS.
M'R#XT@9>[)OL.VX@Z[S/+.G@HX=GV?EWWSU#-L'SOV7/_O[#S\]_.L>?E%KP
MR1EFNOG8E5]E/VE&@_:4EIQ,-S\V2*$B%*<P7/"O?XR,RC_KUGC!A#&"T_WX
M7\U'3?/WZ0Q$F@ B/9F!2#,0Z>X!D8@UBLB@IP6DV!/3=!EYFW"@U.HS(,<9
M$9%MD!XE]*):O;Y03PSZ<=;S0.$35O.AE#5?#CPE3%T;B3QJV<U)B:=G7;9(
M/"09^1GK=)=/O%N(YQILDA'.M2*"=ID)CSEE8ZA+!5YG5.-+,#C3GJZ":!)M
MR6.:H:JAASCK-#=GAGOX 0,"HD+JCE6QEY^1;;/!AELF&Y!L54C0)&*,/E)1
MO-F\Y#=-BA257N]3E2%.Z+WYC&&?WXH%/Y0 )8%NB9FQ2K$NG4 (*25A6-P?
M*,M,L?V13@),DWSI ,<1@M]73'V(I &([\?4D586\8G=""A&.<?%?8P-Q^-(
MR:W']->9T;)*KPIS7?[3UQVW*,H )%JD#+(E8C"9+["/JHW5+"WV);U\# AM
MP3',4[':E+6JS@9.;IRB?M<QPX)>T?$5M=] >PKH)"&DB4;OMUFNH_44UZ45
MX#))@KC@W*$%I\70((:]0FZ?BKJ25LS60ZG!(%4XRD(<TL]$'&6HWYO'<K2P
M7R6M[]P^,B$U%U3AIL3R4&<'49ZH8TNI4FKO\CI%M!$9H60$Q,C:A3C?+1M,
M:%-7AN1@AG*LPU<P;0T&FWLH%2Z63=,M\;B&*U_",4)L/T$,DLA1=47P"7]$
M&'K0/W]-G?H^R#MS;RE"-HZ[+82$"EAI?"-,_D$,!Z:F'E(D/$XJZ$B!_Y67
M1KFH?HP/5TDG)4ES;72]XM<Q+_62".2BO'L;5&>QXH 7IA5$5\>.)EJD)=H(
MA#O@"F1/"#L=!92B AZ1/"G8FCEI\Q$ZZ)PW)O&7+765:9E(2XVUY[V,FYAR
MJ418(9G"F F$+^L&-F)6 1M"1@@>X_(8\'!VK>_PUHA:5+%S %<,OLNX# Z]
M?@.JYZ-BU;S5>G.TELIAVTJRG-BXUR2@N-N;YH&@>!]E,].G $]66K_)6>N[
MH0P;?U&_X'2LBE^5!G1JH<!YD(_KB98V&0P_C#]$6+Q"B15Y?[1[8 CDU6JL
M"API#IFZYZUL439\ JFII!6?,2#.CB9@*=U!+*6AQ]J;&4AG<SP6Y?&RKL6"
M'1FNE^,SQ;='ZDKP4C"!0!I6X86%H4^;J'O,F*I@Y1L^32Z" .^V]$SXV91&
ML:Q'[P27MA:YRC8A^22"5B$=0&-Z?^">,&4D[ANZ.+:P2YN+_.H^2VW:+25+
MP-FYHZ<JU_OX-/J$I8F@T/'O.H7,&O*R='8Z&L=XUE3I]M#<.#L1.J<4O-L9
MR*B$Q!5%>#;^PF"]X!I!9KUT54C53IY5H20:%Q75=;%':B47( PD5\DN<R"=
MY&_'N"N9K!@213[(/%F]A'D-9Q[MDHFQX_)UB7FC81([P^BEVQ<\.V0?S7-:
ME#J9C*$1-!IUR(/!!5S<I8L&T2==1)%3'"0)CP.H^(SH4N%D2QOQ!!)-JU_^
MXD*D"1OZ",X^'M^\(VC;5#+$&H^OVJ_+W=L><"GN_\@<44\*\J7@?X_UNHA/
M V-8BBRWR ,J:#IM.X*8R0U[C=[L601F,"#W%4@I60/X:LTI/87\X=B8.5A%
MKHM^=]DPQFEP6-SDT1AN'B$)JAMAE0Y3$/A*:7KPJ^F#N<D'&P,CAB_J-L[;
MQ[_G_RBV+9';+C#ORPJ;Z'<CAI#962V?$!^2VZ*M2NR?@]5<PW\K7O+?;Y!1
M'S<C)O*>:J-"467?ORYWV7=ZAB(Z &F87VP;O[KV.Q=Z&GR%&=MZ5:Q;_\K7
MUA%>>,R;PV^$DCD6I"AP\76Q)%D"YI_*%0"Y5Q3JKFT$2,D>,#[PE&/K[GD8
M['V-%@*RAMVYL%L)A&3P3<$1C^UTP4O%320-_S=VK@AAK^-: G?DA+S[/[0U
MY_OOSZEE2NQ1<H5 I,-,Z/L)XG)*R%-2"RES;:96O&9:;TA_BWGQ*P7^!H2G
M^D9CSRN.R:H%"&5M>O1$^8/9HMRY.OI)@(_/9L#'!.#C\QGP,0,^[E ^^;N0
MH;,NIY4-9RA'@(=R(ST9[9+3Q%5S_0!Y'U:9)!:6C30IPJEA#R%PC.D$2<OD
M<@8:!L(BMK^ E\!'YT3*SB1.N(S^7T7=8[&7.W$^F]/3=_CH"SKV#4G1=YJ>
M%F6[L83]2$;PQ@2U"+1(:)UPQIC^&D<I1XZQ#A9#EE*PMBMUG%<>+5*J2;*@
MX#I[].1/)F[G;^KN<[^:;UI=JE^).A?\S+''FSWZZO,G(E(EB/@BYJR5+G-O
M]*24Y9@QZ%C$]=W70^"ONQGXFQU%_O*3C;&^073\?&JSYL%)7L8(892HUP0Y
MN_.KQ J$W/&4C4K-D$T%QUK\L,4;9KJYSK[ZD[LG%BZYRGV<SHG+%FUH[0KI
MG>__$>!N"_1:*C"U. ?'C>6]P9]=^F?J.C-MB/<'?8-"!13LZ#$+&M$+HF@&
M>[K<<4M5Q\W^\&"4EX57[ */$F> MSW9=&$&4/  (GIT<(:^<O@G+F@CQ]#-
M(P[=CT2@PMT1E_M%"]_=E-VF@.7#((AC5QFNH:"?=7&)O16Z" ^MBDC=RU]T
M5._7U)()!+-[8GI@/A\_.?OR3_=O'EOR3F(UB#AD\PRN*_DZ7)C_]&V3H^'"
MQ(Z:S1L,4BC!I&GZG4I.A2]*^IIR5!BXY9/Y2J3*B%B0EOBR*!LZYD\(\X=5
M 3NJ %EIC]A1PE#<\$HIE@Q"9D[?Y^W?9';*FSQ@Q 9I3A<?>\I2)4%RL![W
MSN]'VZ7&# ^#"VQ:]NU*=-P(R$, KC\3["R4:X3;5QTS' <IWMSDGXU,BN#,
MPB;3X@J>(]PZ-?H#@\F8G:21!B_9W<5K1\"M:^SF7/6>UZZ@=>D"G(ND;D]*
M)."1*?G6\>L,4SM^.Q^_^_3'"U0"5%B2C<QAIQ(%=.JHX&B@(!9$G"@]3I0$
M"P%8>7(1F?,K^<:PVLKW0]9E1NY%53!E$"0P7'I2:X\P6JAMV^S0Y&A;(J/]
MX+2%>2A0X+F[).]LO<9L!UT]95&DCX]N,L<Z=WBSAJ5[JT5+IKXNBDW5_--G
MX.C43;-#Q=LMV_VFO2B8$S]&$Y:^,D'4_&S1I@Y655'*LK?K%_?%.;AW2X%S
MGW== X[>3HGI[!+G[U'?ONZ%%*HS9NTTL1JA$E05J;8D]G3\18!/.-*GV-@#
M]WPI>F^D_REZ]Z=L+^$3C8<*WEIPSI4/,BP#1E#+J20]Q.@)10Z]:#_"..8S
MZ:-Y3CA3W($3(C9A=UL,?FE'E[RI8@^ %%P/'SP$SP)3<2$!V-1MB'O-*3F;
M/9J2K4TG!0'81) 8/#]8^QLE=,4:_ZIGVA#21AKW)H2[I4]AP>-8WHY[EY#D
M'/HS*B<0T$3Y!#2 .:L9FB?CW_C-MFKVWEL=^0[)Y>*GF'R/ZE1L1L&?=,TB
M(B8"-6C8R]3/@>S$&*Q0EP/!O<$@X@_3#"E=$R("\$FW& )["<PH?1"?3+UW
ME[[57()6#<LS9.C<)_H/C'>WHI@?_Q;ZX[FOOP2.6B>;X-"!V[2C' 1N*DZ=
M$W(M*Y:P[81+8E$*5W.OK#GTP84/>Q!1I!""L3 Z=W)1_B1W*P@N*6I;MSV$
MN\QKN$=$'TD542Y-Z#8QY-LT5USO#Y20_"1CXS"[HW=X\Q'KES,\[-I<),X3
MH8"5KYCR>VH3:?$@<E)^%J5V@D,WX$JQK S*;B7G0<11DGXPG4;HF,;F)_"/
M6W3S5).7TJ=P(4HC67[GP M%YI=2@4*9B82SKY0&])4G?$)ZW S[:1IL^^DZ
M[::!QR:->FI6D^08GXFB#Z5$IZ/C^ +&OA/E=L5(L'K<RB-:A@X#FI]I'GQ2
MP I3'S^94S%LR2W5VX BE)K$MF]1UY!O!C.+'9Z<YP^ L$"[?N"OEC@Z8,4D
MJ41PC3B6,_>2Q93CA6+X,7EY'"<G,(U*04FZ :$5E^, \#G:98G)(C W1%*$
M'89UMD&R;3B[$5I;T/O_<([&CU--Z,F,Z9C ='PQ8SH^;DS'!W&L/^.F],F3
M))C8;F2O[3%RY*A 3$;D<AR>1?T6O_[H(;6A.PIOL.,VLE!2T0DS31C,=;'%
M>OK< Q^V[CNJ&-(-\EBTX\M&Z<WQMZ7-UHT&><(US-D6XW"%*/##/G[R)XD,
M2ZRJP(CA,9E*E%I 5'68? INTC$\H1.WA&MR[S'[-31*H>A6X(U\C*^1/EU^
MY,IP;G.;-'>DDT'D,[\(MS0.F#8"+8KZE?;D%16I#7,IKQ&F3G"%I%L:F0#C
ME_*$9,\4""/>/U7R(2_HL"-!_M]*6[@./R=3PQ/AOJ YY)O,1A_9SZUZHOU4
MUZ-O6)*_UC/*^>@JH<EDQ1^FLA5L+7U#&X#B^L'&*\PA<!:T65.W%+*?(B[_
MDX:ZN(3:+VZW5&OV-A<MB/)U)UKQS5H4<S]A!@G,E)(?QH,ME*^6'#XWOL&'
MXW+-)\0M$I>3"SF@4PJ3DRA,3D)V2)ITAU]NFIVF%#CO/DKW[2Y]3/=1H"@<
M(PCOK\DF1<B(!FJ:1AV+&L<DX%BA)Y<F)S"-'77+FE;!=25<\#9WCWRC$&UP
MSR?G/R[VN88K5(^.(1PK)> FLDV&=M1BW0.)RN !2SA%=]JR4VL#D9BT4@D@
MTKP-MP^LBDUQ88Q1@7XB;E/LC8BTH)T23)C'%5% "J<+O$^[(FNQE[B2 V9#
MTN&B6OD!$AU^C=A+B2S(@?X4STPA!\(&5Y486\NY-WDAVPW 1!H=9DS1DN'R
MP'&T(9V+KZ5M*F9#GB+W$0)=SA=CCAN_!4N<CE'?$0$4R1_2L80'&I\&_.)A
MM%L:OA*IQ)WBC,D/06W 0-%;8D"%MR%_10OD0U+ G0WHV[C8RGBDKC:5,HQ#
MDT_Z;;+%Q2>-SC@>YMB)IT9!/B!GNWLSSY07]E7#E#YC6 2G^P+2*_5JP?H1
MT#J0[KBI38@FJL5NU93"7&B:F9TGN6X^GA)]UMTQ)_O_L_>MS6T;V;;?\2M0
M.36G[#J0(LMVGG-2I<B.XZG8<=E.<N^G6R#9$A&#  </R<ROOWOM1W<#!&TK
MK[%IWKHUQQ%)H-'H[OU:>RWDCE@4/8D9 ?79UO6UGCOY:" FR"Z.-1_=31P,
M%/-=YYY:I;ZUM)4(VK?*T,S<48GF3>TDGHY!.'?)/95Y6A9T#"]"J3T@\/BG
M;'=VGGA,2(0KYO-YPW/2QIP;##^&['SH=V?$U/A\&ZQB6W 6,4@58$#KB("A
MY.6]]7RUA2]L1NC:%'&PE?7A963BN?H7F_2H?Q6U!FXH"#XYO;U5T6'):ZN!
MZVFIE8!"1 B#D5P@PQH98R&UU(3BB'E3S/#JT(K]IKAIFT;=9YU]FM?O]G'X
M,@0L*-X2A.)HH,MI\-?I<&8&;E.OY5CO3!ACQYM=H(.MV9OG''3A6OM-K'3Y
MYBHB'+\W\(@-?<&HS."]+*Q!"#491#8"XDS7_,*9Y\>HGN=7TD4L?Q6/=T2*
MV##M?5U47< 8>X*=/)T5'(PG8@$T(G%R<BM\:0*@H*Y^#OK]DA$7.$C!OL:_
MHBFXKH]X&N G!\)&LB%H^0 ?IP033KAE5]+NG%=)1+>HMDH$U33;]?7;GI?I
M0G1,=M0IQNIMM:;1P),;#3Q]R\#36]I((A@6&A@4C]K0 JZ#E,GV>EFHZB4,
MLD*Q)AY1)^Z&\S8SG.:WOQ:!QIA:4.;*%OL*=>AFH+S :1&R;19UC'9 $NV
M;##+,U8@XK-V"P0J^P'#].0M_+ST[#L7U^&@W4.,AN(T@3I4W]JZTA?&.S+F
MU.7=@'RC41&-CFAN]3I_=([#L= V&SE0&01D>*\1 N@ GWB/]\7O :*_!=/K
MU1)'M'7QZI%_L7U&",CQ0Q+!VX1.8L=*Y'-5V4:=KR6T WWX*8B?YN$&Q^4M
MR6"UL;E*=IBKV]'(8\ZCW#H.=3^Q NVZI >S)D'_9,?I&7/ATM5+3LX9RG%,
M7JMTUE 'TX QKRKDSH7%MH5<:CF)3\YBTK3-%@ONKATMG&.;J:.A6]9<@?(_
M'(KLJI::.#?T1B]*5$5H^I[F[2+_=VP2;ULCGRPOAJ:$9[XL+!YA9*/8,GX_
MTN=C!+8'<[4WSXDD/N\G;>"59&;I,8.V/=!C:IM-@%983D>@;KF4]H$AAW38
M!-L;A/=GV3IN!(W\L436*_-?_ZT&DD\F^@*^SZ0X/C"7>-]=N5(*U1+7B^;6
M\!+<&!#/F@J 7O3($\G>,72Q'^4'L[[V$W_TV0%_-($_^N* /]IO_-$'%D>=
MDR.W8IP[=Y_,BZNB]+YPX09J%ZZB13=W@DU7X$)_P(^_SQZ(!D 3_-QO:$7,
M? 9[Z?*%RMF($Q\)E'BNZ1>#HHVJUT3R)NBTL=]M:Y&DID7R<CG,1[V3%HOP
M\+WILC%Q9U)T\7KVF(,+;ORQ+D14"L2M 0!'BTSDG7!)+(+1#]59.!W%[OR:
M!E:+"@R#CGC3^ U#OUPET@)"UY%-1X\ZE%G^M5\8P'Y-X4,AD\>WX ACL$LW
M$VZ:2:!',LWQRQ[*P.S_-OA8MOM+;MEELL8Q7^[VBIVB[#78XZKO)!SG",17
M/'4Q6THW6J:W3&0<:=]F5B@8),FO\V;1"GJ.5ZT*W:Q0BD/N7!+'O/U%.BQ3
MI&,9+A_0F(&I>U57#B7B2M WPJWBUWTM C).]E8RN6-]AF.TG4)TQ1P<7;P%
MR=%$_[#?B;$<\7BS95J4W+:>R438%F7S^8 N-]RW#?,LF832UU.5S35$1/2(
M@KI9K1TCE6*Z@>/TIP&YE@5W6;*T.NSP2EREUF01TCA1DFN7$C&?CHN^R<LX
M'T(SP.TV(=@+;Q0_IU,[S9/&716TGHUNB!9R0*-MS\2%\:7:A<"F4K03:P8+
M+2I21^O$GI,+(OA*Q,:2X.X#HA4Z68_^^[].3^]]?43_U P.1:UYU6T%\E$_
MH,+H<D-QMTY[B;=5*;B:++4RS'B2S\%>38.];%#@;F6KA2$IU0M&+FLK?L "
M(ZY+#\4:=M6B6N(:_[X<)SMG%&;735G\^LHAQ:F'9?$-[7X*Z.FGET;:FR7*
M&=-J @&@KV;C(1F27V5LUF:G8W&KN/)78)Z?-0W66M14'(Y&S91=]C(Y^Q9=
M*9%7&#]USK+=/9.!A2./EYTV V>J^[;K^J9$=9-K)_[:#((3M@5_8]LZ<LI)
MWC?F9N(OA?RBOEU%<"ZTKYE]BM%XN;UKS9XXA! <$CQ1NFB*UR':XN+5DY7;
MZ')^XRF_[O'9E6(;997+:2^'^\%_V)OG?$([ /G'+!F:!$'K XTE@%+?76)+
MPMHJ^7@-3JVB?'5=A@6$2N^0G-_:!3:BP^G@;-/)DJC1<57+'<]S=DL@'2?K
M4*]XG#Z,UFQT4SL%(T_%A[JR$R9,,5=VQ- ;/8-I DPD1'F:SNL%[\1S=B6>
MV?%ZG'X;;W<<,)<U[54E5TEWDJOP"$-(8DHS)@/F@PK:P?&CS6"-9?^/GO%-
MSM>.R"/$B3N\G,/&WYOG1*5B.SHP#0FM%R@+IP868J6XL4B]<]IS!3R+&P4.
M.]9FX@,#,)-RFK2#,SH=&_BX *I-Y"DV(JH9W0;5MRKV_G;1!<6>?[+#\^?]
M\ 9O/^_IE9!3,^>,R,RED6E&>2;*H\6)%)4R&IGHY!U,=![-Q]#5C<[BXL)J
MIA'?2_0Y1BX(YQ!(Z)NE2>53+U$$],C'U($/W;_@>!ZGW\45U>BML /!(."Q
MC\&T5Q:#J/; ('[RLW8VF+>_TU0E U.5OJ.IVO_#Y&,Y-(?B*TH@:.@UCAH&
M*S.DS+-A<O.-;$ZR\"AHH^T"I18*:FEW%U7D!B1QOM['%V]*3:3;.D*!-3XT
M?C(1%0<X<Y"^9J,3*NQ/,1"2[-G:R\?I#Y*Z4*BU615$[: QC@;A1<I#@,J[
M38B: O<6/QM_.?9=5">&V4 2W;.=$HT OK@0,A3)F4)(D<'W<Q?XE_O L<LC
M<+AN> _TK/4\:G+B/BX[_$(*!#PJIN&26#L>FZG&'75,O T #%Q+'L>BGO>:
M+ZEP4."G-DEMOP8BYJT_C;RU.U]^?I)^GU_V+GVH3YB0$;V2)K1C\4[UR:+7
M$<G'F!7@"0GAI#XI.<F7?7XIS81(]X=!T*M<%5T7FC0TT\(B/PDGBM0H9/&=
M.CJ2VU(+"_0GN9&8C4YTF 4SDZ6:P9]M@Z0'+C-?N%$8:DW[GYT&V:/)]M;\
M?4GV-^ZP=]WMR5MV>Z$L-V<"D'K. *F#$=F;Y^0 ,=$UQY &]N?4R<[;=*L)
M9A0;1@6MK?#0KT%V0,(*G+ U=9.8"9@T-]?+6F%\ID&*&EW#133MX=5ZWQ1H
M3P^9+.2.YO#+F(,JJAQT$V'(?S+"3;"5/YS-MI] HL\/0*()(-&7!R#1APLD
M8@%F6B5EN48$45W^[R<GG_!_TP_F]M]3T)D99-O_"+AH@"6Z+A;=\BLF Z*'
M[1J[);F7G+VP.:2K#"?UU[Z%RO4GWR3_[!;V*[V:O(1//OUFUT=_*H;ILW \
M=XOXEI/#_=VW>:3@^>=%^RK]+E?FS'!C>K-=@W_BS>Y:U>_T3MYUZ1]@;C>
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MU.<",^ %Z>,83;"$/!KA0\M$^M>X/.G"V3CMD![2#OO_G&"7C-_YV%/SO38
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M:^^(>1[%U8&^T00\M<!655Q)DR-AUP0G7I(G\P4(.[9[S!$H)1D_BRFN O[
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M/G^FEDRI %/371;5;%OF,@R?S^1DVLNGW]'672_SU-)KCW^X\[DRF6&]R#J
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M:,2EU7%GPY0>X'UD >G3%M"+(EP14\#6S7QB02<,889#J2V;?Z45LIX+5=T
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MG"$51L!E4"C)8@GOX'?C5KX?'_.P02J+WY,%$ /76G(>4^[SONWRC\][-F0
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MMFM*1@8TB>%7MU;%8J'\Q0MYN^2.;.1AI.EZW ?"*!\88'D6LZA%Z^WMQ.*
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MO7#<)BWQ9^7 2XQ")Q.+0 !J"S_$[C"G?F,7T-I+(6$>9,M'X/.8-">9I,A
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MLJEA@V?4NJ8><%B.[RM"Z4%8*W"+AE(7,;& JKQ\< _XL1P3>R'3!+[OUH<
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MI*<W10$CEY7!"E3[?HA\3(?E+[28$\'OZR[>IGN\5!&9NEF#N$? L8YA;[P
M=]4VZ&1C2%ZG''!6Z_A3DFO).+G&UW[XY"Q44>)L^@4MX*.N0=HA'OK,V>BV
M%35]Z&/>O/(%&8+BRE%HM3BJ+X[6QLFZ4@O@'0X\=D1LPW(7)3B/N$01Y<4F
M,&?*WXKR34\A!8P)MV?^*Z\T<WIZ=Q2C+1SM=99S&W#IR!-;+14#P'DP3,IM
MMFDIZ<Y1:?0#3,X=]O];]S^9PF2\$(I65XRL(,D?;(7& ]1'YK<<. 2=!MQ2
M8-3BH 0+2 PS(\]+GZN0>R6Q+(RL8S@RSBUFV+1*"U"O:(<L<D&26_:!=]D#
MBBS,M,7>&G[X "#?MFN"EDQ,=B+6E@9;EOFLEIQU$M0@00)6;6A%?''R-0JN
M=!L4S/S-=\_#Q!-++:/2O'BF/)H 2&1O9:^.WI-0?*'4RW35S:K]:K!S;YUF
MDF%QW+\@ T&NY39=MS?F//:)6'QN6+'$V/7V\G4I0*P8QY#L^!4?37S<8SC9
MZ.-!:@/.2ESOP0O/A6Y,XD'Y0I>OI?_NXB+FL^66HT1@67BDUCM@_A;B5BD1
M,?,XH"2T6-=%Y5G@[,R3>WEATC?YDC%E&CM*R>EG.H0W9G-H(%M/S\TE0@,T
M['6 %$KKB^$>W88J4<-"EPQT4^\40Q*V3S)2&!8_8CM!Z!:VV](:K?*UMED5
MC'EF$Z'T;2@?H_&?_IF+Q 2OR@C'H&D 1:Q9(R)MC.06'-&^&O\ _V6!!Q.+
M:D6+_%M4H+6]9%5TG7.W(RB06:N>;ABG,M%FB1+5:X:IE9OT;@"F90D=TP7N
M[OXM$+V9ZZX!BE"":5ZC@Y6@1)#CQU9?'X+03#'I=+;3IB]!58NWV>6OG'(F
MS?G$T\RAJXZ\;VTEM[G3UC-9;8/E94MO<JQ^8^"ZZ3;SKVP O,F6%7,I#/O-
M^=7&+QODGLW4#Y:>#XKL#LY$3>!<,&EOIW,3S;WL+WX[3?VKG/7T?0X2:$66
M#O_ T#<N;X0PA3/1M21M$OT]CTY6A2$^N[KS#(;\!+*QXF?B9U%@X[Y;Z(_)
M$WE<)4\1<&OY8>S:=L,E2+OQCX81H7_5<@!B81(*$XKR #CY&#M%QCH89-KR
M5H2OWUD2X]!K\AZO^1<,^4G\2YOJWE!84-ES+C=J;>",VH C85[GEPJRR3Q0
MF,EL_]T7[-2$9>,7#9<NP8[&"!A_^/C("EY(A54GH,N>'*3C] F4<YF G]L0
MZF96++B4(J#[1E&6.?E3E[]C&2=#E)3-SQ"Y%V-#N3.2I01V1! 2=#!=U: 3
M15HQC]-G=1U(T^J^(Z?(M0GSB@A^=001'4X\(\@#$4B[H7NOLG30\:]MS4)B
ML:M?\SA]&)-<*3XI\0'K5<&9^SZ4C ;D)YP:0BI5>KFE'YS<Q__/WKLVMW$D
M6</?^U=T>-<;9&P#YE67T=@1-"7;G+%LO:(\\^ZGC0;0(-H"NK%](07_^B=/
M9M:MT: (V3.6(&P\SU@D^U)57977DR>7LQ7PC.]RVA=ITS!>E1[A%P+)=RR$
M5<Y6@^3"DTU+)E3/$GP:IRU>+.1Q9#\O:!43^#08Y#Q/F?! #*U%/J[* 5*+
MY6)4,J?62RYJM]3^P&KZ!-D^@Y>_9L=NT:)PT6*$_K5PG$::SPW5"3UAL2+/
M.I^X]N$RVHDT3%+OLM)&T>".J7FK]Y^VS@SW2OFC@^MLA2L[W>/*>G!EYWM<
MV1Y7]J?/\[DH^N@NGV2#FB2T4^^WZ7B<%U =-R!N;>+KB]?7@\OR'X,3GT;2
M</48I4XOH:TA"5Q7+Z'/5*:013D1X#]TRMM,[(6K'Q]%RE:=2^#K;Q=_]ZH5
MDH"/)[ Z^'ZURBPCV<H/B FYK&^VTS<CI9G J%(32XRJ<AJM&U)-.U*0^F2C
M2^ A=FXSE]7ET A#Q5Q:&/FW^.S\"/K_-'ER=.0&9I(XTY1'!:MDJ6'<?@:E
M1JALD'P7!QKQJ,IO%WO)PHPC7\_U(UV:MA8TGU>BEMF897;ARR0^^&O^S:QI
MEO5?OOIJ7-[FD^%X,A[>E+?RTP"Q/$FL9=57_T'.5#&I_U=@?1-RK&;U_THZ
MX'^/CB)T*3F4?+RR\V<:7&X0"N+BU'PN5K-7+ 1/3; *'*_D3ZH8\G4/3G*9
M>^:8G9NG "C895H[NPQ4.3HY&LB^S\FFS<9(6$BC'K9R'[R#Q/U#%7K5<:3L
MBSUO"9XB*JA3;%WNFD.W(5&,7VHC('F-V_4<N[QB7)!02S%%8(7SE)E.,RBS
M5_) OM6<"-,+15CX;,8,B=WL72Y]J>D@#3R(#1UTH)$TQ"H$V8+_8 Y&\F]L
MF_8E.2B(R*<<?9N0,S61V*[)UOCMU[R<=61RUGU)Y V+V"G,L<MN4Q[></;G
M>&?F2?KD4G=0Y.T@Z(;=G_SG\I&OBLA"((^ZY7U>UMLK] OK_"0%U-^UN \K
MTR=W1*+(DANA(S]M(WD@J"$W;>-EM,0*<H<\/U.M-PE&X>6DD4@?D3Z(@,.#
MY6KB>WZ;,5P0=R](YTB->_"\)PS/&\:O82'R93/F)SOX\E!P":8.09KUK>)S
M!F"\6Y'B2!4S.,G>10<FFYG6Y(_^?/+5=_G/)S&'<@Y-8R^M5C!=VCK)= Q-
MX4Z&-9X^D/U2-"_2PFQRMK".>3 G3^R:RO)UM*FW.Z#\[DJ_H)BQ!5G.H;F+
M:A%?)!O6K @_1"F7?[OI<BSQ,.H%#-S9#H>ZVF2%8Y?"[=6%W[SH#$_O+GQ\
M@-6.OXJQWH=[W;8S\_RYB(#5BX\?)T[RN1QFMVSJ'IF"9HZ2#*??>M"&M2-B
M"I6D%2ZV_?%YYT"9OM-T*<K"<(A"N)"536OG@H[-/>>%JS#B= UYP^;XDPA"
M*EG#C04-T.A(PA_/;UDO+-)W8!MPT'&I3Z8?GS (O2/@?8:#$N(>X@;ERBP<
M+QJ[3)*?B8Z?=);1>?,'CXZ^/-3E.W%7'9S1K]F:EV2 G&1>C3E_(@;-5V X
M1]K:;[0H #(27J;O)HEY3=K D^]F-_)"T.1>/M&%(X(2G[YU[+0$?[]*X<N&
M45>!;!18P!FQ2-.\ 0A.+*2E=I"53FMR1P>R8;@D6]>6(E6ZG),G [R3_(8!
MIS_\!0$(QI\D1KUYHHFOIR1$X<>IO/!50J.QC4XX&3C-N->R^:RVI I^%CT)
M;-:.CLOJ2[K1,6C=S$MRVCCWY*5**L$+\MY8*Y% (*:JY?1+X]GY:K&<(5<$
MBRE/%=U_PT=;.T(S#=B4K*EQP\<@FZTF%9JRIM*6"$I+7BYH/>^3#(R,<$3U
MRW9.!A!IPBA;C,IY7B]JMP=IE;@"K1PSZ<U$>CD]Z(O0F4>M95TFD!S9@OX(
M=6L. ,>F!A,2JY5&RY@5Q3*U1MJB2;-- 5N:K-1X3IXWP[<2Q7HVV=@[.(+Y
M\ H<0MA>[T8=QF_NZ#^K >,.L2^COGWY@*.)$1V??AD?G)@JF>/SPQA?FV3P
MR6/ZPYG_!WVB:3XKY]:83[WFI.[X*4.]S;Z:Y RDM,+%.OQB='-JCM&%+<#O
M@J;G#L&LDA8L NV&B-<W1,04>+0E[-@Z8CX)"A-Y.++X@"*.P2AHXJ>(E;0&
MDJG1DOA@GJ5OR>"2@A__42HR9GG-_2)L_,;R4I>CNJD4K^^F8,Z^61CW%UV%
MO56V,_.D;1E)1%\KLB&E.%1G])9H*R'39%-?NU7?M^6M#+SCMG0CD&4IE;3H
MKW5A$'6$P3#^!:A6$O8YC=V8?X*+15P]>2AR=E2"I<OBXX57"N#B "]A&D,W
M9>0;GV)][O?[SLSSJNCYOIV(A91-L2-RG2T;"[OD1)2R0,AZ>?P2=P:"21OL
M])'&4OPD6-27! L 13%8R\A4 ,[%N@0O])MPZ03-^9>"=JV,D"9%VG"FA!=2
MF2L_(/S=J;!XM<E).O[+,>:EKH:)'W3B UKR\$Q8'^WPK7^RQH9W\)34=5\F
M,HF>/OE24I$*PT%') $^'6K%>6^H(:_OL7J?Q6\S@-/02\&_RY'7IK9BEFN]
MH-2-><!ZL\?@W==T?:QXA:V -6=[8$T/L.;1'EBS!]9\'*4-CA!BK:Y!:2?Z
MU760 7EU\=/%RY_]<MT'@](YTA+T>S=%2 )EL?0'-LI-?KQZUJ2E[XG%(-9W
M.GQ*CNLR_IJ^S]'3LT..OBG8QBO9Q+6.Z3-*2;&7E32>]@ Z8_)</5H%"6S>
MF1C51*V8%!6=VKM#B[46&3W/59QUM:O2+M)79G8,]( FQ3V/%#/,LP?CC? 6
M\B\NRW<8L(DWF#<9#SE3HHW>T7#[)/_9,'G\A]LK&>\]00F?*R&S=7;  YN;
MQG85'3U6)\JY89+^0&QM&Y=]*40)@6D.D41IO!P@E\5?@#[GR>/XP)L@6*P<
M*3U7ZF4(W-C1WK-^<PD-==_P]"P^ %HB>$ODOX7VD\TN@2X,  <W(]#1XK;U
M3Y79(C_=P![$RTW9#(<O_J]Y\XS&=*Y? 'R9&HX1Z@Y$58*WFS=U" 32WLOR
M.OAZ;'__$R"1RI 6I(57-GU0?'UR]/30,;A\R.D\0[3)MW5/CH<G7YJ0DRGT
M/7U,OTQH._S&KB0V$Z3M.2WVU[0>QV?TJ;7Q,W.X%%W47Q %"VF7K,ML\QWL
MQQH1)U(MD'22 ]EUW?"YZ$ &?;SV!/^8><!HA^]1'[LT3[)S@F#"NJV#YO$C
M0_D$"?OBEPOE0^*^*064?WHC+%HD%84FK@X)55"'SZ9__*UE7)F1R<R8CY;,
MC4K)4D*E04/AN("ALYERE?(:)4S *H$AOJ\544^UE:85D^C!]ME>UNW,/.D4
M,#.K@K M^Q%*MY2EZ!?96=___,/5MU>7@78^[-]CKF"Q\!@;85=(8US.B#J,
ME?!E1&=/Z.)6 -\2Q^*&H2__@7C7B\N7/^^WW<[,\PK8D[E'"\62MA'$W4ON
MP(R/?R%.EY)]7BR]'-O+BPO9?5YYA\D3UB37R<*^>/W\NG\GF9SOBY<7P^B*
MGMS>M'7CG0%0<Y&9S>UGY1C0^^"NL.>&RD#K"J?>J+@KR9TP=_IM(C1IHIW+
M+W]X^4JO81>2,]U\0(!,I@EP7E-(1:2=AO0+F],I?4RO9XU5-UKV(>,-HM'[
M@[(S\WQ31DHJS>WTF'8FJ\9,.4**6CFL_% )LVF+_X<;%M+.W$(2S(Y18CB+
M,^!&"6("H>0V):DMG1W*$2@9(_]AMC<ZZX42E4[C4"_8)M#P,3DB*=PXENC'
M&58ZGF]_%#7#[[$OH#_V/I]+GLF[]32-*5:0FEW7*S?I3A&&5TZ+GU;>77J@
M%ZETL%GQS%U--3>I$>$B ( *!6C2QB.:@*Y+("6F<30C"SQ^\E-^[51\[E0[
MVF$"CE=)^W:[)2=)2(N26"Z_(K XV:2\#$C\HL:P UYIK;?^U=/K6LG$,BVO
MF-6&+BBT):&C%5.'N.6TE[819RKB-$0TI\WL+L5JW9$G7LN0(^$+-.V(60PS
M:IH$:&DXTKE01.Q<#NUP\10/@4$RPOID0;I@1O38Q010- %A$M,I+9'#SB:&
M$JYP;X_X[776-++UF(-J05^HJ5Q!UWO;E02,J'91[X09JV40E>M34BZ5\8U6
M03H511H7='6%[CCZC%8.@.CU0Y'P'5_%T\31S,9[(WR'YJD=93G2@.VL\'P^
M;J#2*JNW4A<IAZR@\=)KLF4MC(>,#I&=9F$3W?-G3@ ?G*#]FS0D$I9QW<(D
M[+5/IVQE?^?>H!RT4%A(JDU2#7%I0$MH'6%T)4":8-]*<)?FB=(H:XRHB;Z/
MD.W2/$DL2;8'8J9&);=G!+(P"=PSA-737X$@YPL"J;%>_^TZ[P[C[TS)*6G4
M!7-ESF!\,GQ9.O?6Z5SO\=Y./XW:?"[^69'!!$8*S3.1<8E)N+!8G%:I "S;
M2@D4.=Z&"[\"WZ")W#G]C+ZO -.,N6$+?1*^)095(GHZ:B%L)18?H'IDG\R=
M'=U90(C! A5&^(6"7<0,[)RDQ#8Y-+?,\B6,L4@JU V.J&OMRHH8@DI=AK5Y
MAVRO<3[E*$]NV;/W8GIGYGFE53XVTC+* )]62JIPT[&[U1OFZZ5PV"KV%]T7
M^XO?'_N#0\D@',Z"(AQR4V6<SU,[P[1(!;HUG^0IYR0Q('A-54K'<SQ,0"IJ
M?G& =I[HL*+-Q.FL,6:OIH&,LV^Y<CV^+*OE\)##+W!*:CZMOPROAS%[?2A\
M5V)9NF0!<M7^!705]V@FR'@EA(/X26:9R"BK&U1?U%YTB [FT Y9I0T;6O!V
MZ'>@UL)/@_$LE3(15XZO0HHE,>+Y"$4YGI-(Z*\-0H\]-%KUKY;I^"W[F(D2
MM(FP, ]C)ZY?=AD?5GW6VXSE^,09G>+L*L<'RW@L0*2"7KYCQ>VJ@H9 KK"@
M9\.Z-KL<T+ X3;NJHC%\;:17I P%  @?VB6)1,F01E+[-7'*QOP3D =2,TFP
MSHD=0SJ=IGD5]KB]<HZLJ 71;&EA%:-37:&@3B(WY*LW2AM7)UK1%?,'3QC5
M4?#J2^8:5^NEEO"X^^GM!># 3CJ*T&G!!^N^W1>C.PW(/-\#,GL F8_W@,P]
M(/-/G^=%'=T9A7&?NC6!9 D)S23&'%XN,<^;?,RQ^,2$HSUMA!M$"]*#QYGR
MAK%NBXQN:[(42FA9H8)9"DM589,^6)0:L/7NC('^$G6-$E,$J(1!-&4^^5F6
MSIL9URA8A>)QLM9@K)^1@4._3J(*'!!FI%VMJ_-;"0605FBF=_1DCF^;5!EY
M.F+72#!7GH%E G?M2@G@M<HR6!-=[KVVVYEY^FEHS:2-:LN+G'=3.-@P/UW]
M$"];0RR\=D^[G'CIE9N6MO.<V0CO=98L!X(@8O$.[]:ZR3D9D-FD,YQX&+IU
MBWR%M,_4.G M'1(@LRD>PLOAIB@C(L9AV!*W(QGOP0))4IRY@ND<!4/O(JK1
MS:,@]U/#W"F3G&E^W<DI\A0E[KS9':7G+-#=I$]V)!)K9B9@>HEQ ^CWPI-6
M\!B]XD:WT.R;3JITVBAY6\Y+M\"C\LSUFA%RY+N8K9R:75,,3;):"@O 2RR,
M=E)FM7"LK;7?6);<:)3\0G(PP2QIGX!\'4GU&K,B_SDO)#ICO :28R*KU*=P
M60+'SD;+A"A2S5L$^&2W3;A,G>Q[N*2*AI A&\_%>$EK$M*U&[HI)47+*6>)
M.1626!A;2'RX(6S7%)VWZ8N,*VT?)7>\I",98R<$Q-YRB9LNBOM(G7WV01M9
M!M*?S=Y]2?BY2/R_YM]\;S-8)&LTT[5/7.S2/$FMW],;WC1(]+A\6+!"2 AG
MV7_]QY/31V?/SDZ'C^,%$!(^TO9[]&LKXI=D(G*7-KKKA35P(:5>&PY+%/UN
MN.,'5ES=+("/K.B0>]Q#_MFGDY^+(^!,DT@*DJ2Y75LYHDTNM?41':@$PB^%
M2P9UPG[G)*^W64-K/@5EFA'UO(H.NDSZ3JI)'%1N 947N5@H#1$(D]JN^/'P
MS*RXF$+R97(V[B4JQEP&*"[)%R/47IG%>'+T)8MY#0.'!2V()1:HL''-)OG3
M]-+T29JI:*&16T-4$Z!!W,B40TIX#$KI?AF?'C&CUJD <4",E?@U8_1/$[V,
MFNZ3E!<Y?DZ[DX%^I\>)"][;/:L+=GHZ/+5;M+.;7.$"$CUI9>.-F[>9,*/
MM&&<TI*,.E,+_H%*E7>2WFD[<MB>:.MPMF#=!0Y9*\R!^XWQ-AKEIEQHE'$F
M4/>2L7LX=>;&:0A^% _AH#5[O?Y9MDVZOKS<MSWZ:/<L:I OVR8MLK*MH_K_
M6FB-FCNT@,F"G"^ZARG?\2$3Z 8&\7$B2^@P(%60_GH+/F=$PBK3,7&LWH]N
M QLFJ@-B.TZAM 6T!G<YY$P9PJD2&IJ@7V.+*!;?A."3O M_GN$G^&/,E59.
M&W0'4D=W^+O;P%WX722CDZ.CY.B(65#.])_C5.M(>7J@X$=;0QZ0R,HN,U^8
MTK6>G!A"AA:.05[2LJF.CZW",8\?1B_LA:ZA]2TR6J-5?).!]78YHS,T+]5.
M8FMJK26F#)Z><*RS668E6BG::="?BI*#EO8M<*6#13G>_!QDAT'0XF[?N"]J
M?R^DI)*UAIJ\[/G$8PI,)[<I6Y42\&Q2K@L>0_(LW'=(F>&EHM?]$ZVT/'D$
M'#&YLYGMXK#IB7'X1-YYPCJCK,+DIT=\2+B3 1=3TP<?'/-1>?4<__@J=M?J
M973,Z3WNJA_I7[I)70L++(<&.)2ET>R>BID8:5#G1U\Z]LPH:"XV3Y>U\K31
M;#FAV-!0*AB/8TY,6FNA62W5FN#L<1IS1^ EFF]AY 5WB-IU ?@Y"7HZ?9'#
M6D%=0T0@E>WB2)4Y!5J0SOO_5B)R#K!%FQD]M.F@X$^IFO'\- \LX%,MS+.:
M<_)*CQ!5>?V6A^"]#@I$Y4$HK4X&YU^B9E//*E]T?#1@*44JXS9']8)K=\>,
MD^0'%63*?VEP#C>2*F&R3))K$YRJVW)^Z] 9[K9C<]M$#Y 99!902;%4^)TZ
M9OT-TN@.@4 \T<RNX<> P]--3IKH[H_HCLP31]2 TX%F5,\1.O&]P0FH'!+S
MK%-<.Z0-*B"1DXJD@#E2[B!"^^& #2-S%O\P@V_<+EHEJ? -OE@-OJ37XHNV
ML?C>!&C2/U3"15M*N'@["??E@T5<]&$B+GZXB/MD#IH'T?BX<1=; 80>[0%"
M/0"A)WN T!X@]!%H:*50->U=N&X</+\.99VC>%Y9'HY-(+EJ\X#Z%"[=71DP
M^$H'DX =F]N['' WD\-NXQ+DJ$D5CW)E)V%IOLP6HXK.]&\M[N<[OST4O8A6
M@W$Y^E5:G5F$CM2PI5)^+#2AW3I-Y,&;=E':*'>W8C-"LV()8M.:H,D).KLL
MN.,)OUF:-S3E'&A?,3=\2F(T<XC?.YW$+WY#O$3[ZGC#C38,UT&:[?.#SC%6
M,>])5W9LGCBR%W6DFQUPH1B(GG*:T.@[33\L@S%.L'00R@L]XG3WRD]B5FTQ
MR*4-B=>%I)-'+ MI)D!2X"R)GT32@R516B-I!I':9QPGC]9[F60<E(&H0.=,
M9.9209W+LV,F,RH$5)XO?.9 F8(YYMYDH[NT-I7?,MD0EA4Z%R9FYCU2%LMT
MM3+&OPS UG3;D?C]Q#UZ_HC+["W7I(O-'5R^7N?R=Y7[TI>KX2R482U>ZV9J
MR0U9'M0<T_RO_WAR<G+T[+5YSPNM^RV+Z++*&2J)#.(U+*+X#>1'S;<</XL/
M7K^XO+I^HX(TZ"_ %".O)6>*I)PO6?9"9$?FR4($/2FB*9Q7.8DX6*Y;C=D+
MTD)$6F3XRCXXC&H\6+Y^CYU;6@;TD;$FVO8>,HIC5OK4;Z4?&R(&: "SKR?<
MF7FJN:G=Z5)KL@5:K+/5.'@XLAV7UGK;E+5 !V=EA_@?':U8^WC=LU BU2*J
MP0KT'LVFW<7X/ZH*.>DD&DHV;D>1,;"6&[VPEC556YI>4V4:FK,DJ?' )][S
MZOS=VO-(3%_3KS=V.I,JL'>-:=%U(,&M0U'$NC0'C_Z8U3A.3OY5ZQ&I"?"
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M-*QC G>VS$%RM_FM8RT-T^7JA>J;I+>47P0,13X!3ZJ8%/QR!0LPMRJS'*8
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MI-<43)P=EG92Z32EBY^L'8EF4/==:BYTBZVH&(Y'H]TV&BB6=]S<U."\DKA
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MYQ&_TA^4ZY,762R,N==VVE.$&_L8C #6V!IPUWW'KXY;IF&?:M4KE );<G4
M/;.(,X6838PU$FD<OWQ+1YX,%C[.K_Z>>-5\B04^N'I&LTA%X/!Y[!=>72"
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M"7"1TFEQ@MI/DJZCJDPGC()MJG8AK!KKN"&TBI.T(.@I(:ZW&H1]SIHF0;X
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M?P7RF.F :Q'&1JMZ(8DD/CTS3^P8DDGD--$4<M\F'3AJD#J+T\%;27\_>>*
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M9:9XKOKOG">?5+[;HE6I%>TATQ-IA-2RK9:E\KMT6IF9H<+A,[VTY!GB5C]
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M$$ZMS6A-B7JUC9VZ&+*)\TF>5AI1O<S(AZX$\0FE(#&=[ZNR75J%QMRP$P0
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M'>$+N-:>O\X65:% I>BZ0"6R5=GHR."4CMBI38NFBH,S14_!YQ\CN%:+3$7
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M,J]V; ^F=1,L@X'Y;F1BG*!'1YQD9\PE8ZJ%SI*]%A/+F+X'4\=W"TF\E3#
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M FKZN="K3N>"<;IE:\<)<]T?]+^B2$VDQ+.G]<G_;)[%&P2)O!:6;TMHX^$
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M#K,D_2Q VJMZ?] NNZ60KW NL3LB6O0GPSDU*O#4)?9YFA5@1\Q+7H7+CQH
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M7")3A55/X@C>AJ(C\K&)I9#S&@?N=$J0UAOF+X=,$)3H@+0*'!<7#^JT/8W
M3H4-C^&D2+C@E*(,[5KZ)W<>1^I)7:P=Q/;)"342V] %18@-KE&XQ7.AB8Q
M1F&#9QS:Z/<9H)HOQH)\S'&$\$<H*0PL8)/='Y9570F )Q4 U$]&&R=\-G]L
M"%9?)@5HW!75C?*:F_=Z026CIS<+R6"));H:\.Z0ADB=Q8]S1H/"ACX;1L"*
M2)MUE7-BDDVU"Q9SH$;,>=R $ DW:TD\<>.IZT7?_1!T/$]YP9#)FLZ+0GDH
M,CGX&F-*U$!=UNF6":?-A.1[)7'X(/Q$N0\6X"XD;H9TB[/P9*29/# $"KI,
M=B/9M.&V@,C#L)C,G(/QI3X<235!VT+Y"Y7V7%O@&!6_J_C=MOQN<V2, CZ
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MGY8NS79U*OF1\3V.L\IA5Y'C<WBV*1:C\]4+#FQ"^78DI(,6]P7@<L^=<>=
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MCG66I1V6YO76#62>/*^W66OR3FT-VJ,'ZA4&LC9(\(VN,5,YL$.1%I)]9=>
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M<[0#$DZ6[+:4\<Q^JUW6[!%"K,3L<A09J&#XS= -O\.O9U'BH\N5S2Q^[ZI
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M"H&>DHFESHU=\*GP)F$41%?TE+P/\FKB-(2+*IVV<$QEK,0"85@:N@-RLH+
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M'+ZK8M<V)S*.*\7S4%"I'Z@9-&J46\(9/M1$%,CAERCQV;V]$],YN5K:F$=
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M!3V4G(<<-+5)(\<6*_P4JX=R=W!G:$,^2&_0VPM<^(?HBHL5'7L$_./.12N
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M407B.-F@$*X$>819 KSW:(]0W XWH$@^K@7#2[;(<H +)74W9'8CPEOQ9A!
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MXU1JZ&MJW_16]>5RD<:B*N1>NWZ@%24U-ZEX+<[.6E#/X%#P]ZFJZ,@7*R<
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M)QO&1,[ P9-0.9X289NYS93W/)<Z.&(X$@XAY?44SG:9!G@]=(3*PU0\+3I
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M0H?ZZ\PTRR_?:=1E5^X=L-[B"8<R%+8WP0LAS+.JT=AI& EUG0FOX)72TBC
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M4W[T?.QG-6%QED6:%5+(BKB'5Y%_/48XXN]4)Z3M3K_5^CRFQL*I@J&GB,I
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MINM^Q,'T_SP>')^67SST9.CPDP1Z-OV/^KI$EFEXS_ODBFFEAQ?X*B27/IC
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M8^/"@1ED-ZU5;QKW6O_V)1S=G]8W6>N.U;BH&S[E?AA@,V(Z!7C0M<NY]]?
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MP82B=+J^",BBN'=G\%;XA<<]H@03X.=S!RD=.O97[]2+M86XA\:"N<#2@M5
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M)+."#+Q4!EFM1:$)KS;QU)F?FKXH;8>)98*[ZW#EAZ"L8WZP8W6-KY03<=T
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M3";!S?PQ92CEQ4/WAZ""2PWIR-6U9G]8*"L/RNL37L(,VZQ^V]5G&DK:H?6
MU/Y"EK^]B.5?]?"N5R@J=]!;V1?Q]M*.W"GT]1EX<R"@0,=RPHB\;]6PEY6I
MRVJ%B1Q7-TFI-C)SV*>XBR"-,SGF%(G=4J7T"'+<(Z1V7I.9R%*=O@_T^2:J
MB1?%(55=ZO9=*NZXQ5]JM_8/#_Y2F5@=ALMW&F;9L1Q"E+Z/@MV#]6$*RCC3
M//B$?00J+P4'P\56U0Q_IT^3(HQL%=^;8N79^ YSWWD,B J<YUN R;@I7ZBL
MZ2RSR?K4(N':'= ]/_ .J)BZLFL:E&F$\481<7^II2L:9));U>%@EEO6X&SU
M1.)Z?EPTWE#+I4FN\AZ+R3#^:/1TZU"*L7I70Q5A_VZ*?='90HQ--_!&U!.T
MA6"\-I#C*84K6$%C*H'@]OQT"*(#K,?8O:-,@XLF/946\&; ':*=;RYVCG<$
MEOGPGL"CTA$N4.8;&I1NH+"BL3C<YRBFMN7<KYO9KX=RJFLW3 DK#JFV+R>?
M!E1"7EY=DD4A+?53Q$U!M"A<^&<J,["Y"A:;/'J>P/[[ ;T#>!KV%P$.1ZRN
M!7;J)S*P#-8;G,6_,7+GC[<=+5:FB2^D3TM:CP0NY#,!,)6#N81V,9GPZ'X(
MV;U+S1W*B&+*D,ED+[@#?XV,'&4:>E%1@+P90V;]UH_5$F8P]5Z6J9H^A;)I
MYM$I6I7([TO[MXV$JLR3HKJPI(V4^EQ%X(),'E"W+4K3-.IA$!K\H1$[/AH,
MC0FZS-\HB!844,ZTBVR,18>CA/K'=24'.AUYQ5 6@L8;RT(&-S$*&3@..ZWQ
MK-0YDQH52P>S33*+.O-U^JB5;D/9ND]P!RA\H@1#)H1/6?*FLOW>!"&CG.L$
MMUM+XG;)Y%1,)HM,9> ?O*^HZ[$;Z\LX"&Q.=CO:#+K5Y",,7] +9KB3F.C%
MHE2)^#@AJ+/RT@=DM967U7915N>%+0^6P==2'ZBW9>]N]*9<N/5;_VF6\=#
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M@.UN)P2NFT"6F]56/;4.BFM*BE-@YL;W1_9;!;:_58KMO[G$OLFE(G"G#I:
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M%X#!'0O+:NY=[P[?!KZAG O^S,$(A?%P# 3A?#\.:O0]'Z1/S(.D"S/BS(M
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M]S*15P(_!%,!S!A+NM\.0]V%/*8.YZQB8XC=26./9M?UP)QPZ'_QAWT:'9N
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MV]'5C75^?OX6F@X+A];:A-*M_9HQ+?CZYNB&ZK5>;97C^BFC/X7%E2@]G@!
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M9^U8*)=;$UCS@"QU<+U5HZ[RT&FF,];U?!+>O[%>[P2[D^%&GOW)"Q/1O0U
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MU]/(:XR9I#JT0NP[P+ZM18E^]]&!RL4\N$M8-?)%HU5Y<(_FG(,-X9PL>M_
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MA;Z-L$X&!T6:SJ:$FQV[XV(;+S!9ET:P>*XM8G1_O?B6(9O.U3..^1D[^,&
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MS3B6T@?I\S]\-^=MU)LM3ZMM>8$"87((JP<H#94ZMXUCE_MVKDEUWGV<EVK
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MAB>4(C^IP1PS7O(;<Q-6M*6.%RWY^(+8XW/Z*UJ(W_)U*&<^;7!7[9[1[[Y
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MF='O6>AV-$Y\-5K"'<5GH_@ZX+GU>[L<)J=4B;C*3'Y;KCS4&3\K3L%>-JL
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M>/K]7:I?3LDQ*6/BA7C(EL-,S^7/DX4Z_=:\K\0,YEM8EOF%7K[Q%LJZR^U
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MNQWVM!WJQASLO!VLLTNG:_3Z_5*\Y77MAR,WD_<$02:REM!YC%5&] \L&WT
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MQ_CW5)^""6#P%@3&AZD/8P8%OX>#)8*=@GH ARW8B7&BC^!5TVE US9\'W:
M@'>EL*4T^NK[GDN#D3]\U;.W^=R]\>"(ALT:&[K'8&#1E$>Y,U6$&>IW<.L/
MGO0I#%4PDB=3-O9!34 -[OR1STW31/A*]]. ;"Z']=-YJ&%)))B_/\/H$6P?
M*+$8&(X:^R)/\:\XP':O'F#0WY1]J=%&# (XQE+"S>JX'?3'.Q_."5Q0.OG
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MV71S]K'>B",_YJ  G'H2_B#+%[-A\OIVSL8G"6$*+M14G26+!047\@+_7M&
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M_Y::75#67-'!D+O\Q<2"R[JI*'UVI/]G0=WS.P(Q 69-=^!!""R(1H%_ZPK
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MI^85/YF#J4UG\31*1!%O[EN+I"AYM])QEA^]R'573 %/5F4:]*W"P</@(AA
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M\9E274.R6-) Q5!JJQ4E+S +1>0H?=(HI.,F^;/OF4?WG9!E:1'Y%][M:<I
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MQ)7[$&'FS]TK8:^?([HJ&_/'5-^8ZAM3?6.J[RB25&.J[[A3?6<7_W+NX-+
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M8:74Y#L.T]9M49+&8=K5V*7TX5";"(LGJ:#<6BIP.5UV]>&4F^"4Z^ G:@Q
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M-=1%QQIY0ADX>XIM5L+8%'K>00MW(PRKT/&C!<4^@B,W<Z)[\GGREPPNFGC
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MV(YW>Z-59D4TR')D71VN2C!0)=B&(1I&N173!74+39%>]01/WXU2T$#0K9X
M1RFO)X173#BFLL[C RH%W0?=:@IPH1IJ7&@WQ)1_]\<@O'6][FV9%UT:,RF"
M!#NC(UCL_YR=ER@Q&ZQ5690D'J/FY?.V9]@!HW;.+ <S]UHT9IYQ;5HT[+!2
M#>YYUZ8IM,"'9-.4J89&C9JV5 .B=LBJ 7JXR(1\/KJ!RX9A!W!J43<H^0XZ
MQO *GQ'#CO/4HG*0BT:6=-15O?_)?2% =6JDI)98TYH(!P))NJ@J^?S%<])$
M/%:*RH[ALG,H.;BY5Q/)O*VD7%:*R@[TTN">=Q51H4G];*V4UG2#A</"1%M]
MW@X,CY&B<@=DFU,-A5WF;1HI*G=,MCG=($\+>BP'&&MY/DAWNM%W3MR6SRX,
M4;= E3'DQ)\A))5N\ISV ['D1G/98.+DG2U&-<:3I%</!(P;+JVQBW!8G@^J
M7?_E>[96I7SO&:H&KK([]4#X]KC+[M0#0=K>RNZ:#[8,%<*N@9C*5^SK^D#Z
MA3[[T2I<HV%Y>+IOQ)'!MLVS"U JIBFJA8P<A)<Z\/!*W4 O+SMWS8^":95M
M1ECJAGIYMYU30(T9)\=:WM*%KE E^']HA( 5+LI:4:' ,(@]Z'B+QAV*;517
M@#V2MR+;#+EHW.'8II5%PZFADX.-*H4EY&K&'?$'^QEKKQPS!.&V%=TL!-Z6
M/MRZY-0&(0BY=U &@;=_^1HC!"$+@M^V.=P5 _0&,0BY=\#/ &/$(!PQ"+?0
M:W;@_9+31T#]#B,56KV!XJ$DFV<7QM1(#:9M4+P) Z@?&])B:^NW</V;XL@#
MH'['(*I'>;XN%XM)S)\4Y,;SJ?0_NM%*"!Y=:B000![WY\R%=1'#8>=;B(2T
M7CP)9G)V[KW9O;!T0@2F@I]OGK:Z#UWZ/,15HH^9)(^AV'>["W"$)6P@(+@^
ML!A16/T(A&#K42+<(TLW!A[RR0$GSQ0I/)?\2L$OR*]4$?1'M'1GB.^S>!(3
M&*)X/Q-\*<F<(F(3^8WKSY,/R; @0HC;,'@0DH^"M(<K @>%G]EHIX1$R>?^
M6L/GW'"! $,"Q7I:!B']S 8E:BK\DWY^0E\:(3@1/@*HLZW6O$B(UC?_AJT@
M'I$C1&[XZ,U</.,48PI#K@2:"80 MQ O1"1K]0.4M3_=%=(%R$L4@9_]>B3
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M6@I!C,K?3"W P,5EK\/Q%+\$CZ0%CG(:)WXR <AE]\'1IGJ@-)VYU)?UW2V
MR''W--;/%:$;K$ELR:+.F=:*W<4+&UO;A[0TU M2=22*UNE<\X4U>=";(VI1
M1]1D&!YZ BQA<^AJGPYNA\XBKB@'^-EQJB%>9+_&W3_+1+6DG9Y:8OAZ)=2)
MH>^W*S7<MK=J69Q0>\?+H#V^G]:K[T?2Z*6)PEZU<==BWJRC:),9>')>T'L&
MQ:OC2-ZDK+OAA6:L^HRB;U0&T:NXC$K/2Z3TYK"@]C>ZQY:Q]<DV]K4^#8J5
M%=]2S(A!"FD3KQZW.]3MGN[.6GKU/B5ZLC08M]O.=I/%%UF56V;I+GS@X#'_
MDL6G^&IYQ,."GV"U$V*DT;(G^J_X'VWM&)>V]:+_.#\7/GKN8OY:^ ;NRAMX
MVE]KUY_AUBS[C4!B2?!WX?P\_B9A6+KD9)U9$$=908G8P7$T\&=E,?LSKIUG
M98\B@:1OIZ"2!<LA;/MXGMU_LO,WPO73$O9\&3HWWNR-\ 5,/$J=+P&205&S
MWWJ5?(U0B+!^P\YB6MV$KO/G^8T+AB4\>$G(GEVO4;!>I&F6.AEN;\1O[\NS
MZ\6-;+C9ML"U>,2VUK^+,TBL:K#*MV  P0<G8H9P,%<K^%_$@8S %5^"KTXL
M]4M__BYX6(;NO>M'WJ/[6Q 5 @'J?)(Z/"127F>'#\735@XY.'N02)4R)%+>
MT4^<>Z!HYHHJZD78FZT@D2HE2*3<)&@$BM3&HDS5$)6" NT]6*0E+.65RF0[
M*80G#<>S[P119C715O<QUDV>V V8:HOJL\5%TZ<7:>26 %\OJH&RLF^7#;ZU
M/5#67:NZ$">L$U#6 @"V>KB$C6&^43%J>K]M;ZYH)TT=R-W'WF0 /'^]"5_!
MTE,83^J<+2^$]EZ> (7>Q.9Q54*?+E<HL&P'+"#0M3'KB8*(_S[/O'YDS'A<
M!LT5<L\E#(EA>/?(]*L.^)28*=D5-<*UX5ZU275!O.6.T76/5G!WR(:XO!W(
M9Q[Y]Z1E,X7^C:E,;E;ZUVT8X/B'" 8<_S6%!$[^G0<&KBO:-8&%RUP 15+4
M4E8Q=0%D6'3@X^.WC^[;[1:QQ-ZP"J>A&QQ> :%9#D'P2GM64JS7,E\Z6/14
MY^$F#UZ?:?17C8*%P**F ]\+VSN'0_9]V)D-4+S+Q@2;5  7- $/B=9MBWAO
M70BV1;H0)*D<>JQ?^A>.M.]7XKF;#6S2$6L_)_7"BX#<=,.!+$FH;AC0'T9U
MTWZUO2S)U1!PCXT;>TKKC1Y+ZV5)(3BXI;7U1TIRI@.@#Z8.7Y94Q%S4S=H&
M4%/8NWVY,&524*U)KJDN):LO3T26-#BG2F&]1;ND:Z"_D!>)OZXW(4LZ\28&
M"[]9A6Y].06R9# [!4V3L=#,[T'^>&U[62+(4';YP(W!G5E>V.'F372+T40_
MI3/<NJ4]=!2F@P:SU:?!+$O=HM:V*(X#LGMEF=B]!H]$=@> VY(Q_+OS)*C[
MX(D&*4>6U)LA+(/#:DA':0AO4ZU+0U@F;J51[E4>@;3U9@C+&C&$U1[(V(PA
M7%_^N UA64<!5+MV(1HXL_)0#&'9(! -Y:!$IW2&VS:$9?.(#6%+ZM40ME >
MC]00WA;'(1G"-BI*JP"1O@5#N..8[WKQ))A'9>8JO9FY"KJ9YE$.3MNF6I=F
MKD*]R&.](I5!F+F*0LQ<V>IZ\%=C9FYO,PQDA?A9!:V3@S^SO-,3&C=S%8U<
M@,_K#+=MYBK8U#O5!CM7X;"9VR=6OJP81QSOW1;' 9FYBHG.@]J-F3NT>.\1
M&L*]H<++"D*P2M)Q6L)] ;S+"G$CC>Y-N!;$K3=+6)6.W1+N#4)=5HDKIA[?
M\&!K*&CHLJH<M24\2$1O656/V1+N$X5;5L$S,Z;RD5K"VD M855'2UCAFGEW
M# %?3%@=D:';6Z^AK&)^[SC-W+[:!675) '?H:?OF.C6GYE+NOXLFZ'K<J!F
M;F_->[)*_"RY:W.B@3,[F!X\34(2,@Q;.J4SW+:9J\G';.;VVA&G*<<<\!UJ
M8YNF#CS@RPKIWIAU?.4N5P085Y MQM&D>]94+#N%</H'9'+08TFM_CKO-'![
M3:9ZXT[9Q?BRG*7 /-VB C^Z-/DU4DE:,*GJ&+C!_++:+.G-F]!HNZ!JEM?Z
M#I-#A3[)4$X-MZ.B$6 =^SB/35M*;#!-CII%XAC5!Y\.@3L#5&JMNU<VHWMU
MLOS:X[GUVIJI,[9FGBQ3F [1@)Q"769U"AFIV$!"I%U^'?HR [ LEP^7G05:
M@B1;V:NK\&P64>VOK50G8WE,51=-!J3'7;XH>Q!PCURMM"#DXS['?8[['/<Y
M[K/-?>Y.#\T-WASG=?4X<)#7RN$:UB?KZB'+9L_ 0;5LX"!OG0SG'C3< P[8
M*ZJ/:6?@H%HR<)"7BTW,&Y1UC(++Q=3@&C=8=S><XP9E'1'6)5U4E3S"USAO
ML/M%)U&RR=Q[]. E\TC T7I;+\"PSKGW\_S>F\,G7@OT3WCE;'5NP4GUO46\
M:Q0CP5DLZ.2H5#(77H0GU;D)'MV1JQTLFOC'$SHQ:C.R2/ B 0[I;$VFP@B@
M$E CWCB11U2GXX.UL("GS(4'>.#]XBG[71PNDRA8G!?L^$]_^T]+D<TW4<QM
M^CH<+$,^M'"BE7 +6GB"X< (?NW.7#1LR&]QU!@=DHG#JT:AZ&#1U_?N),2,
M'[(Q6*]F 7[_-KX8W5@1D%E-":,]/UJ%:S(R6KAW(N'&=7TZ6PFEAWZ%3I'&
M?]/C+MP'BSG(P(U[[SQZ\'2/REDT<WTG]()H A=1!+HF'%5\9WQ/M+OPA"/1
M"2_]0/#@&,]6PGSMHA6%3 *3RCN?>XLUM1@6SCJ"'T9@*]QZ/K46\6.*))O"
MMX7C9QF8]SI.;M[ZOD0(#MZE&W?GEZN=H;^7Z]5]$'J10T/J'SW?\6>>L]B,
M8R\:\2N?"2Z85$NLD K7;D&<GO<5&WM,,12\O_DY<[X*EH0[Z0\2IY40M#G6
M_'IS\7XJ? E6\*U85&>9R?;PCF2CJ+IND_T+RR#RD"9T$ESFV-8YN)WM^J"Z
MB5^-P8#D,&R'"?Z]CE;>[1-][FO!6\'/9R1,W=Q>A=QF7X-B 5=BP? .PE9Y
M*G"?K/?NRO$6[ORS3]T78/3E#=QLW\)@Z8:K)]10JTM__N&OM;=$Z:A]T.J\
M<=L/,L\NDB^!UIT+;O*-?#;S5$2W=#QZ0_R\.,[9Z-FSFXQXY,X<]C22,N%4
M/%82!#O^6T:\#T<[3V=*^^7\$6XA\*61 DOGB5Q/SV?[UP%<.,ULEW^4:,&#
MWP513@@;HJ*\K508B/0"#.JX!+'CL:NUAEX:VB][*72Y$I)I+[*(@55E=V.)
MKORE4)8J$)Y99 ^_L;DZ]_@]=OE[6*HCP,OBC-+NO3#?.6'X!-2]? "^KRY7
M>!B^WGYWR>3W^644N:L(WUI<:KIMP2!0BZ@8IFBPSV^4]\E-+<:, K41*'!5
MF>*V>K(HMO^U%%EY$SO"(VN'J"O4(>L*NV==P5,A" ;<G 0/4J.MCQ8_N(^Y
M&!L[K^D>OJ[NW?#ZWO&O[^'.O[M_NXX\WXVB=\'#C>?3(.Y>46!BLB$!DPU)
MU.SASAU@U8X&Z0S9K_.&V RJ2'Q)^AXD16Y*4KH%!=Q[X22]5,+<N[UU0Q?<
M/C9/[V@[-&NJI<_^+'2=R'WOTC]C4?OBKA)2OM]0LJ:P*6<7B@Y<KMZ]$=\V
MO&5?P^<PJSHT2]3ALR-<BWJXRZ.AMGLTFNS+V$07@#"TCU[=$U_HR%%HU3MH
MQ"4P!^P2&*3$3]-5457+L6":=RR?D9"P:GF+3\N/3*A_4NTAGU2]CY/:CF4_
M$)]>YBN_[<%30S1\7925X<[49M5N]C&Z]#+?1*(>!,5L2%"X(G7OO6@91$"C
M@Q<,+4Q)BA7P \G/#MXOC,_@O/58'QB+RXM6%,O/URD%@?/?W947DFHJ)IF(
M8'UP]@X)!\[T%G4&-)(:M,[E3T^.]ZRJSI9*5%U?NSH>4I<=,]Y!<>T>,[N[
M8S8&7MN++K6CXUL++Y4+IHF9(4U4-:6Y.!-;N<R0V<RLSN4Q^MJ!<N[S?,BM
MG8^&H7$* [ J1UCGU)%M%'G(]1@F0;_1;%G4E>H0@?71;YZ)@+ J>*6B@A\9
MT,@)U8=\0M4^3FA+0==. FGE'^PPJG?TBZEC-S"(W?[J\=EL_1 WJ,]=[!GW
M'-K 5]=H;9R G9O=XPZ:V4&W@P68VR*>3S*TS('C!1MJ\&)F<-JTLPO;5E$2
M6DV*'HYKG[2<,!O0ZEBYT-MAY9W4T>UAU3L]K,U.:'R?L8.$V;T3WKDI; MB
MZ[1L/I8) &_MRE=@/^S)O_L-XVS19Q\!:5+$BNRF$:3*AX]\]1.AN5K?_-N=
MK:Z#K^'?W<7\8Q"2A["Y5@A!)JNB9?-,*W[9,K69=9XVS'J&$FE1>%L:>Y,6
MLP%I&;-E_64#^-13G]D ;*PU1981P6.V+*\7]3%;UH%"[O-\V*V=CRZR93Q^
M_PG$XLO$D+>BIE,WPI((+K&BB9I<O12Z2E2>Q^L_ 2EAUO)E#;ICRJR=8\K7
M]=GU,94[/J;=VO=#CP@HO(G5OGP\2SF[L%71Y&I''TQ H*Q)=Z ! =XFQ=Z$
M1:TO+,TT.?32D<)]N&N4/N_GA48KGGE",X/J3K++>B\'V9W$?79;D06]&5D8
M8W5]X29PJI;N<1,0'DA61</@3B:=;+2)6>&5M6,^.\*UH6E[.!IFNT=CK&?O
MS?4_BD2_15%))5FTM>HB.$;H&HO0R5)9%^H8HFOEG*J\+>#=GE.[XW,ZEK:/
MBZEO0K"7_8%Q!1\(_B23SMSZYNDP2J?''?2_@[[*UT?</49G3>6M<0.=\194
MQC]18R2W<64/#-$_5,42;24_*Y91_L:ZZ$8-8<[^_9$+=4\B;ZJBF7,H=W\.
MQ^A(3[W$*F^W?S.BAA#7EBWJ9GZH]NAU=QWW&+OY^SB!O9X_M?OSEZCZ5V36
MX5%.U\W/"]X=?;DU?[>38<*YJ;__<7XN?,2AR:^%;\X=".N5^]<:$R7P4AL>
M0R0'_BZ<G\??)"<K77*RSNS\35DI&,!IX,_*S"*^8;U92:*3YQCG@7X\S^X_
MV?D;X?II"7N^#)T;;_9&^ +'B5+G2X!D4+3LMUXE7R,4(GS?L+.85C>AZ_QY
M?N/"(88'+PG9L^LU"M:+-,U2)\/MC>SM?7EVO;B1#3=/:'KUUO#5IN=5*V?Y
M>:Z\DZ]S;-R9<ER5!:T/,59J##'^_]8X=!THXCVZNX-OO^-]$-RN(Y=&V6O/
M+^9\V?9MIYU=D,^>![?G=#X\?OQTYQ:WMFK&L<CU)>3B."<B,X1'#P]*9GY
MV5C5>A-S&=_W=NTM<+FL0X*K;^-H2?/."4>JY-Y79<0R!UFZ'[M<0L+,?&7&
M[13-5^X[F9*J1D/[A047Z/!#"N>4UHSK'ND(5)4WWKM[B=+2!G+)7JW#Y6+-
MBMIGDQIDQ0*9,+A'I31#_5%J6*6&%VVJ.:G!<F)%%V65.U,PRLQQ#%MN3F9,
MU#2:9(NJW8NF.>*)RFJM8NIT#]?!+C?9.(?#4"Q9U)1RO@V\:TF6RH#7!MFV
MU-"<9%[^VTWQOQ?;-;^D9]BIQ*E!?E;JQ"!#N[Z%P:,7H;BQ")>"1=?8?J%5
MQXP^^08;9J6FC:U)[6O3#LZ"W.Y9Z&FZ,6NMT(G7=BDJ+^YD4S:X@I4>BJB;
M=IW)+<V[:\].$C3>CI?F)$&M[<&/<M#?%.7FY$!#C6""7:V9Y8-0QU')+(>[
M%CYA36=-D1 W&J&DRFV(0;JZ6C/S@WFI9YQ=:+8H2</%9^EB^C(O];"57I-
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MOM[^$5]?3(Z1JI!\EJV(IEQ][,N(^M&8"/#6QS8@ IBVL$7)'M%_>N-_CPI
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MHF:5(XX_N\K.]N"\:C ,R]P54=<543(;G)O8U-TU^N/=GGWJD\TQPTD,G>L
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M(9%PF4QWHDW(5_]\2S_XFPOR[?\9_^.W=]OBLOW51'2F71RF_NYE9?O,XFC
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MDA#<300*^Q*!D[V)P(0T..869]?"-X%VX-MMA8+DN/ A)E J'!YPQ",&46P
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M=9/(3CX)DY-)$5\_ )<9,&DPI2V=WV@JVB.A]!4%[!EX'RN=^Y,X.'*LBD(
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MZ:0J!62!U].MF#GQ<UN-HJHT1;8K:!^7'5)D]Z\>P /9W34YM+A]3@WE#S=
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M-=:_8B8V2'4:>W+Q#.0EW57OHCJUM\#*QAN%T;MJ#0JC?TY;&/T>#T*X$I\
M]$R/+NE42\1PM*%84OHH1EC^5IW"=4>;J[[M^9#P45=._D6ZH>+YD_1%QZ97
M4UQN45RNEZ6X7"'UW5;!T)3K7N>%!"4-T\-R<PYQ)C:BD/(3TC'9CB6)%$BB
M!9JCO][S+X#0399S[KQ3F'KY'O[JF9]LTPJ5P4<\V(;1NNNCR<6-QEB;PG#+
M.IY_,[Z'LN^;1]QZ>6JA S)6V%T?\#-8F;>N@Z\,!:RP5^B C!7VUP<DFWEB
M&]=1R?ZPSU\*%LJP8FVO$^BL3V# @M8 4GO07\.!SZ@Y"54<HX+X17#;L)R9
ML.0(0VSE,Y7-NQ)#H@IC8@P)=VY:^!IH7.BNC2?C?8'C H'V^-*(S5FL*/Y^
M<+@\,?PQP=L\@#O[ZR&*J?CH_7DR9...\]087H8T!^[]>3)$ZD[SA-9I&>;9
M8TR-(7RO;+#7'==,(^TW#,G:#8;X90<:I1%%VP_/$,;A\)\!$K+ATOX97W73
MC;]A D/&!!C"F&H>8()=Y0QK0(;P_:SC"SV,A[P;.VK?=VZ.Q\@%FQ._^0#%
M5BE$]15A[8]E4D'[P9#( &"XZ E+0/,949FX<?"M!U88\I<<P"O/"U!8>I9&
MN.UX"EB#,V0L7J@+<>+GB/[[\.0ZP>2)S(DX+<)P\H=$'=S=SPA(^[79,21K
M4;/;-#V&U%(8 G6;(Y1E2):56L@ARC WED3-<(*R#,TR;3.>H4W#]QG#,V3I
M*I]> ?SRB-R;\8UK8 7CSLD$/3)#(S&O4+OFLR]L@[>4 Z0QIL>V@DN9'H.L
M:E(RO[XULXM7:(OF(4Q8BBC=AP0LA*)J>H&]-K'=)1*#AFIZ&9W_A!2&TE"+
ME<K,(3F1RLRY[4<J*PP;5V5(Y;V+1>:>I)#7>Y(["@,;4/F1VBJ+K RIG>,!
M4QD$ZS)LY#(.F,K"#5D2&;CW9GSQG\#TY[N.R=H/EM#-<TP&V;L,N5KX.IFX
M #<GH<N0K65-;\"87@KYNZ_I,>Z>77ZD,'-ZZ:5P_H8- Z?M#I>LT1,2(4""
M/RX==UVMKH!8EZXS70663/L<6FVXN4"Y:]X-ALA>GG,\U^C?[2"_+"X7AJS>
M[Z18.\40YK<TWH:0;7ONVGX*#-F>WIF8@0X,N9[;>*SU,01UH>MC2-Y"U\<0
MI5MY2S,LD2$>\QR2M4HF1%OH*OL,*9;GD!I#;?<90BJ[FW3#^ S%UV?(HZ+&
M'S",OCY#&!4V/L.JZS.$4V'CLWB.(:P*&Y\!>_5SC1/8,#X#4>KG&B:P87P6
M_S,D6U'C#QE!"GV&F"MJ?(:4U5C^J*S#;Q\BDJ?PVWYTAN@+]3;+@,[!FZ P
M#J#&$( 12D9N0J$=&!F&QI6]=D$Z<5W 0^!E8I:S /SZ6:;).*<:0TZ6/4V&
M.M48XK3L:3*DCL:0NB5/4V4175NZA2[ V]G2W,Y)&]PTZ.VF*; (.F!.@>+&
M;T\A\(PX=F5[7PQS)L-,,UF*HLDP$P;W##I[)4N7%5LGET$6YDR4,LBB,4S9
M@;HTD^0Y)AH$&>M7^K<GD"'>L;LT/NC-$1[T'!)]D&WDX:14.@P3>M!;&O?6
M=6;(]>>W%EXS5N2 %\] 2IWIKCN'DH,D.>G$IU<KK'&AY[M!D:N.O+-OJL-P
MI X8\O8D3&OR2/G>AR?=#@&^T\"#G"KOS)D^FC:-?WQS43G$BS$GG!XN_8I\
MAD.DT DSI.-@P!43L *,!@Q3FQLF8$UXN"SGSTUOYGBZ!=;Q'3:-7:+[LT\J
MRXS2!R3LGRUEAHT_5/AB2X:1-52YFJ+"T"S#9<T2AH7;$U)AUJ,Q!?>^[A.&
M/$<S%X7IT^'=S;NQHV7=T^S9!^?&_159QJ7CDH<4,^WT'KO]<RLK%F#8YXL5
M&-?5H<8_*["F/2A3E#)GE#X<K@3F9,5,=SK[Y<Z-P32L2/O.RL4$^:>.\^-W
M&#J:\'9[M6D2S"0;9<^38!AD<H<!+"W,G0?G#G*GG7'@H;2)#YDFL:PYMF%P
M8I'=+@IMY,#572;#]'B:(7,/^QS-L,?<0XVC&?89EH#<&:S,T,?3,!^MM,R_
M:4SFKNQZWUB=Y>(WGQW'>#$M:W<9RIRXG"H4FDG.E2EO/^--\V6)6UDNEKBL
M'#96'B!WQ&68';*LIK"$\IA<QNEE5QA%\Y[&$BSRJOK(E_<TQBU!9J43AN71
M"6_MA7KLF657!(53C\EMQ:H%5L"%S,H]W#_U6#-3TN!-)4YO5<SSPURLR!)9
M40IEK@%++2GJFS>/E?%WM?=9PI"5L!C>^TE:'KX4/C@4*;@9?W%>R(TP#%EU
MW.]0$>X.C9R);5+$ $V)P^17W3M%R/[F+>6(Y!0-*;,R&;F:-,OD8>5 <C5I
M)G.R A=I&OR=_G*M^\@UJ;@)W\7W B,@#[^'^J<Y!>4R,%B9E3N9]]0R;-BR
MR_F;/39MTWM"!LBM'*(N63NQD@>Y_9@9ULG*<[S<:M@L"V58\-L-FF6EK+R:
M..:<M"?((6B8N=[WRVZD'CJ#7F"E)>94=2:#P'\C4W$/LV%)\C?2$_<P&Y;-
MHBX;Q"GR2@HIUZ(N"[Y$$\-B(O.4(</9*;,2$1=M?L\1-HY-?ZFKXIGN/0&J
MB[4MRF5>S.HYRV9P6 9^98O.G.D40E\PY49Q@\="#G=7V99EJ&,@A\/=8<DY
M5NHB*;6VV@]S.2YI>Z7""H.0NRM!./@&,O)OQE#Q%1:]%@Z5X[I9H8_(/T?X
M#N0B TN3;=:>8A8R2[BRTA +V7V6MU_N:GO8??:Z&09DH;O/BAJ2NPQL@6P\
MR -SD?>V$&+TAK#]C>"M66<Y,;UE@Y/8(71>A1S0WK+X3'=IRFV'LAQL5LH@
M]T1=QB'.])F)R6K^A155.M)N')6%$+$R#3G:*59$E<S*5N1ISBPQV^L7=639
MPVD<'UFF-F#E2W)/U&&Q1Y:EKU@9E_O;I^VOCJQLS6204YJ8G,P:GS6?MU.8
MBLFIEUGYFEE&?*MQ GVV@<Q/)WC?#-B[2TN?T)G0;E8:MK6.Q[KEH=5:]UL]
M_]P9!>3Q)C30HFT6+O%[WO)8PX/CRS_6!TH_S@5T1YF?&(:+/._6\?"A^I<Y
M.W,,M#10#SJ0P7_6QGIW*#G+4'*FH1BK.D/0/]"ZL@WT^AN:+X^BD%%DK3/H
MQWUQ$T/!.Y2W%H1S413==OPWR[1_?/)&3VBJX_&E5_+WDPM3 0%U".T%9?S?
MHU=RH,C'_AR:;GCF=&8!QY$A$L^,!O&<P"5CD+]HT2#OR9R1UCQX, \6\>_.
MOX'E)?Q*IJ^6\^&6_^S#]Y3%+]3%J^[B58^\.I!\)SF$X_BVXR]=/=Z>4G_Q
M,&WQ:K!X-8PGG)B['+^,YR?'$Y3C&<J]^&4\E*RM3UQ>F?B&><OQ).5XEDH\
M2R6>I1+/4HEGJ<2S5.)9*O$LE7A'E'@T)1Y-C4=3X]'4!,WBT=1X-#4>38U'
M4^/1U'@T-1ZM&X_6E=?W3]F2\-UXFMT$;W77GZRN4>;UT;7,3^%1)B<4'V4Z
MJ"2%GY(63O-C\M;B34@;\@':<B5R#O'1>O+]V:>/'U]>7HX\-#J:.,\?SZY^
M6S[HJS]>#/5Q9:S$^#,B?E?&Q_++]<]U'QW#63_LR/B_T4/BSZ3P\8FU&/&/
M9.50E>.1Z2?)V2Q&!HFTM%7'K)V3#Q8#[G'KXBU!$]!9B46''QEX(J\SRQR9
M_C5MP6J84ZCYY]@,W8"\\ 5T!SEY-;V#8_A.'*=D^YBOZ(/HK-:>?QS.Z^/*
MQ*I":*440F^]=::--PCO^_H>1)_LL >J&'NPQ#Y*%O91<F>?KH!;)V?9.CGW
MK>N)L76)DZ?D?O+Z(JJ99-6DJ =N5"^2*IGX&\L%8#=HFL7L\E V";IU<J>;
M5G6ZT5*](3BTD6R"4&U0=:J14W;KHJD93#<131":#:M.L[).&H\F@0P7ULI2
MNCQ=R"6MY2K3NAQ)S"6=E2K3F0O[5LY=Z\IJE8G&@7%; ,FZ5299Z99M 03K
M59E@7)BUG("$<K_*E.;$K.6%UEJ5:<V!6<L+G0=5IC,79FW^<+L\K#+1.#!K
M\R>94FE(J'2SM@""51K7X<*LY25THD%VBC=K>:%UI0$A#LQ:7NA<:12)"[,V
M__@MI4&2BC5K"R!9I2&ATLW: @A6:5R'5,JZ0QYRGU/(Q4)(EG_HB%)IB.8.
M^;II(^-"=VW3GFRBFB@TJS1"$[[K^Z[Y&/CZHX4>G)L7&[GX%[<ZU)NJ3(2D
MNG_<AK,-J#0.4IKTX3'$1:TT$,*7T.*2_I4&1\JR#;FD=+7AD?)O ?F'V:B5
M!D=XN 440+-*HR-\*=1B";E_U(2S#6@PB,)O 9Q$!*D-=%'KR+]NI2-5N+@%
M\$+I2D,['-P"\H]*ZE8:HN'A%E  S2H-J_"E4(LE9*51$SZ,8$[BA[J51EOX
M.K-<TK_2R T71C OE&X"8D0+.NLV8%3!1G !-&M0I6H$Z?9$AH>PKIB0]F$W
M8U*/'QF8.M#B9$%0:'PYMO2[U\_3QU_K;@7U1 :(1*$U)V!@3V1D:0M:WS[I
M[E0?H< W1U *?E3O1)F>R."4@&3GY;3O'\K:T:'=.50[>9HQ^P=X=F,<L@49
M(L>2^Y8'XX@,C*21%Y\1EA/V-736]=TY-OB-8$2Z')"V\A[2W=%3=8QY@<&/
M.]V>H-6+V*GC^\X4DQ<^W$RFJBMW@8$2)GD?G%E*VE:<L *C*6\V'3N=A^VB
M[0EIG';OZWZ0%,U?]$<'?^ZX\\5OTD&:C6#)F?_Z H- 8O)?(_E"SA,8DLK*
M>9$O9SPV1R@]ZS6RKQ@.%!@H$Y4#&^D7\E[5T;H;TA77^^QB_D1&*F(W BYO
M)A,YS(U?)FMD6,A>(H;6@1]AY$R)7D3PB"].B K&;!6A@UBOGJ-G9#E$28;M
MW^ON2NZ+B!MOIGI4* I9%C:=/B,;&U$69H 38TH19/SU9Y26!RK. @*#S=!X
M%E2*Z?U8LXK/7&28/GQ4&;] 7V#@^!R-(7SN%)_%L>G#36<)PW'LR0-RI_A@
MPPR>$7Q!P=.K=;A[7V \62AZ<^+^UP3&;[/1NU_K\ZT)C)H*16]>SK? &"7/
M" TOY!48!N03&^&%L%6'WBY>T2@ ,7VMV_H$I?$B%$1Q3BJQ:2*B86)2G)<S
M+B(2)B;%>;&^!0:^3@,/6]^>=^9,'TV;@)])6C\\F:XQP]LZ#S'.%-THJDYM
M@;$S@:C-BS07&#D3B-J<6&L#@7&S#=2^F,XL9XY0B+-X*6E>;5D^$!@W$XK>
MG$CS@<"XF5#TYD6>"PRD;:(W*4GA(=^WD$$:63WJ'ES7YDU42DQ_@?$VH>G/
MB[P7&'W;0/\O:$(BD<[PVX$%@=V7J.G_.A 8?!.+X+R<\.IB;YP1G!>3KKKP
M&RGF5SX6PXLHKR[RQ@FA.1'AP^J";IP0FA/1/:PNVA9CZ??(?39'C?P>#:N+
MM?%$;5Z$>'61-IZHS8LDKRZN=JW;P5@?^8&++UPWXS/+M*&BX#7>,=?$_]8[
MQVM874"-4\+S(M^K"ZQQ2GA>1'UU ;912.E;%T4O[_W ,&O?,V-878R-/YKS
M(N"K"[?Q1W-.9+O< >BMHE3GVT'.#0?(U>6 *]L+7-T>H?0(;+7UNMQ1&FK7
MQC4N=]2&VC62Y-WJ4OL<S;#M9M+:3%/']<V_R.NF\!(E?:\A?3UO;7*GWY"^
MKI<WK;JDAY:,^$=)<E\Z[E?'1E'R\:FCN\:YB1G$=]S&VRYW!@TWE,\-W*B%
M8<,-Y7,#+YI"KC#,]UV?(._$-NYU2W<;UXTL5QC0XX76O$AYN<)P'B^TYD:&
M5QC,NW?P+<^ZQ]K;Q6LZP^LF?=;A6XBF-;L>\>#47KA7&./CG@FXD?H51ONX
M9P)NU$&%<;]4GOL&\I'E"@. O/, -\J@PK ?[SS C2ZH,-A',B@WD;CB<EZI
M,'Q7)GUYD>%*A2&[,NG+BWQ61(;IPLY8:^KWQ'6AGC^\9/1>W*M23K3*6CF=
M.;3*DA61@;<MJ??]Y.)V?X>U8+J)C)6)=>KD J@G,L@ERJDK@FXBXU("G#H^
M+R@B U%<'U8^R2TRYB3:&>?FDBHRR"3.&>>%W*K(F), 9[S0]LZR*C*BQ/5A
M+9AN(B-%J9J'T;.6LHEKU0TI561H"<*P'1L.X\V8>NJV%ZD9AOV*_.6.P5],
M_=&T8'C/0SX'K%8LK*6*#&N]RS-I!'G#,EE81F0LK1$SI>!XJL@X7B-F2F$9
MD5' 1LP(93B+C$ VTDDD3A,9]FR$FDB0:U=DR+41:B)QFLCP<"/42H&FNT)#
MTXUT*H-EA(:WTW@SOCCVY &YTRM[!!-Y1B$)M;HG*G<KBU+SH&%X8+MB(>MN
M92%K#K3-CNRSW;3NP&>_&#QR\3LS+%7ADZKX6+H-7EYEACUU?-^9IN19D>1L
M@]GSR[<"^'RZ#1#/+?N(KZ>+8-C*XOD-P_*BIPM@VUYE?0.-GN88QNE5UE'0
M2,N2U#N??-XX-ZK,Y^59!7QRN]!^F<:8V)+M>(DZZ%76)]0(61Z,"6[XO/%=
M59G/.3$FN.'VRCJ^&F,BW/]"@X1ZE?5 -=*R? ]"$0S;N+RJS+!<>!"*8%NA
M'5_!-+!TX(>+\1B-_!-BZMR,KVS3-W7K9 :/H'U"8U[ZAVX'NCOOEG0=X:7Z
M;)^ZCO[V?PX/I?_Y?OU[[W__YY^C6?#ZA]T;&G]ISY,_YO:W\^#EL^8.M=^4
M/[\]S#U+>Q[]U;'^X7_T[]$__M+4'Z_RZ(O?^=?EI7+_V\?GU].S/SK/QKVK
M__K/R:5Q.GZ<OYJ*\3@_O9C\//O7]S]FSW_T5.1U?YM?_?;7HX7/_(/=M__\
M_/GG?_[K\S^]OOSRZWSTXV2BV*_/I^:/"]EX./]Y>JY=_OQT\S2_[?[CVV_G
M^L\77UY>GQX&U_^:_+@8__SC7[\]#;]XI[U3JR=_\R__^(XN]=\ZW_YS>?&Y
M;QJ?O_^IF+KWNW/Q].=]]_[K7YK]^?/XY>3B&0WO+VWG[+_-_O>[4_WT;&;W
M/O[S53_Y>?R?D[__KW1V?W=X&+%L<SIV-V\YDZM\GDJA/6N[,-R-W9!?[@OM
M<-H3^1NIDSO;">WYR<1V@3574EYJ*DQWH5TO1=.]D3.Y\YO0+I#,_)9"MU6=
M\$)[ PHG?"-I<F<XH=T'.QC2\F;M5G'/8U]H('X/I*^.M.&&Y>H*HLLI5%S%
M::\)G8*Q#]HW\B9WGJL=2GR'9BY^L#TYP?]:LMKP@%8[J#@K#S3R)W?>JQU>
M7"+O-0'4$=?5#JW^ZCR31RIR::X*;HA?.^AX:^(W>BYWIJL?;$WO=@\O>.3Y
MI1-LZM%>$ /PDA*IU15&WHX!JB-YN&&\NH+8,>.EB@BJ.AO4%5C.P@:-%,J;
M_0:UP[:O]?G#D^GZ\]+\&MS0OG88\[:T;^1-[CQ7.TP;PH3NT3.RRXK:X(;T
MM8.4MR1](VUR9[G:X<D+EFNLF]K!R=O2OI$WN?-<_=!DS'-?31OY:*.6JSKM
MZP<D;TG[1M[DSG.UPY#OT<PGS[PP)T^-T!G4#CW.Q "-Y,F;\88EX,8[[9RL
M9=@Y_*/\=TYDU'7Y:+Q^NC9M<QI,:^_%&XH,:ZX157]MB I$%1FPY.VD\A+P
M-109$N3MI')#5*&Q/CU%O^%KW?V!_%O7F;CZ)GI7G=A"@VR"$)L;'5P"JK;S
MSN&KQF#;G5OZ42X[5P(VM/7.+54^[70/U<[BX3E4/AT*C8ZDD13WOC/Z0<N5
MU]U<5SHBA[(]S&>$T*;WPUN%GLY<9)@^?+1/&A?:?ECIB(R"G/B^:SX&<.IN
MQA>O,_P-Y)W.O^I^X*('Y^$)F>YE8(]6H,LSQ_.+R2H\LW3/ _[!-@.FA#^'
MXMG^B6U I>\9K'65IV[\)^2^^>V]V1R%]L[$#VV8K!0F>_UT8CSK]@C=ZG/X
M8%,K#6$82F1$: \,)0()1<9_1)8)?"D>'I$-I2,RC"4R;Y:GK_CD0Y$1-E'4
M')^4%SF(360)Q)=V+/CN+W+4FLA,QL6UK B&$AGG%45?%4M"663P5F29P)?B
MX=*Q(#=8==WT%9]\V,#9]8RV5N0&=VZT8\%]8A6Y0<;KIN8*9J@&SM[KM:P(
M$M8."8Y^.QK1[#1DG*.9BT8F342SC9.IX_JFIV\1<U4_]52 XU:N'30M%"MR
MH<2*8+O:@=5%L)T(A*X=B"R4?.%+U7'IO%5JAZ$+Q<&<H)G<<&OM4'5N%2N?
M_%$[M%LH:<:7/B[6.:W4#GX7BA6YN'H6P7:U ^2YU9 %$[IV0+E0\H4O5<>E
M@UII_ 0\<S G5T]NN+5Q)?"B6/GDCP;SYUF:\:6/BW7 *XU7@F=6Y.+J60#;
MJ8TK@1<-63"A14;AJZ S"H 35)&1<]&$;Q'T$QENKL*9+$+.BHSEBG8FBZ!?
M[2#:O03'G^!__+6"=Z>!B9]D3ZH20ZC6#ATMD7E^1T_FR$*;>"?>)@'XIW9X
M9:V$#Y?A-VKM,-"ZR2P^V:YV>&>M1%VQ%^=N[5#+NLFL@OE'9#!4-/XIV<[B
MQ=?<%1FL%8WGRK>SN&$[D3%FT=BN5#NK #"T*S*8+1KSE&UG%<$_M0/3.0IJ
MX5!$%0"9=FL'N7//8F4+LB*XK'; //=<UL#WE#-K!]]SSYGE7SZY8<[:@?S<
M,V?57 &]VKD"N&>QLNV_(KBL=@X#[KFL<2M0SJR=6X%[SBS?_N.&.6OG?.">
M.:OFHNC5SD7!/8N5;?\5P64B.S)XE@A%V.HB>P0X/UI%D$MD:)WGHU6$&!09
M;.;\:!5!KMK!KWL)W[BR,64FYJ.%0DZRC<^.8[R8EK7*5&?.=!;XR+UWQOZ+
M[J*4YI@ 'M%^[7!7;GAKD7KKW>JF<>FDY2YA6*MV8"LWK,6!V.+2D=FO'<K*
M#4N6+^WXY,C:0:O<<"0'0K+8*WF_=I@J-[Q5OK0KF+5$!E+%9BT.Q!:73LJ^
MR'BQV"Q9OK3CDR-%AL3%YD@.A&2QF'!?9 A?;-XJ7]H5S%HU=#<DHC!HV,5?
M>PB[$$^0%8 2:S5T0'#+;5R)MB*8K88NB=V8302BUA#4YU:"<*"ON,3YM1KB
M_-PR:?EJCD\>K:&_@ /MR"<OU!#@YU9><:!4BW4G:37$[KGEMO*U8\',5D-8
MG@,U5S!1:XB'<RM!.-!77#H$M099YX=)RU=S7/+HH,'C2[\$<L,+#5S.C[SB
M0*D6ZW<>-#@^/]Q6OG8LF-D:/+[D2V 11!49P!98&11PGQ^(C#^+*VF+H*3(
MV*[ A[((^2HR<BKNH2R"DB+#I0M*7IHVII&I6U=X2]P 'NHE2'B.9HYG^MZO
MR#*N[&_WYXYEZ6Z*RB#"4%%D/%%,*A:@((<B(V[9J'@1N$YUCN%09)A,. (6
M<0)%1I[2$O!,]YZVEJ'BG$&1\1P!25C$*:P$>K,%"=,(46'.7R7P&A&(5\3)
M$QFB>9C/@'1WIO=CK1CDM>[^0#Y\5'M?[E!D[.8]&I^YR# ;&A,:BXSJO$?C
M+^9_ A-3>9Z&S%4GLLB@SYUN3U!"HWY'^@_\K9.)#GJLUI%7:D=D'&B5L/>^
MB^R)_Y22M%4_M6I'2(SH]=/%Z^@)2'N'-^ L<#%11_,=+.+*DUE()&DK,J<#
M'JI.9Y'AIFN($\+33>IATW\R[1L;_8%T=X^'N%!00NV(C"AQ1"4^CZ#(B!.#
MN"=C'[DA;4\#_ZOC7SLN>L!B^=)\)N]6"*]7.R)#3@)0C\\C*S(&Q2#ZUB06
MYG2*#"3Q12@^#Z+(&!)'AE&A;AE5%AD0XHA*/!98464A 2%Q#*""CZ:0.(\X
MU./SR%8,].'#?"WB=%8,]^'%?.7F( H)_;Q^^N*,])6<S/.+JMP992$1'291
MOMFFCXQ['_,IUHF5"51792'Q%Y[.31'*2DBLA=]S4P2)1(9+SC U)HYKDN J
M1++_;['>QG\G*'?QBD:!C\T+^J2]9E=QB9 I(F,O8I&<%ZM2$1F1247RKXZ-
MEJE>9V^4(C*&(Q"]N3G?(L,W6XITW=8G" :LRNU2$1G2$8IX!=C/BI!XC8C$
MR[^]CJH(B>MD59.GCNX:-^-STT4CWZE[F*LB)& D-NVY,9>$Q*7$IKV<A?9R
M ;2O/.#%!>V+-9G5RD-8O!&Q --9K14HQ0,1<S&A ]ND%/2>=!?AI28F,$6Z
M%[CH.)PV^4+TF.BS^,'PI+6GHL ]6%!EY;&FYW056?MT\>UN[:E2<LIO/?D6
MN8M9+XU@F,^8659V#G[Y-9@B5\<$.U[BDM1S6J+CR@/7!CM'MC,U[?#3-P9\
M=V^90ZX\-DGNQ;HW[-T,/_T=2L/'S-6_^]# ,PHDR+?[\PH3!._=QF/RQ@ZL
M/OFC^?H)3]T)W!'RZ)]/2#>(%,)?Q3,ZCO[_T3'FQ_B])W]J'?]_4$L#!!0
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MMU@B'I(3KN08+V,YGB25CO,PD2.9L$:SUFR?WKZ<X<9/M9]RRPTHKY]%2>Z
M#'U!:D_.&K5W$7SX,1R9J/75UM=GY\&"B N/3A(=6:^6#T8Z2?34/JMT>L[0
M'5P.>EUW<'/-+CXR][W#;H>#Z][@MGM5+CE_.KT/[N /A]U<0LP9LML/P[L/
MW6N7N3??S^T[IV<=?E-OPC'K]%UW>-&]=NY.;OZ\<CZR;L^E-\UZ?>?>'KJM
M]4JG?;'<L8O.B^G-/F58Z0P@-X&\82[GT;W .$_$B0P6+)GPY/QE3?Z\!8%N
M]^+*83WGZNJVV^\/KG_[M5*OV/N[VVZON/]"X\_N:HO-I9],2%_]!RRU.RS,
MS&@)/*X*J$#+)G;^2@VM$>6.MMLOAN7JZK7FF0PW!R@18.KMRQO@>&TN)T;^
M+;()53J-6ON4!"BU]3MK>K=:?E[7@$WX3+!8S*28"Q^;*0WKAF'*5;DT%)&.
M$Z9#=JGC*2![<LETP 9AH/CP@5W7_JBUUEVA%.L.Z9KVJO,BP'Y%P8Z=:^Z#
M@DS1!3?86FSC=,'N0SU7PA^+:K;7<;;'OL;RA#IA'NQP&3(>+E@:)G$JRB63
M\$1,D09I]SG6!OE0<L4"[N%1S/04Q2K1S,H]$0B%)XSA\8)$IOQ>P+!@2YT&
MSWQX YN*RA_9( %/QEXZA5B(X7#%%W&Y-)](;\),2A\K!7,1BUP+36$JC1+<
ME^$86Y9,,$43"<]Z2(HC^*9]3!3[AF49+=87HK4=R"^4I5_!O /,;UX S((%
M,@1:"'@K<%2!9(CC->"S$I!A@)3&$PE%,O14ZD,I(+@&A2K@*V.U8!$ 1."G
MJ%!JA>X<5^:1;420+TEQE212!0% 6@-VUIPIE\@CCYL)"Y2>FR7@]32BJ./T
M)',;/E;7,&L*5Y[X^@K;[P+;M_O#UEWM\(^Q^93JELE06? H2E<Z""1NC\RQ
MW?X!XS'2+^$,N)$C)0@13 #=(R7-A(:0W!0)FY(VW?O2>$J;-!8VE<=:&2L3
MQ=H3/AX;=@2$^0* S6#D/'@3'HX%ZR)'#E,%B<8;?M(X.Q*9&XTS/[L[SJ K
MB0^'&=+) *-,NA8 &23)F;TM!1N6@N-C.]&-J,!KHBKGKTC_>J17G@#V*P.!
M[Q\(?6%P!T#8*OYYN%:)87@\1=8'$]EO#)7ZD0#T<E.6/3"=QC"*5#J3QJ9G
M2(G0ZJ$>9I78UXM#+!2W6,[90X[':KF4E0UZ)9'BX8G12OH\L5,;&>E+'DOR
M7V84QU:KD/2DAEB'C7YC*8I-YMH(N).@=-"@B-,VIXI3!<*DK LK]H(1E@N5
M2^LL#E<C09*H$U @_->Z\&^,EM&71LO>F1?P7$;-@4/WCQW$VTSZU#QRHT-.
MY8D;A!,Q=CP<\YBB@Q!*MTKRD50R61#?V6:70M@BW&(WB[X-T37&;\O@0SZC
M*(TC!(^Q!,WS=.Q;#RSW'XL0O$NI!4J7YXF(HI-DT-ID<8(HEA$JT?\S4NBH
M]/EHJ>3'J;O1_P3>Q63=_J%C#P\EK[9Y )&;*ZZ^>.>>+J(]FSUGS=K;72O[
MU'=GQE5J*P(!6P0!V@4Y R3-8]9?<,)R:8_JEMUN[P1LI&(@:A,%*H1'.DUV
MV]]AKEQ:K\!\*2ZHF0H^WT>S4=&FV>PCLH6 0RW23H&0Y3Z*-@O"US.C[U^7
M_ /J4@:;I_ CKIZS?/MF"\(/*$5$R[3GI3$A["D+VL >JH\]MRP\L8,GW"QY
M'8@4MR$@_*P^6J_SVK5@2MX+E1]2/1I0W3:1_4MJ[7]96[Y[=W[VK;MSZD>7
M"1N@6B4]2L)3;1)@@+X^6LM_E#WWIW&/NHZE;QR-1Z)C4Y FL!MZ0G)3F21"
M["@O;*3!RNBE+^&:57&$2$ \&2H6^$^M3Q%FXE,JX3G-($A#SQY?';]VX/_&
MW'U !]Y5X-*XEX SQ];2"8TG!;"7<XME(SP7_)[(0L:M+<ZROL">^A<GF@=!
M.FM;Z6!K>^[E/@8:L4R]VTM(T4I@ & ,QE_-^)'!%IMTBMW$TMBYY,5@Z\EO
MSD6VH_D5R_^%_OAY15V0D2!&:JP"=L+F<P#7?D>40[Q*[2FGL_V95C-!9"'D
MX_S+KCBO 6(:*;T0>#N?Z.P+4[X100#\+KIS$$MXYJO4;P/)E_N!0!\+>LY^
MYS&"N]FHLF:]^?8;F-D94NLA]#C$#C:^%BTME,S8%_&)IY7BD<$DBZLO;)]S
M?45X7BCNW;-&[0QNV1/$I?FW-E:?!?BI.7WTNXRM[?"CN'Q'BM>Z]%47MN]<
M/N-6;R)%P"Z7&+_)F-/V5OU;.G)TFQWPP(>5-U06NJLSH-RYXP.\>\DRL1/;
MI_0KM>QG:_3KMG\ 4$L#!!0    ( ),[=5B.[4!,(P0  -$.   =    96$P
M,C R,#,X,#%E>#$S+3%?:6YF;&%R>"YH=&WM5]]OVD@0?D?B?Q@A791(QM@0
MVB10)&-,@T0!&:=J'A=[#7NUU^YZ:>#^^ILU=@3YU29'VY?CP=B>V9GY9KZ9
M77>OO4_C7K72O7:L ?Z#^G6]D3=V>MW&[A^EC4+<[4\'MS#W;L?.AUJ8<'D%
MII%*\%A,,YC0.W"3F'!M]T*#.14LK.%"7#I[[;H.Q$0L&;\"I7JN7^)5W1D=
MD'0CZR1B2Q0*MES)6J_;[SF;%5LP"69+-[N-/@*8'<5U^UQ_7_ANO]?;J3P,
MP*=<4I%'<,(76=KY,[YMQ_5&PY%M>:/I!/JWX%T[,'-'$WLTL\;5BO/%L6^\
MT6<'ID-4<UR8W;CS&VOB@3?],R&;%W"CSW5;A[ECYV&;K;:A@34':S"=><[@
M-\1HZ!>,/QMB&=BE\0[SEN=T;KE]:^+,Z],O8^>V6K%L3XF:AM$\9HC&+V*4
ML;L^Q!S1$+O(6U%$+R0+F4\D2SAD5$*8"+F"!8V2.V 9WC"^A&R]B)F4- #&
MJQ4_X9SZ^8H[ALH2#5F<KTD$+DUQ/:!DF(@8\U0?0A+"B(<1<3<PT3_K<*KT
M3Z+@VSKIV$F<$KX]$?G3F?*>FPM9YJ.Y+24"* _0\8#Z-%Y0 2U3JU::1K-U
M8&CGN+2CP4B#":-1!BZC <4T89YV8+>0KD6V)ER"3&"/E@6D'2U)!B1(4@5Y
M7[U40HI4*PA,13 G8D$XS>K3342W8/E20584T5!.I*86*L4%S7)1O(6O/+F+
M:+"D5X]+_;!2'7@SJ4I&%2X\JS]VP';&XYDU&(PF'S_4C%K^/)]9=OG\1L;5
M99+FCN]?+!(ID[AX=\<"N5+VC+^0[)Y;NOFNBH*U+A&CE4.R_KW.5-74SM+U
M!N6RPIRA-]M/L[L[G.(DV<-2S]@_= >HUC/U;D,IJ(UOT-NS^]B0JEQ!ZW =
M15OPD;,1PX3<DU_0;VLF:(RC)%,%+EA2K9BM4W(&R&FS?1J<04D8ZJ\%D\J$
ML_%7A"]IR1KSLG7> <*#/"ZU&WNNBE$5+J_A46;-_[1XAA;-GZ?%RX94F1G'
M:1;O)BN.3$D8+P;H/J4($\BI5-!,L4=#.9 HPESAKL1P!*(@13IE6C$7.>&^
M>H\6 Y;;1K8HK76T(U^24I$[S4J^%4/V -MOHM:Q]J]:;X )N8)/1/@K:)H:
MSM?F^7'=J*.DJMVSW;'?#0^[Y=7^]XC?@44B BKJ?A)%),T09WE7R\_I+_=%
MK3C+[]&UL%=V6C\B_E<PU?D,LB1BP;W[\[SM'E$Y)#&+ME<_PO"(]HVL\7#;
M/23=@SB+*-ZI*,JTJ\93U'P5\"-BL%>,ACB8<4A+]IW"-,3S$15/XOAO09=:
M*0D"/&7=E^LB?7*^O!70Z4PPG!DI#HU'J,Y>+,^3@3T)^7Z,_-)6;*A/TMTW
MJOJ4_1=02P,$%     @ DSMU6/_UD<\-!   &PX  !T   !E83 R,#(P,S@P
M,65X,3,M,E]I;F9L87)X+FAT;>U76V_:2!1^1^(_'%G:*)' V%S:)E D8YS&
M$@4$3M4\#O889F/&[GB\@?WU>\87EM!M=K--LB_+@[$]YWSG]ITSX\&-]WDR
MK-<&-XXUQG]0OX'G>A-G.&@5_[C:*I<'H]GX#I;>W<3YJ(4QEU=@&HD$CVUI
M"E/Z (MX2WBC>-& )14LU% 15>?/U>O#EH@UXU>@1+OZ)5[5G=$'27>R22*V
MQD7!UANI#0>CH;/;L!638';T]J UP@#F+V*ZU]7?E[9[[_5>(A\[X%,NJ="&
M9WR5)OTW-HIAV\["<Z]=V_+<V11&=^#=.#!?N%/;G5N3>LWYZMBWGOO%@=DU
MBCD+F-\NEK?6U -O]A_D"5TV/\"MOM1M'9:.G;MM=GI& ZPE6./9W'/&;^"C
MH7]@_(<N5HY=&N\P;WE.E]9B9$V=97/V=>+<U6N6[:FEMF&\*-V,W'[%II_#
M/0XNHJ&L+#5EG.36#B_R-KI2S56^6,52QMM<2!MZ&XK)$9*%S">2Q1Q2*B&,
MA=S BD;Q [ 4;QA?0YJMMDQ*&@#C]9H?<T[]7..!H;!$((OSC$2PH GJ0QR"
MR\.(+'8PU;_H<*Y$SJ+@6Q;W[7B;$+X_$_G3A3*8(X0L]1%A3XD R@.T-:8^
MW:ZH@([9P(JT.SE.O58"%;8JG :XF*@-)BP%CY#DGF+BBO#VD&0BS0B7(&,X
MXFD91,%3U"-!G*@@C\4K(<49#"MW8$G$BG":-F>[B.[!\O.(%6<:*$!D0RFJ
MF%8TS9>V>[CG\4-$@S6]>D%.G8PGSQI-'+"=R61NC<?N]--'S=#RY^7<LJOG
M?VGT>WH=L:F/3 CD1N$9OR#7O45EYC=5 BQLQ5A$>4SA7[-4U4CM* -O7*F5
M<(;>[ITVM.(\FKB>X2 YBJ69LM]I$9 V-/5!2PFH#6\\/,+]'DC5J:1MF$71
M'GPD:,0P(0=R"_HM8X)N<9*DJIPE)^HULW-.+@ );/;.@XN2'VHY$TPJ"&?G
M;PA?TXHCYF6GVP?"@]POM0M["^6C*EQ>P_]I\9JT:/]S6CP-I,K,.(ZN;3$Y
M<21*PG@Y((\I19A 3B6"IHH]#5P'$D68*]R4&,X[7$B03FFC'(*<<%^]1\2
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M%9=YH^5TV_PPCX^JUK!?9OFGFOVB^PU02P,$%     @ DSMU6(")5%7C 0
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M>$":VWU\#/2V:6,O.,+,YDSO#OGF7_ #4$L#!!0    ( ),[=5C3?G?=_Q4
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M0:SY"F:"&>G!%(#W0>%LGY9@!4X@D1@0_T\ *\A9\!S>D],I< ; CY=!#>3
MI/>+A'MG'_JC_K'H_[??NQP//O0O'LG86S8;,@;%B;9-M%:>@S1/C+Q%PV !
M4K.P *+I5'MHDK' 9;K\*A-H5OJ)7ZAKHQR;C9)V+&NX/Z35Q+<JM6;C5EJM
M15.F.;QDS%$5ZJB$'Y@Y07LSB)8*/ES/T699LBK*8(,)Y_@3.--78)3@:)/?
M !>\&V@U&6FS':,[7A2@-H4Y@R7CJBQ7KD@R]1U8F^T7)RBL>"!#D\U?.0D
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MD$)<,*O-%C/9_ L %"Q/VM] 2<R"SG7<MKD18Q$ZLDAC8*BI!N X)K4H'!R
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MN2 GP^K%'(5/&UU7"_C)VXQL66RMV.\O3&P/G5X./4RB!0$=\LDS5Y!O\@]
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M#B5D3<J,,=B1OCBR17#(6H"CNU]4,'\+Z)]NZ92!4J<ZRQ?F!E)A!CTA"Q3
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M.J(6)F/M?\[X_UI-&SG.Y*1>G\UF;PSV##4@ 12[Q "4?Z#5:FS 8,@6 7S
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M!=8(/P"^I"J_2^0  NB3P6G9.J70@L \I2JSTYORM8W[R[P0!"KP$GE#=:U
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MI\!G;#!<%2/7]?!L)C&1L\C;3&'BEQ1UK3-,")[Q5@&KFTF5CB,?=]NI!<4
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M6$6GAGLLLFGU0M&NP:3GCX&!K9N^2QH;3D 6!3N9)IDYEW6I2(HN%>:2Y>J
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MO6%=>QQDY3'\Y)B9CJ:9Y*-I<A2*"37&V-F*Q$%XN+G/8CL]-64AYW"NX#-
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MEO.-X^34TBL,LUM+"L=^$X7#,/3VH%O'M3(TB-B*]I[B_/P6II(^9RN6$A<
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M56909668Q+< JU8/OX#62<JR210EJRQZ^B%K6G$+'/PI9N/T*? 7F>V$?_P
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M/U"J4#CA#,+84$%//?,+TQC$#&(;IT@AW;UR9*X(@>6&P#@1ZG",/-2ER!]
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M0H_1Y6-T^1A=/D:7M0Q'>2#1"Z-*?@]Q+/WMA;1YB>":NI"E$$Q745> 6E;
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M;J=#[&S7J!R<Y.FL?CFF/YN\YYJYS^J':Q^SGX_9S\?LY]T3]9].F#AH^ZU
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MQ.]1;-6EFTB<X,:?@V:KIAS'DW?O?S0F"4J0/<B[3"DWN@.0*I3$@Q]]OD0
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M$!\W#6F;7^'+11B378!Y -PXNHZC5.DYH;-($7J,$:;68GNZ_1#YX>)7X"W
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M*SZ%>QC%3O!O?ZW([4Y==A#BW4:6@@^R0V)^?DM /3D1($+X_P%02P,$%
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MV$/U/%HFU$OI"<W_/(]XM\Q!Y7]PL^/!"[D-X@RLV@PA!"QT>5/@U2^:<HM
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M5:'JSB419$A-A_S,*>'4:C&3:_]:B')>1ETL78IJO[G5'/E>XD\"+@E9I&L
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ML9NXL<][R7H]?:+),DC9\KK8S +F?880[HGI\J;,%(WS;P@M6OGXMITI"+2
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MCQ_%,4N>;<5\X1_O@^5]H0:YZCQ]HFM1B_H'+SVB-/J4.BR0/C';&""==@@
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MU[ ;S+X254!.^J4_,*LX&&-%6M_!;,ZLCDB*+CIA]>-XO::)./A;9L&#!-6
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M>1%R%A<@E9-?[:CP*$>\Q'JT#4(_B.ZD$M]G7F.G7Y=) '(6H&3&XJOYZ!!
M9)TL.LG@K&VPO]/[8!G*+UCO$2.=;G'LJ#83D$7NR0N/X !$+JXV/B3#LDP=
M:5A0S7(Z)CN(DH+;]" E+QIV<JM4$CXB-,53[S&#PQ]C__*"-ELV_]?Q*GL$
M*HGL49\ W3LT592,0"8M8^!>U&XXOSE(BQ8S@):63-M*1S%NVU2(PBA*+[V
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MU[4K[:;*)OSPD6:72;RD5/,XH_F]Z[?3RHX5SZ9MBD]058ID3IOOI;6&86<
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M_L#Z-LE2-K7WY;IY22KJ/H)D)P*]P#9"9+\Y'$1.EC3I>P@@:H2FJ.YR6W&
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MRS+/D\H>C*W2Z"8!P#U45(^L(()0M'?L%&[UG3195&^//EUL(9RUOJ.K\JF
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MGQ!F!D-[ZQ;I_^QY/;Z:%^.KH$KH)>7_O2G0G>L1T*/0P7=A)BB1=ZF@]1Z
MITMT:AM#?J),U53VS5-YG! #;RCAGS?ET;D@J)_FE2QHX<(\+TZ60^OX-&=_
M>/I""UIA6=A%NLV*#(Y8,-&-*$&B]QEYXOTQ<B[I49B-?N3'J>4%,$%*X>[[
MQ=-319\ Z4_!1+5MG+8QZ<'"QC/7&T>O7?L.'H,GV?9UYV5Q7A:I]>89O@\
MB/(1.L2/)C4SXO5@Z#$=-(RW9]N$K,GKBE(Y.H E48LJX(%*4[MR5O].UJP_
MN_O%+ %FZ-F@.L43IQ+W9CF&;P_K\"0)AO/*9!)'9#06GK?E\"RF>/CP3QA]
M[(9'C(W!L)B-/-V[HMMLOW6+F:>S[WC3V506U,=ON;<M? :,^A&9NK=5MJ*3
MZ^;(W@2[(P"14C%'!4&)6H3=CTF3(]A;-@%A'SATT92Z>&V7N=7%<_"BS<8H
MWP%N 4 J/]_764'K6A3==1]/LC&1=85_^QKSA+*.7Y7V")/AB@RU<1A)D7#
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M*^;-,,)YB#7?+YM0W#?;YJJJRNJBK*".,V EY<F31\4(:4_MD$V1#ND(D=^
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MC@+6R:B"SQL3WCHB"HUI\#:M76<P?*%M2$$4#GC,UF5':)N28"RYW<]9%#D
M>NIBK&/(RI#YR!GA/_#=D::(_ML==@(;^'Q?9P6M:W9+/K*'++:QHF;:34&"
MNGI]2+3E1_$%LE(^<>:&,8T^UZ>1E\T7?KJY"+N*[@!FM:"I7-6V]2#;M9LY
MKFEJ.&SSM)B9"UWPC"V."I8 ^W%9/90OQ4BM,]'^C$ /4E8$^L2S,UF8&%Y3
M3EXCQ_$)7)9]4S,U$9#=;)J8(T1/XM1T1.8'R*KQJ2ELTP043E_F5C!+UH[+
M!CB6L11<<;9RHBO/(TP'#X[S$KP0]6^):/??\2]VEY@=O(6,]1H4^_H%(MW
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MG3V+!<<+12QW<L0DP2';*F-BD;3^N*'IMANY7[W,1\X!6>$@2=KR0+(:\;D
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MTG6-\>S9\WV+5I:8!@AS1 W31@X:3!_H$%.@"W*+"[(; :C-WHNM*F <=*K
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MT'NWI\N\*C@\P3VW6M<W*<^(OFWA=SZ#OM*T;@6/56.NM\:=;9V4>Z<$D,B
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M[KF5JCNT0(9<:*KVT?"W:YU/QMYF@0:WST[!;4D9X7#*=AB70P)D</NL<=?
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MW5QX7$,%O5>2_LHWX GIG?7/^^I&,! ZUH-!ZRAX7]D/O4>COBVZ1V95X'A
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M(*_):$X_ST@YBZ-['-UA@J9+)[CR-LE/50KBRX\&H<[:D5'@!H0_I LT#4
M)YJ(P&ACO8'R6'T_48U9KY;S&/;@7Q,<AE7"K)V^_-F!/"J&KR+EPUK 9ZCR
M&9?S.7*C\?PBJW#F!0LI+<;[#N24/P!87)Y /\&X1]%%-NO4>8'8HV(*A@*\
M%+>!2GLF?KYD%7(^CN+O]^_*RH6GQ *HTIQ91>?TK6ZPF.*4H/'\%C]OV&OY
MY'W.%2:?EYZ[?$ N7@1))LWE"UHEKX=_=L(SA()/X=X]VJQJC<[81W.+KZ7-
M F&PW;%.V2-&>X%)E.Q=#D>Z+BV).F2Q)&,4#T8B#P*GJ5".8@N<M4=UK?<G
MG4K^R*E_-1AH.0S)@/FNKS$VRB6F0).Q\3Q:(GHSB=<AE4(WCNA-?U_*PD I
MAL)<X_DTF^N1,Y=N/0;U"=1-L"3R?1/,,5DY_#XLBBR56:/Q24'7K1:G.\C$
MT 4%M+<"TT/F11"R23HKD(.)EY0W9&8<FDT<D@0NK79(;R8#1%X.I6JJE2F:
M 0"4C<NDNE*89K=@4J;.<FA0AA;H[L]26ZF,OA2+JZW052_+-7%4B)2(OP9_
MDRO/[P86P+@4[W& <IK.L$-FS-%)D$M_4R6,)3%,;_:$#$M,/E8:SEER&-/0
M=E?GKO>0UFM&GS$7.-\:.&8PEM4A[WSG<+E<K7V\1>@,!6CNV6XU*B8#1!E(
MWC/D>0D5N)PXV[1<6M5_4WSJEB51!PO%7H;:@T-$6B0AU6<8<"]G;GG&431:
ML1<)(9J=XVK!RT->%J6H@1"#0ZM\942 $NF2^TQQK?+ATM)7PSRX.=SI;47A
M.VK2DZ0+:YZF,<&^YU*=E7'MM:[.89D??E)N?SP_7[)J0.%-L)_F,HP\"H_H
MD<@AG[:J$J9\/6QEJKSK6G(HC<._=60U/[/"<-"EJ70E,\GCE(36?L6V_?HF
M!*\1B;83WTGJ,[-"!6NFS<ZV8_H/2:@_,6!8U9+8KJ-8AS8@3Y7:+JX5X5&'
M .[IB"*YEGW'>M1!:YD.N["3+ F]SBJB0:4.$_;S[6XV!;^F^&MPIW-'5!KX
M EXI9#R?>RYJQ.N0CAKN['W'NY6[!@W_4P3XF$YPR;BN_4<FIZCN$**ZUXBL
MG.#."SQZQ]B.YY>SV$T9$\Q8FR*ZQ*7"B:LP'+1=) ^("H^@FJF-DVS3\)K0
MXP7-%!#C?@A^7,J#PU^XZ6ZII\KTASWEZC7F-1Z#^-V-F(0.VZ=7:5+8-]S<
M:NDB]I1/'LV*D3B*\(IN<C:R9;[SYH9_N=T" 9=A^J?.!I$G;$#A3?$:!L3:
MQ.!G5PN =4[I'U9U]'JA]U5<_OION3KGK5YCRM^ W;(3Z\+B"_KJQ,?J>6X)
M+M<9"%N>^(:R+5AX5!JS,+?[[]BC!)QM/SO4KJ^0:PUN1;)Z*@RJS(?(5)D@
MXC)V+A EJ"X#H@RCVE<P=UL]A#AK-IP?JYDE!*9^1?/W"54);NI?M,1FAQS4
M#XQU_CD.DK!V>.6]T.L]7226>T3?\#G$[4D/H"8>0+Q?3Q.^_E0"HOI-KTZF
MVH*-O<[6-C@_A8C^_]:;TZN!P_)"9J,PI6X\9^4 A4$D:ZI1G\+^[$PC>)AZ
M4:ZVAX,@3A^VCZB*IB?ZXY+R9D(\%ZGLZM91CO:FR=_H[5S)T/H>REU\@4*7
M>.OT'3$KAN)&:/8K9M50?"_:)@27'=WVLA3523O.&&O+7M>!(!.;OQNPH#1+
M[;HNB='L)G#Q"M'_^C$K-Y\;%>D]RYJD2!'3*Q-!E=&9/'P$[-!A&?/BG#V%
MML2VW.D U9WR)MC096*R_4P\JF+P<_#AW?OW%CU1W.G[:+N).)DC;.:EML47
M$J(VCUGZ&/U7)YBQUR $+5F_Q@UBO3?WKR<4C9-2<CIWZG%AZA%G:GJ(4KLX
M25)4>H%[F)G5,QH[,5RE0T?G:12/C$XSUK;=X19W6WZI85\''70/I*6FNXL8
MY N/*?TMEJ'CA5_L9GG6)@8K+VU*1U2"Q#7&FH'9 ,ZVX_OUJ:$S!T52+X;0
MR%N(@DN?0N]%;&3+8-0F!D^VD,.BSC"H/,U3OCR@5K602Z\M#J=T^B&DT]^P
MB]O#R_7JZ6>%'.SZ5]!'G#Q[.2N&TJVG"G42%>I.*?$#.,A,I\N?DN5/R?*G
M9/E3LOS1 6@G65X]7#_W C3+"N>Q[ ^[=S;1_% M&@YSR FY;.))@#'@+>]@
M,07 %[*6/=$*K>C^I50M! >+*2*KFX!E-%-!8R-_>/?^>Y6:(2UCP)H<$EQN
M98+&^?<QW3X!BK2UIXBL[PQ@\UW?L?G.^"5-S6G!LEIVJOL69Z_;:T>:T'TA
M_GX(1U(C?TQE#1L [ *O'"_[;Q?@2N, 68@2,MD 39D3'1JGY^4=1L'L FV0
MCY/TWJQ=G8+FDAGGN#DMQ0GXJ,HC\ND_+*ZI$B:.3XD=S59IX0Z'Z=L&Y YH
MM"D1!76IEI0#758;;[7:V^/$5/J-_A.#[M&J1\='+.'ESB%?4%*L-$7;WI82
M$=!+5^]M<RZCF-OZ[ZDYWI!.&M>Z )2G'23L%<X:.UT[Y)>GA>*1U3K]M8G[
M> RT8%UG+E!O\H)KMLGBLQ?O::1BB-N^A>]&GVUK%D9I-OFLR48;'0/4$ZVL
M-_5V7%LXLJX7[#)A]X3(YAP@Z"66&GRFKM1J$.V;Q-1/?X';H_81A(?6/#)U
M7AA[[JW_<(P.A,(HE9)Q<('6.+39($U(P!"/:#&WC;TD5Q&#I*4;BRND%T3F
M<'A$;DSDFZ0UC]"_)& N?BULTG_-;>1Z-75>+N=SY$;C^14FR%L$]"</K/^+
MO?00,0D#/%6;&&[J);>V/L\HNGQQD\9 U[60S@'%@#?W$+4XE\?F7H";09XM
M!PKY9.ZO /F4QV9?AG=SL.TZ,4(XV?:3#^3@;V-QCKR!I$)=Z]TEK/G+!4K_
M?Q.,?!\_,V=@5O^ 2FSZB(VME;T#@)(3 Z0.T)8P 6 NA1J>O6[1\\]4%RXI
M4^YC%JIE3]U7*QPD%8_"<1R%$>6+%RRD+A*R8PU$LTBS+@?7@%].+>LN9!7K
M$H(D4^P*'_0P>8N+4ID+.1164[8N7Q!QO3 M.S>>%V2C6%E,"B+)H89CM\GR
M+@?6;M%%NEYJ!(24!'9WE$*P\LE =&&5$3D<EJLJ9D4>I<$H_OXPW-,E#N0H
M='=K:5H5.36()6,6BN;%3E)9M9LN[#S)0/9>=V;G<F+ Y:5W!^JZA _OWG^T
M=@LR0NQ0S"O3&.:9+_:SVNZ<%V\5KWC6_&A#U\]"!O0B)]\:0FG @>@B-2;F
M8%OVNM%IZ?V;I'5]PWT/#"E4A1\/!$$Q<W*T+%>1J.B5*\<COSI^7"G(?!$3
MJD^F2_0;<N2>9>B,.PP;48NC.?I@'JHJM4WD?@KERMWKCCT8+Z8V<W-QL)UK
M5O('),4!U/TFZ6<#]9%D/,GQZ9XJIH).4Y\" 3+'T#_ /"2";@$?#"2)*27N
M97;88X3=+QE-U/R:(T\6GN81!H)6"YMR\"P[LW*J,H+R7:Z&6^WC@4%69TZ.
ME@&GE]K!E+8-N? VW@P%,UE_?O6KH3@&./S(D3'1(\-B\?U['*$PPM$2B;BT
M"^=.6"8H>X.^J[RO^:XN'WQ<'YM?3_^0K^UDB-%(*M=FJWQ]_:YS:%Q7]*>L
M;:,#+6T_#W2E414Q3Y1^5Y$Q44C]5"U?"W5#V]U&J?Q3G?Q3G?Q3G7RCQ3)/
M9?+[H$XMU,@_%<BWL.&/M$!^^O1J0O""."N% EJ\[WK#8>ZB0:IY%+Q;"LRO
M?P5M6LCSGK-B@Y4U3K7P84\KTX7P3Z7PC[H4_IT7L-02E7.C],61%JRO+ NJ
MBF*6N*-T*K_T@+OE9<%K_U/Y?UF](2S_;Z;ZT:D-AQT8F]IP:"2/B-IP]-.8
M,1(L,-$2P5QA9+GH1<L0O?-1<T.@;7S2+^!IMV*RO4BC'#E]V_9<X5 'P9QI
MJ.N-#9?C.)K[^/D*DUOVU-FF#Y8S><\\KRURP.<OO,GZF; T*/P<A ^(/?)S
M_' \OPDV=+&)%\::#+02 G$//I@XM+-=WQ[N].25K#'53"BM?S9U7J0.?,YG
M_7-&<1'C,<1<(4XE!V^R%BHVV\>8FAT.D4R.YGTW!-7*Y0=0"<TI<69,-B3M
MX\*O#\,6+J[?8,%,S2,M>^Z0EH"C-E96_,W:22::?V"6K9#-QBIEJNU!%MOD
M0BW:A<4/!H%-F04@52]WTK [+QDQ#\C%=!6^EV8;CZ(K-&/7(;;2F ZR+?UV
M]BQ1+L7:X'S#T,5&$3!8+=.X&-$?/J(H\E,N)?RBUVO6W<@W+4$24WT]PB/#
M=V.U-C7;&#A>$&;EV(+SI!+D39"^@F4589\=,KO,Z-_](*]D$-ZC:#ROW7P.
MV>S "+4#N7 9!]%@\4]=@_13$(=H1JE)5T-I_;STW.4]OLBHH?^4U ID&VT1
MU)^!'5#X=&@;AJ[KB$^'TJ(=["M*R9D3>IFS*(S8PEFC DKS3F5/8K+&LK$:
MI0&'X#=0XR!8Z<Y"J'Q?S7PGHO82"WB3#T$,VOAKK*RGXNYF\Y\[A&SGZ8DF
MO8OK'PY#3?-Y E+JDY+"8OR\%DAB7 I?#,1$J[#!7'%.[=AE3-C2\]XM])1&
MWJ;^C/20 4PA!</2E0V<-E845"E>E=)#[Y_W.,C^TE@_713 DAAG&.I4BF/&
M2HNJ8'GEO:!9+EE2J)6_&(AVK;#!8/5.131*,G%%EWJ--X@$;$U)Y9MPM&+E
M[R61DAUM %%^!=9U*(C9X1)Y$2,%[/:_/82SK+!V@P4J%;,LG+47.?ZX5(SQ
M)@QCR?(_3=\/(I#5R""@2I5[(VCBI&7T^.T7#FAEUB8>ADG2Q%ESA2G5TJ#V
ME6TE$Z *'PQC"Y988+ @I*D^2KL:8:U:]( [4I&LH>U7550ZU*WL6/^[*,XJ
M)VW]LX%<,W@,,5C'4JVQ1V(G/V)_]BF@%(P6!"5KFN('M$Z2^T*4^/^\8*%@
MN&H,.XP-JL-/8V4PE<JI);437(0DW=S%WQ_ 1;&T?'.5+96VWH(*QX+2KVSR
M\+\< "H"EABK;ZG[FBNA@[TZ(QLT8]%*IK63#9Z521T%^_P'^N^/CH_&<QZB
MAWSDU8G*8:A?8YCE3T#L>H=RE32>T_F2%B^2[ECNA\. E,^3')_.#B05>!+I
M>6:M[8/%A1<F+4CE-#;_RP%H; %+<GCL9NCL=W_2DCA[X'FVO7>BV**OB#OY
M$!RX;?S-4>_L,=+1F<S7KZTW:Q\/ 2XQ9W*@3#09T=RAN_+E$\>;E5T6UC9J
M$PT#T,V2S,Z%P<#+/>.B8-W/+T/+$'2#(O=S&>GLGE)Z=LOF/G-"E#1(H$=-
MQF?"\M'9HL^V^U^9.%OVHQ%+4LL]H:/9+&&$XR>_-XJC)2;>GY(.R -./PS+
M_)#XY )GU2>V<S],,D]=TOA)S253_G00\2@16W*,+#>$V9%S$U#2'3\W;=1P
MJGX\!*4NYDP.E?77A/=X15?@)Z%E.3]S\8-!;)\R"_(*%@:*4RDUD"L=[/)P
M\+X;PE;A\B/'QGI64HD:%CR2/W@$GPYBYXC8DN,$EH:TZVL'D?C G7P(>[*-
MOSGL5MU+3.Q&D?Q^+/[^ 'P(I>7G '1W&VDKQ]P$5=>-NR\'@(J )3D^=GO3
M3O*)/E&K4R'!A_?=$-08EQ\Y-("UF3([=$SH;J:+63M^FH!2Z!%W$X01B9/&
M<4$2S0DB+X@3#,;S.^2$,4E8,HIV#:VG2X+CQ7)"\-R+QH2]%SQ#KA.'*.U[
M=$%O()NDWN9-^(D]]<9W3N LT+XKDKV#\U@9, "-U ,N[_:@Y>I8S#GF!-M4
M$V3I];(9D/4/A^$ZY/,D!\CJV[>]Y.:==1^0MWJ*Z7B)A+)()Q6[C1>RI!%K
MRDJ*F&$(@RH"N9C830<K9>T&ER\N"L/Q7-F_)3',$(P@&6[E%4.MUVG/8A$L
MZVODNB3>12?DDGD:/A_ 2=[$G!PQN_W5?G6(QQZZAS\CGZ7LA9$CF8;._W(
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M7B,2;2?TC&:%5]GE-FD6;,W8DZ,&PL$@8:)57HK),=98]V7=$U7Y] 32\)(
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MQ&66#NIB0B5C?T*>LY8S9'N.9R;2@YK'[\4I)<6H'$:#+Z8TLVJS_['EO#<
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MGC(I8\0X?L#R(*:6R]W=I3@"6WZ"31CI26BAJP5KG UR-K[CEUJT7N&H>BF
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M],*+0?J,ZS#RAP/:ZI&+5_1B?*63\U$6#1CE7H-<H$2PT1%CQZ0![/%2MJ*
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MO@=O2X[QQ#>?&LB-KI[\T7GW$HB)=>"&\;NS.M)>'74E>BTO[)IS)R<_?ZC
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MWG^\0J/\1[_DG:1C[J[=..77!@D@$TI3.Z>*1)BQMY@?LV#:<G8P]S<XE2
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M35J.K*E]/FM&+KJ0ZYY'ND4:Z89,<3"S8^,.&WZ*U4?UN7EO^NT-/DWZQEU
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M<"$1L+\@7:A@PS+(]+3A4F3SL\$W21FI;(/.JB?PVTL_8W$O_1T6][]"SQ_
MX/^/RCPO6"F\'JF3&BG/W-UJVLV+3#-@5I((L$G#X[^)N#K)4(KZ)Z,4SQ:5
M#F<IR +*XP8Z/E^A>P&FI%2\U/O0ISN7Z!F5KL**I9XPOO0SFMK.QH'^J:+>
M8)X/4.V4+00">V:NGV^>E.8C.3V>8+L0?FK:=H0PA-?U)=&G4<17NIDLP4-G
M>1PH-2L%"&M&&QF_MK[L^YW:>8X#B0 +Y$F8+1O$:;9@2F1,Q.=)'#T)XQ=A
MS\<HXQ!6B*"([,1.]C_WFS?XZNX6%MJ&/;/3[[)S4_K-U8)@R4U2ZKU,138(
MA,?V#7/G]?BO=!3(U_]J?+YAGHSV[!^_H?*TTR*-DZ>W32J#MJG1"P<RW1)[
M>Y*"\\07"QS9&_,C"=2Q8_W0A1O'OR8/8RQ^:2B7MZL6S&9F05,PY$>44O_"
M^)R/AU>V_AW3JK("L7QY42/_4Z9!@;/>^TX*'M*G%Z T8=\V<: >7KETX9N0
MDDX<2+2+T3P>ZYD(B@R-^?XOV2^S.%"RF3]S>N:A*&+K4]^N)W0^(?7,0IYX
M#P]FB\\WV6A_SN+4[[E'9]/D4& \1*0$UIA^0M][VD4]Y83G=_I3])1LWUG"
MO@L$R4K+G_#,^"Y0XN+@<88A.\S^H8&J%''HUY?,L]?\.?I4OXO[W^7\:W^\
M'YGN+7D3D_;ZTRD'*_"_K^._*9@+<;"#@<8^%IP ZTX$7J$RO7Z&,MJ&NX)Q
M#*P+@DOK'!(,8]:]Q!M< 6H&?PX53;_OE[!W!M >HM1S@QHI)U<9WRX;;34L
MX)51FG^_^MX1!#_>B+T(':=4._EZ:34YN%F1?^+J,_;.=@G\E.]G(./_ 4;$
M@;Z:_PD+1.Q?.4$V<D LQ>?\?H8V0C=Y?T(9HC#A?PN4_-[_=\BB/5;F;]&#
MWWO_ $ *XD#,?XM$/.G] TQ)BP-%_1VJ\7OG/X"9.%#[WT$DO_>V^(O)?X.X
M/.G_._;QN\5_@]_\>Y?] QCT?SSV/Q[[TV-WDPEZF26>VPOG+KQU9<?'@1BR
MCO<52 &A01",OLQS#/:CO%0U.^;737\,1(P@PWJ, 3E+'W&,\7MJ =UJG<>!
M\(!0,OTV/3WR?[7WE5%Q/=N>C2=H0G :2)#@$MPA)%@([DZ"-AK< @T$"6X!
M H'&W:%Q#\'=H;$@H;'&7:>3_WWWS;WOOIDW:\V'6;/>AUK5M7?ML^OLU>>W
M:Y^J.MO3G< 2O^?W<4F9$"0ZV(,/.(SO6*(OI'@E+M><[P'^3O> 0\TQ55E1
M9,@48IKVS[I^+_W3W!PVW /:&\ 719L%V1##SKG.RM^O!!]G(H&-,OT&)^G/
MD<!_&(J+QN_4H;LKLW#PRH/1>P \<N0.8^!O!P+_YZ$TLC#!DSZ<?=AU;OO'
MT1?\B]MV'JCW%G036O['X6N _W$H96%A0K^0<:<(</\?1R_QCT/1EI;^*XGM
M?]OQO^WX_[(=^6X>9L@%T=>F39YJ-<9\N@=$:\LC(>KWC5>H2A-C!/V)E=5?
M%3IE^K^;M(R5Q,\*LW*U8"$CH9(4#0.X$JGQ8*@-2J(5\@*@:JADJ ^>GM F
M_FU!/G.R0;*]8ING-_]_\35%8J5CU;#^U6$L;<O&I ')EGKZ>$07P""KH#6?
MT%I-)] M400,?4'6S>,GGI<;<&@&#?9,VD70P@=B@V5K +I9!2"O%&MA6^VR
M (QX1Y6A64*>*XLR\BQT-%J\3CHV(2+ %7,DFQ41-"RST>RTR,NB("4XI:XD
MZ\'<5XZ-;;1'^#Z'DJ2;><F/  H%6)DC>@%[Q[MG%JM,*? 88EHZ]O@HGBZD
MDB+90KT!;[X4^>05E>'69$2Z$;.=P^MI1P-%\EINER@M<N H1A'S0P"A',"=
M=RJ17W*'EI@1$$SVW(]&FK?WDYNAS%+S2:999)V=JXCO&8%R*4 X[/T 9:6F
MJP6:(!8CT=6?G0JEHL-Q[Y0PQ5@XH0.W^^-ISG=-!P5X5HG!=E7*?RCQ"+5[
M@(>O)HW7&S>I)H9KC>4EF@0!A#,822//&S-CK3*N5;Y=N<161E:'E]B!X]1?
M=@-VORZ-_&Z]\G;\0YQ0))%J8A28H5FF.>_-$3C_4Q?@\4Y4X53US.^!6R7V
M8^5O,YUO#^\!'\/*0%!=[-TJ5\KTRTTD0\Z5LOS/#\U(WC$SX&#-;2YR:BB&
M=7O$W 9S!Q^/@I=IBRGL1)XY<X]-<2#_@1GW@%9I@6NMXSNOZ.MU377%[ 0L
M'O8TO;_:ZDKEWDAQV=LCELP\"K9/R4GXE7\1#I@E:AW:X,A'HQ5#C1?&%C1X
MG:14 T;R0I"\?+TVY./2>7=!+#>A**X!'&EPV4D)N3FC.6_/$=[+_*L7BW]>
MBI"*L_BOXW)KB>,%\#)J3LTA,<P@L^'# 1P7U4^VQ2P%E-L?,CCR2E;WL2$9
M=T4O78MP YC .I@9XTO/NNEUE3?-FVW6AZP\'DW%R"=!+N,_6RC_YU*FH'98
M,=Y*"X*0-%2RDF2CR6/ DSL<T^/MQ5J\PW9L1EI9+B2T#MF#D[Q75D-+077B
MMFS#3W[1093KU26!29&B[J:K8+QM=O%O7HV^::72(*+I&8B^4J>;\J(HKLLY
M<*I40*=FU/>%QXY&BYN^OB(W.0TP%9!*H.;ERT>2?3"O7GOQ,O?"C:":2I53
M^G3I,B# 22&MIPQ%]4(S3;E]1K@M] 8D>NX6H[-]9:!@)Y&*C[W[[*LK3L+.
MF\W<AV*Q]B-K>+"17(,=:N+&":BAEBIQ[K$23?QHU9J?UZVP18.'J&+1A?/J
M3-3&^ EEY/M7E8MT\=8_PC(2&;%F_%CZ#GHB^*X)""Z\?]#,D0@KA=*K#[D2
MC[HG$+U36IH#FJW-P$J,-UMYQSXZK"Y:OHJ62UG6F'^L'YZK)3D0Y)L-A'^:
MX34DF!NIODX>5S@$*XGCCKL6BXG;A"^J.=LXF "9CU]VHO;X80&OPWX<$D0;
M_X"@'R:&%X B\[;/2-ZM![YED)&2'2P1/J5),UO^R-SXJ5T8[XNVL-U28<X2
M=$8KZ8E=F#HS>E=3U(<B$<N4-JQ ^[R#GE!VVH/6H,S%)7T<09*EZT%/^L6X
MB!\_78"N69M"#'.WG:)\[N:DH7<T.95+-2NC MFYP[-^V O<IO$=<+JZW+?B
MH@9I+_C %Z^1?_HJT_HCCK+ ->M:#YR>0<>3DV(*[4 ^$0<B#_XSV>HCET4&
MZ'4 !U&L^ REY/ZD2TGN 775/0##\J"Q)MXZB2)>D1 GEZ6?[$GP5NRG+M*7
M?1PC>\+[^#>JZ5J'/JU!A1=..V^N79ZO=LNG/F$!R"W4KSVE*"W[J#[]48S'
M<-L(KZ%N3&NM5X#;(.-+Q$^!I!DL(%@X[EJRJ?DB887=Z6$I17__=[E<L)AS
M/2L:%/P(?2;%&HPGJEB@NSS?9YEKM*S\8094HEAH(?\.*ZM0$*V!<4MZU%OH
M#.PLL"<J76B5#ORH[)B]&;_#,_".9/:]3Z8&FZU.NO*VS>0-WAJE ]##7DQO
M":O.!T$T*M07V:,*68L!4QQ_6Z3I%A:(KG$@]/ 5H]V@+'Z0->?H4J2+RL0A
M1(:2U*:WTTKJX=I,M<+SKL!H7CQ3-&_OI^Q3EF\'1 1&G]+5I4>=%*JOHX["
MF/(D_^GC^7^*MD#1/'_A:K&(.<2*!+:XP2WUH;T26XANE&*+J7W8<0CP0:V+
MGA]"!Q;V7)*GJPR35](YP8H1T\N<,JL,/?VZGPDJRWQ=5Q58**+RM),SGY'^
M6CO3Q(M C[]0Z*EEGJ,D,/KLM8!77G3N@FSK4G_/4"R!C&D0X.[U-,-!)63\
MZJ$)9Y&"!_NJ80C_83!V_0G9S;%1@G_J>0Z,)Q7W:M5/D/V]_H.]TZ#)9SR*
MZ,QX$1CRWQ'7 ULCZ@C%1C_]A:UI;7>2 WW]6>:7SH]=/ F6!-%1.Y>:CHJ4
MY,BW4E4T]<D!:Y,J6#2WT0[L9^$YU<UGB=/[3K_\*8\D 5&=\3VY6A4A@Y7C
M[*92E0;;3@8L*-^[ V/$4PF&FTIPX<!Q$]P/@EN2P&?\*N6A98ED75=O=BAV
M+V,>$3T^I4]QRR<NK5E*0[T4B)N7IBJ>?1,8AR]N=GY>!K=>3\N&-*M"[1?]
MTPU4,&G"Q/MADC4IA^RBW9C<VV_XE]QJ12BZ; JTE4:?U]=$?5_<@X&DGCU,
MP +UV*8^-JQ4Z<1%H3XA1C=!(BW \Q0!,[2Z2E@/ELN>=$7W(\S_$/HB/JH%
M)7]PNG;41KOQK3>;=,H\:X%@HHR8;"'YCF'N<#K>XE3.$<E0=9(T5H!<CT0:
M*<Q%./!Q)\<*Q9NJ%8\^]1B"&H"3GAHHQCHQB<)*PJ(2ZM;<@.W[7K)=/#_
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M[--T:T."!M+NCG=V]/ 2LR"RQ.+5M_[Y>= ;FG0HNRWI)$LZ%-C@8-P7N^V
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MG+5^K<B$*I2O=_1GONH@.'2^'K:&>)<YM+DR4/C]'<DW2K5$V'G99DJ!# #
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M)0.K!\.!-*S1'W_7%('0=.]*4RH,$0! Y)=?_Z AA?XI;MJ@0#BPT(IW=HJ
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M!.H_=<C&;P5RL_RY]L36!7U%XHXN)"Q7JUEO >O"!3X/[U;<1X7B]^X&F02
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MZMFP(U*4NQ?.?[Z)'9[<CQ%YBK3FJ=]]EK;8A<P3+IO[_'18ZP&X-K8R96%
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M7)ARH$W\ASZ-"_6:QXH=$9%\6_-EED\/K[)U![YC3?8ZG8=ILZ.&H@(P;&L
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M7?D.1\(*/1#O^$.<89_<]U< X6)2F].NKLWDKB\E1!*D_ORZ9# QXH0^ZL5
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M=N/)W+^)_1BF7W@JB#YG=+_1?YER^#7>/R?@)(&W=I1@?GI.#H.E4-)/"4D
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M4/EK)B\7-06E!1I8V% HXD4H82+9:B@(?_;"C<WPX#1HKHLV\0EG<^NJ\V4
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M%]%OW6&.L'*"5V"(<4976DE&3W(K>DYFV4,Y&@4YM.!V3^34\C$SX8<\]U?
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M;2/!J;[9FUH4H?>AV@L9-=P=DA+26T?'94SYKU_##\H8<QZ[ Y>%')(RMPE
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M\WDS31HEWQ!N#BX9$"$$83>;;V0(F2"0@ "G_!SS;$Q*AOV6.V:0PU?=!/R
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M=Y/ B?O?1D_6'H)1>>_47)F8MI2PJJIU:/NS#BPXFY'N00$9TZ!V^#!['H[
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M6#^[RL]"T)2G7#\=N[XV^DV?AG+!:3$^9QAL%$(X9"?.\ >00[^_7HT HE:
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MY 1AQUC1YJK3%S6DX3_BR8NS"NQ^9K7@H9A=,J1SX?_5U2@?LGK(+ADOMI5
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MXH@Z 8_]H,H1D%@K)+55&49S/JD8O;TAT5#.4NBS40=@H3,%[/V_T@_E=>X
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M:?+6X^GFJ[[DK'Y<K;WSYI-I;[[GBQ9W ,&8DZP^YA!>,.?/8J%?Q0DGX+A
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M"1-TK>0OFI/I)RT(UH?V(7@Q((JK5AZAO"C#IXQ^0LE.%R.4+E6V\F%"P]+
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M^!D>Y#BL%'!$0[/4\-.G)%OBKTT?O.,3+.8Z;O?;4 ATWC9CYO#0"C((2[
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MF?>48W;/%=8!!^]8B@).HJ>VY93T=/::J(#C&FDUJ$*<\C'@M*5P.#<S5[I
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MGGO/O>O^:]W_#*M63W=75]?>M?>SGUU5 W(4.0T0WI61EP$@$ AP'_P#D&/
M;0 + P,3 QT+$Q,3&QL+!Y<4#_?2)5PJ8A("4CIJ!GHZ:EI:1N;KK(Q7.)EH
M:=EN7N.\P<//S\_ *BPNQ"MVG8^?]Z(1"!8V-NXE7$H\/$K>R[27>?_+'V0]
M0(2%@HYB@ JY J 005")(,@F@ $ (.B07S[ ;Q\("BH:.@8F%C;.);!"*2&
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M"<YQ!(0TA=X\E2VW6K&.W"%_XYESGO*%#H4T5MLP(3X6.N$GPQ"1Y-!Z[['
ML'\@\#9)#]#[9SGUYWXD,&\W@@0FRI! +W5Y#J8"$HBL-D8";F-(0-(*F$P)
M80/^5TK-D]E/[[TM9_7OE%4GD@I:W6V]K*)TM!0RC03*2HU/L(U@4X=(@'HE
M#),MPSG6(Y!*:/3$+N1;]*FU)FA*,4OG2,!^)_6'L^R3XDWEX3B3E2J.1>6-
M/&U$@';2T7E=2\3WWW,D9@[2+YIJV7X;P?VT)(O9S=WZ$6>GDWRSS0B'EIO(
M0%6%JC1I$.EO/G!19+F:;LCL*O [IIE<[ZY'/TD<7)Z7-]%E<G5Y$&,JC.;U
MQ,#)(LHJ86)>9K;?E]'X/&5!,)KI+N%#EAYTJ<_G'-Z-<)<JK2@N4ZPT!:9<
MQ[>Y5MURJNL04DB.-%F7]<@(^4E7#:M:Q<=B:W>W* Y'QNN4 #;[Z'3276#%
M(M]M]G!U<T]I@/]< <7:K"+J@(CNG48F)>58N_W=RIG3L3<YUIGV=(\JBBN]
MW5Y=G^*CO%PX^E(:L/[!U89J#1#OV&5G)[R]T;^,F4 W!0 74@UCJR<(KX(E
M67@R$DC,^=:+5O+O2_]'+V&&^X!.'IG2@Z@!S>*VU][J%N*Z7)1'8F\J!H.)
M4=)6K0/92O\QT8(6@@E$BA+>"[B0"-^&G3V'RYY[9>SF5=5O!S9Q3)\S4Y$R
M%&7 K."G&@Q[0S"1W?0=OM%G#<\M,C\-89X=&'='E$HA 7'MO2RVV) 7&RJP
M'LVSY=_J G]<696\#4BUB86 D)5I=SUO@U"\JTDE2PB/*1 -P0]I-KQ:\Y@G
M$3Y@.+BQ:?\(Y4YY^6T<B7$_G?R;M@S&>JLEPFA5>D2^7)MT@UWLZ ]O$TH!
M^$\?5N(I<;QV-:WL%U DUG?VL'<S&-\P??G^%J](@?!!?DYC[ OSU!3??(Y*
M>ME8W10HDRB/6>M'5E)(GBX\9(U%ZCSA4$+7X$8E7HQ$*MWCM[[6,B' 8NKV
MPF0\?L*)81.7JSE)PY2%&K&F$]6G+:9%*K*L5,M^R^&BYPNZ=G8LEHNNE(8;
MHP22 $.@19\D^OT5V.Y-:R2P.09;QM,?^BD0 O;WO53]5Z1)@?\C1\@L$J
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M$"WQ2;2"7">9 @\ B5*V MJ+=EB2?#.YHGQ3A-]=:F(M]VC*%GG%B;%N%L5
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MNGQ_H&X;WT_DB2WJK<LW6A[2$6;"H3B>8?CC*6=O"^@D8K[ S([G$$%XHD@
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M,<]B1'@VS(T#0O^ZG&=L?/+:^5F=&^4)^9&XWT'RI>+CH&Y1!>%IW<VNV:T
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MHKFCY YK4ZWS.R&P6OOGS?Z 5/*_OR*[*F90]FX-4'?R#(%Z/K A296( HX
M#>A6^=#!$5F#.O_K#XU15P PNU(_;USUS4DY-3 JN)@1.59!&_Q'DOW!#3[\
M45M37&U1<, <*'-# @XGYVRHH2"W#OZ%6WLW,NP<W#Q-&M3"LSVVTPQ?5/MZ
M^NY5XER_GT@V.\,?,C#\^:[;+"GO_VA9]7=ADK%S?B0+4W\^L0>C;RNRWHGI
MENBNE6)HFBR!=/R!LNLG!&<OX.[GWK*@TX;LA!S2X2]>[>4_N%K$-<?@@ 1<
MO%4P2O].JY>C557.\[FU+^:6SMB^4XQ>QED -^S7.%##?R"PD?"N4S%M$M!G
MP?Q%S4;,?^(HSC_PGWD$FFM$4Z:^T.Y4,FNI5]SOK_\.4!-"GOUN(K*_WZ[$
M[[?Z>Z4!.U,_KX<9(H'F2G)E$CVR;HF6U)>R.W5Y_W3KV=(9DS/Q\6UYM++'
MG4GUOA(QI;_K__?ULK_K5EK*/^K5=[75 JBDZ CX_]SR')-OL;NF-65&_;2L
M]^:4W)S65 #6?+@P78Y6"-!:V;M0J2\?GBYB1?XYQJZ/A#-OD*RE7XBN6K.+
M3^F%0LDNDWMD/%S^ZLN%-#=A3JL%$$U_]-4?J( *QL%WH8+VAU@_<G6ZY]LE
MCPQ$0\19H&O)+S%"TU 9(74SZ=>XJ)6=#W)&QC<])]-(X 0[&=?^NUB?[UQO
MO,L$\J_6DX3EY5\2WS^Q?NC+'Q$ </B#P]I[F" D/B !YY.0SW_R9TDZ\=^B
M-,3(? <5(8-5MS8!VV<IN%? =^P/2H9F?+!9=T*B@GGM]_BA7;P,W>6VG#K8
M8$ $<+1P?-UG^$91LG5R& &&*U+(>VE2-<J+:*?^,]/M^/G"[SSW#HC>-7L7
MZT'XJ?707;Z,<V?8@E&>D?HTPS>J 41EW6Z!5@$KU9ERY/K]NL ]T'XJ\7LO
M$OUFQ%]6F A^SDV5XNHCV,MWP"Z1O7]YT:]]=]"'YI7ZH6M#T!C;8=;OST9B
MN)\G-DF0@I8B+_4/-YO_F^[]_Y+ND<5GK1;ICH]]A>O15+<W\C8OHD$HJ!XV
MT>)+KDRF];OR9.OQ?R /T)FW,'L>?E?D+5'DR-J6),7:3W-5D[ETW B9#=CY
MF/TY)!/5ZX]= *#Y*WQ.VB7?43X/9/B&LV;]TSS6KS\W^@$5<C2UP=LO%9=^
M<:I>C)M^=?,RH"U'' CTC0A_EXB[_ HPXOH(*6>0G)Y;+?P13_V$K-A27O^R
M&>$["[D__ =-O/@E-5O:C0N0^1$4M#]HQY])@L(%<)\<&9]C9Z*^^B, _X *
M9',_!42@]_=9L*QL6-N5HU\FX:P;E=6-%GXZC[UDYNF!!$*N@,,RZ?GY8AA5
MOX>%:]L$9Z$KH(-,?=/.^2X%!JW1X)G%_^IFR3_F'U&U2'2.@SJT]'4WN9IK
M8G=?N%Q?ULE!+7&2[0AGM\<?ZZ&K7>AJXKHT:5C;T(0$/$FGK_OB4P@=Y26P
M ;G6/?BMSID=OOBI,'/.+SEL99$:$N/3+S7VGNCSJV!0G#$Y@3(TYL&FP.1\
M%H25IW;&)Y2N!:=G26?2=GV2E,;;81T@T<4O10*P:"00G(H@JH0M/QBNV]J%
M[9!52P,/8 TWN<]Q14;.$<J(*Q'',@L@=#[30P)U[4B@26L#S%,(GATJ\ ^P
M%.;),F\MWNV;6)^<S, 1SH U8-N#HSD!0P*H/<?:VB# )6T'Z(/]<0>MNWX/
M0?K/:X1-<VBKY>5;-\M]QCB>COA2]84-]6W)=H".7JNU9=X:X6?*!IEB%E+8
M%-G-'T6]^'UHPX_B,OPD:AZ<#?72]^*2CFQ7WPUD,![6558Q4X+M?)E*\1.&
M'4MMP):Y<O[4(/T((@!>_HLZ+GZN&/?CI8@?ZG-D_J4)=CD?QMBFUZZU#["G
M8^*AQR$K;,FXW#_I514)8(W7[=]8,S[Z!E:92/&[43=#$X<(HK-&( %6)$ D
M^T_E5:O>IGMWUJ!?JZV9("D8Y!DMM'\:,P0R"_LS#EM6!*R4^_0DZ4R183NO
M).D;8K!N:Q6V(_#UOWS?4GK&!.T:J=YA461*H"8)"T"'.9X?\"]H_P=#*[=(
MQL7<KNZ@D3E!%+75YZ#R.A&<H10A@1D]2X:]TRS8%)CWSEH7IV3)Y\5?YXE=
MGH/^< =,)P,MTV ]FV"&#0-![WE^=\CC?M^O$MUT<>..2=MY_!'?SG^5B1_6
M4-(/73I2 W6?!>I^Q%R:OM]WU%O(S=BQ'>Z!TM+@*)"?D7V;C7*\F,41Y->:
M2. O;D#&55YI=<TB,O#'@8/^.&CZ)6I4_ZR&"B9#YIG(@(#GL.]ME<%-4\W1
M N:LEY6L#,[C0\K'&I_HD4 BF&H?'<".$S:7L]6B5A6>&BW/0&?4CKT1WJ#?
M3 W])K_"S-:W#="W8-H7\F^&""^,&T2N.R1M9_F((P%Q,%78 MGPA?SIVT=G
MAV"$K,NYD-]=FG9WDS9RW;D,04P>VS<VME;5I-+R7I7\44.$<B6HIA\'*HOS
MOS_4/]N_UB#/Z_OA?$QMJK>VG&-M\#,FD_[)1JI_E[^41VO4I9.O^\Z39*OK
MM-"*)=M03$8<R6Y+[3PZV2F/XL(YH1'^S.&R_@:#;P137$9$6_KFR7/H!/1+
MS687'.J?N]RLHR>!)<2TQ ]9WM?&R]9CP#EF4AE<-Z^(5JL(NLS5611[-=YO
M(L"A8MPQPOYNP8,TJUBOLGC'#\OE;E*F*(>ZI1"VA"LWFN,<.\S1B"3IGVA>
M+Q75%^T0U9WG$)@KNB487>$?O3];L]<$NU]9,NQ*Q]NJ65%5:LZJ1G%5C8HB
MBI2<2G4 >)AO?6*8F)?G<6MVE\63&Z(;'!GG0$1.1T";. A9UM FREI1F3A>
M4NJ_-T(TRO)J['VXEC&/YB"ZR=NY#)\=#?XDO+$I@[43WZ&)]5@]GP4NQM/;
M$/)YO+=/HF0\NAV/>S%358V,7&WO@E;]B;CD@7A?G2?YC,F;#L]8L1GWZ!8'
MOK60H0%. 7&1.0V>E>(5^.U18<(.-Y:Q&YLU41"ZQZ\@$T,R@WG:6HJ<;8^'
MM^,;;*$.M"2)[Q0]<ZLL/AZ[9QQ'B5:7#3V48]9-<*M7^R)HVRTX/9<A4 B;
M.><]FGVJ((;;8"N0X7-W[CJS"@%FN*A+,OYAB$U8$:M-8$-T=*]VY->5E8*5
M!-53_"S! O$O[>[NK F%8OK/3>I$W6*6,?DA:X/:>)DK/-8,A.'O',4;1C_$
MYF_+<K!%$Q-"&)=0"Q84;#_H'S]K@M<FINS5)L9>+B\K)>'UPWE4^;F=M5#B
M%61<U>B!HZLS9E I!XDK_\>5DW&5VQR57 M;MTO*?<S)!JUWBXX[&B)S7M+K
MAWTA,)Z@!_FW%T=/B2_*2!/QVE;FA.&-%VH)0IKFICHB=/6H(VLK>D:4"DE$
MQZ(R%=5UU2$6II/]MT[O?:9ZA7& !DD UI8O"%_/1DE.$K%':M,57V_=TO#^
M&:80484"+DF.Q-<"RV3M'NH(F0ARV,@\[ 0=N(D@Y#Y)\ %Y,<@FS\,>K>EQ
M]039\XOFV!.NN6/XJEWR9*JJOAX:JN11OU\@G7^[M<Z],>F0M@P)?,U$+0!S
M@(,[L4B@E<<R+&M"#_[IW>+KY-<MCQY<IB5JFQM( ,:'2C7[8SM+9)1+)F1M
M;CB6E'F><]RJF3<85WA@:RLP&.?X]3B2:R919KS[R0=E)UX9WVQE$F.E.9V:
M 1HM2_Y=S27]/E+"JDPAHJ4E.KZ77KV8[U4-O#L<\X_#Z41F3Q:')_A'-P/T
MOCRT- S'YA2N;U5^;!6;ZIAE8#T,%R.>G-)O?,@R9>M1MB5JSZY3T>(8>M]=
MK!=3/W,U)V-B97B#R-D;&H4E-.H6VU-WM[= M/:9AN G^O*AS;32I%/5/I8]
MS7FB==M*NS>%+; \"22@^FE[//%R2=&GBLH0>(MH,'SQ-I_D>K-RIR<3@R!!
M.N"%1];<@U:%D?I>T3)GRHAF+2; 8O,Z;@Y[492AU&E%RV,#G TV(%]B2_M3
M^.8CW39-)^#,^F,^SBD"N@E=2X6) (7GI9FPGL;'FCG)JQ0WW9V8=^-4J1@9
M#$(6<YP;&< 4G?O<"=JI3C0X;%=<8'F"7N.\2D(Y+(OEKU'(NLQQMZ:\.2&X
MNFQXT]ZFE#2&Q]J,NEN9BXGXFOE46*63N!=P#7>?3EF_J/_.E9ET3W-F:5P>
M_B@)D1D-$G_5YEEQ=D-Z10U#])+@F,AW=R]63C5V:<1,J'*M%5Y5[ISGKA==
MZ4I-NFQV*Q0K;HE&F7'.]KX1&:*_[BVA#>9S+I\6!O?+@/V9MQWHN.,KB8P?
MA^R8RY[VD'5:T38Z7KISJBP#\6/V'DYWJGK?$U'2<_59/'V2DVFKRM/\<80X
MQ[L@<7FQ:^]7U_)7C6VK$BGI$@S;"\?L!.FQZ=SIG27IXZ4=!L8-/1XC :.2
M9VJ5493[A>XD1G*F/!VQ!@&>K:CAKWKPOTY.K&EI&YD5TM4(+N1+3R .8M5#
MR32=L$XGGV200KY:48=]B#$;<2_.O9&%ZKBI+(FIIIR<32[!.F!?0-SI^V%R
M4?*>X\18#8NDR,8X!@RG9^?V%8^(AEV#:;U+E:CDIRFWJ7;WCO=36TR-%'&P
M@F_F937T^A\%A,9!%2N[ !MKO<6DF5.&TE4^REE.T@<*Q+Y^9ZO*&_K*&VS\
MN^O769_V4+([?,'JD:@)Y^BI>9#IFRW^6&&,2^IQ#RK\*ZKEY6#4L-VXEK[J
M9.%E\35G[4HITYDM(IFHIM@XG*AOA:\>D#[IL'D2@.&6-.PG(B3P@N;=P[6[
M(3:3>BDU6>'^5<[?'KM>34RUA0F,:ZWKYIGNFHK*0;:Q@:-5CH#2>/Z.#@+R
M[EO-F08&Z8U(8(!ED?N<'+J5O5I#9[7M83=I&72=FRH?S/*];E?OHQ$T_+KQ
MG*/]ZHY665$%Q>Y]DE%8H->$QR,DL 9R8H]>C/*SJPE+YVC,9\^.M<VGWZGM
MJ9=56[?#M614TN;"2Q<UEXWQZ^:Z3\\/$#*OPX<_;OKHI\$-%$BCE-0P=Q??
M<4VD/*^EJJ\7BTBWTWX]+NOMG&X==^(3(B9F]RAJMFL<VQ1'.4&S<!>#:?/M
MTJ#9R^XUM9%U_LHK(68)NHMJ*W@E7!PQ=/I6 8Y;<CZRZ7A4K@_</G1U#YFJ
MZ;X1@E/DK^^$FA66Z*;$M=[L]U,U&^!**].:#OYD$^JK>!\>0QWSZC1N'6]6
M/RI48N4JEAIT6C\3M:K_8(S.<#%D(EU^IO4-V@Z_&J,XMA8P?3(<XYA0$NAC
MDJ5@<VI$AWXV?#L@K^+5TDA6[HQM9J/)S)NTD5)NJ)K%3*59G%.,18=/MH<:
MS^>U@V2".RD5EZH[)HBGFK7<3L(:\])4Q$OB>*GHJ.\%H-)[^8?N=QEL+\0,
M)EZVKH?7N/'H;^P6%-1,]$>WX] %\:Q-)2?COU$?LBEY\4!\O8'?#,L/I7/=
M"UVU7:(AQW*2:>" H]@BR.-ZV1:AH>1V-7<F+H9L?[% T)V=HV<)2RBH> U-
M^LFO UOGRH7.+'9X=,449H(?,$YRC<G[#SW$<H]>%B'( ZRMJ1'ODEM1ISI-
M]N:)6L@4B!\_*5?R774=W'BC[<OM?"G]J7))UN=;CB^]]XSL9WWE#/6MRN/*
M1$+=Z7U4]'*^RA>Q:6DR;[;PSILCOI$-6,=%ZJXF$ 0?MI-5<MLZF-X*+6RK
M-*R?#N4-_U0"J3/-'5VE.!K6&K"O*+H?G8\%EVL[&8RE#BM+I^W7JWP48A[X
M7$W"5$CH8*G6\R#]\W;/Z)F48Z!(WKNFZ*6:2CX9B8JKLOW5QKB6&Q\\[%K@
M4J=;G&(90V.+]H,)P B8[D.H;E]3[PVE;E/&'64-(G@VV''(1!6QY7/,*NZH
M3ZJ";KG.E5]R]+$B6,%FYYM-V(1C2$?A=HT6Q8VVJ@\YG"H,$Y^Y^BQ&0O%%
M(M?E+XAU?,6V1+SC8457\XG>A*@\5YH[^L/K$_KV(V]=#G/@<4'KI:(THN91
MB^1%[+9+ 8I1,I*MF"O@BS!L]*Z6Z,64)3]*5'CC;5R4TW;ZXKK4U5I]ICR)
M ;FRXLI!UA>/3U?0HDTKNB=JO!S8STDA%ZE+;/QYH'7:PP=XJ?8!FB]S"\OD
MQRE=Q!)B.QIWX%SU<2J#]K@[KU^/C]O#,WKO [X[":,I?CR+VT-/$=014K";
MZXXIC(T^HVI82_2#5I,TI4,%M@5ZLYO#JQ-W.<N*/6U4=C5.0L!'&&MT$UIF
M; ^I.FV8IKYLME(==GF&E07Z8CRW-\^P%%E(+*N6JCR5&7/U.>MJG"XP0AG)
M[I,D9>J_;VARJON"IMB&:W1I@1U_,[$RVRLB<$, [\XJMK.WJ5L;L;S-(D\\
MJ0O>Z&S9<C+N@QE?9H_'BB1M+-T&<1U1ZTU+CG;519 N[>)MMR3+++U5;D=?
M5T\KY3B!SH5NG)BQ'AN2@5H7?A5,[/1C?L/Q-?7)]DQ=@>:SRE.Q11XQ5LIQ
MT?!/Y]89;QH/>;^.ZC'&8G$^DK\L9U# T<N@JO?JUQEA U*2-2_,YZXK#[<W
MAO8IRK&9G:2O9-8;N.<?A@#S=3/L([#E>Q?9V(JN5VUW]:QH+3GJS)MJH8U2
M(;M'L?*:?IJLXA)UZ5YXI("V>);'0SSCIH##$TJS8O+'<FIRKKZG15@KK508
M5=1LJ.+\BKP<HM9RZW,*WI9H'UMJT!W[:GM8\[1KMLN>9QHJ.+MF2#,7X\K)
M,T(IVX'IM^YK%Z9AB@2>E;Q39%3H8%L@G[.19>:-N/?DK;>J^\S&E1.LRXD-
M5V+G;$1Y@WB6TQTD#_-$V%"YSH13.TSQWB;X<-EC<T9^;$,+P#X22U24:+S5
MO]]AF;?!F1)^K6[X2>R>4&NGDOS<< F8].6)-NH)QCC9V>1>";$A9(C2H'_O
M]%AUG4>O1%42W9E"@JXF85&7; :^J6,:4=!?Y<6&"F:33\V.$%Y22,"783N/
MBT:N8F#32%Z/-_>-3+^R,/WD4.G%;\$/OXRI%D?U;U[F)#9Q(I84$J83K\\!
M?0M/07J@-#@U'#'$0O3V/7.0\7O**S'\MH+BG"LO3(%")@R\I&LGIZ=#JVRH
MHHJ]+K673<D%+;%?/91I-WNPK!/EN*%$+9C(R94KG7V>\'5H)H(5ZXM31H&)
M-FA'8=:W%67ZC\=X/\.<;0_M2PB52)BG(Y24EW3@]H&;#X=RKX\I]Y<TE[2;
M9,1R26C3Z,08Q]4)YS>$  &[7T942KVMVY@2,4_[VBHQ"O4_BU!*VFZDE;Y3
M6MY\$/^T,.E0)[JU7-EJV2(9IYR<T,BRR\0#KXF;(8YEKR/"QZ2@E&LB,._@
M:>S-&\^YT@S#J%C1-!/84"66;@]P\[_JW^2<BVI&"7RZ!' K>WW*)KJ5"9&L
M1RWE^G6G@?8;^6D\W7DS$MWIM^>'%W,J_1;)!/Q((- W!PGT>$-/-^J.$U9]
M6-\;6K@=\4R(W7MDRK%0*,ZWBIGGHJ$"T1DX5K]56>V=53*J)VN[-<A1GL,F
M*G\2\C7%CZ]4'%-A& UF7QRN3M@@>+<H0E(*DW[P&ZAQ0T[+"%-(D0K*YV(<
MG@'Z9Y,%JI)4PWKX<1FZ/=:6YK0.XR@L0-2CME9.)67Z@VO]N?>T'&E<OS[Z
MG->BO-E&27E&X%4I#3Q8FV0P5%"N4X"RTU1_IHR91\O-?G:9II<HLC5/I5_L
MIJ-]OE1F;7C\!V8>$4J77>6W^@P^&ZK^X4("0WV29/;[:^)J@V/&^K*.V,+P
M.2&)U-[38:EMHU!_H^YK-G8J"]?S%AZP'8X[1ZX[B>>\3_'C,-+1MQ(,&MZ]
MS,^<Q=Y*Q1A 0#]-K2BK6#R4F]A]@IXXL5-)&?F6-CS&*@1(]4Y=.0G+%1QQ
MR^*\451CX1S(,4"9,_@/]H7\1\61GFGG'2(L3\$4C;R'FOVEH4ZBI'AP_F1-
M7*OQKH !K"KI!"L_EY-)&"XWW]RM$CB[D>6.()?(^6-'LV;!3!V5\9I(IYOS
M9YO(HL*K9/[3YI4"BP?]QR0@\8&.7ZRPV>J1#M+(3:<;I28H&2KK9H\D!,8F
MAAR5NQVVM4(^O&1DW1$PJR@@C(]NN=&3H2.;8Y@7*6\S7T_X_N'M9V(HRI2K
MD@6,A^'UXV,O[$OB9PEM)Q:W:!S7$E]_@!OK&3<NZ4Y(.9,[?J)"#3V7]EQ(
MT5?\X&&O-&X$MU4R+I/<6=>(O U]I;$/J?;&26JJ["L-L]QO(O2LHE%@#+:%
M-&[@^4^A[6U(TG52OPL<ZHP=/AH>4&:8"A'6C'^<3!M2:B"3]^'K2H)[D!W_
MJ<=L L>81]^<"E7,9UQL.B=A_CB1UN!$/*\3^&:_J"_[K&0D/TV"J0JVFI/@
MSKBS)%TS63M\M6I0Y%/8X<J&:=E0S Z:*MD-PC<ME$EO_)^\Y*#G)K&F?C=1
MI;OZ,;US)(CB8WB/9Q!C$\6D$@&J\$H7X'55_87V@-UU^#"=3+]"S!K.O?36
M:7QKAE:^#LQ ,Z(O?9[]S;A1USYK>)+I+)6C1;3D'.?<[L\3H_*R79\NLQ;"
M+=N5\=>[::01(-P-)E?+6P(T=.)D6_9<&S'AJ(KLR=#XC#<=FH2QE4^QVW2>
M.YXVR#A\JO'2$M_H?H,1B)&7J]?(/&4N%10L6GP#\V%X6C2\\BN_?BW?3!HW
MLS<WYU5$GYQ_3\PS[H^^I)&2=&/C]7%$8S5]N?TH:KSU?) 1U*QF[B0"N$3/
M8D92.2RNPF[LK3F=8^+!4M50#_SLEI@\:K1]:FT12D:0O.=+)#!U/2G&18_P
MU/VY:Y?&[HLKHPW.9SRA9=#I>S!V8.67I9S@G:W0K3,.1U.ZM^3]SX?B:Q9,
M0HD&T+Q&[(T4=J(14/Z"DR76/;(\TK?]9@)I<QA]"@AR1"5HK"*P\VTD<*8I
MP?TB83SZ"@T7%+>>(1()'&?O9<>.(20>(@$?F,C&H<JZ@[?5NYXL-F9(E ,Z
MF;;*P,:!PFUKE]Q>'O0^@_QI45I7^J'%Q"Q.BAL&C4OZ/;2%3C=;9N+":T*"
M1C0&MLP\;+GS,F*AGR+OY6NO0F8_BF&C*4[O0,+NL7@_99/M*.]Z$.KU,)F\
M+&Y2N%!$L43U=EI:P*J'"GNL:4-SJYK(Q?]A6AH$65H4W'O-(I_Y-%*>/:>\
MER1:J?I3R<#LGKU=<EGH6_L$R2=0=0.M=QEPJT_D.V03^T0*S@+-(_%,F9QO
ML'$@&WX8;-M+9TH"8^2#<[J=U,S$=XK"&IVC:S]Z;V-8H%:%Z"P^-WT^+#=J
MJJLD1=^29.1I[^OY?M3JH^6MJQHCTC78C)U6!>4<Z[S*=P<4(DB2"!7?O[O;
M%FUS/7#IZ^-'-"'KV-68B?/[R?@-(3./=FQ!O3*=/!I0MK<4:!XL&Z%XK.L:
MT7'])EK/_^OM/(.:X*(T'#H*2!%$-#031.D]A** M(A4(?1>$DKH58H(@O02
MI84J54J4&EI .H1.0@^@] \0I$BS[O?M[H^=G=G9V9V=_7'^WKGSSKGOG#EG
MSG-]/ZIBY@XS#LK>J8;ZA :+8?NV%,TU/KX!J]"-TSU%_P-N6%X^+2ADR3S;
M94 2!BY+Z:5/92[$[-I>()HQT&)/N/:\5&&?J7B%I6I5\"=KS&]P_A=\MBC1
MX*9F4FX\X!M!.;S2?P_I$19>:6:A'H_PL<NZKE9"#UXQE?]+JB/<1X6;J;.R
M8GE)N:/I5PVIXE,*-.-?'S5&.%N,8Y&K)-TP :I)+7RM:/TM3P;!RGQA)7A$
MIYDH:A_G*D*TGKA*8SR\ZC"TJ^>K92>$_47^B[/S?D-J+#Y>;%^K!AVQ4_<'
M0+GX_!9@O[@=AR'O2UII"'1>.3'IMKI6H2RDO9&"1)OEVT H,J8W))3IE??&
MT) IO&+UA=Y=+YEE#90';&/0)^FW+?Z#5O,+46QQ%'_<FDJ",N F.X7 _]3&
M_ZL(^9CXC=OH#Z#OZ80[0J1.JHBQ)#J&8X<=WEC5YKNE:>(J5+>)2'[>(_S^
M^:2"UW!S&&_1;B8/?VQH-?1.G##EJ/R/\HX["2MFK8_%Y*"KT2^=2G,GA6_]
MZ"4$5')KSOX^Z-E?9X4)M!J!#8>HI=('GLV.<0P$9HNN*E*58N/0&PI+X>^L
MKSP,NSL>-KK.]5,R94:@,!9K!TD-4CH_6=':F! E4&=?7@(, ,""*-R[HFL1
M(SW>%DN+,+FWX4$<67*U5@IOXM8!AQ0.=( Z^>J'AZF6X:_@C2<N"Y4$,#HO
MJ=*;@CS8'/8/-37K;CS52)G.%NSC$Z:-I*0'!A5C@V_WK>"%Y>[P3 F+1<L]
M>%NQ3J:HO)PVPV8M XLI]6<*S#?,/<J.7\FX"D?9C TURY L][<'P@7MA^8=
M=7)/]Q9+<7O10-]ZJ4HZ4-!(%A7W3<PNLNB:VW8OY[,\'&?0(GYJ92&6?C:]
M*.GUSU"@W&T@XA@;JJN\6H>>/3@+7;W[2&F58E%3\CA2\B*H>MJ EC9_59A)
ML3=(X19!"7?.WY<*HMSV'K0*!%!\PS)QPJ(?$=_6-H=P@PCB_"-0,!IV ).-
M^+<-!.&QSGM_*90W!%3(Y3N+=B4#H:HDL$/'W8066/\RJ_S]P8Q"Q><]S&M>
MWZF6?JN51G?S"%C&+32&IE%1ZM&$,VB@3G,"H;^K>59-/F#+VILD>D-D2]#,
MN?1&O>0MZH@,EX0MA5$F4"^=5EU+PRO33C272<^KX^[D;+2YMH$?^AE))I4!
M5ES#:KD7M+5X8WE#JK_IDD"X\KI@&_H^(0&P[8GG1_G(KHS\V NU'#P10_&G
MT6\Z3A]#&,^[N:HA*\"HW;65K=FM=?W6YL0A&.KQ">\YO9TJ53/P'ZYQ;"='
MG:X8 S7:NVY9E*QMZ3?"AUIPT(+*!KMZ)_LTH;YNR[8T+PPLMS<CYJ!_RTC'
M6GT1\(7SL8Y9 $.B3FAB?!EZW*#YJA.!PMMT<P2X7D#C'NP@^EBNP[WD&4YD
MY$S[:Y[2R. HC/I07P4F.SFE<G/N-W?"5\/?4SA\6VW'/5 (*N=Y<$F1LYWJ
MH&/2C.)#1FO7MKPY>%M-/78MIMT]@^D^'PL7T-&5)QNTV&9QCRJ7&"9X-Z5.
M"_5^]X$:;$OF21TKOZ"@S\(_<E1C/L1^.0U_JC<M& *WY%RJ>@GX&47E,T2C
MBDVX1\6SUQMH&@%NF@.[1DQYYE)2'4.LV)0UUU.Q'O_-N(5C; ^S4E&Q)P?'
M9=(&"SQ4C S^?$3*<WPHIL]!-%1AOV[6B/ZM(R.%K\M_/W*='3X0F#4@G;+P
M5C;Q_MN&X#*P3:7[\[2?\]8K>3Y[YH4+"J]^@LL/P+&+"_F8H(3 ATCK%HH2
M$,6+P=%KP548S_@:5;%4IF'S1)2,=I1Z>N+CJQQ/D^Q#G9PF:3XR!Y?/&3?4
MI82DDA&)/@^>"BE29%[M0X&?4<'MC_0R?*"Q4$%!@FOO[1!*&?>9:-:HA_D.
M9&0;7B$BQRN4XUWT8ZTW,M?&29#,84Y7*M[@[0*?Q7J\'*)5NV;#OPVC*[F_
M&KQ]3=24:C.-^K:O-Q3\L^6\Z%IWF&&9,GI%A-@HMGKG#MUH:5)R-)>GLC2Q
M'#?GO]>(0U8([K,UWL/>%J8S@,&IG;4!I_V(B5+;?M3;,60M+*"\?"!62RB%
M,?0V(T4W=TO5IWF+*H]I$Y3%'\ /E17EC]GJH4\B;"8OQGVB\WR15#;K?1;.
M]3<R WEWF#P R?%2+]!%%(3!;;C_K\=SQCCIQ78I87:[OPPS7AD81ZI^GQ/P
M<:R:'ZN0'D2>OW8[7A*B\Q)GNN[3SD67A."81+:AQO 6+^<Z+:QLQUV"UQQ&
M>(>K &#&PZ)MJM<J#'3QC=6Y=5[L1&FYU=LA8FQJ'6IR$H/178)E\,/W'WRP
MY*4575"("]QLS=TE=<1@E&XTX@\ @)@\,A&1439Q(/KOE359*HN9I"-2U&Q0
M56H_6VX_.R'\<D>HUN;J$MEF?<LUT'!%/<U;FO;?6578YP8L;K,S!/"?2('N
MK#S1[JVJ))] :K=J(/$R=8Y,\QA-V'PI,JU=>_3!X3SMER3@4;]!W:3G/M;_
MYE)_6X\KCQ7$Q90*Z'<>HX;AJ70.Y7GKD4G2Y1XCA; ]-I#QD^ [Z.YE*FGV
M4[F%7=,5]< >O#S8\>Z_H[T6F)X=OEK+U/7/B<;$G[K4W\W:6]^T9O[MJ&8.
M+JX<9B]BJ 1?3' 8B3*8U!>0G\:@7#I.#@0PM.EH"0%R#XX9A-P&GA"+'G!-
MS][6B671":#I'TUE#Y)2>U^/"P[88'TQMQ()X>W[;H2MO-Z>6S3 GL+I@BJE
M_<P8=66#)V\ZVI8T7B021@A;&TUX(L:ZH/FXVI'Z,P_%OK',V#5+7<V>[:%8
MZH0KL]JS+EG,H&KO,<)?ON%N19--\;+5EHE9,*.5TVUI6=()%R,'7 1E1$%U
M>%[$L&B;\.7K-W+NPCIF5EX 21Z-[Y+WK4YZ1Y ',J;I"1OU&N&FX;8-#0?Q
M.!@PO5X!B,BPHU_'; L<GI6)I?M5I ..OR9O-D8%VD*D<N1P@/MS7-3?9W$Q
M%007,9>",='R_*Q <JL8 \U-+L1OM<@[I)^&KL'?LS%05$EM>L9F)L1$J,@7
M!J":T.OX,3.F:%DW(X 6#GJC<^N5Y!A#'_G?!@X)0ZV3 0QQ 2,L=F;BSIP2
M^G@T[\8EEP_I_IPR\^-6>^=*?>P?@)N;H26Y,7!@^4[4T[N^W8EL*M]NWCPM
M8B!4+\+>=22YF&9*-RTX.,3-CS.L(^6WN;Z:,"?XIZ&A!?JBH)!'E^(X#5N\
MP3I3JL<,S#_T4DE]CA4LAR-*_E!/UUMHT<U500YUV?F<()1,4)R]3Q=EFSI.
M\Z0TW*^K9_&B,LXIVX/C.TV&]B:(D1!/V3&%J;,Q7\YS7N0X47,T\II6)1_%
M]-D[WKY%8SA17^98O6ZH3@'&4%T-6:;1GE!NV:KE.PR_G/)<;2T0Q#-?M90(
MI"+$O$@V2U%5VN:6AJ\?_IJ.@F+&;[MV+E!_R"6(,8"="O'K'Y0H5&XU!+_6
M;59WM7$>C7 77_@D6>[3.B 5'3W'+31>\<SCF^7(1:"V?7/(:Z5J>QBW(IP'
M6V2M6[-LH^K%/0WQ+C72/*\G?Q%._\G%2*_,?(I-_*5<?K@YGN_):KY_B[Y;
M$"EP->796N3]/X >#?;7.RSD"7?IE0<+)F!&@Q#G%L#W)#_3XED11,*XV9:
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MOP!J4-92,&/U=G@27%QXOLJ16[[->M="8L_!B+8"1W$4-$>^8&5T0UAPQ_\
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M /B9:-DL?WBF3SY'O&Q$9;;M"ZQ&F+O>Y*-AB>FW;]=FK_T4FC39!]@'C2R
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MKRA\5'T -*RANV"!M'\^&O;AW,KZXZ[L/T[&?SZUK;OY9XN2@3:F(@G@K3P
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MOS<AJ(2 @#0H2#<#2#D@TEU#2TD,*5T2@J#44 (*$M(=$D.#= \PA+3D2)>
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M,>K9Q#PIUBJ?HE[\;B=@=/#P&DA3N 9>AS]%W+LXB$;/-L7]:3U<M:8&X@2
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M/WDA1I?CG>=-5=T(1T[+.$I//R^H)3AOMD]45\"*L=T-*LL:?4IIY 5;5WB
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M,C R,#,X+3(P9E]I;F9L87)X+FAT;5!+ 0(4 Q0    ( ),[=5C-Q!56AP<
M )DE   =              "  5@S!0!E83 R,#(P,S@P,65X,3(M,5]I;F9L
M87)X+FAT;5!+ 0(4 Q0    ( ),[=5@@9;GHC0<  .0F   =
M  "  1H[!0!E83 R,#(P,S@P,65X,3(M,E]I;F9L87)X+FAT;5!+ 0(4 Q0
M   ( ),[=5B.[4!,(P0  -$.   =              "  >)"!0!E83 R,#(P
M,S@P,65X,3,M,5]I;F9L87)X+FAT;5!+ 0(4 Q0    ( ),[=5C_]9'/#00
M !L.   =              "  4!'!0!E83 R,#(P,S@P,65X,3,M,E]I;F9L
M87)X+FAT;5!+ 0(4 Q0    ( ),[=5B;(E8M2P,  -@-   =
M  "  8A+!0!E83 R,#(P,S@P,65X,34M,5]I;F9L87)X+FAT;5!+ 0(4 Q0
M   ( ),[=5B B515XP$  !(&   <              "  0Y/!0!E83 R,#(P
M,S@P,65X."TQ7VEN9FQA<G@N:'1M4$L! A0#%     @ DSMU6--^=]W_%0
M&W4  !T              ( !*U$% &5A,#(P,C S.# Q97@Y-RTQ7VEN9FQA
M<G@N:'1M4$L! A0#%     @ DSMU6.ZD+X:1(0  .;,! !$
M ( !96<% &EF<G@M,C R,S$R,S$N>'-D4$L! A0#%     @ DSMU6(\0)Q_Y
M#   39\  !4              ( !)8D% &EF<G@M,C R,S$R,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( ),[=5CSC8!8[U(   ML!0 5              "  5&6
M!0!I9G)X+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4    " "3.W580K7*8*G@
M   2X0H %0              @ %SZ04 :69R>"TR,#(S,3(S,5]L86(N>&UL
M4$L! A0#%     @ DSMU6/#"%[KG4P  NJ<% !4              ( !3\H&
M &EF<G@M,C R,S$R,S%?<')E+GAM;%!+ 0(4 Q0    ( ),[=5BW@=FQ"+,
M $7=   -              "  6D>!P!I;6%G95\P,#$N:G!G4$L! A0#%
M  @ DSMU6)KF<B:B;@  DXP   T              ( !G-$' &EM86=E7S P
M,BYJ<&=02P$"% ,4    " "3.W58[5^6P6HU   9/@  #0
M@ %I0 @ :6UA9V5?,# S+FIP9U!+ 0(4 Q0    ( ),[=5A)B$N/,(4   JK
M   -              "  ?YU" !I;6%G95\P,#0N:G!G4$L! A0#%     @
MDSMU6&HM$WAJ6P  KW8   T              ( !6?L( &EM86=E7S P-2YJ
M<&=02P$"% ,4    " "3.W5893Q0GR>F  "YP@  #0              @ 'N
F5@D :6UA9V5?,# V+FIP9U!+!08     $P 3   %  ! _0D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>ea0202038-20f_inflarx_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:ifrx="http://www.inflarx.de.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ifrx-20231231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:InflaRxPharmaceuticalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2021-10-30</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:GermanMinistryOfEducationAndResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:PropertyPlantAndEquipmentByOperatingLeaseStatusAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:OptionsGrantedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:OptionsGrantedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:IncomeStatementLocationAxis">ifrx:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:IncomeStatementLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">ifrx:LongTermIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EmployeeBenefitsExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EmployeeBenefitsExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EmployeeBenefitsExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:LegalAndConsultingFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:LegalAndConsultingFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:LegalAndConsultingFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ThirdpartyServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ManufacturingOfClinicalMaterialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ManufacturingOfClinicalMaterialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:ManufacturingOfClinicalMaterialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:clinicalPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:clinicalPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:clinicalPreclinicalStudiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:InsuranceExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:InsuranceExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:InsuranceExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:DepreciationAmortizationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:DepreciationAmortizationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:DepreciationAmortizationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:CompensationExpenseForNonexecutiveBoardDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:CompensationExpenseForNonexecutiveBoardDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:CompensationExpenseForNonexecutiveBoardDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:WagesAndSalariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:WagesAndSalariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:WagesAndSalariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:SocialSecurityContributionsemployersShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:SocialSecurityContributionsemployersShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:SocialSecurityContributionsemployersShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:EquitysettledSharebasedPaymentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">ifrx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrx:WAEPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:OptionPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrx:WAEPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">ifrx:LongTermIncentivePlan2017Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January4OneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:July2OneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:January12OneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:RepricingApril13Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:RepricingApril13Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:RepricingApril13Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:November21Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:November21Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JanuaryTwentyFourOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:MayThirtyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:MayThirtyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulySevenOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulyNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:JulyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:SeptemberEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrx:SeptemberEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:MarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:MarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2023-07-08</startDate>
            <endDate>2023-07-08</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OtherPropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrx:AdvancePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:CostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:AttributionOfExpensesByNatureToTheirFunctionAxis">ifrx:AccumulatedAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrx:AdvancesPaidForSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:DepositsHeldInEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">ifrx:CashHeldInUSEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:MarketRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:WeakensAgainstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrx:StrengthsAgainstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:ExchangeRateCurrencyAxis">ifrx:CashHeldInUSEuroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:ExchangeRateCurrencyAxis">ifrx:CashHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:WithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:AfterOneYearButNotMoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrx:MoreThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:DEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:UnitedStateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:DEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrx:LocationAxis">ifrx:UnitedStateOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:ExecutiveManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrx:NonexecutiveBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="eurPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-29454">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-29455">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-29456">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-29457">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-29458">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-29459">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-29460">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-29461">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-29462">001-38283</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-125">InflaRx N.V.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-29463">P7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-144">Winzerlaer Str. 2</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0" id="ixv-29464">07745</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-29465">Jena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-29466">DE</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-29467">Dr. Thomas Taapken</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1" id="ixv-29468">+49</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-29469">(3641) 508 180</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-29470">Winzerlaer Str. 2</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1" id="ixv-29471">07745</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-29472">Jena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-29473">DE</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0" id="ixv-218">Ordinary Shares, nominal value &#x20ac;0.12 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-222">IFRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-226">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-29474"
      unitRef="shares">58883272</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-29475">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-29476">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-29477">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-29478">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-29479">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-29480">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-29481">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-29482">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c0" id="ixv-29483">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0" id="ixv-29484">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0" id="ixv-29485">1251</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0" id="ixv-29486">EY GmbH &amp; Co. KG Wirtschaftspr&#xfc;fungsgesellschaft</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-19833">Munich, Germany</dei:AuditorLocation>
    <ifrs-full:Revenue contextRef="c0" decimals="0" id="ixv-29487" unitRef="eur">63089</ifrs-full:Revenue>
    <ifrs-full:CostOfSales contextRef="c0" decimals="0" id="ixv-29488" unitRef="eur">532262</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit contextRef="c0" decimals="0" id="ixv-29489" unitRef="eur">-469173</ifrs-full:GrossProfit>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="0" id="ixv-29490" unitRef="eur">4001299</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-29491" unitRef="eur">41024131</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c3" decimals="0" id="ixv-29492" unitRef="eur">37526090</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-29493" unitRef="eur">35697935</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-29494" unitRef="eur">12628756</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c3" decimals="0" id="ixv-29495" unitRef="eur">14869564</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-29496" unitRef="eur">11984722</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherIncome contextRef="c0" decimals="0" id="ixv-29497" unitRef="eur">13219704</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c3" decimals="0" id="ixv-29498" unitRef="eur">20159169</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c4" decimals="0" id="ixv-29499" unitRef="eur">54221</ifrs-full:OtherIncome>
    <ifrs-full:OtherExpenseByFunction contextRef="c0" decimals="0" id="ixv-29500" unitRef="eur">4440</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="c3" decimals="0" id="ixv-29501" unitRef="eur">1381</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction contextRef="c4" decimals="0" id="ixv-29502" unitRef="eur">6381</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c0" decimals="0" id="ixv-29503" unitRef="eur">-44908096</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c3" decimals="0" id="ixv-29504" unitRef="eur">-32237866</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c4" decimals="0" id="ixv-29505" unitRef="eur">-47634817</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="0" id="ixv-29506" unitRef="eur">3804827</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c3" decimals="0" id="ixv-29507" unitRef="eur">608679</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c4" decimals="0" id="ixv-29508" unitRef="eur">109391</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="0" id="ixv-29509" unitRef="eur">35628</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c3" decimals="0" id="ixv-29510" unitRef="eur">45250</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c4" decimals="0" id="ixv-29511" unitRef="eur">24769</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c0" decimals="0" id="ixv-29512" unitRef="eur">-1841872</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c3" decimals="0" id="ixv-29513" unitRef="eur">2442297</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c4" decimals="0" id="ixv-29514" unitRef="eur">1964135</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c0" decimals="0" id="ixv-29515" unitRef="eur">313240</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c3" decimals="0" id="ixv-29516" unitRef="eur">-252471</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c4" decimals="0" id="ixv-29517" unitRef="eur">-44000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-29518" unitRef="eur">-42667529</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" id="ixv-29519" unitRef="eur">-29484611</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-29520" unitRef="eur">-45630059</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations contextRef="c0" decimals="0" id="ixv-29521" unitRef="eur">125085</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations contextRef="c3" decimals="0" id="ixv-29522" unitRef="eur">4206810</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations contextRef="c4" decimals="0" id="ixv-29523" unitRef="eur">6777061</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOtherThanTranslationOfForeignOperations>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" id="ixv-29524" unitRef="eur">-42542444</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c3" decimals="0" id="ixv-29525" unitRef="eur">-25277801</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="0" id="ixv-29526" unitRef="eur">-38852998</ifrs-full:ComprehensiveIncome>
    <ifrs-full:WeightedAverageShares
      contextRef="c0"
      decimals="INF"
      id="ixv-29527"
      unitRef="shares">54940137</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c3"
      decimals="INF"
      id="ixv-29528"
      unitRef="shares">44207873</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="c4"
      decimals="INF"
      id="ixv-29529"
      unitRef="shares">41629974</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-29530"
      unitRef="eurPershares">-0.78</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c3"
      decimals="2"
      id="ixv-29531"
      unitRef="eurPershares">-0.67</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-29532"
      unitRef="eurPershares">-1.1</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-29533" unitRef="eur">-42667529</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" id="ixv-29534" unitRef="eur">-29484611</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-29535" unitRef="eur">-45630059</ifrs-full:ProfitLoss>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c2" decimals="0" id="ixv-29536" unitRef="eur">289577</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-29537" unitRef="eur">328920</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c2" decimals="0" id="ixv-29538" unitRef="eur">1071666</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c5" decimals="0" id="ixv-29539" unitRef="eur">1311809</ifrs-full:RightofuseAssets>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c2" decimals="0" id="ixv-29540" unitRef="eur">68818</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c5" decimals="0" id="ixv-29541" unitRef="eur">138905</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:OtherNoncurrentAssets contextRef="c2" decimals="0" id="ixv-29542" unitRef="eur">257267</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c5" decimals="0" id="ixv-29543" unitRef="eur">308066</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c2" decimals="0" id="ixv-29544" unitRef="eur">9052741</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c5" decimals="0" id="ixv-29545" unitRef="eur">2900902</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentAssets contextRef="c2" decimals="0" id="ixv-29546" unitRef="eur">10740069</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c5" decimals="0" id="ixv-29547" unitRef="eur">4988602</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c2" decimals="0" id="ixv-29548" unitRef="eur">11367807</ifrs-full:Inventories>
    <ifrs-full:OtherCurrentAssets contextRef="c2" decimals="0" id="ixv-29549" unitRef="eur">4036650</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c5" decimals="0" id="ixv-29550" unitRef="eur">14170510</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c2" decimals="0" id="ixv-29551" unitRef="eur">3791564</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent contextRef="c5" decimals="0" id="ixv-29552" unitRef="eur">1432087</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentFinancialAssets contextRef="c5" decimals="0" id="ixv-29553" unitRef="eur">732971</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:OtherFinancialAssets contextRef="c2" decimals="0" id="ixv-29554" unitRef="eur">77504518</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets contextRef="c5" decimals="0" id="ixv-29555" unitRef="eur">64810135</ifrs-full:OtherFinancialAssets>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="0" id="ixv-29556" unitRef="eur">12767943</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" id="ixv-29557" unitRef="eur">16265355</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c2" decimals="0" id="ixv-29558" unitRef="eur">109468483</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c5" decimals="0" id="ixv-29559" unitRef="eur">97411058</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c2" decimals="0" id="ixv-29560" unitRef="eur">120208552</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="0" id="ixv-29561" unitRef="eur">102399660</ifrs-full:Assets>
    <ifrs-full:IssuedCapital contextRef="c2" decimals="0" id="ixv-29562" unitRef="eur">7065993</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c5" decimals="0" id="ixv-29563" unitRef="eur">5364452</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c2" decimals="0" id="ixv-29564" unitRef="eur">334211338</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c5" decimals="0" id="ixv-29565" unitRef="eur">282552633</ifrs-full:SharePremium>
    <ifrs-full:OtherReserves contextRef="c2" decimals="0" id="ixv-29566" unitRef="eur">40050053</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c5" decimals="0" id="ixv-29567" unitRef="eur">36635564</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings contextRef="c2" decimals="0" id="ixv-29568" unitRef="eur">-286127819</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c5" decimals="0" id="ixv-29569" unitRef="eur">-243460290</ifrs-full:RetainedEarnings>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c2" decimals="0" id="ixv-29570" unitRef="eur">7382166</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c5" decimals="0" id="ixv-29571" unitRef="eur">7257081</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity contextRef="c2" decimals="0" id="ixv-29572" unitRef="eur">102581730</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="0" id="ixv-29573" unitRef="eur">88349440</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c2" decimals="0" id="ixv-29574" unitRef="eur">745716</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c5" decimals="0" id="ixv-29575" unitRef="eur">987307</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c2" decimals="0" id="ixv-29576" unitRef="eur">36877</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities contextRef="c5" decimals="0" id="ixv-29577" unitRef="eur">36877</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c2" decimals="0" id="ixv-29578" unitRef="eur">782593</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c5" decimals="0" id="ixv-29579" unitRef="eur">1024184</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c2" decimals="0" id="ixv-29580" unitRef="eur">11974362</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="0" id="ixv-29581" unitRef="eur">4987538</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentGovernmentGrants contextRef="c5" decimals="0" id="ixv-29582" unitRef="eur">6209266</ifrs-full:CurrentGovernmentGrants>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c2" decimals="0" id="ixv-29583" unitRef="eur">374329</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c5" decimals="0" id="ixv-29584" unitRef="eur">369376</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits contextRef="c2" decimals="0" id="ixv-29585" unitRef="eur">1609766</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits contextRef="c5" decimals="0" id="ixv-29586" unitRef="eur">1312248</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:OtherCurrentLiabilities contextRef="c2" decimals="0" id="ixv-29587" unitRef="eur">2885772</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c5" decimals="0" id="ixv-29588" unitRef="eur">147608</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c2" decimals="0" id="ixv-29589" unitRef="eur">16844229</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c5" decimals="0" id="ixv-29590" unitRef="eur">13026036</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c2" decimals="0" id="ixv-29591" unitRef="eur">17626822</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c5" decimals="0" id="ixv-29592" unitRef="eur">14050220</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c2" decimals="0" id="ixv-29593" unitRef="eur">120208552</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c5" decimals="0" id="ixv-29594" unitRef="eur">102399660</ifrs-full:EquityAndLiabilities>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="ixv-29595"
      unitRef="shares">28228415</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c7" decimals="0" id="ixv-29596" unitRef="eur">3387410</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c8" decimals="0" id="ixv-29597" unitRef="eur">220289876</ifrs-full:Equity>
    <ifrx:IssuanceOfCommonShare
      contextRef="c10"
      decimals="0"
      id="ixv-29598"
      unitRef="shares">15610022</ifrx:IssuanceOfCommonShare>
    <ifrs-full:IssueOfEquity contextRef="c9" decimals="0" id="ixv-29599" unitRef="eur">1873203</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c11" decimals="0" id="ixv-29600" unitRef="eur">63269346</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c11" decimals="0" id="ixv-29601" unitRef="eur">4219222</ifrs-full:ShareIssueRelatedCost>
    <ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares
      contextRef="c10"
      decimals="0"
      id="ixv-29602"
      unitRef="shares">365326</ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c9" decimals="0" id="ixv-29603" unitRef="eur">43839</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c11" decimals="0" id="ixv-29604" unitRef="eur">970744</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c12"
      decimals="0"
      id="ixv-29605"
      unitRef="shares">44203763</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c13" decimals="0" id="ixv-29606" unitRef="eur">5304452</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c14" decimals="0" id="ixv-29607" unitRef="eur">280310744</ifrs-full:Equity>
    <ifrx:IssuanceOfCommonShare
      contextRef="c16"
      decimals="0"
      id="ixv-29608"
      unitRef="shares">500000</ifrx:IssuanceOfCommonShare>
    <ifrs-full:IssueOfEquity contextRef="c15" decimals="0" id="ixv-29609" unitRef="eur">60000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c17" decimals="0" id="ixv-29610" unitRef="eur">2289624</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c17" decimals="0" id="ixv-29611" unitRef="eur">47735</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c18"
      decimals="0"
      id="ixv-29612"
      unitRef="shares">44703763</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c19" decimals="0" id="ixv-29613" unitRef="eur">5364452</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c20" decimals="0" id="ixv-29614" unitRef="eur">282552633</ifrs-full:Equity>
    <ifrx:IssuanceOfCommonShare
      contextRef="c22"
      decimals="0"
      id="ixv-29615"
      unitRef="shares">14059252</ifrx:IssuanceOfCommonShare>
    <ifrs-full:IssueOfEquity contextRef="c21" decimals="0" id="ixv-29616" unitRef="eur">1687110</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c23" decimals="0" id="ixv-29617" unitRef="eur">54796819</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c23" decimals="0" id="ixv-29618" unitRef="eur">3360626</ifrs-full:ShareIssueRelatedCost>
    <ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares
      contextRef="c22"
      decimals="0"
      id="ixv-29619"
      unitRef="shares">120257</ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c21" decimals="0" id="ixv-29620" unitRef="eur">14431</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c23" decimals="0" id="ixv-29621" unitRef="eur">222512</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c24"
      decimals="0"
      id="ixv-29622"
      unitRef="shares">58883272</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity contextRef="c25" decimals="0" id="ixv-29623" unitRef="eur">7065993</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c26" decimals="0" id="ixv-29624" unitRef="eur">334211338</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c27" decimals="0" id="ixv-29625" unitRef="eur">26259004</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c28" decimals="0" id="ixv-29626" unitRef="eur">-168345620</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c29" decimals="0" id="ixv-29627" unitRef="eur">-3726791</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c30" decimals="0" id="ixv-29628" unitRef="eur">77863880</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c31" decimals="0" id="ixv-29629" unitRef="eur">-45630059</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-29630" unitRef="eur">-45630059</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c32" decimals="0" id="ixv-29631" unitRef="eur">6777061</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c4" decimals="0" id="ixv-29632" unitRef="eur">6777061</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="c31" decimals="0" id="ixv-29633" unitRef="eur">-45630059</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c32" decimals="0" id="ixv-29634" unitRef="eur">6777061</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c4" decimals="0" id="ixv-29635" unitRef="eur">-38852998</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c4" decimals="0" id="ixv-29636" unitRef="eur">65142549</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c4" decimals="0" id="ixv-29637" unitRef="eur">4219222</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c33" decimals="0" id="ixv-29638" unitRef="eur">4332205</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c4" decimals="0" id="ixv-29639" unitRef="eur">4332205</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c4" decimals="0" id="ixv-29640" unitRef="eur">1014583</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:Equity contextRef="c34" decimals="0" id="ixv-29641" unitRef="eur">30591209</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c35" decimals="0" id="ixv-29642" unitRef="eur">-213975679</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c36" decimals="0" id="ixv-29643" unitRef="eur">3050270</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c37" decimals="0" id="ixv-29644" unitRef="eur">105280996</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c38" decimals="0" id="ixv-29645" unitRef="eur">-29484611</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" id="ixv-29646" unitRef="eur">-29484611</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c39" decimals="0" id="ixv-29647" unitRef="eur">4206810</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c3" decimals="0" id="ixv-29648" unitRef="eur">4206810</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="c38" decimals="0" id="ixv-29649" unitRef="eur">-29484611</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c39" decimals="0" id="ixv-29650" unitRef="eur">4206810</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c3" decimals="0" id="ixv-29651" unitRef="eur">-25277801</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c3" decimals="0" id="ixv-29652" unitRef="eur">2349624</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c3" decimals="0" id="ixv-29653" unitRef="eur">47735</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c40" decimals="0" id="ixv-29654" unitRef="eur">6044356</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c3" decimals="0" id="ixv-29655" unitRef="eur">6044356</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c41" decimals="0" id="ixv-29656" unitRef="eur">36635564</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c42" decimals="0" id="ixv-29657" unitRef="eur">-243460290</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c43" decimals="0" id="ixv-29658" unitRef="eur">7257080</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="0" id="ixv-29659" unitRef="eur">88349440</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c44" decimals="0" id="ixv-29660" unitRef="eur">-42667529</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-29661" unitRef="eur">-42667529</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c45" decimals="0" id="ixv-29662" unitRef="eur">125085</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c0" decimals="0" id="ixv-29663" unitRef="eur">125085</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="c44" decimals="0" id="ixv-29664" unitRef="eur">-42667529</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c45" decimals="0" id="ixv-29665" unitRef="eur">125085</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" id="ixv-29666" unitRef="eur">-42542444</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IssueOfEquity contextRef="c0" decimals="0" id="ixv-29667" unitRef="eur">56483929</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c0" decimals="0" id="ixv-29668" unitRef="eur">3360626</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c46" decimals="0" id="ixv-29669" unitRef="eur">3414489</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c0" decimals="0" id="ixv-29670" unitRef="eur">3414489</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c0" decimals="0" id="ixv-29671" unitRef="eur">236943</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:Equity contextRef="c47" decimals="0" id="ixv-29672" unitRef="eur">40050053</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c48" decimals="0" id="ixv-29673" unitRef="eur">-286127819</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c49" decimals="0" id="ixv-29674" unitRef="eur">7382166</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c2" decimals="0" id="ixv-29675" unitRef="eur">102581730</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" id="ixv-29676" unitRef="eur">-42667529</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" id="ixv-29677" unitRef="eur">-29484611</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c4" decimals="0" id="ixv-29678" unitRef="eur">-45630059</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c0" decimals="0" id="ixv-29679" unitRef="eur">567780</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c3" decimals="0" id="ixv-29680" unitRef="eur">596597</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense contextRef="c4" decimals="0" id="ixv-29681" unitRef="eur">669434</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c0" decimals="0" id="ixv-29682" unitRef="eur">2240566</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c3" decimals="0" id="ixv-29683" unitRef="eur">2753255</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="c4" decimals="0" id="ixv-29684" unitRef="eur">2004757</ifrs-full:AdjustmentsForFinanceIncomeCost>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c0" decimals="0" id="ixv-29685" unitRef="eur">3414489</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c3" decimals="0" id="ixv-29686" unitRef="eur">6044356</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c4" decimals="0" id="ixv-29687" unitRef="eur">4332205</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c0" decimals="0" id="ixv-29688" unitRef="eur">413017</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c3" decimals="0" id="ixv-29689" unitRef="eur">385359</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c4" decimals="0" id="ixv-29690" unitRef="eur">111606</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars contextRef="c0" decimals="0" id="ixv-29691" unitRef="eur">732971</ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars>
    <ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars contextRef="c3" decimals="0" id="ixv-29692" unitRef="eur">-732971</ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c0" decimals="0" id="ixv-29693" unitRef="eur">7825182</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c3" decimals="0" id="ixv-29694" unitRef="eur">-3308485</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c4" decimals="0" id="ixv-29695" unitRef="eur">-7094467</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c0" decimals="0" id="ixv-29696" unitRef="eur">297518</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c3" decimals="0" id="ixv-29697" unitRef="eur">-64024</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c4" decimals="0" id="ixv-29698" unitRef="eur">-3290</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c0" decimals="0" id="ixv-29699" unitRef="eur">2738164</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c3" decimals="0" id="ixv-29700" unitRef="eur">9403</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c4" decimals="0" id="ixv-29701" unitRef="eur">19863</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived contextRef="c0" decimals="0" id="ixv-29702" unitRef="eur">-6209266</ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived>
    <ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived contextRef="c3" decimals="0" id="ixv-29703" unitRef="eur">-2090734</ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived>
    <ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived contextRef="c4" decimals="0" id="ixv-29704" unitRef="eur">8300000</ifrx:AdjustmentsForIncreaseDecreaseInLiabilitiesFromGovernmentGrantReceived>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c0" decimals="0" id="ixv-29705" unitRef="eur">6986824</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c3" decimals="0" id="ixv-29706" unitRef="eur">-3586706</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c4" decimals="0" id="ixv-29707" unitRef="eur">316112</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="0" id="ixv-29708" unitRef="eur">-11367807</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c0" decimals="0" id="ixv-29709" unitRef="eur">1732284</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c3" decimals="0" id="ixv-29710" unitRef="eur">1287200</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c4" decimals="0" id="ixv-29711" unitRef="eur">1070235</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c0" decimals="0" id="ixv-29712" unitRef="eur">36025</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c3" decimals="0" id="ixv-29713" unitRef="eur">44946</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c4" decimals="0" id="ixv-29714" unitRef="eur">23633</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-29715" unitRef="eur">-37812966</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c3" decimals="0" id="ixv-29716" unitRef="eur">-33742817</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c4" decimals="0" id="ixv-29717" unitRef="eur">-39936751</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c0" decimals="0" id="ixv-29718" unitRef="eur">81100</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c3" decimals="0" id="ixv-29719" unitRef="eur">162391</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets contextRef="c4" decimals="0" id="ixv-29720" unitRef="eur">37778</ifrs-full:PurchaseOfPropertyPlantAndEquipmentIntangibleAssetsOtherThanGoodwillInvestmentPropertyAndOtherNoncurrentAssets>
    <ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets contextRef="c0" decimals="0" id="ixv-29721" unitRef="eur">104051972</ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets>
    <ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets contextRef="c3" decimals="0" id="ixv-29722" unitRef="eur">64474543</ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets>
    <ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets contextRef="c4" decimals="0" id="ixv-29723" unitRef="eur">97516417</ifrx:PurchaseOfCurrentAndNoncurrentFinancialAssets>
    <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="c0" decimals="0" id="ixv-29724" unitRef="eur">86436456</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
    <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="c3" decimals="0" id="ixv-29725" unitRef="eur">83995029</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
    <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="c4" decimals="0" id="ixv-29726" unitRef="eur">71603310</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-29727" unitRef="eur">-17696616</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c3" decimals="0" id="ixv-29728" unitRef="eur">19358095</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c4" decimals="0" id="ixv-29729" unitRef="eur">-25950885</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c0" decimals="0" id="ixv-29730" unitRef="eur">56483929</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c3" decimals="0" id="ixv-29731" unitRef="eur">2349624</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c4" decimals="0" id="ixv-29732" unitRef="eur">65142549</ifrs-full:ProceedsFromIssuingShares>
    <ifrx:TransactionCostsFromIssuanceOfCommonShares contextRef="c0" decimals="0" id="ixv-29733" unitRef="eur">3360626</ifrx:TransactionCostsFromIssuanceOfCommonShares>
    <ifrx:TransactionCostsFromIssuanceOfCommonShares contextRef="c3" decimals="0" id="ixv-29734" unitRef="eur">47735</ifrx:TransactionCostsFromIssuanceOfCommonShares>
    <ifrx:TransactionCostsFromIssuanceOfCommonShares contextRef="c4" decimals="0" id="ixv-29735" unitRef="eur">4219222</ifrx:TransactionCostsFromIssuanceOfCommonShares>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c0" decimals="0" id="ixv-29736" unitRef="eur">236943</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c4" decimals="0" id="ixv-29737" unitRef="eur">1014583</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c0" decimals="0" id="ixv-29738" unitRef="eur">373977</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c3" decimals="0" id="ixv-29739" unitRef="eur">364430</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="c4" decimals="0" id="ixv-29740" unitRef="eur">360644</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-29741" unitRef="eur">52986269</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c3" decimals="0" id="ixv-29742" unitRef="eur">1937459</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c4" decimals="0" id="ixv-29743" unitRef="eur">61577266</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="0" id="ixv-29744" unitRef="eur">-2523313</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c3" decimals="0" id="ixv-29745" unitRef="eur">-12447262</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c4" decimals="0" id="ixv-29746" unitRef="eur">-4310369</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="0" id="ixv-29747" unitRef="eur">-974099</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c3" decimals="0" id="ixv-29748" unitRef="eur">2462622</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c4" decimals="0" id="ixv-29749" unitRef="eur">4591683</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" id="ixv-29750" unitRef="eur">16265355</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c37" decimals="0" id="ixv-29751" unitRef="eur">26249995</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c30" decimals="0" id="ixv-29752" unitRef="eur">25968681</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c2" decimals="0" id="ixv-29753" unitRef="eur">12767943</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" id="ixv-29754" unitRef="eur">16265355</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c37" decimals="0" id="ixv-29755" unitRef="eur">26249995</ifrs-full:CashAndCashEquivalents>
    <ifrx:DisclosureOfCorporateInformationTextBlock contextRef="c0" id="ixv-22788">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;1. Corporate information&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of InflaRx N.V. and its subsidiaries (collectively, the &#x201c;Group&#x201d;) for the year ended December
31, 2023 were authorized for issue in accordance with a resolution of the Board of Directors on March 20, 2024. InflaRx N.V. (the &#x201c;Company&#x201d;)
is a Dutch public company with limited liability (&lt;i&gt;naamloze vennootschap&lt;/i&gt;) with its corporate seat in Amsterdam, The Netherlands,
and is registered in the Commercial Register of The Netherlands Chamber of Commerce Business Register under CCI number 68904312. The
Company&#x2019;s registered office is at Winzerlaer Stra&#xdf;e 2 in 07745 Jena, Germany. Since November 10, 2017, the Company&#x2019;s
ordinary shares have been listed on the Nasdaq Global Select Market under the symbol &#x201c;IFRX&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and its subsidiaries, collectively, are a biotechnology group pioneering anti-inflammatory therapeutics by applying its proprietary
anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation
factor known as C5a and its receptor C5aR.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiaries
are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable
returns from its involvement with the entity and could affect those returns through its power to direct the activities of the entity.
Subsidiaries are fully consolidated from the date on which control is obtained by the Group. They are deconsolidated from the date control
ceases. The acquisition method of accounting is used to account for business combinations by the Group. Intercompany transactions, balances
and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated unless the transaction
provides evidence of an impairment of the transferred asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s subsidiaries as at December 31, 2023 are set out below. Unless otherwise stated, such subsidiaries have share capital consisting
solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights
held by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Place&#160;of&#160;business/&lt;br/&gt;
country&#160;of&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Functional&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership
interest&lt;br/&gt;
held by the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold"&gt;Name&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;incorporation&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;currency&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Principal activities&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; font-weight: bold"&gt;InflaRx GmbH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Jena and Munich, Germany&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;EUR&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Operating subsidiary, R&amp;amp;D, holder of all IP&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; width: 35%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;InflaRx Pharmaceuticals, Inc.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"&gt;Ann Arbor, MI, United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: left; padding-bottom: 1.5pt"&gt;Operating subsidiary, R&amp;amp;D, US commercialization&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrx:DisclosureOfCorporateInformationTextBlock>
    <ifrx:DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory contextRef="c0" id="ixv-29756">Unless otherwise stated, such subsidiaries have share capital consisting
solely of ordinary shares that are held directly by the Company, and the proportion of ownership interests held equals the voting rights
held by the Company.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Place&#160;of&#160;business/&lt;br/&gt;
country&#160;of&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;Functional&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership
interest&lt;br/&gt;
held by the Company&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: bottom; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left; font-weight: bold"&gt;Name&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;incorporation&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;currency&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"&gt;&lt;b&gt;Principal activities&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; font-weight: bold"&gt;InflaRx GmbH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;Jena and Munich, Germany&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: center"&gt;EUR&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;100&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Operating subsidiary, R&amp;amp;D, holder of all IP&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; width: 35%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;InflaRx Pharmaceuticals, Inc.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 14%; text-align: center; padding-bottom: 1.5pt"&gt;Ann Arbor, MI, United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; width: 7%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 20%; text-align: left; padding-bottom: 1.5pt"&gt;Operating subsidiary, R&amp;amp;D, US commercialization&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrx:DisclosureOfShareCapitalConsistingSolelyOfOrdinarySharesExplanatory>
    <ifrs-full:CountryOfIncorporation contextRef="c50" id="ixv-29757">Jena and Munich, Germany</ifrs-full:CountryOfIncorporation>
    <ifrs-full:DescriptionOfFunctionalCurrency contextRef="c50" id="ixv-29758">EUR</ifrs-full:DescriptionOfFunctionalCurrency>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c50" decimals="2" id="ixv-29759" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c51" decimals="2" id="ixv-29760" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities contextRef="c50" id="ixv-29761">Operating subsidiary, R&amp;D, holder of all IP</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:CountryOfIncorporation contextRef="c52" id="ixv-29762">Ann Arbor, MI, United States</ifrs-full:CountryOfIncorporation>
    <ifrs-full:DescriptionOfFunctionalCurrency contextRef="c52" id="ixv-22880">USD</ifrs-full:DescriptionOfFunctionalCurrency>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c52" decimals="2" id="ixv-29763" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary contextRef="c53" decimals="2" id="ixv-29764" unitRef="pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities contextRef="c52" id="ixv-29765">Operating subsidiary, R&amp;D, US commercialization</ifrs-full:DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities>
    <ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory contextRef="c0" id="ixv-22897">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B.
Material accounting policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;1.
Basis of preparation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as issued
by the International Accounting Standards Board (herein &#x201c;IFRS&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a historical cost basis. These consolidated financial statements of the Group
comprise the Company and its wholly owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc. The consolidated financial statements
are presented in Euro (&#x20ac;). The presentation currency of the Group is the Euro, as the functional currency of the largest operating
company, InflaRx GmbH, continues to be the Euro. Effective January 1, 2023, the functional currency of InflaRx N.V. changed from the
U.S. dollar to the Euro due to a change in the Company&#x2019;s operational function and, in turn, a change in the primary currency of
its underlying transactions. This change in functional currency has been accounted for prospectively. The functional currency of InflaRx
Pharmaceuticals, Inc. is the U.S. dollar ($), as most of their income and expenses occurred in U.S. dollars in 2023. All financial information
presented in Euro has been rounded to the nearest Euro, unless stated otherwise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2.
Summary of material accounting policies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
section describes material accounting policies adopted in the preparation of these consolidated financial statements. These policies
have been consistently applied to all the years presented, unless otherwise stated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;New and amended standards adopted by the Group&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            17 insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 8 accounting policies, changes in accounting estimates and errors: definition of accounting
                                            estimates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 12 deferred tax related to assets and liabilities arising from a single transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 and IFRS practice statement 2 - disclosure of accounting policies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting
policies for the following IFRS standards have been applied starting in Q2 2023 for the first time, as no transactions in the scope of
these IFRS standards had been previously recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS
                                            2 inventories&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to IAS 2, inventories are stated at the lower amount of their cost or at their net realizable value. Cost comprises direct material cost
and, where applicable, direct labor costs and those overhead costs that have been incurred in bringing the inventories to their present
location and condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling
price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Recognizing inventories
at net realizable value includes writing down inventories considered excess or obsolete.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            15 revenue from contracts with customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
present, the Company exclusively uses distributors to sell its products to end customers (e.g., hospitals). The end customers (e.g. hospitals)
have been determined to be the customer in these sales arrangements. As such, payments received from the distributors are not contract
liabilities but are rather &#x201c;other liabilities&#x201d; recognized in &#x201c;other accrued liabilities.&#x201d; Revenue is therefore
recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer, that is,
when the customer obtains control of that asset and is measured considering estimated return liabilities and expected rebates or cash
discounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;New standard not yet adopted&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following standards issued will be adopted in a future period, and the potential impact on the Group&#x2019;s consolidated financial statements,
if any, is being assessed:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IFRS 16 leases: leases on sale and leaseback&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 presentation of financial statements: classification of liabilities as current or
                                            non-current and non-current liabilities with covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 21 effects of changes in foreign exchange rates: lack of exchangeability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Current and non-current classification&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group presents assets and liabilities in the statement of financial position based on current/non-current classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
assets include assets that are sold, consumed or realized as part of the normal operating cycle (operating cycle is assumed to be 12
months), or cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after
the reporting period. All other assets are classified as non-current.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
liabilities, such as trade payables, lease liabilities or employee benefits with a term of up to 12 months, and payables for operating
costs or social security charges, are part of the working capital used in the Company&#x2019;s normal operating cycle. Such operating
items are classified as current liabilities even if they are due to be settled more than 12 months after the reporting period. All other
liabilities are classified as non-current.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(d)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Foreign currency transactions&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
in a foreign currency are initially translated into the respective functional currency using the spot rate prevailing on the dates of
the transaction. Monetary items which are not denominated in the functional currency are subsequently translated using the rate applicable
at the end of the period. The resulting currency gains and losses are recognized directly in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
consolidation, the assets and liabilities of operations in a currency other than Euro (the presentation currency of the Company) are
translated into Euros at the rate of exchange prevailing at the reporting date and their statements of operations are translated with
monthly average exchange rates during the reporting period. The exchange differences arising on translation for consolidation are recognized
in &#x2018;other comprehensive income&#x2019; (OCI). On disposal of a foreign operation, the component of OCI relating to that particular
foreign operation is reclassified to profit or loss. OCI is disclosed as &#x2018;other components of equity&#x2019; in consolidated statements
of financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(e)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Grants from government and similar bodies&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects.
The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If
grant funds are received prior to qualifying expenses being incurred or assets purchased or prior to all grant conditions have been met,
such amounts are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other
operating income in the period in which the corresponding expenses are incurred (or, for expenses incurred prior to all grant conditions
being met, in the period in which reasonable assurance that all grant conditions will be met is attained). If the funds reimburse purchased
assets, the liability is reduced with a corresponding amount deducted from the asset&#x2019;s carrying amount upon recording of the qualified
asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group up
to five years after concluding the project sponsored by the government.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2021, the Group announced that it received a grant of up to &#x20ac;43.7 million from the German Ministry of Education and Research
and the German Ministry of Health to support its development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent
changes in the Group&#x2019;s research and development plan and fewer costs projected within the timeframe of the grant, it was notified
that the amount available to it was &#x20ac;41.4 million. The grant is structured as a reimbursement of 80% of certain pre-specified expenses
related to the clinical development and manufacturing of vilobelimab. The grant period ended on June 30, 2023. In total, during the duration
of the grant period through December 31, 2023, the Group received &#x20ac;33.3 million to support its activities regarding the development
of vilobelimab as a new therapeutic agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial
scale manufacturing process to ensure the ability of being able to provide such treatment to the broader population.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(f)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Notes to the cash flow statement, cash, and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated statements of cash flows have been prepared using the indirect method for cash flows from operating activities. The cash
disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash comprises cash on hand and demand
deposits. Cash equivalents are short-term bank deposits that are readily convertible to a known amount of cash and are not subject to
a significant risk of changes in value with an original maturity of three months or less. Interest paid and received is included in the
cash from operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(g)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses comprise third party services, wages and salaries, cost of materials, intellectual property related expenses,
depreciation and amortization of relevant equipment and intangibles as well as overhead. Research and development expenses mainly consist
of costs for clinical trials and manufacturing of the Company&#x2019;s clinical drug products; additionally, costs are incurred for pre-clinical
activities as well as basic research activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Development
expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development expenses were capitalized because
management assessed that not all the recognition criteria of IAS&#160;38 had been met. This assessment is due to the general uncertainties
in drug development and the unpredictability of regulatory requirements. Therefore, research and development expenditures are expensed
when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(h)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Employee benefits&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)
Short-term employee benefits&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
for wages and salaries and cash bonuses are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as employee benefits in the consolidated statements of financial position. A liability is recognized if the Group has a
present legal or constructive obligation to pay such amount as a result of past service provided by the employee and if such obligation
can be estimated reliably.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Share-based payment transactions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense,
with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect
the number of awards for which the related service conditions are expected to be met, including an estimate of forfeitures, such that
the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based
payment awards with immediate vesting, the&#160;grant-date fair value of the share-based payment is measured to reflect such conditions and
there is no gain or loss recognized for differences between expected and actual outcomes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Lease arrangements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of one
to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)
Right-of-use assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#x2019;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Lease liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)
Short-term leases and leases of low-value assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iv) Determining the lease term of contracts&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(j)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Interest income&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(k)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over three years. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(l)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Property and equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory equipment: three to 13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment: one to five years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets&#x2019; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#x2018;other income&#x2019;
or &#x2018;other expenses&#x2019; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(m)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Impairment of assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#x2019;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
there has been a change in the estimates used to determine the asset&#x2019;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no impairments or reversals of impairments in 2021, 2022 or 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(n)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Financial assets and liabilities (financial instruments)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(i) Definition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#x2019;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;amp;D projects).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Criteria for the recognition and derecognition, initial measurement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iii) Subsequent measurement method&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Considering
the Group&#x2019;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#x2018;3.8
Financial assets and financial liabilities.&#x2019;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iv) Criteria for realization of income and expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#x2018;C.8. Net Financial Result&#x2019;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(o)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Fair Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#x2018;D.8. Financial
assets and financial liabilities&#x2019;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1, quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(p)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(i) Current income tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(ii) Deferred income tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#x2019;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3. Significant accounting judgements, estimates and assumptions&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#x2019;s accounting policies involve the following areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Accounting for share-based payments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#x2018;C.10.(b). Measurement of fair values of share options granted&#x2019;). In 2023, the Company&#x2019;s share price volatility
for the purposes of the calculation was determined on the basis of the 5-year annualized average share price, which management believes
will be indicative of the share price development of the Company in future periods. This led to a range of applied volatility rates in
2023 of 135% to 145.66% for the different options granted during the year of this report.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company must estimate the number of equity instruments which will vest in future periods as awards may be forfeited prior to vesting
due to an awardee&#x2019;s failure to satisfy a performance condition, including due to employment termination. An assumption of the forfeiture
rate is regularly made on the basis of historical information and adjusted to reflect future expectations. Revisions to the forfeiture
rate could result in a cumulative effect of the change in estimate for current and prior periods to be recognized in the period of change.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Measurement of third-party R&amp;amp;D clinical trial and contracted manufacturing expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
measuring R&amp;amp;D expenses for the reporting period, the Company estimates the amount of expense to recognize and liability to accrue
to the extent that invoices of the Company&#x2019;s contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations
(&#x201c;CDMOs&#x201d;) are not yet received and exceed any prepayments made. The timing of the invoicing of project services by CROs follow
contractual billing schedules and can occur several months prior to or following a reporting period. This estimation involves determining
a percentage-of-completion whereby the degree to which services have been rendered for the individual project activities contracted from
the CRO and CDMOs is assessed and estimated by in-house R&amp;amp;D project managers and reviewed by the controlling department. This percentage-of-completion
is used to measure the amount of the unbilled project activities which have already been rendered by the reporting date and the associated
R&amp;amp;D expense and liability to recognize as a result.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
percentage-of-completion estimates are based on the best information available at the time. However, additional information may become
available in the future and management may adjust the estimate in such future periods. In this event, the Company may be required to
record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. The
Company considers resulting increases or decreases in expenses as changes in estimates and reflects such changes in research and development
expenses in the period identified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrued &#x20ac;4.4 million as of December 31, 2023 and &#x20ac;2.3 million as of December 31, 2022 (see Note &#x2018;D.11. Trade and other
payables&#x2019;) in third-party accruals in relation to its ongoing clinical trials and manufacturing activities. As of these dates, prepayments
were recorded for those payments made against which no services had yet been rendered (2023: &#x20ac;3.7 million, 2022: &#x20ac;9.8 million,
see Note &#x2018;D.6. Other assets&#x2019;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Realizability of Inventories&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are valued at the lower of cost and net realizable value. Net realizable value comprises the estimated sales proceeds less the necessary
expected costs up to the time of sale. For determining the net realizable value, at each reporting date, the Company estimates excess
and obsolete inventory primarily using a model of expected future sales and using assumptions with significant estimation uncertainty
such as expected medical need and expected market penetration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
these estimates rely, in part, on management&#x2019;s assumptions about future events outside of the Company&#x2019;s control, such as
continuation of the emergency use authorization in the United States and granting of marketing authorization in the European Union. In
making these assumptions, management assesses the probability of these authorizations remaining in place or being granted, as applicable,
by considering correspondence with the relevant regulatory authorities and the Company&#x2019;s actions to achieve any required conditions
for the authorizations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furthermore,
the possible alternative uses for raw materials, unfinished and finished products is taken into consideration.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly assesses market and sales trends, market conditions, disease prevalence, competitive landscape, and regulatory environment
to refine estimates for excess and obsolete inventory. Based on these assessments, and taking manufacturing lead-times into consideration,
management takes operational decisions to order inventory based on inventory aging and the criteria mentioned above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-downs for the year ended December 31, 2023 amounted to &#x20ac;521k (prior year: &#x20ac;0k) and were mainly due to the expiration
of shelf life of finished goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assumptions
included in the model of expected future demand may require revision in future periods which could result in changes to the estimate
of excess and obsolete inventory and in inventory write-downs.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0" id="ixv-22903">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;1.
Basis of preparation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards as issued
by the International Accounting Standards Board (herein &#x201c;IFRS&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements have been prepared on a historical cost basis. These consolidated financial statements of the Group
comprise the Company and its wholly owned subsidiaries, InflaRx GmbH and InflaRx Pharmaceuticals, Inc. The consolidated financial statements
are presented in Euro (&#x20ac;). The presentation currency of the Group is the Euro, as the functional currency of the largest operating
company, InflaRx GmbH, continues to be the Euro. Effective January 1, 2023, the functional currency of InflaRx N.V. changed from the
U.S. dollar to the Euro due to a change in the Company&#x2019;s operational function and, in turn, a change in the primary currency of
its underlying transactions. This change in functional currency has been accounted for prospectively. The functional currency of InflaRx
Pharmaceuticals, Inc. is the U.S. dollar ($), as most of their income and expenses occurred in U.S. dollars in 2023. All financial information
presented in Euro has been rounded to the nearest Euro, unless stated otherwise.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrx:DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock contextRef="c0" id="ixv-22935">&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;2.
Summary of material accounting policies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
section describes material accounting policies adopted in the preparation of these consolidated financial statements. These policies
have been consistently applied to all the years presented, unless otherwise stated.&lt;/span&gt;&lt;/p&gt;</ifrx:DisclosureOfSummaryOfMaterialAccountingPoliciesExplanatoryPolicyTextBlock>
    <ifrx:DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock contextRef="c0" id="ixv-22947">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;New and amended standards adopted by the Group&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            17 insurance contracts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 8 accounting policies, changes in accounting estimates and errors: definition of accounting
                                            estimates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 12 deferred tax related to assets and liabilities arising from a single transaction&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 and IFRS practice statement 2 - disclosure of accounting policies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting
policies for the following IFRS standards have been applied starting in Q2 2023 for the first time, as no transactions in the scope of
these IFRS standards had been previously recognized.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS
                                            2 inventories&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to IAS 2, inventories are stated at the lower amount of their cost or at their net realizable value. Cost comprises direct material cost
and, where applicable, direct labor costs and those overhead costs that have been incurred in bringing the inventories to their present
location and condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling
price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. Recognizing inventories
at net realizable value includes writing down inventories considered excess or obsolete.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            15 revenue from contracts with customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
present, the Company exclusively uses distributors to sell its products to end customers (e.g., hospitals). The end customers (e.g. hospitals)
have been determined to be the customer in these sales arrangements. As such, payments received from the distributors are not contract
liabilities but are rather &#x201c;other liabilities&#x201d; recognized in &#x201c;other accrued liabilities.&#x201d; Revenue is therefore
recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer, that is,
when the customer obtains control of that asset and is measured considering estimated return liabilities and expected rebates or cash
discounts.&lt;/span&gt;&lt;/p&gt;</ifrx:DisclosureOfNewAndAmendedStandardsAdoptedByTheGroupExplanatoryPolicyTextBlock>
    <ifrx:DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock contextRef="c0" id="ixv-23036">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;New standard not yet adopted&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following standards issued will be adopted in a future period, and the potential impact on the Group&#x2019;s consolidated financial statements,
if any, is being assessed:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IFRS 16 leases: leases on sale and leaseback&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 presentation of financial statements: classification of liabilities as current or
                                            non-current and non-current liabilities with covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 21 effects of changes in foreign exchange rates: lack of exchangeability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrx:DescriptionOfAccountingPolicyNewStandardsNotYetAdoptedExplanatoryPolicyTextBlock>
    <ifrx:DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock contextRef="c0" id="ixv-23080">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Current and non-current classification&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group presents assets and liabilities in the statement of financial position based on current/non-current classification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
assets include assets that are sold, consumed or realized as part of the normal operating cycle (operating cycle is assumed to be 12
months), or cash and cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after
the reporting period. All other assets are classified as non-current.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
liabilities, such as trade payables, lease liabilities or employee benefits with a term of up to 12 months, and payables for operating
costs or social security charges, are part of the working capital used in the Company&#x2019;s normal operating cycle. Such operating
items are classified as current liabilities even if they are due to be settled more than 12 months after the reporting period. All other
liabilities are classified as non-current.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</ifrx:DescriptionOfAccountingPolicyCurrentAndNoncurrentClassificationExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c0" id="ixv-23119">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(d)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Foreign currency transactions&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions
in a foreign currency are initially translated into the respective functional currency using the spot rate prevailing on the dates of
the transaction. Monetary items which are not denominated in the functional currency are subsequently translated using the rate applicable
at the end of the period. The resulting currency gains and losses are recognized directly in profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
consolidation, the assets and liabilities of operations in a currency other than Euro (the presentation currency of the Company) are
translated into Euros at the rate of exchange prevailing at the reporting date and their statements of operations are translated with
monthly average exchange rates during the reporting period. The exchange differences arising on translation for consolidation are recognized
in &#x2018;other comprehensive income&#x2019; (OCI). On disposal of a foreign operation, the component of OCI relating to that particular
foreign operation is reclassified to profit or loss. OCI is disclosed as &#x2018;other components of equity&#x2019; in consolidated statements
of financial position.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrx:DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock contextRef="c0" id="ixv-23138">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(e)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Grants from government and similar bodies&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group receives grants from government agencies and similar bodies for the active participation in specific research and development projects.
The grants are recognized when there is reasonable assurance that the grant will be received and all grant conditions will be met. If
grant funds are received prior to qualifying expenses being incurred or assets purchased or prior to all grant conditions have been met,
such amounts are recorded as a liability in other liabilities. If the funds reimburse expenses, the liability is amortized into other
operating income in the period in which the corresponding expenses are incurred (or, for expenses incurred prior to all grant conditions
being met, in the period in which reasonable assurance that all grant conditions will be met is attained). If the funds reimburse purchased
assets, the liability is reduced with a corresponding amount deducted from the asset&#x2019;s carrying amount upon recording of the qualified
asset. According to the terms of the grants, grantors generally have the right to audit qualifying expenses submitted by the Group up
to five years after concluding the project sponsored by the government.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
October 2021, the Group announced that it received a grant of up to &#x20ac;43.7 million from the German Ministry of Education and Research
and the German Ministry of Health to support its development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent
changes in the Group&#x2019;s research and development plan and fewer costs projected within the timeframe of the grant, it was notified
that the amount available to it was &#x20ac;41.4 million. The grant is structured as a reimbursement of 80% of certain pre-specified expenses
related to the clinical development and manufacturing of vilobelimab. The grant period ended on June 30, 2023. In total, during the duration
of the grant period through December 31, 2023, the Group received &#x20ac;33.3 million to support its activities regarding the development
of vilobelimab as a new therapeutic agent for the treatment of critically ill COVID-19 patients and for the establishment of a commercial
scale manufacturing process to ensure the ability of being able to provide such treatment to the broader population.&lt;/span&gt;&lt;/p&gt;</ifrx:DescriptionOfAccountingPolicyForGrantsFromGovernmentPoilcyTextBlock>
    <ifrs-full:GovernmentGrants contextRef="c54" decimals="-5" id="ixv-29766" unitRef="eur">43700000</ifrs-full:GovernmentGrants>
    <ifrs-full:IntangibleAssetsAcquiredByWayOfGovernmentGrant contextRef="c54" decimals="-5" id="ixv-29767" unitRef="eur">41400000</ifrs-full:IntangibleAssetsAcquiredByWayOfGovernmentGrant>
    <ifrx:PercentageOfGrant contextRef="c55" decimals="2" id="ixv-29768" unitRef="pure">0.80</ifrx:PercentageOfGrant>
    <ifrs-full:CurrentGovernmentGrants contextRef="c56" decimals="-5" id="ixv-29769" unitRef="eur">33300000</ifrs-full:CurrentGovernmentGrants>
    <ifrx:NotesToTheCashFlowStatementPolicyTextBlock contextRef="c0" id="ixv-23157">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(f)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Notes to the cash flow statement, cash, and cash equivalents&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated statements of cash flows have been prepared using the indirect method for cash flows from operating activities. The cash
disclosed in the consolidated statements of cash flows is comprised of cash and cash equivalents. Cash comprises cash on hand and demand
deposits. Cash equivalents are short-term bank deposits that are readily convertible to a known amount of cash and are not subject to
a significant risk of changes in value with an original maturity of three months or less. Interest paid and received is included in the
cash from operating activities.&lt;/span&gt;&lt;/p&gt;</ifrx:NotesToTheCashFlowStatementPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-23171">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(g)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Research and development expenses&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses comprise third party services, wages and salaries, cost of materials, intellectual property related expenses,
depreciation and amortization of relevant equipment and intangibles as well as overhead. Research and development expenses mainly consist
of costs for clinical trials and manufacturing of the Company&#x2019;s clinical drug products; additionally, costs are incurred for pre-clinical
activities as well as basic research activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Development
expenses must be capitalized if the criteria of IAS 38 are met. In the periods presented, no development expenses were capitalized because
management assessed that not all the recognition criteria of IAS&#160;38 had been met. This assessment is due to the general uncertainties
in drug development and the unpredictability of regulatory requirements. Therefore, research and development expenditures are expensed
when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="c0" id="ixv-23205">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(h)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Employee benefits&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)
Short-term employee benefits&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities
for wages and salaries and cash bonuses are measured at the amounts expected to be paid when the liabilities are settled. The liabilities
are presented as employee benefits in the consolidated statements of financial position. A liability is recognized if the Group has a
present legal or constructive obligation to pay such amount as a result of past service provided by the employee and if such obligation
can be estimated reliably.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Share-based payment transactions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense,
with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect
the number of awards for which the related service conditions are expected to be met, including an estimate of forfeitures, such that
the amount ultimately recognized is based on the number of awards that meet the related service conditions at the vesting date. For share-based
payment awards with immediate vesting, the&#160;grant-date fair value of the share-based payment is measured to reflect such conditions and
there is no gain or loss recognized for differences between expected and actual outcomes.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Lease arrangements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of one
to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)
Right-of-use assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#x2019;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Lease liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)
Short-term leases and leases of low-value assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iv) Determining the lease term of contracts&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(j)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Interest income&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(k)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over three years. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(l)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Property and equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory equipment: three to 13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment: one to five years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets&#x2019; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#x2018;other income&#x2019;
or &#x2018;other expenses&#x2019; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(m)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Impairment of assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#x2019;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
there has been a change in the estimates used to determine the asset&#x2019;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no impairments or reversals of impairments in 2021, 2022 or 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(n)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Financial assets and liabilities (financial instruments)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(i) Definition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#x2019;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;amp;D projects).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Criteria for the recognition and derecognition, initial measurement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iii) Subsequent measurement method&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Considering
the Group&#x2019;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#x2018;3.8
Financial assets and financial liabilities.&#x2019;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iv) Criteria for realization of income and expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#x2018;C.8. Net Financial Result&#x2019;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(o)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Fair Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#x2018;D.8. Financial
assets and financial liabilities&#x2019;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1, quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(p)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(i) Current income tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(ii) Deferred income tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#x2019;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3. Significant accounting judgements, estimates and assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#x2019;s accounting policies involve the following areas:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Accounting for share-based payments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#x2018;C.10.(b).</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c0" id="ixv-23237">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(i)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Lease arrangements&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group leases various properties, laboratory and office equipment and cars. Rental contracts are typically made for fixed periods of one
to three years but may have renewal options. The lease agreements do not impose any covenants, but leased assets may not be used as collateral
for borrowing purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)
Right-of-use assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use).
Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any re-measurement
of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred,
and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain
to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line
basis over the shorter of its estimated useful life and the lease term. On&#160;December&#160;31, 2023, the remaining useful lives of
the Company&#x2019;s right-of-use assets ranged between 3 and 41 months. Right-of-use assets are subject to impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Lease liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made
over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable,
variable lease payments which depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease
payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties
for terminating a lease, if the lease term reflects the Group exercising the option to terminate. The variable lease payments that do
not depend on an index or a rate are recognized as expense in the period on which the event or condition that triggers the payment occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date, since
the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is
increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities
is re-measured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change
in the assessment to purchase the underlying asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(iii)
Short-term leases and leases of low-value assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group applies the short-term lease recognition exemption to its short-term leases of equipment (i.e., those leases that have a lease
term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets
recognition exemption to leases of office equipment that are considered of low value. Lease payments on short-term leases and leases
of low-value assets are recognized as expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iv) Determining the lease term of contracts&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within
its control and affects its ability to exercise the option to renew.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group further determines the lease term as the non-cancellable term of the lease, together with any periods covered by an option to extend
the lease if it is reasonably certain to be exercised, or any periods covered by an option to terminate the lease, if it is reasonably
certain not to be exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
leases which currently also result in the capitalization of a right of use asset, do not include any renewal options. For future lease
contracts with potential renewal options the Company applies judgement in evaluating whether it is reasonably certain to exercise the
option to renew. In doing so, management would consider all relevant factors that create an economic incentive for it to exercise the
renewal.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrx:RentalContractsFixedPeriod contextRef="c57" id="ixv-29770">P1Y</ifrx:RentalContractsFixedPeriod>
    <ifrx:RentalContractsFixedPeriod contextRef="c58" id="ixv-29771">P3Y</ifrx:RentalContractsFixedPeriod>
    <ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory contextRef="c0" id="ixv-23338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(j)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Interest income&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is derived from interest-bearing financial assets, including cash equivalents. Interest income on cash and cash equivalents, financial
assets at amortized cost calculated using the effective interest rate method is recognized in the consolidated statements of operations
and comprehensive loss as part of finance income.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForInterestIncomeAndExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="c0" id="ixv-23354">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(k)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Intangible assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets mainly comprise purchased IT software. Intangible assets are initially measured at acquisition cost, including any directly attributable
costs of preparing the asset for its intended use less accumulated amortization and accumulated impairment losses, if any. Amortization
begins when an asset is available for use and amortization is calculated using the straight-line method to allocate cost over the estimated
useful lives. The useful lives of intangible assets are reviewed at each reporting date. Software is amortized over three years. The
effect of any adjustment to useful lives is recognized prospectively as a change of accounting estimate. The Group only owns intangible
assets with a definite useful life.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <ifrx:AmortizedPeriod contextRef="c0" id="ixv-29773">P3Y</ifrx:AmortizedPeriod>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-23370">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(l)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Property and equipment&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory
and office equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical
cost includes expenditure that is directly attributable to the acquisition of the items.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
repairs and maintenance are recognized in profit or loss during the financial period in which they are incurred, because they do not
constitute a separate asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
on laboratory and office equipment is calculated using the straight-line method to allocate their cost over their estimated useful lives,
as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Laboratory equipment: three to 13 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment: one to five years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assets&#x2019; residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognized within &#x2018;other income&#x2019;
or &#x2018;other expenses&#x2019; in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c59" id="ixv-29774">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c60" id="ixv-29775">P13Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c61" id="ixv-29777">P1Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="c62" id="ixv-29778">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="c0" id="ixv-23446">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(m)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Impairment of assets&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting date, the Group assesses whether there is an indication that an asset may be impaired. If there is any indication of impairment
or if an annual impairment test is required, the Group estimates the recoverable amount of the asset. The recoverable amount of an asset
is the higher of the asset&#x2019;s fair value less costs of disposal and its value-in-use. It is determined for an individual asset,
unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which
case it is determined at the level of the cash-generating unit. If the carrying amount of an asset exceeds its recoverable amount, the
asset is impaired and written down to its recoverable amount. In assessing value in use, the estimated future cash flows are discounted
to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
there has been a change in the estimates used to determine the asset&#x2019;s recoverable amount since the last impairment loss was recognized,
any impairment loss previously recognized is reversed. The reversal may not exceed the carrying amount that would have been determined
after amortization or depreciation had no impairment loss been recognized for the asset in prior periods. The amount of the reversal
is recognized in profit or loss for the period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no impairments or reversals of impairments in 2021, 2022 or 2023.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="c0" id="ixv-23474">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(n)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Financial assets and liabilities (financial instruments)&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(i) Definition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument
of another entity. The Group&#x2019;s financial assets include predominantly quoted fixed-interest debt securities. The financial liabilities
comprise trade and other payables (incl. accrued liabilities from the R&amp;amp;D projects).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(ii)
Criteria for the recognition and derecognition, initial measurement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
general purchases or sales of financial assets are recognized on the settlement date, i.e., the date that the Group renders or receives
the counter performance (typically cash). The Group initially measures a financial asset at its fair value plus transaction costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group initially recognizes non-derivative financial liabilities on the date that they are originated at fair value net of directly attributable
transaction costs. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled, or expire.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iii) Subsequent measurement method&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Considering
the Group&#x2019;s business model for managing the financial assets, with an objective to hold them in order to collect contractual cash
flows, and their contractual cash flow characteristics, that are solely payments of principal and interest on the principal amount outstanding,
the Group classifies the quoted debt securities with fixed interest rates as subsequently measured at amortized cost using the effective
interest method (EIR). The financial assets are also subject to impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s financial liabilities are classified as subsequently measured at amortized cost which is calculated by considering any
discount or premium on acquisition and fees or costs that are an integral part of the EIR.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An
analysis of the carrying amounts from the consolidated statements of financial position by measurement category is disclosed under &#x2018;3.8
Financial assets and financial liabilities.&#x2019;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(iv) Criteria for realization of income and expenses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is accrued using the relevant effective interest rate. Interest expense on liabilities, if any, is also accrued based on the effective
interest rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on the disposal of financial instruments are recognized in full when all significant risks and rewards have been transferred.
In the case of a partial transfer of risks and rewards, a distinction would be made as to whether control remains with the company or
is transferred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment
losses on financial assets are recognized in profit or loss. The Group recognizes an allowance for expected credit losses (ECLs) for
the financial assets held, see Note &#x2018;C.8. Net Financial Result&#x2019;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ECLs
are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group
expects to receive, discounted at an approximation of the original effective interest rate. ECLs are generally recognized in two stages.
For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided
for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures
for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses
expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL). For the quoted debt securities
with fixed interest rates, which have high credit ratings and no significant increases in credit risk since initial recognition, the
Group determines the exposure to credit default using CDS pricing information (i.e., credit default swap values) published by credit
agencies and recognizes a 12-month ECL.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c0" id="ixv-23587">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(o)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Fair Value Measurement&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group does not measure any financial asset or liability at fair value. The carrying amount of all financial instruments approximates
their fair value, with the exception of quoted debt securities for which fair values are disclosed (see Note &#x2018;D.8. Financial
assets and financial liabilities&#x2019;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
measuring the fair value of an asset or a liability, the Group would use observable market data as far as possible. Fair values are categorized
into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            1, quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            2, inputs other than quoted prices included within Level 1 that are observable for the instrument,
                                            either directly (as prices) or indirectly (derived from prices).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
                                            3, inputs for instruments that are not based on observable market data (unobservable inputs).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the
fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is
significant to the entire measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group would recognize transfers between levels of the fair value hierarchy at the end of the reporting period during which the change
has occurred.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="c0" id="ixv-23654">&lt;p style="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(p)
&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&lt;span style="font-variant: normal; font-weight: normal"&gt;Income tax&lt;/span&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Income
taxes comprise current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they
relate to items recognized directly in equity or in other comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(i) Current income tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current
income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Expected
tax payable or receivable on the taxable income or loss for the year, are calculated using tax rates enacted or substantively enacted
at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the periods presented; the Group did not incur income tax expense. Taxes withheld by banks and remitted to tax authorities were reimbursed
after filing of the annual tax declaration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;
(ii) Deferred income tax&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets
and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that
affects neither accounting nor tax profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have
been enacted or substantively enacted by the reporting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax assets arising from tax loss carryforwards are recognized only to the extent that the Group has sufficient taxable temporary differences
or there is convincing evidence that sufficient future taxable profit will be available against which the unused tax losses can be utilized.
As of December 31, 2023 and 2022, based on management&#x2019;s judgment, it was not probable that taxable profit will be available against
which the unused tax losses can be utilized; no deferred tax assets were therefore recognized in the consolidated statements of financial
position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrx:DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock contextRef="c0" id="ixv-23728">&lt;p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3. Significant accounting judgements, estimates and assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions
that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results
may differ from these estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which
the estimates are revised and in any future periods affected. In preparing these consolidated financial statements, the critical judgments
made by management in applying the Group&#x2019;s accounting policies involve the following areas:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(a)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Accounting for share-based payments&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
determining the grant date fair value of share-based payment awards, assumptions must be made regarding the key parameters of the calculation
(see Note &#x2018;C.10.(b). Measurement of fair values of share options granted&#x2019;). In 2023, the Company&#x2019;s share price volatility
for the purposes of the calculation was determined on the basis of the 5-year annualized average share price, which management believes
will be indicative of the share price development of the Company in future periods. This led to a range of applied volatility rates in
2023 of 135% to 145.66% for the different options granted during the year of this report.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company must estimate the number of equity instruments which will vest in future periods as awards may be forfeited prior to vesting
due to an awardee&#x2019;s failure to satisfy a performance condition, including due to employment termination. An assumption of the forfeiture
rate is regularly made on the basis of historical information and adjusted to reflect future expectations. Revisions to the forfeiture
rate could result in a cumulative effect of the change in estimate for current and prior periods to be recognized in the period of change.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(b)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Measurement of third-party R&amp;amp;D clinical trial and contracted manufacturing expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
measuring R&amp;amp;D expenses for the reporting period, the Company estimates the amount of expense to recognize and liability to accrue
to the extent that invoices of the Company&#x2019;s contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations
(&#x201c;CDMOs&#x201d;) are not yet received and exceed any prepayments made. The timing of the invoicing of project services by CROs follow
contractual billing schedules and can occur several months prior to or following a reporting period. This estimation involves determining
a percentage-of-completion whereby the degree to which services have been rendered for the individual project activities contracted from
the CRO and CDMOs is assessed and estimated by in-house R&amp;amp;D project managers and reviewed by the controlling department. This percentage-of-completion
is used to measure the amount of the unbilled project activities which have already been rendered by the reporting date and the associated
R&amp;amp;D expense and liability to recognize as a result.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
percentage-of-completion estimates are based on the best information available at the time. However, additional information may become
available in the future and management may adjust the estimate in such future periods. In this event, the Company may be required to
record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. The
Company considers resulting increases or decreases in expenses as changes in estimates and reflects such changes in research and development
expenses in the period identified.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accrued &#x20ac;4.4 million as of December 31, 2023 and &#x20ac;2.3 million as of December 31, 2022 (see Note &#x2018;D.11. Trade and other
payables&#x2019;) in third-party accruals in relation to its ongoing clinical trials and manufacturing activities. As of these dates, prepayments
were recorded for those payments made against which no services had yet been rendered (2023: &#x20ac;3.7 million, 2022: &#x20ac;9.8 million,
see Note &#x2018;D.6. Other assets&#x2019;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;(c)&lt;/i&gt;&lt;/b&gt;&lt;/span&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Realizability of Inventories&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are valued at the lower of cost and net realizable value. Net realizable value comprises the estimated sales proceeds less the necessary
expected costs up to the time of sale. For determining the net realizable value, at each reporting date, the Company estimates excess
and obsolete inventory primarily using a model of expected future sales and using assumptions with significant estimation uncertainty
such as expected medical need and expected market penetration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
these estimates rely, in part, on management&#x2019;s assumptions about future events outside of the Company&#x2019;s control, such as
continuation of the emergency use authorization in the United States and granting of marketing authorization in the European Union. In
making these assumptions, management assesses the probability of these authorizations remaining in place or being granted, as applicable,
by considering correspondence with the relevant regulatory authorities and the Company&#x2019;s actions to achieve any required conditions
for the authorizations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furthermore,
the possible alternative uses for raw materials, unfinished and finished products is taken into consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly assesses market and sales trends, market conditions, disease prevalence, competitive landscape, and regulatory environment
to refine estimates for excess and obsolete inventory. Based on these assessments, and taking manufacturing lead-times into consideration,
management takes operational decisions to order inventory based on inventory aging and the criteria mentioned above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-downs for the year ended December 31, 2023 amounted to &#x20ac;521k (prior year: &#x20ac;0k) and were mainly due to the expiration
of shelf life of finished goods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assumptions
included in the model of expected future demand may require revision in future periods which could result in changes to the estimate
of excess and obsolete inventory and in inventory write-downs.&lt;/span&gt;&lt;/p&gt;</ifrx:DisclosureOfSignificantAccountingJudgementsEstimatesAndAssumptionsPolicyTextBlock>
    <ifrx:AnnualizedAverageSharePricePeriod contextRef="c0" id="ixv-29781">P5Y</ifrx:AnnualizedAverageSharePricePeriod>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c63" decimals="2" id="ixv-29782" unitRef="pure">1.35</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c64" decimals="4" id="ixv-29783" unitRef="pure">1.4566</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:AccruedIncomeIncludingContractAssets contextRef="c2" decimals="-5" id="ixv-29784" unitRef="eur">4400000</ifrs-full:AccruedIncomeIncludingContractAssets>
    <ifrs-full:AccruedIncomeIncludingContractAssets contextRef="c5" decimals="-5" id="ixv-29785" unitRef="eur">2300000</ifrs-full:AccruedIncomeIncludingContractAssets>
    <ifrs-full:OtherAssets contextRef="c2" decimals="-5" id="ixv-29786" unitRef="eur">3700000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c5" decimals="-5" id="ixv-29787" unitRef="eur">9800000</ifrs-full:OtherAssets>
    <ifrs-full:InventoryWritedown2011 contextRef="c0" decimals="-3" id="ixv-29788" unitRef="eur">521000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011 contextRef="c3" decimals="-3" id="ixv-29789" unitRef="eur">0</ifrs-full:InventoryWritedown2011>
    <ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory contextRef="c0" id="ixv-23846">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;C. Consolidated statements of operations and comprehensive loss&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1. Revenues&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;63,089&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;63,089&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2023, the Group began the commercialization of GOHIBIC (vilobelimab) in the United States. In connection with the start of the commercialization,
the Group entered into agreements with certain subsidiaries of Cencora Inc. (&#x201c;Cencora&#x201d;) (formerly known as AmerisourceBergen
Corp.) to act as the Group&#x2019;s U.S. distributor and make GOHIBIC (vilobelimab) available for order by U.S. hospital customers. Cencora
provides cold storage, cold-chain distribution services, inventory management and secondary labeling/packaging, among other services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2023, the Company realized revenues from the product sales for the first time since its inception. Revenues reported are sales to end
customers (hospitals). Sales to distributors do not constitute completion of a performance obligation towards a customer and, thus, do
not result in the recognition of revenue for the Company under IFRS 15.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2. Cost of sales&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in"&gt;Cost of Sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;532,262&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;532,262&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost
of sales recognized during the twelve months ended December 31, 2023, are related to GOHIBIC (vilobelimab) revenues in the United States
and to write-downs of inventory.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
of sales for products sold in these periods do not include costs of materials, as the associated costs of these materials were incurred
in prior periods, before the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) granted an Emergency Use Authorization (the &#x201c;EUA&#x201d;)
for GOHIBIC (vilobelimab) in April 2023. These materials were recorded as &#x2018;research and development expenses&#x2019; in the periods
they were incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
cost of sales during the twelve months ended December 31, 2023 mainly consists of write-downs of inventories that will expire prior to
their expected sale.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;3. Sales and marketing expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Third-party expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,851,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee benefits expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,040,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which equity-settled share-based payment expense&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;67,462&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Legal and consulting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,054,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,583&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total sales and marketing expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,001,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the twelve months ended December 31, 2023 the Group incurred &#x20ac;4.0 million of sales and marketing expenses in the United States of
America. These expenses are mainly composed of &#x20ac;1.0 million in personnel costs and &#x20ac;1.9 million in external services for distribution
of GOHIBIC (vilobelimab). The Group started with its commercialization activities when the EUA was granted in April 2023. Prior to that,
no sales and marketing expenses had been incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;4. Research and development expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses increased in 2023 compared to 2022 by &#x20ac;3.5 million. The table below shows the composition of research and
development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Third-party services&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31,802,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,543,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,247,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which clinical material and related manufacturing services&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;18,109,345&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;16,194,152&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;6,615,840&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which clinical, pre-clinical studies&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;13,693,638&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;12,349,351&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;21,631,240&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee benefits expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,776,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,957,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,941,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which equity-settled share-based payment expense&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;1,500,670&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;2,456,571&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;1,622,898&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Legal and consulting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,758,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,690,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,074,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;686,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;334,273&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;434,331&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;41,024,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;37,526,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;35,697,935&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;5. General and administrative expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses decreased by &#x20ac;2.2 million in 2023 from the prior year, predominantly due to lower costs from equity-settled
share-based payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Employee benefits expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,392,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,125,798&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,500,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which equity-settled share-based payment expense&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;1,846,356&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;3,587,785&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;2,709,307&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Legal and consulting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,239,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,104,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,065,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,934,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,330,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,615,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation &amp;amp; amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;551,566&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Compensation expense for non-executive directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,984&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,247,273&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,533,469&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;979,884&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,628,756&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,869,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,984,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;6. Other income&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income was &#x20ac;13.2 million, which is primarily attributable to income recognized from grant payments received from the German federal
government for the development of vilobelimab in severe COVID-19 patients, including expenses related to clinical development and manufacturing
process development. Other income decreased in 2023, compared to the prior year, due to the incurrence of less expenses eligible for
reimbursement under the grant and the end of the grant period on June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: 0in"&gt;Other income from government grants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,155,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,116,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in"&gt;Further other income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;13,219,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;20,159,169&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;54,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;7. Employee benefits expenses&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the items of employee benefits expenses:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Wages and salaries&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,192,143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,863,423&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,919,166&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Social security contributions (employer&#x2019;s share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;944,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;671,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equity-settled share-based payment expenses (see Note C.10. Share-based payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,414,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,044,356&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,332,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659,002&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;503,351&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;519,425&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;13,210,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,083,664&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,442,493&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
number of employees as of December 31, 2023 increased to 66 (equivalent to 62.2 full time equivalents (FTEs)) from 48 employees (equivalent
to 44.3 FTEs) at the end of 2022 and 59 employees (equivalent to 55.9 FTEs) at the end of 2021. These numbers are as of December 31 and
do not constitute annual average numbers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;8. Net financial result&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,804,827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;608,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;109,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Interest expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,303&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,714&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Financial result&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,769,199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;563,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;84,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,529,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,924,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,569,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign exchange expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,371,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,482,399&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,605,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Foreign exchange result&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,841,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,442,298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,964,135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other financial result&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(252,471&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(44,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Net financial result&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,240,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,753,256&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,004,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
financial result decreased by &#x20ac;0.5&#160;million from 2022 to 2023. This overall decrease was comprised of higher interest income
of &#x20ac;3.2&#160;million from marketable securities and short-term deposits in U.S. dollars held by the Company and its subsidiaries
(from &#x20ac;0.6&#160;million in 2022 to &#x20ac;3.8&#160;million in 2023), a reduction in foreign exchange by &#x20ac;4.3&#160;million (from
a gain of &#x20ac;2.4&#160;million in 2022 to a loss of &#x20ac;1.8&#160;million in 2023) and higher other financial result of &#x20ac;0.6&#160;million
(from a loss of &#x20ac;0.3&#160;million in 2022 to a gain of &#x20ac;0.3&#160;million in 2023) due to an adjustment to the expected credit
loss allowance in 2023, which is deducted from the Company&#x2019;s current and non-current financial assets (please also refer to Note
D.6. &#x2018;Other assets&#x2019;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
currency income and expenses arise from the translation of cash and cash equivalents, marketable securities and other financial assets
and liabilities denominated in foreign currencies at the exchange rates prevailing at the balance sheet date. All resulting translation
differences are recognized in the income statement. These gains and losses are caused by a change in exchange rates at the reporting
dates and may not ultimately be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;9. Loss per share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loss
per ordinary share is calculated by dividing the loss of the period by the weighted average number of ordinary shares outstanding during
the period. The weighted number of ordinary shares outstanding for the financial year 2023 was 54,940,137, for 2022 it amounted to 44,207,873
and for 2021 it was 41,629,974. Loss per share was &#x20ac;0.78, &#x20ac;0.67 and &#x20ac;1.10 in 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Company is in a loss-making situation, the diluted loss per share is the same as basic loss per share, because the weighted average
number of shares to be issued upon the exercise of the stock options, the only dilutive instruments issued, would produce an anti-dilutive
effect. Refer to Note &#x2018;C.10. for the balances of outstanding share options.&#x2019;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;10. Share-based payments&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;a) Equity-settled share-based payment arrangements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the course of its historical financing rounds prior to 2016, InflaRx GmbH established equity-settled share-based payment programs. Those
InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. in November 2017:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Outstanding at January 1&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Outstanding at December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercisable at December 31&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
average share price (WAEP)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
exercise price for all options granted prior to 2016 outstanding at the end of the year was &#x20ac;0.01 per share or less (2022: &#x20ac;0.01
or less).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms and conditions of the share option plan of 2016 (the &#x201c;2016 Plan&#x201d;), InflaRx GmbH granted rights to subscribe for
InflaRx GmbH&#x2019;s common shares to directors, senior management, and key employees. Those InflaRx GmbH options were converted into
options for ordinary shares of the Company in November 2017:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Outstanding at January 1&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.35/&#x20ac;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80; -sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Outstanding at December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercisable at December 31&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversion
rates used for one &#x20ac;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31,2022 $0.9376, average rate 2022 $0.9489&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining contractual life for the share options outstanding under the 2016 Plan as of December&#160;31,&#160;2023 was
7.94 years (2022: 8.94 years).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the closing of its initial public offering, InflaRx N.V. established a new incentive plan (the &#x201c;2017 Plan&#x201d;).
The initial maximum number of ordinary shares available for issuance under equity incentive awards granted pursuant to the 2017 Plan
equals 2,341,097 ordinary shares. On January 1, 2021 and on January 1 of each calendar year thereafter, an additional number of shares
equal to 4% of the total outstanding ordinary shares on December 31 of the immediately preceding year (or any lower number of shares
as determined by the Board of Directors) will become available for issuance under equity incentive awards granted pursuant to the 2017
Plan:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Outstanding at January 1&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,985,523&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.97 /&#x20ac;1.84&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,170,046&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.95 /&#x20ac;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,735,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.58/&#x20ac;2.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,966,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.98 / &#x20ac;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.70/&#x20ac;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(136,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22 /&#x20ac;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(105,327&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.16/&#x20ac;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,930&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86 /&#x20ac;1.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Outstanding at December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6,584,946&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.12/&#x20ac;1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,985,523&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.97 /&#x20ac;1.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercisable at December 31&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,577,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.01/&#x20ac;1.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,157,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.93 /&#x20ac;1.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversion
rates used for one &#x20ac;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31, 2022 $0.9376, average rate 2022 $0.9489&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average remaining contractual life for the share options outstanding under the 2017 Plan as of December 31, 2023 was 6.61 years
(2022: 6.70 years).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
Options granted in 2023 vest over one year except for options granted on July 7, 2023 which partially vest over three years. Options
granted before 2023 vest over a period of one, two or three years, depending on the grant, with 1/2 or 1/3, respectively, of the options
vesting after the end of the 1st year from vesting start and the remaining options vesting quarterly in equal portions thereafter. Vesting
of these unvested share options is subject to a service condition at the time of vesting, and no market or performance conditions are
applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average fair value of options granted during 2023 was $2.58/&#x20ac;2.39 (2022 after repricing: $1.70/&#x20ac;1.61). The range of
exercise prices for options outstanding at the end of the year was $1.86/&#x20ac;1.74 to $5.14/&#x20ac;4.82 (after repricing in 2022: $1.86/&#x20ac;1.74
to $5.14/&#x20ac;4.82).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
shares issued for share options exercised during the year were recorded to the commercial register by December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;b)
Measurement of fair values of share options granted under the 2017 Plan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of options granted under the 2017 Plan was determined using the Black-Scholes valuation model. As the Company&#x2019;s ordinary
shares are listed on the Nasdaq Global Select Market, the closing price of the ordinary shares at grant date was used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
significant inputs into the model are as follows (weighted average):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Share options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;FX rate as&lt;br/&gt;
 of grant&lt;br/&gt;
 date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price&lt;br/&gt;
 at grant&lt;br/&gt;
 date/&lt;br/&gt;
 Exercise&lt;br/&gt;
 price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
 volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Expected life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(midpoint&lt;br/&gt;
 based)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk-free&lt;br/&gt;
 rate&lt;br/&gt;
 (interpolated,&lt;br/&gt;
 U.S.&lt;br/&gt;
 sovereign&lt;br/&gt;
 strips curve)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 31.5%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;839,260&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4.53&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.8133&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.68&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;327,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.98&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.66&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8458&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,219,074&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Of
the 1,219,074 options granted in 2021, 1,134,436 were granted to members of the executive management or the Board of Directors. In 2021,
36,400 options were forfeited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Share options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value per share option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;FX rate as of grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value per share option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date/ Exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected life (midpoint based)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk-free rate (interpolated, U.S. sovereign strips curve)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 9%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January&#160;12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,516,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.8795&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#x20ac;3.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.57%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January&#160;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8795&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x20ac;3.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.59%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Repricing,&#160;April&#160;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.20-$1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x20ac;1.11-&#x20ac;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.83-4.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2.60%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;November&#160;21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;405,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x20ac;1.99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.15%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;b&gt;1,966,666&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Of
the 1,966,666 options granted in 2022, 1,223,500 were granted to members of the executive management or the Board of Directors. In 2022,
136,259 options were forfeited, 14,930 were exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Share options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;FX rate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of&lt;br/&gt;
 grant&lt;br/&gt;
 date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Share&lt;br/&gt;
 price at&lt;br/&gt;
 grant&lt;br/&gt;
 date/&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt;
 price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
 volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Expected&lt;br/&gt;
 life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(midpoint based)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk-free&lt;br/&gt;
 rate&lt;br/&gt;
 (interpolated,&lt;br/&gt;
 U.S.&lt;br/&gt;
 sovereign&lt;br/&gt;
 strips curve)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 31.5%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,454,250&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2.11&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1.90&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5.30&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.571&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.565&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.820&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.320&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.286&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.320&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September 18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;3.15&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.9378&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;3.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.320&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,735,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Of
the 1,735,750 options granted in 2023, 1,136,000 were granted to members of the executive management or the Board of Directors. In 2023,
31,000 options were forfeited, 105,327 were exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
dividends are &lt;span style="-sec-ix-hidden: hidden-fact-84"&gt;nil&lt;/span&gt; for all share options listed above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
price volatility is calculated on the basis of annualized monthly volatility rate of the Company&#x2019;s share price over the last five
years preceding the valuation date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
range of outcomes for the expected life of the instruments has been based on expectations on option holder behavior in the scenarios
considered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
dividend yield has no impact due to the anti-dilution clause as defined in the 2017 Plan.&lt;/span&gt;&lt;/p&gt;</ifrx:DisclosureOfConsolidatedStatementsOfOperationsAndComprehensiveLossExplanatory>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="c0" id="ixv-29790">Revenues&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;63,089&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;63,089&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <ifrs-full:Revenue contextRef="c0" decimals="0" id="ixv-29791" unitRef="eur">63089</ifrs-full:Revenue>
    <ifrs-full:Revenue contextRef="c0" decimals="0" id="ixv-29792" unitRef="eur">63089</ifrs-full:Revenue>
    <ifrs-full:DisclosureOfCostOfSalesExplanatory contextRef="c0" id="ixv-29793">Cost of sales&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt; text-indent: 0in"&gt;Cost of Sales&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;532,262&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;532,262&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCostOfSalesExplanatory>
    <ifrs-full:CostOfSales contextRef="c0" decimals="0" id="ixv-29794" unitRef="eur">532262</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales contextRef="c0" decimals="0" id="ixv-29795" unitRef="eur">532262</ifrs-full:CostOfSales>
    <ifrx:DisclosureOfSalesAndMarketingExpenseTextBlock contextRef="c0" id="ixv-29796">Sales and marketing expenses&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Third-party expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,851,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee benefits expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,040,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which equity-settled share-based payment expense&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;67,462&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Legal and consulting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,054,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,583&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total sales and marketing expenses&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,001,299&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrx:DisclosureOfSalesAndMarketingExpenseTextBlock>
    <ifrs-full:SalesAndMarketingExpense contextRef="c77" decimals="0" id="ixv-29797" unitRef="eur">1851158</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c80" decimals="0" id="ixv-29798" unitRef="eur">1040587</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c83" decimals="0" id="ixv-29799" unitRef="eur">67462</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c85" decimals="0" id="ixv-29800" unitRef="eur">1054971</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c88" decimals="0" id="ixv-29801" unitRef="eur">54583</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="0" id="ixv-29802" unitRef="eur">4001299</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="-5" id="ixv-29803" unitRef="eur">4000000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SellingExpense contextRef="c0" decimals="-5" id="ixv-29804" unitRef="eur">1000000</ifrs-full:SellingExpense>
    <ifrs-full:OtherFinanceCost contextRef="c0" decimals="-5" id="ixv-29805" unitRef="eur">1900000</ifrs-full:OtherFinanceCost>
    <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="c0" id="ixv-24143">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and development expenses increased in 2023 compared to 2022 by &#x20ac;3.5 million. The table below shows the composition of research and
development expenses.&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Third-party services&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;31,802,983&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,543,503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;28,247,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which clinical material and related manufacturing services&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;18,109,345&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;16,194,152&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;6,615,840&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which clinical, pre-clinical studies&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;13,693,638&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;12,349,351&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;21,631,240&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Employee benefits expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,776,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,957,866&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,941,813&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which equity-settled share-based payment expense&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;1,500,670&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;2,456,571&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;1,622,898&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Legal and consulting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,758,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,690,448&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,074,710&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;686,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;334,273&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;434,331&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;41,024,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;37,526,090&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;35,697,935&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c65" decimals="-5" id="ixv-29806" unitRef="eur">3500000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c91" decimals="0" id="ixv-29807" unitRef="eur">31802983</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c92" decimals="0" id="ixv-29808" unitRef="eur">28543503</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c93" decimals="0" id="ixv-29809" unitRef="eur">28247081</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c94" decimals="0" id="ixv-29810" unitRef="eur">18109345</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c95" decimals="0" id="ixv-29811" unitRef="eur">16194152</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c96" decimals="0" id="ixv-29812" unitRef="eur">6615840</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c97" decimals="0" id="ixv-29813" unitRef="eur">13693638</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c98" decimals="0" id="ixv-29814" unitRef="eur">12349351</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c99" decimals="0" id="ixv-29815" unitRef="eur">21631240</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c80" decimals="0" id="ixv-29816" unitRef="eur">6776853</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c81" decimals="0" id="ixv-29817" unitRef="eur">6957866</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c82" decimals="0" id="ixv-29818" unitRef="eur">5941813</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c83" decimals="0" id="ixv-29819" unitRef="eur">1500670</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c84" decimals="0" id="ixv-29820" unitRef="eur">2456571</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c100" decimals="0" id="ixv-29821" unitRef="eur">1622898</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c85" decimals="0" id="ixv-29822" unitRef="eur">1758283</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c86" decimals="0" id="ixv-29823" unitRef="eur">1690448</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c87" decimals="0" id="ixv-29824" unitRef="eur">1074710</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c88" decimals="0" id="ixv-29825" unitRef="eur">686012</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c89" decimals="0" id="ixv-29826" unitRef="eur">334273</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c90" decimals="0" id="ixv-29827" unitRef="eur">434331</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-29828" unitRef="eur">41024131</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c3" decimals="0" id="ixv-29829" unitRef="eur">37526090</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" id="ixv-29830" unitRef="eur">35697935</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="c0" id="ixv-24291">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;General
and administrative expenses decreased by &#x20ac;2.2 million in 2023 from the prior year, predominantly due to lower costs from equity-settled
share-based payments.&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Employee benefits expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,392,905&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,125,798&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,500,680&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;of which equity-settled share-based payment expense&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;1,846,356&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;3,587,785&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;2,709,307&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Legal and consulting fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,239,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,104,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,065,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Insurance expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,934,880&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,330,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,615,920&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation &amp;amp; amortization expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,905&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;526,325&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;551,566&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Compensation expense for non-executive directors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,984&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,247,273&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,533,469&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;979,884&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,628,756&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,869,564&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,984,722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c66" decimals="-5" id="ixv-29831" unitRef="eur">2200000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c80" decimals="0" id="ixv-29832" unitRef="eur">5392905</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c81" decimals="0" id="ixv-29833" unitRef="eur">7125798</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c82" decimals="0" id="ixv-29834" unitRef="eur">6500680</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c83" decimals="0" id="ixv-29835" unitRef="eur">1846356</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c84" decimals="0" id="ixv-29836" unitRef="eur">3587785</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c100" decimals="0" id="ixv-29837" unitRef="eur">2709307</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c85" decimals="0" id="ixv-29838" unitRef="eur">3239809</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c86" decimals="0" id="ixv-29839" unitRef="eur">3104624</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c87" decimals="0" id="ixv-29840" unitRef="eur">2065423</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c101" decimals="0" id="ixv-29841" unitRef="eur">1934880</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c102" decimals="0" id="ixv-29842" unitRef="eur">2330624</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c103" decimals="0" id="ixv-29843" unitRef="eur">1615920</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c104" decimals="0" id="ixv-29844" unitRef="eur">507905</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c105" decimals="0" id="ixv-29845" unitRef="eur">526325</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c106" decimals="0" id="ixv-29846" unitRef="eur">551566</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c107" decimals="0" id="ixv-29847" unitRef="eur">305984</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c108" decimals="0" id="ixv-29848" unitRef="eur">248724</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c109" decimals="0" id="ixv-29849" unitRef="eur">271248</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c88" decimals="0" id="ixv-29850" unitRef="eur">1247273</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c89" decimals="0" id="ixv-29851" unitRef="eur">1533469</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c90" decimals="0" id="ixv-29852" unitRef="eur">979884</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-29853" unitRef="eur">12628756</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c3" decimals="0" id="ixv-29854" unitRef="eur">14869564</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-29855" unitRef="eur">11984722</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:OtherIncome contextRef="c0" decimals="-5" id="ixv-29856" unitRef="eur">13200000</ifrs-full:OtherIncome>
    <ifrx:DisclosureOfOtherIncomeExplanatoryTextBlock contextRef="c0" id="ixv-29857">Other income decreased in 2023, compared to the prior year, due to the incurrence of less expenses eligible for
reimbursement under the grant and the end of the grant period on June 30, 2023.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: 0in"&gt;Other income from government grants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,155,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20,116,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0in"&gt;Further other income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,454&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,627&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;54,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: 0in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;13,219,704&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;20,159,169&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;54,221&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrx:DisclosureOfOtherIncomeExplanatoryTextBlock>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c0" decimals="0" id="ixv-29858" unitRef="eur">13155250</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants contextRef="c3" decimals="0" id="ixv-29859" unitRef="eur">20116542</ifrs-full:RevenueFromGovernmentGrants>
    <ifrx:LiabilityForFuturePolicyBenefitPeriodExpense contextRef="c0" decimals="0" id="ixv-29860" unitRef="eur">64454</ifrx:LiabilityForFuturePolicyBenefitPeriodExpense>
    <ifrx:LiabilityForFuturePolicyBenefitPeriodExpense contextRef="c3" decimals="0" id="ixv-29861" unitRef="eur">42627</ifrx:LiabilityForFuturePolicyBenefitPeriodExpense>
    <ifrx:LiabilityForFuturePolicyBenefitPeriodExpense contextRef="c4" decimals="0" id="ixv-29862" unitRef="eur">54221</ifrx:LiabilityForFuturePolicyBenefitPeriodExpense>
    <ifrs-full:OtherFinanceIncome contextRef="c0" decimals="0" id="ixv-29863" unitRef="eur">13219704</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c3" decimals="0" id="ixv-29864" unitRef="eur">20159169</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c4" decimals="0" id="ixv-29865" unitRef="eur">54221</ifrs-full:OtherFinanceIncome>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="c0" id="ixv-24532">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the items of employee benefits expenses:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Wages and salaries&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,192,143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,863,423&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,919,166&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Social security contributions (employer&#x2019;s share)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;944,712&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;672,534&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;671,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equity-settled share-based payment expenses (see Note C.10. Share-based payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,414,488&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,044,356&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,332,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;659,002&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;503,351&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;519,425&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;13,210,345&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,083,664&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,442,493&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrx:Employeebenefitsexpense contextRef="c110" decimals="0" id="ixv-29866" unitRef="eur">8192143</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c111" decimals="0" id="ixv-29867" unitRef="eur">6863423</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c112" decimals="0" id="ixv-29868" unitRef="eur">6919166</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c113" decimals="0" id="ixv-29869" unitRef="eur">944712</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c114" decimals="0" id="ixv-29870" unitRef="eur">672534</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c115" decimals="0" id="ixv-29871" unitRef="eur">671697</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c116" decimals="0" id="ixv-29872" unitRef="eur">3414488</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c117" decimals="0" id="ixv-29873" unitRef="eur">6044356</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c118" decimals="0" id="ixv-29874" unitRef="eur">4332205</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c119" decimals="0" id="ixv-29875" unitRef="eur">659002</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c120" decimals="0" id="ixv-29876" unitRef="eur">503351</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c121" decimals="0" id="ixv-29877" unitRef="eur">519425</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c0" decimals="0" id="ixv-29878" unitRef="eur">13210345</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c3" decimals="0" id="ixv-29879" unitRef="eur">14083664</ifrx:Employeebenefitsexpense>
    <ifrx:Employeebenefitsexpense contextRef="c4" decimals="0" id="ixv-29880" unitRef="eur">12442493</ifrx:Employeebenefitsexpense>
    <ifrx:DisclosureOfNetFinancialResultTextBlock contextRef="c0" id="ixv-29881">Net financial result&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,804,827&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;608,679&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;109,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Interest expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(16,538&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(23,303&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,714&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(19,090&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,947&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,055&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Financial result&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,769,199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;563,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;84,622&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Foreign exchange income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,529,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,924,697&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,569,836&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign exchange expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,371,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,482,399&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,605,701&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Foreign exchange result&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,841,872&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,442,298&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,964,135&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other financial result&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;313,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(252,471&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(44,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Net financial result&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,240,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,753,256&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,004,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrx:DisclosureOfNetFinancialResultTextBlock>
    <ifrs-full:RevenueFromInterest contextRef="c0" decimals="0" id="ixv-29882" unitRef="eur">3804827</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c3" decimals="0" id="ixv-29883" unitRef="eur">608679</ifrs-full:RevenueFromInterest>
    <ifrs-full:RevenueFromInterest contextRef="c4" decimals="0" id="ixv-29884" unitRef="eur">109391</ifrs-full:RevenueFromInterest>
    <ifrs-full:InterestExpense contextRef="c0" decimals="0" id="ixv-29885" unitRef="eur">16538</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c3" decimals="0" id="ixv-29886" unitRef="eur">23303</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c4" decimals="0" id="ixv-29887" unitRef="eur">10714</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c0" decimals="0" id="ixv-29888" unitRef="eur">19090</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c3" decimals="0" id="ixv-29889" unitRef="eur">21947</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c4" decimals="0" id="ixv-29890" unitRef="eur">14055</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:FinanceIncomeCost contextRef="c0" decimals="0" id="ixv-29891" unitRef="eur">3769199</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c3" decimals="0" id="ixv-29892" unitRef="eur">563429</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost contextRef="c4" decimals="0" id="ixv-29893" unitRef="eur">84622</ifrs-full:FinanceIncomeCost>
    <ifrx:ForeignExchangeIncome contextRef="c0" decimals="0" id="ixv-29894" unitRef="eur">5529389</ifrx:ForeignExchangeIncome>
    <ifrx:ForeignExchangeIncome contextRef="c3" decimals="0" id="ixv-29895" unitRef="eur">6924697</ifrx:ForeignExchangeIncome>
    <ifrx:ForeignExchangeIncome contextRef="c4" decimals="0" id="ixv-29896" unitRef="eur">5569836</ifrx:ForeignExchangeIncome>
    <ifrx:ForeignExchangeExpense contextRef="c0" decimals="0" id="ixv-29897" unitRef="eur">7371261</ifrx:ForeignExchangeExpense>
    <ifrx:ForeignExchangeExpense contextRef="c3" decimals="0" id="ixv-29898" unitRef="eur">4482399</ifrx:ForeignExchangeExpense>
    <ifrx:ForeignExchangeExpense contextRef="c4" decimals="0" id="ixv-29899" unitRef="eur">3605701</ifrx:ForeignExchangeExpense>
    <ifrx:ForeignExchangeResult contextRef="c0" decimals="0" id="ixv-29900" unitRef="eur">-1841872</ifrx:ForeignExchangeResult>
    <ifrx:ForeignExchangeResult contextRef="c3" decimals="0" id="ixv-29901" unitRef="eur">2442298</ifrx:ForeignExchangeResult>
    <ifrx:ForeignExchangeResult contextRef="c4" decimals="0" id="ixv-29902" unitRef="eur">1964135</ifrx:ForeignExchangeResult>
    <ifrx:OtherFinancialResult contextRef="c0" decimals="0" id="ixv-29903" unitRef="eur">313240</ifrx:OtherFinancialResult>
    <ifrx:OtherFinancialResult contextRef="c3" decimals="0" id="ixv-29904" unitRef="eur">-252471</ifrx:OtherFinancialResult>
    <ifrx:OtherFinancialResult contextRef="c4" decimals="0" id="ixv-29905" unitRef="eur">-44000</ifrx:OtherFinancialResult>
    <ifrx:NetFinancialResult contextRef="c0" decimals="0" id="ixv-29906" unitRef="eur">2240566</ifrx:NetFinancialResult>
    <ifrx:NetFinancialResult contextRef="c3" decimals="0" id="ixv-29907" unitRef="eur">2753256</ifrx:NetFinancialResult>
    <ifrx:NetFinancialResult contextRef="c4" decimals="0" id="ixv-29908" unitRef="eur">2004757</ifrx:NetFinancialResult>
    <ifrx:NetFinancialCost contextRef="c2" decimals="-5" id="ixv-29909" unitRef="eur">500000</ifrx:NetFinancialCost>
    <ifrs-full:InterestIncomeOnDeposits contextRef="c0" decimals="-5" id="ixv-29910" unitRef="eur">3200000</ifrs-full:InterestIncomeOnDeposits>
    <ifrx:ShortTermMarketableSecurities contextRef="c3" decimals="-5" id="ixv-29911" unitRef="eur">600000</ifrx:ShortTermMarketableSecurities>
    <ifrx:ShortTermMarketableSecurities contextRef="c0" decimals="-5" id="ixv-29912" unitRef="eur">3800000</ifrx:ShortTermMarketableSecurities>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c0" decimals="-5" id="ixv-29913" unitRef="eur">4300000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:ForeignExchangeGain contextRef="c3" decimals="-5" id="ixv-29914" unitRef="eur">2400000</ifrs-full:ForeignExchangeGain>
    <ifrs-full:ForeignExchangeLoss contextRef="c0" decimals="-5" id="ixv-29915" unitRef="eur">1800000</ifrs-full:ForeignExchangeLoss>
    <ifrs-full:OtherFinancialAssets contextRef="c67" decimals="-5" id="ixv-29916" unitRef="eur">600000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets contextRef="c3" decimals="-5" id="ixv-29917" unitRef="eur">300000</ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets contextRef="c0" decimals="-5" id="ixv-29918" unitRef="eur">300000</ifrs-full:IncreaseDecreaseInAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrx:WeightedNumberOfCommonSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-29919"
      unitRef="shares">54940137</ifrx:WeightedNumberOfCommonSharesOutstanding>
    <ifrx:WeightedNumberOfCommonSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-29920"
      unitRef="shares">44207873</ifrx:WeightedNumberOfCommonSharesOutstanding>
    <ifrx:WeightedNumberOfCommonSharesOutstanding
      contextRef="c37"
      decimals="0"
      id="ixv-29921"
      unitRef="shares">41629974</ifrx:WeightedNumberOfCommonSharesOutstanding>
    <ifrx:LossPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-29922"
      unitRef="eurPershares">0.78</ifrx:LossPerShare>
    <ifrx:LossPerShare
      contextRef="c3"
      decimals="2"
      id="ixv-29923"
      unitRef="eurPershares">0.67</ifrx:LossPerShare>
    <ifrx:LossPerShare
      contextRef="c4"
      decimals="2"
      id="ixv-29924"
      unitRef="eurPershares">1.1</ifrx:LossPerShare>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0" id="ixv-24869">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the course of its historical financing rounds prior to 2016, InflaRx GmbH established equity-settled share-based payment programs. Those
InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. in November 2017:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Outstanding at January 1&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Outstanding at December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercisable at December 31&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted
average share price (WAEP)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c122"
      decimals="0"
      id="ixv-29925"
      unitRef="pure">148433</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c123"
      decimals="2"
      id="ix_0_fact"
      unitRef="pure">0.01</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c124"
      decimals="0"
      id="ixv-29927"
      unitRef="pure">148433</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c125"
      decimals="2"
      id="ix_1_fact"
      unitRef="pure">0.01</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c130"
      decimals="0"
      id="ixv-29929"
      unitRef="pure">148433</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c131"
      decimals="2"
      id="ix_2_fact"
      unitRef="pure">0.01</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c122"
      decimals="0"
      id="ixv-29931"
      unitRef="pure">148433</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c123"
      decimals="2"
      id="ix_3_fact"
      unitRef="pure">0.01</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c130"
      decimals="0"
      id="ixv-29933"
      unitRef="usdPershares">148433</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c131"
      decimals="2"
      id="ix_4_fact"
      unitRef="eurPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c122"
      decimals="0"
      id="ixv-29935"
      unitRef="usdPershares">148433</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c123"
      decimals="2"
      id="ix_5_fact"
      unitRef="eurPershares">0.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrx:ExercisePriceOfOutstandingShareOptions
      contextRef="c0"
      decimals="2"
      id="ixv-29937"
      unitRef="eurPershares">0.01</ifrx:ExercisePriceOfOutstandingShareOptions>
    <ifrx:ExercisePriceOfOutstandingShareOptions
      contextRef="c3"
      decimals="2"
      id="ixv-29938"
      unitRef="eurPershares">0.01</ifrx:ExercisePriceOfOutstandingShareOptions>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c132" id="ixv-29939">Those InflaRx GmbH options were converted into
options for ordinary shares of the Company in November 2017:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Outstanding at January 1&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.35/&#x20ac;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80; -sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Outstanding at December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercisable at December 31&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.68&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86/&#x20ac;1.74&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversion
rates used for one &#x20ac;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31,2022 $0.9376, average rate 2022 $0.9489&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding
      contextRef="c133"
      decimals="0"
      id="ixv-29940"
      unitRef="shares">888632</ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c134"
      decimals="2"
      id="ix_6_fact"
      unitRef="usdPershares">1.86</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c134"
      decimals="2"
      id="ix_7_fact"
      unitRef="eurPershares">1.74</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding
      contextRef="c135"
      decimals="0"
      id="ixv-29943"
      unitRef="shares">888632</ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c136"
      decimals="2"
      id="ix_8_fact"
      unitRef="usdPershares">3.35</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c136"
      decimals="2"
      id="ix_9_fact"
      unitRef="eurPershares">2.96</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding
      contextRef="c141"
      decimals="0"
      id="ixv-29946"
      unitRef="shares">888632</ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c142"
      decimals="2"
      id="ix_10_fact"
      unitRef="usdPershares">1.86</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c142"
      decimals="2"
      id="ix_11_fact"
      unitRef="eurPershares">1.68</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding
      contextRef="c133"
      decimals="0"
      id="ixv-29949"
      unitRef="shares">888632</ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c134"
      decimals="2"
      id="ix_12_fact"
      unitRef="usdPershares">1.86</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:NumberOfWeightedAverageSharesOutstanding
      contextRef="c134"
      decimals="2"
      id="ix_13_fact"
      unitRef="eurPershares">1.74</ifrx:NumberOfWeightedAverageSharesOutstanding>
    <ifrx:NumberOfSharesOptionsExercisable
      contextRef="c141"
      decimals="0"
      id="ixv-29952"
      unitRef="shares">888632</ifrx:NumberOfSharesOptionsExercisable>
    <ifrx:WAEPExercisables
      contextRef="c138"
      decimals="2"
      id="ix_14_fact"
      unitRef="usdPershares">1.86</ifrx:WAEPExercisables>
    <ifrx:WAEPExercisables
      contextRef="c138"
      decimals="2"
      id="ix_15_fact"
      unitRef="eurPershares">1.68</ifrx:WAEPExercisables>
    <ifrx:NumberOfSharesOptionsExercisable
      contextRef="c133"
      decimals="0"
      id="ixv-29955"
      unitRef="shares">888632</ifrx:NumberOfSharesOptionsExercisable>
    <ifrx:WAEPExercisables
      contextRef="c140"
      decimals="2"
      id="ix_16_fact"
      unitRef="usdPershares">1.86</ifrx:WAEPExercisables>
    <ifrx:WAEPExercisables
      contextRef="c140"
      decimals="2"
      id="ix_17_fact"
      unitRef="eurPershares">1.74</ifrx:WAEPExercisables>
    <ifrx:ConversionRate
      contextRef="c68"
      decimals="4"
      id="ixv-29958"
      unitRef="eurPershares">0.905</ifrx:ConversionRate>
    <ifrx:AverageRate
      contextRef="c68"
      decimals="4"
      id="ixv-29959"
      unitRef="eurPershares">0.9246</ifrx:AverageRate>
    <ifrx:ConversionRate
      contextRef="c69"
      decimals="4"
      id="ixv-29960"
      unitRef="eurPershares">0.9376</ifrx:ConversionRate>
    <ifrx:AverageRate
      contextRef="c69"
      decimals="4"
      id="ixv-29961"
      unitRef="eurPershares">0.9489</ifrx:AverageRate>
    <ifrx:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="c69" id="ixv-29962">P2016Y</ifrx:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c70" id="ixv-29963">P7Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c71" id="ixv-29964">P8Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c143" id="ixv-25124">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the closing of its initial public offering, InflaRx N.V. established a new incentive plan (the &#x201c;2017 Plan&#x201d;).
The initial maximum number of ordinary shares available for issuance under equity incentive awards granted pursuant to the 2017 Plan
equals 2,341,097 ordinary shares. On January 1, 2021 and on January 1 of each calendar year thereafter, an additional number of shares
equal to 4% of the total outstanding ordinary shares on December 31 of the immediately preceding year (or any lower number of shares
as determined by the Board of Directors) will become available for issuance under equity incentive awards granted pursuant to the 2017
Plan:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022 &lt;br/&gt;WAEP*&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold"&gt;Outstanding at January 1&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;4,985,523&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.97 /&#x20ac;1.84&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-weight: bold; text-align: right"&gt;3,170,046&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$3.95 /&#x20ac;3.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,735,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.58/&#x20ac;2.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,966,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.98 / &#x20ac;1.88&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(31,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.70/&#x20ac;2.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(136,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.22 /&#x20ac;2.11&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Exercised during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(105,327&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.16/&#x20ac;2.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,930&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.86 /&#x20ac;1.76&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Outstanding at December 31&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6,584,946&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.12/&#x20ac;1.92&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4,985,523&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.97 /&#x20ac;1.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Exercisable at December 31&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,577,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$2.01/&#x20ac;1.82&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,157,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.93 /&#x20ac;1.81&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Conversion
rates used for one &#x20ac;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31, 2022 $0.9376, average rate 2022 $0.9489&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrx:MaximumNumberOfCommonSharesAvailableForGrant
      contextRef="c68"
      decimals="0"
      id="ixv-29965"
      unitRef="shares">2341097</ifrx:MaximumNumberOfCommonSharesAvailableForGrant>
    <ifrx:ordinarySharesPercentage contextRef="c68" decimals="2" id="ixv-29966" unitRef="pure">0.04</ifrx:ordinarySharesPercentage>
    <ifrx:NumberOfOutstandingSharesOption
      contextRef="c144"
      decimals="INF"
      id="ixv-29967"
      unitRef="shares">4985523</ifrx:NumberOfOutstandingSharesOption>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c145"
      decimals="2"
      id="ix_18_fact"
      unitRef="usdPershares">1.97</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c146"
      decimals="2"
      id="ix_19_fact"
      unitRef="eurPershares">1.84</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOutstandingSharesOption
      contextRef="c147"
      decimals="INF"
      id="ixv-29970"
      unitRef="shares">3170046</ifrx:NumberOfOutstandingSharesOption>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c148"
      decimals="2"
      id="ix_20_fact"
      unitRef="usdPershares">3.95</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c149"
      decimals="2"
      id="ix_21_fact"
      unitRef="eurPershares">3.49</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfShareOptionGrantedInSharebasedPaymentArrangement
      contextRef="c150"
      decimals="INF"
      id="ixv-29973"
      unitRef="shares">1735750</ifrx:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement
      contextRef="c151"
      decimals="2"
      id="ix_22_fact"
      unitRef="usdPershares">2.58</ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement
      contextRef="c152"
      decimals="2"
      id="ix_23_fact"
      unitRef="eurPershares">2.39</ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement>
    <ifrx:NumberOfShareOptionGrantedInSharebasedPaymentArrangement
      contextRef="c153"
      decimals="INF"
      id="ixv-29976"
      unitRef="shares">1966666</ifrx:NumberOfShareOptionGrantedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement
      contextRef="c154"
      decimals="2"
      id="ix_24_fact"
      unitRef="usdPershares">1.98</ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement
      contextRef="c155"
      decimals="2"
      id="ix_25_fact"
      unitRef="eurPershares">1.88</ifrx:NumberOfWeightedAverageEarningPershareGrantedInSharebasedPaymentArrangement>
    <ifrx:NumberOfShareOptionExercisedInSharebasedPaymentArrangement
      contextRef="c150"
      decimals="INF"
      id="ixv-29979"
      unitRef="shares">-31000</ifrx:NumberOfShareOptionExercisedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement
      contextRef="c151"
      decimals="2"
      id="ix_26_fact"
      unitRef="usdPershares">2.7</ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement
      contextRef="c152"
      decimals="2"
      id="ix_27_fact"
      unitRef="eurPershares">2.5</ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement>
    <ifrx:NumberOfShareOptionExercisedInSharebasedPaymentArrangement
      contextRef="c153"
      decimals="INF"
      id="ixv-29982"
      unitRef="shares">-136259</ifrx:NumberOfShareOptionExercisedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement
      contextRef="c154"
      decimals="2"
      id="ix_28_fact"
      unitRef="usdPershares">2.22</ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement
      contextRef="c155"
      decimals="2"
      id="ix_29_fact"
      unitRef="eurPershares">2.11</ifrx:NumberOfWeightedAverageEarningPershareExercisedInSharebasedPaymentArrangement>
    <ifrx:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement
      contextRef="c150"
      decimals="INF"
      id="ixv-29985"
      unitRef="shares">-105327</ifrx:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement
      contextRef="c151"
      decimals="2"
      id="ix_30_fact"
      unitRef="usdPershares">2.16</ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement
      contextRef="c152"
      decimals="2"
      id="ix_31_fact"
      unitRef="eurPershares">2</ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement>
    <ifrx:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement
      contextRef="c153"
      decimals="INF"
      id="ixv-29988"
      unitRef="shares">-14930</ifrx:NumberOfShareOptionForfeitedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement
      contextRef="c154"
      decimals="2"
      id="ix_32_fact"
      unitRef="usdPershares">1.86</ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement
      contextRef="c155"
      decimals="2"
      id="ix_33_fact"
      unitRef="eurPershares">1.76</ifrx:NumberOfWeightedAverageEarningPershareForfeitedInSharebasedPaymentArrangement>
    <ifrx:NumberOfOutstandingSharesOption
      contextRef="c156"
      decimals="INF"
      id="ixv-29991"
      unitRef="shares">6584946</ifrx:NumberOfOutstandingSharesOption>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c157"
      decimals="2"
      id="ix_34_fact"
      unitRef="usdPershares">2.12</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c158"
      decimals="2"
      id="ix_35_fact"
      unitRef="eurPershares">1.92</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOutstandingSharesOption
      contextRef="c144"
      decimals="INF"
      id="ixv-29994"
      unitRef="shares">4985523</ifrx:NumberOfOutstandingSharesOption>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c145"
      decimals="2"
      id="ix_36_fact"
      unitRef="usdPershares">1.97</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOutstandingsWeightedAverageEarningPershare
      contextRef="c146"
      decimals="2"
      id="ix_37_fact"
      unitRef="eurPershares">1.84</ifrx:NumberOfOutstandingsWeightedAverageEarningPershare>
    <ifrx:NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement
      contextRef="c150"
      decimals="INF"
      id="ixv-29997"
      unitRef="shares">5577384</ifrx:NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement
      contextRef="c151"
      decimals="2"
      id="ix_38_fact"
      unitRef="usdPershares">2.01</ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement
      contextRef="c152"
      decimals="2"
      id="ix_39_fact"
      unitRef="eurPershares">1.82</ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement>
    <ifrx:NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement
      contextRef="c153"
      decimals="INF"
      id="ixv-30000"
      unitRef="shares">4157148</ifrx:NumberOfOtherEquityInstrumentExercisableInSharebasedPaymentsArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement
      contextRef="c154"
      decimals="2"
      id="ix_40_fact"
      unitRef="usdPershares">1.93</ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement>
    <ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement
      contextRef="c155"
      decimals="2"
      id="ix_41_fact"
      unitRef="eurPershares">1.81</ifrx:NumberOfWeightedAverageEarningPershareExercisableInSharebasedPaymentsArrangement>
    <ifrx:ConversionRate
      contextRef="c50"
      decimals="4"
      id="ixv-30003"
      unitRef="usdPershares">0.905</ifrx:ConversionRate>
    <ifrx:AverageRate
      contextRef="c50"
      decimals="4"
      id="ixv-30004"
      unitRef="usdPershares">0.9246</ifrx:AverageRate>
    <ifrx:ConversionRate
      contextRef="c51"
      decimals="4"
      id="ixv-30005"
      unitRef="usdPershares">0.9376</ifrx:ConversionRate>
    <ifrx:AverageRate
      contextRef="c51"
      decimals="4"
      id="ixv-30006"
      unitRef="usdPershares">0.9489</ifrx:AverageRate>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c68" id="ixv-30007">P6Y7M9D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c69" id="ixv-30008">P6Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrx:WeightedAverageFairValueOptionsGrantedDuringTheYear
      contextRef="c0"
      decimals="2"
      id="ixv-30009"
      unitRef="usdPershares">2.58</ifrx:WeightedAverageFairValueOptionsGrantedDuringTheYear>
    <ifrx:WeightedAverageFairValueOptionsGrantedDuringTheYear
      contextRef="c0"
      decimals="2"
      id="ixv-30010"
      unitRef="eurPershares">2.39</ifrx:WeightedAverageFairValueOptionsGrantedDuringTheYear>
    <ifrx:WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd
      contextRef="c3"
      decimals="2"
      id="ixv-30011"
      unitRef="usdPershares">1.7</ifrx:WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd>
    <ifrx:WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd
      contextRef="c3"
      decimals="2"
      id="ixv-30012"
      unitRef="eurPershares">1.61</ifrx:WeightedAverageFairValueeOptionsGrantedDuringTheYearUsd>
    <ifrx:ExercisePriceRange
      contextRef="c57"
      decimals="2"
      id="ixv-30013"
      unitRef="usdPershares">1.86</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c57"
      decimals="2"
      id="ixv-30014"
      unitRef="eurPershares">1.74</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c58"
      decimals="2"
      id="ixv-30015"
      unitRef="usdPershares">5.14</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c58"
      decimals="2"
      id="ixv-30016"
      unitRef="eurPershares">4.82</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c72"
      decimals="2"
      id="ixv-30017"
      unitRef="usdPershares">1.86</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c72"
      decimals="2"
      id="ixv-30018"
      unitRef="eurPershares">1.74</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c73"
      decimals="2"
      id="ixv-30019"
      unitRef="usdPershares">5.14</ifrx:ExercisePriceRange>
    <ifrx:ExercisePriceRange
      contextRef="c73"
      decimals="2"
      id="ixv-30020"
      unitRef="eurPershares">4.82</ifrx:ExercisePriceRange>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c0" id="ixv-25306">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
significant inputs into the model are as follows (weighted average):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Share options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;FX rate as&lt;br/&gt;
 of grant&lt;br/&gt;
 date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price&lt;br/&gt;
 at grant&lt;br/&gt;
 date/&lt;br/&gt;
 Exercise&lt;br/&gt;
 price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
 volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Expected life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(midpoint&lt;br/&gt;
 based)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk-free&lt;br/&gt;
 rate&lt;br/&gt;
 (interpolated,&lt;br/&gt;
 U.S.&lt;br/&gt;
 sovereign&lt;br/&gt;
 strips curve)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 31.5%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;839,260&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4.53&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.8133&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.68&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,668&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.57&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;327,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8458&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.98&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 2&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,710&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.66&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8458&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.25&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.99&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.49&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,219,074&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;Share options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value per share option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;FX rate as of grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value per share option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share price at grant date/ Exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected life (midpoint based)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk-free rate (interpolated, U.S. sovereign strips curve)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 9%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January&#160;12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,516,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.8795&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#x20ac;3.22&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.57%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January&#160;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8795&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x20ac;3.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.59%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Repricing,&#160;April&#160;13&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$1.20-$1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9237&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x20ac;1.11-&#x20ac;1.50&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.86&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.83-4.94&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2.60%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;November&#160;21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;405,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x20ac;1.99&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4.15%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;b&gt;1,966,666&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Share options granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;FX rate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;as of&lt;br/&gt;
 grant&lt;br/&gt;
 date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value&lt;br/&gt;
 per share&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Share&lt;br/&gt;
 price at&lt;br/&gt;
 grant&lt;br/&gt;
 date/&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt;
 price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Expected&lt;br/&gt;
 volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Expected&lt;br/&gt;
 life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(midpoint based)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Risk-free&lt;br/&gt;
 rate&lt;br/&gt;
 (interpolated,&lt;br/&gt;
 U.S.&lt;br/&gt;
 sovereign&lt;br/&gt;
 strips curve)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; font-weight: bold"&gt;2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 31.5%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,454,250&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2.11&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1.90&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;5.30&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 0.5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3.571&lt;/td&gt;&lt;td style="width: 0.5%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;January 24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.565&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 31&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;60,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.61&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9361&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.820&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;57,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.320&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.64&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.34&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.89&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.286&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 19&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.8911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.320&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;September 18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;3.15&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;0.9378&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.95&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;3.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;1.46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;4.320&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,735,750&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c159"
      decimals="0"
      id="ixv-30021"
      unitRef="shares">839260</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c159"
      decimals="2"
      id="ixv-30022"
      unitRef="usdPershares">4.53</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c159"
      decimals="4"
      id="ixv-30023"
      unitRef="usdPershares">0.8133</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c159"
      decimals="2"
      id="ixv-30024"
      unitRef="eurPershares">3.68</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c160"
      decimals="2"
      id="ixv-30025"
      unitRef="usdPershares">5.14</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c159"
      decimals="4"
      id="ixv-30026"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c159" id="ixv-30027">P5Y3M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c159"
      decimals="3"
      id="ixv-30028"
      unitRef="pure">0.005</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c161"
      decimals="0"
      id="ixv-30029"
      unitRef="shares">31668</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c161"
      decimals="2"
      id="ixv-30030"
      unitRef="usdPershares">4.57</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c161"
      decimals="4"
      id="ixv-30031"
      unitRef="usdPershares">0.8133</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c161"
      decimals="2"
      id="ixv-30032"
      unitRef="eurPershares">3.72</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c162"
      decimals="2"
      id="ixv-30033"
      unitRef="usdPershares">5.14</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c161"
      decimals="4"
      id="ixv-30034"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c161" id="ixv-30035">P5Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c161"
      decimals="3"
      id="ixv-30036"
      unitRef="pure">0.005</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c163"
      decimals="0"
      id="ixv-30037"
      unitRef="shares">327436</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c163"
      decimals="2"
      id="ixv-30038"
      unitRef="usdPershares">2.64</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c163"
      decimals="4"
      id="ixv-30039"
      unitRef="usdPershares">0.8458</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c163"
      decimals="2"
      id="ixv-30040"
      unitRef="eurPershares">2.23</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c164"
      decimals="2"
      id="ixv-30041"
      unitRef="usdPershares">2.99</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c163"
      decimals="4"
      id="ixv-30042"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c163" id="ixv-30043">P5Y3M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c163"
      decimals="4"
      id="ixv-30044"
      unitRef="pure">0.0098</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c165"
      decimals="0"
      id="ixv-30045"
      unitRef="shares">20710</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c165"
      decimals="2"
      id="ixv-30046"
      unitRef="usdPershares">2.66</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c165"
      decimals="4"
      id="ixv-30047"
      unitRef="usdPershares">0.8458</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c165"
      decimals="2"
      id="ixv-30048"
      unitRef="eurPershares">2.25</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c166"
      decimals="2"
      id="ixv-30049"
      unitRef="usdPershares">2.99</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c165"
      decimals="4"
      id="ixv-30050"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c165" id="ixv-30051">P5Y5M26D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c165"
      decimals="4"
      id="ixv-30052"
      unitRef="pure">0.0101</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c4"
      decimals="0"
      id="ixv-30053"
      unitRef="shares">1219074</ifrx:ShareOptionsGrantedOptions>
    <ifrx:OptionsGranted
      contextRef="c4"
      decimals="0"
      id="ixv-30054"
      unitRef="shares">1219074</ifrx:OptionsGranted>
    <ifrx:OptionsGranted
      contextRef="c74"
      decimals="0"
      id="ixv-30055"
      unitRef="shares">1134436</ifrx:OptionsGranted>
    <ifrx:NumberOfStockOptionsForfeited
      contextRef="c4"
      decimals="0"
      id="ixv-30056"
      unitRef="shares">36400</ifrx:NumberOfStockOptionsForfeited>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c167"
      decimals="0"
      id="ixv-30057"
      unitRef="shares">1516666</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c167"
      decimals="2"
      id="ixv-30058"
      unitRef="usdPershares">3.66</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c167"
      decimals="4"
      id="ixv-30059"
      unitRef="usdPershares">0.8795</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c167"
      decimals="2"
      id="ixv-30060"
      unitRef="eurPershares">3.22</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c168"
      decimals="2"
      id="ixv-30061"
      unitRef="usdPershares">4.13</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c167"
      decimals="4"
      id="ixv-30062"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c167" id="ixv-30063">P5Y3M21D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c167"
      decimals="4"
      id="ixv-30064"
      unitRef="pure">0.0157</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c169"
      decimals="0"
      id="ixv-30065"
      unitRef="shares">45000</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c169"
      decimals="2"
      id="ixv-30066"
      unitRef="usdPershares">3.68</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c169"
      decimals="4"
      id="ixv-30067"
      unitRef="usdPershares">0.8795</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c169"
      decimals="2"
      id="ixv-30068"
      unitRef="eurPershares">3.24</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c170"
      decimals="2"
      id="ixv-30069"
      unitRef="usdPershares">4.13</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c169"
      decimals="4"
      id="ixv-30070"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c169" id="ixv-30071">P5Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c169"
      decimals="4"
      id="ixv-30072"
      unitRef="pure">0.0159</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:FairValuePerOptions
      contextRef="c172"
      decimals="2"
      id="ixv-30073"
      unitRef="usdPershares">1.2</ifrx:FairValuePerOptions>
    <ifrx:FairValuePerOptions
      contextRef="c173"
      decimals="2"
      id="ixv-30074"
      unitRef="usdPershares">1.63</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c171"
      decimals="4"
      id="ixv-30075"
      unitRef="usdPershares">0.9237</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c172"
      decimals="2"
      id="ixv-30076"
      unitRef="eurPershares">1.11</ifrx:FairValuesPerOptions>
    <ifrx:FairValuesPerOptions
      contextRef="c173"
      decimals="2"
      id="ixv-30077"
      unitRef="eurPershares">1.5</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c172"
      decimals="2"
      id="ixv-30078"
      unitRef="usdPershares">1.86</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c171"
      decimals="4"
      id="ixv-30079"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c172" id="ixv-30080">P1Y9M29D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c173" id="ixv-30081">P4Y11M8D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c171"
      decimals="4"
      id="ixv-30082"
      unitRef="pure">0.026</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c174"
      decimals="0"
      id="ixv-30083"
      unitRef="shares">405000</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c174"
      decimals="2"
      id="ixv-30084"
      unitRef="usdPershares">2.04</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c174"
      decimals="4"
      id="ixv-30085"
      unitRef="usdPershares">0.976</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c174"
      decimals="2"
      id="ixv-30086"
      unitRef="eurPershares">1.99</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c175"
      decimals="2"
      id="ixv-30087"
      unitRef="usdPershares">2.44</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c174"
      decimals="4"
      id="ixv-30088"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c174" id="ixv-30089">P4Y</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c174"
      decimals="4"
      id="ixv-30090"
      unitRef="pure">0.0415</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c3"
      decimals="0"
      id="ixv-30091"
      unitRef="shares">1966666</ifrx:ShareOptionsGrantedOptions>
    <ifrx:OptionsGranted
      contextRef="c3"
      decimals="0"
      id="ixv-30092"
      unitRef="shares">1966666</ifrx:OptionsGranted>
    <ifrx:OptionsGranted
      contextRef="c75"
      decimals="0"
      id="ixv-30093"
      unitRef="shares">1223500</ifrx:OptionsGranted>
    <ifrx:NumberOfStockOptionsForfeited
      contextRef="c75"
      decimals="0"
      id="ixv-30094"
      unitRef="shares">136259</ifrx:NumberOfStockOptionsForfeited>
    <ifrx:NumberOfOptionsExercised
      contextRef="c3"
      decimals="0"
      id="ixv-30095"
      unitRef="shares">14930</ifrx:NumberOfOptionsExercised>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c176"
      decimals="0"
      id="ixv-30096"
      unitRef="shares">1454250</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c176"
      decimals="2"
      id="ixv-30097"
      unitRef="usdPershares">2.11</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c176"
      decimals="4"
      id="ixv-30098"
      unitRef="usdPershares">0.9008</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c176"
      decimals="2"
      id="ixv-30099"
      unitRef="eurPershares">1.9</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c177"
      decimals="2"
      id="ixv-30100"
      unitRef="usdPershares">2.37</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c176"
      decimals="4"
      id="ixv-30101"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c176" id="ixv-30102">P5Y3M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c176"
      decimals="5"
      id="ixv-30103"
      unitRef="pure">0.03571</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c178"
      decimals="0"
      id="ixv-30104"
      unitRef="shares">52500</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c178"
      decimals="2"
      id="ixv-30105"
      unitRef="usdPershares">2.13</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c178"
      decimals="4"
      id="ixv-30106"
      unitRef="usdPershares">0.9008</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c178"
      decimals="2"
      id="ixv-30107"
      unitRef="eurPershares">1.92</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c179"
      decimals="2"
      id="ixv-30108"
      unitRef="usdPershares">2.37</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c178"
      decimals="4"
      id="ixv-30109"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c178" id="ixv-30110">P5Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c178"
      decimals="5"
      id="ixv-30111"
      unitRef="pure">0.03565</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c180"
      decimals="0"
      id="ixv-30112"
      unitRef="shares">60500</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c180"
      decimals="2"
      id="ixv-30113"
      unitRef="usdPershares">3.61</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c180"
      decimals="4"
      id="ixv-30114"
      unitRef="usdPershares">0.9361</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c180"
      decimals="2"
      id="ixv-30115"
      unitRef="eurPershares">3.38</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c181"
      decimals="2"
      id="ixv-30116"
      unitRef="usdPershares">4.19</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c180"
      decimals="4"
      id="ixv-30117"
      unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c180" id="ixv-30118">P4Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c180"
      decimals="5"
      id="ixv-30119"
      unitRef="pure">0.0382</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c182"
      decimals="0"
      id="ixv-30120"
      unitRef="shares">57000</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c182"
      decimals="2"
      id="ixv-30121"
      unitRef="usdPershares">3.59</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c182"
      decimals="4"
      id="ixv-30122"
      unitRef="usdPershares">0.9184</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c182"
      decimals="2"
      id="ixv-30123"
      unitRef="eurPershares">3.3</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c183"
      decimals="2"
      id="ixv-30124"
      unitRef="usdPershares">3.89</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c182"
      decimals="4"
      id="ixv-30125"
      unitRef="pure">0.0146</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c182" id="ixv-30126">P5Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c182"
      decimals="5"
      id="ixv-30127"
      unitRef="pure">0.0432</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c184"
      decimals="0"
      id="ixv-30128"
      unitRef="shares">100000</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c184"
      decimals="2"
      id="ixv-30129"
      unitRef="usdPershares">3.64</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c184"
      decimals="4"
      id="ixv-30130"
      unitRef="usdPershares">0.9184</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c184"
      decimals="2"
      id="ixv-30131"
      unitRef="eurPershares">3.34</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c185"
      decimals="2"
      id="ixv-30132"
      unitRef="usdPershares">3.89</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c184"
      decimals="4"
      id="ixv-30133"
      unitRef="pure">0.0146</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c184" id="ixv-30134">P6Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c184"
      decimals="5"
      id="ixv-30135"
      unitRef="pure">0.04286</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c186"
      decimals="0"
      id="ixv-30136"
      unitRef="shares">4000</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c186"
      decimals="2"
      id="ixv-30137"
      unitRef="usdPershares">3.55</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c186"
      decimals="4"
      id="ixv-30138"
      unitRef="usdPershares">0.8911</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c186"
      decimals="2"
      id="ixv-30139"
      unitRef="eurPershares">3.16</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c187"
      decimals="2"
      id="ixv-30140"
      unitRef="usdPershares">3.99</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c186"
      decimals="4"
      id="ixv-30141"
      unitRef="pure">0.0146</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c186" id="ixv-30142">P5Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c186"
      decimals="5"
      id="ixv-30143"
      unitRef="pure">0.0432</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c188"
      decimals="0"
      id="ixv-30144"
      unitRef="shares">7500</ifrx:ShareOptionsGrantedOptions>
    <ifrx:FairValuePerOptions
      contextRef="c188"
      decimals="2"
      id="ixv-30145"
      unitRef="usdPershares">3.15</ifrx:FairValuePerOptions>
    <ifrx:ForeignExchangeRateAsOfGrantDate
      contextRef="c188"
      decimals="4"
      id="ixv-30146"
      unitRef="usdPershares">0.9378</ifrx:ForeignExchangeRateAsOfGrantDate>
    <ifrx:FairValuesPerOptions
      contextRef="c188"
      decimals="2"
      id="ixv-30147"
      unitRef="eurPershares">2.95</ifrx:FairValuesPerOptions>
    <ifrx:SharePriceAtGrantDateExercisePrices
      contextRef="c189"
      decimals="2"
      id="ixv-30148"
      unitRef="usdPershares">3.54</ifrx:SharePriceAtGrantDateExercisePrices>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="c188"
      decimals="4"
      id="ixv-30149"
      unitRef="pure">0.0146</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c188" id="ixv-30150">P5Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="c188"
      decimals="5"
      id="ixv-30151"
      unitRef="pure">0.0432</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c0"
      decimals="0"
      id="ixv-30152"
      unitRef="shares">1735750</ifrx:ShareOptionsGrantedOptions>
    <ifrx:OptionsGranted
      contextRef="c0"
      decimals="0"
      id="ixv-30153"
      unitRef="shares">1735750</ifrx:OptionsGranted>
    <ifrx:OptionsGranted
      contextRef="c76"
      decimals="0"
      id="ixv-30154"
      unitRef="shares">1136000</ifrx:OptionsGranted>
    <ifrx:NumberOfStockOptionsForfeited
      contextRef="c0"
      decimals="0"
      id="ixv-30155"
      unitRef="shares">31000</ifrx:NumberOfStockOptionsForfeited>
    <ifrx:NumberOfOptionsExercised
      contextRef="c0"
      decimals="0"
      id="ixv-30156"
      unitRef="shares">105327</ifrx:NumberOfOptionsExercised>
    <ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory contextRef="c0" id="ixv-26284">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;D. Notes to the consolidated statements of financial position&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;1. Property and equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Property&lt;br/&gt;
 and&lt;br/&gt;
 equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Advance &lt;br/&gt;payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;1,267,611&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;1,267,611&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,453,339&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,453,339&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right"&gt;(2,595&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right"&gt;(2,595&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,491,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,491,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(993,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(993,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(113,894&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(113,894&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,124,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,124,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,201,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,201,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Net book value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;328,920&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;328,920&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;289,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;289,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2. Right-of-use assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Buildings&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Cars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; font-weight: bold"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;2,284,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;125,130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;2,409,399&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,579,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;125,130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,704,473&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,661,118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;174,134&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,835,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(925,306&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(76,015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,001,321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(354,408&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,024&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(384,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,286,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(106,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,392,664&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(353,398&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24,527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(377,925&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,633,020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(130,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,763,586&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,292,717&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;19,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,311,809&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,028,098&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;43,568&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,071,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;3. Intangible Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Purchased&lt;br/&gt;
 IT-software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Advances&lt;br/&gt;
 paid for&lt;br/&gt;
 software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; font-weight: bold"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;720,942&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;720,942&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;723,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;723,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;716,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;742,107&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(485,726&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(485,726&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Amortization charge for the year*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98,271&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98,271&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(584,345&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(584,345&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,063&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,063&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(673,289&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(673,289&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;138,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;138,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;42,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;68,818&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
of intangible assets is included in the line items &#x2018;research and development expenses&#x2019; (2023: &#x20ac;858, 2022: &#x20ac;858,
2021: &#x20ac;10,192) and &#x2018;general and administrative expenses&#x2019; (2023: &#x20ac;95,205, 2022: &#x20ac;97,413, 2021: &#x20ac;105,790)
in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;4. Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
obligations consist of payments pursuant to non-cancellable lease agreements mainly relating to the Company&#x2019;s leases of office
space. The lease terms of the Company&#x2019;s premises expire as follows: Jena, Germany in December 2025, Martinsried, Germany in May
2027 and Ann Arbor, Michigan, United States in April 2026.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below, are the carrying amounts and the movements of the Group&#x2019;s lease liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;As of January 1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,356,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,432,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Derecognition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(353,422&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(343,874&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term liability for accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(396&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign exchange difference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,120,048&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,356,684&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the amounts recognized in profit or loss:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Depreciation expense of right-of-use assets (see Note E.2.)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;377,925&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;384,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;371,551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,947&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rental expense from leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;Thereof short-term leases (included in administrative expenses)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Thereof leases of low-value assets (included in administrative expenses)&lt;/td&gt;&lt;td style="font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total amounts recognized in profit or loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;403,276&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;412,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;391,867&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group had total cash outflows for leases of &#x20ac;0.4 million in 2023 (&#x20ac;0.4 million in 2022, &#x20ac;0.4&#160;million in 2021).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;5. Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Raw material and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;423,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Unfinished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,614,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;330,087&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,367,807&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s inventory consists of materials relating to GOHIBIC (vilobelimab) primarily manufactured following the EUA for the US
market at the beginning of April 2023 (refer to Note A.2.) In the year ended December 31, 2023, inventory write-downs of &#x20ac;0.5 million
were recognized due to the expected expiry of the shelf-life, prior to sale, of the related inventories and are included in cost of sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Other assets&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160; 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;br/&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;257,267&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;257,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepayments on research &amp;amp; development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,670,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,776,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,841,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,482&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,036,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;14,170,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total other assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,293,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,478,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Prepayments on research &amp;amp; development projects
consists of prepayments on CRO and manufacturing contracts. Prepaid expenses mainly consist of prepaid insurance expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;7.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Income tax Income tax reconciliation&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The table below shows a reconciliation between
the product of loss before tax multiplied by the Company&#x2019;s applicable tax rate and current income taxes recognized in profit or
loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;InflaRx Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Loss for the period (accounting profit before income tax)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(42,667,529&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(29,484,611&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(45,630,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax benefits at tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,160,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,610,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,001,984&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Temporary differences and tax losses for which no deferred tax asset was recognized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,127,977&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,480,169&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,988,805&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Non-recognition of tax effect on share-based payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32,182&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,251,830&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,959,606&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Non-deductible expenses for tax purposes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(46,907&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,067&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Other differences due to tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143,686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(49,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Income tax&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The tax rate applied above represents the weighted
average of the statutory tax rates in Germany and the United States. In Germany, InflaRx N.V. and its subsidiary InflaRx GmbH are subject
to corporate income tax (2023/2022/2021: 15%), a solidarity surcharge (2023/2022/2021: 0.8%) and trade taxes (2023: 13.065%; 2022: 13.7%;
2021: 12.8%). This equals an average total tax rate of 28.99 % in 2023 (2022: 29.5%; 2021: 28.6%). InflaRx Pharmaceuticals, Inc., Ann
Arbor, Michigan, United States is subject to an average total tax rate of 25.74% in 2023 (2022 25.74%; 2021: 25.74%), which is made up
of U.S. federal tax (2023, 2022, 2021: 21%) and state tax of 4.74% in 2023 (2022 and 2021: 4.74%).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;a)&lt;/td&gt;&lt;td&gt;Tax losses carried forward&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group has total tax loss carryforwards of
&#x20ac;243.8 million (2022: &#x20ac;211.3 million) from three areas that cannot be utilized outside these areas:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2023 the Group had &#x20ac;196 million
(2022: &#x20ac;163.4 million) for corporate income purposes and &#x20ac;164 million (2022: &#x20ac;131.6 million) for trade tax purposes of
unrecognized and unused tax losses carried forward attributable to the tax group formed by InflaRx N.V. since 2018; these tax losses do
not expire and may not be used to offset taxable income elsewhere in the Group. Since January 1, 2018, InflaRx GmbH has distributed its
losses to the parent Company InflaRx N.V. under a profit and loss transfer agreement. This tax group was formed in Germany and is subject
to German tax legislation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&#x25cf;&lt;/td&gt;&lt;td style="text-align: left"&gt;Tax losses of InflaRx GmbH until December 31, 2017 (&#x20ac;34.8
million) are frozen from 2018 onwards due to the creation of a tax group with InflaRx N.V. Those losses of InflaRx GmbH do not expire
and may be used to offset future taxable income of InflaRx GmbH only.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;In addition, the Group still has tax loss carryforwards of $14.3 million or &#x20ac;12.97 million (2022:&#160;$14.1&#160;million or
&#x20ac;13.2 million) from the operations of InflaRx Pharmaceuticals, Inc. which can also only be utilized there, generally do not expire,
but are generally limited to offset tax obligation for 80% of taxable income.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2023, 2022 and 2021, no deferred
tax assets were recognized for the carryforward of unused tax losses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;b)&lt;/td&gt;&lt;td&gt;Current income tax receivable&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Current income tax receivable includes tax claims
because of income tax withheld on interest income earned by the Group on the financial assets (2023: &#x20ac;1,390,280, 2022: &#x20ac;791,344).
The Company is reimbursed for the payments after filing a tax return.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;8.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Financial assets and financial
liabilities&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Set out below is an overview of financial assets
and liabilities, other than cash and short-term deposits included in cash equivalents, held by the Group as at December 31, 2023 and December
31, 2022:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Financial assets and financial liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Non-current financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,052,741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,900,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial assets from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;732,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,504,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,791,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial liabilities at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,209,266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,716,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,987,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The fair value of current and non-current financial
assets amounted to &#x20ac;85.5 million (level 1; 2022:&#160;&#x20ac;68.5 million). The Group&#x2019;s financial assets at amortized cost consist
mainly of quoted debt securities with fixed interest rates with high credit rating (investment grade securities) by international rating
agencies such as S&amp;amp;P Global and, therefore, are considered low credit risk investments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The maturities of all securities held as of December
31, 2023 are between one and seventeen months (2022: between one and sixteen months); they bear nominal fixed interest in the range of
0.3% to 4.125% (2022: 0.0% to 4.125%).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2023, financial assets and
liabilities from government grants amount to &#x20ac; &lt;span style="-sec-ix-hidden: hidden-fact-142"&gt;nil million&lt;/span&gt;, due to the end of the grant period on June 30, 2023 (&#x20ac;6.2&#160;million
as of December 31, 2022).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;9.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Deposits held in U.S. dollars&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,120,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deposits held in Euro&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,020,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,140,951&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash at banks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash held in U.S. dollars&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,041,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,645,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash held in Euro&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;2,585,190&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;7,616,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;7,626,991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;16,261,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,767,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;16,265,354&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;10.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Equity&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;a)&lt;/td&gt;&lt;td&gt;Issued capital&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2023, the issued capital of
the Company is divided into 58,883,272 ordinary shares (2022: 44,703,763). The nominal value per share is &#x20ac;0.12. All shares issued
are fully paid and have the same rights on the distribution of dividends and the repayment of capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;On July&#160;8, 2020, the Company filed&#160;a&#160;Form
F-3&#160;(2020-Registration Statement)&#160;with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;)&#160;with respect
to the offer and sale of securities of the Company.&#160;The Company&#160;also&#160;filed&#160;with the SEC a prospectus&#160;supplement&#160;relating
to&#160;an&#160;at-the-market&#160;program providing for the sale of up to&#160;$50.0 million&#160;of its&#160;ordinary&#160;shares&#160;over
time&#160;pursuant a Sales Agreement with SVB&#160;Leerink&#160;LLC (the &#x201c;Sales Agreement&#x201d;).&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;As of December 31, 2022, the Company had issued
2,568,208 ordinary shares resulting in &#x20ac;11.8 million in net proceeds to the Company with a remaining value authorized for sale under
the Sales Agreement of $35.2 million. During the fiscal year 2023, the Company issued 3,235,723 ordinary shares under its at-the-market
program resulting in &#x20ac;14.4 million or $15.7 million in net proceeds. Following these and previous issuances under this program, the
remaining value authorized for sale under the Sales Agreement amounted to $19.0 million as of July&#160;8, 2023; the term of the at-the-market
program expired on July&#160;8, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Through an underwritten public offering in April
2023, the Company sold and issued an aggregate of 10,823,529 ordinary shares, of which 1,411,764 were sold pursuant to the exercise of
an overallotment option by the underwriters. The ordinary shares were sold at a price of $4.25 per share and have a nominal value of &#x20ac;0.12
per share. Proceeds of this offering after deducting &#x20ac;2.5 million ($2.8 million) in underwriting discounts amounted to &#x20ac;39.1
million ($43.2 million). Other offering expenses amounted to &#x20ac;0.4 million, resulting in a total of &#x20ac;38.7 million in net proceeds
from this offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In connection with amending the Co-Development
Agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd. (&#x201c;Staidson&#x201d;) on December 21, 2022, the Company entered into
a share purchase agreement with Staidson pursuant to which Staidson purchased ordinary shares of the Company for an aggregate amount of
$2.5 million (&#x20ac;2.3 million) at a price of $5.00 per share, resulting in the sale of 500,000 additional shares. Under the terms of
the share purchase agreement, at the Company&#x2019;s option, Staidson may purchase additional shares for an aggregate purchase price of
$7.5 million, which is subject to certain conditions. The accounting impact of this put option is not material. On June&#160;30, 2023,
the Company filed&#160;a&#160;Form F-3&#160;(2023 Registration Statement)&#160;with the SEC&#160;with respect to the offer and sale of
securities of the Company, which became effective on July&#160;11, 2023. The aggregate initial offering price of the securities that the
Company may offer and sell under this prospectus will not exceed $250 million. No ordinary shares were issued by the Company under the
2023 Registration Statement in the fiscal year 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;During 2023, the Company issued a total of 120,257
ordinary shares after former employees exercised stock option rights granted under the 2017 Long-Term Incentive Plan. The ordinary shares
have a nominal value of &#x20ac;0.12 per share. Therefrom, 98,754 ordinary shares were sold at a price of $1.85 per share, and 21,503 ordinary
shares were sold at a price of $3.35. The ordinary shares were registered in 2023, except 14,930 stock options which were exercised in
December 2022 with resulting ordinary shares having been registered in January 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;b)&lt;/td&gt;&lt;td&gt;Authorized capital&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;According to the articles of association of the
Company, up to 110,000,000 ordinary shares and up to 110,000,000 preferred shares with a nominal value of &#x20ac;0.12 per share are authorized
to be issued. All shares are registered shares. No share certificates shall be issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In order to deter acquisition bids, the Company&#x2019;s
general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation, to exercise
a call option pursuant to the call option agreement, upon which preferred shares will be issued by the Company to the protective foundation
of up to 100% of the Company&#x2019;s issued capital held by others than the protective foundation, minus one share. The protective foundation
is expected to enter into a finance arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation
may request the Company to provide, or cause the Company&#x2019;s subsidiaries to provide, sufficient funding to the protective foundation
to enable it to satisfy its payment obligation under the call option agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;These preferred shares will have both a liquidation
and dividend preference over the Company&#x2019;s ordinary shares and will accrue cash dividends at a pre-determined rate. The protective
foundation would be expected to require the Company to cancel its preferred shares once the perceived threat to the Company and its stakeholders
has been removed or sufficiently mitigated or neutralized. The Company believes that the call option does not represent a significant
fair value based on a level 3 valuation since the preferred shares are restricted in use and can be cancelled by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;For the year ended December 31, 2023, the Company
expensed &#x20ac;70,000 of ongoing costs to reimburse expenses incurred by the protective foundation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;c)&lt;/td&gt;&lt;td&gt;Nature and purpose of equity reserves&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In addition to the issued capital, the Company
discloses the following other reserves:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;&lt;i&gt;Share premium&lt;/i&gt; records the amounts paid in upon issuance of ordinary shares in excess of nominal value of &#x20ac;0.12 per share,
net of related transaction costs.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;The &lt;i&gt;other capital reserves&lt;/i&gt; include the expense resulting from the issue of share options.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;&lt;i&gt;Accumulated deficit&lt;/i&gt; includes the losses of previous reporting periods.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in"&gt;&lt;i&gt;Other components of equity&lt;/i&gt; exclusively include
currency reserves from the conversion of financial statements in foreign currencies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;11.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Trade and other payables&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued liabilities from R&amp;amp;D projects&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,414,143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,254,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued liabilities from commercial activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,400,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,102,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,566,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accrued liabilities and payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,942,909&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,314,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total trade and other payables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,860,134&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5,135,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accrued liabilities from R&amp;amp;D projects include
services from the Company&#x2019;s ongoing projects that have not yet been invoiced to the Company as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Accrued liabilities from commercial activities
include services provided by commercial manufacturing partners that have not yet been invoiced to the Company as of the reporting date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Other accrued liabilities and payables include
payments for GOHIBIC (vilobelimab) received from our distribution partner under the title distribution model, against which revenue will
be recognized at the time of final sale and delivery to hospital customers. These accrued liabilities payments amount to &#x20ac;2.7 million
as of December 31, 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;12.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Financial risk management&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;a)&lt;/td&gt;&lt;td&gt;Financial risk management objectives and policies&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group&#x2019;s financial risks are predominantly
controlled by central treasury activities under an investment policy approved by the Board of Directors on November 3, 2022, as revised
on October, 27, 2023. Those treasury activities identify, evaluate and manage financial risks consistent with the Group&#x2019;s operating
needs. The Board of Directors provides policies for overall risk management, covering specific areas, such as foreign exchange risk and
credit risk. The Company does not intend to use derivative financial instruments because the Group&#x2019;s future risk exposures cannot
be reliably forecasted (volume of business activity, liquidity needs, foreign exchange exposure).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Hedging is not applied as most of the business
activity is intended to be executed in U.S. dollars and paid with the U.S. dollars funds raised in public offerings. The foreign exchange
exposure from costs incurred in currencies other than Euro is deemed immaterial.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group&#x2019;s principal financial assets
comprise quoted debt securities with high credit ratings. Besides these financial assets, the Group has significant cash and cash equivalents.
The Group&#x2019;s principal financial liabilities comprise trade and other payables. The main purpose of these financial assets, cash/cash
equivalents and liabilities are to finance the Group&#x2019;s development activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group is exposed to market risk, credit risk
and liquidity risk. The Board of Directors reviews and adopts policies for managing each of these risks, which are summarized below. The
Group&#x2019;s senior management oversees the management of these risks.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding: 1.5pt; border: black 1pt solid; text-align: center; width: 12%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 37%; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exposure&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Measurement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 31%; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Risk Management&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future development costs; Recognized financial assets and liabilities not denominated in Euro&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forecasted cash flows Sensitivity analysis&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Achievement of a natural hedge&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;in the future&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Cash and cash equivalents,&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;current and non-current&lt;br/&gt; financial assets&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Credit&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;rating&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Diversification of bank deposits, Investment guidelines for&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;debt investments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;R&amp;amp;D and G&amp;amp;A cost, equity, trade and other payables&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Rolling&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;cash flow forecast&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Availability of funds through financing rounds or public offerings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;b)&lt;/td&gt;&lt;td&gt;Market risk&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Market risk is the risk that changes in market
prices (e.g., due to foreign exchange rates) will affect the Group&#x2019;s income, expenses or the value of its holdings of financial
instruments. The objective of market risk management is to identify, manage and control market risk exposures within acceptable parameters.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Foreign exchange risk arises when commercial
transactions or recognized assets or liabilities are denominated in a currency that is not an entity&#x2019;s functional currency. The
Group is exposed to transactional foreign currency risk to the extent that there is a mismatch between the currencies in which costs and
purchases are denominated and the respective functional currencies of Group companies. The functional currencies of Group companies are
primarily the Euro and U.S. dollars. The currencies in which these transactions and financial assets are primarily denominated are Euro
and U.S. dollars. The Group is exposed to the exchange rate between the Euro and the U.S. dollars. Due to the Company&#x2019;s various
registered offerings of ordinary shares in U.S. dollars, the Group has significant cash and cash equivalents in U.S. dollars. Currently
the Group does not hedge U.S. dollars but intends to achieve a natural hedge by contracting suppliers in U.S. dollars in the future. In
2023, the Group recognized significant foreign exchange gains and losses as the natural hedge is not yet achieved and the functional currency
for InflaRx N.V. and InflaRx GmbH is Euro.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group is primarily exposed to changes in
U.S. dollar to Euro exchange rates. The sensitivity of profit or loss to changes in the exchange rates arises mainly from U.S. dollar
denominated financial instruments at InflaRx N.V. and InflaRx GmbH.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In 2023, if the Euro had weakened/strengthened
by 10% against the U.S. dollar with all other variables held constant, the Group&#x2019;s loss would have been &#x20ac;1 million higher/&#x20ac;1
million lower, mainly as a result of foreign exchange on translation of U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx GmbH&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022 *&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Current and non current financial assets (securities and accrued interest)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,935,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,376,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,051,366&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,356,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total assets exposed to the risk&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;88,986,563&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,733,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Conversion rate Euro to U.S. dollars at reporting date 1/1.1050 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Sensitivity analysis:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Conversion&lt;br/&gt;
 rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Profit/(loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;carrying&lt;br/&gt;
 amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Euro weakens against U.S. dollars&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.2155&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,887,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98,873,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Euro strengths against U.S. dollars&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,089,688&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,896,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Based on the exchange rate fluctuations from
the last three years, the Company expects that exchange rate fluctuations of the Euro to the U.S. dollar between 0.9945 and 1.2155 could
be reasonably possible. Compared to the exchange rate on the statement of financial position date (Euro to U.S. dollar at reporting date
is 1/1.1050), these rates could have a material impact on the Company&#x2019;s total loss of the period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;c)&lt;/td&gt;&lt;td&gt;Credit risk&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Credit risk is the risk that a counterparty will
not meet its obligations leading to a financial loss for the Company. The Company is exposed to credit risk mainly from its financing
activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Credit risk from balances with banks and financial
institutions is managed by the Company in accordance with the Company&#x2019;s investment policy. Investment of financial resources which
are currently not used to fund R&amp;amp;D or G&amp;amp;A activities, are made only with counterparties within the credit limits approved by the
investment policy. For investments in Euro or U.S. dollar debt securities, a BBB+ to AAA credit rating (Standard &amp;amp; Poors and Fitch
ratings; or equivalent ratings by Moody&#x2019;s and DBRS) is required. Complex financial products as well as other investments denominated
in currencies other than Euros or U.S. dollars are not permitted by the investment policy. Counterparty credit limits and the investment
policy are discussed with the Company&#x2019;s Audit Committee on an annual basis and may be updated throughout the year subject to approval
of the Company&#x2019;s Audit Committee. The limits are set to minimize the concentration of risks and therefore mitigate financial loss
through a counterparty&#x2019;s potential failure to make payments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The maximum exposure to counterparty credit risk
is &#x20ac;99.3 million at December 31, 2023 (December 31, 2022: &#x20ac;84.0 million). This amount equals the carrying amount at year end
of cash and cash equivalents (2023: &#x20ac;12.8 million; 2022: &#x20ac;16.3 million) and financial assets (2023: &#x20ac;86.6 million; 2022:
&#x20ac;67.7 million).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;d)&lt;/td&gt;&lt;td&gt;Liquidity risk&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company monitors its risk of a shortage of
funds in every quarterly forecast as well as on an ongoing basis. The Company disclosed the maturities of its principal liabilities under
Note E &#x2018;Commitments&#x2019;. Prudent liquidity risk management involves maintaining sufficient cash and marketable securities and
the availability of funding to meet obligations when due. The Group continually monitors its risk of a shortage of funds using short and
mid-term liquidity planning. This takes into account of the expected cash flows from all activities. The management team performs regular
reviews of the budget.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company has a history of significant operating
losses. Management expects that the Company incurs significant and increasing losses for the foreseeable future; as the Company may not
achieve or maintain profitability in the near future, it is dependent on capital contributions or other funding.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group raised significant funding from various
registered offerings that it estimates will enable the Group to fund operating expenses and capital expenditure requirements for at least
24 months from December 31, 2023. The Group expects to require additional funding to continue to advance the development of product candidates.
In the event regulatory approval is received and the Company implements a strategy to commercialize the products itself, the Group would
require additional capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;In 2023, as a result of the BMBF agreements (see
Notes C.6.) the Company received &#x20ac;8.8 million in cash from the German Federal Government grant which contributes to its financing
of its operations. Such funds were used for finalizing the Company&#x2019;s COVID-19 clinical research and development program, support
regulatory activities, establish a fully validated manufacturing process and to transfer the fill and finish process from China to Germany
to ensure future security of supply in Germany.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;At the end of the reporting period, the Group
held the following deposits that are expected to readily generate cash inflows to meet the outstanding financial commitments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Liquidity&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,140,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash at banks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,626,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,261,932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities (current and non-current)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,727,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,175,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other (non-current portion)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other (current)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;701,407&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;278,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total funds available&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;99,434,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;83,957,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;13.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Capital management&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group&#x2019;s policy for capital management
is to ensure that it maintains its liquidity in order to finance its operating activities, future business development and meet its liabilities
when due. The Group manages its capital structure primarily through equity. The Group does not have any financial liabilities, other
than trade and other payables or leasing liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;No changes were made in the objectives, policies
or processes for managing capital during the year.&lt;/p&gt;</ifrs-full:DisclosureOfAuthorisationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c0" id="ixv-30157">Property and equipment&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Property&lt;br/&gt;
 and&lt;br/&gt;
 equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Advance &lt;br/&gt;payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; padding-bottom: 1.5pt"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;1,267,611&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-85"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;1,267,611&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;25,236&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,453,339&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,453,339&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,123&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right"&gt;(2,595&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right"&gt;(2,595&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,491,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,491,525&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(993,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(993,238&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(113,894&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(113,894&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,286&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,124,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,124,419&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,668&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,201,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,201,948&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Net book value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;328,920&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;328,920&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;289,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;289,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c201" decimals="0" id="ixv-30158" unitRef="eur">1267611</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c203" decimals="0" id="ixv-30159" unitRef="eur">1267611</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c204" decimals="0" id="ixv-30160" unitRef="eur">160491</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c206" decimals="0" id="ixv-30161" unitRef="eur">160491</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c204" decimals="0" id="ixv-30162" unitRef="eur">25236</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c206" decimals="0" id="ixv-30163" unitRef="eur">25236</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c207" decimals="0" id="ixv-30164" unitRef="eur">1453339</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c209" decimals="0" id="ixv-30165" unitRef="eur">1453339</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c210" decimals="0" id="ixv-30166" unitRef="eur">55123</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c212" decimals="0" id="ixv-30167" unitRef="eur">55123</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrx:DisposalsAndRetirementPropertyPlantAndEquipment contextRef="c210" decimals="0" id="ixv-30168" unitRef="eur">-2595</ifrx:DisposalsAndRetirementPropertyPlantAndEquipment>
    <ifrx:DisposalsAndRetirementPropertyPlantAndEquipment contextRef="c212" decimals="0" id="ixv-30169" unitRef="eur">-2595</ifrx:DisposalsAndRetirementPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c210" decimals="0" id="ixv-30170" unitRef="eur">-14342</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c212" decimals="0" id="ixv-30171" unitRef="eur">-14342</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c213" decimals="0" id="ixv-30172" unitRef="eur">1491525</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c215" decimals="0" id="ixv-30173" unitRef="eur">1491525</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c216" decimals="0" id="ixv-30174" unitRef="eur">-993238</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c218" decimals="0" id="ixv-30175" unitRef="eur">-993238</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease contextRef="c219" decimals="0" id="ixv-30176" unitRef="eur">113894</ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease>
    <ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease contextRef="c221" decimals="0" id="ixv-30177" unitRef="eur">113894</ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c219" decimals="0" id="ixv-30178" unitRef="eur">-17286</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c221" decimals="0" id="ixv-30179" unitRef="eur">-17286</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c222" decimals="0" id="ixv-30180" unitRef="eur">-1124419</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c224" decimals="0" id="ixv-30181" unitRef="eur">-1124419</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease contextRef="c225" decimals="0" id="ixv-30182" unitRef="eur">93791</ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease>
    <ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease contextRef="c227" decimals="0" id="ixv-30183" unitRef="eur">93791</ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease>
    <ifrx:DisposalsAndRetirementPropertyPlantAndEquipment contextRef="c225" decimals="0" id="ixv-30184" unitRef="eur">2594</ifrx:DisposalsAndRetirementPropertyPlantAndEquipment>
    <ifrx:DisposalsAndRetirementPropertyPlantAndEquipment contextRef="c227" decimals="0" id="ixv-30185" unitRef="eur">2594</ifrx:DisposalsAndRetirementPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c225" decimals="0" id="ixv-30186" unitRef="eur">13668</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment contextRef="c227" decimals="0" id="ixv-30187" unitRef="eur">13668</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c228" decimals="0" id="ixv-30188" unitRef="eur">-1201948</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01 contextRef="c230" decimals="0" id="ixv-30189" unitRef="eur">-1201948</ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01>
    <ifrx:NetBookValuePropertyAndEquipment contextRef="c231" decimals="0" id="ixv-30190" unitRef="eur">328920</ifrx:NetBookValuePropertyAndEquipment>
    <ifrx:NetBookValuePropertyAndEquipment contextRef="c5" decimals="0" id="ixv-30191" unitRef="eur">328920</ifrx:NetBookValuePropertyAndEquipment>
    <ifrx:NetBookValuePropertyAndEquipment contextRef="c233" decimals="0" id="ixv-30192" unitRef="eur">289577</ifrx:NetBookValuePropertyAndEquipment>
    <ifrx:NetBookValuePropertyAndEquipment contextRef="c2" decimals="0" id="ixv-30193" unitRef="eur">289577</ifrx:NetBookValuePropertyAndEquipment>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c0" id="ixv-30194">Right-of-use assets&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Buildings&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Cars&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; font-weight: bold"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 64%"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;2,284,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;125,130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right"&gt;2,409,399&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,645&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,579,342&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;125,130&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;2,704,473&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,125&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,004&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,661,118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;174,134&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,835,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(925,306&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(76,015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,001,321&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(354,408&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30,024&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(384,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,911&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,286,625&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(106,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(1,392,664&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Depreciation charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(353,398&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(24,527&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(377,925&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;7,003&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,633,020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(130,566&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(1,763,586&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,292,717&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;19,092&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;1,311,809&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,028,098&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;43,568&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,071,666&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c235" decimals="0" id="ixv-30195" unitRef="eur">2284269</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c236" decimals="0" id="ixv-30196" unitRef="eur">125130</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c203" decimals="0" id="ixv-30197" unitRef="eur">2409399</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c237" decimals="0" id="ixv-30198" unitRef="eur">281429</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c206" decimals="0" id="ixv-30199" unitRef="eur">281429</ifrs-full:AdditionsToRightofuseAssets>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c237" decimals="0" id="ixv-30200" unitRef="eur">13645</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c206" decimals="0" id="ixv-30201" unitRef="eur">13645</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c239" decimals="0" id="ixv-30202" unitRef="eur">2579342</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c240" decimals="0" id="ixv-30203" unitRef="eur">125130</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c209" decimals="0" id="ixv-30204" unitRef="eur">2704473</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c241" decimals="0" id="ixv-30205" unitRef="eur">91125</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c242" decimals="0" id="ixv-30206" unitRef="eur">49004</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c212" decimals="0" id="ixv-30207" unitRef="eur">140128</ifrs-full:AdditionsToRightofuseAssets>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c241" decimals="0" id="ixv-30208" unitRef="eur">-9349</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c212" decimals="0" id="ixv-30209" unitRef="eur">-9349</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c243" decimals="0" id="ixv-30210" unitRef="eur">2661118</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c244" decimals="0" id="ixv-30211" unitRef="eur">174134</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c215" decimals="0" id="ixv-30212" unitRef="eur">2835253</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c245" decimals="0" id="ixv-30213" unitRef="eur">-925306</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c246" decimals="0" id="ixv-30214" unitRef="eur">-76015</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c218" decimals="0" id="ixv-30215" unitRef="eur">-1001321</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrs-full:DepreciationExpense contextRef="c247" decimals="0" id="ixv-30216" unitRef="eur">354408</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c248" decimals="0" id="ixv-30217" unitRef="eur">30024</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c221" decimals="0" id="ixv-30218" unitRef="eur">384432</ifrs-full:DepreciationExpense>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c247" decimals="0" id="ixv-30219" unitRef="eur">-6911</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c221" decimals="0" id="ixv-30220" unitRef="eur">-6911</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c249" decimals="0" id="ixv-30221" unitRef="eur">-1286625</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c250" decimals="0" id="ixv-30222" unitRef="eur">-106039</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c224" decimals="0" id="ixv-30223" unitRef="eur">-1392664</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrs-full:DepreciationExpense contextRef="c251" decimals="0" id="ixv-30224" unitRef="eur">353398</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c252" decimals="0" id="ixv-30225" unitRef="eur">24527</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense contextRef="c227" decimals="0" id="ixv-30226" unitRef="eur">377925</ifrs-full:DepreciationExpense>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c251" decimals="0" id="ixv-30227" unitRef="eur">7003</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions contextRef="c227" decimals="0" id="ixv-30228" unitRef="eur">7003</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c253" decimals="0" id="ixv-30229" unitRef="eur">-1633020</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c254" decimals="0" id="ixv-30230" unitRef="eur">-130566</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:RightofuseAssetsRevaluationSurplus01 contextRef="c230" decimals="0" id="ixv-30231" unitRef="eur">-1763586</ifrx:RightofuseAssetsRevaluationSurplus01>
    <ifrx:NetBookValueOfRightOfUseAsset contextRef="c255" decimals="0" id="ixv-30232" unitRef="eur">1292717</ifrx:NetBookValueOfRightOfUseAsset>
    <ifrx:NetBookValueOfRightOfUseAsset contextRef="c256" decimals="0" id="ixv-30233" unitRef="eur">19092</ifrx:NetBookValueOfRightOfUseAsset>
    <ifrx:NetBookValueOfRightOfUseAsset contextRef="c5" decimals="0" id="ixv-30234" unitRef="eur">1311809</ifrx:NetBookValueOfRightOfUseAsset>
    <ifrx:NetBookValueOfRightOfUseAsset contextRef="c257" decimals="0" id="ixv-30235" unitRef="eur">1028098</ifrx:NetBookValueOfRightOfUseAsset>
    <ifrx:NetBookValueOfRightOfUseAsset contextRef="c258" decimals="0" id="ixv-30236" unitRef="eur">43568</ifrx:NetBookValueOfRightOfUseAsset>
    <ifrx:NetBookValueOfRightOfUseAsset contextRef="c2" decimals="0" id="ixv-30237" unitRef="eur">1071666</ifrx:NetBookValueOfRightOfUseAsset>
    <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="c0" id="ixv-30238">Intangible Assets&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Purchased&lt;br/&gt;
 IT-software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Advances&lt;br/&gt;
 paid for&lt;br/&gt;
 software&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center; font-weight: bold"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;At January 1, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;720,942&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;720,942&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;408&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;723,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;723,250&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-113"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;716,130&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;742,107&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;At January 1, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(485,726&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(485,726&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Amortization charge for the year*&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98,271&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98,271&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(584,345&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(584,345&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization charge for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,063&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(96,063&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,009&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exchange differences&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(673,289&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(673,289&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;At December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;138,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;138,905&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;At December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;42,841&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;25,977&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;68,818&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
    <ifrx:IntangibleAssets contextRef="c259" decimals="0" id="ixv-30239" unitRef="eur">720942</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c203" decimals="0" id="ixv-30240" unitRef="eur">720942</ifrx:IntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c261" decimals="0" id="ixv-30241" unitRef="eur">1900</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c206" decimals="0" id="ixv-30242" unitRef="eur">1900</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c261" decimals="0" id="ixv-30243" unitRef="eur">408</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c206" decimals="0" id="ixv-30244" unitRef="eur">408</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IntangibleAssets contextRef="c263" decimals="0" id="ixv-30245" unitRef="eur">-723250</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c209" decimals="0" id="ixv-30246" unitRef="eur">-723250</ifrx:IntangibleAssets>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c266" decimals="0" id="ixv-30247" unitRef="eur">25977</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="c212" decimals="0" id="ixv-30248" unitRef="eur">25977</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill contextRef="c265" decimals="0" id="ixv-30249" unitRef="eur">7009</ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill>
    <ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill contextRef="c212" decimals="0" id="ixv-30250" unitRef="eur">7009</ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c265" decimals="0" id="ixv-30251" unitRef="eur">-111</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c212" decimals="0" id="ixv-30252" unitRef="eur">-111</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IntangibleAssets contextRef="c267" decimals="0" id="ixv-30253" unitRef="eur">-716130</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c268" decimals="0" id="ixv-30254" unitRef="eur">-25977</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c215" decimals="0" id="ixv-30255" unitRef="eur">-742107</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c269" decimals="0" id="ixv-30256" unitRef="eur">-485726</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c271" decimals="0" id="ixv-30257" unitRef="eur">-485726</ifrx:IntangibleAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c272" decimals="0" id="ixv-30258" unitRef="eur">98271</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c274" decimals="0" id="ixv-30259" unitRef="eur">98271</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c272" decimals="0" id="ixv-30260" unitRef="eur">-348</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c274" decimals="0" id="ixv-30261" unitRef="eur">-348</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IntangibleAssets contextRef="c275" decimals="0" id="ixv-30262" unitRef="eur">584345</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c277" decimals="0" id="ixv-30263" unitRef="eur">584345</ifrx:IntangibleAssets>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c278" decimals="0" id="ixv-30264" unitRef="eur">96063</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="c280" decimals="0" id="ixv-30265" unitRef="eur">96063</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill contextRef="c278" decimals="0" id="ixv-30266" unitRef="eur">-7009</ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill>
    <ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill contextRef="c280" decimals="0" id="ixv-30267" unitRef="eur">-7009</ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c278" decimals="0" id="ixv-30268" unitRef="eur">111</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill contextRef="c280" decimals="0" id="ixv-30269" unitRef="eur">111</ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill>
    <ifrx:IntangibleAssets contextRef="c281" decimals="0" id="ixv-30270" unitRef="eur">673289</ifrx:IntangibleAssets>
    <ifrx:IntangibleAssets contextRef="c283" decimals="0" id="ixv-30271" unitRef="eur">673289</ifrx:IntangibleAssets>
    <ifrx:NetBookValueIntangibleAsset contextRef="c284" decimals="0" id="ixv-30272" unitRef="eur">138905</ifrx:NetBookValueIntangibleAsset>
    <ifrx:NetBookValueIntangibleAsset contextRef="c5" decimals="0" id="ixv-30273" unitRef="eur">138905</ifrx:NetBookValueIntangibleAsset>
    <ifrx:NetBookValueIntangibleAsset contextRef="c286" decimals="0" id="ixv-30274" unitRef="eur">42841</ifrx:NetBookValueIntangibleAsset>
    <ifrx:NetBookValueIntangibleAsset contextRef="c287" decimals="0" id="ixv-30275" unitRef="eur">25977</ifrx:NetBookValueIntangibleAsset>
    <ifrx:NetBookValueIntangibleAsset contextRef="c2" decimals="0" id="ixv-30276" unitRef="eur">68818</ifrx:NetBookValueIntangibleAsset>
    <ifrx:ResearchAndDevelopmentExpenses contextRef="c0" decimals="0" id="ixv-30277" unitRef="eur">858</ifrx:ResearchAndDevelopmentExpenses>
    <ifrx:ResearchAndDevelopmentExpenses contextRef="c3" decimals="0" id="ixv-30278" unitRef="eur">858</ifrx:ResearchAndDevelopmentExpenses>
    <ifrx:ResearchAndDevelopmentExpenses contextRef="c4" decimals="0" id="ixv-30279" unitRef="eur">10192</ifrx:ResearchAndDevelopmentExpenses>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-30280" unitRef="eur">95205</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c3" decimals="0" id="ixv-30281" unitRef="eur">97413</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="0" id="ixv-30282" unitRef="eur">105790</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:DisclosureOfLeasePrepaymentsExplanatory contextRef="c0" id="ixv-27354">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below, are the carrying amounts and the movements of the Group&#x2019;s lease liabilities:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;As of January 1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,356,684&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,432,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,128&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281,429&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Derecognition&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20,555&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(353,422&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(343,874&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term liability for accrued interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(396&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;304&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Foreign exchange difference&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,391&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,854&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,120,048&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,356,684&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfLeasePrepaymentsExplanatory>
    <ifrs-full:LeaseLiabilities contextRef="c5" decimals="0" id="ixv-30283" unitRef="eur">1356684</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c37" decimals="0" id="ixv-30284" unitRef="eur">1432526</ifrs-full:LeaseLiabilities>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c0" decimals="0" id="ixv-30285" unitRef="eur">140128</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions contextRef="c3" decimals="0" id="ixv-30286" unitRef="eur">281429</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets contextRef="c0" decimals="0" id="ixv-30287" unitRef="eur">20555</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:DecreaseThroughDerecognitionFinancialAssets contextRef="c3" decimals="0" id="ixv-30288" unitRef="eur">20555</ifrs-full:DecreaseThroughDerecognitionFinancialAssets>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c0" decimals="0" id="ixv-30289" unitRef="eur">353422</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c3" decimals="0" id="ixv-30290" unitRef="eur">343874</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c0" decimals="0" id="ixv-30291" unitRef="eur">-396</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss contextRef="c3" decimals="0" id="ixv-30292" unitRef="eur">304</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrx:GainsLossesOnExchangeDifferenceOnTranslationNetOfTax contextRef="c0" decimals="0" id="ixv-30293" unitRef="eur">-2391</ifrx:GainsLossesOnExchangeDifferenceOnTranslationNetOfTax>
    <ifrx:GainsLossesOnExchangeDifferenceOnTranslationNetOfTax contextRef="c3" decimals="0" id="ixv-30294" unitRef="eur">6854</ifrx:GainsLossesOnExchangeDifferenceOnTranslationNetOfTax>
    <ifrs-full:LeaseLiabilities contextRef="c2" decimals="0" id="ixv-30295" unitRef="eur">1120048</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c5" decimals="0" id="ixv-30296" unitRef="eur">1356684</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory contextRef="c0" id="ixv-27446">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the amounts recognized in profit or loss:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Depreciation expense of right-of-use assets (see Note E.2.)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;377,925&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;384,432&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;371,551&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,947&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,055&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rental expense from leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left"&gt;Thereof short-term leases (included in administrative expenses)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-124"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-125"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-126"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-style: italic; text-align: left; padding-bottom: 1.5pt"&gt;Thereof leases of low-value assets (included in administrative expenses)&lt;/td&gt;&lt;td style="font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-style: italic; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total amounts recognized in profit or loss&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;403,276&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;412,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;391,867&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialInstrumentsDesignatedAtFairValueThroughProfitOrLossExplanatory>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c0" decimals="0" id="ixv-30297" unitRef="eur">377925</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c3" decimals="0" id="ixv-30298" unitRef="eur">384432</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss contextRef="c4" decimals="0" id="ixv-30299" unitRef="eur">371551</ifrs-full:DepreciationAmortisationAndImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:InterestExpenseOnBonds contextRef="c0" decimals="0" id="ixv-30300" unitRef="eur">19090</ifrs-full:InterestExpenseOnBonds>
    <ifrs-full:InterestExpenseOnBonds contextRef="c3" decimals="0" id="ixv-30301" unitRef="eur">21947</ifrs-full:InterestExpenseOnBonds>
    <ifrs-full:InterestExpenseOnBonds contextRef="c4" decimals="0" id="ixv-30302" unitRef="eur">14055</ifrs-full:InterestExpenseOnBonds>
    <ifrs-full:RentalExpense contextRef="c0" decimals="0" id="ixv-30303" unitRef="eur">6261</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c3" decimals="0" id="ixv-30304" unitRef="eur">6261</ifrs-full:RentalExpense>
    <ifrs-full:RentalExpense contextRef="c4" decimals="0" id="ixv-30305" unitRef="eur">6261</ifrs-full:RentalExpense>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities contextRef="c0" decimals="0" id="ixv-30306" unitRef="eur">6261</ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities contextRef="c3" decimals="0" id="ixv-30307" unitRef="eur">6261</ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities contextRef="c4" decimals="0" id="ixv-30308" unitRef="eur">6261</ifrs-full:ExpenseRelatingToVariableLeasePaymentsNotIncludedInMeasurementOfLeaseLiabilities>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c0" decimals="0" id="ixv-30309" unitRef="eur">403276</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c3" decimals="0" id="ixv-30310" unitRef="eur">412640</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c4" decimals="0" id="ixv-30311" unitRef="eur">391867</ifrs-full:GainsLossesOnFinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:CashOutflowForLeases contextRef="c0" decimals="1" id="ixv-30312" unitRef="eur">0.4</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c3" decimals="1" id="ixv-30313" unitRef="eur">0.4</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c4" decimals="1" id="ixv-30314" unitRef="eur">0.4</ifrs-full:CashOutflowForLeases>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c0" id="ixv-30315">Inventory&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Raw material and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;423,560&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-127"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-128"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Unfinished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,614,159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-129"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-130"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;330,087&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-131"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-132"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,367,807&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-133"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-134"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies contextRef="c2" decimals="0" id="ixv-30316" unitRef="eur">423560</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
    <ifrx:UnfinishedGoods contextRef="c2" decimals="0" id="ixv-30317" unitRef="eur">10614159</ifrx:UnfinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c2" decimals="0" id="ixv-30318" unitRef="eur">330087</ifrs-full:FinishedGoods>
    <ifrs-full:InventoriesTotal contextRef="c2" decimals="0" id="ixv-30319" unitRef="eur">11367807</ifrs-full:InventoriesTotal>
    <ifrs-full:WritedownsReversalsOfInventories contextRef="c0" decimals="-5" id="ixv-30320" unitRef="eur">500000</ifrs-full:WritedownsReversalsOfInventories>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="c0" id="ixv-27675">&lt;span style="font-style: normal"&gt;Other assets&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160; 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;br/&gt;
&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Non-current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;257,267&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;257,267&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepayments on research &amp;amp; development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,670,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,776,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;272,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,841,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;93,482&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;4,036,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;14,170,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total other assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,293,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,478,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ifrx:PrepaidExpense contextRef="c0" decimals="0" id="ixv-30321" unitRef="eur">257267</ifrx:PrepaidExpense>
    <ifrx:PrepaidExpense contextRef="c3" decimals="0" id="ixv-30322" unitRef="eur">308066</ifrx:PrepaidExpense>
    <ifrx:NonCurrentOtherAssets contextRef="c2" decimals="0" id="ixv-30323" unitRef="eur">257267</ifrx:NonCurrentOtherAssets>
    <ifrx:NonCurrentOtherAssets contextRef="c5" decimals="0" id="ixv-30324" unitRef="eur">308066</ifrx:NonCurrentOtherAssets>
    <ifrs-full:Prepayments contextRef="c2" decimals="0" id="ixv-30325" unitRef="eur">3670167</ifrs-full:Prepayments>
    <ifrs-full:Prepayments contextRef="c5" decimals="0" id="ixv-30326" unitRef="eur">9776505</ifrs-full:Prepayments>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c2" decimals="0" id="ixv-30327" unitRef="eur">272999</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c5" decimals="0" id="ixv-30328" unitRef="eur">1841935</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="0" id="ixv-30329" unitRef="eur">93482</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c3" decimals="0" id="ixv-30330" unitRef="eur">2552071</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c0" decimals="0" id="ixv-30331" unitRef="eur">4036648</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrs-full:OtherAdjustmentsToReconcileProfitLoss contextRef="c3" decimals="0" id="ixv-30332" unitRef="eur">14170511</ifrs-full:OtherAdjustmentsToReconcileProfitLoss>
    <ifrx:TotalOtherAsset contextRef="c2" decimals="0" id="ixv-30333" unitRef="eur">4293915</ifrx:TotalOtherAsset>
    <ifrx:TotalOtherAsset contextRef="c5" decimals="0" id="ixv-30334" unitRef="eur">14478577</ifrx:TotalOtherAsset>
    <ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory contextRef="c0" id="ixv-30335">The table below shows a reconciliation between
the product of loss before tax multiplied by the Company&#x2019;s applicable tax rate and current income taxes recognized in profit or
loss.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; font-weight: bold"&gt;InflaRx Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left"&gt;Loss for the period (accounting profit before income tax)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(42,667,529&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(29,484,611&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(45,630,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Tax benefits at tax rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,160,545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,610,381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,001,984&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Temporary differences and tax losses for which no deferred tax asset was recognized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12,127,977&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,480,169&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,988,805&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Non-recognition of tax effect on share-based payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32,182&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,251,830&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,959,606&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Non-deductible expenses for tax purposes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(46,907&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,067&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Other differences due to tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;46,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143,686&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(49,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Income tax&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-135"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-136"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-137"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialInstrumentsAtFairValueThroughProfitOrLossExplanatory>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="0" id="ixv-30336" unitRef="eur">-42667529</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c3" decimals="0" id="ixv-30337" unitRef="eur">-29484611</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c4" decimals="0" id="ixv-30338" unitRef="eur">-45630059</ifrs-full:ProfitLossBeforeTax>
    <ifrx:TaxRate contextRef="c0" decimals="3" id="ixv-30339" unitRef="pure">0.286</ifrx:TaxRate>
    <ifrx:TaxRate contextRef="c3" decimals="3" id="ixv-30340" unitRef="pure">0.292</ifrx:TaxRate>
    <ifrx:TaxRate contextRef="c4" decimals="3" id="ixv-30341" unitRef="pure">0.285</ifrx:TaxRate>
    <ifrx:TaxBenefitsAtTaxRate contextRef="c0" decimals="0" id="ixv-30342" unitRef="eur">12160545</ifrx:TaxBenefitsAtTaxRate>
    <ifrx:TaxBenefitsAtTaxRate contextRef="c3" decimals="0" id="ixv-30343" unitRef="eur">8610381</ifrx:TaxBenefitsAtTaxRate>
    <ifrx:TaxBenefitsAtTaxRate contextRef="c4" decimals="0" id="ixv-30344" unitRef="eur">13001984</ifrx:TaxBenefitsAtTaxRate>
    <ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone contextRef="c0" decimals="0" id="ixv-30345" unitRef="eur">-12127977</ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone>
    <ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone contextRef="c3" decimals="0" id="ixv-30346" unitRef="eur">-7480169</ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone>
    <ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone contextRef="c4" decimals="0" id="ixv-30347" unitRef="eur">-10988805</ifrx:TaxLossesForWhichNoDeferredTaxAssetWasRecognizedone>
    <ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment contextRef="c0" decimals="0" id="ixv-30348" unitRef="eur">-32182</ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment>
    <ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment contextRef="c3" decimals="0" id="ixv-30349" unitRef="eur">-1251830</ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment>
    <ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment contextRef="c4" decimals="0" id="ixv-30350" unitRef="eur">-1959606</ifrx:NonrecognitionOfTaxEffectOnSharebasedPayment>
    <ifrx:NondeductibleExpensesForTaxPurposesinDollars contextRef="c0" decimals="0" id="ixv-30351" unitRef="eur">-46907</ifrx:NondeductibleExpensesForTaxPurposesinDollars>
    <ifrx:NondeductibleExpensesForTaxPurposesinDollars contextRef="c3" decimals="0" id="ixv-30352" unitRef="eur">-22067</ifrx:NondeductibleExpensesForTaxPurposesinDollars>
    <ifrx:NondeductibleExpensesForTaxPurposesinDollars contextRef="c4" decimals="0" id="ixv-30353" unitRef="eur">-3758</ifrx:NondeductibleExpensesForTaxPurposesinDollars>
    <ifrx:OtherDifferencesDueToTaxRateinDollars contextRef="c0" decimals="0" id="ixv-30354" unitRef="eur">46521</ifrx:OtherDifferencesDueToTaxRateinDollars>
    <ifrx:OtherDifferencesDueToTaxRateinDollars contextRef="c3" decimals="0" id="ixv-30355" unitRef="eur">143686</ifrx:OtherDifferencesDueToTaxRateinDollars>
    <ifrx:OtherDifferencesDueToTaxRateinDollars contextRef="c4" decimals="0" id="ixv-30356" unitRef="eur">-49815</ifrx:OtherDifferencesDueToTaxRateinDollars>
    <ifrx:CorporateIncomeTax contextRef="c0" decimals="2" id="ixv-30357" unitRef="pure">0.15</ifrx:CorporateIncomeTax>
    <ifrx:CorporateIncomeTax contextRef="c3" decimals="2" id="ixv-30358" unitRef="pure">0.15</ifrx:CorporateIncomeTax>
    <ifrx:CorporateIncomeTax contextRef="c4" decimals="2" id="ixv-30359" unitRef="pure">0.15</ifrx:CorporateIncomeTax>
    <ifrx:SolidaritySurcharge contextRef="c0" decimals="3" id="ixv-30360" unitRef="pure">0.008</ifrx:SolidaritySurcharge>
    <ifrx:SolidaritySurcharge contextRef="c3" decimals="3" id="ixv-30361" unitRef="pure">0.008</ifrx:SolidaritySurcharge>
    <ifrx:SolidaritySurcharge contextRef="c4" decimals="3" id="ixv-30362" unitRef="pure">0.008</ifrx:SolidaritySurcharge>
    <ifrx:TradeTaxes contextRef="c0" decimals="5" id="ixv-30363" unitRef="pure">0.13065</ifrx:TradeTaxes>
    <ifrx:TradeTaxes contextRef="c3" decimals="3" id="ixv-30364" unitRef="pure">0.137</ifrx:TradeTaxes>
    <ifrx:TradeTaxes contextRef="c4" decimals="3" id="ixv-30365" unitRef="pure">0.128</ifrx:TradeTaxes>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c3" decimals="3" id="ixv-30366" unitRef="pure">0.295</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate contextRef="c4" decimals="3" id="ixv-30367" unitRef="pure">0.286</ifrs-full:AverageEffectiveTaxRate>
    <ifrx:TotalTaxRate contextRef="c0" decimals="4" id="ixv-30368" unitRef="pure">0.2574</ifrx:TotalTaxRate>
    <ifrx:TotalTaxRate contextRef="c3" decimals="4" id="ixv-30369" unitRef="pure">0.2574</ifrx:TotalTaxRate>
    <ifrx:TotalTaxRate contextRef="c4" decimals="4" id="ixv-30370" unitRef="pure">0.2574</ifrx:TotalTaxRate>
    <ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent contextRef="c0" decimals="2" id="ixv-30371" unitRef="pure">0.21</ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent>
    <ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent contextRef="c3" decimals="2" id="ixv-30372" unitRef="pure">0.21</ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent>
    <ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent contextRef="c4" decimals="2" id="ixv-30373" unitRef="pure">0.21</ifrx:EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent>
    <ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent contextRef="c0" decimals="4" id="ixv-30374" unitRef="pure">0.0474</ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent>
    <ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent contextRef="c4" decimals="4" id="ixv-30375" unitRef="pure">0.0474</ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent>
    <ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent contextRef="c3" decimals="4" id="ixv-30376" unitRef="pure">0.0474</ifrx:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocalPercent>
    <ifrs-full:GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax contextRef="c0" decimals="-5" id="ixv-30377" unitRef="eur">243800000</ifrs-full:GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax>
    <ifrs-full:GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax contextRef="c3" decimals="-5" id="ixv-30378" unitRef="eur">211300000</ifrs-full:GainsLossesOnChangeInValueOfForwardElementsOfForwardContractsNetOfTax>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c2" decimals="-6" id="ixv-30379" unitRef="eur">196000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c5" decimals="-5" id="ixv-30380" unitRef="eur">163400000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrx:TaxBasisOfInvestmentCostForIncomeTaxPurposes contextRef="c0" decimals="-6" id="ixv-30381" unitRef="eur">164000000</ifrx:TaxBasisOfInvestmentCostForIncomeTaxPurposes>
    <ifrx:TaxBasisOfInvestmentCostForIncomeTaxPurposes contextRef="c3" decimals="-5" id="ixv-30382" unitRef="eur">131600000</ifrx:TaxBasisOfInvestmentCostForIncomeTaxPurposes>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="c190"
      decimals="-5"
      id="ixv-30383"
      unitRef="eur">34800000</ifrs-full:TaxEffectOfTaxLosses>
    <ifrx:TaxLossCarryforwards contextRef="c0" decimals="-5" id="ixv-30384" unitRef="usd">14300000</ifrx:TaxLossCarryforwards>
    <ifrx:TaxLossCarryforwards contextRef="c0" decimals="-4" id="ixv-30385" unitRef="eur">12970000</ifrx:TaxLossCarryforwards>
    <ifrx:TaxLossCarryforwards contextRef="c3" decimals="-5" id="ixv-30386" unitRef="usd">14100000</ifrx:TaxLossCarryforwards>
    <ifrx:TaxLossCarryforwards contextRef="c3" decimals="-5" id="ixv-30387" unitRef="eur">13200000</ifrx:TaxLossCarryforwards>
    <ifrx:TaxableIncome contextRef="c0" decimals="2" id="ixv-30388" unitRef="pure">0.80</ifrx:TaxableIncome>
    <ifrs-full:CurrentInterestReceivable contextRef="c2" decimals="0" id="ixv-30389" unitRef="eur">1390280</ifrs-full:CurrentInterestReceivable>
    <ifrs-full:CurrentInterestReceivable contextRef="c5" decimals="0" id="ixv-30390" unitRef="eur">791344</ifrs-full:CurrentInterestReceivable>
    <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="c0" id="ixv-30391">Set out below is an overview of financial assets
and liabilities, other than cash and short-term deposits included in cash equivalents, held by the Group as at December 31, 2023 and December
31, 2022:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Financial assets and financial liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Non-current financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,052,741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,900,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial assets from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-138"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;732,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,504,518&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,791,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Financial liabilities at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-139"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,209,266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,716,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,987,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c2" decimals="0" id="ixv-30392" unitRef="eur">9052741</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c5" decimals="0" id="ixv-30393" unitRef="eur">2900902</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrx:FinancialAssetsFromGovernmentGrants contextRef="c5" decimals="0" id="ixv-30394" unitRef="eur">732971</ifrx:FinancialAssetsFromGovernmentGrants>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c2" decimals="0" id="ixv-30395" unitRef="eur">77504518</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c5" decimals="0" id="ixv-30396" unitRef="eur">64791088</ifrs-full:OtherCurrentFinancialAssets>
    <ifrx:LiabilitiesFromGovernmentGrants contextRef="c5" decimals="0" id="ixv-30397" unitRef="eur">6209266</ifrx:LiabilitiesFromGovernmentGrants>
    <ifrs-full:TradeAndOtherPayables contextRef="c2" decimals="0" id="ixv-30398" unitRef="eur">14716441</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c5" decimals="0" id="ixv-30399" unitRef="eur">4987538</ifrs-full:TradeAndOtherPayables>
    <ifrx:CurrentAndNonCurrentFinancialAssets contextRef="c2" decimals="1" id="ixv-30400" unitRef="eur">85.5</ifrx:CurrentAndNonCurrentFinancialAssets>
    <ifrx:CurrentAndNonCurrentFinancialAssets contextRef="c5" decimals="-5" id="ixv-30401" unitRef="eur">68500000</ifrx:CurrentAndNonCurrentFinancialAssets>
    <ifrx:FixedInterest
      contextRef="c191"
      decimals="3"
      id="ixv-30402"
      unitRef="pure">0.003</ifrx:FixedInterest>
    <ifrx:FixedInterest
      contextRef="c192"
      decimals="5"
      id="ixv-30403"
      unitRef="pure">0.04125</ifrx:FixedInterest>
    <ifrx:FixedInterest
      contextRef="c193"
      decimals="3"
      id="ixv-30404"
      unitRef="pure">0</ifrx:FixedInterest>
    <ifrx:FixedInterest
      contextRef="c194"
      decimals="5"
      id="ixv-30405"
      unitRef="pure">0.04125</ifrx:FixedInterest>
    <ifrx:DueAmount contextRef="c3" decimals="-5" id="ixv-30406" unitRef="eur">6200000</ifrx:DueAmount>
    <ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory contextRef="c0" id="ixv-28113">&lt;span style="font-style: normal"&gt;Cash and cash equivalents&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Deposits held in U.S. dollars&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,120,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deposits held in Euro&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,020,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-140"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,140,951&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash at banks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash held in U.S. dollars&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,041,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,645,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash held in Euro&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;2,585,190&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;7,616,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;7,626,991&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;16,261,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,767,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;16,265,354&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c288" decimals="0" id="ixv-30407" unitRef="eur">4120951</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c289" decimals="0" id="ixv-30408" unitRef="eur">3422</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c290" decimals="0" id="ixv-30409" unitRef="eur">1020000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="0" id="ixv-30410" unitRef="eur">5140951</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c5" decimals="0" id="ixv-30411" unitRef="eur">3422</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:Cash contextRef="c292" decimals="0" id="ixv-30412" unitRef="eur">5041802</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c293" decimals="0" id="ixv-30413" unitRef="eur">8645014</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c294" decimals="0" id="ixv-30414" unitRef="eur">2585190</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c295" decimals="0" id="ixv-30415" unitRef="eur">7616918</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c2" decimals="0" id="ixv-30416" unitRef="eur">7626991</ifrs-full:Cash>
    <ifrs-full:Cash contextRef="c5" decimals="0" id="ixv-30417" unitRef="eur">16261932</ifrs-full:Cash>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c2" decimals="0" id="ixv-30418" unitRef="eur">12767942</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c5" decimals="0" id="ixv-30419" unitRef="eur">16265354</ifrs-full:OtherCashAndCashEquivalents>
    <ifrx:CapitalOrdinarySharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-30420"
      unitRef="shares">58883272</ifrx:CapitalOrdinarySharesIssued>
    <ifrx:CapitalOrdinarySharesIssued
      contextRef="c5"
      decimals="0"
      id="ixv-30421"
      unitRef="shares">44703763</ifrx:CapitalOrdinarySharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-30422"
      unitRef="eurPershares">0.12</ifrs-full:ParValuePerShare>
    <ifrx:CommonShares contextRef="c0" decimals="-5" id="ixv-30423" unitRef="usd">50000000</ifrx:CommonShares>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c195"
      decimals="0"
      id="ixv-30424"
      unitRef="shares">2568208</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrx:CommonSharesIssued contextRef="c5" decimals="-5" id="ixv-30425" unitRef="eur">11800000</ifrx:CommonSharesIssued>
    <ifrx:AssetsSoldUnderAgreementToRepurchaseCarryingAmount contextRef="c3" decimals="-5" id="ixv-30426" unitRef="usd">35200000</ifrx:AssetsSoldUnderAgreementToRepurchaseCarryingAmount>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c196"
      decimals="0"
      id="ixv-30427"
      unitRef="shares">3235723</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrx:NetProceeds contextRef="c0" decimals="-5" id="ixv-30428" unitRef="eur">14400000</ifrx:NetProceeds>
    <ifrx:NetProceeds contextRef="c0" decimals="-5" id="ixv-30429" unitRef="usd">15700000</ifrx:NetProceeds>
    <ifrx:AssetsSoldUnderAgreementToRepurchaseCarryingAmount
      contextRef="c197"
      decimals="-5"
      id="ixv-30430"
      unitRef="usd">19000000</ifrx:AssetsSoldUnderAgreementToRepurchaseCarryingAmount>
    <ifrx:AggregateCommonShares
      contextRef="c198"
      decimals="0"
      id="ixv-30431"
      unitRef="shares">10823529</ifrx:AggregateCommonShares>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c198"
      decimals="0"
      id="ixv-30432"
      unitRef="shares">1411764</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:ParValuePerShare
      contextRef="c198"
      decimals="2"
      id="ixv-30433"
      unitRef="usdPershares">4.25</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="c198"
      decimals="2"
      id="ixv-30434"
      unitRef="eurPershares">0.12</ifrs-full:ParValuePerShare>
    <ifrx:ProceedsOfferingCost contextRef="c0" decimals="-5" id="ixv-30435" unitRef="eur">2500000</ifrx:ProceedsOfferingCost>
    <ifrx:ProceedsOfferingCost contextRef="c0" decimals="-5" id="ixv-30436" unitRef="usd">2800000</ifrx:ProceedsOfferingCost>
    <ifrx:UnderwritingDiscounts contextRef="c0" decimals="-5" id="ixv-30437" unitRef="eur">39100000</ifrx:UnderwritingDiscounts>
    <ifrx:UnderwritingDiscounts contextRef="c0" decimals="-5" id="ixv-30438" unitRef="usd">43200000</ifrx:UnderwritingDiscounts>
    <ifrs-full:OtherExpenseByNature contextRef="c0" decimals="-5" id="ixv-30439" unitRef="eur">400000</ifrs-full:OtherExpenseByNature>
    <ifrx:ProceedsFromOfferingCost contextRef="c0" decimals="-5" id="ixv-30440" unitRef="eur">38700000</ifrx:ProceedsFromOfferingCost>
    <ifrs-full:DividendsPaidOrdinaryShares contextRef="c0" decimals="-5" id="ixv-30441" unitRef="usd">2500000</ifrs-full:DividendsPaidOrdinaryShares>
    <ifrs-full:DividendsPaidOrdinaryShares contextRef="c0" decimals="-5" id="ixv-30442" unitRef="eur">2300000</ifrs-full:DividendsPaidOrdinaryShares>
    <ifrs-full:DividendsPaidOrdinarySharesPerShare
      contextRef="c0"
      decimals="2"
      id="ixv-30443"
      unitRef="usdPershares">5</ifrs-full:DividendsPaidOrdinarySharesPerShare>
    <ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized
      contextRef="c0"
      decimals="0"
      id="ixv-30444"
      unitRef="shares">500000</ifrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalShareAuthorized>
    <ifrx:AggregatePurchasePrice contextRef="c0" decimals="-5" id="ixv-30445" unitRef="usd">7500000</ifrx:AggregatePurchasePrice>
    <ifrx:AggregateInitialOffering contextRef="c0" decimals="-6" id="ixv-30446" unitRef="usd">250000000</ifrx:AggregateInitialOffering>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c0"
      decimals="0"
      id="ixv-30447"
      unitRef="shares">120257</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrx:NominalValue
      contextRef="c0"
      decimals="2"
      id="ixv-30448"
      unitRef="eurPershares">0.12</ifrx:NominalValue>
    <ifrx:OrdinarySharesValue
      contextRef="c2"
      decimals="0"
      id="ixv-30449"
      unitRef="shares">98754</ifrx:OrdinarySharesValue>
    <ifrx:OrdinaryShareSoldPrice
      contextRef="c0"
      decimals="2"
      id="ixv-30450"
      unitRef="usdPershares">1.85</ifrx:OrdinaryShareSoldPrice>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c2"
      decimals="0"
      id="ixv-30451"
      unitRef="shares">21503</ifrs-full:NumberOfSharesIssued>
    <ifrx:SoldAtPrice
      contextRef="c0"
      decimals="2"
      id="ixv-30452"
      unitRef="usdPershares">3.35</ifrx:SoldAtPrice>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c199"
      decimals="0"
      id="ixv-30453"
      unitRef="shares">14930</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrx:OrdinarySharePurchase
      contextRef="c2"
      decimals="0"
      id="ixv-30454"
      unitRef="shares">110000000</ifrx:OrdinarySharePurchase>
    <ifrx:PreferredUnitIssued
      contextRef="c2"
      decimals="0"
      id="ixv-30455"
      unitRef="shares">110000000</ifrx:PreferredUnitIssued>
    <ifrs-full:NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk contextRef="c2" decimals="2" id="ixv-30456" unitRef="eur">0.12</ifrs-full:NominalOrPrincipalAmountOfFinancialInstrumentOnDiscontinuationOfMeasurementAtFairValueThroughProfitOrLossBecauseCreditDerivativeIsUsedToManageCreditRisk>
    <ifrx:CompanyIssuedCapital contextRef="c0" decimals="2" id="ixv-30457" unitRef="pure">1</ifrx:CompanyIssuedCapital>
    <ifrs-full:ExpectedReimbursementOtherProvisions contextRef="c2" decimals="0" id="ixv-30458" unitRef="eur">70000</ifrs-full:ExpectedReimbursementOtherProvisions>
    <ifrx:CommonSharesInExcessOfNominalValue
      contextRef="c0"
      decimals="2"
      id="ixv-30459"
      unitRef="eurPershares">0.12</ifrx:CommonSharesInExcessOfNominalValue>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c0" id="ixv-28318">&lt;span style="font-style: normal"&gt;Trade and other payables&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued liabilities from R&amp;amp;D projects&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,414,143&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,254,550&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued liabilities from commercial activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,400,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-141"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,102,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,566,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accrued liabilities and payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,942,909&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,314,196&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total trade and other payables&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,860,134&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5,135,146&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c2" decimals="0" id="ixv-30460" unitRef="eur">4414143</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="c5" decimals="0" id="ixv-30461" unitRef="eur">2254550</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrx:AccruedLiabilitiesFromCommercialActivities contextRef="c2" decimals="0" id="ixv-30462" unitRef="eur">1400382</ifrx:AccruedLiabilitiesFromCommercialActivities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c2" decimals="0" id="ixv-30463" unitRef="eur">5102700</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers contextRef="c5" decimals="0" id="ixv-30464" unitRef="eur">1566400</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherPayables contextRef="c2" decimals="0" id="ixv-30465" unitRef="eur">3942909</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables contextRef="c5" decimals="0" id="ixv-30466" unitRef="eur">1314196</ifrs-full:OtherPayables>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="c2" decimals="0" id="ixv-30467" unitRef="eur">14860134</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows contextRef="c5" decimals="0" id="ixv-30468" unitRef="eur">5135146</ifrs-full:TradeAndOtherPayablesUndiscountedCashFlows>
    <ifrx:PaymentsForAccruedPayments contextRef="c2" decimals="-5" id="ixv-30469" unitRef="eur">2700000</ifrx:PaymentsForAccruedPayments>
    <ifrs-full:DisclosureOfMarketRiskExplanatory contextRef="c0" id="ixv-30470">The Group is exposed to market risk, credit risk
and liquidity risk. The Board of Directors reviews and adopts policies for managing each of these risks, which are summarized below. The
Group&#x2019;s senior management oversees the management of these risks.&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="padding: 1.5pt; border: black 1pt solid; text-align: center; width: 12%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 37%; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exposure&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 20%; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Measurement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 31%; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Risk Management&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Market risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future development costs; Recognized financial assets and liabilities not denominated in Euro&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Forecasted cash flows Sensitivity analysis&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Achievement of a natural hedge&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;in the future&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit risk&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Cash and cash equivalents,&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;current and non-current&lt;br/&gt; financial assets&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Credit&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;rating&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Diversification of bank deposits, Investment guidelines for&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;debt investments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;R&amp;amp;D and G&amp;amp;A cost, equity, trade and other payables&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;Rolling&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;cash flow forecast&lt;/p&gt;&lt;/td&gt;
    &lt;td style="padding: 1.5pt; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Availability of funds through financing rounds or public offerings&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfMarketRiskExplanatory>
    <ifrs-full:DescriptionOfExposureToRisk contextRef="c296" id="ixv-28451">Future development costs; Recognized financial assets and liabilities not denominated in Euro</ifrs-full:DescriptionOfExposureToRisk>
    <ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets contextRef="c296" id="ixv-28454">Forecasted cash flows Sensitivity analysis</ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets>
    <ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets contextRef="c296" id="ixv-28457">Achievement of a natural hedge in the future</ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets>
    <ifrs-full:DescriptionOfExposureToRisk contextRef="c297" id="ixv-28465">Cash and cash equivalents, current and non-current financial assets</ifrs-full:DescriptionOfExposureToRisk>
    <ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets contextRef="c297" id="ixv-28470">Credit rating</ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets>
    <ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets contextRef="c297" id="ixv-28474">Diversification of bank deposits, Investment guidelines for debt investments</ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets>
    <ifrs-full:DescriptionOfExposureToRisk contextRef="c298" id="ixv-28482">R&amp;D and G&amp;A cost, equity, trade and other payables</ifrs-full:DescriptionOfExposureToRisk>
    <ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets contextRef="c298" id="ixv-28485">Rolling cash flow forecast</ifrs-full:DescriptionOfReasonsForFairValueMeasurementAssets>
    <ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets contextRef="c298" id="ixv-28489">Availability of funds through financing rounds or public offerings</ifrs-full:DescriptionOfHowEntityReflectsItsRiskManagementStrategyByUsingHedgeAccountingAndDesignatingHedgingRelationshipsThatItFrequentlyResets>
    <ifrx:DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock contextRef="c0" id="ixv-30471">In 2023, if the Euro had weakened/strengthened
by 10% against the U.S. dollar with all other variables held constant, the Group&#x2019;s loss would have been &#x20ac;1 million higher/&#x20ac;1
million lower, mainly as a result of foreign exchange on translation of U.S. dollar-denominated assets of InflaRx N.V. and InflaRx GmbH.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Cash, cash equivalents and financial assets denominated in U.S. dollars, InflaRx N.V. and InflaRx GmbH&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022 *&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Current and non current financial assets (securities and accrued interest)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;80,935,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,376,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,051,366&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,356,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total assets exposed to the risk&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;88,986,563&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,733,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Conversion rate Euro to U.S. dollars at reporting date 1/1.1050 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in; text-align: left"&gt;*&lt;/td&gt;&lt;td style="text-align: justify"&gt;The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</ifrx:DisclosureCashCashEquivalentsAndFinancialAssetsTextBlock>
    <ifrx:VariablesHeldConstant contextRef="c0" decimals="2" id="ixv-30472" unitRef="pure">0.10</ifrx:VariablesHeldConstant>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c58" decimals="-6" id="ixv-30473" unitRef="eur">1000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax contextRef="c57" decimals="-6" id="ixv-30474" unitRef="eur">1000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest contextRef="c2" decimals="0" id="ixv-30475" unitRef="eur">80935197</ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest>
    <ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest contextRef="c5" decimals="0" id="ix_42_fact" unitRef="eur">7376866</ifrx:CurrentAndNonCurrentFinancialAssetssecuritiesAndAccruedInterest>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c2" decimals="0" id="ixv-30477" unitRef="eur">8051366</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="c5" decimals="0" id="ix_43_fact" unitRef="eur">4356512</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk contextRef="c2" decimals="0" id="ixv-30479" unitRef="eur">88986563</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk contextRef="c5" decimals="0" id="ix_44_fact" unitRef="eur">11733378</ifrs-full:FinancialAssetsHeldForManagingLiquidityRisk>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="c0" id="ixv-28585">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Sensitivity analysis:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Conversion&lt;br/&gt;
 rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Profit/(loss)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;carrying&lt;br/&gt;
 amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Euro weakens against U.S. dollars&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.2155&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;9,887,396&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;98,873,959&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Euro strengths against U.S. dollars&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9945&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(8,089,688&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,896,875&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <ifrx:SensitivityAnalysisConversionRate
      contextRef="c299"
      decimals="4"
      id="ixv-30482"
      unitRef="eurPershares">1.2155</ifrx:SensitivityAnalysisConversionRate>
    <ifrs-full:ProfitLoss contextRef="c299" decimals="0" id="ixv-30483" unitRef="eur">9887396</ifrs-full:ProfitLoss>
    <ifrx:SensitivityAnalysisCarryingAmount contextRef="c299" decimals="0" id="ixv-30484" unitRef="eur">98873959</ifrx:SensitivityAnalysisCarryingAmount>
    <ifrx:SensitivityAnalysisConversionRate
      contextRef="c300"
      decimals="4"
      id="ixv-30485"
      unitRef="eurPershares">0.9945</ifrx:SensitivityAnalysisConversionRate>
    <ifrs-full:ProfitLoss contextRef="c300" decimals="0" id="ixv-30486" unitRef="eur">-8089688</ifrs-full:ProfitLoss>
    <ifrx:SensitivityAnalysisCarryingAmount contextRef="c300" decimals="0" id="ixv-30487" unitRef="eur">80896875</ifrx:SensitivityAnalysisCarryingAmount>
    <ifrx:ExchangeRateFluctuations
      contextRef="c57"
      decimals="4"
      id="ixv-30488"
      unitRef="eurPershares">0.9945</ifrx:ExchangeRateFluctuations>
    <ifrx:ExchangeRateFluctuations
      contextRef="c58"
      decimals="4"
      id="ixv-30489"
      unitRef="eurPershares">1.2155</ifrx:ExchangeRateFluctuations>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c2" decimals="-5" id="ixv-30490" unitRef="eur">99300000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:MaximumExposureToCreditRisk contextRef="c5" decimals="-5" id="ixv-30491" unitRef="eur">84000000</ifrs-full:MaximumExposureToCreditRisk>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c2" decimals="-5" id="ixv-30492" unitRef="eur">12800000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents contextRef="c5" decimals="-5" id="ixv-30493" unitRef="eur">16300000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:FinancialAssets contextRef="c67" decimals="-5" id="ixv-30494" unitRef="eur">86600000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="c200"
      decimals="-5"
      id="ixv-30495"
      unitRef="eur">67700000</ifrs-full:FinancialAssets>
    <ifrs-full:CashOnHand contextRef="c2" decimals="-5" id="ixv-30496" unitRef="eur">8800000</ifrs-full:CashOnHand>
    <ifrs-full:DisclosureOfCommitmentsExplanatory contextRef="c0" id="ixv-30497">At the end of the reporting period, the Group
held the following deposits that are expected to readily generate cash inflows to meet the outstanding financial commitments.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Liquidity&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Short-term deposits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,140,951&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Cash at banks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,626,992&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,261,932&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Marketable Securities (current and non-current)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;85,727,461&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;67,175,879&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other (non-current portion)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,621&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other (current)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;701,407&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;278,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;Total funds available&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;99,434,432&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;83,957,344&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCommitmentsExplanatory>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c2" decimals="0" id="ixv-30498" unitRef="eur">5140951</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents contextRef="c5" decimals="0" id="ixv-30499" unitRef="eur">3422</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:BalancesWithBanks contextRef="c2" decimals="0" id="ixv-30500" unitRef="eur">7626992</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks contextRef="c5" decimals="0" id="ixv-30501" unitRef="eur">16261932</ifrs-full:BalancesWithBanks>
    <ifrs-full:DebtSecurities contextRef="c2" decimals="0" id="ixv-30502" unitRef="eur">85727461</ifrs-full:DebtSecurities>
    <ifrs-full:DebtSecurities contextRef="c5" decimals="0" id="ixv-30503" unitRef="eur">67175879</ifrs-full:DebtSecurities>
    <ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings contextRef="c2" decimals="0" id="ixv-30504" unitRef="eur">237621</ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings contextRef="c5" decimals="0" id="ixv-30505" unitRef="eur">237296</ifrs-full:NoncurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings contextRef="c2" decimals="0" id="ixv-30506" unitRef="eur">701407</ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings>
    <ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings contextRef="c5" decimals="0" id="ixv-30507" unitRef="eur">278815</ifrs-full:OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings>
    <ifrx:TotalFundsAvailable contextRef="c2" decimals="0" id="ixv-30508" unitRef="eur">99434432</ifrx:TotalFundsAvailable>
    <ifrx:TotalFundsAvailable contextRef="c5" decimals="0" id="ixv-30509" unitRef="eur">83957344</ifrx:TotalFundsAvailable>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c0" id="ixv-28777">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;E.&lt;/td&gt;&lt;td style="padding-right: 54.4pt"&gt;Commitments&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Operating contracts or services&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group enters into contracts in the normal
course of business with CROs and clinical sites for the conduct of clinical trials, professional consultants for expert advice and other
vendors for clinical supply manufacturing or other services. These contracts can usually be terminated with 30 to 180 days&#x2019; notice.
In addition to this minimum duration, these contracts require full payment for services already rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;During 2023, the Group did not have any commitments
to purchase property, plant and equipment or patents and trademarks (respectively &lt;span style="-sec-ix-hidden: hidden-fact-161"&gt;nil&lt;/span&gt; in 2022).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Lease obligations&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The maturity analysis of lease liabilities is
disclosed in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity analysis for capitalized leases in 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Contractual&lt;br/&gt;
 minimum&lt;br/&gt;
 lease&lt;br/&gt;
 obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Effect of&lt;br/&gt;
 discounting&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;391,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;374,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;760,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,151,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;31,389&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,120,045&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity analysis for capitalized leases in 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Contractual&lt;br/&gt;
 minimum&lt;br/&gt;
 lease&lt;br/&gt;
 obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Effect of&lt;br/&gt;
 discounting&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lease&lt;br/&gt;
 liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;380,518&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;369,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;999,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;987,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,380,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;23,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,356,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Maturity analysis for all lease obligations in 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Low value&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;leases&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Short-term&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capitalized&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;397,942&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;391,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;760,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;760,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,158,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,968&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,151,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity analysis for all lease obligations in 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Low value&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Short-term&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capitalized&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;386,779&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;380,518&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,004,444&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;999,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,391,223&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,223&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,380,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Anticipated future lease expenses were converted
with the exchange rate as of December 31, 2023, 1&#160;Euro&#160;=&#160;1.1050 U.S. dollar.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group applies the &#x2018;lease of low-value
assets&#x2019; recognition exemptions. The Group also applied the &#x2018;short-term lease&#x2019; exemption for leases with a maturity of
less than 12 months.&lt;/p&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="c0" id="ixv-30510">The maturity analysis of lease liabilities is
disclosed in the following table:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity analysis for capitalized leases in 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Contractual&lt;br/&gt;
 minimum&lt;br/&gt;
 lease&lt;br/&gt;
 obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Effect of&lt;br/&gt;
 discounting&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;391,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;374,329&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;760,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,559&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;745,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-143"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-144"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-145"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,151,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;31,389&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,120,045&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity analysis for capitalized leases in 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Contractual&lt;br/&gt;
 minimum&lt;br/&gt;
 lease&lt;br/&gt;
 obligations&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Effect of&lt;br/&gt;
 discounting&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Lease&lt;br/&gt;
 liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;380,518&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;369,376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;999,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;987,307&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-146"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-147"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-148"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,380,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;23,317&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,356,683&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Maturity analysis for all lease obligations in 2023&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Low value&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;leases&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Short-term&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capitalized&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;397,942&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,816&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,968&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;391,158&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;760,421&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-149"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;760,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-150"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-151"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-152"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-153"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,158,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,962&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,968&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,151,434&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity analysis for all lease obligations in 2022&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Low value&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Short-term&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Capitalized&lt;br/&gt;
 leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Within one year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;386,779&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,261&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-154"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;380,518&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;After one year but not more than five years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,004,444&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-155"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;999,482&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;More than five years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-156"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-157"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-158"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-159"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,391,223&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;11,223&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-160"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,380,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities contextRef="c303" decimals="0" id="ixv-30511" unitRef="usd">391158</ifrs-full:GrossLeaseLiabilities>
    <ifrx:EffectOfDiscounting contextRef="c304" decimals="0" id="ixv-30512" unitRef="usd">16829</ifrx:EffectOfDiscounting>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c303" decimals="0" id="ixv-30513" unitRef="usd">374329</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c305" decimals="0" id="ixv-30514" unitRef="usd">760275</ifrs-full:GrossLeaseLiabilities>
    <ifrx:EffectOfDiscounting contextRef="c306" decimals="0" id="ixv-30515" unitRef="usd">14559</ifrx:EffectOfDiscounting>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c305" decimals="0" id="ixv-30516" unitRef="usd">745716</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c2" decimals="0" id="ixv-30517" unitRef="usd">1151434</ifrs-full:GrossLeaseLiabilities>
    <ifrx:EffectOfDiscounting contextRef="c0" decimals="0" id="ixv-30518" unitRef="usd">31389</ifrx:EffectOfDiscounting>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c2" decimals="0" id="ixv-30519" unitRef="usd">1120045</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c309" decimals="0" id="ixv-30520" unitRef="usd">380518</ifrs-full:GrossLeaseLiabilities>
    <ifrx:EffectOfDiscounting contextRef="c310" decimals="0" id="ixv-30521" unitRef="usd">11142</ifrx:EffectOfDiscounting>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c309" decimals="0" id="ixv-30522" unitRef="usd">369376</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c311" decimals="0" id="ixv-30523" unitRef="usd">999482</ifrs-full:GrossLeaseLiabilities>
    <ifrx:EffectOfDiscounting contextRef="c312" decimals="0" id="ixv-30524" unitRef="usd">12175</ifrx:EffectOfDiscounting>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c311" decimals="0" id="ixv-30525" unitRef="usd">987307</ifrs-full:NetDeferredTaxLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c5" decimals="0" id="ixv-30526" unitRef="usd">1380000</ifrs-full:GrossLeaseLiabilities>
    <ifrx:EffectOfDiscounting contextRef="c3" decimals="0" id="ixv-30527" unitRef="usd">23317</ifrx:EffectOfDiscounting>
    <ifrs-full:NetDeferredTaxLiabilities contextRef="c5" decimals="0" id="ixv-30528" unitRef="usd">1356683</ifrs-full:NetDeferredTaxLiabilities>
    <ifrx:TotalLeases contextRef="c304" decimals="0" id="ixv-30529" unitRef="usd">397942</ifrx:TotalLeases>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed contextRef="c304" decimals="0" id="ixv-30530" unitRef="usd">4816</ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="c303" decimals="0" id="ixv-30531" unitRef="usd">1968</ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrx:CapitalizedLeases contextRef="c304" decimals="0" id="ixv-30532" unitRef="usd">391158</ifrx:CapitalizedLeases>
    <ifrx:TotalLeases contextRef="c306" decimals="0" id="ixv-30533" unitRef="usd">760421</ifrx:TotalLeases>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed contextRef="c306" decimals="0" id="ixv-30534" unitRef="usd">146</ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed>
    <ifrx:CapitalizedLeases contextRef="c306" decimals="0" id="ixv-30535" unitRef="usd">760275</ifrx:CapitalizedLeases>
    <ifrx:TotalLeases contextRef="c0" decimals="0" id="ixv-30536" unitRef="usd">1158363</ifrx:TotalLeases>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed contextRef="c0" decimals="0" id="ixv-30537" unitRef="usd">4962</ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="c2" decimals="0" id="ixv-30538" unitRef="usd">1968</ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrx:CapitalizedLeases contextRef="c0" decimals="0" id="ixv-30539" unitRef="usd">1151434</ifrx:CapitalizedLeases>
    <ifrx:TotalLeases contextRef="c310" decimals="0" id="ixv-30540" unitRef="usd">386779</ifrx:TotalLeases>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed contextRef="c310" decimals="0" id="ixv-30541" unitRef="usd">6261</ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed>
    <ifrx:CapitalizedLeases contextRef="c310" decimals="0" id="ixv-30542" unitRef="usd">380518</ifrx:CapitalizedLeases>
    <ifrx:TotalLeases contextRef="c312" decimals="0" id="ixv-30543" unitRef="usd">1004444</ifrx:TotalLeases>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed contextRef="c312" decimals="0" id="ixv-30544" unitRef="usd">4962</ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed>
    <ifrx:CapitalizedLeases contextRef="c312" decimals="0" id="ixv-30545" unitRef="usd">999482</ifrx:CapitalizedLeases>
    <ifrx:TotalLeases contextRef="c3" decimals="0" id="ixv-30546" unitRef="usd">1391223</ifrx:TotalLeases>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed contextRef="c3" decimals="0" id="ixv-30547" unitRef="usd">11223</ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed>
    <ifrx:CapitalizedLeases contextRef="c3" decimals="0" id="ixv-30548" unitRef="usd">1380000</ifrx:CapitalizedLeases>
    <ifrx:ExchangeRate contextRef="c301" decimals="0" id="ixv-30549" unitRef="eur">1</ifrx:ExchangeRate>
    <ifrx:ExchangeRate contextRef="c302" decimals="4" id="ixv-30550" unitRef="usd">1.105</ifrx:ExchangeRate>
    <ifrs-full:DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory contextRef="c0" id="ixv-29213">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;F.&lt;/td&gt;&lt;td style="padding-right: 54.4pt"&gt;Other information&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Segment reporting&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Group predominantly operates as a R&amp;amp;D
focused biopharmaceutical company applying its proprietary anti-C5a and C5aR technologies towards the development of novel therapeutic
products targeting diseases of high unmet medical need. However, since the EUA of its lead product vilobelimab for the treatment of severe
COVID-19 patient in April 2023, it also has commercial activities around the sales and marketing of GOHIBIC (vilobelimab) in the U.S.
The Group is not steered by segments. The Board of Directors is the chief operating decision maker. Management of resources and reporting
to the decision maker is based on the Group as a whole.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;All operational activities are conducted in Germany
and the United States. Revenues in the amount of $63,089 were generated in 2023 (&lt;span style="-sec-ix-hidden: hidden-fact-162"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-163"&gt;Nil&lt;/span&gt;&lt;/span&gt; in 2022 and 2021). All revenues were generated in
the United States of America. The geographic location of the Group&#x2019;s non-current assets are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;December 31, 2023: &#x20ac;10.6 million in Germany and &#x20ac;0.1 million in the United States; and&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&#x25cf;&lt;/td&gt;&lt;td&gt;December 31, 2022: &#x20ac;4.9 million in Germany and &#x20ac;0.1 million in the United States.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;None of the non-current assets are in the country
where the Company is incorporated (the Netherlands).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-style: normal"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-style: normal"&gt;Related party transactions&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"&gt;Compensation of the Group&#x2019;s executive
management for the 12 months ending December 31, 2023:&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Executive and Board compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Executive management&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,783,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,774,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,817,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,507,453&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,808,094&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,347,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Sub-total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,291,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;7,582,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,164,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-executive Board of Directors members&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payments&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;285,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;529,859&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;488,937&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Sub-total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;591,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;778,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;760,185&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5,882,288&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8,361,163&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6,925,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Executive management comprises executive Directors
of the Board of Directors and members of the Senior management of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The table above discloses short-term employee
benefits that were contractually agreed for the Board of Directors and executive management. As of December 31, 2023, &#x20ac;0.8 million
were not paid but accrued (2022: &#x20ac;0.9 million) for executive management and &#x20ac;0.1 million (2022: &#x20ac;0.1 million) for non-executive
members of the Board of Directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;Remuneration of the Group&#x2019;s executive management
comprises fixed and variable components and share-based payment awards. In addition, executive management receive supplementary benefits
and allowances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company entered into indemnification agreements
with its directors and senior management. The indemnification agreements and the Company&#x2019;s Articles of Association require the Company
to indemnify its directors to the fullest extent permitted by law.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;The Company&#x2019;s current and future directors
(and such other officer or employee as designated by the Board of Directors) have the benefit of indemnification provisions in the Articles
of Association of InflaRx N.V. These provisions give the indemnified persons the right to recover from the Company amounts, including,
but not limited to, litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the performance
of their duties. However, there is no entitlement to indemnification for acts or omissions which are considered to constitute malice,
gross negligence, intentional recklessness and/or serious culpability attributable to such indemnified person. These agreements also provide,
subject to certain exceptions, for indemnification for related expenses including, among others, attorneys&#x2019; fees, judgements, penalties,
fines and settlement amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, the
Company provides its directors with directors&#x2019; and officers&#x2019; liability insurance.&lt;/p&gt;</ifrs-full:DisclosureOfInformationAboutMethodsInputsAndAssumptionsUsedForMeasuringObligationsForReturnsRefundsAndOtherSimilarObligationsExplanatory>
    <ifrs-full:Revenue contextRef="c0" decimals="0" id="ixv-30551" unitRef="eur">63089</ifrs-full:Revenue>
    <ifrs-full:NoncurrentAssets
      contextRef="c315"
      decimals="-5"
      id="ixv-30552"
      unitRef="eur">10600000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c316"
      decimals="-5"
      id="ixv-30553"
      unitRef="eur">100000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c317"
      decimals="-5"
      id="ixv-30554"
      unitRef="eur">4900000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="c318"
      decimals="-5"
      id="ixv-30555"
      unitRef="eur">100000</ifrs-full:NoncurrentAssets>
    <ifrx:DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory contextRef="c0" id="ixv-30556">Compensation of the Group&#x2019;s executive
management for the 12 months ending December 31, 2023:&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Executive and Board compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Executive management&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,783,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,774,485&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,817,792&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,507,453&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,808,094&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,347,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Sub-total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,291,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;7,582,579&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,164,995&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-executive Board of Directors members&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Short-term employee benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;305,983&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;248,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,248&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share-based payments&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;285,177&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;529,859&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;488,937&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Sub-total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;591,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;778,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;760,185&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Total compensation&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;5,882,288&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;8,361,163&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6,925,180&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrx:DisclosureOfCompensationOfTheGroupsExecutiveManagementExplanatory>
    <ifrs-full:OtherShorttermEmployeeBenefits contextRef="c76" decimals="0" id="ixv-30557" unitRef="eur">2783675</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits contextRef="c75" decimals="0" id="ixv-30558" unitRef="eur">2774485</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits contextRef="c74" decimals="0" id="ixv-30559" unitRef="eur">2817792</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c76" decimals="0" id="ixv-30560" unitRef="eur">2507453</ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c75" decimals="0" id="ixv-30561" unitRef="eur">4808094</ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c74" decimals="0" id="ixv-30562" unitRef="eur">3347203</ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c323" decimals="0" id="ixv-30563" unitRef="eur">5291128</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c324" decimals="0" id="ixv-30564" unitRef="eur">7582579</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c325" decimals="0" id="ixv-30565" unitRef="eur">6164995</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrs-full:OtherShorttermEmployeeBenefits contextRef="c326" decimals="0" id="ixv-30566" unitRef="eur">305983</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits contextRef="c327" decimals="0" id="ixv-30567" unitRef="eur">248725</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits contextRef="c328" decimals="0" id="ixv-30568" unitRef="eur">271248</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c326" decimals="0" id="ixv-30569" unitRef="eur">285177</ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c327" decimals="0" id="ixv-30570" unitRef="eur">529859</ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="c328" decimals="0" id="ixv-30571" unitRef="eur">488937</ifrx:PaymentOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c329" decimals="0" id="ixv-30572" unitRef="eur">591160</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c330" decimals="0" id="ixv-30573" unitRef="eur">778584</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrs-full:CurrentFinancialAssetsAtAmortisedCost contextRef="c331" decimals="0" id="ixv-30574" unitRef="eur">760185</ifrs-full:CurrentFinancialAssetsAtAmortisedCost>
    <ifrx:TotalCompensation contextRef="c0" decimals="0" id="ixv-30575" unitRef="eur">5882288</ifrx:TotalCompensation>
    <ifrx:TotalCompensation contextRef="c3" decimals="0" id="ixv-30576" unitRef="eur">8361163</ifrx:TotalCompensation>
    <ifrx:TotalCompensation contextRef="c4" decimals="0" id="ixv-30577" unitRef="eur">6925180</ifrx:TotalCompensation>
    <ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued
      contextRef="c319"
      decimals="-5"
      id="ixv-30578"
      unitRef="eur">800000</ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued>
    <ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued
      contextRef="c320"
      decimals="-5"
      id="ixv-30579"
      unitRef="eur">900000</ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued>
    <ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued
      contextRef="c321"
      decimals="-5"
      id="ixv-30580"
      unitRef="eur">100000</ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued>
    <ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued
      contextRef="c322"
      decimals="-5"
      id="ixv-30581"
      unitRef="eur">100000</ifrs-full:InterestIncomeOnImpairedFinancialAssetsAccrued>
    <ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory contextRef="c0" id="ixv-29433">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;G.&lt;/td&gt;&lt;td style="padding-right: 54.4pt"&gt;Significant events after the reporting date&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;None.&lt;/p&gt;</ifrs-full:DisclosureOfNonadjustingEventsAfterReportingPeriodExplanatory>
    <ifrs-full:Revenue
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c4"
      id="hidden-fact-1"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c4"
      id="hidden-fact-3"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GrossProfit
      contextRef="c4"
      id="hidden-fact-5"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c3"
      id="hidden-fact-6"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c3"
      id="hidden-fact-9"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c3"
      decimals="2"
      id="hidden-fact-11"
      unitRef="eurPershares">-0.67</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-12"
      unitRef="eurPershares">-0.78</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c4"
      decimals="2"
      id="hidden-fact-13"
      unitRef="eurPershares">-1.10</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Inventories
      contextRef="c5"
      id="hidden-fact-14"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CurrentFinancialAssets
      contextRef="c2"
      id="hidden-fact-15"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CurrentGovernmentGrants
      contextRef="c2"
      id="hidden-fact-16"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c9"
      id="hidden-fact-17"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c9"
      id="hidden-fact-18"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c9"
      id="hidden-fact-19"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c9"
      id="hidden-fact-20"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c9"
      id="hidden-fact-21"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c11"
      id="hidden-fact-22"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c15"
      id="hidden-fact-23"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c15"
      id="hidden-fact-24"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c15"
      id="hidden-fact-25"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c15"
      id="hidden-fact-26"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c16"
      id="hidden-fact-27"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c15"
      id="hidden-fact-28"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c17"
      id="hidden-fact-29"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughExerciseOfOptionsShares
      contextRef="c16"
      id="hidden-fact-30"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c15"
      id="hidden-fact-31"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c17"
      id="hidden-fact-32"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c21"
      id="hidden-fact-33"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c21"
      id="hidden-fact-34"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c21"
      id="hidden-fact-35"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="c22"
      id="hidden-fact-36"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c21"
      id="hidden-fact-37"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c23"
      id="hidden-fact-38"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c32"
      id="hidden-fact-39"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c31"
      id="hidden-fact-40"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c33"
      id="hidden-fact-41"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c31"
      id="hidden-fact-42"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c32"
      id="hidden-fact-43"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c31"
      id="hidden-fact-44"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c32"
      id="hidden-fact-45"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c38"
      id="hidden-fact-46"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c39"
      id="hidden-fact-47"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c39"
      id="hidden-fact-48"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:AdjustmentsForIncreaseDecreaseInFinancialAssetsFromGovernmentGrantsinDollars
      contextRef="c4"
      id="hidden-fact-49"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c3"
      id="hidden-fact-50"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c4"
      id="hidden-fact-51"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c3"
      id="hidden-fact-52"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c3"
      id="hidden-fact-53"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c4"
      id="hidden-fact-54"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c3"
      id="hidden-fact-55"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c4"
      id="hidden-fact-56"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c3"
      id="hidden-fact-57"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c4"
      id="hidden-fact-58"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c3"
      id="hidden-fact-59"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CostOfSales
      contextRef="c4"
      id="hidden-fact-60"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c78"
      id="hidden-fact-61"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c79"
      id="hidden-fact-62"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c81"
      id="hidden-fact-63"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c82"
      id="hidden-fact-64"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c84"
      id="hidden-fact-65"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c86"
      id="hidden-fact-66"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c87"
      id="hidden-fact-67"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c89"
      id="hidden-fact-68"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c90"
      id="hidden-fact-69"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c3"
      id="hidden-fact-70"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c4"
      id="hidden-fact-71"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="c4"
      id="hidden-fact-72"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c126"
      id="hidden-fact-73"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c127"
      id="hidden-fact-74"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c128"
      id="hidden-fact-75"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="c129"
      id="hidden-fact-76"
      unitRef="pure"
      xsi:nil="true"/>
    <ifrx:NumberOfOpionsExercisedDuring
      contextRef="c137"
      id="hidden-fact-77"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrx:NumberOfSharesExercisedDuring
      contextRef="c138"
      id="hidden-fact-78"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrx:NumberOfSharesExercisedDuring
      contextRef="c138"
      id="hidden-fact-79"
      unitRef="eurPershares"
      xsi:nil="true"/>
    <ifrx:NumberOfOpionsExercisedDuring
      contextRef="c139"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrx:NumberOfSharesExercisedDuring
      contextRef="c140"
      id="hidden-fact-81"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <ifrx:NumberOfSharesExercisedDuring
      contextRef="c140"
      id="hidden-fact-82"
      unitRef="eurPershares"
      xsi:nil="true"/>
    <ifrx:ShareOptionsGrantedOptions
      contextRef="c171"
      id="hidden-fact-83"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrx:ExpectedDividends
      contextRef="c0"
      id="hidden-fact-84"
      unitRef="shares"
      xsi:nil="true"/>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01
      contextRef="c202"
      id="hidden-fact-85"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c205"
      id="hidden-fact-86"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="c205"
      id="hidden-fact-87"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01
      contextRef="c208"
      id="hidden-fact-88"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="c211"
      id="hidden-fact-89"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:DisposalsAndRetirementPropertyPlantAndEquipment
      contextRef="c211"
      id="hidden-fact-90"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="c211"
      id="hidden-fact-91"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01
      contextRef="c214"
      id="hidden-fact-92"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01
      contextRef="c217"
      id="hidden-fact-93"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease
      contextRef="c220"
      id="hidden-fact-94"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="c220"
      id="hidden-fact-95"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01
      contextRef="c223"
      id="hidden-fact-96"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:OperatingLeasesIncomeStatementDepreciationExpensesOnPropertySubjectToOrHeldForLease
      contextRef="c226"
      id="hidden-fact-97"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:DisposalsAndRetirementPropertyPlantAndEquipment
      contextRef="c226"
      id="hidden-fact-98"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="c226"
      id="hidden-fact-99"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets01
      contextRef="c229"
      id="hidden-fact-100"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:NetBookValuePropertyAndEquipment
      contextRef="c232"
      id="hidden-fact-101"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:NetBookValuePropertyAndEquipment
      contextRef="c234"
      id="hidden-fact-102"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="c238"
      id="hidden-fact-103"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions
      contextRef="c238"
      id="hidden-fact-104"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions
      contextRef="c242"
      id="hidden-fact-105"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions
      contextRef="c248"
      id="hidden-fact-106"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceOtherProvisions
      contextRef="c252"
      id="hidden-fact-107"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IntangibleAssets
      contextRef="c260"
      id="hidden-fact-108"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="c262"
      id="hidden-fact-109"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill
      contextRef="c262"
      id="hidden-fact-110"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IntangibleAssets
      contextRef="c264"
      id="hidden-fact-111"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="c265"
      id="hidden-fact-112"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill
      contextRef="c266"
      id="hidden-fact-113"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill
      contextRef="c266"
      id="hidden-fact-114"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IntangibleAssets
      contextRef="c270"
      id="hidden-fact-115"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="c273"
      id="hidden-fact-116"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill
      contextRef="c273"
      id="hidden-fact-117"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IntangibleAssets
      contextRef="c276"
      id="hidden-fact-118"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="c279"
      id="hidden-fact-119"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:DisposalsAndRetirementIntangibleAssetsOtherThanGoodwill
      contextRef="c279"
      id="hidden-fact-120"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IncreaseDecreaseThroughNetExchangeDifferenceIntangibleAssetOtherThanGoodwill
      contextRef="c279"
      id="hidden-fact-121"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:IntangibleAssets
      contextRef="c282"
      id="hidden-fact-122"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:NetBookValueIntangibleAsset
      contextRef="c285"
      id="hidden-fact-123"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c0"
      id="hidden-fact-124"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c3"
      id="hidden-fact-125"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ExpenseRelatingToLeasesOfLowvalueAssetsForWhichRecognitionExemptionHasBeenUsed
      contextRef="c4"
      id="hidden-fact-126"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies
      contextRef="c5"
      id="hidden-fact-127"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies
      contextRef="c37"
      id="hidden-fact-128"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:UnfinishedGoods
      contextRef="c5"
      id="hidden-fact-129"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:UnfinishedGoods
      contextRef="c37"
      id="hidden-fact-130"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:FinishedGoods
      contextRef="c5"
      id="hidden-fact-131"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:FinishedGoods
      contextRef="c37"
      id="hidden-fact-132"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:InventoriesTotal
      contextRef="c5"
      id="hidden-fact-133"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:InventoriesTotal
      contextRef="c37"
      id="hidden-fact-134"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-135"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c3"
      id="hidden-fact-136"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c4"
      id="hidden-fact-137"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:FinancialAssetsFromGovernmentGrants
      contextRef="c2"
      id="hidden-fact-138"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:LiabilitiesFromGovernmentGrants
      contextRef="c2"
      id="hidden-fact-139"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="c291"
      id="hidden-fact-140"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:AccruedLiabilitiesFromCommercialActivities
      contextRef="c5"
      id="hidden-fact-141"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrx:FinancialAssetsFromGovernmentGrantsAmount
      contextRef="c0"
      id="hidden-fact-142"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c307"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:EffectOfDiscounting
      contextRef="c308"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NetDeferredTaxLiabilities
      contextRef="c307"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="c313"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:EffectOfDiscounting
      contextRef="c314"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:NetDeferredTaxLiabilities
      contextRef="c313"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="c305"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:TotalLeases
      contextRef="c308"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed
      contextRef="c308"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="c307"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:CapitalizedLeases
      contextRef="c308"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="c309"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="c311"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:TotalLeases
      contextRef="c314"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:ExpenseRelatingToLeasesOfLowvalueAssetForWhichRecognitionExemptionHasBeenUsed
      contextRef="c314"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="c313"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrx:CapitalizedLeases
      contextRef="c314"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="c5"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="c3"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c3"
      id="hidden-fact-162"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:Revenue
      contextRef="c4"
      id="hidden-fact-163"
      unitRef="eur"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-30748">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-30749">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-30750">00000</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-30751">00000</dei:EntityAddressPostalZipCode>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-30752">0001708688</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-74"
          xlink:label="hidden-fact-74"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-76"
          xlink:label="hidden-fact-76"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
average share price (WAEP)</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-74"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-76"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#x20ac;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31,2022 $0.9376, average rate 2022 $0.9489</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_23_fact"
          xlink:label="ix_23_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_38_fact"
          xlink:label="ix_38_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_41_fact"
          xlink:label="ix_41_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_36_fact"
          xlink:label="ix_36_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_27_fact"
          xlink:label="ix_27_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_29_fact"
          xlink:label="ix_29_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_40_fact"
          xlink:label="ix_40_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_34_fact"
          xlink:label="ix_34_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_26_fact"
          xlink:label="ix_26_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_33_fact"
          xlink:label="ix_33_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_39_fact"
          xlink:label="ix_39_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_35_fact"
          xlink:label="ix_35_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_30_fact"
          xlink:label="ix_30_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_28_fact"
          xlink:label="ix_28_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_31_fact"
          xlink:label="ix_31_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_37_fact"
          xlink:label="ix_37_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_22_fact"
          xlink:label="ix_22_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_25_fact"
          xlink:label="ix_25_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_24_fact"
          xlink:label="ix_24_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_32_fact"
          xlink:label="ix_32_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion
rates used for one &#x20ac;: December 31,2023 $0.9050, average rate 2023 $0.9246, December 31, 2022 $0.9376, average rate 2022 $0.9489</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_23_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_38_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_41_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_36_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_27_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_29_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_40_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_34_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_26_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_33_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_39_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_35_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_30_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_28_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_31_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_37_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_22_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_25_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_24_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_32_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_43_fact"
          xlink:label="ix_43_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_42_fact"
          xlink:label="ix_42_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_44_fact"
          xlink:label="ix_44_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The 2022 figures do not include InflaRx N.V. given the 2022
functional currency was in USD.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_43_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_42_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_44_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
